PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Molnar, J; Ujfaludi, Z; Fong, SFT; Bollinger, JA; Waro, G; Fogelgren, B; Dooley, DM; Mink, M; Csiszar, K				Molnar, J; Ujfaludi, Z; Fong, SFT; Bollinger, JA; Waro, G; Fogelgren, B; Dooley, DM; Mink, M; Csiszar, K			Drosophila lysyl Oxidases Dmloxl-1 and Dmloxl-2 are differentially expressed and the active DmLOXL-1 influences gene expression and development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION-EFFECT VARIEGATION; X-CHROMOSOME; HISTONE ACETYLATION; GROWTH-FACTOR; PROTEIN; MOUSE; LOX; TRANSFORMATION; LOCALIZATION; PROCOLLAGEN	Mammalian lysyl oxidase (LOX) is essential for the catalysis of lysyl-derived cross-links in fibrillar collagens and elastin in the extracellular matrix and has also been implicated in cell motility, differentiation, and tumor cell invasion. The active LOX has been shown to translocate to the nuclei of smooth muscle cells and regulate chromatin structure and transcription. It is difficult to interpret the role of the LOX protein as it is co-expressed with other members of the LOX amine oxidase family in most mammalian cells. To investigate the function of the LOX proteins, we have characterized the Drosophila lysyl oxidases Dmloxl-1 and Dmloxl-2. We present the gene, domain structure, and expression pattern of Dmloxl-1 and Dmloxl-2 during development. In early development, only Dmloxl-1 was expressed, which allowed functional studies. We have expressed Dmloxl-1 in S2 cells and determined that it is a catalytically active enzyme, inhibited by beta-amino-proprionitrile (BAPN), a specific LOX inhibitor. We localized DmLOXL-1 in the nuclei in embryos and in adult salivary gland cells in the nuclei, cytoplasm, and cell surface, using immunostaining and a DmLOXL-1 antibody. To address the biological function of Dmloxl-1, we raised larvae under BAPN inhibitory conditions and over-expressed Dmloxl1 in transgenic Drosophila. DmLOXL-1 inhibition resulted in developmental delay and a shift in sex ratio; over-expression in the w(m4) variegating strain increased drosopterin production, demonstrating euchromatinization. Our previous data on the transcriptional down-regulation of seven ribosomal genes and the glue gene under inhibitory conditions and the current results collectively support a nuclear role for Dmloxl-1 in euchromatinization and gene regulation.	Univ Hawaii, John A Burns Sch Med, Cardiovasc Res Ctr, Honolulu, HI USA; Univ Szeged, Dept Genet & Mol Biol, H-6726 Szeged, Hungary; Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA	University of Hawaii System; Szeged University; Montana State University System; Montana State University Bozeman	Csiszar, K (corresponding author), 1960 East West Rd, Honolulu, HI 96822 USA.	kcsiszar@aol.com	molnar, joseph/D-4375-2013; Ujfaludi, Zsuzsanna/AAC-7657-2020	Ujfaludi Dr., Zsuzsanna/0000-0003-4738-0963	NCRR NIH HHS [RR03061] Funding Source: Medline; NIAMS NIH HHS [AR47713] Funding Source: Medline; NIGMS NIH HHS [GM27659] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [S11AR047713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027659] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler DA, 1997, P NATL ACAD SCI USA, V94, P9244, DOI 10.1073/pnas.94.17.9244; ASHBURNER M, 1989, DROSOPHILA LAB MANUA, P28; Asuncion L, 2001, MATRIX BIOL, V20, P487, DOI 10.1016/S0945-053X(01)00161-5; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bhadra U, 2000, GENETICS, V155, P753; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; Borel A, 2001, J BIOL CHEM, V276, P48944, DOI 10.1074/jbc.M109499200; BUTLER E, 1987, EXP CELL RES, V173, P174, DOI 10.1016/0014-4827(87)90343-0; CHVAPIL M, 1981, J SURG RES, V31, P151, DOI 10.1016/0022-4804(81)90043-3; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; Contente S, 1999, MOL CELL BIOCHEM, V194, P79, DOI 10.1023/A:1006913122261; Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8; Di Donato A, 1997, FEBS LETT, V419, P63, DOI 10.1016/S0014-5793(97)01420-8; Eberl DF, 1997, GENETICS, V146, P951; Giampuzzi M, 2003, BBA-PROTEINS PROTEOM, V1647, P245, DOI 10.1016/S1570-9639(03)00059-1; Gilad GM, 2001, EUR J PHARMACOL, V430, P69, DOI 10.1016/S0014-2999(01)01354-1; Gu WG, 1998, DEV GENET, V22, P56, DOI 10.1002/(SICI)1520-6408(1998)22:1<56::AID-DVG6>3.0.CO;2-6; Hayashi K, 2004, J MOL HISTOL, V35, P845, DOI 10.1007/s10735-004-2340-1; Hein S, 2001, PLACENTA, V22, P49, DOI 10.1053/plac.2000.0580; Hornstra IK, 2003, J BIOL CHEM, V278, P14387, DOI 10.1074/jbc.M210144200; Hynes RO, 2000, J CELL BIOL, V150, pF89, DOI 10.1083/jcb.150.2.F89; Ito H, 2001, J BIOL CHEM, V276, P24023, DOI 10.1074/jbc.M100861200; Jourdan-Le Saux C, 2000, MATRIX BIOL, V19, P179, DOI 10.1016/S0945-053X(00)00061-5; Jourdan-Le Saux C, 2001, GENOMICS, V74, P211, DOI 10.1006/geno.2001.6545; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; KAGAN HM, 1983, BIOCHEM BIOPH RES CO, V115, P186, DOI 10.1016/0006-291X(83)90987-7; KENYON K, 1993, J BIOL CHEM, V268, P18435; Kim MS, 2003, J BIOL CHEM, V278, P52071, DOI 10.1074/jbc.M308856200; Kim YH, 1999, J CELL BIOCHEM, V72, P181, DOI 10.1002/(SICI)1097-4644(19990201)72:2<181::AID-JCB3>3.0.CO;2-D; Kirschmann DA, 2002, CANCER RES, V62, P4478; Klapper M, 1997, J CELL SCI, V110, P2519; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; Lazarus HM, 1995, MATRIX BIOL, V14, P727, DOI 10.1016/S0945-053X(05)80015-0; Li WD, 2000, J CELL BIOCHEM, V78, P550, DOI 10.1002/1097-4644(20000915)78:4<550::AID-JCB4>3.3.CO;2-#; Li WD, 2003, J CELL BIOCHEM, V88, P152, DOI 10.1002/jcb.10304; Li WD, 1997, P NATL ACAD SCI USA, V94, P12817, DOI 10.1073/pnas.94.24.12817; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lucchesi JC, 1998, CURR OPIN GENET DEV, V8, P179, DOI 10.1016/S0959-437X(98)80139-1; Maki JM, 2002, CIRCULATION, V106, P2503, DOI 10.1161/01.CIR.0000038109.84500.1E; Maki JM, 2001, BIOCHEM J, V355, P381, DOI 10.1042/0264-6021:3550381; MELLO MLS, 1995, EXP CELL RES, V220, P374, DOI 10.1006/excr.1995.1328; Mink M, 2001, GENOMICS, V74, P234, DOI 10.1006/geno.2001.6548; Molnar J, 2003, BBA-PROTEINS PROTEOM, V1647, P220, DOI 10.1016/S1570-9639(03)00053-0; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nellaiappan K, 2000, J CELL BIOCHEM, V79, P576, DOI 10.1002/1097-4644(20001215)79:4<576::AID-JCB60>3.0.CO;2-A; Noblesse E, 2004, J INVEST DERMATOL, V122, P621, DOI 10.1111/j.0022-202X.2004.22330.x; Palamakumbura AH, 2002, ANAL BIOCHEM, V300, P245, DOI 10.1006/abio.2001.5464; Paro R., 2000, DROSOPHILA PROTOCOLS, P131; Real MD, 1985, DROS INF SERV, V61, P198; RIEMER D, 1995, J CELL SCI, V108, P3189; ROBERTS DB, 1998, DROSOPHILA PRACTICAL, P219; Saito H, 1997, J BIOL CHEM, V272, P8157, DOI 10.1074/jbc.272.13.8157; Sarrias MR, 2004, CRIT REV IMMUNOL, V24, P1; Schotta G, 2003, SEMIN CELL DEV BIOL, V14, P67, DOI 10.1016/S1084-9521(02)00138-6; Slee RB, 2001, ENDOCRINOLOGY, V142, P1082, DOI 10.1210/en.142.3.1082; Smith-Mungo LI, 1998, MATRIX BIOL, V16, P387, DOI 10.1016/S0945-053X(98)90012-9; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; Stuurman N, 1996, J STRUCT BIOL, V117, P1, DOI 10.1006/jsbi.1996.0064; TANG SS, 1983, J BIOL CHEM, V258, P4331; Tchaparian EH, 2000, ARCH BIOCHEM BIOPHYS, V379, P71, DOI 10.1006/abbi.2000.1842; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122	61	19	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22977	22985		10.1074/jbc.M503006200	http://dx.doi.org/10.1074/jbc.M503006200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15811848	hybrid			2022-12-27	WOS:000229741800052
J	Gleenberg, IO; Avidan, O; Goldgur, Y; Herschhorn, A; Hizi, A				Gleenberg, IO; Avidan, O; Goldgur, Y; Herschhorn, A; Hizi, A			Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN ANTIBODY; DNA-BINDING DOMAIN; HIV-1 INTEGRASE; IN-VITRO; CATALYTIC DOMAIN; ACTIVE-SITE; PREINTEGRATION COMPLEXES; ESCHERICHIA-COLI; RETROVIRAL INTEGRASE; MONOCLONAL-ANTIBODY	Recent studies have shown that the integrase ( IN) of HIV-1 is inhibited in vitro by HIV-1 reverse transcriptase (RT). We further investigated the specific protein sequences of RT that were involved in this inhibition by screening a complete library of RT-derived peptides for their inhibition of IN activities. Two 20-residue peptides, peptide 4286, derived from the RT DNA polymerase domain, and the one designated 4321, from the RT ribonuclease H domain, inhibit the enzymatic activities of IN in vitro. The former peptide inhibits all three IN-associated activities (3'-end processing, strand transfer, and disintegration), whereas the latter one inhibits primarily the first two functions. We showed the importance of the sequences and peptide length for the effective inhibition of IN activities. Binding assays of the peptides to IN ( with no DNA substrate present) indicated that the two inhibitory peptides ( as well as several non-inhibitory peptides) interact directly with IN. Moreover, the isolated catalytic core domain of IN also interacted directly with the two inhibitory peptides. Nevertheless, only peptide 4286 can inhibit the disintegration activity associated with the IN core domain, because this activity is the only one exhibited by this domain. This result was expected from the lack of inhibition of disintegration of full-length IN by peptide 4321. The data and the three-dimensional models presented suggested that the inhibition resulted from steric hindrance of the catalytic domain of IN. This information can substantially facilitate the development of novel drugs against HIV INs and thus contribute to the fight against AIDS.	Tel Aviv Univ, Sackler Sch Med, Dept Cell & Dev Biol, IL-69978 Tel Aviv, Israel; Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel	Tel Aviv University; Sackler Faculty of Medicine; Ben Gurion University	Hizi, A (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Cell & Dev Biol, IL-69978 Tel Aviv, Israel.	ahizy@post.tau.ac.il						AIGAR A, 1996, J VIROL, V70, P3571; Barsov EV, 1996, J VIROL, V70, P4484, DOI 10.1128/JVI.70.7.4484-4494.1996; Brodin P, 2002, BIOCHEMISTRY-US, V41, P1529, DOI 10.1021/bi015732y; Bujacz G, 1996, FEBS LETT, V398, P175, DOI 10.1016/S0014-5793(96)01236-7; BURKINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; Chow SA, 1997, METHODS, V12, P306, DOI 10.1006/meth.1997.0484; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CLARK PK, 1990, AIDS RES HUM RETROV, V6, P753, DOI 10.1089/aid.1990.6.753; Coffin J, 1997, RETROVIRUSES; CRAIGIE R, 2002, RETROVIRAL DNA INTEG, P613; de Soultrait VR, 2003, CURR MED CHEM, V10, P1765; de Soultrait VR, 2002, J MOL BIOL, V318, P45, DOI 10.1016/S0022-2836(02)00033-5; de Soultrait VR, 2002, J MOL BIOL, V324, P195, DOI 10.1016/S0022-2836(02)01064-1; de Soultrait VR, 2002, BBA-GENE STRUCT EXPR, V1575, P40, DOI 10.1016/S0167-4781(02)00241-5; Desjobert C, 2004, BIOCHEMISTRY-US, V43, P13097, DOI 10.1021/bi049385e; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Fouchier RAM, 1999, ADV VIRUS RES, V52, P275, DOI 10.1016/S0065-3527(08)60302-4; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Grobler JA, 2002, P NATL ACAD SCI USA, V99, P6661, DOI 10.1073/pnas.092056199; Harris D, 2000, J BIOL CHEM, V275, P39671, DOI 10.1074/jbc.M002626200; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Hehl EA, 2004, J VIROL, V78, P5056, DOI 10.1128/JVI.78.10.5056-5067.2004; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; Hindmarsh P, 1999, J VIROL, V73, P2994, DOI 10.1128/JVI.73.4.2994-3003.1999; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HU SC, 1986, J VIROL, V60, P267, DOI 10.1128/JVI.60.1.267-274.1986; Ishikawa T, 1999, J VIROL, V73, P4475, DOI 10.1128/JVI.73.5.4475-4480.1999; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kitamura Y, 1999, J ACQ IMMUN DEF SYND, V20, P105, DOI 10.1097/00042560-199902010-00001; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; LEEHUANG S, 1995, P NATL ACAD SCI USA, V92, P8818, DOI 10.1073/pnas.92.19.8818; LevyMintz P, 1996, J VIROL, V70, P8821, DOI 10.1128/JVI.70.12.8821-8832.1996; Lubkowski J, 1998, P NATL ACAD SCI USA, V95, P4831, DOI 10.1073/pnas.95.9.4831; LUTZKE RAP, 1995, P NATL ACAD SCI USA, V92, P11456, DOI 10.1073/pnas.92.25.11456; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; Marchand C, 2002, J BIOL CHEM, V277, P12596, DOI 10.1074/jbc.M110758200; Maroun RG, 2001, BIOCHEMISTRY-US, V40, P13840, DOI 10.1021/bi011328n; Maurin C, 2003, CURR MED CHEM, V10, P1795, DOI 10.2174/0929867033456981; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Okui N, 1998, J VIROL, V72, P6960, DOI 10.1128/JVI.72.8.6960-6964.1998; Oz I, 2002, BIOCHEM J, V361, P557, DOI 10.1042/0264-6021:3610557; Ren J, 2000, STRUCTURE, V8, P1089, DOI 10.1016/S0969-2126(00)00513-X; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; Sevilya Z, 2001, J MOL BIOL, V311, P957, DOI 10.1006/jmbi.2001.4904; SHALKA AM, 1993, REVERSE TRANSCRIPTAS; Sourgen F, 1996, EUR J BIOCHEM, V240, P765, DOI 10.1111/j.1432-1033.1996.0765h.x; Tasara T, 2001, FEBS LETT, V507, P39, DOI 10.1016/S0014-5793(01)02945-3; THANG KC, 2004, CURR TOP MED CHEM, V4, P965; VANGENT DC, 1993, NUCLEIC ACIDS RES, V21, P3373, DOI 10.1093/nar/21.15.3373; VASU N, 2002, REV MED VIROL, V12, P179; Wu XY, 1999, J VIROL, V73, P2126, DOI 10.1128/JVI.73.3.2126-2135.1999; Yang F, 2003, BIOCHEMISTRY-US, V42, P6249, DOI 10.1021/bi034177s; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; Yi JZ, 2002, J BIOL CHEM, V277, P12164, DOI 10.1074/jbc.M105072200; Yung E, 2001, NAT MED, V7, P920, DOI 10.1038/90959; Zhao L, 2003, BIOORG MED CHEM LETT, V13, P1175, DOI 10.1016/S0960-894X(03)00040-4	66	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21987	21996		10.1074/jbc.M414679200	http://dx.doi.org/10.1074/jbc.M414679200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15790559	hybrid			2022-12-27	WOS:000229557900041
J	Kim, IM; Ramakrishna, S; Gusarova, GA; Yoder, HM; Costa, RH; Kalinichenko, VV				Kim, IM; Ramakrishna, S; Gusarova, GA; Yoder, HM; Costa, RH; Kalinichenko, VV			The forkhead box M1 transcription factor is essential for embryonic development of pulmonary vasculature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG BRANCHING MORPHOGENESIS; DNA-BINDING-DOMAIN; GROWTH-FACTOR-BETA; MOUSE LUNG; CELL-DIFFERENTIATION; GENE-EXPRESSION; SONIC HEDGEHOG; LIVER-REGENERATION; MESENCHYMAL CELLS; FACTOR TRIDENT	Transgenic and gene knock-out studies demonstrated that the mouse Forkhead Box m1 (Foxm1 or Foxm1b) transcription factor (previously called HFH-11B, Trident, Win, or MPP2) is essential for hepatocyte entry into mitosis during liver development, regeneration, and liver cancer. Targeted deletion of Foxm1 gene in mice produces an embryonic lethal phenotype due to severe abnormalities in the development of liver and heart. In this study, we show for the first time that Foxm1(-/-) lungs exhibit severe hypertrophy of arteriolar smooth muscle cells and defects in the formation of peripheral pulmonary capillaries as evidenced by significant reduction in platelet endothelial cell adhesion molecule 1 staining of the distal lung. Consistent with these findings, significant reduction in proliferation of the embryonic Foxm1(-/-) lung mesenchyme was found, yet proliferation levels were normal in the Foxm1-deficient epithelial cells. Severe abnormalities of the lung vasculature in Foxm1(-/-) embryos were associated with diminished expression of the transforming growth factor beta receptor II, a disintegrin and metalloprotease domain 17 (ADAM-17), vascular endothelial growth factor receptors, Polo-like kinase 1, Aurora B kinase, laminin alpha 4 (Lama4), and the Forkhead Box f1 transcription factor. Cotransfection studies demonstrated that Foxm1 stimulates transcription of the Lama4 promoter, and this stimulation requires the Foxm1 binding sites located between -1174 and -1145 bp of the mouse Lama4 promoter. In summary, development of mouse lungs depends on the Foxm1 transcription factor, which regulates expression of genes essential for mesenchyme proliferation, extracellular matrix remodeling, and vasculogenesis.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Comm Dev Biol, Chicago, IL 60637 USA; Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Chicago; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kalinichenko, VV (corresponding author), Univ Chicago, Dept Math, 5841 S Maryland Ave,MC 6076, Chicago, IL 60637 USA.	vkalin@medicine.bsd.uchicago.edu		Kim, Il-man/0000-0002-9268-8337; Ramakrishna, Sneha/0000-0001-7445-3190	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054687] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 54687-06] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Bellusci S, 1996, DEVELOPMENT, V122, P1693; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; BREIER G, 1992, DEVELOPMENT, V114, P521; Brody SL, 2000, AM J RESP CELL MOL, V23, P45, DOI 10.1165/ajrcmb.23.1.4070; Calonge MJ, 2004, J BIOL CHEM, V279, P23759, DOI 10.1074/jbc.M402178200; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen JC, 1998, J CLIN INVEST, V102, P1077, DOI 10.1172/JCI4786; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; Drissi MH, 2003, J CELL BIOCHEM, V90, P1287, DOI 10.1002/jcb.10677; Evans PC, 2001, TRANSPLANTATION, V71, P457, DOI 10.1097/00007890-200102150-00020; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Getsios S, 1998, J REPROD FERTIL, V114, P357; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Golan T, 2004, J BIOL CHEM, V279, P14879, DOI 10.1074/jbc.M306421200; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; KAESTNER KH, 1993, P NATL ACAD SCI USA, V90, P7628, DOI 10.1073/pnas.90.16.7628; Kalinichenko VV, 2004, AM J PHYSIOL-LUNG C, V286, pL521, DOI 10.1152/ajplung.00212.2003; Kalinichenko VV, 2003, J BIOL CHEM, V278, P37888, DOI 10.1074/jbc.M305555200; Kalinichenko VV, 2003, HEPATOLOGY, V37, P107, DOI 10.1053/jhep.2003.50005; Kalinichenko VV, 2002, J BIOL CHEM, V277, P12369, DOI 10.1074/jbc.M112162200; Kalinichenko VV, 2002, AM J PHYSIOL-LUNG C, V282, pL1253, DOI 10.1152/ajplung.00463.2001; Kalinichenko VV, 2001, DEV BIOL, V235, P489, DOI 10.1006/dbio.2001.0322; Kalinichenko VV, 2001, AM J PHYSIOL-LUNG C, V280, pL695, DOI 10.1152/ajplung.2001.280.4.L695; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kawabata M, 1999, ANN NY ACAD SCI, V886, P73, DOI 10.1111/j.1749-6632.1999.tb09402.x; Korver W, 1998, CURR BIOL, V8, P1327, DOI 10.1016/S0960-9822(07)00563-5; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Krupczak-Hollis K, 2004, DEV BIOL, V276, P74, DOI 10.1016/j.ydbio.2004.08.022; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Lu Min Min, 2002, Gene Expression Patterns, V2, P223, DOI 10.1016/S1567-133X(02)00058-3; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Mahlapuu M, 2001, DEVELOPMENT, V128, P2397; Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; Mullberg J, 2000, EUR CYTOKINE NETW, V11, P27; Muller WA, 1999, J LEUKOCYTE BIOL, V66, P698, DOI 10.1002/jlb.66.5.698; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Ohmichi H, 1998, DEVELOPMENT, V125, P1315; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; Peterson RS, 1997, MECH DEVELOP, V69, P53, DOI 10.1016/S0925-4773(97)00153-6; Rausa FM, 2000, MOL CELL BIOL, V20, P8264, DOI 10.1128/MCB.20.21.8264-8282.2000; Rausa FM, 2003, MOL CELL BIOL, V23, P437, DOI 10.1128/MCB.23.2.437-449.2003; Relan NK, 1999, J CELL BIOL, V147, P1341, DOI 10.1083/jcb.147.6.1341; Reynolds PR, 2004, J BIOL CHEM, V279, P37124, DOI 10.1074/jbc.M405254200; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Samadani U, 1996, GENE EXPRESSION, V6, P23; Samadani U, 1996, MOL CELL BIOL, V16, P6273; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shannon JM, 2004, ANNU REV PHYSIOL, V66, P625, DOI 10.1146/annurev.physiol.66.032102.135749; Shu WG, 2001, J BIOL CHEM, V276, P27488, DOI 10.1074/jbc.M100636200; Shu WG, 2002, DEVELOPMENT, V129, P4831; Tan YJ, 2001, GENE EXPRESSION, V9, P237, DOI 10.3727/000000001783992542; Thyboll J, 2002, MOL CELL BIOL, V22, P1194, DOI 10.1128/MCB.22.4.1194-1202.2002; Tichelaar JW, 2000, J BIOL CHEM, V275, P11858, DOI 10.1074/jbc.275.16.11858; Wan HJ, 2004, DEVELOPMENT, V131, P953, DOI 10.1242/dev.00966; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; Weaver M, 1999, DEVELOPMENT, V126, P4005; Wells NJ, 1999, J CELL SCI, V112, P3361; Whitsett JA, 1999, AM J RESP CELL MOL, V21, P153, DOI 10.1165/ajrcmb.21.2.f159; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zeng X, 1998, DEV DYNAM, V211, P215, DOI 10.1002/(SICI)1097-0177(199803)211:3<215::AID-AJA3>3.0.CO;2-K; Zhao JS, 1998, MECH DEVELOP, V72, P89, DOI 10.1016/S0925-4773(98)00019-7; Zhao JS, 1998, DEV BIOL, V194, P182, DOI 10.1006/dbio.1997.8825; Zhao JS, 2001, DEV BIOL, V232, P204, DOI 10.1006/dbio.2001.0176; Zhao JS, 1996, DEV BIOL, V180, P242, DOI 10.1006/dbio.1996.0298	79	124	132	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22278	22286		10.1074/jbc.M500936200	http://dx.doi.org/10.1074/jbc.M500936200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817462	hybrid			2022-12-27	WOS:000229557900073
J	Bubikat, A; De Windt, LJ; Zetsche, B; Fabritz, L; Sickler, H; Eckardt, D; Godecke, A; Baba, HA; Kuhn, M				Bubikat, A; De Windt, LJ; Zetsche, B; Fabritz, L; Sickler, H; Eckardt, D; Godecke, A; Baba, HA; Kuhn, M			Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLYL CYCLASE-A; ACTIVATED PROTEIN-KINASES; ANGIOTENSIN-II; CALCINEURIN-NFAT; GENE-EXPRESSION; RECEPTOR; LACKING; FIBROBLASTS; MYOCYTES; INHIBIT	The crucial functions of atrial natriuretic peptide (ANP) and endothelial nitric oxide/NO in the regulation of arterial blood pressure have been emphasized by the hypertensive phenotype of mice with systemic inactivation of either the guanylyl cyclase-A receptor for ANP (GC-A-/-) or endothelial nitric-oxide synthase (eNOS-/-). Intriguingly, similar levels of arterial hypertension are accompanied by marked cardiac hypertrophy in GC-A-/-, but not in eNOS-/-, mice, suggesting that changes in local pathways regulating cardiac growth accelerate cardiac hypertrophy in the former and protect the heart of the latter. Our recent observations in mice with conditional, cardiomyocyte-restricted GC-A deletion demonstrated that ANP locally inhibits cardiomyocyte growth. Abolition of these local, protective effects may enhance the cardiac hypertrophic response of GC-A-/- mice to persistent increases in hemodynamic load. Notably, eNOS-/- mice exhibit markedly increased cardiac ANP levels, suggesting that increased activation of cardiac GC-A can prevent hypertensive heart disease. To test this hypothesis, we generated mice with systemic inactivation of eNOS and cardiomyocyte-restricted deletion of GC-A by crossing eNOS-/- and cardiomyocyte-restricted GC-A-deficient mice. Cardiac deletion of GC-A did not affect arterial hypertension but significantly exacerbated cardiac hypertrophy and fibrosis in eNOS-/- mice. This was accompanied by marked cardiac activation of both the mitogen-activated protein kinase ( MAPK) ERK 1/2 and the phosphatase calcineurin. Our observations suggest that local ANP/GC-A/cyclic GMP signaling counter-regulates MAPK/ERK- and calcineurin/nuclear factor of activated T cells-dependent pathways of cardiac myocyte growth in hypertensive eNOS-/- mice.	Univ Wurzburg, Inst Physiol, D-97070 Wurzburg, Germany; Univ Klinikum Munster, Dept Pharmacol & Toxicol, D-48129 Munster, Germany; Univ Klinikum Munster, Dept Cardiol & Angiol, D-48129 Munster, Germany; Univ Klinikum Munster, Interdisciplinary Ctr Clin Res, D-48129 Munster, Germany; Royal Netherlands Acad Sci, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Royal Netherlands Acad Sci, Interuniv Cardiol Inst Netherlands, NL-3584 CT Utrecht, Netherlands; Univ Dusseldorf, Inst Herz & Kreislaufphysiol, D-40001 Dusseldorf, Germany; Univ Duisburg Essen, Inst Pathol, D-45147 Essen, Germany	University of Wurzburg; University of Munster; University of Munster; University of Munster; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Interuniversity Cardiology Institute of the Netherlands; Utrecht University; Heinrich Heine University Dusseldorf; University of Duisburg Essen	Kuhn, M (corresponding author), Univ Wurzburg, Inst Physiol, Rontgenring 9, D-97070 Wurzburg, Germany.	kuhn@mail.uni-wuerzburg.de	de Windt, Leon/AAO-6395-2020	de Windt, Leon/0000-0002-7793-2856; Fabritz, Larissa/0000-0002-9241-1733				Airhart N, 2003, J BIOL CHEM, V278, P38693, DOI 10.1074/jbc.M304098200; Balligand JL, 1997, ARTERIOSCL THROM VAS, V17, P1846, DOI 10.1161/01.ATV.17.10.1846; Barouch LA, 2002, NATURE, V416, P337, DOI 10.1038/416337a; Bueno OF, 2002, CIRC RES, V91, P776, DOI 10.1161/01.RES.0000038488.38975.1A; Calderone A, 1998, J CLIN INVEST, V101, P812, DOI 10.1172/JCI119883; de Bold AJ, 2001, CAN J PHYSIOL PHARM, V79, P705, DOI 10.1139/cjpp-79-8-705; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; Fiedler B, 2002, P NATL ACAD SCI USA, V99, P11363, DOI 10.1073/pnas.162100799; Friddle CJ, 2000, P NATL ACAD SCI USA, V97, P6745, DOI 10.1073/pnas.100127897; FUJISAKI H, 1995, J CLIN INVEST, V96, P1059, DOI 10.1172/JCI118092; Godecke A, 1998, CIRC RES, V82, P186; Gyurko R, 2000, AM J PHYSIOL-HEART C, V278, pH971, DOI 10.1152/ajpheart.2000.278.3.H971; Holtwick R, 2003, J CLIN INVEST, V111, P1399, DOI 10.1172/JCI200317061; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Ichinose F, 2004, AM J PHYSIOL-HEART C, V286, pH1070, DOI 10.1152/ajpheart.00940.2003; Ito T, 2003, CIRCULATION, V107, P807, DOI 10.1161/01.CIR.0000057794.29667.08; Kirchhefer U, 2001, J BIOL CHEM, V276, P4142, DOI 10.1074/jbc.M006443200; Kishimoto I, 2001, P NATL ACAD SCI USA, V98, P2703, DOI 10.1073/pnas.051625598; Knowles JW, 2001, J CLIN INVEST, V107, P975, DOI 10.1172/JCI11273; Kuhn M, 2003, CIRC RES, V93, P700, DOI 10.1161/01.RES.0000094745.28948.4D; Kuhn M, 2002, HEART, V87, P368, DOI 10.1136/heart.87.4.368; Li YH, 2002, CIRCULATION, V106, P1722, DOI 10.1161/01.CIR.0000029923.57048.61; Liang QR, 2003, J MOL CELL CARDIOL, V35, P1385, DOI 10.1016/j.yjmcc.2003.10.001; LOPEZ MJ, 1995, NATURE, V378, P65, DOI 10.1038/378065a0; Molkentin JD, 2004, CARDIOVASC RES, V63, P467, DOI 10.1016/j.cardiores.2004.01.021; Ritchie RH, 1998, AM J PHYSIOL-HEART C, V275, pH1370, DOI 10.1152/ajpheart.1998.275.4.H1370; Rosenkranz S, 2004, CARDIOVASC RES, V63, P423, DOI 10.1016/j.cardiores.2004.04.030; Sanna B, 2005, MOL CELL BIOL, V25, P865, DOI 10.1128/MCB.25.3.865-878.2005; Sharma GD, 2002, MOL CELL BIOCHEM, V233, P165, DOI 10.1023/A:1015882302796; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Sugimoto T, 1996, J BIOL CHEM, V271, P544, DOI 10.1074/jbc.271.1.544; Tamura N, 2000, P NATL ACAD SCI USA, V97, P4239, DOI 10.1073/pnas.070371497; van Rooij E, 2004, CIRC RES, V94, pE18, DOI 10.1161/01.RES.0000118597.54416.00; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027; Zolle O, 2000, J BIOL CHEM, V275, P25892, DOI 10.1074/jbc.M000786200; Zou YZ, 2001, CIRCULATION, V104, P97, DOI 10.1161/01.CIR.104.1.97	37	49	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21594	21599		10.1074/jbc.m501103200	http://dx.doi.org/10.1074/jbc.m501103200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15793309	hybrid			2022-12-27	WOS:000229438800083
J	Best, A; Handoko, L; Schluter, E; Goringer, HU				Best, A; Handoko, L; Schluter, E; Goringer, HU			In vitro synthesized small interfering RNAs elicit RNA interference in African trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; MESSENGER-RNA; GENETIC INTERFERENCE; HUMAN DICER; C-ELEGANS; CAENORHABDITIS-ELEGANS; MAMMALIAN-CELLS; DISTINCT ROLES; BRUCEI; DROSOPHILA	RNA interference (RNAi) describes an epigenetic gene silencing reaction by which gene-specific doublestranded RNA acts as a trigger to induce the ribonucleolytic degradation of homologous transcripts. RNAi in African trypanosomes has been shown to be involved in regulating the transcript abundance of retroposons, and the process currently represents the method of choice in gene function studies of the parasite. However, little is known concerning the mechanistic and structural aspects of the processing reaction. This is in part due to the absence of a trypanosome-specific RNAi in vitro system. Here we demonstrate that both the Dicer and the RNA-induced silencing complex steps of the RNAi reaction pathway can be monitored in vitro using cell-free trypanosome extracts. The two in vitro activities and the generated small interfering RNAs (siRNAs) are characterized by features known from other organisms, and we demonstrate that chemically as well as enzymatically synthesized siRNAs are functional in the parasite. Thus, the transfection of synthetic siRNAs can be used to rapidly monitor gene knockdown phenotypes in Trypanosoma brucei, which should be helpful in genome-wide, RNAi-based screening experiments.	Tech Univ Darmstadt, Dept Genet & Microbiol, D-64287 Darmstadt, Germany	Technical University of Darmstadt	Goringer, HU (corresponding author), Tech Univ Darmstadt, Dept Genet & Microbiol, Schnittspahnstr 10, D-64287 Darmstadt, Germany.	goringer@hrzpub.tu-darmstadt.de	Handoko, Lusy/C-3645-2017	Handoko, Lusy/0000-0001-7989-4243				Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Blaszczyk J, 2001, STRUCTURE, V9, P1225, DOI 10.1016/S0969-2126(01)00685-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUN R, 1979, ACTA TROP, V36, P289; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; DaRocha WD, 2004, MOL BIOCHEM PARASIT, V133, P175, DOI 10.1016/j.molbiopara.2003.10.005; Djikeng A, 2001, RNA, V7, P1522; Durand-Dubief M, 2003, BMC BIOL, V1, DOI 10.1186/1741-7007-1-2; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Liang XH, 2003, P NATL ACAD SCI USA, V100, P7521, DOI 10.1073/pnas.1332001100; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Martens H, 2002, MOL BIOL CELL, V13, P445, DOI 10.1091/mbc.01-04-0211; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Motyka SA, 2004, CURR OPIN MICROBIOL, V7, P362, DOI 10.1016/j.mib.2004.06.004; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Nicholson Allen W., 2003, P149; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Robinson KA, 2003, MOL BIOCHEM PARASIT, V128, P217, DOI 10.1016/S0166-6851(03)00079-3; Schwarz DS, 2004, CURR BIOL, V14, P787, DOI 10.1016/j.cub.2004.03.008; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; Shi HF, 2004, EUKARYOT CELL, V3, P1445, DOI 10.1128/EC.3.6.1445-1453.2004; Shi HF, 2004, MOL CELL BIOL, V24, P420, DOI 10.1128/MCB.24.1.420-427.2004; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Terskikh A, 2000, SCIENCE, V290, P1585, DOI 10.1126/science.290.5496.1585; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Tomari Y, 2004, CELL, V116, P831, DOI 10.1016/S0092-8674(04)00218-1; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Ullu E, 2004, CELL MICROBIOL, V6, P509, DOI 10.1111/j.1462-5822.2004.00399.x; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168; Wheeler DB, 2004, NAT METHODS, V1, P127, DOI 10.1038/NMETH711; Wirtz E, 1998, NUCLEIC ACIDS RES, V26, P4626, DOI 10.1093/nar/26.20.4626; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zhang HD, 2004, CELL, V118, P57, DOI 10.1016/j.cell.2004.06.017; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582	60	11	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20573	20579		10.1074/jbc.M414534200	http://dx.doi.org/10.1074/jbc.M414534200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781462	hybrid			2022-12-27	WOS:000229242000052
J	Zhang, Y; Baranov, PV; Atkins, JF; Gladyshev, VN				Zhang, Y; Baranov, PV; Atkins, JF; Gladyshev, VN			Pyrrolysine and selenocysteine use dissimilar decoding strategies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMATE DEHYDROGENASE H; GENETIC-CODE; ESCHERICHIA-COLI; TRANSFER-RNA; TRANSLATIONAL TERMINATION; SELENOPROTEIN SYNTHESIS; RELEASE FACTOR; STOP CODON; CRYSTAL-STRUCTURE; MESSENGER-RNA	Selenocysteine (Sec) and pyrrolysine (Pyl) are known as the 21st and 22nd amino acids in protein. Both are encoded by codons that normally function as stop signals. Sec specification by UGA codons requires the presence of a cis-acting selenocysteine insertion sequence ( SECIS) element. Similarly, it is thought that Pyl is inserted by UAG codons with the help of a putative pyrrolysine insertion sequence (PYLIS) element. Herein, we analyzed the occurrence of Pyl-utilizing organisms, Pyl-associated genes, and Pyl-containing proteins. The Pyl trait is restricted to several microbes, and only one organism has both Pyl and Sec. We found that methanogenic archaea that utilize Pyl have few genes that contain in-frame UAG codons, and many of these are followed with nearby UAA or UGA codons. In addition, unambiguous UAG stop signals could not be identified. This bias was not observed in Sec-utilizing organisms and non-Pyl-utilizing archaea, as well as with other stop codons. These observations as well as analyses of the coding potential of UAG codons, overlapping genes, and release factor sequences suggest that UAG is not a typical stop signal in Pyl-utilizing archaea. On the other hand, searches for conserved Pyl-containing proteins revealed only four protein families, including methylamine methyltransferases and transposases. Only methylamine methyltransferases matched the Pyl trait and had conserved Pyl, suggesting that this amino acid is used primarily by these enzymes. These findings are best explained by a model wherein UAG codons may have ambiguous meaning and Pyl insertion can effectively compete with translation termination for UAG codons obviating the need for a specific PYLIS structure. Thus, Sec and Pyl follow dissimilar decoding and evolutionary strategies.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA; Natl Univ Ireland Univ Coll Cork, Biosci Inst, Cork, Ireland	University of Nebraska System; University of Nebraska Lincoln; Utah System of Higher Education; University of Utah; University College Cork	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	vgladyshev1@unl.edu	Baranov, Pavel/A-2782-2011; Gladyshev, Vadim N/A-9894-2013; Gladyshev, Vadim N/J-6187-2013	Baranov, Pavel/0000-0001-9017-0270; Atkins, John/0000-0001-7933-0165; Gladyshev, Vadim/0000-0002-0372-7016	NIGMS NIH HHS [GM061603, GM48152] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061603, R01GM048152] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Atkins JF, 2002, SCIENCE, V296, P1409, DOI 10.1126/science.1073339; Barrett G.C, 1999, AMINO ACID DERIVATIV; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; Bjornsson A, 1996, EMBO J, V15, P1696, DOI 10.1002/j.1460-2075.1996.tb00515.x; Blight SK, 2004, NATURE, V431, P333, DOI 10.1038/nature02895; Bock A, 2000, Biofactors, V11, P77; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BOCK A, 1991, TRENDS BIOCHEM SCI, V16, P463, DOI 10.1016/0968-0004(91)90180-4; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; Buczek O, 2005, J BIOL CHEM, V280, P4247, DOI 10.1074/jbc.M405835200; Carlson BA, 2002, METHOD ENZYMOL, V347, P24; Castellano S, 2004, EMBO REP, V5, P71, DOI 10.1038/sj.embor.7400036; Commans S, 1999, FEMS MICROBIOL REV, V23, P335, DOI 10.1111/j.1574-6976.1999.tb00403.x; Copeland PR, 2000, EMBO J, V19, P306, DOI 10.1093/emboj/19.2.306; Copeland PR, 2001, MOL CELL BIOL, V21, P1491, DOI 10.1128/MCB.21.5.1491-1498.2001; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; EHRENREICH A, 1992, EUR J BIOCHEM, V206, P767, DOI 10.1111/j.1432-1033.1992.tb16983.x; Fenske C, 2003, ANGEW CHEM INT EDIT, V42, P606, DOI 10.1002/anie.200390174; Fourmy D, 2002, J MOL BIOL, V324, P137, DOI 10.1016/S0022-2836(02)01030-6; Frolova L, 2002, RNA, V8, P129, DOI 10.1017/S1355838202013262; Fukuda Y, 2003, GENE, V323, P181, DOI 10.1016/j.gene.2003.09.021; Goodchild A, 2004, MOL MICROBIOL, V53, P309, DOI 10.1111/j.1365-2958.2004.04130.x; Hao B, 2002, SCIENCE, V296, P1462, DOI 10.1126/science.1069556; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; HOFACKER IL, 1994, MONATSH CHEM, V125, P167, DOI 10.1007/BF00818163; Ibba M, 2004, GENE DEV, V18, P731, DOI 10.1101/gad.1187404; Ibba M, 2002, CURR BIOL, V12, pR464, DOI 10.1016/S0960-9822(02)00947-8; Inagaki Y, 2001, NUCLEIC ACIDS RES, V29, P921, DOI 10.1093/nar/29.4.921; Kervestin S, 2001, EMBO REP, V2, P680, DOI 10.1093/embo-reports/kve156; Khangulov SV, 1998, BIOCHEMISTRY-US, V37, P3518, DOI 10.1021/bi972177k; Kisselev LL, 2000, TRENDS BIOCHEM SCI, V25, P561, DOI 10.1016/S0968-0004(00)01669-8; Knight RD, 2000, CELL, V101, P569, DOI 10.1016/S0092-8674(00)80866-1; Knight RD, 2001, NAT REV GENET, V2, P49, DOI 10.1038/35047500; Kryukov GV, 2004, EMBO REP, V5, P538, DOI 10.1038/sj.embor.7400126; Kryukov GV, 1999, J BIOL CHEM, V274, P33888, DOI 10.1074/jbc.274.48.33888; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Krzycki JA, 2004, CURR OPIN CHEM BIOL, V8, P484, DOI 10.1016/j.cbpa.2004.08.012; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; Lozupone CA, 2001, CURR BIOL, V11, P65, DOI 10.1016/S0960-9822(01)00028-8; Medzihradszky KF, 2004, MOL CELL PROTEOMICS, V3, P429, DOI 10.1074/mcp.M300140-MCP200; Mottagui-Tabar S, 1998, GENE, V212, P189, DOI 10.1016/S0378-1119(98)00176-0; Nakamura Y, 2000, CELL, V101, P349, DOI 10.1016/S0092-8674(00)80845-4; Namy O, 2004, MOL CELL, V13, P157, DOI 10.1016/S1097-2765(04)00031-0; OSAWA S, 1992, MICROBIOL REV, V56, P229, DOI 10.1128/MMBR.56.1.229-264.1992; OW SC, 1996, TRENDS BIOCHEM SCI, V21, P203; Pezo V, 2004, P NATL ACAD SCI USA, V101, P8593, DOI 10.1073/pnas.0402893101; Polycarpo C, 2004, P NATL ACAD SCI USA, V101, P12450, DOI 10.1073/pnas.0405362101; Polycarpo C, 2003, MOL CELL, V12, P287, DOI 10.1016/S1097-2765(03)00280-6; Poole E, 2000, BBA-GENE STRUCT EXPR, V1493, P1, DOI 10.1016/S0167-4781(00)00162-7; Poole ES, 1997, RNA, V3, P974; Poole ES, 1998, NUCLEIC ACIDS RES, V26, P954, DOI 10.1093/nar/26.4.954; Rogozin IB, 2002, TRENDS GENET, V18, P228, DOI 10.1016/S0168-9525(02)02649-5; Rother M, 2001, BIOFACTORS, V14, P75, DOI 10.1002/biof.5520140111; Santos MAS, 2004, TRENDS GENET, V20, P95, DOI 10.1016/j.tig.2003.12.009; Santos MAS, 1997, MOL MICROBIOL, V26, P423, DOI 10.1046/j.1365-2958.1997.5891961.x; Schimmel P, 2004, NATURE, V431, P257, DOI 10.1038/431257a; Silva Raquel M., 2004, Briefings in Functional Genomics & Proteomics, V3, P35, DOI 10.1093/bfgp/3.1.35; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; Srinivasan G, 2002, SCIENCE, V296, P1459, DOI 10.1126/science.1069588; Tate WP, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1342; Thanbichler M, 2002, METHOD ENZYMOL, V347, P3; Thanbichler M, 2001, BIOFACTORS, V14, P53, DOI 10.1002/biof.5520140108; Theobald-Dietrich A, 2004, NUCLEIC ACIDS RES, V32, P1091, DOI 10.1093/nar/gkh266; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tormay P, 1996, MOL MICROBIOL, V21, P1253, DOI 10.1046/j.1365-2958.1996.881450.x; TOURANCHEAU AB, 1995, EMBO J, V14, P3262, DOI 10.1002/j.1460-2075.1995.tb07329.x; VERES Z, 1994, J BIOL CHEM, V269, P10597	68	82	88	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20740	20751		10.1074/jbc.M501458200	http://dx.doi.org/10.1074/jbc.M501458200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788401	Green Published, hybrid			2022-12-27	WOS:000229242000072
J	Batsche, E; Desroches, J; Bilodeau, S; Gauthier, Y; Drouin, J				Batsche, E; Desroches, J; Bilodeau, S; Gauthier, Y; Drouin, J			Rb enhances p160/SRC coactivator-dependent activity of nuclear receptors and hormone responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; GLUCOCORTICOID-RECEPTOR; TRANSCRIPTIONAL REPRESSION; ADIPOCYTE DIFFERENTIATION; MEDIATES TRANSACTIVATION; ACTIVATION FUNCTIONS; GROWTH SUPPRESSION; SUBFAMILY	The retinoblastoma tumor suppressor protein (Rb) is best known as a repressor of genes involved in cell cycle progression. Rb has also been implicated in activation of transcription, in particular by nuclear receptors (NRs) and by differentiation-related transcription factors, but the relevance of this activity is unclear. We show that Rb and the related proteins p107 and p130 enhance the activity of NRs related to NGFI-B (Nur factors) through direct interactions with NGFI-B and SRC-2. Although recruitment of SRC/p160 coactivators to the NGFI-BAF1 domain is independent of Rb, its presence enhances SRC-dependent transcription. Rb potentiation of SRC coactivators is exerted on a subset ( Nur factors, hepatocyte nuclear factor-4 (HNF-4), SF-1, and ER) but not all NRs. The levels of Rb-related proteins modulate hormone responsiveness of the NGFI-B-dependent pituitary proopiomelanocortin gene and HNF-4-dependent transcription during enterocyte differentiation. Increased Rb expression upon cell differentiation may promote differentiated functions, at least in part, by potentiation of NR activity.	Inst Rech Clin Montreal, Mol Genet Lab, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Drouin, J (corresponding author), Inst Rech Clin Montreal, Mol Genet Lab, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada.	jacques.drouin@ircm.qc.ca		Batsche, Eric/0000-0002-5145-5270; Bilodeau, Steve/0000-0002-9799-3832; Drouin, Jacques/0000-0001-8226-5691				Abbondanza C, 2000, P NATL ACAD SCI USA, V97, P3130, DOI 10.1073/pnas.050015697; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BATSCHE E, 2005, J BIOL CHEM; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chang KH, 1997, P NATL ACAD SCI USA, V94, P9040, DOI 10.1073/pnas.94.17.9040; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Chen SL, 2000, GENE DEV, V14, P1209; COPPOLA JA, 1990, ONCOGENE, V5, P1731; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Frost SJ, 1999, MOL ENDOCRINOL, V13, P1801, DOI 10.1210/me.13.11.1801; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAMEL PA, 1992, ONCOGENE, V7, P693; Hinton DR, 1998, CANCER LETT, V126, P209, DOI 10.1016/S0304-3835(98)00013-5; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Lu JM, 1998, J BIOL CHEM, V273, P31528, DOI 10.1074/jbc.273.47.31528; Maira M, 2003, MOL CELL BIOL, V23, P763, DOI 10.1128/MCB.23.3.763-776.2003; Maira M, 1999, MOL CELL BIOL, V19, P7549; Martens C, 2005, MOL ENDOCRINOL, V19, P885, DOI 10.1210/me.2004-0333; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Murphy EP, 1997, MOL ENDOCRINOL, V11, P39, DOI 10.1210/me.11.1.39; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Noe V, 1998, ONCOGENE, V16, P1931, DOI 10.1038/sj.onc.1201718; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Poulin G, 1997, MOL CELL BIOL, V17, P6673, DOI 10.1128/MCB.17.11.6673; Poulin G, 2000, MOL CELL BIOL, V20, P4826, DOI 10.1128/MCB.20.13.4826-4837.2000; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shao ZH, 1997, ONCOGENE, V15, P385, DOI 10.1038/sj.onc.1201204; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; Sterner JM, 1996, CELL GROWTH DIFFER, V7, P53; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032	43	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19746	19756		10.1074/jbc.M413428200	http://dx.doi.org/10.1074/jbc.M413428200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15767262	hybrid			2022-12-27	WOS:000229113700041
J	Braglia, P; Percudani, R; Dieci, G				Braglia, P; Percudani, R; Dieci, G			Sequence context effects on oligo(dT) termination signal recognition by Saccharomyces cerevisiae RNA polymerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION TERMINATION; LA PROTEIN; NUCLEOTIDE-SEQUENCES; CLEAVAGE ACTIVITY; ESCHERICHIA-COLI; CHAIN ELONGATION; 5S-RNA GENES; YEAST; SUBUNIT; NUCLEAR	Eukaryotic RNA polymerase (Pol) III terminates transcription at short runs of T residues in the coding DNA strand. By genomic analysis, we found that T-5 and T-4 are the shortest Pol III termination signals in yeasts and mammals, respectively, and that, at variance with yeast, oligo(dT) terminators longer than T-5 are very rare in mammals. In Saccharomyces cerevisiae, the strength of T-5 as a terminator was found to be largely influenced by both the upstream and the downstream sequence context. In particular, the CT sequence, which is naturally present downstream of T-5 in the 3'-flank of some tDNAs, was found to act as a terminator-weakening element that facilitates translocation by reducing Pol III pausing at T-5. In contrast, tDNA transcription termination was highly efficient when T-5 was followed by an A or G residue. Surprisingly, however, when a termination-proficient T-5 signal was taken out from the tDNA context and placed downstream of a fragment of the SCR1 gene, its termination activity was compromised, both in vitro and in vivo. Even the T-6 sequence, acting as a strong terminator in tRNA gene contexts, was unexpectedly weak within the SNR52 transcription unit, where it naturally occurs. The observed sequence context effects reflect intrinsic recognition properties of Pol III, because they were still observed in a simplified in vitro transcription system only consisting of purified RNA polymerase and template DNA. Our findings strengthen the notion that termination signal recognition by Pol III is influenced in a complex way by the region surrounding the T cluster and suggest that read-through transcription beyond T clusters might play a significant role in the biogenesis of class III gene products.	Univ Parma, Dipartmento Biochim & Biol Mol, I-43100 Parma, Italy	University of Parma	Dieci, G (corresponding author), Univ Parma, Dipartmento Biochim & Biol Mol, Parco Area Sci 23A, I-43100 Parma, Italy.	giorgio.dieci@unipr.it	percudani, riccardo/B-4872-2011; Dieci, Giorgio/B-3434-2012	percudani, riccardo/0000-0001-8452-1062; Dieci, Giorgio/0000-0002-8792-3961; Braglia, Priscilla/0000-0003-3470-0876				ALLISON DS, 1985, EMBO J, V4, P2657, DOI 10.1002/j.1460-2075.1985.tb03984.x; BAKER RE, 1982, EMBO J, V1, P291, DOI 10.1002/j.1460-2075.1982.tb01162.x; BARDELEBEN C, 1994, J MOL BIOL, V235, P1193, DOI 10.1006/jmbi.1994.1073; Bobkova EV, 1997, J BIOL CHEM, V272, P22832, DOI 10.1074/jbc.272.36.22832; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P2746; CAMIER S, 1985, EMBO J, V4, P491, DOI 10.1002/j.1460-2075.1985.tb03655.x; CAMPBELL FE, 1992, MOL CELL BIOL, V12, P2260, DOI 10.1128/MCB.12.5.2260; Chakshusmathi G, 2003, EMBO J, V22, P6562, DOI 10.1093/emboj/cdg625; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; COZZARELLI NR, 1983, CELL, V34, P829, DOI 10.1016/0092-8674(83)90540-8; Dieci G, 2000, J MOL BIOL, V299, P601, DOI 10.1006/jmbi.2000.3783; Dieci G, 1996, CELL, V84, P245, DOI 10.1016/S0092-8674(00)80979-4; Dieci G, 2003, TRENDS BIOCHEM SCI, V28, P202, DOI 10.1016/S0968-0004(03)00054-9; Dieci G, 2002, J BIOL CHEM, V277, P6903, DOI 10.1074/jbc.M105036200; EMERSON BM, 1984, J BIOL CHEM, V259, P7926; Ferrari R, 2004, P NATL ACAD SCI USA, V101, P13442, DOI 10.1073/pnas.0403851101; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; Giuliodori S, 2003, J MOL BIOL, V333, P1, DOI 10.1016/j.jmb.2003.08.016; Guffanti E, 2004, J BIOL CHEM, V279, P20708, DOI 10.1074/jbc.M311295200; GUNNERY S, 1995, MOL CELL BIOL, V15, P3597; Gunnery S, 1999, J MOL BIOL, V286, P745, DOI 10.1006/jmbi.1998.2518; Hamada M, 2000, J BIOL CHEM, V275, P29076, DOI 10.1074/jbc.M003980200; Harismendy O, 2003, EMBO J, V22, P4738, DOI 10.1093/emboj/cdg466; HESS J, 1985, J MOL BIOL, V184, P7, DOI 10.1016/0022-2836(85)90039-7; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Holmes SF, 2003, J BIOL CHEM, V278, P35597, DOI 10.1074/jbc.M304496200; Huang Y, 2005, MOL CELL BIOL, V25, P621, DOI 10.1128/MCB.25.2.621-636.2005; Huet J, 1996, METHOD ENZYMOL, V273, P249; Intine RV, 2002, MOL CELL, V9, P1113, DOI 10.1016/S1097-2765(02)00533-6; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; KLEMENZ R, 1982, P NATL ACAD SCI-BIOL, V79, P6191, DOI 10.1073/pnas.79.20.6191; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; MAO JI, 1980, CELL, V21, P509, DOI 10.1016/0092-8674(80)90488-2; Maraia RJ, 2002, GENE EXPRESSION, V10, P41; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MATTHEWS CK, 1972, J BIOL CHEM, V247, P7430; MAZABRAUD A, 1987, J MOL BIOL, V195, P835, DOI 10.1016/0022-2836(87)90488-8; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; Moqtaderi Z, 2004, MOL CELL BIOL, V24, P4118, DOI 10.1128/MCB.24.10.4118-4127.2004; Nedialkov YA, 2003, J BIOL CHEM, V278, P18303, DOI 10.1074/jbc.M301103200; Nudler E, 2002, GENES CELLS, V7, P755, DOI 10.1046/j.1365-2443.2002.00563.x; Palangat M, 2004, J MOL BIOL, V341, P429, DOI 10.1016/j.jmb.2004.06.009; Percudani R, 1997, J MOL BIOL, V268, P322, DOI 10.1006/jmbi.1997.0942; Prescott EM, 2004, P NATL ACAD SCI USA, V101, P6068, DOI 10.1073/pnas.0401393101; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; Roberts DN, 2003, P NATL ACAD SCI USA, V100, P14695, DOI 10.1073/pnas.2435566100; SCHMIDT O, 1980, NATURE, V287, P750, DOI 10.1038/287750a0; Shaaban SA, 1996, MOL CELL BIOL, V16, P6468; Stajich JE, 2002, GENOME RES, V12, P1611, DOI 10.1101/gr.361602; Thuillier V, 1996, EMBO J, V15, P618, DOI 10.1002/j.1460-2075.1996.tb00394.x; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; Wang ZX, 2000, EMBO J, V19, P6823, DOI 10.1093/emboj/19.24.6823; WISE JA, 1991, METHOD ENZYMOL, V194, P405; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; Yarnell WS, 1999, SCIENCE, V284, P611, DOI 10.1126/science.284.5414.611	58	81	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19551	19562		10.1074/jbc.M412238200	http://dx.doi.org/10.1074/jbc.M412238200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15788403	hybrid			2022-12-27	WOS:000229113700017
J	Kim, KT; Choi, HH; Steinmetz, MO; Maco, B; Kammerer, RA; Ahn, SY; Kim, HZ; Lee, GM; Koh, GY				Kim, KT; Choi, HH; Steinmetz, MO; Maco, B; Kammerer, RA; Ahn, SY; Kim, HZ; Lee, GM; Koh, GY			Oligomerization and multimerization are critical for angiopoietin-1 to bind and phosphorylate Tie2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; RECEPTOR; LIGAND; EXPRESSION; GROWTH; MICE; CAVEOLAE	Angiopoietin-1 (Ang1) is an essential molecule for blood vessel formation; however, little is known about the structure-function relationships of Ang1 with its receptor, Tie2 ( tyrosine kinase with immunoglobulin and epidermal growth factor homology domain-2'). In this study, we generated several Ang1 and angiopoietin-2 (Ang2) variants to define the role of the superclustering and oligomerization domains of the Ang1 protein. Then we analyzed the molecular structure of the variants with SDS-PAGE and rotary metal-shadowing transmission electron microscopy (RMSTEM) and determined the effects of these variants on the binding and activation of Tie2. Ang1 exists as heterogeneous multimers with basic trimeric, tetrameric, and pentameric oligomers, whereas Ang2 exists as trimeric, tetrameric, and pentameric oligomers. The variant Ang1C265S, consisting of trimers, tetramers, and pentamers without multimeric forms of Ang1, yielded less Tie2 activation than did Ang1, whereas monomeric Ang1 (Ang1/FD), dimeric Ang1 variants (Ang1D2, and Ang1D3), and dimeric and trimeric Ang1 variant (Ang1D1) dramatically lost their ability to bind and activate Tie2. An Ang1 protein in which two cysteines ( amino acids 41 and 54) were replaced with serines (Ang1C41S/C54S) formed mostly dimers and trimers that were not able to bind and activate Tie2. In addition, improper creation of a new cysteine in Ang2 (Ang2S263C) dramatically induced Ang2 aggregation without activating Tie2. In conclusion, proper oligomerization of Ang1 having at least four sub-units by the intermolecular disulfide linkage involving cysteines 41 and 54 is critical for Tie2 binding and activation. Thus, our data shed a light on the structure-function relationships of Ang1 with Tie2.	Korea Adv Inst Sci & Technol, Ctr Biomed Res, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Dept Sci Biol, Taejon 305701, South Korea; Paul Scherrer Inst, CH-5232 Villigen, Switzerland; Univ Basel, ME Muller Inst, Biozentrum, CH-4056 Basel, Switzerland; Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Sch Biol Sci, Manchester M13 9PT, Lancs, England	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST); Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; University of Basel; University of Manchester	Koh, GY (corresponding author), Korea Adv Inst Sci & Technol, Ctr Biomed Res, 373-1,Guseong-Dong, Taejon 305701, South Korea.	gykoh@kaist.ac.kr	Steinmetz, Michel O/AAA-3349-2022; Koh, Gou Young/C-1615-2011; Lee, Gyun Min/C-2020-2011	Steinmetz, Michel O/0000-0001-6157-3687; Maco, Bohumil/0000-0001-8444-313X; Kammerer, Richard/0000-0003-4570-5197				Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chae JK, 2000, ARTERIOSCL THROM VAS, V20, P2573, DOI 10.1161/01.ATV.20.12.2573; Cho CH, 2004, P NATL ACAD SCI USA, V101, P5547, DOI 10.1073/pnas.0307574101; Dallabrida SM, 2003, BIOCHEM BIOPH RES CO, V311, P563, DOI 10.1016/j.bbrc.2003.10.007; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Davis S, 2003, NAT STRUCT BIOL, V10, P38, DOI 10.1038/nsb880; Fiedler U, 2004, BLOOD, V103, P4150, DOI 10.1182/blood-2003-10-3685; FOWLER WE, 1983, J ULTRA MOL STRUCT R, V83, P319, DOI 10.1016/S0022-5320(83)90139-9; Ge HF, 2004, J LIPID RES, V45, P2071, DOI 10.1194/jlr.M400138-JLR200; Hori S, 2004, J NEUROCHEM, V89, P503, DOI 10.1111/j.1471-4159.2004.02343.x; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; Kim I, 2000, J BIOL CHEM, V275, P18550, DOI 10.1074/jbc.M910084199; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim I, 2001, CARDIOVASC RES, V49, P872, DOI 10.1016/S0008-6363(00)00295-9; Kim I, 2001, CIRC RES, V89, P477, DOI 10.1161/hh1801.097034; Kwak HJ, 2000, CIRCULATION, V101, P2317, DOI 10.1161/01.CIR.101.19.2317; Lee HJ, 2004, FASEB J, V18, P1200, DOI 10.1096/fj.03-1466com; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Parton RG, 2003, NAT REV MOL CELL BIO, V4, P162, DOI 10.1038/nrm1017; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Teichert-Kuliszewska K, 2001, CARDIOVASC RES, V49, P659, DOI 10.1016/S0008-6363(00)00231-5; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; Ward NL, 2004, BIOCHEM BIOPH RES CO, V323, P937, DOI 10.1016/j.bbrc.2004.08.185; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yla-Herttuala S, 2003, NAT MED, V9, P694, DOI 10.1038/nm0603-694; Yoon M, 2003, BIOCHEM BIOPH RES CO, V308, P101, DOI 10.1016/S0006-291X(03)01341-X	32	121	128	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20126	20131		10.1074/jbc.M500292200	http://dx.doi.org/10.1074/jbc.M500292200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769741	hybrid, Green Published			2022-12-27	WOS:000229113700084
J	Singh, SV; Srivastava, SK; Choi, S; Lew, KL; Antosiewicz, J; Xiao, D; Zeng, Y; Watkins, SC; Johnson, CS; Trump, DL; Lee, YJ; Xiao, H; Herman-Antosiewicz, A				Singh, SV; Srivastava, SK; Choi, S; Lew, KL; Antosiewicz, J; Xiao, D; Zeng, Y; Watkins, SC; Johnson, CS; Trump, DL; Lee, YJ; Xiao, H; Herman-Antosiewicz, A			Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; OXIDATIVE STRESS; CYCLE ARREST; ISOTHIOCYANATE SULFORAPHANE; CHEMOPREVENTIVE AGENT; MEDIATED APOPTOSIS; EPITHELIAL-CELLS; IN-VIVO; BROCCOLI; INDUCTION	We have shown previously that sulforaphane (SFN), a constituent of many edible cruciferous vegetables including broccoli, suppresses growth of prostate cancer cells in culture as well as in vivo by causing apoptosis, but the sequence of events leading to cell death is poorly defined. Using PC-3 and DU145 human prostate cancer cells as a model, we now demonstrate, for the first time, that the initial signal for SFN-induced apoptosis is derived from reactive oxygen species (ROS). Exposure of PC-3 cells to growth-suppressive concentrations of SFN resulted in ROS generation, which was accompanied by disruption of mitochondrial membrane potential, cytosolic release of cytochrome c, and apoptosis. All these effects were significantly blocked on pretreatment with N-acetylcysteine and overexpression of catalase. The SFN-induced ROS generation was significantly attenuated on pretreatment with mitochondrial respiratory chain complex I inhibitors, including diphenyleneiodonium chloride and rotenone. SFN treatment also caused a rapid and significant depletion of GSH levels. Collectively, these observations indicate that SFN-induced ROS generation is probably mediated by a nonmitochondrial mechanism involving GSH depletion as well as a mitochondrial component. Ectopic expression of Bcl-xL, but not Bcl-2, in PC-3 cells offered significant protection against the cell death caused by SFN. In addition, SFN treatment resulted in an increase in the level of Fas, activation of caspase-8, and cleavage of Bid. Furthermore, SV40-immortalized mouse embryonic fibroblasts (MEFs) derived from Bid knock-out mice displayed significant resistance toward SFN-induced apoptosis compared with wild-type MEFs. In conclusion, the results of the present study indicate that SFN-induced apoptosis in prostate cancer cells is initiated by ROS generation and that both intrinsic and extrinsic caspase cascades contribute to the cell death caused by this highly promising cancer chemopreventive agent.	Univ Pittsburgh, Inst Canc, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA; Roswell Pk Canc Inst, Buffalo, NY 14263 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Roswell Park Cancer Institute	Singh, SV (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Res Pavil Ste 2-32A,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	singhs@msx.upmc.edu	Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552; Herman-Antosiewicz, Anna/0000-0003-0526-2168	NCI NIH HHS [CA101753, CA076348] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101753, R01CA076348] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ambrosone CB, 2004, J NUTR, V134, P1134, DOI 10.1093/jn/134.5.1134; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barcelo S, 1996, CARCINOGENESIS, V17, P277, DOI 10.1093/carcin/17.2.277; Brooks JD, 2001, CANCER EPIDEM BIOMAR, V10, P949; Buccellato LJ, 2004, J BIOL CHEM, V279, P6753, DOI 10.1074/jbc.M310145200; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Choi S, 2005, CANCER RES, V65, P2035, DOI 10.1158/0008-5472.CAN-04-3616; Chung FL, 2000, CARCINOGENESIS, V21, P2287, DOI 10.1093/carcin/21.12.2287; Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61; Conaway CC, 2002, CURR DRUG METAB, V3, P233, DOI 10.2174/1389200023337496; Denning TL, 2002, FREE RADICAL BIO MED, V33, P1641, DOI 10.1016/S0891-5849(02)01141-3; Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367; Fahey JW, 2001, PHYTOCHEMISTRY, V56, P5, DOI 10.1016/S0031-9422(00)00316-2; Fahey JW, 2002, P NATL ACAD SCI USA, V99, P7610, DOI 10.1073/pnas.112203099; Fimognari C, 2002, CARCINOGENESIS, V23, P581, DOI 10.1093/carcin/23.4.581; Gamet-Payrastre L, 2000, CANCER RES, V60, P1426; Genova ML, 2004, ANN NY ACAD SCI, V1011, P86, DOI 10.1196/annals.1293.010; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hecht SS, 2000, DRUG METAB REV, V32, P395, DOI 10.1081/DMR-100102342; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Hu R, 2004, J PHARMACOL EXP THER, V310, P263, DOI 10.1124/jpet.103.064261; Jackson SJT, 2004, CARCINOGENESIS, V25, P219, DOI 10.1093/carcin/bgg192; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KOBLYAKOV V A, 1976, Biokhimiya, V41, P1497; KOLM RH, 1995, BIOCHEM J, V311, P453, DOI 10.1042/bj3110453; Leach JK, 2001, CANCER RES, V61, P3894; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li NY, 2003, FREE RADICAL BIO MED, V34, P465, DOI 10.1016/S0891-5849(02)01325-4; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Misiewicz I, 2003, ONCOL REP, V10, P2045; Murata M, 2000, FREE RADICAL BIO MED, V28, P797, DOI 10.1016/S0891-5849(00)00168-4; Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326; Narayanan PK, 1997, CANCER RES, V57, P3963; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Paolini M, 2004, CARCINOGENESIS, V25, P61, DOI 10.1093/carcin/bgg174; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reed JC, 1997, SEMIN HEMATOL, V34, P9; Ricci JE, 2003, CELL DEATH DIFFER, V10, P488, DOI 10.1038/sj.cdd.4401225; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Singh AV, 2004, CARCINOGENESIS, V25, P83, DOI 10.1093/carcin/bgg178; Singh SV, 2004, J BIOL CHEM, V279, P25813, DOI 10.1074/jbc.M313538200; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verhoeven DTH, 1996, CANCER EPIDEM BIOMAR, V5, P733; Wang LG, 2004, INT J ONCOL, V24, P187; WATKINS SC, 1987, J NEUROL SCI, V82, P181, DOI 10.1016/0022-510X(87)90017-7; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Xiao D, 2004, ONCOGENE, V23, P5594, DOI 10.1038/sj.onc.1207747; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Ye LX, 2001, CARCINOGENESIS, V22, P1987, DOI 10.1093/carcin/22.12.1987; Zhang SMM, 2000, CANCER EPIDEM BIOMAR, V9, P477; ZHANG Y, 1994, P NATL ACAD SCI USA, V91, P2147; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	60	296	308	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19911	19924		10.1074/jbc.M412443200	http://dx.doi.org/10.1074/jbc.M412443200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15764812	hybrid			2022-12-27	WOS:000229113700061
J	Tsuneoka, M; Teye, K; Arima, N; Soejima, M; Otera, H; Ohashi, K; Koga, Y; Fujita, H; Shirouzu, K; Kimura, H; Koda, Y				Tsuneoka, M; Teye, K; Arima, N; Soejima, M; Otera, H; Ohashi, K; Koga, Y; Fujita, H; Shirouzu, K; Kimura, H; Koda, Y			A novel Myc-target gene, mimitin, that is involved in cell proliferation of esophageal squamous cell carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE-DECARBOXYLASE GENE; C-MYC; CHROMATIN IMMUNOPRECIPITATION; PROGNOSTIC-SIGNIFICANCE; HISTONE ACETYLATION; MYC/MAX/MAD NETWORK; EXPRESSION; PROTEIN; CANCER; GROWTH	Myc is a ubiquitous mediator of cell proliferation that transactivates the expression of various genes through E-box sites. Here we report a novel gene, mimitin (Myc-induced mitochondrial protein), that encodes a mitochondrial protein with a molecular mass of 20 kDa. We demonstrated that the transcription of mimitin is directly stimulated by c-Myc. To investigate the role of Mimitin, its expression was suppressed by the RNA interference (RNAi) technique. Whereas specific inhibition of mimitin expression did not affect cell proliferation in human cervical carcinoma, colon adenocarcinoma, and hepatocarcinoma cell lines, it did suppress cell proliferation in human glioblastoma, esophageal squamous cell carcinoma (ESCC), and embryonic lung fibroblastic cells, with the greatest suppression efficiency in ESCC cells. To investigate whether mimitin is related to tumorigenesis in ESCC in vivo, the expression of Mimitin protein in ESCC tissues was studied. Mimitin was highly expressed in 80% (28 of 35) of ESCC tumors, suggesting that high expression of Mimitin is a characteristic feature of ESCC. The expression level of Mimitin was found to be correlated with that of c-Myc and cell proliferation, but not with the histopathological grade, stage of cancer, or age of patients. Taken together, these results suggest that the novel gene mimitin is a direct transcriptional target of c-Myc, and is involved in Myc-dependent cell proliferation at least in ESCC cells.	Kurume Univ, Sch Med, Div Human Genet, Dept Forens Med, Kurume, Fukuoka 8300011, Japan; Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka 8300011, Japan; Kurume Univ, Sch Med, Dept Pediat & Child Hlth, Kurume, Fukuoka 8300011, Japan; Kurume Univ, Sch Med, Dept Surg, Kurume, Fukuoka 8300011, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan; Chiba Univ, Grad Sch Sci & Technol, Chiba 2638522, Japan; Chiba Inst Sci, Choshi 2880025, Japan	Kurume University; Kurume University; Kurume University; Kurume University; Kyushu University; Chiba University	Tsuneoka, M (corresponding author), Kurume Univ, Sch Med, Div Human Genet, Dept Forens Med, Kurume, Fukuoka 8300011, Japan.	tsuneoka@med.kurume-u.ac.jp	Koda, Yoshiro/AAY-6902-2020	Koda, Yoshiro/0000-0003-1368-0116				Albertsson M, 2002, ACTA ONCOL, V41, P118, DOI 10.1080/028418602753669472; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; CATTORETTI G, 1992, J PATHOL, V168, P357, DOI 10.1002/path.1711680404; Coggi G, 1997, CANCER, V79, P425, DOI 10.1002/(SICI)1097-0142(19970201)79:3<425::AID-CNCR1>3.0.CO;2-H; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEMETER J, 1995, P NATL ACAD SCI USA, V92, P1436, DOI 10.1073/pnas.92.5.1436; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; GERDES J, 1984, J IMMUNOL, V133, P1710; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HICKSTEIN DD, 1989, J BIOL CHEM, V264, P21812; HOZUMI M, 1983, ADV CANCER RES, V38, P121, DOI 10.1016/S0065-230X(08)60189-X; Ikeda G, 1999, CANCER, V86, P1396, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1396::AID-CNCR3>3.0.CO;2-H; KANDA Y, 1994, INT J CANCER, V58, P291, DOI 10.1002/ijc.2910580224; Kim JW, 2004, MOL CELL BIOL, V24, P5923, DOI 10.1128/MCB.24.13.5923-5936.2004; Koda Y, 1997, J BIOL CHEM, V272, P7501, DOI 10.1074/jbc.272.11.7501; Koda Y, 1997, EUR J BIOCHEM, V246, P750, DOI 10.1111/j.1432-1033.1997.t01-1-00750.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Mandard AM, 2000, MUTAT RES-REV MUTAT, V462, P335, DOI 10.1016/S1383-5742(00)00019-3; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEKADA E, 1982, BIOCHEM BIOPH RES CO, V109, P792, DOI 10.1016/0006-291X(82)92009-5; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; Morrish F, 2003, GENE DEV, V17, P240, DOI 10.1101/gad.1032503; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; NISHIHIRA T, 1994, ATLAS HUMAN TUMOR CE; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Pendeville H, 2001, MOL CELL BIOL, V21, P6549, DOI 10.1128/MCB.21.19.6549-6558.2001; PORSCHEN R, 1994, CANCER RES, V54, P587; Saeki K, 2000, J BIOL CHEM, V275, P31996, DOI 10.1074/jbc.M004794200; SAWAI S, 1993, DEVELOPMENT, V117, P1445; SCHWARTZ B, 1995, BIOCHEM J, V312, P83, DOI 10.1042/bj3120083; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Skehel JM, 1998, FEBS LETT, V438, P301, DOI 10.1016/S0014-5793(98)01317-9; Sobin LH., 2002, UICC INT UNION CANC; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; Teye K, 2004, AM J PATHOL, V164, P205, DOI 10.1016/S0002-9440(10)63111-2; Triepels R, 2000, HUM GENET, V106, P385, DOI 10.1007/s004390000278; TSUNEOKA M, 1992, J BIOL CHEM, V267, P9107; Tsuneoka M, 2004, CLIN CANCER RES, V10, P7347, DOI 10.1158/1078-0432.CCR-03-0543; Tsuneoka M, 1997, ONCOGENE, V14, P2301, DOI 10.1038/sj.onc.1201067; Tsuneoka M, 2000, ONCOGENE, V19, P115, DOI 10.1038/sj.onc.1203232; Tsuneoka M, 2002, J BIOL CHEM, V277, P35450, DOI 10.1074/jbc.M204458200; WANG DY, 1994, CANCER-AM CANCER SOC, V74, P3089, DOI 10.1002/1097-0142(19941215)74:12<3089::AID-CNCR2820741205>3.0.CO;2-N; Wonsey DR, 2002, P NATL ACAD SCI USA, V99, P6649, DOI 10.1073/pnas.102523299; YANO H, 1988, ACTA PATHOL JAPON, V38, P953; YOSHIDA K, 1995, CANCER, V75, P1467, DOI 10.1002/1097-0142(19950315)75:6+<1467::AID-CNCR2820751514>3.0.CO;2-Y; YOUSSEF EM, 1995, CANCER, V76, P358, DOI 10.1002/1097-0142(19950801)76:3<358::AID-CNCR2820760303>3.0.CO;2-C	59	27	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19977	19985		10.1074/jbc.M501231200	http://dx.doi.org/10.1074/jbc.M501231200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774466	hybrid			2022-12-27	WOS:000229113700067
J	Smith, EM; Finn, SG; Tee, AR; Browne, G; Proud, CG				Smith, EM; Finn, SG; Tee, AR; Browne, G; Proud, CG			The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; 4E-BINDING PROTEIN-1; ELONGATION-FACTOR-2 KINASE; PHOSPHORYLATION SITE; GENE-PRODUCTS; MTOR; BINDING; TRANSLATION; ACTIVATION; RHEB	Amino acids positively regulate signaling through the mammalian target of rapamycin ( mTOR). Recent work demonstrated the importance of the tuberous sclerosis protein TSC2 for regulation of mTOR by insulin. TSC2 contains a GTPase-activator domain that promotes hydrolysis of GTP bound to Rheb, which positively regulates mTOR signaling. Some studies have suggested that TSC2 also mediates the control of mTOR by amino acids. In cells lacking TSC2, amino acid withdrawal still results in dephosphorylation of S6K1, ribosomal protein S6, the eukaryotic initiation factor 4E-binding protein, and elongation factor-2 kinase. The effects of amino acid withdrawal are diminished by inhibiting protein synthesis or adding back amino acids. These studies demonstrate that amino acid signaling to mTOR occurs independently of TSC2 and involves additional unidentified inputs. Although TSC2 is not required for amino acid control of mTOR, amino acid withdrawal does decrease the proportion of Rheb in the active GTP-bound state. Here we also show that Rheb and mTOR form stable complexes, which are not, however, disrupted by amino acid withdrawal. Mutants of Rheb that cannot bind GTP or GDP can interact with mTOR complexes. We also show that the effects of hydrogen peroxide and sorbitol, cell stresses that impair mTOR signaling, are independent of TSC2. Finally, we show that the ability of energy depletion (which impairs mTOR signaling in TSC2(+/+) cells) to increase the phosphorylation of eukaryotic elongation factor 2 is also independent of TSC2. This likely involves the phosphorylation of the elongation factor-2 kinase by the AMP-activated protein kinase.	Univ Dundee, Sch Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland	University of Dundee	Proud, CG (corresponding author), Univ British Columbia, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z4, Canada.	cgpr@interchange.ubc.ca		Tee, Andrew/0000-0002-5577-4631; Proud, Christopher/0000-0003-0704-6442; Smith, Ewan/0000-0002-3992-3748				AMONS R, 1990, BIOCHIM BIOPHYS ACTA, V1037, P401, DOI 10.1016/0167-4838(90)90043-F; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200; BEUGNET A, 2002, BIOCHEM J, V372, P566; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Browne GJ, 2004, MOL CELL BIOL, V24, P2986, DOI 10.1128/MCB.24.7.2986-2997.2004; Browne GJ, 2004, J BIOL CHEM, V279, P12220, DOI 10.1074/jbc.M309773200; Browne GJ, 2002, EUR J BIOCHEM, V269, P5360, DOI 10.1046/j.1432-1033.2002.03290.x; Christie GR, 2002, J BIOL CHEM, V277, P9952, DOI 10.1074/jbc.M107694200; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Fattori R, 2003, LANCET, V361, P247, DOI 10.1016/S0140-6736(03)12275-1; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gingras AC, 2001, PROG MOLEC, V27, P143; GLEESON M, 1986, CLIN CHIM ACTA, V156, P97, DOI 10.1016/0009-8981(86)90184-1; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Henin N, 1996, BBA-GEN SUBJECTS, V1290, P197, DOI 10.1016/0304-4165(96)00021-9; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Houghton PJ, 2003, CURR TOP MICROBIOL, V279, P339; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kimball SR, 2002, CURR OPIN CLIN NUTR, V5, P63, DOI 10.1097/00075197-200201000-00012; Knebel A, 2002, BIOCHEM J, V367, P525, DOI 10.1042/BJ20020916; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Martin ME, 2000, BIOCHEM J, V351, P327, DOI 10.1042/0264-6021:3510327; McLeod LE, 2002, FEBS LETT, V531, P448, DOI 10.1016/S0014-5793(02)03582-2; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Patel J, 2002, EUR J BIOCHEM, V269, P3076, DOI 10.1046/j.1432-1033.2002.02992.x; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; PRICE NT, 1989, BIOCHIM BIOPHYS ACTA, V1008, P177, DOI 10.1016/0167-4781(80)90005-6; Proud CG, 2003, CURR TOP MICROBIOL, V279, P215; Proud CG, 2004, DNA REPAIR, V3, P927, DOI 10.1016/j.dnarep.2004.03.012; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; SAKAIDA I, 1990, MOL PHARMACOL, V37, P435; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Tabancay AP, 2003, J BIOL CHEM, V278, P39921, DOI 10.1074/jbc.M306553200; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Tinton SA, 1999, FEBS LETT, V446, P55, DOI 10.1016/S0014-5793(99)00185-4; Vary TC, 2000, AM J PHYSIOL-ENDOC M, V279, pE1178, DOI 10.1152/ajpendo.2000.279.5.E1178; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Wang XM, 1997, BIOCHEM BIOPH RES CO, V238, P207, DOI 10.1006/bbrc.1997.7273; Wang XM, 2003, MOL CELL BIOL, V23, P1546, DOI 10.1128/MCB.23.5.1546-1557.2003; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhu JL, 1999, GASTROENTEROLOGY, V117, P1198, DOI 10.1016/S0016-5085(99)70406-3	57	291	311	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18717	18727		10.1074/jbc.M414499200	http://dx.doi.org/10.1074/jbc.M414499200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15772076	hybrid			2022-12-27	WOS:000228932300023
J	Fisher, TS; Des Etages, S; Hayes, L; Crimin, K; Li, BY				Fisher, TS; Des Etages, S; Hayes, L; Crimin, K; Li, BY			Analysis of ARD1 function in hypoxia response using retroviral RNA interference	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR 1-ALPHA; PROLYL HYDROXYLATION/; O-2 HOMEOSTASIS; HIF-ALPHA; FAMILY; HIF-1-ALPHA; PROTEIN; ERYTHROPOIETIN; IDENTIFICATION; DESTRUCTION	Cellular hypoxia response is regulated at the level of hypoxia-inducible factor (HIF) activity. A number of recently identified oxygen sensors are HIF-modifying enzymes that respond to low oxygen by altering HIF modification and thus lead to its activation. In addition to the HIF proline hydroxylases and asparagine hydroxylases, ARD1 is recently described as a HIF-1 alpha acetylase that regulates its stability. We found that ARD1 is down-regulated in a number of cell lines in response to hypoxia and hypoxia mimic compounds. After surveying these lines for erythropoietin production and retroviral transfection efficiency, we chose to use HepG2 cells to study the function of ARD1. ARD1 short hairpin RNA delivered by a retroviral vector caused >80% reduction in ARD1 message. We observed decreases in erythropoietin and vascular endothelial growth factor protein production, whereas there was no change in the HIF-1 alpha protein level. A gene chip analysis of HepG2 cells transduced with virus expressing ARD1 short hairpin RNA under normoxia and hypoxia conditions or with virus overexpressing recombinant ARD1 confirmed that inhibition of ARD1 does not cause activation of HIF and downstream target genes. However, this analysis revealed that ARD1 is involved in cell proliferation and in regulating a series of cellular metabolic pathways that are regulated during hypoxia response. The role of ARD1 in cell proliferation is confirmed using fluorescence labeling analysis of cell division. From these studies we conclude that ARD1 is not required to suppress HIF but is required to maintain cell proliferation in mammalian cells.	Pfizer Global Res & Dev, Dept Antibacterials Immunol & Canc, Groton, CT 06340 USA; Pfizer Global Res & Dev, Dept Genom & Proteom Sci, Groton, CT 06340 USA; Pfizer Global Res & Dev, Dept Nonclin Biostat, Groton, CT 06340 USA	Pfizer; Pfizer; Pfizer	Li, BY (corresponding author), Pfizer Global Res & Dev, Dept Antibacterials Immunol & Canc, Eastern Point Rd, Groton, CT 06340 USA.	Baiyong.li@pfizer.com						Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Baugh LR, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.5.e29; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Berra E, 2001, EMBO REP, V2, P615, DOI 10.1093/embo-reports/kve130; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393; COSTAGIOMI P, 1990, J BIOL CHEM, V265, P10185; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ingram AK, 2000, MOL BIOCHEM PARASIT, V111, P309, DOI 10.1016/S0166-6851(00)00322-4; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Stopka T, 1998, BLOOD, V91, P3766; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; TRIBIOLI C, 1994, HUM MOL GENET, V3, P1061, DOI 10.1093/hmg/3.7.1061; VanBelzen N, 1995, EUR J BIOCHEM, V234, P843; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	32	76	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17749	17757		10.1074/jbc.M412055200	http://dx.doi.org/10.1074/jbc.M412055200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15755738	hybrid			2022-12-27	WOS:000228807200025
J	Premkumar, L; Sawkar, AR; Boldin-Adamsky, S; Toker, L; Silman, I; Kelly, JW; Futerman, AH; Sussman, JL				Premkumar, L; Sawkar, AR; Boldin-Adamsky, S; Toker, L; Silman, I; Kelly, JW; Futerman, AH; Sussman, JL			X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide - Implications for Gaucher disease.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL STORAGE DISORDERS; N-GLYCOSIDASE-F; CONFORMATIONAL-CHANGES; ENZYME-ACTIVITY; MUTATIONS; GLUCOCEREBROSIDASE; PEPTIDE; SITE; CRYSTALLOGRAPHY; IDENTIFICATION	Gaucher disease is an inherited metabolic disorder caused by mutations in the lysosomal enzyme acid-beta-glucosidase (GlcCerase). We recently determined the x-ray structure of GlcCerase to 2.0 angstrom resolution (Dvir, H., Harel, M., McCarthy, A. A., Toker, L., Silman, I., Futerman, A. H., and Sussman, J. L. ( 2003) EMBO Rep. 4, 704-709) and have now solved the structure of GlcCerase conjugated with an irreversible inhibitor, conduritol-B- epoxide ( CBE). The crystal structure reveals that binding of CBE to the active site does not induce a global conformational change in GlcCerase and confirms that Glu(340) is the catalytic nucleophile. However, only one of two alternative conformations of a pair of flexible loops ( residues 345-349 and 394-399) located at the entrance to the active site in native GlcCerase is observed in the GlcCerase-CBE structure, a conformation in which the active site is accessible to CBE. Analysis of the dynamics of these two alternative conformations suggests that the two loops act as a lid at the entrance to the active site. This possibility is supported by a cluster of mutations in loop 394-399 that cause Gaucher disease by reducing catalytic activity. Moreover, in silico mutational analysis demonstrates that all these mutations stabilize the conformation that limits access to the active site, thus providing a mechanistic explanation of how mutations in this loop result in Gaucher disease.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Scripps Research Institute; Scripps Research Institute	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	tony.futerman@weizmann.ac.il		Sussman, Joel/0000-0003-0306-3878; Futerman, Anthony/0000-0003-0013-0115				Amaral O, 1996, HUM MUTAT, V8, P280, DOI 10.1002/(SICI)1098-1004(1996)8:3<280::AID-HUMU15>3.3.CO;2-6; Amaral O, 2000, EUR J HUM GENET, V8, P95, DOI 10.1038/sj.ejhg.5200422; BEUTLER E, 1994, HUM GENET, V93, P209; BEUTLER E, 2001, METABOLIC MOL BASES, P3635; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHU FK, 1986, J BIOL CHEM, V261, P172; DINUR T, 1986, P NATL ACAD SCI USA, V83, P1660, DOI 10.1073/pnas.83.6.1660; Fan JQ, 2003, TRENDS PHARMACOL SCI, V24, P355, DOI 10.1016/S0165-6147(03)00158-5; Futerman AH, 2004, TRENDS PHARMACOL SCI, V25, P147, DOI 10.1016/j.tips.2004.01.004; Futerman AH, 2004, NAT REV MOL CELL BIO, V5, P554, DOI 10.1038/nrm1423; GRACE ME, 1994, J BIOL CHEM, V269, P2283; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; Hrmova M, 2001, STRUCTURE, V9, P1005, DOI 10.1016/S0969-2126(01)00673-6; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MEIVARLEVY I, 1994, BIOCHEM J, V303, P377, DOI 10.1042/bj3030377; MIAO SC, 1994, J BIOL CHEM, V269, P10975; Qasba PK, 2005, TRENDS BIOCHEM SCI, V30, P53, DOI 10.1016/j.tibs.2004.11.005; Sawkar AR, 2002, P NATL ACAD SCI USA, V99, P15428, DOI 10.1073/pnas.192582899; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Seeman PJV, 1996, NEUROLOGY, V46, P1102, DOI 10.1212/WNL.46.4.1102; Stone DL, 1999, EUR J HUM GENET, V7, P505, DOI 10.1038/sj.ejhg.5200315; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Zeev-Ben-Mordehai T, 2003, BIOPOLYMERS, V68, P395, DOI 10.1002/bip.10287	28	81	83	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23815	23819		10.1074/jbc.M502799200	http://dx.doi.org/10.1074/jbc.M502799200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15817452	hybrid, Green Submitted			2022-12-27	WOS:000229880000053
J	Camandola, S; Cutler, RG; Gary, DS; Milhavet, O; Mattson, MP				Camandola, S; Cutler, RG; Gary, DS; Milhavet, O; Mattson, MP			Suppression of calcium release from inositol 1,4,5-trisphosphate-sensitive stores mediates the anti-apoptotic function of nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; INTRACELLULAR CA2+ STORES; ENDOPLASMIC-RETICULUM; HIPPOCAMPAL-NEURONS; OXIDATIVE STRESS; BCL-2 EXPRESSION; IP3 RECEPTOR; CELL-DEATH; NEURODEGENERATIVE DISORDERS; PRESENILIN-1 MUTATIONS	The activation of the transcription factor nuclear factor-kappa B (NF-kappa B) by growth factors, cytokines, and cellular stress can prevent apoptosis, but the underlying mechanism is unknown. Here we provide evidence for an action of NF-kappa B on calcium signaling that accounts for its anti-apoptotic function. Embryonic fibroblasts lacking the transactivating subunit of NF-kappa B RelA (p65) exhibit enhanced inositol 1,4,5- trisphosphate (IP3) receptor-mediated calcium release and increased sensitivity to apoptosis, which are restored upon re-expression of RelA. The size of the endoplasmic reticulum (ER) calcium pool and the number of IP3 receptors per cell are decreased in response to stimuli that activate NF-kappa B and are increased when NF-kappa B activity is suppressed. The selective antagonism of IP3 receptors blocks apoptosis in RelA-deficient cells, whereas activation of NF-kappa B in normal cells leads to decreased levels of the type 1 IP3 receptor and decreased calcium release. Overexpression of Bcl-2 normalizes ER calcium homeostasis and prevents calcium-mediated apoptosis in RelA-deficient cells. These findings establish an ER calcium channel as a pivotal target for NF-kappa B-mediated cell survival signaling.	NIA, Neurosci Lab, Gerontol Res Ctr, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University	Camandola, S (corresponding author), NIA, Neurosci Lab, Gerontol Res Ctr, GRC 4F01,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	camandolasi@grc.nia.nih.gov	Mattson, Mark P/F-6038-2012; Cutler, Roy G./L-5572-2013	Milhavet, Ollivier/0000-0001-6236-0499	NATIONAL INSTITUTE ON AGING [ZIAAG000314, Z01AG000314, ZIAAG000313, Z01AG000313] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AnandApte B, 1997, STEM CELLS, V15, P259, DOI 10.1002/stem.150259; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERRIDGE MJ, 1985, J CELL SCI, P187; BYRON KL, 1992, J BIOL CHEM, V267, P108; Camandola S, 2000, J NEUROSCI RES, V61, P134, DOI 10.1002/1097-4547(20000715)61:2<134::AID-JNR3>3.0.CO;2-P; Camandola S, 2000, MOL BRAIN RES, V85, P53, DOI 10.1016/S0169-328X(00)00234-5; Chan SL, 2000, J BIOL CHEM, V275, P18195, DOI 10.1074/jbc.M000040200; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Cutler RG, 2002, ANN NEUROL, V52, P448, DOI 10.1002/ana.10312; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Diaz F, 2000, CELL CALCIUM, V27, P315, DOI 10.1054/ceca.2000.0126; Esser MT, 1998, J EXP MED, V187, P1057, DOI 10.1084/jem.187.7.1057; Fisher TE, 2001, PROG BIOPHYS MOL BIO, V77, P269, DOI 10.1016/S0079-6107(01)00017-7; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; Glazner GW, 2001, J BIOL CHEM, V276, P22461, DOI 10.1074/jbc.M101315200; GONZALEZ FA, 1989, P NATL ACAD SCI USA, V86, P4530, DOI 10.1073/pnas.86.12.4530; Granville DJ, 2001, CELL CALCIUM, V30, P343, DOI 10.1054/ceca.2001.0243; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Guo Q, 1999, J NEUROSCI RES, V56, P457, DOI 10.1002/(SICI)1097-4547(19990601)56:5<457::AID-JNR2>3.0.CO;2-P; Hajnoczky G, 1997, EMBO J, V16, P3533, DOI 10.1093/emboj/16.12.3533; Hogan B, 1994, MANIPULATING MOUSE E; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; Kass GEN, 1999, ENVIRON HEALTH PERSP, V107, P25, DOI 10.2307/3434469; Kim BC, 2002, J BIOL CHEM, V277, P31381, DOI 10.1074/jbc.M203465200; Kirkwood KL, 1997, J BIOL CHEM, V272, P22425, DOI 10.1074/jbc.272.36.22425; Kobrinsky E, 1999, AM J PHYSIOL-CELL PH, V277, pC665, DOI 10.1152/ajpcell.1999.277.4.C665; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kumasaka S, 1999, ANTIOXID REDOX SIGN, V1, P55, DOI 10.1089/ars.1999.1.1-55; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Magnusson C, 1999, IMMUNOL CELL BIOL, V77, P41, DOI 10.1046/j.1440-1711.1999.00800.x; MARKS AR, 1997, AM J PHYSIOL, V272, pH587; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; Mattson MP, 2001, BIOESSAYS, V23, P733, DOI 10.1002/bies.1103; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; METCALFE JC, 1986, BRIT MED BULL, V42, P405, DOI 10.1093/oxfordjournals.bmb.a072159; Mikoshiba K, 1997, CURR OPIN NEUROBIOL, V7, P339, DOI 10.1016/S0959-4388(97)80061-X; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nozaki S, 2001, ONCOGENE, V20, P2178, DOI 10.1038/sj.onc.1204292; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Pollock J, 2002, NEUROPHARMACOLOGY, V42, P93, DOI 10.1016/S0028-3908(01)00163-0; Reyes M, 1996, J NEUROSCI, V16, P5951; Rosemblit N, 1999, DEV BIOL, V206, P163, DOI 10.1006/dbio.1998.9120; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; VAN AD, 1996, SCIENCE, V274, P787; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yoshiyama Y, 2001, NEUROREPORT, V12, P2641, DOI 10.1097/00001756-200108280-00011; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999; ZACCHETTI D, 1991, J BIOL CHEM, V266, P20152; Zhang C, 2001, J BIOL CHEM, V276, P35867, DOI 10.1074/jbc.M100747200; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200	71	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22287	22296		10.1074/jbc.M410923200	http://dx.doi.org/10.1074/jbc.M410923200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15814613	hybrid			2022-12-27	WOS:000229557900074
J	Strassmaier, T; Bond, CT; Sailer, CA; Knaus, HG; Maylie, J; Adelman, JP				Strassmaier, T; Bond, CT; Sailer, CA; Knaus, HG; Maylie, J; Adelman, JP			A novel isoform of SK2 assembles with other SK subunits in mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNELS; ACTIVATED POTASSIUM CHANNELS; SMALL-CONDUCTANCE; EXPRESSION; AFTERHYPERPOLARIZATION; CALMODULIN; CURRENTS; NEURONS; APAMIN; SYSTEM	The SK2 subtype of small conductance Ca2+-activated K+ channels is widely distributed throughout the central nervous system and modulates neuronal excitability by contributing to the afterhyperpolarization that follows an action potential. Western blots of brain membrane proteins prepared from wild type and SK2-null mice reveal two isoforms of SK2, a 49-kDa band corresponding to the previously reported SK2 protein (SK2-S) and a novel 78-kDa form. Complementary DNA clones from brain and Western blots probed with an antibody specific for the longer form, SK2-L, identified the larger molecular weight isoform as an N-terminally extended SK2 protein. The N-terminal extension of SK2-L is cysteinerich and mediates disulfide bond formation between SK2-L subunits or with heterologous proteins. Immunohistochemistry revealed that in brain SK2-L and SK2-S are expressed in similar but not identical patterns. Heterologous expression of SK2-L results in functional homomeric channels with Ca2+ sensitivity similar to that of SK2-S, consistent with their shared core and intracellular C-terminal domains. In contrast to the diffuse, uniform surface distribution of SK2-S, SK2-L channels cluster into sharply defined, distinct puncta suggesting that the extended cysteine-rich N-terminal domain mediates this process. Immunoprecipitations from transfected cells and mouse brain demonstrate that SK2-L co-assembles with the other SK subunits. Taken together, the results show that the SK2 gene encodes two subunit proteins and suggest that native SK2-L subunits may preferentially partition into heteromeric channel complexes with other SK subunits.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97239 USA; Univ Innsbruck, Inst Biochem Pharmacol, A-6020 Innsbruck, Austria	Oregon Health & Science University; Oregon Health & Science University; University of Innsbruck	Adelman, JP (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	adelman@ohsu.edu						ABACIOGLU YH, 1994, AIDS RES HUM RETROV, V10, P371, DOI 10.1089/aid.1994.10.371; Benton DCH, 2003, J PHYSIOL-LONDON, V553, P13, DOI 10.1113/jphysiol.2003.054551; Bildl W, 2004, NEURON, V43, P847, DOI 10.1016/j.neuron.2004.08.033; Bond CT, 2000, SCIENCE, V289, P1942, DOI 10.1126/science.289.5486.1942; Bond CT, 2004, J NEUROSCI, V24, P5301, DOI 10.1523/JNEUROSCI.0182-04.2004; Bond CT, 1999, ANN NY ACAD SCI, V868, P370, DOI 10.1111/j.1749-6632.1999.tb11298.x; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jager H, 2000, FEBS LETT, V469, P196, DOI 10.1016/S0014-5793(00)01236-9; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Kramar EA, 2004, J NEUROSCI, V24, P5151, DOI 10.1523/JNEUROSCI.0800-04.2004; Lee WS, 2003, J BIOL CHEM, V278, P25940, DOI 10.1074/jbc.M302091200; Maylie J, 2004, J PHYSIOL-LONDON, V554, P255, DOI 10.1113/jphysiol.2003.049072; Monaghan AS, 2004, J BIOL CHEM, V279, P1003, DOI 10.1074/jbc.M308070200; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; SAH P, 1991, NEURON, V7, P257, DOI 10.1016/0896-6273(91)90264-Z; Sailer CA, 2004, MOL CELL NEUROSCI, V26, P458, DOI 10.1016/j.mcn.2004.03.002; Sailer CA, 2002, J NEUROSCI, V22, P9698; Stackman RW, 2002, J NEUROSCI, V22, P10163; Stocker M, 1999, P NATL ACAD SCI USA, V96, P4662, DOI 10.1073/pnas.96.8.4662; Stocker M, 2000, MOL CELL NEUROSCI, V15, P476, DOI 10.1006/mcne.2000.0842; ZHANG L, 1995, J PHYSIOL-LONDON, V488, P661, DOI 10.1113/jphysiol.1995.sp020998	24	63	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21231	21236		10.1074/jbc.M413125200	http://dx.doi.org/10.1074/jbc.M413125200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797870	hybrid			2022-12-27	WOS:000229438800041
J	Clatworthy, AE; Valencia-Burton, MA; Haber, JE; Oettinger, MA				Clatworthy, AE; Valencia-Burton, MA; Haber, JE; Oettinger, MA			The MRE11-RAD50-XRS2 complex, in addition to other non-homologous end-joining factors, is required for V(D)J joining in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN BREAKAGE SYNDROME; DNA-LIGASE-IV; DOUBLE-STRAND BREAKS; TELANGIECTASIA-LIKE DISORDER; CLASS-SWITCH RECOMBINATION; SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA; RAG PROTEINS; CELL-CYCLE; IN-VIVO	Lymphoid cells of the vertebrate immune system rely on factors in the non-homologous end-joining (NHEJ) DNA repair pathway to form signal joints during V(D)J recombination. Unlike other end-joining reactions, signal joint formation is a specialized case of NHEJ that also requires the lymphoid-specific RAG proteins. Whether V(D) J recombination requires the Mre11-Rad50-Nbs1 complex remains an open question, as null mutations in any member of the complex are lethal in mammals. However, Saccharomyces cerevisiae strains carrying null mutations in components of the homologous Mre11p-Rad50p-Xrs2p (MRX) complex are viable. We therefore took advantage of a recently developed V(D) J recombination assay in yeast to assess the role of MRX in V(D) J joining. Here we confirmed that signal joint formation in yeast is dependent on the same NHEJ factors known to be required in mammalian cells. In addition, we showed an absolute requirement for the MRX complex in signal joining, suggesting that the Mre11-Rad50-Nbs1 complex may be required for signal joint formation in mammalian cells as well.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Rosensteil Ctr, Waltham, MA 02454 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Brandeis University; Brandeis University	Oettinger, MA (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, 50 Blossom St, Boston, MA 02114 USA.	oettinger@frodo.mgh.harvard.edu		Haber, James/0000-0002-1878-0610	NIGMS NIH HHS [GM48026, GM20056] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048026, R01GM020056, R37GM020056] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Bender CF, 2002, GENE DEV, V16, P2237, DOI 10.1101/gad.1007902; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Brachmann CB, 1998, YEAST, V14, P115; Brendel M, 2003, MUTAT RES-REV MUTAT, V544, P179, DOI 10.1016/j.mrrev.2003.06.018; Cannon JP, 2004, IMMUNOL REV, V200, P12, DOI 10.1111/j.0105-2896.2004.00166.x; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; Clatworthy AE, 2003, MOL CELL, V12, P489, DOI 10.1016/S1097-2765(03)00305-8; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Demuth I, 2004, HUM MOL GENET, V13, P2385, DOI 10.1093/hmg/ddh278; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; Feldmann H, 1996, J BIOL CHEM, V271, P27765, DOI 10.1074/jbc.271.44.27765; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank-Vaillant M, 2001, GENE DEV, V15, P3005, DOI 10.1101/gad.206801; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, J BIOL CHEM, V273, P24708, DOI 10.1074/jbc.273.38.24708; Harfst E, 2000, MOL IMMUNOL, V37, P915, DOI 10.1016/S0161-5890(01)00008-6; Herrmann G, 1998, EMBO J, V17, P4188, DOI 10.1093/emboj/17.14.4188; Hiom K, 1997, CELL, V88, P65, DOI 10.1016/S0092-8674(00)81859-0; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; Huang JR, 2002, NUCLEIC ACIDS RES, V30, P667, DOI 10.1093/nar/30.3.667; Huye LE, 2002, MOL CELL BIOL, V22, P3460, DOI 10.1128/MCB.22.10.3460-3473.2002; Jiang H, 2004, J BIOL CHEM, V279, P8478, DOI 10.1074/jbc.M311219200; Jones JM, 2001, P NATL ACAD SCI USA, V98, P12926, DOI 10.1073/pnas.221471198; Kegel A, 2001, CURR BIOL, V11, P1611, DOI 10.1016/S0960-9822(01)00488-2; Kracker S, 2005, P NATL ACAD SCI USA, V102, P1584, DOI 10.1073/pnas.0409191102; Lahdesmaki A, 2004, J BIOL CHEM, V279, P16479, DOI 10.1074/jbc.M312796200; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; Lee JH, 2003, J BIOL CHEM, V278, P45171, DOI 10.1074/jbc.M308705200; Lee SE, 2002, DNA REPAIR, V1, P27, DOI 10.1016/S1568-7864(01)00003-9; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MALONE RE, 1980, P NATL ACAD SCI-BIOL, V77, P503, DOI 10.1073/pnas.77.1.503; Manolis KG, 2001, EMBO J, V20, P210, DOI 10.1093/emboj/20.1.210; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Moreau S, 1999, MOL CELL BIOL, V19, P556; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Ooi SL, 2001, SCIENCE, V294, P2552, DOI 10.1126/science.1065672; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Paull TT, 2000, P NATL ACAD SCI USA, V97, P6409, DOI 10.1073/pnas.110144297; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Qiu JX, 2001, MOL CELL, V7, P77, DOI 10.1016/S1097-2765(01)00156-3; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; Reina-San-Martin B, 2005, P NATL ACAD SCI USA, V102, P1590, DOI 10.1073/pnas.0406289102; Rooney S, 2004, IMMUNOL REV, V200, P115, DOI 10.1111/j.0105-2896.2004.00165.x; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; Schultz HY, 2001, MOL CELL, V7, P65, DOI 10.1016/S1097-2765(01)00155-1; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Theunissen JWF, 2003, MOL CELL, V12, P1511, DOI 10.1016/S1097-2765(03)00455-6; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Tsai CL, 2002, GENE DEV, V16, P1934, DOI 10.1101/gad.984502; Valencia M, 2001, NATURE, V414, P666, DOI 10.1038/414666a; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Yu JH, 2004, MOL CELL BIOL, V24, P1351, DOI 10.1128/MCB.24.3.1351-1364.2004; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	78	12	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20247	20252		10.1074/jbc.M500126200	http://dx.doi.org/10.1074/jbc.M500126200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15757898	hybrid			2022-12-27	WOS:000229242000012
J	Hansen, IA; Attardo, GM; Roy, SG; Raikhel, AS				Hansen, IA; Attardo, GM; Roy, SG; Raikhel, AS			Target of rapamycin-dependent activation of S6 kinase is a central step in the transduction of nutritional signals during egg development in a mosquito	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA FAT-BODY; AEDES-AEGYPTI; VITELLOGENIN SYNTHESIS; MAMMALIAN TARGET; CELLULAR GROWTH; PROTEIN; GENE; EXPRESSION; ECDYSONE; TRANSLATION	Female mosquitoes are effective disease vectors, because they take blood from vertebrate hosts to obtain nutrients for egg development. Amino acid signaling via the target of rapamycin ( TOR) pathway has been identified as a key requirement for the activation of egg development after a blood meal. We report the characterization of the TOR kinase and one of its major downstream targets, S6 kinase, of the yellow fever mosquito Aedes aegypti during egg development in adult females. Both TOR and S6K mRNA are expressed at high levels in the ovaries and in lower levels in fat body and other tissues. After a blood meal, the subcellular localization of TOR shifts from the cytoplasm to the plasma membrane of fat body cells. By detecting phosphothreonine 388 of mosquito S6 kinase, we show that TOR activity strongly increases in fat body and ovaries after a blood meal in vivo. Furthermore, phosphorylation of S6 kinase increases in in vitro cultured fat bodies after stimulation with amino acids. This increase is sensitive to the TOR inhibitor rapamycin in a concentration-dependent manner but not to the phosphatidylinositol 3-kinase/phosphatidylinositol 3-kinase-related kinase inhibitor LY294002, the MAPK inhibitor PD98059, or the translational inhibitor cycloheximide. RNA interference-mediated reduction of S6 kinase strongly inhibits the amino acid-induced up-regulation of the major yolk protein vitellogenin in vitro and effectively disrupts egg development after a blood meal in vivo. Our data show that TOR-dependent activation of S6 kinase is a central step in the transduction of nutritional information during egg development in mosquitoes.	Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA; Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Raikhel, AS (corresponding author), Univ Calif Riverside, Dept Entomol, 3401 Watkins Dr, Riverside, CA 92521 USA.	raikhel@ucr.edu	Attardo, Geoffrey Michael/I-3320-2019	Attardo, Geoffrey Michael/0000-0001-6265-2969	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024716] Funding Source: NIH RePORTER; NIAID NIH HHS [5 R37 AI024716, R01 AI024716] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Clements AN., 1992, BIOL MOSQUITOES DEV; Colombani J, 2003, CELL, V114, P739, DOI 10.1016/S0092-8674(03)00713-X; FALLON AM, 1974, J INSECT PHYSIOL, V20, P1815, DOI 10.1016/0022-1910(74)90211-X; Hansen IA, 2004, P NATL ACAD SCI USA, V101, P10626, DOI 10.1073/pnas.0403460101; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HAYS AR, 1990, ROUX ARCH DEV BIOL, V199, P114, DOI 10.1007/BF02029559; Hennig KM, 2002, GENESIS, V34, P107, DOI 10.1002/gene.10139; HOTCHKIN PG, 1987, BIOCHIM BIOPHYS ACTA, V924, P352, DOI 10.1016/0304-4165(87)90033-X; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kokoza VA, 2001, GENE, V274, P47, DOI 10.1016/S0378-1119(01)00602-3; Martin D, 2001, MOL CELL BIOL, V21, P164, DOI 10.1128/MCB.21.1.164-174.2001; Martin D, 2001, MOL CELL ENDOCRINOL, V173, P75, DOI 10.1016/S0303-7207(00)00413-5; Menand B, 2002, P NATL ACAD SCI USA, V99, P6422, DOI 10.1073/pnas.092141899; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Pierceall WE, 1999, MOL CELL ENDOCRINOL, V150, P73, DOI 10.1016/S0303-7207(99)00022-2; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Raikhel A. S., 1997, The molecular biology of insect disease vectors: a methods manual., P507; RAIKHEL AS, 1983, TISSUE CELL, V15, P281, DOI 10.1016/0040-8166(83)90023-X; RAIKHEL AS, 1992, ANNU REV ENTOMOL, V37, P217, DOI 10.1146/annurev.en.37.010192.001245; Rusten TE, 2004, DEV CELL, V7, P179, DOI 10.1016/j.devcel.2004.07.005; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Sun GQ, 2004, MOL CELL ENDOCRINOL, V218, P95, DOI 10.1016/j.mce.2003.12.014; Thomas G., 2004, TOR TARGET RAPAMYCIN; Uchida K, 2003, J MED ENTOMOL, V40, P441, DOI 10.1603/0022-2585-40.4.441; Withers DJ, 1997, BIOCHEM BIOPH RES CO, V241, P704, DOI 10.1006/bbrc.1997.7878; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	35	116	119	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20565	20572		10.1074/jbc.M500712200	http://dx.doi.org/10.1074/jbc.M500712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788394	hybrid			2022-12-27	WOS:000229242000051
J	Thompson, AJ; Price, KL; Reeves, DC; Chan, SL; Chau, PL; Lummis, SCR				Thompson, AJ; Price, KL; Reeves, DC; Chan, SL; Chau, PL; Lummis, SCR			Locating an antagonist in the 5-HT3 receptor binding site using modeling and radioligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; AGONIST-BINDING; EXTRACELLULAR DOMAIN; DIRECTED MUTAGENESIS; AUTOMATED DOCKING; GLYCINE RECEPTOR; RESIDUES; SUBUNIT; CELLS; GABA	We have used a homology model of the extracellular domain of the 5-HT3 receptor to dock granisetron, a 5-HT3 receptor antagonist, into the binding site using AUTODOCK. This yielded 13 alternative energetically favorable models. The models fell into 3 groups. In model type A the aromatic rings of granisetron were between Trp-90 and Phe-226 and its azabicyclic ring was between Trp-183 and Tyr-234, in model type B this orientation was reversed, and in model type C the aromatic rings were between Asp-229 and Ser-200 and the azabicyclic ring was between Phe-226 and Asn-128. Residues located no more than 5 angstrom from the docked granisetron were identified for each model; of 26 residues identified, 8 were found to be common to all models, with 18 others being represented in only a subset of the models. To identify which of the docking models best represents the ligand-receptor complex, we substituted each of these 26 residues with alanine and a residue with similar chemical properties. The mutant receptors were expressed in human embryonic kidney (HEK)293 cells and the affinity of granisetron determined using radioligand binding. Mutation of 2 residues (Trp-183 and Glu-129) ablated binding, whereas mutation of 14 other residues caused changes in the [H-3] granisetron binding affinity in one or both mutant receptors. The data showed that residues both in and close to the binding pocket can affect antagonist binding and overall were found to best support model B.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Albert Einstein Coll Med, Bronx, NY 10461 USA; Chem Comp Grp Inc, Montreal, PQ H3A 2R7, Canada; Inst Pasteur, Paris, France; MRC, Mol Biol Lab, Div Neurobiol, Cambridge CB2 2QH, England	University of Cambridge; Yeshiva University; Albert Einstein College of Medicine; Chemical Computing Group; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; MRC Laboratory Molecular Biology	Lummis, SCR (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	sl120@cam.ac.uk		Thompson, Andrew/0000-0002-7046-6792; Price, Kerry/0000-0002-5563-4567	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; Beene DL, 2002, BIOCHEMISTRY-US, V41, P10262, DOI 10.1021/bi020266d; Boess FG, 1997, NEUROPHARMACOLOGY, V36, P637, DOI 10.1016/S0028-3908(97)00044-0; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; GILL CH, 1995, BRIT J PHARMACOL, V114, P1211, DOI 10.1111/j.1476-5381.1995.tb13335.x; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARGREAVES AC, 1994, MOL PHARMACOL, V46, P1120; Huang XQ, 2001, J MED CHEM, V44, P1883, DOI 10.1021/jm000557p; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Le Novere N, 2002, P NATL ACAD SCI USA, V99, P3210, DOI 10.1073/pnas.042699699; LUMMIS SCR, 1993, EUR J PHARMACOL, V243, P7, DOI 10.1016/0014-2999(93)90160-J; Maksay G, 2003, J RECEPT SIG TRANSD, V23, P255, DOI 10.1081/RRS-120025568; Martin M, 1996, J BIOL CHEM, V271, P13497, DOI 10.1074/jbc.271.23.13497; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Mu TW, 2003, J AM CHEM SOC, V125, P6850, DOI 10.1021/ja0348086; Newell JG, 2003, J BIOL CHEM, V278, P13166, DOI 10.1074/jbc.M211905200; Niemeyer MI, 1998, BRIT J PHARMACOL, V123, P661, DOI 10.1038/sj.bjp.0701657; Niesler B, 2003, GENE, V310, P101, DOI 10.1016/S0378-1119(03)00503-1; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Price KL, 2004, J BIOL CHEM, V279, P23294, DOI 10.1074/jbc.M314075200; Reeves DC, 2003, BIOPHYS J, V84, P2338, DOI 10.1016/S0006-3495(03)75039-5; Reeves DC, 2002, MOL MEMBR BIOL, V19, P11, DOI 10.1080/09687680110110048; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schapira Matthieu, 2002, BMC Structural Biology, V2, P1, DOI 10.1186/1472-6807-2-1; SCHMIEDEN V, 1993, SCIENCE, V262, P256, DOI 10.1126/science.8211147; Spier AD, 2000, J BIOL CHEM, V275, P5620, DOI 10.1074/jbc.275.8.5620; Spier AD, 1999, MOL BRAIN RES, V71, P369; Turchin A, 1999, BIOTECHNIQUES, V26, P672, DOI 10.2144/99264st02; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; VANDENBERG RJ, 1992, NEURON, V9, P491, DOI 10.1016/0896-6273(92)90186-H; Venkataraman P, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-15; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Yan D, 1998, NEUROPHARMACOLOGY, V37, P251, DOI 10.1016/S0028-3908(98)00010-0; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	41	65	67	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20476	20482		10.1074/jbc.M413610200	http://dx.doi.org/10.1074/jbc.M413610200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781467	hybrid			2022-12-27	WOS:000229242000040
J	Xin, H; Xu, XL; Li, LY; Ning, HX; Rong, Y; Shang, Y; Wang, YY; Fu, XY; Chang, ZJ				Xin, H; Xu, XL; Li, LY; Ning, HX; Rong, Y; Shang, Y; Wang, YY; Fu, XY; Chang, ZJ			CHIP controls the sensitivity of transforming growth factor-beta signaling by modulating the basal level of Smad3 through ubiquitin-mediated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; DEPENDENT DEGRADATION; TRANSCRIPTIONAL ACTIVATION; PROTEASOMAL DEGRADATION; INTERACTING PROTEIN; MAMMALIAN-CELLS; LIGASE COMPLEX; E3 LIGASE; C-JUN; TRANSDUCTION	Transforming growth factor-beta (TGF-beta) signaling is critical in a variety of biological processes such as cell proliferation, differentiation, and apoptosis. TGF-beta signaling is mediated by a group of proteins including TGF-beta receptors and Smads. It is known that different cells can exhibit different sensitivities to TGF-beta. Several molecular mechanisms, such as the differential expression of the receptor levels, have been suggested as contributing to these differences. Here, we report evidence for a novel mechanism of regulating TGF-beta sensitivity that depends on the role of CHIP ( carboxyl terminus of Hsc70-interacting protein) in regulating the basal level of Smad3 via the ubiquitin-dependent degradation pathway. First, using a luciferase assay we found that overexpression of CHIP inhibited TGF-beta signaling, whereas silencing CHIP expression by small interfering RNAs led to increased TGF-beta signaling sensitivity. Second, based on the results of cell proliferation assays and JunB expression, we found that TGF-beta signaling could be abolished by stably overexpressing CHIP. Third, in those cell lines with stably expressed CHIP, we observed that the Smad3 protein level was dramatically decreased. Finally, we demonstrated that CHIP served as a U-box dependent E3 ligase that can directly mediate ubiquitination and degradation of Smad3 and that this action of CHIP was independent of TGF-beta signaling. Taken together, these findings suggest that CHIP can modulate the sensitivity of the TGF-beta signaling by controlling the basal level of Smad3 through ubiquitin-mediated degradation.	Tsing Hua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China; Tsing Hua Univ, Inst Biomed, Beijing 100084, Peoples R China; Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA	Tsinghua University; Tsinghua University; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Xin, H (corresponding author), Tsing Hua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China.	zhijiec@mail.tsinghua.edu.cn	Chang, Zhijie/AAH-8109-2019	Chang, Zhijie/0000-0003-1567-3227				Bai RY, 2002, NAT CELL BIOL, V4, P181, DOI 10.1038/ncb753; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Cardozo CP, 2003, ARCH BIOCHEM BIOPHYS, V410, P134, DOI 10.1016/S0003-9861(02)00680-X; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim RH, 2000, GENE DEV, V14, P1605; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Li LY, 2004, MOL CELL BIOL, V24, P856, DOI 10.1128/MCB.24.2.856-864.2004; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lin Y, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-15; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Miyazono K, 2000, J CELL SCI, V113, P1101; Moustakas A, 2001, J CELL SCI, V114, P4359; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nourry C, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-20; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wang TW, 2003, FRONT BIOSCI, V8, pD1109, DOI 10.2741/1057; Wiederkehr T, 2002, CURR BIOL, V12, pR26, DOI 10.1016/S0960-9822(01)00644-3; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200; Zhu HJ, 1999, J BIOL CHEM, V274, P32258, DOI 10.1074/jbc.274.45.32258	50	77	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20842	20850		10.1074/jbc.M412275200	http://dx.doi.org/10.1074/jbc.M412275200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781469	hybrid			2022-12-27	WOS:000229242000082
J	Roper, JR; Guther, MLS; MacRae, JI; Prescott, AR; Hallyburton, I; Acosta-Serrano, A; Ferguson, MAJ				Roper, JR; Guther, MLS; MacRae, JI; Prescott, AR; Hallyburton, I; Acosta-Serrano, A; Ferguson, MAJ			The suppression of galactose metabolism in procylic form Trypanosoma brucei causes cessation of cell growth and alters procyclin glycoprotein structure and copy number	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; ACIDIC REPETITIVE PROTEIN; BLOOD-STREAM FORMS; POLY-N-ACETYLLACTOSAMINE; AFRICAN TRYPANOSOMES; TRANS-SIALIDASE; GLYCOSYLATION MUTANTS; ANTIGENIC VARIATION; MEMBRANE ANCHOR; LINKED GLYCANS	Galactose metabolism is essential in bloodstream form Trypanosoma brucei and is initiated by the enzyme UDP-Glc 4'-epimerase. Here, we show that the parasite epimerase is a homodimer that can interconvert UDPGlc and UDP-Gal but not UDP-GlcNAc and UDP-GalNAc. The epimerase was localized to the glycosomes by immunofluorescence microscopy and subcellular fractionation, suggesting a novel compartmentalization of galactose metabolism in this organism. The epimerase is encoded by the TbGALE gene and procyclic form T. brucei single-allele knockouts, and conditional (tetracycline-inducible) null mutants were constructed. Under non-permissive conditions, conditional null mutant cultures ceased growth after 8 days and resumed growth after 15 days. The resumption of growth coincided with constitutive re-expression epimerase mRNA. These data show that galactose metabolism is essential for cell growth in procyclic form T. brucei. The epimerase is required for glycoprotein galactosylation. The major procyclic form glycoproteins, the procyclins, were analyzed in TbGALE single-allele knockouts and in the conditional null mutant after removal of tetracycline. The procyclins contain glycosylphosphatidylinositol membrane anchors with large poly-N-acetyl-lactosamine side chains. The single allele knockouts exhibited 30% reduction in procyclin galactose content. This example of haploid insufficiency suggests that epimerase levels are close to limiting in this life cycle stage. Similar analyses of the conditional null mutant 9 days after the removal of tetracycline showed that the procyclins were virtually galactose-free and greatly reduced in size. The parasites compensated, ultimately unsuccessfully, by expressing 10-fold more procyclin. The implications of these data with respect to the relative roles of procyclin polypeptide and carbohydrate are discussed.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland	University of Dundee	Ferguson, MAJ (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.	m.a.j.ferguson@dundee.ac.uk	Ferguson, Michael A. J./F-7829-2010; Prescott, Alan/Y-5956-2018; Acosta-Serrano, Alvaro/L-5503-2015	Ferguson, Michael A. J./0000-0003-1321-8714; Prescott, Alan/0000-0002-0747-7317; Acosta-Serrano, Alvaro/0000-0002-2576-7959; Hallyburton, Irene/0000-0003-4883-5560; MacRae, James/0000-0002-1464-8583				Acosta-Serrano A, 2000, J MOL BIOL, V304, P633, DOI 10.1006/jmbi.2000.4246; Acosta-Serrano A, 2004, EUKARYOT CELL, V3, P255, DOI 10.1128/EC.3.2.255-263.2004; Acosta-Serrano A, 1999, J BIOL CHEM, V274, P29763, DOI 10.1074/jbc.274.42.29763; Acosta-Serrano A, 2001, P NATL ACAD SCI USA, V98, P1513, DOI 10.1073/pnas.041611698; Atrih A, 2005, J BIOL CHEM, V280, P865, DOI 10.1074/jbc.M411061200; BRICKMAN MJ, 1990, J PROTOZOOL, V37, P219, DOI 10.1111/j.1550-7408.1990.tb01131.x; BRUN R, 1979, ACTA TROP, V36, P289; Butikofer P, 1999, J CELL SCI, V112, P1785; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; DECARVALHO LCP, 1993, J EXP MED, V177, P465, DOI 10.1084/jem.177.2.465; ENGSTLER M, 1993, MOL BIOCHEM PARASIT, V61, P1, DOI 10.1016/0166-6851(93)90153-O; Ferguson M. A. J., 1993, GLYCOBIOLOGY, P349; FERGUSON MAJ, 1993, BIOCHEM J, V291, P51, DOI 10.1042/bj2910051; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; Hwa KY, 2000, MOL BIOCHEM PARASIT, V111, P173, DOI 10.1016/S0166-6851(00)00310-8; Lillico S, 2003, MOL BIOL CELL, V14, P1182, DOI 10.1091/mbc.E02-03-0167; MacRae JI, 2005, GLYCOBIOLOGY, V15, P131, DOI 10.1093/glycob/cwh149; Mehlert A, 1998, MOL BIOCHEM PARASIT, V91, P145, DOI 10.1016/S0166-6851(97)00187-4; Mehlert A, 1999, MOL BIOCHEM PARASIT, V98, P291, DOI 10.1016/S0166-6851(98)00168-6; Mehlert A, 1998, J MOL BIOL, V277, P379, DOI 10.1006/jmbi.1997.1600; Michels PAM, 2000, PARASITOL TODAY, V16, P482, DOI 10.1016/S0169-4758(00)01810-X; Montagna G, 2002, EUR J BIOCHEM, V269, P2941, DOI 10.1046/j.1432-1033.2002.02968.x; Morris JC, 2002, EMBO J, V21, P4429, DOI 10.1093/emboj/cdf474; MOWATT MR, 1987, MOL CELL BIOL, V7, P2838, DOI 10.1128/MCB.7.8.2838; Nagamune K, 2004, J EXP MED, V199, P1445, DOI 10.1084/jem.20030635; Nolan DP, 1999, CURR BIOL, V9, P1169, DOI 10.1016/S0960-9822(00)80018-4; Parsons M, 2004, MOL MICROBIOL, V53, P717, DOI 10.1111/j.1365-2958.2004.04203.x; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; RODITI I, 1987, NATURE, V325, P272, DOI 10.1038/325272a0; RODITI I, 1989, J CELL BIOL, V108, P737, DOI 10.1083/jcb.108.2.737; Roditi I, 1999, MOL BIOCHEM PARASIT, V103, P99, DOI 10.1016/S0166-6851(99)00124-3; Roper JR, 2003, MOL BIOCHEM PARASIT, V132, P47, DOI 10.1016/j.molbiopara.2003.07.002; Roper JR, 2002, P NATL ACAD SCI USA, V99, P5884, DOI 10.1073/pnas.092669999; Schlaeppi AC, 2003, J BIOL CHEM, V278, P49980, DOI 10.1074/jbc.M309548200; SCHNEIDER P, 1994, J BIOL CHEM, V269, P18332; Schuck P, 2004, BIOPHYS CHEM, V108, P187, DOI 10.1016/j.bpc.2003.10.016; Shaw MP, 2003, MOL BIOCHEM PARASIT, V126, P173, DOI 10.1016/S0166-6851(02)00243-8; SOMMER JM, 1994, ANNU REV MICROBIOL, V48, P105, DOI 10.1146/annurev.mi.48.100194.000541; STEIGER RF, 1980, EUR J BIOCHEM, V105, P163, DOI 10.1111/j.1432-1033.1980.tb04486.x; Tetaud E, 1997, BIOCHEM J, V325, P569, DOI 10.1042/bj3250569; Thoden JB, 2001, J BIOL CHEM, V276, P15131, DOI 10.1074/jbc.M100220200; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Vanhamme L, 2001, TRENDS PARASITOL, V17, P338, DOI 10.1016/S1471-4922(01)01922-5; Vassella E, 2000, GENE DEV, V14, P615; Vassella E, 2004, MOL BIOL CELL, V15, P3986, DOI 10.1091/mbc.E04-04-0341; Vassella E, 2003, MOL BIOL CELL, V14, P1308, DOI 10.1091/mbc.E02-10-0694; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244	52	62	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19728	19736		10.1074/jbc.M502370200	http://dx.doi.org/10.1074/jbc.M502370200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15767252	hybrid			2022-12-27	WOS:000229113700039
J	Vincent, F; Davies, GJ; Brannigan, JA				Vincent, F; Davies, GJ; Brannigan, JA			Structure and kinetics of a monomeric glucosamine 6-phosphate deaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; N-ACETYLGLUCOSAMINE-6-PHOSPHATE DEACETYLASE; 6-PHOSPHOGLUCONOLACTONASE; PURIFICATION; REFINEMENT; MECHANISM; ENZYME	Glucosamine 6-phosphate is converted to fructose 6-phosphate and ammonia by the action of the enzyme glucosamine 6-phosphate deaminase, NagB. This reaction is the final step in the specific GlcNAc utilization pathway and thus decides the metabolic fate of GlcNAc. Sequence analyses suggest that the NagB "superfamily" consists of three main clusters: multimeric and allosterically regulated glucosamine-6-phosphate deaminases ( exemplified by Escherichia coli NagB), phosphogluconolactonases, and monomeric hexosamine-6-phosphate deaminases. Here we present the three-dimensional structure and kinetics of the first member of this latter group, the glucosamine-6-phosphate deaminase, NagB, from Bacillus subtilis. The structures were determined in ligand-complexed forms at resolutions around 1.4 angstrom. BsuNagB is monomeric in solution and as a consequence is active (k(cat) 28 s(-1), K-m(app) 0.13 mM) without the need for allosteric activators. A decrease in activity at high substrate concentrations may reflect substrate inhibition ( with K-i of similar to 4 mM). The structure completes the NagB superfamily structural landscape and thus allows further interrogation of genomic data in terms of the regulation of NagB and the metabolic fate(s) of glucosamine 6-phosphate.	Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England	University of York - UK	Davies, GJ (corresponding author), Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	davies@ysbl.york.ac.uk	Vincent, Florence/F-7137-2016; Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X; vincent, Florence/0000-0002-8564-4184				Alice AF, 2003, MICROBIOL-SGM, V149, P1687, DOI 10.1099/mic.0.26231-0; Arreola R, 2003, FEBS LETT, V551, P63, DOI 10.1016/S0014-5793(03)00896-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAUER HP, 1983, EUR J BIOCHEM, V133, P163, DOI 10.1111/j.1432-1033.1983.tb07442.x; Berg JM, 2002, BIOCHEMISTRY-US, V5th; Cisneros DA, 2004, ARCH BIOCHEM BIOPHYS, V421, P77, DOI 10.1016/j.abb.2003.09.041; Clarke JL, 2001, EUR J BIOCHEM, V268, P2013, DOI 10.1046/j.1432-1327.2001.02078.x; Collard F, 1999, FEBS LETT, V459, P223, DOI 10.1016/S0014-5793(99)01247-8; DeLano W, 2002, PYMOL 0 99; Ferreira FM, 2000, ACTA CRYSTALLOGR D, V56, P670, DOI 10.1107/S0907444900003668; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hamada K, 2003, J BIOL CHEM, V278, P49183, DOI 10.1074/jbc.M309272200; HOFER HW, 1987, CELL BIOCHEM FUNCT, V5, P97, DOI 10.1002/cbf.290050203; Horjales E, 1999, STRUCTURE, V7, P527, DOI 10.1016/S0969-2126(99)80069-0; KAWADA M, 1962, BIOCHIM BIOPHYS ACTA, V57, P404, DOI 10.1016/0006-3002(62)91145-9; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; Komatsuzawa H, 2004, MOL MICROBIOL, V53, P1221, DOI 10.1111/j.1365-2958.2004.04200.x; LEATHERBARROW RJ, 2001, GRASFIT; MIDELFORT CF, 1977, BIOCHEMISTRY-US, V16, P1590, DOI 10.1021/bi00627a010; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Oldfield TJ, 2001, ACTA CRYSTALLOGR D, V57, P82, DOI 10.1107/S0907444900014098; Oliva G, 1995, STRUCTURE, V3, P1323, DOI 10.1016/S0969-2126(01)00270-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rakitzis ET, 1995, BIOCHEM MOL BIOL INT, V37, P747; Roos AK, 2005, J BIOL CHEM, V280, P6416, DOI 10.1074/jbc.M412018200; Rudino-Pinera E, 2002, ACTA CRYSTALLOGR D, V58, P10, DOI 10.1107/S0907444901016699; Shakeri-Garakani A, 2004, MOL GENET GENOMICS, V271, P717, DOI 10.1007/s00438-004-1022-8; Souza JM, 1997, ARCH BIOCHEM BIOPHYS, V340, P338, DOI 10.1006/abbi.1997.9780; Vincent F, 2004, J BIOL CHEM, V279, P2809, DOI 10.1074/jbc.M310165200; Warren L., 1972, BIOSYNTHESIS METABOL	32	34	35	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19649	19655		10.1074/jbc.M502131200	http://dx.doi.org/10.1074/jbc.M502131200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15755726	Green Published, hybrid			2022-12-27	WOS:000229113700029
J	El Ghachi, M; Derbise, A; Bouhss, A; Mengin-Lecreulx, D				El Ghachi, M; Derbise, A; Bouhss, A; Mengin-Lecreulx, D			Identification of multiple genes encoding membrane proteins with undecaprenyl pyrophosphate phosphatase (UppP) activity in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACITRACIN ABC TRANSPORTER; BACILLUS-LICHENIFORMIS; BACA GENE; PEPTIDOGLYCAN SYNTHESIS; DIPHOSPHATE SYNTHASE; CYTOPLASMIC STEPS; RESISTANCE; PURIFICATION; SUBTILIS; SEQUENCE	The bacA gene product of Escherichia coli was recently purified to near homogeneity and identified as an undecaprenyl pyrophosphate phosphatase activity ( El Ghachi, M., Bouhss, A., Blanot, D., and Mengin-Lecreulx, D. ( 2004) J. Biol. Chem. 279, 30106-30113). The enzyme function is to synthesize the carrier lipid undecaprenyl phosphate that is essential for the biosynthesis of peptidoglycan and other cell wall components. The inactivation of the chromosomal bacA gene was not lethal but led to a significant, but not total, depletion of undecaprenyl pyrophosphate phosphatase activity in E. coli membranes, suggesting that other(s) protein( s) should exist and account for the residual activity and viability of the mutant strain. Here we report that inactivation of two additional genes, ybjG and pgpB, is required to abolish growth of the bacA mutant strain. Overexpression of either of these genes, or of a fourth identified one, yeiU, is shown to result in bacitracin resistance and increased levels of undecaprenyl pyrophosphate phosphatase activity, as previously observed for bacA. A thermosensitive conditional triple mutant Delta bacA,Delta ybjG,Delta pgpB in which the expression of bacA is impaired at 42 degrees C was constructed. This strain was shown to accumulate soluble peptidoglycan nucleotide precursors and to lyse when grown at the restrictive temperature, due to the depletion of the pool of undecaprenyl phosphate and consequent arrest of cell wall synthesis. This work provides evidence that two different classes of proteins exhibit undecaprenyl pyrophosphate phosphatase activity in E. coli and probably other bacterial species; they are the BacA enzyme and several members from a superfamily of phosphatases that, different from BacA, share in common a characteristic phosphatase sequence motif.	Univ Paris 11, CNRS, UMR 8619,Lab Enveloppes Bacteriennes & Antibiot, Inst Biochim Biophys Mol & Cellulaire, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Mengin-Lecreulx, D (corresponding author), Univ Paris 11, CNRS, UMR 8619,Lab Enveloppes Bacteriennes & Antibiot, Inst Biochim Biophys Mol & Cellulaire, Batiment 430, F-91405 Orsay, France.	dominique.mengin-lecreulx@ebp.u-psud.fr		MENGIN-LECREULX, Dominique/0000-0003-3205-0275				ALLEN CM, 1985, METHOD ENZYMOL, V110, P281; Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483-492.1999; Bernard R, 2003, FEMS MICROBIOL LETT, V228, P93, DOI 10.1016/S0378-1097(03)00738-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIN BD, 1993, J BACTERIOL, V175, P3784, DOI 10.1128/JB.175.12.3784-3789.1993; Cao M, 2002, J BACTERIOL, V184, P6123, DOI 10.1128/JB.184.22.6123-6129.2002; Chalker AF, 2000, MICROBIOL-SGM, V146, P1547, DOI 10.1099/00221287-146-7-1547; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; El Ghachi M, 2004, J BIOL CHEM, V279, P30106, DOI 10.1074/jbc.M401701200; FIEDLER W, 1988, J BIOL CHEM, V263, P14684; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; Fujihashi M, 2001, P NATL ACAD SCI USA, V98, P4337, DOI 10.1073/pnas.071514398; FUNK CR, 1992, J BACTERIOL, V174, P205, DOI 10.1128/jb.174.1.205-213.1992; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Harel YM, 1999, J BACTERIOL, V181, P6176, DOI 10.1128/JB.181.19.6176-6178.1999; ICHO T, 1983, J BACTERIOL, V153, P722, DOI 10.1128/JB.153.2.722-730.1983; Kato JI, 1999, J BACTERIOL, V181, P2733, DOI 10.1128/JB.181.9.2733-2738.1999; MENGINLECREULX D, 1982, J BACTERIOL, V151, P1109, DOI 10.1128/JB.151.3.1109-1117.1982; MENGINLECREULX D, 1983, J BACTERIOL, V154, P1284, DOI 10.1128/JB.154.3.1284-1290.1983; MENGINLECREULX D, 1985, J BACTERIOL, V163, P208, DOI 10.1128/JB.163.1.208-212.1985; MEYER W, 1992, EUR J BIOCHEM, V207, P741, DOI 10.1111/j.1432-1033.1992.tb17104.x; Miller J. H., 1972, EXPT MOL GENETICS, P431; Neuhaus FC, 2003, MICROBIOL MOL BIOL R, V67, P686, DOI 10.1128/MMBR.67.4.686-723.2003; Neuwald AF, 1997, PROTEIN SCI, V6, P1764, DOI 10.1002/pro.5560060817; Ohki R, 2003, J BACTERIOL, V185, P51, DOI 10.1128/JB.185.1.51-59.2003; PODLESEK Z, 1995, MOL MICROBIOL, V16, P969, DOI 10.1111/j.1365-2958.1995.tb02322.x; Podlesek Z, 2000, FEMS MICROBIOL LETT, V188, P103, DOI 10.1111/j.1574-6968.2000.tb09176.x; POLLOCK TJ, 1994, J BACTERIOL, V176, P6229, DOI 10.1128/jb.176.20.6229-6237.1994; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rick P, 1996, ESCHERICHIA COLI SAL, P104; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shimizu N, 1998, J BIOL CHEM, V273, P19476, DOI 10.1074/jbc.273.31.19476; SIEWERT G, 1967, P NATL ACAD SCI USA, V57, P767, DOI 10.1073/pnas.57.3.767; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; STONE KJ, 1971, P NATL ACAD SCI USA, V68, P3223, DOI 10.1073/pnas.68.12.3223; STORM DR, 1973, J BIOL CHEM, V248, P3940; Stukey J, 1997, PROTEIN SCI, V6, P469; TOSCANO WA, 1987, ANTIBIOTIC INHIBITOR, P101; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	42	111	116	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18689	18695		10.1074/jbc.M412277200	http://dx.doi.org/10.1074/jbc.M412277200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15778224	hybrid			2022-12-27	WOS:000228932300019
J	Rangaswami, H; Bulbule, A; Kundu, GC				Rangaswami, H; Bulbule, A; Kundu, GC			RETRACTED: JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation (Retracted Article. See vol 282, pg 5968, 2007)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							BREAST-CANCER CELLS; B-MEDIATED SECRETION; KAPPA-B; PLASMINOGEN-ACTIVATOR; MATRIX-METALLOPROTEINASE; SIGNALING PATHWAYS; PROTEIN-KINASE; MELANOMA-CELLS; GELATINASE-B; UROKINASE	We have recently demonstrated that nuclear factor-inducing kinase (NIK) plays a crucial role in osteopontin (OPN)-induced mitogen-activated protein kinase/I kappa B alpha kinase-dependent nuclear factor kappa B (NF kappa B)-mediated promatrix metalloproteinase-9 activation (Rangaswami, H., Bulbule, A., and Kundu, G. C. ( 2004) J. Biol. Chem. 279, 38921-38935). However, the molecular mechanism(s) by which OPN regulates NIK/MEKK1-dependent activating protein-1 (AP-1)-mediated promatrix metalloproteinase-9 activation and whether JNK1 plays any role in regulating both these pathways that control the cell motility are not well defined. Here we report that OPN induces alpha v beta 3 integrin-mediated MEKK1 phosphorylation and MEKK1-dependent JNK1 phosphorylation and activation. Overexpression of NIK enhances OPN-induced c-Jun expression, whereas overexpressed NIK had no role in OPN-induced JNK1 phosphorylation and activation. Sustained activation of JNK1 by overexpression of wild type but not kinase negative MEKK1 resulted in suppression of ERK1/2 activation. But this did not affect the OPN-induced NIK-dependent ERK1/2 activation. OPN stimulated both NIK and MEKK1-dependent c-Jun expression, leading to AP-1 activation, whereas NIK-dependent AP-1 activation is independent of JNK1. OPN also enhanced JNK1-dependent/independent AP-1-mediated urokinase type plasminogen activator (uPA) secretion, uPA-dependent promatrix metalloproteinase-9 (MMP-9) activation, cell motility, and invasion. OPN stimulates tumor growth, and the levels of c-Jun, AP-1, urokinase type plasminogen activator, and MMP-9 were higher in OPN-induced tumor compared with control. To our knowledge this is first report that OPN induces NIK/MEKK1-mediated JNK1-dependent/independent AP-1-mediated pro-MMP-9 activation and regulates the negative crosstalk between NIK/ERK1/2 and MEKK1/JNK1 pathways that ultimately controls the cell motility, invasiveness, and tumor growth.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), Natl Ctr Cell Sci, NCCS Complex, Pune 411007, Maharashtra, India.	kundu@nccs.res.in	Kundu, Gopal C./ABA-9897-2020					ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; BROWN LF, 1994, AM J PATHOL, V145, P610; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Das R, 2004, J BIOL CHEM, V279, P11051, DOI 10.1074/jbc.M310256200; Das R, 2003, J BIOL CHEM, V278, P28593, DOI 10.1074/jbc.M303445200; DAVIES B, 1993, CANCER RES, V53, P5365; DECESARE D, 1995, ONCOGENE, V11, P365; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dubois B, 1999, J CLIN INVEST, V104, P1507, DOI 10.1172/JCI6886; Folkman J, 1999, NAT BIOTECHNOL, V17, P749, DOI 10.1038/11676; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; HOUDE M, 1993, INT J CANCER, V53, P395, DOI 10.1002/ijc.2910530309; Hrabec E, 2001, RESP MED, V95, P1, DOI 10.1053/rmed.2000.0923; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Liaw L, 1998, J CLIN INVEST, V101, P1468; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P6209, DOI 10.1074/jbc.M208905200; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mukhina S, 2000, J BIOL CHEM, V275, P16450, DOI 10.1074/jbc.M909080199; MURPHY G, 1994, ANN NY ACAD SCI, V732, P31, DOI 10.1111/j.1749-6632.1994.tb24722.x; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Philip S, 2003, J BIOL CHEM, V278, P14487, DOI 10.1074/jbc.M207309200; PRINCE CW, 1989, CONNECT TISSUE RES, V21, P345, DOI 10.3109/03008208909049991; Rangaswami H, 2004, J BIOL CHEM, V279, P38921, DOI 10.1074/jbc.M404674200; Rittling SR, 1997, CELL GROWTH DIFFER, V8, P1061; Sakamoto Y, 2000, INT J ONCOL, V17, P237; Scorilas A, 2001, BRIT J CANCER, V84, P1488, DOI 10.1054/bjoc.2001.1810; Sehgal G, 1998, AM J PATHOL, V152, P591; SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; She QB, 2002, CANCER RES, V62, P1343; Shen KH, 2000, ANTICANCER RES, V20, P1307; Shen YH, 2003, J BIOL CHEM, V278, P26715, DOI 10.1074/jbc.M303264200; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; YAN MH, 1994, NATURE, V372, P798; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	50	45	47	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19381	19392		10.1074/jbc.M414204200	http://dx.doi.org/10.1074/jbc.M414204200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757900	hybrid			2022-12-27	WOS:000228932300096
J	Li, XD; Ikebe, R; Ikebe, M				Li, XD; Ikebe, R; Ikebe, M			Activation of myosin Va function by melanophilin, a specific docking partner of myosin Va	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCONVENTIONAL MYOSIN; MELANOSOME TRANSPORT; MOTOR-ACTIVITY; LINKS RAB27A; ACTIN; SLAC2-A/MELANOPHILIN; MUTATIONS; BINDING; PROTEIN; DOMAIN	It is known that melanophilin is a myosin Va-targeting molecule that links myosin Va and the cargo vesicles in cells. Here we found that melanophilin directly activates the actin-activated ATPase activity of myosin Va and thus its motor activity. The actin-activated ATPase activity of the melanocyte-type myosin Va having exon-F was significantly activated by melanophilin by 4-fold. Although Rab27a binds to myosin Va/melanophilin complex, it did not affect the melanophilin-induced activation of myosin Va. Deletion of the C-terminal actin binding domain and N-terminal Rab binding domain of melanophilin resulted in no change in the activation of the ATPase by melanophilin, indicating that the myosin Va binding domain (MBD) is sufficient for the activation of myosin Va. Among MBDs, the interaction of MBD-2 with exon-F of myosin Va is critical for the binding of myosin Va and melanophilin, whereas MBD-1 interacting with the globular tail of myosin Va plays a more significant role in the activation of myosin Va ATPase activity. This is the first demonstration that the binding of the cargo molecule directly activates myosin motor activity. The present finding raises the idea that myosin motors are switched upon their binding to the cargo molecules, thus avoiding the waste of ATP consumption.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	Mitsuo.Ikebe@umassmed.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048526, R01AR041653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006103] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR048526, AR41653] Funding Source: Medline; NIDCD NIH HHS [DC006103] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; Fukuda M, 2004, J CELL SCI, V117, P583, DOI 10.1242/jcs.00891; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; Huang JD, 1998, GENETICS, V148, P1963; Karcher RL, 2001, SCIENCE, V293, P1317, DOI 10.1126/science.1061086; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; Kuroda TS, 2003, MOL CELL BIOL, V23, P5245, DOI 10.1128/MCB.23.15.5245-5255.2003; Langford GM, 2002, TRAFFIC, V3, P859, DOI 10.1034/j.1600-0854.2002.31202.x; Li XD, 2004, BIOCHEM BIOPH RES CO, V315, P538, DOI 10.1016/j.bbrc.2004.01.084; Maruta S, 1998, EUR J BIOCHEM, V256, P229, DOI 10.1046/j.1432-1327.1998.2560229.x; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Nagashima K, 2002, FEBS LETT, V517, P233, DOI 10.1016/S0014-5793(02)02634-0; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; SEPERACK PK, 1995, EMBO J, V14, P2326, DOI 10.1002/j.1460-2075.1995.tb07227.x; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Wang F, 2004, J BIOL CHEM, V279, P2333, DOI 10.1074/jbc.C300488200; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; Wu XF, 2002, MOL BIOL CELL, V13, P1735, DOI 10.1091/mbc.01-12-0595; Wu XF, 1997, J CELL SCI, V110, P847; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760	32	77	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17815	17822		10.1074/jbc.M413295200	http://dx.doi.org/10.1074/jbc.M413295200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15760894	hybrid			2022-12-27	WOS:000228807200033
J	Park, SY; Choi, GH; Choi, HI; Ryu, JW; Jung, CY; Lee, W				Park, SY; Choi, GH; Choi, HI; Ryu, JW; Jung, CY; Lee, W			Depletion of mitochondrial DNA causes impaired glucose utilization and insulin resistance in L6 GLUT4myc myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKELETAL-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; DIABETES-MELLITUS; ETHIDIUM BROMIDE; RAT ADIPOCYTES; RECEPTOR SUBSTRATE-1; SIGNALING PATHWAYS; TRANSPORTER GLUT4; PLASMA-MEMBRANE; NIDDM SUBJECTS	Mitochondrial dysfunction contributes to a number of human diseases, such as hyperlipidemia, obesity, and diabetes. The mutation and reduction of mitochondrial DNA (mtDNA) have been suggested as factors in the pathogenesis of diabetes. To elucidate the association of cellular mtDNA content and insulin resistance, we produced L6 GLUT4myc myocytes depleted of mtDNA by long term treatment with ethidium bromide. L6 GLUT4myc cells cultured with 0.2 mu g/ml ethidium bromide (termed depleted cells) revealed a marked decrease in cellular mtDNA and ATP content, concomitant with a lack of mRNAs encoded by mtDNA. Interestingly, the mtDNA-depleted cells showed a drastic decrease in basal and insulin-stimulated glucose uptake, indicating that L6 GLUT4myc cells develop impaired glucose utilization and insulin resistance. The repletion of mtDNA normalized basal and insulin-stimulated glucose uptake. The mRNA level and expression of insulin receptor substrate (IRS)-1 associated with insulin signaling were decreased by 76 and 90% in the depleted cells, respectively. The plasma membrane (PM) GLUT4 in the basal state was decreased, and the insulin-stimulated GLUT4 translocation to the PM was drastically reduced by mtDNA depletion. Moreover, insulin-stimulated phosphorylation of IRS-1 and Akt2/protein kinase B were drastically reduced in the depleted cells. Those changes returned to control levels after mtDNA repletion. Taken together, our data suggest that PM GLUT4 content and insulin signal pathway intermediates are modulated by the alteration of cellular mtDNA content, and the reductions in the expression of IRS-1 and insulin-stimulated phosphorylation of IRS-1 and Akt2/protein kinase B are associated with insulin resistance in the mtDNA-depleted L6 GLUT4myc myocytes.	Dongguk Univ, Dept Biochem, Coll Med, Kyungju 780714, South Korea; SUNY Buffalo, Sch Med, Dept Physiol & Biophys, Vet Affairs Med Ctr,Biophys Lab, Buffalo, NY 14215 USA	Dongguk University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Lee, W (corresponding author), Dongguk Univ, Dept Biochem, Coll Med, Kyungju 780714, South Korea.	wanlee@mail.dongguk.ac.kr	Lee, Wan/B-6252-2013	Lee, Wan/0000-0002-5181-2135; Ryu, Jiwon/0000-0003-0251-7858				Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ANTONETTI DA, 1995, J CLIN INVEST, V95, P1383, DOI 10.1172/JCI117790; Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Biswas G, 2003, J CELL BIOL, V161, P507, DOI 10.1083/jcb.200211104; Bjornholm M, 1997, DIABETES, V46, P524, DOI 10.2337/diabetes.46.3.524; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; CHEN LB, 1989, METHOD CELL BIOL, V29, P103; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; Froguel P, 2001, RECENT PROG HORM RES, V56, P91, DOI 10.1210/rp.56.1.91; Gerbitz KD, 1996, DIABETES, V45, P113, DOI 10.2337/diabetes.45.2.113; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; Han JC, 2003, ARCH BIOCHEM BIOPHYS, V413, P213, DOI 10.1016/S0003-9861(03)00120-6; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; Hayakawa T, 1998, J BIOL CHEM, V273, P20300, DOI 10.1074/jbc.273.32.20300; HERZBERG NH, 1993, BIOCHIM BIOPHYS ACTA, V1181, P63, DOI 10.1016/0925-4439(93)90091-E; Higaki Y, 1999, J BIOL CHEM, V274, P20791, DOI 10.1074/jbc.274.30.20791; Holman GD, 2001, TRENDS CELL BIOL, V11, P173, DOI 10.1016/S0962-8924(01)01953-5; Huang C, 2002, DIABETES, V51, P2090, DOI 10.2337/diabetes.51.7.2090; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403; KANAI F, 1993, J BIOL CHEM, V268, P14523; Kanzaki M, 2003, CURR BIOL, V13, pR574, DOI 10.1016/S0960-9822(03)00478-0; Kelley DE, 2001, DIABETES CARE, V24, P933, DOI 10.2337/diacare.24.5.933; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Khan AH, 2002, DIABETOLOGIA, V45, P1475, DOI 10.1007/s00125-002-0974-7; Khayat ZA, 2000, J CELL SCI, V113, P279; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HK, 1998, DIABETES RES CLIN PR, V42, P161, DOI 10.1016/S0168-8227(98)00110-7; Lee W, 2000, BIOCHEMISTRY-US, V39, P9358, DOI 10.1021/bi0007021; Lee W, 1999, J BIOL CHEM, V274, P37755, DOI 10.1074/jbc.274.53.37755; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; Li Y, 2004, J BIOL CHEM, V279, P45304, DOI 10.1074/jbc.C400186200; Malide D, 1997, J HISTOCHEM CYTOCHEM, V45, P1083, DOI 10.1177/002215549704500806; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Park KS, 2001, AM J PHYSIOL-ENDOC M, V280, pE1007, DOI 10.1152/ajpendo.2001.280.6.E1007; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Seidel-Rogol BL, 2002, NUCLEIC ACIDS RES, V30, P1929, DOI 10.1093/nar/30.9.1929; SERRADAS P, 1995, ENDOCRINOLOGY, V136, P5623, DOI 10.1210/en.136.12.5623; Simoneau JA, 1999, FASEB J, V13, P2051, DOI 10.1096/fasebj.13.14.2051; SIMONEAU JA, 1995, FASEB J, V9, P273, DOI 10.1096/fasebj.9.2.7781930; Simoneau JA, 1997, J APPL PHYSIOL, V83, P166, DOI 10.1152/jappl.1997.83.1.166; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; Ueyama A, 1999, AM J PHYSIOL-ENDOC M, V277, pE572, DOI 10.1152/ajpendo.1999.277.3.E572; Wang QH, 1998, FEBS LETT, V427, P193, DOI 10.1016/S0014-5793(98)00423-2; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Watson RT, 2001, RECENT PROG HORM RES, V56, P175, DOI 10.1210/rp.56.1.175; White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952; Whitehead JP, 2000, CURR OPIN CELL BIOL, V12, P222, DOI 10.1016/S0955-0674(99)00079-4; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8; ZYLBER E, 1969, J MOL BIOL, V44, P195, DOI 10.1016/0022-2836(69)90414-8	66	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	2005	280	11					9855	9864		10.1074/jbc.M409399200	http://dx.doi.org/10.1074/jbc.M409399200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	905HQ	15764607	hybrid			2022-12-27	WOS:000227559600015
J	Sher, D; Fishman, Y; Zhang, ML; Lebendiker, M; Gaathon, A; Mancheno, JM; Zlotkin, E				Sher, D; Fishman, Y; Zhang, ML; Lebendiker, M; Gaathon, A; Mancheno, JM; Zlotkin, E			Hydralysins, a new category of beta-pore-forming toxins in Cnidaria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; CYTOLYSIN EQUINATOXIN-II; PROTEIN TOXINS; FLAMMULINA-VELUTIPES; LIPID RAFTS; AEROLYSIN; BINDING; RECEPTOR; SPHINGOMYELIN; PROAEROLYSIN	Cnidaria are venomous animals that produce diverse protein and polypeptide toxins, stored and delivered into the prey through the stinging cells, the nematocytes. These include pore-forming cytolytic toxins such as well studied actinoporins. In this work, we have shown that the non-nematocystic paralytic toxins, hydralysins, from the green hydra Chlorohydra viridissima comprise a highly diverse group of beta-pore-forming proteins, distinct from other cnidarian toxins but similar in activity and structure to bacterial and fungal toxins. Functional characterization of hydralysins reveals that as soluble monomers they are rich in beta-structure, as revealed by far UV circular dichroism and computational analysis. Hydralysins bind erythrocyte membranes and form discrete pores with an internal diameter of similar to 1.2 nm. The cytolytic effect of hydralysin is cell type-selective, suggesting a specific receptor that is not a phospholipid or carbohydrate. Multiple sequence alignment reveals that hydralysins share a set of conserved sequence motifs with known pore-forming toxins such as aerolysin, epsilon-toxin, alpha-toxin, and LSL and that these sequence motifs are found in and around the pore-forming domains of the toxins. The importance of these sequence motifs is revealed by the cloning, expression, and mutagenesis of three hydralysin isoforms that strongly differ in their hemolytic and paralytic activities. The correlation between the paralytic and cytolytic activities of hydralysin suggests that both are a consequence of receptor-mediated pore formation. Hydralysins and their homologues exemplify the wide distribution of beta-pore formers in biology and provide a useful model for the study of their molecular mode of action.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Cell & Anim Biol, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Wolfson Ctr Appl Struct Biol, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Med, Bletterman Lab Macromol, IL-91120 Jerusalem, Israel; CSIC, Inst Quim Fis Rocasolano, Dept Cristalog, E-28006 Madrid, Spain	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	Zlotkin, E (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Cell & Anim Biol, IL-91904 Jerusalem, Israel.	zlotkin@vms.huji.ac.il	Mancheno, Jose/K-4984-2014	Mancheno, Jose/0000-0001-6943-3291				Abrami L, 2000, TRENDS MICROBIOL, V8, P168, DOI 10.1016/S0966-842X(00)01722-4; Abrami L, 2002, FEBS LETT, V512, P249, DOI 10.1016/S0014-5793(02)02274-3; Abrami L, 1998, J BIOL CHEM, V273, P32656, DOI 10.1074/jbc.273.49.32656; Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anderluh G, 2005, J MOL BIOL, V347, P27, DOI 10.1016/j.jmb.2004.12.058; Anderluh G, 1999, TOXICON, V37, P1391, DOI 10.1016/S0041-0101(99)00082-3; Anderluh G, 2002, TOXICON, V40, P111, DOI 10.1016/S0041-0101(01)00191-X; Athanasiadis A, 2001, STRUCTURE, V9, P341, DOI 10.1016/S0969-2126(01)00592-5; BALLARD J, 1993, MOL MICROBIOL, V10, P627, DOI 10.1111/j.1365-2958.1993.tb00934.x; Bashford CL, 1996, J MEMBRANE BIOL, V150, P37, DOI 10.1007/s002329900028; Ben-Zimra M, 2002, MOL ENDOCRINOL, V16, P1864, DOI 10.1210/me.2002-0056; BERNIER F, 1987, GENE, V59, P265, DOI 10.1016/0378-1119(87)90334-9; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cole AR, 2004, NAT STRUCT MOL BIOL, V11, P797, DOI 10.1038/nsmb804; Cole DS, 2003, CLIN SCI, V104, P455, DOI 10.1042/CS20020362; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cromer BA, 2002, EUR BIOPHYS J BIOPHY, V31, P356, DOI 10.1007/s00249-002-0219-1; de Maagd RA, 2001, TRENDS GENET, V17, P193, DOI 10.1016/S0168-9525(01)02237-5; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Edwards L, 2000, TOXICON, V38, P1015, DOI 10.1016/S0041-0101(99)00213-5; EITAN M, 1990, BIOCHEMISTRY-US, V29, P5941, DOI 10.1021/bi00477a009; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Gilbert RJC, 2002, CELL MOL LIFE SCI, V59, P832, DOI 10.1007/s00018-002-8471-1; Gouaux E, 1997, CURR OPIN STRUC BIOL, V7, P566, DOI 10.1016/S0959-440X(97)80123-6; Hinds MG, 2002, J MOL BIOL, V315, P1219, DOI 10.1006/jmbi.2001.5321; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; Kiyokawa E, 2004, BIOCHEMISTRY-US, V43, P9766, DOI 10.1021/bi049561j; KUGA S, 1981, J CHROMATOGR, V206, P449, DOI 10.1016/S0021-9673(00)88914-1; Lazebnik Y, 2001, CURR BIOL, V11, pR767, DOI 10.1016/S0960-9822(01)00465-1; Lenhoff H.M., 1983, P29; Mancheno JM, 2003, STRUCTURE, V11, P1319, DOI 10.1016/j.str.2003.09.019; MANCHENO JM, 2005, J BIOL CHEM; MEINARDI E, 1995, BIOCHEM BIOPH RES CO, V216, P348, DOI 10.1006/bbrc.1995.2630; MEINARDI E, 1994, COMP BIOCHEM PHYS B, V109, P153, DOI 10.1016/0305-0491(94)90152-X; Melton JA, 2004, J BIOL CHEM, V279, P14315, DOI 10.1074/jbc.M313758200; Nagai H, 2000, BIOCHEM BIOPH RES CO, V275, P589, DOI 10.1006/bbrc.2000.3352; Nagai H, 2000, BIOCHEM BIOPH RES CO, V275, P582, DOI 10.1006/bbrc.2000.3353; Parker MW, 2005, PROG BIOPHYS MOL BIO, V88, P91, DOI 10.1016/j.pbiomolbio.2004.01.009; Parker MW, 2003, TOXICON, V42, P1, DOI 10.1016/S0041-0101(03)00106-5; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Parry-Smith DJ, 1998, GENE, V221, pGC57, DOI 10.1016/S0378-1119(97)00650-1; Perera OP, 1999, ARCH INSECT BIOCHEM, V40, P157, DOI 10.1002/(SICI)1520-6327(1999)40:3&lt;157::AID-ARCH5&gt;3.0.CO;2-W; PRIMOR N, 1975, TOXICON, V13, P227, DOI 10.1016/0041-0101(75)90128-2; REED L. J., 1938, AMER JOUR HYG, V27, P493; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Rossjohn J, 1997, EMBO J, V16, P3426, DOI 10.1093/emboj/16.12.3426; Rossjohn J, 1998, J STRUCT BIOL, V121, P92, DOI 10.1006/jsbi.1997.3947; Rossjohn J, 1998, BIOCHEMISTRY-US, V37, P741, DOI 10.1021/bi9721039; Sekiya K, 1998, J ELECTRON MICROSC, V47, P543, DOI 10.1093/oxfordjournals.jmicro.a023627; SHER D, 2005, IN PRESS TOXICON; Sollod BL, 2005, PEPTIDES, V26, P131, DOI 10.1016/j.peptides.2004.07.016; Sreerama N, 1999, PROTEIN SCI, V8, P370; TARDENT P, 1995, BIOESSAYS, V17, P351, DOI 10.1002/bies.950170411; Tateno H, 2003, J BIOL CHEM, V278, P40455, DOI 10.1074/jbc.M306836200; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tomita T, 2004, J BIOL CHEM, V279, P54161, DOI 10.1074/jbc.M408783200; Tomita T, 1998, BIOCHEM J, V333, P129, DOI 10.1042/bj3330129; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yamaji-Hasegawa A, 2003, J BIOL CHEM, V278, P22762, DOI 10.1074/jbc.M213209200; Zhang ML, 2003, BIOCHEMISTRY-US, V42, P8939, DOI 10.1021/bi0343929; Zhuang MB, 2002, J BIOL CHEM, V277, P13863, DOI 10.1074/jbc.M110057200	64	65	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22847	22855		10.1074/jbc.M503242200	http://dx.doi.org/10.1074/jbc.M503242200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15824108	hybrid			2022-12-27	WOS:000229741800037
J	Kinoshita, T; Wang, YT; Hasegawa, M; Imamura, R; Suda, T				Kinoshita, T; Wang, YT; Hasegawa, M; Imamura, R; Suda, T			PYPAF3, a PYRIN-containing APAF-1-like protein, is a feedback regulator of caspase-1-dependent interleukin-1 beta secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CONTAINING APAF1-LIKE PROTEIN; CASPASE-1 ACTIVATION; INFLAMMATION; APOPTOSIS; INHIBITOR; VECTOR; BETA; ASC	PYPAF3 is a member of the PYRIN-containing apoptotic protease-activating factor-1-like proteins (PYPAFs, also called NALPs). Among the members of this family, PYPAF1, PYPAF5, PYPAF7, and NALP1 have been shown to induce caspase-1-dependent interleukin-1 beta secretion and NF-kappa B activation in the presence of the adaptor molecule ASC. On the other hand, we recently discovered that PYNOD, another member of this family, is a suppressor of these responses. Here, we show that PYPAF3 is the second member that inhibits caspase-1-dependent interleukin-1 beta secretion. In contrast, PYPAF2/NALP2 does not inhibit this response but rather inhibits the NF-kappa B activation that is induced by the combined expression of PYPAF1 and ASC. Both PYPAF2 and PYPAF3 mRNAs are broadly expressed in a variety of tissues; however, neither is expressed in skeletal muscle, and only PYPAF2 mRNA is expressed in heart and brain. They are also expressed in many cell lines of both hematopoietic and non-hematopoietic lineages. Stimulation of monocytic THP-1 cells with lipopolysaccharide or interleukin-1 beta induced PYPAF3 mRNA expression. Furthermore, the stable expression of PYPAF3 in THP-1 cells abrogated the ability of the cells to produce interleukin-1 beta in response to lipopolysaccharide. These results suggest that PYPAF3 is a feedback regulator of interleukin-1 beta secretion. Thus, PYPAF2 and PYPAF3, together with PYNOD, constitute an anti-inflammatory subgroup of PYPAFs.	Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan	Kanazawa University	Suda, T (corresponding author), Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan.	sudat@kenroku.kanazawa-u.ac.jp	KINOSHITA, Takeshi/D-8436-2015; IMAMURA, Ryu/D-8433-2015					Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; DINARELLO CA, 1992, INT J TISSUE REACT, V14, P65; DINARELLO CA, 1984, NEW ENGL J MED, V311, P1413; Fiorentino L, 2002, J BIOL CHEM, V277, P35333, DOI 10.1074/jbc.M200446200; Fukui M, 2003, J IMMUNOL, V171, P1868, DOI 10.4049/jimmunol.171.4.1868; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Lee SH, 2001, J BIOL CHEM, V276, P34495, DOI 10.1074/jbc.M101415200; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Razmara M, 2002, J BIOL CHEM, V277, P13952, DOI 10.1074/jbc.M107811200; Reed JC, 2003, GENOME RES, V13, P1376, DOI 10.1101/gr.1053803; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Wang YT, 2004, INT IMMUNOL, V16, P777, DOI 10.1093/intimm/dxh081	19	111	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21720	21725		10.1074/jbc.M410057200	http://dx.doi.org/10.1074/jbc.M410057200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817483	hybrid, Green Submitted			2022-12-27	WOS:000229557900007
J	Lee, YI; Seo, M; Kim, Y; Kim, SY; Kang, UG; Kim, YS; Juhnn, YS				Lee, YI; Seo, M; Kim, Y; Kim, SY; Kang, UG; Kim, YS; Juhnn, YS			Membrane depolarization induces the undulating phosphorylation/dephosphorylation of glycogen synthase kinase 3 beta and this dephosphorylation involves protein phosphatases 2A and 2B in SH-SY5Y human neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; POTASSIUM DEPOLARIZATION; KINASE; PHOSPHORYLATION; CALCINEURIN; SURVIVAL; INSULIN; BINDING	Changes in plasma membrane electrical potential evoke signals that regulate the expressions of various genes in the nervous system. However, the role of glycogen synthase kinase 3 beta (GSK-3 beta) in this process has not been elucidated. Thus, this study was performed to examine whether membrane depolarization can regulate the phosphorylation of GSK-3 beta and to identify the molecular mechanisms involved in this regulation. The depolarization by treating with 100 mM KCl for 5 min resulted in the undulating phosphorylation of GSK-3 beta at Ser-9 in SH-SY5Y human neuroblastoma cells, in H19-7/ IGF-IR rat embryonic hippocampal cells, and in PC12 rat pheochromocytoma cells, but not in A172 human glioblastoma cells. Cellular beta-catenin contents showed a temporal pattern similar to that of the Ser-9 phosphorylation of GSK-3 beta. Treatment with wortmannin or calphostin C or the expression of dominant negative Akt inhibited phosphorylation of GSK-3 beta at Ser-9 following the KCl-induced depolarization of SH-SY5Y cells. Moreover, pretreatment with okadaic acid or cyclosporin A blocked the dephosphorylation of GSK-3 beta at Ser-9 at 0, 15, and 30 min after KCl-induced depolarization, and the activity of protein phosphatases (PP) 2A and 2B increased at these times. Treatment with nifedipine or calcium-free medium inhibited GSK-3 beta dephosphorylation following membrane depolarization, and the amounts of co-immunoprecipitated GSK-3 beta and PP2A changed in parallel with GSK-3 beta dephosphorylation. Our study demonstrated that KCl-induced depolarization caused undulating GSK-3 beta phosphorylation/dephosphorylation, which was regulated for the most part by phosphatidylinositol 3-kinase and Akt (phosphorylation) and PP2A and PP2B (dephosphorylation), respectively.	Seoul Natl Univ, Coll Med, Dept Biochem, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Juhnn, YS (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, 28 Yongon Dong, Seoul 110799, South Korea.	juhnn@snu.ac.kr	Kang, Ung Gu/J-2729-2012; Juhnn, Yong-Sung/J-2790-2012					Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cedazo-Minguez A, 2003, J NEUROCHEM, V87, P1152, DOI 10.1046/j.1471-4159.2003.02088.x; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Crowder RJ, 1999, J NEUROCHEM, V73, P466, DOI 10.1046/j.1471-4159.1999.0730466.x; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Koivisto L, 2003, J CELL SCI, V116, P3749, DOI 10.1242/jcs.00693; Lewis RS, 2003, BIOCHEM SOC T, V31, P925; Miller TM, 1997, J BIOL CHEM, V272, P9847; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Roh MS, 2003, PROG NEURO-PSYCHOPH, V27, P1, DOI 10.1016/S0278-5846(02)00307-X; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Schaffer B, 2003, GENE, V302, P73, DOI 10.1016/S0378-1119(02)01092-2; Schmidt J, 1996, REV PHYSIOL BIOCH P, V127, P251, DOI 10.1007/BFb0048269; Seo MR, 2004, J BIOL CHEM, V279, P17366, DOI 10.1074/jbc.M312442200; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Vaillant AR, 1999, J CELL BIOL, V146, P955, DOI 10.1083/jcb.146.5.955; WOODGETT JR, 2001, SCI STKE, pRE12	35	52	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22044	22052		10.1074/jbc.M413987200	http://dx.doi.org/10.1074/jbc.M413987200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15799972	hybrid			2022-12-27	WOS:000229557900048
J	Park, KH; Hernandez, L; Cai, SQ; Wang, Y; Sesti, F				Park, KH; Hernandez, L; Cai, SQ; Wang, Y; Sesti, F			A family of K+ channel ancillary subunits regulate taste sensitivity in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINK-RELATED PEPTIDES; C-ELEGANS; POTASSIUM CHANNEL; CARDIAC-ARRHYTHMIA; NEURONS; GENE; KCNQ1; IDENTIFICATION; CHEMOTAXIS; K(V)LQT1	We have identified a family of ancillary subunits of K+ channels in Caenorhabditis elegans. MPS-1 and its related members MPS-2, MPS-3, and MPS-4 are detected in the nervous system of the nematode. Electrophysiological analysis in ASE neurons and mammalian cells and epigenetic inactivation by double-stranded RNA interference (RNAi) in vivo show that each MPS can associate with and functionally endow the voltage-gated K+ channel KVS-1. In the chemosensory neuron ADF, three different MPS subunits combine with KVS-1 to form both binary (MPS-1 center dot KVS-1) and ternary (MPS-2 center dot MPS-3 center dot KVS-1) complexes. RNAi of mps-2, mps-3, or both, enhance the taste of the animal for sodium without altering the susceptibility to other attractants. When sodium is introduced in the test plate as background or as antagonist attractant, the nematode loses the ability to recognize a second attractant. Thus, it appears that the chemosensory apparatus of C. elegans uses sensory thresholds and that a voltage-gated K+ channel is specifically required for this mechanism.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Sesti, F (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 683 Hoes Lane, Piscataway, NJ 08854 USA.	sestife@umdnj.edu	Hernandez, Leonardo H/A-5363-2013; Park, Ki Ho/E-8921-2011; wang, yi/C-4312-2012; Park, Ki Ho/N-8153-2017	Hernandez, Leonardo H/0000-0002-8570-5848; Park, Ki Ho/0000-0002-6193-9826	NIGMS NIH HHS [R01 GM 68581] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068581] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Abbott GW, 2001, CELL, V104, P217, DOI 10.1016/S0092-8674(01)00207-0; Anantharam A, 2003, J BIOL CHEM, V278, P11739, DOI 10.1074/jbc.M212751200; Angelo K, 2002, BIOPHYS J, V83, P1997, DOI 10.1016/S0006-3495(02)73961-1; BARGMANN C, 1997, C ELEGANS 2, V1, P717; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bianchi L, 2003, J BIOL CHEM, V278, P12415, DOI 10.1074/jbc.M212788200; Christensen M, 2002, NEURON, V33, P503, DOI 10.1016/S0896-6273(02)00591-3; de Bono M, 2002, NATURE, V419, P899, DOI 10.1038/nature01169; Goodman MB, 1998, NEURON, V20, P763, DOI 10.1016/S0896-6273(00)81014-4; Grunnet M, 2003, BIOPHYS J, V85, P1525, DOI 10.1016/S0006-3495(03)74585-8; Lundquist Andrew L, 2005, J Mol Cell Cardiol, V38, P277, DOI 10.1016/j.yjmcc.2004.11.012; McCrossan ZA, 2004, NEUROPHARMACOLOGY, V47, P787, DOI 10.1016/j.neuropharm.2004.06.018; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Piccini M, 1999, GENOMICS, V60, P251, DOI 10.1006/geno.1999.5904; Pierce-Shimomura JT, 2001, NATURE, V410, P694, DOI 10.1038/35070575; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; WARD S, 1973, P NATL ACAD SCI USA, V70, P817, DOI 10.1073/pnas.70.3.817; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384	24	23	29	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21893	21899		10.1074/jbc.M502732200	http://dx.doi.org/10.1074/jbc.M502732200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15799965	hybrid			2022-12-27	WOS:000229557900029
J	Luna-Medina, R; Cortes-Canteli, M; Alonso, M; Santos, A; Martinez, A; Perez-Castillo, A				Luna-Medina, R; Cortes-Canteli, M; Alonso, M; Santos, A; Martinez, A; Perez-Castillo, A			Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); ALZHEIMERS-DISEASE; MICROGLIA; EXPRESSION; ASTROCYTES; NEUROTOXICITY; INDUCTION; APOPTOSIS	In most neurodegenerative disorders, including multiple sclerosis, Parkinson disease, and Alzheimer disease, a massive neuronal cell death occurs as a consequence of an uncontrolled inflammatory response, where activated astrocytes and microglia and their cytotoxic agents play a crucial pathological role. Current treatments for these diseases are not effective. In the present study we investigate the effect of thiadiazolidinone derivatives, which have been recently suggested to play a role in neurodegenerative disorders. We have found that thiadiazolidinones are potent neuroprotector compounds. Thiadiazolidinones inhibited inflammatory activation of cultured brain astrocytes and microglia by diminishing lipopolysaccharide-induced interleukin 6, tumor necrosis factor alpha, inducible nitric-oxide synthase, and inducible cyclooxygenase type 2 expression. In addition, thiadiazolidinones inhibited tumor necrosis factor-alpha and nitric oxide production and, concomitantly, protected cortical neurons from cell death induced by the cell-free supernatant from activated microglia. The neuroprotective effects of thiadiazolidinones are completely inhibited by the peroxisome proliferator-activated receptor gamma antagonist GW9662. In contrast the glycogen synthase kinase 3 beta inhibitor LiCl did not show any effect. These findings suggest that thiadiazolidinones potently attenuate lipopolysaccharide-induced neuroinflammation and reduces neuronal death by a mechanism dependent of peroxisome proliferator-activated receptor gamma activation.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed, E-28049 Madrid, Spain; Neuropharma SA, Madrid 28760, Spain; Univ Complutense Madrid, Fac Med, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Complutense University of Madrid	Perez-Castillo, A (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28049 Madrid, Spain.	aperez@iib.uam.es	Cortes-Canteli, Marta/L-5449-2014; Martinez, Ana/L-6414-2014; Santos, Angel/K-3744-2014; Perez-Castillo, Ana/A-9505-2015	Cortes-Canteli, Marta/0000-0001-8802-4338; Martinez, Ana/0000-0002-2707-8110; Santos, Angel/0000-0002-7551-8483; Perez-Castillo, Ana/0000-0002-2632-5853				ALONSO M, 2004, 8 INT MONTR SPRINGF; ALONSO M, 2004, 18 INT S MED CHEM CO, P337; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Aschner M, 1998, NEUROTOXICOLOGY, V19, P269; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Bernardo A, 2000, EUR J NEUROSCI, V12, P2215, DOI 10.1046/j.1460-9568.2000.00110.x; Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje; CHOWEN JA, 1992, NEUROENDOCRINOLOGY, V56, P895, DOI 10.1159/000126321; CollacoMoraes Y, 1996, J CEREBR BLOOD F MET, V16, P1366, DOI 10.1097/00004647-199611000-00035; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; DAWSON VL, 1994, NEUROPHARMACOLOGY, V33, P1425, DOI 10.1016/0028-3908(94)90045-0; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; Diab A, 2002, J IMMUNOL, V168, P2508, DOI 10.4049/jimmunol.168.5.2508; Dorronsoro I, 2002, EXPERT OPIN THER PAT, V12, P1527, DOI 10.1517/13543776.12.10.1527; Feinstein DL, 2002, ANN NEUROL, V51, P694, DOI 10.1002/ana.10206; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; Giri S, 2004, J IMMUNOL, V173, P5196, DOI 10.4049/jimmunol.173.8.5196; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Han KH, 2000, J CLIN INVEST, V106, P793, DOI 10.1172/JCI10052; Heneka MT, 1998, J NEUROCHEM, V71, P88; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kielian T, 2003, J NEUROSCI RES, V71, P315, DOI 10.1002/jnr.10501; Klappacher GW, 2002, CURR OPIN LIPIDOL, V13, P305, DOI 10.1097/00041433-200206000-00011; LASSMANN H, 1994, NEUROPATH APPL NEURO, V20, P195; Lee P, 2001, BRAIN RES, V892, P380, DOI 10.1016/S0006-8993(00)03257-1; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Maggi LB, 2000, DIABETES, V49, P346, DOI 10.2337/diabetes.49.3.346; Martinez A, 2002, MED RES REV, V22, P373, DOI 10.1002/med.10011; Martinez A, 2002, J MED CHEM, V45, P1292, DOI 10.1021/jm011020u; Marx N, 2000, J IMMUNOL, V164, P6503, DOI 10.4049/jimmunol.164.12.6503; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MincGolomb D, 1996, J NEUROCHEM, V66, P1504; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; OTTMANN G, 1966, ANGEW CHEM INT EDIT, V5, P672, DOI 10.1002/anie.196606722; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Ricote M, 1999, J LEUKOCYTE BIOL, V66, P733, DOI 10.1002/jlb.66.5.733; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; SATO I, 1995, NEUROSCI LETT, V184, P145, DOI 10.1016/0304-3940(94)11191-K; Schoderbock P, 1996, APPL SURF SCI, V93, P109, DOI 10.1016/0169-4332(95)00327-4; Sheng JG, 1997, ACTA NEUROPATHOL, V94, P1, DOI 10.1007/s004010050664; SKAPER SD, 1995, J NEUROCHEM, V64, P266; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Uryu S, 2002, BRAIN RES, V924, P229, DOI 10.1016/S0006-8993(01)03242-5; Varley CL, 2004, J CELL SCI, V117, P2029, DOI 10.1242/jcs.01042; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Zhang CX, 2004, J EXP MED, V199, P763, DOI 10.1084/jem.20031619	50	170	177	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21453	21462		10.1074/jbc.M414390200	http://dx.doi.org/10.1074/jbc.M414390200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15817469	Green Submitted, hybrid			2022-12-27	WOS:000229438800066
J	Asensio, JL; Albert, A; Munoz-Espin, D; Gonzalez, C; Hermoso, J; Villar, L; Jimenez-Barbero, J; Salas, M; Meijer, WJJ				Asensio, JL; Albert, A; Munoz-Espin, D; Gonzalez, C; Hermoso, J; Villar, L; Jimenez-Barbero, J; Salas, M; Meijer, WJJ			Structure of the functional domain of phi 29 replication organizer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; PROTEIN P16.7; PHI-29 DNA; PROGRAM; CRYSTALLOGRAPHY; POLYMERASE; SEQUENCES; SUITE	The Bacillus subtilis phage phi 29-encoded membrane protein p16.7 is one of the few proteins involved in prokaryotic membrane-associated DNA replication that has been characterized at a functional and biochemical level. In this work we have determined both the solution and crystal structures of its dimeric functional domain, p16.7C. Although the secondary structure of p16.7C is remarkably similar to that of the DNA binding homeodomain, present in proteins belonging to a large family of eukaryotic transcription factors, the tertiary structures of p16.7C and homeodomains are fundamentally different. In fact, p16.7C defines a novel dimeric six-helical fold. We also show that p16.7C can form multimers in solution and that this feature is a key factor for efficient DNA binding. Moreover, a combination of NMR and x-ray approaches, combined with functional analyses of mutants, revealed that multimerization of p16.7C dimers is mediated by a large protein surface that is characterized by a striking self-complementarity. Finally, the structural analyses of the p16.7C dimer and oligomers provide important clues about how protein multimerization and DNA binding are coupled.	CSIC, Dept Quim Organ Biol, Inst Quim Organ Gen, E-28006 Madrid, Spain; CSIC, Grp Cristalog Macromol & Biol Estruct, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; CSIC, Grp RMN, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Inst Biol Mol Eladio Vinuela, E-28049 Madrid, Spain; CSIC, Ctr Invest Biol, Grp Biol Estruct Prot, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Organica General (IQOG); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Meijer, WJJ (corresponding author), CSIC, Dept Quim Organ Biol, Inst Quim Organ Gen, Plaza Murillo 2, E-28006 Madrid, Spain.	wmeijer@cbm.uam.es	JIMENEZ-BARBERO, JESUS/D-4431-2014; Gonzalez, Carlos/A-4734-2013; Albert, Armando/J-2373-2012; Hermoso, Juan/J-3433-2012; Asensio, Juan L./J-1996-2015; Salas, Margarita/J-9873-2014	JIMENEZ-BARBERO, JESUS/0000-0001-5421-8513; Gonzalez, Carlos/0000-0001-8796-1282; Albert, Armando/0000-0002-0026-6816; Hermoso, Juan/0000-0002-1862-8950; Asensio, Juan L./0000-0001-7536-5221; Salas, Margarita/0000-0001-5939-3441; Meijer, Wilfried/0000-0003-1842-0049	NIGMS NIH HHS [2R01-GM27242-24] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; FIRSHEIN W, 1989, ANNU REV MICROBIOL, V43, P89, DOI 10.1146/annurev.micro.43.1.89; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Johnson CS, 1999, PROG NUCL MAG RES SP, V34, P203, DOI 10.1016/S0079-6565(99)00003-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kalodimos CG, 2004, SCIENCE, V305, P386, DOI 10.1126/science.1097064; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; Meijer WJJ, 2000, EMBO J, V19, P4182, DOI 10.1093/emboj/19.15.4182; Meijer WJJ, 2001, MOL MICROBIOL, V39, P731, DOI 10.1046/j.1365-2958.2001.02260.x; Meijer WJJ, 2001, MICROBIOL MOL BIOL R, V65, P261, DOI 10.1128/MMBR.65.2.261-287.2001; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; MUNOZESPIN D, 2004, J BIOL CHEM, V1, P1; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neidigh JW, 2002, NAT STRUCT BIOL, V9, P425, DOI 10.1038/nsb798; Noirot-Gros MF, 2002, P NATL ACAD SCI USA, V99, P8342, DOI 10.1073/pnas.122040799; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SALAS M, 1996, DNA REPLICATION EUKA, P131; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Santelli E, 2000, J MOL BIOL, V297, P437, DOI 10.1006/jmbi.2000.3568; Serna-Rico A, 2002, J BIOL CHEM, V277, P6733, DOI 10.1074/jbc.M109312200; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	38	9	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20730	20739		10.1074/jbc.M501687200	http://dx.doi.org/10.1074/jbc.M501687200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15772069	hybrid			2022-12-27	WOS:000229242000071
J	Ferreon, JC; Ferreon, ACM; Li, K; Lemon, SM				Ferreon, JC; Ferreon, ACM; Li, K; Lemon, SM			Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; POLYPROLINE-II HELIX; DOUBLE-STRANDED-RNA; CRYSTAL-STRUCTURE; REGULATORY FACTOR-3; INTERFERON RESPONSE; SIGNALING PATHWAYS; SERINE PROTEINASE; ADAPTER PROTEIN; SH3 DOMAIN	Persistent infections with hepatitis C virus (HCV) are a major cause of liver disease and reflect its ability to disrupt virus-induced signaling pathways activating cellular antiviral defenses. HCV evasion of double-stranded RNA signaling through Toll-like receptor 3 is mediated by the viral protease NS3/4A, which directs proteolysis of its proline-rich adaptor protein, Toll-IL-1 receptor domain containing adaptor-inducing interferon-beta (TRIF). The TRIF cleavage site has remarkable homology with the viral NS4B/5A substrate, although an 8-residue polyproline track extends upstream from the P-6 position in lieu of the acidic residue present in viral substrates. Circular dichroism (CD) spectroscopy confirmed that a substantial fraction of TRIF exists as polyproline II helices, and inclusion of the polyproline track increased affinity of P side TRIF peptides for the HCV-BK protease. A polyproline II peptide representing an SH3 binding motif (PPPVPPRRR, Sos) bound NS3 with moderate affinity, resulting in inhibition of proteolytic activity. Chemical shift perturbations in NMR spectra indicated that Sos binds a 310 helix close to the protease active site. Thus, a polyproline II interaction with the 310 helix likely facilitates NS3/4A recognition of TRIF, indicating a significant difference from NS3/4A recognition of viral substrates. Because SH3 binding motifs are also present in NS5A, a viral protein that interacts with NS3, we speculate that the NS3 3(10) helix may be a site of interaction with other viral proteins.	Univ Texas, Med Branch, Inst Human Infect & Immun, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Ctr Hepatitis Res, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Lemon, SM (corresponding author), Univ Texas, Med Branch, Inst Human Infect & Immun, Dept Microbiol & Immunol, 5-220 Mary Moody No Pavil,301 Univ Blvd, Galveston, TX 77555 USA.	smlemon@utmb.edu		Allan Chris, Ferreon/0000-0002-8538-1732; Ferreon, Josephine/0000-0002-3175-5700	NIAID NIH HHS [U19-AI40035] Funding Source: Medline; NIDA NIH HHS [R21-DA018054] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI040035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA018054] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Archer SJ, 2002, CHEM BIOL, V9, P79, DOI 10.1016/S1074-5521(01)00096-5; Asabe SI, 1997, J VIROL, V71, P790, DOI 10.1128/JVI.71.1.790-796.1997; BARTENSCHLAGER R, 1995, J VIROL, V69, P7519, DOI 10.1128/JVI.69.12.7519-7528.1995; Cicero DO, 1999, J MOL BIOL, V289, P385, DOI 10.1006/jmbi.1999.2746; De Francesco R, 2000, CURR TOP MICROBIOL, V242, P149; Dimitrova M, 2003, J VIROL, V77, P5401, DOI 10.1128/JVI.77.9.5401-5414.2003; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Ferguson MR, 2004, PROTEIN SCI, V13, P626, DOI 10.1110/ps.03470504; Ferreon JC, 2003, PROTEIN SCI, V12, P982, DOI 10.1110/ps.0238003; Ferreon JC, 2004, BIOCHEMISTRY-US, V43, P7787, DOI 10.1021/bi049752m; Ferreon JC, 2003, PROTEIN SCI, V12, P447, DOI 10.1110/ps.0237803; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Foy E, 2005, P NATL ACAD SCI USA, V102, P2986, DOI 10.1073/pnas.0408707102; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gallinari P, 1999, BIOCHEMISTRY-US, V38, P5620, DOI 10.1021/bi982892+; Gosert R, 2003, J VIROL, V77, P5487, DOI 10.1128/JVI.77.9.5487-5492.2003; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; He YP, 2002, J VIROL, V76, P9207, DOI 10.1128/JVI.76.18.9207-9217.2002; Hiscott J, 1999, J INTERF CYTOK RES, V19, P1, DOI 10.1089/107999099314360; Howe AYM, 1999, PROTEIN SCI, V8, P1332, DOI 10.1110/ps.8.6.1332; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kelly MA, 2001, BIOCHEMISTRY-US, V40, P14376, DOI 10.1021/bi011043a; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Koch U, 2001, BIOCHEMISTRY-US, V40, P631, DOI 10.1021/bi002160t; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lamarre D, 2003, NATURE, V426, P186, DOI 10.1038/nature02099; Landro JA, 1997, BIOCHEMISTRY-US, V36, P9340, DOI 10.1021/bi963054n; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIN C, 1995, J VIROL, V69, P4373, DOI 10.1128/JVI.69.7.4373-4380.1995; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Ma K, 2001, BIOCHEMISTRY-US, V40, P3427, DOI 10.1021/bi0022792; McCoy MA, 2001, J MOL BIOL, V305, P1099, DOI 10.1006/jmbi.2000.4365; McHutchison John G, 2003, Clin Liver Dis, V7, P149, DOI 10.1016/S1089-3261(02)00077-6; Neddermann P, 1999, J VIROL, V73, P9984, DOI 10.1128/JVI.73.12.9984-9991.1999; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Proft T, 1996, GENE, V171, P79, DOI 10.1016/0378-1119(96)00014-5; Randolph JT, 2004, CURR TOP MED CHEM, V4, P1079, DOI 10.2174/1568026043388330; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Santoro MG, 2003, EMBO J, V22, P2552, DOI 10.1093/emboj/cdg267; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Servant MJ, 2002, BIOCHEM PHARMACOL, V64, P985, DOI 10.1016/S0006-2952(02)01165-6; Taliani M, 1996, ANAL BIOCHEM, V240, P60, DOI 10.1006/abio.1996.0331; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Tan SL, 2001, VIROLOGY, V284, P1, DOI 10.1006/viro.2001.0885; Taremi SS, 1998, PROTEIN SCI, V7, P2143, DOI 10.1002/pro.5560071011; Urbani A, 1997, J BIOL CHEM, V272, P9204; Wong JB, 2000, AM J PUBLIC HEALTH, V90, P1562, DOI 10.2105/AJPH.90.10.1562; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; ZARRINPAR A, 2003, SCI STKE         APR, P8	57	96	110	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20483	20492		10.1074/jbc.M500422200	http://dx.doi.org/10.1074/jbc.M500422200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15767257	hybrid			2022-12-27	WOS:000229242000041
J	Brunet, E; Alberti, P; Perrouault, LC; Babu, R; Wengel, J; Giovannangeli, C				Brunet, E; Alberti, P; Perrouault, LC; Babu, R; Wengel, J; Giovannangeli, C			Exploring cellular activity of locked nucleic acid-modified triplex-forming oligonucleotides and defining its molecular basis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX FORMATION; ANTISENSE OLIGONUCLEOTIDES; TRANSCRIPTION ELONGATION; PHYSIOLOGICAL PH; RNA CLEAVAGE; IN-VITRO; DNA; INHIBITION; LNA; STABILITY	Triplex-forming oligonucleotides (TFOs), as DNA-binding molecules that recognize specific sequences, offer unique potential for the understanding of processes occurring on DNA and associated functions. They are also powerful DNA recognition elements for the positioning of ubiquitous molecules acting on DNA, such as anticancer drugs. A prerequisite for further development of DNA code-reading molecules including TFOs is their ability to form a complex in a cellular context: their binding affinities must be comparable to those of DNA-associated proteins. To reach this goal, chemically modified TFOs must be developed. In this work, we present triplex-forming properties ( kinetics and thermodynamics) and cellular activity of G-containing locked nucleic acid-modified TFOs (TFO/LNAs). In conditions simulating physiological ones, these TFO/LNAs strongly enhanced triplex stability compared with the non-modified TFO or with the pyrimidine TFO/LNA directed against the same oligopyrimidine oligopurine sequence, mainly by decreasing the dissociation rate constant and conferring an entropic gain. We provide evidence of their biological activity by a triplex-based mechanism, in vitro and in a cellular context, under conditions in which the parent phosphodiester oligonucleotide did not exhibit any inhibitory effect.	Museum Natl Hist Nat, USM 503, Biophys Lab, CNRS,UMR 5153,U565, F-75005 Paris, France; Univ So Denmark, Nucle Acid Ctr, Dept Chem, DK-5230 Odense, Denmark	Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); University of Southern Denmark	Giovannangeli, C (corresponding author), Museum Natl Hist Nat, USM 503, Biophys Lab, CNRS,UMR 5153,U565, 43 Rue Cuvier, F-75005 Paris, France.	giovanna@mnhn.fr	BRUNET, ERIKA/H-9297-2017; BRUNET, ERIKA/K-7154-2016; wengel, jesper/K-1177-2013	BRUNET, ERIKA/0000-0002-1726-4673; BRUNET, ERIKA/0000-0002-1726-4673; Alberti, Patrizia/0000-0002-5231-3768; Wengel, Jesper/0000-0001-9835-1009				Alberti P, 2002, NUCLEIC ACIDS RES, V30, P5407, DOI 10.1093/nar/gkf675; Arimondo PB, 2001, BIOCONJUGATE CHEM, V12, P501, DOI 10.1021/bc000162k; Besch R, 2004, CURR DRUG TARGETS, V5, P691, DOI 10.2174/1389450043345100; Brown PM, 1998, BIOCHEMISTRY-US, V37, P16139, DOI 10.1021/bi981768n; Buchini S, 2003, CURR OPIN CHEM BIOL, V7, P717, DOI 10.1016/j.cbpa.2003.10.007; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Crinelli R, 2004, NUCLEIC ACIDS RES, V32, P1874, DOI 10.1093/nar/gkh503; DIVIACCO S, 1992, GENE, V122, P313, DOI 10.1016/0378-1119(92)90220-J; Elayadi AN, 2002, BIOCHEMISTRY-US, V41, P9973, DOI 10.1021/bi025907j; Faria M, 2000, P NATL ACAD SCI USA, V97, P3862, DOI 10.1073/pnas.97.8.3862; Faria M, 2001, J MOL BIOL, V306, P15, DOI 10.1006/jmbi.2000.4386; Fluiter K, 2003, NUCLEIC ACIDS RES, V31, P953, DOI 10.1093/nar/gkg185; Francois JC, 2004, NUCL ACID M, V13, P223; Giovannangeli C, 1996, J MOL BIOL, V261, P386, DOI 10.1006/jmbi.1996.0471; Giovannangeli C, 1997, P NATL ACAD SCI USA, V94, P79, DOI 10.1073/pnas.94.1.79; GIOVANNANGELI C, 1992, P NATL ACAD SCI USA, V89, P8631, DOI 10.1073/pnas.89.18.8631; Hertoghs KML, 2003, NUCLEIC ACIDS RES, V31, P5817, DOI 10.1093/nar/gkg801; Kamiya M, 1996, J AM CHEM SOC, V118, P4532, DOI 10.1021/ja952287j; Koizumi M, 2003, NUCLEIC ACIDS RES, V31, P3267, DOI 10.1093/nar/gkg416; Koshkin AA, 1998, TETRAHEDRON LETT, V39, P4381, DOI 10.1016/S0040-4039(98)00706-0; Kurreck J, 2002, NUCLEIC ACIDS RES, V30, P1911, DOI 10.1093/nar/30.9.1911; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; Mills M, 1999, J MOL BIOL, V291, P1035, DOI 10.1006/jmbi.1999.3014; Nulf CJ, 2004, NUCLEIC ACIDS RES, V32, P3792, DOI 10.1093/nar/gkh706; Obika S, 2001, BIOORGAN MED CHEM, V9, P1001, DOI 10.1016/S0968-0896(00)00325-4; Obika S, 1998, TETRAHEDRON LETT, V39, P5401, DOI 10.1016/S0040-4039(98)01084-3; Parekh-Olmedo H, 2002, CHEM BIOL, V9, P1073, DOI 10.1016/S1074-5521(02)00236-3; Randazzo A, 2004, NUCLEIC ACIDS RES, V32, P3083, DOI 10.1093/nar/gkh629; Roberts RW, 1996, P NATL ACAD SCI USA, V93, P4320, DOI 10.1073/pnas.93.9.4320; ROBERTS RW, 1992, SCIENCE, V258, P1463, DOI 10.1126/science.1279808; Schmidt KS, 2004, NUCLEIC ACIDS RES, V32, P5757, DOI 10.1093/nar/gkh862; Seidman MM, 2003, J CLIN INVEST, V112, P487, DOI 10.1172/JCI200319552; Sorensen JJ, 2004, NUCLEIC ACIDS RES, V32, P6078, DOI 10.1093/nar/gkh942; Sun BW, 2004, BIOCHEMISTRY-US, V43, P4160, DOI 10.1021/bi036064e; Torigoe H, 2001, J BIOL CHEM, V276, P2354, DOI 10.1074/jbc.M007783200; Vester B, 2002, J AM CHEM SOC, V124, P13682, DOI 10.1021/ja0276220; Wengel J, 2003, NUCLEOS NUCLEOT NUCL, V22, P601, DOI 10.1081/NCN-120021963; Whitehouse I, 2003, MOL CELL BIOL, V23, P1935, DOI 10.1128/MCB.23.6.1935-1945.2003	38	36	37	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20076	20085		10.1074/jbc.M500021200	http://dx.doi.org/10.1074/jbc.M500021200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15760901	hybrid			2022-12-27	WOS:000229113700078
J	Xie, Q; Lin, TX; Zhang, Y; Zheng, JP; Bonanno, JA				Xie, Q; Lin, TX; Zhang, Y; Zheng, JP; Bonanno, JA			Molecular cloning and characterization of a human AIF-like gene with ability to induce apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; CELL-DEATH; REGULATES APOPTOSIS; SERINE-PROTEASE; BINDING; IDENTIFICATION; MITOCHONDRIA; EXPRESSION; SEQUENCE; XIAP	In this study, we cloned and characterized a human gene homologous to the apoptosis-inducing factor (AIF), which is named AIF-like (AIFL). Human AIFL has 598 amino acids, with a characteristic Rieske domain and a pyridine nucleotide-disulfide oxidoreductase domain ( Pyr_redox). AIFL shares 35% homology with AIF, mainly in the Pyr_redox domain. Reverse transcriptase-PCR analysis showed the expression of AIFL mRNA in all tissues tested, i.e. brain, colon, heart, kidney, liver, lung, muscle, ovary, pancreas, placenta, small intestine, and testis. We developed antibodies against human AIFL using fusion proteins as antigens. The antibodies specifically recognized the antigen and heterologously expressed AIFL proteins. The expression of AIFL proteins in human tissues was also ubiquitous, demonstrated by immunohistochemistry in tissue array slides. Subcellular fractionation and immunofluorescence staining studies revealed that AIFL is predominantly localized to the mitochondria. Similar to AIF, overexpression of AIFL induced apoptosis, as shown by increased cytoplasmic nucleosomes and subdiploid cell populations in AIFL-transfected cells. The segment 1-190 containing the Rieske domain induced apoptosis, whereas the segment containing the Pyr_redox domain did not contribute to the pro-apoptotic function. The mitochondrial membrane potential of cells transfected with AIFL was significantly more depolarized than that of the control. AIFL transfection-induced cytochrome c release and cleavage of caspase 3. Furthermore, the pan-caspase inhibitor Z-VAD-fmk inhibited AIFL induced apoptosis. In summary, AIFL induces apoptosis in a caspase-dependent manner when heterologously expressed.	Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA; Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Urol Surg, Guangzhou 510120, Peoples R China	University of Southern California; Indiana University System; Indiana University Bloomington; Sun Yat Sen University	Zheng, JP (corresponding author), Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.	jianping@usc.edu; jbonanno@indiana.edu			NATIONAL EYE INSTITUTE [R01EY008834] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY008834-13, R01 EY008834] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adams JM, 2002, CURR OPIN CELL BIOL, V14, P715, DOI 10.1016/S0955-0674(02)00381-2; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; Brdiczka D, 1998, BIOFACTORS, V8, P235, DOI 10.1002/biof.5520080311; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DARZYNKIEWICZ Z, 1999, APOPTOSIS PRACTICAL, P63; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Guda C, 2004, BIOINFORMATICS, V20, P1785, DOI 10.1093/bioinformatics/bth171; Guda C, 2004, NUCLEIC ACIDS RES, V32, pW372, DOI 10.1093/nar/gkh374; HANSEN TM, 2003, SCI STKE, V193, pPE31; Hatada S, 1997, GENE, V194, P297, DOI 10.1016/S0378-1119(97)00208-4; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Link TA, 1999, ADV INORG CHEM, V47, P83, DOI 10.1016/S0898-8838(08)60077-X; Lipton SA, 2002, CELL, V111, P147, DOI 10.1016/S0092-8674(02)01046-2; Liu MQ, 2000, J BIOL CHEM, V275, P29400, DOI 10.1074/jbc.M002173200; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Milon L, 2000, J BIOL CHEM, V275, P14264, DOI 10.1074/jbc.275.19.14264; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Ohiro Y, 2002, FEBS LETT, V524, P163, DOI 10.1016/S0014-5793(02)03049-1; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; RANALLI M, 2003, CELL PROLIFERATION A, P340; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Sun XC, 2000, AM J PHYSIOL-CELL PH, V279, pC1648, DOI 10.1152/ajpcell.2000.279.5.C1648; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Valgardsdottir R, 2004, EXP CELL RES, V299, P294, DOI 10.1016/j.yexcr.2004.05.019; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wu M, 2004, ONCOGENE, V23, P6815, DOI 10.1038/sj.onc.1207909; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhang JH, 1997, GENOME RES, V7, P649, DOI 10.1101/gr.7.6.649; Zheng JP, 1997, AM J PATHOL, V150, P2009; Zhu H, 2004, J BIOL CHEM, V279, P30316, DOI 10.1074/jbc.M402664200	66	49	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19673	19681		10.1074/jbc.M409517200	http://dx.doi.org/10.1074/jbc.M409517200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15764604	hybrid			2022-12-27	WOS:000229113700032
J	Maeda, A; Maeda, T; Imanishi, Y; Kuksa, V; Alekseev, A; Bronson, JD; Zhang, HB; Zhu, L; Sun, WY; Saperstein, DA; Rieke, F; Baehr, W; Palczewski, K				Maeda, A; Maeda, T; Imanishi, Y; Kuksa, V; Alekseev, A; Bronson, JD; Zhang, HB; Zhu, L; Sun, WY; Saperstein, DA; Rieke, F; Baehr, W; Palczewski, K			Role of photoreceptor-specific retinol dehydrogenase in the retinoid cycle in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; STARGARDT MACULAR DYSTROPHY; LEBER CONGENITAL AMAUROSIS; ROD OUTER SEGMENTS; ALL-TRANS-RETINOL; VERTEBRATE RETINA; SUBSTRATE-SPECIFICITY; PIGMENT EPITHELIUM; METARHODOPSIN-II; VISUAL PIGMENT	The retinoid cycle is a recycling system that replenishes the 11-cis-retinal chromophore of rhodopsin and cone pigments. Photoreceptor-specific retinol dehydrogenase (prRDH) catalyzes reduction of all-trans-retinal to all-trans-retinol and is thought to be a key enzyme in the retinoid cycle. We disrupted mouse prRDH ( human gene symbol RDH8) gene expression by targeted recombination and generated a homozygous prRDH knock-out (prRDH-/-) mouse. Histological analysis and electron microscopy of retinas from 6- to 8-week-old prRDH-/- mice revealed no structural differences of the photoreceptors or inner retina. For brief light exposure, absence of prRDH did not affect the rate of 11-cis-retinal regeneration or the decay of Meta II, the activated form of rhodopsin. Absence of prRDH, however, caused significant accumulation of all-trans-retinal following exposure to bright lights and delayed recovery of rod function as measured by electroretinograms and single cell recordings. Retention of all-trans-retinal resulted in slight overproduction of A2E, a condensation product of all-trans-retinal and phosphatidylethanolamine. We conclude that prRDH is an enzyme that catalyzes reduction of all-trans-retinal in the rod outer segment, most noticeably at higher light intensities and prolonged illumination, but is not an essential enzyme of the retinoid cycle.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Neurobiol & Anat, Salt Lake City, UT 84112 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu	Imanishi, Yoshikazu/E-8178-2010; Zhang, Houbin/A-8887-2012	Imanishi, Yoshikazu/0000-0003-4696-4836; Zhang, Houbin/0000-0002-2968-7454	NATIONAL EYE INSTITUTE [R01EY013385, R29EY008061, R01EY008061, R01EY011850, R01EY008123] Funding Source: NIH RePORTER; NEI NIH HHS [EY11850, EY13385, R01 EY008123, R01 EY013385, EY08123, EY08061, R01 EY008061, R01 EY011850] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; Ahn J, 2000, METHOD ENZYMOL, V315, P864; Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; ALPERN M, 1971, J PHYSIOL-LONDON, V217, P447, DOI 10.1113/jphysiol.1971.sp009580; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BONDS AB, 1974, J PHYSIOL-LONDON, V242, P237, DOI 10.1113/jphysiol.1974.sp010704; BRETON ME, 1994, INVEST OPHTH VIS SCI, V35, P295; Buczylko J, 1996, J BIOL CHEM, V271, P20621, DOI 10.1074/jbc.271.34.20621; CICERONE CM, 1981, J PHYSIOL-LONDON, V314, P213, DOI 10.1113/jphysiol.1981.sp013702; Cideciyan AV, 2000, VISUAL NEUROSCI, V17, P667, DOI 10.1017/S0952523800175029; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; ELDRED GE, 1993, NATURE, V364, P396; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Field GD, 2002, NEURON, V35, P733, DOI 10.1016/S0896-6273(02)00822-X; Field GD, 2002, NEURON, V34, P773, DOI 10.1016/S0896-6273(02)00700-6; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; Fishman GA, 2004, ARCH OPHTHALMOL-CHIC, V122, P70, DOI 10.1001/archopht.122.1.70; Haeseleer F, 2002, J BIOL CHEM, V277, P45537, DOI 10.1074/jbc.M208882200; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; Han W, 2004, J HUM GENET, V49, P16, DOI 10.1007/s10038-003-0100-9; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Hetling JR, 1999, J PHYSIOL-LONDON, V516, P593, DOI 10.1111/j.1469-7793.1999.0593v.x; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; Janecke AR, 2004, NAT GENET, V36, P850, DOI 10.1038/ng1394; Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200; Jang GF, 2000, J BIOL CHEM, V275, P28128; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kim TS, 2005, J BIOL CHEM, V280, P8694, DOI 10.1074/jbc.M413172200; Kuksa V, 2003, VISION RES, V43, P2959, DOI 10.1016/S0042-6989(03)00482-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199; Luo WQ, 2004, J NEUROSCI, V24, P2623, DOI 10.1523/JNEUROSCI.5302-03.2004; Maeda T, 2003, J NEUROCHEM, V85, P944, DOI 10.1046/j.1471-4159.2003.01741.x; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; Palczewski K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; PERLMAN I, 1978, J PHYSIOL-LONDON, V278, P141, DOI 10.1113/jphysiol.1978.sp012297; Perrault I, 2004, AM J HUM GENET, V75, P639, DOI 10.1086/424889; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Rattner A, 2004, J BIOL CHEM, V279, P42202, DOI 10.1074/jbc.M407928200; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Zhu L, 2004, J BIOL CHEM, V279, P53828, DOI 10.1074/jbc.M408472200	58	121	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18822	18832		10.1074/jbc.M501757200	http://dx.doi.org/10.1074/jbc.M501757200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755727	Green Accepted, hybrid			2022-12-27	WOS:000228932300034
J	Neutzner, A; Youle, RJ				Neutzner, A; Youle, RJ			Instability of the mitofusin Fzo1 regulates mitochondrial morphology during the mating response of the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED GTPASE; FUSION-COMPETENT MITOCHONDRIA; PROGRAMMED CELL-DEATH; SHUTTLE VECTORS; FISSION; PROTEIN; APOPTOSIS; EXPRESSION; MAINTENANCE; SPORULATION	Mitochondria form a highly dynamic network that is shaped by continuous fission and fusion of these organelles. In the yeast Saccharomyces cerevisiae two machineries are involved in this process, one of which includes the mitochondrial fusion promoting GTPase Fzo1. Although a role for the F-box protein Mdm30 in regulating the stability of Fzo1 has been proposed, the molecular basis for the regulation of the fission to fusion ratio of mitochondria remains unknown. To discern the mechanism of the regulation of mitochondrial morphology, we arrested cells at different stages of the cell cycle and examined mitochondrial morphology as well as the stability of mitochondrial fission and fusion proteins. In response to a G(1) arrest evoked by the mating pheromone alpha factor the mitochondrial network fragmented into small pieces, which was accompanied by dramatic down-regulation of Fzo1. Mating pheromone also triggered the degradation of Fzo1 produced under the control of a constitutive promoter, and Fzo1 was stabilized upon proteasome inhibition, indicating a role for the proteasome system in the degradation of Fzo1. However, deletion of MDM30 did not stabilize Fzo1 after mating pheromone treatment, showing a different mechanism from the previously reported process of steady state Fzo1 regulation. We show an example for a regulated change of the mitochondrial fission to fusion ratio during the life cycle of budding yeast. Proteasomal degradation of Fzo1 in response to the mating pheromone is proposed to mediate the remodeling of the mitochondrial network during the process of mating.	NINDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Youle, RJ (corresponding author), NINDS, Biochem Sect, Surg Neurol Branch, NIH, 35 Convent Dr, Bethesda, MD 20892 USA.	youler@ninds.nih.gov	Neutzner, Albert/ABC-4368-2020	Neutzner, Albert/0000-0001-9254-5558	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002859, Z01NS002859] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; Elion EA, 2000, CURR OPIN MICROBIOL, V3, P573, DOI 10.1016/S1369-5274(00)00143-0; Fannjiang Y, 2004, GENE DEV, V18, P2785, DOI 10.1101/gad.1247904; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Fritz S, 2003, MOL BIOL CELL, V14, P2303, DOI 10.1091/mbc.E02-12-0831; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gorsich SW, 2004, MOL BIOL CELL, V15, P4369, DOI 10.1091/mbc.E03-12-0875; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; Hwa JJ, 2002, MECH DEVELOP, V116, P213, DOI 10.1016/S0925-4773(02)00141-7; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Jensen RE, 2000, MICROSC RES TECHNIQ, V51, P573, DOI 10.1002/1097-0029(20001215)51:6<573::AID-JEMT7>3.0.CO;2-2; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Kawano S, 1995, INT REV CYTOL, V161, P49; Kimata Y, 2000, J BIOL CHEM, V275, P10655, DOI 10.1074/jbc.275.14.10655; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; MIYAKAWA I, 1984, J CELL SCI, V66, P21; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Santel A, 2001, J CELL SCI, V114, P867; Scott SV, 2003, CURR OPIN CELL BIOL, V15, P482, DOI 10.1016/S0955-0674(03)00070-X; Sesaki H, 2001, J CELL BIOL, V152, P1123, DOI 10.1083/jcb.152.6.1123; Severin FF, 2002, CURR BIOL, V12, pR233, DOI 10.1016/S0960-9822(02)00776-5; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; SIKORSKI RS, 1989, GENETICS, V122, P19; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	35	81	84	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18598	18603		10.1074/jbc.M500807200	http://dx.doi.org/10.1074/jbc.M500807200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15760898	hybrid			2022-12-27	WOS:000228932300008
J	Xu, AM; Chan, KW; Hoo, RLC; Wang, Y; Tan, KCB; Zhang, JL; Chen, BY; Lam, MC; Tse, C; Cooper, GJS; Lam, KSL				Xu, AM; Chan, KW; Hoo, RLC; Wang, Y; Tan, KCB; Zhang, JL; Chen, BY; Lam, MC; Tse, C; Cooper, GJS; Lam, KSL			Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT-RELATED PROTEIN; PHOSPHOLIPASE-C BETA-1; INSULIN-RESISTANCE; FAT DISTRIBUTION; PLASMA-PROTEIN; ACRP30/ADIPONECTIN; EXPRESSION; ANDROGENS; GLUCOSE; ACRP30	The antidiabetic hormone adiponectin circulates in blood as several oligomeric complexes, and the ratios between them are critical in determining insulin sensitivity. In this study we investigated the role of testosterone in regulating the oligomeric complex distribution of adiponectin. Gel filtration analysis revealed that circulating adiponectin existed as the forms of high molecular weight (HMW), middle molecular weight, and low molecular weight complexes in both human and mice. The concentration of HMW adiponectin in female was significantly higher than that in male, whereas there were no gender differences for the other two forms. Castration induced a dramatic elevation of the HMW form but had no effect on either the middle molecular weight or the low molecular weight form in mice. Testosterone treatment, on the other hand, caused a specific reduction of HMW adiponectin in the circulation. Pulse-chase labeling experiments in rat adipocytes revealed that the three oligomeric forms of adiponectin were secreted into the culture medium at different rates and that testosterone selectively impeded the secretion of HMW adiponectin but not the other two forms. The inhibitory effect of testosterone on secretion of HMW adiponectin was largely restored by the transcription inhibitor actinomycin D, suggesting the involvement of a transcriptional event in this process. The selective inhibition of HMW adiponectin by testosterone might contribute to the sex dimorphism of adiponectin in terms of its oligomeric complex distribution and could partly explain why men have higher risk to insulin resistance and atherosclerosis than women.	Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Res Ctr Heart Brain Hormone & Hlth Aging, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Genome Res Ctr, Hong Kong, Hong Kong, Peoples R China; Univ Auckland, Ctr Mol Biodiscovery, Auckland 1020, New Zealand	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Auckland	Xu, AM (corresponding author), Univ Hong Kong, Dept Med, 21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	amxu@hkucc.hku.hk	Tan, Kathryn Choon Beng/C-4407-2009; Lam, Karen Siu Ling/C-4315-2009; Wang, Yu/B-4534-2009; Xu, Aimin/D-3291-2013; Cooper, Garth JS/I-3201-2015; Hoo, Ruby/C-4556-2009	Xu, Aimin/0000-0002-0668-033X; Cooper, Garth JS/0000-0001-5241-3163; wang, yu/0000-0001-8697-2940				Arita Y, 2002, CIRCULATION, V105, P2893, DOI 10.1161/01.CIR.0000018622.84402.FF; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Bogan JS, 1999, J CELL BIOL, V146, P609, DOI 10.1083/jcb.146.3.609; Bottner A, 2004, J CLIN ENDOCR METAB, V89, P4053, DOI 10.1210/jc.2004-0303; Bradley RL, 2001, RECENT PROG HORM RES, V56, P329, DOI 10.1210/rp.56.1.329; Bruun JM, 2003, AM J PHYSIOL-ENDOC M, V285, pE527, DOI 10.1152/ajpendo.00110.2003; Cnop M, 2003, DIABETOLOGIA, V46, P459, DOI 10.1007/s00125-003-1074-z; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Combs TP, 2003, DIABETES, V52, P268, DOI 10.2337/diabetes.52.2.268; Frias JP, 2001, DIABETES, V50, P1344, DOI 10.2337/diabetes.50.6.1344; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Gavrila A, 2003, J CLIN ENDOCR METAB, V88, P4823, DOI 10.1210/jc.2003-030214; Gui YT, 2004, OBES RES, V12, P1481, DOI 10.1038/oby.2004.185; KALIN MF, 1990, STEROIDS, V55, P330, DOI 10.1016/0039-128X(90)90058-J; Kobayashi H, 2004, CIRC RES, V94, pE27, DOI 10.1161/01.RES.0000119921.86460.37; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Lanfranco F, 2004, CLIN ENDOCRINOL, V60, P500, DOI 10.1111/j.1365-2265.2004.02007.x; Liu PY, 2003, ENDOCR REV, V24, P313, DOI 10.1210/er.2003-0005; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Matsuda M, 2002, J BIOL CHEM, V277, P37487, DOI 10.1074/jbc.M206083200; Mora S, 2002, DIABETES-METAB RES, V18, P345, DOI 10.1002/dmrr.321; Mudali S, 2004, MECH AGEING DEV, V125, P297, DOI 10.1016/j.mad.2004.01.004; Nishizawa H, 2002, DIABETES, V51, P2734, DOI 10.2337/diabetes.51.9.2734; Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; Pajvani UB, 2004, J BIOL CHEM, V279, P12152, DOI 10.1074/jbc.M311113200; Panidis D, 2003, HUM REPROD, V18, P1790, DOI 10.1093/humrep/deg353; Roy AK, 1999, VITAM HORM, V55, P309; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shibata R, 2004, NAT MED, V10, P1384, DOI 10.1038/nm1137; Song DZ, 2004, HYPERTENSION, V43, P667, DOI 10.1161/01.HYP.0000118018.77344.4e; Tsao TS, 2002, EUR J PHARMACOL, V440, P213, DOI 10.1016/S0014-2999(02)01430-9; Tsao TS, 2002, J BIOL CHEM, V277, P29359, DOI 10.1074/jbc.C200312200; Tsao TS, 2003, J BIOL CHEM, V278, P50810, DOI 10.1074/jbc.M309469200; Waki H, 2003, J BIOL CHEM, V278, P40352, DOI 10.1074/jbc.M300365200; Wang Y, 2002, J BIOL CHEM, V277, P19521, DOI 10.1074/jbc.M200601200; Xu AM, 2004, ENDOCRINOLOGY, V145, P487, DOI 10.1210/en.2003-1140; Xu AM, 2003, J CLIN INVEST, V112, P91, DOI 10.1172/JCI200317797; Xu AM, 2001, MOL CELL BIOL, V21, P2981, DOI 10.1128/MCB.21.9.2981-2990.2001; Xu AM, 2001, J BIOL CHEM, V276, P14980, DOI 10.1074/jbc.M009144200; Xu AM, 1999, BIOCHEM J, V342, P683, DOI 10.1042/0264-6021:3420683; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yang WS, 2001, J CLIN ENDOCR METAB, V86, P3815, DOI 10.1210/jc.86.8.3815	46	348	365	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18073	18080		10.1074/jbc.M414231200	http://dx.doi.org/10.1074/jbc.M414231200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15760892	hybrid			2022-12-27	WOS:000228807200064
J	Sanders, MA; Basson, MD				Sanders, MA; Basson, MD			p130(cas) but not paxillin is essential for caco-2 intestinal epithelial cell spreading and migration on collagen IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CRK-ASSOCIATED SUBSTRATE; ADAPTER PROTEIN CAS; C-SRC ACTIVITY; TYROSINE PHOSPHORYLATION; IN-VITRO; V-CRK; ACTIN CYTOSKELETON; DEPENDENT MANNER; ERK ACTIVATION	We have previously observed that collagen IV regulates Caco-2 intestinal epithelial cell spreading and migration via Src kinase and stimulates Src-dependent tyrosine phosphorylation of p130(cas). We observed that collagen IV also stimulated Src-dependent phosphorylation of both paxillin Tyr(31) and paxillin Tyr(118). Caco-2 transfection with paxillin or p130(cas) siRNAs inhibited expression of these proteins by more than 90% for at least 5 days after transfection. Although p130(cas) siRNA inhibited cell spreading on collagen IV by 33%, three different paxillin siRNAs did not inhibit cell spreading. p130cas siRNA did not affect Src Tyr(416) or Src Tyr(527) phosphorylation, FAK Tyr(397) phosphorylation, or Src-dependent phosphorylation of FAK Tyr(925), suggesting that p130cas did not inhibit cell spreading by altering FAK or Src activity. Rat p130(cas) expression after siRNA knock-out of endogenous human p130(cas) in Caco-2 cells reduced cell spreading inhibition by 71%. In contrast, expression of rat p130(cas) from which the Src-phosphorylated substrate domain was deleted did not rescue siRNA inhibition of cell spreading. Combined treatment with siRNAs to Crk and CrkL, which bind to the p130cas substrate domain, inhibited cell spreading by 54%. Both p130(cas) siRNA and the combined Crk/CrkL siRNAs strongly inhibited ( 52 and 46% inhibition, respectively) Caco-2 sheet migration on collagen IV and noticeably inhibited lamellipodial extension, whereas paxillin siRNA only inhibited migration by 18% and did not noticeably affect lamellipodial extension. These results suggest that Src may regulate Caco-2 migration on collagen IV via both p130cas and paxillin but that Src phosphorylation of p130cas is more important for this process.	Wayne State Univ, Dept Surg, Detroit, MI 48202 USA; Dept Vet Affairs Med Ctr, Surg Serv, Detroit, MI 48201 USA	Wayne State University	Sanders, MA (corresponding author), Wayne State Univ, Dept Surg, Detroit, MI 48202 USA.	aj2198@wayne.edu			NIDDK NIH HHS [R01DK60771] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060771] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abassi YA, 2003, J BIOL CHEM, V278, P35636, DOI 10.1074/jbc.M306438200; Basson MD, 1998, CLIN EXP PHARMACOL P, V25, P280, DOI 10.1111/j.1440-1681.1998.t01-10-.x; BASSON MD, 1992, J CLIN INVEST, V90, P15, DOI 10.1172/JCI115828; Basson MD, 2001, LIFE SCI, V69, P3005, DOI 10.1016/S0024-3205(01)01408-4; Beaulieu JF, 1997, PROG HISTOCHEM CYTOC, V31, P1; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; De Arcangelis A, 1996, J CELL BIOL, V133, P417, DOI 10.1083/jcb.133.2.417; Di Stefano P, 2004, MOL BIOL CELL, V15, P787, DOI 10.1091/mbc.E03-09-0689; Dignass AU, 2001, INFLAMM BOWEL DIS, V7, P68, DOI 10.1097/00054725-200102000-00014; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Huang C, 2004, J CELL BIOL, V164, P593, DOI 10.1083/jcb.200307081; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Huang JH, 2002, J BIOL CHEM, V277, P27265, DOI 10.1074/jbc.M203063200; Ku H, 2000, J BIOL CHEM, V275, P11333, DOI 10.1074/jbc.275.15.11333; Lamorte L, 2003, MOL BIOL CELL, V14, P2818, DOI 10.1091/mbc.E02-08-0497; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Lotz MM, 2000, AM J PATHOL, V156, P985, DOI 10.1016/S0002-9440(10)64966-8; Lotz MM, 1997, AM J PATHOL, V150, P747; Lussier C, 2000, MICROSC RES TECHNIQ, V51, P169; MADRI JA, 1988, AM J PATHOL, V132, P18; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; PETERSON MD, 1993, J CELL SCI, V105, P461; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Podolsky DK, 1999, AM J PHYSIOL-GASTR L, V277, pG495, DOI 10.1152/ajpgi.1999.277.3.G495; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Sanders MA, 2000, J BIOL CHEM, V275, P38040, DOI 10.1074/jbc.M003871200; Sanders MA, 2004, AM J PHYSIOL-GASTR L, V286, pG547, DOI 10.1152/ajpgi.00262.2003; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Stupack DG, 2000, IMMUNOL RES, V21, P83, DOI 10.1385/IR:21:2-3:83; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; VACHON PH, 1995, AM J PHYSIOL, V268, P857; Wolpert S, 1996, AM J SURG, V171, P109, DOI 10.1016/S0002-9610(99)80083-X; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; Yano H, 2004, J CELL BIOL, V166, P283, DOI 10.1083/jcb.200312013; Yu CF, 2000, AM J PHYSIOL-GASTR L, V278, pG952, DOI 10.1152/ajpgi.2000.278.6.G952; ZHANG J, 2003, FASEB J	45	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23516	23522		10.1074/jbc.M413165200	http://dx.doi.org/10.1074/jbc.M413165200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15817476	hybrid			2022-12-27	WOS:000229880000015
J	Schuurman-Wolters, GK; Poolman, B				Schuurman-Wolters, GK; Poolman, B			Substrate specificity and ionic regulation of GlnPQ from Lactococcus lactis - An ATP-binding cassette transporter with four extracytoplasmic substrate-binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; GLUTAMINE; SYSTEM; MECHANISM	We report on the functional characterization of GlnPQ, an ATP-binding cassette transporter with four extracytoplasmic substrate-binding domains. The first predicted transmembrane helix of GlnP was cleaved off in the mature protein and most likely serves as the signal sequence for the extracytoplasmic substrate-binding domains. Deletion analysis showed that the substrate-binding domain, in the primary sequence of GlnP nearest to the translocator domain, is used as the receptor that delivers the substrate to the translocator. Membrane reconstitution of the detergent-solubilized and purified GlnPQ complex yielded proteoliposomes that transported glutamine and glutamic acid at the expense of ATP. The transport activity of GlnPQ increased with lumenal salt concentration and internal pH, but the mechanism of ionic activation of the transporter is distinct from that of other osmoregulatory ATP-binding cassette transporters and does not depend on the presence of anionic lipids. The regulation of GlnPQ conforms to an electrostatic switch in which protein domain(s) and low molecular weight electrolytes participate.	Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands	University of Groningen	Poolman, B (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	b.poolman@rug.nl	Poolman, Bert/D-1882-2012					Biemans-Oldehinkel E, 2003, EMBO J, V22, P5983, DOI 10.1093/emboj/cdg581; HAGTING A, 1994, J BIOL CHEM, V269, P11391; Holland I. B., 2003, ABC PROTEINS BACTERI; Hsiao CD, 1996, J MOL BIOL, V262, P225, DOI 10.1006/jmbi.1996.0509; Khademi S, 2004, SCIENCE, V305, P1587, DOI 10.1126/science.1101952; Knol J, 1998, BIOCHEMISTRY-US, V37, P16410, DOI 10.1021/bi981596u; Kunji ERS, 2003, BBA-BIOMEMBRANES, V1610, P97, DOI 10.1016/S0005-2736(02)00712-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOLENAAR D, 1993, J BACTERIOL, V175, P5438, DOI 10.1128/JB.175.17.5438-5444.1993; POOLMAN B, 1987, J BACTERIOL, V169, P2755, DOI 10.1128/jb.169.6.2755-2761.1987; Poolman B, 2004, BBA-BIOMEMBRANES, V1666, P88, DOI 10.1016/j.bbamem.2004.06.013; POOLMAN B, 1987, J BACTERIOL, V169, P2272, DOI 10.1128/jb.169.5.2272-2276.1987; Racher KI, 2001, BIOCHEMISTRY-US, V40, P7324, DOI 10.1021/bi002331u; Rubenhagen R, 2001, EMBO J, V20, P5412, DOI 10.1093/emboj/20.19.5412; Sun YJ, 1998, J MOL BIOL, V278, P219, DOI 10.1006/jmbi.1998.1675; Tamura GS, 2002, INFECT IMMUN, V70, P2877, DOI 10.1128/IAI.70.6.2877-2885.2002; van der Heide T, 2000, P NATL ACAD SCI USA, V97, P7102, DOI 10.1073/pnas.97.13.7102; van der Heide T, 2002, EMBO REP, V3, P938, DOI 10.1093/embo-reports/kvf201; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022	19	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23785	23790		10.1074/jbc.M500522200	http://dx.doi.org/10.1074/jbc.M500522200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15795228	hybrid, Green Published			2022-12-27	WOS:000229880000049
J	Henson, BS; Neubig, RR; Jang, I; Ogawa, T; Zhang, ZC; Carey, TE; D'Silva, NJ				Henson, BS; Neubig, RR; Jang, I; Ogawa, T; Zhang, ZC; Carey, TE; D'Silva, NJ			Galanin receptor 1 has anti-proliferative effects in oral squamous cell carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CHROMOSOMAL LOCALIZATION; STRUCTURAL ORGANIZATION; SIGNALING PATHWAYS; GALR1; HEAD; 18Q; IMMUNOREACTIVITY; MODULATION; EXPRESSION	In the United States, oral cancer accounts for more deaths annually than cervical cancer, leukemias, or Hodgkin's lymphoma. Studies have shown that aberrations of chromosome 18q develop with tumor progression and are associated with significantly decreased survival in head and neck cancer patients. The G-protein-coupled receptor, galanin receptor 1 ( GALR1), maps to this region of chromosome 18q. Although the role of GALR1 has been well characterized in neuronal cells, little is known regarding this receptor in nonneuronal cells. In this study, the expression, mitogenic function, and signaling mechanism of GALR1 are investigated in normal and malignant oral epithelial cells. mRNA expression was determined via reverse transcriptase-PCR. Protein quantification was done via immunoblot analysis and enzyme-linked immunosorbent assay. For functional and signaling studies, an inhibitory antibody was generated to the N-terminal ligand binding domain of GALR1. GALR1 protein and mRNA expression and GAL secretion were detected at variable levels in immortalized human oral keratinocytes and human oropharyngeal squamous cell carcinoma cell lines. Upon competitive inhibition of GALR1, proliferation was up-regulated in immortalized and malignant keratinocytes. Furthermore, studies with the inhibitory antibody and U0126, the MAPK inhibitor, show that GALR1 inhibits proliferation in immortalized and malignant keratinocytes by inactivating the MAPK pathway. GALR1s inhibitory effects on proliferation in epithelial cells raises the possibility that inactivation or disregulation of this receptor can lead to uncontrolled proliferation and neoplastic transformation.	Univ Michigan, Sch Dent, Dept Oral Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Dept Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Lab Head & Neck Canc Biol, Ann Arbor, MI 48109 USA; Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	D'Silva, NJ (corresponding author), Univ Michigan, Sch Dent, Dept Oral Med, 1011 N Univ Ave,Rm 5217, Ann Arbor, MI 48109 USA.	njdsilva@umich.edu	D'Silva, Nisha J/B-4734-2013	Carey, Thomas/0000-0002-5202-7518; Neubig, Richard/0000-0003-0501-0008	NATIONAL CANCER INSTITUTE [P50CA097248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K08DE014620] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA97248] Funding Source: Medline; NIDCR NIH HHS [DE00452-01, K08 DE14620-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Albanell J, 2001, CANCER RES, V61, P6500; BEDECS K, 1995, INT J BIOCHEM CELL B, V27, P337, DOI 10.1016/1357-2725(95)00008-D; Benya RV, 1999, AM J PHYSIOL-GASTR L, V276, pG64, DOI 10.1152/ajpgi.1999.276.1.G64; Berger A, 2004, ENDOCRINOLOGY, V145, P500, DOI 10.1210/en.2003-0649; Branchek TA, 2000, TRENDS PHARMACOL SCI, V21, P109, DOI 10.1016/S0165-6147(00)01446-2; Carey TE, 1994, ATLAS HUMAN TUMOR CE, P79; CRAWLEY JN, 1995, REGUL PEPTIDES, V59, P1, DOI 10.1016/0167-0115(95)00083-N; Frank CJ, 1997, CANCER RES, V57, P824; Goetzl EJ, 2004, IMMUNOL LETT, V93, P63, DOI 10.1016/j.imlet.2004.02.007; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hammond PJ, 1996, J NEUROENDOCRINOL, V8, P457, DOI 10.1046/j.1365-2826.1996.04747.x; Hochol A, 2000, PEPTIDES, V21, P147, DOI 10.1016/S0196-9781(99)00184-9; Holmes FE, 2000, P NATL ACAD SCI USA, V97, P11563, DOI 10.1073/pnas.210221897; HOYLE CHV, 1989, J ANAT, V166, P23; Iismaa TP, 1998, ANN NY ACAD SCI, V863, P56, DOI 10.1111/j.1749-6632.1998.tb10683.x; Jacoby AS, 1997, GENOMICS, V45, P496, DOI 10.1006/geno.1997.4960; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kakuyama H, 1997, EUR J PHARMACOL, V329, P85, DOI 10.1016/S0014-2999(97)10109-1; LANSFORD CD, 1999, HUMAN CELL CULTURE, V2, P185; Lingen MW, 1996, AM J PATHOL, V149, P247; Mazarati AM, 1998, J NEUROSCI, V18, P10070; Mazarati AM, 2000, J NEUROSCI, V20, P6276, DOI 10.1523/JNEUROSCI.20-16-06276.2000; McDonald AC, 2003, BONE, V33, P788, DOI 10.1016/S8756-3282(03)00244-8; Mitra RS, 2003, ONCOGENE, V22, P6243, DOI 10.1038/sj.onc.1206534; Nicholl J, 1995, GENOMICS, V30, P629, DOI 10.1006/geno.1995.1292; O'Meara G, 2000, P NATL ACAD SCI USA, V97, P11569, DOI 10.1073/pnas.210254597; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; Pearlstein RP, 1998, GENE CHROMOSOME CANC, V21, P333, DOI 10.1002/(SICI)1098-2264(199804)21:4<333::AID-GCC7>3.0.CO;2-#; Perumal P, 2003, J ENDOCRINOL, V179, P145, DOI 10.1677/joe.0.1790145; RATTAN S, 1991, GASTROENTEROLOGY, V100, P1762, DOI 10.1016/0016-5085(91)90682-B; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Seufferlein T, 1996, CANCER RES, V56, P5758; SKOFITSCH G, 1986, PEPTIDES, V7, P609, DOI 10.1016/0196-9781(86)90035-5; Sullivan KA, 1997, BIOCHEM BIOPH RES CO, V233, P823, DOI 10.1006/bbrc.1997.6542; Takebayashi S, 2000, CANCER RES, V60, P3397; Todd R, 1997, J ORAL MAXIL SURG, V55, P613, DOI 10.1016/S0278-2391(97)90495-X; Trejter M, 2002, INT J MOL MED, V10, P183; Wang S, 1998, BIOCHEMISTRY-US, V37, P6711, DOI 10.1021/bi9728405; Wittau N, 2000, ONCOGENE, V19, P4199, DOI 10.1038/sj.onc.1203777	39	49	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22564	22571		10.1074/jbc.M414589200	http://dx.doi.org/10.1074/jbc.M414589200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15767248	hybrid			2022-12-27	WOS:000229741800004
J	Staniszewska, MM; Nagaraj, RH				Staniszewska, MM; Nagaraj, RH			3-Hydroxykynurenine-mediated modification of human lens proteins - Structure determination of a major modification using a monoclonal antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CRYSTALLIN; INDOLEAMINE 2,3-DIOXYGENASE; CATARACTOUS LENSES; OXIDATION-PRODUCTS; BOUND KYNURENINE; NUCLEAR CATARACT; GLUTATHIONE; GLUCOSIDE; GLYCATION; CONSEQUENCES	Tryptophan can be oxidized in the eye lens by both enzymatic and non-enzymatic mechanisms. Oxidation products, such as kynurenines, react with proteins to form yellow-brown pigments and cause covalent cross-linking. We generated a monoclonal antibody against 3-hydroxykynurenine (30HKYN)-modified keyhole limpet hemocyanin and characterized it using 30HKYN-modified amino acids and proteins. This monoclonal antibody reacted with 30HKYN-modified N-alpha-acetyl lysine, N-alpha-acetyl histidine, N-alpha-acetyl arginine, and N-alpha-acetyl cysteine. Among the several tryptophan oxidation products tested, 30HKYN produced the highest concentration of antigen when reacted with human lens proteins. A major antigen from the reaction of 30HKYN and N-alpha-acetyl lysine was purified by reversed phase high pressure liquid chromatography, which was characterized by spectroscopy and identified as 2-amino-3-hydroxyl-alpha-((5S)-5-acetamino-5-carboxypentyl amino)-gamma-oxo-benzene butanoic acid. Enzyme-digested cataractous lens proteins displayed 30HKYN-derived modifications. Immunohistochemistry revealed 3-HKYN modifications in proteins associated with the lens fiber cell plasma membrane. The low molecular products (< 10,000 Da) isolated from normal lenses after reaction with glucosidase followed by incubation with proteins generated 30HKYN-derived products. Human lens epithelial cells incubated with 30HKYN showed intense immunoreactivity. We also investigated the effect of glycation on tryptophan oxidation and kynurenine-mediated modification of lens proteins. The results showed that glycation products failed to oxidize tryptophan or generate kynurenine modifications in proteins. Our studies indicate that 30HKYN modifies lens proteins independent of glycation to form products that may contribute to protein aggregation and browning during cataract formation.	Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Nagaraj, RH (corresponding author), Case Western Reserve Univ, Dept Ophthalmol, Wearn Bldg,Rm 643, Cleveland, OH 44106 USA.	ram.nagaraj@case.edu	Staniszewska, PhD, DSc, Associate Professor, Magdalena/AAE-9903-2019	Staniszewska, Magdalena/0000-0003-1119-2397	NEI NIH HHS [P30 EY 11373, R01 EY 09912] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009912, P30EY011373] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aquilina JA, 1999, BIOCHEMISTRY-US, V38, P11455, DOI 10.1021/bi990458h; Aquilina JA, 1997, EXP EYE RES, V64, P727, DOI 10.1006/exer.1996.0258; Aquilina JA, 2001, BIOCHEM BIOPH RES CO, V285, P1107, DOI 10.1006/bbrc.2001.5288; Baynes JW, 2001, EXP GERONTOL, V36, P1527, DOI 10.1016/S0531-5565(01)00138-3; Bova LM, 2001, INVEST OPHTH VIS SCI, V42, P200; Bron AJ, 2000, OPHTHALMOLOGICA, V214, P86, DOI 10.1159/000027475; Brownlee M, 2000, METABOLISM, V49, P9, DOI 10.1016/S0026-0495(00)80078-5; Cheng RZ, 2004, J BIOL CHEM, V279, P45441, DOI 10.1074/jbc.M405664200; Cobb BA, 2000, J BIOL CHEM, V275, P6664, DOI 10.1074/jbc.275.9.6664; Daubener W, 1999, ADV EXP MED BIOL, V467, P517; de Jong W.W., 1988, Advances in Experimental Medicine and Biology, V231, P95; Dillon J, 1999, PHOTOCHEM PHOTOBIOL, V69, P248, DOI 10.1562/0031-8655(1999)069<0248:TPAOTG>2.3.CO;2; DYER DG, 1991, Z ERNAHRUNGSWISS, V30, P29, DOI 10.1007/BF01910730; Garner B, 2000, BBA-PROTEIN STRUCT M, V1476, P265, DOI 10.1016/S0167-4838(99)00234-4; Garner B, 1999, J BIOL CHEM, V274, P20847, DOI 10.1074/jbc.274.30.20847; Goda K, 2003, ADV EXP MED BIOL, V527, P687; Goldstein LE, 2000, BIOCHEMISTRY-US, V39, P7266, DOI 10.1021/bi992997s; Grant RS, 2000, J VIROL, V74, P4110, DOI 10.1128/JVI.74.9.4110-4115.2000; Hood BD, 1999, J BIOL CHEM, V274, P32547, DOI 10.1074/jbc.274.46.32547; Kamei A, 1998, BIOL PHARM BULL, V21, P982; LYONS TJ, 1991, DIABETES, V40, P1010, DOI 10.2337/diabetes.40.8.1010; MIYATA S, 1992, J CLIN INVEST, V89, P1102, DOI 10.1172/JCI115690; Ortwerth BJ, 1997, PHOTOCHEM PHOTOBIOL, V65, P666, DOI 10.1111/j.1751-1097.1997.tb01909.x; Oya T, 1999, J BIOL CHEM, V274, P18492, DOI 10.1074/jbc.274.26.18492; Padayatti PS, 2001, INVEST OPHTH VIS SCI, V42, P1299; Parker NR, 2004, FREE RADICAL BIO MED, V37, P1479, DOI 10.1016/j.freeradbiomed.2004.07.015; PAU H, 1990, EXP EYE RES, V50, P17, DOI 10.1016/0014-4835(90)90005-F; PEARSON SJ, 1992, NEUROSCI LETT, V144, P199, DOI 10.1016/0304-3940(92)90749-W; REDDY VN, 1971, EXP EYE RES, V11, P310, DOI 10.1016/S0014-4835(71)80043-X; Sala A, 2004, J BIOL CHEM, V279, P51033, DOI 10.1074/jbc.M408242200; Shamsi FA, 1998, INVEST OPHTH VIS SCI, V39, P2355; Shirao Y, 2000, JPN J OPHTHALMOL, V44, P198, DOI 10.1016/S0021-5155(00)00151-9; Simat TJ, 1998, J AGR FOOD CHEM, V46, P490, DOI 10.1021/jf970818c; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; SPECTOR A, 1972, ISRAEL J MED SCI, V8, P1577; Streete IM, 2004, INVEST OPHTH VIS SCI, V45, P4091, DOI 10.1167/iovs.04-0178; Taylor LM, 2002, EXP EYE RES, V75, P165, DOI 10.1006/exer.2002.2012; Vazquez S, 2000, FREE RADICAL RES, V32, P11, DOI 10.1080/10715760000300021; Vazquez S, 2004, INVEST OPHTH VIS SCI, V45, P879, DOI 10.1167/iovs.03-0558; Vazquez S, 2002, J BIOL CHEM, V277, P4867, DOI 10.1074/jbc.M107529200; Wolf AM, 2004, CLIN IMMUNOL, V113, P47, DOI 10.1016/j.clim.2004.05.004; XIE PY, 1991, OPHTHALMIC RES, V23, P133, DOI 10.1159/000267112; Zampighi GA, 2000, EXP EYE RES, V71, P415, DOI 10.1006/exer.2000.0895; Zhang H, 2004, FREE RADICAL BIO MED, V36, P1355, DOI 10.1016/j.freeradbiomed.2004.02.038	44	22	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22154	22164		10.1074/jbc.M501419200	http://dx.doi.org/10.1074/jbc.M501419200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817458	hybrid			2022-12-27	WOS:000229557900060
J	Gianakopoulos, PJ; Skerjanc, IS				Gianakopoulos, PJ; Skerjanc, IS			Hedgehog signaling induces cardiomyogenesis in P19 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER FACTOR 2C; CENTRAL-NERVOUS-SYSTEM; HEART TUBE FORMATION; LEFT-RIGHT ASYMMETRY; SONIC-HEDGEHOG; TRANSCRIPTION FACTOR; MUSCLE DEVELOPMENT; SKELETAL-MUSCLE; MUTANT MICE; GLI PROTEINS	Sonic Hedgehog (Shh) is a critical signaling factor for a variety of developmental pathways during embryogenesis, including the specification of left-right asymmetry in the heart. Mice that lack Hedgehog signaling show a delay in the induction of cardiomyogenesis, as indicated by a delayed expression of Nkx2-5. To further examine a role for Shh in cardiomyogenesis, clonal populations of P19 cells that stably express Shh, termed P19( Shh) cells, were isolated. In monolayer P19( Shh) cultures the Shh pathway was functional as shown by the up-regulation of Ptc1 and Gli1 expression, but no cardiac muscle markers were activated. However, Shh expression induced cardiomyogenesis following cellular aggregation, resulting in the expression of factors expressed in cardiac muscle including GATA-4, MEF2C, and Nkx2-5. Furthermore, aggregated P19 cell lines expressing Gli2 or Meox1 also up-regulated the expression of cardiac muscle factors, leading to cardiomyogenesis. Meox1 up-regulated the expression of Gli1 and Gli2 and, thus, can modify the Shh signaling pathway. Finally, Shh, Gli2, and Meox1 all up-regulated BMP-4 expression, implying that activation of the Hedgehog pathway can regulate bone morphogenetic protein signals. Taken together, we propose a model in which Shh, functioning via Gli1/2, can specify mesodermal cells into the cardiac muscle lineage.	Univ Ottawa, Dep Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	University of Ottawa; Western University (University of Western Ontario)	Skerjanc, IS (corresponding author), Univ Ottawa, Dep Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	iskerjan@uottawa.ca	Skerjanc, Ilona/AAN-3318-2020					ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Alsan BH, 2002, DEVELOPMENT, V129, P1935; Andree B, 1998, MECH DEVELOP, V70, P119, DOI 10.1016/S0925-4773(97)00186-X; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Borycki AG, 2000, DEVELOPMENT, V127, P2075; Cai J, 2000, GENESIS, V27, P6, DOI 10.1002/1526-968X(200005)27:1<6::AID-GENE20>3.3.CO;2-F; Candia AF, 1996, INT J DEV BIOL, V40, P1179; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; Craven SE, 2004, DEVELOPMENT, V131, P1165, DOI 10.1242/dev.01024; Ding Q, 1998, DEVELOPMENT, V125, P2533; Dodou E, 2004, DEVELOPMENT, V131, P3931, DOI 10.1242/dev.01256; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Eisenberg CA, 1999, DEV DYNAM, V216, P45, DOI 10.1002/(SICI)1097-0177(199909)216:1<45::AID-DVDY7>3.0.CO;2-L; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Grepin C, 1997, DEVELOPMENT, V124, P2387; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jamali M, 2001, J BIOL CHEM, V276, P42252, DOI 10.1074/jbc.M107814200; Kawai S, 2001, BONE, V29, P54, DOI 10.1016/S8756-3282(01)00470-7; Kim JH, 2001, CLIN GENET, V59, P306, DOI 10.1034/j.1399-0004.2001.590503.x; Kos L, 1998, MECH DEVELOP, V70, P25, DOI 10.1016/S0925-4773(97)00168-8; Koyabu Y, 2001, J BIOL CHEM, V276, P6889, DOI 10.1074/jbc.C000773200; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lee J, 1997, DEVELOPMENT, V124, P2537; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Mankoo BS, 2003, DEVELOPMENT, V130, P4655, DOI 10.1242/dev.00687; Mankoo BS, 1999, NATURE, V400, P69, DOI 10.1038/21892; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Matise MP, 1998, DEVELOPMENT, V125, P2759; Ming JE, 1998, MOL MED TODAY, V4, P343, DOI 10.1016/S1357-4310(98)01299-4; Mizugishi K, 2001, J BIOL CHEM, V276, P2180, DOI 10.1074/jbc.M004430200; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Nakamura T, 2003, P NATL ACAD SCI USA, V100, P5834, DOI 10.1073/pnas.0935626100; Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016/S0012-1606(02)00026-X; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; Ogura H, 2001, BEHAV GENET, V31, P317, DOI 10.1023/A:1012235510600; Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921; Petropoulos H, 2004, J BIOL CHEM, V279, P23874, DOI 10.1074/jbc.M312612200; Petropoulos H, 2002, J BIOL CHEM, V277, P15393, DOI 10.1074/jbc.M112141200; Platt KA, 1997, MECH DEVELOP, V62, P121, DOI 10.1016/S0925-4773(96)00648-X; Purandare SM, 2002, DEVELOPMENT, V129, P2293; Reecy JM, 1999, DEVELOPMENT, V126, P839; Reifers F, 2000, DEVELOPMENT, V127, P225; Ridgeway AG, 2000, J BIOL CHEM, V275, P41, DOI 10.1074/jbc.275.1.41; Ridgeway AG, 2001, J BIOL CHEM, V276, P19033, DOI 10.1074/jbc.M011491200; Ridgeway AG, 2000, J BIOL CHEM, V275, P32398, DOI 10.1074/jbc.M004349200; Rodrigo I, 2004, MOL CELL BIOL, V24, P2757, DOI 10.1128/MCB.24.7.2757-2766.2004; Rogerson PJ, 2002, FEBS LETT, V524, P134, DOI 10.1016/S0014-5793(02)03024-7; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Schilling TF, 1999, DEV BIOL, V210, P277, DOI 10.1006/dbio.1999.9214; Schultheiss TM, 1997, COLD SPRING HARB SYM, V62, P413; Searcy RD, 1998, DEVELOPMENT, V125, P4461; SKERJANC IS, 1994, MOL CELL BIOL, V14, P8451, DOI 10.1128/MCB.14.12.8451; Skerjanc IS, 2000, FEBS LETT, V472, P53, DOI 10.1016/S0014-5793(00)01438-1; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; Skerjanc IS, 1999, TRENDS CARDIOVAS MED, V9, P139, DOI 10.1016/S1050-1738(99)00017-1; Skopicki HA, 1997, CIRC RES, V80, P452, DOI 10.1161/01.RES.80.4.452; Tsukui T, 1999, P NATL ACAD SCI USA, V96, P11376, DOI 10.1073/pnas.96.20.11376; Wilton S, 1999, IN VITRO CELL DEV-AN, V35, P175; Zhang XM, 2001, CELL, V105, P781, DOI 10.1016/S0092-8674(01)00385-3	72	55	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21022	21028		10.1074/jbc.M502977200	http://dx.doi.org/10.1074/jbc.M502977200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15793308	hybrid			2022-12-27	WOS:000229438800016
J	Gravielle, MC; Faris, R; Russek, SJ; Farb, DH				Gravielle, MC; Faris, R; Russek, SJ; Farb, DH			GABA induces activity dependent delayed-onset uncoupling of GABA/benzodiazepine site interactions in neocortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT MESSENGER-RNAS; CHRONIC BENZODIAZEPINE TREATMENT; AMINOBUTYRIC ACID(A) RECEPTORS; NEONATAL-RAT HIPPOCAMPUS; CHRONIC AGONIST EXPOSURE; A RECEPTOR; DOWN-REGULATION; CORTICAL-NEURONS; ALLOSTERIC INTERACTIONS; INHIBITORY SYNAPSES	Changes in the function of type A gamma-aminobutyric acid receptors ( GABAARs) are associated with neuronal development and tolerance to the sedative-hypnotic effects of GABA(A)R positive modulators. Persistent activation of GABAARs by millimolar concentrations of GABA occurs under physiological conditions as GABAergic fast-spiking neurons in neocortex and cerebellum exhibit basal firing rates of 5 to 50 Hz and intermittent rates up to 250 Hz, leaving a substantial fraction of synaptic receptors occupied persistently by GABA. Persistent exposure of neurons to GABA has been shown to cause a down-regulation of receptor number and an uncoupling of GABA/benzodiazepine (BZD) site interactions with a half-life of similar to 24 h. Here, we report that a single brief exposure of neocortical neurons in primary culture to GABA for 5 - 10 min (t(1/ 2) = 3.2 +/- 0.2 min) initiates a process that results in uncoupling hours later (t(1/ 2) = 12.1 +/- 2.2 h). Initiation of delayed-onset uncoupling is blocked by co-incubation with picrotoxin or alpha-amanitin but is insensitive to nifedipine, indicating that uncoupling is contingent upon receptor activation and transcription but is not dependent on voltage-gated Ca2+ influx. Delayed-onset uncoupling occurs without a change in receptor number or a change in the proportion of alpha 1 subunit pharmacology, as zolpidem binding affinity is unaltered. Such activity dependent latent modulation of GABAAR function that manifests as delayed-onset uncoupling may be relevant to physiological, pathophysiological, and pharmacological conditions where synaptic receptors are transiently exposed to GABA agonists for several minutes.	Boston Univ, Sch Med, Dept Pharmacol, Mol Neurobiol Lab, Boston, MA 02118 USA	Boston University	Farb, DH (corresponding author), Boston Univ, Sch Med, Dept Pharmacol, Mol Neurobiol Lab, Boston, MA 02118 USA.	dfarb@bu.edu	Farb, david H/C-7089-2014	Farb, david H/0000-0002-9050-6480; Russek, Shelley/0000-0001-7547-3089; Gravielle, Maria/0000-0003-4353-5526				Ali NJ, 2001, J NEUROCHEM, V79, P1100, DOI 10.1046/j.1471-4159.2001.00664.x; BAUMGARTNER BJ, 1994, MOL BRAIN RES, V26, P9, DOI 10.1016/0169-328X(94)90068-X; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; Benes FM, 1996, NEUROSCIENCE, V75, P1021, DOI 10.1016/0306-4522(96)00328-4; Benke D, 2004, J BIOL CHEM, V279, P43654, DOI 10.1074/jbc.M407154200; Bianchi MT, 2001, J NEUROSCI, V21, P9083, DOI 10.1523/JNEUROSCI.21-23-09083.2001; BORDEN LA, 1988, MOL PHARMACOL, V34, P354; BORDEN LA, 1984, SCIENCE, V226, P857, DOI 10.1126/science.6093257; Brandon NJ, 2002, PHARMACOL THERAPEUT, V94, P113, DOI 10.1016/S0163-7258(02)00175-4; Caillard O, 1999, J NEUROSCI, V19, P7568, DOI 10.1523/JNEUROSCI.19-17-07568.1999; Caillard O, 1999, J PHYSIOL-LONDON, V518, P109, DOI 10.1111/j.1469-7793.1999.0109r.x; Chen S, 1999, NEUROSCIENCE, V93, P33, DOI 10.1016/S0306-4522(99)00118-9; Cheron G, 2004, J NEUROSCI, V24, P434, DOI 10.1523/JNEUROSCI.3197-03.2004; CHOI DW, 1977, NATURE, V269, P342, DOI 10.1038/269342a0; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; Cohen I, 2002, SCIENCE, V298, P1418, DOI 10.1126/science.1076510; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; Czurko A, 1999, EUR J NEUROSCI, V11, P344, DOI 10.1046/j.1460-9568.1999.00446.x; Follesa P, 2000, MOL PHARMACOL, V57, P1262; FRIEDMAN L, 1993, MOL PHARMACOL, V44, P191; Friedman LK, 1996, BRAIN RES, V707, P100, DOI 10.1016/0006-8993(95)01226-5; Fujiwara-Tsukamoto Y, 2004, J PHYSIOL-LONDON, V557, P961, DOI 10.1113/jphysiol.2003.059915; Gaiarsa JL, 2002, TRENDS NEUROSCI, V25, P564, DOI 10.1016/S0166-2236(02)02269-5; GALLAGER DW, 1984, NATURE, V308, P74, DOI 10.1038/308074a0; GYENES M, 1994, MOL PHARMACOL, V46, P542; HAIGH JRM, 1988, TRENDS PHARMACOL SCI, V9, P361, DOI 10.1016/0165-6147(88)90255-6; Hajos N, 2004, J NEUROSCI, V24, P9127, DOI 10.1523/JNEUROSCI.2113-04.2004; Holt RA, 1999, J NEUROCHEM, V72, P2219, DOI 10.1046/j.1471-4159.1999.0722219.x; HU XJ, 1994, MOL PHARMACOL, V45, P618; HU XJ, 1994, J PHARMACOL EXP THER, V270, P485; Hutchinson PJ, 2002, J NEUROL NEUROSUR PS, V72, P99, DOI 10.1136/jnnp.72.1.99; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; Kanematsu T, 2002, EMBO J, V21, P1004, DOI 10.1093/emboj/21.5.1004; Khaliq ZM, 2005, J NEUROSCI, V25, P454, DOI 10.1523/JNEUROSCI.3045-04.2005; KLEIN RL, 1994, J NEUROCHEM, V63, P2349; Luscher B, 2004, PHARMACOL THERAPEUT, V102, P195, DOI 10.1016/j.pharmthera.2004.04.003; Lyons HR, 2001, J NEUROCHEM, V78, P1114, DOI 10.1046/j.1471-4159.2001.00501.x; Lyons HR, 2000, J NEUROCHEM, V74, P1041, DOI 10.1046/j.1471-4159.2000.0741041.x; Mehta AK, 1999, MOL BRAIN RES, V67, P194, DOI 10.1016/S0169-328X(99)00020-0; Miranda JD, 1997, J BIOL CHEM, V272, P16288, DOI 10.1074/jbc.272.26.16288; MONTPIED P, 1991, J BIOL CHEM, V266, P6011; MOUNTCASTLE VB, 1969, J NEUROPHYSIOL, V32, P452, DOI 10.1152/jn.1969.32.3.452; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; Poulter MO, 1997, J NEUROCHEM, V68, P631; PRASAD A, 1992, BRAIN RES, V591, P327, DOI 10.1016/0006-8993(92)91714-P; PUIA G, 1991, MOL PHARMACOL, V39, P691; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2; ROCA DJ, 1990, MOL PHARMACOL, V37, P710; ROCA DJ, 1990, MOL PHARMACOL, V37, P37; ROCA DJ, 1988, MOL PHARMACOL, V33, P481; Russek SJ, 2000, P NATL ACAD SCI USA, V97, P8600, DOI 10.1073/pnas.97.15.8600; SEIDEL WF, 1985, PSYCHOPHARMACOLOGY, V87, P194, DOI 10.1007/BF00431806; Smith AJ, 2001, MOL PHARMACOL, V59, P1108, DOI 10.1124/mol.59.5.1108; Smith SS, 1998, J NEUROSCI, V18, P5275, DOI 10.1523/JNEUROSCI.18-14-05275.1998; Sun MK, 2001, J NEUROPHYSIOL, V85, P269, DOI 10.1152/jn.2001.85.1.269; SWIFT CG, 1984, AGE AGEING, V13, P335, DOI 10.1093/ageing/13.6.335; Takayama C, 2004, NEUROSCI RES, V50, P447, DOI 10.1016/j.neures.2004.08.012; Tietz EI, 1999, NEUROSCIENCE, V91, P327, DOI 10.1016/S0306-4522(98)00516-8; Tietz EI, 1999, J PHARMACOL EXP THER, V291, P932; Timofeev I, 2002, NEUROSCIENCE, V114, P1115, DOI 10.1016/S0306-4522(02)00300-7; WAFFORD KA, 1993, MOL PHARMACOL, V43, P240; Walsh LA, 1999, J PHARMACOL EXP THER, V289, P1626; West AE, 2002, NAT REV NEUROSCI, V3, P921, DOI 10.1038/nrn987; WONG G, 1994, MOL PHARMACOL, V46, P1056	65	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20954	20960		10.1074/jbc.M500131200	http://dx.doi.org/10.1074/jbc.M500131200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15805111	hybrid, Green Published			2022-12-27	WOS:000229438800008
J	Hu, XY; Kohler, K; Falick, AM; Moore, AMF; Jones, PR; Sparkman, OD; Vierra, C				Hu, XY; Kohler, K; Falick, AM; Moore, AMF; Jones, PR; Sparkman, OD; Vierra, C			Egg case protein-1 - A new class of silk proteins with fibroin-like properties from the spider Latrodectus hesperus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR AMPULLATE SILK; MECHANICAL-PROPERTIES; DRAGLINE SILK; GENE FAMILY; BLACK-WIDOW; SEQUENCE; CONSERVATION; ARANEIDAE; FIBER; CDNA	Spiders produce multiple types of silk that exhibit diverse mechanical properties and biological functions. Most molecular studies of spider silk have focused on fibroins from dragline silk and capture silk, two important silk types involved in the survival of the spider. In our studies we have focused on the characterization of egg case silk, a third silk fiber produced by the black widow spider, Latrodectus hesperus. Analysis of the physical structure of egg case silk using scanning electron microscopy demonstrates the presence of small and large diameter fibers. By using the strong protein denaturant 8 M guanidine hydrochloride to solubilize the fibers, we demonstrated by SDS-PAGE and protein silver staining that an abundant component of egg case silk is a 100-kDa protein doublet. Combining matrix-assisted laser desorption ionization tandem time-of-flight mass spectrometry and reverse genetics, we have isolated a novel gene called ecp-1, which encodes for one of the protein components of the 100-kDa species. BLAST searches of the NCBInr protein data base using the primary sequence of ECP-1 revealed similarity to fibroins from spiders and silkworms, which mapped to two distinct regions within the ECP-1. These regions contained the conserved repetitive fibroin motifs poly( Ala) and poly(Gly-Ala), but surprisingly, no larger ensemble repeats could be identified within the primary sequence of ECP-1. Consistent with silk gland-restricted patterns of expression for fibroins, ECP-1 was demonstrated to be predominantly produced in the tubuliform gland, with lower levels detected in the major and minor ampullate glands. ECP-1 monomeric units were also shown to assemble into higher aggregate structures through the formation of disulfide bonds via a unique cysteine-rich N-terminal region. Collectively, our findings provide new insight into the components of egg case silk and identify a new class of silk proteins with distinctive molecular features relative to traditional members of the spider silk gene family.	Univ Pacific, Dept Sci Biol, Stockton, CA 95211 USA; Univ Pacific, Dept Chem, Stockton, CA 95211 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of the Pacific; University of the Pacific; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Vierra, C (corresponding author), Univ Pacific, Dept Sci Biol, 3601 Pacific Ave, Stockton, CA 95211 USA.	cvierra@pacific.edu		Kohler, Kristin/0000-0001-7753-843X				Altman GH, 2002, BIOMATERIALS, V23, P4131, DOI 10.1016/S0142-9612(02)00156-4; Arcidiacono S, 1998, APPL MICROBIOL BIOT, V49, P31, DOI 10.1007/s002530051133; BECKWITT R, 1994, J BIOL CHEM, V269, P6661; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; CANDELAS G, 1983, BIOCHEM BIOPH RES CO, V116, P1033, DOI 10.1016/S0006-291X(83)80246-0; Casem ML, 1999, INT J BIOL MACROMOL, V24, P103, DOI 10.1016/S0141-8130(98)00078-6; Colgin MA, 1998, PROTEIN SCI, V7, P667, DOI 10.1002/pro.5560070315; Draper N, 2003, NAT GENET, V34, P434, DOI 10.1038/ng1214; Foradori MJ, 2002, J MORPHOL, V252, P218, DOI 10.1002/jmor.1100; FORLIX RF, 1996, BIOL SPIDERS, P1; Gatesy J, 2001, SCIENCE, V291, P2603, DOI 10.1126/science.1057561; Gosline JM, 1999, J EXP BIOL, V202, P3295; Guerette PA, 1996, SCIENCE, V272, P112, DOI 10.1126/science.272.5258.112; Hayashi CY, 1999, INT J BIOL MACROMOL, V24, P271, DOI 10.1016/S0141-8130(98)00089-0; Hayashi CY, 2004, MOL BIOL EVOL, V21, P1950, DOI 10.1093/molbev/msh204; Hayashi CY, 2000, SCIENCE, V287, P1477, DOI 10.1126/science.287.5457.1477; Hayashi CY, 1998, J MOL BIOL, V275, P773, DOI 10.1006/jmbi.1997.1478; HINMAN MB, 1992, J BIOL CHEM, V267, P19320; Hoffman RT, 1996, J BIOL CHEM, V271, P9809, DOI 10.1074/jbc.271.16.9809; JIMENEZ CR, 1998, CURRENT PROTOCOLS PR; Jin HJ, 2003, NATURE, V424, P1057, DOI 10.1038/nature01809; Lawrence BA, 2004, BIOMACROMOLECULES, V5, P689, DOI 10.1021/bm0342640; MELLO CM, 1994, ACS SYM SER, V544, P67; Mitchell B, 2000, BBA-GENE STRUCT EXPR, V1492, P320, DOI 10.1016/S0167-4781(00)00109-3; Nguyen L, 2001, NUCLEIC ACIDS RES, V29, P4423, DOI 10.1093/nar/29.21.4423; Parkhe AD, 1997, J MOL RECOGNIT, V10, P1, DOI 10.1002/(SICI)1099-1352(199701/02)10:1<1::AID-JMR338>3.0.CO;2-7; Sambrook J., 2002, MOL CLONING LAB MANU; Sekiguchi K., 1955, Science Reports Tokyo Kyoiku Daigaku, V8B, P23; Tian MZ, 2004, BIOMACROMOLECULES, V5, P657, DOI 10.1021/bm034391w; TILLINGHAST EK, 1981, NATURWISSENSCHAFTEN, V68, P526, DOI 10.1007/BF00365384; Vollrath F, 2001, NATURE, V410, P541, DOI 10.1038/35069000; XU M, 1990, P NATL ACAD SCI USA, V87, P7120, DOI 10.1073/pnas.87.18.7120	32	45	48	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21220	21230		10.1074/jbc.M412316200	http://dx.doi.org/10.1074/jbc.M412316200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797873	hybrid			2022-12-27	WOS:000229438800040
J	Park, EH; Lee, JM; Blais, JD; Bell, JC; Pelletier, J				Park, EH; Lee, JM; Blais, JD; Bell, JC; Pelletier, J			Internal translation initiation mediated by the angiogenic factor Tie2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; RIBOSOME ENTRY SITE; FACTOR MESSENGER-RNA; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; GROWTH-FACTOR GENE; C-MYC; EFFICIENT TRANSLATION; ENDOTHELIAL-CELLS; ORNITHINE DECARBOXYLASE; SECONDARY STRUCTURE	Tie2 is an endothelium-specific receptor tyrosine kinase required for normal blood vessel maturation. We report that Tie2 mRNA translation is maintained under hypoxic conditions. To identify the mechanism responsible for this, we undertook structure/function analysis of the Tie2 5'-untranslated region (UTR). Transcription start site mapping indicates the existence of a several mRNA isoforms containing unusually long 5'-UTRs (> 350 nucleotides) with five upstream open reading frames. We find internal ribosome binding activity that allows the Tie2 mRNA to initiate in a cap-independent fashion. Our data provide a framework for understanding how Tie2 mRNA is translated despite a cumbersome structured 5'-UTR and how its production is secured under unfavorable environmental conditions.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Ottawa Reg Canc Ctr, Res Labs, Ottawa, ON K1H 8L6, Canada	McGill University; McGill University; University of Ottawa; Ottawa Hospital Research Institute	Park, EH (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,Rom 810,3655 Promenade Sir, Montreal, PQ H3G 1Y6, Canada.	jerry.pelletier@mcgill.ca						Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Christensen RA, 2002, J CELL BIOCHEM, V85, P505, DOI 10.1002/jcb.10148; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Fadel BM, 1998, BIOCHEM J, V330, P335; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GEHRKE L, 1983, BIOCHEMISTRY-US, V22, P5157, DOI 10.1021/bi00291a015; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gorlach A, 2000, BBA-GENE STRUCT EXPR, V1493, P125, DOI 10.1016/S0167-4781(00)00172-X; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hewett PW, 1998, BIOCHEM BIOPH RES CO, V252, P546, DOI 10.1006/bbrc.1998.9690; HOFMANN GE, 1994, P NATL ACAD SCI USA, V91, P8492, DOI 10.1073/pnas.91.18.8492; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Jones N, 2001, EMBO REP, V2, P438, DOI 10.1093/embo-reports/kve093; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Lin SK, 2002, BIOCHEM BIOPH RES CO, V296, P710, DOI 10.1016/S0006-291X(02)00924-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Miller DL, 1998, FEBS LETT, V434, P417, DOI 10.1016/S0014-5793(98)01025-4; Nanbru C, 2001, ONCOGENE, V20, P4270, DOI 10.1038/sj.onc.1204548; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Park YS, 2003, MICROVASC RES, V65, P125, DOI 10.1016/S0026-2862(02)00035-3; PARKIN NT, 1988, EMBO J, V7, P2831, DOI 10.1002/j.1460-2075.1988.tb03139.x; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Seidel ER, 1997, BRIT J PHARMACOL, V120, P571, DOI 10.1038/sj.bjp.0700936; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Svitkin YV, 2001, RNA, V7, P1743; Tinton SA, 1999, FEBS LETT, V446, P55, DOI 10.1016/S0014-5793(99)00185-4; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Willam C, 2000, CIRC RES, V87, P370; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3	50	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20945	20953		10.1074/jbc.M412744200	http://dx.doi.org/10.1074/jbc.M412744200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802272	hybrid			2022-12-27	WOS:000229438800007
J	Sakamoto, A; Chen, M; Nakamura, T; Xie, T; Karsenty, G; Weinstein, LS				Sakamoto, A; Chen, M; Nakamura, T; Xie, T; Karsenty, G; Weinstein, LS			Deficiency of the G-protein alpha-subunit G(s)alpha in osteoblasts leads to differential effects on trabecular and cortical bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID-HORMONE; IN-VITRO; ALPHA-SUBUNIT; GROWTH-PLATE; OSTEOPROGENITOR CELLS; PTH/PTHRP RECEPTOR; PROSTAGLANDIN E-2; MC3T3-E1 CELLS; KNOCKOUT MICE; EXPRESSION	The G-protein alpha-subunit G(s)alpha is required for the intracellular cAMP responses to hormones and other agonists. G(s)alpha is known to mediate the cAMP response to parathyroid hormone and other hormones and cytokines in bone and cartilage. To analyze the in vivo role of G(s)alpha signaling in osteoblasts, we developed mice with osteoblast/osteocyte-specific G(s)alpha deficiency (BGsKO) by mating G(s)alpha-floxed mice with collagen I alpha 1 promoter-Cre recombinase transgenic mice. Early skeletal development was normal in BGsKO mice, because formation of the initial cartilage template and bone collar was unaffected. The chondrocytic zones of the growth plates also appeared normal in BGsKO mice. BGsKO mice had a defect in the formation of the primary spongiosa with reduced immature osteoid (new bone formation) and overall length, which led to reduced trabecular bone volume. In contrast, cortical bone was thickened with narrowing of the bone marrow cavity. This was probably due to decreased cortical bone resorption, because osteoclasts were markedly reduced on the endosteal surface of cortical bone. In addition, the expression of alkaline phosphatase, an early osteoblastic differentiation marker, was normal, whereas the expression of the late osteoblast differentiation markers osteopontin and osteocalcin was reduced, suggesting that the number of mature osteoblasts in bone is reduced. Expression of the osteoclast- stimulating factor receptor activator of NF-kappa B ligand was also reduced. Overall, our findings have similarities to parathyroid hormone null mice and confirm that the differential effects of parathyroid hormone on trabecular and cortical bone are primarily mediated via G(s)alpha in osteoblasts. Osteoblast-specific G(s)alpha deficiency leads to reduced bone turnover.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Baylor College of Medicine	Weinstein, LS (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Rm 8C101, Bethesda, MD 20892 USA.	leew@amb.niddk.nih.gov	Nakamura, Takashi/P-7796-2016; Nakamura, Takashi/A-8931-2012; Weinstein, Lee S/I-5575-2015	Nakamura, Takashi/0000-0001-9904-1037; Nakamura, Takashi/0000-0001-9904-1037; Weinstein, Lee/0000-0002-1899-5152	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK043302, Z01DK043302] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bastepe M, 2004, P NATL ACAD SCI USA, V101, P14794, DOI 10.1073/pnas.0405091101; BELLOWS CG, 1990, ENDOCRINOLOGY, V127, P3111, DOI 10.1210/endo-127-6-3111; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296; Cao J, 2003, J BONE MINER RES, V18, P270, DOI 10.1359/jbmr.2003.18.2.270; Choi JY, 1996, J CELL BIOCHEM, V61, P609, DOI 10.1002/(SICI)1097-4644(19960616)61:4<609::AID-JCB15>3.3.CO;2-Q; Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226; Ishii-Suzuki M, 1999, ANAT REC, V255, P452, DOI 10.1002/(SICI)1097-0185(19990801)255:4<452::AID-AR10>3.0.CO;2-E; Ishizeki K, 2003, ANN ANAT, V185, P403, DOI 10.1016/S0940-9602(03)80097-3; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Kanematsu M, 2000, J BONE MINER RES, V15, P1321, DOI 10.1359/jbmr.2000.15.7.1321; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Lanske B, 1999, J CLIN INVEST, V104, P399, DOI 10.1172/JCI6629; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552; Li X, 2002, BONE, V30, P567, DOI 10.1016/S8756-3282(02)00683-X; Li XD, 2000, ENDOCRINOLOGY, V141, P2054, DOI 10.1210/en.141.6.2054; Liu J, 2005, P NATL ACAD SCI USA, V102, P5513, DOI 10.1073/pnas.0408262102; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; Miao DS, 2002, J CLIN INVEST, V109, P1173, DOI 10.1172/JCI200214817; NISHIDA S, 1994, BONE, V15, P717, DOI 10.1016/8756-3282(94)90322-0; NODA M, 1988, J BIOL CHEM, V263, P18574; Okahashi N, 2004, INFECT IMMUN, V72, P1706, DOI 10.1128/IAI.72.3.1706-1714.2004; PARISIEN M, 1990, J CLIN ENDOCR METAB, V70, P930, DOI 10.1210/jcem-70-4-930; QUARLES LD, 1992, J BONE MINER RES, V7, P683; Rosen CJ, 2004, TRENDS ENDOCRIN MET, V15, P229, DOI 10.1016/j.tem.2004.05.005; Sakamoto A, 2005, J BONE MINER RES, V20, P663, DOI 10.1359/JBMR.041210; Sakamoto A, 2004, HUM MOL GENET, V13, P819, DOI 10.1093/hmg/ddh098; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; Skinner JA, 2002, GENOMICS, V80, P373, DOI 10.1006/geno.2002.6842; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Suda M, 1996, ENDOCRINOLOGY, V137, P1698, DOI 10.1210/en.137.5.1698; TURKSEN K, 1990, J CELL PHYSIOL, V142, P61, DOI 10.1002/jcp.1041420109; Weinstein LS, 2001, ENDOCR REV, V22, P675, DOI 10.1210/er.22.5.675; WEINSTEIN LS, 2002, PRINCIPLES BONE BIOL, P1165; Yu SH, 1998, P NATL ACAD SCI USA, V95, P8715, DOI 10.1073/pnas.95.15.8715; zur Nieden NI, 2003, DIFFERENTIATION, V71, P18, DOI 10.1046/j.1432-0436.2003.700602.x	40	68	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21369	21375		10.1074/jbc.M500346200	http://dx.doi.org/10.1074/jbc.M500346200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797856	hybrid			2022-12-27	WOS:000229438800056
J	Kim, H; von Heijne, G; Nilsson, I				Kim, H; von Heijne, G; Nilsson, I			Membrane topology of the STT3 subunit of the oligosaccharyl transferase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; N-LINKED GLYCOSYLATION; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PROTEIN TOPOLOGY; IN-VIVO; SIGNAL; DEGRADATION; TRANSLOCASE; SEQUENCES	The highly conserved membrane protein STT3 is part of the oligosaccharyl transferase complex in the endoplasmic reticulum of eukaryotic cells. Various experimental observations strongly suggest that STT3 contains the active site of the complex. Here, we report a detailed topology study of STT3 from two different organisms, Saccharomyces cerevisiae and mouse, using in vivo and in vitro topology mapping assays. Our results suggest that STT3 has 11 transmembrane helices and an overall N-cyt-C-lum orientation.	Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden	Stockholm University	Nilsson, I (corresponding author), Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	ingmarie@dbb.su.se	Nilsson, IngMarie/H-2887-2012; von Heijne, Gunnar/AAH-9389-2019; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569				Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Chavan M, 2003, J BIOL CHEM, V278, P51441, DOI 10.1074/jbc.M310456200; Deak PM, 2001, J BIOL CHEM, V276, P10663, DOI 10.1074/jbc.M008608200; Devoto A, 1999, J BIOL CHEM, V274, P34993, DOI 10.1074/jbc.274.49.34993; Gilstring CF, 2000, J BIOL CHEM, V275, P31488, DOI 10.1074/jbc.M005047200; Hong GZ, 1996, GENOMICS, V31, P295, DOI 10.1006/geno.1996.0051; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; Karaoglu D, 1997, J BIOL CHEM, V272, P32513, DOI 10.1074/jbc.272.51.32513; Kelleher DJ, 2003, MOL CELL, V12, P101, DOI 10.1016/S1097-2765(03)00243-0; Kim H, 2003, J BIOL CHEM, V278, P10208, DOI 10.1074/jbc.M300163200; Kim H, 2003, P NATL ACAD SCI USA, V100, P7460, DOI 10.1073/pnas.1332735100; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Li GT, 2005, J BIOL CHEM, V280, P1864, DOI 10.1074/jbc.M410969200; LILJESTROM P, 1991, J VIROL, V65, P147; Melen K, 2003, J MOL BIOL, V327, P735, DOI 10.1016/S0022-2836(03)00182-7; Mingarro I, 2000, BMC Cell Biol, V1, P3, DOI 10.1186/1471-2121-1-3; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; Nilsson I, 2003, J CELL BIOL, V161, P715, DOI 10.1083/jcb.200301043; Nilsson I, 2000, J BIOL CHEM, V275, P17338, DOI 10.1074/jbc.M002317200; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Strahl-Bolsinger S, 1999, J BIOL CHEM, V274, P9068, DOI 10.1074/jbc.274.13.9068; van Geest M, 1999, J BIOL CHEM, V274, P2816, DOI 10.1074/jbc.274.5.2816; Von Heijne G, 1998, ACTA PHYSIOL SCAND, V163, P17; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; Wilhovsky S, 2000, MOL BIOL CELL, V11, P1697, DOI 10.1091/mbc.11.5.1697; Yan G, 2002, J BIOL CHEM, V277, P47692, DOI 10.1074/jbc.M208136200; YOSHIDA S, 1992, MOL GEN GENET, V231, P337, DOI 10.1007/BF00292700; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	31	28	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20261	20267		10.1074/jbc.M412213200	http://dx.doi.org/10.1074/jbc.M412213200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781470	hybrid			2022-12-27	WOS:000229242000014
J	Lanzino, M; De Amicis, F; McPhaul, MJ; Marsico, S; Panno, ML; Ando, S				Lanzino, M; De Amicis, F; McPhaul, MJ; Marsico, S; Panno, ML; Ando, S			Endogenous coactivator ARA70 interacts with estrogen receptor alpha (ER alpha) and modulates the functional ER alpha/androgen receptor interplay in MCF-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; HUMAN ANDROGEN RECEPTOR; MAMMARY-GLAND; GROWTH; EXPRESSION; GENE; TUMORIGENESIS; TRANSCRIPTION; RESISTANCE; PROSTATE	Overexpression of androgen receptor (AR) decreases estrogen receptor alpha (ER alpha) transactivation, which plays a basic role in hormone-dependent breast cancer. This transcriptional interference can be due to shared coactivators. Here we demonstrated that in MCF-7 cells ARA70, an AR-specific coactivator, interacted with endogenous ER alpha, increasing its transcriptional activity, and it was recruited to the pS2 gene promoter. Moreover, a dominant negative ARA70 down-regulated ER alpha transcriptional activity as well as pS2 mRNA. ARA70 overexpression reversed the AR down-regulatory effect on ER alpha signaling. However, in the presence of a progressive increase of transfected AR, ARA70 switched into enhancing the inhibitory effect of AR on ER alpha signaling. These opposite effects of ARA70 were further evidenced by coimmunoprecipitation assay in MCF-7wt, MCF-7-overexpressing AR, and HeLa cells, exogenously expressing an excess of ER alpha with respect to AR or an excess of AR with respect to ER alpha. Thus, ARA70 is a coactivator for ER alpha and may represent a functional link between ER alpha/AR modulating their cross-talk in models of estrogen signaling in MCF-7 and HeLa cells.	Univ Calabria, Dept Cell Biol, I-87030 Commenda Di Rende, Italy; Univ Calabria, Dept Pharmacobiol, I-87030 Commenda Di Rende, Italy; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Calabria; University of Calabria; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ando, S (corresponding author), Univ Calabria, Dept Cell Biol, I-87030 Commenda Di Rende, Italy.	sebastiano.ando@unical.it	McPhaul, Michael/AAC-7124-2020; MARSICO, Stefania/J-9938-2019	MARSICO, Stefania/0000-0003-1598-0526; De Amicis, Francesca/0000-0001-7079-1037; Lanzino, Marilena/0000-0002-6362-5396	NIDDK NIH HHS [DK03892] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK003892] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ando S, 2002, MOL CELL ENDOCRINOL, V193, P121, DOI 10.1016/S0303-7207(02)00105-3; BERNS EM, 2003, BREAST CANC RES THRE, V1, P121; Birrell SN, 1998, J MAMMARY GLAND BIOL, V3, P95, DOI 10.1023/A:1018730519839; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; FOEKENS JA, 1989, CANCER RES, V49, P5823; Fuqua SAW, 2001, J MAMMARY GLAND BIOL, V6, P407, DOI 10.1023/A:1014782813943; Gao Xiuhua, 2002, Mol Cancer, V1, P7, DOI 10.1186/1476-4598-1-7; Giguere Y, 2001, CANCER RES, V61, P5869; GOLDENBERG IS, 1975, CANCER, V36, P308, DOI 10.1002/1097-0142(197508)36:2<308::AID-CNCR2820360203>3.0.CO;2-1; Hackenberg R, 1996, J STEROID BIOCHEM, V56, P113, DOI 10.1016/0960-0760(95)00228-6; Kollara A, 2001, BREAST CANCER RES TR, V67, P245, DOI 10.1023/A:1017938608460; Liao DJ, 2002, J STEROID BIOCHEM, V80, P175, DOI 10.1016/S0960-0760(01)00185-6; LOBACCARO JM, 1993, NAT GENET, V5, P109, DOI 10.1038/ng1093-109; MARCELLI M, 1990, MOL ENDOCRINOL, V4, P1105, DOI 10.1210/mend-4-8-1105; Murphy LC, 2000, CANCER RES, V60, P6266; Murphy LC, 2002, BIOMED PHARMACOTHER, V56, P65, DOI 10.1016/S0753-3322(01)00157-3; POULIN R, 1989, ENDOCRINOLOGY, V125, P392, DOI 10.1210/endo-125-1-392; Rahman MM, 2003, J BIOL CHEM, V278, P19619, DOI 10.1074/jbc.M210941200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Sommer S, 2001, SEMIN CANCER BIOL, V11, P339, DOI 10.1006/scbi.2001.0389; THORPE SM, 1988, ACTA ONCOL, V27, P1; Tikkanen MK, 2000, P NATL ACAD SCI USA, V97, P12536, DOI 10.1073/pnas.220427297; TILLEY WD, 1990, J BIOL CHEM, V265, P13776; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527; ZOPPI S, 1992, MOL ENDOCRINOL, V6, P409, DOI 10.1210/me.6.3.409	30	70	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20421	20430		10.1074/jbc.M413576200	http://dx.doi.org/10.1074/jbc.M413576200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15772083	hybrid			2022-12-27	WOS:000229242000034
J	Basso, E; Fante, L; Fowlkes, J; Petronilli, V; Forte, MA; Bernardi, P				Basso, E; Fante, L; Fowlkes, J; Petronilli, V; Forte, MA; Bernardi, P			Properties of the permeability transition pore in mitochondria devoid of cyclophilin D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; INNER MEMBRANE; CULTURED-HEPATOCYTES; INORGANIC-PHOSPHATE; RAT HIPPOCAMPUS; CELL-DEATH; DAMAGE; MODULATION; REPERFUSION; PROTECTION	We have studied the properties of the permeability transition pore (PTP) in mitochondria from the liver of mice where the Ppif gene encoding for mitochondrial Cyclophilin D (CyP-D) had been inactivated. Mitochondria from Ppif(-/-) mice had no CyP-D and displayed a striking desensitization of the PTP to Ca2+, in that pore opening required about twice the Ca2+ load necessary to open the pore in strain-matched, wild-type mitochondria. Mitochondria lacking CyP-D were insensitive to Cyclosporin A (CsA), which increased the Ca2+ retention capacity only in mitochondria from wild-type mice. The PTP response to ubiquinone 0, depolarization, pH, adenine nucleotides, and thiol oxidants was similar in mitochondria from wild-type and Ppif(-/-) mice. These experiments demonstrate that (i) the PTP can form and open in the absence of CyP-D, (ii) that CyP-D represents the target for PTP inhibition by CsA, and (iii) that CyP-D modulates the sensitivity of the PTP to Ca2+ but not its regulation by the proton electrochemical gradient, adenine nucleotides, and oxidative stress. These results have major implications for our current understanding of the PTP and its modulation in vitro and in vivo.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Inst Neurosci, CNR, I-35121 Padua, Italy	Oregon Health & Science University; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Forte, MA (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, L474,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	forte@ohsu.edu; bernardi@bio.unipd.it	Basso, Emy/F-7687-2015; Petronilli, Valeria/C-3558-2015; Bernardi, Paolo/C-3656-2008	Basso, Emy/0000-0003-2962-7213; Petronilli, Valeria/0000-0003-4026-6404; Bernardi, Paolo/0000-0001-9187-3736	NIGMS NIH HHS [GM69883] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069883] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basso E, 2004, BIOPHYS J, V86, p357A; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BROEKEMEIER KM, 1992, FEBS LETT, V304, P192, DOI 10.1016/0014-5793(92)80616-O; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; CROMPTON M, 1988, BIOCHEM J, V255, P357; Crouser ED, 2002, CRIT CARE MED, V30, P276, DOI 10.1097/00003246-200202000-00002; DAVIDSON AM, 1990, BIOCHEM J, V268, P147, DOI 10.1042/bj2680147; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; Feldmann G, 2000, HEPATOLOGY, V31, P674, DOI 10.1002/hep.510310318; Ferrand-Drake M, 1999, NEUROSCIENCE, V90, P1325, DOI 10.1016/S0306-4522(98)00559-4; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; GRIFFITHS EJ, 1993, J MOL CELL CARDIOL, V25, P1461, DOI 10.1006/jmcc.1993.1162; HALESTRAP AP, 1991, BIOCHEM J, V278, P715, DOI 10.1042/bj2780715; Haouzi D, 2002, APOPTOSIS, V7, P395, DOI 10.1023/A:1020026923038; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; Irwin WA, 2003, NAT GENET, V35, P367, DOI 10.1038/ng1270; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Keep M, 2001, BRAIN RES, V894, P327, DOI 10.1016/S0006-8993(01)02012-1; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P10014, DOI 10.1073/pnas.1633614100; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; LENARTOWICZ E, 1991, J BIOENERG BIOMEMBR, V23, P679, DOI 10.1007/BF00785817; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Lin DT, 2002, J BIOL CHEM, V277, P31134, DOI 10.1074/jbc.M112035200; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; SELWYN MJ, 1970, FEBS LETT, V10, P1, DOI 10.1016/0014-5793(70)80402-1; SNYDER JW, 1992, BIOCHEM PHARMACOL, V44, P833, DOI 10.1016/0006-2952(92)90425-I; Soriano ME, 2004, J BIOL CHEM, V279, P36803, DOI 10.1074/jbc.M405297200; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; ZOETEWEIJ JP, 1993, J BIOL CHEM, V268, P3384	44	646	672	2	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18558	18561		10.1074/jbc.C500089200	http://dx.doi.org/10.1074/jbc.C500089200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15792954	hybrid			2022-12-27	WOS:000228932300002
J	Huang, C; Thirone, ACP; Huang, XD; Klip, A				Huang, C; Thirone, ACP; Huang, XD; Klip, A			Differential contribution of insulin receptor substrates 1 versus 2 to insulin signaling and glucose uptake in L6 myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; STIMULATED GLUT4 TRANSLOCATION; SKELETAL-MUSCLE CELLS; KINASE C-ZETA; 3T3-L1 ADIPOCYTES; CORTICAL ACTIN; TYROSINE PHOSPHORYLATION; PROTEIN EXPRESSION; POTENTIAL ROLE; P38 MAPK	Insulin receptor substrates-1 and 2 (IRS-1 and IRS-2) are pivotal in relaying insulin signaling in insulin-responsive tissues such as muscle. However, the precise contribution of IRS-1 vis-a-vis IRS-2 in insulin-mediated metabolic and mitogenic responses has not been compared directly in differentiated muscle cells. This study aimed to determine the relative contribution of IRS-1 versus IRS-2 in these responses, using small interfering RNA ( siRNA)mediated specific gene silencing. In L6 myotubes, transfection of siRNA targeted specifically against IRS-1 (siIRS-1) or IRS-2 (siIRS-2) reduced the cognate protein expression by 70-75%. Insulin-induced ERK phosphorylation was much more sensitive to IRS-2 than IRS-1 ablation, whereas p38MAPK phosphorylation was reduced by 43 or 62% in myotubes treated with siIRS-1 or siIRS-2, respectively. Insulin-induced Akt1 and Akt2 phosphorylation was reduced in myotubes treated with siIRS-1, but only Akt2 phosphorylation was reduced in myotubes treated with siIRS-2. In contrast, siIRS-1 treatment caused a marked reduction in insulin-induced actin remodeling, glucose uptake, and GLUT4 translocation, and siIRS-2 was without effect on these responses. Notably, combined siIRS-1 and siIRS-2, although reducing each IRS by around 75%, caused no further drop in glucose uptake than that achieved with siIRS-1 alone, but abolished p38MAPK phosphorylation. We conclude that insulin-stimulated Akt1 phosphorylation, actin remodeling, GLUT4 translocation, and glucose uptake are regulated mainly by IRS-1, whereas IRS-2 contributes selectively to ERK signaling, and Akt2 and p38MAPK lie downstream of both IRS in muscle cells.	Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Klip, A (corresponding author), Hosp Sick Children, Cell Biol Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	amira@sickkids.ca	Huang, Carol/H-2248-2014					ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Arribas M, 2003, FEBS LETT, V536, P161, DOI 10.1016/S0014-5793(03)00049-8; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Bazuine M, 2003, EUR J BIOCHEM, V270, P3891, DOI 10.1046/j.1432-1033.2003.03771.x; Bjornholm M, 1997, DIABETES, V46, P524, DOI 10.2337/diabetes.46.3.524; Brozinick JT, 2004, J BIOL CHEM, V279, P40699, DOI 10.1074/jbc.M402697200; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Cai DS, 2003, J BIOL CHEM, V278, P25323, DOI 10.1074/jbc.M212430200; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Carvalho E, 1999, FASEB J, V13, P2173, DOI 10.1096/fasebj.13.15.2173; Fasshauer M, 2000, J BIOL CHEM, V275, P25494, DOI 10.1074/jbc.M004046200; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Higaki Y, 1999, J BIOL CHEM, V274, P20791, DOI 10.1074/jbc.274.30.20791; Huang C, 2002, DIABETES, V51, P2090, DOI 10.2337/diabetes.51.7.2090; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; Jebailey L, 2004, MOL ENDOCRINOL, V18, P359, DOI 10.1210/me.2003-0294; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; KANAI F, 1993, J BIOL CHEM, V268, P14523; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Khayat ZA, 2000, J CELL SCI, V113, P279; Krook A, 2000, DIABETES, V49, P284, DOI 10.2337/diabetes.49.2.284; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Leng Y, 2004, DIABETES, V53, P1436, DOI 10.2337/diabetes.53.6.1436; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; Miele C, 1999, J BIOL CHEM, V274, P3094, DOI 10.1074/jbc.274.5.3094; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; Niu WY, 2003, J BIOL CHEM, V278, P17953, DOI 10.1074/jbc.M211136200; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; Oriente F, 2001, J BIOL CHEM, V276, P37109, DOI 10.1074/jbc.M104405200; Patel N, 2003, MOL CELL BIOL, V23, P4611, DOI 10.1128/MCB.23.13.4611-4626.2003; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; Pirola L, 2003, J BIOL CHEM, V278, P15641, DOI 10.1074/jbc.M208984200; Previs SF, 2000, J BIOL CHEM, V275, P38990, DOI 10.1074/jbc.M006490200; QUON MJ, 1994, J BIOL CHEM, V269, P27920; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; Sasaoka T, 2004, J BIOL CHEM, V279, P14835, DOI 10.1074/jbc.M311534200; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Sciacca L, 2003, ENDOCRINOLOGY, V144, P2650, DOI 10.1210/en.2002-0136; Sesti G, 2001, DIABETES-METAB RES, V17, P363, DOI 10.1002/dmrr.225; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Solow BT, 1999, MOL ENDOCRINOL, V13, P1784, DOI 10.1210/me.13.10.1784; Somwar R, 2000, DIABETES, V49, P1794, DOI 10.2337/diabetes.49.11.1794; Somwar R, 1998, CLIN THER, V20, P125, DOI 10.1016/S0149-2918(98)80040-4; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Ueyama A, 1999, AM J PHYSIOL-ENDOC M, V277, pE572, DOI 10.1152/ajpendo.1999.277.3.E572; Valverde AM, 1998, MOL ENDOCRINOL, V12, P688, DOI 10.1210/me.12.5.688; Wang QH, 1998, FEBS LETT, V427, P193, DOI 10.1016/S0014-5793(98)00423-2; Wang QH, 1999, MOL CELL BIOL, V19, P4008; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Zhou LX, 1997, J BIOL CHEM, V272, P29829, DOI 10.1074/jbc.272.47.29829; Zierath JR, 2000, DIABETOLOGIA, V43, P821, DOI 10.1007/s001250051457	62	123	127	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19426	19435		10.1074/jbc.M412317200	http://dx.doi.org/10.1074/jbc.M412317200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15764603	hybrid			2022-12-27	WOS:000228932300101
J	Kobayashi, M; Takaori-Kondo, A; Miyauchi, Y; Iwai, K; Uchiyama, T				Kobayashi, M; Takaori-Kondo, A; Miyauchi, Y; Iwai, K; Uchiyama, T			Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VIRION INFECTIVITY FACTOR; LIGASE COMPLEX; SOCS-BOX; ANTIVIRAL ACTIVITY; ENZYME APOBEC3G; PROTEIN; DEGRADATION; PRIMATE; P53	The human immunodeficiency virus type 1 (HIV-1) virion infectivity factor (Vif) overcomes the antiviral activity of APOBEC3G to protect HIV-1 DNA from G-to-A hypermutation. Vif targets APOBEC3G for ubiquitination and proteasomal degradation by forming an SCF-like E3 ubiquitin ligase complex composed of Cullin5, Elongin B, and Elongin C (Vif-BC-Cul5) through a novel SOCS-box motif. In this paper, we have established an in vitro ubiquitin conjugation assay with purified Vif-BC-Cul5 complex and reported that the Vif-BC-Cul5 complex could function as an E3 ligase for APOBEC3G in vitro. A Vif-BC-Cul5 complex promotes the in vitro ubiquitination of the wild type, APOBEC3G but not that of D128K mutant, which does not interact with Vif. We have also investigated several loss-of-function Vif mutants. One mutant, SLQ144/146AAA, lost its activity on APOBEC3G because it could not form a complex due to mutations in SOCS-box motif. Other mutants, C114S and C133S, also lost their activity because of loss of the E3 ligase activity of a Vif-BC-Cul5 complex, although these mutants retained the ability to bind to APOBEC3G as well as Cul5 complex. These findings suggest that the E3 ubiquitin ligase activity of the Vif-BC-Cul5 complex is essential for Vif function against APOBEC3G.	Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, Kyoto 6068507, Japan; Osaka City Univ, Grad Sch Med, Dept Mol Cell Biol, Osaka 5458585, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Kyoto University; Osaka Metropolitan University; Japan Science & Technology Agency (JST)	Takaori-Kondo, A (corresponding author), Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, 54 Shogoin Kawaracho, Kyoto 6068507, Japan.	atakaori@kuhp.kyoto-u.ac.jp	IWAI, KAZUHIRO/GSN-7385-2022	Iwai, Kazuhiro/0000-0001-5620-5951				Blanchette P, 2004, MOL CELL BIOL, V24, P9619, DOI 10.1128/MCB.24.21.9619-9629.2004; Bogerd HP, 2004, P NATL ACAD SCI USA, V101, P3770, DOI 10.1073/pnas.0307713101; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Desrosiers RC, 1998, J VIROL, V72, P1431, DOI 10.1128/JVI.72.2.1431-1437.1998; GONCALVES J, 1994, J VIROL, V68, P704, DOI 10.1128/JVI.68.2.704-712.1994; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kobayashi M, 2004, J VIROL, V78, P8238, DOI 10.1128/JVI.78.15.8238-8244.2004; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mangeat B, 2004, J BIOL CHEM, V279, P14481, DOI 10.1074/jbc.C400060200; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mehle A, 2004, GENE DEV, V18, P2861, DOI 10.1101/gad.1249904; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schrofelbauer R, 2004, P NATL ACAD SCI USA, V101, P3927, DOI 10.1073/pnas.0307132101; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200; Simon JHM, 1999, J VIROL, V73, P2675, DOI 10.1128/JVI.73.4.2675-2681.1999; SIMON JHM, 1995, J VIROL, V69, P4166, DOI 10.1128/JVI.69.7.4166-4172.1995; Simon JHM, 1998, EMBO J, V17, P1259, DOI 10.1093/emboj/17.5.1259; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Xu HZ, 2004, P NATL ACAD SCI USA, V101, P5652, DOI 10.1073/pnas.0400830101; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Yu YK, 2004, GENE DEV, V18, P2867, DOI 10.1101/gad.1250204; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	33	126	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18573	18578		10.1074/jbc.C500082200	http://dx.doi.org/10.1074/jbc.C500082200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15781449	hybrid			2022-12-27	WOS:000228932300005
J	Ran, XY; Song, JX				Ran, XY; Song, JX			Structural insight into the binding diversity between the Tyr-phosphorylated human EphrinBs and Nck2 SH2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPH RECEPTORS; BACKBONE DYNAMICS; PHOSPHOTYROSYL PEPTIDE; CRYSTAL-STRUCTURE; ADAPTER PROTEIN; SPECIFICITY; REVERSE; FAMILY; LIGANDS; PROGRAM	The binding interaction between the Nck2 SH2 domain and the phosphorylated ephrinB initiates a critical pathway for the reverse signaling network mediated by Eph receptor-ephrinB. Previously, the NMR structure and Tyr phosphorylations of the human ephrinB cytoplasmic domain have been studied. To obtain a complete story, it would be of significant interest to determine the structure of the Nck2 SH2 domain that shows a low sequence identity to other SH2 domains with known structures. Here, we report the determination of the solution structure of the human Nck2 SH2 domain and investigate its interactions with three phosphorylated ephrinB fragments by NMR spectroscopy. The results indicate that: 1) although the human Nck2 SH2 domain adopts a core tertiary fold common to all SH2 domains, it owns some unique properties such as a shorter C-terminal helix and unusual electrostatic potential surface. However, the most striking finding is that the C-terminal tail of the human Nck2 SH2 domain adopts a short antiparallel beta-sheet that, to the best of our knowledge, has never been identified in other SH2 domains. The truncation study suggests that one function of the C-terminal tail is to control the folding/solubility of the SH2 domain. 2) In addition to [Tyr(P)(304)]ephrinB2(301-322) and [Tyr(P)(316)]ephrinB2(301-322), here we identified [Tyr(P)(330)]ephrinB2(324-333) also capable of binding to the SH2 domain. The detailed NMR study indicated that the binding mechanisms for the three ephrinB fragments might be different. The binding with [Tyr(P)(304)]ephrinB2(301-322) and [Tyr(P)(316)]ephrinB2(301-322) might be mostly involved in the residues over the N-half of the SH2 domain and provoked a significant increase in the backbone and side chain dynamics of the SH2 domain on the microsecond-millisecond time scale. In contrast, binding with [Tyr(P)(330)]ephrinB2(324-333) might have most residues over both halves engaged but induced less profound conformational dynamics on the mu s-ms time scale.	Natl Univ Singapore, Dept Biochem, Singapore 119260, Singapore; Natl Univ Singapore, Dept Sci Biol, Singapore 119260, Singapore	National University of Singapore; National University of Singapore	Song, JX (corresponding author), Natl Univ Singapore, Dept Biochem, 10 Kent Ridge Crescent, Singapore 119260, Singapore.	bchsj@nus.edu.sg	Song, Jianxing/J-3617-2013; Song, Jianxing/H-8026-2012	Song, Jianxing/0000-0003-0224-6322				Battaglia AA, 2003, NAT NEUROSCI, V6, P339, DOI 10.1038/nn1034; Bradshaw JM, 2003, ADV PROTEIN CHEM, V61, P161; Braverman LE, 1999, J BIOL CHEM, V274, P5542, DOI 10.1074/jbc.274.9.5542; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; Campbell SJ, 2003, PROTEIN ENG, V16, P217, DOI 10.1093/proeng/gzg025; Chen M, 2000, MOL CELL BIOL, V20, P7867, DOI 10.1128/MCB.20.21.7867-7880.2000; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cowan CA, 2002, TRENDS CELL BIOL, V12, P339, DOI 10.1016/S0962-8924(02)02317-6; Cowan CA, 2001, NATURE, V413, P174, DOI 10.1038/35093123; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Fournier AE, 2001, CURR OPIN NEUROBIOL, V11, P89, DOI 10.1016/S0959-4388(00)00178-1; Gauthier LR, 2003, LIFE SCI, V74, P207, DOI 10.1016/j.lfs.2003.09.029; Guntert Peter, 2004, Methods Mol Biol, V278, P353; Himanen JP, 1998, NATURE, V396, P486, DOI 10.1038/24904; Himanen JP, 2003, TRENDS NEUROSCI, V26, P46, DOI 10.1016/S0166-2236(02)00005-X; Holder N, 1999, DEVELOPMENT, V126, P2033; Huyer G, 1998, BIOCHEMISTRY-US, V37, P2741, DOI 10.1021/bi9722913; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kay LE, 1996, BIOCHEMISTRY-US, V35, P361, DOI 10.1021/bi9522312; Kay LE, 1998, NAT STRUCT BIOL, V5, P156, DOI 10.1038/nsb0298-156; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kristensen SM, 2000, J MOL BIOL, V299, P771, DOI 10.1006/jmbi.2000.3760; Ladbury JE, 2000, CHEM BIOL, V7, pR3, DOI 10.1016/S1074-5521(00)00067-3; Li MF, 2004, EUR J BIOCHEM, V271, P3512, DOI 10.1111/j.0014-2956.2004.04286.x; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Lu Q, 2001, CELL, V105, P69, DOI 10.1016/S0092-8674(01)00297-5; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; Murai KK, 2002, NEURON, V33, P159, DOI 10.1016/S0896-6273(02)00565-2; Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Sandvig A, 2004, GLIA, V46, P225, DOI 10.1002/glia.10315; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Shi JH, 2004, J BIOL CHEM, V279, P24765, DOI 10.1074/jbc.M311744200; Song JX, 2003, J BIOL CHEM, V278, P24714, DOI 10.1074/jbc.M210625200; Song JX, 2002, BIOCHEMISTRY-US, V41, P10942, DOI 10.1021/bi025815u; Song JX, 2001, J BIOL CHEM, V276, P41205, DOI 10.1074/jbc.M103449200; Song JX, 1997, BIOCHEMISTRY-US, V36, P3760, DOI 10.1021/bi962720h; SONGYANG Z, 1995, J BIOL CHEM, V270, P26029, DOI 10.1074/jbc.270.44.26029; Toth J, 2001, DEV CELL, V1, P83, DOI 10.1016/S1534-5807(01)00002-8; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zhang WX, 1998, BIOCHEMISTRY-US, V37, P7119, DOI 10.1021/bi972077e; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19205	19212		10.1074/jbc.M500330200	http://dx.doi.org/10.1074/jbc.M500330200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15764601	hybrid			2022-12-27	WOS:000228932300077
J	Cebecauer, M; Guillaume, P; Mark, S; Michielin, O; Boucheron, N; Bezard, M; Meyer, BH; Segura, JM; Vogel, H; Luescher, IF				Cebecauer, M; Guillaume, P; Mark, S; Michielin, O; Boucheron, N; Bezard, M; Meyer, BH; Segura, JM; Vogel, H; Luescher, IF			CD8+ cytotoxic T lymphocyte activation by soluble major histocompatibility complex-peptide dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; LIGAND-SPECIFIC OLIGOMERIZATION; MHC-PEPTIDE; SIGNAL-TRANSDUCTION; CORECEPTOR FUNCTION; STRUCTURAL BASIS; BINDING; TCR; RECOGNITION; MOLECULES	CD8+ cytotoxic T lymphocyte (CTL) can recognize and kill target cells that express only a few cognate major histocompatibility complex class I-peptide (pMHC) complexes. To better understand the molecular basis of this sensitive recognition process, we studied dimeric pMHC complexes containing linkers of different lengths. Although dimers containing short (10-30-angstrom) linkers efficiently bound to and triggered intracellular calcium mobilization and phosphorylation in cloned CTL, dimers containing long linkers (>= 80 angstrom) did not. Based on this and on fluorescence resonance energy transfer experiments, we describe a dimeric binding mode in which two T cell receptors engage in an anti-parallel fashion two pMHC complexes facing each other with their constant domains. This binding mode allows integration of diverse low affinity interactions, which increases the overall binding and, hence, the sensitivity of antigen recognition. In proof of this, we demonstrated that pMHC dimers containing one agonist and one null ligand efficiently activate CTL, corroborating the importance of endogenous pMHC complexes in antigen recognition.	Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland; Swiss Fed Inst Technol, Inst Chem Sci & Engn, Lab Phys Chem Polymers & Membranes, CH-1015 Lausanne, Switzerland	Ludwig Institute for Cancer Research; University of Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Luescher, IF (corresponding author), Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland.	immanuel.luescher@isrec.unil.ch	Cebecauer, Marek/F-5169-2014; Michielin, Olivier/ABE-7924-2020	Cebecauer, Marek/0000-0002-4606-1218; Boucheron, Nicole/0000-0002-4979-8311				Alam SM, 1999, IMMUNITY, V10, P227, DOI 10.1016/S1074-7613(00)80023-0; Alarcon B, 2003, IMMUNOL REV, V191, P38, DOI 10.1034/j.1600-065X.2003.00017.x; Arcaro A, 2001, J EXP MED, V194, P1485, DOI 10.1084/jem.194.10.1485; Arora PS, 2002, J AM CHEM SOC, V124, P13067, DOI 10.1021/ja0208355; Backstrom BT, 1996, IMMUNITY, V5, P437, DOI 10.1016/S1074-7613(00)80500-2; Baker BM, 2001, IMMUNITY, V14, P681, DOI 10.1016/S1074-7613(01)00160-1; Bhatnagar A, 2003, MOL IMMUNOL, V39, P953, DOI 10.1016/S0161-5890(03)00027-0; Bodnar A, 2003, INT IMMUNOL, V15, P331, DOI 10.1093/intimm/dxg042; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Buslepp J, 2003, IMMUNITY, V19, P595, DOI 10.1016/S1074-7613(03)00269-3; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Call ME, 2004, EMBO J, V23, P2348, DOI 10.1038/sj.emboj.7600245; Capps GG, 2004, BIOPHYS J, V86, P2896, DOI 10.1016/S0006-3495(04)74341-6; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; Cochran JR, 2000, IMMUNITY, V12, P241, DOI 10.1016/S1074-7613(00)80177-6; Cochran JR, 2001, J BIOL CHEM, V276, P28068, DOI 10.1074/jbc.M103280200; Dick TP, 1998, EUR J IMMUNOL, V28, P2478, DOI 10.1002/(SICI)1521-4141(199808)28:08<2478::AID-IMMU2478>3.3.CO;2-L; Doucey MA, 2003, J BIOL CHEM, V278, P26983, DOI 10.1074/jbc.M302709200; Doucey MA, 2003, J BIOL CHEM, V278, P3257, DOI 10.1074/jbc.M208119200; Doucey MA, 2001, EUR J IMMUNOL, V31, P1561, DOI 10.1002/1521-4141(200105)31:5&lt;1561::AID-IMMU1561&gt;3.0.CO;2-W; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Fernandez-Miguel G, 1999, P NATL ACAD SCI USA, V96, P1547, DOI 10.1073/pnas.96.4.1547; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; Frank SJ, 2002, ENDOCRINOLOGY, V143, P2, DOI 10.1210/en.143.1.2; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Gaspar R, 2001, J IMMUNOL, V166, P5078, DOI 10.4049/jimmunol.166.8.5078; Ge Q, 2002, P NATL ACAD SCI USA, V99, P13729, DOI 10.1073/pnas.212515299; Guillaume P, 2003, J BIOL CHEM, V278, P4500, DOI 10.1074/jbc.M208863200; HARPUR AG, 1993, IMMUNOL LETT, V35, P235, DOI 10.1016/0165-2478(93)90188-8; Hudrisier D, 1998, J IMMUNOL, V161, P553; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; Kessler BM, 1997, J EXP MED, V185, P629, DOI 10.1084/jem.185.4.629; Kjer-Nielsen L, 2002, J IMMUNOL, V169, P5153, DOI 10.4049/jimmunol.169.9.5153; La Gruta NL, 2004, J IMMUNOL, V172, P3662, DOI 10.4049/jimmunol.172.6.3662; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; LUESCHER IF, 1995, IMMUNITY, V3, P51, DOI 10.1016/1074-7613(95)90158-2; LUESCHER IF, 1991, NATURE, V351, P72, DOI 10.1038/351072a0; O'Herrin SM, 2001, J IMMUNOL, V167, P2555, DOI 10.4049/jimmunol.167.5.2555; Purbhoo MA, 2004, NAT IMMUNOL, V5, P524, DOI 10.1038/ni1058; Reich Z, 1997, NATURE, V387, P617, DOI 10.1038/42500; Sasada T, 2001, J EXP MED, V194, P883, DOI 10.1084/jem.194.7.883; SCHAMEL WW, 2004, CELL, V109, P901; SCHNECK J, 1989, P NATL ACAD SCI USA, V86, P8516, DOI 10.1073/pnas.86.21.8516; SCHWEITZERSTENNER R, 1987, BIOCHEMISTRY-US, V26, P3602, DOI 10.1021/bi00386a053; Stanasila L, 2003, J BIOL CHEM, V278, P40239, DOI 10.1074/jbc.M306085200; STREYER L, 1967, BIOCHEMISTRY-US, V6, P719; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; Velloso LM, 2004, J IMMUNOL, V172, P5504, DOI 10.4049/jimmunol.172.9.5504; WATTS JD, 1993, J BIOL CHEM, V268, P23275; Wulfing C, 2002, NAT IMMUNOL, V3, P42, DOI 10.1038/ni741; Wyer JR, 1999, IMMUNITY, V10, P219, DOI 10.1016/S1074-7613(00)80022-9; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	54	46	50	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23820	23828		10.1074/jbc.M500654200	http://dx.doi.org/10.1074/jbc.M500654200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15805102	hybrid			2022-12-27	WOS:000229880000054
J	Lakka, SS; Gondi, CS; Dinh, DH; Olivero, WC; Gujrati, M; Rao, VH; Sioka, C; Rao, JS				Lakka, SS; Gondi, CS; Dinh, DH; Olivero, WC; Gujrati, M; Rao, VH; Sioka, C; Rao, JS			RETRACTED: Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas (Retracted article. See vol. 295, pg. 13135, 2020)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							SIGNAL-REGULATED KINASE; IV COLLAGENASE; DOWN-REGULATION; GLIOBLASTOMA CELLS; ELEVATED LEVELS; ANTISENSE GENE; PROTEIN-KINASE; INHIBITION; MMP-9; INVASIVENESS	We have previously demonstrated the effectiveness of adenovirus-mediated expression of antisense urokinase-type plasminogen activator receptor ( uPAR) and matrix metalloproteinase-9 (MMP-9) in inhibiting tumor invasion in vitro and ex vivo. However, the therapeutic effect of the adenovirus-mediated antisense approach was shown to be transient and required potentially toxic, high viral doses. In contrast, RNA interference (RNAi)-mediated gene targeting may be superior to the traditional antisense approach, because the target mRNA is completely degraded and the molar ratio of siRNA required to degrade the target mRNA is very low. Here, we have examined the siRNA-mediated target RNA degradation of uPAR and MMP-9 in human glioma cell lines. Using RNAi directed toward uPAR and MMP-9, we achieved specific inhibition of uPAR and MMP-9. This bicistronic construct (pUM) inhibited the formation of capillary-like structures in both in vitro and in vivo models of angiogenesis. We demonstrated that blocking the expression of these genes results in significant inhibition of glioma tumor invasion in Matrigel and spheroid invasion assay models. RNAi for uPAR and MMP-9 inhibited cell proliferation, and significantly reduced the levels of phosphorylated forms of MAPK, ERK, and AKT signaling pathway molecules when compared with parental and empty vector/scrambled vector-transfected SNB19 cells. Furthermore, using RNAi to simultaneously target two proteases resulted in total regression of pre-established intracerebral tumor growth. Our results provide evidence that the use of hairpin siRNA expression vectors for uPAR and MMP-9 may provide an effective tool for cancer therapy.	Univ Illinois, Dept Biomed & Therapeut Sci, Program Canc Biol, Coll Med, Peoria, IL 61656 USA; Univ Illinois, Dept Neurosurg, Coll Med, Peoria, IL 61656 USA; Univ Illinois, Dept Pathol, Coll Med, Peoria, IL 61656 USA; Boys Town Natl Res Hosp, Dept Genet, Omaha, NE 68131 USA; Army Share Found Hosp 417, Dept Nucl Med, Athens 11521, Greece	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; Boys Town National Research Hospital	Rao, JS (corresponding author), Univ Illinois, Dept Biomed & Therapeut Sci, Program Canc Biol, Coll Med, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu	Sioka, Chrissa/J-3381-2019	Sioka, Chrissa/0000-0002-2184-4945; Gondi, Christopher/0000-0002-3036-9920	NATIONAL CANCER INSTITUTE [R01CA075557, R01CA092393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047699] Funding Source: NIH RePORTER; NCI NIH HHS [CA 92393, CA 75557] Funding Source: Medline; NINDS NIH HHS [NS 47699] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adachi Y, 2001, J BIOL CHEM, V276, P47171, DOI 10.1074/jbc.M104334200; Aoki I, 2003, J STEROID BIOCHEM, V84, P217, DOI 10.1016/S0960-0760(03)00031-1; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Choe GY, 2002, CLIN CANCER RES, V8, P2894; Cullen BR, 2003, TRENDS BIOCHEM SCI, V28, P419, DOI 10.1016/S0968-0004(03)00142-7; Degryse B, 2001, J CELL BIOL, V152, P1197, DOI 10.1083/jcb.152.6.1197; Drummond AH, 1999, ANN NY ACAD SCI, V878, P228, DOI 10.1111/j.1749-6632.1999.tb07688.x; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; ELLIS V, 1993, J BIOL CHEM, V268, P4806; Forsyth PA, 1999, BRIT J CANCER, V79, P1828, DOI 10.1038/sj.bjc.6690291; Giannelli V, 1997, INFECT IMMUN, V65, P331, DOI 10.1128/IAI.65.1.331-334.1997; Giese A, 1996, NEUROSURGERY, V39, P235, DOI 10.1097/00006123-199608000-00001; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Guo YJ, 2000, FASEB J, V14, P1400, DOI 10.1096/fj.14.10.1400; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hidalgo M, 2001, Adv Intern Med, V47, P159; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kin Y, 2000, INT J ONCOL, V17, P61; Konakova M, 1998, EUR J BIOCHEM, V253, P421, DOI 10.1046/j.1432-1327.1998.2530421.x; Kondraganti S, 2000, CANCER RES, V60, P6851; LAIHO M, 1989, CANCER RES, V49, P2533; Lakka SS, 2002, ONCOGENE, V21, P8011, DOI 10.1038/sj.onc.1205894; Lakka SS, 2002, ONCOGENE, V21, P5601, DOI 10.1038/sj.onc.1205646; Lakka SS, 2000, CLIN EXP METASTAS, V18, P245, DOI 10.1023/A:1006724826083; Lee KH, 2004, EXP MOL MED, V36, P57, DOI 10.1038/emm.2004.8; LEUNIG M, 1992, CANCER RES, V52, P6553; Lozonschi L, 1999, CANCER RES, V59, P1252; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Mohan PM, 1999, CANCER RES, V59, P3369; Mohan PM, 1999, CLIN EXP METASTAS, V17, P617, DOI 10.1023/A:1006779902978; Mohan RR, 2000, INVEST OPHTH VIS SCI, V41, P1327; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; Mori T, 2000, J NEURO-ONCOL, V46, P115, DOI 10.1023/A:1006339717748; Moses MA, 1997, STEM CELLS, V15, P180, DOI 10.1002/stem.150180; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; OSSOWSKI L, 1991, CANCER RES, V51, P274; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Park MJ, 2002, CANCER RES, V62, P6318; Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; RAO JS, 1993, CANCER RES, V53, P2208; Sawaya R, 1998, BIOCHEM BIOPH RES CO, V251, P632, DOI 10.1006/bbrc.1998.9466; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Simon C, 1998, CANCER RES, V58, P1135; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; Trisciuoglio D, 2004, J BIOL CHEM, V279, P6737, DOI 10.1074/jbc.M308938200; YAMAMOTO M, 1994, CANCER RES, V54, P5016; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Yu Q, 1996, DEV DYNAM, V207, P204; Yu Q, 2000, GENE DEV, V14, P163; Zeng Y, 2003, RNA, V9, P112, DOI 10.1261/rna.2780503	58	114	127	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21882	21892		10.1074/jbc.M408520200	http://dx.doi.org/10.1074/jbc.M408520200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824107	hybrid			2022-12-27	WOS:000229557900028
J	Mendillo, ML; Mazur, DJ; Kolodner, RD				Mendillo, ML; Mazur, DJ; Kolodner, RD			Analysis of the interaction between the Saccharomyces cerevisiae MSH2-MSH6 and MLH1-PMS1 complexes with DNA using a reversible DNA end-blocking system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MISMATCH REPAIR; ESCHERICHIA-COLI MUTS; COLORECTAL-CANCER; SLIDING-CLAMP; TRANSLOCATION MECHANISM; MISPAIR-BINDING; YEAST MSH2-MSH6; GENE-PRODUCT; HMUTS-ALPHA; HUMAN-CELLS	The Lac repressor-operator interaction was used as a reversible DNA end-blocking system in conjunction with an IAsys biosensor instrument ( Thermo Affinity Sensors), which detects total internal reflectance and allows monitoring of binding and dissociation in real time, in order to develop a system for studying the ability of mismatch repair proteins to move along the DNA. The MSH2-MSH6 complex bound to a mispaired base was found to be converted by ATP binding to a form that showed rapid sliding along the DNA and dissociation via the DNA ends and also showed slow, direct dissociation from the DNA. In contrast, the MSH2-MSH6 complex bound to a base pair containing DNA only showed direct dissociation from the DNA. The MLH1-PMS1 complex formed both mispair-dependent and mispair-independent ternary complexes with the MSH2-MSH6 complex on DNA. The mispair-independent ternary complexes were formed most efficiently on DNA molecules with free ends under conditions where ATP hydrolysis did not occur, and only exhibited direct dissociation from the DNA. The mispair-dependent ternary complexes were formed in the highest yield on DNA molecules with blocked ends, required ATP and magnesium for formation, and showed both dissociation via the DNA ends and direct dissociation from the DNA.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ctr Canc, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	rkolodner@ucsd.edu	Classen, Scott/AAY-8176-2020	Mendillo, Marc/0000-0001-8128-0128	NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006] Funding Source: NIH RePORTER; NCI NIH HHS [CA 92584, F32 CA210407] Funding Source: Medline; NIGMS NIH HHS [R01 GM050006, GM 50006, F32 GM106598] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Antony E, 2003, BIOCHEMISTRY-US, V42, P7682, DOI 10.1021/bi034602h; AU KG, 1992, J BIOL CHEM, V267, P12142; Baitinger C, 2003, J BIOL CHEM, V278, P49505, DOI 10.1074/jbc.M308738200; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Blackwell LJ, 2001, J BIOL CHEM, V276, P34339, DOI 10.1074/jbc.M104256200; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Bowers J, 2000, J MOL BIOL, V302, P327, DOI 10.1006/jmbi.2000.4081; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Burdett V, 2001, P NATL ACAD SCI USA, V98, P6765, DOI 10.1073/pnas.121183298; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Fu TJ, 1996, EMBO J, V15, P4414, DOI 10.1002/j.1460-2075.1996.tb00814.x; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hess MT, 2002, J BIOL CHEM, V277, P25545, DOI 10.1074/jbc.M202282200; Joshi A, 2000, NUCLEIC ACIDS RES, V28, P853, DOI 10.1093/nar/28.4.853; Kijas AW, 2003, J MOL BIOL, V331, P123, DOI 10.1016/S0022-2836(03)00694-6; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Lynch HT, 1999, J MED GENET, V36, P801; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Matthews KS, 1998, PROG NUCLEIC ACID RE, V58, P127; Mazurek A, 2002, J BIOL CHEM, V277, P8260, DOI 10.1074/jbc.M111269200; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Peltomaki P, 2003, J CLIN ONCOL, V21, P1174, DOI 10.1200/JCO.2003.04.060; Plotz G, 2002, NUCLEIC ACIDS RES, V30, P711, DOI 10.1093/nar/30.3.711; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; Raschle M, 2002, J BIOL CHEM, V277, P21810, DOI 10.1074/jbc.M108787200; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; Saenko EL, 1998, J BIOL CHEM, V273, P27918, DOI 10.1074/jbc.273.43.27918; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Selmane T, 2003, J MOL BIOL, V334, P949, DOI 10.1016/j.jmb.2003.10.010; SU SS, 1988, J BIOL CHEM, V263, P6829; Tran PT, 2000, MOL CELL BIOL, V20, P6390, DOI 10.1128/MCB.20.17.6390-6398.2000; Wang TF, 1999, P NATL ACAD SCI USA, V96, P13914, DOI 10.1073/pnas.96.24.13914; WELSH KM, 1987, J BIOL CHEM, V262, P15624; Wheeler JMD, 2000, GUT, V47, P148, DOI 10.1136/gut.47.1.148	56	104	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22245	22257		10.1074/jbc.M407545200	http://dx.doi.org/10.1074/jbc.M407545200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15811858	hybrid			2022-12-27	WOS:000229557900070
J	Stallings, JD; Tall, EG; Pentyala, S; Rebecchi, MJ				Stallings, JD; Tall, EG; Pentyala, S; Rebecchi, MJ			Nuclear translocation of phospholipase C-delta(1) is linked to the cell cycle and nuclear phosphatidylinositol 4,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; MESSENGER-RNA EXPORT; BASIC-AMINO-ACIDS; INOSITOL LIPIDS; C ISOZYMES; S-PHASE; BINDING; PHOSPHOINOSITIDES; C-DELTA-1; MEMBRANE	Nuclear phosphoinositides, especially phosphatidylinositol 4,5-bisphosphate, fluctuate throughout the cell cycle and are linked to proliferation and differentiation. Here we report that phospholipase C-delta(1) accumulates in the nucleus at the G1/S boundary and in G(0) phases of the cell cycle. Furthermore, as wild-type protein accumulated in the nucleus, nuclear phosphatidylinositol 4,5-bisphosphate levels were elevated 3-5-fold, whereas total levels were decreased compared with asynchronous cultures. To test whether phosphatidylinositol 4,5-bisphosphate binding is important during this process, we introduced a R40D point mutation within the pleckstrin homology domain of phospholipase C-delta(1), which disables high affinity phosphatidylinositol 4,5-bisphosphate binding, and found that nuclear translocation was significantly reduced at G(1)/S and in G(0). These results demonstrate a cell cycle-dependent compartmentalization of phospholipase C-delta(1) and support the idea that relative levels of phosphoinositides modulate the portioning of phosphoinositide-binding proteins between the nucleus and other compartments.	SUNY Stony Brook, Hlth Sci Ctr, Dept Anesthesiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Rebecchi, MJ (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Anesthesiol, Level 4,Rm 076, Stony Brook, NY 11794 USA.	mrebecchi@notes.cc.sunysb.edu	Stallings, Jonathan D/H-7779-2013	Stallings, Jonathan D/0000-0002-6430-5888				ASANO M, 1994, J BIOL CHEM, V269, P12360; Auger K. R., 1990, METHODS INOSITIDE RE, P159; Baek KJ, 2001, J BIOL CHEM, V276, P5591, DOI 10.1074/jbc.M008252200; Balla Tamas, 2002, Sci STKE, V2002, ppl3, DOI 10.1126/stke.2002.125.pl3; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Clarke JH, 2001, BIOCHEM J, V357, P905, DOI 10.1042/0264-6021:3570905; Cocco L, 2001, MARC MALPIG SYMP SER, V7, P31; D'Santos CS, 1998, BBA-MOL CELL BIOL L, V1436, P201, DOI 10.1016/S0005-2760(98)00146-5; DeLillo N, 2003, MOL GENET GENOMICS, V269, P261, DOI 10.1007/s00438-003-0832-4; Divecha N, 1997, BIOCHEM SOC T, V25, P571, DOI 10.1042/bst0250571; Flygare J, 2001, EXP CELL RES, V268, P61, DOI 10.1006/excr.2001.5265; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Gillooly DJ, 2001, J CELL BIOL, V155, P15, DOI 10.1083/jcb.200109001; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Hammond G, 2004, CURR TOP MICROBIOL, V282, P177; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Kobayashi M, 2004, BIOCHEMISTRY-US, V43, P7522, DOI 10.1021/bi035966c; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Liu NS, 1996, J BIOL CHEM, V271, P355, DOI 10.1074/jbc.271.1.355; Lomasney JW, 1999, J BIOL CHEM, V274, P21995, DOI 10.1074/jbc.274.31.21995; Martelli AM, 2004, PHARMACOL THERAPEUT, V101, P47, DOI 10.1016/j.pharmthera.2003.10.003; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nakamura Y, 2003, EMBO J, V22, P2981, DOI 10.1093/emboj/cdg302; Okada M, 2002, GENES CELLS, V7, P985, DOI 10.1046/j.1365-2443.2002.00577.x; Osborne SL, 2001, J CELL SCI, V114, P2501; Pagon Z, 2003, J CELL BIOCHEM, V89, P733, DOI 10.1002/jcb.10549; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Percival JM, 2000, CELL MOTIL CYTOSKEL, V47, P189, DOI 10.1002/1097-0169(200011)47:3<189::AID-CM3>3.0.CO;2-C; Rando OJ, 2002, P NATL ACAD SCI USA, V99, P2824, DOI 10.1073/pnas.032662899; REBECCHI MJ, 1984, BASIC MED SCI PROGRA, P168; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Santagata S, 2001, SCIENCE, V292, P2041, DOI 10.1126/science.1061233; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shimohama S, 1998, BIOCHEM BIOPH RES CO, V243, P210, DOI 10.1006/bbrc.1998.8090; Tabellini G, 2003, EXP CELL RES, V287, P143, DOI 10.1016/S0014-4827(03)00115-0; Tall E, 1997, BIOCHEMISTRY-US, V36, P7239, DOI 10.1021/bi9702288; Tall EG, 2000, CURR BIOL, V10, P743, DOI 10.1016/S0960-9822(00)00541-8; TALL EG, 2002, PHYSL BIOPHYSICS, P224; Vann LR, 1997, BIOCHEM J, V327, P569; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; Williams RL, 1996, STRUCTURE, V4, P1387, DOI 10.1016/S0969-2126(96)00146-3; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; Yamaga M, 1999, J BIOL CHEM, V274, P28537, DOI 10.1074/jbc.274.40.28537; Yamaga M, 2004, GENES CELLS, V9, P25, DOI 10.1111/j.1356-9597.2004.00698.x; Yashiroda Y, 2003, CURR MED CHEM, V10, P741, DOI 10.2174/0929867033457791; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; YORK JD, 1994, J BIOL CHEM, V269, P7847; Yu HY, 1998, EUR J BIOCHEM, V251, P281, DOI 10.1046/j.1432-1327.1998.2510281.x; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	56	53	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22060	22069		10.1074/jbc.M413813200	http://dx.doi.org/10.1074/jbc.M413813200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15809301	hybrid			2022-12-27	WOS:000229557900050
J	Cao, DL; Leffert, JJ; McCabe, J; Kim, B; Pizzorno, G				Cao, DL; Leffert, JJ; McCabe, J; Kim, B; Pizzorno, G			Abnormalities in uridine homeostatic regulation and pyrimidine nucleotide metabolism as a consequence of the deletion of the uridine phosphorylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; SALVAGE; URACIL; SLEEP; CELLS; 5-FLUOROURACIL; BIOSYNTHESIS; MODULATION; ACTIVATION; RELEASE	We report in the present study the critical role of uridine phosphorylase (UPase) in uridine homeostatic regulation and pyrimidine nucleotide metabolism, employing newly developed UPase-/- mice. Our data demonstrate that the abrogation of UPase activity led to greater than a 6-fold increase in uridine concentrations in plasma, a 5-6-fold increase in lung and gut, and a 2-3-fold increase in liver and kidney, as compared with wild type mice. Urine uridine levels increased 24-fold normal in UPase-/- mice. Uridine half-life and the plasma retention of pharmacological doses of uridine were significantly prolonged. Further, in these UPase-/- mice, abnormal uridine metabolism led to disorders of various nucleotide metabolisms. In the liver, gut, kidney, and lung of UPase-/- mice, total uridine ribonucleotide concentrations increased 2-3 times as compared with control mice. Cytidine ribonucleotides and adenosine and guanosine ribonucleotides also increased, although to a lesser extent, in these organs. Most significant deoxyribonucleotide changes were present in the gut and lung of UPase-/- mice. In these tissues, dTTP concentration increased more than 4-fold normal, and dCTP, dGTP, and dATP concentrations rose 1-2 times normal. In kidney, dTTP concentration increased 2-fold normal, and dCTP and dGTP concentrations rose less than 1-fold normal. In addition, the accumulated uridine in plasma and tissues efficiently reduced 5-fluorouracil host toxicity and altered the anesthetic effect of pentobarbital. These data indicate that UPase is a critical enzyme in the regulation of uridine homeostasis and pyrimidine nucleotide metabolism, and 5-fluorouracil activity.	Yale Univ, Sch Med, Dept Internal Med Oncol, New Haven, CT 06520 USA; So Illinois Univ, Sch Med, Inst Canc, Springfield, IL 62702 USA; Nevada Canc Inst, Las Vegas, NV 89135 USA	Yale University; Southern Illinois University System; Southern Illinois University; University of California System; University of California San Diego	Pizzorno, G (corresponding author), Yale Univ, Sch Med, Dept Internal Med Oncol, 333 Cedar St,SHM I 220, New Haven, CT 06520 USA.	Giuseppe.Pizzorno@yale.edu		Kim, Bradford/0000-0002-1832-5298	NCI NIH HHS [CA67035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson CM, 1997, TRENDS PHARMACOL SCI, V18, P387, DOI 10.1016/S0165-6147(97)01106-1; Barsotti C, 2002, J BIOL CHEM, V277, P9865, DOI 10.1074/jbc.M111418200; BECROFT DMO, 1969, J PEDIATR, V75, P885; Cao DL, 2004, DRUG TODAY, V40, P431, DOI 10.1358/dot.2004.40.5.850491; Cao DL, 2002, CANCER RES, V62, P2313; Cao DL, 1999, CANCER RES, V59, P4997; Cao DL, 1998, J BIOL CHEM, V273, P11429, DOI 10.1074/jbc.273.19.11429; Connolly GP, 1999, TRENDS PHARMACOL SCI, V20, P218, DOI 10.1016/S0165-6147(99)01298-5; DAGANI F, 1984, NEUROCHEM RES, V9, P1085, DOI 10.1007/BF00964804; DARNOWSKI JW, 1991, BIOCHEM PHARMACOL, V41, P2031, DOI 10.1016/0006-2952(91)90146-V; GASSER T, 1981, SCIENCE, V213, P777, DOI 10.1126/science.7256279; GELLER E, 1989, NEUROPHARMACOLOGY, V28, P271, DOI 10.1016/0028-3908(89)90103-2; Grem JL, 2000, INVEST NEW DRUG, V18, P299, DOI 10.1023/A:1006416410198; Harden TK, 1997, TRENDS PHARMACOL SCI, V18, P43, DOI 10.1016/S0165-6147(97)89795-7; HONDA K, 1985, NEUROSCI LETT, V62, P137, DOI 10.1016/0304-3940(85)90297-6; INOUE S, 1995, BEHAV BRAIN RES, V69, P91, DOI 10.1016/0166-4328(95)00014-K; Johansson M, 2003, BIOCHEM BIOPH RES CO, V307, P41, DOI 10.1016/S0006-291X(03)01062-3; KARLE JM, 1984, J BIOL CHEM, V259, P67; KIMURATAKEUCHI M, 1993, BRAIN RES BULL, V31, P33, DOI 10.1016/0361-9230(93)90007-X; KOUNI MH, 1993, CANCER RES, V53, P3687; Liu MP, 1998, CANCER RES, V58, P5418; LUCAS ZJ, 1967, SCIENCE, V156, P1237, DOI 10.1126/science.156.3779.1237; MOYER JD, 1985, BIOCHEM PHARMACOL, V34, P101, DOI 10.1016/0006-2952(85)90107-8; Page T, 1997, P NATL ACAD SCI USA, V94, P11601, DOI 10.1073/pnas.94.21.11601; PIZZORNO G, 1992, CANCER RES, V52, P1660; Pizzorno G, 2002, BBA-MOL BASIS DIS, V1587, P133, DOI 10.1016/S0925-4439(02)00076-5; SHAMBAUGH GE, 1979, AM J CLIN NUTR, V32, P1290, DOI 10.1093/ajcn/32.6.1290; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; Traut TW, 1996, PROG NUCLEIC ACID RE, V53, P1, DOI 10.1016/S0079-6603(08)60142-7; VANGROENINGEN CJ, 1989, J NATL CANCER I, V81, P157; WICE BM, 1982, J BIOL CHEM, V257, P2578	31	44	47	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21169	21175		10.1074/jbc.M412343200	http://dx.doi.org/10.1074/jbc.M412343200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15772079	hybrid			2022-12-27	WOS:000229438800034
J	Carpaneto, A; Geiger, D; Bamberg, E; Sauer, N; Fromm, J; Hedrich, R				Carpaneto, A; Geiger, D; Bamberg, E; Sauer, N; Fromm, J; Hedrich, R			Phloem-localized, proton-coupled sucrose carrier ZmSUT1 mediates sucrose efflux under the control of the sucrose gradient and the proton motive force	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTER; EXPRESSION; POTATO; GENE; COTRANSPORT; VOLTAGE; CLONING; HEXOSE; H+	The phloem network is as essential for plants as the vascular system is for humans. This network, assembled by nucleus- and vacuole- free interconnected living cells, represents a long distance transport pathway for nutrients and information. According to the Munch hypothesis, osmolytes such as sucrose generate the hydrostatic pressure that drives nutrient and water flow between the source and the sink phloem (Munch, E. (1930) Die Stoffbewegungen in der Pflanze, Gustav Fischer, Jena, Germany). Although proton-coupled sucrose carriers have been localized to the sieve tube and the companion cell plasma membrane of both source and sink tissues, knowledge of the molecular representatives and the mechanism of the sucrose phloem efflux is still scant. We expressed ZmSUT1, a maize sucrose/ proton symporter, in Xenopus oocytes and studied the transport characteristics of the carrier by electrophysiological methods. Using the patch clamp techniques in the giant inside-out patch mode, we altered the chemical and electrochemical gradient across the sucrose carrier and analyzed the currents generated by the proton flux. Thereby we could show that ZmSUT1 is capable of mediating both the sucrose uptake into the phloem in mature leaves ( source) as well as the desorption of sugar from the phloem vessels into heterotrophic tissues ( sink). As predicted from a perfect molecular machine, the ZmSUT1-mediated sucrose-coupled proton current was reversible and depended on the direction of the sucrose and pH gradient as well as the membrane potential across the transporter.	Julius Von Sachs Inst Biosci Mol Plant Physiol &, D-97082 Wurzburg, Germany; CNR, Ist Biofis, I-16149 Genoa, Italy; Max Planck Inst Biophys, D-60439 Frankfurt, Germany; Univ Erlangen Nurnberg, D-91058 Erlangen, Germany; Tech Univ Munich, Holzforsch, D-80797 Munich, Germany	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); Max Planck Society; University of Erlangen Nuremberg; Technical University of Munich	Hedrich, R (corresponding author), Julius Von Sachs Inst Biosci Mol Plant Physiol &, Julius Von Sachs Pl 2, D-97082 Wurzburg, Germany.	hedrich@botanik.uni-wuerzburg.de	Carpaneto, Armando/F-7754-2013; Geiger, Dietmar/AAH-8140-2019; Geiger, Dietmar/D-6914-2014; Hedrich, Rainer/G-8771-2011	Geiger, Dietmar/0000-0003-0715-5710; Geiger, Dietmar/0000-0003-0715-5710; Hedrich, Rainer/0000-0003-3224-1362; Carpaneto, Armando/0000-0002-5060-3657				Ache P, 2001, PLANT J, V27, P571, DOI 10.1046/j.1365-313X.2001.t01-1-01116.x; Aoki N, 1999, PLANT CELL PHYSIOL, V40, P1072, DOI 10.1093/oxfordjournals.pcp.a029489; Becker D, 1996, P NATL ACAD SCI USA, V93, P8123, DOI 10.1073/pnas.93.15.8123; Bel A. J. E. van, 1993, Progress in Botany, V54, P134; Boorer KJ, 1996, J BIOL CHEM, V271, P25139, DOI 10.1074/jbc.271.41.25139; Deeken R, 2002, PLANTA, V216, P334, DOI 10.1007/s00425-002-0895-1; EVERT RF, 1993, AM J BOT, V80, P1310, DOI 10.2307/2445716; Gottwald JR, 2000, P NATL ACAD SCI USA, V97, P13979, DOI 10.1073/pnas.250473797; Hilgemann Donald W., 1995, P307; Hirose T, 1997, PLANT CELL PHYSIOL, V38, P1389, DOI 10.1093/oxfordjournals.pcp.a029134; KOMOR E, 1974, J GEN PHYSIOL, V64, P568, DOI 10.1085/jgp.64.5.568; KOMOR E, 1974, NATURE, V248, P511, DOI 10.1038/248511a0; Kuhn C, 2003, PLANT BIOLOGY, V5, P215, DOI 10.1055/s-2003-40798; Kuhn C, 2003, PLANT PHYSIOL, V131, P102, DOI 10.1104/pp.011676; Kuhn C, 1997, SCIENCE, V275, P1298, DOI 10.1126/science.275.5304.1298; Lalonde S, 2003, PLANT CELL ENVIRON, V26, P37, DOI 10.1046/j.1365-3040.2003.00847.x; Lemoine R, 1999, FEBS LETT, V454, P325, DOI 10.1016/S0014-5793(99)00843-1; Lohaus G, 2000, J EXP BOT, V51, P1721, DOI 10.1093/jexbot/51.351.1721; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Munch E., 1930, STOFFBEWEGUNGEN PFLA; Quick M, 2003, BIOCHEMISTRY-US, V42, P9147, DOI 10.1021/bi034842x; Roitsch T, 2003, J EXP BOT, V54, P513, DOI 10.1093/jxb/erg050; Saier M H Jr, 1999, J Mol Microbiol Biotechnol, V1, P257; Sauer GA, 2000, FEBS LETT, V469, P98, DOI 10.1016/S0014-5793(00)01255-2; Tegeder M, 1999, PLANT J, V18, P151, DOI 10.1046/j.1365-313X.1999.00439.x; TRUERNIT E, 1995, PLANTA, V196, P564, DOI 10.1007/BF00203657; van Bel AJE, 2000, EXPTL BIOL REV, P85; Viola R, 2001, PLANT CELL, V13, P385, DOI 10.1105/tpc.13.2.385; Weber H, 1997, PLANT CELL, V9, P895, DOI 10.1105/tpc.9.6.895; WRIGHT JP, 1981, PLANT PHYSIOL, V67, P845, DOI 10.1104/pp.67.4.845; Zeuthen T, 1996, J PHYSIOL-LONDON, V497, P3, DOI 10.1113/jphysiol.1996.sp021745; Zhou JJ, 1997, J MEMBRANE BIOL, V159, P113, DOI 10.1007/s002329900275	32	158	166	2	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21437	21443		10.1074/jbc.M501785200	http://dx.doi.org/10.1074/jbc.M501785200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15805107	hybrid			2022-12-27	WOS:000229438800064
J	Kouchi, Z; Shikano, T; Nakamura, Y; Shirakawa, H; Fukami, K; Miyazaki, S				Kouchi, Z; Shikano, T; Nakamura, Y; Shirakawa, H; Fukami, K; Miyazaki, S			The role of EF-hand domains and C2 domain in regulation of enzymatic activity of phospholipase C xi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; CA2+ OSCILLATIONS; MOUSE EGGS; LIVING CELLS; TROPONIN-C; PLC-ZETA; ACTIVATION; CALCIUM; BINDING; PROTEIN	Sperm-specific phospholipase C-xi(PLC xi) induces Ca2+ oscillations and egg activation when injected into mouse eggs. PLC xi has such a high Ca2+ sensitivity of PLC activity that the enzyme can be active in resting cells at similar to 100 nM Ca2+, suitable for a putative sperm factor to be introduced into the egg at fertilization (Kouchi, Z., Fukami, K., Shikano, T., Oda, S., Nakamura, Y., Takenawa, T., and Miyazaki, S. (2004) J. Biol. Chem. 279, 10408 - 10412). In the present structure-function analysis, deletion of EF1 and EF2 of the N-terminal four EF-hand domains caused marked reduction of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2)- hydrolyzing activity in vitro and loss of Ca2+ oscillation-inducing activity in mouse eggs after injection of RNA encoding the mutant. However, deletion of EF1 and EF2 or mutation of EF1 or EF2 at the x and z positions of the putative Ca2+-binding loop little affected the Ca2+ sensitivity of the PLC activity, whereas deletion of EF1 to EF3 caused 12-fold elevation of the EC50 of Ca2+ concentration. Thus, EF1 and EF2 are important for the PLC xi activity, and EF3 is responsible for its high Ca2+ sensitivity. Deletion of four EF-hand domains or the C-terminal C2 domain caused complete loss of PLC activity, indicating that both regions are prerequisites for PLC xi activity. Screening of interactions between the C2 domain and phosphoinositides revealed that C2 has substantial affinity to PI(3) P and, to the lesser extent, to PI(5) P but not to PI(4,5)P-2 or acidic phospholipids. PI(3) P and PI(5) P reduced PLC xi activity in vitro, suggesting that the interaction could play a role for negative regulation of PLC xi.	Tokyo Womens Med Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1628666, Japan; Tokyo Univ Pharm & Life Sci, Lab Genome & Biosignal, Hachioji, Tokyo 1920392, Japan	Tokyo Women's Medical University; Tokyo University of Pharmacy & Life Sciences	Miyazaki, S (corresponding author), Tokyo Womens Med Univ, Sch Med, Dept Physiol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	shunm@research.twmu.ac.jp		Nakamura, Yoshikazu/0000-0001-8355-1091				Aida T, 2001, MOL HUM REPROD, V7, P1039, DOI 10.1093/molehr/7.11.1039; Ananthanarayanan B, 2002, J BIOL CHEM, V277, P3568, DOI 10.1074/jbc.M109705200; BABU A, 1992, J BIOL CHEM, V267, P15469; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Catz SD, 2002, P NATL ACAD SCI USA, V99, P11652, DOI 10.1073/pnas.172382799; Corpet F, 2000, NUCLEIC ACIDS RES, V28, P267, DOI 10.1093/nar/28.1.267; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fukami K, 2002, J BIOCHEM, V131, P293, DOI 10.1093/oxfordjournals.jbchem.a003102; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Jones KT, 1998, INT J DEV BIOL, V42, P1; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Kouchi Z, 2004, J BIOL CHEM, V279, P10408, DOI 10.1074/jbc.M313801200; Larman MG, 2004, J CELL SCI, V117, P2513, DOI 10.1242/jcs.01109; Lomasney JW, 1999, J BIOL CHEM, V274, P21995, DOI 10.1074/jbc.274.31.21995; MIYAZAKI S, 1993, JPN J PHYSIOL, V43, P409, DOI 10.2170/jjphysiol.43.409; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; Nagano K, 1999, J BIOL CHEM, V274, P2872, DOI 10.1074/jbc.274.5.2872; NAKASHIMA S, 1995, BIOCHEM BIOPH RES CO, V211, P364, DOI 10.1006/bbrc.1995.1822; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oda S, 1999, DEV BIOL, V209, P172, DOI 10.1006/dbio.1999.9233; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Saunders CM, 2002, DEVELOPMENT, V129, P3533; SHIAVO G, 1996, P NATL ACAD SCI USA, V93, P13327; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Swann K, 1996, Rev Reprod, V1, P33, DOI 10.1530/ror.0.0010033; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Wang T, 1999, P NATL ACAD SCI USA, V96, P7843, DOI 10.1073/pnas.96.14.7843; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; Yoda A, 2004, DEV BIOL, V268, P245, DOI 10.1016/j.ydbio.2003.12.028	40	92	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21015	21021		10.1074/jbc.M412123200	http://dx.doi.org/10.1074/jbc.M412123200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15790568	hybrid			2022-12-27	WOS:000229438800015
J	Ledee, DR; Gao, CY; Seth, R; Fariss, RN; Tripathi, BK; Zelenka, PS				Ledee, DR; Gao, CY; Seth, R; Fariss, RN; Tripathi, BK; Zelenka, PS			A specific interaction between muskelin and the cyclin-dependent kinase 5 activator p39 promotes peripheral localization of muskelin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KELCH-REPEAT SUPERFAMILY; DIRECTED PROTEIN-KINASE; LENS FIBER CELLS; NEURONAL DIFFERENTIATION; EPITHELIAL-CELLS; P35/CDK5 KINASE; BOVINE BRAIN; CDK5; PHOSPHORYLATION; EXPRESSION	Previous studies implicate cyclin-dependent kinase 5 in cell adhesion and migration of epithelial cells of the cornea and lens. To explore molecular interactions underlying these functions, we performed yeast two-hybrid screening of an embryonic rat lens library for proteins that interact with cyclin-dependent kinase 5 and its regulators, p35 and p39. This screen identified a specific interaction between p39 and muskelin, an intracellular protein known to affect cytoskeletal organization in adherent cells. Immunohistochemistry detected muskelin in the developing lens and in other tissues, including brain and muscle. Glutathione S-transferase pull-down experiments and co-immunoprecipitations confirmed the specificity of the p39-muskelin interaction. Deletion analysis of p39 showed that muskelin binds to the p39 C terminus, which contains a short insertion ( amino acids 329-366) absent from p35. Similar analysis of muskelin mapped the interaction with p39 to the fifth kelch repeat. Co-expression of p39 and muskelin in COS1 cells or lens epithelial cells altered the intracellular localization of muskelin, recruiting it to the cell periphery. These findings demonstrate a novel interaction between muskelin and the cyclin-dependent kinase 5 activator p39 and suggest that p39 may regulate the subcellular localization of muskelin.	NEI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Zelenka, PS (corresponding author), NEI, NIH, Bldg 7,Rm 102,7 Mem Dr,MSC 0704, Bethesda, MD 20892 USA.	zelenkap@nei.nih.gov	Fariss, Robert/ABI-1771-2020	Ledee, Dolena/0000-0003-1041-4795; Fariss, Robert/0000-0003-3227-7170	NATIONAL EYE INSTITUTE [ZIAEY000238, Z01EY000238] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Adams JC, 1998, EMBO J, V17, P4964, DOI 10.1093/emboj/17.17.4964; Alexander K, 2004, MOL CELL BIOL, V24, P2808, DOI 10.1128/MCB.24.7.2808-2819.2004; AUSUBEL FM, 1998, CURRENT PROTOCOLS MO, V2; Bassnett S, 1999, J CELL SCI, V112, P2155; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Chen F, 2001, BLOOD, V97, P3763, DOI 10.1182/blood.V97.12.3763; Dhavan R, 2002, J NEUROSCI, V22, P7879; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Gao C, 2002, MOL CANCER RES, V1, P12; GAO CY, 1995, DEV BIOL, V169, P185, DOI 10.1006/dbio.1995.1136; Gao CY, 2004, J CELL SCI, V117, P4089, DOI 10.1242/jcs.01271; Gao CY, 1997, DEV GENET, V20, P267; Gilmore EC, 1998, J NEUROSCI, V18, P6370; Hasegawa H, 2000, BIOCHEM BIOPH RES CO, V276, P350, DOI 10.1006/bbrc.2000.3467; He HY, 1998, DEV DYNAM, V211, P26, DOI 10.1002/(SICI)1097-0177(199801)211:1<26::AID-AJA3>3.0.CO;2-9; Honjyo Y, 1999, NEUROREPORT, V10, P3375, DOI 10.1097/00001756-199911080-00022; Humbert S, 2000, J CELL SCI, V113, P975; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; Kato G, 1999, J BIOCHEM-TOKYO, V126, P957, DOI 10.1093/oxfordjournals.jbchem.a022540; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; Lilja L, 2004, J BIOL CHEM, V279, P29534, DOI 10.1074/jbc.M312711200; Negash S, 2002, J CELL SCI, V115, P2109; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Prag S, 2004, BIOCHEM J, V381, P547, DOI 10.1042/BJ20040253; Prag S, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-42; Rashid T, 2001, J BIOL CHEM, V276, P49043, DOI 10.1074/jbc.M105599200; Takahashi S, 2003, J BIOL CHEM, V278, P10506, DOI 10.1074/jbc.M211964200; Tanaka T, 2001, J NEUROSCI, V21, P550, DOI 10.1523/JNEUROSCI.21-02-00550.2001; Tarricone C, 2001, MOL CELL, V8, P657, DOI 10.1016/S1097-2765(01)00343-4; Umeda M, 2003, GENE, V303, P47, DOI 10.1016/S0378-1119(02)01153-8; Xie ZG, 2003, CELL, V114, P469, DOI 10.1016/S0092-8674(03)00605-6; Xiong W, 1997, MOL CELL BIOL, V17, P6585, DOI 10.1128/MCB.17.11.6585; Zhang Q, 1997, DEV BIOL, V183, P222, DOI 10.1006/dbio.1996.8494; Zheng M, 1998, J NEUROBIOL, V35, P141, DOI 10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4	38	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21376	21383		10.1074/jbc.M501215200	http://dx.doi.org/10.1074/jbc.M501215200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797862	hybrid			2022-12-27	WOS:000229438800057
J	Paumet, F; Rahimian, V; Di Liberto, M; Rothman, JE				Paumet, F; Rahimian, V; Di Liberto, M; Rothman, JE			Concerted auto-regulation in yeast endosomal t-SNAREs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; MEMBRANE-FUSION; CRYSTAL-STRUCTURE; SYNTAXIN 7; 3-DIMENSIONAL STRUCTURE; GOLGI TRANSPORT; COMPLEX; SPECIFICITY; HOMOLOG; TRAFFICKING	In yeast, the assembly of the target (t)-SNAREs [Tlg2p/Tlg1p, Vti1p] and [Pep12p/Tlg1p, Vti1p] with the vesicular (v)- SNARE Snc2p promotes endocytic fusion. Here, selected mutations and truncations of SNARE proteins were tested in an in vitro fusion assay to identify potential regulatory regions in these proteins, and two distinct regions were found. The first is represented by the combined effect of the three t-SNARE N-terminal regions and the second is located within the Tlg1p SNARE motif. These internal controls provide a potential mechanism to enable SNARE-dependent fusion to be regulated.	Columbia Univ, Ctr Med, Dept Physiol & Biophys, New York, NY 10032 USA	Columbia University	Rothman, JE (corresponding author), Columbia Univ, Ctr Med, Dept Physiol & Biophys, Russ Berrie Pavil,1150 St Nicholas Av, New York, NY 10032 USA.	jr2269@columbia.edu		Paumet, Fabienne/0000-0003-4466-6966	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027044] Funding Source: NIH RePORTER; NIDDK NIH HHS [5R01DK27044-27] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonin W, 2002, J BIOL CHEM, V277, P36449, DOI 10.1074/jbc.M204369200; Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Conibear E, 2003, MOL BIOL CELL, V14, P1610, DOI 10.1091/mbc.E02-10-0654; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Dulubova I, 2001, NAT STRUCT BIOL, V8, P258, DOI 10.1038/85012; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Fukuda R, 2000, NATURE, V407, P198, DOI 10.1038/35025084; Gonzalez LC, 2001, J BIOL CHEM, V276, P24203, DOI 10.1074/jbc.M101584200; Gurunathan S, 2000, MOL BIOL CELL, V11, P3629, DOI 10.1091/mbc.11.10.3629; Laage R, 2001, MOL BIOL CELL, V12, P3375, DOI 10.1091/mbc.12.11.3375; McNew JA, 1998, FEBS LETT, V435, P89, DOI 10.1016/S0014-5793(98)01044-8; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Melia TJ, 2002, J CELL BIOL, V158, P929, DOI 10.1083/jcb.200112081; Misura KMS, 2002, P NATL ACAD SCI USA, V99, P9184, DOI 10.1073/pnas.132274599; Mullock BM, 2000, MOL BIOL CELL, V11, P3137, DOI 10.1091/mbc.11.9.3137; Munson M, 2000, NAT STRUCT BIOL, V7, P894; Nakamura N, 2000, J BIOL CHEM, V275, P6523, DOI 10.1074/jbc.275.9.6523; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Parlati F, 2002, P NATL ACAD SCI USA, V99, P5424, DOI 10.1073/pnas.082100899; Paumet F, 2004, P NATL ACAD SCI USA, V101, P3376, DOI 10.1073/pnas.0400271101; Paumet F, 2001, J CELL BIOL, V155, P961, DOI 10.1083/jcb.200104092; Pelham HRB, 2001, TRENDS CELL BIOL, V11, P99, DOI 10.1016/S0962-8924(01)01929-8; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Siniossoglou S, 2001, EMBO J, V20, P5991, DOI 10.1093/emboj/20.21.5991; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Wang H, 1997, GENE, V199, P39, DOI 10.1016/S0378-1119(97)00343-0; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X	33	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21137	21143		10.1074/jbc.M500841200	http://dx.doi.org/10.1074/jbc.M500841200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799968	hybrid			2022-12-27	WOS:000229438800030
J	Yonezawa, N; Kudo, K; Terauchi, H; Kanai, S; Yoda, N; Tanokura, M; Ito, K; Miura, K; Katsumata, T; Nakano, M				Yonezawa, N; Kudo, K; Terauchi, H; Kanai, S; Yoda, N; Tanokura, M; Ito, K; Miura, K; Katsumata, T; Nakano, M			Recombinant porcine zona pellucida glycoproteins expressed in Sf9 cells bind to bovine sperm but not to porcine sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED CARBOHYDRATE CHAINS; MOUSE SPERM; STRUCTURAL-CHARACTERIZATION; ALPHA-GLYCOPROTEIN; EGG-COAT; ZP3; RECEPTOR; OLIGOSACCHARIDES; FERTILIZATION; SPERMATOZOA	The zona pellucida, which surrounds the mammalian oocyte, consists of the ZPA, ZPB, and ZPC glycoproteins and plays roles in species-selective sperm-egg interactions via its carbohydrate moieties. In the pig, this activity is conferred by tri- and tetraantennary complex type chains; in cattle, it is conferred by a chain of 5 mannose residues. In this study, porcine zona glycoproteins were expressed as secreted forms, using the baculovirus-Sf9 insect cell system. The sperm binding activities of the recombinant proteins were examined in three different assays. The assays clearly demonstrated that recombinant ZPB bound bovine sperm weakly but did not bind porcine sperm; when recombinant ZPC was also present, bovine sperm binding activity was greatly increased, but porcine sperm still was not bound. The major sugar chains of ZPB were pauci and high mannose type chains that were similar in structure to the major neutral N-linked chain of the bovine zona. In fact, the nonreducing terminal alpha-mannose residues were necessary for the sperm binding activity. These results show that the carbohydrate moieties of zona glycoproteins, but not the polypeptide moieties, play an essential role in species-selective recognition of porcine and bovine sperm. Moreover, Asn to Asp mutations at either of two of the N-glycosylation sites of ZPB, residue 203 or 220, significantly reduced the sperm binding activity of the ZPB/ZPC mixture, whereas a similar mutation at the third N-glycosylation site, Asn-333, had no effect on binding. These results suggest that the N-glycans located in the N-terminal half of the ZP domain of porcine ZPB are involved in sperm-zona binding.	Chiba Univ, Fac Sci, Dept Chem, Inage Ku, Chiba 2638522, Japan; Chiba Univ, Grad Sch Sci & Technol, Inage Ku, Chiba 2638522, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; Gakushuin Univ, Inst Biomol Sci, Tokyo 1718588, Japan; Tokyo Med & Dent Univ, Coll Liberal Arts & Sci, Ichikawa, Chiba 2720827, Japan	Chiba University; Chiba University; University of Tokyo; Gakushuin University; Tokyo Medical & Dental University (TMDU)	Nakano, M (corresponding author), Chiba Univ, Fac Sci, Dept Chem, Inage Ku, 1-33 Yayoi Cho, Chiba 2638522, Japan.	mnakano@faculty.chiba-u.jp	Yonezawa, Naoto/F-8300-2011	Tanokura, Masaru/0000-0001-5072-2480				Amari S, 2001, MOL REPROD DEV, V59, P221, DOI 10.1002/mrd.1026; BERGER T, 1989, J REPROD FERTIL, V86, P559, DOI 10.1530/jrf.0.0860559; BLEIL JD, 1988, P NATL ACAD SCI USA, V85, P6778, DOI 10.1073/pnas.85.18.6778; Boja ES, 2003, J BIOL CHEM, V278, P34189, DOI 10.1074/jbc.M304026200; BRACKETT BG, 1975, BIOL REPROD, V12, P260, DOI 10.1095/biolreprod12.2.260; Butters TD, 1998, GLYCOCONJUGATE J, V15, P83, DOI 10.1023/A:1006999718552; Chapman NR, 1998, BIOCHEM J, V330, P839; Chen J, 1998, P NATL ACAD SCI USA, V95, P6193, DOI 10.1073/pnas.95.11.6193; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNWALL GA, 1991, BIOL REPROD, V44, P913, DOI 10.1095/biolreprod44.5.913; Dell A, 2003, P NATL ACAD SCI USA, V100, P15631, DOI 10.1073/pnas.2635507100; Easton RL, 2000, J BIOL CHEM, V275, P7731, DOI 10.1074/jbc.275.11.7731; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; Gahlay GK, 2002, J REPROD IMMUNOL, V53, P67, DOI 10.1016/S0165-0378(01)00083-3; Granovsky M, 2000, NAT MED, V6, P306; GUPTA SK, 1995, MOL REPROD DEV, V42, P220, DOI 10.1002/mrd.1080420211; Harris JD, 1999, PROTEIN EXPRES PURIF, V16, P298, DOI 10.1006/prep.1999.1060; HARRIS JD, 1994, DNA SEQUENCE, V4, P361, DOI 10.3109/10425179409010186; HEDRICK JL, 1987, DEV BIOL, V121, P478, DOI 10.1016/0012-1606(87)90184-9; Hoodbhoy T, 2004, REPRODUCTION, V127, P417, DOI 10.1530/rep.1.00181; Johnston DS, 1998, J BIOL CHEM, V273, P1888, DOI 10.1074/jbc.273.4.1888; Jungnickel MK, 2003, CELL, V114, P401, DOI 10.1016/S0092-8674(03)00648-2; Katsumata T, 1996, EUR J BIOCHEM, V240, P448, DOI 10.1111/j.1432-1033.1996.0448h.x; Kiefer SM, 2002, BIOL REPROD, V66, P407, DOI 10.1095/biolreprod66.2.407; Kudo K, 1998, EUR J BIOCHEM, V252, P492, DOI 10.1046/j.1432-1327.1998.2520492.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITSCHER ES, 1995, BIOCHEMISTRY-US, V34, P4662, DOI 10.1021/bi00014a020; LITSCHER ES, 1993, TRENDS GLYCOSCI GLYC, V5, P369; LOPEZ LC, 1985, J CELL BIOL, V101, P1501, DOI 10.1083/jcb.101.4.1501; Lu QX, 1997, DEVELOPMENT, V124, P4121; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; Mori E, 1997, BIOCHEM BIOPH RES CO, V238, P95, DOI 10.1006/bbrc.1997.7249; NOGUCHI S, 1993, BIOCHIM BIOPHYS ACTA, V1158, P217, DOI 10.1016/0304-4165(93)90018-4; NOGUCHI S, 1992, EUR J BIOCHEM, V204, P1089, DOI 10.1111/j.1432-1033.1992.tb16733.x; NOGUCHI S, 1994, BBA-GEN SUBJECTS, V1201, P7, DOI 10.1016/0304-4165(94)90143-0; PRASAD SV, 1995, BIOL REPROD, V52, P1167, DOI 10.1095/biolreprod52.5.1167; Rankin TL, 2003, DEV CELL, V5, P33, DOI 10.1016/S1534-5807(03)00195-3; SACCO AG, 1989, BIOL REPROD, V41, P523, DOI 10.1095/biolreprod41.3.523; Shi SL, 2004, MOL CELL BIOL, V24, P9920, DOI 10.1128/MCB.24.22.9920-9929.2004; Thaler CD, 1996, J BIOL CHEM, V271, P23289, DOI 10.1074/jbc.271.38.23289; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; Topfer-Petersen E, 1999, HUM REPROD UPDATE, V5, P314, DOI 10.1093/humupd/5.4.314; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYODA Y, 1974, J REPROD FERTIL, V36, P9, DOI 10.1530/jrf.0.0360009; Tsubamoto H, 1999, PROTEIN EXPRES PURIF, V17, P8, DOI 10.1006/prep.1999.1091; Tsubamoto H, 1999, BIOL REPROD, V61, P1649, DOI 10.1095/biolreprod61.6.1649; VANDUIN M, 1994, BIOL REPROD, V51, P607, DOI 10.1095/biolreprod51.4.607; VOSS T, 1993, EUR J BIOCHEM, V217, P913, DOI 10.1111/j.1432-1033.1993.tb18321.x; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Williams Z, 2001, BIOCHEMISTRY-US, V40, P929, DOI 10.1021/bi002275x; Yonezawa N, 1997, EUR J BIOCHEM, V248, P86, DOI 10.1111/j.1432-1033.1997.00086.x; Yonezawa N, 2003, BIOCHEM BIOPH RES CO, V307, P877, DOI 10.1016/S0006-291X(03)01297-X; YONEZAWA N, 1995, EUR J BIOCHEM, V233, P35, DOI 10.1111/j.1432-1033.1995.035_1.x; Yonezawa N, 2001, EUR J BIOCHEM, V268, P3587, DOI 10.1046/j.1432-1327.2001.02269.x; YUREWICZ EC, 1987, J BIOL CHEM, V262, P564; YUREWICZ EC, 1991, MOL REPROD DEV, V30, P126, DOI 10.1002/mrd.1080300209; YUREWICZ EC, 1993, MOL REPROD DEV, V36, P382, DOI 10.1002/mrd.1080360315; Yurewicz EC, 1998, J BIOL CHEM, V273, P7488, DOI 10.1074/jbc.273.13.7488; Zhao M, 2002, MOL CELL BIOL, V22, P3111, DOI 10.1128/MCB.22.9.3111-3120.2002	59	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20189	20196		10.1074/jbc.M414242200	http://dx.doi.org/10.1074/jbc.M414242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788399	hybrid			2022-12-27	WOS:000229242000005
J	Avril, T; Freeman, SD; Attrill, H; Clarke, RG; Crocker, PR				Avril, T; Freeman, SD; Attrill, H; Clarke, RG; Crocker, PR			Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASES SHP-1; CD33-RELATED SIGLECS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; HUMAN MONOCYTES; MSIGLEC-E; RECEPTOR; EXPRESSION; CELLS; CD33	Siglec-5 (CD170) is a member of the recently described human CD33-related siglec subgroup of sialic acid binding Ig-like lectins and is expressed on myeloid cells of the hemopoietic system. Similar to other CD33-related siglecs, Siglec-5 contains two tyrosine-based motifs in its cytoplasmic tail implicated in signaling functions. To investigate the role of these motifs in Siglec-5-dependent signaling, we used transfected rat basophil leukemia cells as a model system. Tyrosine phosphorylation of Siglec-5 led to recruitment of the tyrosine phosphatases SHP-1 and SHP-2, as seen in both pull-down assays and microscopy. Siglec-5 could efficiently inhibit Fc epsilon RI-mediated calcium fluxing and serotonin release after co-cross-linking. Surprisingly, a double tyrosine to alanine mutant of Siglec-5 could still mediate strong inhibition of serotonin release in the absence of detectable tyrosine phosphorylation, whereas a double tyrosine to phenylalanine mutant lost all inhibitory activity. In comparison, suppression of Siglec-5-dependent adhesion to red blood cells was reversed by either tyrosine to alanine or tyrosine to phenylalanine mutations of the membrane proximal tyrosine-based motif. Using an in vitro phosphatase assay with synthetic and recombinant forms of the cytoplasmic tail, it was shown that a double alanine mutant of Siglec-5 had weak, but significant SHP-1 activating properties similar to those of wild type, non-phosphorylated cytoplasmic tail, whereas a double phenylalanine mutant was inactive. These findings establish that Siglec-5 can be classified as an inhibitory receptor with the potential to mediate SHP-1 and/or SHP-2-dependent signaling in the absence of tyrosine phosphorylation.	Univ Dundee, Wellcome Trust Bioctr, Div Cell Biol & Immunol, Sch Life Sci, Dundee DD1 5EH, Scotland; Univ Birmingham, Sch Med, Dept Immunol, Birmingham B15 2TT, W Midlands, England	University of Dundee; University of Birmingham	Crocker, PR (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Div Cell Biol & Immunol, Sch Life Sci, Dow St, Dundee DD1 5EH, Scotland.	p.r.crocker@dundee.ac.uk	Avril, Tony/ABG-7611-2020	Avril, Tony/0000-0002-1129-8514; Crocker, Paul/0000-0001-6230-0293; Attrill, Helen/0000-0003-3212-6364; Freeman, Sylvie/0000-0003-1869-180X				Angata T, 2002, J BIOL CHEM, V277, P24466, DOI 10.1074/jbc.M202833200; Angata T, 2004, P NATL ACAD SCI USA, V101, P13251, DOI 10.1073/pnas.0404833101; Avril T, 2004, J IMMUNOL, V173, P6841, DOI 10.4049/jimmunol.173.11.6841; Beebe KD, 2000, BIOCHEMISTRY-US, V39, P13251, DOI 10.1021/bi0014397; Blery M, 1997, J BIOL CHEM, V272, P8989; Connolly NP, 2002, BRIT J HAEMATOL, V119, P221, DOI 10.1046/j.1365-2141.2002.03808.x; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Dietrich J, 2000, MICROBES INFECT, V2, P323, DOI 10.1016/S1286-4579(00)00294-X; Erickson-Miller CL, 2003, EXP HEMATOL, V31, P382, DOI 10.1016/S0301-472X(03)00046-8; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Ikehara Y, 2004, J BIOL CHEM, V279, P43117, DOI 10.1074/jbc.M403538200; Jackson DE, 2003, FEBS LETT, V540, P7, DOI 10.1016/S0014-5793(03)00224-2; Jones C, 2003, MOL MICROBIOL, V49, P1213, DOI 10.1046/j.1365-2958.2003.03634.x; Kitzig F, 2002, BIOCHEM BIOPH RES CO, V296, P355, DOI 10.1016/S0006-291X(02)00885-9; Lajaunias F, 2005, EUR J IMMUNOL, V35, P243, DOI 10.1002/eji.200425273; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; Lock K, 2004, IMMUNOBIOLOGY, V209, P199, DOI 10.1016/j.imbio.2004.04.007; Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Nathan C, 2001, NAT IMMUNOL, V2, P17, DOI 10.1038/83124; Paul SP, 2000, BLOOD, V96, P483; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Schoenwaelder SM, 2000, CURR BIOL, V10, P1523, DOI 10.1016/S0960-9822(00)00831-9; Shlapatska LM, 2001, J IMMUNOL, V166, P5480, DOI 10.4049/jimmunol.166.9.5480; Staub E, 2004, CELL SIGNAL, V16, P435, DOI 10.1016/j.cellsig.2003.08.013; Stebbins CC, 2003, MOL CELL BIOL, V23, P6291, DOI 10.1128/MCB.23.17.6291-6299.2003; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; Tridandapani S, 2002, J BIOL CHEM, V277, P5082, DOI 10.1074/jbc.M110277200; Ulyanova T, 1999, EUR J IMMUNOL, V29, P3440, DOI 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.3.CO;2-3; Ulyanova T, 2001, J BIOL CHEM, V276, P14451, DOI 10.1074/jbc.M011650200; Yang J, 2003, J BIOL CHEM, V278, P6516, DOI 10.1074/jbc.M210430200; Yu ZB, 2001, BIOCHEM J, V353, P483, DOI 10.1042/0264-6021:3530483; Yu ZB, 2001, J BIOL CHEM, V276, P23816, DOI 10.1074/jbc.M102394200; Yusa S, 2002, J IMMUNOL, V168, P5047, DOI 10.4049/jimmunol.168.10.5047; Zhang JQ, 2000, J BIOL CHEM, V275, P22121, DOI 10.1074/jbc.M002788200; Zhang JQQ, 2004, EUR J IMMUNOL, V34, P1175, DOI 10.1002/eji.200324723	40	76	78	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19843	19851		10.1074/jbc.M502041200	http://dx.doi.org/10.1074/jbc.M502041200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769739	hybrid			2022-12-27	WOS:000229113700052
J	De Keersmaecker, SCJ; Varszegi, C; van Boxel, N; Habel, LW; Metzger, K; Daniels, R; Marchal, K; De Vos, D; Vanderleyden, J				De Keersmaecker, SCJ; Varszegi, C; van Boxel, N; Habel, LW; Metzger, K; Daniels, R; Marchal, K; De Vos, D; Vanderleyden, J			Chemical synthesis of (S)-4,5-dihydroxy-2,3-pentanedione, a bacterial signal molecule precursor, and validation of its activity in Salmonella typhimurium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUORUM-SENSING SIGNAL; TO-CELL COMMUNICATION; BIOFILM FORMATION; ESCHERICHIA-COLI; STREPTOCOCCUS-MUTANS; GENE-EXPRESSION; VIBRIO-HARVEYI; BORON BINDING; LUXS; AUTOINDUCER-2	We describe an original, short, and convenient chemical synthesis of enantiopure (S)-4,5-dihydroxy-2,3-pentanedione (DPD), starting from commercial methyl (S) (similar to)-2,2-dimethyl-1,3-dioxolane-4-carboxylate. DPD is the precursor of autoinducer (AI)-2, the proposed signal for bacterial interspecies communication. AI-2 is synthesized by many bacterial species in three enzymatic steps. The last step, a LuxS-catalyzed reaction, leads to the formation of DPD, which spontaneously cyclizes into AI-2. AI-2-like activity of the synthesized molecule was ascertained by the Vibrio harveyi bioassay. To further validate the biological activity of synthetic DPD and to explore its potential in studying DPD (AI-2)-mediated signaling, a Salmonella typhimurium luxS mutant was constructed. Expression of the AI-2 regulated lsr operon can be rescued in this luxS mutant by addition of synthetic DPD or genetic complementation. Biofilm formation by S. typhimurium has been reported to be defective in a luxS mutant, and this was confirmed in this study to test DPD for chemical complementation. However, biofilm formation of the luxS mutant cannot be restored by addition of DPD. In contrast, introduction of luxS under control of its own promoter complemented biofilm formation. Further results demonstrated that biofilm formation of the luxS mutant cannot be restored with luxS under control of the strong nptII promoter. This indicates that altering the intrinsic promoter activity of luxS affects Salmonella biofilm formation. Conclusively, we synthesized biologically active DPD. Using this chemical compound in combination with genetic approaches opens new avenues in studying AI-2- mediated signaling.	Katholieke Univ Leuven, Ctr Microbial & Plant Genet, B-3001 Heverlee, Belgium; Katholieke Univ Leuven, Ctr Surface Chem & Catal, B-3001 Heverlee, Belgium	KU Leuven; KU Leuven	Vanderleyden, J (corresponding author), Katholieke Univ Leuven, Ctr Microbial & Plant Genet, Kasteelpk Arenberg 23, B-3001 Heverlee, Belgium.	jozef.vanderleyden@biw.kuleuven.be	De Keersmaecker, Sigrid/ABB-5332-2021; Marchal, Kathleen/B-5001-2013; Marchal, Kathleen/O-7936-2017	De Keersmaecker, Sigrid/0000-0003-4198-4133; Marchal, Kathleen/0000-0002-2169-4588; Marchal, Kathleen/0000-0002-2169-4588				Bassler BL, 1997, J BACTERIOL, V179, P4043, DOI 10.1128/jb.179.12.4043-4045.1997; Beenken KE, 2004, J BACTERIOL, V186, P4665, DOI 10.1128/JB.186.14.4665-4684.2004; Beeston AL, 2002, J BACTERIOL, V184, P3450, DOI 10.1128/JB.184.13.3450-3456.2002; Ceri H, 1999, J CLIN MICROBIOL, V37, P1771, DOI 10.1128/JCM.37.6.1771-1776.1999; Chen X, 2002, NATURE, V415, P545, DOI 10.1038/415545a; Federle MJ, 2003, J CLIN INVEST, V112, P1291, DOI 10.1172/JCI200320195; Frias J, 2001, INFECT IMMUN, V69, P3431, DOI 10.1128/IAI.69.5.3431-3434.2001; Fuqua C, 2001, ANNU REV GENET, V35, P439, DOI 10.1146/annurev.genet.35.102401.090913; GREENBERG EP, 1979, ARCH MICROBIOL, V120, P87, DOI 10.1007/BF00409093; Hauck T, 2003, BBA-GEN SUBJECTS, V1623, P109, DOI 10.1016/j.bbagen.2003.08.002; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Lupp C, 2004, J BACTERIOL, V186, P3873, DOI 10.1128/JB.186.12.3873-3881.2004; McNab R, 2003, J BACTERIOL, V185, P274, DOI 10.1128/JB.185.1.274-284.2003; Meijler MM, 2004, ANGEW CHEM INT EDIT, V43, P2106, DOI 10.1002/anie.200353150; Merritt J, 2003, INFECT IMMUN, V71, P1972, DOI 10.1128/IAI.71.4.1972-1979.2003; MICHIELS J, 1991, MOL GEN GENET, V228, P486, DOI 10.1007/BF00260644; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; Miller ST, 2004, MOL CELL, V15, P677, DOI 10.1016/j.molcel.2004.07.020; Prouty AM, 2002, INFECT IMMUN, V70, P2640, DOI 10.1128/IAI.70.5.2640-2649.2002; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schauder S, 2001, MOL MICROBIOL, V41, P463, DOI 10.1046/j.1365-2958.2001.02532.x; Semmelhack MF, 2005, ORG LETT, V7, P569, DOI 10.1021/ol047695j; Semmelhack MF, 2004, ORG LETT, V6, P2635, DOI 10.1021/ol048976u; Sperandio V, 2003, P NATL ACAD SCI USA, V100, P8951, DOI 10.1073/pnas.1537100100; Spoering AL, 2001, J BACTERIOL, V183, P6746, DOI 10.1128/JB.183.23.6746-6751.2001; Stepanovic S, 2004, LETT APPL MICROBIOL, V38, P428, DOI 10.1111/j.1472-765X.2004.01513.x; Sturme MHJ, 2002, ANTON LEEUW INT J G, V81, P233, DOI 10.1023/A:1020522919555; Surette MG, 1999, P NATL ACAD SCI USA, V96, P1639, DOI 10.1073/pnas.96.4.1639; Surette MG, 1998, P NATL ACAD SCI USA, V95, P7046, DOI 10.1073/pnas.95.12.7046; Taga ME, 2003, MOL MICROBIOL, V50, P1411, DOI 10.1046/j.1365-2958.2003.03781.x; Taga ME, 2001, MOL MICROBIOL, V42, P777, DOI 10.1046/j.1365-2958.2001.02669.x; Wang L, 2005, J BACTERIOL, V187, P2066, DOI 10.1128/JB.187.6.2066-2076.2005; Wang QF, 2004, MOL MICROBIOL, V52, P169, DOI 10.1111/j.1365-2958.2003.03977.x; WEENEN H, 1998, MAILLARD REACTION FO, P57; Wen ZT, 2002, APPL ENVIRON MICROB, V68, P1196, DOI 10.1128/AEM.68.3.1196-1203.2002; Whitehead NA, 2001, FEMS MICROBIOL REV, V25, P365, DOI 10.1111/j.1574-6976.2001.tb00583.x; Winans SC, 2002, J BACTERIOL, V184, P873, DOI 10.1128/jb.184.4.873-883.2002; Winzer K, 2002, CURR OPIN MICROBIOL, V5, P216, DOI 10.1016/S1369-5274(02)00304-1; Winzer K, 2002, MICROBIOL-SGM, V148, P909, DOI 10.1099/00221287-148-4-909; Withers H, 2001, CURR OPIN MICROBIOL, V4, P186, DOI 10.1016/S1369-5274(00)00187-9; Xavier KB, 2003, CURR OPIN MICROBIOL, V6, P191, DOI 10.1016/S1369-5274(03)00028-6; Xavier KB, 2005, J BACTERIOL, V187, P238, DOI 10.1128/JB.187.1.238-248.2005; Yoshida A, 2002, APPL ENVIRON MICROB, V68, P6283, DOI 10.1128/AEM.68.12.6283-6291.2002; Zhao G, 2003, BIOORG MED CHEM LETT, V13, P3897, DOI 10.1016/j.bmcl.2003.09.015	44	107	111	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19563	19568		10.1074/jbc.M412660200	http://dx.doi.org/10.1074/jbc.M412660200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15790567	hybrid			2022-12-27	WOS:000229113700018
J	Wang, D; Quick, MW				Wang, D; Quick, MW			Trafficking of the plasma membrane gamma-aminobutyric acid transporter GAT1 - Size and rates of an acutely recycling pool	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN DOPAMINE TRANSPORTER; RECEPTOR-MEDIATED ENDOCYTOSIS; BIOGENIC-AMINE TRANSPORTERS; GABA TRANSPORTER; GLUTAMATE TRANSPORTER; SYNTAXIN 1A; NEUROTRANSMITTER TRANSPORTERS; NOREPINEPHRINE TRANSPORTER; TYROSINE PHOSPHORYLATION	Plasma membrane neurotransmitter transporters rapidly traffic to and from the cell surface in neurons. This trafficking may be important in regulating neuronal signaling. Such regulation will be subject to the number of trafficking transporters and their trafficking rates. In the present study, we define an acutely recycling pool of endogenous gamma-aminobutyric acid transporters (GAT1) in cortical neurons that comprises approximately one-third of total cellular GAT1. Kinetic analysis of this pool estimates exocytosis and endocytosis time constants of 1.6 and 0.9 min, respectively, and thus approximately one-third of the recycling pool is plasma membrane resident in the basal state. Recent evidence shows that GAT1 substrates, second messengers, and interacting proteins regulate GAT1 trafficking. These triggers could act by altering trafficking rates or by changing the recycling pool size. In the present study we examine three GAT1 modulators. Calcium depletion decreases GAT1 surface expression by diminishing the recycling pool size. Sucrose increases GAT1 surface expression by blocking clathrin- and dynamin-dependent endocytosis, but it does not change the recycling pool size. Protein kinase C decreases surface GAT1 expression by increasing the endocytosis rate, but it does not change the exocytosis rate or the recycling pool size. Based upon estimates of GAT1 molecules in cortical boutons, the present data suggest that similar to 1000 transporters comprise the acutely recycling pool, of which 300 are on the surface in the basal state, and five transporters insert into the plasma membrane every second. This insertion could represent the fusion of one transporter-containing vesicle.	Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ So Calif, Grad Program Neurosci, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Quick, MW (corresponding author), Univ So Calif, Dept Biol Sci, HNB 228,3641 Watt Way, Los Angeles, CA 90089 USA.	mquick@usc.edu	Wang, Dan Ohtan/AAF-5704-2019; Wang, Dan Ohtan/E-1953-2011	Wang, Dan Ohtan/0000-0002-3126-8558; 	NATIONAL INSTITUTE ON DRUG ABUSE [R29DA010509, R01DA010509] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10509] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Aravanis AM, 2003, NEUROPHARMACOLOGY, V45, P797, DOI 10.1016/S0028-3908(03)00310-1; Bauman AL, 2000, J NEUROSCI, V20, P7571; Becker C, 2001, ENDOCRINOLOGY, V142, P5267, DOI 10.1210/en.142.12.5267; Beckman ML, 1998, J NEUROSCI, V18, P6103; Beckman ML, 1999, J NEUROSCI, V19; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; Chi LM, 2003, J PHARMACOL EXP THER, V307, P729, DOI 10.1124/jpet.103.055095; Chiu CS, 2002, J NEUROSCI, V22, P10251; Conti F, 1998, J COMP NEUROL, V396, P51, DOI 10.1002/(SICI)1096-9861(19980622)396:1<51::AID-CNE5>3.0.CO;2-H; COREY JL, 1994, J BIOL CHEM, V269, P14759; da Costa BLDA, 2000, BRAIN RES, V863, P132; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Deken SL, 2000, NAT NEUROSCI, V3, P998, DOI 10.1038/79939; Deken SL, 2003, J NEUROSCI, V23, P1563; Diamond JS, 2000, J NEUROPHYSIOL, V83, P2835, DOI 10.1152/jn.2000.83.5.2835; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Engel D, 1998, J PHYSIOL-LONDON, V512, P643, DOI 10.1111/j.1469-7793.1998.643bd.x; Ferguson SM, 2003, J NEUROSCI, V23, P9697; Fernandez-Alfonso T, 2004, NEURON, V41, P943, DOI 10.1016/S0896-6273(04)00113-8; Geerlings A, 2001, J BIOL CHEM, V276, P17584, DOI 10.1074/jbc.M010602200; Harwood HJ, 1997, BIOCHEM J, V323, P649, DOI 10.1042/bj3230649; Hesse S, 2003, J NEURAL TRANSM, V110, P923, DOI 10.1007/s00702-003-0008-8; Hoogland G, 2004, J NEUROSCI RES, V76, P881, DOI 10.1002/jnr.20128; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; Jayanthi LD, 2004, J BIOL CHEM, V279, P19315, DOI 10.1074/jbc.M311172200; JEFFERIES WA, 1985, IMMUNOLOGY, V54, P333; Jensen K, 2003, J NEUROPHYSIOL, V90, P2690, DOI 10.1152/jn.00240.2003; Jess U, 2002, BIOCHEM BIOPH RES CO, V294, P272, DOI 10.1016/S0006-291X(02)00460-6; Jiang HB, 2004, J BIOL CHEM, V279, P54380, DOI 10.1074/jbc.M409282200; Kuromi H, 2003, J NEUROCYTOL, V32, P551, DOI 10.1023/B:NEUR.0000020610.13554.3c; Law RM, 2000, J BIOL CHEM, V275, P23986, DOI 10.1074/jbc.M910283199; Lee A, 1999, CURR BIOL, V9, P261, DOI 10.1016/S0960-9822(99)80115-8; Lin CLG, 2001, NATURE, V410, P84, DOI 10.1038/35065084; Little KY, 2002, MOL PHARMACOL, V61, P436, DOI 10.1124/mol.61.2.436; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Lopez-Corcuera B, 2001, MOL MEMBR BIOL, V18, P13, DOI 10.1080/09687680120521; Masliah E, 2000, EXP NEUROL, V163, P381, DOI 10.1006/exnr.2000.7386; Melikian HE, 1999, J NEUROSCI, V19, P7699; Menne C, 2002, EUR J IMMUNOL, V32, P616, DOI 10.1002/1521-4141(200203)32:3<616::AID-IMMU616>3.3.CO;2-0; Morara S, 1996, NEUROREPORT, V7, P2993, DOI 10.1097/00001756-199611250-00039; Quick MW, 2002, P NATL ACAD SCI USA, V99, P5686, DOI 10.1073/pnas.082712899; Quick MW, 1997, J NEUROSCI, V17, P2967; Robinson MB, 2002, J NEUROCHEM, V80, P1, DOI 10.1046/j.0022-3042.2001.00698.x; Royle SJ, 2003, J PHYSIOL-LONDON, V553, P345, DOI 10.1113/jphysiol.2003.049221; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Schikorski T, 1997, J NEUROSCI, V17, P5858; Sung U, 2003, J NEUROSCI, V23, P1697; TANNER LI, 1987, J BIOL CHEM, V262, P8975; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Vanoni C, 2004, J CELL SCI, V117, P5417, DOI 10.1242/jcs.01411; VANRENSWOUDE J, 1982, P NATL ACAD SCI-BIOL, V79, P6186; WARDZALA LJ, 1978, J BIOL CHEM, V253, P8002; Waters J, 2002, J PHYSIOL-LONDON, V541, P811, DOI 10.1113/jphysiol.2001.013485; Whitworth TL, 2001, J BIOL CHEM, V276, P42932, DOI 10.1074/jbc.M107638200; WOOLLEY CS, 1992, J NEUROSCI, V12, P2549	56	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18703	18709		10.1074/jbc.M500381200	http://dx.doi.org/10.1074/jbc.M500381200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15778221	hybrid			2022-12-27	WOS:000228932300021
J	Bannister, AJ; Schneider, R; Myers, FA; Thorne, AW; Crane-Robinson, C; Kouzarides, T				Bannister, AJ; Schneider, R; Myers, FA; Thorne, AW; Crane-Robinson, C; Kouzarides, T			Spatial distribution of di- and tri-methyl lysine 36 of histone H3 at active genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOTOS-SYNDROME; PHOSPHORYLATION; EXPRESSION; SET2	Methylation of lysine 4 of histone H3 (K4/H3) is linked to transcriptional activity, whereas methylation of K9/H3 is tightly associated with gene inactivity. These are well characterized sites of methylation within histones, but there are numerous other, less characterized, sites of modification. In Saccharomyces cerevisiae, methylation of K36/H3 has been linked to active genes, but little is known about this methylation in higher eukaryotes. Here we analyzed for the first time the levels and spatial distribution of di- and tri-methyl (di- and tri-Me) K36/H3 in metazoan genes. We analyzed chicken genes that are developmentally regulated, constitutively active, or inactive. We found that active genes contain high levels of these modifications compared with inactive genes. Furthermore, in actively transcribed regions the levels of di- and tri-Me K36/H3 peak toward the 3' end of the gene. This is in striking contrast to the distributions of di- and tri-Me K4/H3, which peak early in actively transcribed regions. Thus, di/tri-Me K4/H3 and di/tri-Me K36/H3 are both useful markers of active genes, but their genic distribution indicates differing roles. Our data suggest that the unique spatial distribution of di- and tri-Me K36/H3 plays a role in transcriptional termination and/or early RNA processing.	Wellcome Canc Res UK Gurdon Inst, Cambridge CB2 1QN, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QN, England; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany; Univ Portsmouth, Biophys Labs, Inst Biomed & Biomol Sci, Portsmouth PO1 2DT, Hants, England	University of Cambridge; Max Planck Society; University of Portsmouth	Kouzarides, T (corresponding author), Wellcome Canc Res UK Gurdon Inst, Tennis Ct Rd, Cambridge CB2 1QN, England.	tk106@mole.bio.cam.ac.uk	, thorne/AAC-4984-2020	, thorne/0000-0002-8670-2358; Kouzarides, Tony/0000-0002-8918-4162; Bannister, Andrew/0000-0002-6312-4436; Myers, Fiona/0000-0001-5568-1817				Al-Mulla N, 2004, J PEDIAT HEMATOL ONC, V26, P204, DOI 10.1097/00043426-200403000-00013; Bird G, 2004, MOL CELL BIOL, V24, P8963, DOI 10.1128/MCB.24.20.8963-8969.2004; de Boer L, 2004, EUR J ENDOCRINOL, V151, P333, DOI 10.1530/eje.0.1510333; FELSENFELD G, 1993, GENE, V135, P119, DOI 10.1016/0378-1119(93)90056-9; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Landry J, 2003, MOL CELL BIOL, V23, P5972, DOI 10.1128/MCB.23.17.5972-5978.2003; Lin KT, 2004, MOL CELL BIOL, V24, P9176, DOI 10.1128/MCB.24.20.9176-9185.2004; Myers FA, 2001, J BIOL CHEM, V276, P20197, DOI 10.1074/jbc.M009472200; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Rayasam GV, 2003, EMBO J, V22, P3153, DOI 10.1093/emboj/cdg288; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; Visser R, 2003, CURR OPIN PEDIATR, V15, P598, DOI 10.1097/00008480-200312000-00010; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; Zhou MS, 2004, J VIROL, V78, P13522, DOI 10.1128/JVI.78.24.13522-13533.2004	21	300	315	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17732	17736		10.1074/jbc.M500796200	http://dx.doi.org/10.1074/jbc.M500796200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15760899	hybrid			2022-12-27	WOS:000228807200023
J	Callio, J; Oury, TD; Chu, CT				Callio, J; Oury, TD; Chu, CT			Manganese superoxide dismutase protects against 6-hydroxydopamine injury in mouse brains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIGROSTRIATAL DOPAMINE NEURONS; PULMONARY EC-SOD; PARKINSONS-DISEASE; TRANSGENIC MICE; CELL-DEATH; ALPHA-SYNUCLEIN; NITRIC-OXIDE; OXIDATIVE STRESS; GLUTATHIONE-PEROXIDASE; DISTINCT MECHANISMS	Dopaminergic neurons of the substantia nigra are susceptible to toxin-based insults. Intrastriatal injection of 6-hydroxydopamine results in selective toxicity to these neurons. A mechanistic role for reactive oxygen species is supported by observations that antioxidants confer protection from 6-hydroxydopamine. Although cell culture studies have suggested extracellular or nonmitochondrial mechanisms in 6-hydroxydopamine toxicity, the compartmentalization of oxidative injury mechanisms is incompletely defined in vivo. Transgenic mice overexpressing mitochondrial manganese superoxide dismutase or extracellular superoxide dismutase received unilateral intrastriatal injections of 6-hydroxydopamine. Mice that overexpress manganese superoxide dismutase showed significantly smaller striatal lesions than littermate controls. There were no differences in nonspecific striatal injury associated with contralateral vehicle injection. Manganese superoxide dismutase overexpression also protected against loss of neuronal cell bodies in the substantia nigra. In contrast, mice overexpressing extracellular superoxide dismutase showed no protection from 6-hydroxydopamine toxicity in either brain region. Protection of the nigrostriatal system by overexpression of manganese superoxide dismutase supports a role for mitochondrially derived superoxide in 6-hydroxydopamine toxicity. Mitochondrial oxidative stress appears to be a common mechanism among diverse models of Parkinson disease, whether involving toxins, mutated genes, or cybrid cells containing patient mitochondria. Antioxidant therapies that target this subcellular compartment may prove promising.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Chu, CT (corresponding author), UPMC Presbyterian, Dept Pathol, Rm A-516,200 Lothrop St, Pittsburgh, PA 15213 USA.	ctc4@pitt.edu	Chu, Charleen T/B-1601-2008	Chu, Charleen T/0000-0002-5052-8271	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040817] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL063700, R01 HL63700] Funding Source: Medline; NINDS NIH HHS [R01 NS040817, R01 NS40817] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Asanuma M, 1998, NEUROSCIENCE, V85, P907, DOI 10.1016/S0306-4522(97)00665-9; Barkats M, 2002, J NEUROCHEM, V82, P101, DOI 10.1046/j.1471-4159.2002.00952.x; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; Bensadoun JC, 1998, EUR J NEUROSCI, V10, P3231, DOI 10.1046/j.1460-9568.1998.00345.x; BENSHACHAR D, 1991, J NEUROCHEM, V56, P1441, DOI 10.1111/j.1471-4159.1991.tb11444.x; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Betarbet R, 2002, BRAIN PATHOL, V12, P499; Blum D, 2000, NEUROSCI LETT, V283, P193, DOI 10.1016/S0304-3940(00)00948-4; Borisenko GG, 2000, BIOCHEMISTRY-US, V39, P3392, DOI 10.1021/bi992296v; Cassarino DS, 1997, BBA-MOL BASIS DIS, V1362, P77, DOI 10.1016/S0925-4439(97)00070-7; CHANG LY, 1995, LAB INVEST, V73, P29; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E; Chu CT, 2004, EUR J BIOCHEM, V271, P2060, DOI 10.1111/j.1432-1033.2004.04132.x; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Crapo J D, 1978, Methods Enzymol, V53, P382; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; DECKER DE, 1993, RES COMMUN CHEM PATH, V79, P195; Dekker MCJ, 2003, BRAIN, V126, P1722, DOI 10.1093/brain/awg172; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Dickson DW, 2001, CURR OPIN NEUROL, V14, P423, DOI 10.1097/00019052-200108000-00001; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; Fattman CL, 2003, FREE RADICAL BIO MED, V35, P236, DOI 10.1016/S0891-5849(03)00275-2; Fattman CL, 2001, FREE RADICAL BIO MED, V31, P1198, DOI 10.1016/S0891-5849(01)00699-2; Fiskum G, 2003, ANN NY ACAD SCI, V991, P111; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; Fullerton HJ, 1998, ANN NEUROL, V44, P357, DOI 10.1002/ana.410440311; GEE P, 1989, FREE RADICAL BIO MED, V6, P271, DOI 10.1016/0891-5849(89)90054-3; GLINKA YY, 1995, EUR J PHARM-ENVIRON, V292, P329, DOI 10.1016/0926-6917(95)90040-3; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; GRAHAM DG, 1978, MOL PHARMACOL, V14, P644; Hanford LE, 2003, AM J RESP CELL MOL, V29, pS77; HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C; He Y, 2001, BRAIN RES, V909, P187, DOI 10.1016/S0006-8993(01)02681-6; Ho YS, 1998, AM J RESP CELL MOL, V18, P538, DOI 10.1165/ajrcmb.18.4.2959; Holtz WA, 2003, J BIOL CHEM, V278, P19367, DOI 10.1074/jbc.M211821200; Horbinski C, 2005, FREE RADICAL BIO MED, V38, P2, DOI 10.1016/j.freeradbiomed.2004.09.030; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; ICHITANI Y, 1994, EXP NEUROL, V130, P269, DOI 10.1006/exnr.1994.1205; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Kabuto H, 1999, NEUROCHEM RES, V24, P1543, DOI 10.1023/A:1021152115752; Keller JN, 1998, J NEUROSCI, V18, P687; Klivenyi P, 1998, NEUROBIOL DIS, V5, P253, DOI 10.1006/nbdi.1998.0191; Kulich SM, 2003, J BIOSCIENCES, V28, P83, DOI 10.1007/BF02970136; Kulich SM, 2001, J NEUROCHEM, V77, P1058, DOI 10.1046/j.1471-4159.2001.00304.x; Kunikowska G, 2001, BRAIN RES, V922, P51, DOI 10.1016/S0006-8993(01)03149-3; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; LEES GJ, 1984, BRAIN RES, V308, P155, DOI 10.1016/0006-8993(84)90928-4; Levin ED, 1998, BEHAV GENET, V28, P381, DOI 10.1023/A:1021673703129; Li QY, 2001, J NEUROCHEM, V78, P746, DOI 10.1046/j.1471-4159.2001.00457.x; Liang LP, 2000, NEUROSCIENCE, V101, P563, DOI 10.1016/S0306-4522(00)00397-3; Lotharius J, 2000, J BIOL CHEM, V275, P38581, DOI 10.1074/jbc.M005385200; Lotharius J, 1999, J NEUROSCI, V19, P1284; Maragos WF, 2000, BRAIN RES, V878, P218, DOI 10.1016/S0006-8993(00)02707-4; MARKLUND SL, 1990, METHOD ENZYMOL, V186, P260; Marti MJ, 2002, BRAIN RES, V958, P185, DOI 10.1016/S0006-8993(02)03694-6; Mazzio EA, 2004, BRAIN RES, V1004, P29, DOI 10.1016/j.brainres.2003.12.034; McGirt MJ, 2002, STROKE, V33, P2317, DOI 10.1161/01.STR.0000027207.67639.1E; MICHEL PP, 1990, J NEUROSCI RES, V26, P428, DOI 10.1002/jnr.490260405; Munoz AM, 2004, J NEUROSCI RES, V76, P551, DOI 10.1002/jnr.20107; MYTILINEOU C, 1989, BIOCHEM PHARMACOL, V38, P1872, DOI 10.1016/0006-2952(89)90426-7; OBERLEY TD, 1993, HISTOCHEM J, V25, P267, DOI 10.1007/BF00159118; Oh YJ, 1995, NEUROBIOL DIS, V2, P157, DOI 10.1006/nbdi.1995.0017; Oury TD, 2002, AM J PHYSIOL-LUNG C, V283, pL777, DOI 10.1152/ajplung.00011.2002; OURY TD, 1993, J BIOL CHEM, V268, P15394; Oury TD, 1996, LAB INVEST, V75, P617; OURY TD, 1992, P NATL ACAD SCI USA, V89, P9715, DOI 10.1073/pnas.89.20.9715; Pong K, 2000, BRAIN RES, V881, P182, DOI 10.1016/S0006-8993(00)02841-9; PRZEDBORSKI S, 1995, NEUROSCIENCE, V67, P631, DOI 10.1016/0306-4522(95)00066-R; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; Ryu EJ, 2002, J NEUROSCI, V22, P10690; SAUER H, 1994, NEUROSCIENCE, V59, P401, DOI 10.1016/0306-4522(94)90605-X; Sherer TB, 2002, J NEUROSCI, V22, P7006; Song DD, 2004, EXP NEUROL, V186, P158, DOI 10.1016/S0014-4886(03)00342-X; Soto-Otero R, 2000, J NEUROCHEM, V74, P1605, DOI 10.1046/j.1471-4159.2000.0741605.x; Storch A, 2000, J NEURAL TRANSM, V107, P281, DOI 10.1007/s007020050023; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Swerdlow RH, 1998, ANN NEUROL, V44, P873, DOI 10.1002/ana.410440605; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Tan RJ, 2004, J APPL PHYSIOL, V97, P2006, DOI 10.1152/japplphysiol.00480.2004; Thiels E, 2000, J NEUROSCI, V20, P7631; TIFFANYCASTIGLIONI E, 1982, BIOCHEM PHARMACOL, V31, P181, DOI 10.1016/0006-2952(82)90208-8; Uhl GR, 2003, MOVEMENT DISORD, V18, pS71, DOI 10.1002/mds.10578; WAKAI M, 1994, ACTA NEUROPATHOL, V88, P151; Weinberg A, 2004, BRAIN RES, V1012, P13, DOI 10.1016/j.brainres.2004.03.048; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; WEST RW, 1993, CARCINOGENESIS, V14, P285, DOI 10.1093/carcin/14.2.285; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; Wu Y, 1996, NEUROSCI LETT, V221, P69, DOI 10.1016/S0304-3940(96)13276-6; Zhu JH, 2003, BRAIN PATHOL, V13, P473; Zhu JH, 2002, AM J PATHOL, V161, P2087, DOI 10.1016/S0002-9440(10)64487-2	92	77	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18536	18542		10.1074/jbc.M413224200	http://dx.doi.org/10.1074/jbc.M413224200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15755737	Green Accepted, hybrid			2022-12-27	WOS:000228807200118
J	Obata, Y; Yamamoto, K; Miyazaki, M; Shimotohno, K; Kohno, S; Matsuyama, T				Obata, Y; Yamamoto, K; Miyazaki, M; Shimotohno, K; Kohno, S; Matsuyama, T			Role of cyclophilin B in activation of interferon regulatory factor-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; CRYSTAL-STRUCTURE; VIRUS-INFECTION; GENE INDUCTION; DNA-BINDING; IRF-3; TRANSCRIPTION; IDENTIFICATION; PATHWAY; PHOSPHORYLATION	IRF-3 is a member of the interferon regulatory factors (IRFs) and plays a principal role in the induction of interferon-beta (IFN-beta) by virus infection. Virus infection results in the phosphorylation of IRF-3 by I kappa B kinase epsilon and TANK-binding kinase 1, leading to its dimerization and association with the coactivators CREB-binding protein/p300. The IRF-3 holocomplex translocates to the nucleus, where it induces IFN-beta. In the present study, we examined the molecular mechanism of IRF-3 activation. Using bacterial two-hybrid screening, we isolated molecules that interact with IRF-3. One of these was cyclophilin B, a member of the immunophilins with a cis-trans peptidyl-prolyl isomerase activity. A GST pull-down assay suggested that one of the autoinhibition domains of IRF-3 and the peptidyl-prolyl isomerase domain of cyclophilin B are required for the binding. A knockdown of cyclophilin B expression by RNA interference resulted in the suppression of virus-induced IRF-3 phosphorylation, leading to the inhibition of the subsequent dimerization, association with CREB-binding protein, binding to the target DNA element, and induction of IFN-beta. These findings indicate that cyclophilin B plays a critical role in IRF-3 activation.	Nagasaki Univ, Dept Mol Microbiol & Immunol, Grad Sch Biomed Sci, Nagasaki 8528523, Japan; Kyoto Univ, Inst Virus Res, Sakyo Ku, Dept Viral Oncol, Kyoto 6068507, Japan	Nagasaki University; Kyoto University	Matsuyama, T (corresponding author), Nagasaki Univ, Dept Mol Microbiol & Immunol, Grad Sch Biomed Sci, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.	tosim@net.nagasaki-u.ac.jp						Dove SL, 1997, NATURE, V386, P627, DOI 10.1038/386627a0; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Hu JC, 2000, METHODS, V20, P80, DOI 10.1006/meth.1999.0908; Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x; Kay JE, 1996, BIOCHEM J, V314, P361, DOI 10.1042/bj3140361; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P9430, DOI 10.1074/jbc.273.16.9430; Mamane Y, 2000, IMMUNITY, V12, P129, DOI 10.1016/S1074-7613(00)80166-1; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; Mori M, 2004, J BIOL CHEM, V279, P9698, DOI 10.1074/jbc.M310616200; Nagata T, 2000, J IMMUNOL, V165, P4281, DOI 10.4049/jimmunol.165.8.4281; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; PRICE ER, 1994, P NATL ACAD SCI USA, V91, P3931, DOI 10.1073/pnas.91.9.3931; Qin BY, 2003, NAT STRUCT BIOL, V10, P913, DOI 10.1038/nsb1002; Rycyzyn MA, 2002, P NATL ACAD SCI USA, V99, P6790, DOI 10.1073/pnas.092160699; Rycyzyn MA, 2000, MOL ENDOCRINOL, V14, P1175, DOI 10.1210/me.14.8.1175; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; SEN GC, 1992, J BIOL CHEM, V267, P5017; Servant MJ, 2003, J BIOL CHEM, V278, P9441, DOI 10.1074/jbc.M209851200; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Suhara W, 2000, J BIOCHEM-TOKYO, V128, P301, DOI 10.1093/oxfordjournals.jbchem.a022753; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; Takahasi K, 2003, NAT STRUCT BIOL, V10, P922, DOI 10.1038/nsb1001; VILCEK J, 1996, VIROLOGY, P375; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	29	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18355	18360		10.1074/jbc.M501684200	http://dx.doi.org/10.1074/jbc.M501684200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15764595	hybrid			2022-12-27	WOS:000228807200096
J	Yamada, T; Carson, AR; Caniggia, I; Umebayashi, K; Yoshimori, T; Nakabayashi, K; Scherer, SW				Yamada, T; Carson, AR; Caniggia, I; Umebayashi, K; Yoshimori, T; Nakabayashi, K; Scherer, SW			Endothelial nitric-oxide synthase antisense (NOS3AS) gene encodes an autophagy-related protein (APG9-like2) highly expressed in trophoblast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLE TARGETING PATHWAY; SUSCEPTIBILITY LOCUS; MAMMALIAN-CELLS; ENOS-GENE; PREECLAMPSIA; YEAST; MEMBRANE; BECLIN-1; TUMORIGENESIS; DEGRADATION	Macroautophagy is an intracellular degradation system for the majority of proteins and some organelles that is conserved in all eukaryotic species. The precise role of autophagy in mammalian development and potential involvement in disease remain to be discerned. Yeast Atg9p is the first integral membrane protein shown to be essential for the cytoplasm to vacuole targeting (Cvt) pathway and autophagy, whereas its mammalian functional orthologue has yet to be identified. We have identified two human genes homologous to yeast Atg9p and designated these as APG9L1 and APG9L2. We have previously identified APG9L2 as NOS3AS, which participates in the post-transcriptional regulation of the endothelial nitric-oxide synthase (NOS3) gene on chromosome 7 through its antisense overlap. In human adult tissues, APG9L1 was ubiquitously expressed, whereas APG9L2 was highly expressed in placenta (trophoblast cells) and pituitary gland. In transient transfection assays we found that both proteins were primarily localized to the perinuclear region and also scattered throughout the cytosol as dots, a subset of which colocalized with an autophagosome-specific marker LC3 under starvation conditions. Finally, by the small interfering RNA-mediated knockdown of APG9L1 in HeLa cells, we demonstrated that APG9L1 is essential for starvation-induced autophagosome formation. In addition, APG9L2 can functionally complement APG9L1 in this process. These results, taken together with those of phylogenetic and sequence analyses, suggest that both APG9L1 and APG9L2 are functionally orthologous to the yATG9 in autophagosome formation. Moreover, APG9L2 is a vertebrate-specific gene that may have gained critical roles in mammalian-specific developmental events, such as placentation, through rapid evolution.	Hosp Sick Children, Program Genet & Genom Biol, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5G 2M9, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Dev & Fetal Hlth, Toronto, ON M5G 1X5, Canada; Natl Inst Genet, Dept Cell Genet, Mishima, Shizuoka 4110801, Japan	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Scherer, SW (corresponding author), Hosp Sick Children, Program Genet & Genom Biol, Res Inst, Rm 9107,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	steve@genet.sickkids.on.ca	Yamada, Takahiro/A-4001-2011; Scherer, Stephen W./B-3785-2013; Caniggia, Isabella/G-6466-2013	Scherer, Stephen W./0000-0002-8326-1999; Caniggia, Isabella/0000-0001-7340-2359				Arngrimsson R, 1999, HUM MOL GENET, V8, P1799, DOI 10.1093/hmg/8.9.1799; Arngrimsson R, 1997, AM J HUM GENET, V61, P354, DOI 10.1086/514843; Doelling JH, 2002, J BIOL CHEM, V277, P33105, DOI 10.1074/jbc.M204630200; Emanuelsson O, 2001, METHOD CELL BIOL, V65, P175, DOI 10.1016/S0091-679X(01)65011-8; Guo GL, 1999, HUM GENET, V105, P641, DOI 10.1007/s004390051156; Hanaoka H, 2002, PLANT PHYSIOL, V129, P1181, DOI 10.1104/pp.011024; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Lade JA, 1999, HYPERTENS PREGNANCY, V18, P81, DOI 10.3109/10641959909009613; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Lewis I, 1999, AM J HUM GENET, V64, P310, DOI 10.1086/302179; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Marino G, 2003, J BIOL CHEM, V278, P3671, DOI 10.1074/jbc.M208247200; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Reggiori F, 2004, DEV CELL, V6, P79, DOI 10.1016/S1534-5807(03)00402-7; Robb GB, 2004, J BIOL CHEM, V279, P37982, DOI 10.1074/jbc.M400271200; Scherer SW, 2003, SCIENCE, V300, P767, DOI 10.1126/science.1083423; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Sun K, 1997, ENDOCRINOLOGY, V138, P4912, DOI 10.1210/en.138.11.4912; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tucker KA, 2003, J BIOL CHEM, V278, P48445, DOI 10.1074/jbc.M309238200; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	37	90	138	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18283	18290		10.1074/jbc.M413957200	http://dx.doi.org/10.1074/jbc.M413957200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15755735	hybrid			2022-12-27	WOS:000228807200087
J	Watanabe, Y; Takano, M; Yoshida, M				Watanabe, Y; Takano, M; Yoshida, M			ATP binding to nucleotide binding domain (NBD)1 of the ClpB chaperone induces motion of the long coiled-coil, stabilizes the hexamer, and activates NBD2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE HSP104; HEAT-INACTIVATED PROTEINS; THERMUS-THERMOPHILUS; AGGREGATED PROTEINS; MITOCHONDRIAL HSP78; FLUORESCENT-PROBE; ESCHERICHIA-COLI; SITES; DNAK; MECHANISM	The molecular chaperone ClpB can rescue the heat-damaged proteins from an aggregated state in cooperation with other chaperones. It has two nucleotide binding domains (NBD1 and NBD2) and forms a hexamer ring in a manner dependent on ATP binding to NBD1. In the crystal structure of ClpB with both NBDs filled by nucleotides, the linker between two NBDs forms an 85-angstrom-long coiled-coil that extends on the outside of the hexamer and leans to NBD1. To probe the possible motion of the coiled-coil, we tested the accessibility of a labeling reagent, fluorescence change of a labeled dye, and cross-linking between the coiled-coil and NBD1 by using the mutants with defective NBD1 or NBD2. The results suggest that the coiled-coil is more or less parallel to the main body of ClpB in the absence of nucleotide and that ATP binding to NBD1 brings it to the leaning position as seen in the crystal structure. This motion results in stabilization of the hexamer form of ClpB and promotion of ATP hydrolysis at NBD2.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan	Tokyo Institute of Technology	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Nagatsuta 4259,R-1, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp						Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Hattendorf DA, 2002, P NATL ACAD SCI USA, V99, P2732, DOI 10.1073/pnas.261693199; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIRATSUKA T, 1993, J BIOL CHEM, V268, P24742; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Krzewska J, 2001, J MOL BIOL, V314, P901, DOI 10.1006/jmbi.2001.5190; Krzewska J, 2001, FEBS LETT, V489, P92, DOI 10.1016/S0014-5793(00)02423-6; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Lum R, 2004, J BIOL CHEM, V279, P29139, DOI 10.1074/jbc.M403777200; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Neuwald AF, 1999, GENOME RES, V9, P27; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schlee S, 2001, J MOL BIOL, V306, P889, DOI 10.1006/jmbi.2001.4455; Schlieker C, 2004, NAT STRUCT MOL BIOL, V11, P607, DOI 10.1038/nsmb787; Stiggall D L, 1979, Methods Enzymol, V55, P308; TOYOOKA T, 1985, ANAL CHEM, V57, P1931, DOI 10.1021/ac00286a032; Watanabe Y, 2004, J BIOL CHEM, V279, P15723, DOI 10.1074/jbc.M308782200; Watanabe YH, 2000, J BIOL CHEM, V275, P12388, DOI 10.1074/jbc.275.17.12388; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; Weibezahn J, 2004, CELL, V119, P653, DOI 10.1016/j.cell.2004.11.027; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	28	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24562	24567		10.1074/jbc.M414623200	http://dx.doi.org/10.1074/jbc.M414623200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15809298	hybrid			2022-12-27	WOS:000230114000034
J	Bomberger, JM; Spielman, WS; Hall, CS; Weinman, EJ; Parameswaran, N				Bomberger, JM; Spielman, WS; Hall, CS; Weinman, EJ; Parameswaran, N			Receptor activity-modifying protein (RAMP) isoform-specific regulation of adrenomedullin receptor trafficking by NHERF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; BETA(2)-ADRENERGIC RECEPTOR; MEDIATED INHIBITION; PARATHYROID-HORMONE; BINDING; INTERNALIZATION; EXCHANGE; COMPLEX; FAMILY; DOMAIN	Receptor activity-modifying proteins (RAMPs 1-3) are single transmembrane accessory proteins critical to various G-protein coupled receptors for plasma membrane expression and receptor phenotype. A functional receptor for the vasodilatory ligand, adrenomedullin (AM), is comprised of RAMP2 or RAMP3 and calcitonin receptor-like receptor (CRLR). It is now known that RAMP3 protein-protein interactions regulate the recycling of the AM2 receptor. The major aim of this study was to identify other interaction partners of RAMP3 and determine their role in CRLR-RAMP3 trafficking. Trafficking of G-protein-coupled receptors has been shown to be regulated by the Na+/H+ exchanger regulatory factor-1 (NHERF-1), an adaptor protein containing two tandem PSD-95/Discs-large/ZO-1 homology (PDZ) domains. In HEK 293T cells expressing the AM2 receptor, the complex undergoes agonist-induced desensitization and internalization. However, in the presence of NHERF-1, although the AM receptor (CRLR/RAMP3) undergoes desensitization, the internalization of the receptor complex is blocked. Overlay assays and mutational analysis indicated that RAMP3 and NHERF-1 interact via a PDZ type I domain on NHERF-1. The internalization of the CRLR-RAMP complex was not affected by NHERF-1 when CRLR was co-expressed with RAMP1 or RAMP2. Mutation of the ezrin/radixin/moesin (ERM) domain on NHERF-1 indicated that NHERF-1 inhibits CRLR/RAMP3 complex internalization by tethering the complex to the actin cytoskeleton. When examined in a primary culture of human proximal tubule cells endogenously expressing the CRLR-RAMP3 complex and NHERF-1, the CRLR-RAMP complex desensitizes but is unable to internalize upon agonist stimulation. Knock-down of either RAMP3 or NHERF-1 by RNA interference technology enabled agonist-induced internalization of the CRLR-RAMP complex. These results, using both endogenous and overexpressed cellular models, indicate a novel function for NHERF-1 and RAMP3 in the internalization of the AM receptor and suggest additional regulatory mechanisms for receptor trafficking.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA	Michigan State University; University System of Maryland; University of Maryland Baltimore	Spielman, WS (corresponding author), Michigan State Univ, Dept Physiol, 2201 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.	spielman@msu.edu	Parameswaran, Narayanan/V-1969-2019	Parameswaran, Narayanan/0000-0002-8894-5564				Aiyar N, 2002, BIOCHEM PHARMACOL, V63, P1949, DOI 10.1016/S0006-2952(02)00990-5; AIYAR N, 1987, MOL PHARMACOL, V31, P180; Bomberger JM, 2005, J BIOL CHEM, V280, P9297, DOI 10.1074/jbc.M413786200; Brain SD, 2004, PHYSIOL REV, V84, P903, DOI 10.1152/physrev.00037.2003; Buhlmann N, 1999, ENDOCRINOLOGY, V140, P2883, DOI 10.1210/en.140.6.2883; Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Kamitani S, 1999, FEBS LETT, V448, P111, DOI 10.1016/S0014-5793(99)00358-0; Kurihara H, 2003, HYPERTENS RES, V26, pS105, DOI 10.1291/hypres.26.S105; Kuwasako K, 2000, J BIOL CHEM, V275, P29602, DOI 10.1074/jbc.M004534200; Lazar CS, 2004, MOL BIOL CELL, V15, P5470, DOI 10.1091/mbc.E04-03-0239; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; Mahon MJ, 2004, J BIOL CHEM, V279, P23550, DOI 10.1074/jbc.M313229200; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Nowak W, 2002, AM J PHYSIOL-CELL PH, V282, pC1322, DOI 10.1152/ajpcell.00561.2001; Parameswaran N, 2000, EUR J PHARMACOL, V407, P205, DOI 10.1016/S0014-2999(00)00656-7; Roh J, 2004, J BIOL CHEM, V279, P7264, DOI 10.1074/jbc.M305332200; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Sneddon WB, 2003, J BIOL CHEM, V278, P43787, DOI 10.1074/jbc.M306019200; Voltz JW, 2001, ONCOGENE, V20, P6309, DOI 10.1038/sj.onc.1204774; Weinman EJ, 2001, AM J PHYSIOL-RENAL, V281, pF374, DOI 10.1152/ajprenal.2001.281.2.F374; Xia ZQ, 2003, J BIOL CHEM, V278, P21901, DOI 10.1074/jbc.M301905200	28	54	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23926	23935		10.1074/jbc.M501751200	http://dx.doi.org/10.1074/jbc.M501751200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15805108	hybrid			2022-12-27	WOS:000229880000067
J	Wang, KW; Brems, JJ; Gamelli, RL; Ding, JW				Wang, KW; Brems, JJ; Gamelli, RL; Ding, JW			Reversibility of caspase activation and its role during glycochenodeoxycholate-induced hepatocyte apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SALT-INDUCED APOPTOSIS; FAS-INDUCED APOPTOSIS; RAT HEPATOCYTES; NEURONAL APOPTOSIS; EXPRESSION; GENE; NECROSIS; INHIBITION; RESISTANCE	The accumulation of glycochenodeoxycholate (GCDC) induced hepatocyte apoptosis in cholestasis. However, many hepatocytes still survived GCDC-induced apoptosis. The molecular mechanism for the survival of hepatocytes remains unclear. In the present study, isolated rat hepatocytes were cultured in William's E medium and treated with 50 mu M GCDC. DNA, RNA, cell lysate, and nuclear proteins were collected at different intervals for DNA fragmentation assay, reverse transcription PCR, Western blotting, and gel mobility shift assay, respectively. GCDC-induced active caspases were detected as early as 2 h by Western blotting and kinetic caspase assay, whereas hepatocyte apoptosis was found at 4 h by DNA fragmentation and terminal deoxynucleotidyl transferase-mediated dUPT nick-end labeling assay. When GCDC was removed, the increased caspases as well as NF-kappa B could be restored to control level. A1/Bfl-1 and inducible nitric oxide synthase ( iNOS) were up-regulated in 2 h of GCDC stimulation. After GCDC was removed, hepatocytes decreased expression of A1/Bfl-1, but not iNOS, to the control level. NF-kappa B activation coincided with the change of A1/Bfl-1. Survivin, cIAP1, cIAP2, XIAP, and A1/Bfl-1, but not iNOS, were down-regulated by pan-caspase inhibitor benzyloxycarbonyl-VAD- fluoromethyl ketone. In addition, benzyloxycarbonyl-VAD- fluoromethyl ketone inhibited release of cytochrome c and suppressed NF-kappa B activation. Our data suggested that caspase pathway is an important regulatory factor during hepatocyte apoptosis. GCDC-induced caspase response is reversible, which may activate anti-apoptotic genes to protect hepatocytes from apoptosis.	Loyola Univ, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA; Loyola Univ, Ctr Med, Dept Surg, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago	Wang, KW (corresponding author), Loyola Univ, Dept Cell Biol Neurobiol & Anat, Bldg 101,Rm 2726, Maywood, IL 60153 USA.	kwang1@lumc.edu						Albright CD, 2003, EXP MOL PATHOL, V74, P256, DOI 10.1016/S0014-4800(03)00002-9; Chan SL, 1999, J NEUROSCI RES, V57, P315, DOI 10.1002/(SICI)1097-4547(19990801)57:3<315::AID-JNR3>3.3.CO;2-R; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Chiou Shiun-Kwei, 2003, Med Sci Monit, V9, pPI25; Contestabile Antonio, 2002, Cerebellum, V1, P41, DOI 10.1080/147342202753203087; Conway EM, 2002, GASTROENTEROLOGY, V123, P619, DOI 10.1053/gast.2002.34753; DEBELDER AJ, 1994, J HYPERTENS, V12, P617; Denault JB, 2003, J BIOL CHEM, V278, P34042, DOI 10.1074/jbc.M305110200; Ding JW, 1997, J VIROL, V71, P9223, DOI 10.1128/JVI.71.12.9223-9230.1997; Domachowske JB, 2000, J INFECT DIS, V181, P824, DOI 10.1086/315319; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Gonzalez B, 2000, MOL CELL BIOCHEM, V207, P19, DOI 10.1023/A:1007021710825; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hatano E, 2001, GASTROENTEROLOGY, V120, P1251, DOI 10.1053/gast.2001.23239; Hofmann AF, 2002, LIVER, V22, P14, DOI 10.1034/j.1600-0676.2002.00002.x; Kim PKM, 2002, ANN NY ACAD SCI, V962, P42, DOI 10.1111/j.1749-6632.2002.tb04054.x; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1998, MOL MED, V4, P179, DOI 10.1007/BF03401915; Knight TR, 2002, TOXICOL APPL PHARM, V181, P133, DOI 10.1006/taap.2002.9407; Kwon YH, 2003, J BIOL CHEM, V278, P30348, DOI 10.1074/jbc.M300996200; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LAUTERBURG BH, 1980, INT J ARTIF ORGANS, V3, P281, DOI 10.1177/039139888000300510; LI J, 1999, AM J PHYSIOL, V276, P1069; Lieser MJ, 1998, GASTROENTEROLOGY, V115, P693, DOI 10.1016/S0016-5085(98)70149-0; McNaughton L, 2002, P NATL ACAD SCI USA, V99, P17161, DOI 10.1073/pnas.0134112100; Muzio M, 1998, INT J CLIN LAB RES, V28, P141, DOI 10.1007/s005990050035; Newton K, 2003, GENE DEV, V17, P819, DOI 10.1101/gad.1077403; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Park IC, 1997, ANTICANCER RES, V17, P4619; Qi L, 2000, APOPTOSIS, V5, P379, DOI 10.1023/A:1009695811147; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Schoemaker MH, 2003, J HEPATOL, V39, P153, DOI 10.1016/S0168-8278(03)00214-9; Schoemaker MH, 2002, J HEPATOL, V36, P742, DOI 10.1016/S0168-8278(02)00063-6; Sodeman T, 2000, AM J PHYSIOL-GASTR L, V278, pG992, DOI 10.1152/ajpgi.2000.278.6.G992; Sola S, 2002, CLIN SCI, V103, P475, DOI 10.1042/CS20020196; Tatton WG, 1996, NEUROLOGY, V47, pS171, DOI 10.1212/WNL.47.6_Suppl_3.171S; Thompson MB, 1996, TOXICOL PATHOL, V24, P62, DOI 10.1177/019262339602400109; Tzeng E, 1998, SURGERY, V124, P278, DOI 10.1067/msy.1998.90569; Wang CY, 1999, MOL CELL BIOL, V19, P5923; XIE QW, 1994, J BIOL CHEM, V269, P4705; Xiong SG, 2003, J BIOL CHEM, V278, P17646, DOI 10.1074/jbc.M210905200; Zeid IM, 1997, HEPATOLOGY, V25, P81, DOI 10.1053/jhep.1997.v25.pm0008985269; ZEISEL SH, 1995, ADV EXP MED BIOL, V375, P65	47	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23490	23495		10.1074/jbc.M411607200	http://dx.doi.org/10.1074/jbc.M411607200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15767249	hybrid			2022-12-27	WOS:000229880000012
J	Jhandier, MN; Kruglov, EA; Lavoie, EG; Sevigny, J; Dranoff, JA				Jhandier, MN; Kruglov, EA; Lavoie, EG; Sevigny, J; Dranoff, JA			Portal fibroblasts regulate the proliferation of bile duct epithelia via expression of NTPDase2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLANGIOCYTE GROWTH; BILIARY; CELLS; RECEPTORS; CLONING; LIVER; URSODEOXYCHOLATE; MODULATION; ACTIVATION; SECRETION	Bile duct epithelia are the target of a number of "cholangiopathies" characterized by disordered bile ductular proliferation. Although mechanisms for bile ductular proliferation are unknown, recent evidence suggests that extracellular nucleotides regulate cell proliferation via activation of P2Y receptors. Portal fibroblasts may regulate bile duct epithelial P2Y receptors via expression of the ecto-nucleotidase NTPDase2. Thus, we tested the hypothesis that portal fibroblasts regulate bile duct epithelial proliferation via expression of NTPDase2. We generated a novel co-culture model of MzChA-1 human cholangiocarcinoma cells and primary portal fibroblasts. Cell proliferation was measured by bromodeoxyuridine uptake. NTPDase2 expression was assessed by immunofluorescence and quantitative real-time reverse transcription PCR. NTPDase2 expression in portal fibroblasts was blocked using short interfering RNA. NTPDase2 overexpression in portal myofibroblasts isolated from bile duct-ligated rats was achieved by cDNA transfection. Co-culture of Mz-ChA-1 cells with portal fibroblasts decreased their proliferation to 26% of control. Similar decreases in Mz-ChA-1 proliferation were induced by the soluble ecto-nucleotidase apyrase and the P2 receptor inhibitor suramin. The proliferation of Mz-ChA-1 cells returned to baseline when NTPDase2 expression in portal fibroblasts was inhibited using NT-PDase2-specific short interfering RNA. Untransfected portal myofibroblasts lacking NTPDase2 had no effect on Mz-ChA-1 proliferation, yet portal myofibroblasts transfected with NTPDase2 cDNA inhibited Mz-ChA-1 proliferation. We conclude that portal fibroblasts inhibit bile ductular proliferation via expression of NTPDase2 and blockade of P2Y activation. Loss of NTPDase2 may mediate the bile ductular proliferation typical of obstructive cholestasis. This novel cross-talk signaling pathway may mediate pathologic alterations in bile ductular proliferation in other cholangiopathic conditions.	Yale Univ, Sch Med, Sect Digest Dis, New Haven, CT 06520 USA; Yale Univ, Sch Med, Yale Liver Ctr, New Haven, CT 06520 USA; Univ Laval, Ctr Rech Rheumatol & Immunol, Ste Foy, PQ G1K 7P4, Canada	Yale University; Yale University; Laval University	Dranoff, JA (corresponding author), Yale Univ, Sch Med, Sect Digest Dis, 333 Cedar St,LMP 1080, New Haven, CT 06520 USA.	jonathan.dranoff@yale.edu	Sévigny, Jean/AGH-9323-2022; Sevigny, Jean/E-8039-2012	Sévigny, Jean/0000-0003-2922-1600; Sevigny, Jean/0000-0003-2922-1600	Canadian Institutes of Health Research [49460] Funding Source: Medline; NIDDK NIH HHS [DK066287, DK02379] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK066287] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alpini G, 2002, HEPATOLOGY, V35, P1256, DOI 10.1053/jhep.2002.33541; Alpini G, 2002, HEPATOLOGY, V35, P1041, DOI 10.1053/jhep.2002.32712; Aoki S, 2004, MOL BIOL CELL, V15, P4647, DOI 10.1091/mbc.E04-01-0038; Bigonnesse F, 2004, BIOCHEMISTRY-US, V43, P5511, DOI 10.1021/bi0362222; Braun N, 2000, BIOCHEM J, V351, P639, DOI 10.1042/0264-6021:3510639; Burnstock G, 2002, ARTERIOSCL THROM VAS, V22, P364, DOI 10.1161/hq0302.105360; Chadwick BP, 1998, GENOMICS, V50, P357, DOI 10.1006/geno.1998.5317; Dranoff JA, 2004, J INVEST MED, V52, P475, DOI 10.1136/jim-52-07-42; Dranoff JA, 2004, AM J PHYSIOL-GASTR L, V287, pG417, DOI 10.1152/ajpgi.00294.2003; Dranoff JA, 2004, MED INTELL UNIT, P96; Dranoff JA, 2002, HEPATOLOGY, V36, P1135, DOI 10.1053/jhep.2002.36823; Dranoff JA, 2001, AM J PHYSIOL-GASTR L, V281, pG1059, DOI 10.1152/ajpgi.2001.281.4.G1059; Eichhorst ST, 2004, NAT MED, V10, P602, DOI 10.1038/nm1049; Elghazi L, 2002, P NATL ACAD SCI USA, V99, P3884, DOI 10.1073/pnas.062321799; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Everson GT, 2004, HEPATOLOGY, V40, P774, DOI 10.1002/hep.20431; Fitz JG, 2002, SEMIN LIVER DIS, V22, P211, DOI 10.1055/s-2002-34510; Friedman SL, 1999, GASTROENTEROLOGY, V117, P1244, DOI 10.1016/S0016-5085(99)70413-0; Fuster D, 2004, P NATL ACAD SCI USA, V101, P10482, DOI 10.1073/pnas.0403930101; Gerasimovskaya EV, 2002, J BIOL CHEM, V277, P44638, DOI 10.1074/jbc.M203012200; Glaser S, 2000, HEPATOLOGY, V32, P17; Grzmil M, 2003, AM J PATHOL, V163, P543, DOI 10.1016/S0002-9440(10)63682-6; ISHII M, 1989, GASTROENTEROLOGY, V97, P1236, DOI 10.1016/0016-5085(89)91695-8; Kanno N, 2002, HEPATOLOGY, V35, P1329, DOI 10.1053/jhep.2002.33330; KARPEN SJ, 2001, LIVER DIS CHILDREN, P3; KELLER BB, 2004, HURSTS HEART, P155; Kittel A, 2004, J HISTOCHEM CYTOCHEM, V52, P861, DOI 10.1369/jhc.3A6167.2004; Kruglov EA, 2002, J INVEST MED, V50, P179, DOI 10.2310/6650.2002.33431; Kuehn EW, 2002, AM J PHYSIOL-RENAL, V283, pF1326, DOI 10.1152/ajprenal.00166.2002; Kukulski F, 2005, Purinergic Signal, V1, P193, DOI 10.1007/s11302-005-6217-x; Lavoie EG, 2004, BIOCHEM PHARMACOL, V67, P1917, DOI 10.1016/j.bcp.2004.02.012; Lazaridis KN, 2004, GASTROENTEROLOGY, V127, P1565, DOI 10.1053/j.gastro.2004.08.006; LeSage G, 2001, LIVER, V21, P73, DOI 10.1034/j.1600-0676.2001.021002073.x; Libbrecht L, 2002, LIVER, V22, P252, DOI 10.1046/j.0106-9543.2002.01674.x; MCGILL JM, 1994, GASTROENTEROLOGY, V107, P236, DOI 10.1016/0016-5085(94)90082-5; Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860; Okada H, 2000, KIDNEY INT, V58, P587, DOI 10.1046/j.1523-1755.2000.00205.x; Park JM, 2002, CAMPBELLS UROLOGY, P1737; Ramadori G, 2002, LIVER, V22, P283, DOI 10.1034/j.1600-0676.2002.01726.x; ROMAN J, 1998, FISHMANS PULM DIS DI, P73; Roman RM, 1996, AM J PHYSIOL-GASTR L, V271, pG239, DOI 10.1152/ajpgi.1996.271.2.G239; Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015; Selman M, 2001, RESP RES, V3, DOI 10.1186/rr175; Shigetani Y, 2002, SCIENCE, V296, P1316, DOI 10.1126/science.1068310; SHIMOKURA GH, 1995, GASTROENTEROLOGY, V109, P965, DOI 10.1016/0016-5085(95)90407-7; Smyth I, 2004, P NATL ACAD SCI USA, V101, P13560, DOI 10.1073/pnas.0402760101; Sneddon P, 1999, PROG BRAIN RES, V120, P11; Soares-Da-Silva P, 2004, FASEB J, V18, P1489, DOI 10.1096/fj.04-1787com; Somasiri A, 2001, J CELL SCI, V114, P1125; Strazzabosco M, 2000, J GASTROEN HEPATOL, V15, P244, DOI 10.1046/j.1440-1746.2000.02091.x; Tadlock L, 2003, AM J PHYSIOL-GASTR L, V284, pG924, DOI 10.1152/ajpgi.00355.2002	51	86	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22986	22992		10.1074/jbc.M412371200	http://dx.doi.org/10.1074/jbc.M412371200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15799977	hybrid			2022-12-27	WOS:000229741800053
J	Wang, J; Liu, H; Lin, CM; Aladjem, MI; Epner, EM				Wang, J; Liu, H; Lin, CM; Aladjem, MI; Epner, EM			Targeted deletion of the chicken beta-globin regulatory elements reveals a cooperative gene silencing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; RNA-POLYMERASE-II; OPEN CHROMATIN-STRUCTURE; DEVELOPMENTAL REGULATION; HYPERSENSITIVE SITES; HISTONE ACETYLATION; DNA METHYLATION; DELTA-GLOBIN; EXPRESSION; TRANSCRIPTION	The chicken beta-globin locus represents a well characterized system to study the role of both proximal and distal regulatory elements in a eukaryotic multigene domain. The function of the chicken beta(A)/epsilon-intergenic enhancer and upstream regulatory elements 5'-HS1 and 5'-HS2 were studied using a gene targeting approach in chicken DT40 cells followed by microcell-mediated chromosome transfer into human erythroleukemia cells ( K562). These regulatory elements all repressed expression of the rho- and beta(H)-chicken globin genes in the chromosome transfer assay. No rho- or beta(H)-globin gene expression was detected in K562 cells containing the chicken chromosome without deletions, whereas rho- and beta(H)-mRNA was activated in K562 cells containing chicken chromosomes with deletions of the intergenic enhancers, 5'-HS1 and 5'-HS2. Transcriptional activation of the rho- and beta(H)-globin genes correlated with hyperacetylation of histones H3 and H4, loss of histone H3 lysine 9 methylation, and binding of RNA polymerase II to the gene promoters. Surprisingly, the status of CpG dinucleotide methylation at the promoters did not correlate with the transcriptional status of the genes. Our results using a chromosomal transfer assay demonstrate an identical silencing function for these regulatory elements, which suggests they function as part of a common silencing pathway or complex.	Oregon Hlth & Sci Univ, Dept Med, Oregon Canc Inst, Ctr Hematol Malignancies, Portland, OR 97239 USA; NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA	Oregon Health & Science University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Epner, EM (corresponding author), Oregon Hlth & Sci Univ, Dept Med, Oregon Canc Inst, Ctr Hematol Malignancies, Portland, OR 97239 USA.	epnere@ohsu.edu	Aladjem, Mirit/G-2169-2010	Aladjem, Mirit/0000-0002-1875-3110	NATIONAL CANCER INSTITUTE [ZIABC010411, Z01BC010411] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056798] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRUZZO LV, 1994, J BIOL CHEM, V269, P32565; Bender MA, 1998, BLOOD, V92, P4394, DOI 10.1182/blood.V92.11.4394.423k48_4394_4403; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; Bender MA, 2001, BLOOD, V98, P2022, DOI 10.1182/blood.V98.7.2022; Brand M, 2004, NAT STRUCT MOL BIOL, V11, P73, DOI 10.1038/nsmb713; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Bulger M, 2002, CURR OPIN GENET DEV, V12, P170, DOI 10.1016/S0959-437X(02)00283-6; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; Dieken ES, 1996, NAT GENET, V12, P174, DOI 10.1038/ng0296-174; Donda A, 1996, EUR J IMMUNOL, V26, P493, DOI 10.1002/eji.1830260232; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; Epner E, 1998, MOL CELL, V2, P447, DOI 10.1016/S1097-2765(00)80144-6; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; FOLEY KP, 1994, P NATL ACAD SCI USA, V91, P7252, DOI 10.1073/pnas.91.15.7252; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GLAUBER JG, 1991, MOL CELL BIOL, V11, P4690, DOI 10.1128/MCB.11.9.4690; GROUDINE M, 1981, CELL, V24, P393, DOI 10.1016/0092-8674(81)90329-9; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Jackson DA, 2003, NUCLEIC ACIDS RES, V31, P1180, DOI 10.1093/nar/gkg217; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Johnson KD, 2001, MOL CELL, V8, P465, DOI 10.1016/S1097-2765(01)00309-4; Klebe RJ, 1996, BIOTECHNIQUES, V21, P1094; Kyrylenko S, 2003, CELL MOL LIFE SCI, V60, P1990, DOI 10.1007/s00018-003-3090-z; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Liu H, 2004, BLOOD, V104, P2505, DOI 10.1182/blood-2004-02-0483; MASON MM, 1995, MOL CELL BIOL, V15, P407, DOI 10.1128/MCB.15.1.407; MCGHEE JD, 1979, NATURE, V280, P419, DOI 10.1038/280419a0; MOOKERJEE B, 1992, BLOOD, V79, P820; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; Mutskov VJ, 2002, GENE DEV, V16, P1540, DOI 10.1101/gad.988502; Nahlik KW, 2003, ACTA BIOCHIM POL, V50, P667; Oberley MJ, 2003, J BIOL CHEM, V278, P42466, DOI 10.1074/jbc.M307733200; Peterson KR, 1996, P NATL ACAD SCI USA, V93, P6605, DOI 10.1073/pnas.93.13.6605; Poddie D, 2003, HEMOGLOBIN, V27, P219, DOI 10.1081/HEM-120026046; Prioleau MN, 1999, EMBO J, V18, P4035, DOI 10.1093/emboj/18.14.4035; Prioleau MN, 2003, MOL CELL BIOL, V23, P3536, DOI 10.1128/MCB.23.10.3536-3549.2003; RAICH N, 1992, BLOOD, V79, P861; Recillas-Targa F, 2001, CRIT REV EUKAR GENE, V11, P227; Reik A, 1998, MOL CELL BIOL, V18, P5992, DOI 10.1128/MCB.18.10.5992; REITMAN M, 1990, NATURE, V348, P749, DOI 10.1038/348749a0; REITMAN M, 1995, NUCLEIC ACIDS RES, V23, P1790, DOI 10.1093/nar/23.10.1790; REITMAN M, 1990, MOL CELL BIOL, V10, P2774, DOI 10.1128/MCB.10.6.2774; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; Sawado T, 2003, GENE DEV, V17, P1009, DOI 10.1101/gad.1072303; Singal R, 2002, BLOOD, V100, P4217, DOI 10.1182/blood-2002-02-0457; Taniuchi I, 2002, MOL CELL, V10, P1083, DOI 10.1016/S1097-2765(02)00735-9; Wandersee NJ, 1996, MOL CELL BIOL, V16, P236; WANG J, 1991, MOL CELL BIOL, V11, P75, DOI 10.1128/MCB.11.1.75; WEINTRAUB H, 1994, GENE DEV, V8, P2203, DOI 10.1101/gad.8.18.2203; YOUNG K, 1985, NUCLEIC ACIDS RES, V13, P5203, DOI 10.1093/nar/13.14.5203; Zou YR, 2001, NAT GENET, V29, P332, DOI 10.1038/ng750	58	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23340	23348		10.1074/jbc.M501161200	http://dx.doi.org/10.1074/jbc.M501161200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15824098	hybrid			2022-12-27	WOS:000229741800093
J	Kim, H; Ki, H; Park, HS; Kim, K				Kim, H; Ki, H; Park, HS; Kim, K			Presenilin-1 D257A and D385A mutants fail to cleave notch in their endoproteolyzed forms, but only presenilin-1 D385A mutant can restore its gamma-secretase activity with the compensatory overexpression of normal C-terminal fragment gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; INTRACELLULAR DOMAIN; INTRAMEMBRANE PROTEOLYSIS; ALZHEIMERS-DISEASE; COMPLEX; PEN-2; NICASTRIN; LOCALIZATION; APH-1; APP	The enzyme gamma-secretase is involved in the cleavage of several type I membrane proteins, such as Notch 1 and amyloid precursor protein. Presenilin-1 (PS-1) is one of the critical integral membrane protein components of the gamma-secretase complex and is processed endoproteolytically, generating N- and C-terminal fragments (NTF and CTF, respectively). PS-1 is also known to incorporate into a high molecular weight complex by binding to other gamma- secretase components such as Nicastrin, Aph-1, and Pen-2. Mutations on PS-1 can alter the effects of gamma- secretase on its many substrates to different extents. Here, we showed that PS-1 mutants have a different activity for Notch cleavage, which depended on the PS-1 mutation site. We demonstrated that defective PS-1 mutants located in CTF, i. e. D385A and C410Y, could restore their gamma- secretase activities with the compensatory overexpression of wild type CTF or of minimal deleted CTF ( amino acids 349 - 467). However, the defective PS-1 D257A mutant could not restore their gamma- secretase activities with the compensatory overexpression of wild type NTF. In comparison, both D257A NTF and D385A CTF could abolish the gamma- secretase activity of wild type and pathogenic PS-1 mutants. We also showed that PS-1 NTF but not CTF forms strong high molecular weight aggregates in SDS-PAGE. Taken together, results have shown that NTF and CTF integrate differently into high molecular weight aggregates and that PS-1 Asp-257 and Asp385 have different accessibilities in their unendoproteolyzed conformation.	Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Chonnam Natl Univ, Sch Biol Sci & Technol, Kwangju 500757, South Korea	Chonnam National University; Chonnam National University	Kim, H (corresponding author), Chonnam Natl Univ, Coll Pharm, Bldg 1-211,300 Yongbong Dong, Kwangju 500757, South Korea.	koskim@chonnam.ac.kr						Bergman A, 2004, J BIOL CHEM, V279, P45564, DOI 10.1074/jbc.M407717200; Bergman A, 2004, J BIOL CHEM, V279, P16744, DOI 10.1074/jbc.M313999200; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Cruts M, 1998, HUM MUTAT, V11, P183, DOI 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.3.CO;2-M; Crystal AS, 2004, BIOCHEMISTRY-US, V43, P3555, DOI 10.1021/bi0361214; Czech C, 2000, PROG NEUROBIOL, V60, P363, DOI 10.1016/S0301-0082(99)00033-7; da Costa CA, 2003, J BIOL CHEM, V278, P12064, DOI 10.1074/jbc.M212379200; DE SB, 1999, NATURE, V398, P518; De Strooper B, 2001, J CELL BIOL, V152, pF17, DOI 10.1083/jcb.152.4.F17; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Fluhrer R, 2004, J BIOL CHEM, V279, P1585, DOI 10.1074/jbc.M306653200; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Gu YJ, 2004, J BIOL CHEM, V279, P31329, DOI 10.1074/jbc.M401548200; Hebert SS, 2003, FEBS LETT, V550, P30, DOI 10.1016/S0014-5793(03)00813-5; Iwatsubo T, 2004, CURR OPIN NEUROBIOL, V14, P379, DOI 10.1016/j.conb.2004.05.010; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Knappenberger KS, 2004, BIOCHEMISTRY-US, V43, P6208, DOI 10.1021/bi036072v; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Laudon H, 2004, J BIOL CHEM, V279, P23925, DOI 10.1074/jbc.M401277200; Laudon H, 2004, J NEUROCHEM, V89, P44, DOI 10.1046/j.1471-4159.2003.02298.x; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Levitan D, 2001, P NATL ACAD SCI USA, V98, P12186, DOI 10.1073/pnas.211321898; Lleo A, 2003, J BIOL CHEM, V278, P47370, DOI 10.1074/jbc.M308480200; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Murakami D, 2003, ONCOGENE, V22, P1511, DOI 10.1038/sj.onc.1206298; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Rogaeva EA, 2001, NEUROLOGY, V57, P621, DOI 10.1212/WNL.57.4.621; Ross DA, 2001, MOL CELL BIOL, V21, P7537, DOI 10.1128/MCB.21.22.7537-7544.2001; Rubinsztein DC, 1997, PROG NEUROBIOL, V52, P447, DOI 10.1016/S0301-0082(97)00014-2; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Six E, 2003, P NATL ACAD SCI USA, V100, P7638, DOI 10.1073/pnas.1230693100; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Takasugi N, 2002, J BIOL CHEM, V277, P50198, DOI 10.1074/jbc.M205352200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Xia XF, 2002, P NATL ACAD SCI USA, V99, P8760, DOI 10.1073/pnas.132045399; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	53	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22462	22472		10.1074/jbc.M502769200	http://dx.doi.org/10.1074/jbc.M502769200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15797863	hybrid			2022-12-27	WOS:000229557900092
J	Koo, BK; Yoon, KJ; Yoo, KW; Lim, HS; Song, R; So, JH; Kim, CH; Kong, YY				Koo, BK; Yoon, KJ; Yoo, KW; Lim, HS; Song, R; So, JH; Kim, CH; Kong, YY			Mind bomb-2 is an E3 ligase for notch ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE; EMBRYONIC LETHALITY; DOWN-REGULATION; DEFECTS; PROTEIN; ACTIVATION; HOMOLOG; DIFFERENTIATION; INTERNALIZATION; DEGRADATION	The zebrafish gene, mind bomb (mib), encodes a protein that positively regulates of the Delta-mediated Notch signaling. It interacts with the intracellular domain of Delta to promote its ubiquitination and endocytosis. In our search for the mouse homologue of zebrafish mind bomb, we cloned two homologues in the mouse genome: a mouse orthologue (mouse mib1) and a paralogue, named mind bomb-2 (mib2), which is evolutionarily conserved from Drosophila to human. Both Mib1 and Mib2 have an E3 ubiquitin ligase activity in their C-terminal RING domain and interact with Xenopus Delta (XD) via their N-terminal region. Mib2 is also able to ligate ubiquitin to XD and shift the membrane localization of Delta to intracellular vesicles. Importantly, Mib2 rescues both the neuronal and vascular defects in the zebrafish mib(ta52b) mutants. In contrast to the functional similarities between Mib1 and Mib2, mib2 is highly expressed in adult tissues, but almost not at all in embryos, whereas mib1 is abundantly expressed in both embryos and adult tissues. These data suggest that Mib2 has functional similarities to Mib1, but might have distinct roles in Notch signaling as an E3 ubiquitin ligase.	Chungnam Natl Univ, Dept Biol, Taejon 305764, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, Kyungbuk, South Korea	Chungnam National University; Pohang University of Science & Technology (POSTECH)	Kim, CH (corresponding author), Chungnam Natl Univ, Dept Biol, Taejon 305764, South Korea.	zebrakim@cnu.ac.kr; ykong@postech.ac.kr	Koo, Bon-Kyoung/V-5219-2017; Yoon, Ki-Jun/S-8170-2018	Koo, Bon-Kyoung/0000-0002-4134-8033; Yoon, Ki-Jun/0000-0003-2985-2541; Lim, Hyoung Soo/0000-0001-6268-8208; Kim, Cheol-Hee/0000-0002-3019-0699				Aguilar RC, 2003, CURR OPIN CELL BIOL, V15, P184, DOI 10.1016/S0955-0674(03)00010-3; Annaert W, 1999, TRENDS NEUROSCI, V22, P439, DOI 10.1016/S0166-2236(99)01455-1; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Deblandre GA, 2001, DEV CELL, V1, P795, DOI 10.1016/S1534-5807(01)00091-0; Duarte A, 2004, GENE DEV, V18, P2474, DOI 10.1101/gad.1239004; Dunwoodie SL, 2002, DEVELOPMENT, V129, P1795; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Gale NW, 2004, P NATL ACAD SCI USA, V101, P15949, DOI 10.1073/pnas.0407290101; Haddon C, 1998, DEVELOPMENT, V125, P4637; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hitoshi S, 2002, GENE DEV, V16, P846, DOI 10.1101/gad.975202; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046; Jin YJ, 2002, J BIOL CHEM, V277, P46980, DOI 10.1074/jbc.M208585200; Kim CH, 1996, NEUROSCI LETT, V216, P109, DOI 10.1016/0304-3940(96)13021-4; KRAMER H, 2000, SCI STKE; KREBS LT, 2000, GENE DEV, V18, P2469; Kusumi K, 1998, NAT GENET, V19, P274, DOI 10.1038/961; Lai EC, 2001, DEV CELL, V1, P783, DOI 10.1016/S1534-5807(01)00092-2; Lai EC, 2002, CURR BIOL, V12, pR74, DOI 10.1016/S0960-9822(01)00679-0; Lawson ND, 2001, DEVELOPMENT, V128, P3675; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Moore KA, 2004, CURR OPIN HEMATOL, V11, P107, DOI 10.1097/01.moh.0000133652.06863.47; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nam Y, 2003, J BIOL CHEM, V278, P21232, DOI 10.1074/jbc.M301567200; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Pavlopoulos E, 2001, DEV CELL, V1, P807, DOI 10.1016/S1534-5807(01)00093-4; Pfeffer S, 2003, CELL, V112, P507, DOI 10.1016/S0092-8674(03)00118-1; Sidow A, 1997, NATURE, V389, P722, DOI 10.1038/39587; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Takeuchi T, 2003, AM J PATHOL, V163, P1395, DOI 10.1016/S0002-9440(10)63497-9; Thelu Jacques, 2002, BMC Dermatol, V2, P7, DOI 10.1186/1471-5945-2-7; THOMAS JB, 1990, FASEB J, V4, P2476, DOI 10.1096/fasebj.4.8.2185974; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723	40	76	79	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22335	22342		10.1074/jbc.M501631200	http://dx.doi.org/10.1074/jbc.M501631200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824097	hybrid			2022-12-27	WOS:000229557900079
J	Lu, G; Seta, KA; Millhorn, DE				Lu, G; Seta, KA; Millhorn, DE			Novel role for cyclin-dependent kinase 2 in neuregulin-induced acetylcholine receptor epsilon subunit expression in differentiated myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; ACTIVATED PROTEIN-KINASE; MOLECULAR-WEIGHT FORMS; HUMAN-MELANOMA CELLS; LARGE T-ANTIGEN; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; CDK COMPLEXES; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE	Cyclin-dependent kinases (CDKs) are a family of evolutionarily conserved serine/threonine kinases. CDK2 acts as a checkpoint for the G(1)/S transition in the cell cycle. Despite a down-regulation of CDK2 activity in postmitotic cells, many cell types, including muscle cells, maintain abundant levels of CDK2 protein. This led us to hypothesize that CDK2 may have a function in postmitotic cells. We show here for the first time that CDK2 can be activated by neuregulin (NRG) in differentiated C2C12 myotubes. In addition, this activity is required for expression of the acetylcholine receptor (AChR) epsilon subunit. The switch from the fetal AChR gamma subunit to the adult-type AChR epsilon is required for synapse maturation and the neuromuscular junction. Inhibition of CDK2 activity with either the specific CDK2 inhibitory peptide Tat-LFG or by RNA interference abolished neuregulin-induced AChR epsilon expression. Neuregulin-induced activation of CDK2 also depended on the ErbB receptor, MAPK, and PI3K, all of which have previously been shown to be required for AChR epsilon expression. Neuregulin regulated CDK2 activity through coordinating phosphorylation of CDK2 on Thr-160, accumulation of CDK2 in the nucleus, and down-regulation of the CDK2 inhibitory protein p27 in the nucleus. In addition, we also observed a novel mechanism of regulation of CDK2 activity by a low molecular weight variant of cyclin E in response to NRG. These findings establish CDK2 as an intermediate molecule that integrates NRG-activated signals from both the MAPK and PI3K pathways to AChR epsilon expression and reveal an undiscovered physiological role for CDK2 in postmitotic cells.	Univ Cincinnati, Genome Res Inst, Dept Genome Sci, Cincinnati, OH 45237 USA	University of Cincinnati	Millhorn, DE (corresponding author), Univ Cincinnati, Genome Res Inst, Dept Genome Sci, 2180 E Galbraith Rd, Cincinnati, OH 45237 USA.	david.millhorn@uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059945, R37HL033831, R01HL033831, R01HL066312] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 66312, HL 33831, HL 59945] Funding Source: Medline; NIDDK NIH HHS [DK 58811] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMCZEWSKI JP, 1993, J VIROL, V67, P6551, DOI 10.1128/JVI.67.11.6551-6557.1993; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Akli S, 2004, BREAST CANCER RES, V6, P188, DOI 10.1186/bcr905; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Bales E, 2005, CANCER RES, V65, P692; Baliga RR, 1999, AM J PHYSIOL-HEART C, V277, pH2026, DOI 10.1152/ajpheart.1999.277.5.H2026; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Blanchard DA, 2000, ONCOGENE, V19, P4184, DOI 10.1038/sj.onc.1203761; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; Chiariello M, 2000, BIOCHEM J, V349, P869, DOI 10.1042/bj3490869; Chu CY, 2000, BBA-MOL CELL RES, V1497, P175, DOI 10.1016/S0167-4889(00)00064-1; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; Ding QM, 1998, AM J PHYSIOL-CELL PH, V275, pC1193, DOI 10.1152/ajpcell.1998.275.5.C1193; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; Gladden AB, 2003, CANCER CELL, V4, P160, DOI 10.1016/S1535-6108(03)00217-4; Grim JE, 2003, TRENDS CELL BIOL, V13, P396, DOI 10.1016/S0962-8924(03)00148-X; GU Y, 1988, NEURON, V1, P117, DOI 10.1016/0896-6273(88)90195-X; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; GUO K, 1995, MOL CELL BIOL, V15, P3823; Hamburger AW, 1997, ANTICANCER RES, V17, P2197; HARPER JW, 1993, CELL, V75, P805; Harwell RM, 2000, CANCER RES, V60, P481; Hauck L, 2002, CIRC RES, V91, P782, DOI 10.1161/01.RES.0000041030.98642.41; Hinds PW, 2003, CANCER CELL, V3, P305, DOI 10.1016/S1535-6108(03)00084-9; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Jackman M, 2002, MOL BIOL CELL, V13, P1030, DOI 10.1091/mbc.01-07-0361; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Lazaro JB, 1997, J CELL SCI, V110, P1251; Le XF, 2000, CLIN CANCER RES, V6, P260; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Love S, 2003, NEUROSCI LETT, V353, P29, DOI 10.1016/j.neulet.2003.09.004; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MARTE BM, 1995, ONCOGENE, V10, P167; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Missias AC, 1997, DEVELOPMENT, V124, P5075; MORGAN DO, 1991, ANNU REV CELL DEV BI, V19, P261; Mumberg D, 1997, NUCLEIC ACIDS RES, V25, P2098, DOI 10.1093/nar/25.11.2098; Ng YP, 1997, MOL CELL NEUROSCI, V9, P132, DOI 10.1006/mcne.1997.0613; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Pagano M, 2004, CELL, V118, P535, DOI 10.1016/j.cell.2004.08.013; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter DC, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.23.e101; Puricelli L, 2002, INT J CANCER, V100, P642, DOI 10.1002/ijc.10533; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; SEWING A, 1994, J CELL SCI, V107, P581; Si JT, 1996, J BIOL CHEM, V271, P19752, DOI 10.1074/jbc.271.33.19752; Si JT, 1999, MOL BRAIN RES, V67, P18, DOI 10.1016/S0169-328X(99)00028-5; Suzuki JI, 1997, NAT MED, V3, P900, DOI 10.1038/nm0897-900; Tansey MG, 1996, J CELL BIOL, V134, P465, DOI 10.1083/jcb.134.2.465; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Tedesco D, 1997, J VIROL, V71, P2217, DOI 10.1128/JVI.71.3.2217-2224.1997; USDIN TB, 1986, J CELL BIOL, V103, P493, DOI 10.1083/jcb.103.2.493; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Wang XD, 2003, ONCOGENE, V22, P769, DOI 10.1038/sj.onc.1206166; Watanabe Y, 1999, BRAIN RES, V842, P342, DOI 10.1016/S0006-8993(99)01844-2; Witzemann V, 1996, P NATL ACAD SCI USA, V93, P13286, DOI 10.1073/pnas.93.23.13286; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	86	8	8	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21731	21738		10.1074/jbc.M412498200	http://dx.doi.org/10.1074/jbc.M412498200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824106	hybrid			2022-12-27	WOS:000229557900009
J	Giangrossi, M; Zattoni, S; Tramonti, A; De Biase, D; Falconi, M				Giangrossi, M; Zattoni, S; Tramonti, A; De Biase, D; Falconi, M			Antagonistic role of H-NS and GadX in the regulation of the glutamate decarboxylase-dependent acid resistance system in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CURVED DNA; GENE-EXPRESSION; STRESS CONDITIONS; VIRF PROMOTER; PROTEIN; SHIGELLA; OPERON; REPRESSION; ACTIVATOR; THERMOREGULATION	One of the most efficient systems of acid resistance in Escherichia coli, the gad system, is based on the coordinated action of two isoforms of glutamate decarboxylase (GadA and GadB) and of a specific glutamate/gamma-aminobutyrate antiporter (GadC). The gadA/BC genes, activated in response to acid stress and in stationary phase cells, are subjected to complex circuits of regulation involving sigma(70), sigma(S), cAMP receptor protein, H-NS, EvgAS, TorRS, GadE, GadX, GadW, and YdeO. Herein, we provide evidence that the nucleoid-associated protein H-NS directly functions as repressor of gadA, one of the structural genes, and gadX, a regulatory gene encoding one of the primary activators of the gad system. Band shift and DNase I footprints reveal that H-NS indeed binds to specific sites in the promoter regions of gadA and gadX and represses the transcription of these genes both in an in vitro system and in vivo. Moreover, we show that a maltose-binding protein MalE-GadX fusion is able to stimulate the promoter activity of gadA/BC, thus indicating that GadX is by itself able to up-regulate the gad genes and that a functional competition between H-NS and GadX takes place at the gadA promoter. Altogether, our results indicate that H-NS directly inhibits gadA and gadX transcription and, by controlling the intracellular level of the activator GadX, indirectly affects the expression of the whole gad system.	Univ Camerino, Dipartimento Biol MCA, Genet Lab, I-62032 Camerino, MC, Italy; Univ Roma La Sapienza, CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy; Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy	University of Camerino; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Sapienza University Rome	Falconi, M (corresponding author), Univ Camerino, Dipartimento Biol MCA, Genet Lab, I-62032 Camerino, MC, Italy.	maurizio.falconi@unicam.it	Falconi, Maurizio/AAW-2929-2020; De Biase, Daniela/H-3678-2019; Messier, Claude/A-2322-2008; Tramonti, Angela/K-5325-2019	Falconi, Maurizio/0000-0002-4646-6741; De Biase, Daniela/0000-0003-3536-9927; Messier, Claude/0000-0002-4791-1763; Tramonti, Angela/0000-0002-5625-1170; Giangrossi, Mara/0000-0003-3065-9327				Atlung T, 1997, MOL MICROBIOL, V24, P7, DOI 10.1046/j.1365-2958.1997.3151679.x; Brandi A, 1999, EMBO J, V18, P1653, DOI 10.1093/emboj/18.6.1653; Dame RT, 2000, NUCLEIC ACIDS RES, V28, P3504, DOI 10.1093/nar/28.18.3504; De Biase D, 1999, MOL MICROBIOL, V32, P1198, DOI 10.1046/j.1365-2958.1999.01430.x; DeBiase D, 1996, PROTEIN EXPRES PURIF, V8, P430; Dorman CJ, 2004, NAT REV MICROBIOL, V2, P391, DOI 10.1038/nrmicro883; FALCONI M, 1993, MOL MICROBIOL, V10, P273, DOI 10.1111/j.1365-2958.1993.tb01953.x; FALCONI M, 1988, MOL MICROBIOL, V2, P323, DOI 10.1111/j.1365-2958.1988.tb00035.x; Falconi M, 1998, EMBO J, V17, P7033, DOI 10.1093/emboj/17.23.7033; Falconi M, 2001, MOL MICROBIOL, V42, P439, DOI 10.1046/j.1365-2958.2001.02646.x; Foster JW, 1999, CURR OPIN MICROBIOL, V2, P170, DOI 10.1016/S1369-5274(99)80030-7; Foster JW, 2004, NAT REV MICROBIOL, V2, P898, DOI 10.1038/nrmicro1021; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; Haack KR, 2003, INFECT IMMUN, V71, P384, DOI 10.1128/IAI.71.1.384-392.2003; Hommais F, 2004, MICROBIOL-SGM, V150, P61, DOI 10.1099/mic.0.26659-0; Hommais F, 2001, MOL MICROBIOL, V40, P20, DOI 10.1046/j.1365-2958.2001.02358.x; JORDI BJAM, 1992, EMBO J, V11, P2627, DOI 10.1002/j.1460-2075.1992.tb05328.x; Lin JS, 1996, APPL ENVIRON MICROB, V62, P3094, DOI 10.1128/AEM.62.9.3094-3100.1996; LIN JS, 1995, J BACTERIOL, V177, P4097, DOI 10.1128/jb.177.14.4097-4104.1995; LUCHT JM, 1994, J BIOL CHEM, V269, P6578; Ma Z, 2004, J BACTERIOL, V186, P7378, DOI 10.1128/JB.186.21.7378-7389.2004; Ma Z, 2003, MOL MICROBIOL, V49, P1309, DOI 10.1046/j.1365-2958.2003.03633.x; Ma Z, 2002, J BACTERIOL, V184, P7001, DOI 10.1128/JB.184.24.7001-7012.2002; Masuda N, 2003, MOL MICROBIOL, V48, P699, DOI 10.1046/j.1365-2958.2003.03477.x; Merrell DS, 2002, CURR OPIN MICROBIOL, V5, P51, DOI 10.1016/S1369-5274(02)00285-0; Miller J.H., 1972, EXPT MOL GENETICS; Prosseda G, 2004, MOL MICROBIOL, V51, P523, DOI 10.1046/j.1365-2958.2003.03848.x; Rimsky S, 2001, MOL MICROBIOL, V42, P1311, DOI 10.1046/j.1365-2958.2001.02706.x; Sambrook J., 2002, MOL CLONING LAB MANU; Schroder O, 2002, BIOL CHEM, V383, P945, DOI 10.1515/BC.2002.101; Shin S, 2001, MOL MICROBIOL, V41, P1133, DOI 10.1046/j.1365-2958.2001.02570.x; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Spurio R, 1997, EMBO J, V16, P1795, DOI 10.1093/emboj/16.7.1795; TANAKA K, 1991, MOL GEN GENET, V226, P367, DOI 10.1007/BF00260648; TIPPNER D, 1994, MOL MICROBIOL, V11, P589, DOI 10.1111/j.1365-2958.1994.tb00339.x; Tramonti A, 2003, BBA-PROTEINS PROTEOM, V1647, P376, DOI 10.1016/S1570-9639(03)00098-0; Tramonti A, 2002, J BACTERIOL, V184, P2603, DOI 10.1128/JB.184.10.2603-2613.2002; Tucker DL, 2003, J BACTERIOL, V185, P3190, DOI 10.1128/JB.185.10.3190-3201.2003; TUPPER AE, 1994, EMBO J, V13, P258, DOI 10.1002/j.1460-2075.1994.tb06256.x; Waterman SR, 2003, J BACTERIOL, V185, P4644, DOI 10.1128/JB.185.15.4644-4647.2003; YAMADA H, 1990, J BIOCHEM-TOKYO, V108, P420, DOI 10.1093/oxfordjournals.jbchem.a123216; YAMASHINO T, 1995, EMBO J, V14, P594, DOI 10.1002/j.1460-2075.1995.tb07035.x; YOSHIDA T, 1993, BIOSCI BIOTECH BIOCH, V57, P1568, DOI 10.1271/bbb.57.1568	43	44	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21498	21505		10.1074/jbc.M413255200	http://dx.doi.org/10.1074/jbc.M413255200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15795232	hybrid, Green Published			2022-12-27	WOS:000229438800071
J	Hong, JW; Ryu, MS; Lim, IK				Hong, JW; Ryu, MS; Lim, IK			Phosphorylation of serine 147 of tis21/BTG2/pc3 by p-Erk1/2 induces Pin-1 binding in cytoplasm and cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL ISOMERASE PIN1; DEPENDENT PROLINE ISOMERIZATION; GROWTH-FACTOR; PROTEIN-KINASE; BREAST-CANCER; TIS21 PROTEIN; CYCLIN D1; TUMOR PROMOTERS; MESSENGER-RNA; BETA-CATENIN	Treatment of U937 cells with epidermal growth factor (EGF) induces phosphorylation of tis21 and subsequent interaction of tis21 with Pin-1, resulting in the increased cell death with mitochondrial depolarization. Ser(147) and Ser(149) residues of tis21 were strongly phosphorylated by p-Erk1/2 and p-p38(MAPK), respectively, but not by JNK. To investigate the significance of phosphorylation of the Ser147 residue, Pin-1, one of the mitotic regulators that binds to the Ser(P)/Thr(P)-Pro region, was employed. Wild type tis21 phosphorylated by p-Erk1/2 clearly increased its binding to Pin-1, but not the P148A mutant, indicating that Pin-1 was bound to the Ser(P)(147)-Pro(148) region of tis21. Transfection of tis21 significantly enhanced EGF-induced Pin-1 diffusion to cytoplasm, compared with that in the vector-transfected cells. Knockdown of tis21 expression by using shRNAi significantly inhibited EGF-induced Pin-1 diffusion, and analysis by flow cytometry after JC-1 stain and confocal microscope revealed that EGF aggravated tis21-induced mitochondrial depolarization and cell death. Furthermore, tis21 was bound to cyclin B1 and Cdc2 and inhibited its activity in vivo and in vitro. In summary, treatment of U937 cells with EGF activates Erk1/2, which in turn phosphorylates Ser147 of tis21 and induces tis21 and Pin-1 binding and mitochondrial depolarization. These data suggest, for the first time, a mechanism of how EGF can be antiproliferative in human tumor cells: binding of tis21/ BTG2/pc3 to Pin-1 or cyclin B1-Cdc2 complex and induction of mitochondrial depolarization.	Ajou Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 443721, South Korea	Ajou University	Lim, IK (corresponding author), Ajou Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 443721, South Korea.	iklim@ajou.ac.kr		Lim, In Kyoung/0000-0002-2399-607X				Ayala G, 2003, CANCER RES, V63, P6244; Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; CHURCH JG, 1988, J BIOL CHEM, V263, P4242; Duriez C, 2002, GENE, V282, P207, DOI 10.1016/S0378-1119(01)00825-3; Eales-Reynolds LJ, 2001, CYTOKINE, V16, P169, DOI 10.1006/cyto.2001.0966; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Harding A, 2003, J BIOL CHEM, V278, P16747, DOI 10.1074/jbc.M301015200; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Jakus J, 1996, ONCOGENE, V12, P2369; Joseph James D, 2003, Prog Cell Cycle Res, V5, P477; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; Lim IK, 1998, BIOCHEM MOL BIOL INT, V45, P871; Lim IK, 1998, MOL CARCINOGEN, V23, P25, DOI 10.1002/(SICI)1098-2744(199809)23:1<25::AID-MC4>3.0.CO;2-G; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Lin WJ, 2001, BIOCHEM J, V354, P635, DOI 10.1042/0264-6021:3540635; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 2002, J BIOL CHEM, V277, P2381, DOI 10.1074/jbc.C100228200; Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X; Miyashita H, 2003, ONCOL REP, V10, P1045; Miyashita H, 2003, ONCOL REP, V10, P455; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Pang R, 2004, ONCOGENE, V23, P4182, DOI 10.1038/sj.onc.1207493; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; Rippmann JF, 2000, CELL GROWTH DIFFER, V11, P409; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Ryo A, 2003, J CELL SCI, V116, P773, DOI 10.1242/jcs.00276; Ryo A, 2002, MOL CELL BIOL, V22, P5281, DOI 10.1128/MCB.22.15.5281-5295.2002; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Ryu MS, 2004, EXP CELL RES, V299, P159, DOI 10.1016/j.yexcr.2004.05.014; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Shah OJ, 2003, J BIOL CHEM, V278, P16433, DOI 10.1074/jbc.M300435200; Struckmann K, 2004, CANCER RES, V64, P1632, DOI 10.1158/0008-5472.CAN-03-1687; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; Walter SA, 1997, MOL BIOL CELL, V8, P2157, DOI 10.1091/mbc.8.11.2157; Wang WL, 2003, J BIOL CHEM, V278, P37705, DOI 10.1074/jbc.M304619200; Wei L, 2004, J CELL BIOCHEM, V91, P325, DOI 10.1002/jcb.10760; Wulf G, 2003, BREAST CANCER RES, V5, P76, DOI 10.1186/bcr572; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120	47	45	48	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21256	21263		10.1074/jbc.M500318200	http://dx.doi.org/10.1074/jbc.M500318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15788397	hybrid			2022-12-27	WOS:000229438800044
J	Kauppinen, KP; Duan, FP; Wels, JI; Manor, D				Kauppinen, KP; Duan, FP; Wels, JI; Manor, D			Regulation of the Dbl proto-oncogene by heat shock cognate protein 70 (Hsc70)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGE FACTOR; DNA-BINDING; RHO; ONCOGENE; RAC; ACTIVATION; EXPRESSION; CDC42; ATP; AUTOINHIBITION	The dbl oncogene product is the defining member of a family of onco-proteins known as Dbl guanine nucleotide exchange factors ( GEFs) that facilitate the activation of the small GTP-binding proteins Cdc42, Rac, and Rho. Oncogenic activation of proto-Dbl occurs through loss of the amino-terminal 497 residues, rendering the protein constitutively active. Because both onco- and proto-Dbl contain the structural elements required for GEF activity (i.e. the Dbl homology (DH) and pleckstrin homology (PH) domains), it is thought that the amino terminus of proto-Dbl somehow inhibits the biochemical activity of the protein. To better understand the molecular basis of this regulation, we set forth to identify cellular proteins that preferentially bind the proto-oncogenic form of Dbl. We identified the molecular chaperone heat shock cognate protein (Hsc70) as a binding partner that preferentially interacts with the proto-oncogenic form of Dbl. Dbl is complexed with Hsc70 in transfected cells, as well as in native mouse brain extracts. The interaction between Hsc70 and proto-Dbl is mediated by at least two regions in Dbl, the amino-terminal spectrin homology domain (residues 224-417) and the pleckstrin homology domain (residues 711-808). Overexpression of a dominant negative Hsc70 mutant leads to activation of proto-Dbl GEF activity, indicating that the chaperone negatively regulates proto-Dbl function in vivo. We propose that Hsc70 attenuates Dbl activity by maintaining an inactive conformation in which the amino terminus is "folded over" the catalytic DH-PH domain.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	Cornell University	Manor, D (corresponding author), Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA.	dm43@cornell.edu			NATIONAL CANCER INSTITUTE [R01CA082391, R24CA088336, R55CA082391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007158] Funding Source: NIH RePORTER; NCI NIH HHS [CA82391, CA88336] Funding Source: Medline; NIDDK NIH HHS [T32DK-007158-30] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Arbeitman MN, 2000, CELL, V101, P67, DOI 10.1016/S0092-8674(00)80624-8; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chang HC, 2002, J CELL BIOL, V159, P477, DOI 10.1083/jcb.200205086; Diehl JA, 2003, MOL CELL BIOL, V23, P1764, DOI 10.1128/MCB.23.5.1764-1774.2003; Elefant F, 1999, MOL BIOL CELL, V10, P2101, DOI 10.1091/mbc.10.7.2101; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; Hannan LA, 1998, MOL BIOL CELL, V9, P2217, DOI 10.1091/mbc.9.8.2217; Holstein SEH, 1996, J CELL BIOL, V135, P925, DOI 10.1083/jcb.135.4.925; HONING S, 1994, J CELL SCI, V107, P1185; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Johnson ER, 1999, BIOCHEMISTRY-US, V38, P10823, DOI 10.1021/bi990816g; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Lagaudriere-Gesbert C, 2002, P NATL ACAD SCI USA, V99, P1515, DOI 10.1073/pnas.042688099; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Newmyer SL, 2001, J CELL BIOL, V152, P607, DOI 10.1083/jcb.152.3.607; Niyaz Y, 2003, NUCLEIC ACIDS RES, V31, P2209, DOI 10.1093/nar/gkg303; OBrien MC, 1996, J BIOL CHEM, V271, P15874, DOI 10.1074/jbc.271.27.15874; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rajapandi T, 2000, J BIOL CHEM, V275, P22597, DOI 10.1074/jbc.M002035200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RON D, 1989, ONCOGENE, V4, P1067; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schneikert J, 2000, EMBO J, V19, P6508, DOI 10.1093/emboj/19.23.6508; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; VAN AL, 1997, GENE DEV, V11, P2295; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	46	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21638	21644		10.1074/jbc.M413984200	http://dx.doi.org/10.1074/jbc.M413984200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802271	hybrid			2022-12-27	WOS:000229438800089
J	Vives, RR; Imberty, A; Sattentau, QJ; Lortat-Jacob, H				Vives, RR; Imberty, A; Sattentau, QJ; Lortat-Jacob, H			Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RECEPTOR-BINDING; CONFORMATIONAL-CHANGES; TYPE-1 ATTACHMENT; PROTEOGLYCANS; MECHANISM; CELLS; GLYCOSAMINOGLYCANS; CHEMOKINES; INFECTION	Human immunodeficiency virus (HIV) attachment to host cells is a multi-step process that involves interaction of the viral envelope gp120 with the primary receptor CD4 and coreceptors. HIV gp120 also binds to other cell surface components, including heparan sulfate (HS), a sulfated polysaccharide whose wide interactive properties are exploited by many pathogens for attachment and concentration at the cell surface. To analyze the structural features of gp120 binding to HS, we used soluble CD4 to constrain gp120 in a specific conformation. We first found that CD4 induced conformational change of gp120, dramatically increasing binding to HS. We then showed that HS binding interface on gp120 comprised, in addition to the well characterized V3 loop, a CD4-induced epitope. This epitope is efficiently targeted by nanomolar concentrations of size-defined heparin/ HS- derived oligosaccharides. Because this domain of the protein also constitutes the binding site for the viral coreceptors, these results support an implication of HS at late stages of the virus- cell attachment process and suggest potential therapeutic applications.	Univ Grenoble 1, CNRS, Commissariat Energie Atom, Inst Biol Struct, F-38027 Grenoble, France; CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble, France; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Oxford	Lortat-Jacob, H (corresponding author), Univ Grenoble 1, CNRS, Commissariat Energie Atom, Inst Biol Struct, 41 Rue Horowitz, F-38027 Grenoble, France.	Hugues.Lortat-Jacob@ibs.fr	Vives, Romain/I-9372-2012; Imberty, Anne/P-6451-2018	Imberty, Anne/0000-0001-6825-9527				Argyris EG, 2003, J VIROL, V77, P12140, DOI 10.1128/JVI.77.22.12140-12151.2003; Basmaciogullari S, 2002, J VIROL, V76, P10791, DOI 10.1128/JVI.76.21.10791-10800.2002; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bobardt MD, 2003, IMMUNITY, V18, P27, DOI 10.1016/S1074-7613(02)00504-6; Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327; Choe H, 2003, CELL, V114, P161, DOI 10.1016/S0092-8674(03)00508-7; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; Cros S, 1997, BIOORGAN MED CHEM, V5, P1301, DOI 10.1016/S0968-0896(97)00087-4; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Hsu STD, 2004, PROTEINS, V55, P582, DOI 10.1002/prot.20061; IMBERTY A, 1999, PERSPECTIVES STRUCTU, P392; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000; Kwong PD, 2000, STRUCTURE, V8, P1329, DOI 10.1016/S0969-2126(00)00547-5; Lortat-Jacob H, 2002, P NATL ACAD SCI USA, V99, P1229, DOI 10.1073/pnas.032497699; Mikhailov D, 1997, BIOCHEM J, V328, P51, DOI 10.1042/bj3280051; Mondor I, 1998, J VIROL, V72, P3623, DOI 10.1128/JVI.72.5.3623-3634.1998; Moore JP, 2000, NAT REV MOL CELL BIO, V1, P40, DOI 10.1038/35036060; Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000; Mulloy B, 2001, CURR OPIN STRUC BIOL, V11, P623, DOI 10.1016/S0959-440X(00)00257-8; Ohshiro Y, 1996, MICROBIOL IMMUNOL, V40, P827, DOI 10.1111/j.1348-0421.1996.tb01148.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; RODERIQUEZ G, 1995, J VIROL, V69, P2233, DOI 10.1128/JVI.69.4.2233-2239.1995; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; Saphire ACS, 2001, J VIROL, V75, P9187, DOI 10.1128/JVI.75.19.9187-9200.2001; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; Sharon M, 2003, STRUCTURE, V11, P225, DOI 10.1016/S0969-2126(03)00011-X; Spillmann D, 2001, BIOCHIMIE, V83, P811, DOI 10.1016/S0300-9084(01)01290-1; Stanfield RL, 2004, STRUCTURE, V12, P193, DOI 10.1016/j.str.2004.01.003; Stone A, 2002, NAT REV DRUG DISCOV, V1, P977, DOI 10.1038/nrd959; *TRIP INC, 1997, SYBYL VERS 6 4; Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2; Vives RR, 2004, J BIOL CHEM, V279, P54327, DOI 10.1074/jbc.M409760200; Vives RR, 2002, BIOCHEMISTRY-US, V41, P14779, DOI 10.1021/bi026459i; Waldherr-Teschner M., 1992, Advances in Scientific Visualization, P58; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Zhang YJ, 2002, J VIROL, V76, P6332, DOI 10.1128/JVI.76.12.6332-6343.2002	42	101	103	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21353	21357		10.1074/jbc.M500911200	http://dx.doi.org/10.1074/jbc.M500911200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797855	hybrid			2022-12-27	WOS:000229438800054
J	Brand, LA; Strauss, E				Brand, LA; Strauss, E			Characterization of a new pantothenate kinase isoform from Helicobacter pylori.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-DISULFIDE REDUCTASE; COENZYME-A; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; FEEDBACK-REGULATION; COMPARATIVE GENOMICS; GENE; EXPRESSION; BIOSYNTHESIS; CLONING	Pantothenate kinase (PanK) catalyzes the first step in the biosynthesis of the essential and ubiquitous cofactor coenzyme A (CoA) in all organisms. Two well characterized isoforms of the enzyme are known: a prokaryotic PanK that predominates in eubacteria and a eukaryotic isoform that has primarily been characterized from mammalian and plant sources. Curiously, the genomes of certain pathogenic bacteria, including Helicobacter pylori and Pseudomonas aeruginosa, do not contain a PanK similar to either isoform, although these organisms possess all the other biosynthetic machinery required for CoA production. In this study we cloned, overexpressed and characterized an enzyme from Bacillus subtilis and its homologue from H. pylori and show that they catalyze the ATP-dependent phosphorylation of pantothenate. These enzymes do not share sequence homology with any known PanK, and unlike the bacterial and eukaryotic PanK isoforms their activity is not regulated by either CoA or acetyl-CoA. They also do not accept the pantothenic acid antimetabolite N-pentylpantothenamide as a substrate or are inhibited by it. Taken together, these results point to the identification of a third distinct isoform of PanK that accounts for the only known activity of the enzyme in pathogens such as H. pylori and P. aeruginosa.	Univ Stellenbosch, Dept Chem, ZA-7602 Matieland, South Africa	Stellenbosch University	Strauss, E (corresponding author), Univ Stellenbosch, Dept Chem, Private Bag X1, ZA-7602 Matieland, South Africa.	estrauss@sun.ac.za	Strauss, Erick/G-1783-2010	Strauss, Erick/0000-0002-9898-8226				Allen KN, 2004, TRENDS BIOCHEM SCI, V29, P495, DOI 10.1016/j.tibs.2004.07.008; Begley TP, 2001, VITAM HORM, V61, P157; Calder RB, 1999, J BIOL CHEM, V274, P2014, DOI 10.1074/jbc.274.4.2014; Cheek S, 2002, J MOL BIOL, V320, P855, DOI 10.1016/S0022-2836(02)00538-7; Choudhry AE, 2003, ANTIMICROB AGENTS CH, V47, P2051, DOI 10.1128/AAC.47.6.2051-2055.2003; delCardayre SB, 1998, J BIOL CHEM, V273, P5744, DOI 10.1074/jbc.273.10.5744; DESHAZER D, 1995, J BACTERIOL, V177, P3801, DOI 10.1128/jb.177.13.3801-3807.1995; Genschel U, 2004, MOL BIOL EVOL, V21, P1242, DOI 10.1093/molbev/msh119; Jackowski S., 1996, ESCHERICHIA COLI SAL, P687; Leonardi R, 2005, J BIOL CHEM, V280, P3314, DOI 10.1074/jbc.M411608200; Luba J, 1999, BIOCHEMISTRY-US, V38, P2725, DOI 10.1021/bi9825899; Osterman A, 2003, CURR OPIN CHEM BIOL, V7, P238, DOI 10.1016/S1367-5931(03)00027-9; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; Ramaswamy G, 2004, J LIPID RES, V45, P17, DOI 10.1194/jlr.M300279-JLR200; Rock CO, 2003, J BACTERIOL, V185, P3410, DOI 10.1128/JB.185.11.3410-3415.2003; Rock CO, 2002, GENE, V291, P35, DOI 10.1016/S0378-1119(02)00564-4; Rock CO, 2000, J BIOL CHEM, V275, P1377, DOI 10.1074/jbc.275.2.1377; Rudolph F B, 1979, Methods Enzymol, V63, P138; Singh SK, 2004, J BIOL CHEM, V279, P13166, DOI 10.1074/jbc.M311393200; SONG WJ, 1994, J BIOL CHEM, V269, P27051; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; Strauss E, 2002, J BIOL CHEM, V277, P48205, DOI 10.1074/jbc.M204560200; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; Wood GE, 2000, FEMS MICROBIOL LETT, V193, P25, DOI 10.1016/S0378-1097(00)00448-1; Yocum RR., 2004, US Patent, Patent No. [6830898, 6,830,898]; Yun M, 2000, J BIOL CHEM, V275, P28093; Zhang YM, 2004, J BIOL CHEM, V279, P50969, DOI 10.1074/jbc.M409607200	27	59	62	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20185	20188		10.1074/jbc.C500044200	http://dx.doi.org/10.1074/jbc.C500044200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15795230	hybrid			2022-12-27	WOS:000229242000004
J	Dateki, M; Horii, T; Kasuya, Y; Mochizuki, R; Nagao, Y; Ishida, J; Sugiyama, F; Tanimoto, K; Yagami, K; Imai, H; Fukamizu, A				Dateki, M; Horii, T; Kasuya, Y; Mochizuki, R; Nagao, Y; Ishida, J; Sugiyama, F; Tanimoto, K; Yagami, K; Imai, H; Fukamizu, A			Neurochondrin negatively regulates CaMKII phosphorylation, and nervous system-specific gene disruption results in epileptic seizure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTGROWTH-RELATED PROTEIN; II MUTANT MICE; KINASE-II; NEURITE-OUTGROWTH; ADULT-RAT; DEFICIENT; BRAIN; NEUROGENESIS; HIPPOCAMPUS; ASTROCYTES	Neurochondrin is a novel cytoplasmic protein and possibly involved in neurite outgrowth, chondrocyte differentiation, and bone metabolism. Our previous trial in disclosing its role by the loss of function in mice failed because of the lethality in utero. In this study, we eliminated the neurochondrin gene expression preferentially in the nervous system by the conditional knockout strategy. Our results showed that neurochondrin is a negative regulator of Ca2+/calmodulin-dependent protein kinase II phosphorylation and essential for the spatial learning process but not for the differentiation or neurite outgrowth of the neuron. In addition, the nervous system-specific homozygous gene disruption resulted in epileptic seizure.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Kyoto Univ, Grad Sch Agr, Reprod Physiol Lab, Kyoto 6068502, Japan; Chiba Univ, Grad Sch Med, Dept Mol Pharmacol & Biochem, Chiba 2608670, Japan; Univ Tsukuba, Lab Anim Source Ctr, Tsukuba, Ibaraki 3058577, Japan	University of Tsukuba; Kyoto University; Chiba University; University of Tsukuba	Fukamizu, A (corresponding author), Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan.	akif@tara.tsukuba.ac.jp	fukamizu, akiyoshi/J-5350-2012; Tanimoto, Keiji/B-2600-2014	fukamizu, akiyoshi/0000-0002-8786-6020; Tanimoto, Keiji/0000-0003-1971-6546; Kasuya, Yoshitoshi/0000-0003-0614-5836				Armon C, 2000, J CLIN NEUROPHYSIOL, V17, P511, DOI 10.1097/00004691-200009000-00011; Asada S, 1999, BIOCHEM BIOPH RES CO, V260, P441, DOI 10.1006/bbrc.1999.0917; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; Bendotti C, 2000, EXP NEUROL, V161, P317, DOI 10.1006/exnr.1999.7262; Bodian D, 1936, ANAT REC, V65, P89, DOI 10.1002/ar.1090650110; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; BUTLER LS, 1995, P NATL ACAD SCI USA, V92, P6852, DOI 10.1073/pnas.92.15.6852; Coussens CM, 1996, SYNAPSE, V24, P97, DOI 10.1002/(SICI)1098-2396(199610)24:2<97::AID-SYN1>3.0.CO;2-9; CRAWLEY JN, 2000, WHATS WRONG MY MOUSE, P83; Dateki M, 2004, NEUROSCI LETT, V356, P107, DOI 10.1016/j.neulet.2003.11.026; Elgersma Y, 2002, NEURON, V36, P493, DOI 10.1016/S0896-6273(02)01007-3; Freitag S, 2003, BEHAV BRAIN RES, V145, P189, DOI 10.1016/S0166-4328(03)00109-8; FUKUNAGA K, 1993, J BIOL CHEM, V268, P133; Hama H, 1997, J NEUROSCI RES, V47, P590, DOI 10.1002/(SICI)1097-4547(19970315)47:6<590::AID-JNR4>3.0.CO;2-8; Ishizuka Y, 1999, BBA-MOL CELL RES, V1450, P92, DOI 10.1016/S0167-4889(99)00039-7; KHURGEL M, 1995, NEUROBIOL DIS, V2, P23, DOI 10.1006/nbdi.1995.0003; Ktistakis NT, 2003, BIOCHEM SOC T, V31, P94, DOI 10.1042/bst0310094; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Mochizuki R, 2003, BIOCHEM BIOPH RES CO, V310, P1219, DOI 10.1016/j.bbrc.2003.09.153; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morimoto K, 2004, PROG NEUROBIOL, V73, P1, DOI 10.1016/j.pneurobio.2004.03.009; Ohoka Y, 2001, BIOCHEM BIOPH RES CO, V280, P237, DOI 10.1006/bbrc.2000.4080; Osada T, 1999, J NEUROSCI, V19, P6068, DOI 10.1523/JNEUROSCI.19-14-06068.1999; Parent JM, 1997, J NEUROSCI, V17, P3727; Reisel D, 2002, NAT NEUROSCI, V5, P868, DOI 10.1038/nn910; Shinozaki K, 1999, MOL BRAIN RES, V71, P364, DOI 10.1016/S0169-328X(99)00181-3; Shinozaki K, 1997, BIOCHEM BIOPH RES CO, V240, P766, DOI 10.1006/bbrc.1997.7660; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703	30	36	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20503	20508		10.1074/jbc.M414033200	http://dx.doi.org/10.1074/jbc.M414033200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15790563	hybrid			2022-12-27	WOS:000229242000043
J	Galindo, M; Pratap, J; Young, DW; Hovhannisyan, H; Im, HJ; Choi, JY; Lian, JB; Stein, JL; Stein, GS; van Wijnen, AJ				Galindo, M; Pratap, J; Young, DW; Hovhannisyan, H; Im, HJ; Choi, JY; Lian, JB; Stein, JL; Stein, GS; van Wijnen, AJ			The bone-specific expression of Runx2 oscillates during the cell cycle to support a G(1)-related antiproliferative function in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; SKELETAL GENE-EXPRESSION; GROWTH-FACTOR BETA-1; MORPHOGENETIC PROTEIN-2; TRANSCRIPTION FACTORS; CLEIDOCRANIAL DYSPLASIA; SUBNUCLEAR DOMAINS; RUNX/CBFA/AML FACTORS; PARATHYROID-HORMONE; SIGNALING PATHWAYS	The Runx2 (CBFA1/AML3/PEBP2 alpha A) transcription factor promotes skeletal cell differentiation, but it also has a novel cell growth regulatory activity in osteoblasts. We addressed here whether Runx2 activity is functionally linked to cell cycle-related mechanisms that control normal osteoblast proliferation and differentiation. We found that the levels of Runx2 gene transcription, mRNA and protein, are each up-regulated with cessation of cell growth (i.e. G(0)/G(1) transition) in preconfluent MC3T3 osteoblastic cells that do not yet express mature bone phenotypic gene expression. Cell growth regulation of Runx2 is also observed in primary calvarial osteoblasts and other osteoblastic cells with relatively normal cell growth characteristics, but not in osteosarcoma cells (e. g. SAOS-2 and ROS17/2.8). Runx2 levels are cell cycle-regulated in MC3T3 cells with respect to the G(1)/S and M/G(1) transitions: expression oscillates from maximal levels during early G(1) to minimal levels during early S phase and mitosis. However, in normal or immortalized (e. g. ATDC5) chondrocytic cells, Runx2 expression is suppressed during quiescence, and Runx2 levels are not regulated during G(1) and S phase in ATDC5 cells. Antisense or small interfering RNA-mediated reduction of the low physiological levels of Runx2 in proliferating MC3T3 cells does not accelerate cell cycle progression. However, forced expression of Runx2 suppresses proliferation of MC3T3 preosteoblasts or C2C12 mesenchymal cells which have osteogenic potential. Forced elevation of Runx2 in synchronized MC3T3 cells causes a delay in G(1). We propose that Runx2 levels and function are biologically linked to a cell growth-related G(1) transition in osteoblastic cells.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA; Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA; Rush Univ, Med Ctr, Dept Internal Med, Rheumatol Sect, Chicago, IL 60612 USA; Kyungpook Natl Univ, Sch Med, Dept Biochem, Taegu 700422, South Korea	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Rush University; Rush University; Kyungpook National University	van Wijnen, AJ (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	andre.vanwijnen@umassmed.edu	van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053220, R01AR039588, P01AR048818, R01AR049069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002647] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR48818, AR49069, AR39588, R01 AR039588, R01 AR053220, R01 AR053220-04, P01 AR048818, R01 AR049069] Funding Source: Medline; NIDDK NIH HHS [5P30 DK32520, P30 DK032520] Funding Source: Medline; BLRD VA [I01 BX002647] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); BLRD VA		Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Bernardin-Fried F, 2004, J BIOL CHEM, V279, P15678, DOI 10.1074/jbc.M310023200; Bodine PVN, 1996, ENDOCRINOLOGY, V137, P4592, DOI 10.1210/en.137.11.4592; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Chang WZ, 2002, GENE, V299, P65, DOI 10.1016/S0378-1119(02)01013-2; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Drissi H, 2002, EXP CELL RES, V274, P323, DOI 10.1006/excr.2002.5474; Friedman AD, 2002, J CELL BIOCHEM, V86, P624, DOI 10.1002/jcb.10271; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Gurlek A, 2002, ENDOCR REV, V23, P763, DOI 10.1210/er.2001-0044; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Harrington KS, 2002, J CELL SCI, V115, P4167, DOI 10.1242/jcs.00095; Hoffmann A, 2001, CRIT REV EUKAR GENE, V11, P23; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Javed A, 1999, MOL CELL BIOL, V19, P7491; Javed A, 2000, J CELL SCI, V113, P2221; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kitzmann M, 1998, J CELL BIOL, V142, P1447, DOI 10.1083/jcb.142.6.1447; KODAMA HA, 1982, J CELL PHYSIOL, V112, P83, DOI 10.1002/jcp.1041120113; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1; Lian JB, 2003, CONNECT TISSUE RES, V44, P141, DOI 10.1080/03008200390152232; Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378-1119(03)00748-0; McCarthy TL, 2000, CRIT REV ORAL BIOL M, V11, P409, DOI 10.1177/10454411000110040201; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 2001, INT J HEMATOL, V74, P252, DOI 10.1007/BF02982057; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Pratap J, 2003, CANCER RES, V63, P5357; Puri PL, 1997, ONCOGENE, V14, P1171, DOI 10.1038/sj.onc.1200941; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; Reynaud EG, 2000, J BIOL CHEM, V275, P18767, DOI 10.1074/jbc.M907412199; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Staal A, 1996, ENDOCRINOLOGY, V137, P2001, DOI 10.1210/en.137.5.2001; Stein GS, 2003, CONNECT TISSUE RES, V44, P149, DOI 10.1080/03008900390152241; Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676; Sudhakar S, 2001, BIOCHEM BIOPH RES CO, V289, P616, DOI 10.1006/bbrc.2001.6033; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Tintignac LA, 2000, EXP CELL RES, V259, P300, DOI 10.1006/excr.2000.4973; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756-3282(97)00267-6; van Wijnen AJ, 2004, ONCOGENE, V23, P4209, DOI 10.1038/sj.onc.1207758; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Whitfield JF, 2002, CRIT REV EUKAR GENE, V12, P23, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i1.20; Wotton SF, 2004, ONCOGENE, V23, P5476, DOI 10.1038/sj.onc.1207729; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Xiao ZS, 2001, J CELL BIOCHEM, V82, P647, DOI 10.1002/jcb.1192; Xiao ZS, 2003, J CELL BIOCHEM, V88, P493, DOI 10.1002/jcb.10375; Yagi K, 2003, J CELL BIOCHEM, V88, P1077, DOI 10.1002/jcb.10467; Yakar S, 2002, ENDOCRINE, V19, P239, DOI 10.1385/ENDO:19:3:239; Yang XL, 2002, TRENDS MOL MED, V8, P340, DOI 10.1016/S1471-4914(02)02340-7; Zaidi SK, 2001, J CELL SCI, V114, P3093; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zaidi SK, 2003, P NATL ACAD SCI USA, V100, P14852, DOI 10.1073/pnas.2533076100; Zambotti A, 2002, J BIOL CHEM, V277, P41497, DOI 10.1074/jbc.M204271200; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	77	194	203	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20274	20285		10.1074/jbc.M413665200	http://dx.doi.org/10.1074/jbc.M413665200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781466	hybrid, Green Accepted			2022-12-27	WOS:000229242000016
J	Pan, L; Glenn, ST; Jones, CA; Gross, KW				Pan, L; Glenn, ST; Jones, CA; Gross, KW			Activation of the rat renin promoter by HOXD10 center dot PBX1b center dot PREP1, ets-1, and the intracellular domain of notch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RBP-J-KAPPA; BINDING-PROTEIN; TRANSCRIPTION FACTORS; RESPONSIVE ELEMENT; PROXIMAL PROMOTER; DEVELOPING KIDNEY; GENE-EXPRESSION; MOUSE; REGION; CELLS	Renin gene expression is subject to complex developmental and tissue-specific regulation. A comparison of the promoter sequences of the human, rat, and mouse renin genes has revealed a highly conserved sequence homologous to the DNA recognition sequence for CBF1 (CSL/RBP-J kappa/Su(H)/LAG1/RBPSUH). Electrophoretic mobility shift assays document that As4.1 cell nuclear protein complex binding to the putative rat renin CBF1-binding ;site (-175 to - 168 bp) contains CBF1. Transient transfection analyses in COS-7 cells further document that a CBF1-VP16 fusion protein and the intracellular domain of Notch1 robustly activate a promoter containing multiple copies of the rat renin CBF1-binding site. An Ets-binding site (-143 to -138 bp) has also been identified in the rat renin promoter by sequence comparisons and electrophoretic mobility shift assays. Transcription factor Ets-1 is capable of activating the rat renin promoter through the Ets-binding site. Mutation of the CBF-binding site significantly increases transcriptional activity of the rat renin promoter in Calu-6 and COS-7 cells but not in As4.1 cells, whereas mutation of the Ets-binding site reduces promoter activity of the rat renin gene in all three cell lines. Finally, we show that the intracellular domain of Notch1, Ets-1, and HOXD10 (.) PBX1b (.) PREP1 activate the rat renin promoter cooperatively in COS-7 cells. These results strongly suggest that the renin gene is a downstream target of the Notch signaling pathway.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Gross, KW (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton Sts, Buffalo, NY 14263 USA.	gross@acsu.buffalo.edu			NCI NIH HHS [CA-16056] Funding Source: Medline; NHLBI NIH HHS [HL48459] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048459] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beatus P, 1999, DEVELOPMENT, V126, P3925; BORENSZTEIN P, 1994, CIRC RES, V74, P764, DOI 10.1161/01.RES.74.5.764; Chen HW, 2000, BIOCHEMISTRY-US, V39, P1675, DOI 10.1021/bi991786k; Domenga V, 2004, GENE DEV, V18, P2730, DOI 10.1101/gad.308904; Florence B, 1998, GENETICS, V150, P1497; Furriols M, 2001, CURR BIOL, V11, P60, DOI 10.1016/S0960-9822(00)00044-0; Ghosh D, 2005, MOL ENDOCRINOL, V19, P1049, DOI 10.1210/me.2004-0320; Gomez RA, 1999, J HISTOCHEM CYTOCHEM, V47, P1643; GOMEZ RA, 1989, AM J PHYSIOL, V257, pF850, DOI 10.1152/ajprenal.1989.257.5.F850; HAMAGUCHI Y, 1992, J BIOCHEM-TOKYO, V112, P314, DOI 10.1093/oxfordjournals.jbchem.a123898; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Jones CA, 2000, PHYSIOL GENOMICS, V4, P75, DOI 10.1152/physiolgenomics.2000.4.1.75; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Konoshita T, 2004, J CELL BIOCHEM, V93, P327, DOI 10.1002/jcb.20151; Konoshita T, 1996, KIDNEY INT, V50, P1515, DOI 10.1038/ki.1996.466; Kopan R, 2002, J CELL SCI, V115, P1095; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Krebs LT, 2003, GENESIS, V37, P139, DOI 10.1002/gene.10241; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; LANG JA, 1995, HYPERTENSION, V25, P704, DOI 10.1161/01.HYP.25.4.704; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Palmieri M, 1999, NUCLEIC ACIDS RES, V27, P2785, DOI 10.1093/nar/27.13.2785; Pan L, 2005, HYPERTENSION, V45, P3, DOI 10.1161/01.HYP.0000149717.55920.45; Pan L, 2004, AM J PHYSIOL-RENAL, V286, pF1107, DOI 10.1152/ajprenal.00319.2003; Pan L, 2001, J BIOL CHEM, V276, P45530, DOI 10.1074/jbc.M103010200; Pan L, 2001, J BIOL CHEM, V276, P32489, DOI 10.1074/jbc.M011541200; Petcherski AG, 2000, NATURE, V405, P364, DOI 10.1038/35012645; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; Reddi V, 1998, J AM SOC NEPHROL, V9, P63; Ross DA, 2001, MOL CELL BIOL, V21, P7537, DOI 10.1128/MCB.21.22.7537-7544.2001; Sato Y, 2001, CELL STRUCT FUNCT, V26, P19, DOI 10.1247/csf.26.19; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Shawber CJ, 2004, BIOESSAYS, V26, P225, DOI 10.1002/bies.20004; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; Wang JH, 2001, J IMMUNOL, V167, P289, DOI 10.4049/jimmunol.167.1.289; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644	38	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20860	20866		10.1074/jbc.M414618200	http://dx.doi.org/10.1074/jbc.M414618200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15792957	hybrid			2022-12-27	WOS:000229242000084
J	Zhang, XY; Zajac, A; Zhang, J; Wang, PY; Li, M; Murray, J; TerBush, D; Guo, W				Zhang, XY; Zajac, A; Zhang, J; Wang, PY; Li, M; Murray, J; TerBush, D; Guo, W			The critical role of exo84p in the organization and polarized localization of the exocyst complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; SECRETORY VESICLES; SPATIAL REGULATION; PROTEIN-TRANSPORT; SEC6/8 COMPLEX; EXOCYTOSIS; SEC3P; DELIVERY	The exocyst complex plays an essential role in tethering secretory vesicles to specific domains of the plasma membrane for exocytosis. However, how the exocyst complex is assembled and targeted to sites of secretion is unclear. Here, we have investigated the role of the exocyst component Exo84p in these processes. We have generated an array of temperature-sensitive yeast exo84 mutants. Electron microscopy and cargo protein traffic analyses of these mutants indicated that Exo84p is specifically involved in the post-Golgi stage of secretion. Using various yeast mutants, we systematically studied the localization of Exo84p and other exocyst proteins by fluorescence microscopy. We found that pre-Golgi traffic and polarized actin organization are required for Exo84p localization. However, none of the exocyst proteins controls Exo84p polarization. In addition, Sec3p is not responsible for the polarization of Exo84p or any other exocyst component to the daughter cell. On the other hand, several exocyst members, including Sec10p, Sec15p, and Exo70p, clearly require Exo84p for their polarization. Biochemical analyses of the exocyst composition indicated that the assembly of Sec10p, Sec15p, and Exo70p with the rest of the complex requires Exo84p. We propose that there are at least two distinct regulatory mechanisms for exocyst polarization, one for Sec3p and one for the other members, including Exo84p. Exo84p plays a critical role in both the assembly of the exocyst and its targeting to sites of secretion.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Uniformed Serv Univ Hlth Sci, Dept Biochem, Bethesda, MD 20814 USA	University of Pennsylvania; University of Pennsylvania; Uniformed Services University of the Health Sciences - USA	Guo, W (corresponding author), Univ Penn, Dept Biol, 415 S Univ Ave, Philadelphia, PA 19104 USA.	guowei@sas.upenn.edu			NIGMS NIH HHS [R01-GM64690] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064690] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; Boyd C, 2004, J CELL BIOL, V167, P889, DOI 10.1083/jcb.200408124; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Chu S, 2004, TOP CURR GENET, V10, P89; Finger FP, 1998, CELL, V92, P559, DOI 10.1016/S0092-8674(00)80948-4; Finger FP, 1997, MOL BIOL CELL, V8, P647, DOI 10.1091/mbc.8.4.647; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Grote E, 2000, MOL BIOL CELL, V11, P4051, DOI 10.1091/mbc.11.12.4051; Guo W, 2004, TRENDS CELL BIOL, V14, P61, DOI 10.1016/j.tcb.2003.12.008; Guo W, 1999, J BIOL CHEM, V274, P23558, DOI 10.1074/jbc.274.33.23558; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Guo W, 2000, TRENDS CELL BIOL, V10, P251, DOI 10.1016/S0962-8924(00)01754-2; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Guthrie C, 1991, METHODS ENZYMOL, V194; Haarer BK, 1996, GENETICS, V144, P495; HARSAY E, 1995, J CELL BIOL, V131, P297, DOI 10.1083/jcb.131.2.297; Hsu SC, 2004, INT REV CYTOL, V233, P243, DOI 10.1016/S0074-7696(04)33006-8; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; Lipschutz JH, 2002, CURR BIOL, V12, pR212, DOI 10.1016/S0960-9822(02)00753-4; Moskalenko S, 2003, J BIOL CHEM, V278, P51743, DOI 10.1074/jbc.M308702200; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Novick P, 2002, TRENDS CELL BIOL, V12, P247, DOI 10.1016/S0962-8924(02)02293-6; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Pruyne DW, 1998, J CELL BIOL, V143, P1931, DOI 10.1083/jcb.143.7.1931; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Scott BL, 2004, J CELL BIOL, V167, P75, DOI 10.1083/jcb.200405018; Spiliotis ET, 2003, CURR OPIN CELL BIOL, V15, P430, DOI 10.1016/S0955-0674(03)00074-7; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; Wiederkehr A, 2003, MOL BIOL CELL, V14, P4770, DOI 10.1091/mbc.E03-04-0229; Yeaman C, 2001, J CELL BIOL, V155, P593, DOI 10.1083/jcb.200107088; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2; Zajac A, 2005, MOL BIOL CELL, V16, P1500, DOI 10.1091/mbc.E04-10-0896; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200	44	34	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20356	20364		10.1074/jbc.M500511200	http://dx.doi.org/10.1074/jbc.M500511200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788396	hybrid			2022-12-27	WOS:000229242000026
J	Dirr, HW; Little, T; Kuhnert, DC; Sayed, Y				Dirr, HW; Little, T; Kuhnert, DC; Sayed, Y			A conserved N-capping motif contributes significantly to the stabilization and dynamics of the C-terminal region of class alpha glutathione S-transferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING-PROTEIN; HIGH CATALYTIC EFFICIENCY; LIGAND-BINDING; HEAT-CAPACITY; ACTIVE-SITE; ELECTROSTATIC INTERACTIONS; HETEROLOGOUS EXPRESSION; LIPID-PEROXIDATION; CRYSTAL-STRUCTURES; ANOMALOUS PK(A)	Helix 9, the major structural element in the C-terminal region of class Alpha glutathione transferases, forms part of the active site of these enzymes where its dynamic properties modulate both catalytic and ligandin functions. A conserved aspartic acid N-capping motif for helix 9 was identified by sequence alignments of the C-terminal regions of class Alpha glutathione S-transferases (GSTs) and an analysis by the helix-coil algorithm AGADIR. The contribution of the N-capping motif to the stability and dynamics of the region was investigated by replacing the N-cap residue Asp-209 with a glycine in human glutathione S-transferase A1-1 (hGST A1-1) and in a peptide corresponding to its C-terminal region. Far-UV circular dichroism and AGADIR analyses indicate that, in the absence of tertiary interactions, the wild-type peptide displays a low intrinsic tendency to form a helix and that this tendency is reduced significantly by the Asp-to-Gly mutation. Disruption of the N-capping motif of helix 9 in hGST A1-1 alters the conformational dynamics of the C-terminal region and, consequently, the features of the H-site to which hydrophobic substrates (e. g. 1-chloro-2,4-dinitrobenzene (CDNB)) and nonsubstrates (e. g. 8-anilino-1-naphthalene sulfonate (ANS)) bind. Isothermal calorimetric and fluorescence data for complex formation between ANS and protein suggest that the D209G-induced perturbation in the C-terminal region prevents normal ligand-induced localization of the region at the active site, resulting in a less hydrophobic and more solvent-exposed H-site. Therefore, the catalytic efficiency of the enzyme with CDNB is diminished due to a lowered affinity for the electrophilic substrate and a lower stabilization of the transition state.	Univ Witwatersrand, Sch Mol & Cell Biol, Prot Struct Funct Res Programme, ZA-2050 Wits, South Africa	University of Witwatersrand	Dirr, HW (corresponding author), Univ Witwatersrand, Sch Mol & Cell Biol, Prot Struct Funct Res Programme, Jan Smuts Ave, ZA-2050 Wits, South Africa.	heinid@gecko.biol.wits.ac.za	Sayed, Yasien/AAA-3302-2021; Dirr, Heini W/F-7228-2010	Sayed, Yasien/0000-0002-1781-2115; Dirr, Heini/0000-0003-1455-7769				Aceto A, 1997, BIOCHEM J, V322, P229, DOI 10.1042/bj3220229; Allardyce CS, 1999, BIOCHEM J, V343, P525, DOI 10.1042/0264-6021:3430525; Anderson TA, 2003, BIOPHYS CHEM, V100, P341, DOI 10.1016/S0301-4622(02)00291-0; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Atkins WM, 1997, PROTEIN SCI, V6, P873; BICO P, 1995, BBA-PROTEIN STRUCT M, V1247, P225, DOI 10.1016/0167-4838(94)00236-A; BJORNESTEDT R, 1995, J MOL BIOL, V247, P765; BOARD PG, 1991, BIOCHEM J, V275, P171, DOI 10.1042/bj2750171; BRANDTS JF, 1973, BIOCHEMISTRY-US, V12, P2011, DOI 10.1021/bi00734a027; BROWN JE, 1971, BIOCHEMISTRY-US, V10, P470, DOI 10.1021/bi00779a019; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; BUETLER TM, 1992, BIOCHEM BIOPH RES CO, V188, P597, DOI 10.1016/0006-291X(92)91098-B; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; CHAKRABARTTY A, 1993, BIOCHEMISTRY-US, V32, P5560, DOI 10.1021/bi00072a010; Cocco R, 2001, J BIOL CHEM, V276, P32177, DOI 10.1074/jbc.M104057200; DASGUPTA S, 1993, INT J PEPT PROT RES, V41, P499; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Dirr HW, 1999, BIOCHEMISTRY-US, V38, P15631, DOI 10.1021/bi991179x; Doig AJ, 1997, PROTEIN SCI, V6, P147; Dragani B, 1997, J BIOL CHEM, V272, P25518, DOI 10.1074/jbc.272.41.25518; DUNITZ JD, 1994, SCIENCE, V264, P670, DOI 10.1126/science.264.5159.670; ELMASRY NF, 1994, PROTEIN ENG, V7, P777, DOI 10.1093/protein/7.6.777; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Freire E, 1997, PURE APPL CHEM, V69, P2253, DOI 10.1351/pac199769112253; Gustafsson A, 1999, BIOCHEMISTRY-US, V38, P16268, DOI 10.1021/bi991482y; Habig W H, 1981, Methods Enzymol, V77, P398; HAYES JD, 1992, BIOCHEM J, V285, P173, DOI 10.1042/bj2850173; Ibarra C, 2001, BIOCHEMISTRY-US, V40, P10614, DOI 10.1021/bi010672h; Ibarra CA, 2003, J BIOL CHEM, V278, P19257, DOI 10.1074/jbc.M301566200; Johnson WW, 1997, BIOCHEMISTRY-US, V36, P3056, DOI 10.1021/bi962537o; KETLEY JN, 1975, J BIOL CHEM, V250, P8670; Kirk WR, 1996, BIOPHYS J, V70, P69, DOI 10.1016/S0006-3495(96)79592-9; Kolobe D, 2004, BIOCHEM J, V382, P703, DOI 10.1042/BJ20040056; Kumaran S, 1999, J PEPT RES, V53, P284, DOI 10.1034/j.1399-3011.1999.00027.x; KURIAN E, 1998, THESIS MAYO FDN ROCH; Lacroix E, 1998, J MOL BIOL, V284, P173, DOI 10.1006/jmbi.1998.2145; Ladbury JE, 2004, CURR OPIN STRUC BIOL, V14, P562, DOI 10.1016/j.sbi.2004.08.001; Ladner JE, 2004, BIOCHEMISTRY-US, V43, P352, DOI 10.1021/bi035832z; Lartigue A, 2003, J BIOL CHEM, V278, P30213, DOI 10.1074/jbc.M304688200; LE T, 2002, PROTEINS, V48, P618; Loladze VV, 2001, PROTEIN SCI, V10, P1343, DOI 10.1110/ps.370101; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; MAKHATADZE GI, 1990, J MOL BIOL, V213, P375, DOI 10.1016/S0022-2836(05)80197-4; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Matulis D, 1998, BIOPHYS J, V74, P422, DOI 10.1016/S0006-3495(98)77799-9; Mosebi S, 2003, BIOCHEMISTRY-US, V42, P15326, DOI 10.1021/bi035671z; Myers JK, 1998, PROTEIN SCI, V7, P383; Nieslanik BS, 1999, BIOCHEMISTRY-US, V38, P6971, DOI 10.1021/bi9829130; Nieslanik BS, 2001, BIOCHEMISTRY-US, V40, P3536, DOI 10.1021/bi001869x; Nieslanik BS, 2000, J BIOL CHEM, V275, P17447, DOI 10.1074/jbc.M002083200; Nilsson LO, 2000, P NATL ACAD SCI USA, V97, P9408, DOI 10.1073/pnas.150084897; Nilsson LO, 2002, BBA-PROTEIN STRUCT M, V1597, P157; Oakley AJ, 1999, J MOL BIOL, V291, P913, DOI 10.1006/jmbi.1999.3029; Ory JJ, 1999, BIOPHYS J, V77, P1107, DOI 10.1016/S0006-3495(99)76961-4; Pal A, 2001, BIOCHEMISTRY-US, V40, P7047, DOI 10.1021/bi010363r; Ralat LA, 2004, J BIOL CHEM, V279, P50204, DOI 10.1074/jbc.M407445200; Ralat LA, 2003, PROTEIN SCI, V12, P2575, DOI 10.1110/ps.03249303; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Rohl CA, 1996, PROTEIN SCI, V5, P2623, DOI 10.1002/pro.5560051225; SACCHETTINI JC, 1992, J BIOL CHEM, V267, P23534; Sayed Y, 2000, FEBS LETT, V465, P169, DOI 10.1016/S0014-5793(99)01747-0; Sayed Y, 2002, BIOCHEM J, V363, P341, DOI 10.1042/0264-6021:3630341; SCHOLTZ JM, 1992, ANNU REV BIOPH BIOM, V21, P95, DOI 10.1146/annurev.bb.21.060192.000523; Schonbrunn E, 2000, P NATL ACAD SCI USA, V97, P6345, DOI 10.1073/pnas.120120397; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; Sluis-Cremer N, 1998, EUR J BIOCHEM, V257, P434, DOI 10.1046/j.1432-1327.1998.2570434.x; SluisCremer N, 1996, EUR J BIOCHEM, V241, P484, DOI 10.1111/j.1432-1033.1996.00484.x; Sobolev V, 1996, PROTEINS, V25, P120, DOI 10.1002/(SICI)1097-0134(199605)25:1<120::AID-PROT10>3.3.CO;2-1; STENBERG G, 1992, PROTEIN EXPRES PURIF, V3, P80, DOI 10.1016/1046-5928(92)90060-A; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; VANGUNSTEREN WF, 1990, ANGEW CHEM INT EDIT, V29, P992, DOI 10.1002/anie.199009921; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wallace LA, 2000, BBA-PROTEIN STRUCT M, V1478, P325, DOI 10.1016/S0167-4838(00)00023-6; Wallace LA, 1998, BIOCHEMISTRY-US, V37, P5320, DOI 10.1021/bi972936z; Wallace LA, 1999, BIOCHEMISTRY-US, V38, P16686, DOI 10.1021/bi991239z; Wan WY, 1999, J MOL BIOL, V286, P1633, DOI 10.1006/jmbi.1999.2552; WANG RW, 1993, PROTEIN SCI, V2, P2085, DOI 10.1002/pro.5560021209; WIDERSTEN M, 1994, BIOCHEMISTRY-US, V33, P11717, DOI 10.1021/bi00205a007; Wiesner S, 1999, J MOL BIOL, V286, P233, DOI 10.1006/jmbi.1998.2490; Zhan YP, 2004, BIOCHEMISTRY-US, V43, P7244, DOI 10.1021/bi0363329	82	20	20	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19480	19487		10.1074/jbc.M413608200	http://dx.doi.org/10.1074/jbc.M413608200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15757902	hybrid			2022-12-27	WOS:000229113700009
J	Feldman, RI; Wu, JM; Polokoff, MA; Kochanny, MJ; Dinter, H; Zhu, DG; Biroc, SL; Alicke, B; Bryant, J; Yuan, SD; Buckman, BO; Lentz, D; Ferrer, M; Whitlow, M; Adler, M; Finster, S; Chang, Z; Arnaiz, DO				Feldman, RI; Wu, JM; Polokoff, MA; Kochanny, MJ; Dinter, H; Zhu, DG; Biroc, SL; Alicke, B; Bryant, J; Yuan, SD; Buckman, BO; Lentz, D; Ferrer, M; Whitlow, M; Adler, M; Finster, S; Chang, Z; Arnaiz, DO			Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; IN-VIVO; PHOSPHORYLATION; ACTIVATION; PDK1; AKT; IDENTIFICATION; SER-473; TRANSFORMATION; 3-KINASE	The phosphoinositide 3-kinase/3-phosphoinositide-dependent kinase 1 (PDK1)/Akt signaling pathway plays a key role in cancer cell growth, survival, and tumor angiogenesis and represents a promising target for anticancer drugs. Here, we describe three potent PDK1 inhibitors, BX-795, BX-912, and BX-320 (IC50 = 11-30 nM) and their initial biological characterization. The inhibitors blocked PDK1/Akt signaling in tumor cells and inhibited the anchorage-dependent growth of a variety of tumor cell lines in culture or induced apoptosis. A number of cancer cell lines with elevated Akt activity were > 30-fold more sensitive to growth inhibition by PDK1 inhibitors in soft agar than on tissue culture plastic, consistent with the cell survival function of the PDK1/Akt signaling pathway, which is particularly important for unattached cells. BX-320 inhibited the growth of LOX melanoma tumors in the lungs of nude mice after injection of tumor cells into the tail vein. The effect of BX-320 on cancer cell growth in vitro and in vivo indicates that PDK1 inhibitors may have clinical utility as anticancer agents.	Berlex Biosci, Dept Canc Res, Richmond, CA 94804 USA; Berlex Biosci, Dept Pharmacol, Richmond, CA 94804 USA; Berlex Biosci, Dept Chem, Richmond, CA 94804 USA; Berlex Biosci, Dept Syst Biol, Richmond, CA 94804 USA		Feldman, RI (corresponding author), Berlex Biosci, Dept Canc Res, 2600 Hilltop Dr, Richmond, CA 94804 USA.	rick_feldman@berlex.com						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Beattie JF, 2003, BIOORG MED CHEM LETT, V13, P2955, DOI 10.1016/S0960-894X(03)00202-6; Biondi RM, 2002, EMBO J, V21, P4219, DOI 10.1093/emboj/cdf437; BRYANT J, 2004, Patent No. 2004048343; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Flynn P, 2000, CURR BIOL, V10, P1439, DOI 10.1016/S0960-9822(00)00801-0; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Kawakami Y, 2004, J BIOL CHEM, V279, P47720, DOI 10.1074/jbc.M408797200; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Partovian C, 2004, CELL SIGNAL, V16, P951, DOI 10.1016/j.cellsig.2004.01.008; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Sayle KL, 2003, BIOORG MED CHEM LETT, V13, P3079, DOI 10.1016/S0960-894X(03)00651-6; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Storz P, 2002, FRONT BIOSCI-LANDMRK, V7, pD886, DOI 10.2741/storz; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toker Alex, 2003, Methods Mol Biol, V233, P171; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3	42	166	182	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19867	19874		10.1074/jbc.M501367200	http://dx.doi.org/10.1074/jbc.M501367200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772071	hybrid			2022-12-27	WOS:000229113700055
J	Camden, JM; Schrader, AM; Camden, RE; Gonzalez, FA; Erb, L; Seye, CI; Weisman, GA				Camden, JM; Schrader, AM; Camden, RE; Gonzalez, FA; Erb, L; Seye, CI; Weisman, GA			P2Y(2) nucleotide receptors enhance alpha-secretase-dependent amyloid precursor protein processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ADHESION MOLECULE-1 EXPRESSION; GROWTH-FACTOR RECEPTOR; KINASE-C; CONVERTING-ENZYME; ALZHEIMERS-DISEASE; CELL-ADHESION; EXTRACELLULAR ATP; ADAMS FAMILY; RELEASE	The amyloid precursor protein (APP) is proteolytically processed by beta- and gamma-secretases to release amyloid beta, the main component in senile plaques found in the brains of patients with Alzheimer disease. Alternatively, APP can be cleaved within the amyloid beta domain by alpha-secretase releasing the non-amyloidogenic product sAPP alpha, which has been shown to have neuroprotective properties. Several G protein-coupled receptors are known to activate alpha-secretase-dependent processing of APP; however, the role of G protein-coupled nucleotide receptors in APP processing has not been investigated. Here it is demonstrated that activation of the G protein-coupled P2Y(2) receptor (P2Y(2)R) subtype expressed in human 1321N1 astrocytoma cells enhanced the release of sAPP alpha in a time- and dose-dependent manner. P2Y(2)R-mediated sAPP alpha release was dependent on extracellular calcium but was not affected by 1,2-bis(2-aminophenoxy)ethane-N,N,N,-trimethylammonium salt, an intracellular calcium chelator, indicating that P2Y(2)R-stimulated intracellular calcium mobilization was not involved. Inhibition of protein kinase C (PKC) with GF109203 or by PKC down-regulation with phorbol ester pre-treatment had no effect on UTP-stimulated sAPP alpha release, indicating a PKC-independent mechanism. U0126, an inhibitor of the mitogen-activated protein kinase pathway, partially inhibited sAPP alpha release by UTP, whereas inhibitors of Src-dependent epidermal growth factor receptor transactivation by P2Y(2)Rs had no effect. The metalloprotease inhibitors phenanthroline and TAPI-2 and the furin inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethylketone also diminished UTP-induced sAPP alpha release. Furthermore, small interfering RNA silencing of an endogenous adamalysin, ADAM10 or ADAM17/TACE, partially suppressed P2Y(2)R-activated sAPP alpha release, whereas treatment of cells with both ADAM10 and ADAM17/TACE small interfering RNAs completely abolished UTP-activated sAPP alpha release. These results may contribute to an understanding of the non-amyloidogenic processing of APP.	Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; Univ Puerto Rico, Dept Chem, Rio Piedras, PR 00931 USA	University of Missouri System; University of Missouri Columbia; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico Rio Piedras	Weisman, GA (corresponding author), Univ Missouri, Dept Biochem, 540E Life Sci Ctr,1201 Rollins Rd, Columbia, MO 65211 USA.	weismang@missouri.edu		Erb, Laurie/0000-0001-6372-3378	NCRR NIH HHS [1 P20-RR15565] Funding Source: Medline; NIA NIH HHS [1 P01-AG18357] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015565] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG018357] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahn JS, 2000, AM J PHYSIOL-CELL PH, V279, pC286, DOI 10.1152/ajpcell.2000.279.2.C286; Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737; Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blacker M, 2002, J NEUROCHEM, V83, P1349, DOI 10.1046/j.1471-4159.2002.01228.x; BLAUG S, 2003, AM J PHYSIOL, V284, pC894; BOARDER MR, 1995, TRENDS PHARMACOL SCI, V16, P133, DOI 10.1016/S0165-6147(00)89001-X; BOWES MP, 1994, EXP NEUROL, V129, P112, DOI 10.1006/exnr.1994.1152; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CHECLER F, 1995, J NEUROCHEM, V65, P1431; DAVISSALINAS J, 1994, J BIOL CHEM, V269, P22623; Desdouits-Magnen J, 1998, J NEUROCHEM, V70, P524; Endres K, 2003, EUR J BIOCHEM, V270, P2386, DOI 10.1046/j.1432-1033.2003.03606.x; Erb L, 2001, J CELL BIOL, V153, P491, DOI 10.1083/jcb.153.3.491; ERB L, 1994, DRUG DEVELOP RES, V31, P267; Garrad RC, 1998, J BIOL CHEM, V273, P29437, DOI 10.1074/jbc.273.45.29437; Gendron Fernand-Pierre, 2003, Biomedical Research (Aligarh), V14, P47; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hotoda N, 2002, BIOCHEM BIOPH RES CO, V293, P800, DOI 10.1016/S0006-291X(02)00302-9; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Jolly-Tornetta C, 1998, J BIOL CHEM, V273, P14015, DOI 10.1074/jbc.273.22.14015; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; Kaido T, 2004, J BIOL CHEM, V279, P17731, DOI 10.1074/jbc.M308425200; KIM K, 1990, NEUROSCI RES COMMUN, V2, P121; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Lazarowski ER, 2001, NEWS PHYSIOL SCI, V16, P1; Le Gall SM, 2003, J BIOL CHEM, V278, P45255, DOI 10.1074/jbc.M307745200; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; Liu J, 2004, J BIOL CHEM, V279, P8212, DOI 10.1074/jbc.M312230200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSTIG KD, 1992, BIOCHIM BIOPHYS ACTA, V1134, P61, DOI 10.1016/0167-4889(92)90028-A; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Murdoch C, 2000, BLOOD, V95, P3032; Nitsch R M, 1994, J Neural Transm Suppl, V44, P21; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; NITSCH RM, 1993, ANN NY ACAD SCI, V695, P122, DOI 10.1111/j.1749-6632.1993.tb23039.x; NITSCH RM, 1995, ARZNEIMITTEL-FORSCH, V45-1, P435; Nitsch RM, 1997, J NEUROCHEM, V69, P704; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; Parkin ET, 2002, BIOCHEMISTRY-US, V41, P4972, DOI 10.1021/bi015936e; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Racchi M, 1999, J NEUROCHEM, V72, P2464, DOI 10.1046/j.1471-4159.1999.0722464.x; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SCHRADER AM, 2005, IN PRESS ARCH ORAL B, V50; Schultze-Mosgau A, 2000, MOL HUM REPROD, V6, P435, DOI 10.1093/molehr/6.5.435; Schwiebert EM, 2003, BBA-BIOMEMBRANES, V1615, P7, DOI 10.1016/S0005-2736(03)00210-4; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Seye CI, 2004, J BIOL CHEM, V279, P35679, DOI 10.1074/jbc.M401799200; Seye CI, 2003, J BIOL CHEM, V278, P24960, DOI 10.1074/jbc.M301439200; Seye CI, 2002, CIRCULATION, V106, P2720, DOI 10.1161/01.CIR.0000038111.00518.35; Seye CI, 1997, ARTERIOSCL THROM VAS, V17, P3602, DOI 10.1161/01.ATV.17.12.3602; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Slack BE, 1997, BIOCHEM J, V327, P245, DOI 10.1042/bj3270245; SLACK BE, 1993, ANN NY ACAD SCI, V695, P128, DOI 10.1111/j.1749-6632.1993.tb23040.x; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; Turner JT, 1998, AM J PHYSIOL-CELL PH, V275, pC367, DOI 10.1152/ajpcell.1998.275.2.C367; Turner JT, 1997, AM J PHYSIOL-CELL PH, V273, pC1100, DOI 10.1152/ajpcell.1997.273.3.C1100; Wallace WC, 1997, MOL BRAIN RES, V52, P201, DOI 10.1016/S0169-328X(97)00258-1; Weerasinghe D, 1998, J CELL BIOL, V142, P595, DOI 10.1083/jcb.142.2.595; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Weisman GA, 1996, J PHARMACOL EXP THER, V277, P1; WOLF BA, 1995, J BIOL CHEM, V270, P4916, DOI 10.1074/jbc.270.9.4916	79	110	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18696	18702		10.1074/jbc.M500219200	http://dx.doi.org/10.1074/jbc.M500219200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15778502	hybrid			2022-12-27	WOS:000228932300020
J	Gong, QM; Keeney, DR; Molinari, M; Zhou, ZF				Gong, QM; Keeney, DR; Molinari, M; Zhou, ZF			Degradation of trafficking-defective long QT syndrome type II mutant channels by the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; RETICULUM (ER)-ASSOCIATED DEGRADATION; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; N-GLYCANASE; MISFOLDED GLYCOPROTEINS; RETRO-TRANSLOCATION; CARDIAC-ARRHYTHMIA; SURFACE EXPRESSION; SECRETORY PROTEIN	Mutations in the human ether-a-go-go-related gene (hERG) cause chromosome 7-linked long QT syndrome type II (LQT2). We have shown previously that LQT2 mutations lead to endoplasmic reticulum ( ER) retention and rapid degradation of mutant hERG proteins. In this study we examined the role of the ubiquitin-proteasome pathway in the degradation of the LQT2 mutation Y611H. We showed that proteasome inhibitors N-acetyl-L-leucyl-L-leucyl-L-norleucinal and lactacystin but not lysosome inhibitor leupeptin inhibited the degradation of Y611H mutant channels. In addition, ER mannosidase I inhibitor kifunensine and down-regulation of EDEM ( ER degradation-enhancing alpha-mannosidase-like protein) also suppressed the degradation of Y611H mutant channels. Proteasome inhibition but not mannosidase inhibition led to the accumulation of full-length hERG protein in the cytosol. The hERG protein accumulated in the cytosol was deglycosylated. Proteasome inhibition also resulted in the accumulation of polyubiquitinated hERG channels. These results suggest that the degradation of LQT2 mutant channels is mediated by the cytosolic proteasome in a process that involves mannose trimming, polyubiquitination, and deglycosylation of mutant channels.	Oregon Hlth & Sci Univ, Dept Med, Div Mol Med, Portland, OR 97239 USA; Inst Res Biomed, CH-6500 Bellinzona, Switzerland	Oregon Health & Science University; Universita della Svizzera Italiana	Zhou, ZF (corresponding author), Oregon Hlth & Sci Univ, Dept Med, Div Mol Med, NRC3,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	zhouzh@ohsu.edu	Molinari, Maurizio/N-2587-2019	Molinari, Maurizio/0000-0002-7636-5829	NHLBI NIH HHS [HL68854, R01 HL068854] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068854] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; Blom D, 2004, EMBO J, V23, P650, DOI 10.1038/sj.emboj.7600090; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; Delisle BP, 2004, CIRC RES, V94, P1418, DOI 10.1161/01.RES.0000128561.28701.ea; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fagioli C, 2001, J BIOL CHEM, V276, P12885, DOI 10.1074/jbc.M009603200; Ficker E, 2003, CIRC RES, V92, pE87, DOI 10.1161/01.RES.0000079028.31393.15; Gong QM, 2004, J MOL CELL CARDIOL, V37, P1225, DOI 10.1016/j.yjmcc.2004.10.002; Gong QM, 2002, AM J PHYSIOL-HEART C, V283, pH77, DOI 10.1152/ajpheart.00008.2002; Gouas L, 2004, CARDIOVASC RES, V63, P60, DOI 10.1016/j.cardiores.2004.02.011; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hirsch C, 2003, EMBO J, V22, P1036, DOI 10.1093/emboj/cdg107; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; January CT, 2000, J CARDIOVASC ELECTR, V11, P1413, DOI 10.1046/j.1540-8167.2000.01413.x; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kagan A, 2000, J BIOL CHEM, V275, P11241, DOI 10.1074/jbc.275.15.11241; Khanna R, 2001, J BIOL CHEM, V276, P34028, DOI 10.1074/jbc.M105248200; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; Mancini R, 2000, FASEB J, V14, P769, DOI 10.1096/fasebj.14.5.769; Manganas LN, 2001, J BIOL CHEM, V276, P49427, DOI 10.1074/jbc.M109325200; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Park H, 2001, P NATL ACAD SCI USA, V98, P11163, DOI 10.1073/pnas.201393498; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; Suzuki T, 2000, J CELL BIOL, V149, P1039, DOI 10.1083/jcb.149.5.1039; Tokunaga F, 2000, J BIOL CHEM, V275, P40757, DOI 10.1074/jbc.M001073200; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; VanSlyke JK, 2002, J CELL BIOL, V157, P381, DOI 10.1083/jcb.200111045; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Xiong XM, 1999, J BIOL CHEM, V274, P2616, DOI 10.1074/jbc.274.5.2616; Yamashita F, 2001, J MOL CELL CARDIOL, V33, P197, DOI 10.1006/jmcc.2000.1300; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	52	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19419	19425		10.1074/jbc.M502327200	http://dx.doi.org/10.1074/jbc.M502327200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15760896	hybrid			2022-12-27	WOS:000228932300100
J	Soccio, RE; Adams, RM; Maxwell, KN; Breslow, JL				Soccio, RE; Adams, RM; Maxwell, KN; Breslow, JL			Differential gene regulation of StarD4 and StarD5 cholesterol transfer proteins - Activation of StarD4 by sterol regulatory element-binding protein-2 and StarD5 by endoplasmic reticulum stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; LIVER-X-RECEPTOR; FATTY-ACID SYNTHESIS; LXR-ALPHA; NF-Y; TRANSCRIPTIONAL REGULATION; SYNTHASE PROMOTER; REDUCTASE GENE; TARGET GENES; EXPRESSION	The StarD4 and StarD5 proteins share similar to 30% identity, and each is a steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) domain. We previously showed StarD4 expression is sterol-repressed, consistent with regulation by sterol regulatory element-binding proteins (SREBPs), whereas StarD5 is not sterol-regulated. Here we further address the regulation and function of StarD4 and StarD5. Unlike StAR, the START family prototype, StarD4 and StarD5 were not induced by steroidogenic stimuli in Leydig cells. However, StarD4 and StarD5 showed StAR-like activity in a cell culture steroidogenesis assay, indicating cholesterol transfer. In transgenic mice expressing active SREBPs, StarD4 was predominantly activated by SREBP-2 rather than SREBP-1a. The mouse and human StarD4 proximal promoters share similar to 70% identity, including several potential sterol regulatory elements (SREs). Reporters driven by the StarD4 promoter from either species were transfected into NIH-3T3 cells, and reporter activity was highly repressed by sterols. Site-directed mutagenesis of potential SREs identified a conserved functional SRE in the mouse (TCGGTCCAT) and human (TCATTCCAT) promoters. StarD5 was not sterol-repressed via SREBPs nor was it sterol-activated via liver X receptors (LXRs). Even though StarD4 and StarD5 were not LXR targets, their overexpression stimulated LXR reporter activity, suggesting roles in cholesterol metabolism. StarD5 expression increased 3-fold in free cholesterol-loaded macrophages, which activate the endoplasmic reticulum (ER) stress response. When NIH-3T3 cells were treated with agents to induce ER stress, StarD5 expression increased 6-8-fold. Because StarD4 is regulated by sterols via SREBP-2, whereas StarD5 is activated by ER stress, they likely serve distinct functions in cholesterol metabolism.	Rockefeller Univ, Biochem Genet & Metab Lab, New York, NY 10021 USA	Rockefeller University	Breslow, JL (corresponding author), Rockefeller Univ, Biochem Genet & Metab Lab, 1230 York Ave, New York, NY 10021 USA.	breslow@rockefeller.edu	Breslow, Jan L/B-7544-2008; Soccio, Raymond/M-7517-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032435] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32435] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amemiya-Kudo M, 2002, J LIPID RES, V43, P1220, DOI 10.1194/jlr.M100417-JLR200; Annicotte JS, 2001, BIOTECHNIQUES, V31, P993; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; Bose HS, 2000, BIOCHEMISTRY-US, V39, P11722, DOI 10.1021/bi000911l; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Costet P, 2000, J BIOL CHEM, V275, P28240; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Edwards PA, 2000, BBA-MOL CELL BIOL L, V1529, P103, DOI 10.1016/S1388-1981(00)00140-2; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Ikeda Y, 2001, J BIOL CHEM, V276, P34259, DOI 10.1074/jbc.M103848200; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; Inoue J, 1998, J BIOCHEM-TOKYO, V123, P1191; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kim JH, 2001, J BIOL CHEM, V276, P18153, DOI 10.1074/jbc.M101661200; Lichtman AH, 1999, ARTERIOSCL THROM VAS, V19, P1938, DOI 10.1161/01.ATV.19.8.1938; Lund EG, 2003, ARTERIOSCL THROM VAS, V23, P1169, DOI 10.1161/01.ATV.0000056743.42348.59; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Maxwell KN, 2003, J LIPID RES, V44, P2109, DOI 10.1194/jlr.M300203-JLR200; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; OKUDA KI, 1994, J LIPID RES, V35, P361; Pandak WM, 2002, J BIOL CHEM, V277, P48158, DOI 10.1074/jbc.M205244200; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Russell DW, 2000, BBA-MOL CELL BIOL L, V1529, P126, DOI 10.1016/S1388-1981(00)00142-6; Schoonjans K, 2000, BBA-MOL CELL BIOL L, V1529, P114, DOI 10.1016/S1388-1981(00)00141-4; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Soccio RE, 2004, ARTERIOSCL THROM VAS, V24, P1150, DOI 10.1161/01.ATV.0000131264.66417.d5; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Soccio RE, 2002, P NATL ACAD SCI USA, V99, P6943, DOI 10.1073/pnas.052143799; Spencer TA, 2001, J MED CHEM, V44, P886, DOI 10.1021/jm0004749; Stocco DM, 2001, ANNU REV PHYSIOL, V63, P193, DOI 10.1146/annurev.physiol.63.1.193; Strauss JF, 2002, STEROIDS, V67, P947, DOI 10.1016/S0039-128X(02)00042-9; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; Szanto A, 2004, MOL CELL BIOL, V24, P8154, DOI 10.1128/MCB.24.18.8154-8166.2004; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462; Zhang M, 2002, J BIOL CHEM, V277, P33300, DOI 10.1074/jbc.M200003200	52	86	88	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19410	19418		10.1074/jbc.M501778200	http://dx.doi.org/10.1074/jbc.M501778200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15760897	hybrid			2022-12-27	WOS:000228932300099
J	Mathai, JP; Germain, M; Shore, GC				Mathai, JP; Germain, M; Shore, GC			BH3-only BIK regulates BAX, BAK-dependent release of Ca2+ from endoplasmic reticulum stores and mitochondrial apoptosis during stress-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBERS; PROTEIN; INDUCTION; FISSION; BAP31; ASSOCIATION; SUPPRESSION; ADENOVIRUS; INTERACTS	BIK, a pro-apoptotic BH3-only member of the BCL-2 family, targets the membrane of the endoplasmic reticulum (ER). It is induced in human cells in response to several stress stimuli, including genotoxic stress ( radiation, doxorubicin) and overexpression of E1A or p53 but not by ER stress pathways resulting from protein malfolding. BIK initiates an early release of Ca2+ from ER upstream of the activation of effector caspases. Release of the mobile ER Ca2+ stores in baby mouse kidney cells doubly deficient in BAX and BAK, on the other hand, is resistant to BIK but is sensitive to ectopic BAK. Over-expression of p53 stimulates recruitment of BAK to the ER, and both its recruitment and assembly into higher order structures is inhibited by BIK small interfering RNA. Employing small interfering RNA knockdowns, we also demonstrated that release of ER Ca2+ and mitochondrial apoptosis in human epithelial cells requires BIK and that a Ca2+-regulated target, the dynamin-related GTPase DRP1, is involved in p53-induced mitochondrial fission and release of cytochrome c to the cytosol. Endogenous cellular BIK, therefore, regulates a BAX, BAK-dependent ER pathway that contributes to mitochondrial apoptosis.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Shore, GC (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg, Montreal, PQ H3G 1Y6, Canada.	gordon.shore@mcgill.ca						Amanna IJ, 2001, J IMMUNOL, V167, P6069, DOI 10.4049/jimmunol.167.11.6069; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Boatright KM, 2003, BIOCHEM SOC SYMP, V70, P233, DOI 10.1042/bss0700233; Bouillet P, 2002, J CELL SCI, V115, P1567; BOYD JM, 1995, ONCOGENE, V11, P1921; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Castells A, 2000, CANCER RES, V60, P2836; Coultas L, 2004, MOL CELL BIOL, V24, P1570, DOI 10.1128/MCB.24.4.1570-1581.2004; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; GERMAIN M, 2003, SCI STKE; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Han J, 1996, MOL CELL BIOL, V16, P5857; Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101; Jiang AM, 2001, J IMMUNOL, V166, P6025, DOI 10.4049/jimmunol.166.10.6025; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Oakes SA, 2003, BIOCHEM PHARMACOL, V66, P1335, DOI 10.1016/S0006-2952(03)00482-9; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Thomenius MJ, 2003, J CELL SCI, V116, P4493, DOI 10.1242/jcs.00829; TOLLOCZKO B, 1995, AM J PHYSIOL-LUNG C, V269, pL234, DOI 10.1152/ajplung.1995.269.2.L234; Verma S, 2000, GENE, V254, P157, DOI 10.1016/S0378-1119(00)00276-6; Wang B, 2003, J BIOL CHEM, V278, P14461, DOI 10.1074/jbc.M209684200; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084; Zuppini A, 2002, BIOCHEMISTRY-US, V41, P2850, DOI 10.1021/bi015967+	41	146	167	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23829	23836		10.1074/jbc.M500800200	http://dx.doi.org/10.1074/jbc.M500800200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15809295	hybrid			2022-12-27	WOS:000229880000055
J	Moro, L; Arbini, AA; Marra, E; Greco, M				Moro, L; Arbini, AA; Marra, E; Greco, M			Down-regulation of BRCA2 expression by collagen type I promotes prostate cancer cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-MEDIATED PROTEOLYSIS; GROWTH-FACTOR RECEPTOR; INTEGRIN EXPRESSION; CYCLE PROGRESSION; C-MYC; CARCINOMA; AKT; ACTIVATION; SUSCEPTIBILITY; KINASE	BRCA2 is a tumor suppressor gene that when mutated confers an increased susceptibility to developing breast and prostate carcinoma. Besides its role in mediating DNA repair, new evidence suggests that BRCA2 may also play a role in suppressing cancer cell growth. Because altered interactions between neoplastic cells and the surrounding extracellular matrix (ECM) play a pivotal role in unchecked cancer cell proliferation and metastatic progression, we hypothesized that the ECM may have an effect in BRCA2 expression. By using normal and prostate carcinoma cell lines, we demonstrated that although normal cells transiently increase BRCA2 protein levels when adhering to the ECM protein collagen type I (COL1), carcinoma cells exhibit a significant reduction in BRCA2 protein. This aberrant effect is independent from de novo protein synthesis and results from COL1-beta(1) integrin signaling through phosphatidylinositol (PI) 3-kinase leading to BRCA2 ubiquitination and degradation in the proteasome. BRCA2 protein depletion after cancer cell adhesion to COL1 or in small RNA interference assays triggers new DNA synthesis, a trophic effect that is abrogated by recombinant BRCA2 expression. Blocking or inhibiting beta(1) integrin, PI 3-kinase, or proteasome activity all have a negative effect on COL1-mediated DNA synthesis in cancer cells. In normal cells, the transient increase in BRCA2 expression is independent from beta(1) integrin or PI 3-kinase and has no effect in cell proliferation. In summary, these results unravel a novel mechanism whereby prostate carcinoma cell proliferation is enhanced by the down- regulation of BRCA2 expression when interacting with COL1, a major component of the ECM at osseous metastatic sites.	CNR, Inst Biomembranes & Bioenerget, CNR, I-70126 Bari, Italy; Univ Rochester, Sch Med, Dept Pathol & Lab Med, Rochester, NY 14642 USA	Consiglio Nazionale delle Ricerche (CNR); University of Rochester	Moro, L (corresponding author), CNR, Inst Biomembranes & Bioenerget, CNR, Via Amendola 165-A, I-70126 Bari, Italy.	l.moro@ibbe.cnr.it	Moro, Loredana/F-4790-2010	Arbini, Arnaldo/0000-0003-0345-4174				Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; Bashir T, 2003, ADV CANCER RES, V88, P101, DOI 10.1016/S0065-230X(03)88305-7; Benaud CM, 2001, ONCOGENE, V20, P759, DOI 10.1038/sj.onc.1204152; Blaess S, 2004, J NEUROSCI, V24, P3402, DOI 10.1523/JNEUROSCI.5241-03.2004; Brothman AR, 2002, AM J MED GENET, V115, P150, DOI 10.1002/ajmg.10694; Bruun D, 2003, DNA REPAIR, V2, P1007, DOI 10.1016/S1568-7864(03)00112-5; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COLLINS N, 1995, ONCOGENE, V10, P1673; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; DEGEORGES A, 1995, INT J CANCER, V62, P724, DOI 10.1002/ijc.2910620613; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fornaro M, 2000, MOL BIOL CELL, V11, P2235, DOI 10.1091/mbc.11.7.2235; Gao N, 2003, BIOCHEM BIOPH RES CO, V310, P1124, DOI 10.1016/j.bbrc.2003.09.132; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; GREEN J, 1994, MINER ELECTROL METAB, V20, P7; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; HaywoodReid PL, 1997, PROSTATE, V31, P1, DOI 10.1002/(SICI)1097-0045(19970401)31:1<1::AID-PROS1>3.0.CO;2-S; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hirsch E, 2002, J CELL BIOL, V157, P481, DOI 10.1083/jcb.200111065; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Juliano Rudy, 1996, Bioessays, V18, P911, DOI 10.1002/bies.950181110; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; Kiefer JA, 2001, MATRIX BIOL, V20, P429, DOI 10.1016/S0945-053X(01)00159-7; Kostenuik PJ, 1996, CLIN EXP METASTAS, V14, P19, DOI 10.1007/BF00157682; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JW, 2004, MOL CELLS, V17, P188; Liede A, 2004, J CLIN ONCOL, V22, P735, DOI 10.1200/JCO.2004.05.055; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Malik SN, 2002, CLIN CANCER RES, V8, P1168; Manes T, 2003, J CELL BIOL, V161, P817, DOI 10.1083/jcb.200212172; Miralem T, 2003, MOL CELL BIOL, V23, P579, DOI 10.1128/MCB.23.2.579-593.2003; Moro L, 2004, J BIOL CHEM, V279, P1692, DOI 10.1074/jbc.M307857200; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; OHNUKI Y, 1980, CANCER RES, V40, P524; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Perrin BJ, 2002, INT J BIOCHEM CELL B, V34, P722, DOI 10.1016/S1357-2725(02)00009-2; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Rubin MA, 2000, CLIN CANCER RES, V6, P1038; Schoenfeld AR, 2004, MOL CELL BIOL, V24, P7444, DOI 10.1128/MCB.24.17.7444-7455.2004; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shin MS, 2004, CANCER RES, V64, P4419, DOI 10.1158/0008-5472.CAN-03-3885; Simard J, 2003, ENDOCR-RELAT CANCER, V10, P225, DOI 10.1677/erc.0.0100225; Spurgers KB, 2004, ONCOGENE, V23, P1712, DOI 10.1038/sj.onc.1207293; Su LK, 1998, ONCOGENE, V17, P2377, DOI 10.1038/sj.onc.1202162; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang SC, 2002, CANCER RES, V62, P1311; Wang SC, 2001, CANCER RES, V61, P2838; Wei JY, 1998, J BIOL CHEM, V273, P5903, DOI 10.1074/jbc.273.10.5903; Wu KJ, 2003, J BIOL CHEM, V278, P15652, DOI 10.1074/jbc.M211297200; Yu VPCC, 2000, GENE DEV, V14, P1400; ZETTER BR, 1990, NEW ENGL J MED, V322, P605; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	67	24	27	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22482	22491		10.1074/jbc.M414091200	http://dx.doi.org/10.1074/jbc.M414091200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15805113	hybrid			2022-12-27	WOS:000229557900094
J	Aroca-Aguilar, JD; Sanchez-Sanchez, F; Ghosh, S; Coca-Prados, M; Escribano, J				Aroca-Aguilar, JD; Sanchez-Sanchez, F; Ghosh, S; Coca-Prados, M; Escribano, J			Myocilin mutations causing glaucoma inhibit the intracellular endoproteolytic cleavage of myocilin between amino acids Arg(226) and Ile(227)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRABECULAR MESHWORK CELLS; OLFACTOMEDIN DOMAIN; NON-SECRETION; CILIARY BODY; GENE; MUTANT; PROTEIN; TIGR; LOCALIZATION; EXPRESSION	Myocilin is a secreted glycoprotein of unknown function that is ubiquitously expressed in many human organs, including the eye. Mutations in this protein produce glaucoma, a leading cause of blindness worldwide. To explore the biological role of myocilin and the pathogenesis of glaucoma, we have analyzed the expression of recombinant wild type and four representative pathogenic myocilin mutations (E323K, Q368X, P370L, and D380A) in transiently transfected cell lines derived from ocular and nonocular tissues. We found that wild type myocilin undergoes an intracellular endoproteolytic processing at the C terminus of Arg(226). This cleavage predicts the production of two fragments, one of 35 kDa containing the C-terminal olfactomedin-like domain, and another of 20 kDa containing the N-terminal leucine zipper-like domain. Here we have analyzed the 35-kDa processed fragment, and we have found that it is co-secreted with the nonprocessed protein. Western immunoblot analyses showed that human aqueous humor and some ocular tissues also contain the processed 35-kDa myocilin, indicating that the endoproteolytic cleavage occurs in vivo. Mutant myocilins accumulated in the endoplasmic reticulum of transfected cells as insoluble aggregates. Interestingly, the four pathogenic myocilins inhibited the endoproteolytic processing with varying efficiency. Furthermore, the mutation P370L, which produces the most severe glaucoma phenotype, also elicited the most potent endoproteolytic cleavage inhibition. We propose that the endoproteolytic processing might regulate the activity of myocilin and that the inhibition of the processing by pathogenic mutations impairs the normal role of myocilin.	Univ Castilla La Mancha, Fac Med, Ctr Reg Invest Biomed, Area Genet, Albacete 02006, Spain; Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06510 USA	Universidad de Castilla-La Mancha; Yale University	Escribano, J (corresponding author), Univ Castilla La Mancha, Fac Med, Ctr Reg Invest Biomed, Area Genet, Avda Almansa Sn, Albacete 02006, Spain.	julio.escribano@uclm.es	Escribano, Julio/D-9742-2015; Aroca-Aguilar, Jose Daniel/R-5513-2019; Aroca-Aguilar, J.Daniel/B-7842-2008	Escribano, Julio/0000-0002-8919-8134; Aroca-Aguilar, Jose Daniel/0000-0001-6487-1612; Aroca-Aguilar, J.Daniel/0000-0001-6487-1612	NEI NIH HHS [EY04873] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004873] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adam MF, 1997, HUM MOL GENET, V6, P2091, DOI 10.1093/hmg/6.12.2091; BAL RS, 1993, BIOCHEMISTRY-US, V32, P1047, DOI 10.1021/bi00055a008; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Caballero M, 2001, BIOCHEM BIOPH RES CO, V282, P662, DOI 10.1006/bbrc.2001.4624; Caballero M, 2000, BBA-MOL BASIS DIS, V1502, P447, DOI 10.1016/S0925-4439(00)00068-5; Coca-Prados M, 1999, PROG RETIN EYE RES, V18, P403, DOI 10.1016/S1350-9462(98)00026-3; COCAPRADOS M, 1986, P NATL ACAD SCI USA, V83, P8754, DOI 10.1073/pnas.83.22.8754; ESCRIBANO J, 1995, J BIOCHEM-TOKYO, V118, P921, DOI 10.1093/jb/118.5.921; Fautsch MP, 2001, INVEST OPHTH VIS SCI, V42, P2324; Goldwich A, 2003, INVEST OPHTH VIS SCI, V44, P1953, DOI 10.1167/iovs.02-0863; Huang W, 2000, Ophthalmic Genet, V21, P155, DOI 10.1076/1381-6810(200009)21:3;1-Z;FT155; Jacobson N, 2001, HUM MOL GENET, V10, P117, DOI 10.1093/hmg/10.2.117; Joe MK, 2003, BIOCHEM BIOPH RES CO, V312, P592, DOI 10.1016/j.bbrc.2003.10.162; Karali A, 2000, INVEST OPHTH VIS SCI, V41, P729; Kennan AM, 1998, J MED GENET, V35, P957, DOI 10.1136/jmg.35.11.957; Kim BS, 2001, MOL CELL BIOL, V21, P7707, DOI 10.1128/MCB.21.22.7707-7713.2001; Kubota R, 1997, GENOMICS, V41, P360, DOI 10.1006/geno.1997.4682; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam DSC, 2000, INVEST OPHTH VIS SCI, V41, P1386; Li G, 1997, ELECTROPHORESIS, V18, P391, DOI 10.1002/elps.1150180313; Liu YH, 2004, HUM MOL GENET, V13, P1193, DOI 10.1093/hmg/ddh128; Mertts M, 1999, LAB INVEST, V79, P1237; Morissette J, 1998, NAT GENET, V19, P319, DOI 10.1038/1203; Mukhopadhyay A, 2002, MOL VIS, V8, P271; Nagy I, 2003, BIOCHEM BIOPH RES CO, V302, P554, DOI 10.1016/S0006-291X(03)00198-0; Nguyen TD, 1998, J BIOL CHEM, V273, P6341, DOI 10.1074/jbc.273.11.6341; O'Brien ET, 2000, INVEST OPHTH VIS SCI, V41, P3842; Ortego J, 1997, FEBS LETT, V413, P349, DOI 10.1016/S0014-5793(97)00934-4; Polansky JR, 1997, OPHTHALMOLOGICA, V211, P126, DOI 10.1159/000310780; Polansky JR, 1993, BASIC ASPECTS GLAUCO, P307; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774; QUIGLEY HA, 1992, OPHTHALMOLOGY, V99, P19; Rao PV, 2000, EXP EYE RES, V71, P637, DOI 10.1006/exer.2000.0920; Rozsa F W, 1998, Mol Vis, V4, P20; Russell P, 2001, INVEST OPHTH VIS SCI, V42, P983; Sarfarazi M, 1997, HUM MOL GENET, V6, P1667, DOI 10.1093/hmg/6.10.1667; Shimizu S, 2000, AM J OPHTHALMOL, V130, P165, DOI 10.1016/S0002-9394(00)00536-5; Sohn S, 2002, INVEST OPHTH VIS SCI, V43, P3680; Stamer WD, 1998, INVEST OPHTH VIS SCI, V39, P1804; Stoilova D, 1998, J MED GENET, V35, P989, DOI 10.1136/jmg.35.12.989; Suyama M, 2003, BIOINFORMATICS, V19, P673, DOI 10.1093/bioinformatics/btg031; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Ueda J, 2000, J HISTOCHEM CYTOCHEM, V48, P1321, DOI 10.1177/002215540004801003; Wentz-Hunter K, 2003, MOL VIS, V9, P308; WILSON CM, 1983, METHOD ENZYMOL, V91, P236; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; Zhou ZH, 1999, HUM MOL GENET, V8, P2221, DOI 10.1093/hmg/8.12.2221; Zimmerman CC, 1999, MOL VIS, V5	49	65	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21043	21051		10.1074/jbc.M501340200	http://dx.doi.org/10.1074/jbc.M501340200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15795224	hybrid			2022-12-27	WOS:000229438800019
J	Fiedor, L; Scheer, H				Fiedor, L; Scheer, H			Trapping of an assembly intermediate of photosynthetic LH1 antenna beyond B820 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; RHODOSPIRILLUM-RUBRUM; CRYSTAL-STRUCTURE; RHODOBACTER-SPHAEROIDES; SPECTROSCOPIC CHARACTERIZATION; PERIDININ-CHLOROPHYLL; CIRCULAR-DICHROISM; PURPLE BACTERIA; CORE COMPLEX; BACTERIOCHLOROPHYLL	Most photosynthetic LH1 antennae undergo dissociation into B820 subunits, suggesting their universal character as structural modules. However, dissociation into subunits seems to occur reversibly only in the absence of carotenoids and the subunits were never found to bind carotenoids. The interactions of carotenoids with B820 have been studied in a newly developed reconstitution assay of the LH1 antenna from Rhodospirillum rubrum (Fiedor, L., Akahane, J., and Koyama, Y. ( 2004) Biochemistry 43, 16487 - 16496). These model studies show that B820 subunits strongly interact with carotenoids and spontaneously form stable LH1-like complexes with substoichiometric carotenoid content. This is the first experimental evidence that B820 may occur as a short-lived intermediate in the assembly of LH1 in vivo. The resulting complex of B820 subunits with carotenoid, termed iB873, is homogeneous, according to ion exchange chromatography and reproducible pigment composition. The iB873-bound carotenoid is as efficient in energy transfer to bacteriochlorophyll as the one in native antenna. To our knowledge, iB873 is the first complex binding functional carotenoid, with the spectral and biochemical properties intermediate between that of B820 and the fully assembled LH1.	Jagiellonian Univ, Fac Biotechnol, PL-30387 Krakow, Poland; Univ Munich, Dept Biol 1, D-80638 Munich, Germany	Jagiellonian University; University of Munich	Fiedor, L (corresponding author), Jagiellonian Univ, Fac Biotechnol, Gronostajowa 7, PL-30387 Krakow, Poland.	lfiedor@mol.uj.edu.pl						Arluison V, 2002, BIOCHEMISTRY-US, V41, P11812, DOI 10.1021/bi0202124; Bahatyrova S, 2004, NATURE, V430, P1058, DOI 10.1038/nature02823; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; CHANG MC, 1990, BIOCHEMISTRY-US, V29, P421, DOI 10.1021/bi00454a017; Cogdell R. J., 1995, ANOXYGENIC PHOTOSYNT, P315; COGDELL RJ, 1985, PHOTOCHEM PHOTOBIOL, V42, P669, DOI 10.1111/j.1751-1097.1985.tb01629.x; DAVIS CM, 1995, J BIOL CHEM, V270, P5793, DOI 10.1074/jbc.270.11.5793; DEISENHOFER J, 1993, PHOTOSYNTHETIC REACT, V1, P541; Drews G, 1996, ARCH MICROBIOL, V166, P151, DOI 10.1007/s002030050370; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Fiedor L, 2004, BIOCHEMISTRY-US, V43, P16487, DOI 10.1021/bi0481287; Fiedor L, 2000, CHEM PHYS LETT, V319, P145, DOI 10.1016/S0009-2614(00)00112-3; Fiedor L, 2001, BIOCHEMISTRY-US, V40, P3737, DOI 10.1021/bi002257f; Fujii R, 2001, J PHYS CHEM A, V105, P5348, DOI 10.1021/jp010150b; GHOSH R, 1988, BIOCHEMISTRY-US, V27, P1004, DOI 10.1021/bi00403a025; Hofmann E, 1996, SCIENCE, V272, P1788, DOI 10.1126/science.272.5269.1788; KARRASCH S, 1995, EMBO J, V14, P631, DOI 10.1002/j.1460-2075.1995.tb07041.x; Koepke J, 1996, STRUCTURE, V4, P581, DOI 10.1016/S0969-2126(96)00063-9; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Loach P. A., 1995, ANOXYGENIC PHOTOSYNT, P437; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; Meyer M, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL I, P919; MILLER JF, 1987, BIOCHEMISTRY-US, V26, P5055, DOI 10.1021/bi00390a026; Moskalenko A, 1996, Z NATURFORSCH C, V51, P309; NOGUCHI T, 1990, BIOCHIM BIOPHYS ACTA, V1017, P280, DOI 10.1016/0005-2728(90)90194-9; Pandit A, 2003, PHOTOSYNTH RES, V75, P235, DOI 10.1023/A:1023988722299; PICOREL R, 1983, BIOCHEMISTRY-US, V22, P2491, DOI 10.1021/bi00279a028; Pilch M, 1998, J CHEM SOC FARADAY T, V94, P227, DOI 10.1039/a705173e; Prince SM, 2003, J MOL BIOL, V326, P307, DOI 10.1016/S0022-2836(02)01361-X; Pugh RJ, 1998, BBA-BIOENERGETICS, V1366, P301, DOI 10.1016/S0005-2728(98)00131-5; Roszak AW, 2003, SCIENCE, V302, P1969, DOI 10.1126/science.1088892; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scheuring S, 2004, P NATL ACAD SCI USA, V101, P11293, DOI 10.1073/pnas.0404350101; SMITH JRL, 1966, J AM CHEM SOC, V88, P4500, DOI 10.1021/ja00971a036; STURGIS JN, 1994, J MOL BIOL, V238, P445, DOI 10.1006/jmbi.1994.1303; Sundstrom V, 1999, J PHYS CHEM B, V103, P2327, DOI 10.1021/jp983722+; SUNDSTROM V, 1995, ADV PHOTOSYNTHESIS R, P00349; van Amerongen H., 2000, PHOTOSYNTHETIC EXCIT; van Oijen AM, 1999, SCIENCE, V285, P400, DOI 10.1126/science.285.5426.400; Vegh AP, 2002, FEBS LETT, V528, P222, DOI 10.1016/S0014-5793(02)03314-8; Wang YL, 2002, J AM CHEM SOC, V124, P8445, DOI 10.1021/ja025618i; Wang ZY, 2002, J AM CHEM SOC, V124, P1072, DOI 10.1021/ja0112994; WESTERHUIS WHJ, 1992, PHOTOSYNTH RES, V34, P112; Zhang JP, 2001, J PHYS CHEM B, V105, P7312, DOI 10.1021/jp004360k; Zhang JP, 1998, J PHYS CHEM B, V102, P1632, DOI 10.1021/jp9728058	45	16	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20921	20926		10.1074/jbc.M501212200	http://dx.doi.org/10.1074/jbc.M501212200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15788392	hybrid			2022-12-27	WOS:000229438800003
J	Kim, H; Rhee, SH; Kokkotou, E; Na, X; Savidge, T; Moyer, MP; Pothoulakis, C; LaMont, JT				Kim, H; Rhee, SH; Kokkotou, E; Na, X; Savidge, T; Moyer, MP; Pothoulakis, C; LaMont, JT			Clostridium difficile toxin A regulates inducible cyclooxygenase-2 and prostaglandin E-2 synthesis in colonocytes via reactive oxygen species and activation of p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; COLON-CANCER CELLS; NF-KAPPA-B; MESSENGER-RNA; CHOLERA-TOXIN; TRANSCRIPTIONAL REGULATION; SIGNAL-TRANSDUCTION; RESPONSIVE ELEMENT; HYDROGEN-PEROXIDE; INDUCED ENTERITIS	Clostridium difficile toxin A induces acute colitis with neutrophil infiltration and up-regulation of numerous pro-inflammatory mediators, but the contribution of cyclooxygenase-2 (COX-2) induction in this infection is unknown. We report here that toxin A induces expression of COX-2 and secretion of prostaglandin E2 (PGE(2)) in a dose- and time-dependent manner in cultured NCM460 human colonocytes and in human intestinal xenografts. This induction was blocked by SB203580, a p38 MAPK inhibitor, which also decreased the phosphorylation of MSK-1, CREB/ATF-1, and COX-2 promoter activity following toxin A stimulation. Gel shift assays indicated that CREB/ATF-1 was the major proteins binding to the COX-2-CRE. Moreover, colonocytes exposed to toxin A produced reactive oxygen species (ROS), which activated p38 MAPK, MSK-1, and CREB/ATF-1, leading to subsequent COX-2 induction and PGE2 secretion. In intact mice, blockage of p38 MAPK inhibited toxin A-mediated induction of COX-2 in enterocytes as well as lamina propria cells, and significantly blocked the toxin A-induced ileal secretion of fluid and PGE2. Furthermore, a selective COX-2 inhibitor also diminished toxin A-associated ileal fluid and PGE2 secretion. The main signaling pathway for toxin A induction of human COX-2 involves ROS-mediated activation of p38 MAPK, MSK-1, CREB, and ATF-1. Toxin A triggers ileal inflammation and secretion of fluid via COX-2 induction and release of PGE2.	Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat, Boston, MA 02215 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Gastroenterol, Boston, MA 02215 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Nutr, Boston, MA 02215 USA; INCELL Corp, San Antonio, TX 78249 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	LaMont, JT (corresponding author), Beth Israel Deaconess Med Ctr, Div Gastroenterol, Dana 501,330 Brookline Ave, Boston, MA 02215 USA.	jlamont@bidmc.harvard.edu			NIDDK NIH HHS [DK R37-38458, DK R01-33506] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alcantara C, 2001, J INFECT DIS, V184, P648, DOI 10.1086/322799; Beubler E, 2001, J PHARMACOL EXP THER, V297, P940; Beubler E, 2000, ANN NY ACAD SCI, V915, P339; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; ChavesOlarte E, 1997, J CLIN INVEST, V100, P1734, DOI 10.1172/JCI119698; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; D HE, 2000, GASTROENTEROLOGY, V119, P139, DOI 10.1053/gast.2000.8526; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Devaux Y, 2001, J IMMUNOL, V167, P3962, DOI 10.4049/jimmunol.167.7.3962; Ding M, 2002, MOL CELL BIOCHEM, V234, P81, DOI 10.1023/A:1015901232124; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Eckmann L, 1997, J CLIN INVEST, V100, P296, DOI 10.1172/JCI119535; Faour WH, 2003, J BIOL CHEM, V278, P26897, DOI 10.1074/jbc.M212790200; He D, 2002, GASTROENTEROLOGY, V122, P1048, DOI 10.1053/gast.2002.32386; HECHT G, 1988, J CLIN INVEST, V82, P1516, DOI 10.1172/JCI113760; Houglum K, 1997, J CLIN INVEST, V99, P1322, DOI 10.1172/JCI119291; Huang CS, 2001, J BIOL CHEM, V276, P40234, DOI 10.1074/jbc.M103684200; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Ishida Y, 2004, J IMMUNOL, V172, P3018, DOI 10.4049/jimmunol.172.5.3018; Jefferson KK, 1999, J IMMUNOL, V163, P5183; Jones MK, 1999, FASEB J, V13, P2186, DOI 10.1096/fasebj.13.15.2186; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; Kyne L, 2002, CLIN INFECT DIS, V34, P346, DOI 10.1086/338260; LANZA FL, 1991, AM J GASTROENTEROL, V86, P1743; Mahida YR, 1996, GUT, V38, P337, DOI 10.1136/gut.38.3.337; MATUCHANSKY C, 1976, GASTROENTEROLOGY, V71, P274; Mifflin RC, 2004, MOL PHARMACOL, V65, P470, DOI 10.1124/mol.65.2.470; NAKAYAMA H, 1992, NUCLEIC ACIDS RES, V20, P4939, DOI 10.1093/nar/20.18.4939; Nie M, 2003, MOL CELL BIOL, V23, P9233, DOI 10.1128/MCB.23.24.9233-9244.2003; Pothoulakis C, 1996, J CLIN INVEST, V98, P641, DOI 10.1172/JCI118835; POTHOULAKIS C, 1991, J CLIN INVEST, V88, P119, DOI 10.1172/JCI115267; Pothoulakis C, 2001, AM J PHYSIOL-GASTR L, V280, pG178, DOI 10.1152/ajpgi.2001.280.2.G178; POTHOULAKIS C, 1993, GASTROENTEROLOGY, V105, P701, DOI 10.1016/0016-5085(93)90886-H; Powell DW, 1991, HDB PHYSL GASTROINTE, P591; RIEGLER M, 1995, J CLIN INVEST, V95, P2004, DOI 10.1172/JCI117885; Roze C, 1998, GASTROENTEROLOGY, V115, P591, DOI 10.1016/S0016-5085(98)70138-6; Saukkonen K, 2003, CANCER RES, V63, P3032; Savidge TC, 2003, GASTROENTEROLOGY, V125, P413, DOI 10.1016/S0016-5085(03)00902-8; SAVIDGE TC, 1995, DIFFERENTIATION, V58, P361, DOI 10.1046/j.1432-0436.1995.5850361.x; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Tang QB, 2001, ONCOGENE, V20, P5164, DOI 10.1038/sj.onc.1204667; TRIADAFILOPOULOS G, 1989, GASTROENTEROLOGY, V97, P1186, DOI 10.1016/0016-5085(89)91689-2; TRIADAFILOPOULOS G, 1987, GASTROENTEROLOGY, V93, P273, DOI 10.1016/0016-5085(87)91014-6; Warny M, 2000, J CLIN INVEST, V105, P1147, DOI 10.1172/JCI7545; WEYMER A, 1985, J CLIN INVEST, V76, P1828, DOI 10.1172/JCI112175; Wu DY, 2003, J BIOL CHEM, V278, P10983, DOI 10.1074/jbc.M207470200; Yamaoka K, 1998, J IMMUNOL, V160, P838; Ying LH, 1997, J BIOL CHEM, V272, P2412; Yu Y, 1998, J IMMUNOL, V161, P3746; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200	52	79	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21237	21245		10.1074/jbc.M413842200	http://dx.doi.org/10.1074/jbc.M413842200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15767259	hybrid			2022-12-27	WOS:000229438800042
J	Wu, HY; Yuen, EY; Lu, YF; Matsushita, M; Matsui, H; Yan, Z; Tomizawa, K				Wu, HY; Yuen, EY; Lu, YF; Matsushita, M; Matsui, H; Yan, Z; Tomizawa, K			Regulation of N-methyl-D-aspartate receptors by calpain in cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MOLECULAR DIVERSITY; HIPPOCAMPAL-NEURONS; MEDIATED CLEAVAGE; NMDA RECEPTORS; PROTEOLYSIS; INACTIVATION; ACTIVATION; CHANNELS; PHOSPHORYLATION	The N-methyl-D-aspartate (NMDA) receptor is a cation channel highly permeable to calcium and plays critical roles in governing normal and pathologic functions in neurons. Calcium entry through NMDA receptors (NMDARs) can lead to the activation of the Ca2+-dependent protease, calpain. Here we investigated the involvement of calpain in regulation of NMDAR channel function. After prolonged (5-min) treatment with NMDA or glutamate, the whole-cell NMDAR-mediated current was significantly reduced in both acutely dissociated and cultured cortical pyramidal neurons. The down-regulation of NMDAR current was blocked by bath application of selective calpain inhibitors. Intracellular injection of a specific calpain inhibitory peptide also eliminated the down-regulation of NMDAR current induced by prolonged NMDA treatment. In contrast, dynamin inhibitory peptide had no effect on the depression of NMDAR current, suggesting the lack of involvement of dynamin/clathrin-mediated NMDAR internalization in this process. Immunoblotting analysis showed that the NR2A and NR2B subunits of NMDARs were markedly degraded in cultured cortical neurons treated with glutamate, and the degradation of NR2 subunits was prevented by calpain inhibitors. Taken together, our results suggest that prolonged activation of NMDARs in neurons activates calpain, and activated calpain in turn down-regulates the function of NMDARs, which provides a neuroprotective mechanism against NMDAR overstimulation accompanying ischemia and stroke.	Okayama Univ, Grad Sch Med & Dent, Dept Physiol, Okayama 7008558, Japan; SUNY Buffalo, Dept Physiol & Biophys, Sch Med & Biomed Sci, Buffalo, NY 14214 USA; Japan Sci & Technol Corp, Prot Therapy, New Technoventure Oriented R&D, Okayama 7008558, Japan	Okayama University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Japan Science & Technology Agency (JST)	Tomizawa, K (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Physiol, 2-5-1 Shikata, Okayama 7008558, Japan.	tomikt@md.okayama-u.ac.jp	Tomizawa, Kazuhito/F-2405-2015	Tomizawa, Kazuhito/0000-0002-5663-2627	NIMH NIH HHS [MH63128] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063128] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adamec R, 1998, NEUROSCI BIOBEHAV R, V23, P301, DOI 10.1016/S0149-7634(98)00032-3; Bi RF, 2000, J BIOL CHEM, V275, P26477, DOI 10.1074/jbc.M003763200; Bi XN, 1998, BRAIN RES, V790, P245, DOI 10.1016/S0006-8993(98)00067-5; Chen GJ, 2004, P NATL ACAD SCI USA, V101, P2596, DOI 10.1073/pnas.0308618100; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Dingledine R, 1999, PHARMACOL REV, V51, P7; Feng J, 2001, J NEUROSCI, V21, P6502, DOI 10.1523/JNEUROSCI.21-17-06502.2001; Garcia JH, 1997, STROKE, V28, P2303, DOI 10.1161/01.STR.28.11.2303; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Guttmann RP, 2002, J PHARMACOL EXP THER, V302, P1023, DOI 10.1124/jpet.102.036962; Guttmann RP, 2001, J NEUROCHEM, V78, P1083, DOI 10.1046/j.1471-4159.2001.00493.x; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; KAWASAKI H, 1989, J BIOCHEM, V106, P274, DOI 10.1093/oxfordjournals.jbchem.a122844; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P9870, DOI 10.1073/pnas.152336999; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; Kittler JT, 2000, J NEUROSCI, V20, P7972; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LEGENDRE P, 1993, J NEUROSCI, V13, P674; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; Lissin DV, 1998, P NATL ACAD SCI USA, V95, P7097, DOI 10.1073/pnas.95.12.7097; Lynch DR, 2002, J PHARMACOL EXP THER, V300, P717, DOI 10.1124/jpet.300.3.717; MAKI M, 1989, J BIOL CHEM, V264, P18866; Medina I, 1996, J PHYSIOL-LONDON, V495, P411, DOI 10.1113/jphysiol.1996.sp021603; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Nong Y, 2003, NATURE, V422, P302, DOI 10.1038/nature01497; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patzke H, 2002, J BIOL CHEM, V277, P8054, DOI 10.1074/jbc.M109645200; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Simpkins KL, 2003, J NEUROSCI, V23, P11322; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Tomizawa K, 2002, J NEUROSCI, V22, P2590, DOI 10.1523/JNEUROSCI.22-07-02590.2002; Vissel B, 2001, NAT NEUROSCI, V4, P587, DOI 10.1038/88404; VYKLICKY L, 1993, J PHYSIOL-LONDON, V470, P575, DOI 10.1113/jphysiol.1993.sp019876; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang X, 2003, J NEUROSCI, V23, P9852; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Wu HY, 2003, NEUROSCI RES, V47, P131, DOI 10.1016/S0168-0102(03)00195-0; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	48	86	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21588	21593		10.1074/jbc.M501603200	http://dx.doi.org/10.1074/jbc.M501603200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15790561	hybrid			2022-12-27	WOS:000229438800082
J	Guo, RT; Ko, TP; Chen, APC; Kuo, CJ; Wang, AHJ; Liang, PH				Guo, RT; Ko, TP; Chen, APC; Kuo, CJ; Wang, AHJ; Liang, PH			Crystal structures of undecaprenyl pyrophosphate synthase in complex with magnesium, isopentenyl pyrophosphate, and farnesyl thiopyrophosphate - Roles of the metal ion and conserved residues in catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SUBSTRATE-BINDING; CONFORMATIONAL-CHANGE; DIPHOSPHATE SYNTHASE; CHAIN ELONGATION; FLEXIBLE LOOP; MECHANISM; LENGTH; PRENYLTRANSFERASE; IDENTIFICATION	Undecaprenyl pyrophosphate synthase ( UPPs) catalyzes the consecutive condensation reactions of a farnesyl pyrophosphate (FPP) with eight isopentenyl pyrophosphates (IPP), in which new cis-double bonds are formed, to generate undecaprenyl pyrophosphate that serves as a lipid carrier for peptidoglycan synthesis of bacterial cell wall. The structures of Escherichia coli UPPs were determined previously in an orthorhombic crystal form as an apoenzyme, in complex with Mg2+/sulfate/ Triton, and with bound FPP. In a further search of its catalytic mechanism, the wild-type UPPs and the D26A mutant are crystallized in a new trigonal unit cell with Mg2+/IPP/farnesyl thiopyrophosphate (an FPP analogue) bound to the active site. In the wild-type enzyme, Mg2+ is coordinated by the pyrophosphate of farnesyl thiopyrophosphate, the carboxylate of Asp26, and three water molecules. In the mutant enzyme, it is bound to the pyrophosphate of IPP. The [Mg2+] dependence of the catalytic rate by UPPs shows that the activity is maximal at [Mg2+] = 1 mM but drops significantly when Mg2+ ions are in excess (50 mm). Without Mg2+, IPP binds to UPPs only at high concentration. Mutation of Asp26 to other charged amino acids results in significant decrease of the UPPs activity. The role of Asp26 is probably to assist the migration of Mg2+ from IPP to FPP and thus initiate the condensation reaction by ionization of the pyrophosphate group from FPP. Other conserved residues, including His(43), Ser(71), Asn(74), and Arg(77), may serve as general acid/base and pyrophosphate carrier. Our results here improve the understanding of the UPPs enzyme reaction significantly.	Acad Sinica, Taiwan Int Grad Program, Taipei 115, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University	Wang, AHJ (corresponding author), Acad Sinica, Taiwan Int Grad Program, Taipei 115, Taiwan.	ahjwang@gate.sinica.edu.tw; phliang@gate.sinica.edu.tw	Liang, Po-Huang/H-6610-2015	Liang, Po-Huang/0000-0003-1207-5256; Kuo, Chih-Jung/0000-0002-4988-5124; Guo, Rey-Ting/0000-0003-2942-7246				ALLEN CM, 1985, METHOD ENZYMOL, V110, P281; Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483-492.1999; ASAI K, 1994, BIOCHEM BIOPH RES CO, V202, P340, DOI 10.1006/bbrc.1994.1933; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang SY, 2004, PROTEIN SCI, V13, P971, DOI 10.1110/ps.03519904; Chang SY, 2003, BIOCHEMISTRY-US, V42, P14452, DOI 10.1021/bi035283x; Chang SY, 2003, J BIOL CHEM, V278, P29298, DOI 10.1074/jbc.M302687200; CHEN AJ, 1994, PROTEIN SCI, V3, P600; Chen APC, 2005, BIOCHEM J, V386, P169, DOI 10.1042/BJ20040785; Chen YH, 2002, J BIOL CHEM, V277, P7369, DOI 10.1074/jbc.M110014200; da Costa BMT, 2005, BIOMACROMOLECULES, V6, P279, DOI 10.1021/bm049606w; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fujihashi M, 2001, P NATL ACAD SCI USA, V98, P4337, DOI 10.1073/pnas.071514398; Fujikura K, 2003, BIOCHEMISTRY-US, V42, P4035, DOI 10.1021/bi027236v; Guo RT, 2004, J BIOL CHEM, V279, P4903, DOI 10.1074/jbc.M310161200; Guo RT, 2004, BIOCHEMISTRY-US, V43, P7678, DOI 10.1021/bi036336d; Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200; JOLY A, 1993, J BIOL CHEM, V268, P26983; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kellogg BA, 1997, CURR OPIN CHEM BIOL, V1, P570, DOI 10.1016/S1367-5931(97)80054-3; KING HL, 1977, BIOCHEMISTRY-US, V16, P3815, DOI 10.1021/bi00636a015; Ko TP, 2001, J BIOL CHEM, V276, P47474, DOI 10.1074/jbc.M106747200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432-1033.2002.03014.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Ogura K, 1998, CHEM REV, V98, P1263, DOI 10.1021/cr9600464; Ogura K, 1997, Subcell Biochem, V28, P57; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan JJ, 2000, BIOCHEMISTRY-US, V39, P10936, DOI 10.1021/bi000992l; Pan JJ, 2000, BIOCHEMISTRY-US, V39, P13856, DOI 10.1021/bi001226h; Pan JJ, 2002, BBA-PROTEIN STRUCT M, V1594, P64, DOI 10.1016/S0167-4838(01)00283-7; POULTER CD, 1977, J AM CHEM SOC, V99, P957, DOI 10.1021/ja00445a056; ROBYT J, 1998, ESSENTIALS CARBOHYDR, P305; Shimizu N, 1998, J BIOL CHEM, V273, P19476, DOI 10.1074/jbc.273.31.19476	36	98	100	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20762	20774		10.1074/jbc.M502121200	http://dx.doi.org/10.1074/jbc.M502121200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788389	Green Published, hybrid			2022-12-27	WOS:000229242000074
J	Hoegy, FO; Celia, H; Mislin, GL; Vincent, M; Gallay, J; Schalk, IJ				Hoegy, FO; Celia, H; Mislin, GL; Vincent, M; Gallay, J; Schalk, IJ			Binding of iron-free siderophore, a common feature of siderophore outer membrane transporters of Escherichia coli and Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR FPVA; PYOVERDIN RECEPTOR; CRYSTAL-STRUCTURE; TONB; PROTEIN; FHUA; MECHANISM; PYOCHELIN; ACQUISITION; INHIBITION	TonB-dependent iron transporters present in the outer membranes of Gram-negative bacteria transport ferric-siderophore complexes into the periplasm. This requires proton motive force and an integral inner membrane complex, TonB-ExbB-ExbD. Recognition of iron-free siderophores by TonB-dependent outer membrane transporters (OMT) has only been described for a subfamily called OMTN. These OMT(N)s have an additional domain at the N terminus, which interacts with an inner membrane regulatory protein to activate a cytoplasmic sigma factor. This induces transcription of iron transport genes. Here we showed that the ability to bind aposiderophores is not specific to the OMTN subfamily but may be a more general feature of OMTs. FhuA, the ferrichrome OMT in Escherichia coli, and FptA, the pyochelin (Pch) OMT in Pseudomonas aeruginosa, were both able to bind in vitro and in vivo the apo-forms and the ferric forms of their corresponding siderophore at a common binding site. FptA produced in P. aeruginosa cells grown in an iron-deficient medium copurifies with a ligand that, as characterized by fluorescence, is iron-free Pch. As described previously for the FpvA transporter ( pyoverdine OMT in P. aeruginosa), it appears that in conditions of iron limitation all the FptA receptors at the cell surface are loaded with apoPch. This FptA-Pch complex is less stable in vitro than the previously described copurified FpvA-Pvd complex and can be loaded with iron in vitro in the presence of Pch-Fe, citrate-Fe, or ferrichrome-Fe. These findings improved our understanding of the iron uptake mechanism via siderophores in Gram-negative bacteria.	ESBS, CNRS, UPR 9050, Dept Recepteurs & Prot Membranaires, F-67413 Illkirch Graffenstaden, France; Univ Paris 11, CNRS, UMR 8619, IBBMC, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Schalk, IJ (corresponding author), ESBS, CNRS, UPR 9050, Dept Recepteurs & Prot Membranaires, Bld Sebastien Brant,BP 10412, F-67413 Illkirch Graffenstaden, France.	schalk@esbs.u-strasbg.fr						ALBRECHTGARY AM, 1994, INORG CHEM, V33, P6391, DOI 10.1021/ic00104a059; ANKENBAUER R, 1986, J BACTERIOL, V167, P7, DOI 10.1128/jb.167.1.7-11.1986; ANKENBAUER RG, 1994, J BACTERIOL, V176, P307, DOI 10.1128/JB.176.2.307-319.1994; Bonhivers M, 2001, BIOCHEMISTRY-US, V40, P2606, DOI 10.1021/bi001725i; Boukhalfa H, 2002, BIOMETALS, V15, P325, DOI 10.1023/A:1020218608266; Braun V, 1997, ARCH MICROBIOL, V167, P325, DOI 10.1007/s002030050451; Braun V, 2003, FRONT BIOSCI-LANDMRK, V8, pS1409, DOI 10.2741/1232; Braun V, 2002, FEBS LETT, V529, P78, DOI 10.1016/S0014-5793(02)03185-X; Braun V, 2001, INT J MED MICROBIOL, V291, P67, DOI 10.1078/1438-4221-00103; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Clement E, 2004, BIOCHEMISTRY-US, V43, P7954, DOI 10.1021/bi049768c; Cobessi D, 2005, J MOL BIOL, V347, P121, DOI 10.1016/j.jmb.2005.01.021; COX CD, 1981, P NATL ACAD SCI-BIOL, V78, P4256, DOI 10.1073/pnas.78.7.4256; DEMANGE P, 1990, BIOL MET, V3, P155; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Folschweiller N, 2000, MOL MEMBR BIOL, V17, P123; Folschweiller N, 2002, BIOCHEMISTRY-US, V41, P14591, DOI 10.1021/bi0259711; Hantke K, 2001, CURR OPIN MICROBIOL, V4, P172, DOI 10.1016/S1369-5274(00)00184-3; KADNER RJ, 1995, J BACTERIOL, V177, P4829, DOI 10.1128/jb.177.17.4829-4835.1995; Letoffe S, 2004, J BACTERIOL, V186, P4067, DOI 10.1128/JB.186.13.4067-4074.2004; Letoffe S, 2001, MOL MICROBIOL, V41, P439, DOI 10.1046/j.1365-2958.2001.02530.x; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Moeck GS, 1998, MOL MICROBIOL, V28, P675, DOI 10.1046/j.1365-2958.1998.00817.x; Moeck GS, 2001, J BACTERIOL, V183, P2755, DOI 10.1128/JB.183.9.2755-2764.2001; Namiranian S, 1997, PHOTOCHEM PHOTOBIOL, V65, P777, DOI 10.1111/j.1751-1097.1997.tb01924.x; Newton SMC, 1999, MOL MICROBIOL, V32, P1153, DOI 10.1046/j.1365-2958.1999.01424.x; POOLE K, 1993, J BACTERIOL, V175, P4597, DOI 10.1128/JB.175.15.4597-4604.1993; Postle K, 2003, MOL MICROBIOL, V49, P869, DOI 10.1046/j.1365-2958.2003.03629.x; ROYLE PL, 1981, J BACTERIOL, V145, P145, DOI 10.1128/JB.145.1.145-155.1981; Schalk IJ, 1999, BIOCHEMISTRY-US, V38, P9357, DOI 10.1021/bi990421x; Schalk IJ, 2004, MOL MICROBIOL, V54, P14, DOI 10.1111/j.1365-2958.2004.04241.x; Schalk IJ, 2002, BIOCHEMISTRY-US, V41, P1663, DOI 10.1021/bi0157767; Schalk IJ, 2001, MOL MICROBIOL, V39, P351, DOI 10.1046/j.1365-2958.2001.02207.x; SCHALK IJ, 2005, PSEUDOMONAS MOL BIOL, V4; Shouldice SR, 2005, J BIOL CHEM, V280, P5820, DOI 10.1074/jbc.M411238200; Stintzi A, 2000, P NATL ACAD SCI USA, V97, P10691, DOI 10.1073/pnas.200318797; Stojiljkovic I, 1997, J BACTERIOL, V179, P805, DOI 10.1128/jb.179.3.805-812.1997; Takase H, 2000, INFECT IMMUN, V68, P1834, DOI 10.1128/IAI.68.4.1834-1839.2000; Vasil ML, 1999, MOL MICROBIOL, V34, P399, DOI 10.1046/j.1365-2958.1999.01586.x; Vincent M, 2000, J PHYS CHEM B, V104, P11286, DOI 10.1021/jp000638x; Visca P, 2002, MOL MICROBIOL, V45, P1177, DOI 10.1046/j.1365-2958.2002.03088.x; Winkelmann G, 2002, BIOCHEM SOC T, V30, P691, DOI 10.1042/BST0300691; Xiao R, 1997, MICROBIOL-UK, V143, P2509, DOI 10.1099/00221287-143-7-2509; Yue WW, 2003, J MOL BIOL, V332, P353, DOI 10.1016/S0022-2836(03)00855-6; Zamri A, 2000, TETRAHEDRON, V56, P249, DOI 10.1016/S0040-4020(99)00946-1	48	47	49	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20222	20230		10.1074/jbc.M500776200	http://dx.doi.org/10.1074/jbc.M500776200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15784620	hybrid			2022-12-27	WOS:000229242000009
J	Misra, S; Ghatak, S; Toole, BP				Misra, S; Ghatak, S; Toole, BP			Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-CARCINOMA CELLS; MULTIDRUG-RESISTANCE; CD44 INTERACTION; SURFACE CD44; CANCER-CELLS; TUMOR-CELLS; IN-VIVO; GROWTH; ACTIVATION; PHOSPHORYLATION	Multidrug resistance is a potent barrier to effective, long term therapy in cancer patients. It is frequently attributed to enhanced expression of multidrug transporters or to the action of receptor kinases, such as ErbB2, and downstream anti-apoptotic signaling pathways, such as the phosphoinositide 3-kinase/Akt pathway. However, very few connections have been made between receptor kinases or anti-apoptotic pathways and multidrug transporter expression or function. Data presented herein show that constitutive interaction of the pericellular polysaccharide, hyaluronan, with its receptor, CD44, regulates assembly and activation of an ErbB2-containing signaling complex, which in turn stimulates phosphoinositide 3-kinase activity in multi-drug-resistant MCF-7/Adr human breast carcinoma cells. Phosphoinositide 3-kinase activates Akt and downstream anti-apoptotic events, which contribute to drug resistance. However, hyaluronan and phosphoinositide 3-kinase stimulate expression of the multidrug transporter, MDR1 (P-glycoprotein), in an interdependent, but Akt-independent, manner. Furthermore, constitutively active phosphoinositide 3-kinase, but not Akt, stimulates hyaluronan production. These Akt-independent effects are dominant over the effects of Akt on doxorubicin resistance in MCF-7/Adr cells. Thus hyaluronan, phosphoinositide 3-kinase, and ErbB2 form a positive feedback loop that strongly amplifies MDR1 expression and regulates drug resistance in these cells. This pathway may also be important in progression of other malignant characteristics. These results illustrate the potential importance of hyaluronan as a therapeutic target in multidrug-resistant carcinomas.	Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA	Medical University of South Carolina	Misra, S (corresponding author), Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA.	misra@musc.edu; toolebp@musc.edu			NATIONAL CANCER INSTITUTE [R01CA082867, R01CA073839] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017698] Funding Source: NIH RePORTER; NCI NIH HHS [CA73839, CA82867] Funding Source: Medline; NCRR NIH HHS [RR-17698] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Chen JS, 2003, DRUG RESIST UPDATE, V6, P129, DOI 10.1016/S1368-7646(03)00040-2; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; Gordon LB, 2003, HUM GENET, V113, P178, DOI 10.1007/s00439-003-0958-9; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943; Itano N, 2004, J BIOL CHEM, V279, P18679, DOI 10.1074/jbc.M313178200; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; Lee JT, 2004, CANCER RES, V64, P8397, DOI 10.1158/0008-5472.CAN-04-1612; Lesley J, 2000, J BIOL CHEM, V275, P26967; Li RS, 2001, J CELL PHYSIOL, V186, P371, DOI 10.1002/1097-4652(2000)9999:999<000::AID-JCP1042>3.0.CO;2-8; Misra S, 2003, J BIOL CHEM, V278, P25285, DOI 10.1074/jbc.C300173200; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Ouskova G, 2004, GLYCOBIOLOGY, V14, P931, DOI 10.1093/glycob/cwh115; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Prehm P, 2004, BIOCHEM PHARMACOL, V68, P1401, DOI 10.1016/j.bcp.2004.06.017; Schroeder JA, 2003, J MOL MED-JMM, V81, P392, DOI 10.1007/s00109-003-0456-5; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Tsatas D, 2002, J CLIN NEUROSCI, V9, P282, DOI 10.1054/jocn.2001.1063; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; Ward JA, 2003, AM J PATHOL, V162, P1403, DOI 10.1016/S0002-9440(10)64273-3; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Wobus M, 2002, APPL IMMUNOHISTO M M, V10, P34, DOI 10.1097/00022744-200203000-00006; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Zeng CX, 1998, INT J CANCER, V77, P396; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200	38	206	213	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20310	20315		10.1074/jbc.M500737200	http://dx.doi.org/10.1074/jbc.M500737200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15784621	hybrid			2022-12-27	WOS:000229242000020
J	Krauser, JA; Guengerich, FP				Krauser, JA; Guengerich, FP			Cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation stereochemistry, kinetic deuterium isotope effects, and rate-limiting steps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CYTOCHROME-P-450-CATALYZED OXIDATION REACTIONS; LIVER MICROSOMAL CYTOCHROME-P-450; ACTIVE-SITE; DRUG-METABOLISM; ALIPHATIC HYDROXYLATION; MECHANISTIC ASPECTS; MULTIPLE PRODUCTS; MASS-SPECTROMETRY; ENZYMIC REACTIONS; N-DEALKYLATION	Testosterone 6 beta-hydroxylation is a prototypic reaction of cytochrome P450 ( P450) 3A4, the major human P450. Biomimetic reactions produced a variety of testosterone oxidation products with 6 beta-hydroxylation being only a minor reaction, indicating that P450 3A4 has considerable control over the course of steroid hydroxylation because 6 beta-hydroxylation is not dominant in a thermodynamically controlled oxidation of the substrate. Several isotopically labeled testosterone substrates were prepared and used to probe the catalytic mechanism of P450 3A4: (i) 2,2,4,6,6-H-2(5); (ii) 6,6(2)H(2); (iii) 6 alpha-H-2; (iv) 6 beta-H-2; and (v) 6 beta-H-3 testosterone. Only the 6 beta-hydrogen was removed by P450 3A4 and not the 6 alpha, indicating that P450 3A4 abstracts hydrogen and rebounds oxygen only at the beta face. Analysis of the rates of hydroxylation of 6 beta-H-1-, 6 beta-H-2-, and 6 beta-H-3-labeled testosterone and application of the Northrop method yielded an apparent intrinsic kinetic deuterium isotope effect ((D)k) of 15. The deuterium isotope effects on k(cat) and k(cat)/K-m in non-competitive reactions were only 2-3. Some "switching" to other hydroxylations occurred because of 6 beta-H-2 substitution. The high Dk value is consistent with an initial hydrogen atom abstraction reaction. Attenuation of the high Dk in the non-competitive experiments implies that C-H bond breaking is not a dominant rate-limiting step. Considerable attenuation of a high Dk value was also seen with a slower P450 3A4 reaction, the O-dealkylation of 7-benzyloxyquinoline. Thus P450 3A4 is an enzyme with regioselective flexibility but also considerable regioselectivity and stereoselectivity in product formation, not necessarily dominated by the ease of C-H bond breaking.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu			NATIONAL CANCER INSTITUTE [R01CA090426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, T32ES007028] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA90426] Funding Source: Medline; NIEHS NIH HHS [T32 ES07028, P30 ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Atkins WM, 2002, J BIOL CHEM, V277, P33258, DOI 10.1074/jbc.M204425200; Bell LC, 1997, J BIOL CHEM, V272, P29643, DOI 10.1074/jbc.272.47.29643; Bell-Parikh LC, 1999, J BIOL CHEM, V274, P23833, DOI 10.1074/jbc.274.34.23833; BJORKHEM I, 1972, EUR J BIOCHEM, V27, P354, DOI 10.1111/j.1432-1033.1972.tb01845.x; BJORKHEM I, 1982, HEPATIC CYTOCHROME P, V108, P645; BOND AM, 1988, ANAL CHEM, V60, P1023, DOI 10.1021/ac00161a015; CHA Y, 1989, SCIENCE, V243, P1325, DOI 10.1126/science.2646716; CLELAND WW, 1987, BIOORG CHEM, V15, P283, DOI 10.1016/0045-2068(87)90026-5; CLELAND WW, 1982, CRC CR REV BIOCH MOL, V13, P385; Dabrowski MJ, 2002, J AM CHEM SOC, V124, P11866, DOI 10.1021/ja027552x; DARBYSHIRE JF, 1994, BIOCHEMISTRY-US, V33, P2938, DOI 10.1021/bi00176a025; DJERASSI C, 1947, J AM CHEM SOC, V69, P2404, DOI 10.1021/ja01202a048; FLEISCHER EB, 1971, J AM CHEM SOC, V93, P3162, DOI 10.1021/ja00742a012; FOSTER AB, 1974, CHEM-BIOL INTERACT, V9, P327, DOI 10.1016/0009-2797(74)90128-8; Francisco WA, 2002, J AM CHEM SOC, V124, P8194, DOI 10.1021/ja025758s; Galetin A, 2003, DRUG METAB DISPOS, V31, P1108, DOI 10.1124/dmd.31.9.1108; GELB MH, 1982, BIOCHEMISTRY-US, V21, P370, DOI 10.1021/bi00531a026; GILLETTE JR, 1994, BIOCHEMISTRY-US, V33, P2927, DOI 10.1021/bi00176a024; GROVES JT, 1980, J AM CHEM SOC, V102, P6375, DOI 10.1021/ja00540a050; GROVES JT, 1979, J AM CHEM SOC, V101, P1032, DOI 10.1021/ja00498a040; GROVES JT, 1978, BIOCHEM BIOPH RES CO, V81, P154, DOI 10.1016/0006-291X(78)91643-1; Guengerich F. P., 2001, PRINCIPLES METHODS T, P1625; Guengerich FP, 1996, J BIOL CHEM, V271, P27321, DOI 10.1074/jbc.271.44.27321; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; GUENGERICH FP, 1986, J BIOL CHEM, V261, P5051; Guengerich FP, 2004, BIOCHEMISTRY-US, V43, P10775, DOI 10.1021/bi0491393; Guengerich FP, 2002, J BIOL CHEM, V277, P33711, DOI 10.1074/jbc.M205146200; Guengerich FP, 1997, BIOCHEMISTRY-US, V36, P14741, DOI 10.1021/bi9719399; GUENGERICH FP, 1988, J BIOL CHEM, V263, P8176; GUENGERICH FP, 2002, CYTOCHROME P450 STRU, P377; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; Han MC, 2000, J LABELLED COMPD RAD, V43, P1149, DOI 10.1002/1099-1344(20001030)43:12<1149::AID-JLCR401>3.0.CO;2-4; Hanna IH, 1998, ARCH BIOCHEM BIOPHYS, V350, P324, DOI 10.1006/abbi.1997.0534; HARADA N, 1984, J BIOL CHEM, V259, P3005; Harlow GR, 1998, P NATL ACAD SCI USA, V95, P6636, DOI 10.1073/pnas.95.12.6636; HILL DH, 1994, J AM CHEM SOC, V116, P2889, DOI 10.1021/ja00086a022; HJELMELAND LM, 1977, BIOCHEM BIOPH RES CO, V76, P541, DOI 10.1016/0006-291X(77)90758-6; HOFLE G, 1978, ANGEW CHEM INT EDIT, V17, P569, DOI 10.1002/anie.197805691; HOLLAND HL, 1978, CAN J CHEM, V56, P3121, DOI 10.1139/v78-510; Hosea NA, 2000, BIOCHEMISTRY-US, V39, P5929, DOI 10.1021/bi992765t; HOSODA H, 1978, CHEM PHARM BULL, V26, P2181; HU Y, 1997, J CHEM SOC P1, V1, P3665; IMAOKA S, 1992, BIOCHEMISTRY-US, V31, P6063, DOI 10.1021/bi00141a015; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JONES JB, 1972, BIOCHIM BIOPHYS ACTA, V258, P800, DOI 10.1016/0005-2744(72)90181-7; Jones SR, 1996, STEROIDS, V61, P565, DOI 10.1016/S0039-128X(96)00114-6; Kenworthy KE, 2001, DRUG METAB DISPOS, V29, P1644; Khan KK, 2003, DRUG METAB DISPOS, V31, P356, DOI 10.1124/dmd.31.4.356; KIM JM, 1993, J AM CHEM SOC, V115, P10591, DOI 10.1021/ja00076a017; Knapp MJ, 2002, EUR J BIOCHEM, V269, P3113, DOI 10.1046/j.1432-1033.2002.03022.x; Kohen A, 1998, ACCOUNTS CHEM RES, V31, P397, DOI 10.1021/ar9701225; Korzekwa KR, 1998, BIOCHEMISTRY-US, V37, P4137, DOI 10.1021/bi9715627; KORZEKWA KR, 1989, BIOCHEMISTRY-US, V28, P9012, DOI 10.1021/bi00449a009; KORZEKWA KR, 1990, DRUG METAB DISPOS, V18, P974; Krafft ME, 1999, J ORG CHEM, V64, P2475, DOI 10.1021/jo982319w; Krauser JA, 2004, EUR J BIOCHEM, V271, P3962, DOI 10.1111/j.1432-1033.2004.04339.x; Kumar D, 2003, J AM CHEM SOC, V125, P13024, DOI 10.1021/ja036906x; MALHOTRA SK, 1964, J AM CHEM SOC, V86, P1997, DOI 10.1021/ja01064a018; Mash EA, 2000, SYNTHETIC COMMUN, V30, P367, DOI 10.1080/00397910008087329; Matsson O, 1998, ADV PHYS ORG CHEM, V31, P143; MAYER RT, 1990, BIOCHEM PHARMACOL, V40, P1645, DOI 10.1016/0006-2952(90)90467-Y; MICHAUD DP, 1985, J ORG CHEM, V50, P1835, DOI 10.1021/jo00211a009; MITOMA C, 1967, BIOCHIM BIOPHYS ACTA, V136, P566, DOI 10.1016/0304-4165(67)90016-5; MIWA GT, 1984, J BIOL CHEM, V259, P3000; MIWA GT, 1985, ARCH BIOCHEM BIOPHYS, V239, P155, DOI 10.1016/0003-9861(85)90822-7; MIWA GT, 1987, BIOESSAYS, V7, P215, DOI 10.1002/bies.950070506; Nomura K, 2000, CHEM PHARM BULL, V48, P344, DOI 10.1248/cpb.48.344; Northrop D. B., 1977, ISOTOPE EFFECTS ENZY, P122; NORTHROP DB, 1981, BIOCHEMISTRY-US, V20, P4056, DOI 10.1021/bi00517a017; NORTHROP DB, 1975, BIOCHEMISTRY-US, V14, P2644, DOI 10.1021/bi00683a013; NORTHROP DB, 1982, METHOD ENZYMOL, V87, P607; NUMAZAWA M, 1979, STEROIDS, V34, P347, DOI 10.1016/0039-128X(79)90085-0; Obach RS, 2000, DRUG METAB DISPOS, V28, P1069; Obach RS, 2001, DRUG METAB DISPOS, V29, P1599; OKAZAKI O, 1993, J BIOL CHEM, V268, P1546; OLEARY MH, 1989, ANNU REV BIOCHEM, V58, P377; Ortiz de Montellano P. R., 2005, CYTOCHROME P450 STRU; Parikh A, 1997, NAT BIOTECHNOL, V15, P784, DOI 10.1038/nbt0897-784; ROSENKRANZ G, 1950, J AM CHEM SOC, V72, P4077, DOI 10.1021/ja01165a066; Saltzman H., 1973, ORG SYNTH, P658; SHAPIRO RH, 1964, J AM CHEM SOC, V86, P2837, DOI 10.1021/ja01068a016; Shapley PA, 2000, J AM CHEM SOC, V122, P1079, DOI 10.1021/ja982171y; SHOU M, 1994, BIOCHEMISTRY-US, V33, P6450, DOI 10.1021/bi00187a009; Shou M, 2001, J BIOL CHEM, V276, P2256, DOI 10.1074/jbc.M008799200; Shou MG, 1999, BIOCHEM J, V340, P845, DOI 10.1042/0264-6021:3400845; Singh SB, 2003, J MED CHEM, V46, P1330, DOI 10.1021/jm020400s; SMITH DA, 1992, BIOCHEM PHARMACOL, V44, P2089, DOI 10.1016/0006-2952(92)90333-E; Smith M.B., 2007, ADV ORGANIC CHEM REA, V6th ed, DOI 10.1002/9780470084960.ch15; Stresser DM, 2002, DRUG METAB DISPOS, V30, P845, DOI 10.1124/dmd.30.7.845; Timberlake LD, 1999, J AM CHEM SOC, V121, P3618, DOI 10.1021/ja9808595; TOFT P, 1973, J LABELLED COMPD, V9, P413, DOI 10.1002/jlcr.2590090304; Ueng YF, 1997, BIOCHEMISTRY-US, V36, P370, DOI 10.1021/bi962359z; WAHALA K, 1995, J LABELLED COMPD RAD, V36, P493, DOI 10.1002/jlcr.2580360513; WAXMAN DJ, 1988, ARCH BIOCHEM BIOPHYS, V263, P424, DOI 10.1016/0003-9861(88)90655-8; WHITE RE, 1986, J AM CHEM SOC, V108, P6024, DOI 10.1021/ja00279a059; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; Xu YC, 1996, J ORG CHEM, V61, P9086, DOI 10.1021/jo961257b; YAN SJ, 1984, J AM CHEM SOC, V106, P2961, DOI 10.1021/ja00322a037; Yang D, 1998, J AM CHEM SOC, V120, P5943, DOI 10.1021/ja980428m; Yang D, 1998, J ORG CHEM, V63, P8952, DOI 10.1021/jo981270r; Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200; Yun CH, 2005, J BIOL CHEM, V280, P12279, DOI 10.1074/jbc.M411019200; Yun CH, 2000, BIOCHEMISTRY-US, V39, P11319, DOI 10.1021/bi000869u	103	75	77	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19496	19506		10.1074/jbc.M501854200	http://dx.doi.org/10.1074/jbc.M501854200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772082	hybrid			2022-12-27	WOS:000229113700011
J	Kuma, Y; Sabio, G; Bain, J; Shpiro, N; Marquez, R; Cuenda, A				Kuma, Y; Sabio, G; Bain, J; Shpiro, N; Marquez, R; Cuenda, A			BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELLULAR STRESSES; IDENTIFICATION; SUBSTRATE; PHOSPHORYLATION; SPECIFICITIES; MECHANISM; CYTOKINES; PATHWAY; FAMILY	The compound BIRB796 inhibits the stress-activated protein kinases p38 alpha and p38 beta and is undergoing clinical trials for the treatment of inflammatory diseases. Here we report that BIRB796 also inhibits the activity and the activation of SAPK3/p38 gamma. This occurs at higher concentrations of BIRB796 than those that inhibit p38 alpha and p38 alpha and at lower concentrations than those that inhibit the activation of JNK isoforms. We also show that at these concentrations, BIRB796 blocks the stress-induced phosphorylation of the scaffold protein SAP97, further establishing that this is a physiological substrate of SAPK3/p38 gamma. Our results demonstrate that BIRB796, in combination with SB203580, a compound that inhibits p38 alpha and p38 beta, but not the other p38 isoforms, can be used to identify physiological substrates of SAPK3/p38 gamma as well as those of p38 alpha and p38 beta.	Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Univ Dundee, Div Signal Transduct Therapy, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Cuenda, A (corresponding author), Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland.	a.i.cuenda@dundee.ac.uk	Marquez, Rudi/F-4045-2014; Sabio, Guadalupe/H-9733-2015	Sabio, Guadalupe/0000-0002-2822-0625; Marquez, Rudi/0000-0001-9777-2012				Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Branger J, 2002, J IMMUNOL, V168, P4070, DOI 10.4049/jimmunol.168.8.4070; Branger J, 2003, BLOOD, V101, P4446, DOI 10.1182/blood-2002-11-3338; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Feijoo C, 2005, J CELL SCI, V118, P397, DOI 10.1242/jcs.01655; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hasegawa M, 1999, J BIOL CHEM, V274, P12626, DOI 10.1074/jbc.274.18.12626; Haydon CE, 2002, ARCH BIOCHEM BIOPHYS, V397, P224, DOI 10.1006/abbi.2001.2625; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kuma Y, 2004, BIOCHEM J, V379, P133, DOI 10.1042/BJ20031559; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; Pargellis C, 2002, NAT STRUCT BIOL, V9, P268, DOI 10.1038/nsb770; Regan J, 2002, J MED CHEM, V45, P2994, DOI 10.1021/jm020057r; Sabio G, 2005, EMBO J, V24, P1134, DOI 10.1038/sj.emboj.7600578; Sabio G, 2004, BIOCHEM J, V380, P19, DOI 10.1042/BJ20031628; Van den Blink B, 2004, J CLIN IMMUNOL, V24, P37, DOI 10.1023/B:JOCI.0000018061.58504.75	25	230	247	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19472	19479		10.1074/jbc.M414221200	http://dx.doi.org/10.1074/jbc.M414221200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15755732	hybrid			2022-12-27	WOS:000229113700008
J	Hostetler, HA; Petrescu, AD; Kier, AB; Schroeder, F				Hostetler, HA; Petrescu, AD; Kier, AB; Schroeder, F			Peroxisome proliferator-activated receptor alpha interacts with high affinity and is conformationally responsive to endogenous ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING PROTEIN; FATTY-ACYL-COA; STEROL CARRIER PROTEIN-2; ORPHAN NUCLEAR RECEPTORS; COENZYME-A; PPAR-ALPHA; RAT-LIVER; MOLECULAR RECOGNITION; BETA-OXIDATION; PHYTANIC ACID	Although the peroxisome proliferator-activated receptor (PPAR alpha) binds and is activated by a variety of synthetic xenobiotics, the identity of the high affinity endogenous ligand(s) is incompletely resolved. Likewise, it is not known how putative endogenous ligands alter PPAR alpha conformation in order to affect transcriptional regulation. Direct fluorescence binding and fluorescence displacement assays showed for the first time that PPAR alpha exhibits high affinity (1-14 nM K-d values) for unsaturated long chain fatty acyl-CoAs as well as unsaturated long chain fatty acids commonly found in mammalian cells. Fluorescence resonance energy transfer between PPAR alpha aromatic amino acids and bound corresponding naturally occurring fluorescent ligands (i.e. cis-parinaroyl-CoA, trans-parinaric acid) yielded intermolecular distances of 25-29 angstrom, confirming close molecular interaction. Interestingly, although PPAR alpha also exhibited high affinity for saturated long chain fatty acyl-CoAs, regardless of chain length (1-13 nM K-d values), saturated long chain fatty acids were not significantly bound. In contrast to the similar affinities of PPAR alpha for fatty acyl-CoAs and unsaturated fatty acids, CoA thioesters of peroxisome proliferator drugs were bound with 5-6-fold higher affinities than their free acid forms. Circular dichroism demonstrated that high affinity ligands ( long chain fatty acyl-CoAs, unsaturated fatty acids), but not weak affinity ligands ( saturated fatty acids), elicited conformational changes in PPAR alpha structure, a hallmark of ligand-activated nuclear receptors. Finally, these ligand specificities and induced conformational changes correlated functionally with co-activator binding. In summary, since nuclear concentrations of these ligands are in the nanomolar range, long chain fatty acyl-CoAs and unsaturated fatty acids may both represent endogenous PPAR alpha ligands. Furthermore, the finding that saturated fatty acyl-CoAs, rather than saturated fatty acids, are high affinity PPAR alpha ligands provides a mechanism accounting for saturated fatty acid transactivation in cell-based assays.	Texas A&M Univ, Texas Vet Med Ctr, Dept Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Texas Vet Med Ctr, Dept Pathobiol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Schroeder, F (corresponding author), Texas A&M Univ, Texas Vet Med Ctr, Dept Physiol & Pharmacol, College Stn, TX 77843 USA.	fschroeder@cvm.tamu.edu			NIDDK NIH HHS [DK066732, DK41402, F32 DK066732, F32 DK066732-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK066732, R01DK041402] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARSLAND A, 1991, BIOCHEM PHARMACOL, V41, P53, DOI 10.1016/0006-2952(91)90010-3; BANNER CD, 1993, J LIPID RES, V34, P1583; BARTANA J, 1985, J BIOL CHEM, V260, P8404; BERGE RK, 1987, BIOCHIM BIOPHYS ACTA, V918, P60, DOI 10.1016/0005-2760(87)90009-9; Blanquart C, 2003, J STEROID BIOCHEM, V85, P267, DOI 10.1016/S0960-0760(03)00214-0; Bonilla S, 2000, BRIT J NUTR, V83, P665, DOI 10.1017/S0007114500000842; Cronet P, 2001, STRUCTURE, V9, P699, DOI 10.1016/S0969-2126(01)00634-7; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; Egea PF, 2002, MOL ENDOCRINOL, V16, P987, DOI 10.1210/me.16.5.987; Elholm M, 2001, J BIOL CHEM, V276, P21410, DOI 10.1074/jbc.M101073200; Ellinghaus P, 1999, J BIOL CHEM, V274, P2766, DOI 10.1074/jbc.274.5.2766; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORSTER TH., 1967, COMPREHENSIVE BIOCH, P61; Francis GA, 2003, ANNU REV PHYSIOL, V65, P261, DOI 10.1146/annurev.physiol.65.092101.142528; Frolov A, 1998, J BIOL CHEM, V273, P11049, DOI 10.1074/jbc.273.18.11049; Frolov A, 1997, BIOCHEMISTRY-US, V36, P6545, DOI 10.1021/bi970205t; Frolov A, 2000, J BIOL CHEM, V275, P12769, DOI 10.1074/jbc.275.17.12769; Frolov A, 1997, LIPIDS, V32, P1201, DOI 10.1007/s11745-997-0154-5; Frolov A, 1996, J BIOL CHEM, V271, P31878, DOI 10.1074/jbc.271.50.31878; Gossett RE, 1996, LIPIDS, V31, P895, DOI 10.1007/BF02522684; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; HERTZ R, 1987, BIOCHEM J, V245, P387, DOI 10.1042/bj2450387; HIBI AK, 2002, CELL MOL LIFE SCI, V59, P645; Huang H, 2002, J BIOL CHEM, V277, P29139, DOI 10.1074/jbc.M202923200; Huang H, 2004, BIOCHEMISTRY-US, V43, P2484, DOI 10.1021/bi0352318; HUBBELL T, 1994, BIOCHEMISTRY-US, V33, P3327, DOI 10.1021/bi00177a025; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; Jia YZ, 2003, J BIOL CHEM, V278, P47232, DOI 10.1074/jbc.M306363200; Jorgensen C, 2002, ANN NY ACAD SCI, V967, P431; KAWAGUCHI A, 1981, J BIOCHEM-TOKYO, V89, P337, DOI 10.1093/oxfordjournals.jbchem.a133207; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Lin QO, 1999, BIOCHEMISTRY-US, V38, P185, DOI 10.1021/bi9816094; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Martin GG, 2003, BIOCHEMISTRY-US, V42, P11520, DOI 10.1021/bi0346749; McArthur MJ, 1999, J LIPID RES, V40, P1371; Murakami K, 2001, BIOCHEM J, V353, P231, DOI 10.1042/0264-6021:3530231; NEMECZ G, 1991, J BIOL CHEM, V266, P17112; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; Petrescu AD, 2002, J BIOL CHEM, V277, P23988, DOI 10.1074/jbc.M201241200; Petrescu AD, 2001, J BIOL CHEM, V276, P36970, DOI 10.1074/jbc.M101939200; Potier N, 2003, PROTEIN SCI, V12, P725, DOI 10.1110/ps.0232503; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; Rolf B, 1995, BBA-LIPID LIPID MET, V1259, P245, DOI 10.1016/0005-2760(95)00170-0; SCHROEDER F, 1995, BIOCHEMISTRY-US, V34, P11919, DOI 10.1021/bi00037a033; Serrero G, 2000, BBA-MOL CELL BIOL L, V1488, P245, DOI 10.1016/S1388-1981(00)00128-1; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Stehlin C, 2001, EMBO J, V20, P5822, DOI 10.1093/emboj/20.21.5822; Svensson S, 2003, EMBO J, V22, P4625, DOI 10.1093/emboj/cdg456; Wahli W, 1999, ADV EXP MED BIOL, V447, P199; Wolfrum C, 1999, J LIPID RES, V40, P708; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Xu HE, 2001, P NATL ACAD SCI USA, V98, P13919, DOI 10.1073/pnas.241410198; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195	62	140	143	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18667	18682		10.1074/jbc.M412062200	http://dx.doi.org/10.1074/jbc.M412062200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15774422	hybrid			2022-12-27	WOS:000228932300017
J	Jacquiau, HR; van Waardenburg, RCAM; Reid, RJD; Woo, MH; Guo, H; Johnson, ES; Bjornsti, MA				Jacquiau, HR; van Waardenburg, RCAM; Reid, RJD; Woo, MH; Guo, H; Johnson, ES; Bjornsti, MA			Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOA4 DEUBIQUITINATING ENZYME; ACTIVE-SITE; PROTEIN SUMOYLATION; YEAST; CAMPTOTHECIN; MECHANISM; ISOPEPTIDASE; RESISTANCE; COMPLEX; BINDING	Eukaryotic DNA topoisomerase I (Top1p) has important functions in DNA replication, transcription, and recombination. This enzyme also constitutes the cellular target of camptothecin (CPT), which induces S-phase-dependent cytotoxicity. To define cellular pathways that regulate cell sensitivity to Top1p-induced DNA lesions, we described a yeast genetic screen for conditional tah ( top1T722A-hypersensitive) mutants with enhanced sensitivity to low levels of the CPT mimetic mutant top1T722A (Reid, R. J., Fiorani, P., Sugawara, M., and Bjornsti, M. A. ( 1999) Proc. Natl. Acad. Sci. U. S. A. 96, 11440 - 11445; Fiorani, P., Reid, R. J., Schepis, A., Jacquiau, H. R., Guo, H., Thimmaiah, P., Benedetti, P., and Bjornsti, M. A. (2004) J. Biol. Chem. 279, 21271 - 21281). Here we report that tah mutant ubc9-10 harbors a hypomorphic allele of UBC9, which encodes the essential SUMO ( small ubiquitin-related modifier) E2-conjugating enzyme. The same conditional ubc9P123L mutant was also isolated in an independent screen for enhanced sensitivity to a distinct Top1p poison, Top1N726Hp. The ubc9-10 mutant exhibited a decrease in global protein sumoylation and increased sensitivity to a wide range of DNA-damaging agents independent of Top1p. Deletion of the Ulp2 SUMO protease failed to restore ubc9-10 cell resistance to Top1p poisons or hydroxyurea yet adversely affected wild-type TOP1 cell genetic stability and sensitivity to hydroxyurea. Moreover, although mutation of different consensus SUMO sites in the N terminus and linker region of yeast Top1p failed to recapitulate ubc9-10 mutant phenotypes, they revealed distinct and subtle effects on cell sensitivity to CPT. These results provide insights into the complexities of SUMO conjugation and the confounding effects of SUMO modification on Top1p function and cell sensitivity to genotoxic agents.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA	St Jude Children's Research Hospital; Jefferson University	Bjornsti, MA (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale, Memphis, TN 38105 USA.	Mary-Ann.Bjornsti@stjude.org	Reid, Robert/AAR-1560-2020	Reid, Robert/0000-0002-7424-3537	NATIONAL CANCER INSTITUTE [P01CA023099, P30CA021765, R01CA058755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062268] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, CA23099, CA58755] Funding Source: Medline; NIGMS NIH HHS [GM62268] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; Bastin-Shanower SA, 2003, MOL CELL BIOL, V23, P3487, DOI 10.1128/MCB.23.10.3487-3496.2003; Bencsath KP, 2002, J BIOL CHEM, V277, P47938, DOI 10.1074/jbc.M207442200; Bennett CB, 2001, NAT GENET, V29, P426, DOI 10.1038/ng778; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bylebyl GR, 2003, J BIOL CHEM, V278, P44113, DOI 10.1074/jbc.M308357200; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Christensen MO, 2004, J BIOL CHEM, V279, P21873, DOI 10.1074/jbc.M400498200; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Colley WC, 2004, J BIOL CHEM, V279, P54069, DOI 10.1074/jbc.M409764200; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Denison C, 2005, MOL CELL PROTEOMICS, V4, P246, DOI 10.1074/mcp.M400154-MCP200; Desai SD, 2001, CANCER RES, V61, P5926; ENG WK, 1988, MOL PHARMACOL, V34, P755; Fertala J, 2000, J BIOL CHEM, V275, P15246, DOI 10.1074/jbc.275.20.15246; Fiorani P, 1999, MOL PHARMACOL, V56, P1105, DOI 10.1124/mol.56.6.1105; Fiorani P, 2004, J BIOL CHEM, V279, P21271, DOI 10.1074/jbc.M312338200; Fiorani P, 2000, ANN NY ACAD SCI, V922, P65; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Haluska P, 1998, ADV ENZYME REGUL, V38, P253, DOI 10.1016/S0065-2571(97)00008-3; Hann CL, 1998, J BIOL CHEM, V273, P31519, DOI 10.1074/jbc.273.47.31519; Harlow E, 1987, ANTIBODIES LAB MANUA; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Horie K, 2002, ONCOGENE, V21, P7913, DOI 10.1038/sj.onc.1205917; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 2003, J CELL BIOL, V160, P1069, DOI 10.1083/jcb.200212052; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Li TK, 2003, CANCER RES, V63, P8400; Lisby M, 2001, J BIOL CHEM, V276, P20220, DOI 10.1074/jbc.M010991200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Mo YY, 2004, CANCER RES, V64, P2793, DOI 10.1158/0008-5472.CAN-03-2410; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Panse VG, 2004, J BIOL CHEM, V279, P41346, DOI 10.1074/jbc.M407950200; Panse VG, 2003, NAT CELL BIOL, V5, P21, DOI 10.1038/ncb893; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Rallabhandi P, 2002, J BIOL CHEM, V277, P40020, DOI 10.1074/jbc.M200388200; Redon C, 2003, EMBO REP, V4, P678, DOI 10.1038/sj.embor.embor871; Reid RJD, 1998, BBA-GENE STRUCT EXPR, V1400, P289, DOI 10.1016/S0167-4781(98)00142-0; Reid RJD, 1999, P NATL ACAD SCI USA, V96, P11440, DOI 10.1073/pnas.96.20.11440; Rodriguez-Galindo C, 2000, MED PEDIATR ONCOL, V35, P385, DOI 10.1002/1096-911X(20001001)35:4<385::AID-MPO1>3.0.CO;2-E; Ruchelman AL, 2002, BIOORG MED CHEM LETT, V12, P3333, DOI 10.1016/S0960-894X(02)00737-0; SIKORSKI RS, 1989, GENETICS, V122, P19; Stewart L, 1999, J BIOL CHEM, V274, P32950, DOI 10.1074/jbc.274.46.32950; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wohlschlegel JA, 2004, J BIOL CHEM, V279, P45662, DOI 10.1074/jbc.M409203200; Woo MH, 2002, J BIOL CHEM, V277, P3813, DOI 10.1074/jbc.M110484200; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	61	39	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23566	23575		10.1074/jbc.M500947200	http://dx.doi.org/10.1074/jbc.M500947200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15817450	hybrid			2022-12-27	WOS:000229880000021
J	Morinaga, N; Iwamaru, Y; Yahiro, K; Tagashira, M; Moss, J; Noda, M				Morinaga, N; Iwamaru, Y; Yahiro, K; Tagashira, M; Moss, J; Noda, M			Differential activities of plant polyphenols on the binding and internalization of cholera toxin in vero cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLTRANSFERASE ACTIVITY; INDUCED FLUID ACCUMULATION; ENDOPLASMIC-RETICULUM; ADENYLATE-CYCLASE; MEMBRANE; IDENTIFICATION; GANGLIOSIDES; INHIBITION; ACTIVATION; MECHANISM	Plant polyphenols, RG-tannin, and applephenon had been reported to inhibit cholera toxin (CT) ADP-ribosyltransferase activity and CT-induced fluid accumulation in mouse ileal loops. A high molecular weight fraction of hop bract extract (HBT) also inhibited CT ADP-ribosyltransferase activity. We report here the effect of those polyphenols on the binding and entry of CT into Vero cells. Binding of CT to Vero cells or to ganglioside GM1, a CT receptor, was inhibited in a concentration-dependent manner by HBT and applephenon but not RG-tannin. These observations were confirmed by fluorescence microscopy using Cy3-labeled CT. Following toxin binding to cells, applephenon, HBT, and RG-tannin suppressed its internalization. HBT or applephenon precipitated CT, CTA, and CTB from solution, creating aggregates larger than 250 kDa. In contrast, RG-tannin precipitated CT poorly; it formed complexes with CT, CTA, or CTB, which were demonstrated with sucrose density gradient centrifugation and molecular weight exclusion filters. In agreement, CTA blocked the inhibition of CT internalization by RG-tannin. These data suggest that some plant polyphenols, similar to applephenon and HBT, bind CT, forming large aggregates in solution or, perhaps, on the cell surface and thereby suppress CT binding and internalization. In contrast, RG-tannin binding to CT did not interfere with its binding to Vero cells or GM1, but it did inhibit internalization.	Chiba Univ, Grad Sch Med, Dept Mol Infectiol, Chuo Ku, Chiba 2608670, Japan; Asahi Brewery Co Ltd, Fundamental Res Labs, Moriya, Ibaraki 3020106, Japan; NHLBI, NIH, Pulm Crit Care Med Branch, Bethesda, MD 20892 USA	Chiba University; Asahi Group Holdings Ltd.; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Morinaga, N (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Infectiol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	nmorinaga@faculty.chiba-u.jp		Yahiro, Kinnosuke/0000-0002-9813-0780	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000659, Z01HL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; Charlton AJ, 2002, J AGR FOOD CHEM, V50, P1593, DOI 10.1021/jf010897z; CUATRECASAS P, 1973, BIOCHEMISTRY-US, V12, P3558, DOI 10.1021/bi00742a032; FIELD M, 1972, J CLIN INVEST, V51, P796, DOI 10.1172/JCI106874; Fujinaga Y, 2003, MOL BIOL CELL, V14, P4783, DOI 10.1091/mbc.E03-06-0354; GILL DM, 1978, P NATL ACAD SCI USA, V75, P3050, DOI 10.1073/pnas.75.7.3050; Haslam E, 1996, J NAT PROD, V59, P205, DOI 10.1021/np960040+; HOLMGREN J, 1975, P NATL ACAD SCI USA, V72, P2520, DOI 10.1073/pnas.72.7.2520; Le PU, 2003, J CELL SCI, V116, P1059, DOI 10.1242/jcs.00327; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOSS J, 1977, J BIOL CHEM, V252, P2455; Oi H, 2002, P NATL ACAD SCI USA, V99, P3042, DOI 10.1073/pnas.052709499; Saito T, 2002, MICROBIOL IMMUNOL, V46, P249, DOI 10.1111/j.1348-0421.2002.tb02693.x; Schmitz A, 2000, J CELL BIOL, V148, P1203, DOI 10.1083/jcb.148.6.1203; TAGASHIRA M, 2003, US JAP CHOL OTH BACT, P45; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Teter K, 2002, INFECT IMMUN, V70, P6166, DOI 10.1128/IAI.70.11.6166-6171.2002; Torgersen ML, 2001, J CELL SCI, V114, P3737; Tsai M, 2002, J CELL BIOL, V159, P207, DOI 10.1083/jcb.200207120; Wolf AA, 1998, J CELL BIOL, V141, P917, DOI 10.1083/jcb.141.4.917; Yanagida A, 2000, J CHROMATOGR A, V890, P251, DOI 10.1016/S0021-9673(00)00614-2	24	52	55	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23303	23309		10.1074/JBC.M502093200	http://dx.doi.org/10.1074/JBC.M502093200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15814610	hybrid			2022-12-27	WOS:000229741800089
J	Chubykin, AA; Liu, XR; Comoletti, D; Tsigelny, I; Taylor, P; Sudhof, TC				Chubykin, AA; Liu, XR; Comoletti, D; Tsigelny, I; Taylor, P; Sudhof, TC			Dissection of synapse induction by neuroligins - Effect of a neuroligin mutation associated with autism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LATROTOXIN RECEPTORS; CELL-SURFACE PROTEINS; NEUREXIN I-ALPHA; EXCITATORY SYNAPSES; ADHESION MOLECULES; QUALITY-CONTROL; BETA-NEUREXINS; F-ACTIN; BINDING; GENES	To study synapse formation by neuroligins, we cocultured hippocampal neurons with COS cells expressing wild type and mutant neuroligins. The large size of COS cells makes it possible to test the effect of neuroligins presented over an extended surface area. We found that a uniform lawn of wild type neuroligins displayed on the cell surface triggers the formation of hundreds of uniformly sized, individual synaptic contacts that are labeled with neurexin antibodies. Electron microscopy revealed that these artificial synapses contain a presynaptic active zone with docked vesicles and often feature a postsynaptic density. Neuroligins 1, 2, and 3 were active in this assay. Mutations in two surface loops of neuroligin 1 abolished neuroligin binding to neurexin 1 beta, a presumptive presynaptic binding partner for postsynaptic neuroligins, and blocked synapse formation. An analysis of mutant neuroligins with an amino acid substitution that corresponds to a mutation described in patients with an autistic syndrome confirmed previous reports that these mutant neuroligins have a compromised capacity to be transported to the cell surface. Nevertheless, the small percentage of mutant neuroligins that reached the cell surface still induced synapse formation. Viewed together, our data suggest that neuroligins generally promote artificial synapse formation in a manner that is associated with beta-neurexin binding and results in morphologically well differentiated synapses and that a neuroligin mutation found in autism spectrum disorders impairs cell-surface transport but does not completely abolish synapse formation activity.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Diego	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, NA4-118,6000 Harry Hines Blvd, Dallas, TX 75390 USA.	Thomas.Sudhof@UTSouthwestern.edu		Chubykin, Alexander/0000-0001-8224-9296	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH052804] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM 18360-29] Funding Source: Medline; NIMH NIH HHS [R37 MH 52804-08] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Biederer T, 2001, J BIOL CHEM, V276, P47869, DOI 10.1074/jbc.M105287200; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; Bolliger MF, 2001, BIOCHEM J, V356, P581, DOI 10.1042/0264-6021:3560581; Cantallops I, 2000, CURR BIOL, V10, pR620, DOI 10.1016/S0960-9822(00)00663-1; Chih B, 2005, SCIENCE, V307, P1324, DOI 10.1126/science.1107470; Comoletti D, 2003, J BIOL CHEM, V278, P50497, DOI 10.1074/jbc.M306803200; Comoletti D, 2004, J NEUROSCI, V24, P4889, DOI 10.1523/JNEUROSCI.0468-04.2004; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; Dean C, 2003, NAT NEUROSCI, V6, P708, DOI 10.1038/nn1074; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; Eaton BA, 2002, NEURON, V34, P729, DOI 10.1016/S0896-6273(02)00721-3; Fu ZY, 2003, J NEUROPHYSIOL, V90, P3950, DOI 10.1152/jn.00647.2003; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; Gilbert M, 2001, GLIA, V34, P151, DOI 10.1002/glia.1050; Goda Y, 2003, NEURON, V40, P243, DOI 10.1016/S0896-6273(03)00608-1; Goslin K., 1998, CULTURING NERVE CELL, P339; Helenius A, 2001, PHILOS T ROY SOC B, V356, P147, DOI 10.1098/rstb.2000.0759; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Jamain S, 2003, NAT GENET, V34, P27, DOI 10.1038/ng1136; Laumonnier F, 2004, AM J HUM GENET, V74, P552, DOI 10.1086/382137; Marchot P, 1996, PROTEIN SCI, V5, P672; Missler M, 2003, NATURE, V423, P939, DOI 10.1038/nature01755; Morales M, 2000, NEURON, V27, P539, DOI 10.1016/S0896-6273(00)00064-7; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Rao A, 2000, NAT NEUROSCI, V3, P747, DOI 10.1038/77636; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; Rowen L, 2002, GENOMICS, V79, P587, DOI 10.1006/geno.2002.6734; Sara Y, 2005, J NEUROSCI, V25, P260, DOI 10.1523/JNEUROSCI.3165-04.2005; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; Song JY, 1999, P NATL ACAD SCI USA, V96, P1100, DOI 10.1073/pnas.96.3.1100; Sudhof TC, 2001, ANNU REV NEUROSCI, V24, P933, DOI 10.1146/annurev.neuro.24.1.933; Sugita S, 1999, NEURON, V22, P489, DOI 10.1016/S0896-6273(00)80704-7; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Tabuchi K, 2002, GENOMICS, V79, P849, DOI 10.1006/geno.2002.6780; Tobaben S, 2002, J BIOL CHEM, V277, P6359, DOI 10.1074/jbc.M111231200; Tsigelny I, 2000, PROTEIN SCI, V9, P180; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; Yamagata M, 2003, CURR OPIN CELL BIOL, V15, P621, DOI 10.1016/S0955-0674(03)00107-8; Zhang WD, 2001, J NEUROSCI, V21, P5169, DOI 10.1523/JNEUROSCI.21-14-05169.2001; Zoghbi HY, 2003, SCIENCE, V302, P826, DOI 10.1126/science.1089071	43	143	147	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22365	22374		10.1074/jbc.M410723200	http://dx.doi.org/10.1074/jbc.M410723200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15797875	hybrid			2022-12-27	WOS:000229557900082
J	Ferraroni, M; Seifert, J; Travkin, VM; Thiel, M; Kaschabek, S; Scozzafava, A; Golovleva, L; Schlomann, M; Briganti, F				Ferraroni, M; Seifert, J; Travkin, VM; Thiel, M; Kaschabek, S; Scozzafava, A; Golovleva, L; Schlomann, M; Briganti, F			Crystal structure of the hydroxyquinol 1,2-dioxygenase from Nocardioides simplex 3E, a key enzyme involved in polychlorinated aromatics biodegradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOCATECHUATE 3,4-DIOXYGENASE; 2,4,5-TRICHLOROPHENOXYACETIC ACID; BURKHOLDERIA-CEPACIA; P-NITROPHENOL; GENE-CLUSTER; PATTERN-RECOGNITION; SEQUENCE-ANALYSIS; DEGRADATION; PURIFICATION; METABOLISM	Hydroxyquinol 1,2- dioxygenase ( 1,2-HQD) catalyzes the ring cleavage of hydroxyquinol ( 1,2,4-trihydroxybenzene), a central intermediate in the degradation of aromatic compounds including a variety of particularly recalcitrant polychloro- and nitroaromatic pollutants. We report here the primary sequence determination and the analysis of the crystal structure of the 1,2-HQD from Nocardioides simplex 3E solved at 1.75 angstrom resolution using the multiple wavelength anomalous dispersion of the two catalytic irons (1 Fe/293 amino acids). The catalytic Fe(III) coordination polyhedron composed by the side chains of Tyr(164), Tyr(197), His(221), and His(223) resembles that of the other known intradiol-cleaving dioxygenases, but several of the tertiary structure features are notably different. One of the most distinctive characteristics of the present structure is the extensive openings and consequent exposure to solvent of the upper part of the catalytic cavity arranged to favor the binding of hydroxyquinols but not catechols. A co- crystallized benzoate-like molecule is also found bound to the metal center forming a distinctive hydrogen bond network as observed previously also in 4-chlorocatechol 1,2-dioxygenase from Rhodococcus opacus 1CP. This is the first structure of an intradiol dioxygenase specialized in hydroxyquinol ring cleavage to be investigated in detail.	Univ Florence, Dipartimento Chim, I-50019 Sesto Fiorentino, Italy; TU Bergakad Freiberg, Interdisziplinares Okol Zentrum, D-09599 Freiberg, Germany; Russian Acad Sci, Skryabin Inst Biochem & Physol Microorganisms, Pushchino 142290, Moscow Region, Russia	University of Florence; Technical University Freiberg; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences	Briganti, F (corresponding author), Univ Florence, Dipartimento Chim, Via Lastruccia 3, I-50019 Sesto Fiorentino, Italy.	fabrizio.briganti@unifi.it	Briganti, Fabrizio/C-6661-2012; Ferraroni, Marta/P-6441-2016	Ferraroni, Marta/0000-0001-7258-738X; Seifert, Jana/0000-0002-7690-8539; Scozzafava, Andrea/0000-0001-5020-3322; Ludmila, Golovleva/0000-0001-9773-8957				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON JJ, 1980, J BACTERIOL, V141, P534, DOI 10.1128/JB.141.2.534-543.1980; APAJALAHTI JHA, 1987, J BACTERIOL, V169, P5125, DOI 10.1128/jb.169.11.5125-5130.1987; Armengaud J, 1999, J BACTERIOL, V181, P3452, DOI 10.1128/JB.181.11.3452-3461.1999; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASHFORD D, 1997, ISCOPE97, V1343, P233; Benvenuti M, 1999, ACTA CRYSTALLOGR D, V55, P901, DOI 10.1107/S0907444998017715; Briganti F, 1998, FEBS LETT, V433, P58, DOI 10.1016/S0014-5793(98)00884-9; CHAPMAN PJ, 1976, J BACTERIOL, V125, P975, DOI 10.1128/JB.125.3.975-984.1976; Chauhan A, 2000, J APPL MICROBIOL, V88, P764, DOI 10.1046/j.1365-2672.2000.01018.x; Chauhan A, 2000, BIOCHEM BIOPH RES CO, V270, P733, DOI 10.1006/bbrc.2000.2500; D'Argenio DA, 1999, J BACTERIOL, V181, P6478; Daubaras DL, 1996, APPL ENVIRON MICROB, V62, P4276, DOI 10.1128/AEM.62.11.4276-4279.1996; DAUBARAS DL, 1995, APPL ENVIRON MICROB, V61, P1279, DOI 10.1128/AEM.61.4.1279-1289.1995; DeLano W.L, PYMOL MOL GRAPHICS S; DORN E, 1978, BIOCHEM J, V174, P73, DOI 10.1042/bj1740073; Eley KL, 2001, J ORG CHEM, V66, P2091, DOI 10.1021/jo001669r; Elgren TE, 1997, BIOCHEMISTRY-US, V36, P11504, DOI 10.1021/bi970691k; Eulberg D, 1997, J BACTERIOL, V179, P370, DOI 10.1128/jb.179.2.370-381.1997; Ferraroni M, 2004, J BIOL CHEM, V279, P27646, DOI 10.1074/jbc.M401692200; Golovleva L A, 1991, Biodegradation, V2, P201, DOI 10.1007/BF00124494; Golovleva LA, 1990, BIODEGRADATION, V1, P263, DOI 10.1007/BF00119763; HAGGBLOM MM, 1989, APPL ENVIRON MICROB, V55, P516; Hatta T, 1999, J BIOSCI BIOENG, V87, P267, DOI 10.1016/S1389-1723(99)80030-9; Huang C. C., 1996, PAC S BIOCOMPUT, P724, DOI DOI 10.1142/9789814531399; JAIN RK, 1994, APPL ENVIRON MICROB, V60, P3030, DOI 10.1128/AEM.60.8.3030-3032.1994; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kitagawa W, 2004, J BACTERIOL, V186, P4894, DOI 10.1128/JB.186.15.4894-4902.2004; KIYOHARA H, 1992, APPL ENVIRON MICROB, V58, P1276, DOI 10.1128/AEM.58.4.1276-1283.1992; KOZYREVA LP, 1993, MICROBIOLOGY+, V62, P78; Lange SJ, 1998, CURR OPIN CHEM BIOL, V2, P159, DOI 10.1016/S1367-5931(98)80057-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LATUS M, 1995, APPL ENVIRON MICROB, V61, P2453, DOI 10.1128/AEM.61.7.2453-2460.1995; Louie TM, 2002, J BACTERIOL, V184, P3492, DOI 10.1128/JB.184.13.3492-3500.2002; MALTSEVA OV, 1994, EUR J BIOCHEM, V226, P1053, DOI 10.1111/j.1432-1033.1994.01053.x; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCLACHLAN AD, 1982, ACTA CRYSTALLOGR A, V38, P871, DOI 10.1107/S0567739482001806; Meulenberg R, 1996, BIODEGRADATION, V7, P303, DOI 10.1007/BF00115744; Murakami S, 1999, BIOSCI BIOTECH BIOCH, V63, P859, DOI 10.1271/bbb.63.859; NAKAI C, 1988, ARCH BIOCHEM BIOPHYS, V267, P701, DOI 10.1016/0003-9861(88)90079-3; Nielsen JE, 1999, PROTEIN ENG, V12, P657, DOI 10.1093/protein/12.8.657; OHLENDORF DH, 1988, NATURE, V336, P403, DOI 10.1038/336403a0; OHLENDORF DH, 1994, J MOL BIOL, V244, P586, DOI 10.1006/jmbi.1994.1754; Orville AM, 1997, BIOCHEMISTRY-US, V36, P10039, DOI 10.1021/bi970468n; Orville AM, 1997, BIOCHEMISTRY-US, V36, P10052, DOI 10.1021/bi970469f; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padilla L, 2000, J BASIC MICROB, V40, P243, DOI 10.1002/1521-4028(200008)40:4<243::AID-JOBM243>3.0.CO;2-D; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pieper DH, 2002, J BACTERIOL, V184, P1466, DOI 10.1128/JB.184.5.1466-1470.2002; Que L, 2001, SCIENCE, V292, P651; RIEBLE S, 1994, J BACTERIOL, V176, P4838, DOI 10.1128/jb.176.16.4838-4844.1994; Ritchie DW, 1999, J COMPUT CHEM, V20, P383, DOI 10.1002/(SICI)1096-987X(199903)20:4<383::AID-JCC1>3.0.CO;2-M; Sambrook J., 2001, MOL CLONING LAB MANU; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Solyanikova IP, 1996, BIOCHEMISTRY-MOSCOW+, V61, P461; STOLZ A, 1993, FEMS MICROBIOL LETT, V108, P219, DOI 10.1111/j.1574-6968.1993.tb06102.x; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; SZE ISY, 1984, J BACTERIOL, V159, P353, DOI 10.1128/JB.159.1.353-359.1984; Takenaka S, 2003, APPL ENVIRON MICROB, V69, P5410, DOI 10.1128/AEM.69.9.5410-5413.2003; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Travkin VM, 1997, FEBS LETT, V407, P69, DOI 10.1016/S0014-5793(97)00297-4; Uotila J. S., 1995, Biodegradation, V6, P119, DOI 10.1007/BF00695342; UOTILA JS, 1992, J BACTERIOL, V174, P5669, DOI 10.1128/JB.174.17.5669-5675.1992; VARGA J M, 1970, European Journal of Biochemistry, V12, P427, DOI 10.1111/j.1432-1033.1970.tb00869.x; Vetting MW, 2000, BIOCHEMISTRY-US, V39, P7943, DOI 10.1021/bi000151e; VONQUANTA, 1997, QUANTA SIMULATION SE; WILSON K, 2000, CURRENT PROTOCOLS MO, V1; Xun LY, 2004, J BIOL CHEM, V279, P6696, DOI 10.1074/jbc.M312072200; Xun LY, 1999, BIOCHEM BIOPH RES CO, V266, P322, DOI 10.1006/bbrc.1999.1805; ZABORINA O, 1995, J BACTERIOL, V177, P229, DOI 10.1128/jb.177.1.229-234.1995	72	39	41	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21144	21154		10.1074/jbc.M500666200	http://dx.doi.org/10.1074/jbc.M500666200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15772073	hybrid			2022-12-27	WOS:000229438800031
J	Lyu, J; Joo, CK				Lyu, J; Joo, CK			Wnt-7a up-regulates matrix metalloproteinase-12 expression and promotes cell proliferation in corneal epithelial cells during wound healing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; VERTEBRATE GASTRULATION; SIGNALING PATHWAY; ACTIVATION; KINASE; GENE; RHO; DIFFERENTIATION; METALLOELASTASE; MECHANISMS	Corneal wound repair involves the rapid coverage of a denuded area by residual epithelial cells. During wound healing, there are different cell behaviors in different regions of the epithelium: cell proliferation in the peripheral epithelium and cell migration in the central epithelium. We found that Wnt-7a was rapidly induced in the wounded cornea, promoted the proliferation of corneal epithelial cells, and enhanced wound closure. Matrix metalloproteinase-12 (MMP-12) was detected in the peripheral epithelium, where cell proliferation was enhanced, but was diminished in the migrating central epithelium. Wnt-7a induced the accumulation of b-catenin and the activation of Rac and b-catenin, and Rac synergistically induced the transcription of MMP-12. Blocking the function of MMP-12 delayed wound closure induced by Wnt-7a. Our results also suggest that, in addition to the b-catenin pathway, Wnt-7a might induce a b-catenin-independent pathway. By regulating the proliferation of corneal epithelial cells, Wnt-7a and MMP-12 appear to contribute to corneal wound healing.	Catholic Univ Korea, Coll Med, Dept Ophthalmol & Visual Sci, Seoul 137040, South Korea	Catholic University of Korea	Joo, CK (corresponding author), Catholic Univ Korea, Coll Med, Dept Ophthalmol & Visual Sci, 505 Banpo Dong, Seoul 137040, South Korea.	ckjoo@catholic.ac.kr						Block ER, 2004, J BIOL CHEM, V279, P24307, DOI 10.1074/jbc.M401058200; Bonniaud P, 2004, J IMMUNOL, V173, P2099, DOI 10.4049/jimmunol.173.3.2099; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; Daniels JT, 2003, EXP EYE RES, V77, P653, DOI 10.1016/j.exer.2003.08.010; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Hussein SM, 2003, J BIOL CHEM, V278, P48805, DOI 10.1074/jbc.M305472200; Jormsjo S, 2000, CIRC RES, V86, P998, DOI 10.1161/01.RES.86.9.998; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Kilian B, 2003, MECH DEVELOP, V120, P467, DOI 10.1016/S0925-4773(03)00004-2; Kishida S, 2004, MOL CELL BIOL, V24, P4487, DOI 10.1128/MCB.24.10.4487-4501.2004; KRUSE FE, 1994, INVEST OPHTH VIS SCI, V35, P2405; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Larsen PH, 2004, J NEUROSCI, V24, P7597, DOI 10.1523/JNEUROSCI.2092-04.2004; Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100; Marchenko GN, 2002, BIOCHEM J, V363, P253, DOI 10.1042/0264-6021:3630253; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Nawrocki-Raby B, 2003, AM J PATHOL, V163, P653, DOI 10.1016/S0002-9440(10)63692-9; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Poon R, 2001, ONCOGENE, V20, P451, DOI 10.1038/sj.onc.1204107; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Viti J, 2003, J NEUROSCI, V23, P5919; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Watanabe H, 2004, J BIOL CHEM, V279, P1676, DOI 10.1074/jbc.M303650200; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wu LH, 2003, GENES CELLS, V8, P225, DOI 10.1046/j.1365-2443.2003.00628.x; Xu KP, 2004, INVEST OPHTH VIS SCI, V45, P813, DOI 10.1167/iovs.03-0851; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Ye HQQ, 2000, INVEST OPHTH VIS SCI, V41, P2894; Zieske JD, 2000, PROG RETIN EYE RES, V19, P257, DOI 10.1016/S1350-9462(99)00018-X	40	61	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21653	21660		10.1074/jbc.m500374200	http://dx.doi.org/10.1074/jbc.m500374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802269	hybrid			2022-12-27	WOS:000229438800091
J	Sengupta, P; Xu, Y; Wang, L; Widom, R; Smith, BD				Sengupta, P; Xu, Y; Wang, L; Widom, R; Smith, BD			Collagen alpha 1(I) gene (COL1A1) is repressed by RFX family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II TRANSACTIVATOR; BARE LYMPHOCYTE SYNDROME; DNA-BINDING PROTEIN; CHICK-EMBRYO FIBROBLASTS; ALPHA-2(I) COLLAGEN GENE; MESSENGER-RNA LEVELS; REGULATORY FACTOR-X; CANCER-CELL-LINES; INTERFERON-GAMMA; IN-VITRO	Collagen type I is composed of three polypeptide chains transcribed from two separate genes (COL1A1 and COL1A2) with different promoters requiring coordinate regulation. Our recent publications, centering on COL1A2 regulation, demonstrate that methylation in the first exon of COL1A2 at a regulatory factor for X box (RFX) site (at -1 to +20) occurs in human cancer cells and correlates with increased RFX1 binding and decreased collagen transcription (Sengupta, P. K., Erhlich, M., and Smith, B. D. ( 1999) J. Biol. Chem. 274, 36649 36655; Sengupta, S., Smith, E. M., Kim, K., Murnane, M. J., and Smith, B. D. ( 2003) Cancer Res. 63, 1789 - 1797). In normal cells, RFX5 complex along with major histocompatibility class II transactivator ( CIITA) is induced by interferon-gamma to occupy this site and repress collagen transcription (Xu, Y., Wang, L., Buttice, G., Sengupta, P. K., and Smith, B. D. ( 2004) J. Biol. Chem. 279, 41319 41332). In this paper, we demonstrate that COL1A1 has an RFX consensus binding site surrounding the transcription start site (- 11 to +10) that contains three methylation sites rather than one in the COL1A2 gene RFX binding site. RFX1 interacts weakly with the unmethylated COL1A1 site, and binds with higher affinity to the methylated site. RFX1 represses the unmethylated COL1A1 less efficiently than COL1A2. COL1A1 promoter activity is sensitive to DNA methylation and the COL1A1 gene is methylated in human cancer cells with coordinately decreased collagen expression. The DNA methylation inhibitor, 5- aza-2'-deoxycytidine (aza- dC) increases collagen gene expression with time in human cancer cells. On the other hand, RFX5 interacts with both collagen type I genes with a similar binding affinity and represses both promoters equally in transient transfections. Two dominant negative forms of RFX5 activate both collagen genes coordinately. Finally, CIITA RNA interference experiments indicate that CIITA induction is required for interferon gamma-mediated repression of both collagen type I genes.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Ctr Arthritis, Boston, MA 02118 USA; Vet Affairs Boston Healthcare Syst, Boston, MA 02118 USA	Boston University; Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Sengupta, P (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	smith@biochem.bumc.bu.edu		Smith, Barbara/0000-0002-5375-7627	NHLBI NIH HHS [R01 HL068094, P01 HL013262] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262, R01HL068094] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399; BARKER DD, 1991, MOL CELL BIOL, V11, P5154, DOI 10.1128/MCB.11.10.5154; CHAN H, 1991, MOL CELL BIOL, V11, P47, DOI 10.1128/MCB.11.1.47; Chen M, 2002, NAT GENET, V32, P670, DOI 10.1038/ng1041; Chen M, 2003, CLIN EXP DERMATOL, V28, P193, DOI 10.1046/j.1365-2230.2003.01191.x; DeSandro AM, 2000, MOL CELL BIOL, V20, P6587, DOI 10.1128/MCB.20.17.6587-6599.2000; Di Natale P, 2002, EUR J BIOCHEM, V269, P2764, DOI 10.1046/j.1432-1033.2002.02951.x; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Dishart KL, 2003, J MOL CELL CARDIOL, V35, P739, DOI 10.1016/S0022-2828(03)00136-6; DURAND B, 1994, MOL CELL BIOL, V14, P6839, DOI 10.1128/MCB.14.10.6839; El-Osta A, 2004, CANCER BIOL THER, V3, P816, DOI 10.4161/cbt.3.9.1100; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; Esteller M, 2003, ADV EXP MED BIOL, V532, P39; Gerolami R, 2000, CANCER GENE THER, V7, P1286, DOI 10.1038/sj.cgt.7700225; Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529; Gourley T, 1999, IMMUNITY, V10, P377, DOI 10.1016/S1074-7613(00)80037-0; Gourley TS, 2001, J IMMUNOL, V166, P2917, DOI 10.4049/jimmunol.166.5.2917; Gouze E, 2003, MOL THER, V7, P460, DOI 10.1016/S1525-0016(03)00024-8; GUENETTE DK, 1992, BIOCHEM J, V283, P699, DOI 10.1042/bj2830699; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; HARTUNG S, 1986, NATURE, V320, P365, DOI 10.1038/320365a0; Hirtenlehner K, 2002, EUR CYTOKINE NETW, V13, P234; HUANG LH, 1984, NATURE, V308, P293, DOI 10.1038/308293a0; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jorgensen HF, 2002, MENT RETARD DEV D R, V8, P87, DOI 10.1002/mrdd.10021; Katan-Khaykovich Y, 1998, J BIOL CHEM, V273, P24504, DOI 10.1074/jbc.273.38.24504; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Moreno CS, 1997, J IMMUNOL, V158, P5841; Nagarajan UM, 2002, J IMMUNOL, V169, P5078, DOI 10.4049/jimmunol.169.9.5078; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nekrep N, 2000, MOL CELL BIOL, V20, P4455, DOI 10.1128/MCB.20.12.4455-4461.2000; Ravot E, 2002, J GENE MED, V4, P161, DOI 10.1002/jgm.256; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; RHODES K, 1994, MOL CELL BIOL, V14, P5950, DOI 10.1128/MCB.14.9.5950; Rhodes Katherine, 1992, Gene Expression, V2, P59; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; SANDMEYER S, 1981, CANCER RES, V41, P830; Santos AN, 1997, IMMUNOL LETT, V58, P53, DOI 10.1016/S0165-2478(97)02712-0; Sengupta PK, 2003, CANCER RES, V63, P1789; Sengupta PK, 2002, J BIOL CHEM, V277, P24926, DOI 10.1074/jbc.M111712200; Sengupta PK, 1998, BBA-GENE STRUCT EXPR, V1443, P75, DOI 10.1016/S0167-4781(98)00188-2; Sengupta PK, 1999, J BIOL CHEM, V274, P36649, DOI 10.1074/jbc.274.51.36649; SILACCI P, 1994, J EXP MED, V180, P1329, DOI 10.1084/jem.180.4.1329; Sisk TJ, 2000, J IMMUNOL, V165, P2511, DOI 10.4049/jimmunol.165.5.2511; SMITH BD, 1990, ANN NY ACAD SCI, V580, P459, DOI 10.1111/j.1749-6632.1990.tb17960.x; SMITH BD, 1980, BIOCHEMISTRY-US, V19, P1820, DOI 10.1021/bi00550a014; SMITH BD, 1988, BIOCHEM J, V253, P269, DOI 10.1042/bj2530269; Stathopulos PB, 2003, BIOTECHNOL ADV, V21, P513, DOI 10.1016/S0734-9750(03)00102-2; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Takatsu M, 1999, MECH AGEING DEV, V110, P37, DOI 10.1016/S0047-6374(99)00041-X; Taxman DJ, 2000, J IMMUNOL, V165, P1410, DOI 10.4049/jimmunol.165.3.1410; THOMPSON JP, 1991, J BIOL CHEM, V266, P2549; Villani GRD, 2002, BIOCHEM J, V364, P747, DOI 10.1042/BJ20011872; Villard J, 2001, MEDICINE, V80, P405, DOI 10.1097/00005792-200111000-00006; Westerheide SD, 1997, J IMMUNOL, V158, P4812; Widom RL, 2001, MATRIX BIOL, V20, P451, DOI 10.1016/S0945-053X(01)00167-6; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Xu Y, 2004, J BIOL CHEM, V279, P41319, DOI 10.1074/jbc.M404174200; Xu Y, 2003, J BIOL CHEM, V278, P49134, DOI 10.1074/jbc.M309003200; Yamane K, 2005, J CELL PHYSIOL, V202, P822, DOI 10.1002/jcp.20205; Yee CSK, 2004, J IMMUNOL, V172, P5528, DOI 10.4049/jimmunol.172.9.5528; Yuan WH, 1999, J CELL PHYSIOL, V179, P97, DOI 10.1002/(SICI)1097-4652(199904)179:1<97::AID-JCP12>3.3.CO;2-5; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810; ZHANG XY, 1990, NUCLEIC ACIDS RES, V18, P6253, DOI 10.1093/nar/18.21.6253; Zhu XS, 2001, MOL CELL BIOL, V21, P7078, DOI 10.1128/MCB.21.20.7078-7088.2001	69	52	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21004	21014		10.1074/jbc.M413191200	http://dx.doi.org/10.1074/jbc.M413191200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15788405	hybrid, Green Accepted			2022-12-27	WOS:000229438800014
J	Thomas, M; Yu, ZG; Dadgar, N; Varambally, S; Yu, JJ; Chinnaiyan, AM; Lieberman, AP				Thomas, M; Yu, ZG; Dadgar, N; Varambally, S; Yu, JJ; Chinnaiyan, AM; Lieberman, AP			The unfolded protein response modulates toxicity of the expanded glutamine androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MOUSE MODEL; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; ER STRESS; TRANSLATIONAL CONTROL; ATF6; DEGRADATION; IRE1; EXPRESSION; SITE	Kennedy disease, a degenerative disorder caused by an expanded glutamine tract, is mediated by misfolding of the mutant androgen receptor (AR) protein, a process that may disrupt proteasome function. We hypothesized that this might lead to endoplasmic reticulum ( ER) stress and induction of the unfolded protein response (UPR), a complex physiologic pathway that regulates cell survival. To test this hypothesis, we used amino-terminal fragments of wild type (AR16Q) or mutant (AR112Q) AR that triggered glutamine length-dependent cell death and activated an ER stress-inducible promoter. To evaluate the role of the UPR, we examined the contributions of three proximal sensors of ER stress: activating transcription factor 6 (ATF6), inositol requiring 1 (IRE1), and PKR-like endoplasmic reticulum kinase ( PERK). AR112Q toxicity was significantly increased by a dominant negative ATF6 mutant and significantly decreased by a constitutively active ATF6 mutant, indicating that ATF6 promoted cell survival. In contrast, co-transfection with three separate IRE1 alpha dominant negative mutants failed to alter glutamine length-dependent toxicity, suggesting that this arm of the UPR did not significantly affect AR112Q induced cell death. Activation of PERK, an ER transmembrane protein that functions as the third proximal UPR sensor, promoted glutamine length-dependent toxicity. Although nuclear localization sequence-and nuclear export sequence-targeted proteins both activated the UPR, this pathway more potently influenced toxicity when proteins were targeted to the cytoplasm. Taken together, our data demonstrate that the UPR is activated in cells expressing long glutamine tracts and that this pathway modulates polyglutamine toxicity.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Lieberman, AP (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine,4233 Med Sci 1, Ann Arbor, MI 48109 USA.	liebermn@umich.edu	Longo, Kenneth A/A-5631-2010; Yu, Zhigang/A-6893-2009	Varambally, Sooryanarayana/0000-0002-2277-1127	NATIONAL INSTITUTE ON AGING [P50AG008671, K08AG024758] Funding Source: NIH RePORTER; NIA NIH HHS [K08 AG024758, P50 AG08671] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adachi H, 2003, J NEUROSCI, V23, P2203; Bailey CK, 2002, HUM MOL GENET, V11, P515, DOI 10.1093/hmg/11.5.515; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chevalier-Larsen ES, 2004, J NEUROSCI, V24, P4778, DOI 10.1523/JNEUROSCI.0808-04.2004; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Forman MS, 2003, TRENDS NEUROSCI, V26, P407, DOI 10.1016/S0166-2236(03)00197-8; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Kanuka H, 2003, P NATL ACAD SCI USA, V100, P11723, DOI 10.1073/pnas.1934748100; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kouroku Y, 2002, HUM MOL GENET, V11, P1505, DOI 10.1093/hmg/11.13.1505; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Lieberman AP, 2002, HUM MOL GENET, V11, P1967, DOI 10.1093/hmg/11.17.1967; Lieberman AP, 2000, MUSCLE NERVE, V23, P843, DOI 10.1002/(SICI)1097-4598(200006)23:6<843::AID-MUS2>3.0.CO;2-8; McCampbell A, 2001, P NATL ACAD SCI USA, V98, P15179, DOI 10.1073/pnas.261400698; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; McManamny P, 2002, HUM MOL GENET, V11, P2103, DOI 10.1093/hmg/11.18.2103; Merry DE, 1998, HUM MOL GENET, V7, P693, DOI 10.1093/hmg/7.4.693; Miranda E, 2004, J BIOL CHEM, V279, P28283, DOI 10.1074/jbc.M313166200; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Orr HT, 2001, GENE DEV, V15, P925, DOI 10.1101/gad.888401; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Southwood CM, 2002, NEURON, V36, P585, DOI 10.1016/S0896-6273(02)01045-0; Szebenyi G, 2003, NEURON, V40, P41, DOI 10.1016/S0896-6273(03)00569-5; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; Thomas M, 2004, J BIOL CHEM, V279, P8389, DOI 10.1074/jbc.M311761200; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang Y, 2000, J BIOL CHEM, V275, P27013; Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	47	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21264	21271		10.1074/jbc.M500144200	http://dx.doi.org/10.1074/jbc.M500144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799970	hybrid			2022-12-27	WOS:000229438800045
J	Binks, MJ; Fernie-King, BA; Seilly, DJ; Lachmann, PJ; Sriprakash, KS				Binks, MJ; Fernie-King, BA; Seilly, DJ; Lachmann, PJ; Sriprakash, KS			Attribution of the various inhibitory actions of the streptococcal inhibitor of complement (SIC) to regions within the molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; EXTRACELLULAR PROTEIN; PYOGENES; GENE; STRAINS; VARIANTS; EPIDEMIC; EMM12	Some strains of Streptococcus pyogenes secrete a virulence factor called the streptococcal inhibitor of complement ( SIC) function. SIC is a polyfunctional protein that interacts with a number of host proteins and peptides, especially with those that are involved in host defense systems. In addition to inhibiting the complement-mediated lysis of cells, SIC inhibits lysozyme, secretory leukocyte proteinase inhibitor, and beta-defensins. SIC also binds to proteins associated with the cytoskeleton and thereby may cause cytoskeletal derangement. The SIC molecule has three distinct structural domains constituting the N-proximal short repeat region (SRR), the central long repeat region (LRR), and the C-proximal proline-rich region (PRR). To map various functions to the structural domains, we have analyzed recombinant subclones expressing various parts of SIC and elastase-generated discrete fragments of SIC for binding to various ligands and for determining their biological properties. The results demonstrate the following. ( a) SRR alone was sufficient to confer inhibition of complement function. (b) Anti-defensin and anti-lysozyme activities were mapped to the SRR plus LRR. ( c) The LRR plus PRR harbored ezrin binding activity.	Queensland Inst Med Res, Brisbane, Qld 4006, Australia; Univ Cambridge, Dept Vet Med, Cambridge CB3 0ES, England	QIMR Berghofer Medical Research Institute; University of Cambridge	Sriprakash, KS (corresponding author), Queensland Inst Med Res, 300 Herston Rd, Brisbane, Qld 4006, Australia.	sriS@qimr.edu.au	Lachmann, P J/I-7968-2019	Lachmann, P J/0000-0003-2849-3524; Sriprakash, Kadaba/0000-0001-7844-323X				Akesson P, 1996, J BIOL CHEM, V271, P1081, DOI 10.1074/jbc.271.2.1081; Binks M, 2004, INFECT IMMUN, V72, P3981, DOI 10.1128/IAI.72.7.3981-3986.2004; Binks M, 2003, INFECT IMMUN, V71, P6701, DOI 10.1128/IAI.71.12.6701-6706.2003; Fernie-King BA, 2004, IMMUNOLOGY, V111, P444, DOI 10.1111/j.0019-2805.2004.01837.x; Fernie-King BA, 2002, INFECT IMMUN, V70, P4908, DOI 10.1128/IAI.70.9.4908-4916.2002; Fernie-King BA, 2001, IMMUNOLOGY, V103, P390, DOI 10.1046/j.1365-2567.2001.01249.x; Frick IM, 2003, J BIOL CHEM, V278, P16561, DOI 10.1074/jbc.M301995200; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Hartas J, 1999, MICROB PATHOGENESIS, V26, P25, DOI 10.1006/mpat.1998.0244; Hoe NP, 1999, NAT MED, V5, P924, DOI 10.1038/11369; Hoe NP, 2002, P NATL ACAD SCI USA, V99, P7646, DOI 10.1073/pnas.112039899; Hoe NP, 2001, J INFECT DIS, V183, P633, DOI 10.1086/318543; Hoe NP, 2000, J INFECT DIS, V182, P1425, DOI 10.1086/315882; LACHMANN PJ, 1970, J EXP MED, V131, P643, DOI 10.1084/jem.131.4.643; Lachmann PJ, 2004, MOL IMMUNOL, V41, P265; Lukomski S, 2000, INFECT IMMUN, V68, P535, DOI 10.1128/IAI.68.2.535-542.2000; Ma XM, 2002, J CLIN MICROBIOL, V40, P3835, DOI 10.1128/JCM.40.10.3835-3837.2002; PODBIELSKI A, 1993, MOL GEN GENET, V237, P287, DOI 10.1007/BF00282810; Sriprakash KS, 2002, J MED MICROBIOL, V51, P589, DOI 10.1099/0022-1317-51-7-589	19	23	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20120	20125		10.1074/jbc.M414194200	http://dx.doi.org/10.1074/jbc.M414194200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769742	hybrid			2022-12-27	WOS:000229113700083
J	Buhrke, T; Loscher, S; Lenz, O; Schlodder, E; Zebger, I; Andersen, LK; Hildebrandt, P; Meyer-Klaucke, W; Dau, H; Friedrich, B; Haumann, M				Buhrke, T; Loscher, S; Lenz, O; Schlodder, E; Zebger, I; Andersen, LK; Hildebrandt, P; Meyer-Klaucke, W; Dau, H; Friedrich, B; Haumann, M			Reduction of unusual iron-sulfur clusters in the H-2-sensing regulatory Ni-Fe hydrogenase from Ralstonia eutropha H16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-ABSORPTION; HISTIDINE PROTEIN-KINASE; ACTIVE-SITE; ALCALIGENES-EUTROPHUS; MANGANESE COMPLEX; H-2 SENSOR; RHODOBACTER-CAPSULATUS; STRUCTURAL-CHANGES; PHOTOSYSTEM-II; SPECTROSCOPY	The regulatory Ni-Fe hydrogenase (RH) from Ralstonia eutropha functions as a hydrogen sensor. The RH consists of the large subunit HoxC housing the Ni-Fe active site and the small subunit HoxB containing Fe-S clusters. The heterolytic cleavage of H-2 at the Ni-Fe active site leads to the EPR-detectable Ni-C state of the protein. For the first time, the simultaneous but EPR-invisible reduction of Fe-S clusters during Ni-C state formation was demonstrated by changes in the UV-visible absorption spectrum as well as by shifts of the iron K-edge from x-ray absorption spectroscopy in the wildtype double dimeric RHWT [HoxBC](2) and in a monodimeric derivative designated RHstop lacking the C-terminal 55 amino acids of HoxB. According to the analysis of iron EXAFS spectra, the Fe-S clusters of HoxB pronouncedly differ from the three Fe-S clusters in the small subunits of crystallized standard Ni-Fe hydrogenases. Each HoxBC unit of RHWT seems to harbor two [2Fe-2S] clusters in addition to a 4Fe species, which may be a [4Fe-3S-3O] cluster. The additional 4Fe-cluster was absent in RHstop. Reduction of Fe-S clusters in the hydrogen sensor RH may be a first step in the signal transduction chain, which involves complex formation between [HoxBC](2) and tetrameric HoxJ protein, leading to the expression of the energy converting Ni-Fe hydrogenases in R. eutropha.	Free Univ Berlin, FB Phys, D-14195 Berlin, Germany; Humboldt Univ, Inst Biol Mikrobiol, D-10115 Berlin, Germany; Tech Univ Berlin, Inst Chem, Max Volmer Lab Biophys Chem, D-10623 Berlin, Germany; DESY, EMBL Outstn, D-22603 Hamburg, Germany	Free University of Berlin; Humboldt University of Berlin; Technical University of Berlin; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Haumann, M (corresponding author), Free Univ Berlin, FB Phys, Arnimallee 14, D-14195 Berlin, Germany.	haumann@physik.fu-berlin.de	Lenz, Oliver/N-5130-2019; Meyer-Klaucke, Wolfram/G-1148-2010; Lenz, Oliver/C-1582-2019; Schlodder, Eberhard/AAP-6766-2021; Hildebrandt, Peter/J-5658-2014; MIchael, Haumann/A-7087-2013	Lenz, Oliver/0000-0003-4550-5128; Lenz, Oliver/0000-0003-4550-5128; Hildebrandt, Peter/0000-0003-1030-5900; Dau, Holger/0000-0001-6482-7494				Agarwalla S, 2004, J BIOL CHEM, V279, P34123, DOI 10.1074/jbc.M405702200; ALBRACHT SPJ, 1994, BBA-BIOENERGETICS, V1188, P167, DOI 10.1016/0005-2728(94)90036-1; Albracht SPJ, 2003, BBA-BIOENERGETICS, V1557, P41, DOI 10.1016/S0005-2728(02)00393-6; Arendsen AF, 1998, J BIOL INORG CHEM, V3, P81, DOI 10.1007/s007750050210; Armstrong FA, 2004, CURR OPIN CHEM BIOL, V8, P133, DOI 10.1016/j.cbpa.2004.02.004; Bernhard M, 2001, J BIOL CHEM, V276, P15592, DOI 10.1074/jbc.M009802200; BLACK LK, 1994, J BACTERIOL, V176, P7102, DOI 10.1128/JB.176.22.7102-7106.1994; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brecht M, 2003, J AM CHEM SOC, V125, P13075, DOI 10.1021/ja036624x; Buhrke T, 2004, MOL MICROBIOL, V51, P1677, DOI 10.1111/j.1365-2958.2003.03933.x; Cammack R., 1997, HYDROGEN FUEL LEARNI; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; COLPAS GJ, 1991, INORG CHEM, V30, P920, DOI 10.1021/ic00005a010; Cosper NJ, 2002, PROTEIN SCI, V11, P2969, DOI 10.1110/ps.0222402; Dau H, 2003, ANAL BIOANAL CHEM, V376, P562, DOI 10.1007/s00216-003-1982-2; Dau H, 2004, PHYS CHEM CHEM PHYS, V6, P4781, DOI 10.1039/b408146c; Drennan CL, 2001, P NATL ACAD SCI USA, V98, P11973, DOI 10.1073/pnas.211429998; Elsen S, 2003, J BACTERIOL, V185, P7111, DOI 10.1128/JB.185.24.7111-7119.2003; Elsen S, 1996, J BACTERIOL, V178, P5174, DOI 10.1128/jb.178.17.5174-5181.1996; Fischer J, 1996, ARCH MICROBIOL, V165, P289, DOI 10.1007/s002030050329; Frey M, 2002, CHEMBIOCHEM, V3, P153, DOI 10.1002/1439-7633(20020301)3:2/3<153::AID-CBIC153>3.0.CO;2-B; Garcin E, 1999, STRUCT FOLD DES, V7, P557, DOI 10.1016/S0969-2126(99)80072-0; Haumann M, 2003, BIOCHEMISTRY-US, V42, P11004, DOI 10.1021/bi034804d; Higuchi Y, 1999, STRUCT FOLD DES, V7, P549, DOI 10.1016/S0969-2126(99)80071-9; Kleihues L, 2000, J BACTERIOL, V182, P2716, DOI 10.1128/JB.182.10.2716-2724.2000; Klockenkamper R., 1996, TOTAL REFLECTION XRA; Kounosu A, 2004, J BIOL CHEM, V279, P12519, DOI 10.1074/jbc.M305923200; Lenz O, 1998, P NATL ACAD SCI USA, V95, P12474, DOI 10.1073/pnas.95.21.12474; Lippard S. J., 1994, PRINCIPLES BIOINORGA; Matias PM, 2001, J BIOL INORG CHEM, V6, P63, DOI 10.1007/s007750000167; MCDERMOTT AE, 1989, BIOCHEMISTRY-US, V28, P8056, DOI 10.1021/bi00446a013; Meinke C, 2000, BIOCHEMISTRY-US, V39, P7033, DOI 10.1021/bi9924258; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Nagashima S, 1998, NAT STRUCT BIOL, V5, P347, DOI 10.1038/nsb0598-347; Nakamaru-Ogiso E, 2002, J BIOL CHEM, V277, P1680, DOI 10.1074/jbc.M108796200; PENNERHAHN JE, 1983, J BIOL CHEM, V258, P2761; PETTIFER RF, 1985, J APPL CRYSTALLOGR, V18, P404, DOI 10.1107/S0021889885010627; Pierik AJ, 1998, FEBS LETT, V438, P231, DOI 10.1016/S0014-5793(98)01306-4; Pikus JD, 1996, BIOCHEMISTRY-US, V35, P9106, DOI 10.1021/bi960456m; Rousset M, 1998, P NATL ACAD SCI USA, V95, P11625, DOI 10.1073/pnas.95.20.11625; SCHINK B, 1978, BIOCHIMIE, V60, P297, DOI 10.1016/S0300-9084(78)80826-8; SCHINK B, 1979, BIOCHIM BIOPHYS ACTA, V567, P315, DOI 10.1016/0005-2744(79)90117-7; SCHNEIDER K, 1976, BIOCHIM BIOPHYS ACTA, V452, P66, DOI 10.1016/0005-2744(76)90058-9; TSANG HT, 1989, BIOCHEMISTRY-US, V28, P7233, DOI 10.1021/bi00444a015; Volbeda A, 1996, J AM CHEM SOC, V118, P12989, DOI 10.1021/ja962270g; VOLBEDA A, 1995, NATURE, V373, P556; Wolfe MT, 2002, J BACTERIOL, V184, P5898, DOI 10.1128/JB.184.21.5898-5902.2002; ZABINSKY SI, 1995, PHYS REV B, V52, P2995, DOI 10.1103/PhysRevB.52.2995	48	43	45	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19488	19495		10.1074/jbc.M500601200	http://dx.doi.org/10.1074/jbc.M500601200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15764814	hybrid			2022-12-27	WOS:000229113700010
J	Erwin, PA; Lin, AJ; Golan, DE; Michel, T				Erwin, PA; Lin, AJ; Golan, DE; Michel, T			Receptor-regulated dynamic S-nitrosylation of endothelial nitric-oxide synthase in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; PLASMALEMMAL CAVEOLAE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; ENOS ACTIVATION; ENZYME-ACTIVITY; PALMITOYLATION; AKT; TETRAHYDROBIOPTERIN; PHOSPHORYLATION	The endothelial isoform of nitric-oxide synthase (eNOS) is regulated by a complex pattern of post-translational modifications. In these studies, we show that eNOS is dynamically regulated by S-nitrosylation, the covalent adduction of nitric oxide (NO)-derived nitrosyl groups to the cysteine thiols of proteins. We report that eNOS is tonically S-nitrosylated in resting bovine aortic endothelial cells and that the enzyme undergoes rapid transient denitrosylation after addition of the eNOS agonist, vascular endothelial growth factor. eNOS is thereafter progressively renitrosylated to basal levels. The receptor-mediated decrease in eNOS S-nitrosylation is inversely related to enzyme phosphorylation at Ser(1179), a site associated with eNOS activation. We also document that targeting of eNOS to the cell membrane is required for eNOS S-nitrosylation. Acylation-deficient mutant eNOS, which is targeted to the cytosol, does not undergo S-nitrosylation. Using purified eNOS, we show that eNOS S-nitrosylation by exogenous NO donors inhibits enzyme activity and that eNOS inhibition is reversed by denitrosylation. We determine that the cysteines of the zinc-tetrathiolate that comprise the eNOS dimer interface are the targets of S-nitrosylation. Mutation of the zinc-tetrathiolate cysteines eliminates eNOS S-nitrosylation but does not eliminate NO synthase activity, arguing strongly that disruption of the zinc-tetrathiolate does not necessarily lead to eNOS monomerization in vivo. Taken together, these studies suggest that eNOS S-nitrosylation may represent an important mechanism for regulation of NO signaling pathways in the vascular wall.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Vet Affairs Boston Healthcare Syst, W Roxbury, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Michel, T (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St,Thorn Bldg,1210A, Boston, MA 02115 USA.	tmichel@research.bwh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046457, R01HL032854, R37HL032854, U54HL070819, R01HL046457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036259, R37GM036259] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL070819, HL32854, HL46457] Funding Source: Medline; NIGMS NIH HHS [GM36259] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrew PJ, 1999, CARDIOVASC RES, V43, P521, DOI 10.1016/S0008-6363(99)00115-7; Ausubel FM, 2003, CURRENT PROTOCOLS MO; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200; BUSCONI L, 1995, MOL PHARMACOL, V47, P655; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; Davis KL, 2001, ANNU REV PHARMACOL, V41, P203, DOI 10.1146/annurev.pharmtox.41.1.203; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gonzalez E, 2004, J BIOL CHEM, V279, P40659, DOI 10.1074/jbc.M407051200; Gonzalez E, 2002, J BIOL CHEM, V277, P39554, DOI 10.1074/jbc.M207299200; Griffith OW, 1996, METHOD ENZYMOL, V268, P375; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Heller R, 1999, J BIOL CHEM, V274, P8254, DOI 10.1074/jbc.274.12.8254; Heller R, 2001, J BIOL CHEM, V276, P40, DOI 10.1074/jbc.M004392200; Hemmens B, 2000, J BIOL CHEM, V275, P35786, DOI 10.1074/jbc.M005976200; Hogg N, 1999, ANAL BIOCHEM, V272, P257, DOI 10.1006/abio.1999.4199; HUANG A, 2001, AM J PHYSIOL, V21, pC719; Igarashi J, 2003, P NATL ACAD SCI USA, V100, P10664, DOI 10.1073/pnas.1934494100; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; JAFFREY SR, 2001, SCI STKE; Kim JE, 2004, J BIOL CHEM, V279, P9758, DOI 10.1074/jbc.M312722200; Kolodziejski PJ, 2003, P NATL ACAD SCI USA, V100, P14263, DOI 10.1073/pnas.2435290100; Kou RQ, 2002, J BIOL CHEM, V277, P29669, DOI 10.1074/jbc.M204519200; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; Martinez-Ruiz A, 2004, CARDIOVASC RES, V62, P43, DOI 10.1016/j.cardiores.2004.01.013; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; Prabhakar P, 2000, J BIOL CHEM, V275, P19416, DOI 10.1074/jbc.M001952200; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Ravi K, 2004, P NATL ACAD SCI USA, V101, P2619, DOI 10.1073/pnas.0300464101; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stuart-Smith K, 2002, J CLIN PATHOL-MOL PA, V55, P360, DOI 10.1136/mp.55.6.360; Takahashi S, 2003, J BIOL CHEM, V278, P30821, DOI 10.1074/jbc.M304471200; Ting HH, 1996, J CLIN INVEST, V97, P22, DOI 10.1172/JCI118394; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; Wink DA, 1996, METHOD ENZYMOL, V268, P12; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891	46	157	159	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19888	19894		10.1074/jbc.M413058200	http://dx.doi.org/10.1074/jbc.M413058200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774480	hybrid			2022-12-27	WOS:000229113700058
J	Kapur, S; Mohan, S; Baylink, DJ; Lau, KHW				Kapur, S; Mohan, S; Baylink, DJ; Lau, KHW			Fluid shear stress synergizes with insulin-like growth factor-I (IGF-I) on osteoblast proliferation through integrin-dependent activation of IGF-I mitogenic signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNLOADING INDUCES RESISTANCE; ALPHA-V-BETA-3 INTEGRIN; TYROSINE PHOSPHORYLATION; MECHANICAL STIMULATION; BONE-RESORPTION; MESSENGER-RNA; RECEPTOR; RESPONSES; EXPRESSION; TRANSDUCTION	This study tested the hypothesis that shear stress interacts with the insulin-like growth factor-I (IGF-I) pathway to stimulate osteoblast proliferation. Human TE85 osteosarcoma cells were subjected to a steady shear stress of 20 dynes/cm(2) for 30 min followed by 24-h incubation with IGF-I (0-50 ng/ml). IGF-I increased proliferation dose-dependently (1.5-2.5-fold). Shear stress alone increased proliferation by 70%. The combination of shear stress and IGF-I stimulated proliferation (3.5- to 5.5-fold) much greater than the additive effects of each treatment alone, indicating a synergistic interaction. IGF-I dose-dependently increased the phosphorylation level of Erk1/2 by 1.2-5.3-fold and that of IGF-I receptor (IGF-IR) by 2-4- fold. Shear stress alone increased Erk1/2 and IGF-IR phosphorylation by 2- fold each. The combination treatment also resulted in synergistic enhancements in both Erk1/2 and IGF-IR phosphorylation ( up to 12- and 8-fold, respectively). Shear stress altered IGF-IR binding only slightly, suggesting that the synergy occurred primarily at the post-ligand binding level. Recent studies have implicated a role for integrin in the regulation of IGF-IR phosphorylation and IGF-I signaling. To test whether the synergy involves integrin-dependent mechanisms, the effect of echistatin ( a disintegrin) on proliferation in response to shear stress +/- IGF-I was measured. Echistatin reduced basal proliferation by similar to 60% and the shear stress-induced mitogenic response by similar to 20%. It completely abolished the mitogenic effect of IGF-I and that of the combination treatment. Shear stress also significantly reduced the amounts of co-immunoprecipitated SHP-2 and -1 with IGF-IR, suggesting that the synergy between shear stress and IGF-I in osteoblast proliferation involves integrin-dependent recruitment of SHP-2 and - 1 away from IGF-IR.	Loma Linda Univ, Jerry L Pettis Mem Vet Affairs Med Ctr, Musculoskeletal Dis Ctr 151, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Med, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Biochem, Loma Linda, CA 92357 USA	Loma Linda University; Loma Linda University; Loma Linda University	Lau, KHW (corresponding author), Loma Linda Univ, Jerry L Pettis Mem Vet Affairs Med Ctr, Musculoskeletal Dis Ctr 151, 11201 Benton St, Loma Linda, CA 92357 USA.	William.Lau@med.va.gov		Lau, Kin-Hing/0000-0003-1109-5052				ALENGHAT FJ, 2002, SCI STKE; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CANALIS E, 1988, J CLIN INVEST, V81, P277, DOI 10.1172/JCI113318; Carter DR, 2004, CLIN ORTHOP RELAT R, pS69, DOI 10.1097/01.blo.0000144970.05107.7e; Carter DR, 1998, CLIN ORTHOP RELAT R, pS41; CARVALHO RS, 1995, ARCH ORAL BIOL, V40, P257, DOI 10.1016/0003-9969(95)98814-F; Cheng MZ, 2002, J BONE MINER RES, V17, P593, DOI 10.1359/jbmr.2002.17.4.593; Clemmons DR, 2005, MOL ENDOCRINOL, V19, P1, DOI 10.1210/me.2004-0376; CLOVER J, 1994, BONE, V15, P585, DOI 10.1016/8756-3282(94)90305-0; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Gronthos S, 1997, J BONE MINER RES, V12, P1189, DOI 10.1359/jbmr.1997.12.8.1189; HILLAM RA, 1995, J BONE MINER RES, V10, P683; HILLSLEY MV, 1994, BIOTECHNOL BIOENG, V43, P573, DOI 10.1002/bit.260430706; HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo-122-1-254; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; Kapur S, 2004, BONE, V35, P525, DOI 10.1016/j.bone.2004.04.007; Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756-3282(02)00979-1; Lau KHW, 2002, BONE, V30, P705, DOI 10.1016/S8756-3282(02)00671-3; LAU KHW, 1985, BIOCHIM BIOPHYS ACTA, V840, P56, DOI 10.1016/0304-4165(85)90162-X; LAU KHW, J BONE MINER RES S1, V19, pS79; LEAN JM, 1995, AM J PHYSIOL-ENDOC M, V268, pE318, DOI 10.1152/ajpendo.1995.268.2.E318; Lee HS, 2000, J BONE MINER RES, V15, P1501, DOI 10.1359/jbmr.2000.15.8.1501; Lin TH, 1997, J BIOL CHEM, V272, P8849; Ling Y, 2005, J BIOL CHEM, V280, P3151, DOI 10.1074/jbc.M411035200; Ling Y, 2003, MOL ENDOCRINOL, V17, P1824, DOI 10.1210/me.2003-0143; Maile LA, 2003, MOL BIOL CELL, V14, P3519, DOI 10.1091/mbc.E03-04-0239; Maile LA, 2002, J BIOL CHEM, V277, P8955, DOI 10.1074/jbc.M109258200; Maile LA, 2002, ENDOCRINOLOGY, V143, P4259, DOI 10.1210/en.2002-220395; Mauck RL, 2003, TISSUE ENG, V9, P597, DOI 10.1089/107632703768247304; MikuniTakagaki Y, 1996, ENDOCRINOLOGY, V137, P2028, DOI 10.1210/en.137.5.2028; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MOHAN S, 1991, CLIN ORTHOP RELAT R, V263, P30; Mosley JR, 2000, J REHABIL RES DEV, V37, P189; Sakata T, 2004, J BONE MINER RES, V19, P436, DOI 10.1359/JBMR.0301241; Sakata T, 2003, BONE, V32, P669, DOI 10.1016/S8756-3282(03)00088-7; Salter DM, 1997, J BONE MINER RES, V12, P1133, DOI 10.1359/jbmr.1997.12.7.1133; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Tokimasa C, 2000, ARCH ORAL BIOL, V45, P871, DOI 10.1016/S0003-9969(00)00057-1; WERGEDAL JE, 1990, J BONE MINER RES, V5, P179, DOI 10.1002/jbmr.5650050212; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	42	52	56	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20163	20170		10.1074/jbc.M501460200	http://dx.doi.org/10.1074/jbc.M501460200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15778506	hybrid			2022-12-27	WOS:000229113700089
J	Prakash, A; Smith, E; Lee, CK; Levy, DE				Prakash, A; Smith, E; Lee, CK; Levy, DE			Tissue-specific positive feedback requirements for production of type I interferon following virus infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; PLASMACYTOID DENDRITIC CELLS; TOLL-LIKE RECEPTORS; DIFFERENTIAL REGULATION; TARGETED DISRUPTION; REGULATORY FACTOR-7; ALPHA PRODUCTION; ACTIVATION; INNATE; EXPRESSION	Type I interferon (IFN) is synthesized by most nucleated cells following viral infection. Robust IFN production in cell culture requires positive feedback expression of inducible signaling components, such as the transcription factor IRF7. However, the role of positive feedback and IRF7 in vivo may be more complex. We found that IFN produced locally in the respiratory tract of influenza virus-infected mice displayed characteristics of positive feedback, including Stat1-dependent induction of IRF7 and IFN gene expression. IRF7 expression was similarly stimulus-dependent in most tissues. However, lymphoid tissue constitutively expressed high levels of IRF7 in the absence of induction or positive feedback, and this expression was largely confined to plasmacytoid dendritic cells ( DC). These cells rapidly produced large quantities of multiple IFN alpha species following viral infection without positive feedback, whereas other hematopoietic cells, including other DC subtypes, expressed little IRF7 and were poor IFN producers in the absence of positive feedback. These data reveal a dual mechanism for the regulation of IFN production by differential expression of IRF7, involving positive feedback at local sites of infection combined with robust systemic production by IRF7-expressing plasmacytoid DC.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	New York University; New York University; New York University	Levy, DE (corresponding author), NYU, Sch Med, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.	del243@med.nyu.edu	Lee, Chien-Kuo/AAZ-1039-2020; Levy, David/AAG-6202-2019; Levy, David/GPS-4945-2022	Lee, Chien-Kuo/0000-0001-8189-6045; Levy, David/0000-0002-7320-7788; 	NIAID NIH HHS [R01 AI028900, R01 AI046503] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046503, R01AI028900] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Barchet W, 2002, J EXP MED, V195, P507, DOI 10.1084/jem.20011666; Barton GM, 2002, CURR TOP MICROBIOL, V270, P81; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Boonstra A, 2003, J EXP MED, V197, P101, DOI 10.1084/jem.20021908; Dai JH, 2004, J IMMUNOL, V173, P1535, DOI 10.4049/jimmunol.173.3.1535; Dalod M, 2003, J EXP MED, V197, P885, DOI 10.1084/jem.20021522; Dalod M, 2002, J EXP MED, V195, P517, DOI 10.1084/jem.20011672; Diebold SS, 2003, NATURE, V424, P324, DOI 10.1038/nature01783; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Durbin JE, 2000, J IMMUNOL, V164, P4220, DOI 10.4049/jimmunol.164.8.4220; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Garcia-Sastre A, 1998, J VIROL, V72, P8550; Gilliet M, 2002, J EXP MED, V195, P953, DOI 10.1084/jem.20020045; Hata N, 2001, BIOCHEM BIOPH RES CO, V285, P518, DOI 10.1006/bbrc.2001.5159; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; Honda K, 2003, P NATL ACAD SCI USA, V100, P10872, DOI 10.1073/pnas.1934678100; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Izaguirre A, 2003, J LEUKOCYTE BIOL, V74, P1125, DOI 10.1189/jlb.0603255; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Kerkmann M, 2003, J IMMUNOL, V170, P4465, DOI 10.4049/jimmunol.170.9.4465; Lee CK, 1999, J EXP MED, V190, P1451, DOI 10.1084/jem.190.10.1451; LeibundGut-Landmann S, 2004, NAT IMMUNOL, V5, P899, DOI 10.1038/ni1109; Levy DE, 2004, NAT IMMUNOL, V5, P699, DOI 10.1038/ni0704-699; Levy DE, 2003, CURR OPIN IMMUNOL, V15, P52, DOI 10.1016/S0952-7915(02)00011-0; Levy DE, 2002, J EXP MED, V195, pF15, DOI 10.1084/jem.20020075; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TOVEY MG, 1988, J IMMUNOL, V141, P3106; Tsujimura H, 2003, J IMMUNOL, V170, P1131, DOI 10.4049/jimmunol.170.3.1131; Tsujimura H, 2003, BLOOD, V101, P961, DOI 10.1182/blood-2002-05-1327; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	40	95	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18651	18657		10.1074/jbc.M501289200	http://dx.doi.org/10.1074/jbc.M501289200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15767254	Green Published, Green Accepted, Green Submitted, hybrid			2022-12-27	WOS:000228932300015
J	Fukushima, K; Ikehara, Y; Yamashita, K				Fukushima, K; Ikehara, Y; Yamashita, K			Functional role played by the glycosylphosphatidylinositol anchor glycan of CD48 in interleukin-18-induced interferon-gamma production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-A GENE; CARBOHYDRATE MOIETY; OLIGOSACCHARIDES; IDENTIFICATION; CYTOKINE; LECTIN; ALPHA	Interleukin (IL)-18 induces T cells and natural killer cells to produce not only interferon-gamma but also other cytokines by binding to the IL-18 receptor (IL-18R) alpha and beta subunits. However, little is known about how IL-18, IL-18R alpha, and IL-18R beta form a high-affinity complex on the cell surface and transduce the signal. We found that IL-18 and IL-18R alpha bind to glycosylphosphatidylinositol (GPI) glycan via the third mannose 6-phosphate diester and the second beta-GlcNAc-deleted mannose 6-phosphate of GPI glycan, respectively. To determine which GPI-anchored glycoprotein is involved in the complex of IL-18 and IL-18R alpha, IL-18R alpha of IL-18-stimulated KG-1 cells was immunoprecipitated together with CD48 by anti-IL-18R alpha antibody. More than 90% of CD48 was detected as beta-GlcNAc-deleted GPI-anchored glycoprotein, and soluble recombinant human CD48 without GPI glycan bound to IL-18R alpha,indicating that CD48 is associated with IL-18R alpha via both the peptide portion and the GPI glycan. To investigate whether the carbohydrate recognition of IL-18 is involved in physiological activities, KG-1 cells were digested with phosphatidylinositol- specific phospholipase C before IL-18 stimulation. Phosphatidylinositol-specific phospholipase C treatment inhibited the phosphorylation of tyrosine kinases and the following IL-18-dependent interferon-gamma production. These observations suggest that the complex formation of IL-18 alpha IL-18R alpha center dot CD48 via both the peptide portion and GPI glycan triggers the binding to IL-18R beta, and the IL-18 center dot IL-18R alpha center dot CD48 center dot IL-18R beta complex induces cellular signaling.	Sasaki Inst, Dept Biochem, Chiyoda Ku, Tokyo 1010062, Japan; Fukuoka Univ, Sch Med, Dept Cell Biol, Jonan Ku, Fukuoka 8140133, Japan	Fukuoka University	Yamashita, K (corresponding author), Sasaki Inst, Dept Biochem, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.	yamashita@sasaki.or.jp						BAENZIGER JU, 1979, J BIOL CHEM, V254, P789; Born TL, 2000, J BIOL CHEM, V275, P41529; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; ENDO T, 1988, J BIOCHEM-TOKYO, V103, P182, DOI 10.1093/oxfordjournals.jbchem.a122228; Fontes W, 1997, ARCH BIOCHEM BIOPHYS, V347, P201, DOI 10.1006/abbi.1997.0358; Fukushima K, 2004, ARCH BIOCHEM BIOPHYS, V426, P298, DOI 10.1016/j.abb.2004.02.028; Fukushima K, 2003, J BIOL CHEM, V278, P36296, DOI 10.1074/jbc.M304341200; Fukushima K, 1997, J BIOL CHEM, V272, P10579; GARNETT D, 1993, EUR J IMMUNOL, V23, P2540, DOI 10.1002/eji.1830231024; Gordon VM, 1999, J BIOL CHEM, V274, P27274, DOI 10.1074/jbc.274.38.27274; HEFTA SA, 1988, P NATL ACAD SCI USA, V85, P4648, DOI 10.1073/pnas.85.13.4648; ITO S, 1977, J BIOCHEM, V81, P1621, DOI 10.1093/oxfordjournals.jbchem.a131621; Kato Z, 2003, NAT STRUCT BIOL, V10, P966, DOI 10.1038/nsb993; KOCHIBE N, 1989, J BIOL CHEM, V264, P173; Kumar S, 2000, J BIOL CHEM, V275, P10308, DOI 10.1074/jbc.275.14.10308; LIANG CJ, 1980, J BIOCHEM-TOKYO, V88, P51; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Micallef MJ, 1996, EUR J IMMUNOL, V26, P1647, DOI 10.1002/eji.1830260736; Nelson KL, 2000, J BIOL CHEM, V275, P19839, DOI 10.1074/jbc.M002785200; OGATA S, 1988, J BIOL CHEM, V263, P10489; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; RINDLER MJ, 1990, J BIOL CHEM, V265, P20784; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; SPIK G, 1975, FEBS LETT, V50, P296, DOI 10.1016/0014-5793(75)90053-8; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAI T, 1975, J BIOL CHEM, V250, P8569; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TAMM I, 1952, J EXP MED, V95, P71, DOI 10.1084/jem.95.1.71; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; TsujiTakayama K, 1997, BIOCHEM BIOPH RES CO, V237, P126, DOI 10.1006/bbrc.1997.7099; YAMASHITA K, 1981, J BIOL CHEM, V256, P4789	31	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18056	18062		10.1074/jbc.M413297200	http://dx.doi.org/10.1074/jbc.M413297200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15760905	hybrid			2022-12-27	WOS:000228807200062
J	Zhao, K; Liu, MZ; Burgess, RR				Zhao, K; Liu, MZ; Burgess, RR			The global transcriptional response of Escherichia coli to induced sigma(32) protein involves sigma(32) regulon activation followed by inactivation and degradation of sigma(32) in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK RESPONSE; ATP-DEPENDENT PROTEASE; RNA-POLYMERASE; BACILLUS-SUBTILIS; GENE-EXPRESSION; GROWTH-CONDITIONS; DNAK; K-12; GENOME; PURIFICATION	sigma(32) is the first alternative sigma factor discovered in Escherichia coli and can direct transcription of many genes in response to heat shock stress. To define the physiological role of sigma(32), we have used transcription profiling experiments to identify, on a genome-wide basis, genes under the control of sigma(32) in E. coli by moderate induction of a plasmid-borne rpoH gene under defined, steady-state growth conditions. Together with a bioinformatics approach, we successfully confirmed genes known previously to be directly under the control of sigma(32) and also assigned many additional genes to the sigma(32) regulon. In addition, to understand better the functional relevance of the increased amount of sigma(32) to changes in the transcriptional level of sigma(32)-dependent genes, we measured the protein level of sigma(32) both before and after induction by a newly developed quantitative Western blot method. At a normal constant growth temperature (37 degrees C), we found that the sigma(32) protein level rapidly increased, plateaued, and then gradually decreased after induction, indicating sigma(32) can be regulated by genes in its regulon and that the mechanisms of sigma(32) synthesis, inactivation, and degradation are not strictly temperature-dependent. The decrease in the transcriptional level of sigma(32)-dependent genes occurs earlier than the decrease in full-length sigma(32) in the wild type strain, and the decrease in the transcriptional level of sigma(32)-dependent genes is greatly diminished in a Delta DnaK strain, suggesting that DnaK can act as an anti-sigma factor to functionally inactivate sigma(3)2 and thus reduce sigma(32)-dependent transcription in vivo.	Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Comp Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Burgess, RR (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	rburgess@wisc.edu		Burgess, Richard/0000-0001-9545-3165	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028575] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28575] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthony LC, 2003, METHOD ENZYMOL, V370, P181; Baichoo N, 2002, MOL MICROBIOL, V45, P1613, DOI 10.1046/j.1365-2958.2002.03113.x; Bailey TL, 1998, J COMPUT BIOL, V5, P211, DOI 10.1089/cmb.1998.5.211; Bergendahl V, 2003, METHOD ENZYMOL, V370, P192; Bergendahl V, 2003, J IMMUNOL METHODS, V277, P117, DOI 10.1016/S0022-1759(03)00183-2; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bockhorst J, 2003, BIOINFORMATICS, V19, pi34, DOI 10.1093/bioinformatics/btg1003; Britton RA, 2002, J BACTERIOL, V184, P4881, DOI 10.1128/JB.184.17.4881-4890.2002; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; BURGESS RR, 1970, FED PROC, V29, P1164; Cao M, 2002, J MOL BIOL, V316, P443, DOI 10.1006/jmbi.2001.5372; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHUANG SE, 1993, J BACTERIOL, V175, P2026, DOI 10.1128/JB.175.7.2026-2036.1993; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; ERICKSON JW, 1989, GENE DEV, V3, P1462, DOI 10.1101/gad.3.9.1462; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; Gomez JE, 1997, TUBERCLE LUNG DIS, V78, P175, DOI 10.1016/S0962-8479(97)90024-1; Goryshin IY, 1998, J BIOL CHEM, V273, P7367, DOI 10.1074/jbc.273.13.7367; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; GROSS CA, 1996, CELLULAR MOL BIOL, P1399; HALDENWANG WG, 1995, MICROBIOL REV, V59, P1; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Helmann JD, 2001, J BACTERIOL, V183, P7318, DOI 10.1128/JB.183.24.7318-7328.2001; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Ishihama A, 2000, ANNU REV MICROBIOL, V54, P499, DOI 10.1146/annurev.micro.54.1.499; Jishage M, 1996, J BACTERIOL, V178, P5447, DOI 10.1128/jb.178.18.5447-5451.1996; Kang YS, 2004, J BACTERIOL, V186, P4921, DOI 10.1128/JB.186.15.4921-4930.2004; KELLER JA, 1988, MOL MICROBIOL, V2, P31, DOI 10.1111/j.1365-2958.1988.tb00004.x; Kuczynska-Wisnik D, 2001, BIOCHEM BIOPH RES CO, V284, P57, DOI 10.1006/bbrc.2001.4926; LEMAUX PG, 1978, CELL, V13, P427, DOI 10.1016/0092-8674(78)90317-3; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; Liu X, 2001, Pac Symp Biocomput, P127; Liu XY, 1996, MOL MICROBIOL, V21, P613, DOI 10.1111/j.1365-2958.1996.tb02569.x; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; McCarty JS, 1996, J MOL BIOL, V256, P829, DOI 10.1006/jmbi.1996.0129; Molle V, 2003, MOL MICROBIOL, V50, P1683, DOI 10.1046/j.1365-2958.2003.03818.x; Muffler A, 1997, J BACTERIOL, V179, P445; NAGAI H, 1994, P NATL ACAD SCI USA, V91, P10280, DOI 10.1073/pnas.91.22.10280; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Richmond CS, 1999, NUCLEIC ACIDS RES, V27, P3821, DOI 10.1093/nar/27.19.3821; Salgado H, 2004, NUCLEIC ACIDS RES, V32, pD303, DOI 10.1093/nar/gkh140; SAUER U, 1995, FEMS MICROBIOL REV, V17, P331, DOI 10.1111/j.1574-6976.1995.tb00216.x; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Stintzi A, 2003, J BACTERIOL, V185, P2009, DOI 10.1128/JB.185.6.2009-2016.2003; STRAUS DB, 1987, NATURE, V329, P348, DOI 10.1038/329348a0; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; STRAUS DB, 1989, GENE DEV, V3, P2003, DOI 10.1101/gad.3.12a.2003; Tatsuta T, 1998, MOL MICROBIOL, V30, P583, DOI 10.1046/j.1365-2958.1998.01091.x; THOMPSON NE, 1992, BIOCHEMISTRY-US, V31, P7003, DOI 10.1021/bi00145a019; Tomoyasu T, 1998, MOL MICROBIOL, V30, P567, DOI 10.1046/j.1365-2958.1998.01090.x; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; WANG QP, 1989, J BACTERIOL, V171, P4248, DOI 10.1128/JB.171.8.4248-4253.1989; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Wosten MMSM, 1998, FEMS MICROBIOL REV, V22, P127, DOI 10.1016/S0168-6445(98)00011-4; YURA MKT, 2000, HEAT SHOCK RESPONSE, P3; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	65	108	115	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17758	17768		10.1074/jbc.M500393200	http://dx.doi.org/10.1074/jbc.M500393200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15757896	hybrid			2022-12-27	WOS:000228807200026
J	Loiarro, M; Sette, C; Gallo, G; Ciacci, A; Fanto, N; Mastroianni, D; Carminati, P; Ruggiero, V				Loiarro, M; Sette, C; Gallo, G; Ciacci, A; Fanto, N; Mastroianni, D; Carminati, P; Ruggiero, V			Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL/INTERLEUKIN-1 RECEPTOR DOMAINS; SIGNAL-TRANSDUCTION; GENE; MICE; IL-1; PROTEINS; ADAPTERS; KINASE; IRAK	Myeloid differentiation factor 88 (MyD88) plays a crucial role in the signaling pathways triggered by interleukin (IL)-1 and Toll-like receptors in several steps of innate host defense. A crucial event in this signaling pathway is represented by dimerization of MyD88, which allows the recruitment of downstream kinases like IRAK-1 and IRAK-4. Herein, we have investigated the function of the Toll/IL-1 receptor (TIR) domain in MyD88 homodimerization in cell-free and in vitro experimental settings by using epta-peptides that mimic the BB-loop region of the conserved TIR domain of different proteins. By using a pull-down assay with purified glutathione S-transferase-MyD88 TIR or co-immunoprecipitation experiments, we found that epta-peptides derived from the TIR domain of MyD88 and IL-18R are the most effective in inhibiting homodimerization with either the isolated TIR or full-length MyD88. Moreover, we demonstrated that a cell permeable analog of MyD88 epta-peptide inhibits homodimerization of MyD88 TIR domains in an in vitro cell system and significantly reduces IL-1 signaling, as assayed by activation of the downstream transcription factor NF-kappa B. Our results indicate that the BB-loop in TIR domain of MyD88 is a good target for specific inhibition of MyD88-mediated signaling in vivo.	Sigma Tau Ind Farmaceut Riunite SpA, Dept Immunol, I-00040 Pomezia, RM, Italy; Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, I-00173 Rome, Italy; Tecnogen SCpA, I-81015 Piana Di Monte Verna, CE, Italy	University of Rome Tor Vergata	Ruggiero, V (corresponding author), Sigma Tau Ind Farmaceut Riunite SpA, Dept Immunol, Bldg LABIO,Via Pontina Km 30-400, I-00040 Pomezia, RM, Italy.	vito.ruggiero@Sigma-Tau.it	Sette, Claudio/S-4307-2019	Sette, Claudio/0000-0003-2864-8266				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bartfai T, 2003, P NATL ACAD SCI USA, V100, P7971, DOI 10.1073/pnas.0932746100; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bjorkbacka H, 2004, NAT MED, V10, P416, DOI 10.1038/nm1008; BODANSZKY M, 1993, PRINCIPLES PEPTIDE S; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Choe JY, 2003, J EXP MED, V197, P537, DOI 10.1084/jem.20021850; Dunne A, 2003, J BIOL CHEM, V278, P41443, DOI 10.1074/jbc.M301742200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hardiman G, 1996, ONCOGENE, V13, P2467; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Janssens S, 2002, TRENDS BIOCHEM SCI, V27, P474, DOI 10.1016/S0968-0004(02)02145-X; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Joosten LAB, 2003, J IMMUNOL, V171, P6145, DOI 10.4049/jimmunol.171.11.6145; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kueltzo LA, 2003, J PHARM SCI-US, V92, P1754, DOI 10.1002/jps.10448; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; O'Neill LAJ, 2004, SCIENCE, V303, P1481, DOI 10.1126/science.1096113; O'Neill LAJ, 2003, BIOCHEM SOC T, V31, P643, DOI 10.1042/BST0310643; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Radons J, 2002, J BIOL CHEM, V277, P16456, DOI 10.1074/jbc.M201000200; *SCHROD LLC, 2003, MACROMODEL 8 5; Takeuchi O, 2002, CURR TOP MICROBIOL, V270, P155; Ulevitch RJ, 2004, NAT REV IMMUNOL, V4, P512, DOI 10.1038/nri1396; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600	29	150	176	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					15809	15814		10.1074/jbc.C400613200	http://dx.doi.org/10.1074/jbc.C400613200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15755740	hybrid			2022-12-27	WOS:000228444800044
J	Lin, CF; Chen, CL; Chang, WT; Jan, MS; Hsu, LJ; Wu, RH; Fang, YT; Tang, MJ; Chang, WC; Lin, YS				Lin, CF; Chen, CL; Chang, WT; Jan, MS; Hsu, LJ; Wu, RH; Fang, YT; Tang, MJ; Chang, WC; Lin, YS			Bcl-2 rescues ceramide- and etoposide-induced mitochondrial apoptosis through blockage of caspase-2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CELL-DEATH; NEURONAL APOPTOSIS; TUMOR-CELLS; INTRACELLULAR ACIDIFICATION; SIGNAL-TRANSDUCTION; CANCER CELLS; PROTEIN; STRESS; DEPHOSPHORYLATION	Recent studies indicate that caspase-2 is involved in the early stage of apoptosis before mitochondrial damage. Although the activation of caspase-2 has been shown to occur in a large protein complex, the mechanisms of caspase-2 activation remain unclear. Here we report a regulatory role of Bcl-2 on caspase-2 upstream of mitochondria. Stress stimuli, including ceramide and etoposide, caused caspase-2 activation, mitochondrial damage followed by downstream caspase-9 and -3 activation, and cell apoptosis in human lung epithelial cell line A549. When A549 cells were pretreated with the caspase-2 inhibitor benzyloxycarbonyl-Val-Asp(-OMe)Val-Ala-Asp(-OMe)-fluoromethyl ketone or transfected with caspase-2 short interfering RNA, both ceramide- and etoposide-induced mitochondrial damage and apoptosis were blocked. Overexpression of Bcl-2 prevented ceramide- and etoposide-induced caspase-2 activation and mitochondrial apoptosis. Furthermore, caspase-2 was activated when A549 cells were introduced with Bcl-2 short interfering RNA or were treated with Bcl-2 inhibitor, which provided direct evidence of a negative regulatory effect of Bcl-2 on caspase-2. Cell survival was observed when caspase-2 was inhibited in Bcl-2-silencing cells. Blockage of the mitochondrial permeability transition pore and caspase-9 demonstrated that Bcl-2-modulated caspase-2 activity occurred upstream of mitochondria. Further studies showed that Bcl-2 was dephosphorylated at serine 70 after ceramide and etoposide treatment. A protein phosphatase inhibitor, okadaic acid, rescued Bcl-2 dephosphorylation and blocked caspase-2 activation, mitochondrial damage, and cell death. Taken together, ceramide and etoposide induced mitochondria-mediated apoptosis by initiating caspase-2 activation, which was, at least in part, regulated by Bcl-2.	Natl Cheng Kung Univ, Dept Microbiol & Immunol, Coll Med, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Dept Biochem, Coll Med, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Dept Physiol, Coll Med, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Dept Pharmacol, Coll Med, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan 70101, Taiwan; Chung Shan Med Univ, Dept Microbiol & Immunol, Taichung 402, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Chung Shan Medical University	Lin, YS (corresponding author), Natl Cheng Kung Univ, Dept Microbiol & Immunol, Coll Med, Tainan 70101, Taiwan.	yslin1@mail.ncku.edu.tw	Hsu, Li-Jin/G-7822-2011	Tang, Ming-Jer/0000-0002-0883-4363				An J, 2004, J BIOL CHEM, V279, P19133, DOI 10.1074/jbc.M400295200; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eliseev RA, 2003, EXP CELL RES, V289, P275, DOI 10.1016/S0014-4827(03)00278-7; Elliott MJ, 1999, CANCER CHEMOTH PHARM, V44, P1, DOI 10.1007/s002800050938; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Haviv R, 1998, J NEUROSCI RES, V52, P491, DOI 10.1002/(SICI)1097-4547(19980601)52:5<491::AID-JNR1>3.0.CO;2-7; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; JAFFREZOU JP, 2004, B CANC PARIS, V91, P133; Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603; Johnson VL, 1999, EXP CELL RES, V251, P175, DOI 10.1006/excr.1999.4557; Kawahara A, 1998, ONCOGENE, V17, P2549, DOI 10.1038/sj.onc.1202192; Kim PK, 2004, MOL CELL, V14, P523, DOI 10.1016/S1097-2765(04)00263-1; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lin CF, 2004, J BIOL CHEM, V279, P40755, DOI 10.1074/jbc.M404726200; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Raffo A, 2004, CLIN CANCER RES, V10, P3195, DOI 10.1158/1078-0432.CCR-03-0287; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Schweizer A, 2003, J BIOL CHEM, V278, P42441, DOI 10.1074/jbc.M304895200; SMITH MJ, 1996, BIOCHEM J, V316, P25; Stoica BA, 2003, MOL CELL NEUROSCI, V22, P365, DOI 10.1016/S1044-7431(02)00028-3; Swanton E, 1999, ONCOGENE, V18, P1781, DOI 10.1038/sj.onc.1202490; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Toman RE, 2002, J NEUROSCI RES, V68, P323, DOI 10.1002/jnr.10190; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wolf CM, 1997, EXP CELL RES, V230, P22, DOI 10.1006/excr.1996.3401; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhang JD, 1999, J CELL BIOL, V145, P99, DOI 10.1083/jcb.145.1.99; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	54	51	56	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23758	23765		10.1074/jbc.M412292200	http://dx.doi.org/10.1074/jbc.M412292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15817479	hybrid			2022-12-27	WOS:000229880000045
J	Saifudeen, Z; Diavolitsis, V; Stefkova, J; Dipp, S; Fan, H; El-Dahr, SS				Saifudeen, Z; Diavolitsis, V; Stefkova, J; Dipp, S; Fan, H; El-Dahr, SS			Spatiotemporal switch from Delta Np73 to TAp73 Isoforms during nephrogenesis - Impact on differentiation gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; FAMILY-MEMBER; P73; P63; TARGET; ZEBRAFISH; STABILITY; RECEPTOR; TRANSACTIVATION; OVEREXPRESSION	p73 is a member of the p53 gene family, which also includes p53 and p63. These proteins share sequence similarity and target genes but also have divergent roles in cancer and development. Unlike p53, transcription of the p73 gene yields multiple full-length (transactivation (TA) domain) and amino terminus-truncated (Delta N) isoforms. Delta Np73 acts in a dominant negative fashion to inhibit the actions of TAp73 and p53 on their target genes, promoting cell survival and proliferation and suppressing apoptosis. The balance between TAp73 and its negative regulator, Delta Np73, may therefore represent an important determinant of developmental cell fate. There is little if anything known regarding the developmental regulation of the p73 gene. In this study, we showed that TAp73 and Delta Np73 exhibit reciprocal spatiotemporal expression and functions during nephrogenesis. TAp73 was predominantly expressed in the differentiation domain of the renal cortex in an overlapping manner with the vasopressin-sensitive water channel aquaporin-2 (AQP-2). Chromatin immunoprecipitation assays demonstrated that the endogenous AQP-2 promoter was occupied by TAp73 in a developmentally regulated manner. Furthermore TAp73 stimulated AQP-2 promoter-driven reporter expression. TAp73 also activated the bradykinin B2 receptor (B2R) promoter, a developmentally regulated gene involved in regulation of sodium excretion. The transcriptional effects of TAp73 on AQP-2 and B2R were independent of p53. In marked contrast to TAp73, Delta Np73 isoforms were induced early in development and were preferentially expressed in proliferating nephron precursors. Moreover Delta Np73 was a potent repressor of B2R gene transcription. We conclude that the p73 gene is developmentally regulated during kidney organogenesis. The spatiotemporal switch from Delta Np73 to TAp73 may play an important role in the terminal differentiation program of the developing nephron.	Tulane Univ, Hlth Sci Ctr, Dept Pediat, Sect Pediat Nephrol, New Orleans, LA 70112 USA	Tulane University	El-Dahr, SS (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Pediat, Sect Pediat Nephrol, Sl-37,1430 Tulane Ave, New Orleans, LA 70112 USA.	seldahr@tulane.edu						ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Amariglio F, 1997, ONCOGENE, V15, P2191, DOI 10.1038/sj.onc.1201395; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Barrera FN, 2003, J BIOL CHEM, V278, P46878, DOI 10.1074/jbc.M307846200; Billon N, 2004, DEVELOPMENT, V131, P1211, DOI 10.1242/dev.01035; Bonilla-Felix M, 2004, AM J PHYSIOL-RENAL, V287, pF1093, DOI 10.1152/ajprenal.00119.2004; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; ElDahr SS, 1997, KIDNEY INT, V51, P739, DOI 10.1038/ki.1997.105; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; HOEVER M, 1994, ONCOGENE, V9, P109; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kartasheva NN, 2003, ONCOGENE, V22, P8246, DOI 10.1038/sj.onc.1207138; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lain S, 2003, BIOCHEM SOC T, V31, P482, DOI 10.1042/BST0310482; Langheinrich U, 2002, CURR BIOL, V12, P2023, DOI 10.1016/S0960-9822(02)01319-2; Levine EM, 2004, DEVELOPMENT, V131, P2241, DOI 10.1242/dev.01180; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Levrero M, 2000, J CELL SCI, V113, P1661; Li ZR, 1998, CANCER RES, V58, P4282; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Maisse C, 2003, BIOCHEM PHARMACOL, V66, P1555, DOI 10.1016/S0006-2952(03)00511-2; Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X; Marks J, 2003, J BIOL CHEM, V278, P34158, DOI 10.1074/jbc.M304543200; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Miro-Mur F, 2003, ONCOGENE, V22, P5451, DOI 10.1038/sj.onc.1206538; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Nadasdy T, 1998, PEDIATR DEVEL PATHOL, V1, P49, DOI 10.1007/s100249900006; Nakagawa T, 2003, CANCER LETT, V197, P105, DOI 10.1016/S0304-3835(03)00090-9; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Rentzsch F, 2003, GENE, V323, P19, DOI 10.1016/j.gene.2003.10.002; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Saifudeen Z, 2002, AM J PHYSIOL-RENAL, V283, pF727, DOI 10.1152/ajprenal.00114.2002; Saifudeen Z, 2002, J CLIN INVEST, V109, P1021, DOI 10.1172/JCI200213972; Saifudeen Z, 2000, J BIOL CHEM, V275, P15557, DOI 10.1074/jbc.M909810199; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; SCHMID P, 1991, DEVELOPMENT, V113, P857; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; Tchang F, 1999, EXP CELL RES, V251, P46, DOI 10.1006/excr.1999.4570; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; Thisse C, 2000, DIFFERENTIATION, V66, P61, DOI 10.1046/j.1432-0436.2000.660201.x; Tomasini R, 2003, J BIOL CHEM, V278, P37722, DOI 10.1074/jbc.M301979200; Ueda Y, 2001, BIOCHEM J, V356, P859, DOI 10.1042/0264-6021:3560859; Ueda Y, 2001, BIOCHEM BIOPH RES CO, V283, P327, DOI 10.1006/bbrc.2001.4788; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; White JD, 2002, INT J DEV BIOL, V46, P577; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yosipiv IV, 2001, AM J PHYSIOL-RENAL, V281, pF795, DOI 10.1152/ajprenal.0020.2001; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zheng XJ, 2001, FEBS LETT, V489, P4, DOI 10.1016/S0014-5793(00)02437-6	70	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23094	23102		10.1074/jbc.M414575200	http://dx.doi.org/10.1074/jbc.M414575200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15805112	hybrid			2022-12-27	WOS:000229741800066
J	Chen, DQ; Texada, DE; Duggan, C; Liang, CP; Reden, TB; Kooragayala, LM; Langford, MP				Chen, DQ; Texada, DE; Duggan, C; Liang, CP; Reden, TB; Kooragayala, LM; Langford, MP			Surface calreticulin mediates muramyl dipeptide-induced apoptosis in RK13 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; ENDOPLASMIC-RETICULUM; BINDING; INDUCTION; RECEPTOR; PEPTIDOGLYCAN; PROTEIN; EXPRESSION; PEPTIDES; PATHWAYS	Calreticulin (CRT) is a binding protein for apoptotic N-acetylmuramyl-L-alanyl-D-isoglutamine (L,D-MDP) or peptidoglycan in RK13 cells. CRT on RK13 cell surface (srCRT) forms complex(es) with tumor necrosis factor receptor 1 (TNFR1) and TNFR-associated death domain ( TRADD) protein of the cell membrane. CRT polyclonal or monoclonal antibody binding to RK13 srCRT dose-dependently inhibited L,D-MDP- induced apoptosis. In RK13 cells, L,D-MDP up-regulated the TNFR1.TRADD complex of the plasma membrane and subsequently induced cytosolic TRADD-Fas-associated death domain protein complex. Biotinylated srCRT was capable of calcium-dependent binding of Sepharose-immobilized L, D-MDP or peptidoglycan. However, Toll-like receptors TLR-2 and TLR-4, Nod2, and CD14 of RK13 cells did not specifically bind Sepharose-immobilized L, D-MDP. High concentrations (5-40 mM) of EGTA dose- dependently inhibited free L,D-MDP binding to purified RK13 cell CRT and promoted free L,D-MDP dissociation from RK13 cell CRT.MDP complex. Different concentrations of EGTA (0-40mM) added to Dulbecco's modified essential medium with 1.8 mM calcium or phosphate-buffered saline with 0.18 mM calcium have different effects on medium free calcium concentrations but have identical inhibiting effects on L, D-MDP induced apoptosis. More inhibition of theL,D-MDP-induced apoptotic DNA ladders and caspase-3 activity in RK13 cells was obtained with EGTA pretreatment ( 83%) than just EGTA + L,D-MDP ( 47%). The knocking down of srCRT by antisense oligonucleotide CRTAS121 ( 250 nmol/ ml) and stealth small interfering RNA CRT_siR479 (150 pM/ ml) for 2 days ( 44 and 66%, respectively), resulted in the inhibition of L,D-MDP-induced caspase-3 activity ( 47 and 65%, respectively). The results suggest that (a) the binding of L, D-MDP to srCRT is calcium-dependent, i.e. on srCRT- bound calcium, and ( b) it is srCRT, not TLR-2, TLR-4, Nod2 or CD14, that mediates L,D-MDP-induced RK13 cell apoptosis through activating the TNFR1.TRADD-Fas-associated death domain protein apoptotic pathway.	Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Chen, DQ (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, 1501 Kingshighway, Shreveport, LA 71130 USA.	dchen@lsuhsc.edu						Barnhart BC, 2003, CELL, V114, P148, DOI 10.1016/S0092-8674(03)00561-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; BURROUGHS M, 1993, J CLIN INVEST, V92, P297, DOI 10.1172/JCI116565; Chen D.-Y., UNPUB; Chen DQ, 2004, BIOCHEMISTRY-US, V43, P11796, DOI 10.1021/bi0490789; Cottagnoud P, 2003, INFECT IMMUN, V71, P3663, DOI 10.1128/IAI.71.6.3663-3666.2003; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; DEWHIRST FE, 1982, INFECT IMMUN, V35, P133, DOI 10.1128/IAI.35.1.133-137.1982; DOUGHERTY PM, 1987, EUR J PHARMACOL, V141, P253, DOI 10.1016/0014-2999(87)90270-6; Drummer HE, 2003, FEBS LETT, V546, P385, DOI 10.1016/S0014-5793(03)00635-5; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Fulda S, 2004, BBA-REV CANCER, V1705, P27, DOI 10.1016/j.bbcan.2004.09.003; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HURLEY WL, 1990, METHOD ENZYMOL, V184, P429; IKEBE T, 1990, ARTHRITIS RHEUM, V33, P1801, DOI 10.1002/art.1780331207; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; Kaisho T, 2002, BBA-MOL CELL RES, V1589, P1, DOI 10.1016/S0167-4889(01)00182-3; KOGA T, 1986, MICROBIOL IMMUNOL, V30, P717, DOI 10.1111/j.1348-0421.1986.tb02997.x; KOTANI S, 1986, FASEB J, V45, P2534; Langford MP, 2002, MOL CELL BIOCHEM, V236, P63, DOI 10.1023/A:1016110429204; LIU NG, 1994, J BIOL CHEM, V269, P28635; McDonnell JM, 1996, J BIOL CHEM, V271, P7891, DOI 10.1074/jbc.271.14.7891; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; Natoli G, 1998, BIOCHEM PHARMACOL, V56, P915, DOI 10.1016/S0006-2952(98)00154-3; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Patil AR, 2000, J BIOL CHEM, V275, P24348, DOI 10.1074/jbc.M003102200; RIVAS RJ, 1989, J CELL BIOL, V109, P51, DOI 10.1083/jcb.109.1.51; ROOTBERNSTEIN RS, 1990, BRAIN RES BULL, V25, P827, DOI 10.1016/0361-9230(90)90178-3; Sambrook J, 1989, MOL CLONING; Shakibaei M, 2005, ANTIOXID REDOX SIGN, V7, P482, DOI 10.1089/ars.2005.7.482; Sheikh MS, 2003, CELL CYCLE, V2, P550, DOI 10.4161/cc.2.6.566; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; WATERS RV, 1986, INFECT IMMUN, V51, P816, DOI 10.1128/IAI.51.3.816-825.1986; Weidemann B, 1997, INFECT IMMUN, V65, P858, DOI 10.1128/IAI.65.3.858-864.1997; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; Xiao GQ, 1999, J NEUROSCI RES, V58, P652, DOI 10.1002/(SICI)1097-4547(19991201)58:5<652::AID-JNR6>3.0.CO;2-H; Yoshimura A, 2000, J ENDOTOXIN RES, V6, P407, DOI 10.1177/09680519000060050201	42	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22425	22436		10.1074/jbc.M413380200	http://dx.doi.org/10.1074/jbc.M413380200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817475	hybrid			2022-12-27	WOS:000229557900088
J	Chen, LY; Doerner, A; Lehmann, PF; Huang, S; Zhong, GM; Pan, ZXK				Chen, LY; Doerner, A; Lehmann, PF; Huang, S; Zhong, GM; Pan, ZXK			A novel protein kinase C (PKEe) is required for fMET-Leu-Phe-induced activation of NF-kB in human peripheral blood monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; WEIGHT GTPASE RHOA; GENE-EXPRESSION; HUMAN NEUTROPHILS; BETA; EPSILON; CELLS; TRANSCRIPTION; PHOSPHORYLATION; INVOLVEMENT	We have reported that the chemoattractant, fMet-LeuPhe ( fMLP), induces the activation of NF-kB in human peripheral blood monocytes and that this requires the activity of small GTPase, RhoA ( Huang, S., Chen, L.-Y., Zuraw, B. L., Ye, R. D., and Pan, Z. K. (2001) J. Biol. Chem. 276, 40977-40981). Here we showed that the novel protein kinase C isozyme, PKCe, associates functionally with RhoA in fMLP-stimulated monocytes and that PKCe acted as a signaling component downstream of the GTPase RhoA during fMLP-induced activation of NF-kB. Stimulation of monocytes with fMLP resulted in activation of both PKCe and NF-kB. This latter activation was largely blocked by specific inhibitors of PKCe by transient expression of a dominant-negative form of PKCe and by PKCe- specific short interfering RNA. These findings demonstrate, for the first time, that fMLP- induced activation of NF-kB utilizes a signaling pathway, which requires activity of PKCe, and that PKCe acts as a signaling component downstream of RhoA in cytokine gene transcription stimulated by a chemoattractant. The specificity of this response suggests an important role for the Rho GTPase- PKCe- NF-kB pathway in host defense and represents a novel and potentially important mechanism through which fMLP not only attracts leukocytes but may also contribute directly to inflammation.	Med Coll Ohio, Dept Med Microbiol & Immunol, Toledo, OH 43614 USA; Med Coll Ohio, Dept Med, Toledo, OH 43699 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol & Immunol, San Antonio, TX 78229 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of Texas System; University of Texas Health San Antonio; Scripps Research Institute; Scripps Research Institute	Pan, ZXK (corresponding author), Med Coll Ohio, Dept Med Microbiol & Immunol, 3055 Arlington Ave, Toledo, OH 43614 USA.	zkpan@mco.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007469, R01AI043524, R56AI043524] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR 00833] Funding Source: Medline; NIAID NIH HHS [R01 AI043524-11, T32 AI 07469, R01 AI043524, AI 43524] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aksoy E, 2002, EUR J IMMUNOL, V32, P3040, DOI 10.1002/1521-4141(200211)32:11<3040::AID-IMMU3040>3.0.CO;2-M; Aktories K, 1997, J CLIN INVEST, V99, P827, DOI 10.1172/JCI119245; Browning DD, 1997, J BIOL CHEM, V272, P7995, DOI 10.1074/jbc.272.12.7995; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; Chen LY, 2004, J BIOL CHEM, V279, P7208, DOI 10.1074/jbc.M309542200; Chen LY, 2002, J IMMUNOL, V169, P3934, DOI 10.4049/jimmunol.169.7.3934; Dang PMC, 2001, J IMMUNOL, V166, P1206, DOI 10.4049/jimmunol.166.2.1206; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Foryst-Ludwig A, 2000, J BIOL CHEM, V275, P39779, DOI 10.1074/jbc.M007617200; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; GOMEZCAMBRONERO J, 1987, BIOCHEM BIOPH RES CO, V148, P38, DOI 10.1016/0006-291X(87)91073-4; Huang S, 2001, J BIOL CHEM, V276, P40977, DOI 10.1074/jbc.M105242200; Ivaska J, 2003, NAT CELL BIOL, V5, P363, DOI 10.1038/ncb957; Kempiak SJ, 1999, J IMMUNOL, V162, P3176; Korchak HM, 1998, J BIOL CHEM, V273, P27292, DOI 10.1074/jbc.273.42.27292; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MAJUMDAR S, 1993, BIOCHIM BIOPHYS ACTA, V1176, P276, DOI 10.1016/0167-4889(93)90056-U; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MERRITT JE, 1991, CELL SIGNAL, V3, P73, DOI 10.1016/0898-6568(91)90010-R; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; PAN ZX, 1995, J BIOL CHEM, V270, P7787, DOI 10.1074/jbc.270.14.7787; Pan ZXK, 2000, J IMMUNOL, V164, P404, DOI 10.4049/jimmunol.164.1.404; Pan ZXK, 1998, BBA-GENE STRUCT EXPR, V1443, P90, DOI 10.1016/S0167-4781(98)00198-5; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; Valledor AF, 2000, J IMMUNOL, V164, P29, DOI 10.4049/jimmunol.164.1.29	35	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22497	22501		10.1074/jbc.M413033200	http://dx.doi.org/10.1074/jbc.M413033200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15809302	hybrid			2022-12-27	WOS:000229557900096
J	Puri, N; Lai-Zhang, J; Meier, S; Mueller, DM				Puri, N; Lai-Zhang, J; Meier, S; Mueller, DM			Expression of bovine F-1-ATPase with functional complementation in yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; ATP SYNTHASE; UNCOUPLING PROTEINS; NUCLEAR GENE; MITOCHONDRIAL ATPASE; BETA-SUBUNIT; ROTATION; COMPLEX; F1-ATPASE; MEMBRANE	The mitochondrial F1F0- ATP synthase is a multimeric enzyme complex composed of at least 16 unique peptides with an overall molecular mass of similar to 600 kDa. F-1-ATPase is composed of alpha(3)beta(3)gamma delta epsilon with an overall molecular mass of 370 kDa. The genes encoding bovine F-1-ATPase have been expressed in a quintuple yeast Saccharomyces cerevisiae deletion mutant (Delta alpha Delta beta Delta gamma Delta delta Delta epsilon). This strain expressing bovine F-1 is unable to grow on medium containing a non-fermentable carbon source (YPG), indicating that the enzyme is non-functional. However, daughter strains were easily selected for growth on YPG medium and these were evolved for improved growth on YPG medium. The evolution of the strains was presumably due to mutations, but mutations in the genes encoding the subunits of the bovine F-1-ATPase were not required for the ability of the cell to grow on YPG medium. The bovine enzyme expressed in yeast was partially purified to a specific activity of about half of that of the enzyme purified from bovine heart mitochondria. These results indicate that the molecular machinery required for the assembly of the mitochondrial ATP synthase is conserved from bovine and yeast and suggest that yeast may be useful for the expression, mutagenesis, and analysis of the mammalian F-1- or F1F0-ATP synthase.	Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, Abbott Pk, IL 60064 USA	Rosalind Franklin University Medical & Science	Mueller, DM (corresponding author), Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, Abbott Pk, IL 60064 USA.	david.mueller@RosalindFranklin.edu			NIGMS NIH HHS [R01 GM 066223, R01 GM 067091] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067091, R01GM066223] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ackerman SH, 2002, BBA-BIOENERGETICS, V1555, P101, DOI 10.1016/S0005-2728(02)00262-1; ACKERMAN SH, 1991, FEBS LETT, V278, P234, DOI 10.1016/0014-5793(91)80124-L; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; AVISE JC, 1991, ANNU REV GENET, V25, P45, DOI 10.1146/annurev.ge.25.120191.000401; Bonnefoy N, 2002, METHOD ENZYMOL, V350, P97, DOI 10.1016/S0076-6879(02)50958-7; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CLARKWALKER GD, 1991, CURR GENET, V20, P195, DOI 10.1007/BF00326232; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Garlid KD, 2000, BBA-BIOENERGETICS, V1459, P383, DOI 10.1016/S0005-2728(00)00175-4; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; Hoogenraad NJ, 2001, IUBMB LIFE, V51, P345; Jie LZ, 1999, EMBO J, V18, P58, DOI 10.1093/emboj/18.1.58; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Klingenberg M, 2001, BBA-BIOENERGETICS, V1504, P128, DOI 10.1016/S0005-2728(00)00242-5; KNOWLES AF, 1972, J BIOL CHEM, V247, P6617; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai-Zhang J, 2000, EUR J BIOCHEM, V267, P2409, DOI 10.1046/j.1432-1327.2000.01253.x; Mabuchi T, 2000, J BIOL CHEM, V275, P10492, DOI 10.1074/jbc.275.14.10492; Maniatis T., 1982, MOL CLONING; Mihara K, 2000, BIOESSAYS, V22, P364, DOI 10.1002/(SICI)1521-1878(200004)22:4<364::AID-BIES6>3.0.CO;2-N; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Mueller DM, 2004, ACTA CRYSTALLOGR D, V60, P1441, DOI 10.1107/S0907444904012661; MUELLER DM, 1988, J BIOL CHEM, V263, P5634; Nishio K, 2002, P NATL ACAD SCI USA, V99, P13448, DOI 10.1073/pnas.202149599; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; PRESCOTT M, 1995, BIOCHEM BIOPH RES CO, V207, P943, DOI 10.1006/bbrc.1995.1276; Rassow J, 2000, TRAFFIC, V1, P457, DOI 10.1034/j.1600-0854.2000.010603.x; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; Rial E, 2001, BBA-BIOENERGETICS, V1504, P70, DOI 10.1016/S0005-2728(00)00240-1; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Tanabe M, 2001, J BIOL CHEM, V276, P15269, DOI 10.1074/jbc.M100289200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; Velours J, 2001, J BIOL CHEM, V276, P8602, DOI 10.1074/jbc.M008123200; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WALKER JE, 1994, CURR OPIN STRUC BIOL, V4, P912, DOI 10.1016/0959-440X(94)90274-7; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; Wang ZG, 2001, J BIOL CHEM, V276, P30773, DOI 10.1074/jbc.M104133200; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627	57	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22418	22424		10.1074/jbc.M411113200	http://dx.doi.org/10.1074/jbc.M411113200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817482	hybrid			2022-12-27	WOS:000229557900087
J	Thoden, JB; Holden, HM				Thoden, JB; Holden, HM			The molecular architecture of galactose mutarotase/UDP-galactose 4-epimerase from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-STRUCTURE; UDP-GALACTOSE; GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; 3-DIMENSIONAL STRUCTURE; LACTOCOCCUS-LACTIS; ESCHERICHIA-COLI; II GALACTOSEMIA; SUGAR BINDING; GALACTOKINASE; MECHANISM	The metabolic pathway by which beta-D-galactose is converted to glucose 1-phosphate is known as the Leloir pathway and consists of four enzymes. In most organisms, these enzymes appear to exist as soluble entities in the cytoplasm. In yeast such as Saccharomyces cerevisiae, however, the first and last enzymes of the pathway, galactose mutarotase and UDP-galactose 4-epimerase, are contained within a single polypeptide chain referred to as Gal10p. Here we report the three-dimensional structure of Gal10p in complex with NAD(+), UDP-glucose, and beta-D-galactose determined to 1.85-angstrom resolution. The enzyme is dimeric with dimensions of similar to 91 angstrom x 135 angstrom x 108 angstrom and assumes an almost V-shaped appearance. The overall architecture of the individual subunits can be described in terms of two separate N-and C-terminal domains connected by a Type II turn formed by Leu-357 to Val-360. The first 356 residues of Gal10p fold into the classical bilobal topology observed for all other UDP-galactose 4-epimerases studied thus far. This N-terminal domain contains the binding sites for NAD(+) and UDP-glucose. The polypeptide chain extending from Glu-361 to Ser-699 adopts a beta-sandwich motif and harbors the binding site for beta-D-galactose. The two active sites of Gal10p are separated by over 50 angstrom. This investigation represents the first structural analysis of a dual function enzyme in the Leloir pathway.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	Hazel_Holden@biochem.wisc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK047814, R01DK047814] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brahma A, 2004, EUR J BIOCHEM, V271, P58, DOI 10.1046/j.1432-1033.2003.03902.x; Christacos NC, 2000, MOL GENET METAB, V70, P272, DOI 10.1006/mgme.2000.3019; Duax WL, 2000, VITAM HORM, V58, P121, DOI 10.1016/S0083-6729(00)58023-6; Hartley A, 2004, J MOL BIOL, V337, P387, DOI 10.1016/j.jmb.2004.01.043; Holden HM, 2004, CELL MOL LIFE SCI, V61, P2471, DOI 10.1007/s00018-004-4160-6; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; KIM JM, 1990, BIOCHEMISTRY-US, V29, P10590, DOI 10.1021/bi00499a003; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Majumdar S, 2004, EUR J BIOCHEM, V271, P753, DOI 10.1111/j.1432-1033.2003.03974.x; Novelli G, 2000, MOL GENET METAB, V71, P62, DOI 10.1006/mgme.2000.3073; Petry KG, 1998, TRENDS GENET, V14, P98, DOI 10.1016/S0168-9525(97)01379-6; Segal S, 1995, METABOLIC MOL BASIS, P967; Thoden JB, 2005, J BIOL CHEM, V280, P9662, DOI 10.1074/jbc.M412916200; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P5691, DOI 10.1021/bi000215l; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P1212, DOI 10.1021/bi9626517; Thoden JB, 2004, J BIOL CHEM, V279, P23431, DOI 10.1074/jbc.M402347200; Thoden JB, 1996, PROTEIN SCI, V5, P2149, DOI 10.1002/pro.5560051102; Thoden JB, 2003, J BIOL CHEM, V278, P33305, DOI 10.1074/jbc.M304789200; Thoden JB, 2003, PROTEIN SCI, V12, P1051, DOI 10.1110/ps.0243203; Thoden JB, 2002, J BIOL CHEM, V277, P20854, DOI 10.1074/jbc.M201415200; Thoden JB, 2002, J BIOL CHEM, V277, P45458, DOI 10.1074/jbc.M208395200; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; Wedekind JE, 1996, BIOCHEMISTRY-US, V35, P11560, DOI 10.1021/bi9612677	25	42	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21900	21907		10.1074/jbc.M502411200	http://dx.doi.org/10.1074/jbc.M502411200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15795221	hybrid			2022-12-27	WOS:000229557900030
J	Kim, YJ; Nakatomi, R; Akagi, T; Hashikawa, T; Takahashi, R				Kim, YJ; Nakatomi, R; Akagi, T; Hashikawa, T; Takahashi, R			Unsaturated fatty acids induce cytotoxic aggregate formation of amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASTROCYTIC HYALINE INCLUSIONS; PROTEIN MISFOLDING DISEASES; MOLECULAR-WEIGHT COMPLEXES; SOLUBLE AMYLOID OLIGOMERS; FIBRILLIZATION IN-VITRO; SUPEROXIDE-DISMUTASE; ALPHA-SYNUCLEIN; COMMON MECHANISM; TRANSGENIC MICE; SPINAL-CORDS	Formation of misfolded protein aggregates is a remarkable hallmark of various neurodegenerative diseases including Alzheimer disease, Parkinson disease, Huntington disease, prion encephalopathies, and amyotrophic lateral sclerosis (ALS). Superoxide dismutase 1 (SOD1) immunoreactive inclusions have been found in the spinal cord of ALS animal models and patients, implicating the close involvement of SOD1 aggregates in ALS pathogenesis. Here we examined the molecular mechanism of aggregate formation of ALS-related SOD1 mutants in vitro. We found that long-chain unsaturated fatty acids (FAs) promoted aggregate formation of SOD1 mutants in both dose- and time-dependent manners. Metal-deficient SOD1s, wild-type, and mutants were highly oligomerized compared with holo-SOD1s by incubation in the presence of unsaturated FAs. Oligomerization of SOD1 is closely associated with its structural instability. Heat-treated holo-SOD1 mutants were readily oligomerized by the addition of unsaturated FAs, whereas wild-type SOD1 was not. The monounsaturated FA, oleic acid, directly bound to SOD1 and was characterized by a solid-phase FA binding assay using oleate-Sepharose. The FA binding characteristics were closely correlated with the oligomerization propensity of SOD1 proteins, which indicates that FA binding may change SOD1 conformation in a way that favors the formation of aggregates. High molecular mass aggregates of SOD1 induced by FAs have a granular morphology and show significant cytotoxicity. These findings suggest that SOD1 mutants gain FA binding abilities based on their structural instability and form cytotoxic granular aggregates.	Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Takahashi, R (corresponding author), Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	ryosuket@kuhp.kyoto-u.ac.jp	Kim, Yeon-Jeong/X-5633-2018	Kim, Yeon-Jeong/0000-0003-1482-7319				Bartnikas TB, 2003, J BIOL CHEM, V278, P33602, DOI 10.1074/jbc.M305435200; Boissinot M, 1997, EMBO J, V16, P2171, DOI 10.1093/emboj/16.9.2171; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chirita CN, 2003, J BIOL CHEM, V278, P25644, DOI 10.1074/jbc.M301663200; Crow JP, 1997, J NEUROCHEM, V69, P1936; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DiDonato M, 2003, J MOL BIOL, V332, P601, DOI 10.1016/S0022-2836(03)00889-1; Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935; FRIED R, 1975, BIOCHIMIE, V57, P657, DOI 10.1016/S0300-9084(75)80147-7; Gamblin TC, 2000, BIOCHEMISTRY-US, V39, P14203, DOI 10.1021/bi001876l; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Kato S, 1999, HISTOL HISTOPATHOL, V14, P973, DOI 10.14670/HH-14.973; Kato S, 1997, AM J PATHOL, V151, P611; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Lindberg MJ, 2002, P NATL ACAD SCI USA, V99, P16607, DOI 10.1073/pnas.262527099; Necula M, 2003, J BIOL CHEM, V278, P46674, DOI 10.1074/jbc.M308231200; PETERS T, 1973, J BIOL CHEM, V248, P2447; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Shibata N, 1996, DEV NEUROSCI-BASEL, V18, P492, DOI 10.1159/000111445; Shibata N, 1998, ACTA NEUROPATHOL, V95, P136, DOI 10.1007/s004010050777; Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; Strange RW, 2003, J MOL BIOL, V328, P877, DOI 10.1016/S0022-2836(03)00355-3; Tateno M, 2004, HUM MOL GENET, V13, P2183, DOI 10.1093/hmg/ddh246; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Urushitani M, 2004, J NEUROCHEM, V90, P231, DOI 10.1111/j.1471-4159.2004.02486.x; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Wang J, 2002, NEUROBIOL DIS, V10, P128, DOI 10.1006/nbdi.2002.0498; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443; Wilson DM, 1997, AM J PATHOL, V150, P2181	39	160	168	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21515	21521		10.1074/jbc.M502230200	http://dx.doi.org/10.1074/jbc.M502230200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799963	hybrid			2022-12-27	WOS:000229438800073
J	Whittaker, J; Whittaker, L				Whittaker, J; Whittaker, L			Characterization of the functional insulin binding epitopes of the full-length insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANINE-SCANNING MUTAGENESIS; FACTOR-I RECEPTOR; STRUCTURAL BASIS; NEGATIVE COOPERATIVITY; AFFINITY; DOMAIN; SITE; DETERMINANTS; ISOFORM; REGION	Mutational analyses of the secreted recombinant insulin receptor extracellular domain have identified a ligand binding site composed of residues located in the L1 domain (amino acids 1 - 470) and at the C terminus of the alpha subunit (amino acids 705 - 715). To evaluate the physiological significance of this ligand binding site, we have transiently expressed cDNAs encoding full-length receptors with alanine mutations of the residues forming the functional epitopes of this binding site and determined their insulin binding properties. Insulin bound to wild-type receptors with complex kinetics, which were fitted to a two-component sequential model; the K-d of the high affinity component was 0.03 nM and that of the low affinity component was 0.4 nM. Mutations of Arg(14), Phe(64), Phe(705), Glu(706), Tyr(708), Asn(711), and Val(715) inactivated the receptor. Alanine mutation of Asn(15) resulted in a 20-fold decrease in affinity, whereas mutations of Asp(12), Gln(34), Leu(36), Leu(37), Leu(87), Phe(89), Tyr(91), Lys(121), Leu(709), and Phe(714) all resulted in 4-10-fold decreases. When the effects of the mutations were compared with those of the same mutations of the secreted recombinant receptor, significant differences were observed for Asn(15), Leu(37), Asp(707), Leu(709), Tyr(708), Asn(711), Phe714, and Val715, suggesting that the molecular basis for the interaction of each form of the receptor with insulin differs. We also examined the effects of alanine mutations of Asn(15), Gln(34), and Phe(89) on insulin-induced receptor autophosphorylation. They had no effect on the maximal response to insulin but produced an increase in the EC50 commensurate with their effect on the affinity of the receptor for insulin.	Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Whittaker, J (corresponding author), Case Western Reserve Univ, Dept Nutr, Dent Bldg,2123 Abington Rd,Rm 201, Cleveland, OH 44106 USA.	Jonathan.Whittaker@case.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065890] Funding Source: NIH RePORTER; NIDDK NIH HHS [5 R01 DK065890] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; Chen JW, 2003, AM J PHYSIOL-ENDOC M, V284, pE1149, DOI 10.1152/ajpendo.00410.2002; CHOTHIA C, 1983, NATURE, V302, P500, DOI 10.1038/302500a0; CHRISTOFFERSEN CT, 1994, ENDOCRINOLOGY, V135, P472, DOI 10.1210/en.135.1.472; CUTFIELD JF, 1979, J MOL BIOL, V132, P85, DOI 10.1016/0022-2836(79)90497-2; De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917; DEGER A, 1986, BIOCHEM BIOPH RES CO, V135, P458; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; Denley A, 2004, MOL ENDOCRINOL, V18, P2502, DOI 10.1210/me.2004-0183; EMDIN SO, 1980, DIABETES, V29, P301, DOI 10.2337/diabetes.29.4.301; FABRY M, 1992, J BIOL CHEM, V267, P8950; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; HEDO JA, 1981, BIOCHEMISTRY-US, V20, P3385, DOI 10.1021/bi00515a013; HUA QX, 1991, NATURE, V354, P238, DOI 10.1038/354238a0; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; Marino-Buslje C, 1998, FEBS LETT, V441, P331, DOI 10.1016/S0014-5793(98)01509-9; MARKUSSEN J, 1991, J BIOL CHEM, V266, P18814; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; Sambrook J., 2001, MOL CLONING LAB MANU; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; VOLUND A, 1991, DIABETIC MED, V8, P839, DOI 10.1111/j.1464-5491.1991.tb02122.x; Ward CW, 1999, GROWTH FACTORS, V16, P315, DOI 10.3109/08977199909069149; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; Whittaker J, 2002, J BIOL CHEM, V277, P47380, DOI 10.1074/jbc.M208371200; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; Whittaker J, 2001, J BIOL CHEM, V276, P43980, DOI 10.1074/jbc.M102863200; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858	35	35	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20932	20936		10.1074/jbc.M411320200	http://dx.doi.org/10.1074/jbc.M411320200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799978	hybrid			2022-12-27	WOS:000229438800005
J	Furutani, Y; Kato, A; Fibriani, A; Hirata, T; Kawai, R; Jeon, JH; Fujii, Y; Kim, IG; Kojimao, S; Hirose, S				Furutani, Y; Kato, A; Fibriani, A; Hirata, T; Kawai, R; Jeon, JH; Fujii, Y; Kim, IG; Kojimao, S; Hirose, S			Identification, evolution, and regulation of expression of guinea pig trappin with an unusually long transglutaminase substrate domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEY ACIDIC PROTEIN; ELASTASE-SPECIFIC INHIBITOR; SEMINAL-VESICLE EPITHELIUM; CROSS-LINKING ENZYMES; IN-SITU HYBRIDIZATION; CHAIN FV FRAGMENT; 4-DISULFIDE CORE; GENE FAMILY; DIFFERENTIAL EXPRESSION; MOLECULAR-CLONING	Trappins are found in human, bovine, hippopotamus, and members of the pig family, but not in rat and mouse. To clarify the evolution of the trappin genes and the functional significance of their products, we isolated the trappin gene in guinea pig, a species belonging to a rodent family distinct from rat and mouse. Guinea pig trappin was confirmed to encode the same domain structure as trappin, consisting of a signal sequence, an extra large transglutaminase substrate domain, and a whey acidic protein motif. Northern blot analysis and in situ hybridization histochemistry as well as immunohistochemistry demonstrated that guinea pig trappin is expressed solely in the secretory epithelium of the seminal vesicle and that its expression is androgen-dependent. We confirmed that guinea pig trappin is crosslinked by prostate transglutaminase and that the whey acidic protein motif derived from guinea pig trappin has an inhibitory activity against leukocyte elastase. Genome sequence analysis showed that guinea pig trappin belongs to the family of REST (rapidly evolving seminal vesicle transcribed) genes.	Tokyo Inst Technol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; RIKEN, Mol Cellular Pathol Res Unit, Wako, Saitama 3510198, Japan; Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Aging & Apoptosis Res Ctr, Seoul 110799, South Korea; Tokyo Med & Dent Univ, Dept Urol & Reprod Med, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Institute of Technology; RIKEN; Seoul National University (SNU); Tokyo Medical & Dental University (TMDU)	Hirose, S (corresponding author), Tokyo Inst Technol, Dept Biol Sci, Midori Ku, 4259-B19 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.	shirose@bio.titech.ac.jp	Kojima, Soichi/N-7104-2015; Jeon, Ju-Hong/D-5740-2012; Kim, In-Gyu/J-2747-2012; Kato, Akira/E-6328-2010; Furutani, Yutaka/C-3652-2017	Kojima, Soichi/0000-0002-5252-1612; Kato, Akira/0000-0002-9083-1443; Furutani, Yutaka/0000-0002-2945-0166; Jeon, Ju-Hong/0000-0002-5603-2955				AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; ARAKI K, 1989, BIOCHEM BIOPH RES CO, V164, P496, DOI 10.1016/0006-291X(89)91747-6; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clauss A, 2002, BIOCHEM J, V368, P233, DOI 10.1042/BJ20020869; CORONEL CE, 1990, J BIOL CHEM, V265, P6854; DEAR TN, 1988, CANCER RES, V48, P5203; DEAR TN, 1991, BIOCHEM BIOPH RES CO, V176, P247, DOI 10.1016/0006-291X(91)90916-U; Dubbink HJ, 1996, BIOCHEM J, V315, P901, DOI 10.1042/bj3150901; Furukawa M, 1996, J BIOL CHEM, V271, P29517, DOI 10.1074/jbc.271.47.29517; Furutani Y, 2004, BIOL REPROD, V71, P1583, DOI 10.1095/biolreprod.104.028993; Furutani Y, 2001, J HISTOCHEM CYTOCHEM, V49, P247, DOI 10.1177/002215540104900212; Furutani Y, 1998, J BIOCHEM-TOKYO, V124, P491, DOI 10.1093/oxfordjournals.jbchem.a022140; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; HAGSTROM J, 1992, BIOL REPROD, V47, P768, DOI 10.1095/biolreprod47.5.768; Hagstrom JE, 1996, J BIOL CHEM, V271, P21114, DOI 10.1074/jbc.271.35.21114; HENNIGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P2677, DOI 10.1093/nar/10.8.2677; Jukes TH, 1969, EVOLUTION PROTEIN MO; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Larsen M, 1998, J BIOL CHEM, V273, P4574, DOI 10.1074/jbc.273.8.4574; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Lundwall A, 1996, BIOCHEM BIOPH RES CO, V221, P323, DOI 10.1006/bbrc.1996.0594; MAJMUDAR G, 1994, MOL CARCINOGEN, V11, P29, DOI 10.1002/mc.2940110106; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; MOORE JT, 1986, MOL CELL ENDOCRINOL, V46, P205, DOI 10.1016/0303-7207(86)90002-X; MOORE JT, 1987, P NATL ACAD SCI USA, V84, P6712, DOI 10.1073/pnas.84.19.6712; Murphy WJ, 2001, NATURE, V409, P614, DOI 10.1038/35054550; NARA K, 1994, J BIOCHEM, V115, P441, DOI 10.1093/oxfordjournals.jbchem.a124357; NEI M, 1986, MOL BIOL EVOL, V3, P418; SAHEKI T, 1992, BIOCHEM BIOPH RES CO, V185, P240, DOI 10.1016/S0006-291X(05)80981-7; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schalkwijk J, 1999, BIOCHEM J, V340, P569, DOI 10.1042/0264-6021:3400569; SEAGEL HI, 1975, ENZYME KINETICS; Shen XY, 1997, J BIOL CHEM, V272, P32472, DOI 10.1074/jbc.272.51.32472; Simpson KJ, 2000, J BIOL CHEM, V275, P23074, DOI 10.1074/jbc.M002161200; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; STETLER G, 1986, NUCLEIC ACIDS RES, V14, P7883, DOI 10.1093/nar/14.20.7883; Suzuki Y, 2000, HISTOCHEM CELL BIOL, V114, P15; Swanson WJ, 2002, NAT REV GENET, V3, P137, DOI 10.1038/nrg733; Tamechika I, 1996, J BIOL CHEM, V271, P7012, DOI 10.1074/jbc.271.12.7012; Tanaka N, 2000, BRIT J DERMATOL, V143, P728, DOI 10.1046/j.1365-2133.2000.03766.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Torres AM, 2003, J BIOL CHEM, V278, P40097, DOI 10.1074/jbc.M305322200; Tsumoto K, 1998, J IMMUNOL METHODS, V219, P119, DOI 10.1016/S0022-1759(98)00127-6; Tsunemi M, 1996, BIOCHEMISTRY-US, V35, P11570, DOI 10.1021/bi960900l; ULVSBACK M, 1992, J BIOL CHEM, V267, P18080; Umetsu M, 2003, J BIOL CHEM, V278, P8979, DOI 10.1074/jbc.M212247200; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; Zaidi SHE, 1999, J CLIN INVEST, V103, P1211, DOI 10.1172/JCI5099; Zeeuwen PLJM, 1997, J BIOL CHEM, V272, P20471, DOI 10.1074/jbc.272.33.20471; ZHANG M, 1995, CANCER RES, V55, P2537	52	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20204	20215		10.1074/jbc.M501678200	http://dx.doi.org/10.1074/jbc.M501678200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15778505	hybrid			2022-12-27	WOS:000229242000007
J	Matsushita, M; Kozak, JA; Shimizu, Y; McLachlin, DT; Yamaguchi, H; Wei, FY; Tomizawa, K; Matsui, H; Chait, BT; Cahalan, MD; Nairn, AC				Matsushita, M; Kozak, JA; Shimizu, Y; McLachlin, DT; Yamaguchi, H; Wei, FY; Tomizawa, K; Matsui, H; Chait, BT; Cahalan, MD; Nairn, AC			Channel function is dissociated from the intrinsic kinase activity and autophosphorylation of TRPM7/ChaK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-2 KINASE; HEAVY-CHAIN KINASE; MIC CHANNELS; PROTEIN; PHOSPHORYLATION; HYPOMAGNESEMIA; MUTATION; DOMAIN; CRAC; MG2+	TRPM7/ChaK1 is a unique channel/kinase that contains a TRPM channel domain with 6 transmembrane segments fused to a novel serine-threonine kinase domain at its C terminus. The goal of this study was to investigate a possible role of kinase activity and autophosphorylation in regulation of channel activity of TRPM7/ChaK1. Residues essential for kinase activity were identified by site-directed mutagenesis. Two major sites of autophosphorylation were identified in vitro by mass spectrometry at Ser(1511) and Ser(1567), and these sites were found to be phosphorylated in intact cells. TRPM7/ChaK1 is a cation-selective channel that exhibits strong outward rectification and inhibition by millimolar levels of internal [Mg2+]. Mutation of the two autophosphorylation sites or of a key catalytic site that abolished kinase activity did not alter channel activity measured by whole-cell recording or Ca2+ influx. Inhibition by internal Mg2+ was also unaffected in the autophosphorylation site or "kinase-dead" mutants. Moreover, kinase activity was enhanced by Mg2+, was decreased by Zn2+, and was unaffected by Ca2+. In contrast, channel activity was inhibited by all three of these divalent cations. However, deletion of much of C-terminal kinase domain resulted in expression of an apparently inactive channel. We conclude that neither current activity nor regulation by internal Mg2+ is affected by kinase activity or autophosphorylation but that the kinase domain may play a structural role in channel assembly or subcellular localization.	Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06508 USA; Okayama Univ, Sch Med, Dept Physiol 1, Okayama 7008558, Japan; Nara Inst Sci & Technol, Dept Biol Struct, Nara 6300101, Japan; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Rockefeller Univ, Lab Mass Spectrometry, New York, NY 10021 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	Yale University; Okayama University; Nara Institute of Science & Technology; Rockefeller University; Rockefeller University; University of California System; University of California Irvine	Nairn, AC (corresponding author), Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06508 USA.	angus.nairn@yale.edu	Wei, Fan-Yan/AAD-8461-2021; Tomizawa, Kazuhito/F-2405-2015	Tomizawa, Kazuhito/0000-0002-5663-2627; Wei, Fan-Yan/0000-0002-4843-724X; Nairn, Angus/0000-0002-7075-0195	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS014609, R01NS014609] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00862] Funding Source: Medline; NIGMS NIH HHS [GM50402] Funding Source: Medline; NINDS NIH HHS [NS14609] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chubanov V, 2004, P NATL ACAD SCI USA, V101, P2894, DOI 10.1073/pnas.0305252101; Clapham DE, 2003, PHARMACOL REV, V55, P591, DOI 10.1124/pr.55.4.6; Diggle TA, 1999, FEBS LETT, V457, P189, DOI 10.1016/S0014-5793(99)01034-0; Drennan D, 2004, PROG BIOPHYS MOL BIO, V85, P1, DOI 10.1016/S0079-6107(03)00060-9; Fleig A, 2004, TRENDS PHARMACOL SCI, V25, P633, DOI 10.1016/j.tips.2004.10.004; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; Jiang XP, 2003, J BIOL CHEM, V278, P42867, DOI 10.1074/jbc.M304487200; Kolman MF, 1997, J BIOL CHEM, V272, P16904, DOI 10.1074/jbc.272.27.16904; Kozak JA, 2003, BIOPHYS J, V84, P922, DOI 10.1016/S0006-3495(03)74909-1; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; Krutchinsky AN, 2001, ANAL CHEM, V73, P5066, DOI 10.1021/ac010682o; Luo X, 2001, J BIOL CHEM, V276, P17836, DOI 10.1074/jbc.M009366200; MONTIES B, 2001, BIOPOLYMERS, V1, P1; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; Nairn AC, 2001, PROG MOLEC, V27, P91; NAIRN AC, 2003, ATYPICAL PROTEIN KIN, P567; Pavur KS, 2000, BIOCHEMISTRY-US, V39, P12216, DOI 10.1021/bi0007270; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Ryazanov AG, 2002, FEBS LETT, V514, P26, DOI 10.1016/S0014-5793(02)02299-8; Ryazanova LV, 2004, J BIOL CHEM, V279, P3708, DOI 10.1074/jbc.M308820200; Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901; Yamaguchi H, 2001, MOL CELL, V7, P1047, DOI 10.1016/S1097-2765(01)00256-8; Zakharov SI, 2003, BRIT J PHARMACOL, V138, P234, DOI 10.1038/sj.bjp.0705074	30	148	150	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20793	20803		10.1074/jbc.M413671200	http://dx.doi.org/10.1074/jbc.M413671200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781465	hybrid, Green Published			2022-12-27	WOS:000229242000077
J	Patnaik, SK; Stanley, P				Patnaik, SK; Stanley, P			Mouse large can modify complex N- and mucin O-glycans on alpha-dystroglycan to induce laminin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARY GLYCOSYLATION MUTANTS; DYSTROPHIN-GLYCOPROTEIN COMPLEX; CONGENITAL MUSCULAR-DYSTROPHY; UDP-GLUCOSE-GLYCOPROTEIN; HUMAN LARGE GENE; MOLECULAR-CLONING; MENTAL-RETARDATION; EPIMERASE DOMAIN; CELL MUTANTS; GDP-MANNOSE	The human LARGE gene encodes a protein with two putative glycosyltransferase domains and is required for the generation of functional alpha-dystroglycan (alpha-DG). Monoclonal antibodies IIH6 and VIA4-1 recognize the functional glycan epitopes of alpha-DG that are necessary for binding to laminin and other ligands. Overexpression of full-length mouse Large generated functionally glycosylated alpha-DG in Pro(-)5 Chinese hamster ovary (CHO) cells, and the amount was increased by co-expression of protein: O-mannosyl N-acetylglucosaminyltransferase 1. However, functional alpha-DG represented only a small fraction of the alpha-DG synthesized by CHO cells or expressed from an alpha-DG construct. To identify features of the glycan epitopes induced by Large, the production of functionally glycosylated alpha-DG was investigated in several CHO glycosylation mutants. Mutants with defective transfer of sialic acid (Lec2), galactose (Lec8), or fucose (Lec13) to glycoconjugates, and the Lec15 mutant that cannot synthesize O-mannose glycans, all produced functionally glycosylated alpha-DG upon overexpression of Large. Laminin binding and the alpha-DG glycan epitopes were enhanced in Lec2 and Lec8 cells. In Lec15 cells, functional alpha-DG was increased by co-expression of core 2 N- acetylglucosaminyltransferase 1 with Large. Treatment with N- glycanase markedly reduced functionally glycosylated alpha-DG in Lec2 and Lec8 cells. The combined data provide evidence that Large does not transfer to Gal, Fuc, or sialic acid on alpha-DG nor induce the transfer of these sugars to alpha-DG. In addition, the data suggest that human LARGE may restore functional alpha-DG to muscle cells from patients with defective synthesis of O-mannose glycans via the modification of N- glycans and/or mucin O-glycans on alpha-DG.	Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Stanley, P (corresponding author), 1300 Morris Pk Ave, Bronx, NY 10461 USA.	stanley@aecom.yu.edu		Stanley, Pamela/0000-0001-5704-3747	PHS HHS [R01 36434, P01 13330] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akasaka-Manya K, 2004, BIOCHEM BIOPH RES CO, V325, P75, DOI 10.1016/j.bbrc.2004.10.001; Aravind L, 1999, CURR BIOL, V9, pR836, DOI 10.1016/S0960-9822(00)80039-1; Arnold SM, 2000, BIOCHEMISTRY-US, V39, P2149, DOI 10.1021/bi9916473; Barresi R, 2004, NAT MED, V10, P696, DOI 10.1038/nm1059; Brancaccio Andrea, 2003, Ital J Biochem, V52, P68; Brennan PA, 2004, EJSO, V30, P589, DOI 10.1016/j.ejso.2004.03.014; Breton C, 2002, BIOCHEM SOC SYMP, V69, P23; Broccolini A, 2005, NEUROMUSCULAR DISORD, V15, P177, DOI 10.1016/j.nmd.2004.10.001; Brockington M, 2005, HUM MOL GENET, V14, P657, DOI 10.1093/hmg/ddi062; Brown SC, 1999, J CELL SCI, V112, P209; Chai WG, 1999, EUR J BIOCHEM, V263, P879, DOI 10.1046/j.1432-1327.1999.00572.x; CHANEY W, 1989, J CELL BIOL, V109, P2089, DOI 10.1083/jcb.109.5.2089; Chen W, 2003, GLYCOBIOLOGY, V13, P43, DOI 10.1093/glycob/cwg003; Chiba A, 1997, J BIOL CHEM, V272, P2156; de Bernabe DBV, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.013870; de Bernabe DBV, 2003, J MED GENET, V40, P845; Dejgaard S, 2004, CURR ISSUES MOL BIOL, V6, P29; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Doucey MA, 1998, MOL BIOL CELL, V9, P291, DOI 10.1091/mbc.9.2.291; Eckhardt M, 1998, J BIOL CHEM, V273, P20189, DOI 10.1074/jbc.273.32.20189; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Ervasti JM, 1993, CURR OPIN CELL BIOL, V5, P82, DOI 10.1016/S0955-0674(05)80012-2; Ervasti JM, 1997, J BIOL CHEM, V272, P22315, DOI 10.1074/jbc.272.35.22315; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Grewal PK, 2001, NAT GENET, V28, P151, DOI 10.1038/88865; Harel T, 2004, EUR J HUM GENET, V12, P38, DOI 10.1038/sj.ejhg.5201087; Holzfeind PJ, 2002, HUM MOL GENET, V11, P2673, DOI 10.1093/hmg/11.21.2673; Hong YJ, 2003, J BIOL CHEM, V278, P53045, DOI 10.1074/jbc.M309967200; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Inamori K, 2004, J BIOL CHEM, V279, P2337, DOI 10.1074/jbc.C300480200; Inamori K, 2003, J BIOL CHEM, V278, P43102, DOI 10.1074/jbc.M308255200; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; Kanagawa M, 2004, CELL, V117, P953, DOI 10.1016/j.cell.2004.06.003; Kobayashi K, 1998, NATURE, V394, P388, DOI 10.1038/28653; KOSTROMINOVA TY, 1995, J CELL BIOCHEM, V58, P527, DOI 10.1002/jcb.240580416; Kovach MJ, 2001, MOL GENET METAB, V74, P458, DOI 10.1006/mgme.2001.3256; Kunz S, 2001, J CELL BIOL, V155, P301, DOI 10.1083/jcb.200104103; Longman C, 2003, HUM MOL GENET, V12, P2853, DOI 10.1093/hmg/ddg307; Louhichi N, 2004, NEUROGENETICS, V5, P27, DOI 10.1007/s10048-003-0165-9; Manya H, 2004, P NATL ACAD SCI USA, V101, P500, DOI 10.1073/pnas.0307228101; Manya H, 2003, BIOCHEM BIOPH RES CO, V306, P93, DOI 10.1016/S0006-291X(03)00924-0; Marchler-Bauer A, 2002, NUCLEIC ACIDS RES, V30, P281, DOI 10.1093/nar/30.1.281; McDearmon EL, 2003, J BIOL CHEM, V278, P44868, DOI 10.1074/jbc.M307026200; Mercuri E, 2003, ANN NEUROL, V53, P537, DOI 10.1002/ana.10559; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Muntoni F, 2004, CURR OPIN NEUROL, V17, P205, DOI 10.1097/00019052-200404000-00020; Muschler J, 2002, CANCER RES, V62, P7102; Oelmann S, 2001, J BIOL CHEM, V276, P26291, DOI 10.1074/jbc.M011124200; Ohyama C, 1998, J BIOL CHEM, V273, P14582, DOI 10.1074/jbc.273.23.14582; Patnaik SK, 2000, ARCH BIOCHEM BIOPHYS, V375, P322, DOI 10.1006/abbi.1999.1693; Peng HB, 1998, CELL ADHES COMMUN, V5, P475, DOI 10.3109/15419069809005605; Peyrard M, 1999, P NATL ACAD SCI USA, V96, P598, DOI 10.1073/pnas.96.2.598; Pu LX, 2003, BIOCHEM BIOPH RES CO, V312, P555, DOI 10.1016/j.bbrc.2003.10.152; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Rando TA, 2001, MUSCLE NERVE, V24, P1575, DOI 10.1002/mus.1192; RIPKA J, 1986, ARCH BIOCHEM BIOPHYS, V249, P533, DOI 10.1016/0003-9861(86)90031-7; RUTTLEDGE MH, 1994, GENE CHROMOSOME CANC, V10, P122, DOI 10.1002/gcc.2870100207; Saito F, 2004, NEUROMUSCULAR DISORD, V14, P158, DOI 10.1016/j.nmd.2003.09.006; SASAKI H, 1987, J BIOL CHEM, V262, P12059; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Sasaki T, 1998, BBA-GEN SUBJECTS, V1425, P599, DOI 10.1016/S0304-4165(98)00114-7; Schachter H, 2003, GLYCOCONJUGATE J, V20, P291, DOI 10.1023/B:GLYC.0000033626.65127.e4; Sherman DL, 2001, NEURON, V30, P677, DOI 10.1016/S0896-6273(01)00327-0; SMALHEISER NR, 1987, P NATL ACAD SCI USA, V84, P6457, DOI 10.1073/pnas.84.18.6457; SMALHEISER NR, 1995, J BIOL CHEM, V270, P15425, DOI 10.1074/jbc.270.25.15425; Smalheiser NR, 1998, J BIOL CHEM, V273, P23698, DOI 10.1074/jbc.273.37.23698; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STANLEY P, 1975, P NATL ACAD SCI USA, V72, P3323, DOI 10.1073/pnas.72.9.3323; STANLEY P, 1980, J CELL BIOL, V85, P60, DOI 10.1083/jcb.85.1.60; STANLEY P, 1980, ACS SYM SER, V128, P213; STOLL J, 1982, P NATL ACAD SCI-BIOL, V79, P2296, DOI 10.1073/pnas.79.7.2296; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; Sullivan FX, 1998, J BIOL CHEM, V273, P8193, DOI 10.1074/jbc.273.14.8193; Tessier DC, 2000, GLYCOBIOLOGY, V10, P403, DOI 10.1093/glycob/10.4.403; Yamada H, 1996, J NEUROCHEM, V66, P1518; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Yudate HT, 2001, NUCLEIC ACIDS RES, V29, P185, DOI 10.1093/nar/29.1.185	86	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20851	20859		10.1074/jbc.M500069200	http://dx.doi.org/10.1074/jbc.M500069200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788414	hybrid			2022-12-27	WOS:000229242000083
J	Tafolla, E; Wang, SH; Wong, B; Leong, J; Kapila, YL				Tafolla, E; Wang, SH; Wong, B; Leong, J; Kapila, YL			JNK1 and JNK2 oppositely regulate p53 in signaling linked to apoptosis triggered by an altered fibronectin matrix - JNK links FAK and p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAIN; FOCAL ADHESION KINASE; GINGIVAL CREVICULAR FLUID; V-REGION; MOLECULAR-FORMS; ACTIVATION; PHOSPHORYLATION; DEGRADATION; SUPPRESSION; EXPRESSION	The extracellular matrix regulates many cellular processes, including survival, and alterations in the matrix or in matrix survival signals can trigger apoptosis. Previously, we showed that an altered fibronectin matrix triggers apoptosis in primary cells via a novel pathway regulated by transcriptionally mediated decreases in p53 and c-Myc levels. Here we report that this apoptotic mechanism is propagated by decreased phosphorylation of focal adhesion kinase (FAK), which is linked to increased phosphorylation of c-Jun N-terminal kinase (JNK) and to decreased levels of p53. FAK is physically and spatially linked to JNK and p53, which relocalize from the nucleus to the cell membrane to mediate this interaction. Further, p53 participates in a feedback mechanism with JNK to regulate this apoptotic process and is oppositely regulated by JNK1 and JNK2.	Univ Michigan, Sch Dent, Dept Periodont Prevent Geriatr, Ann Arbor, MI 48109 USA; Univ Calif San Francisco, Sch Dent, Dept Stomatol, San Francisco, CA 94143 USA	University of Michigan System; University of Michigan; University of California System; University of California San Francisco	Kapila, YL (corresponding author), Univ Michigan, Sch Dent, Dept Periodont Prevent Geriatr, Rm 5213,1011 N Univ Ave, Ann Arbor, MI 48109 USA.	ykapila@umich.edu	Kapila, Yvonne/AAG-5418-2021		NIDCR NIH HHS [R01 DE13725, T35-DE07103, T32-DE07306] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [T32DE007306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013725, T35DE007103] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; AKHTAR S, 1991, LIFE SCI, V49, P1793, DOI 10.1016/0024-3205(91)90480-Y; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Buschmann T, 2000, CANCER RES, V60, P896; CARSONS S, 1985, ARTHRITIS RHEUM, V28, P601, DOI 10.1002/art.1780280602; CLEMMENSEN I, 1982, ARTHRITIS RHEUM, V25, P25, DOI 10.1002/art.1780250104; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; GRIFFITHS AM, 1989, CLIN CHIM ACTA, V184, P133, DOI 10.1016/0009-8981(89)90283-0; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Huynh QH, 2002, J PERIODONTOL, V73, P1101, DOI 10.1902/jop.2002.73.10.1101; Ilic D, 1998, J CELL BIOL, V143, P547; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kapila YL, 1997, J BIOL CHEM, V272, P18932, DOI 10.1074/jbc.272.30.18932; Kapila YL, 1996, MATRIX BIOL, V15, P251, DOI 10.1016/S0945-053X(96)90116-X; Kapila YL, 2002, J BIOL CHEM, V277, P8482, DOI 10.1074/jbc.M108932200; Kapila YL, 1999, J BIOL CHEM, V274, P30906, DOI 10.1074/jbc.274.43.30906; Kapila YL, 1998, J PERIODONTOL, V69, P1008, DOI 10.1902/jop.1998.69.9.1008; LALLIER T, 1993, SCIENCE, V259, P692, DOI 10.1126/science.8430321; Metzler B, 2000, AM J PATHOL, V156, P1875, DOI 10.1016/S0002-9440(10)65061-4; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Shklyaev SS, 2001, ANTICANCER RES, V21, P2569; TAFOLLA E, 2003, J DENT RES B, V82, P2213; TAFOLLA E, 2004, J DENT RES B, V83, P1621; TALONPOIKA J, 1993, SCAND J DENT RES, V101, P375; TALONPOIKA J, 1989, SCAND J DENT RES, V97, P415; Townsend PA, 2000, EUR J CANCER, V36, P397, DOI 10.1016/S0959-8049(99)00275-0; Wang JP, 2000, MOL CARCINOGEN, V29, P179, DOI 10.1002/1098-2744(200011)29:3<179::AID-MC7>3.0.CO;2-K; XIE DL, 1992, J RHEUMATOL, V19, P1448	30	48	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19992	19999		10.1074/jbc.M500331200	http://dx.doi.org/10.1074/jbc.M500331200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15778501	hybrid			2022-12-27	WOS:000229113700069
J	Kuwada, SK; Kuang, JQ; Li, XF				Kuwada, SK; Kuang, JQ; Li, XF			Integrin alpha 5/beta 1 expression mediates HER-2 down-regulation in colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MALIGNANT PHENOTYPE; COLORECTAL-CANCER; CARCINOMA CELLS; ERBB RECEPTORS; C-CBL; FIBRONECTIN; UBIQUITINATION; GELDANAMYCIN; DEGRADATION	HER-2 is constitutively activated and overexpressed in many cancers, and its inhibition in colon cancer cells diminishes tumorigenicity and induces apoptosis. Little is known about the regulation of HER-2 signaling in colon cancer cells. Integrin alpha 5/beta 1 expression is frequently lost in colorectal cancer cells compared with normal intestinal epithelium, and colon cancer cells lacking integrin alpha 5/beta 1 expression utilize HER-2 signaling for proliferation and tumorigenicity. Re-expression of integrin alpha 5/beta 1 in colon cancer cells abrogated their tumorigenicity, but how this occurs is not well known. Stable expression of integrin alpha 5/beta 1 in colon cancer cells with little or no detectable integrin alpha 5/beta 1 protein expression resulted in the post-transcriptional down-regulation of HER-2 protein. Integrin alpha 5/beta 1 was found to interact with HER-2, and the cytoplasmic domain of integrin alpha 5/beta 1 was sufficient to mediate HER-2 down-regulation. Integrin alpha 5/beta 1-mediated down-regulation of HER-2 was the result of increased lysosomal targeting. The inhibition of HER-2 signaling represents a potential mechanism by which integrin alpha 5/beta 1 exerts its tumor suppressor-like activity in colon cancer cells. These results also suggest that a novel function for integrin alpha 5/beta 1 is the control of HER-2 expression.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Salt Lake City Vet Adv Hlth Care Syst, Dept Med, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Kuwada, SK (corresponding author), 2000 Circle Hope, Salt Lake City, UT 84112 USA.							Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; Baulida J, 1996, J BIOL CHEM, V271, P5251; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; De Bosscher K, 2004, BIOCHEM J, V379, P209, DOI 10.1042/BJ20031886; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Kapitanovic S, 1997, GASTROENTEROLOGY, V112, P1103, DOI 10.1016/S0016-5085(97)70120-3; KAPITANOVIC S, 1994, CANCER DETECT PREV, V18, P97; Klapper LN, 2000, CANCER RES, V60, P3384; Kumar R, 2001, SEMIN ONCOL, V28, P27, DOI 10.1016/S0093-7754(01)90279-9; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; Kuwada SK, 2004, INT J CANCER, V109, P291, DOI 10.1002/ijc.11686; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Li J, 1999, J BIOL CHEM, V274, P11209, DOI 10.1074/jbc.274.16.11209; Mann M, 2001, GASTROENTEROLOGY, V120, P1713, DOI 10.1053/gast.2001.24844; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nakamura I, 2003, ENDOCRINOLOGY, V144, P4739, DOI 10.1210/en.2003-0615; Nathanson DR, 2003, INT J CANCER, V105, P796, DOI 10.1002/ijc.11137; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Normanno N, 2003, J CELL PHYSIOL, V194, P13, DOI 10.1002/jcp.10194; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; Ross JS, 2001, CANCER INVEST, V19, P554, DOI 10.1081/CNV-100103852; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Saci A, 2000, BIOCHEM J, V351, P669, DOI 10.1042/0264-6021:3510669; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Shimizu H, 2003, ONCOGENE, V22, P831, DOI 10.1038/sj.onc.1206203; STALLMACH A, 1994, GASTROENTEROLOGY, V106, P19, DOI 10.1016/S0016-5085(94)94031-2; Tikhomirov O, 2003, CANCER RES, V63, P39; Tikhomirov O, 2001, J BIOL CHEM, V276, P33675, DOI 10.1074/jbc.M101394200; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; Wang DH, 1999, J BIOL CHEM, V274, P12840, DOI 10.1074/jbc.274.18.12840; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; Zutter MM, 1998, CURR TOP MICROBIOL, V231, P167; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	41	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19027	19035		10.1074/jbc.M410540200	http://dx.doi.org/10.1074/jbc.M410540200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757908	hybrid			2022-12-27	WOS:000228932300058
J	Barrett, CF; Cao, YQ; Tsien, RW				Barrett, CF; Cao, YQ; Tsien, RW			Gating deficiency in a familial hemiplegic migraine type 1 mutant P/Q-type calcium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC KIDNEY-CELLS; CA2+ CHANNEL; TRANSMITTER RELEASE; CURRENT-DENSITY; MUTATIONS; CURRENTS; ALPHA(1A); NEURONS; INACTIVATION; MODULATION	Familial hemiplegic migraine type 1 (FHM1) arises from missense mutations in the gene encoding alpha(1A), the pore-forming subunit of P/Q-type calcium channels. The nature of the channel disorder is fundamental to the disease, yet is not well understood. We studied how the most prevalent FHM1 mutation, a threonine to methionine substitution at position 666 (TM), affects both ionic current and gating current associated with channel activation, a previously unexplored feature of P/Q channels. Whole-cell currents were measured in HEK293 cells expressing channels containing either wild-type (WT) or TM alpha(1A). Calcium currents were significantly smaller in cells expressing TM channels, consistent with previous reports. In contrast, surface expression of TM channels, measured by immunostaining against an extracellular epitope, was not decreased, and Western blots demonstrated that TM alpha(1A) subunits were expressed as full-length proteins. WT and TM gating currents were isolated by replacing Ca2+ with the nonpermeant cation La3+. The gating currents generated by the mutant channels were one-third that of WT, a deficiency sufficient to account for the observed attenuation in calcium current; the remaining gating current was no different in kinetics or voltage dependence. Thus, the decreased calcium influx seen with TM channels can be attributed to a reduced number of channels available to undergo the voltage-dependent conformational changes needed for channel opening, not to fewer channel proteins expressed on the cell surface. This identification of an intrinsic defect in FHM1 mutant channels helps explain their impact on neurotransmission when they occupy type-specific slots for P/Q channels at central nerve terminals.	Stanford Univ, Sch Med, Beckman Ctr, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA	Stanford University	Tsien, RW (corresponding author), Stanford Univ, Sch Med, Beckman Ctr, Dept Mol & Cellular Physiol, Rm B105, Stanford, CA 94305 USA.	rwtsien@stanford.edu			NINDS NIH HHS [NS24067] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024067] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altier C, 2002, J BIOL CHEM, V277, P33598, DOI 10.1074/jbc.M202476200; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; BEAN BP, 1989, J GEN PHYSIOL, V94, P65, DOI 10.1085/jgp.94.1.65; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; Cao YQ, 2005, P NATL ACAD SCI USA, V102, P2590, DOI 10.1073/pnas.0409896102; Cao YQ, 2004, NEURON, V43, P387, DOI 10.1016/j.neuron.2004.07.014; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ELMSLIE KS, 1992, J PHYSIOL-LONDON, V451, P229, DOI 10.1113/jphysiol.1992.sp019162; Ferrari MD, 1998, LANCET, V351, P1043, DOI 10.1016/S0140-6736(97)11370-8; Flagg TP, 1999, J GEN PHYSIOL, V114, P685, DOI 10.1085/jgp.114.5.685; Frindt G, 2001, AM J PHYSIOL-RENAL, V280, pF112, DOI 10.1152/ajprenal.2001.280.1.F112; Goadsby PJ, 2002, NEW ENGL J MED, V346, P257, DOI 10.1056/NEJMra010917; HADLEY RW, 1991, J GEN PHYSIOL, V98, P265, DOI 10.1085/jgp.98.2.265; Hans M, 1999, J NEUROSCI, V19, P1610; HONG SJ, 1995, J PHYSIOL-LONDON, V482, P283, DOI 10.1113/jphysiol.1995.sp020517; Jones LP, 1999, BIOPHYS J, V76, P2530, DOI 10.1016/S0006-3495(99)77407-2; Jones LP, 1997, J PHYSIOL-LONDON, V498, P601, DOI 10.1113/jphysiol.1997.sp021886; Jones LP, 1998, J GEN PHYSIOL, V112, P125, DOI 10.1085/jgp.112.2.125; Josephson IR, 1997, PFLUG ARCH EUR J PHY, V433, P321; Josephson IR, 1996, BIOPHYS J, V70, P1285, DOI 10.1016/S0006-3495(96)79685-6; Kors EE, 2003, ARCH NEUROL-CHICAGO, V60, P684, DOI 10.1001/archneur.60.5.684; Kraus RL, 1998, J BIOL CHEM, V273, P5586, DOI 10.1074/jbc.273.10.5586; Kraus RL, 2000, J BIOL CHEM, V275, P9239, DOI 10.1074/jbc.275.13.9239; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; Liu L, 2003, J BIOENERG BIOMEMBR, V35, P671, DOI 10.1023/B:JOBB.0000008031.12485.ee; McDonough SI, 2005, BIOPHYS J, V88, P211, DOI 10.1529/biophysj.104.051714; Melliti K, 2003, J PHYSIOL-LONDON, V546, P337, DOI 10.1113/jphysiol.2002.026716; Meza U, 1998, J NEUROSCI, V18, P5240, DOI 10.1523/JNEUROSCI.18-14-05240.1998; MINTZ IM, 1995, NEURON, V15, P675, DOI 10.1016/0896-6273(95)90155-8; Mullner C, 2004, J BIOL CHEM, V279, P51844, DOI 10.1074/jbc.M408756200; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; PEROZO E, 1993, NEURON, V11, P353, DOI 10.1016/0896-6273(93)90190-3; Piedras-Renteria ES, 2001, J NEUROSCI, V21, P9185, DOI 10.1523/JNEUROSCI.21-23-09185.2001; Pietrobon D, 2002, MOL NEUROBIOL, V25, P31, DOI 10.1385/MN:25:1:031; Pietrobon D, 2003, NAT REV NEUROSCI, V4, P386, DOI 10.1038/nrn1102; Pineda JC, 1998, J NEUROPHYSIOL, V79, P2522, DOI 10.1152/jn.1998.79.5.2522; Protti DA, 1996, NEUROLOGY, V46, P1391, DOI 10.1212/WNL.46.5.1391; Soong TW, 2002, J NEUROSCI, V22, P10142; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; Tottene A, 2002, P NATL ACAD SCI USA, V99, P13284, DOI 10.1073/pnas.192242399; Tsien RW, 1999, CALCIUM AS A CELLULAR REGULATOR, P171; van den Maagdenberg AMJM, 2004, NEURON, V41, P701, DOI 10.1016/S0896-6273(04)00085-6; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	46	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24064	24071		10.1074/jbc.M502223200	http://dx.doi.org/10.1074/jbc.M502223200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15795222	hybrid			2022-12-27	WOS:000229880000080
J	Shlyonsky, V; Goolaerts, A; Van Beneden, R; Sariban-Sohraby, S				Shlyonsky, V; Goolaerts, A; Van Beneden, R; Sariban-Sohraby, S			Differentiation of epithelial Na+ channel function - An in vitro model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY CELL-LINE; DOME FORMATION; II CELLS; LUNG; EXPRESSION; TRANSPORT; CONDUCTANCE; CURRENTS; ATPASE; GENE	Confluent monolayers of epithelial cells grown on nonporous support form fluid-filled hemicysts called domes, which reflect active ion transport across the epithelium. Clara-like H441 lung adenocarcinoma cells grown on glass supports and exposed to 50 nM dexamethasone developed domes in a time-dependent fashion. Uplifting of small groups of cells occurred within 6-12 h, well formed domes appeared between 24 and 48 h, and after 7 days, individual domes started to merge. Cells inside of domes compared with those outside domes, or with monolayers not exposed to dexamethasone, differed by higher surfactant production, an increased cytokeratin expression, and the localization of claudin-4 proteins to the plasma membrane. In patch clamp studies, amiloride-blockable sodium currents were detected exclusively in cells inside domes, whereas in cells outside of domes, sodium crossed the membrane through La3+-sensitive nonspecific cation channels. Cells grown on permeable support without dexamethasone expressed amiloride-sensitive currents only after tight electrical coupling was achieved (transepithelial electrical resistance (R-t) > 1 kilohm). In real-time quantitative PCR experiments, the addition of dexamethasone increased the content of claudin-4, occludin, and Na+ channel gamma-subunit (gamma-ENaC) mRNAs by 1.34-, 1.32-, and 1.80-fold, respectively, after 1 h and was followed by an increase at 6 h in the content of mRNA of alpha- and beta-ENaC and of alpha 1- and beta 1-Na, K-ATPase. In the absence of dexamethasone, neither change in gene expression nor cell uplifting was observed. Our data suggest that during epithelial differentiation, coordinated expression of tight junction proteins precedes the development of vectorial transport of sodium, which in turn leads to the fluid accumulation in basolateral spaces that is responsible for dome formation.	Univ Libre Bruxelles, Lab Physiol & Physiopathol, B-1070 Brussels, Belgium	Universite Libre de Bruxelles	Sariban-Sohraby, S (corresponding author), Univ Libre Bruxelles, Lab Physiol & Physiopathol, Campus Erasme,CP 604,808 Route Lennik, B-1070 Brussels, Belgium.	sohraby@ulb.ac.be		Shlyonsky, Vadim/0000-0003-2999-6553				Abraham V, 2001, AM J PHYSIOL-LUNG C, V280, pL1085, DOI 10.1152/ajplung.2001.280.6.L1085; AKAIKE N, 1994, JPN J PHYSIOL, V44, P433, DOI 10.2170/jjphysiol.44.433; Awayda MS, 2004, AM J PHYSIOL-CELL PH, V287, pC395, DOI 10.1152/ajpcell.00412.2003; Barquin N, 1997, AM J PHYSIOL-LUNG C, V273, pL825, DOI 10.1152/ajplung.1997.273.4.L825; BARRY PH, 1991, J MEMBRANE BIOL, V121, P101, DOI 10.1007/BF01870526; Chalaka S, 1999, AM J PHYSIOL-LUNG C, V277, pL197, DOI 10.1152/ajplung.1999.277.1.L197; CHANDER A, 1986, J BIOL CHEM, V261, P6126; Clunes MT, 2004, J PHYSIOL-LONDON, V557, P809, DOI 10.1113/jphysiol.2004.061143; CUTZ E, 1971, AM J PATHOL, V62, P127; GAZDAR AF, 1990, CANCER RES, V50, P5481; Gonzales LW, 2002, AM J PHYSIOL-LUNG C, V283, pL940, DOI 10.1152/ajplung.00127.2002; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; Hao H, 2003, AM J PHYSIOL-LUNG C, V285, pL593, DOI 10.1152/ajplung.00037.2003; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Inagaki A, 2004, AM J PHYSIOL-CELL PH, V286, pC380, DOI 10.1152/ajpcell.00373.2003; Itani OA, 2002, AM J PHYSIOL-LUNG C, V282, pL631, DOI 10.1152/ajplung.00085.2001; Kemp PJ, 2001, J PHYSIOL-LONDON, V536, P693, DOI 10.1111/j.1469-7793.2001.t01-1-00693.x; Kunzelmann K, 1996, PFLUG ARCH EUR J PHY, V431, P578, DOI 10.1007/BF02191906; Lazrak A, 2003, AM J PHYSIOL-LUNG C, V285, pL443, DOI 10.1152/ajplung.00412.2002; LEVER JE, 1979, P NATL ACAD SCI USA, V76, P1323, DOI 10.1073/pnas.76.3.1323; MASON RJ, 1982, P NATL ACAD SCI-BIOL, V79, P6033, DOI 10.1073/pnas.79.19.6033; Mauro T, 2002, J INVEST DERMATOL, V118, P589, DOI 10.1046/j.1523-1747.2002.01721.x; Nakahari T, 1996, J MEMBRANE BIOL, V154, P35, DOI 10.1007/s002329900130; RABITO CA, 1980, IN VITRO CELL DEV B, V16, P461, DOI 10.1007/BF02626458; Ramminger SJ, 2004, AM J PHYSIOL-LUNG C, V287, pL411, DOI 10.1152/ajplung.00407.2003; RANNELS SR, 1989, J MOL CELL CARDIOL, V21, P151, DOI 10.1016/0022-2828(89)90851-1; Rothen-Rutishauser B, 1998, PHARMACEUT RES, V15, P964, DOI 10.1023/A:1011953405272; SARIBANSOHRABY S, 1983, AM J PHYSIOL, V245, pC167, DOI 10.1152/ajpcell.1983.245.3.C167; Sayegh R, 1999, J BIOL CHEM, V274, P12431, DOI 10.1074/jbc.274.18.12431; SCHNEEBERGER EL, 1997, LUNG SCI FDN, P505; SHEN SS, 1976, J MEMBRANE BIOL, V29, P373, DOI 10.1007/BF01868971; SUGAHARA K, 1984, J CELL BIOL, V99, P1541, DOI 10.1083/jcb.99.4.1541; Thomas CP, 2004, AM J PHYSIOL-LUNG C, V287, pL843, DOI 10.1152/ajplung.00340.2003; Tonoli H, 2000, ENDOCRINOLOGY, V141, P1403, DOI 10.1210/en.141.4.1403; Wadsworth SJ, 1997, AM J PHYSIOL-LUNG C, V273, pL427, DOI 10.1152/ajplung.1997.273.2.L427; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Xu W, 1999, J MEMBRANE BIOL, V171, P117, DOI 10.1007/s002329900564; Zucchi I, 1999, P NATL ACAD SCI USA, V96, P13766, DOI 10.1073/pnas.96.24.13766; Zucchi I, 2001, P NATL ACAD SCI USA, V98, P5608, DOI 10.1073/pnas.091101898	39	48	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24181	24187		10.1074/jbc.M413823200	http://dx.doi.org/10.1074/jbc.M413823200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15817472	hybrid			2022-12-27	WOS:000229880000093
J	Skacel, N; Menon, LG; Mishra, PJ; Peters, R; Banerjees, D; Bertino, JR; Abali, EE				Skacel, N; Menon, LG; Mishra, PJ; Peters, R; Banerjees, D; Bertino, JR; Abali, EE			Identification of amino acids required for the functional up-regulation of human dihydrofolate reductase protein in response to antifolate treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDYLATE SYNTHASE INHIBITOR; MESSENGER-RNA; IN-VITRO; ESCHERICHIA-COLI; POTENT INHIBITOR; BINDING; METHOTREXATE; ENZYME; CELLS; DEHYDROGENASE	Human dihydrofolate reductase ( DHFR) protein levels rapidly increase upon exposure to methotrexate, a potent inhibitor of this enzyme. A model to explain this increase proposes that DHFR inhibits its own translation by binding to its cognate mRNA and that methotrexate disrupts the DHFR protein-mRNA complex allowing its translation to resume. In the present study, Chinese hamster ovary cells lacking DHFR were transfected with wild type and mutants of human DHFR to identify amino acids that are essential for increases in DHFR in response to methotrexate. Glu-30, Leu-22, and Ser-118 were involved in the up-regulation of DHFR protein levels by methotrexate and certain other antifolates. Cells transfected with E30A, L22R, and S118A mutants that did not respond to methotrexate up-regulation had higher basal levels of DHFR, consistent with the model, i.e. lack of feedback regulation of these enzymes. Although cells containing the S118A mutant enzyme had higher levels of DHFR and had catalytic activity similar to that of wild type DHFR, they had the same sensitivity to the cytotoxicity of methotrexate, as were cells with wild type DHFR. This finding provides evidence that the adaptive up-regulation of DHFR by methotrexate contributes to the decreased sensitivity to this drug. Based on these observations, a new model is proposed whereby DHFR exists in two conformations, one bound to DHFR mRNA and the other bound to NADPH. The mutants that are not up-regulated by methotrexate are unable to bind their cognate mRNA.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ 08903 USA; Weill Cornell Grad Sch Med Sci, New York, NY 10021 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar	Bertino, JR (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Rm 3030,195 Little Albany St, New Brunswick, NJ 08903 USA.	abaliem@umdnj.edu; bertinoj@umdnj.edu			NCI NIH HHS [CA 08010] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008010, R37CA008010] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABALI E, 2003, P AM ASSOC CANC RES, V114, P601; APPLEMAN JR, 1988, J BIOL CHEM, V263, P10304; APPLEMAN JR, 1990, J BIOL CHEM, V265, P5579; APPLEMAN JR, 1988, J BIOL CHEM, V263, P9187; BASTOW KF, 1984, ADV ENZYME REGUL, V22, P15, DOI 10.1016/0065-2571(84)90006-2; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; BERTINO JR, 1965, CLIN PHARMACOL THER, V6, P763; BERTINO JR, 1963, J CLIN INVEST, V42, P1899, DOI 10.1172/JCI104875; BERTINO JR, 1970, CANCER RES, V30, P2372; BERTINO JR, 1962, NATURE, V193, P140, DOI 10.1038/193140a0; BERTINO JR, 1997, CANC MED, V2, P907; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; Blakley RL, 1998, HUM MUTAT, V11, P259, DOI 10.1002/(SICI)1098-1004(1998)11:4<259::AID-HUMU1>3.3.CO;2-N; BYSTROFF C, 1991, BIOCHEMISTRY-US, V30, P2227, DOI 10.1021/bi00222a028; CAREY J, 1983, BIOCHEMISTRY-US, V22, P4723, DOI 10.1021/bi00289a017; CHU E, 1994, J BIOL CHEM, V269, P20289; CHU E, 1993, BIOCHEMISTRY-US, V32, P4756, DOI 10.1021/bi00069a009; Chu E., 1996, CANC CHEMOTHERAPY BI, P109; COWAN KH, 1986, MOL PHARMACOL, V30, P69; DOMIN BA, 1982, MOL PHARMACOL, V21, P478; Ercikan E, 1993, Adv Exp Med Biol, V338, P537; Ercikan-Abali E. A., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P163; ErcikanAbali EA, 1997, BIOCHEMISTRY-US, V36, P12317, DOI 10.1021/bi971026e; ErcikanAbali EA, 1996, CANCER RES, V56, P4142; ErcikanAbali EA, 1996, MOL PHARMACOL, V49, P430; HENTZE MW, 1994, TRENDS BIOCHEM SCI, V19, P101, DOI 10.1016/0968-0004(94)90198-8; HILLCOAT BL, 1967, P NATL ACAD SCI USA, V58, P1632, DOI 10.1073/pnas.58.4.1632; HOWELL EE, 1986, SCIENCE, V231, P1123, DOI 10.1126/science.3511529; JACKMAN AL, 1991, CANCER RES, V51, P5579; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LEWIS WS, 1995, J BIOL CHEM, V270, P5057, DOI 10.1074/jbc.270.10.5057; Mayer-Kuckuk P, 2002, P NATL ACAD SCI USA, V99, P3400, DOI 10.1073/pnas.062036899; McGuire JJ, 2003, CURR PHARM DESIGN, V9, P2593, DOI 10.2174/1381612033453712; McPherson J. P., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P676; Nagy E, 2000, BIOCHEM BIOPH RES CO, V275, P253, DOI 10.1006/bbrc.2000.3246; Nowak W, 2001, ACTA BIOCHIM POL, V48, P903; Pioli PA, 2002, J BIOL CHEM, V277, P35738, DOI 10.1074/jbc.M204002200; ROMANIUK PJ, 1985, BIOCHEMISTRY-US, V24, P4239, DOI 10.1021/bi00336a064; Rouault TA, 2000, COLD SPRING HARBOR M, V39, P655; SCHWEITZER BI, 1989, J BIOL CHEM, V264, P20786; Shih C, 1997, CANCER RES, V57, P1116; Tai NW, 2002, NUCLEIC ACIDS RES, V30, P4481, DOI 10.1093/nar/gkf562; THEIL EC, 1990, J BIOL CHEM, V265, P4771; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941; Webber S, 1996, CANCER CHEMOTH PHARM, V37, P509, DOI 10.1007/s002800050422	45	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22721	22731		10.1074/jbc.M500277200	http://dx.doi.org/10.1074/jbc.M500277200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15817466	hybrid			2022-12-27	WOS:000229741800022
J	Wang, TY; Leventis, R; Silvius, JR				Wang, TY; Leventis, R; Silvius, JR			Artificially lipid-anchored proteins can elicit clustering-induced intracellular signaling events in Jurkat T-lymphocytes independent of lipid raft association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-RECEPTOR; IMMUNOLOGICAL SYNAPSE; MEMBRANE DOMAINS; FUNCTIONAL RAFTS; MICRODOMAINS; ACCUMULATION; TRANSDUCTION; RECRUITMENT; ACTIVATION; LIPOSOMES	We have incorporated artificial lipid-anchored streptavidin conjugates with fully saturated or polyunsaturated lipid anchors into the plasma membranes of Jurkat T-lymphocytes to assess previous conclusions that the activation of signaling processes induced in these cells by clustering of endogenous glycosylphosphatidylinositol-anchored proteins or ganglioside GM1 depends specifically on the association of these membrane components with lipid rafts. Lipid-anchored streptavidin conjugates could be incorporated into Jurkat or other mammalian cell surfaces by inserting biotinylated phosphatidylethanolamine-polyethyleneglycols (PE-PEGs) and subsequently binding streptavidin to the cell-incorporated PE-PEGs. Saturated dipalmitoyl-PE-PEG-streptavidin conjugates prepared in this manner partitioned substantially into the detergentin-soluble membrane fraction isolated from Jurkat or fibroblast cells, whereas polyunsaturated dilinoleoyl-PE-PEG-anchored conjugates were wholly excluded from this fraction, consistent with the differences in the affinities of the two types of lipid anchors for liquid-ordered membrane domains. Remarkably, however, antibody-mediated cross-linking of either dipalmitoyl- or dilinoleoyl-PE-PEG-anchored streptavidin conjugates in Jurkat cells induced elevation of cytoplasmic calcium levels and tyrosine phosphorylation of the scaffolding protein linker of T-cell activation in a manner similar to that observed upon cross-linking of endogenous CD59 or ganglioside GM1. The amplitude of the cross-linking-stimulated elevation of cytoplasmic calcium moreover showed an essentially identical dependence on the level of incorporated streptavidin conjugate for either type of lipid anchor. Confocal fluorescence microscopy revealed that PE-PEG-streptavidin conjugates with saturated versus polyunsaturated anchors showed very similar surface distributions vis a vis GM1 or CD59 under conditions where one or both species were cross-linked. These results indicate that cross-linking of diverse proteins anchored only to the outer leaflet of the plasma membrane can induce activation of Jurkat T-cell-signaling responses, but they appear to contradict previous suggestions that this phenomenon rests specifically on the association of such species with lipid rafts.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Silvius, JR (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	john.silvius@mcgill.ca						BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Brunschwig EB, 1999, J IMMUNOTHER, V22, P390, DOI 10.1097/00002371-199909000-00002; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; Burack WR, 2002, J IMMUNOL, V169, P2837, DOI 10.4049/jimmunol.169.6.2837; CINEK T, 1992, J IMMUNOL, V149, P2262; Civenni G, 1998, BLOOD, V91, P1784, DOI 10.1182/blood.V91.5.1784.1784_1784_1792; Comiskey M, 2003, HUM IMMUNOL, V64, P999, DOI 10.1016/j.humimm.2003.08.352; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Fenske DB, 2001, BBA-BIOMEMBRANES, V1512, P259, DOI 10.1016/S0005-2736(01)00327-3; FRA AM, 1994, J BIOL CHEM, V269, P30745; Giurisato E, 2003, J BIOL CHEM, V278, P6771, DOI 10.1074/jbc.M210758200; Glebov OO, 2004, NAT CELL BIOL, V6, P238, DOI 10.1038/ncb1103; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Ilangumaran S, 1997, BBA-BIOMEMBRANES, V1328, P227, DOI 10.1016/S0005-2736(97)00099-0; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Johnsson M, 2003, BIOPHYS J, V85, P3839, DOI 10.1016/S0006-3495(03)74798-5; Jordan S, 2003, J IMMUNOL, V171, P78, DOI 10.4049/jimmunol.171.1.78; Kato K, 2004, BIOTECHNOL PROGR, V20, P897, DOI 10.1021/bp0342093; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Loertscher R, 2002, TRANSPL IMMUNOL, V9, P93, DOI 10.1016/S0966-3274(02)00013-8; LOWRY RR, 1974, LIPIDS, V9, P491, DOI 10.1007/BF02534277; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Palmer LR, 2003, BBA-BIOMEMBRANES, V1611, P204, DOI 10.1016/S0005-2736(03)00058-0; Parmryd I, 2003, EXP CELL RES, V285, P27, DOI 10.1016/S0014-4827(02)00048-4; Pizzo P, 2004, MICROBES INFECT, V6, P686, DOI 10.1016/j.micinf.2004.02.017; Pizzo P, 2004, IMMUNOL LETT, V91, P3, DOI 10.1016/j.imlet.2003.09.008; Pizzo P, 2002, EUR J IMMUNOL, V32, P3082, DOI 10.1002/1521-4141(200211)32:11<3082::AID-IMMU3082>3.0.CO;2-2; Premkumar DRD, 2001, J CELL BIOCHEM, V82, P234, DOI 10.1002/jcb.1154; Rodgers W, 2001, EXP CELL RES, V267, P173, DOI 10.1006/excr.2001.5253; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SILVIUS JR, 1993, BIOCHEMISTRY-US, V32, P3153, DOI 10.1021/bi00063a030; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Tavano R, 2004, J IMMUNOL, V173, P5392, DOI 10.4049/jimmunol.173.9.5392; Tuosto L, 2001, EUR J IMMUNOL, V31, P345, DOI 10.1002/1521-4141(200102)31:2<345::AID-IMMU345>3.3.CO;2-C; VANDENBERG CW, 1995, J CELL BIOL, V131, P669, DOI 10.1083/jcb.131.3.669; Wang TY, 2000, BIOPHYS J, V79, P919, DOI 10.1016/S0006-3495(00)76347-8; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	51	46	46	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22839	22846		10.1074/jbc.M502920200	http://dx.doi.org/10.1074/jbc.M502920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15817446	hybrid			2022-12-27	WOS:000229741800036
J	Carmichael, JA; Lawrence, MC; Graham, LD; Pilling, PA; Epa, VC; Noyce, L; Lovrecz, G; Winkler, DA; Pawlak-Skrzecz, A; Eaton, RE; Hannan, GN; Hill, RJ				Carmichael, JA; Lawrence, MC; Graham, LD; Pilling, PA; Epa, VC; Noyce, L; Lovrecz, G; Winkler, DA; Pawlak-Skrzecz, A; Eaton, RE; Hannan, GN; Hill, RJ			The X-ray structure of a hemipteran ecdysone receptor ligand-binding domain - Comparison with a Lepidopteran ecdysone receptor ligand-binding domain and implications for insecticide design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ECDYSTEROID RECEPTOR; PROTEIN; CAVITIES; SEQUENCE; POCKET; ECR; ACTIVATION; REVEALS; PROGRAM	The ecdysone receptor is a hormone-dependent transcription factor that plays a central role in regulating the expression of vast networks of genes during development and reproduction in the phylum Arthropoda. The functional receptor is a heterodimer of the two nuclear receptor proteins ecdysone receptor (EcR) and ultraspiracle protein. The receptor is the target of the environmentally friendly bisacylhydrazine insecticides, which are effective against Lepidoptera but not against Hemiptera or several other insect orders. Here we present evidence indicating that much of the selectivity of the bisacylhydrazine insecticides can be studied at the level of their binding to purified ecdysone receptor ligand-binding domain (LBD) heterodimers. We report the crystal structure of the ecdysone receptor LBD heterodimer of the hemipteran Bemisia tabaci (Bt, sweet potato whitefly) in complex with the ecdysone analogue ponasterone A. Although comparison with the corresponding known LBD structure from the lepidopteran Heliothis virescens (Hv) ecdysone receptor revealed the overall mode of ponasterone A binding to be very similar in the two cases, we observed that the BtEcR ecdysteroid-binding pocket is structured differently to that of HvEcR in those parts that are not in contact with ponasterone A. We suggest that these differences in the ligand-binding pocket may provide a molecular basis for the taxonomic order selectivity of bisacylhydrazine insecticides.	CSIRO, Hlth Sci & Nutr, Parkville, Vic 3052, Australia; Commonwealth Sci & Ind Org, N Ryde, NSW 1670, Australia; Commonwealth Sci & Ind Org, Clayton S MDC, Vic 3169, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); Commonwealth Scientific & Industrial Research Organisation (CSIRO); Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Lawrence, MC (corresponding author), CSIRO, Hlth Sci & Nutr, 343 Royal Parade, Parkville, Vic 3052, Australia.	mike.lawrence@csiro.au; ron.hill@csiro.au	Lawrence, Michael C/A-5357-2009; Graham, Lloyd/A-1461-2008; Winkler, David/A-3774-2008; Pilling, Patricia/AAT-7845-2021	Graham, Lloyd/0000-0002-9778-1688; Winkler, David/0000-0002-7301-6076; Lawrence, Michael/0000-0003-1999-0801				Bahadur RP, 2004, J MOL BIOL, V336, P943, DOI 10.1016/j.jmb.2003.12.073; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bergman T, 2004, BIOCHEM J, V378, P779, DOI 10.1042/BJ20031302; Billas IML, 2003, NATURE, V426, P91, DOI 10.1038/nature02112; Billas IML, 2001, J BIOL CHEM, V276, P7465, DOI 10.1074/jbc.M008926200; Bonneton F, 2003, MOL BIOL EVOL, V20, P541, DOI 10.1093/molbev/msg054; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Clayton GM, 2001, P NATL ACAD SCI USA, V98, P1549, DOI 10.1073/pnas.041611298; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Dhadialla TS, 1998, ANNU REV ENTOMOL, V43, P545, DOI 10.1146/annurev.ento.43.1.545; Downes M, 2003, MOL CELL, V11, P1079, DOI 10.1016/S1097-2765(03)00104-7; Egea PF, 2002, MOL ENDOCRINOL, V16, P987, DOI 10.1210/me.16.5.987; Elzen GW, 2001, J ECON ENTOMOL, V94, P55, DOI 10.1603/0022-0493-94.1.55; Enmark E, 2001, TRENDS PHARMACOL SCI, V22, P611, DOI 10.1016/S0165-6147(00)01859-9; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Farnegardh M, 2003, J BIOL CHEM, V278, P38821, DOI 10.1074/jbc.M304842200; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Hannan GN, 1997, INSECT BIOCHEM MOLEC, V27, P479, DOI 10.1016/S0965-1748(97)00019-2; Hannan GN, 2001, INSECT BIOCHEM MOLEC, V31, P771, DOI 10.1016/S0965-1748(00)00182-X; Harmatha J, 1997, ARCH INSECT BIOCHEM, V35, P219, DOI 10.1002/(SICI)1520-6327(1997)35:1/2<219::AID-ARCH20>3.3.CO;2-Z; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; Hoerer S, 2003, J MOL BIOL, V334, P853, DOI 10.1016/j.jmb.2003.10.033; Hubbard SJ, 1995, PROTEIN ENG, V8, P1011, DOI 10.1093/protein/8.10.1011; HUBBARD SJ, 1994, PROTEIN ENG, V7, P613, DOI 10.1093/protein/7.5.613; Hubbard SJ, 1996, J MOL BIOL, V261, P289, DOI 10.1006/jmbi.1996.0460; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; Kumar MB, 2004, J BIOL CHEM, V279, P27211, DOI 10.1074/jbc.M403839200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; Lezzi M, 2002, EUR J BIOCHEM, V269, P3237, DOI 10.1046/j.1432-1033.2002.03001.x; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MCPHERSON A, 1982, PREPARATION ANAL PRO, P96; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mi LZ, 2003, MOL CELL, V11, P1093, DOI 10.1016/S1097-2765(03)00112-6; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; Riddiford L M, 2000, Vitam Horm, V60, P1, DOI 10.1016/S0083-6729(00)60016-X; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; Smagghe G, 2002, INSECT BIOCHEM MOLEC, V32, P187, DOI 10.1016/S0965-1748(01)00109-6; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Williams S, 2003, J BIOL CHEM, V278, P27138, DOI 10.1074/jbc.M302260200; WING KD, 1988, SCIENCE, V241, P470, DOI 10.1126/science.241.4864.470; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YUND MA, 1978, P NATL ACAD SCI USA, V75, P6039, DOI 10.1073/pnas.75.12.6039	57	90	97	5	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22258	22269		10.1074/jbc.M500661200	http://dx.doi.org/10.1074/jbc.M500661200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15809296	hybrid			2022-12-27	WOS:000229557900071
J	Chen, H; Tu, SW; Hsieh, JT				Chen, H; Tu, SW; Hsieh, JT			Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABERRANT PROMOTER METHYLATION; H3 LYSINE-27 METHYLATION; PROTEIN HDAB2IP GENE; METHYLTRANSFERASE ACTIVITY; PROLIFERATION; ESTABLISHMENT; REPRESSION; ENHANCER; STATES; SUZ12	Human DAB2IP ( hDAB2IP), a novel GTPase-activating protein modulating the Ras-mediated signaling and tumor necrosis factor-mediated apoptosis, is a potent growth inhibitor in human prostate cancer (PCa). Loss of hDAB2IP expression in PCa is due to altered epigenetic regulation (i.e. DNA methylation and histone modification) of its promoter region. The elevated polycomb Ezh2, a histone methyltransferase, has been associated with PCa progression. In this study, we have demonstrated that an increased Ezh2 expression in normal prostatic epithelial cells can suppress hDAB2IP gene expression. In contrast, knocking down the endogenous Ezh2 levels in PCa by a specific small interfering RNA can increase hDAB2IP expression. The association of Ezh2 complex (including Eed and Suz12) with hDAB2IP gene promoter is also detected in PCa cells but not in normal prostatic epithelial cells. Increased Ezh2 expression in normal prostatic epithelial cells by cDNA transfection facilitates the recruitment of other components of Ezh2 complex to the hDAB2IP promoter region accompanied with the increased levels of methyl histone H3 (H3) and histone deacetylase (HDAC1). Consistently, data from PCa cells transfected with Ezh2 small interfering RNA demonstrated that reduced Ezh2 levels resulted in the dissociation of Ezh2 complex accompanied with decreased levels of both methyl H3 and HDAC1 from hDAB2IP gene promoter. We further unveiled that the methylation status of Lys-27 but not Lys-9 of H3 in hDAB2IP promoter region is consistent with the hDAB2IP levels in both normal prostatic epithelial cells and PCa cells. Together, we conclude that hDAB2IP gene is a target gene of Ezh2 in prostatic epithelium, which provides an underlying mechanism of the down-regulation of hDAB2IP gene in PCa.	Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hsieh, JT (corresponding author), Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX 75390 USA.	JT.Hsieh@UTSouthwestern.edu						Bloyer S, 2003, DEV BIOL, V261, P426, DOI 10.1016/S0012-1606(03)00314-2; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Chen H, 2003, J BIOL CHEM, V278, P3121, DOI 10.1074/jbc.M208230200; Chen H, 2002, GENOMICS, V79, P573, DOI 10.1006/geno.2002.6739; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Dote H, 2004, CLIN CANCER RES, V10, P2082, DOI 10.1158/1078-0432.CCR-03-0236; Fong YY, 2002, SCIENCE, V296, P2235, DOI 10.1126/science.1070790; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Kelly WG, 2002, DEVELOPMENT, V129, P479; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Korenchuk S, 2001, IN VIVO, V15, P163; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Navone NM, 1997, CLIN CANCER RES, V3, P2493; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Oberley MJ, 2004, METHOD ENZYMOL, V376, P315; PAIK WK, 1971, SCIENCE, V174, P114, DOI 10.1126/science.174.4005.114; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Pirrotta V, 2003, GENETICA, V117, P191, DOI 10.1023/A:1022992011833; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5; Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Rossant J, 2001, Harvey Lect, V97, P17; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Sengupta AK, 2004, DEVELOPMENT, V131, P1959, DOI 10.1242/dev.01084; Sewalt RGAB, 2002, MOL CELL BIOL, V22, P5539, DOI 10.1128/MCB.22.15.5539-5553.2002; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; WEIJERMAN PC, 1994, CANCER RES, V54, P5579; Weijerman PC, 1998, UROLOGY, V51, P657, DOI 10.1016/S0090-4295(97)00696-1; Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200	45	177	188	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22437	22444		10.1074/jbc.M501379200	http://dx.doi.org/10.1074/jbc.M501379200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817459	hybrid			2022-12-27	WOS:000229557900089
J	Claperon, A; Rose, C; Gane, P; Collec, E; Bertrand, O; Ouimet, T				Claperon, A; Rose, C; Gane, P; Collec, E; Bertrand, O; Ouimet, T			The Kell protein of the common K2 phenotype is a catalytically active metalloprotease, whereas the rare Kell K1 antigen is inactive - Identification of novel substrates for the Kell protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIN-CONVERTING ENZYME-1; BLOOD-GROUP PROTEIN; MEMBRANE-BOUND METALLOPROTEASE; NEUTRAL ENDOPEPTIDASE-24.11; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; GROUP SYSTEM; NEPRILYSIN; INHIBITION; CELLS	Kell blood group is a highly polymorphic system containing over 20 different antigens borne by the protein Kell, a 93-kDa type II glycoprotein that displays high sequence homology with members of the M13 family of zinc-dependent metalloproteases whose prototypical member is neprilysin. Kell K1 is an antigen expressed in 9% of the Caucasian population, characterized by a point mutation (T193M) of the Kell K2 antigen, and located within a putative N-glycosylation consensus sequence. Recently, a recombinant, non-physiological, soluble form of Kell was shown to cleave Big ET-3 to produce the mature vasoconstrictive peptide. To better characterize the enzymatic activity of the Kell protein and the possible differences introduced by antigenic point mutations affecting post-translational processing, the membrane-bound forms of the Kell K1 and Kell K2 antigens were expressed either in K562 cells, an erythroid cell line, or in HEK293 cells, a non-erythroid system, and their pharmacological profiles and enzymatic specificities toward synthetic and natural peptides were evaluated. Results presented herein reveal that the two antigens possess considerable differences in their enzymatic activities, although not in their trafficking pattern. Indeed, although both antigens are expressed at the cell surface, Kell K1 protein is shown to be inactive, whereas the Kell K2 antigen binds neprilysin inhibitory compounds such as phosphoramidon and thiorphan with high affinity, cleaves the precursors of the endothelin peptides, and inactivates members of the tachykinin family with enzymatic properties resembling those of other members of the M13 family of metalloproteases to which it belongs.	Ctr Paul Broca, INSERM, U573, F-75014 Paris, France; Inst Natl Transfus Sanguine, INSERM, Groupement Interet Publ, UMRS 665, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Ouimet, T (corresponding author), Ctr Paul Broca, INSERM, U573, 2ter Rue Alesia, F-75014 Paris, France.	ouimet@broca.inserm.fr						BARETT AJ, 1998, HDB PROTEOLYTIC ENZY, P1033; Camara-Clayette V, 2001, BIOCHEM J, V356, P171, DOI 10.1042/0264-6021:3560171; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chu THT, 2001, BRIT J HAEMATOL, V113, P32, DOI 10.1046/j.1365-2141.2001.02695.x; Daniels GL, 1996, BLOOD, V88, P4045, DOI 10.1182/blood.V88.10.4045.bloodjournal88104045; Du L, 1996, GENOMICS, V36, P22, DOI 10.1006/geno.1996.0421; Eckman EA, 2001, J BIOL CHEM, V276, P24540, DOI 10.1074/jbc.M007579200; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; Facchinetti P, 2003, NEUROSCIENCE, V118, P627, DOI 10.1016/S0306-4522(02)01002-3; Gane P, 2001, BRIT J HAEMATOL, V113, P680, DOI 10.1046/j.1365-2141.2001.02757.x; GAVRAS H, 1978, NEW ENGL J MED, V298, P991, DOI 10.1056/NEJM197805042981803; Ghaddar G, 2000, BIOCHEM J, V347, P419, DOI 10.1042/0264-6021:3470419; GOOSSENS D, 1987, J IMMUNOL METHODS, V101, P193, DOI 10.1016/0022-1759(87)90150-5; GROS C, 1989, P NATL ACAD SCI USA, V86, P7580, DOI 10.1073/pnas.86.19.7580; HO MF, 1994, CELL, V77, P869, DOI 10.1016/0092-8674(94)90136-8; Ikeda K, 1999, J BIOL CHEM, V274, P32469, DOI 10.1074/jbc.274.45.32469; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; JABER A, 1991, BRIT J HAEMATOL, V79, P311, DOI 10.1111/j.1365-2141.1991.tb04539.x; Johnson GD, 1999, J BIOL CHEM, V274, P4053, DOI 10.1074/jbc.274.7.4053; KHAMLICHI S, 1995, EUR J BIOCHEM, V228, P931, DOI 10.1111/j.1432-1033.1995.0931m.x; Kiryu-Seo S, 2000, P NATL ACAD SCI USA, V97, P4345, DOI 10.1073/pnas.070509897; LAFRANCE MH, 1994, BIOCHEM J, V302, P451, DOI 10.1042/bj3020451; Lee S, 2000, SEMIN HEMATOL, V37, P113, DOI 10.1016/S0037-1963(00)90036-2; Lee S, 1999, BLOOD, V94, P1440, DOI 10.1182/blood.V94.4.1440.416k01_1440_1450; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; Lee S, 2003, BLOOD, V102, P3028, DOI 10.1182/blood-2003-05-1564; LEE SH, 1995, BLOOD, V85, P912, DOI 10.1182/blood.V85.4.912.bloodjournal854912; MALFROY B, 1978, NATURE, V276, P523, DOI 10.1038/276523a0; MARSH WL, 1990, TRANSFUSION, V30, P158, DOI 10.1046/j.1537-2995.1990.30290162904.x; MASOUREDIS S P, 1980, Haematologia, V13, P59; MATSAS R, 1983, P NATL ACAD SCI-BIOL, V80, P3111, DOI 10.1073/pnas.80.10.3111; MILGRAM SL, 1994, J CELL SCI, V107, P737; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; Oefner C, 2000, J MOL BIOL, V296, P341, DOI 10.1006/jmbi.1999.3492; Oefner PJ, 2002, J CHROMATOGR B, V782, P3, DOI 10.1016/S1570-0232(02)00699-2; Ouimet T, 2004, PROTEIN PEPTIDE LETT, V11, P479, DOI 10.2174/0929866043406625; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; PATEY G, 1981, SCIENCE, V212, P113, DOI 10.1126/science.7015510; Petrescu SM, 1997, J BIOL CHEM, V272, P15796, DOI 10.1074/jbc.272.25.15796; ROQUES BP, 1980, NATURE, V288, P286, DOI 10.1038/288286a0; Rose C, 2002, BIOCHEM J, V363, P697, DOI 10.1042/0264-6021:3630697; Russo D, 2000, BLOOD, V96, P340, DOI 10.1182/blood.V96.1.340.013k45_340_346; Russo D, 1999, BBA-BIOMEMBRANES, V1461, P10, DOI 10.1016/S0005-2736(99)00148-0; Russo D, 1998, J BIOL CHEM, V273, P13950, DOI 10.1074/jbc.273.22.13950; Savage P, 1998, J CARDIOVASC PHARM, V31, pS16, DOI 10.1097/00005344-199800001-00007; Schweizer A, 1999, J BIOL CHEM, V274, P20450, DOI 10.1074/jbc.274.29.20450; Shimada K, 1996, BIOCHEM J, V315, P863, DOI 10.1042/bj3150863; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; Tanja O, 2000, BIOCHEM BIOPH RES CO, V271, P565, DOI 10.1006/bbrc.2000.2664; Valdenaire O, 1999, MOL BRAIN RES, V64, P211, DOI 10.1016/S0169-328X(98)00321-0; Voisin S, 2004, J BIOL CHEM, V279, P46172, DOI 10.1074/jbc.M407333200; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	53	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21272	21283		10.1074/jbc.M500100200	http://dx.doi.org/10.1074/jbc.M500100200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15769748	hybrid			2022-12-27	WOS:000229438800046
J	Conner, SD; Schmid, SL				Conner, SD; Schmid, SL			CVAK104 is a novel poly-L-lysine-stimulated kinase that targets the beta 2-subunit of AP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED VESICLES; ENDOCYTOSIS IN-VITRO; PROTEIN-KINASES; PHOSPHORYLATION; BETA-2-ADAPTIN; IDENTIFICATION; APPENDAGE; REVEALS; COMPLEX; CDK5	Isolated clathrin adaptor protein (AP) preparations are known to co-fractionate with endogenous kinase activities, including poly-L-lysine-stimulated kinases that target various constituents of the clathrin coat. We have identified CVAK104 (a coated vesicle-associated kinase of 104 kDa) using a mass spectroscopic analysis of adaptor protein preparations. CVAK104 is a novel serine/threonine kinase that belongs to the SCY1-like family of protein kinases, previously thought to be catalytically inactive. We found that CVAK104 co-fractionates with adaptor protein preparations extracted from clathrin-coated vesicles and directly binds to both clathrin and the plasma membrane adaptor, AP2. CVAK104 binds ATP, and kinase assays indicate that it functions in vitro as a poly-L-lysine-stimulated kinase that is capable of autophosphorylation and phosphorylating the beta 2-adaptin subunit of AP2.	Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Minnesota System; University of Minnesota Twin Cities; Scripps Research Institute	Conner, SD (corresponding author), Univ Minnesota, Dept Genet Cell Biol & Dev, 6-160 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	sdconner@umn.edu		Schmid, Sandra/0000-0002-1690-7024	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH061345] Funding Source: NIH RePORTER; NIMH NIH HHS [R37-MH61345] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BALL CL, 1995, J CELL SCI, V108, P2865; BARZVI D, 1986, J BIOL CHEM, V261, P9614; Blondeau F, 2004, P NATL ACAD SCI USA, V101, P3833, DOI 10.1073/pnas.0308186101; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Conner SD, 2002, J CELL BIOL, V156, P921, DOI 10.1083/jcb.200108123; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cousin MA, 2001, TRENDS NEUROSCI, V24, P659, DOI 10.1016/S0166-2236(00)01930-5; GEORGIEVAHANSON V, 1988, J NEUROCHEM, V50, P307, DOI 10.1111/j.1471-4159.1988.tb13265.x; Greener T, 2000, J BIOL CHEM, V275, P1365, DOI 10.1074/jbc.275.2.1365; Hao WH, 1999, J BIOL CHEM, V274, P22785, DOI 10.1074/jbc.274.32.22785; Harlow E., 1988, ANTIBODIES LAB MANUA; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; Korolchuk VI, 2002, TRAFFIC, V3, P428, DOI 10.1034/j.1600-0854.2002.30606.x; Lauritsen JPH, 2000, BBA-MOL CELL RES, V1497, P297, DOI 10.1016/S0167-4889(00)00065-3; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Morgan JR, 2000, J NEUROSCI, V20, P8667; Olusanya O, 2001, CURR BIOL, V11, P896, DOI 10.1016/S0960-9822(01)00240-8; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; ROBINSON PJ, 1994, TRENDS NEUROSCI, V17, P348, DOI 10.1016/0166-2236(94)90179-1; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Turner KM, 1999, TRENDS NEUROSCI, V22, P459, DOI 10.1016/S0166-2236(99)01436-8; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635	35	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21539	21544		10.1074/jbc.M502462200	http://dx.doi.org/10.1074/jbc.M502462200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15809293	hybrid			2022-12-27	WOS:000229438800076
J	Merkel, M; Loeffler, B; Kluger, M; Fabig, N; Geppert, G; Pennacchio, LA; Laatsch, A; Heeren, J				Merkel, M; Loeffler, B; Kluger, M; Fabig, N; Geppert, G; Pennacchio, LA; Laatsch, A; Heeren, J			Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CHOLESTEROL LEVELS; GENE-CLUSTER; MICE; A5; HYPERTRIGLYCERIDEMIA; METABOLISM; CLEARANCE; MECHANISM; LIPOLYSIS	Apolipoprotein A5 (APOA5) is associated with differences in triglyceride levels and familial combined hyperlipidemia. In genetically engineered mice, apoAV plasma levels are inversely correlated with plasma triglycerides. To elucidate the mechanism by which apoAV influences plasma triglycerides, metabolic studies and in vitro assays resembling physiological conditions were performed. In human APOA5 transgenic mice (hAPOA5tr), catabolism of chylomicrons and very low density lipoprotein (VLDL) was accelerated due to a faster plasma hydrolysis of triglycerides by lipoprotein lipase (LPL). Hepatic VLDL and intestinal chylomicron production were not affected. The functional interplay between apoAV and LPL was further investigated by cross-breeding a human LPL transgene with the apoa5 knock-out and the hAPOA5tr to an lpl-deficient background. Increased LPL activity completely normalized hypertriglyceridemia of apoa5-deficient mice; however, overexpression of human apoAV modulated triglyceride levels only slightly when LPL was reduced. To reflect the physiological situation in which LPL is bound to cell surface proteoglycans, we examined hydrolysis in the presence or absence of proteoglycans. Without proteoglycans, apoAV derived either from triglyceride-rich lipoproteins, hAPOA5tr high density lipoprotein, or a recombinant source did not alter the LPL hydrolysis rate. In the presence of proteoglycans, however, apoAV led to a significant and dose-dependent increase in LPL-mediated hydrolysis of VLDL triglycerides. These results were confirmed in cell culture using a proteoglycan-deficient cell line. A direct interaction between LPL and apoAV was found by ligand blotting. It is proposed, that apoAV reduces triglyceride levels by guiding VLDL and chylomicrons to proteoglycan-bound LPL for lipolysis.	Univ Hamburg, Hosp Eppendorf, Dept Internal Med, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, IBM 2, D-20246 Hamburg, Germany; Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA	University of Hamburg; University of Hamburg; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Merkel, M (corresponding author), Univ Hamburg, Hosp Eppendorf, Dept Internal Med, Martinistr 52, D-20246 Hamburg, Germany.	merkel@uke.uni-hamburg.de		Merkel, Martin/0000-0002-2850-5110; Pennacchio, Len/0000-0002-8748-3732				AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; Baroukh N, 2004, ARTERIOSCL THROM VAS, V24, P1297, DOI 10.1161/01.ATV.0000130463.68272.1d; Beckstead JA, 2003, BIOCHEMISTRY-US, V42, P9416, DOI 10.1021/bi034509t; de Man FHAF, 1997, J LIPID RES, V38, P2465; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Evans D, 2003, J MOL MED-JMM, V81, P645, DOI 10.1007/s00109-003-0465-4; Fruchart-Najib J, 2004, BIOCHEM BIOPH RES CO, V319, P397, DOI 10.1016/j.bbrc.2004.05.003; Goldberg IJ, 1996, J LIPID RES, V37, P693; Groenendijk M, 2001, ATHEROSCLEROSIS, V157, P1, DOI 10.1016/S0021-9150(01)00539-1; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Heeren J, 2002, J MOL MED-JMM, V80, P576, DOI 10.1007/s00109-002-0351-5; Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014; Lai CQ, 2004, J LIPID RES, V45, P2096, DOI 10.1194/jlr.M400192-JLR200; LevakFrank S, 1997, J BIOL CHEM, V272, P17182, DOI 10.1074/jbc.272.27.17182; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; Merkel M, 2002, J BIOL CHEM, V277, P7405, DOI 10.1074/jbc.M107914200; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; O'Brien PJ, 2005, CLIN CHEM, V51, P351, DOI 10.1373/clinchem.2004.040824; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; Pennacchio LA, 2003, ARTERIOSCL THROM VAS, V23, P529, DOI 10.1161/01.ATV.0000054194.78240.45; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Pittman R C, 1986, Methods Enzymol, V129, P612; Sakurabayashi I, 2001, CLIN CHIM ACTA, V312, P87, DOI 10.1016/S0009-8981(01)00591-5; Schaap FG, 2004, J BIOL CHEM, V279, P27941, DOI 10.1074/jbc.M403240200; Talmud PJ, 2002, HUM MOL GENET, V11, P3039, DOI 10.1093/hmg/11.24.3039; van der Vliet HN, 2001, J BIOL CHEM, V276, P44512, DOI 10.1074/jbc.M106888200; Vergnes L, 2000, ARTERIOSCL THROM VAS, V20, P2267, DOI 10.1161/01.ATV.20.10.2267; Weinberg RB, 2003, J BIOL CHEM, V278, P34438, DOI 10.1074/jbc.M303784200; Weinstock PH, 1997, J LIPID RES, V38, P1782; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319	31	234	260	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21553	21560		10.1074/jbc.M411412200	http://dx.doi.org/10.1074/jbc.M411412200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15774484	hybrid			2022-12-27	WOS:000229438800078
J	Yamazaki, T; Sasaki, E; Kakinuma, C; Yano, T; Miura, S; Ezaki, O				Yamazaki, T; Sasaki, E; Kakinuma, C; Yano, T; Miura, S; Ezaki, O			Increased very low density lipoprotein secretion and gonadal fat mass in mice overexpressing liver DGAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA-CHOLESTEROL ACYLTRANSFERASE; B-CONTAINING LIPOPROTEINS; DIACYLGLYCEROL ACYLTRANSFERASE; ACYL-COENZYME; STIMULATES SECRETION; PLASMA-LIPOPROTEINS; OBESITY RESISTANCE; LEPTIN SENSITIVITY; ADIPOSE-TISSUE; INSULIN	Acyl-CoA:diacylglycerol acyltransferases (DGATs) catalyze the last step in triglyceride (TG) synthesis. The genes for two DGAT enzymes, DGAT1 and DGAT2, have been identified. To examine the roles of liver DGAT1 and DGAT2 in TG synthesis and very low density lipoprotein (VLDL) secretion, liver DGAT1- and DGAT2-overexpressing mice were created by adenovirus-mediated gene transfection. DGAT1-overexpressing mice had markedly increased DGAT activity in the presence of the permeabilizing agent alamethicin. This suggests that DGAT1 possesses latent DGAT activity on the lumen of the endoplasmic reticulum. DGAT1-overexpressing mice showed increased VLDL secretion, resulting in increased gonadal ( epididymal or parametrial) fat mass but not subcutaneous fat mass. The VLDL-mediated increase in gonadal fat mass might be due to the 4-fold greater expression of the VLDL receptor protein in gonadal fat than in subcutaneous fat. DGAT2-overexpressing mice had increased liver TG content, but VLDL secretion was not affected. These results indicate that DGAT1 but not DGAT2 has a role in VLDL synthesis and that increased plasma VLDL concentrations may promote obesity, whereas increased DGAT2 activity has a role in steatosis.	Natl Inst Hlth & Nutr, Div Clin Nutr, Shinjuku Ku, Tokyo 1628636, Japan; Mochida Pharmaceut Co Ltd, Shizuoka 4128524, Japan	National Institute of Health & Nutrition - Japan; Mochida Pharmaceutical Co Ltd	Ezaki, O (corresponding author), Natl Inst Hlth & Nutr, Div Clin Nutr, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628636, Japan.	ezaki@nih.go.jp	Miura, Shinji/K-6516-2013	Miura, Shinji/0000-0001-8806-9763				ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; Arion W J, 1976, J Biol Chem, V251, P4891; Buhman KK, 2001, J BIOL CHEM, V276, P40369, DOI 10.1074/jbc.R100050200; Cao JS, 2003, J BIOL CHEM, V278, P25657, DOI 10.1074/jbc.M302835200; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chen HC, 2003, J CLIN INVEST, V111, P1715, DOI [10.1172/JCI15859, 10.1172/JCI200315859]; Chen HC, 2003, AM J PHYSIOL-ENDOC M, V284, pE213, DOI 10.1152/ajpendo.00248.2002; Chen HC, 2002, J CLIN INVEST, V109, P1049, DOI [10.1172/JCI200214672, 10.1172/JCI0214672]; Chen HC, 2002, ENDOCRINOLOGY, V143, P2893, DOI 10.1210/en.143.8.2893; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fried SK, 2003, AM J CLIN NUTR, V78, p873S, DOI 10.1093/ajcn/78.4.873S; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; Ganji SH, 2004, J LIPID RES, V45, P1835, DOI 10.1194/jlr.M300403-JLR200; GIBBONS GF, 1995, ADV ENZYME REGUL, V35, P179, DOI 10.1016/0065-2571(94)00006-O; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; Goudriaan JR, 2001, ARTERIOSCL THROM VAS, V21, P1488, DOI 10.1161/hq0901.095147; HAMILTON RL, 1967, LAB INVEST, V16, P305; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; JONES AL, 1966, P SOC EXP BIOL MED, V123, P4; Joyce CW, 2000, MOL BIOL CELL, V11, P3675, DOI 10.1091/mbc.11.11.3675; KONO T, 1982, J BIOL CHEM, V257, P942; Liang JJ, 2004, J BIOL CHEM, V279, P44938, DOI 10.1074/jbc.M408507200; Lin S, 2003, MOL BIOL CELL, V14, P2447, DOI 10.1091/mbc.E02-11-0725; Meegalla RL, 2002, BIOCHEM BIOPH RES CO, V298, P317, DOI 10.1016/S0006-291X(02)02466-X; NORDLIE RC, 1966, METHOD ENZYMOL, V9, P619; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; Owen MR, 1997, BIOCHEM J, V323, P17, DOI 10.1042/bj3230017; SAMBROOK J, 1989, MOL CLONING LAB MANU, P187; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Siri P, 2001, J BIOL CHEM, V276, P46064, DOI 10.1074/jbc.M108909200; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200; Usui S, 2002, J LIPID RES, V43, P805; Waterman IJ, 2002, DIABETES, V51, P1708, DOI 10.2337/diabetes.51.6.1708; Waterman IJ, 2002, J LIPID RES, V43, P1555, DOI 10.1194/jlr.M200051-JLR200; Wiggins D, 1996, BIOCHEM J, V320, P673, DOI 10.1042/bj3200673; Yahagi N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/jbc.M201584200; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899; Zammit VA, 1996, BIOCHEM J, V314, P1, DOI 10.1042/bj3140001	44	114	126	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21506	21514		10.1074/jbc.M412989200	http://dx.doi.org/10.1074/jbc.M412989200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797871	hybrid			2022-12-27	WOS:000229438800072
J	Zhang, N; Ahsan, MH; Zhu, L; Sambucetti, LC; Purchio, AF; West, DB				Zhang, N; Ahsan, MH; Zhu, L; Sambucetti, LC; Purchio, AF; West, DB			NF-kB and not the MAPK signaling pathway regulates GADD45b expression during acute inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B; KINASE; PROTEIN; MYD118; JNK; SUPPRESSION; INHIBITION; ACTIVATION; INDUCTION; INTERACTS	The GADD45 ( growth arrest and DNA damage-inducible) family of genes is involved in the regulation of cell cycle progression and apoptosis. To study signaling pathways affecting GADD45b expression and to examine systematically in vivo the GADD45b expression in tissues following various toxic stresses, we created a transgenic mouse by fusing the GADD45b promoter to firefly luciferase (Gadd45b-luc). In vivo GADD45b expression was assessed by measuring the luciferase activity in the Gadd45b-luc transgenic mouse using a noninvasive imaging system (IVIS Imaging System, Xenogen Corporation). We found that a number of agents that induce oxidative stress, such as sodium arsenite, CC14, lipopolysaccharide (LPS), or tumor necrosis factor-a, are able to induce luciferase expression throughout the entire animal. In liver, spleen, lung, intestine, kidney, and heart, we observed an induction of luciferase activity after LPS treatment, which correlates with an increase of GADD45b mRNA in these tissues. Processes that induce DNA damage activate the NF-kB signaling pathway. Several inhibitors of the NF-kB signaling pathway, including dexamethasone, thalidomide, and a proteasome inhibitor, bortezomib, showed inhibitory effects on LPS-induced GADD45b expression as indicated by a decrease of the luciferase activity. Northern blot analysis confirmed a broad inhibitory effect of bortezomib on LPS-induced GADD45b mRNA expression in spleen, lung, and intestine. In liver of bortezomib-treated mice, we observed a reverse correlation between the luciferase activity and the GADD45b mRNA level. We speculate that such a discrepancy could be due to severe liver toxicity caused by bortezomib and LPS co-treatment. MAPK inhibitors had transient and inconsistent effects on LPS-induced luciferase expression. Our data are consistent with the notion that NF-kB, but not the MAPK signaling pathways, is involved in the in vivo regulation of GADD45b expression. Thus, NF-kB signaling involves induction of GADD45b expression, which supports the proposed role of GADD45b in protecting cells against DNA damaged under various stress conditions.	Xenogen Corp, Alameda, CA 94501 USA; Telik Inc, Palo Alto, CA 94304 USA		Zhang, N (corresponding author), Xenogen Corp, 860 Atlantic Ave, Alameda, CA 94501 USA.	ning.zhang@xenogen.com						ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Balliet AG, 2001, DNA CELL BIOL, V20, P239, DOI 10.1089/104454901750219125; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; Gebel T, 2000, TOXICOLOGY, V144, P155, DOI 10.1016/S0300-483X(99)00202-4; Jin RG, 2002, DNA CELL BIOL, V21, P491, DOI 10.1089/104454902320219059; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Keifer JA, 2001, J BIOL CHEM, V276, P22382, DOI 10.1074/jbc.M100938200; Lee EC, 2001, GENOMICS, V73, P56, DOI 10.1006/geno.2000.6451; Li QT, 2002, NAT REV IMMUNOL, V2, P975, DOI 10.1038/nri968; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Spiecker M, 2000, J IMMUNOL, V164, P3316, DOI 10.4049/jimmunol.164.6.3316; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Tan C, 2002, CANCER RES, V62, P1083; Tong T, 2001, EXP CELL RES, V269, P64, DOI 10.1006/excr.2001.5312; Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140; Vairapandi M, 1996, ONCOGENE, V12, P2579; Weber LWD, 2003, CRIT REV TOXICOL, V33, P105, DOI 10.1080/713611034; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Zazzeroni F, 2003, BLOOD, V102, P3270, DOI 10.1182/blood-2003-03-0689; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667	29	58	60	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21400	21408		10.1074/jbc.M411952200	http://dx.doi.org/10.1074/jbc.M411952200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797874	hybrid			2022-12-27	WOS:000229438800060
J	Feng, L; Yuan, J; Toogood, H; Tumbula-Hansen, D; Soll, D				Feng, L; Yuan, J; Toogood, H; Tumbula-Hansen, D; Soll, D			Aspartyl-tRNA synthetase requires a conserved proline in the anticodon-binding loop for tRNA(Asn) recognition in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMUS-THERMOPHILUS; ESCHERICHIA-COLI; ASPARAGINE; AMINOACYLATION; MECHANISM; EVOLUTION; IDENTITY	Most prokaryotes require Asp-tRNAAsn for the synthesis of Asn-tRNA(Asn). This misacylated tRNA species is synthesized by a non-discriminating aspartyl-tRNA synthetase (AspRS) that acylates both tRNA(Asp) and tRNA(Asn) with aspartate. In contrast, a discriminating AspRS forms only Asp-tRNA(Asp). Here we show that a conserved proline (position 77) in the L1 loop of the non-discriminating Deinococcus radiodurans AspRS2 is required for tRNA(Asn) recognition in vivo. Escherichia coli trpA34 was transformed with DNA from a library of D. radiodurans aspS2 genes with a randomized codon 77 and then subjected to in vivo selection for Asp-tRNA(Asn) formation by growth in minimal medium. Only proline codons were found at position 77 in the aspS2 genes isolated from 21 of the resulting viable colonies. However, when the aspS temperature-sensitive E. coli strain CS89 was transformed with the same DNA library and then screened for Asp-tRNA(Asp) formation in vivo by growth at the nonpermissive temperature, codons for seven other amino acids besides proline were identified at position 77 in the isolates examined. Thus, replacement of proline 77 by cysteine, isoleucine, leucine, lysine, phenylalanine, serine, or valine resulted in mutant D. radiodurans AspRS2 enzymes still capable of forming Asp-tRNA(Asp) but unable to recognize tRNA(Asn). This strongly suggests that proline 77 is responsible for the non-discriminatory tRNA recognition properties of this enzyme.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Yale University; Yale University	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.	soll@trna.chem.yale.edu		Toogood, Helen/0000-0003-4797-0293; Hansen, Debra T./0000-0003-4395-8297				Becker HD, 1996, BIOCHEMISTRY-US, V35, P7447, DOI 10.1021/bi9601058; Becker HD, 1998, P NATL ACAD SCI USA, V95, P12832, DOI 10.1073/pnas.95.22.12832; Berthet-Colominas C, 1998, EMBO J, V17, P2947, DOI 10.1093/emboj/17.10.2947; Brevet A, 2003, J BIOL CHEM, V278, P30927, DOI 10.1074/jbc.M302618200; Charron C, 2003, EMBO J, V22, P1632, DOI 10.1093/emboj/cdg148; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; Dock-Bregeon AC, 2004, MOL CELL, V16, P375, DOI 10.1016/S1097-2765(04)00591-X; Fechter P, 1998, FEBS LETT, V436, P99, DOI 10.1016/S0014-5793(98)01096-5; Feng L, 2003, P NATL ACAD SCI USA, V100, P5676, DOI 10.1073/pnas.0631525100; FENG L, 2004, AMINOACYL TRNA SYNTH, P314; Hendrickson TL, 2003, MOL B INT U, P34; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Kowal AK, 2001, P NATL ACAD SCI USA, V98, P2268, DOI 10.1073/pnas.031488298; Li T, 1999, FEBS LETT, V462, P302, DOI 10.1016/S0014-5793(99)01550-1; Min B, 2003, J BACTERIOL, V185, P3524, DOI 10.1128/JB.185.12.3524-3526.2003; Min B, 2002, P NATL ACAD SCI USA, V99, P2678, DOI 10.1073/pnas.012027399; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; SHARPLES GJ, 1991, MUTAT RES, V264, P93, DOI 10.1016/0165-7992(91)90122-K; SHIRVANEE L, 1990, J BIOL CHEM, V265, P6624; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; Tumbula-Hansen D, 2002, J BIOL CHEM, V277, P37184, DOI 10.1074/jbc.M204767200	22	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20638	20641		10.1074/jbc.M500874200	http://dx.doi.org/10.1074/jbc.M500874200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781458	hybrid			2022-12-27	WOS:000229242000060
J	Hsieh, TS; Capp, C				Hsieh, TS; Capp, C			Nucleotide- and stoichiometry-dependent DNA supercoiling by reverse gyrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-I; SUPERHELICAL TURNS; MECHANISM; SUBSTRATE; HELICASE; ENZYME; LATCH	Reverse gyrase is a unique type IA topoisomerase that can introduce positive supercoils into DNA. We have investigated some of the biochemical properties of Archaeoglobus fulgidus reverse gyrase. It can mediate three distinct supercoiling reactions depending on the adenine nucleotide cofactor that is present in the reaction. Besides the ATP-driven positive supercoiling reaction, the enzyme can introduce negative supercoils with a nonhydrolyzable analog, adenylyl imidodiphosphate. In the presence of ADP the plasmid DNA is relaxed almost completely, leaving a very low level of positive supercoiling. Surprisingly, the final supercoiling extent for all three distinct reactions depends on the stoichiometry of enzyme to DNA. This dependence is not due to the difference of reaction rate, suggesting that the amount of enzyme bound to DNA is an important determinant for the final supercoiling state of the reaction product. Reverse gyrase also displays exquisite sensitivity toward temperature. Raising the reaction temperatures from 80 to 85 degrees C, both of which are within the optimal growth temperature of A. fulgidus, greatly increases enzyme activity for all the supercoiling reactions. For the reaction with AMPPNP, the product is a hypernegatively supercoiled DNA. This dramatic enhancement of the reverse gyrase activity is also correlated with the appearance of DNA in a pre-melting state at 85 degrees C, likely due to the presence of extensively unwound regions in the plasmid. The possible mechanistic insights from these findings will be presented here.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hsieh, TS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	hsieh@biochem.duke.edu	Hsieh, Tao-shih/G-9305-2012; Wu, Wan-lin/G-8937-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029006] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM029006, GM29006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atomi H, 2004, J BACTERIOL, V186, P4829, DOI 10.1128/JB.186.14.4829-4833.2004; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; Declais AC, 2000, J BIOL CHEM, V275, P19498, DOI 10.1074/jbc.M910091199; Dekker NH, 2002, P NATL ACAD SCI USA, V99, P12126, DOI 10.1073/pnas.132378799; DELATOUR CB, 1990, J BACTERIOL, V172, P6803, DOI 10.1128/jb.172.12.6803-6808.1990; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; DUGUET M, 1993, NUCLEIC ACIDS RES, V21, P463, DOI 10.1093/nar/21.3.463; Duguet M, 2000, METH MOL B, V95, P35; Forterre P, 2002, TRENDS GENET, V18, P236, DOI 10.1016/S0168-9525(02)02650-1; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; HSIEH TS, 1975, BIOCHEMISTRY-US, V14, P527, DOI 10.1021/bi00674a011; HSIEH TS, 1992, NUCLEIC ACIDS RES, V20, P6177, DOI 10.1093/nar/20.23.6177; JAXEL C, 1989, EMBO J, V8, P3135, DOI 10.1002/j.1460-2075.1989.tb08466.x; Kampmann M, 2004, NUCLEIC ACIDS RES, V32, P3537, DOI 10.1093/nar/gkh683; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KIM RA, 1992, J BIOL CHEM, V267, P17178; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Krah R, 1996, P NATL ACAD SCI USA, V93, P106, DOI 10.1073/pnas.93.1.106; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; Plank JL, 2005, J BIOL CHEM, V280, P3564, DOI 10.1074/jbc.M411337200; Rodriguez AC, 2003, BIOCHEMISTRY-US, V42, P5993, DOI 10.1021/bi034188l; Rodriguez AC, 2002, J BIOL CHEM, V277, P29865, DOI 10.1074/jbc.M202853200; Rodriguez AC, 2002, EMBO J, V21, P418, DOI 10.1093/emboj/21.3.418; SHIBATA T, 1987, J BIOL CHEM, V262, P10419; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Viard T, 2001, J BIOL CHEM, V276, P46495, DOI 10.1074/jbc.M107714200; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831	30	23	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20467	20475		10.1074/jbc.M502739200	http://dx.doi.org/10.1074/jbc.M502739200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788400	hybrid			2022-12-27	WOS:000229242000039
J	Li, XF; Zhang, YZ; Kang, HS; Liu, WZ; Liu, P; Zhang, JG; Harris, SE; Wu, DQ				Li, XF; Zhang, YZ; Kang, HS; Liu, WZ; Liu, P; Zhang, JG; Harris, SE; Wu, DQ			Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN-5; HIGH-BONE-MASS; NEGATIVE REGULATOR; DICKKOPF PROTEINS; BMP ANTAGONIST; BETA-CATENIN; GENE; MUTATION; DENSITY; FAMILY	The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass. In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293T cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by overexpression of Wnt co-receptor low density lipoprotein receptor-related protein (LRP) 5. In addition, we found that sclerostin bound to LRP5 as well as LRP6 and identified the first two YWTD-EGF repeat domains of LRP5 as being responsible for the binding. Although these two repeat domains are required for transduction of canonical Wnt signals, canonical Wnt did not appear to compete with sclerostin for binding to LRP5. Examination of the expression of sclerostin and Wnt7b, an autocrine canonical Wnt, during primary calvarial osteoblast differentiation revealed that sclerostin is expressed at late stages of osteoblast differentiation coinciding with the expression of osteogenic marker osteocalcin and trailing after the expression of Wnt7b. Given the plethora of evidence indicating that canonical Wnt signaling stimulates osteogenesis, we believe that the high bone mass phenotype associated with the loss of sclerostin may be attributed, at least in part, to an increase in canonical Wnt signaling resulting from the reduction in sclerostin-mediated Wnt antagonism.	Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64108 USA; Univ Texas, Hlth Sci Ctr, Dept Periodont & Cellular Struct Biol, San Antonio, TX 78229 USA	University of Connecticut; University of Missouri System; University of Missouri Kansas City; University of Texas System; University of Texas Health San Antonio	Wu, DQ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, 263 Farmington Ave, Farmington, CT 06030 USA.							Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006-291X(02)02951-0; Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537; Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003-0498; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100-6110.2002; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Dale TC, 1998, BIOCHEM J, V329, P209; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gumbiner BM, 1998, CURR OPIN GENET DEV, V8, P430, DOI 10.1016/S0959-437X(98)80114-7; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Itasaki N, 2003, DEVELOPMENT, V130, P4295, DOI 10.1242/dev.00674; Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Kusu N, 2003, J BIOL CHEM, V278, P24113, DOI 10.1074/jbc.M301716200; Li L, 2002, J BIOL CHEM, V277, P5977, DOI 10.1074/jbc.M111131200; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Monaghan AP, 1999, MECH DEVELOP, V87, P45, DOI 10.1016/S0925-4773(99)00138-0; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Nusse R, 2001, NATURE, V411, P254, DOI 10.1038/35077199; Pandur P, 2001, BIOESSAYS, V23, P207, DOI 10.1002/1521-1878(200103)23:3<207::AID-BIES1029>3.0.CO;2-0; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454; Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277; Winkler DG, 2004, J BIOL CHEM, V279, P36293, DOI 10.1074/jbc.M400521200; Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200; Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419; Zhang YH, 2004, MOL CELL BIOL, V24, P4677, DOI 10.1128/MCB.24.11.4677-4684.2004	40	1012	1093	3	72	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19883	19887		10.1074/jbc.M413274200	http://dx.doi.org/10.1074/jbc.M413274200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15778503	hybrid			2022-12-27	WOS:000229113700057
J	Ezraty, B; Dahlgren, B; Deutscher, MP				Ezraty, B; Dahlgren, B; Deutscher, MP			The RNase Z homologue encoded by Escherichia coli elaC gene is RNase BN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL NUCLEOTIDES; PROCESSING ENZYME; PRECURSORS; MUTANT; EXORIBONUCLEASES; IDENTIFICATION; SUPPRESSOR; MATURATION; MOLECULES; K-12	In eukaryotes, archaea, and in some eubacteria, removal of 3' precursor sequences during maturation of tRNA is catalyzed by an endoribonuclease, termed RNase Z. In contrast, in Escherichia coli, a variety of exoribonucleases carry out final 3' maturation. Yet, E. coli retains an RNase Z homologue, ElaC, whose function is under active study. We have overexpressed and purified to homogeneity His-tagged ElaC and show here that it is, in fact, the previously described enzyme, RNase BN. Thus, purified ElaC displays structural and catalytic properties identical to those ascribed to RNase BN. In addition, an elaC mutant strain behaves identically to a known RNase BN- strain, CAN. Finally, we show that wild type elaC can complement the mutation in strain CAN and that the elaC gene in strain CAN carries a nonsense mutation that results in loss of RNase BN activity. These data correct a previous misassignment for the gene encoding RNase BN. Based on the fact that the original RNase BN mutation has now been identified, we propose that the elaC gene be renamed rbn.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Deutscher, MP (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA.	mdeutsch@med.miami.edu		Ezraty, Benjamin/0000-0003-3818-6907	NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHA PK, 1983, P NATL ACAD SCI-BIOL, V80, P3301, DOI 10.1073/pnas.80.11.3301; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Callahan C, 1996, J BACTERIOL, V178, P7329, DOI 10.1128/jb.178.24.7329-7332.1996; Cheng ZF, 2002, J BIOL CHEM, V277, P21624, DOI 10.1074/jbc.M202942200; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; de la Sierra-Gallay IL, 2005, NATURE, V433, P657, DOI 10.1038/nature03284; DEUTSCHER MP, 1984, CRC CR REV BIOCH MOL, V17, P45, DOI 10.3109/10409238409110269; DEUTSCHER MP, 1978, NUCLEIC ACIDS RES, V5, P3821, DOI 10.1093/nar/5.10.3821; Deutscher Murray P., 1995, P51; KELLY KO, 1992, J BACTERIOL, V174, P6682, DOI 10.1128/JB.174.20.6682-6684.1992; Li ZW, 2002, RNA, V8, P97, DOI 10.1017/S1355838202014929; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; MAISURIAN AN, 1973, MOL GEN GENET, V120, P227, DOI 10.1007/BF00267154; MAISURYAN AN, 1975, GENETIKA+, V11, P114; Minagawa A, 2004, J BIOL CHEM, V279, P15688, DOI 10.1074/jbc.M313951200; Morl M, 2001, EMBO REP, V2, P17, DOI 10.1093/embo-reports/kve006; Nashimoto M, 1997, NUCLEIC ACIDS RES, V25, P1148, DOI 10.1093/nar/25.6.1148; Pellegrini O, 2003, EMBO J, V22, P4534, DOI 10.1093/emboj/cdg435; Rudd KE, 2000, NUCLEIC ACIDS RES, V28, P60, DOI 10.1093/nar/28.1.60; Schiffer S, 2002, EMBO J, V21, P2769, DOI 10.1093/emboj/21.11.2769; Schilling O, 2005, J BIOL CHEM, V280, P17857, DOI 10.1074/jbc.M500591200; Schilling O, 2004, BIOCHEM BIOPH RES CO, V320, P1365, DOI 10.1016/j.bbrc.2004.05.227; SEIDMAN JG, 1975, CELL, V5, P389, DOI 10.1016/0092-8674(75)90058-6; Vogel A, 2002, J BIOL CHEM, V277, P29078, DOI 10.1074/jbc.M112047200; ZANIEWSKI R, 1984, J BIOL CHEM, V259, P1651; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	27	37	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16542	16545		10.1074/jbc.C500098200	http://dx.doi.org/10.1074/jbc.C500098200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15764599	hybrid			2022-12-27	WOS:000228615500002
J	Naryzhny, SN; Zhao, H; Lee, H				Naryzhny, SN; Zhao, H; Lee, H			Proliferating cell nuclear antigen (PCNA) may function as a double homotrimer complex in the mammalian cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-C; DNA-REPLICATION; CHROMATIN; PROTEINS; IDENTIFICATION; INHERITANCE; INTERACT; PARTNERS; REPAIR; CLAMP	The diverse function of proliferating cell nuclear antigen (PCNA) may be regulated by interactions with different protein partners. Interestingly, the binding sites for all known PCNA-associating proteins are on the outer surface or the C termini ("front") sides of the PCNA trimer. Using cell extracts and purified human PCNA protein, we show here that two PCNA homotrimers form a back-to-back doublet. Mutation analysis suggests that the Arg-5 and Lys-110 residues on the PCNA back side are the contact points of the two homotrimers in the doublet. Furthermore, short synthetic peptides encompassing either Arg-5 or Lys-110 inhibit double trimer formation. We also found that a PCNA double trimer, but not a homotrimer alone, can simultaneously accommodate chromatin assembly factor-1 and polymerase delta. Together, our data supports a model that chromatin remodeling by chromatin assembly factor-1 (and, possibly, many other cellular activities) are tightly coupled with DNA replication (and repair) through a PCNA double trimer complex.	NE Ontario Reg Canc Ctr, Dept Res, Sudbury, ON P3E 5J1, Canada		Lee, H (corresponding author), NE Ontario Reg Canc Ctr, Dept Res, 41 Ramsey Lake Rd, Sudbury, ON P3E 5J1, Canada.	hlee@hrsrh.on.ca	Naryzhny, Stanislav/D-1683-2012	Naryzhny, Stanislav/0000-0002-4102-3423				Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Ellison V, 2001, CELL, V106, P655, DOI 10.1016/S0092-8674(01)00498-6; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Henderson DS, 2000, GENETICS, V154, P1721; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Loor G, 1997, NUCLEIC ACIDS RES, V25, P5041, DOI 10.1093/nar/25.24.5041; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Matsumiya S, 2002, GENES CELLS, V7, P911, DOI 10.1046/j.1365-2443.2002.00572.x; Moggs JG, 2000, MOL CELL BIOL, V20, P1206, DOI 10.1128/MCB.20.4.1206-1218.2000; Naryzhny SN, 1996, ANAL BIOCHEM, V238, P50, DOI 10.1006/abio.1996.0249; Naryzhny SN, 2001, ELECTROPHORESIS, V22, P1764, DOI 10.1002/1522-2683(200105)22:9&lt;1764::AID-ELPS1764&gt;3.0.CO;2-V; Naryzhny SN, 2003, PROTEOMICS, V3, P930, DOI 10.1002/pmic.200300400; Naryzhny SN, 2004, J BIOL CHEM, V279, P20194, DOI 10.1074/jbc.M312850200; Ohta S, 2002, J BIOL CHEM, V277, P40362, DOI 10.1074/jbc.M206194200; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Pascal JM, 2004, NATURE, V432, P473, DOI 10.1038/nature03082; Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335; Schurtenberger P, 1998, J MOL BIOL, V275, P123, DOI 10.1006/jmbi.1997.1435; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; Stucki M, 2001, PROG NUCLEIC ACID RE, V65, P261; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	31	46	53	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13888	13894		10.1074/jbc.M500304200	http://dx.doi.org/10.1074/jbc.M500304200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15805117	hybrid			2022-12-27	WOS:000228095500088
J	Seeliger, MA; Spichty, M; Kelly, SE; Bycroft, M; Freund, SMV; Karplus, M; Itzhaki, LS				Seeliger, MA; Spichty, M; Kelly, SE; Bycroft, M; Freund, SMV; Karplus, M; Itzhaki, LS			Role of conformational heterogeneity in domain swapping and adapter function of the Cks proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE-REGULATORY PROTEIN; SIDE-CHAIN ENTROPY; CELL-CYCLE; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY; UBIQUITIN LIGASE; SACCHAROMYCES-CEREVISIAE; MUTATIONAL ANALYSIS; MOLECULAR-DYNAMICS; PLAUSIBLE MODEL	Cks proteins are adapter molecules that coordinate the assembly of multiprotein complexes. They share the ability to domain swap by exchanging a beta-strand, beta 4. Here we use NMR spectroscopy and molecular dynamics simulations to investigate the dynamic properties of human Cks1 and its response on assembly with components of the SCFSkp2 ubiquitin ligation machinery. In the NMR experiment with the free form of Cks1, a subset of residues displayed elevated R-2 values and the cross-peaks of neighboring residues were missing from the spectrum, indicating a substantial conformational exchange contribution on the microsecond to millisecond time scale. Strikingly the region of greatest conformational variability was the beta 4-strand that domain swaps to form the dimer. Binding of the ligand common to all Cks proteins, Cdk2, suppressed the conformational heterogeneity. This response was specific to Cdk2 binding; in contrast, binding of Skp2, a ligand unique to human Cks1, did not alter the dynamic behavior. Short time (< 5 ns) molecular dynamics simulations indicate that residues of Cks1 that form the binding site for phosphorylated ligands are considerably more flexible in the free form of Cks1 than they are in the Cdk2- Cks1 complex. A cooperative interaction between Cdk2 and Cks1 is suggested, which reduces the configurational entropy of Cks1 and therefore facilitates phosphoprotein binding. Indications of an unusual dynamic behavior of strand beta 4 in the free form of Cks1 were obtained from longer time scale ( 50 ns) dynamics simulations. A spontaneous reversible unzipping of hydrogen bonds between beta 4 and beta 2 was observed, suggesting an early intermediate structure for unfolding and/or domain swapping. We propose that the dynamic properties of the beta-sheet and its modification upon ligand binding underlie the domain swapping ability and the adapter function of Cks proteins.	Univ Cambridge, Chem Lab, MRC Ctr Prot Engn, Cambridge CB2 1EW, England; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Univ Strasbourg 1, Inst Sci & Ingn Supramol, F-67083 Strasbourg, France; Hutchison MRC Res Ctr, MRC Canc Cell Unit, Cambridge CB2 2XZ, England	MRC Laboratory Molecular Biology; University of Cambridge; Harvard University; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Freund, SMV (corresponding author), Univ Cambridge, Chem Lab, MRC Ctr Prot Engn, Lensfield Rd, Cambridge CB2 1EW, England.	smvf100@cus.cam.ac.uk; marci@tammy.harvard.edu; lsi10@cam.ac.uk	Bycroft, Mark/D-9446-2017; Seeliger, Markus A/D-6409-2013	Spichty, Martin/0000-0002-2533-9073; Bycroft, Mark/0000-0002-0673-2216; Seeliger, Markus/0000-0003-0990-1756				Alonso DOV, 2000, STRUCTURE, V8, P101, DOI 10.1016/S0969-2126(00)00083-6; Andricioaei I, 2001, J CHEM PHYS, V115, P6289, DOI 10.1063/1.1401821; ARVAI AS, 1995, J MOL BIOL, V249, P835, DOI 10.1006/jmbi.1995.0341; Barrientos LG, 2002, STRUCTURE, V10, P673, DOI 10.1016/S0969-2126(02)00758-X; BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010; BIRCK C, 1995, FEBS LETT, V363, P145, DOI 10.1016/0014-5793(95)00300-X; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Bourne Y, 2000, STRUCT FOLD DES, V8, P841, DOI 10.1016/S0969-2126(00)00175-1; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; BOURNE Y, 1995, P NATL ACAD SCI USA, V92, P10232, DOI 10.1073/pnas.92.22.10232; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROOKS CL, 1983, J CHEM PHYS, V79, P6312, DOI 10.1063/1.445724; Buchberger A, 2000, BIOCHEMISTRY-US, V39, P11137, DOI 10.1021/bi0008231; COOPER A, 1984, EUR BIOPHYS J BIOPHY, V11, P103, DOI 10.1007/BF00276625; Feher VA, 1999, NATURE, V400, P289, DOI 10.1038/22357; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; Fuentes EJ, 2004, J MOL BIOL, V335, P1105, DOI 10.1016/j.jmb.2003.11.010; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Gouet P, 1999, STRUCTURE, V7, P1517, DOI 10.1016/S0969-2126(00)88342-2; GRZESIEK S, 1993, J AM CHEM SOC, V115, P4369, DOI 10.1021/ja00063a068; KARPLUS M, 1981, MACROMOLECULES, V14, P325, DOI 10.1021/ma50003a019; Kay LE, 1998, NAT STRUCT BIOL, V5, P513, DOI 10.1038/755; Kay LE, 1996, BIOCHEMISTRY-US, V35, P361, DOI 10.1021/bi9522312; Kern D, 2003, CURR OPIN STRUC BIOL, V13, P748, DOI 10.1016/j.sbi.2003.10.008; Khandelwal P, 2002, BIOCHEMISTRY-US, V41, P11425, DOI 10.1021/bi026333l; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; Lazaridis T, 1999, PROTEINS, V35, P133, DOI 10.1002/(SICI)1097-0134(19990501)35:2<133::AID-PROT1>3.0.CO;2-N; Lee AL, 2000, NAT STRUCT BIOL, V7, P72; Lewis RJ, 2002, J MOL BIOL, V316, P235, DOI 10.1006/jmbi.2001.5331; Loh AP, 2001, BIOCHEMISTRY-US, V40, P4590, DOI 10.1021/bi002418f; Lukin JA, 2003, P NATL ACAD SCI USA, V100, P517, DOI 10.1073/pnas.232715799; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; McElroy C, 2002, J MOL BIOL, V323, P463, DOI 10.1016/S0022-2836(02)00940-3; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Morris MC, 2003, NATURE, V423, P1009, DOI 10.1038/nature01720; MOY FJ, 1994, BIOCHEMISTRY-US, V33, P10731, DOI 10.1021/bi00201a022; Odaert B, 2002, J BIOL CHEM, V277, P12375, DOI 10.1074/jbc.M111741200; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; Riek R, 2000, TRENDS BIOCHEM SCI, V25, P462, DOI 10.1016/S0968-0004(00)01665-0; Rousseau F, 1998, J MOL BIOL, V284, P503, DOI 10.1006/jmbi.1998.2173; Rousseau F, 2001, P NATL ACAD SCI USA, V98, P5596, DOI 10.1073/pnas.101542098; Schymkowitz JWH, 2001, NAT STRUCT BIOL, V8, P888, DOI 10.1038/nsb1001-888; Schymkowitz JWH, 2000, STRUCTURE, V8, P89, DOI 10.1016/S0969-2126(00)00084-8; Seeliger MA, 2003, NAT STRUCT BIOL, V10, P718, DOI 10.1038/nsb962; Seeliger MA, 2003, J MOL BIOL, V325, P189, DOI 10.1016/S0022-2836(02)01202-0; Seeliger MA, 2002, BIOCHEMISTRY-US, V41, P1202, DOI 10.1021/bi0113465; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V257, P12, DOI 10.1006/bbrc.1999.0409; Sitry D, 2002, J BIOL CHEM, V277, P42233, DOI 10.1074/jbc.M205254200; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Vitagliano L, 2002, PROTEINS, V46, P97, DOI 10.1002/prot.10033; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; Wand AJ, 2001, NAT STRUCT BIOL, V8, P926, DOI 10.1038/nsb1101-926; Wang CY, 2004, J MOL BIOL, V342, P525, DOI 10.1016/j.jmb.2004.07.001; Xu K, 2003, BIOCHEM J, V371, P957, DOI 10.1042/BJ20021722	58	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 26	2005	280	34					30448	30459		10.1074/jbc.M501450200	http://dx.doi.org/10.1074/jbc.M501450200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	957IC	15772084	hybrid, Green Submitted			2022-12-27	WOS:000231362500058
J	Thomas, EK; Nakamura, M; Wienke, D; Isacke, CM; Pozzio, A; Liang, P				Thomas, EK; Nakamura, M; Wienke, D; Isacke, CM; Pozzio, A; Liang, P			Endo180 binds to the C-terminal region of type I collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; MACROPHAGE MANNOSE RECEPTOR; GENE-EXPRESSION; DIFFERENTIAL DISPLAY; MESSENGER-RNA; TRANSMEMBRANE GLYCOPROTEIN; CELLULAR-TRANSFORMATION; TYROSINE KINASE; RAS; CELLS	Type I collagen is a fibril-forming heterotrimer composed of two alpha 1 and one alpha 2 chains and plays a crucial role in cell-matrix adhesion and cell differentiation. Through a comprehensive differential display screening of oncogenic ras target genes, we have shown that the alpha 1 chain of type I collagen (col1a1) is markedly down-regulated by the ras oncogene through the mitogen-activated protein kinase pathway. Although ras-transformed cells are no longer able to produce and secrete endogenous collagen, they can still adhere to exogenous collagen, suggesting that the cells express a collagen binding factor(s) on the cell surface. When the region of col1a1 encompassing the C-terminal glycine repeat and C-prodomain (amino acids 1000 - 1453) was affinity-labeled with human placental alkaline phosphatase, the secreted trimeric fusion protein could bind to the surface of Ras-transformed cells. Using biochemical purification followed by matrix-assisted laser desorption/ionization mass spectrometry analysis, we identified this collagen binding factor as Endo180 (uPARAP, CD280), a member of the mannose receptor family. Ectopic expression of Endo180 in CosE5 cells followed by in situ staining and quantitative binding assays confirmed that Endo180 indeed recognizes and binds to placental alkaline phosphatase. The interaction between Endo180 and the C-terminal region of type I collagen appears to play an important role in cell-matrix adhesion.	Vanderbilt Univ, Sch Med, Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Hypertens & Nephrol, Nashville, TN 37232 USA; Inst Canc Res, Chester Beatty Labs, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England	Vanderbilt University; Vanderbilt University; Vanderbilt University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Liang, P (corresponding author), Vanderbilt Univ, Sch Med, Ingram Canc Ctr, 658 Preston Res Bldg, Nashville, TN 37232 USA.	peng.liang@vanderbilt.edu		Isacke, Clare/0000-0002-9222-3345	NATIONAL CANCER INSTITUTE [R01CA094849] Funding Source: NIH RePORTER; NCI NIH HHS [R01 T32CA09592, R01 CA94849-01] Funding Source: Medline; Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Now		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Behrendt N, 2000, J BIOL CHEM, V275, P1993, DOI 10.1074/jbc.275.3.1993; Bernocco S, 2001, J BIOL CHEM, V276, P48930, DOI 10.1074/jbc.M108611200; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; COHEN RL, 1989, J BIOL CHEM, V264, P8375; Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200; East L, 2003, EMBO REP, V4, P710, DOI 10.1038/sj.embor.embor882; East L, 2002, BBA-GEN SUBJECTS, V1572, P364, DOI 10.1016/S0304-4165(02)00319-7; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; EIZENBERG O, 1991, BIOCHIM BIOPHYS ACTA, V1129, P34, DOI 10.1016/0167-4781(91)90209-5; Engelholm LH, 2003, J CELL BIOL, V160, P1009, DOI 10.1083/jcb.200211091; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISACKE CM, 1990, MOL CELL BIOL, V10, P2606, DOI 10.1128/MCB.10.6.2606; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kadler KE, 1996, BIOCHEM J, V316, P1; KIARIS H, 1995, BIOCHEM BIOPH RES CO, V214, P788, DOI 10.1006/bbrc.1995.2355; Kjoller L, 2004, EXP CELL RES, V293, P106, DOI 10.1016/j.yexcr.2003.10.008; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEVINE EM, 1965, P NATL ACAD SCI USA, V53, P350, DOI 10.1073/pnas.53.2.350; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1994, P NATL ACAD SCI USA, V91, P12515, DOI 10.1073/pnas.91.26.12515; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Mousavi SA, 2005, BIOCHEM J, V387, P39, DOI 10.1042/BJ20040966; Myllyharju J, 1997, J BIOL CHEM, V272, P21824, DOI 10.1074/jbc.272.35.21824; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pozzi M, 1998, J CELL BIOL, V142, P587; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; Sheikh H, 2000, J CELL SCI, V113, P1021; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; Stein S, 2002, CELL MOL LIFE SCI, V59, P1274, DOI 10.1007/s00018-002-8506-7; TAN JC, 1995, J BIOL CHEM, V270, P12906, DOI 10.1074/jbc.270.21.12906; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; Wienke D, 2003, MOL BIOL CELL, V14, P3592, DOI 10.1091/mbc.E02-12-0814; Wu K, 1996, J BIOL CHEM, V271, P21323, DOI 10.1074/jbc.271.35.21323; Yang ST, 2004, MOL BIOTECHNOL, V27, P197, DOI 10.1385/MB:27:3:197; Zhang R, 1997, ONCOGENE, V14, P1607, DOI 10.1038/sj.onc.1200957; Zhang R, 2000, J BIOL CHEM, V275, P24436, DOI 10.1074/jbc.M001958200	56	30	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22596	22605		10.1074/jbc.M501155200	http://dx.doi.org/10.1074/jbc.M501155200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15817460	hybrid			2022-12-27	WOS:000229741800008
J	McMullen, ME; Bryant, PW; Glembotski, CC; Vincent, PA; Pumiglia, KM				McMullen, ME; Bryant, PW; Glembotski, CC; Vincent, PA; Pumiglia, KM			Activation of p38 has opposing effects on the proliferation and migration of endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PHOSPHATASE-1; N-TERMINAL KINASE; MAP KINASE; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; C-JUN; SMOOTH-MUSCLE; TNF-ALPHA; FOCAL ADHESION; POTENTIAL ROLE	Pathological conditions such as hypertension and hyper-glycemia as well as abrasions following balloon angioplasty all lead to endothelial dysfunction that impacts disease morbidity. These conditions are associated with the elaboration of a variety of cytokines and increases in p38 activity in endothelial cells. However, the relationship between enhanced p38 activity and endothelial cell function remains poorly understood. To investigate the effect of enhanced p38 MAPK activity on endothelial cell function, we expressed an activated mutant of MEK6 (MEK6E), an upstream regulator of p38. Expression of MEK6E activated p38 and resulted in phosphorylation of its downstream substrate, heat shock protein 27 (Hsp27). Activation of p38 was not sufficient to induce apoptosis; however, it did induce p38-dependent cell cycle arrest. MEK6E expression was sufficient to inhibit ERK phosphorylation triggered by growth factors and integrin engagement. MAPK phosphatase-1 (MKP-1) expression was increased upon p38 activation, and expression of a "substrate-trapping" MKP-1 was sufficient to restore ERK activity. Activation of p38 was sufficient to induce cell migration, which was accompanied by alterations in actin architecture characterized by enhanced lamellipodia. Co-expression of a mutant form of Hsp27, lacking all three phosphorylation sites, reversed MEK6E-induced cell migration and altered the cytoskeletal changes induced by p38 activation. Collectively, these results suggest that cellular decisions regarding migration and proliferation are influenced by p38 activity and that prolonged activation of p38 may result in an anti-angiogenic phenotype that contributes to endothelial dysfunction.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA; San Diego State Univ, Inst Heart, San Diego, CA 92182 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	Albany Medical College; Albany Medical College; California State University System; San Diego State University; California State University System; San Diego State University	Pumiglia, KM (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave,MC 165, Albany, NY 12208 USA.	pumiglk@mail.amc.edu		Pumiglia, Kevin/0000-0003-4655-0334	NCI NIH HHS [CA-90653, R01-CA-81419, R01 CA081419, R01 CA081419-06] Funding Source: Medline; NHLBI NIH HHS [HL075573, T32-HL-07194] Funding Source: Medline; NINDS NIH HHS [NS/HL20537] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081419, R01CA090653] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075573, T32HL007194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Avdi NJ, 2002, J BIOL CHEM, V277, P40687, DOI 10.1074/jbc.M204455200; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garcia JGN, 2002, FASEB J, V16, P1064, DOI 10.1096/fj.01-0895com; Gerthoffer WT, 2001, J APPL PHYSIOL, V91, P963, DOI 10.1152/jappl.2001.91.2.963; Goldberg PL, 2002, AM J PHYSIOL-LUNG C, V282, pL146, DOI 10.1152/ajplung.2002.282.1.L146; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Guo YL, 2001, J CELL BIOCHEM, V82, P556, DOI 10.1002/jcb.1180; Harnois C, 2004, J CELL PHYSIOL, V198, P209, DOI 10.1002/jcp.10399; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Hoover HE, 2000, J BIOL CHEM, V275, P23825, DOI 10.1074/jbc.M003864200; Horowitz JC, 2004, J BIOL CHEM, V279, P1359, DOI 10.1074/jbc.M306248200; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Issbrucker K, 2002, FASEB J, V16, P262, DOI 10.1096/fj.02-0329fje; Ju HS, 2003, J PHARMACOL EXP THER, V307, P932, DOI 10.1124/jpet.103.057422; Kevil CG, 2001, ENDOTHELIUM-J ENDOTH, V8, P107, DOI 10.3109/10623320109165320; Kim MS, 2003, CANCER RES, V63, P5454; Kishore R, 2003, CIRC RES, V93, P932, DOI 10.1161/01.RES.0000102400.22370.20; Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Matsumoto T, 2002, J CELL BIOL, V156, P149, DOI 10.1083/jcb.200103096; McGinn S, 2003, AM J PHYSIOL-ENDOC M, V285, pE708, DOI 10.1152/ajpendo.00572.2002; McMullen M, 2004, ONCOGENE, V23, P1275, DOI 10.1038/sj.onc.1207243; Meadows KN, 2004, ONCOGENE, V23, P192, DOI 10.1038/sj.onc.1206921; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; Mudgett JS, 2000, P NATL ACAD SCI USA, V97, P10454, DOI 10.1073/pnas.180316397; Nakagami H, 2001, DIABETES, V50, P1472, DOI 10.2337/diabetes.50.6.1472; Pervin S, 2003, CANCER RES, V63, P8853; Pichon S, 2004, J CELL SCI, V117, P2569, DOI 10.1242/jcs.01110; Piotrowicz RS, 1998, FASEB J, V12, P1481, DOI 10.1096/fasebj.12.14.1481; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Pratt PF, 2003, J BIOL CHEM, V278, P51928, DOI 10.1074/jbc.M309256200; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Reddy ST, 2004, ARTERIOSCL THROM VAS, V24, P1676, DOI 10.1161/01.ATV.0000138342.94314.64; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sandberg EM, 2004, J BIOL CHEM, V279, P1956, DOI 10.1074/jbc.M303540200; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 2001, J CELL SCI, V114, P2553; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sheetz MJ, 2002, JAMA-J AM MED ASSOC, V288, P2579, DOI 10.1001/jama.288.20.2579; Song C, 2002, J NEUROCHEM, V83, P828, DOI 10.1046/j.1471-4159.2002.01182.x; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Uddin S, 2004, P NATL ACAD SCI USA, V101, P147, DOI 10.1073/pnas.0307075101; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yashima R, 2001, J CELL PHYSIOL, V188, P201, DOI 10.1002/jcp.1107; Zhang XC, 2003, J BIOL CHEM, V278, P22061, DOI 10.1074/jbc.M301858200; Zhu WH, 2002, AM J PATHOL, V161, P823, DOI 10.1016/S0002-9440(10)64242-3	63	117	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20995	21003		10.1074/jbc.M407060200	http://dx.doi.org/10.1074/jbc.M407060200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15790570	hybrid			2022-12-27	WOS:000229438800013
J	Chowdhury, AK; Watkins, T; Parinandi, NL; Saatian, B; Kleinberg, ME; Usatyuk, PV; Natarajan, V				Chowdhury, AK; Watkins, T; Parinandi, NL; Saatian, B; Kleinberg, ME; Usatyuk, PV; Natarajan, V			Src-mediated tyrosine phosphorylation of p47(phox) in hyperoxia-induced activation of NADPH oxidase and generation of reactive oxygen species in lung endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; PROTEIN-KINASE-C; VASCULAR NAD(P)H OXIDASES; SUPEROXIDE-PRODUCTION; DIABETIC-NEPHROPATHY; MOLECULAR-MECHANISM; COMPONENT P47(PHOX); ARACHIDONIC-ACID; PHOSPHOLIPASE-D; ANGIOTENSIN-II	Superoxide (O-2(.)) production by nonphagocytes, similar to phagocytes, is by activation of the NADPH oxidase multicomponent system. Although activation of neutrophil NADPH oxidase involves extensive serine phosphorylation of p47(phox), the role of tyrosine phosphorylation of p47(phox) in NADPH oxidase-dependent O-2(.) production is unclear. We have shown recently that hyperoxia-induced NADPH oxidase activation in human pulmonary artery endothelial cells (HPAECs) is regulated by mitogen-activated protein kinase signal transduction. Here we provided evidence on the role of nonreceptor tyrosine kinase, Src, in hyperoxia-induced tyrosine phosphorylation of p47(phox) and NADPH oxidase activation in HPAECs. Exposure of HPAECs to hyperoxia for 1 h resulted in increased O-2(.). and reactive oxygen species (ROS) production and enhanced tyrosine phosphorylation of Src as determined by Western blotting with phospho-Src antibodies. Pretreatment of HPAECs with the Src kinase inhibitor PP2 (1 mu M) or transient expression of a dominant-negative mutant of Src attenuated hyperoxia-induced tyrosine phosphorylation of Src and ROS production. Furthermore, exposure of cells to hyperoxia enhanced tyrosine phosphorylation of p47(phox) and its translocation to cell peripheries that were attenuated by PP2. In vitro, Src phosphorylated recombinant p47(phox) in a time-dependent manner. Src immunoprecipitates of cell lysates from control cells revealed the presence of immunodetectable p47(phox) and p67(phox), suggesting the association of oxidase components with Src under basal conditions. Moreover, exposure of HPAECs to hyperoxia for 1 h enhanced the association of p47(phox), but not p67(phox), with Src. These results indicated that Src-dependent tyrosine phosphorylation of p47(phox) regulates hyperoxia-induced NADPH oxidase activation and ROS production in HPAECs.	Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Dept Med, Baltimore, MD 21224 USA; Ohio State Univ, Dept Med, Div Pulm Crit Care & Sleep, Columbus, OH 43210 USA; Univ Maryland, Sch Med, Div Infect Dis, Baltimore, MD 21201 USA	Johns Hopkins University; University System of Ohio; Ohio State University; University System of Maryland; University of Maryland Baltimore	Natarajan, V (corresponding author), Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Dept Med, Mason F Lord Bldg,Ctr Tower,Rm 675,5200 Eastern A, Baltimore, MD 21224 USA.	vnataraj@jhmi.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069909, P01HL058064] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 69909, P01 HL 58064] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1992, J BIOL CHEM, V267, P16767; Ago T, 2003, P NATL ACAD SCI USA, V100, P4474, DOI 10.1073/pnas.0735712100; Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730; Babior BM, 2002, ANTIOXID REDOX SIGN, V4, P35, DOI 10.1089/152308602753625834; Babior BM, 2000, IUBMB LIFE, V50, P267, DOI 10.1080/15216540051080976; Barazzone C, 1998, AM J RESP CELL MOL, V19, P573, DOI 10.1165/ajrcmb.19.4.3173; Cai H, 2003, TRENDS PHARMACOL SCI, V24, P471, DOI 10.1016/S0165-6147(03)00233-5; Capellier G, 1999, Minerva Anestesiol, V65, P388; Chen QD, 2003, J IMMUNOL, V170, P5302, DOI 10.4049/jimmunol.170.10.5302; Clark L A, 1999, Respir Care Clin N Am, V5, P203; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; Dodd-O JM, 2000, AM J PHYSIOL-HEART C, V279, pH303, DOI 10.1152/ajpheart.2000.279.1.H303; Edwards Steven W., 1996, Methods (Orlando), V9, P563, DOI 10.1006/meth.1996.0064; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; Fisher AB, 1999, CHEST, V116, p25S, DOI 10.1378/chest.116.suppl_1.25S; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; Frey RS, 2002, CIRC RES, V90, P1012, DOI 10.1161/01.RES.0000017631.28815.8E; Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; Hohler B, 2000, HISTOCHEM CELL BIOL, V114, P29; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Iyer S, 1996, J NEUROSCI RES, V46, P531, DOI 10.1002/(SICI)1097-4547(19961201)46:5<531::AID-JNR2>3.0.CO;2-K; Jacobson JR, 2004, AM J RESP CELL MOL, V30, P662, DOI 10.1165/rcmb.2003-0267OC; Kitada M, 2003, DIABETES, V52, P2603, DOI 10.2337/diabetes.52.10.2603; Lal AS, 1999, BIOCHEM J, V338, P359, DOI 10.1042/0264-6021:3380359; Lassegue B, 2003, AM J PHYSIOL-REG I, V285, pR277, DOI 10.1152/ajpregu.00758.2002; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; Li JM, 2003, J AM SOC NEPHROL, V14, pS221, DOI 10.1097/01.ASN.0000077406.67663.E7; Li JM, 2001, CARDIOVASC RES, V52, P477, DOI 10.1016/S0008-6363(01)00407-2; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Meyer JW, 2000, FEBS LETT, V472, P1, DOI 10.1016/S0014-5793(00)01397-1; Oeckler RA, 2003, CIRC RES, V92, P23, DOI 10.1161/01.RES.0000051860.84509.CE; Parinandi NL, 2001, ARCH BIOCHEM BIOPHYS, V396, P231, DOI 10.1006/abbi.2001.2609; PARINANDI NL, 2002, AM J PHYSIOL, V284, P626; Peng GH, 2003, BIOCHEM J, V373, P221, DOI 10.1042/BJ20021629; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Robinson JM, 2004, HISTOCHEM CELL BIOL, V122, P273, DOI 10.1007/s00418-004-0702-0; Roy S, 2003, ANTIOXID REDOX SIGN, V5, P217, DOI 10.1089/152308603764816578; Seshiah PN, 2002, CIRC RES, V91, P406, DOI 10.1161/01.RES.0000033523.08033.16; Shi S, 2000, AM J PHYSIOL-LUNG C, V279, pL441, DOI 10.1152/ajplung.2000.279.3.L441; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Takeya R, 2003, MOL CELLS, V16, P271; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Touyz RM, 2003, ARTERIOSCL THROM VAS, V23, P981, DOI 10.1161/01.ATV.0000069236.27911.68; Usatyuk PV, 2004, J BIOL CHEM, V279, P11789, DOI 10.1074/jbc.M311184200; Wei ZH, 1999, CIRC RES, V85, P682, DOI 10.1161/01.RES.85.8.682; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yuzawa S, 2004, GENES CELLS, V9, P443, DOI 10.1111/j.1356-9597.2004.00733.x	53	122	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20700	20711		10.1074/jbc.M411722200	http://dx.doi.org/10.1074/jbc.M411722200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15774483	hybrid			2022-12-27	WOS:000229242000068
J	Hasan, UA; Trinchieri, G; Vlach, J				Hasan, UA; Trinchieri, G; Vlach, J			Toll-like receptor signaling stimulates cell cycle entry and progression in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INHIBITOR P27(KIP1); LAMINA PROPRIA FIBROBLASTS; KAPPA-B ACTIVATION; GROWTH ARREST; PHOSPHORYLATION; P27; LOCALIZATION; DEGRADATION; INDUCTION; LIPOPOLYSACCHARIDE	Toll-like receptors (TLRs) are proteins involved in recognition of foreign pathogen-associated molecular patterns and activation of processes leading to innate immune recognition. We show that stimulation of fibroblasts with a TLR5 ligand, flagellin, can induce proliferation of serum-starved cells or prevent cell cycle exit upon serum withdrawal independently of autologous growth factor secretion. Other TLR ligands, such as poly(I:C) and lipopolysaccharide, can have a similar effect only if the action of type I interferons is blocked. Flagellin stimulation can prevent cell cycle arrest induced by overexpression of exogenous cyclin-dependent kinase inhibitor p27. Stimulation of TLR5 and overexpression of MyD88, but not TRIF, TIRAP, or TRAM, result in p27 degradation, which can be suppressed by dominant negative Akt and mutation of the p27 C-terminal Thr(187) site. These data provide evidence for a nonimmune and cell autonomous role of TLR signaling, whereby TLR stimulation provides a positive signal for cell division.	Schering Plough Lab Immunol Res, F-69571 Dardilly, France	Merck & Company	Hasan, UA (corresponding author), Int Agcy Res Canc, Infect & Canc Biol Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	Hasan@iarc.fr	hasan, uzma A/G-3247-2013; Trinchieri, Giorgio/F-9369-2015	Trinchieri, Giorgio/0000-0001-5892-7464; Hasan, Uzma/0000-0002-1770-5539				Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chakravortty D, 1997, BIOCHEM BIOPH RES CO, V240, P458, DOI 10.1006/bbrc.1997.7680; Chakravortty D, 1999, MICROBIOL IMMUNOL, V43, P527, DOI 10.1111/j.1348-0421.1999.tb02438.x; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Gewirtz AT, 2003, CURR PHARM DESIGN, V9, P1, DOI 10.2174/1381612033392422; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Hasan UA, 2004, BIOCHEM BIOPH RES CO, V321, P124, DOI 10.1016/j.bbrc.2004.06.134; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; MaasSzabowski N, 1996, J INVEST DERMATOL, V107, P849, DOI 10.1111/1523-1747.ep12331158; Ojaniemi M, 2003, EUR J IMMUNOL, V33, P597, DOI 10.1002/eji.200323376; Pagano M, 2004, MOL CELL, V14, P414, DOI 10.1016/S1097-2765(04)00268-0; Piazuelo E, 2000, EUR SURG RES, V32, P191, DOI 10.1159/000008762; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Srivastava SK, 2004, CARCINOGENESIS, V25, P1701, DOI 10.1093/carcin/bgh179; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Ulevitch RJ, 2004, NAT REV IMMUNOL, V4, P512, DOI 10.1038/nri1396; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Vivarelli MS, 2004, J EXP MED, V200, P399, DOI 10.1084/jem.20040446; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x	35	69	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20620	20627		10.1074/jbc.M500877200	http://dx.doi.org/10.1074/jbc.M500877200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788393	hybrid			2022-12-27	WOS:000229242000058
J	Kahlig, H; Kolarich, D; Zayni, S; Scheberl, A; Kosma, P; Schaffer, C; Messner, P				Kahlig, H; Kolarich, D; Zayni, S; Scheberl, A; Kosma, P; Schaffer, C; Messner, P			N-acetylmuramic acid as capping element of alpha-D-fucose-containing S-layer glycoprotein glycans from Geobacillus tepidamans GS5-97(T)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-SPECIFIC POLYSACCHARIDE; STEAROTHERMOPHILUS NRS 2004/3A; LINKAGE REGION; STRUCTURAL-CHARACTERIZATION; LIPOPOLYSACCHARIDE; CHAIN; STRAINS; TYROSINE; CORE; IDENTIFICATION	Geobacillus tepidamans GS5-97(T) is a novel Gram-positive, moderately thermophilic bacterial species that is covered by a glycosylated surface layer (S-layer) protein. The isolated and purified S-layer glycoprotein SgtA was ultrastructurally and chemically investigated and showed several novel properties. By SDS-PAGE, SgtA was separated into four distinct bands in an apparent molecular mass range of 106-166 kDa. The three high molecular mass bands gave a positive periodic acid-Schiff staining reaction, whereas the 106-kDa band was nonglycosylated. Glycosylation of SgtA was investigated by means of chemical analyses, 600-MHz nuclear magnetic resonance spectroscopy, and electrospray ionization quadrupole time-of-fight mass spectrometry. Glycopeptides obtained after Pronase digestion revealed the glycan structure [-> 2)-alpha-L-Rhap-(1 -> 3)-alpha-D-Fucp-(1 ->](n= similar to 20), with D-fucopyranose having never been identified before as a constituent of S-layer glycans. The rhamnose residue at the nonreducing end of the terminal repeating unit of the glycan chain was di-substituted. For the first time, (R)-N-acetylmuramic acid, the key component of prokaryotic peptidoglycan, was found in an alpha-linkage to carbon 3 of the terminal rhamnose residue, serving as capping motif of an S-layer glycan. In addition, that rhamnose was substituted at position 2 with a beta-N-acetylglucosamine residue. The S-layer glycan chains were bound via the trisaccharide core -> 2)-alpha-L-Rhap-(1 -> 3)-alpha-L-Rhap-(1 -> 3)-alpha-L-Rhap-(1 -> to carbon 3 of beta-D-galactose, which was attached in O-glycosidic linkage to serine and threonine residues of SgtA of G. tepidamans GS5-97T.	Univ Nat Resources & Appl Life Sci, Ctr NanoBiotechnol, A-1180 Vienna, Austria; Univ Vienna, Dept Organ Chem, A-1090 Vienna, Austria; Univ Nat Resources & Appl Life Sci, Dept Chem, A-1190 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; University of Vienna; University of Natural Resources & Life Sciences, Vienna	Schaffer, C (corresponding author), Univ Nat Resources & Appl Life Sci, Ctr NanoBiotechnol, A-1180 Vienna, Austria.	christina.schaeffer@boku.ac.at	Kolarich, Daniel/B-6893-2012; Kolarich, Daniel/AAJ-3550-2020; Schäffer, Christina/V-3404-2018; Kosma, Paul/Y-7443-2019; Messner, Paul/Q-5345-2017	Kolarich, Daniel/0000-0002-8452-1350; Kolarich, Daniel/0000-0002-8452-1350; Schäffer, Christina/0000-0003-1613-7258; Kosma, Paul/0000-0001-5342-7161; Messner, Paul/0000-0002-3246-5801; Kaehlig, Hanspeter/0000-0002-3898-6501				ALTMAN E, 1995, EUR J BIOCHEM, V229, P308, DOI 10.1111/j.1432-1033.1995.0308l.x; ALTMAN E, 1992, BIOCHIM BIOPHYS ACTA, V1117, P71, DOI 10.1016/0304-4165(92)90164-P; ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P84, DOI 10.1007/BF00731873; BOCK K, 1994, J BIOL CHEM, V269, P7137; CHRISTIAN R, 1993, J BACTERIOL, V175, P1250, DOI 10.1128/JB.175.5.1250-1256.1993; Clarke BR, 2004, J BIOL CHEM, V279, P35709, DOI 10.1074/jbc.M404738200; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; Forsberg LS, 2000, J BIOL CHEM, V275, P18851, DOI 10.1074/jbc.M001090200; Gunawardena S, 1998, CARBOHYD RES, V309, P65, DOI 10.1016/S0008-6215(98)00115-3; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; ITO T, 1994, CARBOHYD RES, V256, P113, DOI 10.1016/0008-6215(94)84231-0; Jolly L, 2001, INT DAIRY J, V11, P733, DOI 10.1016/S0958-6946(01)00117-0; Kahlig H, 2002, MONATSH CHEM, V133, P589, DOI 10.1007/s007060200031; Katzenellenbogen E, 2003, EUR J BIOCHEM, V270, P2732, DOI 10.1046/j.1432-1033.2003.03640.x; Kocharova NA, 2002, CARBOHYD RES, V337, P1667, DOI 10.1016/S0008-6215(02)00022-8; LIPKIND GM, 1988, CARBOHYD RES, V175, P59, DOI 10.1016/0008-6215(88)80156-3; LIPKIND GM, 1992, CARBOHYD RES, V237, P11; MESSNER P, 1984, INT J SYST BACTERIOL, V34, P202, DOI 10.1099/00207713-34-2-202; Messner P, 2003, Fortschr Chem Org Naturst, V85, P51; Novotny R, 2003, GLYCOCONJUGATE J, V20, P435, DOI 10.1023/B:GLYC.0000038290.74944.65; Novotny R, 2004, MICROBIOL-SGM, V150, P953, DOI 10.1099/mic.0.26672-0; Olsthoorn MA, 2000, EUR J BIOCHEM, V267, P2014, DOI 10.1046/j.1432-1327.2000.01205.x; Perepelov AV, 2002, CARBOHYD RES, V337, P2463, DOI 10.1016/S0008-6215(02)00226-4; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Reeves PP, 2002, CURR TOP MICROBIOL, V264, P109; Sadovskaya I, 2000, EUR J BIOCHEM, V267, P1640, DOI 10.1046/j.1432-1327.2000.01156.x; Samuel G, 2003, CARBOHYD RES, V338, P2503, DOI 10.1016/j.carres.2003.07.009; Schaffer C, 1996, MICROB DRUG RESIST, V2, P17, DOI 10.1089/mdr.1996.2.17; Schaffer C, 1999, GLYCOBIOLOGY, V9, P407, DOI 10.1093/glycob/9.4.407; Schaffer C, 1999, MICROBIOL-UK, V145, P1575, DOI 10.1099/13500872-145-7-1575; Schaffer C, 2000, EUR J BIOCHEM, V267, P5482, DOI 10.1046/j.1432-1327.2000.01610.x; Schaffer C, 2004, INT J SYST EVOL MICR, V54, P2361, DOI 10.1099/ijs.0.63227-0; Schaffer C, 2002, J BIOL CHEM, V277, P6230, DOI 10.1074/jbc.M108873200; Schaffer C, 2001, BIOCHIMIE, V83, P591, DOI 10.1016/S0300-9084(01)01299-8; Senchenkova SN, 1996, CARBOHYD RES, V293, P71, DOI 10.1016/0008-6215(96)00192-9; Valvano MA, 2003, FRONT BIOSCI-LANDMRK, V8, pS452, DOI 10.2741/1079; van Heijenoort J, 2001, GLYCOBIOLOGY, V11, p25R; Vinogradov E, 2002, CARBOHYD RES, V337, P961; Vinogradov E, 2002, J BIOL CHEM, V277, P25070, DOI 10.1074/jbc.M202683200; Vinogradov E, 2000, EUR J BIOCHEM, V267, P7230, DOI 10.1046/j.1432-1327.2000.01835.x; Yoshida Y, 1999, J BIOL CHEM, V274, P16933, DOI 10.1074/jbc.274.24.16933	41	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20292	20299		10.1074/jbc.M501724200	http://dx.doi.org/10.1074/jbc.M501724200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781455	hybrid			2022-12-27	WOS:000229242000018
J	Lerner, LE; Peng, GH; Gribanova, YE; Chen, SM; Farber, DB				Lerner, LE; Peng, GH; Gribanova, YE; Chen, SM; Farber, DB			Sp4 is expressed in retinal neurons, activates transcription of photoreceptor-specific genes, and synergizes with Crx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONE-ROD DYSTROPHY; BETA-SUBUNIT GENE; HOMEOBOX GENE; CGMP-PHOSPHODIESTERASE; RETINITIS-PIGMENTOSA; RHODOPSIN GENE; MUTATIONS; PROTEINS; PROMOTER; MOUSE	To investigate the molecular mechanisms of photoreceptor-specific gene transcription, we examined the role of the neuronal-enriched Sp4 nuclear protein in transcription from the rod-specific beta-PDE and rod opsin gene promoters and compared it to the ubiquitous members of the Sp family, Sp1 and Sp3. Sp4 activates both the rod opsin and beta-PDE promoters, whereas Sp1 activates only the rod opsin promoter and Sp3 activates neither promoter. Interestingly, Sp1 and Sp3 competitively repress Sp4-mediated activation of the beta-PDE promoter. In addition, Sp4, Sp1, and Sp3 each show functional synergy with the photoreceptor-enriched Crx transcriptional regulator on the rod opsin promoter but not the beta-PDE promoter, although Sp4-mediated activation was the most significant. Sp4, Sp1, and Sp3 bind Crx in co-immunoprecipitation experiments, and their zinc finger domains as well as the Crx homedomain are necessary and sufficient for these interactions. Chromatin immunoprecipitation showed that the rod opsin and beta-PDE promoters are targets of both Sp4 and Crx, which further supports Sp4-Crx interactions in vivo in the context of retinal chromatin environment. In situ hybridization and immunohistochemistry demonstrated that Sp4 is abundantly expressed in various neurons of all retinal layers, and thus co-localizes or overlaps with multiple retina-restricted and - enriched genes, its putative targets. Our results indicate that photoreceptor-specific gene transcription is controlled by the combinatorial action of Sp4 and Crx. The other Sp family members may be involved in photoreceptor-specific transcription directly or through their competition with Sp4. These data suggest the potential importance of Sp4 in retinal neurobiology and pathology.	Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Washington University (WUSTL); Washington University (WUSTL)	Lerner, LE (corresponding author), Univ Penn, Sch Med, Scheie Eye Inst, Ctr Mol Ophthalmol,Stellar Chance Labs 303, 422 Curie Blvd, Philadelphia, PA 19104 USA.	leonid.lerner@uphs.upenn.edu	Huang, Yifei/ABE-7566-2020	Farber, Debora/0000-0002-3207-697X	NATIONAL EYE INSTITUTE [K08EY000369, R01EY012543, R01EY002651] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY12543, R01 EY012543, R01 EY02651, K08 EY00369] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bibb LC, 2001, HUM MOL GENET, V10, P1571, DOI 10.1093/hmg/10.15.1571; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; Chen SM, 2004, HUM MOL GENET, V13, P53, DOI 10.1093/hmg/ddh005; Chen SM, 2002, HUM MOL GENET, V11, P873, DOI 10.1093/hmg/11.8.873; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; FARBER DB, 1992, NEURON, V9, P349, DOI 10.1016/0896-6273(92)90173-B; Farber DB, 1997, CURR OPIN NEUROBIOL, V7, P666, DOI 10.1016/S0959-4388(97)80087-6; Freund CL, 1998, NAT GENET, V18, P311, DOI 10.1038/ng0498-311; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Kimura A, 2000, J BIOL CHEM, V275, P1152, DOI 10.1074/jbc.275.2.1152; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; La Spada AR, 2001, NEURON, V31, P913, DOI 10.1016/S0896-6273(01)00422-6; Lerner LE, 2002, J BIOL CHEM, V277, P25877, DOI 10.1074/jbc.M201407200; Lerner LE, 2001, J BIOL CHEM, V276, P34999, DOI 10.1074/jbc.M103301200; Lerner LE, 2000, METHOD ENZYMOL, V315, P617; Livesey FJ, 2000, CURR BIOL, V10, P301, DOI 10.1016/S0960-9822(00)00379-1; MAJELLO B, 1995, ONCOGENE, V10, P1841; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Sciavolino PJ, 1997, DEV DYNAM, V209, P127, DOI 10.1002/(SICI)1097-0177(199705)209:1<127::AID-AJA12>3.0.CO;2-Z; Sohocki MM, 1998, AM J HUM GENET, V63, P1307, DOI 10.1086/302101; STRYER L, 1991, J BIOL CHEM, V266, P10711; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; Swain PK, 1997, NEURON, V19, P1329, DOI 10.1016/S0896-6273(00)80423-7; Wang XJ, 2002, J BIOL CHEM, V277, P43288, DOI 10.1074/jbc.M207952200	30	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20642	20650		10.1074/jbc.M500957200	http://dx.doi.org/10.1074/jbc.M500957200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781457	hybrid			2022-12-27	WOS:000229242000061
J	Nehring, LC; Miyamoto, A; Hein, PW; Weinmaster, G; Shipley, JM				Nehring, LC; Miyamoto, A; Hein, PW; Weinmaster, G; Shipley, JM			The extracellular matrix protein MAGP-2 interacts with Jagged1 and induces its shedding from the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROFIBRIL-ASSOCIATED GLYCOPROTEIN-2; ELASTIN-ASSOCIATED MICROFIBRILS; NOTCH LIGAND; MOLECULAR-CLONING; DEVELOPMENTAL EXPRESSION; FIBRILLIN GENES; GAMMA-SECRETASE; DELTA; IDENTIFICATION; TISSUE	Elastic fibers are composed of the protein elastin and a network of 10-12-nm microfibrils, which are composed of several glycoproteins, including fibrillin-1, fibrillin-2, and MAGP1/2 (microfibril-associated glycoproteins-1 and -2). Although fibrillins and MAGPs covalently associate, we find that the DSL (Delta/Serrate/LAG2) protein Jagged1, an activating ligand for Notch receptor signaling, also interacts with MAGP-2 in both yeast two-hybrid and coimmunoprecipitation studies. Interaction between Jagged1 and MAGP-2 requires the epidermal growth factor-like repeats of Jagged1. MAGP-2 was found complexed with the Jagged1 extracellular domain shed from 293T cells and COS-7 cells coexpressing full-length Jagged1 and MAGP-2. MAGP- 2 shedding of the Jagged1 extracellular domain was decreased by the metalloproteinase hydroxamate inhibitor BB3103 implicating proteolysis in its release. Although MAGP- 2 also interacted with the other DSL ligands, Jagged2 and Delta1, they were not found associated with MAGP-2 in the conditioned media, identifying differential effects of MAGP- 2 on DSL ligand shedding. The related microfibrillar protein MAGP- 1 was also found to interact with DSL ligands but, unlike MAGP-2, was unable to facilitate the shedding of Jagged1. Our findings suggest that in addition to its role in microfibrils, MAGP-2 may also affect cellular differentiation through modulating the Notch signaling pathway either by binding to cell surface DSL ligands or by facilitating release and/or stabilization of a soluble extracellular form of Jagged1.	Washington Univ, Div Pulm & Crit Care Med, Dept Med, St Louis, MO 63110 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	Washington University (WUSTL); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Shipley, JM (corresponding author), Washington Univ, Div Pulm & Crit Care Med, Dept Med, Box 8052,660 S Euclid Ave, St Louis, MO 63110 USA.	mshipley@im.wustl.edu	Hein, Patrick/F-1180-2015		NHLBI NIH HHS [HL67353] Funding Source: Medline; NINDS NIH HHS [NS31885] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031885, R37NS031885] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMS WR, 1995, GENOMICS, V26, P47, DOI 10.1016/0888-7543(95)80081-V; Aho S, 2004, J CELL BIOCHEM, V92, P1271, DOI 10.1002/jcb.20125; Bland CE, 2003, J BIOL CHEM, V278, P13607, DOI 10.1074/jbc.C300016200; BRESSAN GM, 1993, J CELL BIOL, V121, P201, DOI 10.1083/jcb.121.1.201; Chen N, 2004, DEV CELL, V6, P183, DOI 10.1016/S1534-5807(04)00021-8; Crosnier C, 2000, HEPATOLOGY, V32, P574, DOI 10.1053/jhep.2000.16600; Duan ZJ, 2004, MOL CELL BIOL, V24, P58, DOI 10.1128/MCB.24.1.58-70.2004; FAHRENBACH WH, 1966, ANAT RECORD, V155, P563, DOI 10.1002/ar.1091550409; Ge WH, 2002, J NEUROSCI RES, V69, P848, DOI 10.1002/jnr.10364; Gibson MA, 1998, J HISTOCHEM CYTOCHEM, V46, P871, DOI 10.1177/002215549804600802; Gibson MA, 1999, J BIOL CHEM, V274, P13060, DOI 10.1074/jbc.274.19.13060; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; GODFREY M, 1990, AM J HUM GENET, V46, P652; GREENLEE TK, 1966, J CELL BIOL, V30, P59, DOI 10.1083/jcb.30.1.59; Hicks C, 2002, J NEUROSCI RES, V68, P655, DOI 10.1002/jnr.10263; HORRIGAN SK, 1992, J BIOL CHEM, V267, P10087; Hukriede NA, 1997, GENETICS, V145, P359; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; KAGAN HM, 1986, REGULATION MATRIX AC, P322; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; Kiyota T, 2004, MECH DEVELOP, V121, P573, DOI 10.1016/j.mod.2004.03.034; KOBAYASHI R, 1989, J BIOL CHEM, V264, P17347; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; Lemaire R, 2004, ARTHRITIS RHEUM-US, V50, P915, DOI 10.1002/art.20053; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; Lillie MA, 1998, CONNECT TISSUE RES, V37, P121, DOI 10.3109/03008209809028905; Lindner V, 2001, AM J PATHOL, V159, P875, DOI 10.1016/S0002-9440(10)61763-4; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MARIENCHECK MC, 1995, CONNECT TISSUE RES, V31, P87, DOI 10.3109/03008209509028396; Mishra-Gorur K, 2002, J CELL BIOL, V159, P313, DOI 10.1083/jcb.200203117; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Penner AS, 2002, J BIOL CHEM, V277, P35044, DOI 10.1074/jbc.M206363200; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Ross JM, 1998, THROMB HAEMOSTASIS, V79, P155; Sakamoto H, 1996, J BIOL CHEM, V271, P4916; Segade F, 2002, J BIOL CHEM, V277, P11050, DOI 10.1074/jbc.M110347200; Six E, 2003, P NATL ACAD SCI USA, V100, P7638, DOI 10.1073/pnas.1230693100; STREETEN BW, 1988, CURR EYE RES, V7, P139, DOI 10.3109/02713688808995743; Sun X, 1997, DEVELOPMENT, V124, P3439; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; Zimrin AB, 1996, J BIOL CHEM, V271, P32499, DOI 10.1074/jbc.271.51.32499	48	44	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20349	20355		10.1074/jbc.M500273200	http://dx.doi.org/10.1074/jbc.M500273200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788413	hybrid			2022-12-27	WOS:000229242000025
J	Raja, SM; Metkar, SS; Honing, S; Wang, BK; Russin, WA; Pipalia, NH; Menaa, C; Belting, M; Cao, XF; Dressel, R; Froelich, CJ				Raja, SM; Metkar, SS; Honing, S; Wang, BK; Russin, WA; Pipalia, NH; Menaa, C; Belting, M; Cao, XF; Dressel, R; Froelich, CJ			A novel mechanism for protein delivery - Granzyme B undergoes electrostatic exchange from serglycin to target cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; GRANULE-MEDIATED APOPTOSIS; MANNOSE 6-PHOSPHATE RECEPTORS; CASPASE ACTIVATION; MEMBRANE; REQUIRES; BIOSYNTHESIS; CYTOTOXICITY; COMPLEX; DEATH	The molecular interaction of secreted granzyme B-serglycin complexes with target cells remains undefined. Targets exposed to double-labeled granzyme B-serglycin complexes show solely the uptake of granzyme B. An in vitro model demonstrates the exchange of the granzyme from serglycin to immobilized, sulfated glycosaminoglycans. Using a combination of cell binding and internalization assays, granzyme B was found to exchange to sulfated glycosaminoglycans and, depending on the cell type, to higher affinity sites. Apoptosis induced by purified granzyme B and cytotoxic T-cells was diminished in targets with reduced cell surface glycosaminoglycan content. A mechanism of delivery is proposed entailing electrostatic transfer of granzyme B from serglycin to cell surface proteins.	Evanston Northwestern Healthcare Res Inst, Dept Med, Evanston, IL 60201 USA; Northwestern Univ, Bioimaging Facil, Dept Mol Biol & Cell Biol, Evanston, IL 60208 USA; Univ Gottingen, Dept Biochem 2, D-37073 Gottingen, Germany; Univ Gottingen, Dept Immunogenet, D-37073 Gottingen, Germany; Washington Univ, Sch Med, Siteman Canc Ctr, Dept Med,Div Oncol, St Louis, MO 63110 USA; Cornell Univ, Dept Biochem, New York, NY 10021 USA; Scripps Res Inst, Dept Immunol & Vasc Biol, La Jolla, CA 92037 USA	Northwestern University; University of Gottingen; University of Gottingen; Siteman Cancer Center; Washington University (WUSTL); Cornell University; Scripps Research Institute	Raja, SM (corresponding author), Evanston Northwestern Healthcare Res Inst, Dept Med, 2650 Ridge Ave, Evanston, IL 60201 USA.	s-raja@northwestern.edu; c-froelich@northwestern.edu	Dressel, Ralf/R-7065-2016	Dressel, Ralf/0000-0002-1651-1214; Belting, Mattias/0000-0003-1585-5434	NIAID NIH HHS [5R01AI04494-03] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADRIAN C, 2005, J BIOL CHEM, V280, P4663; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAI XM, 1994, J HISTOCHEM CYTOCHEM, V42, P1043, DOI 10.1177/42.8.8027524; Beerens A. M. J., 2003, Current Gene Therapy, V3, P486, DOI 10.2174/1566523034578258; Beresford PJ, 2001, J BIOL CHEM, V276, P43285, DOI 10.1074/jbc.M108137200; Bossi G, 2002, IMMUNOL REV, V189, P152, DOI 10.1034/j.1600-065X.2002.18913.x; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Dehio C, 1998, EXP CELL RES, V242, P528, DOI 10.1006/excr.1998.4116; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Dressel R, 2004, TRANSPLANTATION, V78, P758, DOI 10.1097/01.TP.0000131815.43399.58; Dressel R, 2004, J BIOL CHEM, V279, P20200, DOI 10.1074/jbc.M313108200; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; Froelich CJ, 2004, CELL DEATH DIFFER, V11, P369, DOI 10.1038/sj.cdd.4401381; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Goping IS, 2003, IMMUNITY, V18, P355, DOI 10.1016/S1074-7613(03)00032-3; Griffiths GM, 2003, J CELL BIOL, V160, P155, DOI 10.1083/jcb.200212143; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; Kett WC, 2003, BBA-GEN SUBJECTS, V1620, P225, DOI 10.1016/S0304-4165(02)00539-1; Kurschus FC, 2005, BLOOD, V105, P2049, DOI 10.1182/blood-2004-06-2180; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; Lin SX, 2004, MOL BIOL CELL, V15, P721, DOI 10.1091/mbc.E03-07-0497; Metkar SS, 2005, J IMMUNOL METHODS, V299, P117, DOI 10.1016/j.jim.2005.02.003; Metkar SS, 2003, J CELL BIOL, V160, P875, DOI 10.1083/jcb.200210158; Metkar SS, 2002, IMMUNITY, V16, P417, DOI 10.1016/S1074-7613(02)00286-8; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Osmond RIW, 2002, ANAL BIOCHEM, V310, P199, DOI 10.1016/S0003-2697(02)00396-2; Pardo J, 2004, J CELL BIOL, V167, P457, DOI 10.1083/jcb.200406115; Pinkoski MJ, 1998, BLOOD, V92, P1044; Raja SM, 2003, CURR OPIN IMMUNOL, V15, P528, DOI 10.1016/S0952-7915(03)00111-0; Raja SM, 2002, J BIOL CHEM, V277, P49523, DOI 10.1074/jbc.M209607200; Shi LF, 1997, J EXP MED, V185, P855, DOI 10.1084/jem.185.5.855; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; Sutton VR, 2003, IMMUNITY, V18, P319, DOI 10.1016/S1074-7613(03)00050-5; Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; Trapani JA, 2003, J CELL BIOL, V160, P223, DOI 10.1083/jcb.200210150; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Veugelers K, 2004, BLOOD, V103, P3845, DOI 10.1182/blood-2003-06-2156; Vongchan P, 2005, BBA-GEN SUBJECTS, V1721, P1, DOI 10.1016/j.bbagen.2004.09.007	42	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20752	20761		10.1074/jbc.M501181200	http://dx.doi.org/10.1074/jbc.M501181200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788411	hybrid			2022-12-27	WOS:000229242000073
J	Williams, DC; Cao, ML; Suh, JY; Peterkofsky, A; Clore, GM				Williams, DC; Cao, ML; Suh, JY; Peterkofsky, A; Clore, GM			Solution NMR structure of the 48-kDa IIA(Mannose)-HPr complex of the Escherichia coli mannose phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYL TRANSFER COMPLEX; MACROMOLECULAR STRUCTURE DETERMINATION; PHOSPHOCARRIER PROTEIN HPR; SIGNAL-TRANSDUCING PROTEIN; N-TERMINAL DOMAIN; BACTERIAL PHOSPHOENOLPYRUVATE; CARBOHYDRATE TRANSPORTERS; STEREOCHEMICAL COURSE; STRUCTURE REFINEMENT; ANGSTROM RESOLUTION	The solution structure of the 48-kDa IIA(Man)-HPr complex of the mannose branch of the Escherichia coli phosphotransferase system has been solved by NMR using conjoined rigid body/torsion angle-simulated annealing on the basis of intermolecular nuclear Overhauser enhancement data and residual dipolar couplings. IIA(Man) is dimeric and has two symmetrically related binding sites per dimer for HPr. A convex surface on HPr, formed primarily by helices 1 and 2, interacts with a deep groove at the interface of the two subunits of IIAMan. The interaction surface on IIAMan is predominantly helical, comprising helix 3 from the subunit that bears the active site His-10 and helices 1, 4, and 5 from the other subunit. The total buried accessible surface area at the protein-protein interface is 1450 angstrom(2). The binding sites on the two proteins are complementary in terms of shape and distribution of hydrophobic, hydrophilic, and charged residues. The active site histidines, His-10 of IIAMan and His-15 ( italics indicate HPr residues) of HPr, are in close proximity. An associative transition state involving a pentacoordinate phosphoryl group with trigonal bipyramidal geometry bonded to the N-is an element of 2 atom of His-10 and the N-delta 1 atom of His-15 can be readily formed with negligible displacement in the backbone coordinates of the residues immediately adjacent to the active site histidines. Comparing the structures of complexes of HPr with three other structurally unrelated phosphotransferase system proteins, enzymes I, IIA(glucose), and IIA(mannitol), reveals a number of common features that provide a molecular basis for understanding how HPr specifically recognizes a wide range of diverse proteins.	NIDDK, Phys Chem Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Cell Biol Labs, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Clore, GM (corresponding author), NIDDK, Phys Chem Lab, NIH, Bldg 5,Rm B1-301, Bethesda, MD 20892 USA.	mariusc@intra.niddk.nih.gov	Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027	NIDDK NIH HHS [Z01 DK029023-15] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029023] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8; BAX A, 1994, METHOD ENZYMOL, V239, P79; BEGLEY GS, 1982, BIOCHEMISTRY-US, V21, P5552, DOI 10.1021/bi00265a026; Cai ML, 2003, J BIOL CHEM, V278, P25191, DOI 10.1074/jbc.M302677200; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Clore GM, 2000, P NATL ACAD SCI USA, V97, P9021, DOI 10.1073/pnas.97.16.9021; Clore GM, 2004, J AM CHEM SOC, V126, P2923, DOI 10.1021/ja0386804; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; Clore GM, 2002, J AM CHEM SOC, V124, P2866, DOI 10.1021/ja017712p; Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9; Clore GM, 1998, P NATL ACAD SCI USA, V95, P5891, DOI 10.1073/pnas.95.11.5891; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; Cornilescu G, 2002, J BIOL CHEM, V277, P42289, DOI 10.1074/jbc.M207314200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; ERNI B, 1985, J BIOL CHEM, V260, P5495; ERNI B, 1989, J BIOL CHEM, V264, P18733; ERNI B, 1987, J BIOL CHEM, V262, P5238; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Garrett DS, 1999, NAT STRUCT BIOL, V6, P166; Goto NK, 1999, J BIOMOL NMR, V13, P369, DOI 10.1023/A:1008393201236; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; JIA ZC, 1993, J BIOL CHEM, V268, P22490; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; Kuszewski J, 1999, J AM CHEM SOC, V121, P2337, DOI 10.1021/ja9843730; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARKOVICHOUSLEY Z, 1994, BIOCHEMISTRY-US, V33, P10977, DOI 10.1021/bi00202a017; MARTINVERSTRAETE I, 1990, J MOL BIOL, V214, P657, DOI 10.1016/0022-2836(90)90284-S; MUELLER EG, 1990, BIOCHEMISTRY-US, V29, P6892, DOI 10.1021/bi00481a019; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nunn RS, 1996, J MOL BIOL, V259, P502, DOI 10.1006/jmbi.1996.0335; Orriss GL, 2003, J MOL BIOL, V327, P1111, DOI 10.1016/S0022-2836(03)00215-8; PELTON JG, 1993, PROTEIN SCI, V2, P543; PERUVSHIN K, 1997, P NATL ACAD SCI USA, V94, P12366; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Robillard GT, 1999, BBA-REV BIOMEMBRANES, V1422, P73, DOI 10.1016/S0304-4157(99)00002-7; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Schauder S, 1998, J MOL BIOL, V276, P591, DOI 10.1006/jmbi.1997.1544; Schwieters CD, 2002, J BIOMOL NMR, V23, P221, DOI 10.1023/A:1019875223132; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Schwieters CD, 2001, J MAGN RESON, V152, P288, DOI 10.1006/jmre.2001.2413; Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300; Siebold C, 2001, FEBS LETT, V504, P104, DOI 10.1016/S0014-5793(01)02705-3; STOLZ B, 1993, J BIOL CHEM, V268, P27094; Tugarinov V, 2002, J AM CHEM SOC, V124, P10025, DOI 10.1021/ja0205636; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; WEHMEIER UF, 1994, BBA-PROTEIN STRUCT M, V1208, P348, DOI 10.1016/0167-4838(94)90124-4; Williams DC, 2004, J BIOL CHEM, V279, P1449, DOI 10.1074/jbc.M309790200; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	50	52	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20775	20784		10.1074/jbc.M501986200	http://dx.doi.org/10.1074/jbc.M501986200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788390	Green Accepted, hybrid			2022-12-27	WOS:000229242000075
J	Fernandez-Tornero, C; Garcia, E; de Pascual-Teresa, B; Lopez, R; Gimenez-Gallego, G; Romero, A				Fernandez-Tornero, C; Garcia, E; de Pascual-Teresa, B; Lopez, R; Gimenez-Gallego, G; Romero, A			Ofloxacin-like antibiotics inhibit pneumococcal cell wall-degrading virulence factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-PNEUMONIAE; LYTIC ENZYMES; AUTOMATED DOCKING; BINDING-PROTEINS; PURIFICATION; AMIDASE; AUTOLYSIN; STEP; INSIGHTS; BIOLOGY	The search for new drugs against Streptococcus pneumoniae (pneumococcus) is driven by the 1.5 million deaths it causes annually. Choline-binding proteins attach to the pneumococcal cell wall through domains that recognize choline moieties, and their involvement in pneumococcal virulence makes them potential targets for drug development. We have defined chemical criteria involved in the docking of small molecules from a three-dimensional structural library to the major pneumococcal autolysin (LytA) choline binding domain. These criteria were used to identify compounds that could interfere with the attachment of this protein to the cell wall, and several quinolones that fit this framework were found to inhibit the cell wall-degrading activity of LytA. Furthermore, these compounds produced similar effects on other enzymes with different catalytic activities but that contained a similar choline binding domain; that is, autolysin (LytC) and the phage lytic enzyme (Cpl-1). Finally, we resolved the crystal structure of the complex between the choline binding domain of LytA and ofloxacin at a resolution of 2.6 angstrom. These data constitute an important launch pad from which effective drugs to combat pneumococcal infections can be developed.	CSIC, Dept Estructura & Func Prot, Madrid 28040, Spain; CSIC, Dept Mol Microbiol, Ctr Invest Biol, Madrid 28040, Spain; Univ San Pablo, Fac Ciencias Expt & Salud, Dept CC Quim, CEU, Madrid 28668, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); San Pablo CEU University	Romero, A (corresponding author), European Mol Biol Lab, Grenoble Outstn, 6 Rue Jules Horowitz,BP 181, F-38042 Grenoble, France.	romero@cib.csic.es	Romero, Antonio/K-5754-2014; Fernandez-Tornero, Carlos/AAV-8028-2021; Fernandez-Tornero, Carlos/I-6888-2015; de Pascual-Teresa, Beatriz/J-4318-2012	Romero, Antonio/0000-0002-6990-6973; Fernandez-Tornero, Carlos/0000-0001-5097-731X; Fernandez-Tornero, Carlos/0000-0001-5097-731X; de Pascual-Teresa, Beatriz/0000-0002-1101-0373; Partearroyo Lacaba, Olvido/0000-0002-1692-4481				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berry AM, 2000, INFECT IMMUN, V68, P133, DOI 10.1128/IAI.68.1.133-140.2000; BRIESE T, 1985, EUR J BIOCHEM, V146, P417, DOI 10.1111/j.1432-1033.1985.tb08668.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen DK, 1999, NEW ENGL J MED, V341, P233, DOI 10.1056/NEJM199907223410403; De las Rivas B, 2002, J BACTERIOL, V184, P4988, DOI 10.1128/JB.184.18.4988-5000.2002; DIAZ E, 1991, J BIOL CHEM, V266, P5464; Fernandez-Tornero C, 2002, J MOL BIOL, V321, P163, DOI 10.1016/S0022-2836(02)00596-X; Fernandez-Tornero C, 2001, NAT STRUCT BIOL, V8, P1020, DOI 10.1038/nsb724; FISCHER W, 2000, STREPTOCOCCUS PNEUMO, P155; GARCIA E, 1985, MOL GEN GENET, V201, P225, DOI 10.1007/BF00425663; GARCIA JL, 1987, J VIROL, V61, P2573; GARCIA JL, 1987, ARCH MICROBIOL, V149, P52, DOI 10.1007/BF00423136; Garcia JL, 2000, STREPTOCOCCUS PNEUMO, P231; Garcia P, 1999, MOL MICROBIOL, V33, P128, DOI 10.1046/j.1365-2958.1999.01455.x; GARCIA P, 1990, GENE, V86, P81, DOI 10.1016/0378-1119(90)90116-9; GIUDICELLI S, 1984, J BACTERIOL, V158, P1188, DOI 10.1128/JB.158.3.1188-1190.1984; Gosink KK, 2000, INFECT IMMUN, V68, P5690, DOI 10.1128/IAI.68.10.5690-5695.2000; Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608; Hollingshead SK, 2001, CURR OPIN MICROBIOL, V4, P71, DOI 10.1016/S1369-5274(00)00167-3; HOLTJE JV, 1975, J BIOL CHEM, V250, P6072; Hooper D. C., 2001, CLIN INFECT DIS   S1, V32, P9; Jedrzejas MJ, 2001, MICROBIOL MOL BIOL R, V65, P187, DOI 10.1128/MMBR.65.2.187-207.2001; Jorgensen WL, 2004, SCIENCE, V303, P1813, DOI 10.1126/science.1096361; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Lopez R, 2004, FEMS MICROBIOL REV, V28, P553, DOI 10.1016/j.femsre.2004.05.002; Lopez R, 2004, PNEUMOCCOCUS, P75; McCormick AW, 2003, NAT MED, V9, P424, DOI 10.1038/nm839; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; PATON JH, 1988, DRUGS, V36, P193, DOI 10.2165/00003495-198836020-00004; Romero P, 2004, J BACTERIOL, V186, P8229, DOI 10.1128/JB.186.24.8229-8239.2004; ROUSSEL A, 1991, TURBO FRODO SILICON, P77; Sahm DF, 2000, ANTIMICROB AGENTS CH, V44, P2521, DOI 10.1128/AAC.44.9.2521-2524.2000; SANCHEZPUELLES JM, 1992, EUR J BIOCHEM, V203, P153, DOI 10.1111/j.1432-1033.1992.tb19840.x; SANZ JM, 1988, FEBS LETT, V232, P308, DOI 10.1016/0014-5793(88)80759-2; Shoichet BK, 2002, CURR OPIN CHEM BIOL, V6, P439, DOI 10.1016/S1367-5931(02)00339-3; Sotriffer CA, 2000, METHODS, V20, P280, DOI 10.1006/meth.1999.0922; TUMMINO PJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P523, DOI 10.1006/abbi.1995.1069; Tuomanen E, 1999, CURR OPIN MICROBIOL, V2, P35, DOI 10.1016/S1369-5274(99)80006-X; Voigt JH, 2001, J CHEM INF COMP SCI, V41, P702, DOI 10.1021/ci000150t; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WREN BW, 1991, MOL MICROBIOL, V5, P797, DOI 10.1111/j.1365-2958.1991.tb00752.x	45	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19948	19957		10.1074/jbc.M501236200	http://dx.doi.org/10.1074/jbc.M501236200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769740	hybrid, Green Published			2022-12-27	WOS:000229113700064
J	Tsai, TC; Lee, YL; Hsiao, WC; Tsao, YP; Chen, SL				Tsai, TC; Lee, YL; Hsiao, WC; Tsao, YP; Chen, SL			NRIP, a novel nuclear receptor interaction protein, enhances the transcriptional activity of nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; ANDROGEN RECEPTOR; GLUCOCORTICOID HORMONES; STEROID-RECEPTORS; CERVICAL-CANCER; BINDING PROTEIN; GENE-EXPRESSION; WD-REPEAT; COACTIVATOR; COREGULATOR	Transcriptional regulation by members of the nuclear hormone receptor superfamily is a modular process requiring the mediation of distinct subclasses of coregulators. In this study, we isolated a novel WD40 repeat-containing gene, human nuclear receptor interaction protein (NRIP). We found NRIP interacts with either androgen or glucocorticoid receptors from in vitro and in vivo pulldown assays. Subsequently, transient transfection and luciferase activity assays suggested that NRIP was a ligand-dependent coactivator of steroid receptors (androgen and glucocorticoid) in distinct promoters. To further clarify the function of NRIP, we found an RNA interference-3-targeted NRIP gene sequence (5'-GATGATACAGCACGAGAAC-3') that could efficiently and specifically knock down endogenous and exogenous NRIP gene expression and that significantly diminished cell proliferation in prostate (LNCaP) and cervical (C33A) cells. Therefore, NRIP may play a role in enhancing the transcriptional activity of nuclear receptors and may be a critical target for developing therapeutic agents against nuclear receptor-mediated progression of prostate and cervical cancers.	Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan; Natl Def Med Ctr, Dept Microbiol & Immunol, Taipei 114, Taiwan; Mackay Mem Hosp, Dept Ophthalmol, Taipei 104, Taiwan	National Defense Medical Center; National Defense Medical Center; Mackay Memorial Hospital	Chen, SL (corresponding author), Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan.	sltsao@mail.ndmctsgh.edu.tw						Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Ahmad A, 1999, J BIOL CHEM, V274, P16646, DOI 10.1074/jbc.274.23.16646; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; BRINTON LA, 1993, GYNECOL ONCOL, V51, P301, DOI 10.1006/gyno.1993.1294; BRINTON LA, 1991, CONTRACEPTION, V43, P581, DOI 10.1016/0010-7824(91)90005-Z; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; Dixon SC, 2001, PHARMACOL REV, V53, P73; FERENCZY A, 1989, CLIN OBSTET GYNECOL, V32, P191, DOI 10.1097/00003081-198903000-00023; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Khare S, 1997, EXP CELL RES, V232, P353, DOI 10.1006/excr.1997.3529; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2001, BBA-REV CANCER, V1551, pM1, DOI 10.1016/S0304-419X(01)00021-X; KLOCK G, 1988, CANCER DETECT PREV, V12, P23; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; Mitsuzawa H, 2001, J BIOL CHEM, V276, P17117, DOI 10.1074/jbc.M100248200; MITTAL R, 1993, OBSTET GYNECOL, V81, P5; Mittal V, 2004, NAT REV GENET, V5, P355, DOI 10.1038/nrg1323; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Moodley M, 2003, INT J GYNECOL CANCER, V13, P103, DOI 10.1136/ijgc-00009577-200303000-00001; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Neely KE, 2002, BBA-REV CANCER, V1603, P19, DOI 10.1016/S0304-419X(02)00067-7; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEGRINI BP, 1990, CANCER RES, V50, P4670; ONATE SA, 1995, SCIENCE, V270, P1354; OREDER RG, 1998, COLD SPRING HARB SYM, V63, P201; PATTILLO R A, 1977, Science (Washington D C), V196, P1456, DOI 10.1126/science.867042; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Rochette-Egly C, 2003, CELL SIGNAL, V15, P355, DOI 10.1016/S0898-6568(02)00115-8; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; Savkur RS, 2004, VITAM HORM, V68, P145; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Stallcup MR, 2000, BIOCHEM SOC T, V28, P415, DOI 10.1042/0300-5127:0280415; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang X, 2001, J BIOL CHEM, V276, P40417, DOI 10.1074/jbc.M104765200; Wen Y, 2000, CANCER RES, V60, P6841; Wiseman H, 2001, BIOCHEM SOC T, V29, P205, DOI 10.1042/BST0290205; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	54	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20000	20009		10.1074/jbc.M412169200	http://dx.doi.org/10.1074/jbc.M412169200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15784617	hybrid			2022-12-27	WOS:000229113700070
J	Abdelrahim, M; Liu, SX; Safe, S				Abdelrahim, M; Liu, SX; Safe, S			Induction of endoplasmic reticulum-induced stress genes in Panc-1 pancreatic cancer cells is dependent on Sp proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; NF-Y CBF; BINDING PROTEIN; CA2+ DEPLETION; ELEMENT; ACTIVATION; PROMOTER; ATF6; IDENTIFICATION; TRANSACTIVATION	Endoplasmic reticulum ( ER) stress plays a critical role in multiple diseases, and pharmacologically active drugs can induce cell death through ER stress pathways. Stress-induced genes are activated through assembly of transcription factors on ER stress response elements (ERSEs) in target gene promoters. Gel mobility shift and chromatin immunoprecipitation assays have confirmed interactions of NF-Y and YY1 with the distal motifs of the tripartite ERSE from the glucose-related protein 78 (GRP78) gene promoter. The GC-rich nonanucleotide (N-9) sequence, which forms the ER stress response binding factor (ERSF) complex binds TFII-I and ATF6; however, we have now shown that in Panc-1 pancreatic cancer cells, this complex also binds Sp1, Sp3, and Sp4 proteins. Sp proteins are constitutively bound to the ERSE; however, activation of GRP78 protein ( or reporter gene) by thapsigargin or tunicamycin is inhibited after cotransfection with small inhibitory RNAs for Sp1, Sp3, and Sp4. This study demonstrates that Sp transcription factors are important for stress-induced responses through their binding to ERSEs.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ Syst Hlth, Ctr Sci, Inst Biosci & Technol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu			NCI NIH HHS [CA108178, P20-CA-10193] Funding Source: Medline; NIEHS NIH HHS [ES09106] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdelrahim M, 2004, CANCER RES, V64, P6740, DOI 10.1158/0008-5472.CAN-04-0713; Abdelrahim M, 2003, MOL PHARMACOL, V63, P1373, DOI 10.1124/mol.63.6.1373; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Foti DM, 1999, J BIOL CHEM, V274, P30402, DOI 10.1074/jbc.274.43.30402; Hagg M, 2004, MOL CANCER THER, V3, P489; Hampton RY, 2000, CURR BIOL, V10, pR518, DOI 10.1016/S0960-9822(00)00583-2; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hong J, 2004, ENDOCRINOLOGY, V145, P5774, DOI 10.1210/en.2004-0686; Ito M, 1997, J CLIN INVEST, V99, P1897, DOI 10.1172/JCI119357; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kokame K, 2001, J BIOL CHEM, V276, P9199, DOI 10.1074/jbc.M010486200; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; LI WWF, 1993, J BIOL CHEM, V268, P12003; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Marcus N, 1997, DNA CELL BIOL, V16, P1123, DOI 10.1089/dna.1997.16.1123; Merad-Boudia M, 1998, BIOCHEM PHARMACOL, V56, P645, DOI 10.1016/S0006-2952(97)00647-3; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Safe S, 2004, PROG NUCLEIC ACID RE, V77, P1, DOI 10.1016/S0079-6603(04)77001-4; Tsutsumi S, 2004, CELL DEATH DIFFER, V11, P1009, DOI 10.1038/sj.cdd.4401436; Wang Y, 2000, J BIOL CHEM, V275, P27013; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	35	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2005	280	16					16508	16513		10.1074/jbc.C500030200	http://dx.doi.org/10.1074/jbc.C500030200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	917GO	15760841	hybrid			2022-12-27	WOS:000228444800125
J	Li, X; Hummer, A; Han, J; Xie, M; Melnik-Martinez, K; Moreno, RL; Buck, M; Mark, MD; Herlitze, S				Li, X; Hummer, A; Han, J; Xie, M; Melnik-Martinez, K; Moreno, RL; Buck, M; Mark, MD; Herlitze, S			G protein beta(2) subunit-derived peptides for inhibition and induction of G protein pathways - Examination of voltage-gated Ca2+ AND G Protein inwardly rectifying K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; BULLFROG SYMPATHETIC NEURONS; GREEN FLUORESCENT PROTEINS; CALCIUM-CHANNELS; N-TYPE; CRYSTAL-STRUCTURE; KINASE-C; HIPPOCAMPAL-NEURONS; INTRACELLULAR LOOP; ALPHA(1) SUBUNIT	Voltage-gated Ca2+ channels of the N-, P/Q-, and R-type and G protein inwardly rectifying K+ channels (GIRK) are modulated via direct binding of G proteins. The modulation is mediated by G protein beta gamma subunits. By using electrophysiological recordings and fluorescence resonance energy transfer, we characterized the modulatory domains of the G protein beta subunit on the recombinant P/Q- type channel and GIRK channel expressed in HEK293 cells and on native non-L-type Ca2+ currents of cultured hippocampal neurons. We found that G beta(2) subunit-derived deletion constructs and synthesized peptides can either induce or inhibit G protein modulation of the examined ion channels. In particular, the 25-amino acid peptide derived from the G beta(2) N terminus inhibits G protein modulation, whereas a 35-amino acid peptide derived from the G beta(2) C terminus induced modulation of voltage-gated Ca2+ channels and GIRK channels. Fluorescence resonance energy transfer ( FRET) analysis of the live action of these peptides revealed that the 25-amino acid peptide diminished the FRET signal between G protein beta(2)gamma(3) subunits, indicating a reorientation between G protein beta(2)gamma(3) subunits in the presence of the peptide. In contrast, the 35-amino acid peptide increased the FRET signal between GIRK1,2 channel subunits, similarly to the G beta gamma-mediated FRET increase observed for this GIRK subunit combination. Circular dichroism spectra of the synthesized peptides suggest that the 25-amino acid peptide is structured. These results indicate that individual G protein beta subunit domains can act as independent, separate modulatory domains to either induce or inhibit G protein modulation for several effector proteins.	Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Flyion GmbH, D-72076 Tubingen, Germany	Case Western Reserve University; Case Western Reserve University	Herlitze, S (corresponding author), Case Western Reserve Univ, Sch Med, Dept Neurosci, Rm E604,10900 Euclid Ave, Cleveland, OH 44106 USA.	sxh106@cwru.edu	Buck, Matthias/B-2106-2017; Mark, Melanie/ABF-9102-2020	Buck, Matthias/0000-0002-2958-0403; Mark, Melanie/0000-0002-2788-6003	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042623] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS42623] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agler HL, 2003, J GEN PHYSIOL, V121, P495, DOI 10.1085/jgp.200208770; Akgoz M, 2002, J BIOL CHEM, V277, P19573, DOI 10.1074/jbc.M201546200; Arnot MI, 2000, J PHYSIOL-LONDON, V527, P203, DOI 10.1111/j.1469-7793.2000.00203.x; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; BOLAND LM, 1993, J NEUROSCI, V13, P516; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Canti C, 1999, J NEUROSCI, V19, P6855, DOI 10.1523/JNEUROSCI.19-16-06855.1999; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Colecraft HM, 2001, J NEUROSCI, V21, P1137; Currie KPM, 1997, J NEUROSCI, V17, P4570; DE WM, 1997, NATURE, V385, P446; Doering CJ, 2004, J BIOL CHEM, V279, P29709, DOI 10.1074/jbc.M308693200; Dolphin AC, 1999, ANN NY ACAD SCI, V868, P160, DOI 10.1111/j.1749-6632.1999.tb11285.x; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Fathallah M, 2002, EUR J NEUROSCI, V16, P219, DOI 10.1046/j.1460-9568.2002.02074.x; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Furukawa T, 1998, J BIOL CHEM, V273, P17595, DOI 10.1074/jbc.273.28.17595; Garcia DE, 1998, J NEUROSCI, V18, P9163; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Herlitze S, 2001, P NATL ACAD SCI USA, V98, P4699, DOI 10.1073/pnas.051628998; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; Herlitze X, 1999, J PHYSIOL-LONDON, V517, P341, DOI 10.1111/j.1469-7793.1999.0341t.x; Hummer A, 2003, J BIOL CHEM, V278, P49386, DOI 10.1074/jbc.M306645200; Hynes TR, 2004, J BIOL CHEM, V279, P30279, DOI 10.1074/jbc.M401432200; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Jarvis SE, 2001, TRENDS PHARMACOL SCI, V22, P519, DOI 10.1016/S0165-6147(00)01800-9; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lee HK, 2000, J NEUROSCI, V20, P3115, DOI 10.1523/JNEUROSCI.20-09-03115.2000; Mark MD, 2000, J PHYSIOL-LONDON, V528, P65, DOI 10.1111/j.1469-7793.2000.00065.x; MARK MD, 1995, J CELL BIOL, V130, P701, DOI 10.1083/jcb.130.3.701; Mirshahi T, 2002, J BIOL CHEM, V277, P36345, DOI 10.1074/jbc.M205359200; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; Myung CS, 2000, P NATL ACAD SCI USA, V97, P9311, DOI 10.1073/pnas.97.16.9311; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; Page KM, 1997, J NEUROSCI, V17, P1330; Patil PG, 1996, BIOPHYS J, V71, P2509, DOI 10.1016/S0006-3495(96)79444-4; Peng LY, 2003, J BIOL CHEM, V278, P50203, DOI 10.1074/jbc.M308299200; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Riven I, 2003, NEURON, V38, P225, DOI 10.1016/S0896-6273(03)00193-4; Rohl CA, 1997, BIOCHEMISTRY-US, V36, P8435, DOI 10.1021/bi9706677; Roth BL, 2004, NAT REV DRUG DISCOV, V3, P353, DOI 10.1038/nrd1346; Ruiz-Velasco V, 2001, J PHYSIOL-LONDON, V537, P679; Sandoz G, 2004, P NATL ACAD SCI USA, V101, P6267, DOI 10.1073/pnas.0306804101; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wittemann S, 2000, J BIOL CHEM, V275, P37807, DOI 10.1074/jbc.M004653200; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; Zamponi GW, 2001, CELL BIOCHEM BIOPHYS, V34, P79, DOI 10.1385/CBB:34:1:79; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9	57	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23945	23959		10.1074/jbc.M414078200	http://dx.doi.org/10.1074/jbc.M414078200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15824105	hybrid			2022-12-27	WOS:000229880000069
J	Sakagami, H; Aoki, J; Natori, Y; Nishikawa, K; Kakehi, Y; Natori, Y; Arai, H				Sakagami, H; Aoki, J; Natori, Y; Nishikawa, K; Kakehi, Y; Natori, Y; Arai, H			Biochemical and molecular characterization of a novel choline-specific glycerophosphodiester phosphodiesterase belonging to the nucleotide pyrophosphatase/phosphodiesterase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN PC-1; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPASE-D; CELL MOTILITY; AUTOTAXIN; IDENTIFICATION; EXPRESSION; PYROPHOSPHATASE; PURIFICATION; STIMULATION	Nucleotide pyrophosphatases/phosphodiesterases (NPPs) are ubiquitous membrane-associated or secreted ectoenzymes that release nucleoside 5'-monophosphate from a variety of nucleotides and nucleotide derivatives. The mammalian NPP family comprises seven members, but only three of these (NPP1-3) have been studied in some detail. Previously we showed that lysophospholipase D, which hydrolyzes lysophosphatidylcholine (LPC) to produce lysophosphatidic acid, is identical to NPP2. More recently an uncharacterized novel NPP member (NPP7) was shown to have alkaline sphingomyelinase activity. These findings raised the possibility that other members of the NPP family act on phospholipids. Here we show that the sixth member of the NPP family, NPP6, is a choline-specific glycerophosphodiester phosphodiesterase. The sequence of NPP6 encodes a transmembrane protein containing an NPP domain with significant homology to NPP4, NPP5, and NPP7/alkaline sphingomyelinase. When expressed in HeLa cells, NPP6 was detected in both the cells and the cell culture medium as judged by Western blotting and by enzymatic activity. Recombinant NPP6 efficiently hydrolyzed the classical substrate for phospholipase C, p-nitrophenyl phosphorylcholine, but not the classical nucleotide phosphodiesterase substrate, p-nitrophenyl thymidine 5'-monophosphate. In addition, NPP6 hydrolyzed LPC to form monoacylglycerol and phosphorylcholine but not lysophosphatidic acid, showing it has a lysophospholipase C activity. NPP6 showed a preference for LPC with short (12:0 and 14:0) or polyunsaturated (18:2 and 20:4) fatty acids. It also hydrolyzed glycerophosphorylcholine and sphingosylphosphorylcholine efficiently. In mice, NPP6 mRNA was predominantly detected in kidney with a lesser expression in brain and heart, and in human it was detected in kidney and brain. The present results suggest that NPP6 has a specific role through the hydrolysis of polyunsaturated LPC, glycerophosphorylcholine, or sphingosylphosphorylcholine in these organs.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Int Med Ctr Japan, Inst Res, Dept Clin Pharmacol, Shinjuku Ku, Tokyo 1628655, Japan; Kagawa Univ, Fac Med, Dept Urol, Kagawa 7610763, Japan	University of Tokyo; National Center for Global Health & Medicine - Japan; Kagawa University	Aoki, J (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	jaoki@mol.f.u-tokyo.ac.jp		Aoki, Junken/0000-0001-9435-1896				Agre P, 2000, J AM SOC NEPHROL, V11, P764, DOI 10.1681/ASN.V114764; Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Beck FX, 1998, PFLUG ARCH EUR J PHY, V436, P814, DOI 10.1007/s004240050710; Belfiore A, 1996, MOL ENDOCRINOL, V10, P1318, DOI 10.1210/me.10.11.1318; BELLI SI, 1993, EUR J BIOCHEM, V217, P421, DOI 10.1111/j.1432-1033.1993.tb18261.x; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Clair T, 2003, CANCER RES, V63, P5446; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; Deterre P, 1996, J IMMUNOL, V157, P1381; Duan RD, 2003, J BIOL CHEM, V278, P38528, DOI 10.1074/jbc.M305437200; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GERLT JA, 1975, J BIOL CHEM, V250, P5053; Gijsbers R, 2003, FEBS LETT, V538, P60, DOI 10.1016/S0014-5793(03)00133-9; Goding JW, 2003, BBA-MOL BASIS DIS, V1638, P1, DOI 10.1016/S0925-4439(03)00058-9; Grobben B, 2000, BRIT J PHARMACOL, V130, P139, DOI 10.1038/sj.bjp.0703289; Grobben B, 1999, J NEUROCHEM, V72, P826, DOI 10.1046/j.1471-4159.1999.0720826.x; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; HESSION C, 1987, SCIENCE, V237, P1479, DOI 10.1126/science.3498215; HUANG R, 1994, J CLIN INVEST, V94, P560, DOI 10.1172/JCI117370; HYNIE I, 1975, CLIN CHEM, V21, P1383; Johnson K, 2001, ARTHRITIS RHEUM, V44, P1071, DOI 10.1002/1529-0131(200105)44:5<1071::AID-ANR187>3.0.CO;2-3; Johnson K, 1999, J BONE MINER RES, V14, P883, DOI 10.1359/jbmr.1999.14.6.883; KANFER JN, 1989, FEBS LETT, V257, P348, DOI 10.1016/0014-5793(89)81568-6; Kishimoto T, 2002, CLIN BIOCHEM, V35, P411, DOI 10.1016/S0009-9120(02)00327-2; Lee HY, 1996, J BIOL CHEM, V271, P24408, DOI 10.1074/jbc.271.40.24408; LIAO TH, 1988, BIOCHEM J, V255, P781, DOI 10.1042/bj2550781; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; Nam SW, 2001, CANCER RES, V61, P6938; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohe Y, 2003, BIOCHEM BIOPH RES CO, V308, P719, DOI 10.1016/S0006-291X(03)01454-2; Okawa A, 1998, NAT GENET, V19, P271, DOI 10.1038/956; Scott LJ, 1997, HEPATOLOGY, V25, P995, DOI 10.1002/hep.510250434; SOK DE, 1990, BIOCHEM BIOPH RES CO, V172, P1317, DOI 10.1016/0006-291X(90)91593-H; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Whitehead JP, 1997, CLIN ENDOCRINOL, V47, P65, DOI 10.1046/j.1365-2265.1997.2171021.x; WIRTHENSOHN G, 1987, PFLUG ARCH EUR J PHY, V409, P411, DOI 10.1007/BF00583795; WIRTHENSOHN G, 1989, AM J PHYSIOL, V256, pF128, DOI 10.1152/ajprenal.1989.256.1.F128; Zheng B, 2003, P NATL ACAD SCI USA, V100, P1745, DOI 10.1073/pnas.0337605100; Zheng B, 2000, P NATL ACAD SCI USA, V97, P3999, DOI 10.1073/pnas.97.8.3999	43	93	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23084	23093		10.1074/jbc.M413438200	http://dx.doi.org/10.1074/jbc.M413438200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15788404	hybrid			2022-12-27	WOS:000229741800065
J	Williams, GJ; Breazeale, SD; Raetz, CRH; Naismith, JH				Williams, GJ; Breazeale, SD; Raetz, CRH; Naismith, JH			Structure and function of both domains of ArnA, a dual function decarboxylase and a formyltransferase, involved in 4-amino-4-deoxy-L-arabinose biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOSE 4-EPIMERASE; POLYMYXIN-RESISTANT MUTANTS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; ANTIMICROBIAL PEPTIDES; CRYSTAL-STRUCTURE; ENZYME; MODEL; PHOSPHOETHANOLAMINE; AMINOTRANSFERASE	Modification of the lipid A moiety of lipopolysaccharide by the addition of the sugar 4-amino-4-deoxy-L-arabinose (L-Ara4N) is a strategy adopted by pathogenic Gram-negative bacteria to evade cationic antimicrobial peptides produced by the innate immune system. L-Ara4N biosynthesis is therefore a potential anti-infective target, because inhibiting its synthesis would render certain pathogens more sensitive to the immune system. The bifunctional enzyme ArnA, which is required for L-Ara4N biosynthesis, catalyzes the NAD(+)-dependent oxidative decarboxylation of UDP-glucuronic acid to generate a UDP-4'-keto-pentose sugar and also catalyzes transfer of a formyl group from N-10-formyltetrahydrofolate to the 4'-amine of UDP-L-Ara4N. We now report the crystal structure of the N-terminal formyltransferase domain in a complex with uridine monophosphate and N-5-formyltetrahydrofolate. Using this structure, we identify the active site of formyltransfer in ArnA, including the key catalytic residues Asn(102), His(104), and Asp(140). Additionally, we have shown that residues Ser(433) and Glu(434) of the decarboxylase domain are required for the oxidative decarboxylation of UDP- GlcUA. An E434Q mutant is inactive, suggesting that chemical rather than steric properties of this residue are crucial in the decarboxylation reaction. Our data suggest that the decarboxylase domain catalyzes both hydride abstraction (oxidation) from the C-4' position and the subsequent decarboxylation.	Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	University of St Andrews; Duke University	Naismith, JH (corresponding author), Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland.		Naismith, James Henderson/AAB-8614-2020; Naismith, James Henderson/H-3408-2012	Naismith, James Henderson/0000-0001-6744-5061; Naismith, James Henderson/0000-0001-6744-5061	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM051310, GM-51310] Funding Source: Medline; Wellcome Trust [081862, 067305] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Allard STM, 2002, STRUCTURE, V10, P81, DOI 10.1016/S0969-2126(01)00694-3; ALMASSY RJ, 1992, P NATL ACAD SCI USA, V89, P6114, DOI 10.1073/pnas.89.13.6114; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker SJ, 1999, MICROBIOL-SGM, V145, P367, DOI 10.1099/13500872-145-2-367; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; Beis K, 2003, J AM CHEM SOC, V125, P11872, DOI 10.1021/ja035796r; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; Breazeale SD, 2005, J BIOL CHEM, V280, P14154, DOI 10.1074/jbc.M414265200; Breazeale SD, 2003, J BIOL CHEM, V278, P24731, DOI 10.1074/jbc.M304043200; Breazeale SD, 2002, J BIOL CHEM, V277, P2886, DOI 10.1074/jbc.M109377200; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DINARELLO CA, 1991, BLOOD, V77, P1627; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans W, 1997, CHEM BRIT, V33, P22; Gatzeva-Topalova PZ, 2004, BIOCHEMISTRY-US, V43, P13370, DOI 10.1021/bi048551f; Gunn JS, 2000, INFECT IMMUN, V68, P6139, DOI 10.1128/IAI.68.11.6139-6146.2000; Gunn JS, 2001, J ENDOTOXIN RES, V7, P57, DOI 10.1177/09680519010070011001; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; Hegeman AD, 2002, BIOCHEMISTRY-US, V41, P2797, DOI 10.1021/bi011748c; Hegeman AD, 2001, BIOCHEMISTRY-US, V40, P6598, DOI 10.1021/bi010441a; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, NEWSLETT PROTEIN CRY, V26, P1; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Noland BW, 2002, STRUCTURE, V10, P1569, DOI 10.1016/S0969-2126(02)00879-1; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Ohl ME, 2001, ANNU REV MED, V52, P259, DOI 10.1146/annurev.med.52.1.259; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Schmitt E, 1998, EMBO J, V17, P6819, DOI 10.1093/emboj/17.23.6819; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Scott MG, 2000, CRIT REV IMMUNOL, V20, P407; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6294, DOI 10.1021/bi970025j; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Wosten MMSM, 2000, CELL, V103, P113, DOI 10.1016/S0092-8674(00)00092-1; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	49	47	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23000	23008		10.1074/jbc.M501534200	http://dx.doi.org/10.1074/jbc.M501534200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15809294	Green Accepted, hybrid			2022-12-27	WOS:000229741800055
J	Baerson, SR; Sanchez-Moreiras, A; Pedrol-Bonjoch, N; Schulz, M; Kagan, IA; Agarwal, AK; Reigosa, MJ; Duke, SO				Baerson, SR; Sanchez-Moreiras, A; Pedrol-Bonjoch, N; Schulz, M; Kagan, IA; Agarwal, AK; Reigosa, MJ; Duke, SO			Detoxification and transcriptome response in Arabidopsis seedlings exposed to the allelochemical benzoxazolin-2(3H)-one	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASES; REGULATORY ELEMENTS; GENE-EXPRESSION; PLANT DEFENSE; DNA-BINDING; MOLECULAR CHARACTERIZATION; SIGNALING PATHWAYS; ABC TRANSPORTERS; SALICYLIC-ACID; FATTY-ACIDS	Benzoxazolin-2(3H)-one (BOA) is an allelochemical most commonly associated with monocot species, formed from the O-glucoside of 2,4-dihydroxy-2H-1,4-benzoxazin-3(4H)-one by a two-step degradation process. The capacity of Arabidopsis to detoxify exogenously supplied BOA was analyzed by quantification of the major known metabolites BOA-6-OH, BOA-6-O-glucoside, and glucoside carbamate, revealing that detoxification occurs predominantly through O-glucosylation of the intermediate BOA-6-OH, most likely requiring the sequential action of as-yet-unidentified cytochrome P450 and UDP-glucosyltransferase activities. Transcriptional profiling experiments were also performed with Arabidopsis seedlings exposed to BOA concentrations, representing I-50 and I-80 levels based on root elongation inhibition assays. One of the largest functional categories observed for BOA-responsive genes corresponded to protein families known to participate in cell rescue and defense, with the majority of these genes potentially associated with chemical detoxification pathways. Further experiments using a subset of these genes revealed that many are also transcriptionally induced by a variety of structurally diverse xenobiotic compounds, suggesting they comprise components of a coordinately regulated, broad specificity xenobiotic defense response. The data significantly expand upon previous studies examining plant transcriptional responses to allelo-chemicals and other environmental toxins and provide novel insights into xenobiotic detoxification mechanisms in plants.	USDA ARS, Nat Prod Utilizat Res Unit, University, MS 38677 USA; Univ Vigo, Fac Ciencias, Lab Ecofisiol Vexetal, Vigo 36310, Spain; SERIDA, Area Nutr Pastos & Forrajes, Estacion Expt La Mata, Grado 33820, Spain; Univ Bonn, Inst Mol Physiol & Biotechnol Pflanzen, D-53115 Bonn, Germany; Univ Mississippi, Natl Ctr Nat Prod Res, University, MS 38677 USA	United States Department of Agriculture (USDA); Universidade de Vigo; Servicio Regional Investigacion Desarrollo Agroalimentario - SERIDA; University of Bonn; University of Mississippi	Baerson, SR (corresponding author), USDA ARS, Nat Prod Utilizat Res Unit, POB 8048, University, MS 38677 USA.	sbaerson@olemiss.edu	Pedrol, Nuria/I-6228-2019; Reigosa, Manuel J/K-3551-2013; Roger, Manuel Joaquín Reigosa/O-4438-2019; Agarwal, Ameeta K./H-3935-2019; Sánchez-Moreiras, Adela M/A-8222-2011	Pedrol, Nuria/0000-0001-6725-373X; Reigosa, Manuel J/0000-0003-0527-1849; Roger, Manuel Joaquín Reigosa/0000-0003-0527-1849; Sánchez-Moreiras, Adela M/0000-0002-0771-9259				Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Andrade MA, 2001, PLANT MOL BIOL, V46, P603, DOI 10.1023/A:1010650809272; Bais HP, 2004, TRENDS PLANT SCI, V9, P26, DOI 10.1016/j.tplants.2003.11.008; Bais HP, 2003, SCIENCE, V301, P1377, DOI 10.1126/science.1083245; Barnes J. P., 1986, The science of allelopathy, P271; Batard Y, 1998, PLANT J, V14, P111, DOI 10.1046/j.1365-313X.1998.00099.x; Campbell EJ, 2003, PLANT PHYSIOL, V133, P1272, DOI 10.1104/pp.103.024182; Cobbett C., 2002, ARABIDOPSIS, P1; COLE DJ, 1994, PESTIC SCI, V42, P209, DOI 10.1002/ps.2780420309; COLE DJ, 2000, METABOLISM ARGROCHEM, P108; Coleman JOD, 1997, TRENDS PLANT SCI, V2, P144, DOI 10.1016/S1360-1385(97)01019-4; COLES B, 1985, DRUG METAB REV, V15, P1307, DOI 10.3109/03602538409029962; Darley CP, 2001, PLANT MOL BIOL, V47, P179, DOI 10.1023/A:1010687600670; Davies J, 1999, PESTIC SCI, V55, P1043, DOI 10.1002/(SICI)1096-9063(199911)55:11&lt;1043::AID-PS60&gt;3.0.CO;2-L; De Veylder L, 1997, PLANT CELL PHYSIOL, V38, P568, DOI 10.1093/oxfordjournals.pcp.a029206; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; DeRidder BP, 2002, PLANT PHYSIOL, V130, P1497, DOI 10.1104/pp.010066; Despres C, 2003, PLANT CELL, V15, P2181, DOI 10.1105/tpc.012849; Dixon DP, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews3004; Duke SO, 2002, J PESTIC SCI, V27, P298; Duval M, 2002, PLANT MOL BIOL, V50, P237, DOI 10.1023/A:1016028530943; ENGELS WR, 1993, TRENDS BIOCHEM SCI, V18, P448, DOI 10.1016/0968-0004(93)90148-G; Eulgem T, 1999, EMBO J, V18, P4689, DOI 10.1093/emboj/18.17.4689; Eulgem T, 2000, TRENDS PLANT SCI, V5, P199, DOI 10.1016/S1360-1385(00)01600-9; Frey M, 1997, SCIENCE, V277, P696, DOI 10.1126/science.277.5326.696; Friebe A., 2001, Journal of Crop Production, V4, P379, DOI 10.1300/J144v04n02_18; Fukuda Y, 1997, PLANT MOL BIOL, V34, P81, DOI 10.1023/A:1005737128339; Gonzalez LF, 1999, PHYTOCHEMISTRY, V50, P931, DOI 10.1016/S0031-9422(98)00635-9; Haselden JN, 1998, BIOCHEM PHARMACOL, V56, P1591, DOI 10.1016/S0006-2952(98)00195-6; Hegedus D, 2003, PLANT MOL BIOL, V53, P383, DOI 10.1023/B:PLAN.0000006944.61384.11; HERSHEY HP, 1991, PLANT MOL BIOL, V17, P679, DOI 10.1007/BF00037053; Inderjit, 2003, PLANTA, V217, P529, DOI 10.1007/s00425-003-1054-z; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; Johnson C, 2001, J BIOL CHEM, V276, P172, DOI 10.1074/jbc.M005143200; Kankainen M, 2004, NUCLEIC ACIDS RES, V32, pW222, DOI 10.1093/nar/gkh463; Klein M, 1996, J BIOL CHEM, V271, P29666, DOI 10.1074/jbc.271.47.29666; Kliewer SA, 2002, ENDOCR REV, V23, P687, DOI 10.1210/er.2001-0038; KOMIVES T, 1991, Z NATURFORSCH C, V46, P798; Krawczyk S, 2002, NUCLEIC ACIDS RES, V30, P775, DOI 10.1093/nar/30.3.775; Lescot M, 2002, NUCLEIC ACIDS RES, V30, P325, DOI 10.1093/nar/30.1.325; Lim EK, 2003, GLYCOBIOLOGY, V13, P139, DOI 10.1093/glycob/cwg017; Lim EK, 2002, J BIOL CHEM, V277, P586, DOI 10.1074/jbc.M109287200; Loutre C, 2003, PLANT J, V34, P485, DOI 10.1046/j.1365-313X.2003.01742.x; Martinoia E, 2002, PLANTA, V214, P345, DOI 10.1007/s004250100661; Matvienko M, 2001, PLANT J, V25, P375, DOI 10.1046/j.1365-313x.2001.00971.x; Nebert DW, 2002, GENET MED, V4, P62, DOI 10.1097/00125817-200203000-00003; Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Oppermann UCT, 2000, TOXICOLOGY, V144, P71, DOI 10.1016/S0300-483X(99)00192-4; Parkinson A, 1996, TOXICOLOGY BASIC SCI, P113; Pflugmacher S, 1998, PLANT PHYSIOL, V117, P123, DOI 10.1104/pp.117.1.123; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; RAMSEY RJL, 2001, ACS SYM SER, V777, P310; Redman JC, 2004, PLANT J, V38, P545, DOI 10.1111/j.1365-313X.2004.02061.x; Richards KD, 1995, PLANT PHYSIOL, V109, P1497; Robatzek S, 2002, GENE DEV, V16, P1139, DOI 10.1101/gad.222702; Rombauts S, 2003, PLANT PHYSIOL, V132, P1162, DOI 10.1104/pp.102.017715; Rosenfeld JM, 2003, MOL ENDOCRINOL, V17, P1268, DOI 10.1210/me.2002-0421; Roth CM, 2000, AGRON J, V92, P855, DOI 10.2134/agronj2000.925855x; Rushmore TH, 2002, CURR DRUG METAB, V3, P481, DOI 10.2174/1389200023337171; Rushton PJ, 1996, EMBO J, V15, P5690, DOI 10.1002/j.1460-2075.1996.tb00953.x; Rushton PJ, 2002, PLANT CELL, V14, P749, DOI 10.1105/tpc.010412; Sanchez-Fernandez R, 1998, MOL GEN GENET, V258, P655, DOI 10.1007/s004380050779; SANDERMANN H, 1992, TRENDS BIOCHEM SCI, V17, P82, DOI 10.1016/0968-0004(92)90507-6; Sandermann H, 2004, TRENDS PLANT SCI, V9, P406, DOI 10.1016/j.tplants.2004.06.001; Sandermann H, 1999, CURR PLANT SCI BIOT, V36, P321; Schulz M, 1999, CHEMOECOLOGY, V9, P133, DOI 10.1007/s000490050044; Sicker D, 2000, INT REV CYTOL, V198, P319; Sicker D, 2001, PHYTOCHEMISTRY, V58, P819, DOI 10.1016/S0031-9422(01)00299-0; SICKER D, 2004, ALLELOPATHY CHEM MOD, P77; Singh KB, 2002, CURR OPIN PLANT BIOL, V5, P430, DOI 10.1016/S1369-5266(02)00289-3; Stiborova M, 2000, PHYTOCHEMISTRY, V54, P353, DOI 10.1016/S0031-9422(00)00123-0; Sueyoshi T, 2001, ANNU REV PHARMACOL, V41, P123, DOI 10.1146/annurev.pharmtox.41.1.123; Theodoulou FL, 2003, PEST MANAG SCI, V59, P202, DOI 10.1002/ps.576; Thijs G, 2002, J COMPUT BIOL, V9, P447, DOI 10.1089/10665270252935566; Tommasini R, 1997, FEBS LETT, V411, P206, DOI 10.1016/S0014-5793(97)00702-3; Uquillas C, 2004, MOL PLANT MICROBE IN, V17, P34, DOI 10.1094/MPMI.2004.17.1.34; van den Brule S, 2002, PLANTA, V216, P95, DOI 10.1007/s00425-002-0889-z; van Helden J, 2003, NUCLEIC ACIDS RES, V31, P3593, DOI 10.1093/nar/gkg567; Vessey DA, 1999, BBA-GEN SUBJECTS, V1428, P455, DOI 10.1016/S0304-4165(99)00088-4; Wagner U, 2002, PLANT MOL BIOL, V49, P515, DOI 10.1023/A:1015557300450; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Weston LA, 2003, CRIT REV PLANT SCI, V22, P367, DOI 10.1080/713610861; WIEGAND RC, 1986, PLANT MOL BIOL, V7, P235, DOI 10.1007/BF00752897; Windsor B, 2003, NAT BIOTECHNOL, V21, P428, DOI 10.1038/nbt809; Wu HW, 2000, J AGR FOOD CHEM, V48, P5321, DOI 10.1021/jf0006473; Xu WY, 2001, GENE, V272, P61, DOI 10.1016/S0378-1119(01)00516-9; Zhang LH, 1997, P NATL ACAD SCI USA, V94, P9984, DOI 10.1073/pnas.94.18.9984	88	142	155	0	50	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21867	21881		10.1074/jbc.M500694200	http://dx.doi.org/10.1074/jbc.M500694200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824099	hybrid, Green Submitted			2022-12-27	WOS:000229557900027
J	Paleotti, O; Macia, E; Luton, F; Klein, S; Partisani, M; Chardin, P; Kirchhausen, T; Franco, M				Paleotti, O; Macia, E; Luton, F; Klein, S; Partisani, M; Chardin, P; Kirchhausen, T; Franco, M			The small G-protein Arf6(GTP) recruits the AP-2 adaptor complex to membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PLASMA-MEMBRANE; PHOSPHOLIPASE-D; EXCHANGE FACTOR; DOWNSTREAM EFFECTOR; CLATHRIN ADAPTERS; ARF6; BINDING; RECEPTOR; DOMAIN	The small GTP-binding protein ADP-ribosylation factor 6 (Arf6) is involved in plasma membrane/endosomes trafficking. However, precisely how the activation of Arf6 regulates vesicular transport is still unclear. Here, we show that, in vitro, recombinant Arf6GTP recruits purified clathrin-adaptor complex AP-2 (but not AP-1) onto phospholipid liposomes in the absence of phosphoinositides. We also show that phosphoinositides and Arf6 tightly cooperate to translocate AP-2 to the membrane. In vivo, Arf6GTP (but not Arf6GDP) was found associated to AP-2. The expression of the GTP-locked mutant of Arf6 leads to the plasma membrane redistribution of AP-2 in Arf6GTP-enriched areas. Finally, we demonstrated that the expression of the GTP-locked mutant of Arf6 inhibits transferrin receptor internalization without affecting its recycling. Altogether, our results demonstrated that Arf6GTP interacts specifically with AP-2 and promotes its membrane recruitment. These findings strongly suggest that Arf6 plays a major role in clathrin-mediated endocytosis by directly controlling the assembly of the AP-2/clathrin coat.	CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Valbonne, France; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Ctr Blood Res, Biomed Res Inst, Boston, MA 02115 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)	Franco, M (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, 660 Route Lucioles, F-06560 Valbonne, France.	franco@ipmc.cnrs.fr	Luton, Frederic/N-7673-2017; FRANCO, michel/AAA-9735-2021; Macia, Eric/AAW-2964-2021	macia, eric/0000-0003-3686-2000; Franco, Michel/0000-0003-1853-8661				Aikawa Y, 2003, J CELL BIOL, V162, P647, DOI 10.1083/jcb.200212142; Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; Blagoveshchenskaya AD, 2002, CELL, V111, P853, DOI 10.1016/S0092-8674(02)01162-5; Boehm M, 2001, MOL BIOL CELL, V12, P2907, DOI 10.1091/mbc.12.10.2907; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chavrier P, 2001, METHOD ENZYMOL, V329, P272; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; FRANCO M, 1993, J BIOL CHEM, V268, P24531; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Houndolo T, 2005, J BIOL CHEM, V280, P5598, DOI 10.1074/jbc.M411456200; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Kirchhausen T, 2002, CELL, V109, P413, DOI 10.1016/S0092-8674(02)00751-1; Krauss M, 2003, J CELL BIOL, V162, P113, DOI 10.1083/jcb.200301006; Macia E, 2000, BIOCHEMISTRY-US, V39, P5893, DOI 10.1021/bi992795w; Macia E, 2004, J CELL SCI, V117, P2389, DOI 10.1242/jcs.01090; Macia E, 2001, J BIOL CHEM, V276, P24925, DOI 10.1074/jbc.M103284200; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; McMahon HT, 2004, CURR OPIN CELL BIOL, V16, P379, DOI 10.1016/j.ceb.2004.06.009; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; Padron D, 2003, J CELL BIOL, V162, P693, DOI 10.1083/jcb.200302051; PALACIOS F, 2002, NAT CELL BIOL, V11, P11; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Rohde G, 2002, J CELL BIOL, V158, P209, DOI 10.1083/jcb.200203103; Traub LM, 2003, J CELL BIOL, V163, P203, DOI 10.1083/jcb.200309175	35	84	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21661	21666		10.1074/jbc.m503099200	http://dx.doi.org/10.1074/jbc.m503099200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802264	hybrid			2022-12-27	WOS:000229438800092
J	Piven, I; Ajlani, G; Sokolenko, A				Piven, I; Ajlani, G; Sokolenko, A			Phycobilisome linker proteins are phosphorylated in Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN PCC-7942; PSBH GENE-PRODUCT; PHOTOSYSTEM-II; CYANOBACTERIAL PHYCOBILISOMES; MOLECULAR CHARACTERIZATION; POLYPEPTIDE COMPOSITION; LESS MUTANT; LIGHT; DEGRADATION; COMPLEX	The controversial issue of protein phosphorylation from the photosynthetic apparatus of Synechocystis sp. PCC 6803 has been reinvestigated using new detection tools that include various immunological and in vivo labeling approaches. The set of phosphoproteins detected with these methods includes ferredoxin-NADPH reductase and the linker proteins of the phycobilisome antenna. Using mutants that lack a specific set of linker proteins and are affected in phycobilisome assembly, we show that the phosphoproteins from the phycobilisomes correspond to the membrane, rod, and rod-core linkers. These proteins are in a phosphorylated state within the assembled phycobilisomes. Their dephosphorylation requires partial disassembly of the phycobilisomes and further contributes to their complete disassembly in vitro. In vivo we observed linker dephosphorylation upon long-term exposure to higher light intensities and under nitrogen limitation, two conditions that lead to remodeling and turnover of phycobilisomes. We conclude that this phosphorylation process is instrumental in the regulation of assembly/disassembly of phycobilisomes and should participate in signaling for their proteolytic cleavage and degradation.	Univ Munich, Bereich Bot, Dept Biol 1, D-80638 Munich, Germany; CEA Saclay, Dept Biol Joliot Curie, Sect Biophys Fonct Membranaires, F-91191 Gif Sur Yvette, France	University of Munich; CEA; UDICE-French Research Universities; Universite Paris Saclay	Sokolenko, A (corresponding author), Univ Munich, Bereich Bot, Dept Biol 1, Menzingerstr 67, D-80638 Munich, Germany.	Anna.Sokolenko@lrz.uni-muenchen.de						Ajlani G, 1998, PLANT MOL BIOL, V37, P577, DOI 10.1023/A:1005924730298; ALLEN JF, 1985, FEBS LETT, V193, P271, DOI 10.1016/0014-5793(85)80167-8; Anderson LK, 1998, MOL MICROBIOL, V30, P467, DOI 10.1046/j.1365-2958.1998.01081.x; [Anonymous], [No title captured]; Baier K, 2004, MICROBIOL-SGM, V150, P2739, DOI 10.1099/mic.0.27153-0; Baier K, 2001, FEMS MICROBIOL LETT, V195, P35, DOI 10.1111/j.1574-6968.2001.tb10494.x; BELKNAP WR, 1987, EMBO J, V6, P871, DOI 10.1002/j.1460-2075.1987.tb04833.x; BLOYE SA, 1992, PLANT PHYSIOL, V99, P601, DOI 10.1104/pp.99.2.601; BONAVENTURA C, 1969, BIOCHIM BIOPHYS ACTA, V189, P366, DOI 10.1016/0005-2728(69)90168-6; BRUCE D, 1989, BIOCHIM BIOPHYS ACTA, V974, P66, DOI 10.1016/S0005-2728(89)80166-5; CAPUANO V, 1991, J BIOL CHEM, V266, P7239; COLLIER JL, 1994, EMBO J, V13, P1039, DOI 10.1002/j.1460-2075.1994.tb06352.x; COLLIER JL, 1992, J BACTERIOL, V174, P4718, DOI 10.1128/JB.174.14.4718-4726.1992; DELORIMIER RM, 1992, PLANT PHYSIOL, V98, P1003, DOI 10.1104/pp.98.3.1003; DEVITRY C, 1991, J BIOL CHEM, V266, P16614; Dolganov N, 1999, J BACTERIOL, V181, P610, DOI 10.1128/JB.181.2.610-617.1999; DUKE CS, 1989, J BACTERIOL, V171, P1960, DOI 10.1128/jb.171.4.1960-1966.1989; FORCHHAMMER K, 1994, J BACTERIOL, V176, P84, DOI 10.1128/JB.176.1.84-91.1994; GARNIER F, 1994, PLANT PHYSIOL, V106, P747, DOI 10.1104/pp.106.2.747; GLAZER AN, 1989, J BIOL CHEM, V264, P1; GOTTSCHALK L, 1991, PHOTOCHEM PHOTOBIOL, V54, P283, DOI 10.1111/j.1751-1097.1991.tb02017.x; Grossman AR, 2001, J BIOL CHEM, V276, P11449, DOI 10.1074/jbc.R100003200; GROSSMAN AR, 1993, J BACTERIOL, V175, P575, DOI 10.1128/JB.175.3.575-582.1993; HARRISON MA, 1991, FEBS LETT, V282, P295, DOI 10.1016/0014-5793(91)80499-S; HARRISON MA, 1990, THESIS U LEEDS UK; HODGES M, 1990, BIOCHIM BIOPHYS ACTA, V1052, P446, DOI 10.1016/0167-4889(90)90154-6; JAMES CA, 1992, BIOCHEM SOC T, V21, pS3; Koivuniemi A, 1995, BIOCHEMISTRY-US, V34, P16022, DOI 10.1021/bi00049a016; Komenda J, 2002, EUR J BIOCHEM, V269, P610, DOI 10.1046/j.0014-2956.2001.02693.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li H, 2002, ARCH MICROBIOL, V178, P256, DOI 10.1007/s00203-002-0446-y; MANN NH, 1994, MICROBIOL-SGM, V140, P3207, DOI 10.1099/13500872-140-12-3207; MURATA N, 1969, BIOCHIM BIOPHYS ACTA, V172, P242, DOI 10.1016/0005-2728(69)90067-X; PAWSON T, 1994, FASEB J, V8, P1112, DOI 10.1096/fasebj.8.14.7958615; Pojidaeva E, 2004, J BACTERIOL, V186, P3991, DOI 10.1128/JB.186.12.3991-3999.2004; Pursiheimo S, 1998, FEBS LETT, V423, P178, DOI 10.1016/S0014-5793(98)00088-X; RACE HL, 1993, FEBS LETT, V323, P35, DOI 10.1016/0014-5793(93)81443-4; Reuter W, 1999, P NATL ACAD SCI USA, V96, P1363, DOI 10.1073/pnas.96.4.1363; RIPPKA R, 1988, METHOD ENZYMOL, V167, P3; RUSCKOWSKI M, 1982, PLANT PHYSIOL, V70, P1055, DOI 10.1104/pp.70.4.1055; Sanders C.E., 1987, PROGR PHOTOSYNTHESIS, V2, P761; SANDERS CE, 1989, BIOCHIM BIOPHYS ACTA, V976, P168, DOI 10.1016/S0005-2728(89)80226-9; SCHLUCHTER WM, 1992, BIOCHEMISTRY-US, V31, P3092, DOI 10.1021/bi00127a009; SCHUSTER G, 1984, BIOCHIM BIOPHYS ACTA, V767, P596, DOI 10.1016/0005-2728(84)90061-6; Schwarz R, 1998, P NATL ACAD SCI USA, V95, P11008, DOI 10.1073/pnas.95.18.11008; SHUKLA VK, 1992, MOL MICROBIOL, V6, P947, DOI 10.1111/j.1365-2958.1992.tb01544.x; Sidler W. A., 1994, MOL BIOL CYANOBACTER, P139, DOI [10.1007/978-94-011-0227-8_7, DOI 10.1007/978-94-011-0227-8_7]; Stec B, 1999, BIOPHYS J, V76, P2912, DOI 10.1016/S0006-3495(99)77446-1; van Waasbergen LG, 2002, J BACTERIOL, V184, P2481, DOI 10.1128/JB.184.9.2481-2490.2002; YAMANAKA G, 1980, ARCH MICROBIOL, V124, P39, DOI 10.1007/BF00407026; Yang DH, 1998, PLANT PHYSIOL, V118, P827, DOI 10.1104/pp.118.3.827; YU MH, 1982, J BIOL CHEM, V257, P3429	52	42	45	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21667	21672		10.1074/jbc.m412967200	http://dx.doi.org/10.1074/jbc.m412967200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15805115	hybrid			2022-12-27	WOS:000229438800093
J	Chow, FA; Anderson, KA; Noeldner, PK; Means, AR				Chow, FA; Anderson, KA; Noeldner, PK; Means, AR			The autonomous activity of calcium/calmodulin-dependent protein kinase IV is required for its role in transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MOLECULAR-CLONING; CALMODULIN-BINDING; SIGNALING COMPLEX; CALCIUM SIGNALS; PHOSPHATASE 2A; ACTIVATION; PHOSPHORYLATION; MECHANISM; NUCLEAR	Calcium/calmodulin-dependent kinase IV (CaMKIV) is a multifunctional serine/threonine kinase that is positively regulated by two main events. The first is the binding of calcium/calmodulin (Ca2+/CaM), which relieves intramolecular autoinhibition of the enzyme and leads to basal kinase activity. The second is activation by the upstream kinase, Ca2+/calmodulin-dependent kinase kinase. Phosphorylation of Ca2+/CaM-bound CaMKIV on its activation loop threonine ( residue Thr(200) in human CaMKIV) by Ca2+/calmodulin-dependent kinase kinase leads to increased CaMKIV kinase activity. It has also been repeatedly noted that activation of CaMKIV is accompanied by the generation of Ca2+/CaM-independent or autonomous activity, although the significance of this event has been unclear. Here we demonstrate the importance of autonomous activity to CaMKIV biological function. We show that phosphorylation of CaMKIV on Thr(200) leads to the generation of a fully Ca2+/CaM-independent enzyme. By analyzing the behavior of wild-type and mutant CaMKIV proteins in biochemical experiments and cellular transcriptional assays, we demonstrate that CaMKIV autonomous activity is necessary and sufficient for CaMKIV-mediated transcription. The ability of wild-type CaMKIV to drive cAMP response element-binding protein-mediated transcription is strictly dependent upon an initiating Ca2+ stimulus, which leads to kinase activation and development of autonomous activity in cells. Mutant CaMKIV proteins that are incapable of developing autonomous activity within a cellular context fail to drive transcription, whereas certain CaMKIV mutants that possess constitutive autonomous activity drive transcription in the absence of a Ca2+ stimulus and independent of Ca2+/ CaM binding or Thr(200) phosphorylation.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	means001@mc.duke.edu			NICHD NIH HHS [HD07503] Funding Source: Medline; NIGMS NIH HHS [GM-33976] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson KA, 2004, J BIOL CHEM, V279, P31708, DOI 10.1074/jbc.M404523200; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Bading H, 2000, EUR J BIOCHEM, V267, P5280, DOI 10.1046/j.1432-1327.2000.01565.x; Bading H, 1997, BIOCHEM BIOPH RES CO, V236, P541, DOI 10.1006/bbrc.1997.7037; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; COLBRAN RJ, 1992, NEUROCHEM INT, V21, P469, DOI 10.1016/0197-0186(92)90080-B; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Finkbeiner S, 1997, BIOESSAYS, V19, P657, DOI 10.1002/bies.950190803; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; Hardingham GE, 1998, CELL CALCIUM, V23, P131, DOI 10.1016/S0143-4160(98)90111-7; Heist EK, 1998, CELL CALCIUM, V23, P103; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Hudmon A, 2002, BIOCHEM J, V364, P593, DOI 10.1042/BJ20020228; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; Kane CD, 2000, EMBO J, V19, P691, DOI 10.1093/emboj/19.4.691; Kitani T, 1997, J BIOCHEM-TOKYO, V122, P243; Krebs J, 1998, BBA-MOL CELL RES, V1448, P183, DOI 10.1016/S0167-4889(98)00142-6; Lemrow SM, 2004, J BIOL CHEM, V279, P11664, DOI 10.1074/jbc.M312613200; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; Means AR, 1997, RECENT PROG HORM RES, V52, P389; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; SAKAGAMI H, 1992, MOL BRAIN RES, V16, P20, DOI 10.1016/0169-328X(92)90189-I; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SLAUGHTER GR, 1985, BIOCHEM BIOPH RES CO, V126, P295, DOI 10.1016/0006-291X(85)90605-9; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; SODERLING TR, 1990, ADV SEC MESS PHOSPH, V24, P206; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tokumitsu H, 1999, J BIOL CHEM, V274, P15803, DOI 10.1074/jbc.274.22.15803; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; Tokumitsu H, 2004, J BIOL CHEM, V279, P40296, DOI 10.1074/jbc.M406534200; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; Tokumitsu H, 2001, BIOCHEMISTRY-US, V40, P13925, DOI 10.1021/bi010863k; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; WILSON IA, 1985, P NATL ACAD SCI USA, V82, P5255, DOI 10.1073/pnas.82.16.5255; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200	46	46	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20530	20538		10.1074/jbc.M500067200	http://dx.doi.org/10.1074/jbc.M500067200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15769749	hybrid			2022-12-27	WOS:000229242000047
J	Coman, D; Russu, IM				Coman, D; Russu, IM			Base pair opening in three DNA-unwinding elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MUTATIONAL DEFECTS; REPLICATION; ENERGETICS; STABILITY; KINETICS; EXCHANGE; INITIATION; SEQUENCES; ACCOUNTS	DNA-unwinding elements are specific base sequences that are located in the origin of DNA replication where they provide the start point for strand separation and unwinding of the DNA double helix. In the present work we have obtained the first characterization of the opening of individual base pairs in DNA-unwinding elements. The three DNA molecules investigated reproduce the 13-mer DNA-unwinding elements present in the Escherichia coli chromosome. The base sequences of the three 13-mers are conserved in the origins of replication of enteric bacterial chromosomes. The exchange of imino protons with solvent protons was measured for each DNA as a function of the concentration of exchange catalyst using nuclear magnetic resonance spectroscopy. The exchange rates provided the rates and the equilibrium constants for opening of individual base pairs in each DNA at 20 degrees C. The results reveal that the kinetics and energetics of the opening reactions for AT/TA base pairs are different in the three DNA-unwinding elements due to long range effects of the base sequence. These differences encompass the AT/TA base pairs that are conserved in various bacterial genomes. Furthermore, a qualitative correlation is observed between the kinetics and energetics of opening of AT/TA base pairs and the location of the corresponding DNA-unwinding element in the origin of DNA replication.	Wesleyan Univ, Dept Chem, Hall Atwater Labs 203, Middletown, CT 06459 USA; Wesleyan Univ, Mol Biophys Program, Hall Atwater Labs 203, Middletown, CT 06459 USA	Wesleyan University; Wesleyan University	Russu, IM (corresponding author), Wesleyan Univ, Dept Chem, Hall Atwater Labs 203, Middletown, CT 06459 USA.	irussu@wesleyan.edu	Coman, Daniel/E-7856-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM065159] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM65159] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENHAM CJ, 1993, P NATL ACAD SCI USA, V90, P2999, DOI 10.1073/pnas.90.7.2999; BENIGHT AS, 1988, J MOL BIOL, V200, P377, DOI 10.1016/0022-2836(88)90248-3; Boulikas T, 1996, J CELL BIOCHEM, V60, P297, DOI 10.1002/(SICI)1097-4644(19960301)60:3<297::AID-JCB2>3.0.CO;2-R; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; Coman D, 2004, NUCLEIC ACIDS RES, V32, P878, DOI 10.1093/nar/gkh228; Coman D, 2002, BIOCHEMISTRY-US, V41, P4407, DOI 10.1021/bi011832s; Davey MJ, 2002, EMBO J, V21, P3148, DOI 10.1093/emboj/cdf308; ENGLANDER SW, 1983, Q REV BIOPHYS, V16, P521, DOI 10.1017/S0033583500005217; Gueron M, 1995, METHOD ENZYMOL, V261, P383; Huang Q, 2004, BIOPHYS J, V87, P14, DOI 10.1529/biophysj.103.024562; Huang YL, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-134; Huang YL, 2003, NUCLEIC ACIDS RES, V31, P3819, DOI 10.1093/nar/gkg562; Kornberg A., 1992, DNA REPLICATION; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; KOWALSKI D, 1989, EMBO J, V8, P4335, DOI 10.1002/j.1460-2075.1989.tb08620.x; LEROY JL, 1988, BIOCHEMISTRY-US, V27, P8894, DOI 10.1021/bi00425a004; LIN S, 1994, J MOL BIOL, V235, P496, DOI 10.1006/jmbi.1994.1009; MOE JG, 1990, NUCLEIC ACIDS RES, V18, P821, DOI 10.1093/nar/18.4.821; MOE JG, 1995, NUCLEIC ACIDS RES, V23, P1984, DOI 10.1093/nar/23.11.1984; NATALE DA, 1992, P NATL ACAD SCI USA, V89, P2654, DOI 10.1073/pnas.89.7.2654; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; Russu IM, 2004, METHOD ENZYMOL, V379, P152; SantaLucia J, 2004, ANNU REV BIOPH BIOM, V33, P415, DOI 10.1146/annurev.biophys.32.110601.141800; UMEK RM, 1990, P NATL ACAD SCI USA, V87, P2486, DOI 10.1073/pnas.87.7.2486; WEAST RC, 1987, CRC HDB CHEM PHYSICS, pD163; ZYSKIND JW, 1983, P NATL ACAD SCI-BIOL, V80, P1164, DOI 10.1073/pnas.80.5.1164	28	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20216	20221		10.1074/jbc.M502773200	http://dx.doi.org/10.1074/jbc.M502773200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15784615	hybrid			2022-12-27	WOS:000229242000008
J	Obhi, RK; Creuzenet, C				Obhi, RK; Creuzenet, C			Biochemical characterization of the Campylobacter jejuni Cj1294, a novel UDP-4-keto-6-deoxy-GlcNAc aminotransferase that generates UDP-4-amino-4,6-dideoxy-GalNAc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; THYMIDINE DIPHOSPHATE 4-ACETAMIDO-4,6-DIDEOXYHEXOSES; PSEUDOMONAS-AERUGINOSA PAO1; ESCHERICHIA-COLI; PROTEIN GLYCOSYLATION; HELICOBACTER-PYLORI; FLAGELLIN GLYCOSYLATION; 4-KETO-6-DEOXY-D-GLUCOSE TRANSAMINASE; POSTTRANSLATIONAL MODIFICATION; GENETIC-CHARACTERIZATION	Campylobacter jejuni produces multiple glycoproteins whose glycans contain 4-amino 6-deoxy sugars or their derivatives, such as diacetamidobacillosamine or pseudaminic acid. Because the proteoglycans contribute to bacterial virulence and their constitutive sugars are not commonly found in humans, inhibitors developed against the enzymes that are responsible for their biosynthesis could be novel therapeutic targets to fight this important food-borne pathogen. The biosynthesis of diacetamidobacillosamine is anticipated to involve a sugar nucleotide C6 dehydratase, a C4 aminotransferase and an acetyltransferase. We have identified a set of genes (cj1293, cj1294, and cj1298) potentially encoding one of each enzymatic activity, and demonstrated earlier that Cj1293 was a UDP-GlcNAc-specific C6 dehydratase. Others have shown that Cj1293 was involved in protein glycosylation. Here, we report on our investigation of the potential activity of Cj1294 as a sugar nucleotide C4 aminotransferase. Our biochemical characterization of overexpressed and purified protein shows that Cj1294 is a pyridoxal phosphate-dependent aminotransferase specific for UDP-4-keto-6-deoxy-GlcNAc that uses preferentially glutamic acid as an amino donor. A detailed physicokinetic study of Cj1294 was performed to determine the K-m of 1.28 +/- 0.2 mM and k(cat) of 11.5 +/- 1.3 min(-1). Also, two residues essential for protein stability and activity, Arg(228) and Lys(181), respectively, were identified by site-directed mutagenesis. Finally, we demonstrated by NMR analysis of purified reaction product that Cj1294 produces UDP-4-amino-4,6-dideoxy-GalNAc. These results indicate that Cj1294 is involved in the biosynthesis of diacetamidofucosamine, a C4 epimer of diacetamidobacillosamine not yet described in C. jejuni proteoglycans, suggesting that the composition of C. jejuni proteoglycans is more variable than anticipated.	Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Creuzenet, C (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, DSB 3031, London, ON N6A 5C1, Canada.	ccreuzen@uwo.ca						AGRAWAL PK, 1992, PHYTOCHEMISTRY, V31, P3307, DOI 10.1016/0031-9422(92)83678-R; Albermann C, 2001, GLYCOBIOLOGY, V11, P655, DOI 10.1093/glycob/11.8.655; Allen AG, 1998, MOL MICROBIOL, V29, P27, DOI 10.1046/j.1365-2958.1998.00878.x; Arora SK, 2001, P NATL ACAD SCI USA, V98, P9342, DOI 10.1073/pnas.161249198; Benz I, 2002, MOL MICROBIOL, V45, P267, DOI 10.1046/j.1365-2958.2002.03030.x; Bilge SS, 1996, INFECT IMMUN, V64, P4795, DOI 10.1128/IAI.64.11.4795-4801.1996; Breazeale SD, 2003, J BIOL CHEM, V278, P24731, DOI 10.1074/jbc.M304043200; Burrows LL, 1996, MOL MICROBIOL, V22, P481, DOI 10.1046/j.1365-2958.1996.1351503.x; Castric P, 2001, J BIOL CHEM, V276, P26479, DOI 10.1074/jbc.M102685200; Creuzenet C, 2000, J BIOL CHEM, V275, P34873, DOI 10.1074/jbc.M006369200; Creuzenet C, 2000, J BIOL CHEM, V275, P19060, DOI 10.1074/jbc.M001171200; Creuzenet C, 2004, FEBS LETT, V559, P136, DOI 10.1016/S0014-5793(04)00057-2; DiGiandomenico A, 2002, MOL MICROBIOL, V46, P519, DOI 10.1046/j.1365-2958.2002.03171.x; Doig P, 1996, MOL MICROBIOL, V19, P379, DOI 10.1046/j.1365-2958.1996.370890.x; Eads JC, 1999, BIOCHEMISTRY-US, V38, P9840, DOI 10.1021/bi990018q; Goon S, 2003, MOL MICROBIOL, V50, P659, DOI 10.1046/j.1365-2958.2003.03725.x; Guerry P, 1996, MOL MICROBIOL, V19, P369, DOI 10.1046/j.1365-2958.1996.369895.x; Hayashi T, 2001, DNA RES, V8, P11, DOI 10.1093/dnares/8.1.11; Hwang BY, 2004, CHEM BIOL, V11, P915, DOI 10.1016/j.chembiol.2004.04.015; Josenhans C, 2002, FEMS MICROBIOL LETT, V210, P165, DOI 10.1016/S0378-1097(02)00638-9; Kuo CC, 1996, J CLIN INVEST, V98, P2813, DOI 10.1172/JCI119109; Lindenthal C, 2001, INFECT IMMUN, V69, P52, DOI 10.1128/IAI.69.1.52-57.2001; Linton D, 2000, MOL MICROBIOL, V35, P1120, DOI 10.1046/j.1365-2958.2000.01780.x; MATSUHASHI M, 1966, J BIOL CHEM, V241, P4738; Messner P, 2003, Fortschr Chem Org Naturst, V85, P51; Miller WL, 2004, J BIOL CHEM, V279, P37551, DOI 10.1074/jbc.M404749200; Nedal A, 2004, APPL MICROBIOL BIOT, V64, P7, DOI 10.1007/s00253-003-1535-9; Noland BW, 2002, STRUCTURE, V10, P1569, DOI 10.1016/S0969-2126(02)00879-1; OHASHI H, 1971, J BIOL CHEM, V246, P2325; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; Pfoestl A, 2003, J BIOL CHEM, V278, P26410, DOI 10.1074/jbc.M300858200; Power PM, 2003, MOL MICROBIOL, V49, P833, DOI 10.1046/j.1365-2958.2003.03602.x; Power PM, 2003, FEMS MICROBIOL LETT, V218, P211, DOI 10.1111/j.1574-6968.2003.tb11520.x; Power PM, 2000, MICROBIOL-UK, V146, P967, DOI 10.1099/00221287-146-4-967; Schaffer C, 2002, J BIOL CHEM, V277, P6230, DOI 10.1074/jbc.M108873200; Schirm M, 2004, J BACTERIOL, V186, P6721, DOI 10.1128/JB.186.20.6721-6727.2004; Schirm M, 2003, MOL MICROBIOL, V48, P1579, DOI 10.1046/j.1365-2958.2003.03527.x; Soo EC, 2004, ANAL CHEM, V76, P619, DOI 10.1021/ac034875i; STIMSON E, 1995, MOL MICROBIOL, V17, P1201, DOI 10.1111/j.1365-2958.1995.mmi_17061201.x; Sweet CR, 2004, J BIOL CHEM, V279, P25400, DOI 10.1074/jbc.M400596200; Szymanski CM, 1999, MOL MICROBIOL, V32, P1022, DOI 10.1046/j.1365-2958.1999.01415.x; Szymanski CM, 2003, TRENDS MICROBIOL, V11, P233, DOI 10.1016/S0966-842X(03)00079-9; Szymanski CM, 2002, INFECT IMMUN, V70, P2242, DOI 10.1128/IAI.70.4.2242-2244.2002; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Xu DQ, 2002, INFECT IMMUN, V70, P4414, DOI 10.1128/IAI.70.8.4414-4423.2002; Young NM, 2002, J BIOL CHEM, V277, P42530, DOI 10.1074/jbc.M206114200	51	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20902	20908		10.1074/jbc.M413832200	http://dx.doi.org/10.1074/jbc.M413832200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15790564	hybrid			2022-12-27	WOS:000229242000089
J	Bebenek, K; Garcia-Diaz, M; Patishall, SR; Kunkel, TA				Bebenek, K; Garcia-Diaz, M; Patishall, SR; Kunkel, TA			Biochemical properties of Saccharomyces cerevisiae DNA polymerase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POL-MU; BETA; EXCISION; LAMBDA; FIDELITY; REPAIR; RIBONUCLEOTIDES; IDENTIFICATION; HOLOENZYME; SUGAR	Although mammals encode multiple family X DNA polymerases implicated in DNA repair, Saccharomyces cerevisiae has only one, DNA polymerase IV ( pol IV). To better understand the repair functions of pol IV, here we characterize its biochemical properties. Like mammalian pol beta and pol lambda, but not pol mu, pol IV has intrinsic 5'-2-deoxyribose-5-phosphate lyase activity. Pol IV has low processivity and can fill short gaps in DNA. Unlike the case with pol beta and pol lambda, the gap-filling activity of pol IV is not enhanced by a 5'-phosphate on the downstream primer but is stimulated by a 5'-terminal synthetic abasic site. Pol IV incorporates rNTPs into DNA with an unusually high efficiency relative to dNTPs, a property in common with pol beta but not pol mu or pol lambda. Finally, pol IV is highly inaccurate, with an unusual error specificity indicating the ability to extend primer termini with limited homology. These properties are consistent with a possible role for pol IV in base excision repair and with its known role in non-homologous end joining of double strand breaks, perhaps including those with damaged ends.	NIEHS, Genet Mol Lab, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kunkel, TA (corresponding author), NIEHS, Genet Mol Lab, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA.	kunkel@niehs.nih.gov	Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065070, Z01ES065070] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200; BOLLUM JF, 1974, ENZYMES, V10, P145; Boule JB, 2001, J BIOL CHEM, V276, P31388, DOI 10.1074/jbc.M105272200; BRAITHWAITE EK, 2005, J BIOL CHEM     0303, DOI DOI 10.1047/JBC.M411864200; CHANG LMS, 1986, CRC CR REV BIOCH MOL, V21, P27, DOI 10.3109/10409238609113608; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Garcia-Diaz M, 2004, MOL CELL, V13, P561, DOI 10.1016/S1097-2765(04)00061-9; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Hashimoto K, 2003, BIOCHEMISTRY-US, V42, P14207, DOI 10.1021/bi0348359; Joyce CM, 1997, P NATL ACAD SCI USA, V94, P1619, DOI 10.1073/pnas.94.5.1619; KUNKEL TA, 1989, MOL CELL BIOL, V9, P4447, DOI 10.1128/MCB.9.10.4447; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; Lee JW, 2004, J BIOL CHEM, V279, P805, DOI 10.1074/jbc.M307913200; LEEM SH, 1994, NUCLEIC ACIDS RES, V22, P3011, DOI 10.1093/nar/22.15.3011; Ma YM, 2004, MOL CELL, V16, P701, DOI 10.1016/j.molcel.2004.11.017; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MCCORMICK PJ, 1983, BIOCHIM BIOPHYS ACTA, V756, P36, DOI 10.1016/0304-4165(83)90021-1; McElhinny SAN, 2003, MOL CELL BIOL, V23, P2309, DOI 10.1128/MCB.23.7.2309-2315.2003; McInnis M, 2002, DNA REPAIR, V1, P311, DOI 10.1016/S1568-7864(02)00007-1; Nagasawa K, 2000, J BIOL CHEM, V275, P31233, DOI 10.1074/jbc.M004263200; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Ruiz JF, 2003, NUCLEIC ACIDS RES, V31, P4441, DOI 10.1093/nar/gkg637; Rydberg B, 2002, P NATL ACAD SCI USA, V99, P16654, DOI 10.1073/pnas.262591699; Shcherbakova PV, 2003, J BIOL CHEM, V278, P43770, DOI 10.1074/jbc.M306893200; Shimizu K, 2002, J BIOL CHEM, V277, P37422, DOI 10.1074/jbc.M204476200; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Tseng HM, 2002, J BIOL CHEM, V277, P45630, DOI 10.1074/jbc.M206861200; Vengrova S, 2004, GENE DEV, V18, P794, DOI 10.1101/gad.289404; Wilson TE, 1999, J BIOL CHEM, V274, P23599, DOI 10.1074/jbc.274.33.23599; Zhang YB, 2001, MOL CELL BIOL, V21, P7995, DOI 10.1128/MCB.21.23.7995-8006.2001	38	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20051	20058		10.1074/jbc.M501981200	http://dx.doi.org/10.1074/jbc.M501981200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15778218	hybrid			2022-12-27	WOS:000229113700075
J	Suntoke, TR; Chan, DC				Suntoke, TR; Chan, DC			The fusion activity of HIV-1 gp41 depends on interhelical interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL MEMBRANE-FUSION; COILED-COIL POCKET; CRYSTAL-STRUCTURE; ENVELOPE GLYCOPROTEIN; HELICAL INTERACTIONS; INHIBITORY-ACTIVITY; ATOMIC-STRUCTURE; CORE STRUCTURE; ECTODOMAIN	Infection by human immunodeficiency virus type I requires the fusogenic activity of gp41, the transmembrane subunit of the viral envelope protein. Crystallographic studies have revealed that fusion-active gp41 is a "trimer-of-hairpins" in which three central N-terminal helices form a trimeric coiled coil surrounded by three antiparallel C-terminal helices. This structure is stabilized primarily by hydrophobic, interhelical interactions, and several critical contacts are made between residues that form a deep cavity in the N-terminal trimer and the C-helix residues that pack into this cavity. In addition, the trimer-of-hairpins structure has an extensive network of hydrogen bonds within a conserved glutamine-rich layer of poorly understood function. Formation of the trimer-of-hairpins structure is thought to directly force the viral and target membranes together, resulting in membrane fusion and viral entry. We test this hypothesis by constructing four series of gp41 mutants with disrupted interactions between the N- and C-helices. Notably, in the three series containing mutations within the cavity, gp41 activity correlates well with the stability of the N- C interhelical interaction. In contrast, a fourth series of mutants involving the glutamine layer residue Gln-653 show fusion defects even though the stability of the hairpin is close to wild-type. These results provide evidence that gp41 hairpin stability is critical for mediating fusion and suggest a novel role for the glutamine layer in gp41 function.	CALTECH, Div Biol, Pasadena, CA 91125 USA; MIT, Div Biol, Cambridge, MA 02139 USA	California Institute of Technology; Massachusetts Institute of Technology (MIT)	Chan, DC (corresponding author), CALTECH, Div Biol, Mc 114-96,1200 E Calif Blvd, Pasadena, CA 91125 USA.	dchan@caltech.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056552] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM56552] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bar S, 2004, J VIROL, V78, P811, DOI 10.1128/JVI.78.2.811-820.2004; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5; Eckert DM, 1998, J MOL BIOL, V284, P859, DOI 10.1006/jmbi.1998.2214; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Ferrer M, 1999, NAT STRUCT BIOL, V6, P953; FERSHT A, 1999, STRUCTURE MECH PROTE, P508; Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5; Greenberg M, 2004, REV MED VIROL, V14, P321, DOI 10.1002/rmv.440; Greenberg ML, 2004, J ANTIMICROB CHEMOTH, V54, P333, DOI 10.1093/jac/dkh330; Ji H, 1999, J VIROL, V73, P8578, DOI 10.1128/JVI.73.10.8578-8586.1999; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Knappenberger JA, 2002, J MOL BIOL, V321, P1, DOI 10.1016/S0022-2836(02)00592-2; Lu J, 2004, J VIROL, V78, P4628, DOI 10.1128/JVI.78.9.4628-4637.2004; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Lu M, 1999, J VIROL, V73, P4433, DOI 10.1128/JVI.73.5.4433-4438.1999; Lu M, 2001, J VIROL, V75, P11146, DOI 10.1128/JVI.75.22.11146-11156.2001; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; Mo HM, 2004, VIROLOGY, V329, P319, DOI 10.1016/j.virol.2004.08.025; Scales SJ, 2001, P NATL ACAD SCI USA, V98, P14262, DOI 10.1073/pnas.251547598; Shu W, 2000, BIOCHEMISTRY-US, V39, P1634, DOI 10.1021/bi9921687; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Thomas ST, 2001, P NATL ACAD SCI USA, V98, P10670, DOI 10.1073/pnas.191381798; Wang SL, 2002, BIOCHEMISTRY-US, V41, P7283, DOI 10.1021/bi025648y; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Xu YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/jbc.M408782200; Yang ZN, 1999, J STRUCT BIOL, V126, P131, DOI 10.1006/jsbi.1999.4116	29	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19852	19857		10.1074/jbc.M502196200	http://dx.doi.org/10.1074/jbc.M502196200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772068	Green Accepted, hybrid			2022-12-27	WOS:000229113700053
J	Bernal, AJ; Pan, QL; Pollack, J; Rose, L; Kozik, A; Willits, N; Luo, Y; Guittet, M; Kochetkova, E; Michelmore, RW				Bernal, AJ; Pan, QL; Pollack, J; Rose, L; Kozik, A; Willits, N; Luo, Y; Guittet, M; Kochetkova, E; Michelmore, RW			Functional analysis of the plant disease resistance gene Pto using DNA shuffling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL SPECK DISEASE; DEPENDENT HYPERSENSITIVE RESPONSE; AVIRULENCE PROTEIN AVRPTO; PSEUDOMONAS-SYRINGAE; MOLECULAR-BASIS; TOMATO; KINASE; RECOGNITION; FAMILY; DOMAIN	Pto is a serine/threonine kinase that mediates resistance in tomato to strains of Pseudomonas syringae pv. tomato expressing the (a) virulence proteins AvrPto or AvrPtoB. DNA shuffling was used as a combinatorial in vitro genetic approach to dissect the functional regions of Pto. The Pto gene was shuffled with four of its paralogs from a resistant haplotype to create a library of recombinant products that was screened for interaction with AvrPto in yeast. All interacting clones and a representative sample of noninteracting clones were sequenced, and their ability to signal downstream was tested by the elicitation of a hypersensitive response in an AvrPto-dependent or -independent manner in planta. Eight candidate regions important for binding to AvrPto or for downstream signaling were identified by statistical correlations between individual amino acid positions and phenotype. A subset of the regions had previously been identified as important for recognition, confirming the validity of the shuffling approach. Three novel regions important for Pto function were validated by site-directed mutagenesis. Several chimeras and point mutants exhibited a differential interaction with (a) virulence proteins in the AvrPto and VirPphA family, demonstrating distinct binding requirements for different ligands. Additionally, the identification of chimeras that are both constitutively active as well as capable of binding AvrPto indicates that elicitation of downstream signaling does not involve a conformational change that precludes binding of AvrPto, as previously hypothesized. The correlations between phenotypes and variation generated by DNA shuffling paralleled natural variation observed between orthologs of Pto from Lycopersicon spp.	Univ Calif Davis, Genome Ctr, Dept Plant Pathol, Dept Stat, Davis, CA 95616 USA; Univ Calif Davis, Dept Plant Sci, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Michelmore, RW (corresponding author), Univ Calif Davis, Genome Ctr, Dept Plant Pathol, Dept Stat, 1 Shields Ave, Davis, CA 95616 USA.	rwmichelmore@ucdavis.edu		Bernal, Adriana/0000-0002-3557-697X				Alexandrov N. N., 1995, Pacific Symposium on Biocomputing '96, P53; Alfano JR, 2004, ANNU REV PHYTOPATHOL, V42, P385, DOI 10.1146/annurev.phyto.42.040103.110731; Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; Chang JH, 2002, MOL PLANT MICROBE IN, V15, P281, DOI 10.1094/MPMI.2002.15.3.281; Chang JH, 2001, MOL PLANT MICROBE IN, V14, P451, DOI 10.1094/MPMI.2001.14.4.451; Ellis J, 2000, CURR OPIN PLANT BIOL, V3, P278, DOI 10.1016/S1369-5266(00)00080-7; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Frederick RD, 1998, MOL CELL, V2, P241, DOI 10.1016/S1097-2765(00)80134-3; Good P, 1994, PERMUTATION TESTS PR; Hammond-Kosack KE, 2003, CURR OPIN BIOTECH, V14, P177, DOI 10.1016/S0958-1669(03)00035-1; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOSMER DW, 1989, APPL LOGISTIC REGRES; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Jackson RW, 1999, P NATL ACAD SCI USA, V96, P10875, DOI 10.1073/pnas.96.19.10875; Jackson RW, 2002, MOL PLANT PATHOL, V3, P205, DOI 10.1046/j.1364-3703.2002.00121.x; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; KELLEY LA, 1999, RECOMB 99 P 3 ANN C; Kim YJ, 2002, CELL, V109, P589, DOI 10.1016/S0092-8674(02)00743-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leister RT, 2000, PLANT J, V22, P345, DOI 10.1046/j.1365-313x.2000.00744.x; LOH YT, 1995, PLANT PHYSIOL, V108, P1735, DOI 10.1104/pp.108.4.1735; Martin GB, 2003, ANNU REV PLANT BIOL, V54, P23, DOI 10.1146/annurev.arplant.54.031902.135035; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MARTIN GB, 1994, PLANT CELL, V6, P1543, DOI 10.1105/tpc.6.11.1543; Pedley KF, 2003, ANNU REV PHYTOPATHOL, V41, P215, DOI 10.1146/annurev.phyto.41.121602.143032; Rathjen JP, 1999, EMBO J, V18, P3232, DOI 10.1093/emboj/18.12.3232; ROSE L, 2002, THESIS U CALIFORNIA; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALMERON J, 1994, EUPHYTICA, V79, P195, DOI 10.1007/BF00022519; SALMERON JM, 1994, PLANT CELL, V6, P511, DOI 10.1105/tpc.6.4.511; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; Scofield SR, 1996, SCIENCE, V274, P2063, DOI 10.1126/science.274.5295.2063; Sessa G, 2000, MICROBES INFECT, V2, P1591, DOI 10.1016/S1286-4579(00)01315-0; Sessa G, 2000, EMBO J, V19, P2257, DOI 10.1093/emboj/19.10.2257; Shan LB, 2000, MOL PLANT MICROBE IN, V13, P592, DOI 10.1094/MPMI.2000.13.6.592; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Stemmer WPC, 2002, J MOL CATAL B-ENZYM, V19, P3, DOI 10.1016/S1381-1177(02)00146-7; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; TANKSLEY SD, 1988, MOL MAPPING PLANT CH; Tu Z, 2003, CELL SIGNAL, V15, P65, DOI 10.1016/S0898-6568(02)00056-6; Wroblewski T, 2005, PLANT BIOTECHNOL J, V3, P259, DOI 10.1111/j.1467-7652.2005.00123.x; Wu AJ, 2004, PLANT CELL, V16, P2809, DOI 10.1105/tpc.104.024141; Wulff BBH, 2004, PLANT J, V40, P942, DOI 10.1111/j.1365-313X.2004.02268.x; Wulff BBH, 2001, PLANT CELL, V13, P255, DOI 10.1105/tpc.13.2.255; Xiang CB, 1999, PLANT MOL BIOL, V40, P711, DOI 10.1023/A:1006201910593; Xiao FM, 2003, PLANT PHYSIOL, V131, P1239, DOI 10.1104/pp.016113; Yang Z., 2000, PHYLOGENETIC ANAL MA	49	19	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23073	23083		10.1074/jbc.M500992200	http://dx.doi.org/10.1074/jbc.M500992200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15790558	hybrid			2022-12-27	WOS:000229741800064
J	Baldwin, J; Michnoff, CH; Malmquist, NA; White, J; Roth, MG; Rathod, PK; Phillips, MA				Baldwin, J; Michnoff, CH; Malmquist, NA; White, J; Roth, MG; Rathod, PK; Phillips, MA			High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA PARASITE; DRUG-RESISTANCE; MECHANISM; LEFLUNOMIDE; IDENTIFICATION; BIOSYNTHESIS; PURIFICATION	Plasmodium falciparum is the causative agent of the most serious and fatal malarial infections, and it has developed resistance to commonly employed chemotherapeutics. The de novo pyrimidine biosynthesis enzymes offer potential as targets for drug design, because, unlike the host, the parasite does not have pyrimidine salvage pathways. Dihydroorotate dehydrogenase (DHODH) is a flavin-dependent mitochondrial enzyme that catalyzes the fourth reaction in this essential pathway. Coenzyme Q (CoQ) is utilized as the oxidant. Potent and species-selective inhibitors of malarial DHODH were identified by high-throughput screening of a chemical library, which contained 220,000 drug-like molecules. These novel inhibitors represent a diverse range of chemical scaffolds, including a series of halogenated phenyl benzamide/naphthamides and urea-based compounds containing napthyl or quinolinyl substituents. Inhibitors in these classes with IC50 values below 600 nM were purified by high pressure liquid chromatography, characterized by mass spectroscopy, and subjected to kinetic analysis against the parasite and human enzymes. The most active compound is a competitive inhibitor of CoQ with an IC50 against malarial DHODH of 16 nM, and it is 12,500-fold less active against the human enzyme. Site-directed mutagenesis of residues in the CoQ-binding site significantly reduced inhibitor potency. The structural basis for the species selective enzyme inhibition is explained by the variable amino acid sequence in this binding site, making DHODH a particularly strong candidate for the development of new anti-malarial compounds.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75230 USA; Univ Washington, Dept Chem & Pathobiol, Seattle, WA 98195 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Phillips, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.	margaret.phillips@UTSouthwestern.edu		Malmquist, Nicholas/0000-0003-2822-8245; Roth, Michael/0000-0002-9056-332X	NIAID NIH HHS [AI 60360, R01 AI053680, AI 26912, AI 053680] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053680, R29AI026912, R01AI026912, R21AI053680, R56AI053680, P01AI060360] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin J, 2002, J BIOL CHEM, V277, P41827, DOI 10.1074/jbc.M206854200; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Copeland RA, 2000, J BIOL CHEM, V275, P33373, DOI 10.1074/jbc.M004451200; Davis JP, 1996, BIOCHEMISTRY-US, V35, P1270, DOI 10.1021/bi952168g; Davis JP, 1997, BIOCHEM PHARMACOL, V54, P459, DOI 10.1016/S0006-2952(97)00197-4; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; Fox RI, 1999, CLIN IMMUNOL, V93, P198, DOI 10.1006/clim.1999.4777; GREENE S, 1995, BIOCHEM PHARMACOL, V50, P861, DOI 10.1016/0006-2952(95)00255-X; GUTTERIDGE WE, 1970, J PROTOZOOL, V17, P89, DOI 10.1111/j.1550-7408.1970.tb05163.x; Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6; Herrmann ML, 2000, IMMUNOPHARMACOLOGY, V47, P273, DOI 10.1016/S0162-3109(00)00191-0; HINES V, 1989, BIOCHEMISTRY-US, V28, P1222, DOI 10.1021/bi00429a040; Jiang SP, 2001, ANTIMICROB AGENTS CH, V45, P2577, DOI 10.1128/AAC.45.9.2577-2584.2001; KANE HJ, 1980, MOL BIOCHEM PARASIT, V1, P347, DOI 10.1016/0166-6851(80)90052-3; KRUNGKRAI J, 1991, BIOCHEMISTRY-US, V30, P1934, DOI 10.1021/bi00221a029; KRUNGKRAI J, 1995, BBA-GEN SUBJECTS, V1243, P351, DOI 10.1016/0304-4165(94)00158-T; Liu SP, 2000, STRUCT FOLD DES, V8, P25, DOI 10.1016/S0969-2126(00)00077-0; Loffler M, 1997, MOL CELL BIOCHEM, V174, P125, DOI 10.1023/A:1006859115450; Marcinkeviciene J, 2000, BIOCHEM PHARMACOL, V60, P339, DOI 10.1016/S0006-2952(00)00348-8; McGovern SL, 2003, J MED CHEM, V46, P4265, DOI 10.1021/jm030266r; McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y; Papageorgiou C, 2001, J MED CHEM, V44, P1986, DOI 10.1021/jm010822m; Rathod PK, 1997, P NATL ACAD SCI USA, V94, P9389, DOI 10.1073/pnas.94.17.9389; REYES P, 1982, MOL BIOCHEM PARASIT, V5, P275, DOI 10.1016/0166-6851(82)90035-4; Ryan AJ, 2003, J MED CHEM, V46, P3448, DOI 10.1021/jm0340896; Seidler J, 2003, J MED CHEM, V46, P4477, DOI 10.1021/jm030191r; SEYMOUR KK, 1994, BIOCHEMISTRY-US, V33, P5268, DOI 10.1021/bi00183a033; WHITE NJ, 1992, J ANTIMICROB CHEMOTH, V30, P571, DOI 10.1093/jac/30.5.571; WILLIAMSON RA, 1995, J BIOL CHEM, V270, P22467, DOI 10.1074/jbc.270.38.22467; Winstanley PA, 2002, MICROBES INFECT, V4, P157, DOI 10.1016/S1286-4579(01)01523-4; Zhang K, 2002, SCIENCE, V296, P545, DOI 10.1126/science.1068274	32	157	168	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21847	21853		10.1074/jbc.M501100200	http://dx.doi.org/10.1074/jbc.M501100200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15795226	hybrid			2022-12-27	WOS:000229557900024
J	Shumskaya, MA; Paithoonrangsarid, K; Kanesaki, Y; Los, DA; Zinchenko, VV; Tanticharoen, M; Suzuki, I; Murata, N				Shumskaya, MA; Paithoonrangsarid, K; Kanesaki, Y; Los, DA; Zinchenko, VV; Tanticharoen, M; Suzuki, I; Murata, N			Identical Hik-Rre systems are involved in perception and transduction of salt signals and hyperosmotic signals but regulate the expression of individual genes to different extents in Synechocystis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSMOTIC-STRESS; SP PCC-6803; HISTIDINE KINASES; MECHANISM; PROTEINS; SENSORS; PATHWAY; SETS	In previous studies, we characterized five histidine kinases (Hiks) and the cognate response regulators (Rres) that control the expression of similar to 70% of the hyperosmotic stress-inducible genes in the cyanobacterium Synechocystis sp. PCC 6803. In the present study, we screened a gene knock-out library of Rres by RNA slot-blot hybridization and with a genome-wide DNA microarray and identified three Hik-Rre systems, namely, Hik33-Rre31, Hik10-Rre3, and Hik16-Hik41-Rre17, as well as another system that included Rre1, that were involved in perception of salt stress and transduction of the signal. We found that these Hik-Rre systems were identical to those that were involved in perception and transduction of the hyperosmotic stress signal. We compared the induction factors of the salt stress- and hyperosmotic stress- inducible genes that are located downstream of each system and found that these genes responded to the two kinds of stress to different respective extents. In addition, the Hik33-Rre31 system regulated the expression of genes that were specifically induced by hyperosmotic stress, whereas the system that included Rre1 regulated the expression of one or two genes that were specifically induced either by salt stress or by hyperosmotic stress. Our observations suggest that the perception of salt and hyperosmotic stress by the Hik-Rre systems is complex and that salt stress and hyperosmotic stress are perceived as distinct signals by the Hik-Rre systems.	Natl Inst Basic Biol, Div Cellular Regulat, Okazaki, Aichi 4448585, Japan; Russian Acad Sci, Inst Plant Physiol, Moscow 127276, Russia; Natl Ctr Genet Engn & Biotechnol, Bangkok 12120, Thailand; Moscow MV Lomonosov State Univ, Dept Genet, Moscow 119899, Russia; Grad Univ Adv Studies, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Russian Academy of Sciences; Timiryazev Institute of Plant Physiology; National Science & Technology Development Agency - Thailand; National Center Genetic Engineering & Biotechnology (BIOTEC); Lomonosov Moscow State University; Graduate University for Advanced Studies - Japan	Murata, N (corresponding author), Natl Inst Basic Biol, Div Cellular Regulat, Okazaki, Aichi 4448585, Japan.	murata@nibb.ac.jp	Murata, Norio/E-6569-2010; Murata, Norio/O-7945-2019; LOS, Dmitry A./C-6608-2013; Shumskaya, Maria/P-5972-2017; Kanesaki, Yu/J-3817-2017; Zinchenko, Vladislav V/K-3363-2017	Murata, Norio/0000-0002-6605-5800; LOS, Dmitry A./0000-0002-0142-7853; Shumskaya, Maria/0000-0001-7916-462X; Kanesaki, Yu/0000-0003-3537-9789; Zinchenko, Vladislav V/0000-0003-1931-2509; , Kalyanee/0000-0001-9121-3295				Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; COMEAU DE, 1985, J BACTERIOL, V164, P578, DOI 10.1128/JB.164.2.578-584.1985; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Figge RM, 2001, MOL MICROBIOL, V39, P455, DOI 10.1046/j.1365-2958.2001.02239.x; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Kaneko T, 2003, DNA RES, V10, P221, DOI 10.1093/dnares/10.5.221; Kaneko T, 1996, DNA Res, V3, P109; Kanesaki Y, 2002, BIOCHEM BIOPH RES CO, V290, P339, DOI 10.1006/bbrc.2001.6201; Kiseleva LL, 2000, J MOL MICROB BIOTECH, V2, P331; Marin K, 2003, P NATL ACAD SCI USA, V100, P9061, DOI 10.1073/pnas.1532302100; Mikami K, 2002, MOL MICROBIOL, V46, P905, DOI 10.1046/j.1365-2958.2002.03202.x; Paithoonrangsarid K, 2004, J BIOL CHEM, V279, P53078, DOI 10.1074/jbc.M410162200; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Sambrook J, 1989, MOL CLONING LAB MANU; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Suzuki I, 2001, MOL MICROBIOL, V40, P235, DOI 10.1046/j.1365-2958.2001.02379.x; Suzuki I, 2000, EMBO J, V19, P1327, DOI 10.1093/emboj/19.6.1327; van Waasbergen LG, 2002, J BACTERIOL, V184, P2481, DOI 10.1128/JB.184.9.2481-2490.2002; Van Wuytswinkel O, 2000, MOL MICROBIOL, V37, P382, DOI 10.1046/j.1365-2958.2000.02002.x; WADA H, 1989, PLANT CELL PHYSIOL, V30, P971; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999	22	123	134	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21531	21538		10.1074/jbc.m412174200	http://dx.doi.org/10.1074/jbc.m412174200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15805106	Green Published, hybrid			2022-12-27	WOS:000229438800075
J	Zheng, H; Kiss, RS; Franklin, V; Wang, MD; Haidar, B; Marcel, YL				Zheng, H; Kiss, RS; Franklin, V; Wang, MD; Haidar, B; Marcel, YL			ApoA-I lipidation in primary mouse hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; CASSETTE TRANSPORTER 1; CHOLESTEROL EFFLUX; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; TANGIER-DISEASE; CHICKEN LIVER; MEDIATED CHOLESTEROL; ABCA1 TRANSPORTER	The liver is the major site of both apolipoprotein A-I (apoA-I) synthesis and ATP-binding cassette transporter A1 (ABCA1) expression. Here, we compare the lipidation with cholesterol and phospholipid of newly synthesized human apoA-I (hapoA-I) using adenoviral vector-mediated endogenous expression or exogenously added hapoA-I in wild type and ABCA1-null hepatocytes. Hepatocytes were labeled with [H-3] cholesterol (delivered with LDL or methyl-beta-cyclodextrin), [3H] mevalonate, or [3H] choline. ABCA1 deficiency decreased apoA-I phospholipidation by 80%, but acquisition of de novo synthesized and exogenous cholesterol only decreased by 40-60%. The transfer of de novo synthesized cholesterol to apoA-I was decreased at all time points, but that of exogenously delivered cholesterol was independent of ABCA1 activity at the early time points. Progesterone does not affect apoA-I synthesis or its lipidation but inhibited the early phase of apoA-I cholesterol lipidation in both wild type and ABCA1-null hepatocytes. Fast protein liquid chromatography analysis of medium lipoproteins confirmed that with ABCA1 deficiency, the proportion of secreted high density lipoprotein-associated apoA-I and cholesterol decreased by about 50%. The very low density lipoprotein (VLDL)/LDL size fraction also contained a significant level of cholesterol in ABCA1 deficiency, consistent with the result of immunoprecipitations showing the presence of lipoproteins with both apoA-I and murine apoB. ApoA-I lipidation with newly synthesized cholesterol in ABCA1-null hepatocytes was significantly decreased by brefeldin A and monensin. In conclusion, we demonstrate that: (i) whereas most hepatic phospholipidation of apoA-I is mediated by ABCA1, acquisition of cholesterol depends on active transfer from intracellular compartments by ABCA1-dependent and -independent pathways, both sensitive to progesterone and (ii) there is separate regulation of phospholipid and cholesterol lipidation of apoA-I in hepatocytes.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Biochem, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Microbiol, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Immunol, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON K1Y 4W7, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa; University of Ottawa	Marcel, YL (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Biochem, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.	ylmarcel@ottawaheart.ca						Atger VM, 1997, J CLIN INVEST, V99, P773, DOI 10.1172/JCI119223; BANERJEE D, 1985, J CELL BIOL, V101, P1219, DOI 10.1083/jcb.101.4.1219; BANERJEE D, 1984, J CELL BIOL, V99, P1917, DOI 10.1083/jcb.99.6.1917; Banerjee D, 1997, EXP CELL RES, V235, P334, DOI 10.1006/excr.1997.3687; BANERJEE D, 1983, J CELL BIOL, V96, P651, DOI 10.1083/jcb.96.3.651; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BRESLOW JL, 1985, ANNU REV BIOCHEM, V54, P699, DOI 10.1146/annurev.biochem.54.1.699; BRESLOW JL, 1987, AM HEART J, V113, P422, DOI 10.1016/0002-8703(87)90608-9; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brown AM, 1999, BBA-MOL CELL BIOL L, V1440, P253, DOI 10.1016/S1388-1981(99)00133-X; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023; CASTLE CK, 1991, J LIPID RES, V32, P439; Cavelier LB, 2001, J BIOL CHEM, V276, P18046, DOI 10.1074/jbc.M100565200; Chisholm JW, 2002, J LIPID RES, V43, P36; Christian AE, 1999, J LIPID RES, V40, P1475; Clay MA, 1999, BIOCHEM J, V337, P445, DOI 10.1042/0264-6021:3370445; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Davidson WS, 1996, P NATL ACAD SCI USA, V93, P13605, DOI 10.1073/pnas.93.24.13605; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; Denis M, 2004, J BIOL CHEM, V279, P41529, DOI 10.1074/jbc.M406881200; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; FORTE TM, 1990, BIOCHIM BIOPHYS ACTA, V1047, P11, DOI 10.1016/0005-2760(90)90254-U; Frank PG, 2000, J LIPID RES, V41, P853; Glomset J A, 1973, Adv Lipid Res, V11, P1; Haghpassand M, 2001, J CLIN INVEST, V108, P1315, DOI 10.1172/JCI200112810; HAMILTON RL, 1991, J LIPID RES, V32, P529; HOWELL KE, 1982, J CELL BIOL, V92, P833, DOI 10.1083/jcb.92.3.833; Ishimori N, 2004, ARTERIOSCL THROM VAS, V24, P161, DOI 10.1161/01.ATV.0000104027.52895.D7; JOHNSON WJ, 1995, J BIOL CHEM, V270, P25037, DOI 10.1074/jbc.270.42.25037; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1990, J BIOL CHEM, V265, P22123; KAPLAN MR, 1985, J CELL BIOL, V101, P441, DOI 10.1083/jcb.101.2.441; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KHAN BV, 1990, BIOCHIM BIOPHYS ACTA, V1044, P297, DOI 10.1016/0005-2760(90)90073-7; Kiss RS, 2003, J BIOL CHEM, V278, P10119, DOI 10.1074/jbc.M300137200; Kojima K, 2001, BBA-MOL CELL BIOL L, V1532, P173, DOI 10.1016/S1388-1981(01)00124-X; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Lange Y, 1997, J BIOL CHEM, V272, P17018, DOI 10.1074/jbc.272.27.17018; LANGE Y, 1994, J BIOL CHEM, V269, P3411; LANGE Y, 1989, J BIOL CHEM, V264, P3786; Langmann T, 2003, CLIN CHEM, V49, P230, DOI 10.1373/49.2.230; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lee JY, 2005, CURR OPIN LIPIDOL, V16, P19, DOI 10.1097/00041433-200502000-00005; LI QQ, 1993, BIOCHEMISTRY-US, V32, P4597, DOI 10.1021/bi00068a016; Marcel YL, 2003, CURR OPIN LIPIDOL, V14, P151, DOI 10.1097/00041433-200304000-00006; Marcil M, 2003, CIRCULATION, V107, P1366, DOI 10.1161/01.CIR.0000056764.53152.F9; MAZZONE T, 1995, J LIPID RES, V36, P544; McManus DC, 2001, J BIOL CHEM, V276, P21292, DOI 10.1074/jbc.M100463200; McManus DC, 2000, J BIOL CHEM, V275, P5043, DOI 10.1074/jbc.275.7.5043; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; Neufeld EB, 2004, J BIOL CHEM, V279, P15571, DOI 10.1074/jbc.M314160200; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Olkkonen VM, 2004, CURR OPIN LIPIDOL, V15, P321, DOI 10.1097/00041433-200406000-00013; Osono Y, 1996, P NATL ACAD SCI USA, V93, P4114, DOI 10.1073/pnas.93.9.4114; Phillips MC, 1998, ATHEROSCLEROSIS, V137, pS13, DOI 10.1016/S0021-9150(97)00312-2; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Ridgway ND, 2000, BBA-MOL CELL BIOL L, V1484, P129, DOI 10.1016/S1388-1981(00)00006-8; Rodrigueza WV, 1997, ARTERIOSCL THROM VAS, V17, P383, DOI 10.1161/01.ATV.17.2.383; Rothblat GH, 1999, J LIPID RES, V40, P781; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sahoo D, 2004, J LIPID RES, V45, P1122, DOI 10.1194/jlr.M300529-JLR200; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Sniderman AD, 2003, J LIPID RES, V44, P527, DOI 10.1194/jlr.M200187-JLR200; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Sparks DL, 1999, BIOCHEMISTRY-US, V38, P1727, DOI 10.1021/bi981945k; Stolowich NJ, 2002, CELL MOL LIFE SCI, V59, P193, DOI 10.1007/s00018-002-8416-8; SUBRAHMANYAN L, 1988, SCAND J IMMUNOL, V27, P251, DOI 10.1111/j.1365-3083.1988.tb02345.x; Swift LL, 2001, J LIPID RES, V42, P218; Tall AR, 2001, J CLIN INVEST, V108, P1273; Tarugi P, 1998, J LIPID RES, V39, P731; THOMAS SS, 1995, BBA-MOL BASIS DIS, V1272, P37, DOI 10.1016/0925-4439(95)00065-C; Tsujita M, 2005, J LIPID RES, V46, P154, DOI 10.1194/jlr.M400402-JLR200; URBANI L, 1990, J BIOL CHEM, V265, P1919; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Yamauchi Y, 2004, J LIPID RES, V45, P1943, DOI 10.1194/jlr.M400264-JLR200; Yamauchi Y, 2002, BBA-MOL CELL BIOL L, V1585, P1, DOI 10.1016/S1388-1981(02)00304-9; Zheng H, 2004, CIRCULATION, V110, P272	84	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21612	21621		10.1074/jbc.m502200200	http://dx.doi.org/10.1074/jbc.m502200200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797865	hybrid			2022-12-27	WOS:000229438800086
J	Miao, WM; Hu, LG; Scrivens, PJ; Batist, G				Miao, WM; Hu, LG; Scrivens, PJ; Batist, G			Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway - Direct cross-talk between phase I and II drug-metabolizing enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR AROMATIC-COMPOUNDS; GENE-EXPRESSION; INDUCIBLE EXPRESSION; AH RECEPTOR; NAD(P)H-QUINONE OXIDOREDUCTASE; CHEMOPREVENTIVE AGENTS; OXIDATIVE STRESS; SUBUNIT GENE; CANCER; IDENTIFICATION	The aryl hydrocarbon receptor (AHR) and NF-E2 p45-related factor (NRF2) are two distinct transcription factors involved in the regulation of drug-metabolizing enzymes. Increasing evidence from several studies implies that AHR and NRF2 have direct links, but the molecular mechanism remains unknown. In this work we demonstrate for the first time that Nrf2 gene transcription is directly modulated by AHR activation. DNA sequence analyses of the mouse Nrf2 promoter revealed one xenobiotic response element (XRE)-like element (XREL1) located at -712 and two additional XRE-like elements located at +755 (XREL2) and +850 (XREL3). Functional analysis using luciferase assay showed that XREL1, XREL2, and XREL3 are all inducible by 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment, with XREL2 being the most potent. The functionality of these XRE-like elements was further confirmed by mutagenesis and gel shift experiments. Finally, we used chromatin immuno-precipitation assay to show a direct binding of AHR to the Nrf2 promoter. Cells with silenced AHR expression using siRNA also lost NRF2 mRNA induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin. These new data position NRF2- antioxidant response element downstream in the AHR-XRE pathway. Moreover, direct regulation of NRF2 by AHR contributes to couple phase I and II enzymes into an integrated system facilitating more effective xenobiotic and carcinogen detoxification.	McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University	Batist, G (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal Ctr Expt Therapeut Canc, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.	gbatist@onc.jgh.mcgill.ca						Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; DENISON MS, 1988, J BIOL CHEM, V263, P17221; Dyer KD, 2004, MAMM GENOME, V15, P126, DOI 10.1007/s00335-003-2304-x; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FUJIIKURIYAMA Y, 1992, FASEB J, V6, P706, DOI 10.1096/fasebj.6.2.1537460; Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4; Kensler TW, 2003, NAT REV CANCER, V3, P321, DOI 10.1038/nrc1076; Klenova E, 2004, J NEUROSCI, V24, P5966, DOI 10.1523/JNEUROSCI.1150-04.2004; Koliopanos A, 2002, ONCOGENE, V21, P6059, DOI 10.1038/sj.onc.1205633; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; Levi MS, 2001, CURR MED CHEM, V8, P1349, DOI 10.2174/0929867013372229; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lin CY, 2004, GENE, V334, P63, DOI 10.1016/j.gene.2004.03.016; Ma Q, 2004, BIOCHEM J, V377, P205, DOI 10.1042/BJ20031123; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Miao WM, 2004, BIOCHEM PHARMACOL, V67, P1897, DOI 10.1016/j.bcp.2004.02.009; Miao WM, 2003, MOL PHARMACOL, V64, P346, DOI 10.1124/mol.64.2.346; Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109; Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Radjendirane V, 1999, BIOCHEM PHARMACOL, V58, P1649, DOI 10.1016/S0006-2952(99)00245-2; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Rushmore TH, 2002, CURR DRUG METAB, V3, P481, DOI 10.2174/1389200023337171; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; Safe S, 2002, INT J ONCOL, V20, P1123; Sato A, 2004, J BIOCHEM, V135, P259, DOI 10.1093/jb/mvh031; Senft AP, 2002, FREE RADICAL BIO MED, V33, P1268, DOI 10.1016/S0891-5849(02)01014-6; Shen GX, 2004, J BIOL CHEM, V279, P23052, DOI 10.1074/jbc.M401368200; Sherratt PJ, 2004, METHOD ENZYMOL, V378, P286; Shertzer HG, 1998, BIOCHEM BIOPH RES CO, V253, P44, DOI 10.1006/bbrc.1998.9753; Sogawa K, 2004, BIOCHEM BIOPH RES CO, V318, P746, DOI 10.1016/j.bbrc.2004.04.090; Sudakin DL, 2003, J TOXICOL-CLIN TOXIC, V41, P195, DOI 10.1081/CLT-120019137; Vasiliou V, 1995, BIOCHEM PHARMACOL, V50, P2057, DOI 10.1016/0006-2952(95)02108-6; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang LY, 1998, J BIOL CHEM, V273, P5174, DOI 10.1074/jbc.273.9.5174; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	40	366	374	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20340	20348		10.1074/jbc.M412081200	http://dx.doi.org/10.1074/jbc.M412081200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15790560	hybrid			2022-12-27	WOS:000229242000024
J	Semov, A; Moreno, MJ; Onichtchenko, A; Abulrob, A; Ball, M; Ekiel, I; Pietrzynski, G; Stanimirovic, D; Alakhov, V				Semov, A; Moreno, MJ; Onichtchenko, A; Abulrob, A; Ball, M; Ekiel, I; Pietrzynski, G; Stanimirovic, D; Alakhov, V			Metastasis-associated protein S100A4 induces angiogenesis through interaction with annexin II and accelerated plasmin formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL SURFACE; CALCIUM-BINDING PROTEIN; MATRIX METALLOPROTEINASES; PROGNOSTIC-SIGNIFICANCE; OSTEOSARCOMA CELLS; NMR-SPECTROSCOPY; E-CADHERIN; T-PA; EXPRESSION; ACTIVATION	Many advanced tumors overexpress and secrete the S100A4 protein that is known to promote angiogenesis and metastasis development. The mechanisms of this effect and the endothelial receptor for S100A4 are both still unknown. Here we report that extracellular S100A4 interacts with annexin II, an endothelial plasminogen co-receptor. Co-localization and direct binding of S100A4 and annexin II were demonstrated, and the binding site was identified in the N-terminal region of annexin II. S100A4 alone or in a complex with annexin II accelerated tissue plasminogen activator-mediated plasminogen activation in solution and on the endothelial cell surface through interaction of the S100A4 C-terminal lysines with the lysine-binding domains of plasminogen. A synthetic peptide corresponding to the N terminus of annexin II prevented S100A4-induced plasmin formation in the endothelial cell culture. Local plasmin formation induced by circulating S100A4 could contribute to tumor-induced angiogenesis and metastasis formation that makes this protein an attractive target for new anti-cancer and anti-angiogenic therapies.	Supratek Pharma Inc, Dorval, PQ H9S 1A9, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	National Research Council Canada; National Research Council Canada	Alakhov, V (corresponding author), Supratek Pharma Inc, 215 Blvd Bouchard,Suite 1315, Dorval, PQ H9S 1A9, Canada.	Valery.Alakhov@Supratek.com						Aberg F, 2000, J COMP NEUROL, V424, P269; Ambartsumian N, 2001, ONCOGENE, V20, P4685, DOI 10.1038/sj.onc.1204636; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Baramova EN, 1997, FEBS LETT, V405, P157, DOI 10.1016/S0014-5793(97)00175-0; Barraclough R, 1998, BBA-MOL CELL RES, V1448, P190, DOI 10.1016/S0167-4889(98)00143-8; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; Bjornland K, 2001, J PEDIATR SURG, V36, P1040, DOI 10.1053/jpsu.2001.24735; Bjornland K, 1999, CANCER RES, V59, P4702; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; Clarkson J, 2003, BIOCHEM SOC T, V31, P1006; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; El-Mousawi M, 2003, J BIOL CHEM, V278, P46681, DOI 10.1074/jbc.M308681200; Endo H, 2002, J BIOL CHEM, V277, P26396, DOI 10.1074/jbc.M202244200; Felez J, 1996, THROMB HAEMOSTASIS, V76, P577; Garbuglia M, 1998, CELL CALCIUM, V24, P177, DOI 10.1016/S0143-4160(98)90127-0; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Greenway S, 2004, AM J PATHOL, V164, P253, DOI 10.1016/S0002-9440(10)63115-X; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hajjar KA, 1998, J BIOL CHEM, V273, P9987, DOI 10.1074/jbc.273.16.9987; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; Hatziapostolou M, 2003, EUR J PHARMACOL, V460, P1, DOI 10.1016/S0014-2999(02)02868-6; Homans SW, 2004, ANGEW CHEM INT EDIT, V43, P290, DOI 10.1002/anie.200300581; Hsieh HL, 2003, BIOCHEM BIOPH RES CO, V307, P375, DOI 10.1016/S0006-291X(03)01190-2; Hsieh HL, 2002, J CELL SCI, V115, P3149; JOHNSSON N, 1986, FEBS LETT, V198, P361, DOI 10.1016/0014-5793(86)80437-9; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; Kimura K, 2000, INT J ONCOL, V16, P1125; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; Kriajevska M, 2000, BBA-MOL CELL RES, V1498, P252, DOI 10.1016/S0167-4889(00)00100-2; KUBE E, 1992, J BIOL CHEM, V267, P14175; Kwaan HC, 2004, J THROMB HAEMOST, V2, P306, DOI 10.1111/j.1538-7933.2004.00593.x; Kwon MJ, 2005, FRONT BIOSCI-LANDMRK, V10, P300, DOI 10.2741/1529; Li CL, 2002, J CLIN PATHOL-MOL PA, V55, P250, DOI 10.1136/mp.55.4.250; Liu Jie, 2003, BMC Biochem, V4, P10, DOI 10.1186/1471-2091-4-10; Mailliard WS, 1996, J BIOL CHEM, V271, P719, DOI 10.1074/jbc.271.2.719; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Masuda K, 2002, ARTHRITIS RES, V4, DOI 10.1186/ar427; Mathisen B, 2003, CLIN EXP METASTAS, V20, P701, DOI 10.1023/B:CLIN.0000006819.21361.03; Mazzucchelli L, 2002, AM J PATHOL, V160, P7, DOI 10.1016/S0002-9440(10)64342-8; Ninomiya I, 2001, INT J ONCOL, V18, P715; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; Onischenko A, 1996, INVAS METAST, V16, P160; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Robertson H, 2004, J AM SOC NEPHROL, V15, P390, DOI 10.1097/01.ASN.0000108521.39082.E1; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Rudland PS, 2000, CANCER RES, V60, P1595; Ryan DG, 2003, INVEST OPHTH VIS SCI, V44, P4255, DOI 10.1167/iovs.03-0578; Schmidt-Hansen B, 2004, ONCOGENE, V23, P5487, DOI 10.1038/sj.onc.1207720; Schmidt-Hansen B, 2004, J BIOL CHEM, V279, P24498, DOI 10.1074/jbc.M400441200; Stanimirovic D, 1996, J CELL PHYSIOL, V169, P455; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; Taylor S, 2002, BRIT J CANCER, V86, P409, DOI 10.1038/sj.bjc.6600071; WATANABE M, 1993, BIOCHEM BIOPH RES CO, V196, P1376, DOI 10.1006/bbrc.1993.2405; Yonemura Y, 2000, CLIN CANCER RES, V6, P4234; ZENG FY, 1993, INT J BIOCHEM, V25, P1019, DOI 10.1016/0020-711X(93)90116-V; Zijlstra A, 2004, J BIOL CHEM, V279, P27633, DOI 10.1074/jbc.M313617200	58	188	205	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20833	20841		10.1074/jbc.M412653200	http://dx.doi.org/10.1074/jbc.M412653200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788416	hybrid			2022-12-27	WOS:000229242000081
J	Imamura, T; Kerjean, A; Heams, T; Kupiec, JJ; Thenevin, C; Paldi, A				Imamura, T; Kerjean, A; Heams, T; Kupiec, JJ; Thenevin, C; Paldi, A			Dynamic CpG and non-CpG methylation of the Peg1/Mest gene in the mouse oocyte and preimplantation embryo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; IMPRINTED GENE; METHYLTRANSFERASES; ESTABLISHMENT; EXPRESSION; REGION; CELLS; H19	In somatic tissues, the CpG island of the imprinted Peg1/Mest gene is methylated on the maternal allele. We have examined the methylation of CpG and non-CpG sites of this differentially methylated CpG island in freshly ovulated oocytes, in vitro aged oocytes, and preimplantation embryos. The CpG methylation pattern was heterogeneous in freshly ovulated oocytes, despite the fact that they all were arrested in metaphase II. After short in vitro culture, Peg1/Mest became hyper-methylated, whereas prolonged in vitro culture resulted in demethylation in a fraction of oocytes. Non-CpG methylation also occurred in a stage-specific manner. On alleles that were fully methylated at CpG sites, this modification was found, and it became reduced in two-cell stage embryos and blastocysts. These observations suggest that the process of establishment of the methylation imprint at this locus is more dynamic than previously thought.	GENETHON, F-91002 Evry, France; Inst Jacques Monod, INSERM E367, F-75005 Paris, France; Inst Cochin, F-75014 Paris, France; Natl Inst Basic Biol, Div Behav Biol, Okazaki, Aichi 4448585, Japan; Ecole Prat Hautes Etud, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE)	Paldi, A (corresponding author), GENETHON, 1 Bis Rue Int,BP60, F-91002 Evry, France.	paldi@genethon.fr	Paldi, Andras/J-5757-2013; Hu, Ruogu/B-2203-2008	IMAMURA, TAKUYA/0000-0002-1825-2084				Aranyi T, 2002, GENOMICS, V80, P558, DOI 10.1006/geno.2002.7011; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Dean W, 1998, DEVELOPMENT, V125, P2273; Doherty AS, 2000, BIOL REPROD, V62, P1526, DOI 10.1095/biolreprod62.6.1526; El-Maarri O, 2001, NAT GENET, V27, P341, DOI 10.1038/85927; Geuns E, 2003, HUM MOL GENET, V12, P2873, DOI 10.1093/hmg/ddg315; Imamura T, 2004, BIOCHEM BIOPH RES CO, V322, P593, DOI 10.1016/j.bbrc.2004.07.159; KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52; Kerjean A, 2000, HUM MOL GENET, V9, P2183, DOI 10.1093/hmg/9.14.2183; Kerjean A, 2003, EUR J HUM GENET, V11, P493, DOI 10.1038/sj.ejhg.5200990; Lefebvre L, 1997, HUM MOL GENET, V6, P1907, DOI 10.1093/hmg/6.11.1907; Lorincz MC, 2001, P NATL ACAD SCI USA, V98, P10034, DOI 10.1073/pnas.201392598; Lucifero D, 2002, GENOMICS, V79, P530, DOI 10.1006/geno.2002.6732; Malone CS, 2001, P NATL ACAD SCI USA, V98, P10404, DOI 10.1073/pnas.181206898; Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656; MCCLELLAND M, 1994, NUCLEIC ACIDS RES, V22, P3640, DOI 10.1093/nar/22.17.3640; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Paldi A, 2003, CURR TOP DEV BIOL, V53, P115, DOI 10.1016/S0070-2153(03)53003-4; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; Rougier N, 1998, GENE DEV, V12, P2108, DOI 10.1101/gad.12.14.2108; Shiota K, 2002, DIFFERENTIATION, V69, P162, DOI 10.1046/j.1432-0436.2002.690406.x; Tarin JJ, 1999, BIOL REPROD, V61, P1347, DOI 10.1095/biolreprod61.5.1347; WONNACOTT R. J., 1972, INTRO STAT; Woodcock DM, 1997, J BIOL CHEM, V272, P7810, DOI 10.1074/jbc.272.12.7810	24	80	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20171	20175		10.1074/jbc.M501749200	http://dx.doi.org/10.1074/jbc.M501749200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15778220	hybrid			2022-12-27	WOS:000229113700090
J	Charruyer, A; Grazide, S; Bezombes, C; Muller, S; Laurent, G; Jaffrezou, JP				Charruyer, A; Grazide, S; Bezombes, C; Muller, S; Laurent, G; Jaffrezou, JP			UV-C light induces raft-associated acid sphingomyelinase and JNK activation and translocation independently on a nuclear signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; ULTRAVIOLET-LIGHT; PLASMA-MEMBRANE; LYSOSOMAL SPHINGOMYELINASE; CERAMIDE GENERATION; TERMINAL KINASE; LIPID RAFTS; PROTEIN; CELLS; SKIN	The initiation of UV light-induced signaling in mammalian cells is largely considered to be subsequent to DNA damage. Several studies have also described ceramide (CER), a lipid second messenger, as a major contributor in mediating UV light-induced c-Jun N-terminal kinase (JNK) activation and cell death. It is demonstrated here that UV-C light irradiation of U937 cells results in the activation and translocation of a Zn2+-independent acid sphingomyelinase, leading to CER accumulation in raft microdomains. These CER-enriched rafts aggregate and play a functional role in JNK activation. The observation that UV-C light also induced CER generation and the externalization of acid sphingomyelinase and JNK in human platelets conclusively rules out the involvement of a nuclear signal generated by DNA damage in the initiation of a UV light response, which is generated at the plasma membrane.	CHU Purpan, Ctr Physiopathol Toulouse Purpan, INSERM, U563, F-31024 Toulouse, France; CHU Purpan, Hematol Serv, F-31059 Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Jaffrezou, JP (corresponding author), CHU Purpan, Ctr Physiopathol Toulouse Purpan, INSERM, U563, F-31024 Toulouse, France.	jean-pierre.jaffrezou@toulouse.inserm.fr	Bezombes, Christine/G-2743-2017; Bezombes, christine/X-8479-2019; Bezombes, Christine/AAC-1724-2020	Bezombes, christine/0000-0003-4079-4872; Muller, Sabina/0000-0002-4580-2758				ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; Barthelman M, 1998, CANCER RES, V58, P711; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Bettaieb A, 1996, BLOOD, V88, P1465, DOI 10.1182/blood.V88.4.1465.bloodjournal8841465; Birch-Machin MA, 2000, CLIN EXP DERMATOL, V25, P141, DOI 10.1046/j.1365-2230.2000.00605.x; Bodin S, 2001, BIOCHEMISTRY-US, V40, P15290, DOI 10.1021/bi0109313; Bugaud F, 1999, BLOOD, V94, P3800, DOI 10.1182/blood.V94.11.3800.423k25_3800_3805; Chang H, 2003, FREE RADICAL RES, V37, P655, DOI 10.1080/1071576031000094907; Chatterjee M, 2001, MOL CELL BIOCHEM, V219, P21, DOI 10.1023/A:1011083818452; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; Dai Q, 2004, ONCOGENE, V23, P3650, DOI 10.1038/sj.onc.1207430; de Gassart A, 2003, BLOOD, V102, P4336, DOI 10.1182/blood-2003-03-0871; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Galjart N, 2003, CURR OPIN CELL BIOL, V15, P48, DOI 10.1016/S0955-0674(02)00007-8; Gniadecki R, 2002, J INVEST DERMATOL, V118, P582, DOI 10.1046/j.1523-1747.2002.01716.x; Goss VL, 2003, CELL SIGNAL, V15, P709, DOI 10.1016/S0898-6568(03)00009-3; Grassme H, 2002, J BIOL CHEM, V277, P30289, DOI 10.1074/jbc.M200494200; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Grazide S, 2002, FASEB J, V16, P1685, DOI 10.1096/fj.01-0794fje; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; Gulbins E, 2004, J MOL MED, V82, P357, DOI 10.1007/s00109-004-0539-y; Gulbins E, 2002, BBA-MOL CELL BIOL L, V1585, P139, DOI 10.1016/S1388-1981(02)00334-7; Herrling T, 2003, FREE RADICAL BIO MED, V35, P59, DOI 10.1016/S0891-5849(03)00241-7; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JAFFREZOU JP, 1995, BBA-MOL CELL RES, V1266, P1, DOI 10.1016/0167-4889(94)00219-5; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kiyokawa E, 2004, BIOCHEMISTRY-US, V43, P9766, DOI 10.1021/bi049561j; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; Magnoni C, 2002, TOXICOL IN VITRO, V16, P349, DOI 10.1016/S0887-2333(02)00024-3; Matsumura Y, 2004, TOXICOL APPL PHARM, V195, P298, DOI 10.1016/j.taap.2003.08.019; Nakai Y, 2000, J NEUROSCI RES, V62, P521, DOI 10.1002/1097-4547(20001115)62:4<521::AID-JNR6>3.0.CO;2-8; Nichols BJ, 2003, CURR BIOL, V13, P686, DOI 10.1016/S0960-9822(03)00209-4; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rajendran L, 2003, P NATL ACAD SCI USA, V100, P8241, DOI 10.1073/pnas.1331629100; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Schissel SL, 1998, J BIOL CHEM, V273, P18250, DOI 10.1074/jbc.273.29.18250; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Solomon S, 2002, IMMUNOBIOLOGY, V205, P108, DOI 10.1078/0171-2985-00114; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Yamaji A, 1998, J BIOL CHEM, V273, P5300, DOI 10.1074/jbc.273.9.5300; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200	45	106	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19196	19204		10.1074/jbc.M412867200	http://dx.doi.org/10.1074/jbc.M412867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15769735	hybrid			2022-12-27	WOS:000228932300076
J	Jones, DH; Li, TY; Arystarkhova, E; Barr, KJ; Wetzel, RK; Peng, J; Markham, K; Sweadner, KJ; Fong, GH; Kidder, GM				Jones, DH; Li, TY; Arystarkhova, E; Barr, KJ; Wetzel, RK; Peng, J; Markham, K; Sweadner, KJ; Fong, GH; Kidder, GM			Na,K-ATPase from mice lacking the gamma subunit (FXYD2) exhibits altered Na+ affinity and decreased thermal stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLEMMAN-LIKE PROTEIN; RENAL MAGNESIUM LOSS; K-ATPASE; IMMUNOCYTOCHEMICAL LOCALIZATION; ALPHA-SUBUNIT; NA/K-ATPASE; PREIMPLANTATION DEVELOPMENT; FUNCTIONAL INTERACTION; CELLULAR-DISTRIBUTION; MOLECULAR-CLONING	The gamma subunit of the Na,K-ATPase, a 7-kDa single-span membrane protein, is a member of the FXYD gene family. Several FXYD proteins have been shown to bind to Na, K-ATPase and modulate its properties, and each FXYD protein appears to alter enzyme kinetics differently. Different results have sometimes been obtained with different experimental systems, however. To test for effects of gamma in a native tissue environment, mice lacking a functional gamma subunit gene (Fxyd2) were generated. These mice were viable and without observable pathology. Prior work in the mouse embryo showed that gamma is expressed at the blastocyst stage. However, there was no delay in blastocele formation, and the expected Mendelian ratios of offspring were obtained even with Fxyd2(-/-) dams. In adult Fxyd2(-/-) mouse kidney, splice variants of gamma that have different nephron segment-specific expression patterns were absent. Purified gamma-deficient renal Na, K-ATPase displayed higher apparent affinity for Na+ without significant change in apparent affinity for K+. Affinity for ATP, which was expected to be decreased, was instead slightly increased. The results suggest that regulation of Na+ sensitivity is a major functional role for this protein, whereas regulation of ATP affinity may be context-specific. Most importantly, this implies that gamma and other FXYD proteins have their effects by local and not global conformation change. Na, K-ATPase lacking the gamma subunit had increased thermal lability. Combined with other evidence that gamma participates in an early step of thermal denaturation, this indicates that FXYD proteins may play an important structural role in the enzyme complex.	Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Obstet & Gynaecol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Pathol, London, ON N6A 5C1, Canada; Childrens Hlth Res Inst, London, ON N6C 2V5, Canada; Massachusetts Gen Hosp, Lab Membrane Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; St Josephs Hlth Ctr, Lawson Res Inst, London, ON N6A 1Y5, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Western University (University of Western Ontario)	Kidder, GM (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Dent Sci Bldg,Dock 15, London, ON N6A 5C1, Canada.	gerald.kidder@fmd.uwo.ca		Markham, Kathryn/0000-0002-8564-2090	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036271] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL36271] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aizman R, 2002, AM J PHYSIOL-RENAL, V283, pF569, DOI 10.1152/ajprenal.00376.2001; ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Arystarkhova E, 2003, ANN NY ACAD SCI, V986, P416, DOI 10.1111/j.1749-6632.2003.tb07223.x; Arystarkhova E, 2002, J BIOL CHEM, V277, P10162, DOI 10.1074/jbc.M111552200; Arystarkhova E, 2002, AM J PHYSIOL-RENAL, V282, pF393, DOI 10.1152/ajprenal.00146.2001; Barcroft LC, 2004, MECH DEVELOP, V121, P417, DOI 10.1016/j.mod.2004.04.005; Barcroft LC, 2002, REPRODUCTION, V124, P387, DOI 10.1530/rep.0.1240387; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; Brown D, 1996, HISTOCHEM CELL BIOL, V105, P261, DOI 10.1007/BF01463929; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; CRAMBERT G, 2003, SCI STKE; DeSousa PA, 1997, J CELL SCI, V110, P1751; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; ERBACH GT, 1994, BIOL REPROD, V50, P1027, DOI 10.1095/biolreprod50.5.1027; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; Feschenko MS, 2003, J NEUROSCI, V23, P2161; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; Fuller W, 2004, FASEB J, V18, P197, DOI 10.1096/fj.03-0213fje; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; Grinberg AV, 2001, EUR J BIOCHEM, V268, P5027, DOI 10.1046/j.0014-2956.2001.02436.x; Houghton FD, 2002, BIOL REPROD, V66, P1403, DOI 10.1095/biolreprod66.5.1403; Jia LG, 2005, AM J PHYSIOL-HEART C, V288, pH1982, DOI 10.1152/ajpheart.00142.2004; Jones DH, 1997, J CELL BIOL, V139, P1545, DOI 10.1083/jcb.139.6.1545; Jones DH, 2001, PHYSIOL GENOMICS, V6, P129, DOI 10.1152/physiolgenomics.2001.6.3.129; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; Laughery MD, 2003, J BIOL CHEM, V278, P34794, DOI 10.1074/jbc.M302899200; Li CM, 2004, J BIOL CHEM, V279, P38895, DOI 10.1074/jbc.M406697200; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; MACPHEE DJ, 1994, DEV BIOL, V162, P259, DOI 10.1006/dbio.1994.1083; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; Mahmmoud YA, 2003, J BIOL CHEM, V278, P37427, DOI 10.1074/jbc.M305126200; Meij IC, 2003, ANN NY ACAD SCI, V986, P437, DOI 10.1111/j.1749-6632.2003.tb07226.x; Meij IC, 2000, NAT GENET, V26, P265, DOI 10.1038/81543; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; Or E, 1996, BIOCHEMISTRY-US, V35, P6853, DOI 10.1021/bi960093q; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEINERBOBIS G, 1994, BBA-BIOMEMBRANES, V1193, P226, DOI 10.1016/0005-2736(94)90157-0; SIEGEL GJ, 1984, J HISTOCHEM CYTOCHEM, V32, P1309, DOI 10.1177/32.12.6094658; Silverman BD, 2005, CARDIOVASC RES, V65, P93, DOI 10.1016/j.cardiores.2004.09.005; STRUDGATSKY D, 2005, J BIOL CHEM, V278, P46064; Sweadner KJ, 2000, BIOCHEM BIOPH RES CO, V279, P196, DOI 10.1006/bbrc.2000.3907; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Therien AG, 2001, J BIOENERG BIOMEMBR, V33, P407, DOI 10.1023/A:1010619623841; Tupling AR, 2004, J BIOL CHEM, V279, P52382, DOI 10.1074/jbc.M409336200; WATSON AJ, 1988, DEV BIOL, V126, P80, DOI 10.1016/0012-1606(88)90241-2; Wetzel RK, 2004, J BIOL CHEM, V279, P41750, DOI 10.1074/jbc.M405622200; Wetzel RK, 2003, AM J PHYSIOL-RENAL, V285, pF121, DOI 10.1152/ajprenal.00241.2002; Wetzel RK, 2001, AM J PHYSIOL-RENAL, V281, pF531, DOI 10.1152/ajprenal.2001.281.3.F531; Zouzoulas A, 2003, J BIOL CHEM, V278, P40437, DOI 10.1074/jbc.M308610200	60	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19003	19011		10.1074/jbc.M500697200	http://dx.doi.org/10.1074/jbc.M500697200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755730	hybrid			2022-12-27	WOS:000228932300055
J	Sharp, DA; Lawrence, DA; Ashkenazi, A				Sharp, DA; Lawrence, DA; Ashkenazi, A			Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; NF-KAPPA-B; C-FLIP; TUMOR-CELLS; EXPRESSION; PROLIFERATION; RECRUITMENT; INTERACTS; MECHANISM; FAS	Death receptors trigger apoptosis by activating the apical cysteine proteases caspase-8 and -10 within a death-inducing signaling complex (DISC). c-FLIP (cellular FLICE inhibitory protein) is an enzymatically inactive relative of caspase-8 and -10 that binds to the DISC. Two major c-FLIP variants result from alternative mRNA splicing: a short, 26-kDa protein (c-FLIPS) and a long, 55-kDa form (c-FLIPL). The role of c-FLIPS as an inhibitor of death receptor-mediated apoptosis is well established; however, the function of c-FLIPL remains controversial. Although overexpression of transfected c-FLIPL inhibits apoptosis, ectopic expression at lower levels supports caspase-8 activation and cell death. Simultaneous ablation of both c-FLIP variants augments death receptor-mediated apoptosis, but the impact of selective depletion of c-FLIPL on caspase-8 activation and subsequent apoptosis is not well defined. To investigate this, we developed small interfering RNAs that specifically knock down expression of c-FLIPL in several cancer cell lines and studied their effect on apoptosis initiation by Apo2L/TRAIL (Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand). Knockdown of c-FLIPL augmented DISC recruitment, activation, processing, and release of caspase-8, thereby enhancing effector-caspase stimulation and apoptosis. Thus, endogenous c-FLIPL functions primarily as an inhibitor of death receptor-mediated apoptosis.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech	Ashkenazi, A (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	aa@gene.com	Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bin LH, 2002, FEBS LETT, V510, P37, DOI 10.1016/S0014-5793(01)03222-7; Boatright KM, 2004, BIOCHEM J, V382, P651, DOI 10.1042/BJ20040809; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Burns TF, 2001, J BIOL CHEM, V276, P37879; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Dutton A, 2004, P NATL ACAD SCI USA, V101, P6611, DOI 10.1073/pnas.0400765101; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ganten TM, 2004, CELL DEATH DIFFER, V11, pS86, DOI 10.1038/sj.cdd.4401437; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Grambihler A, 2003, J BIOL CHEM, V278, P26831, DOI 10.1074/jbc.M303229200; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Mathas S, 2004, J EXP MED, V199, P1041, DOI 10.1084/jem.20031080; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Rippo MR, 2004, ONCOGENE, V23, P7753, DOI 10.1038/sj.onc.1208051; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zhang XP, 2004, CANCER RES, V64, P7086, DOI 10.1158/0008-5472.CAN-04-1498	48	128	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19401	19409		10.1074/jbc.M413962200	http://dx.doi.org/10.1074/jbc.M413962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15760909	hybrid			2022-12-27	WOS:000228932300098
J	Madden, DR; Armstrong, N; Svergun, D; Perez, J; Vachette, P				Madden, DR; Armstrong, N; Svergun, D; Perez, J; Vachette, P			Solution X-ray scattering evidence for agonist- and antagonist-induced modulation of cleft closure in a glutamate receptor ligand-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION CHANNELS; CRYSTAL-STRUCTURES; STRUCTURAL BASIS; AMPA RECEPTOR; PROTEIN; GLUR2; CORE; ACTIVATION; STEREOCHEMISTRY; MECHANISMS	Agonist-induced conformational changes in the ligand-binding domains (LBD) of glutamate receptor ion channels provide the driving force for molecular rearrangements that mediate channel opening and subsequent desensitization. The resulting regulated transmembrane ion fluxes form the basis for most excitatory neuronal signaling in the brain. Crystallographic analysis of the GluR2 LBD core has revealed a ligand-binding cleft located between two lobes. Channel antagonists stabilize an open cleft, whereas agonists stabilize a closed cleft. The crystal structure of the apo form is similar to the antagonist-bound, open state. To understand the conformational behavior of the LBD in the absence of crystal lattice constraints, and thus better to appreciate the thermodynamic constraints on ligand binding, we have undertaken a solution x-ray scattering study using two different constructs encoding either the core or an extended LBD. In agreement with the GluR2 crystal structures, the LBD is more compact in the presence of agonist than it is in the presence of antagonist. However, the time-averaged conformation of the ligand-free core in solution is intermediate between the open, antagonist-bound state and the closed, agonist-bound state, suggesting a conformational equilibrium. Addition of peptide moieties that connect the core domain to the other functional domains in each channel subunit appears to constrain the conformational equilibrium in favor of the open state.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Deutsch Elektron Synchrotron, EMBL, Hamburg Outstn, European Mol Biol Lab, D-22603 Hamburg, Germany; Univ Paris 11, CNRS UMR 00130, Lab Utilisat Rayonnement Electromagnet, F-91898 Orsay, France	Dartmouth College; Columbia University; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); UDICE-French Research Universities; Universite Paris Saclay	Vachette, P (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	patrice.vachette@ibbmc.u-psud.fr		Svergun, Dmitri/0000-0003-0830-5696				Abele R, 2000, J BIOL CHEM, V275, P21355, DOI 10.1074/jbc.M909883199; Abele R, 1999, BIOCHEMISTRY-US, V38, P10949, DOI 10.1021/bi982928y; Arinaminpathy Y, 2002, BIOPHYS J, V82, P676, DOI 10.1016/S0006-3495(02)75430-1; Armstrong N, 2003, P NATL ACAD SCI USA, V100, P5736, DOI 10.1073/pnas.1037393100; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Bjorkman AJ, 1998, J MOL BIOL, V279, P651, DOI 10.1006/jmbi.1998.1785; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; Chen GQ, 2000, TETRAHEDRON, V56, P9409, DOI 10.1016/S0040-4020(00)00825-5; Chen GQ, 1998, PROTEIN SCI, V7, P2623, DOI 10.1002/pro.5560071216; Dingledine R, 1999, PHARMACOL REV, V51, P7; Dubuisson JM, 1997, J APPL CRYSTALLOGR, V30, P49, DOI 10.1107/S002188989600876X; FLOCCO MM, 1994, J BIOL CHEM, V269, P8931; Guinier A., 1955, SMALL ANGLE SCATTERI; Hogner A, 2002, J MOL BIOL, V322, P93, DOI 10.1016/S0022-2836(02)00650-2; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Jin RS, 2003, BIOCHEMISTRY-US, V42, P5201, DOI 10.1021/bi020632t; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Ledvina PS, 1998, PROTEIN SCI, V7, P2550, DOI 10.1002/pro.5560071208; Madden DR, 2000, EUR J BIOCHEM, V267, P4281; Madden DR, 2004, BIOCHEMISTRY-US, V43, P15838, DOI 10.1021/bi048447y; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Madden DR, 2001, J BIOL CHEM, V276, P37821; Magnusson U, 2002, J BIOL CHEM, V277, P14077, DOI 10.1074/jbc.M200514200; MAO B, 1982, J BIOL CHEM, V257, P1131; Mayer ML, 2001, J MOL BIOL, V311, P815, DOI 10.1006/jmbi.2001.4884; McFeeters RL, 2002, BIOCHEMISTRY-US, V41, P10472, DOI 10.1021/bi026010p; NEWCOMER ME, 1981, J BIOL CHEM, V256, P3218; OH BH, 1993, J BIOL CHEM, V268, P11348; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; WALMSLEY AR, 1992, J BIOL CHEM, V267, P8064; WO ZG, 1995, TRENDS NEUROSCI, V18, P161	35	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23637	23642		10.1074/jbc.M414523200	http://dx.doi.org/10.1074/jbc.M414523200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15755731	hybrid			2022-12-27	WOS:000229880000030
J	Bergstrom, AL; Cordes, H; Zsurger, N; Heegaard, PMH; Laursen, H; Chabry, J				Bergstrom, AL; Cordes, H; Zsurger, N; Heegaard, PMH; Laursen, H; Chabry, J			Amidation and structure relaxation abolish the neurotoxicity of the prion peptide PrP106-126 in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CELL-DEATH; RETINAL DEGENERATION; AMYLOID-BETA; PROTEIN PRPC; SCRAPIE; MICE; ACCUMULATION; ACTIVATION; CASPASE-3; CHRISTEN,PHILIPP	One of the major pathological hallmarks of transmissible spongiform encephalopathies (TSEs) is the accumulation of a pathogenic (scrapie) isoform (PrPSc) of the cellular prion protein (PrPC) primarily in the central nervous system. The synthetic prion peptide PrP106-126 shares many characteristics with PrPSc in that it shows PrPC-dependent neurotoxicity both in vivo and in vitro. Moreover, PrP106-126 in vitro neurotoxicity has been closely associated with the ability to form fibrils. Here, we studied the in vivo neurotoxicity of molecular variants of PrP106-126 toward retinal neurons using electroretinographic recordings in mice after intraocular injections of the peptides. We found that amidation and structure relaxation of PrP106-126 significantly reduced the neurotoxicity in vivo. This was also found in vitro in primary neuronal cultures from mouse and rat brain. Thioflavin T binding studies showed that amidation and structure relaxation significantly reduced the ability of PrP106-126 to attain fibrillar structures in physiological salt solutions. This study hence supports the assumption that the neurotoxic potential of PrP106-126 is closely related to its ability to attain secondary structure.	Danish Inst Food & Vet Res, Dept Vet Daignost & Res, DK-1790 Copenhagen, Denmark; CNRS, UMR 6097, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Rigshosp, Neuropathol Lab, DK-2100 Copenhagen, Denmark	Technical University of Denmark; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Rigshospitalet; University of Copenhagen	Bergstrom, AL (corresponding author), Danish Inst Food & Vet Res, Dept Vet Daignost & Res, Bulowsvej 27, DK-1790 Copenhagen, Denmark.	alb@dfvf.dk	Chabry, Joelle/O-2101-2016; Heegaard, Peter/E-9794-2015	Heegaard, Peter/0000-0003-4506-4932				Agostinho P, 2003, EUR J NEUROSCI, V17, P1189, DOI 10.1046/j.1460-9568.2003.02546.x; Armstrong RA, 2003, J NEURAL TRANSM, V110, P1303, DOI 10.1007/s00702-003-0039-1; Brandner S, 1996, P NATL ACAD SCI USA, V93, P13148, DOI 10.1073/pnas.93.23.13148; Brown DR, 1999, FEBS LETT, V460, P559, DOI 10.1016/S0014-5793(99)01343-5; Brown DR, 1999, J NEUROCHEM, V73, P1105, DOI 10.1046/j.1471-4159.1999.0731105.x; BRUCE ME, 1989, NEUROSCI LETT, V102, P1, DOI 10.1016/0304-3940(89)90298-X; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; BUYUKMIHCI N, 1982, J COMP NEUROL, V205, P153, DOI 10.1002/cne.902050206; BUYUKMIHCI NC, 1987, EXP NEUROL, V97, P201, DOI 10.1016/0014-4886(87)90294-9; Chabry J, 1998, J BIOL CHEM, V273, P13203, DOI 10.1074/jbc.273.21.13203; Chabry J, 2003, J NEUROSCI, V23, P462; Chishti MA, 1997, NEUROSCI LETT, V234, P11; CURTIS R, 1989, NEUROPATH APPL NEURO, V15, P75, DOI 10.1111/j.1365-2990.1989.tb01151.x; Ettaiche M, 2000, J BIOL CHEM, V275, P36487, DOI 10.1074/jbc.C000579200; Fioriti L, 2005, MOL CELL NEUROSCI, V28, P165, DOI 10.1016/j.mcn.2004.09.006; Florio T, 1998, J NEUROSCI RES, V54, P341, DOI 10.1002/(SICI)1097-4547(19981101)54:3<341::AID-JNR5>3.0.CO;2-G; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Forloni G, 2000, FEBS LETT, V466, P205, DOI 10.1016/S0014-5793(99)01781-0; Foster J, 1999, NEUROSCI LETT, V260, P1, DOI 10.1016/S0304-3940(98)00903-3; FOSTER JD, 1986, NEUROPATH APPL NEURO, V12, P185, DOI 10.1111/j.1365-2990.1986.tb00049.x; Garcia FL, 2000, P NATL ACAD SCI USA, V97, P8334, DOI 10.1073/pnas.97.15.8334; GIESE A, 1995, BRAIN PATHOL, V5, P213, DOI 10.1111/j.1750-3639.1995.tb00597.x; Gu YP, 2002, J BIOL CHEM, V277, P2275, DOI 10.1074/jbc.M104345200; Haik S, 2000, NEUROBIOL DIS, V7, P644, DOI 10.1006/nbdi.2000.0316; Head MW, 2003, INVEST OPHTH VIS SCI, V44, P342, DOI 10.1167/iovs.01-1273; Heegaard PMH, 2004, FEBS LETT, V577, P127, DOI 10.1016/j.febslet.2004.09.073; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; HOGAN RN, 1981, LAB INVEST, V44, P34; Horiuchi M, 2001, J BIOL CHEM, V276, P15489, DOI 10.1074/jbc.M100288200; Jamieson E, 2001, NEUROREPORT, V12, P3567, DOI 10.1097/00001756-200111160-00039; Jeffrey M, 2001, J COMP PATHOL, V124, P20, DOI 10.1053/jcpa.2000.0423; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kunz B, 1999, FEBS LETT, V458, P65, DOI 10.1016/S0014-5793(99)01123-0; Larsen BD, 1998, J PEPT RES, V52, P470; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Liberski PP, 2004, INT J BIOCHEM CELL B, V36, P2473, DOI 10.1016/j.biocel.2004.04.016; McLaughlin B, 2003, P NATL ACAD SCI USA, V100, P715, DOI 10.1073/pnas.0232966100; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; O'Donovan CN, 2001, J BIOL CHEM, V276, P43516, DOI 10.1074/jbc.M103894200; PATEL AJ, 1999, METHODS NEUROSIC, V18, P493; Peyrin JM, 1999, NEUROREPORT, V10, P723, DOI 10.1097/00001756-199903170-00012; Post K, 2000, ARCH VIROL, P265; Prusiner SB, 1996, TRENDS BIOCHEM SCI, V21, P482, DOI 10.1016/S0968-0004(96)10063-3; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Prusiner SB, 1992, PRION DIS HUMANS ANI; Puig B, 2001, ACTA NEUROPATHOL, V102, P207; Raymond G. J., 2004, TECHNIQUES PRION RES, P16; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; Rosenblum WI, 2002, NEUROBIOL AGING, V23, P225, DOI 10.1016/S0197-4580(01)00283-4; Rymer DL, 2000, J NEUROCHEM, V75, P2536, DOI 10.1046/j.1471-4159.2000.0752536.x; Salmona M, 1999, BIOCHEM J, V342, P207, DOI 10.1042/0264-6021:3420207; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; Turnbull S, 2003, NEUROSCI LETT, V336, P159, DOI 10.1016/S0304-3940(02)01254-5; Vaughan-Thomas A, 2000, INVEST OPHTH VIS SCI, V41, P3299; Yan XX, 2001, J COMP NEUROL, V433, P4, DOI 10.1002/cne.1121; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145	58	20	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23114	23121		10.1074/jbc.M500210200	http://dx.doi.org/10.1074/jbc.M500210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15824101	Green Submitted, hybrid			2022-12-27	WOS:000229741800068
J	Fialcowitz, EJ; Brewer, BY; Keenan, BP; Wilson, GM				Fialcowitz, EJ; Brewer, BY; Keenan, BP; Wilson, GM			A hairpin-like structure within an AU-rich mRNA-destabilizing element regulates trans-factor binding selectivity and mRNA decay kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RESONANCE ENERGY-TRANSFER; ZINC-FINGER PROTEINS; SECONDARY STRUCTURE; MAMMALIAN-CELLS; STABILITY; TURNOVER; HUR; TRISTETRAPROLIN; DEGRADATION	In mammals, rapid mRNA turnover directed by AU-rich elements (AREs) is mediated by selective association of cellular ARE-binding proteins. These trans-acting factors display overlapping RNA substrate specificities and may act to either stabilize or destabilize targeted transcripts; however, the mechanistic features of AREs that promote preferential binding of one trans-factor over another are not well understood. Here, we describe a hairpin-like structure adopted by the ARE from tumor necrosis factor alpha (TNF alpha) mRNA that modulates its affinity for selected ARE- binding proteins. In particular, association of the mRNA-destabilizing factor p37(AUF1) was strongly inhibited by adoption of the higher order ARE structure, whereas binding of the inducible heat shock protein Hsp70 was less severely compromised. By contrast, association of the mRNA-stabilizing protein HuR was only minimally affected by changes in ARE folding. Consistent with the inverse relationship between p37AUF1 binding affinity and the stability of ARE folding, mutations that stabilized the ARE hairpin also inhibited its ability to direct rapid mRNA turnover in transfected cells. Finally, phylogenetic analyses and structural modeling indicate that alpha(TNF alpha) mRNA sequences flanking the ARE are highly conserved and may stabilize the hairpin fold in vivo. Taken together, these data suggest that local higher order structures involving AREs may function as potent regulators of mRNA turnover in mammalian cells by modulating trans- factor binding selectivity.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Fluorescence Spect, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenbaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Wilson, GM (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	gwils001@umaryland.edu	Wilson, Gerald/AAF-3874-2019	Wilson, Gerald/0000-0002-1273-7507	NCI NIH HHS [R01 CA102428, R01 CA 102428] Funding Source: Medline; NCRR NIH HHS [P41 RR 08119, P41 RR008119] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102428] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR008119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Arao Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P228, DOI 10.1006/abbi.2000.1938; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Breslauer KJ, 1995, METHOD ENZYMOL, V259, P221; Brewer BY, 2004, J BIOL CHEM, V279, P27870, DOI 10.1074/jbc.M402551200; Briata P, 2003, MOL CELL, V12, P1201, DOI 10.1016/S1097-2765(03)00407-6; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cok SJ, 2004, J BIOL CHEM, V279, P8196, DOI 10.1074/jbc.M308475200; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Dean JLE, 2003, J BIOL CHEM, V278, P39470, DOI 10.1074/jbc.M306345200; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; Draper DE, 2004, RNA, V10, P335, DOI 10.1261/rna.5205404; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fisher BM, 1998, BIOCHEMISTRY-US, V37, P12121, DOI 10.1021/bi980743l; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; Heilman-Miller SL, 2001, J MOL BIOL, V306, P1157, DOI 10.1006/jmbi.2001.4437; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; Hudson BP, 2004, NAT STRUCT MOL BIOL, V11, P257, DOI 10.1038/nsmb738; Klostermeier D, 2001, METHODS, V23, P240, DOI 10.1006/meth.2000.1135; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; Lapucci A, 2002, J BIOL CHEM, V277, P16139, DOI 10.1074/jbc.M201377200; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Leontis NB, 2002, NUCLEIC ACIDS RES, V30, P3497, DOI 10.1093/nar/gkf481; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Meisner NC, 2004, CHEMBIOCHEM, V5, P1432, DOI 10.1002/cbic.200400219; NELSON DL, 2005, LEHNINGER PRINCIPLES, P284; Norman DG, 2000, BIOCHEMISTRY-US, V39, P6317, DOI 10.1021/bi992944a; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Park-Lee S, 2003, J BIOL CHEM, V278, P39801, DOI 10.1074/jbc.M307105200; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SANTALUCIA J, 1991, BIOCHEMISTRY-US, V30, P8242, DOI 10.1021/bi00247a021; Sarkar B, 2003, MOL CELL BIOL, V23, P6685, DOI 10.1128/MCB.23.18.6685-6693.2003; Sela-Brown A, 2000, J BIOL CHEM, V275, P7424, DOI 10.1074/jbc.275.10.7424; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wang XQ, 2001, NAT STRUCT BIOL, V8, P141, DOI 10.1038/84131; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 2001, J BIOL CHEM, V276, P38400, DOI 10.1074/jbc.M106509200; Wilson GM, 2003, J BIOL CHEM, V278, P33029, DOI 10.1074/jbc.M305772200; Wilson GM, 2003, J BIOL CHEM, V278, P33039, DOI 10.1074/jbc.M305775200; Wilson GM, 1999, METHODS, V17, P74, DOI 10.1006/meth.1998.0709; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Wilson GM, 2001, J BIOL CHEM, V276, P44450, DOI 10.1074/jbc.M108521200; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; Winzen R, 2004, MOL CELL BIOL, V24, P4835, DOI 10.1128/MCB.24.11.4835-4847.2004; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	60	67	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22406	22417		10.1074/jbc.M500618200	http://dx.doi.org/10.1074/jbc.M500618200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15809297	Green Accepted, hybrid			2022-12-27	WOS:000229557900086
J	Miao, B; Yin, XH; Pei, DS; Zhang, QG; Zhang, GY				Miao, B; Yin, XH; Pei, DS; Zhang, QG; Zhang, GY			Neuroprotective effects of preconditioning ischemia on ischemic brain injury through down-regulating activation of JNK1/2 via N-methyl-D-aspartate receptor-mediated Akt1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-SURVIVAL; NMDA RECEPTOR; C-JUN; SIGNAL-TRANSDUCTION; KINASE ACTIVATION; CEREBRAL-ISCHEMIA; NEURONAL DAMAGE; MIXED LINEAGE; MAP KINASE; RAT	Our previous studies have demonstrated that the JNK signaling pathway plays an important role in ischemic brain injury and is mediated via glutamate receptor 6. Others studies have shown that N-methyl-D-aspartate (NMDA) receptor is involved in the neuroprotection of ischemic preconditioning. Here we examined whether ischemic preconditioning down-regulates activation of the mixed lineage kinase-JNK signaling pathway via NMDA receptor-mediated Akt1 activation. In our present results, ischemic preconditioning could not only inhibit activations of mixed lineage kinase 3, JNK1/2, and c-Jun but also enhanced activation of Akt1. In addition, both NMDA (an agonist of NMDA receptor) and preconditioning showed neuroprotective effects. In contrast, ketamine, an antagonist of NMDA receptor, prevented the above effects of preconditioning. Further studies indicated that LY294002, an inhibitor of phosphoinositide 3-kinase that is an upstream signaling protein of Akt1, could block neuroprotection of preconditioning, and KN62, an inhibitor of calmodulin-dependent protein kinase, also achieved the same effects as LY294002. Therefore, both phosphoinositide 3-kinase and calmodulin-dependent protein kinase are involved in the activation of Akt1 in ischemic tolerance. Taken together, our results indicate that preconditioning can inhibit activation of JNK signaling pathway via NMDA receptor-mediated Akt1 activation and induce neuroprotection in hippocampal CA1 region.	Xuzhou Med Coll, Res Ctr Biochem & Mol Biol, Xuzhou 221002, Jiangsu, Peoples R China	Xuzhou Medical University	Zhang, GY (corresponding author), Xuzhou Med Coll, Res Ctr Biochem & Mol Biol, 84 W Huai Hai Rd, Xuzhou 221002, Jiangsu, Peoples R China.	gyzhang@xzmc.edu.cn						Andersson O, 2001, GENOMICS, V78, P178, DOI 10.1006/geno.2001.6666; Azuma Y, 1996, NEUROCHEM INT, V29, P289, DOI 10.1016/0197-0186(95)00157-3; Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Bond A, 1999, EUR J PHARMACOL, V380, P91, DOI 10.1016/S0014-2999(99)00523-3; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chatterton JE, 2002, NATURE, V415, P793, DOI 10.1038/nature715; CHUANG DM, 1992, MOL PHARMACOL, V42, P210; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DEL PL, 1997, SCIENCE, V278, P687; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fukunaga K, 1998, MOL NEUROBIOL, V16, P79, DOI 10.1007/BF02740604; Grabb MC, 1999, J NEUROSCI, V19, P1657; Gu ZL, 2001, NEUROREPORT, V12, P897, DOI 10.1097/00001756-200104170-00006; Hisatsune C, 1999, GENES CELLS, V4, P657, DOI 10.1046/j.1365-2443.1999.00287.x; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KATO H, 1992, NEUROSCI LETT, V139, P118, DOI 10.1016/0304-3940(92)90871-4; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laube B, 1998, J NEUROSCI, V18, P2954; LIU Y, 1992, BRAIN RES, V586, P121, DOI 10.1016/0006-8993(92)91380-W; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Ogita K, 2003, J NEUROCHEM, V85, P1336, DOI 10.1046/j.1471-4159.2003.01778.x; Pei DS, 2004, NEUROSCI LETT, V367, P71, DOI 10.1016/j.neulet.2004.05.082; Perkinton MS, 2002, J NEUROCHEM, V80, P239, DOI 10.1046/j.0022-3042.2001.00699.x; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; SCHRAMM M, 1990, P NATL ACAD SCI USA, V87, P1193, DOI 10.1073/pnas.87.3.1193; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SMITH ML, 1984, ACTA NEUROL SCAND, V69, P385, DOI 10.1111/j.1600-0404.1984.tb07822.x; Takagi N, 2003, J NEUROCHEM, V84, P67, DOI 10.1046/j.1471-4159.2003.01500.x; Tian H, 2003, NEUROSCI RES, V47, P47, DOI 10.1016/S0168-0102(03)00186-X; Tian H, 2003, NEUROSCI RES, V46, P191, DOI 10.1016/S0168-0102(03)00057-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Watson A, 1998, J NEUROSCI, V18, P751; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004	44	67	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21693	21699		10.1074/jbc.M500003200	http://dx.doi.org/10.1074/jbc.M500003200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15797868	hybrid			2022-12-27	WOS:000229557900003
J	Zhang, Q; Szalay, AA; Tieche, JM; Kyeyune-Nyombi, E; Sands, JF; Oberg, KC; Leonora, J				Zhang, Q; Szalay, AA; Tieche, JM; Kyeyune-Nyombi, E; Sands, JF; Oberg, KC; Leonora, J			Cloning and functional study of porcine parotid hormone, a novel proline-rich protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTINAL FLUID TRANSPORT; INTRADENTINAL DYE PENETRATION; SALIVARY PROTEINS; DENTAL-CARIES; ZINC-DEFICIENCY; RAT MOLARS; IN-VITRO; GLANDS; SECRETION; SEQUENCE	A parotid gland hormone that stimulates intradentinal fluid movement is believed to play a significant role in maintaining the vitality of dentin. This hormone has been purified from porcine parotid glands and partially sequenced in our previous study (Tieche, J. M., Leonora, J., and Steinman, R. R. (1980) Endocrinology 106, 1994-2005). We now report the cloning and functional study of porcine cDNAs that code for this hormone and its complete amino acid sequence. Three cDNA clones were isolated from a porcine parotid cDNA library. The last 30 amino acids encoded by two of the cDNAs agreed with the amino acid sequence of the isolated parotid hormone. In situ hybridization and immunohistochemical staining demonstrated that the acinar cells of the parotid glands were the primary location for both the parotid hormone-related mRNAs and the translation products. A 216-bp fragment of the cDNA that contains the coding sequence for the porcine hormone was subcloned into an expression vector, and the protein expression was detected by immunoblot analysis and quantified by enzyme-linked immunosorbent assay. In addition, the 30-amino acid parotid hormone was synthesized. Both the expressed and the synthetic proteins were biologically active in that they enhanced intradentinal fluid movement as measured by intradentinal dye penetration.	Loma Linda Univ, Sch Med, Dept Biochem, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Physiol & Pharmacol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Human Anat & Pathol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Internal Med, Loma Linda, CA 92350 USA	Loma Linda University; Loma Linda University; Loma Linda University; Loma Linda University	Leonora, J (corresponding author), Loma Linda Univ, Sch Med, Dept Biochem, Loma Linda, CA 92350 USA.	jleonora@som.llu.edu		Oberg, Kerby/0000-0002-1241-4273				ALBRECHT U, 1996, MOL CELLULAR METHODS; ALVARES O, 1981, J ORAL PATHOL MED, V10, P430, DOI 10.1111/j.1600-0714.1981.tb01294.x; AZEN E, 1984, P NATL ACAD SCI-BIOL, V81, P5561, DOI 10.1073/pnas.81.17.5561; BENNICK A, 1982, MOL CELL BIOCHEM, V45, P83; Bennick A, 2002, CRIT REV ORAL BIOL M, V13, P184, DOI 10.1177/154411130201300208; CLEMENTS S, 1985, J BIOL CHEM, V260, P3471; FANG MM, 1980, J NUTR, V110, P1032, DOI 10.1093/jn/110.5.1032; FERREIRA FD, 1992, J HISTOCHEM CYTOCHEM, V40, P1393, DOI 10.1177/40.9.1380529; GERZINA TM, 1995, J DENT RES, V74, P369, DOI 10.1177/00220345950740011301; GU M, 1995, ORAL MICROBIOL IMMUN, V10, P54, DOI 10.1111/j.1399-302X.1995.tb00118.x; HAY DI, 1973, ARCH ORAL BIOL, V18, P1517, DOI 10.1016/0003-9969(73)90127-1; Huumonen S, 1998, ACTA ODONTOL SCAND, V56, P276, DOI 10.1080/000163598428446; JAMIESON JD, 1988, CELL TISSUE BIOL TXB, P728; JOHNSON DA, 1988, J DENT RES, V67, P812, DOI 10.1177/00220345880670050301; JOHNSON DA, 1987, J DENT RES, V66, P1563, DOI 10.1177/00220345870660101001; Kagami H, 1996, HUM GENE THER, V7, P2177, DOI 10.1089/hum.1996.7.17-2177; KATCHBURIAN K, 1968, DENTIN PULP THEIR ST, P43; KAUFFMAN DL, 1991, BIOCHEMISTRY-US, V30, P3351, DOI 10.1021/bi00228a001; LEONORA J, 1987, AM J PHYSIOL, V252, pE477, DOI 10.1152/ajpendo.1987.252.4.E477; LEONORA J, 1993, ARCH ORAL BIOL, V38, P763, DOI 10.1016/0003-9969(93)90072-T; Leonora J, 2002, J DENT RES, V81, P259, DOI 10.1177/154405910208100407; LEONORA J, 1993, ARCH ORAL BIOL, V38, P911, DOI 10.1016/0003-9969(93)90101-Q; Leonora J, 2002, ARCH ORAL BIOL, V47, P147, DOI 10.1016/S0003-9969(01)00104-2; LEONORA J, 1988, DIABETES, V37, P441, DOI 10.2337/diabetes.37.4.441; LEONORA J, 1992, ARCH ORAL BIOL, V37, P733, DOI 10.1016/0003-9969(92)90080-R; LYONS KM, 1988, GENETICS, V120, P267; MAEDA N, 1985, J BIOL CHEM, V260, P1123; MAEDA N, 1985, BIOCHEM GENET, V23, P455, DOI 10.1007/BF00499086; MATTHEWS B, 1994, ARCH ORAL BIOL, V39, P87; MUENZER J, 1979, J BIOL CHEM, V254, P5629; Pashley D H, 1992, Proc Finn Dent Soc, V88 Suppl 1, P31; PASHLEY DH, 1993, ARCH ORAL BIOL, V38, P577, DOI 10.1016/0003-9969(93)90122-3; PASHLEY DH, 1994, ARCH ORAL BIOL, V39, pS73, DOI 10.1016/0003-9969(94)90191-0; Robinovitch MR, 2001, ORAL DIS, V7, P86, DOI 10.1034/j.1601-0825.2001.0070204.x; ROBINSON R, 1989, BIOCHEM J, V263, P497, DOI 10.1042/bj2630497; SCHNEIDER L C, 1975, Pharmacology and Therapeutics in Dentistry, V2, P43; Stahl LE, 1996, J CELL SCI, V109, P1637; STEINMAN RR, 1980, J DENT RES, V59, P176, DOI 10.1177/00220345800590021801; STEINMAN RR, 1975, J DENT RES, V54, P570, DOI 10.1177/00220345750540032801; TIECHE JM, 1981, BIOCHEM BIOPH RES CO, V98, P154, DOI 10.1016/0006-291X(81)91882-9; TIECHE JM, 1980, ENDOCRINOLOGY, V106, P1994, DOI 10.1210/endo-106-6-1994; TIECHE JM, 1995, ARCH ORAL BIOL, V40, P559, DOI 10.1016/0003-9969(95)00003-8; Wang C, 1997, IMMUNOPHARMACOLOGY, V36, P221, DOI 10.1016/S0162-3109(97)00025-8; WEINSTOCK M, 1974, J CELL BIOL, V60, P92, DOI 10.1083/jcb.60.1.92; YAMAMOTO T, 1986, CHEM PHARM BULL, V34, P1203; YAMAMOTO T, 1986, CHEM PHARM BULL, V34, P3803; ZIEMER MA, 1984, J BIOL CHEM, V259, P475; ZIEMER MA, 1982, J BIOL CHEM, V257, P1176	48	3	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22233	22244		10.1074/jbc.M501366200	http://dx.doi.org/10.1074/jbc.M501366200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15805110	hybrid			2022-12-27	WOS:000229557900069
J	Agassandian, M; Zhou, JM; Tephly, LA; Ryan, AJ; Carter, AB; Mallampalli, RK				Agassandian, M; Zhou, JM; Tephly, LA; Ryan, AJ; Carter, AB; Mallampalli, RK			Oxysterols inhibit phosphatidylcholine synthesis via ERK docking and phosphorylation of CTP : phosphocholine cytidylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BINDING DOMAIN; RAT-LIVER CTP; PROTEIN-KINASE; CTPPHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHOLIPID-SYNTHESIS; SPATIOTEMPORAL CONTROL; ACTIVATION; IDENTIFICATION; ALPHA; SITE	Surfactant deficiency contributes to acute lung injury and may result from the elaboration of bioactive lipids such as oxysterols. We observed that the oxysterol 22-hydroxycholesterol (22-HC) in combination with its obligate partner, 9-cis-retinoic acid (9-cis-RA), decreased surfactant phosphatidylcholine (PtdCho) synthesis by increasing phosphorylation of the regulatory enzyme CTP:phosphocholine cytidylyltransferase-alpha (CCT alpha). Phosphorylation of CCT alpha decreased its activity. 22-HC/9-cis-RA inhibition of PtdCho synthesis was blocked by PD98059 or dominant-negative ERK (p42 kinase). Overexpression of constitutively active MEK1, the kinase upstream of p42 kinase, increased CCT alpha phosphorylation. Expression of truncated CCT alpha mutants lacking proline-directed sites within the C-terminal phosphorylation domain partially blocked oxysterol-mediated inhibition of PtdCho synthesis. Mutagenesis of Ser(315) within CCT alpha was both required and sufficient to confer significant resistance to 22-HC/9-cis-RA inhibition of PtdCho synthesis. A novel putative ERK-docking domain N-terminal to this phosphoacceptor site was mapped within the CCT alpha membrane-binding domain (residues 287-300). The results are the first demonstration of a physiologically relevant phosphorylation site and docking domain within CCT alpha that serve as targets for ERKs, resulting in inhibition of surfactant synthesis.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Vet Affairs, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; University of Iowa	Mallampalli, RK (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, Div Pulm & Crit Care, C-33K,GH,200 Hawkins Dr, Iowa City, IA 52242 USA.	rama-mallampalli@uiowa.edu	RYAN, Anderson/ACG-0319-2022	RYAN, Anderson/0000-0001-6241-7969	NHLBI NIH HHS [HL071040, HL068135, R01 HL055584, HL080229] Funding Source: Medline; BLRD VA [I01 BX001135] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068135, R01HL055584, R01HL071040, R01HL080229] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BLRD VA; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agassandian M, 2004, AM J RESP CELL MOL, V31, P227, DOI 10.1165/rcmb.2004-0038OC; Ares MPS, 2000, ATHEROSCLEROSIS, V153, P23, DOI 10.1016/S0021-9150(00)00380-4; Bakovic M, 2003, J BIOL CHEM, V278, P14753, DOI 10.1074/jbc.M300162200; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Bjorkhem I, 2002, CURR OPIN LIPIDOL, V13, P247, DOI 10.1097/00041433-200206000-00003; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonacchi A, 2001, J BIOL CHEM, V276, P9945, DOI 10.1074/jbc.M010303200; Carter KB, 2000, J BIOL CHEM, V275, P27858; CORNELL RB, 1995, BIOCHEM J, V310, P699, DOI 10.1042/bj3100699; CORNELL RB, 1983, BIOCHIM BIOPHYS ACTA, V750, P504, DOI 10.1016/0005-2760(83)90191-1; CRAIG L, 1994, J BIOL CHEM, V269, P3311; Dunne SJ, 1996, BIOCHEMISTRY-US, V35, P11975, DOI 10.1021/bi960821+; Edwards PA, 2002, VASC PHARMACOL, V38, P249, DOI 10.1016/S1537-1891(02)00175-1; EMMETT M, 1987, P SOC EXP BIOL MED, V184, P83; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; GILFILLAN AM, 1983, J LIPID RES, V24, P1651; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; Halvorsen EM, 2002, BRAIN RES, V952, P98, DOI 10.1016/S0006-8993(02)03216-X; Heeley EL, 2000, AM J PHYSIOL-LUNG C, V278, pL305, DOI 10.1152/ajplung.2000.278.2.L305; HOUSLAY MD, BIOCH SOC T, V31, P1186; Hu XT, 2000, CELL GROWTH DIFFER, V11, P191; Ishihara K, 2003, FEBS LETT, V550, P107, DOI 10.1016/S0014-5793(03)00846-9; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Kim IS, 2003, LIFE SCI, V73, P447, DOI 10.1016/S0024-3205(03)00312-6; Kurzbauer R, 2004, P NATL ACAD SCI USA, V101, P10984, DOI 10.1073/pnas.0403435101; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; Mallampalli RK, 2000, J BIOL CHEM, V275, P9699, DOI 10.1074/jbc.275.13.9699; Meuillet EJ, 2004, ARCH BIOCHEM BIOPHYS, V429, P123, DOI 10.1016/j.abb.2004.04.020; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Pulfer MK, 2004, J BIOL CHEM, V279, P26331, DOI 10.1074/jbc.M403581200; Ridsdale R, 2001, J BIOL CHEM, V276, P49148, DOI 10.1074/jbc.M103566200; Rosner B., 2011, FUNDAMENTALS BIOSTAT, V7th; Roth G, 2000, J BIOL CHEM, V275, P33302, DOI 10.1074/jbc.M005425200; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Storey MK, 1997, J LIPID RES, V38, P711; Tseu I, 2002, AM J RESP CELL MOL, V26, P506, DOI 10.1165/ajrcmb.26.4.4702; Van Linden AA, 2000, J BIOL CHEM, V275, P6996, DOI 10.1074/jbc.275.10.6996; Volmat V, 2001, J CELL SCI, V114, P3433; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WANG YL, 1995, J BIOL CHEM, V270, P17843, DOI 10.1074/jbc.270.30.17843; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Wieprecht M, 1996, J BIOL CHEM, V271, P9955, DOI 10.1074/jbc.271.17.9955; WIEPRECHT M, 1994, FEBS LETT, V353, P221, DOI 10.1016/0014-5793(94)01040-4; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503; Yu YM, 2003, NEUROREPORT, V14, P941, DOI 10.1097/01.wnr.0000074341.81633.b8; Yue CP, 1998, J BIOL CHEM, V273, P18023, DOI 10.1074/jbc.273.29.18023; Zhang LH, 2001, J BIOL CHEM, V276, P10476, DOI 10.1074/jbc.M008991200; Zhou JM, 2003, J BIOL CHEM, V278, P37032, DOI 10.1074/jbc.M304316200	59	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21577	21587		10.1074/jbc.M412409200	http://dx.doi.org/10.1074/jbc.M412409200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15788406	hybrid			2022-12-27	WOS:000229438800081
J	Bulut, Y; Michelsen, KS; Hayrapetian, L; Naiki, Y; Spallek, R; Singh, M; Arditi, M				Bulut, Y; Michelsen, KS; Hayrapetian, L; Naiki, Y; Spallek, R; Singh, M; Arditi, M			Mycobacterium tuberculosis heat shock proteins use diverse toll-like receptor pathways to activate pro-inflammatory signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DERMAL ENDOTHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; BACTERIAL LIPOPOLYSACCHARIDE; MYD88-DEFICIENT MICE; MACROPHAGE RESPONSES; CELLULAR ACTIVATION; MURINE MACROPHAGES; ADAPTER MOLECULE; IMMUNE-RESPONSE	Although the Toll-like receptors used by Mycobacterium tuberculosis membrane and secreted factors are known, the pathways activated by M. tuberculosis heat shock proteins are not. An efficient immune response against the intracellular pathogen M. tuberculosis is critically dependent on rapid detection of the invading pathogen by the innate immune system and coordinated activation of the adaptive immune response. Macrophage phagocytosis of M. tuberculosis is accompanied by activation of the transcription factor NF-kappa B and secretion of inflammatory mediators that play an important role in granuloma formation and immune protection during M. tuberculosis infection. The interaction between M. tuberculosis and the various Toll-like receptors is complex, and it appears that distinct mycobacterial components may interact with different members of the Toll-like receptor family. Here we show that recombinant, purified, mycobacterial heat shock proteins 65 and 70 induce NF-kappa B activity in a dose-dependent manner in human endothelial cells. Furthermore, we show that whereas mycobacterial heat shock protein 65 signals exclusively through Toll-like receptor 4, heat shock protein 70 also signals through Toll-like receptor 2. Mycobacterial heat shock protein 65-induced NF-kappa B activation was MyD88-, TIRAP-, TRIF-, and TRAM-dependent and required the presence of MD-2. A better understanding of the recognition of mycobacterial heat shock proteins and their role in the host immune response to the pathogen may open the way to a better understanding of the immunological processes induced by this important human pathogen and the host-pathogen interactions and may help in the rational design of more effective vaccines or vaccine adjuvants.	Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Div Pediat Infect Dis, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Div Pediat Crit Care, Los Angeles, CA 90048 USA; Lionex Diagnost & Therapeut GmbH, D-38124 Braunschweig, Germany	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Lionex Diagnostics & Therapeutics GmbH	Arditi, M (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Div Pediat Infect Dis, 8700 Beverly Blvd,Rm 4221, Los Angeles, CA 90048 USA.	moshe.arditi@cshs.org	Bulut, Yonca/V-3290-2019		NHLBI NIH HHS [NHLB 66436] Funding Source: Medline; NIAID NIH HHS [AI 058128] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058128] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abel B, 2002, J IMMUNOL, V169, P3155, DOI 10.4049/jimmunol.169.6.3155; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Bendelac A, 2002, J EXP MED, V195, pF19, DOI 10.1084/jem.20020073; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Branger J, 2004, INT IMMUNOL, V16, P509, DOI 10.1093/intimm/dxh052; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Bulut Y, 2002, J IMMUNOL, V168, P1435, DOI 10.4049/jimmunol.168.3.1435; Bulut Y, 2001, J IMMUNOL, V167, P987, DOI 10.4049/jimmunol.167.2.987; da Costa CP, 2002, EUR J IMMUNOL, V32, P2460, DOI 10.1002/1521-4141(200209)32:9<2460::AID-IMMU2460>3.0.CO;2-M; Drennan MB, 2004, AM J PATHOL, V164, P49, DOI 10.1016/S0002-9440(10)63095-7; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; Faure E, 2001, J IMMUNOL, V166, P2018, DOI 10.4049/jimmunol.166.3.2018; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4; FRIEDLAND JS, 1993, CLIN EXP IMMUNOL, V91, P282, DOI 10.1111/j.1365-2249.1993.tb05896.x; Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200; Harmala LAE, 2002, J IMMUNOL, V169, P5622, DOI 10.4049/jimmunol.169.10.5622; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Jones BW, 2001, J LEUKOCYTE BIOL, V69, P1036; Kamath AB, 2003, INFECT IMMUN, V71, P4112, DOI 10.1128/IAI.71.7.4112-4118.2003; Kawasaki K, 2003, J IMMUNOL, V170, P413, DOI 10.4049/jimmunol.170.1.413; KIESSLING R, 1991, IMMUNOL REV, V121, P91, DOI 10.1111/j.1600-065X.1991.tb00824.x; Lewthwaite JC, 2001, INFECT IMMUN, V69, P7349, DOI 10.1128/IAI.69.12.7349-7355.2001; Means TK, 1999, J IMMUNOL, V163, P3920; Means TK, 2001, J IMMUNOL, V166, P4074, DOI 10.4049/jimmunol.166.6.4074; MORENO C, 1989, CLIN EXP IMMUNOL, V76, P240; Noss EH, 2001, J IMMUNOL, V167, P910, DOI 10.4049/jimmunol.167.2.910; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; Reiling N, 2002, J IMMUNOL, V169, P3480, DOI 10.4049/jimmunol.169.7.3480; Sasu S, 2001, CIRC RES, V89, P244, DOI 10.1161/hh1501.094184; Scanga CA, 2004, INFECT IMMUN, V72, P2400, DOI 10.1128/IAI.72.4.2400-2404.2004; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shim TS, 2003, TUBERCULOSIS, V83, P367, DOI 10.1016/S1472-9792(03)00071-4; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; Stenger S, 2002, CURR OPIN IMMUNOL, V14, P452, DOI 10.1016/S0952-7915(02)00355-2; Sugawara I, 2003, MICROBIOL IMMUNOL, V47, P841, DOI 10.1111/j.1348-0421.2003.tb03450.x; Sugawara I, 2003, MICROBIOL IMMUNOL, V47, P327, DOI 10.1111/j.1348-0421.2003.tb03404.x; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; van Crevel R, 2002, CLIN MICROBIOL REV, V15, P294, DOI 10.1128/CMR.15.2.294-309.2002; Wang YF, 2001, IMMUNITY, V15, P971, DOI 10.1016/S1074-7613(01)00242-4; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; YOUNG DB, 1992, MOL MICROBIOL, V6, P133, DOI 10.1111/j.1365-2958.1992.tb01994.x; YOUNG DB, 1991, INFECT IMMUN, V59, P3086, DOI 10.1128/IAI.59.9.3086-3093.1991; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611; Zugel U, 1999, IMMUNOBIOLOGY, V201, P22	56	176	190	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20961	20967		10.1074/jbc.M411379200	http://dx.doi.org/10.1074/jbc.M411379200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15809303	hybrid			2022-12-27	WOS:000229438800009
J	Halbach, A; Lorenzen, S; Landgraf, C; Volkmer-Engert, R; Erdmann, R; Rottensteiner, H				Halbach, A; Lorenzen, S; Landgraf, C; Volkmer-Engert, R; Erdmann, R; Rottensteiner, H			Function of the PEX19-binding site of human adrenoleukodystrophy protein as targeting motif in man and yeast - PMP targeting is evolutionarily conserved	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL MEMBRANE-PROTEINS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; BIOGENESIS; SIGNALS; IMPORT; MULTIPLE; RECEPTOR; PEX19P; IDENTIFICATION	We predicted in human peroxisomal membrane proteins (PMPs) the binding sites for PEX19, a key player in the topogenesis of PMPs, by virtue of an algorithm developed for yeast PMPs. The best scoring PEX19-binding site was found in the adrenoleukodystrophy protein ( ALDP). The identified site was indeed bound by human PEX19 and was also recognized by the orthologous yeast PEX19 protein. Likewise, both human and yeast PEX19 bound with comparable affinities to the PEX19- binding site of the yeast PMP Pex13p. Interestingly, the identified PEX19- binding site of ALDP coincided with its previously determined targeting motif. We corroborated the requirement of the ALDP PEX19-binding site for peroxisomal targeting in human fibroblasts and showed that the minimal ALDP fragment targets correctly also in yeast, again in a PEX19-binding site-dependent manner. Furthermore, the human PEX19-binding site of ALDP proved interchangeable with that of yeast Pex13p in an in vivo targeting assay. Finally, we showed in vitro that most of the predicted binding sequences of human PMPs represent true binding sites for human PEX19, indicating that human PMPs harbor common PEX19-binding sites that do resemble those of yeast. Our data clearly revealed a role for PEX19- binding sites as PMP-targeting motifs across species, thereby demonstrating the evolutionary conservation of PMP signal sequences from yeast to man.	Ruhr Univ Bochum, Inst Physiol, Abt Syst Biochem, D-44780 Bochum, Germany; Univ Klinikum Charite, Inst Med Immunol, D-10115 Berlin, Germany	Ruhr University Bochum; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Erdmann, R (corresponding author), Ruhr Univ Bochum, Inst Physiol, Abt Syst Biochem, D-44780 Bochum, Germany.	Ralf.Erdmann@rub.de	Lorenzen, Stephan/C-8960-2009	Lorenzen, Stephan/0000-0003-4857-6087; Volkmer, Rudolf/0000-0003-4710-1143				Baerends RJS, 2000, FEMS MICROBIOL REV, V24, P291; Biermanns M, 2003, EUR J CELL BIOL, V82, P155, DOI 10.1078/0171-9335-00310; Biermanns M, 2001, BIOCHEM BIOPH RES CO, V285, P649, DOI 10.1006/bbrc.2001.5220; Brosius U, 2002, J BIOL CHEM, V277, P774, DOI 10.1074/jbc.M108155200; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; Fransen M, 2002, MOL CELL PROTEOMICS, V1, P243, DOI 10.1074/mcp.M100025-MCP200; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; Geuze HJ, 2003, MOL BIOL CELL, V14, P2900, DOI 10.1091/mbc.E02-11-0734; Gloeckner CJ, 2000, BIOCHEM BIOPH RES CO, V271, P144, DOI 10.1006/bbrc.2000.2572; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; Honsho M, 2002, J BIOL CHEM, V277, P44513, DOI 10.1074/jbc.M206139200; Honsho M, 2001, J BIOL CHEM, V276, P9375, DOI 10.1074/jbc.M003304200; Jones JM, 2004, J CELL BIOL, V164, P57, DOI 10.1083/jcb.200304111; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; LANDGRAF C, PLOS BIOL 2004; Landgraf P, 2003, EUR J CELL BIOL, V82, P401, DOI 10.1078/0171-9335-00331; Mullen RT, 1999, PLANT CELL, V11, P2167, DOI 10.1105/tpc.11.11.2167; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Pause B, 2000, FEBS LETT, V471, P23, DOI 10.1016/S0014-5793(00)01332-6; Rottensteiner H, 2004, MOL BIOL CELL, V15, P3406, DOI 10.1091/mbc.E04-03-0188; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Sacksteder KA, 2000, ANNU REV GENET, V34, P623, DOI 10.1146/annurev.genet.34.1.623; Sambrook J., 2002, MOL CLONING LAB MANU; Smith KD, 1999, NEUROCHEM RES, V24, P521, DOI 10.1023/A:1022535930009; Snyder WB, 2000, J CELL BIOL, V149, P1171, DOI 10.1083/jcb.149.6.1171; Stein K, 2002, MOL CELL BIOL, V22, P6056, DOI 10.1128/MCB.22.17.6056-6069.2002; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; Titorenko VI, 1998, TRENDS BIOCHEM SCI, V23, P231, DOI 10.1016/S0968-0004(98)01226-2; Wang XD, 2001, J BIOL CHEM, V276, P10897, DOI 10.1074/jbc.M010883200; Will GK, 1999, MOL CELL BIOL, V19, P2265	35	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21176	21182		10.1074/jbc.M501750200	http://dx.doi.org/10.1074/jbc.M501750200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15781447	hybrid			2022-12-27	WOS:000229438800035
J	Mere, J; Morlon-Guyot, J; Bonhoure, A; Chiche, L; Beaumelle, B				Mere, J; Morlon-Guyot, J; Bonhoure, A; Chiche, L; Beaumelle, B			Acid-triggered membrane insertion of Pseudomonas exotoxin A involves an original mechanism based on pH-regulated tryptophan exposure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-II; PROTEIN; TRANSLOCATION; AERUGINOSA; SITE; IDENTIFICATION; CYTOTOXICITY; IMMUNOTOXINS; INVOLVEMENT; SECRETION	Exposure to low endosomal pH during internalization of Pseudomonas exotoxin A (PE) triggers membrane insertion of its translocation domain. This process is a prerequisite for PE translocation to the cytosol where it inactivates protein synthesis. Although hydrophobic helices enable membrane insertion of related bacterial toxins such as diphtheria toxin, the PE translocation domain is devoid of hydrophobic stretches and the structural features triggering acid-induced membrane insertion of PE are not known. Here we have identified a molecular device that enables PE membrane insertion. This process is promoted by exposure of a key tryptophan residue. At neutral pH, this Trp is buried in a hydrophobic pocket closed by the smallest alpha-helix of the translocation domain. Upon acidification, protonation of the Asp that is the N-cap residue of the helix leads to its destabilization, enabling Trp side chain insertion into the endosome membrane. This tryptophan-based membrane insertion system is surprisingly similar to the membrane-anchoring mechanism of human annexin-V and could be used by other proteins as well.	Univ Montpellier 2, Dept Biol Sante, CNRS, UMR 5539, F-34095 Montpellier, France; Fac Pharm Montpellier, Ctr Biochim Struct, INSERM U554, CNRS UMR 5048, F-34093 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Beaumelle, B (corresponding author), Univ Montpellier 2, Dept Biol Sante, CNRS, UMR 5539, Case 107, F-34095 Montpellier, France.	beaumel@univ-montp2.fr		Beaumelle, Bruno/0000-0002-4912-9134; Bonhoure, Anne/0000-0002-4664-2848				Alami M, 1998, MOL BIOL CELL, V9, P387, DOI 10.1091/mbc.9.2.387; ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Campos B, 1998, BIOCHEMISTRY-US, V37, P8004, DOI 10.1021/bi973142n; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; Chiron MF, 1996, MOL MICROBIOL, V22, P769, DOI 10.1046/j.1365-2958.1996.d01-1721.x; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Eppens EF, 1997, EMBO J, V16, P4295, DOI 10.1093/emboj/16.14.4295; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Hessler JL, 1997, BIOCHEMISTRY-US, V36, P14577, DOI 10.1021/bi971447w; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; JIANG JX, 1990, J BIOL CHEM, V265, P8636; JINNO Y, 1989, J BIOL CHEM, V264, P15953; KASTURI S, 1992, J BIOL CHEM, V267, P23427; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; Kreitman RJ, 1999, CURR OPIN IMMUNOL, V11, P570, DOI 10.1016/S0952-7915(99)00005-9; Lacy DB, 1999, J MOL BIOL, V291, P1091, DOI 10.1006/jmbi.1999.2945; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Morlon-Guyot J, 2003, J BIOL CHEM, V278, P17006, DOI 10.1074/jbc.M209516200; MUFOZ V, 1994, NAT STRUCT BIOL, V1, P399; Musse AA, 2003, J BIOL CHEM, V278, P24491, DOI 10.1074/jbc.M302371200; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; RASPER DM, 1994, BIOCHEMISTRY-US, V33, P12981, DOI 10.1021/bi00248a006; Reiter Y, 1998, TRENDS BIOTECHNOL, V16, P513, DOI 10.1016/S0167-7799(98)01226-8; Ren JH, 1999, BIOCHEMISTRY-US, V38, P976, DOI 10.1021/bi981576s; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Santos JSD, 2000, BIOCHEMISTRY-US, V39, P14065, DOI 10.1021/bi000659h; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; Taupiac MP, 1999, MOL MICROBIOL, V31, P1385, DOI 10.1046/j.1365-2958.1999.01280.x; Vendeville A, 2004, MOL BIOL CELL, V15, P2347, DOI 10.1091/mbc.E03-12-0921; Voulhoux R, 2000, J BACTERIOL, V182, P4051, DOI 10.1128/JB.182.14.4051-4058.2000; Wedekind JE, 2001, J MOL BIOL, V314, P823, DOI 10.1006/jmbi.2001.5195; YOULE RJ, 1982, J BIOL CHEM, V257, P1598; ZDANOVSKY AG, 1993, J BIOL CHEM, V268, P21791	39	19	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21194	21201		10.1074/jbc.M412656200	http://dx.doi.org/10.1074/jbc.M412656200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799975	Green Published, hybrid			2022-12-27	WOS:000229438800037
J	van Buul, JD; Anthony, EC; Fernandez-Borja, M; Burridge, K; Hordijk, PL				van Buul, JD; Anthony, EC; Fernandez-Borja, M; Burridge, K; Hordijk, PL			Proline-rich tyrosine kinase 2 (Pyk2) mediates vascular endothelial- cadherin-based cell-cell adhesion by regulating beta-catenin tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; RHO-FAMILY GTPASES; PHOSPHATIDYLINOSITOL 3-KINASE; BARRIER FUNCTION; IN-VIVO; LEUKOCYTE TRANSMIGRATION; ACTIN CYTOSKELETON; EPITHELIAL-CELLS; RAC; PERMEABILITY	Vascular endothelial-cadherin ( VE-cadherin) controls endothelial cell-cell adhesion and preserves endothelial integrity. In order to maintain endothelial barrier function, VE-cadherin function is tightly regulated through mechanisms that involve protein phosphorylation and cytoskeletal dynamics. Here, we show that loss of VE-cadherin function results in intercellular gap formation and a drop in electrical resistance of monolayers of primary human endothelial cells. Detailed analysis revealed that loss of endothelial cell-cell adhesion, induced by VE-cadherin-blocking antibodies, is preceded by and dependent on a rapid activation of Rac1 and increased production of reactive oxygen species. Moreover, VE-cadherin-associated beta-catenin is tyrosine-phosphorylated upon loss of cell-cell contact. Finally, the redox-sensitive proline-rich tyrosine kinase 2 ( Pyk2) is activated and recruited to cell-cell junctions following the loss of VE-cadherin homotypic adhesion. Conversely, the inhibition of Pyk2 activity in endothelial cells by the expression of CRNK (CADTK/ CAK beta-related non-kinase), an N-terminal deletion mutant that acts in a dominant negative fashion, not only abolishes the increase in beta-catenin tyrosine phosphorylation but also prevents the loss of endothelial cell-cell contact. These results implicate Pyk2 in the reduced cell-cell adhesion induced by the Rac-mediated production of ROS through the tyrosine phosphorylation of beta-catenin. This signaling is initiated upon loss of VE-cadherin function and is important for our insight in the modulation of endothelial integrity.	Univ Amsterdam, Acad Med Ctr, Dept Mol Cell Biol, Sanquin Re & Landsteiner Lab, NL-1066 CX Amsterdam, Netherlands; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of Amsterdam; Academic Medical Center Amsterdam; University of North Carolina; University of North Carolina Chapel Hill	Hordijk, PL (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Mol Cell Biol, Sanquin Re & Landsteiner Lab, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.	p.hordijk@sanquin.nl	van Buul, Jaap D/AAJ-4371-2021	van Buul, Jaap D/0000-0003-0054-7949; Hordijk, Peter/0000-0002-3348-078X	NHLBI NIH HHS [HL45100] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexander JS, 2001, MICROCIRCULATION, V8, P389; [Anonymous], 2000, SCI STKE, V2000, P2000, DOI [10.1126/stke.2000.62.tw8, DOI 10.1126/STKE.2000.62.TW8]; Bogatcheva NV, 2002, VASC PHARMACOL, V39, P201, DOI 10.1016/S1537-1891(03)00009-0; Cheng JJ, 2002, J BIOL CHEM, V277, P48152, DOI 10.1074/jbc.M110937200; Corada M, 2002, BLOOD, V100, P905, DOI 10.1182/blood.V100.3.905; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Daou GB, 2004, FREE RADICAL BIO MED, V37, P208, DOI 10.1016/j.freeradbiomed.2004.04.018; Dejana E, 1999, EXP CELL RES, V252, P13, DOI 10.1006/excr.1999.4601; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Frank GD, 2000, BIOCHEM BIOPH RES CO, V270, P761, DOI 10.1006/bbrc.2000.2505; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Gotsch U, 1997, J CELL SCI, V110, P583; Hordijk PL, 1999, J CELL SCI, V112, P1915; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Kim HS, 2003, J BIOL CHEM, V278, P37497, DOI 10.1074/jbc.M211739200; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Lampugnani MG, 1997, J CELL SCI, V110, P2065; Liao F, 2002, CANCER RES, V62, P2567; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nawroth R, 2002, EMBO J, V21, P4885, DOI 10.1093/emboj/cdf497; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384-4394.2004; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Shaw SK, 2001, J IMMUNOL, V167, P2323, DOI 10.4049/jimmunol.167.4.2323; Sorokin A, 2001, J BIOL CHEM, V276, P21521, DOI 10.1074/jbc.M008869200; Tai LK, 2002, ARTERIOSCL THROM VAS, V22, P1790, DOI 10.1161/01.ATV.0000034475.40227.40; Tang H, 2000, J BIOL CHEM, V275, P8389, DOI 10.1074/jbc.275.12.8389; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; van Buul JD, 2002, J IMMUNOL, V168, P588, DOI 10.4049/jimmunol.168.2.588; van Buul JD, 2004, ARTERIOSCL THROM VAS, V24, P824, DOI 10.1161/01.ATV.0000122854.76267.5c; van Wetering S, 2003, AM J PHYSIOL-CELL PH, V285, pC343, DOI 10.1152/ajpcell.00048.2003; van Wetering S, 2002, J CELL SCI, V115, P1837; Vastrik I, 1999, CURR BIOL, V9, P991, DOI 10.1016/S0960-9822(99)80447-3; Vestweber D, 2000, J PATHOL, V190, P281; Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639; Waschke J, 2004, AM J PHYSIOL-HEART C, V287, pH704, DOI 10.1152/ajpheart.01076.2003; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; Zhao XX, 2003, J BIOL CHEM, V278, P40788, DOI 10.1074/jbc.M302208200	44	93	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21129	21136		10.1074/jbc.M500898200	http://dx.doi.org/10.1074/jbc.M500898200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15778498	Green Published, hybrid			2022-12-27	WOS:000229438800029
J	Baneres, JL; Mesnier, D; Martin, A; Joubert, L; Dumuis, A; Bockaert, J				Baneres, JL; Mesnier, D; Martin, A; Joubert, L; Dumuis, A; Bockaert, J			Molecular characterization of a purified 5-HT4 receptor - A structural basis for drug efficacy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BACTERIAL EXPRESSION; GPCR FUNCTION; AGONISTS; BINDING; RHODOPSIN; OVEREXPRESSION; PURIFICATION; ACTIVATION; PREDICTION	Serotonin 5-HT4(a) receptor, a G-protein-coupled receptor (GPCR), was produced as a functional isolated protein using Escherichia coli as an expression system. The isolated receptor was characterized at the molecular level by circular dichroism (CD) and steady-state fluorescence. A specific change in the near-UV CD band associated with the GPCR disulfide bond connecting the third transmembrane domain to the second extracellular loop (e2) was observed upon agonist binding to the purified receptor. This is a direct experimental evidence for a change in the conformation of the e2 loop upon receptor activation. Different variations were obtained depending whether the ligand was an agonist ( partial or full) or an inverse agonist. In contrast, antagonist binding did not induce any variation. These observations provide a first direct evidence for the fact that free ( or antagonist-occupied), active (partial- or full agonist-occupied) and silent (inverse agonist-occupied) states of the receptor involve different arrangements of the e2 loop. Finally, ligand-induced changes in the fluorescence emission profile of the purified receptor confirmed that the partial agonist stabilized a single, well-defined, conformational state and not a mixture of different states. This result is of particular interest in a pharmacological perspective since it directly demonstrates that the efficacy of a drug is likely due to the stabilization of a ligand-specific state rather than selection of a mixture of different conformational states of the receptor.	Fac Pharm Montpellier, CNRS, UMR 5074, F-34093 Montpellier, France; Univ Montpellier 2, Univ Montpellier 1, INSERM U661, UMR 5203,CNRS, F-34094 Montpellier, France; Inst Genom Fonct, Dept Neurobiol, F-34094 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier	Baneres, JL (corresponding author), Fac Pharm Montpellier, CNRS, UMR 5074, 15 Ave Ch Flahault, F-34093 Montpellier, France.	baneres@univ-montp1.fr		Baneres, jean-louis/0000-0001-7078-1285				Alves ID, 2003, J BIOL CHEM, V278, P48890, DOI 10.1074/jbc.M306866200; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Baneres JL, 2003, J MOL BIOL, V329, P801, DOI 10.1016/S0022-2836(03)00438-8; Bockaert J, 2002, INT REV CYTOL, V212, P63; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Claeysen S, 2003, J BIOL CHEM, V278, P699, DOI 10.1074/jbc.C200588200; Claeysen S, 1996, FEBS LETT, V398, P19, DOI 10.1016/S0014-5793(96)01132-5; Fasman GD, 1996, CIRCULAR DICHROISM C, P381; GERALD C, 1995, EMBO J, V14, P2806, DOI 10.1002/j.1460-2075.1995.tb07280.x; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Joubert L, 2002, J BIOL CHEM, V277, P25502, DOI 10.1074/jbc.M202539200; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; Kiefer H, 2000, RECEPTOR CHANNEL, V7, P109; Kobilka BK, 2002, J PEPT RES, V60, P317, DOI 10.1034/j.1399-3011.2002.21062.x; KULIOPULOS A, 1987, P NATL ACAD SCI USA, V84, P8893, DOI 10.1073/pnas.84.24.8893; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P189; Li M, 2004, PROTEIN EXPRES PURIF, V33, P1, DOI 10.1016/j.pep.2003.08.023; LUMMIS SCR, 1992, MOL PHARMACOL, V41, P18; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; Nikiforovich GV, 2003, BIOCHEMISTRY-US, V42, P9110, DOI 10.1021/bi034586o; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Ryan RO, 2003, PROTEIN EXPRES PURIF, V27, P98, DOI 10.1016/S1046-5928(02)00568-5; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Seifert R, 2001, J PHARMACOL EXP THER, V297, P1218; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; Sillen A, 2001, SPR S FLUOR, V1, P413; Stanasila L, 1998, BIOCHIMIE, V80, P563, DOI 10.1016/S0300-9084(00)80021-8; Surya A, 1998, TRENDS PHARMACOL SCI, V19, P243; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Tate CG, 2001, FEBS LETT, V504, P94, DOI 10.1016/S0014-5793(01)02711-9; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; Weiss HM, 2002, EUR J BIOCHEM, V269, P82, DOI 10.1046/j.0014-2956.2002.02618.x; Woody RW, 1996, CIRCULAR DICHROISM C, P109; Yan ECY, 2003, P NATL ACAD SCI USA, V100, P9262, DOI 10.1073/pnas.1531970100	38	128	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20253	20260		10.1074/jbc.M412009200	http://dx.doi.org/10.1074/jbc.M412009200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15774473	Green Published, hybrid			2022-12-27	WOS:000229242000013
J	Dames, SA; Mulet, JM; Rathgeb-Szabo, K; Hall, MN; Grzesiek, S				Dames, SA; Mulet, JM; Rathgeb-Szabo, K; Hall, MN; Grzesiek, S			The solution structure of the FATC domain of the protein kinase target of rapamycin suggests a role for redox-dependent structural and cellular stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; DISULFIDE BOND FORMATION; MODEL-FREE APPROACH; MAMMALIAN TARGET; SACCHAROMYCES-CEREVISIAE; IN-VITRO; TOR; GROWTH; NMR; COMPLEXES	The target of rapamycin ( TOR) is a highly conserved Ser/Thr kinase that plays a central role in the control of cellular growth. TOR has a characteristic multidomain structure. Only the kinase domain has catalytic function; the other domains are assumed to mediate interactions with TOR substrates and regulators. Except for the rapamycin-binding domain, there are no high-resolution structural data available for TOR. Here, we present a structural, biophysical, and mutagenesis study of the extremely conserved COOH-terminal FATC domain. The importance of this domain for TOR function has been highlighted in several publications. We show that the FATC domain, in its oxidized form, exhibits a novel structural motif consisting of an alpha-helix and a COOH-terminal disulfide-bonded loop between two completely conserved cysteine residues. Upon reduction, the flexibility of the loop region increases dramatically. The structural data, the redox potential of the disulfide bridge, and the biochemical data of a cysteine to serine mutant indicate that the intracellular redox potential can affect the cellular amount of the TOR protein via the FATC domain. Because the amount of TOR mRNA is not changed, the redox state of the FATC disulfide bond is probably influencing the degradation of TOR.	Univ Basel, Dept Biol Struct, CH-4056 Basel, Switzerland; Univ Basel, Dept Biochem, Biozentrum, CH-4056 Basel, Switzerland	University of Basel; University of Basel	Dames, SA (corresponding author), Univ Basel, Dept Biol Struct, Klingelbergstr 70, CH-4056 Basel, Switzerland.	sonja.dames@unibas.ch	Mulet, Jose Miguel/B-9063-2016	Mulet, Jose Miguel/0000-0002-9087-3838; Grzesiek, Stephan/0000-0003-1998-4225; Dames, Sonja/0000-0001-7495-6943; Hall, Michael N/0000-0002-2998-0757				Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Bhattacharyya R, 2003, J MOL BIOL, V331, P925, DOI 10.1016/S0022-2836(03)00759-9; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Cai JY, 2000, FREE RADICAL BIO MED, V29, P334, DOI 10.1016/S0891-5849(00)00312-9; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P157; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Fernandez-Checa JC, 2003, BIOCHEM BIOPH RES CO, V304, P471, DOI 10.1016/S0006-291X(03)00619-3; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; Grauschopf U, 2003, EMBO J, V22, P3503, DOI 10.1093/emboj/cdg356; Grey MJ, 2003, J AM CHEM SOC, V125, P14324, DOI 10.1021/ja0367389; Grzesiek S, 1997, PROTEIN SCI, V6, P1248, DOI 10.1002/pro.5560060613; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harris Thurl E, 2003, Sci STKE, V2003, pre15; Helliwell SB, 1998, GENETICS, V148, P99; Huang CS, 2002, CANCER RES, V62, P5689; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Huth JR, 1997, PROTEIN SCI, V6, P2359; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kirlin WG, 1999, FREE RADICAL BIO MED, V27, P1208, DOI 10.1016/S0891-5849(99)00145-8; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kunz J, 2000, J BIOL CHEM, V275, P37011, DOI 10.1074/jbc.M007296200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Linke K, 2003, ANTIOXID REDOX SIGN, V5, P425, DOI 10.1089/152308603768295168; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Loo G, 2003, J NUTR BIOCHEM, V14, P64, DOI 10.1016/S0955-2863(02)00251-6; Mulet JM, 2004, YEAST, V21, P569, DOI 10.1002/yea.1126; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Ostergaard H, 2004, J CELL BIOL, V166, P337, DOI 10.1083/jcb.200402120; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Takahashi T, 2000, GENES CELLS, V5, P765, DOI 10.1046/j.1365-2443.2000.00365.x; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Zhang XW, 2002, J BIOL CHEM, V277, P28127, DOI 10.1074/jbc.M202625200; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	55	106	116	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20558	20564		10.1074/jbc.M501116200	http://dx.doi.org/10.1074/jbc.M501116200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15772072	hybrid, Green Accepted			2022-12-27	WOS:000229242000050
J	Levy-Adam, F; Abboud-Jarrous, G; Guerrini, M; Beccati, D; Vlodavsky, I; Ilan, N				Levy-Adam, F; Abboud-Jarrous, G; Guerrini, M; Beccati, D; Vlodavsky, I; Ilan, N			Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-METASTASIS; MAMMALIAN HEPARANASE; EXPRESSION; HEPARIN; ANGIOGENESIS; INVOLVEMENT; INHIBITION; CANCER; ROLES; GLYCOSAMINOGLYCANS	The endo-beta-glucuronidase, heparanase, is an enzyme that cleaves heparan sulfate at specific intra-chain sites, yielding heparan sulfate fragments with appreciable size and biological activities. Heparanase activity has been traditionally correlated with cell invasion associated with cancer metastasis, angiogenesis, and inflammation. In addition, heparanase up-regulation has been documented in a variety of primary human tumors, correlating with increased vascular density and poor postoperative survival, suggesting that heparanase may be considered as a target for anticancer drugs. In an attempt to identify the protein motif that would serve as a target for the development of heparanase inhibitors, we looked for protein domains that mediate the interaction of heparanase with its heparan sulfate substrate. We have identified three potential heparin binding domains and provided evidence that one of these is mapped at the N terminus of the 50-kDa active heparanase subunit. A peptide corresponding to this region (Lys(158)-Asp(171)) physically associates with heparin and heparan sulfate. Moreover, the peptide inhibited heparanase enzymatic activity in a dose-responsive manner, presumably through competition with the heparan sulfate substrate. Furthermore, antibodies directed to this region inhibited heparanase activity, and a deletion construct lacking this domain exhibited no enzymatic activity. NMR titration experiments confirmed residues Lys(158)-Asn(162) as amino acids that firmly bound heparin. Deletion of a second heparin binding domain sequence (Gln(270)-Lys(280)) yielded an inactive enzyme that failed to interact with cell surface heparan sulfate and hence accumulated in the culture medium of transfected HEK293 cells to exceptionally high levels. The two heparin/heparan sulfate recognition domains are potentially attractive targets for the development of heparanase inhibitors.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Oncol, IL-91120 Jerusalem, Israel; G Ronzoni Inst Chem & Biochem Res, I-20133 Milan, Italy	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Hebrew University of Jerusalem; Hadassah University Medical Center	Vlodavsky, I (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, POB 9649, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il		Guerrini, Marco/0000-0001-7246-9113	NATIONAL CANCER INSTITUTE [R01CA106456] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106456-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abboud-Jarrous G, 2005, J BIOL CHEM, V280, P13568, DOI 10.1074/jbc.M413370200; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Casu B, 2004, J MED CHEM, V47, P838, DOI 10.1021/jm030893g; Casu B, 2002, BIOCHEMISTRY-US, V41, P10519, DOI 10.1021/bi020118n; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P44084, DOI 10.1074/jbc.M402131200; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Gong F, 2003, J BIOL CHEM, V278, P35152, DOI 10.1074/jbc.M300925200; Goshen R, 1996, MOL HUM REPROD, V2, P679, DOI 10.1093/molehr/2.9.679; HISCOCK DRR, 1994, J BIOL CHEM, V269, P4539; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hulett MD, 2000, BIOCHEMISTRY-US, V39, P15659, DOI 10.1021/bi002080p; Hwang TL, 1998, J MAGN RESON, V135, P280, DOI 10.1006/jmre.1998.1598; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Katz A, 2002, ISRAEL MED ASSOC J, V4, P996; Koliopanos A, 2001, CANCER RES, V61, P4655; Kramer KL, 2003, ANNU REV GENET, V37, P461, DOI 10.1146/annurev.genet.37.061103.090226; Levidiotis V, 2004, J AM SOC NEPHROL, V15, P68, DOI 10.1097/01.ASN.0000103229.25389.40; Levy-Adam F, 2003, BIOCHEM BIOPH RES CO, V308, P885, DOI 10.1016/S0006-291X(03)01478-5; Marchetti D, 2003, INT J CANCER, V104, P167, DOI 10.1002/ijc.10930; McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318; Miao HQ, 1999, INT J CANCER, V83, P424, DOI 10.1002/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.3.CO;2-C; Munoz EM, 2004, ARTERIOSCL THROM VAS, V24, P1549, DOI 10.1161/01.ATV.0000137189.22999.3f; NAKAJIMA M, 1991, J BIOL CHEM, V266, P9661; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Ohkawa T, 2004, LAB INVEST, V84, P1289, DOI 10.1038/labinvest.3700159; Okada Y, 2002, J BIOL CHEM, V277, P42488, DOI 10.1074/jbc.M206510200; Parish CR, 1999, CANCER RES, V59, P3433; PARISH CR, 1987, INT J CANCER, V40, P511, DOI 10.1002/ijc.2910400414; Parish CR, 2001, BIOCHIM BIOPHYS ACTA, V1471, P99, DOI DOI 10.1016/S0304-419X(01)00017-8; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; Pisano C, 2005, GLYCOBIOLOGY, V15, p1C, DOI 10.1093/glycob/cwi007; Rohloff J, 2002, BRIT J CANCER, V86, P1270, DOI 10.1038/sj.bjc.6600232; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Sato T, 2004, J SURG ONCOL, V87, P174, DOI 10.1002/jso.20097; Schulz JG, 2003, J BIOL CHEM, V278, P48651, DOI 10.1074/jbc.M308424200; Simizu S, 2003, CANCER LETT, V193, P83, DOI 10.1016/S0304-3835(02)00719-X; Simons M, 2001, CELL SIGNAL, V13, P855, DOI 10.1016/S0898-6568(01)00190-5; Verrecchio A, 2000, J BIOL CHEM, V275, P7701, DOI 10.1074/jbc.275.11.7701; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Xiao Y, 2003, HEPATOL RES, V26, P192, DOI 10.1016/S1386-6346(03)00107-4; Yang JK, 2004, J MOL BIOL, V335, P155, DOI 10.1016/j.jmb.2003.10.026; Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068; Zetser A, 2003, CANCER RES, V63, P7733	56	110	119	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20457	20466		10.1074/jbc.M414546200	http://dx.doi.org/10.1074/jbc.M414546200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15760902	hybrid			2022-12-27	WOS:000229242000038
J	Chavez, JA; Holland, WL; Bar, J; Sandhoff, K; Summers, SA				Chavez, JA; Holland, WL; Bar, J; Sandhoff, K; Summers, SA			Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE CELLS; NECROSIS-FACTOR-ALPHA; KINASE-B (PKB)/AKT; GLUCOSE-UPTAKE; LIPOPROTEIN-LIPASE; RESISTANCE; SPHINGOSINE; DIACYLGLYCEROL; ACCUMULATION; SENSITIVITY	Recent studies indicate that insulin resistance and type 2 diabetes result from the accumulation of lipids in tissues not suited for fat storage, such as skeletal muscle and the liver. To elucidate the mechanisms linking exogenous fats to the inhibition of insulin action, we evaluated the effects of free fatty acids (FFAs) on insulin signal transduction in cultured C2C12 myotubes. As we described previously ( Chavez, J. A., and Summers, S. A. ( 2003) Arch. Biochem. Biophys. 419, 101 - 109), long-chain saturated FFAs inhibited insulin stimulation of Akt/protein kinase B, a central regulator of glucose uptake and anabolic metabolism. Moreover, these FFAs stimulated the de novo synthesis of ceramide and sphingosine, two sphingolipids shown previously to inhibit insulin action. To determine the contribution of either sphingolipid in FFA-dependent inhibition of insulin action, we generated C2C12 myotubes that constitutively overexpress acid ceramidase (AC), an enzyme that catalyzes the lysosomal conversion of ceramide to sphingosine. AC overexpression negated the inhibitory effects of saturated FFAs on insulin signaling while blocking their stimulation of ceramide accumulation. By contrast, AC overexpression stimulated the accrual of sphingosine. These results support a role for aberrant accumulation of ceramide, but not sphingosine, in the inhibition of muscle insulin sensitivity by exogenous FFAs.	Univ Utah, Dept Internal Med, Div Endocrinol Diabet & Metab, Salt Lake City, UT 84132 USA; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	Utah System of Higher Education; University of Utah; University of Bonn	Summers, SA (corresponding author), Univ Utah, Dept Internal Med, Div Endocrinol Diabet & Metab, Salt Lake City, UT 84132 USA.	scott.summers@hsc.utah.edu	/AAE-5384-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058784] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK58784] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 2004, DIABETES, V53, P25, DOI 10.2337/diabetes.53.1.25; Bachmann OP, 2001, DIABETES, V50, P2579, DOI 10.2337/diabetes.50.11.2579; Chavez JA, 2003, ARCH BIOCHEM BIOPHYS, V419, P101, DOI 10.1016/j.abb.2003.08.020; Chavez JA, 2003, J BIOL CHEM, V278, P10297, DOI 10.1074/jbc.M212307200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Dobrzyn A, 2004, ACTA PHYSIOL SCAND, V181, P313, DOI 10.1111/j.1365-201X.2004.01295.x; Dobrzyn A, 2002, AM J PHYSIOL-ENDOC M, V282, pE277, DOI 10.1152/ajpendo.00151.2001; Edsall LC, 1999, ANAL BIOCHEM, V272, P80, DOI 10.1006/abio.1999.4157; el Bawab Samer, 2002, Subcell Biochem, V36, P187; Ferreira LDMCB, 2001, DIABETES, V50, P1064, DOI 10.2337/diabetes.50.5.1064; Gorski J, 1998, MOL CELL BIOCHEM, V178, P113, DOI 10.1023/A:1006820907955; Hajduch E, 2001, DIABETOLOGIA, V44, P173, DOI 10.1007/s001250051596; Hansen BC, 1999, ANN NY ACAD SCI, V892, P1, DOI 10.1111/j.1749-6632.1999.tb07782.x; Hegarty BD, 2003, ACTA PHYSIOL SCAND, V178, P373, DOI 10.1046/j.1365-201X.2003.01162.x; Helge JW, 2004, EXP PHYSIOL, V89, P119, DOI 10.1113/expphysiol.2003.002605; HUNNICUTT JW, 1994, DIABETES, V43, P540, DOI 10.2337/diabetes.43.4.540; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kim YB, 2002, J BIOL CHEM, V277, P32915, DOI 10.1074/jbc.M204710200; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Li CM, 2002, GENOMICS, V79, P218, DOI 10.1006/geno.2002.6686; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Montell E, 2001, AM J PHYSIOL-ENDOC M, V280, pE229, DOI 10.1152/ajpendo.2001.280.2.E229; MURRAY DK, 1990, LIFE SCI, V46, P1843, DOI 10.1016/0024-3205(90)90236-K; NELSON DH, 1986, BIOCHEM BIOPH RES CO, V138, P463, DOI 10.1016/0006-291X(86)90303-7; Neschen S, 2002, AM J PHYSIOL-ENDOC M, V282, pE395, DOI 10.1152/ajpendo.00414.2001; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Powell DJ, 2003, MOL CELL BIOL, V23, P7794, DOI 10.1128/MCB.23.21.7794-7808.2003; RANDLE PJ, 1963, LANCET, V1, P785; Riboni L, 1999, BIOCHEM J, V338, P147, DOI 10.1042/0264-6021:3380147; Riboni L, 2000, J NEUROCHEM, V75, P503, DOI 10.1046/j.1471-4159.2000.0750503.x; ROBERTSON DG, 1989, J BIOL CHEM, V264, P6773; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Schmitz-Peiffer C, 2000, CELL SIGNAL, V12, P583, DOI 10.1016/S0898-6568(00)00110-8; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; Seelan RS, 2000, GENE CHROMOSOME CANC, V29, P137, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1018>3.0.CO;2-E; Sinha R, 2002, DIABETES, V51, P1022, DOI 10.2337/diabetes.51.4.1022; Storz P, 1999, EUR J BIOCHEM, V266, P17, DOI 10.1046/j.1432-1327.1999.00809.x; Straczkowski M, 2004, DIABETES, V53, P1215, DOI 10.2337/diabetes.53.5.1215; Stratford S, 2004, J BIOL CHEM, V279, P36608, DOI 10.1074/jbc.M406499200; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Summers SA, 1999, ANN NY ACAD SCI, V892, P169, DOI 10.1111/j.1749-6632.1999.tb07795.x; Teruel T, 2001, DIABETES, V50, P2563, DOI 10.2337/diabetes.50.11.2563; Thompson AL, 2000, AM J PHYSIOL-ENDOC M, V279, pE577, DOI 10.1152/ajpendo.2000.279.3.E577; TURINSKY J, 1990, J BIOL CHEM, V265, P16880; Wang CN, 1998, DIABETES, V47, P24, DOI 10.2337/diabetes.47.1.24; Wang Li-Ping, 2003, Methods Mol Med, V83, P127; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200	56	162	170	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20148	20153		10.1074/jbc.M412769200	http://dx.doi.org/10.1074/jbc.M412769200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774472	hybrid			2022-12-27	WOS:000229113700087
J	Fabre-Lafay, S; Garrido-Urbani, S; Reymond, N; Goncalves, A; Dubreuil, P; Lopez, M				Fabre-Lafay, S; Garrido-Urbani, S; Reymond, N; Goncalves, A; Dubreuil, P; Lopez, M			Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; FACTOR-RECEPTOR; TISSUE INHIBITOR; V-DOMAIN; TACE; POLIOVIRUS; CLEAVAGE; FAMILY; MEMBER; GENE	Serum markers are extensively used in diagnostic and follow-up of cancer patients. We recently described Nectin-4, a 66-kDa adhesion molecule of the Nectin family, which is a valuable new histological and serological marker for breast carcinoma. In vivo, Nectin-4 is re-expressed in breast carcinoma, and a circulating form of Nectin-4 is detected in the sera of patients with metastatic breast cancer. In vitro, a soluble form of Nectin-4 is produced in the supernatant of breast tumor cell lines (S. Fabre-Lafay, C. Ginestier, S. Garrido-Urbani, C. Berruyer, R. Sauvan, N. Reymond, J. Adelaide, J. Geneix, P. Dubreuil, J. Jacquemier, D. Birnbaum, and M. Lopez, manuscript in preparation). We have investigated the mechanisms that regulate the production of this soluble form. It was found that the soluble form of Nectin-4 detected in the sera of patients and the supernatant of breast tumor cell lines share similar biochemical and immunological features. The soluble Nectin-4 form (43 kDa) is formed by the entire Nectin-4 ectodomain. Nectin-4 shedding is constitutive, strongly enhanced by 12-O-tetradecanoylphorbol-13-acetate activation, and reduced tumor necrosis factor-alpha protease inhibitor TAPI-1 or by the tissue inhibitor of metalloproteinase-3 (TIMP-3). TAPI-1 and TIMP-3 are inhibitors of the endoprotease tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. Overexpression or small interfering RNA-mediated silencing of TACE enhanced or reduced Nectin-4 shedding, respectively. Nectin-4 is not shed when expressed in TACE-deficient fibroblasts. Interestingly, the active form of TACE is overexpressed in breast tumors and may indicate that TACE is responsible for Nectin-4 shedding not only in vitro but also in vivo.	Canc & Immunol Marseille, INSERM, Inst Canc, UMR 599, F-13009 Marseille, France; Canc & Immunol Marseille, Mol Pharmacol Lab, IFR 137, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Lopez, M (corresponding author), Canc & Immunol Marseille, INSERM, Inst Canc, UMR 599, 27 Bvd Lei Roure, F-13009 Marseille, France.	lopez@marseille.inserm.fr	dubreuil, patrice/F-5346-2011; Dubreuil, Patrice/V-4816-2019	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150				Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Bachman KE, 1999, CANCER RES, V59, P798; Balduyck M, 2000, CLIN EXP METASTAS, V18, P171, DOI 10.1023/A:1006762425323; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2003, BIOCHEM SOC SYMP, V70, P39, DOI 10.1042/bss0700039; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BYRNE JA, 1995, MOL MED, V1, P418, DOI 10.1007/BF03401579; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Contin C, 2003, J BIOL CHEM, V278, P32801, DOI 10.1074/jbc.M209993200; Cruz AC, 2004, J BIOL CHEM, V279, P5612, DOI 10.1074/jbc.M312323200; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Fabre S, 2002, J BIOL CHEM, V277, P27006, DOI 10.1074/jbc.M203228200; Fata JE, 1999, DEV BIOL, V211, P238, DOI 10.1006/dbio.1999.9313; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Fuchs A, 2004, J IMMUNOL, V172, P3994, DOI 10.4049/jimmunol.172.7.3994; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Hinkle CL, 2004, J BIOL CHEM, V279, P24179, DOI 10.1074/jbc.M312141200; Hung CY, 2002, INFECT IMMUN, V70, P3443, DOI 10.1128/IAI.70.7.3443-3456.2002; Itai T, 2001, EUR J BIOCHEM, V268, P2074, DOI 10.1046/j.1432-1327.2001.02085.x; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Lopez M, 2001, J VIROL, V75, P5684, DOI 10.1128/JVI.75.12.5684-5691.2001; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Monvoisin A, 2002, INT J CANCER, V97, P157, DOI 10.1002/ijc.1595; Nawrocki-Raby B, 2003, INT J CANCER, V105, P790, DOI 10.1002/ijc.11168; Nuttall RK, 2003, MOL CANCER RES, V1, P333; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Reymond N, 2000, GENE, V255, P347, DOI 10.1016/S0378-1119(00)00316-4; Reymond N, 2004, J EXP MED, V199, P1331, DOI 10.1084/jem.20032206; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Schantl JA, 2004, BIOCHEM J, V377, P379, DOI 10.1042/BJ20031321; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Tanaka Y, 2002, BIOCHEM BIOPH RES CO, V299, P472, DOI 10.1016/S0006-291X(02)02681-5; Thathiah A, 2003, J BIOL CHEM, V278, P3386, DOI 10.1074/jbc.M208326200; Vincent B, 2001, J BIOL CHEM, V276, P37743; Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200	45	122	133	3	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19543	19550		10.1074/jbc.M410943200	http://dx.doi.org/10.1074/jbc.M410943200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15784625	hybrid			2022-12-27	WOS:000229113700016
J	Katsuma, S; Hatae, N; Yano, T; Ruike, Y; Kimura, M; Hirasawa, A; Tsujimoto, G				Katsuma, S; Hatae, N; Yano, T; Ruike, Y; Kimura, M; Hirasawa, A; Tsujimoto, G			Free fatty acids inhibit serum deprivation-induced apoptosis through GPR120 in a murine enteroendocrine cell line STC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BREAST-CANCER CELLS; SELECTIVE REGULATION; INSULIN-SECRETION; PROLIFERATION; KINASE; ACTIVATION; EXPRESSION; PALMITATE; GPR40	Free fatty acids (FFAs) provide an important energy source and also act as signaling molecules. FFAs are known to exert a variety of physiological responses via their G protein-coupled receptors (GPCRs), such as the GPR40 family. Recently, we identified a novel FFA receptor, GPR120, that promotes secretion of glucagon-like peptide-1 (Hirasawa, A., Tsumaya, K., Awaji, T., Katsuma, S., Adachi, T., Yamada, M., Sugimoto, Y., Miyazaki, S., and Tsujimoto, G. (2005) Nat. Med. 11, 90-94). Here we showed that FFAs inhibit serum deprivation-induced apoptosis of murine enteroendocrine STC-1 cells, which express two types of GPCRs, GPR120 and GPR40, for unsaturated long chain FFA. We first found that linolenic acid potently activated ERK and Akt/protein kinase B (Akt) in STC-1 cells. ERK kinase inhibitors significantly reduced the antiapoptotic effects of linolenic acid. Inhibitors for phosphatidylinositol 3-kinase (PI3K), a major target of which is Akt, significantly reduced the anti-apoptotic effects. Transfection of STC-1 cells with the dominant-negative form of Akt also inhibited the anti-apoptotic effect. These results suggested that the activation of ERK and PI3K-Akt pathways is required for FFA-induced anti-apoptotic effects on STC-1 cells. Transient transfection of STC-1 cells with GPR120 cDNA, but not GPR40 cDNA, enhanced inhibition of caspase-3 activation. RNA interference experiments showed that reduced expression of GPR120, but not GPR40, resulted in reduced ERK activation and reduced effects of FFAs on caspase-3 inhibition. Collectively, these results demonstrated that FFAs promote the activation of ERK and PI3K-Akt pathways mainly via GPR120, leading to the anti-apoptotic effect of STC-1 cells.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Genom Drug Discovery Sci, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Inst Chem Res, Bioinformat Ctr, Kyoto 6110011, Japan	Kyoto University; Kyoto University	Tsujimoto, G (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Genom Drug Discovery Sci, Sakyo Ku, 46-29 Yoshida Shimoadachi Cho, Kyoto 6068501, Japan.	gtsuji@pharm.kyoto-u.ac.jp						Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; Dugourd C, 2003, HYPERTENSION, V41, P882, DOI 10.1161/01.HYP.0000060821.62417.35; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hardy S, 2000, CANCER RES, V60, P6353; Hardy S, 2003, J BIOL CHEM, V278, P31861, DOI 10.1074/jbc.M300190200; Hatae N, 2003, J BIOL CHEM, V278, P17977, DOI 10.1074/jbc.M301312200; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Izumi Y, 2001, CIRC RES, V88, P1120, DOI 10.1161/hh1101.091267; KATADA T, 1986, J BIOL CHEM, V261, P5215; Katsuma S, 2002, GENES CELLS, V7, P1217, DOI 10.1046/j.1365-2443.2002.00594.x; Le Poul E, 2003, J BIOL CHEM, V278, P25481, DOI 10.1074/jbc.M301403200; Listenberger LL, 2001, J BIOL CHEM, V276, P14890, DOI 10.1074/jbc.M010286200; Lu ZH, 2003, BIOCHEM BIOPH RES CO, V303, P1002, DOI 10.1016/S0006-291X(03)00449-2; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Ostrander DB, 2001, J BIOL CHEM, V276, P38061; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Sidhu SS, 2000, J PHYSIOL-LONDON, V528, P165, DOI 10.1111/j.1469-7793.2000.00165.x; Thompson AL, 2000, AM J PHYSIOL-ENDOC M, V279, pE577, DOI 10.1152/ajpendo.2000.279.3.E577; Ulloth JE, 2003, J NEUROCHEM, V84, P655, DOI 10.1046/j.1471-4159.2003.01571.x; Welters HJ, 2004, FEBS LETT, V560, P103, DOI 10.1016/S0014-5793(04)00079-1; Xiong YM, 2004, P NATL ACAD SCI USA, V101, P1045, DOI 10.1073/pnas.2637002100; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yonezawa T, 2004, BIOCHEM BIOPH RES CO, V314, P805, DOI 10.1016/j.bbrc.2003.12.175; Zhan YM, 2003, ARTERIOSCL THROM VAS, V23, P795, DOI 10.1161/01.ATV.0000066132.32063.F2	34	146	162	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19507	19515		10.1074/jbc.M412385200	http://dx.doi.org/10.1074/jbc.M412385200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774482	hybrid			2022-12-27	WOS:000229113700012
J	Onorato, TM; Chakraborty, S; Haldar, D				Onorato, TM; Chakraborty, S; Haldar, D			Phosphorylation of rat liver mitochondrial glycerol-3-phosphate acyltransferase by casein kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCEROL PHOSPHATE ACYLTRANSFERASE; ACETYL-COA CARBOXYLASE; ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; FATTY-ACID OXIDATION; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; GLYCEROPHOSPHATE ACYLTRANSFERASE; TRIACYLGLYCEROL-SYNTHESIS; PHOSPHOLIPID-SYNTHESIS; TERMINAL DOMAIN	We have previously shown rat liver mitochondrial glycerol-3-phosphate acyltransferase (mtGAT), which catalyzes the first step in de novo glycerolipid biosynthesis, is stimulated by casein kinase 2 (CK2) and that a phosphorylated protein of similar to 85 kDa is present in CK2-treated mitochondria. In this paper, we have identified the P-32-labeled 85-kDa protein as mtGAT. We have also investigated whether the phosphorylation of mtGAT is because of CK2. Mitochondria were treated with CK2 and [gamma-P-32]GTP as the phosphate donor. Autoradiography, Western blot, and immunoprecipitation results showed mtGAT was phosphorylated by CK2. Next, we incubated mitochondria with CK2 and either ATP or GTP, in the presence of heparin, a known inhibitor of CK2. Heparin inhibited CK2-induced stimulation of mtGAT activity; this inhibition resulted in decreased P-32-labeling of mtGAT. Additionally, mitochondria were treated with CK2 and [gamma-P-32]ATP in the presence of staurosporine ( a serine/threonine protein kinase inhibitor), genistein ( a tyrosine kinase inhibitor), and 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB, a CK2 inhibitor). Only DRB, the CK2 inhibitor, greatly reduced the amount of P-32-incorporation into mtGAT by CK2. Finally, isolated mitochondrial outer membrane was incubated with cytosol in the presence of [gamma-P-32]GTP; P-32-labeled mtGAT was detected. Collectively, these data suggest that CK2 phosphorylates mtGAT. The impact of our results in the regulation of mtGAT and other anabolic processes is discussed.	St Johns Univ, Dept Sci Biol, Jamaica, NY 11439 USA	Saint John's University	Haldar, D (corresponding author), St Johns Univ, Dept Sci Biol, 8000 Utopia Pkwy, Jamaica, NY 11439 USA.	haldard@stjohns.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM057643] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-57643] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100; Agarwal AK, 2003, TRENDS ENDOCRIN MET, V14, P214, DOI 10.1016/S1043-2760(03)00078-X; Balija VS, 2000, J BIOL CHEM, V275, P31668, DOI 10.1074/jbc.M002963200; BATES EJ, 1979, BIOCHEM J, V182, P751, DOI 10.1042/bj1820751; Bhat BG, 1999, BBA-MOL CELL BIOL L, V1439, P415, DOI 10.1016/S1388-1981(99)00103-1; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARI G, 1971, FEBS LETT, V17, P300, DOI 10.1016/0014-5793(71)80169-2; DESAUTELS M, 1982, J BIOL CHEM, V257, P1673; FAMULSKI KS, 1983, FEBS LETT, V157, P124, DOI 10.1016/0014-5793(83)81129-6; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Gonzalez-Baro MR, 2001, J BIOL CHEM, V276, P43182, DOI 10.1074/jbc.M107885200; Haldar D, 1983, Trans N Y Acad Sci, V41, P173; HALDAR D, 1979, J BIOL CHEM, V254, P4502; HALDAR D, 1990, J BIOL CHEM, V265, P11014; Hammond LE, 2002, MOL CELL BIOL, V22, P8204, DOI 10.1128/MCB.22.23.8204-8214.2002; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P347, DOI 10.1111/j.1432-1033.1988.tb14203.x; HESLER CB, 1985, J BIOL CHEM, V260, P7452; HOLLAND R, 1985, FEBS LETT, V181, P308, DOI 10.1016/0014-5793(85)80282-9; Igal RA, 2001, J BIOL CHEM, V276, P42205, DOI 10.1074/jbc.M103386200; Lewin TM, 2004, J BIOL CHEM, V279, P13488, DOI 10.1074/jbc.M314032200; Lewin TM, 2001, ARCH BIOCHEM BIOPHYS, V396, P119, DOI 10.1006/abbi.2001.2604; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; Linden D, 2004, J LIPID RES, V45, P1279, DOI 10.1194/jlr.M400010-JLR200; MARTOS C, 1985, BIOCHEM J, V225, P321, DOI 10.1042/bj2250321; MONROY G, 1972, J BIOL CHEM, V247, P6884; Muoio DM, 1999, BIOCHEM J, V338, P783, DOI 10.1042/0264-6021:3380783; Mylonis I, 2003, BIOCHEM BIOPH RES CO, V301, P650, DOI 10.1016/S0006-291X(02)03055-3; Niefind K, 1999, NAT STRUCT BIOL, V6, P1100, DOI 10.1038/70033; NIKONOV AV, 1998, RRD LIP RES 2, V2, P207; O'Farrell F, 1999, BBA-PROTEIN STRUCT M, V1433, P68, DOI 10.1016/S0167-4838(99)00147-8; Onorato TM, 2002, BIOCHEM BIOPH RES CO, V296, P1091, DOI 10.1016/S0006-291X(02)02064-8; ONORATO TM, 2002, LIPIDS GLYCEROLIPID; Park H, 2002, J BIOL CHEM, V277, P32571, DOI 10.1074/jbc.M201692200; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; PIEDIMONTE G, 1988, J CELL BIOCHEM, V36, P91, DOI 10.1002/jcb.240360110; ROCK CO, 1981, ARCH BIOCHEM BIOPHYS, V211, P113, DOI 10.1016/0003-9861(81)90436-7; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Ruderman NB, 2003, ACTA PHYSIOL SCAND, V178, P435, DOI 10.1046/j.1365-201X.2003.01164.x; SAGGERSON ED, 1987, BIOCHEM J, V243, P289, DOI 10.1042/bj2430289; Salvi M, 2002, BBA-MOL CELL RES, V1589, P181, DOI 10.1016/S0167-4889(02)00174-X; Sambrook J., 2001, MOL CLONING LAB MANU; Sasaki K, 2003, J BIOL CHEM, V278, P30945, DOI 10.1074/jbc.M212167200; SCHLAME M, 1993, J BIOL CHEM, V268, P74; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Trembley JH, 2003, J BIOL CHEM, V278, P2265, DOI 10.1074/jbc.M207518200; Tuteja N, 2003, PLANT PHYSIOL, V132, P2108, DOI 10.1104/pp.103.024273; Uchida T, 1996, BBA-LIPID LIPID MET, V1304, P89, DOI 10.1016/S0005-2760(96)00109-9; Vaglio P, 1996, FEBS LETT, V380, P25, DOI 10.1016/0014-5793(95)01542-6; van Gurp M, 2003, BIOCHEM BIOPH RES CO, V304, P487, DOI 10.1016/S0006-291X(03)00621-1; VANCURA A, 1991, BIOCHEM BIOPH RES CO, V175, P339, DOI 10.1016/S0006-291X(05)81240-9; VANCURA A, 1992, J BIOL CHEM, V267, P14353; VANCURA A, 1994, J BIOL CHEM, V269, P27209; WEST L, 2005, BIOCHIM BIOPHYS ACTA, V1687, P164; Wu XF, 2003, BIOCHEM BIOPH RES CO, V304, P333, DOI 10.1016/S0006-291X(03)00594-1; YET SF, 1993, BIOCHEMISTRY-US, V32, P9486, DOI 10.1021/bi00087a029	57	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19527	19534		10.1074/jbc.M410422200	http://dx.doi.org/10.1074/jbc.M410422200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15778226	hybrid			2022-12-27	WOS:000229113700014
J	Chandra, D; Choy, G; Daniel, PT; Tang, DG				Chandra, D; Choy, G; Daniel, PT; Tang, DG			Bax-dependent regulation of Bak by voltage-dependent anion channel 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 HOMOLOG BAX; INDUCED APOPTOSIS; CELL-DEATH; MITOCHONDRIAL ACTIVATION; MUTATIONAL INACTIVATION; COLORECTAL CANCERS; DEFICIENT MICE; PATHWAY; REQUIREMENT	Many studies have demonstrated a critical role of Bax in mediating apoptosis, but the role of Bak in regulating cancer cell apoptotic sensitivities in the presence or absence of Bax remains incompletely understood. Using isogenic cells with defined genetic deficiencies, here we show that in response to intrinsic, extrinsic, and endoplasmic reticulum stress stimuli, HCT116 cells show clear-cut apoptotic sensitivities in the order of Bax(+)/Bak(+) > Bax(+)/Bak(-) >> Bax(-)/Bak(+) >> Bax(-)/Bak(-). Small interference RNA-mediated knockdown of Bak in Bax-deficient cells renders HCT116 cells completely resistant to apoptosis induction. Surprisingly, however, Bak knockdown in Bax-expressing cells only slightly affects the apoptotic sensitivities. Bak, like Bax, undergoes the N terminus exposure upon apoptotic stimulation in both Bax-expressing and Bax-deficient cells. Gel filtration, chemical cross-linking, and co-immunoprecipitation experiments reveal that different from Bax, which normally exists as monomers in unstimulated cells and is oligomerized by apoptotic stimulation, most Bak in unstimulated HCT116 cells exists in two distinct protein complexes, one of which contains voltage-dependent anion channel (VDAC) 2. During apoptosis, Bak and Bax form both homo- and hetero-oligomeric complexes that still retain some VDAC-2. However, the oligomeric VDAC-2 complexes are diminished, and Bak does not interact with VDAC-2 in Bax-deficient HCT116 cells. These results highlight VDAC-2 as a critical inhibitor of Bak-mediated apoptotic responses.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	University of Texas System; UTMD Anderson Cancer Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Pk Rd 1C, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Tang, Dean/AAI-3457-2020	Tang, Dean/0000-0001-5029-1174; Chandra, Dhyan/0000-0001-7272-9384	NATIONAL CANCER INSTITUTE [R01CA090297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023374] Funding Source: NIH RePORTER; NCI NIH HHS [CA 90297] Funding Source: Medline; NIA NIH HHS [AG023374] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Barnhart BC, 2004, EMBO J, V23, P3175, DOI 10.1038/sj.emboj.7600325; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Chandra D, 2003, J BIOL CHEM, V278, P17408, DOI 10.1074/jbc.M300750200; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; Chandra D, 2002, J BIOL CHEM, V277, P50842, DOI 10.1074/jbc.M207622200; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; de Bruin EC, 2003, CELL DEATH DIFFER, V10, P1204, DOI 10.1038/sj.cdd.4401296; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Egger L, 2003, CELL DEATH DIFFER, V10, P1188, DOI 10.1038/sj.cdd.4401288; Eischen CM, 2002, CANCER RES, V62, P2184; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; Fannjiang Y, 2003, DEV CELL, V4, P575, DOI 10.1016/S1534-5807(03)00091-1; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; He Q, 2003, ONCOGENE, V22, P2674, DOI 10.1038/sj.onc.1206363; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Kandasamy K, 2003, CANCER RES, V63, P1712; Kondo S, 2000, CANCER RES, V60, P4328; Krajewska M, 1996, AM J PATHOL, V148, P1567; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Liu JW, 2005, ONCOGENE, V24, P2020, DOI 10.1038/sj.onc.1208385; Liu JW, 2002, CANCER RES, V62, P2976; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ravi R, 2002, CANCER RES, V62, P1583; Rostovtseva TK, 2004, J BIOL CHEM, V279, P13575, DOI 10.1074/jbc.M310593200; Seo SY, 2004, J BIOL CHEM, V279, P42240, DOI 10.1074/jbc.M406775200; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; Tang DG, 1998, CANCER RES, V58, P3466; Theodorakis P, 2002, CANCER RES, V62, P3373; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zalk R, 2005, BIOCHEM J, V386, P73, DOI 10.1042/BJ20041356; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	55	81	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19051	19061		10.1074/jbc.M501391200	http://dx.doi.org/10.1074/jbc.M501391200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757910	hybrid			2022-12-27	WOS:000228932300061
J	Luer, C; Schauer, S; Mobius, K; Schulze, J; Schubert, WD; Heinz, DW; Jahn, D; Moser, J				Luer, C; Schauer, S; Mobius, K; Schulze, J; Schubert, WD; Heinz, DW; Jahn, D; Moser, J			Complex formation between glutamyl-tRNA reductase and glutamate-1-semialdehyde 2,1-aminomutase in Escherichia coli during the initial reactions of porphyrin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-SEMIALDEHYDE AMINOTRANSFERASE; CHLOROPHYLL BIOSYNTHESIS; 1ST ENZYME; PURIFICATION; SEQUENCE; HEME; GENE	In Escherichia coli the first common precursor of all tetrapyrroles, 5-aminolevulinic acid, is synthesized from glutamyl-tRNA (Glu-tRNA(Glu)) in a two-step reaction catalyzed by glutamyl-tRNA reductase (GluTR) and glutamate-1-semialdehyde 2,1-aminomutase (GSA-AM). To protect the highly reactive reaction intermediate glutamate-1-semialdehyde (GSA), a tight complex between these two enzymes was proposed based on their solved crystal structures. The existence of this hypothetical complex was verified by two independent biochemical techniques. Co-immunoprecipitation experiments using antibodies directed against E. coli GluTR and GSA-AM demonstrated the physical interaction of both enzymes in E. coli cell-free extracts and between the recombinant purified enzymes. Additionally, the formation of a GluTR.GSA-AM complex was identified by gel permeation chromatography. Complex formation was found independent of Glu-tRNA(Glu) and cofactors. The analysis of a GluTR mutant truncated in the 80-amino acid C-terminal dimerization domain (GluTR-A338Stop) revealed the importance of GluTR dimerization for complex formation. The in silico model of the E. coli GluTR.GSA-AM complex suggested direct metabolic channeling between both enzymes to protect the reactive aldehyde species GSA. In accordance with this proposal, side product formation catalyzed by GluTR was observed via high performance liquid chromatography analysis in the absence of the GluTR.GSA-AM complex.	Tech Univ Carolo Wilhelmina Braunschweig, Inst Microbiol, D-38106 Braunschweig, Germany; Swiss Fed Inst Technol, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland; German Res Ctr Biotechnol, Div Struct Biol, D-38124 Braunschweig, Germany	Braunschweig University of Technology; Swiss Federal Institutes of Technology Domain; ETH Zurich; Helmholtz Association; Helmholtz-Center for Infection Research	Moser, J (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Microbiol, Spielmannstr 7, D-38106 Braunschweig, Germany.	j.moser@tu-bs.de	Schubert, Wolf-Dieter/A-5617-2009	Schubert, Wolf-Dieter/0000-0003-4998-519X; Jahn, Dieter/0000-0002-4064-9205				Beeckmans S, 1999, METHODS, V19, P278, DOI 10.1006/meth.1999.0857; BOREL F, 1993, FEBS LETT, V324, P162, DOI 10.1016/0014-5793(93)81385-D; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; DeLano W.L, PYMOL MOL GRAPHICS S; Frankenberg N, 1999, BIOCHEMISTRY-US, V38, P13968, DOI 10.1021/bi9906468; Hennig M, 1997, P NATL ACAD SCI USA, V94, P4866, DOI 10.1073/pnas.94.10.4866; HOOBER JK, 1988, CARLSBERG RES COMMUN, V53, P11, DOI 10.1007/BF02908411; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; ILAG LL, 1992, BIOCHEMISTRY-US, V31, P7143, DOI 10.1021/bi00146a016; ILAG LL, 1991, J BACTERIOL, V173, P3408, DOI 10.1128/jb.173.11.3408-3413.1991; JAHN D, 1992, TRENDS BIOCHEM SCI, V17, P215, DOI 10.1016/0968-0004(92)90380-R; JORDAN PM, 1990, BIOSYNTHESIS HEME CH; LIN SX, 1992, PROTEIN EXPRES PURIF, V3, P71, DOI 10.1016/1046-5928(92)90058-5; Moser J, 2001, EMBO J, V20, P6583, DOI 10.1093/emboj/20.23.6583; Moser J, 1999, J BIOL CHEM, V274, P30679, DOI 10.1074/jbc.274.43.30679; Reichelt J, 2005, BIOINFORMATICS, V21, P1291, DOI 10.1093/bioinformatics/bti138; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schauer S, 2003, PROTEIN EXPRES PURIF, V31, P271, DOI 10.1016/S1046-5928(03)00184-0; Schauer S, 2002, J BIOL CHEM, V277, P48657, DOI 10.1074/jbc.M206924200; SCHON A, 1986, NATURE, V322, P281, DOI 10.1038/322281a0; Schubert WD, 2002, PHOTOSYNTH RES, V74, P205, DOI 10.1023/A:1020963711861; VERKAMP E, 1989, J BACTERIOL, V171, P4728, DOI 10.1128/jb.171.9.4728-4735.1989; Wang LY, 1999, J BACTERIOL, V181, P1211, DOI 10.1128/JB.181.4.1211-1219.1999	23	57	62	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18568	18572		10.1074/jbc.M500440200	http://dx.doi.org/10.1074/jbc.M500440200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757895	hybrid			2022-12-27	WOS:000228932300004
J	Schwartz, JW; Novarino, G; Piston, DW; DeFelice, LJ				Schwartz, JW; Novarino, G; Piston, DW; DeFelice, LJ			Substrate binding stoichiometry and kinetics of the norepinephrine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; HUMAN DOPAMINE TRANSPORTER; TERNARY COMPLEX MODEL; SEROTONIN TRANSPORTER; MULTIFREQUENCY PHASE; LIVING CELLS; ORTHOSTATIC INTOLERANCE; FUNCTIONAL CONSEQUENCES; MODULATION FLUOROMETRY; TRANSMEMBRANE SEGMENT	The human norepinephrine (NE) transporter (hNET) attenuates neuronal signaling by rapid NE clearance from the synaptic cleft, and NET is a target for cocaine and amphetamines as well as therapeutics for depression, obsessive-compulsive disorder, and post-traumatic stress disorder. In spite of its central importance in the nervous system, little is known about how NET substrates, such as NE, 1-methyl-4-tetrahydropyridinium (MPP+), or amphetamine, interact with NET at the molecular level. Nor do we understand the mechanisms behind the transport rate. Previously we introduced a fluorescent substrate similar to MPP+, which allowed separate and simultaneous binding and transport measurement (Schwartz, J. W., Blakely, R. D., and DeFelice, L. J. (2003) J. Biol. Chem. 278, 9768-9777). Here we use this substrate, 4-(4-(dimethylamino)styrl)-N-methyl-pyridinium (ASP(+)), in combination with green fluorescent protein-tagged hNETs to measure substrate-transporter stoichiometry and substrate binding kinetics. Calibrated confocal microscopy and fluorescence correlation spectroscopy reveal that hNETs, which are homo-multimers, bind one substrate molecule per transporter subunit. Substrate residence at the transporter, obtained from rapid on-off kinetics revealed in fluorescence correlation spectroscopy, is 526 mu s. Substrate residence obtained by infinite dilution is 1000 times slower. This novel examination of substrate-transporter kinetics indicates that a single ASP(+) molecule binds and unbinds thousands of times before being transported or ultimately dissociated from hNET. Calibrated fluorescent images combined with mass spectroscopy give a transport rate of 0.06 ASP(+)/hNET-protein/s, thus 36,000 on-off binding events (and 36 actual departures) occur for one transport event. Therefore binding has a low probability of resulting in transport. We interpret these data to mean that inefficient binding could contribute to slow transport rates.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA; Univ Roma La Sapienza, Dipartimento Biol Cellulare & Sviluppo, I-00185 Rome, Italy	Vanderbilt University; Vanderbilt University; Vanderbilt University; Sapienza University Rome	DeFelice, LJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.	lou.defelice@vanderbilt.edu		De Felice, Louis/0000-0002-4594-3171	NCI NIH HHS [CA68485] Funding Source: Medline; NIDA NIH HHS [DA-6338] Funding Source: Medline; NIMH NIH HHS [MH 58921] Funding Source: Medline; NINDS NIH HHS [NS-34075] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034075] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALCALA JR, 1985, ANAL INSTRUM, V14, P225; Axelrod D, 2001, TRAFFIC, V2, P764, DOI 10.1034/j.1600-0854.2001.21104.x; Axelrod J, 1969, Prog Brain Res, V31, P21; Bacia K, 2003, METHODS, V29, P74, DOI 10.1016/S1046-2023(02)00291-8; Backs J, 2001, J MOL CELL CARDIOL, V33, P461, DOI 10.1006/jmcc.2000.1319; Blakely RD, 2001, J NEUROSCI, V21, P8319, DOI 10.1523/JNEUROSCI.21-21-08319.2001; BONISCH H, 1986, N-S ARCH PHARMACOL, V332, P131, DOI 10.1007/BF00511402; BRUNS D, 1993, NEURON, V10, P559, DOI 10.1016/0896-6273(93)90159-O; Bruns D, 1998, METHOD ENZYMOL, V296, P593; Carvelli L, 2004, P NATL ACAD SCI USA, V101, P16046, DOI 10.1073/pnas.0403299101; Clark MS, 1998, BRAIN RES PROTOC, V2, P273, DOI 10.1016/S1385-299X(98)00004-X; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; DeFelice LJ, 2004, TRENDS NEUROSCI, V27, P352, DOI 10.1016/j.tins.2004.04.007; DELCASTILLO J, 1957, PROC R SOC SER B-BIO, V146, P369; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Foote S., 1995, PHARM PHYSL CENTRAL; FRIEDRICH U, 1986, N-S ARCH PHARMACOL, V333, P246, DOI 10.1007/BF00512937; GALLI A, 1995, J EXP BIOL, V198, P2197; Galli A, 1996, P NATL ACAD SCI USA, V93, P8671, DOI 10.1073/pnas.93.16.8671; Garland EM, 2002, ANN NY ACAD SCI, V971, P506, DOI 10.1111/j.1749-6632.2002.tb04515.x; GRATTON E, 1984, ANNU REV BIOPHYS BIO, V13, P105; Gu HH, 1996, J BIOL CHEM, V271, P6911, DOI 10.1074/jbc.271.12.6911; Hahn MK, 2003, J NEUROSCI, V23, P4470; Hanson KM, 2002, BIOPHYS J, V83, P1682, DOI 10.1016/S0006-3495(02)73936-2; Hastrup H, 2003, J BIOL CHEM, V278, P45045, DOI 10.1074/jbc.C300349200; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Haupts U, 1998, P NATL ACAD SCI USA, V95, P13573, DOI 10.1073/pnas.95.23.13573; Hess ST, 2002, BIOPHYS J, V83, P2300, DOI 10.1016/S0006-3495(02)73990-8; Ingram SL, 2002, NAT NEUROSCI, V5, P971, DOI 10.1038/nn920; JAMESON DM, 1984, APPL SPECTROSC REV, V20, P55, DOI 10.1080/05704928408081716; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Jayanthi LD, 2002, BRIT J PHARMACOL, V135, P1927, DOI 10.1038/sj.bjp.0704658; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Kocabas AM, 2003, J NEUROCHEM, V85, P1513, DOI 10.1046/j.1471-4159.2003.01793.x; LAKOWICZ JR, 1999, PRINCIPLES FLUORESEN; Larsson HP, 1996, BIOPHYS J, V70, P733, DOI 10.1016/S0006-3495(96)79613-3; Maes M, 1999, NEUROPSYCHOPHARMACOL, V20, P188, DOI 10.1016/S0893-133X(98)00058-X; MASON JN, 2004, IN PRESS J NEUROSCI; Meissner O, 2003, BIOCHEMISTRY-US, V42, P1667, DOI 10.1021/bi0263356; Norgaard-Nielsen K, 2002, FEBS LETT, V524, P87, DOI 10.1016/S0014-5793(02)03008-9; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3; Pifl C, 1996, J PHARMACOL EXP THER, V277, P1437; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Ramsey IS, 2002, J BIOL CHEM, V277, P14475, DOI 10.1074/jbc.M110783200; Robertson D, 2001, ANN NY ACAD SCI, V940, P527; Rudnick G, 1998, METHOD ENZYMOL, V296, P233; Sacchetti G, 1999, BRIT J PHARMACOL, V128, P1332, DOI 10.1038/sj.bjp.0702926; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Savchenko V, 2003, MOL CELL NEUROSCI, V24, P1131, DOI 10.1016/S1044-7431(03)00235-5; SCHILDKRAUT JJ, 1965, J PSYCHIAT RES, V3, P213, DOI 10.1016/0022-3956(65)90003-8; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Schwartz JW, 2003, J BIOL CHEM, V278, P9768, DOI 10.1074/jbc.M209824200; Schwille P, 1999, BIOPHYS J, V77, P2251, DOI 10.1016/S0006-3495(99)77065-7; Schwille P, 2001, CELL BIOCHEM BIOPHYS, V34, P383, DOI 10.1385/CBB:34:3:383; Shannon JR, 2000, NEW ENGL J MED, V342, P541, DOI 10.1056/NEJM200002243420803; Siggia ED, 2000, BIOPHYS J, V79, P1761, DOI 10.1016/S0006-3495(00)76428-9; Sitte HH, 2004, MOL INTERV, V4, P38, DOI 10.1124/mi.4.1.38; Stachon A, 1996, CELL PHYSIOL BIOCHEM, V6, P72, DOI 10.1159/000154796; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Trendelenburg AU, 1999, J NEUROCHEM, V73, P1431, DOI 10.1046/j.1471-4159.1999.0731431.x; VALENTINO RJ, 1983, BRAIN RES, V270, P363, DOI 10.1016/0006-8993(83)90615-7; Vrljic M, 2002, BIOPHYS J, V83, P2681, DOI 10.1016/S0006-3495(02)75277-6; Yernool D, 2003, BIOCHEMISTRY-US, V42, P12981, DOI 10.1021/bi030161q; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018	65	45	45	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19177	19184		10.1074/jbc.M412923200	http://dx.doi.org/10.1074/jbc.M412923200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757904	hybrid			2022-12-27	WOS:000228932300074
J	Bi, XH; Slater, DM; Ohmori, H; Vaziri, C				Bi, XH; Slater, DM; Ohmori, H; Vaziri, C			DNA polymerase kappa is specifically required for recovery from the benzo[a]pyrene-dihydrodiol epoxide (BPDE)-induced S-phase checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							Y-FAMILY; POL-KAPPA; REPLICATION MACHINERY; DAMAGE CHECKPOINT; MAMMALIAN-CELLS; ATR; ETA; PCNA; LOCALIZATION; CHK1	Previously we identified an intra-S-phase cell cycle checkpoint elicited by the DNA-damaging carcinogen benzo[ a] pyrene-dihydrodiol epoxide ( BPDE). Here we have investigated the roles of lesion bypass DNA polymerases pol kappa and pol eta in the BPDE- induced S-phase checkpoint. BPDE treatment induced the re-localization of an ectopically expressed green fluorescent protein-pol kappa fusion protein to nuclear foci containing sites of active DNA synthesis in human lung carcinoma H1299 cells. In contrast, a similarly expressed yellow fluorescent protein-pol eta fusion protein showed a constitutive nuclear focal distribution at replication forks ( in the same cells) that was unchanged in response to BPDE. BPDE- induced formation of green fluorescent protein-pol kappa nuclear foci was temporally coincident with checkpoint-mediated S-phase arrest. Unlike "wild-type" cells, Polk(-/-) mouse embryonic fibroblasts (MEFs) failed to recover from BPDE- induced S-phase arrest, while exhibiting normal recovery from S-phase arrest induced by ionizing radiation and hydroxyurea. XPV fibroblasts lacking pol eta showed a normal S-phase checkpoint response to BPDE ( but failed to recover from the UV light-induced S-phase checkpoint), in sharp contrast to Polk(-/-) MEFs. The persistent S-phase arrest in BPDE-treated PolK(-/-) cells was associated with increased levels of histone gamma H2AX ( a marker of DNA double- strand breaks (DSBs)) and activation of the DSB-responsive kinases ATM and Chk2. These data suggest that in the absence of pol kappa, replication forks stall at sites of damage and collapse and generate DSBs. Therefore, we conclude that the trans-lesion synthesis enzyme pol kappa is specifically required for normal recovery from the BPDE- induced S- phase checkpoint.	Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	Boston University; Kyoto University	Vaziri, C (corresponding author), Boston Univ, Sch Med, Dept Genet & Genom, 80 E Concord St, Boston, MA 02118 USA.	cvaziri@bu.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES009558, R01ES012917, R01ES009558] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 12917, ES 09558] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Avkin S, 2004, J BIOL CHEM, V279, P53298, DOI 10.1074/jbc.M409155200; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Baum E, 1978, POLYCYCLIC HYDROCARB, V1, P45; Baynton K, 2000, TRENDS BIOCHEM SCI, V25, P74, DOI 10.1016/S0968-0004(99)01524-8; Bergoglio V, 2002, J CELL SCI, V115, P4413, DOI 10.1242/jcs.00162; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Cleaver JE, 2003, CELL CYCLE, V2, P310, DOI 10.4161/cc.2.4.436; CORDEIROSTONE M, 1986, CARCINOGENESIS, V7, P1775, DOI 10.1093/carcin/7.10.1775; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Guo CX, 2003, EMBO J, V22, P6621, DOI 10.1093/emboj/cdg626; Guo N, 2002, CELL GROWTH DIFFER, V13, P77; Haracska L, 2002, P NATL ACAD SCI USA, V99, P16000, DOI 10.1073/pnas.252524999; Haracska L, 2002, MOL CELL BIOL, V22, P784, DOI 10.1128/MCB.22.3.784-791.2002; Haracska L, 2001, MOL CELL BIOL, V21, P7199, DOI 10.1128/MCB.21.21.7199-7206.2001; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007; Hemminki K, 2000, REGUL TOXICOL PHARM, V32, P264, DOI 10.1006/rtph.2000.1431; Izumi M, 2000, NUCLEIC ACIDS RES, V28, P4769, DOI 10.1093/nar/28.23.4769; Kai M, 2003, MUTAT RES-FUND MOL M, V532, P59, DOI 10.1016/j.mrfmmm.2003.08.010; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kannouche P, 2002, EMBO J, V21, P6246, DOI 10.1093/emboj/cdf618; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kaufmann WK, 2003, MUTAT RES-FUND MOL M, V532, P85, DOI 10.1016/j.mrfmmm.2003.08.012; KAUFMANN WK, 1985, BIOCHIM BIOPHYS ACTA, V824, P146, DOI 10.1016/0167-4781(85)90091-0; Kunz BA, 2000, MUTAT RES-FUND MOL M, V451, P169, DOI 10.1016/S0027-5107(00)00048-8; Lawrence CW, 2002, DNA REPAIR, V1, P425, DOI 10.1016/S1568-7864(02)00038-1; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Liu QH, 2000, GENE DEV, V14, P1448; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Ogi T, 2005, J CELL SCI, V118, P129, DOI 10.1242/jcs.01603; Ogi T, 2002, P NATL ACAD SCI USA, V99, P15548, DOI 10.1073/pnas.222377899; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; Ohashi E, 2004, GENES CELLS, V9, P523, DOI 10.1111/j.1356-9597.2004.00747.x; Ohmori H, 2004, ADV PROTEIN CHEM, V69, P265; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Roos-Mattjus P, 2002, J BIOL CHEM, V277, P43809, DOI 10.1074/jbc.M207272200; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Tissier A, 2004, DNA REPAIR, V3, P1503, DOI 10.1016/j.dnarep.2004.06.015; Ulrich HD, 2004, CELL CYCLE, V3, P15; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Velasco-Miguel S, 2003, DNA REPAIR, V2, P91, DOI 10.1016/S1568-7864(02)00189-1; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	62	116	117	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22343	22355		10.1074/jbc.M501562200	http://dx.doi.org/10.1074/jbc.M501562200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817457	hybrid			2022-12-27	WOS:000229557900080
J	Haguenauer, A; Raimbault, S; Masscheleyn, S; Gonzalez-Barroso, MD; Criscuolo, F; Plamondon, J; Miroux, B; Ricquier, D; Richard, D; Bouillaud, F; Pecqueur, C				Haguenauer, A; Raimbault, S; Masscheleyn, S; Gonzalez-Barroso, MD; Criscuolo, F; Plamondon, J; Miroux, B; Ricquier, D; Richard, D; Bouillaud, F; Pecqueur, C			A new renal mitochondrial carrier, KMCP1, is up-regulated during tubular cell regeneration and induction of antioxidant enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; UNCOUPLING PROTEIN; RAT-BRAIN; EXPRESSION; MEMBRANE; ISOFORMS; SYSTEM; BMCP1; GENE	The mitochondrial carrier family transports a variety of metabolites across the inner mitochondrial membrane. We identified and cloned a new member of this family, KMCP1 ( kidney mitochondrial carrier protein-1), that is highly homologous to the previously identified protein BMCP1 (brain mitochondrial carrier protein-1). Western blotting and in situ experiments showed that this carrier is expressed predominantly within the kidney cortex in the proximal and distal tubules. KMCP1 was increased during fasting and during the regenerative phase of glycerol-induced renal failure. We show that both situations are associated with transiently increased expression of superoxide-generating enzymes, followed by increased mitochondrial metabolism and antioxidant defenses. Given that KMCP1 expression occurs simultaneously with these latter events, we propose that KMCP1 is involved in situations in which mitochondrial metabolism is increased, in particular when the cellular redox balance tends toward a pro-oxidant status.	CNRS, Fac Necker Enfants Malades, F-75730 Paris, France; Univ Laval, Fac Med, Dept Anat & Physiol, Quebec City, PQ G1K 7P4, Canada	Centre National de la Recherche Scientifique (CNRS); Laval University	Pecqueur, C (corresponding author), CNRS, Fac Necker Enfants Malades, 156 Rue Vaugirard, F-75730 Paris, France.	pecqueuc@necker.fr	Miroux, Bruno/E-9267-2017; Bouillaud, Frédéric R/L-3238-2017; Pecqueur, Claire/L-3073-2015	Bouillaud, Frédéric R/0000-0002-7518-9237; Pecqueur, Claire/0000-0002-7612-1672; Miroux, Bruno/0000-0002-3066-4700; GONZALEZ BARROSO, MARIA DEL MAR/0000-0002-0278-8298; haguenauer, anne/0000-0003-2332-2929				Ali BH, 2003, FOOD CHEM TOXICOL, V41, P1447, DOI 10.1016/S0278-6915(03)00186-8; Baliga R, 1998, KIDNEY INT, V53, P394, DOI 10.1046/j.1523-1755.1998.00767.x; Brewster UC, 2004, AM J MED, V116, P263, DOI 10.1016/j.amjmed.2003.09.034; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; Chabardes-Garonne D, 2003, P NATL ACAD SCI USA, V100, P13710, DOI 10.1073/pnas.2234604100; Curthoys NP, 2001, J NUTR, V131, p2491S, DOI 10.1093/jn/131.9.2491S; FAULDS D, 1993, DRUGS, V45, P953, DOI 10.2165/00003495-199345060-00007; Gonzalez-Barroso MM, 1998, J BIOL CHEM, V273, P15528, DOI 10.1074/jbc.273.25.15528; GonzalezBarroso MM, 1996, EUR J BIOCHEM, V239, P445, DOI 10.1111/j.1432-1033.1996.0445u.x; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Harlow E., 1988, ANTIBODIES LAB MANUA; Kim-Han JS, 2001, J NEUROCHEM, V79, P658, DOI 10.1046/j.1471-4159.2001.00604.x; Kondou S, 2000, BBA-BIOENERGETICS, V1457, P182, DOI 10.1016/S0005-2728(00)00099-2; Lengacher S, 2004, J CEREBR BLOOD F MET, V24, P780, DOI 10.1097/01.WCB.0000122743.72175.52; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MIROUX B, 1993, EMBO J, V12, P3739, DOI 10.1002/j.1460-2075.1993.tb06051.x; Mizuno T, 2000, BIOCHEM BIOPH RES CO, V278, P691, DOI 10.1006/bbrc.2000.3859; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Sanchis D, 1998, J BIOL CHEM, V273, P34611, DOI 10.1074/jbc.273.51.34611; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; THIEL G, 1967, NEPHRON, V4, P276, DOI 10.1159/000179588; Walker PD, 1999, RENAL FAILURE, V21, P433, DOI 10.3109/08860229909085109; Yu XX, 2000, FASEB J, V14, P1611, DOI 10.1096/fj.14.11.1611	26	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22036	22043		10.1074/jbc.M412136200	http://dx.doi.org/10.1074/jbc.M412136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15809292	hybrid			2022-12-27	WOS:000229557900047
J	Gao, ZG; Chiao, P; Zhang, X; Zhang, XH; Lazar, MA; Seto, E; Young, HA; Ye, JP				Gao, ZG; Chiao, P; Zhang, X; Zhang, XH; Lazar, MA; Seto, E; Young, HA; Ye, JP			Coactivators and corepressors of NF-kappa B in I kappa Beta alpha gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; HISTONE ACETYLTRANSFERASE ACTIVITY; THYROID-HORMONE RECEPTOR; NUCLEAR RECEPTORS; TRANSCRIPTIONAL COACTIVATOR; TRANSACTIVATION DOMAIN; COR COREPRESSORS; PHOSPHORYLATION; ACTIVATION; P65	In this study, we investigated recruitment of coactivators (SRC-1, SRC-2, and SRC-3) and corepressors (HDAC1, HDAC2, HDAC3, SMRT, and NCoR) to the I kappa B alpha gene promoter after NF-kappa B activation by tumor necrosis factor-alpha. Our data from chromatin immunoprecipitation assay suggest that coactivators and corepressors are simultaneously recruited to the promoter, and their binding to the promoter DNA is oscillated in HEK293 cells. SRC-1, SRC-2, and SRC-3 all enhanced I kappa B alpha transcription. However, the interaction of each coactivator with the promoter exhibited different patterns. After tumor necrosis factor-alpha treatment, SRC-1 signal was increased gradually, but SRC-2 signal was reduced immediately, suggesting replacement of SRC-2 by SRC-1. SRC-3 signal was increased at 30 min, reduced at 60 min, and then increased again at 120 min, suggesting an oscillation of SRC-3. The corepressors were recruited to the promoter together with the coactivators. The binding pattern suggests that the corepressor proteins formed two types of corepressor complexes, SMRT-HDAC1 and NCoR- HDAC3. The two complexes exhibited a switch at 30 and 60 min. The functions of cofactors were confirmed by gene overexpression and RNA interference-mediated gene knockdown. These data suggest that gene transactivation by the transcription factor NF-kappa B is subject to the regulation of a dynamic balance between the coactivators and corepressors. This model may represent a mechanism for integration of extracellular signals into a precise control of gene transcription.	Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; NCI, Cellular & Mol Immunol Sect, Expt Immunol Lab, NIH, Ft Detrick, MD 21702 USA; Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ Penn, Div Endocrinol Diab & Metab, Philadelphia, PA 19104 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University System of Florida; University of South Florida; University of Pennsylvania	Ye, JP (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	yej@pbrc.edu	Ye, Jianping/N-1998-2017; Lazar, Mitchell A/AAF-3738-2019; Zhang, Xia/B-8152-2008; Young, Howard/A-6350-2008	Ye, Jianping/0000-0003-3875-365X; Zhang, Xia/0000-0002-9040-1486; Young, Howard/0000-0002-3118-5111	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK068036, R01DK068036] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK068036, R01 DK068036, R56 DK068036] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen SL, 2001, MOL ENDOCRINOL, V15, P783, DOI 10.1210/me.15.5.783; Espinosa L, 2003, MOL BIOL CELL, V14, P491, DOI 10.1091/mbc.E02-07-0404; Gao ZG, 2003, J BIOL CHEM, V278, P24944, DOI 10.1074/jbc.M300423200; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Glass CK, 2000, GENE DEV, V14, P121; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2001, J BIOL CHEM, V276, P30208, DOI 10.1074/jbc.M103604200; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jonas BA, 2004, J BIOL CHEM, V279, P54676, DOI 10.1074/jbc.M410128200; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Litterst CM, 2003, J BIOL CHEM, V278, P45340, DOI 10.1074/jbc.M303644200; Mark M, 2004, P NATL ACAD SCI USA, V101, P4453, DOI 10.1073/pnas.0400234101; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; ONATE SA, 1995, SCIENCE, V270, P1354; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sengupta N, 2004, J CELL BIOCHEM, V93, P57, DOI 10.1002/jcb.20179; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yu ZT, 2002, J AM SOC NEPHROL, V13, P2009, DOI 10.1097/01.ASN.0000024253.59665.F1; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	53	104	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21091	21098		10.1074/jbc.M500754200	http://dx.doi.org/10.1074/jbc.M500754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15811852	Green Accepted, hybrid			2022-12-27	WOS:000229438800024
J	Jiang, ZY; Zhou, QL; Holik, J; Patel, S; Leszyk, J; Coleman, K; Chouinard, M; Czech, MP				Jiang, ZY; Zhou, QL; Holik, J; Patel, S; Leszyk, J; Coleman, K; Chouinard, M; Czech, MP			Identification of WNK1 as a substrate of Akt/protein kinase B and a negative regulator of insulin-stimulated mitogenesis in 3T3-L1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR SUBSTRATE-1; GLUT4 TRANSLOCATION; MEDIATED PHOSPHORYLATION; GLUCOSE-UPTAKE; AKT SUBSTRATE; PROTEIN; DEGRADATION; PATHWAY	Insulin signaling through protein kinase Akt/protein kinase B (PKB), a downstream element of the phosphatidylinositol 3-kinase (PI3K) pathway, regulates diverse cellular functions including metabolic pathways, apoptosis, mitogenesis, and membrane trafficking. To identify Akt/PKB substrates that mediate these effects, we used antibodies that recognize phosphopeptide sites containing the Akt/PKB substrate motif (RXRXX(p)S/T) to immunoprecipitate proteins from insulin-stimulated adipocytes. Tryptic peptides from a 250-kDa immuno-precipitated protein were identified as the protein kinase WNK1 (with no lysine) by matrix-assisted laser desorption ionization time-of-flight mass spectrometry, consistent with a recent report that WNK1 is phosphorylated on Thr(60) in response to insulin-like growth factor I. Insulin treatment of 3T3-L1 adipocytes stimulated WNK1 phosphorylation, as detected by immunoprecipitation with antibody against WNK1 followed by immunoblotting with the anti-phosphoAkt substrate antibody. WNK1 phosphorylation induced by insulin was unaffected by rapamycin, an inhibitor of p70 S6 kinase pathway but abolished by the PI3K inhibitor wortmannin. RNA interference-directed depletion of Akt1/PKB alpha and Akt2/PKB beta attenuated insulin- stimulated WNK1 phosphorylation, but depletion of protein kinase C lambda did not. Whereas small interfering RNA-induced loss of WNK1 protein did not significantly affect insulin-stimulated glucose transport in 3T3-L1 adipocytes, it significantly enhanced insulin- stimulated thymidine incorporation by about 2-fold. Furthermore, depletion of WNK1 promoted serum-stimulated cell proliferation of 3T3-L1 preadipocytes, as evidenced by a 36% increase in cell number after 48 h in culture. These data suggest that WNK1 is a physiologically relevant target of insulin signaling through PI3K and Akt/PKB and functions as a negative regulator of insulin-stimulated mitogenesis.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	michael.czech@umassmed.edu			NIDDK NIH HHS [DK30648] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Egawa K, 2000, ENDOCRINOLOGY, V141, P1930, DOI 10.1210/en.141.6.1930; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Kahle KT, 2003, NAT GENET, V35, P372, DOI 10.1038/ng1271; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; Lee BH, 2004, MOL CELL, V15, P741, DOI 10.1016/j.molcel.2004.07.018; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741; Ozes ON, 1999, NATURE, V401, P82; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Verissimo F, 2001, ONCOGENE, V20, P5562, DOI 10.1038/sj.onc.1204726; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vitari AC, 2004, BIOCHEM J, V378, P257, DOI 10.1042/BJ20031692; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Wilson FH, 2003, P NATL ACAD SCI USA, V100, P680, DOI 10.1073/pnas.242735399; Xu BE, 2002, J BIOL CHEM, V277, P48456, DOI 10.1074/jbc.M207917200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yang CL, 2003, J CLIN INVEST, V111, P1039, DOI 10.1172/JCI200317443; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou QL, 2004, BIOCHEM SOC T, V32, P817, DOI 10.1042/BST0320817	60	69	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21622	21628		10.1074/jbc.m414464200	http://dx.doi.org/10.1074/jbc.m414464200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799971	hybrid			2022-12-27	WOS:000229438800087
J	LaLonde, DP; Brown, MC; Bouverat, BP; Turner, CE				LaLonde, DP; Brown, MC; Bouverat, BP; Turner, CE			Actopaxin interacts with TESK1 to regulate cell spreading on fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-LINKED KINASE; FOCAL ADHESION PROTEINS; TO-SUBSTRATE CONTACTS; COFILIN PHOSPHORYLATION; ACTIN REORGANIZATION; TESTICULAR PROTEIN-KINASE-1; SUBCELLULAR-LOCALIZATION; ARP2/3 COMPLEX; CH-ILKBP; PAXILLIN	The focal adhesion protein actopaxin contributes to integrin-actin associations and is involved in cell adhesion, spreading, and motility. Herein, we identify and characterize an association between actopaxin and the serine/threonine kinase testicular protein kinase 1 (TESK1), a ubiquitously expressed protein previously reported to regulate cellular spreading and focal adhesion formation via phosphorylation of cofilin. The interaction between actopaxin and TESK1 is direct and the binding sites were mapped to the carboxyl terminus of both proteins. The association between actopaxin and TESK1 is negatively regulated by adhesion to fibronectin, and a phosphomimetic actopaxin mutant that promotes cell spreading also exhibits impaired binding to TESK1. Binding of actopaxin to TESK1 inhibits TESK1 kinase activity in vitro. Expression of the carboxyl terminus of actopaxin has previously been reported to retard cell spreading. This effect was reversed following overexpression of TESK1 and was found to be dependent on an inability of actopaxin carboxyl terminus expressing cells to promote cofilin phosphorylation upon matrix adhesion and caused by retention of TESK1 by this actopaxin mutant. Thus, the association between actopaxin and TESK1, which is likely regulated by phosphorylation of actopaxin, regulates TESK1 activity and subsequent cellular spreading on fibronectin.	SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Turner, CE (corresponding author), SUNY Upstate Med Univ, Dept Cell & Dev Biol, 750 E Adams St, Syracuse, NY 13210 USA.	turnerce@upstate.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070244] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL070244] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bernstein BW, 2000, CELL MOTIL CYTOSKEL, V47, P319, DOI 10.1002/1097-0169(200012)47:4<319::AID-CM6>3.0.CO;2-I; Bhatt A, 2002, J CELL SCI, V115, P3415; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chan AY, 2000, J CELL BIOL, V148, P531, DOI 10.1083/jcb.148.3.531; Clarke DM, 2004, J CELL BIOL, V166, P901, DOI 10.1083/jcb.200404024; Curtis M, 2002, BIOCHEM J, V363, P233, DOI 10.1042/0264-6021:3630233; Dawe HR, 2003, CURR BIOL, V13, P252, DOI 10.1016/S0960-9822(03)00040-X; DesMarais V, 2004, J CELL SCI, V117, P3499, DOI 10.1242/jcs.01211; DesMarais V, 2005, J CELL SCI, V118, P19, DOI 10.1242/jcs.01631; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Ghosh M, 2004, SCIENCE, V304, P743, DOI 10.1126/science.1094561; Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9; Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201; Gupton SL, 2005, J CELL BIOL, V168, P619, DOI 10.1083/jcb.200406063; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Ichetovkin I, 2002, CURR BIOL, V12, P79, DOI 10.1016/S0960-9822(01)00629-7; IZZARD CS, 1980, J CELL SCI, V42, P81; IZZARD CS, 1976, J CELL SCI, V21, P129; Khyrul WAKM, 2004, J BIOL CHEM, V279, P54131, DOI 10.1074/jbc.M410051200; Korenbaum E, 2001, GENE, V279, P69, DOI 10.1016/S0378-1119(01)00743-0; Lin XY, 2003, CURR BIOL, V13, P922, DOI 10.1016/S0960-9822(03)00372-5; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; Mongroo PS, 2004, ONCOGENE, V23, P8959, DOI 10.1038/sj.onc.1208112; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Olski TM, 2001, J CELL SCI, V114, P525; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Ponti A, 2004, SCIENCE, V305, P1782, DOI 10.1126/science.1100533; Raymond K, 2004, J CELL SCI, V117, P2777, DOI 10.1242/jcs.01123; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Rosok O, 1999, GENOMICS, V61, P44, DOI 10.1006/geno.1999.5922; Toshima J, 1995, J BIOL CHEM, V270, P31331, DOI 10.1074/jbc.270.52.31331; Toshima J, 2001, J BIOL CHEM, V276, P31449, DOI 10.1074/jbc.M102988200; Toshima J, 2001, MOL BIOL CELL, V12, P1131, DOI 10.1091/mbc.12.4.1131; Toshima JY, 2001, J BIOL CHEM, V276, P43471, DOI 10.1074/jbc.M104620200; TSUMURA Y, 2005, IN PRESS BIOCH J; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Zhang YJ, 2004, J BIOL CHEM, V279, P41695, DOI 10.1074/jbc.M401563200; Zhang YJ, 2002, J CELL SCI, V115, P4777, DOI 10.1242/jcs.00166	45	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21680	21688		10.1074/jbc.m500752200	http://dx.doi.org/10.1074/jbc.m500752200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15817463	hybrid			2022-12-27	WOS:000229438800095
J	Suzuki, M; Neutzner, A; Tjandra, N; Youle, RJ				Suzuki, M; Neutzner, A; Tjandra, N; Youle, RJ			Novel structure of the N terminus in yeast Fis1 correlates with a specialized function in mitochondrial fission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED GTPASE; DOMINANT OPTIC ATROPHY; TRIPLE-RESONANCE NMR; WD REPEAT PROTEIN; C-13-ENRICHED PROTEINS; OUTER-MEMBRANE; CHEMICAL-SHIFT; DNM1P; SPECTROSCOPY; SENSITIVITY	Mitochondrial fission is facilitated by a multiprotein complex assembled at the division site. The required components of the fission machinery in Saccharomyces cerevisiae include Dnm1, Fis1, and Mdv1. In the present study, we determined the protein structure of yeast Fis1 using NMR spectroscopy. Although the six alpha-helices, as well as their folding, in the yeast Fis1 structure are similar to those of the tetratricopeptide repeat (TPR) domains of the human Fis1 structure, the two structures differ in their N termini. The N-terminal tail of human Fis1 is flexible and unstructured, whereas a major segment of the longer N terminus of yeast Fis1 is fixed to the concave face formed by the six alpha- helices in the TPR domains. To investigate the role of the fixed N terminus, exogenous Fis1 was expressed in yeast lacking the endogenous protein. Expression of yeast Fis1 protein rescued mitochondrial fission in Delta fis1 yeast only when the N-terminal TPR binding segment was left intact. The presence of this segment is also correlated to the recruitment of Mdv1 to mitochondria. The conformation of the N- terminal segment embedded in the TPR pocket indicates an intra-molecular regulation of Fis1 bioactivity. Although the TPR-like helix bundle of Fis1 mediates the interaction with Dnm1 and Mdv1, the N terminus of Fis1 is a prerequisite to recruit Mdv1 to facilitate mitochondrial fission.	NHLBI, Biophys Chem Lab, NIH, Bethesda, MD 20892 USA; NINDS, Biochem Sect, Surg Neurol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Tjandra, N (corresponding author), NHLBI, Biophys Chem Lab, NIH, Bldg 50,Rm 3503,50 Ctr Dr,MSC 8013, Bethesda, MD 20892 USA.	nico@helix.nih.gov; youler@ninds.nih.gov	Neutzner, Albert/ABC-4368-2020	Neutzner, Albert/0000-0001-9254-5558; Suzuki, Motoshi/0000-0002-4346-7677	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002859, Z01NS002859] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Cerveny KL, 2003, MOL BIOL CELL, V14, P4126, DOI 10.1091/mbc.E03-02-0092; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Dohm JA, 2004, PROTEINS, V54, P153, DOI 10.1002/prot.10524; Frieden M, 2004, J BIOL CHEM, V279, P22704, DOI 10.1074/jbc.M312366200; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Luthy L, 2002, J BIOL CHEM, V277, P10187, DOI 10.1074/jbc.M108993200; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Santel A, 2001, J CELL SCI, V114, P867; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Suzuki M, 2003, J MOL BIOL, V334, P445, DOI 10.1016/j.jmb.2003.09.064; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353; Tieu Q, 2002, J CELL BIOL, V158, P445, DOI 10.1083/jcb.200205031; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; Tjandra N, 1997, J AM CHEM SOC, V119, P9576, DOI 10.1021/ja9721374; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003	49	52	59	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21444	21452		10.1074/jbc.M414092200	http://dx.doi.org/10.1074/jbc.M414092200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15809300	hybrid			2022-12-27	WOS:000229438800065
J	Yuan, ZQ; Kim, D; Kaneko, S; Sussman, M; Bokoch, GM; Kruh, GD; Nicosia, SV; Testa, JR; Cheng, JQ				Yuan, ZQ; Kim, D; Kaneko, S; Sussman, M; Bokoch, GM; Kruh, GD; Nicosia, SV; Testa, JR; Cheng, JQ			ArgBP2 gamma interacts with akt and p21 activated kinase-1 and promotes cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; NF-KAPPA-B; MOLECULAR-CLONING; ADAPTER PROTEIN; HOMOLOGY DOMAIN; HEAT-SHOCK; PHOSPHORYLATION; ACTIVATION; PKB/AKT; FAMILY	Akt/protein kinase B is a major cell survival pathway through phosphorylation of proapoptotic proteins Bad and Bax and of additional apoptotic pathways linked to Forkhead proteins glycogen synthase kinase-3 beta and ASK1. To further explore the mechanism by which Akt regulates cell survival, we identified an Akt interaction protein by yeast two-hybrid screening. It is highly homologous to ARG-binding protein 2 ( ArgBP2) with splicing exon 8 of the coding region of the ArgBP2. As two splicing isoforms (ArgBP2 alpha and -beta) of ArgBP2 have been identified (Wang, B., Golemis, E. A., and Kruh, G. D. ( 1997) J. Biol. Chem. 272, 17542 - 17550), it was named ArgBP2 gamma. ArgBP2 gamma contains four Akt phosphorylation consensus sites, a SoHo motif, and three Src homology (SH) 3 domains and binds to C-terminal proline-rich motifs of Akt through its first and second SH3 domains. It also interacts with p21-activated protein kinase ( PAK1) via its first and third SH3 domains, indicating the SH3 domains of ArgBP2 gamma as docking sites for Akt and PAK1. Akt phosphorylates ArgBP2 gamma in vitro and in vivo. Expression of ArgBP2 gamma induces PAK1 activity and overrides apoptosis induced by ectopic expression of Bad or DNA damage. Nonphosphorylatable ArgBP2 gamma-4A and SH3 domain-truncated mutant ArgBP2 inhibit Akt-induced PAK1 activation and reduce Akt and PAK1 phosphorylation of Bad and antiapoptotic function. These data indicate that ArgBP2 gamma is a physiological substrate of Akt, functions as an adaptor for Akt and PAK1, and plays a role in Akt/PAK1 cell survival pathway.	H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Dept Pathol & Interdisciplinary Oncol, Tampa, FL 33612 USA; Scripps Res Inst, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Scripps Research Institute; Fox Chase Cancer Center	Cheng, JQ (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, SRB-3,12902 Magnolia Dr, Tampa, FL 33612 USA.	ChengJQ@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [R29CA077935, R01CA107078, R01CA089242, R01CA077935, R01CA077429] Funding Source: NIH RePORTER; NCI NIH HHS [CA107078, CA77935, CA89242, CA77429] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Kim D, 2005, FRONT BIOSCI-LANDMRK, V10, P975, DOI 10.2741/1592; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Liu AX, 1998, CANCER RES, V58, P2973; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mitsuuchi Y, 1999, ONCOGENE, V18, P4891, DOI 10.1038/sj.onc.1203080; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Ozes ON, 1999, NATURE, V401, P82; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sekulic A, 2000, CANCER RES, V60, P3504; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou GL, 2003, MOL CELL BIOL, V23, P8058, DOI 10.1128/MCB.23.22.8058-8069.2003	50	34	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21483	21490		10.1074/jbc.M500097200	http://dx.doi.org/10.1074/jbc.M500097200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15784622	hybrid			2022-12-27	WOS:000229438800069
J	Bentmann, A; Schmidt, M; Reuss, S; Wolfrum, U; Hankeln, T; Burmester, T				Bentmann, A; Schmidt, M; Reuss, S; Wolfrum, U; Hankeln, T; Burmester, T			Divergent distribution in vascular and avascular mammalian retinae links neuroglobin to cellular respiration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULLER CELLS; OXYGEN DISTRIBUTION; OXIDATIVE STRESS; LIGAND-BINDING; GLOBIN FAMILY; HIGH-ALTITUDE; IN-VIVO; CYTOGLOBIN; PROTEIN; BRAIN	The visual function of the vertebrate retina relies on sufficient supply with oxygen. Neuroglobin is a respiratory protein thought to play an essential role in oxygen homeostasis of neuronal cells. For further understanding of its function, we compared the distribution of neuroglobin and mitochondria in both vascular and avascular mammalian retinae. In the vascular retinae of mouse and rat, oxygen is supplied by the outer choroidal, deep retinal, and inner capillaries. We show that in this type of retina, mitochondria are concentrated in the inner segments of photoreceptor cells, the outer and the inner plexiform layers, and the ganglion cell layer. These are the same regions in which oxygen consumption takes place and in which neuroglobin is present at high levels. In the avascular retina of guinea pig the deep retinal and inner capillaries are absent. Therefore, only the inner segments of the photoreceptors adjacent to choroidal capillaries display an oxidative metabolism. We demonstrate that in the retina of guinea pigs both neuroglobin and mitochondria are restricted to this layer. Our results clearly demonstrate an association of neuroglobin and mitochondria, thus supporting the hypothesis that neuroglobin is a respiratory protein that supplies oxygen to the respiratory chain.	Johannes Gutenberg Univ Mainz, Inst Zool, Dept Mol Anim Physiol, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Dept Anat & Cell Biol, Sch Med, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Dept Expt Morphol, Inst Zool, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Mol Genet, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Burmester, T (corresponding author), Johannes Gutenberg Univ Mainz, Inst Zool, Dept Mol Anim Physiol, Saarstr 21, D-55099 Mainz, Germany.	burmeste@uni-mainz.de	Burmester, Thorsten/I-7225-2013	Burmester, Thorsten/0000-0002-5772-7863; Reuss, Stefan/0000-0003-1064-5067				AMES A, 1992, CAN J PHYSIOL PHARM, V70, pS158, DOI 10.1139/y92-257; ANDERSON B, 1964, ARCH OPHTHALMOL-CHIC, V72, P792; Anderson B Jr, 1968, Trans Am Ophthalmol Soc, V66, P423; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Burmester T, 2004, NEWS PHYSIOL SCI, V19, P110, DOI 10.1152/nips.01513.2003; CHASE J, 1982, OPHTHALMOLOGY, V89, P1518, DOI 10.1016/s0161-6420(82)34608-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRINGLE S, 1996, AM J PHYSIOL, V40, pH1162; Cringle SJ, 2002, INVEST OPHTH VIS SCI, V43, P1922; Cringle SJ, 2002, COMP BIOCHEM PHYS A, V132, P61, DOI 10.1016/S1095-6433(01)00530-X; Cringle SJ, 1999, INVEST OPHTH VIS SCI, V40, P2307; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Epstein FH, 1997, KIDNEY INT, V51, P381, DOI 10.1038/ki.1997.50; Fuchs C, 2004, J BIOL CHEM, V279, P24116, DOI 10.1074/jbc.M402011200; Germer A, 1998, J NEUROCYTOL, V27, P329, DOI 10.1023/A:1006934724566; Germer A, 1998, J NEUROCYTOL, V27, P347, DOI 10.1023/A:1006938825474; Gnaiger E, 2003, ADV EXP MED BIOL, V543, P39; Hankeln T, 2005, J INORG BIOCHEM, V99, P110, DOI 10.1016/j.jinorgbio.2004.11.009; Harper ME, 2004, ACTA PHYSIOL SCAND, V182, P321, DOI 10.1111/j.1365-201X.2004.01370.x; Herold S, 2004, J BIOL CHEM, V279, P22841, DOI 10.1074/jbc.M313732200; HSU SC, 1994, J BIOL CHEM, V269, P17954; Karakucuk S, 2000, OPHTHALMIC RES, V32, P30, DOI 10.1159/000055584; KRAUS DW, 1986, SCIENCE, V232, P90, DOI 10.1126/science.232.4746.90; Kugelstadt D, 2004, BIOCHEM BIOPH RES CO, V325, P719, DOI 10.1016/j.bbrc.2004.10.080; Laufs TL, 2004, NEUROSCI LETT, V362, P83, DOI 10.1016/j.neulet.2004.02.072; Mammen PPA, 2002, J HISTOCHEM CYTOCHEM, V50, P1591, DOI 10.1177/002215540205001203; MATSCHINSKY FM, 1970, BIOCH SIMPLE NEURONA, V2, P217; Merx Marc W., 2001, FASEB Journal, V15, P1077; Organisciak D T, 1989, Prog Clin Biol Res, V314, P493; Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001; PENN JS, 1987, EXP EYE RES, V44, P779, DOI 10.1016/S0014-4835(87)80041-6; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Schmidt M, 2004, J BIOL CHEM, V279, P8063, DOI 10.1074/jbc.M310540200; Schmidt M, 2005, NEUROSCI LETT, V374, P207, DOI 10.1016/j.neulet.2004.10.071; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Tsacopoulos M, 1998, PROG RETIN EYE RES, V17, P429, DOI 10.1016/S1350-9462(98)00010-X; UGA S, 1973, INVEST OPHTH VISUAL, V12, P434; Wakasugi K, 2004, BIOCHEMISTRY-US, V43, P5119, DOI 10.1021/bi0495782; Wakasugi K, 2004, BIOCHEM BIOPH RES CO, V318, P453, DOI 10.1016/j.bbrc.2004.04.045; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200; Wiedman M, 1999, OPHTHALMOLOGY, V106, P1924, DOI 10.1016/S0161-6420(99)90402-5; Wittenberg JB, 2003, J EXP BIOL, V206, P2011, DOI 10.1242/jeb.00243; Wystub S, 2003, NEUROSCI LETT, V346, P114, DOI 10.1016/S0304-3940(03)00563-9; Yu DY, 2002, COMP BIOCHEM PHYS A, V132, P47, DOI 10.1016/S1095-6433(01)00528-1; Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6; Yu DY, 1996, AM J PHYSIOL-HEART C, V270, pH965, DOI 10.1152/ajpheart.1996.270.3.H965; YU DY, 1994, AM J PHYSIOL, V36, pH2498	51	88	96	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20660	20665		10.1074/jbc.M501338200	http://dx.doi.org/10.1074/jbc.M501338200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15793311	hybrid			2022-12-27	WOS:000229242000063
J	Mingorance, J; Tadros, M; Vicente, M; Gonzalez, JM; Rivas, G; Velez, M				Mingorance, J; Tadros, M; Vicente, M; Gonzalez, JM; Rivas, G; Velez, M			Visualization of single Escherichia coli FtsZ filament dynamics with atomic force microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVISION PROTEIN FTSZ; BACTERIAL-CELL-DIVISION; ASSEMBLY DYNAMICS; NUCLEOTIDE TURNOVER; POLYMERIZATION; TUBULIN; GTP; HYDROLYSIS; POLYMERS; HOMOLOG	FtsZ, the prokaryotic homologue of tubulin, is an essential cell division protein. In the cell, it localizes at the center, forming a ring that constricts during division. In vitro, it binds and hydrolyzes GTP and polymerizes in a GTP-dependent manner. We have used atomic force microscopy to study the structure and dynamics of FtsZ polymer assembly on a mica surface under buffer solution. The polymers were highly dynamic and flexible, and they continuously rearranged over the surface. End-to-end joining of filaments and depolymerization from internal zones were observed, suggesting that fragmentation and reannealing may contribute significantly to the dynamics of FtsZ assembly. The shape evolution of the restructured polymers manifested a strong inherent tendency to curve. Polymers formed in the presence of non-hydrolyzable nucleotide analogues or in the presence of GDP and AlF3 were structurally similar but showed a slower dynamic behavior. These results provide experimental evidence supporting the model of single-strand polymerization plus cyclization recently proposed to explain the hydrodynamic behavior of the polymers in solution.	Univ Autonoma Madrid, Fac Ciencias, Inst Nicolas Cabrera, E-28049 Madrid, Spain; Univ Autonoma Madrid, CSIC, E-28049 Madrid, Spain; Univ Autonoma Madrid, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Autonomous University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Mingorance, J (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Inst Nicolas Cabrera, E-28049 Madrid, Spain.	marisela.velez@uam.es	Velez, Marisela/F-2900-2013; Rivas, German/AFL-7528-2022; Mingorance, Jesus/B-7562-2009; Rivas, German/AAG-7458-2022	Velez, Marisela/0000-0002-9424-510X; Rivas, German/0000-0003-3450-7478; Mingorance, Jesus/0000-0001-6173-5711; Rivas, German/0000-0003-3450-7478				Anderson DE, 2004, J BACTERIOL, V186, P5775, DOI 10.1128/JB.186.17.5775-5781.2004; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; CARLIER MF, 1989, BIOCHEMISTRY-US, V28, P3628, DOI 10.1021/bi00434a073; Chen YD, 2005, BIOPHYS J, V88, P505, DOI 10.1529/biophysj.104.044149; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; Gonzalez JM, 2003, J BIOL CHEM, V278, P37664, DOI 10.1074/jbc.M305230200; Gonzalez JM, 2005, P NATL ACAD SCI USA, V102, P1895, DOI 10.1073/pnas.0409517102; Huecas S, 2004, FEBS LETT, V569, P43, DOI 10.1016/j.febslet.2004.05.048; Huecas S, 2003, J BIOL CHEM, V278, P46146, DOI 10.1074/jbc.M307128200; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Mingorance J, 2001, MOL MICROBIOL, V41, P83, DOI 10.1046/j.1365-2958.2001.02498.x; Moreno-Herrero F, 2002, APPL PHYS LETT, V81, P2620, DOI 10.1063/1.1509856; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; Oliva MA, 2004, NAT STRUCT MOL BIOL, V11, P1243, DOI 10.1038/nsmb855; Oliva MA, 2003, J BIOL CHEM, V278, P33562, DOI 10.1074/jbc.M303798200; RAYCHAUDHURI D, 1994, J BIOL CHEM, V269, P22941; Rivas G, 2000, J BIOL CHEM, V275, P11740, DOI 10.1074/jbc.275.16.11740; Romberg L, 2003, ANNU REV MICROBIOL, V57, P125, DOI 10.1146/annurev.micro.57.012903.074300; Romberg L, 2001, J BIOL CHEM, V276, P11743, DOI 10.1074/jbc.M009033200; Romberg L, 2004, BIOCHEMISTRY-US, V43, P282, DOI 10.1021/bi035465r; Rueda S, 2003, J BACTERIOL, V185, P3344, DOI 10.1128/JB.185.11.3344-3351.2003; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Stricker J, 2002, P NATL ACAD SCI USA, V99, P3171, DOI 10.1073/pnas.052595099	24	101	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20909	20914		10.1074/jbc.M503059200	http://dx.doi.org/10.1074/jbc.M503059200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15793307	Green Published, hybrid			2022-12-27	WOS:000229242000090
J	Yamagishi, S; Fujitani, M; Hata, K; Kitajo, K; Mimura, F; Abe, H; Yamashita, T				Yamagishi, S; Fujitani, M; Hata, K; Kitajo, K; Mimura, F; Abe, H; Yamashita, T			Wallerian degeneration involves Rho/Rho-kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL-CORD-INJURY; ENHANCES AXONAL REGENERATION; NERVOUS-SYSTEM; RHO; ACTIVATION; APOPTOSIS; NOGO	Local axon degeneration is a common pathological feature of many neurodegenerative diseases, whereas the underlying molecular mechanisms are largely unknown. In this study, we used the degeneration of transected axons, termed "Wallerian degeneration," as a model to examine the possible involvement of Rho. Nogo-66, a myelin-derived inhibitor of axon regeneration, significantly accelerated axon degeneration of the dorsal root ganglion explant in vitro, whereas inhibiting Rho-kinase activity abolished the effect. Rho activation was observed in the distal part of the injured axons after spinal cord injury. We demonstrate that degeneration of the injured cortico-spinal axons was significantly retarded by a Rho-kinase inhibitor in vivo. Our findings suggest that inhibiting the signaling pathway may retard axon degeneration in pathological conditions.	Chiba Univ, Grad Sch Med, Dept Neurobiol, Chuo Ku, Chiba 2608670, Japan	Chiba University	Yamashita, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Neurobiol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	t-yamashita@faculty.chiba-u.jp	Hata, Katsuhiko/AAA-5015-2021; Fujitani, Masashi/AAD-8874-2022	Yamashita, Toshihide/0000-0003-4559-7018; Fujitani, Masashi/0000-0002-1731-9793				Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Dergham P, 2002, J NEUROSCI, V22, P6570; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Finn JT, 2000, J NEUROSCI, V20, P1333; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Li Z, 2002, NEURON, V33, P741, DOI 10.1016/S0896-6273(02)00621-9; Madura T, 2004, EMBO REP, V5, P412, DOI 10.1038/sj.embor.7400117; McKerracher L, 2002, NEURON, V36, P345, DOI 10.1016/S0896-6273(02)01018-8; Messler W, 1997, NATURE, V385, P151, DOI 10.1038/385151a0; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Rico B, 2004, NAT NEUROSCI, V7, P1059, DOI 10.1038/nn1317; Tanaka H, 2004, NEUROSCIENCE, V127, P155, DOI 10.1016/j.neuroscience.2004.05.010; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhai QW, 2003, NEURON, V39, P217, DOI 10.1016/S0896-6273(03)00429-X	16	36	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20384	20388		10.1074/jbc.M501945200	http://dx.doi.org/10.1074/jbc.M501945200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15799964	hybrid			2022-12-27	WOS:000229242000029
J	Yamaguchi, Y; Kuroki, T; Yasuzawa, H; Higashi, T; Jin, WC; Kawanami, A; Yamagata, Y; Arakawa, Y; Goto, M; Kurosaki, H				Yamaguchi, Y; Kuroki, T; Yasuzawa, H; Higashi, T; Jin, WC; Kawanami, A; Yamagata, Y; Arakawa, Y; Goto, M; Kurosaki, H			Probing the role of Asp-120(81) of metallo-beta-lactamase (IMP-1) by site-directed mutagenesis, kinetic studies, and X-ray crystallography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; BACTEROIDES-FRAGILIS; SERRATIA-MARCESCENS; BIOCHEMICAL-CHARACTERIZATION; CRYSTAL-STRUCTURE; CLINICAL ISOLATE; ACTIVE-SITE; INHIBITORS; GENE; MECHANISM	Metallo-beta-lactamase IMP-1 is a di-Zn(II) metalloenzyme that efficiently hydrolyzes beta-lactam antibiotics. Wild-type (WT) IMP-1 has a conserved Asp-120(81) in the active site, which plays an important role in catalysis. To probe the catalytic role of Asp-120( 81) in IMP-1, the IMP-1 mutants, D120(81)A and D120(81)E, were prepared by site-directed mutagenesis, and various kinetics studies were conducted. The IMP-1 mutants exhibited 10(2)-10(4)-fold drops in k(cat) values compared with WT despite the fact that they contained two Zn(II) ions in the active site. To evaluate the acid-base characteristics of Asp-120( 81), the pH dependence for hydrolysis was examined by stopped-flow studies. No observable pK(a) values between pH 5 and 9 were found for WT and D120( 81) A. The rapid mixing of equimolar amounts of nitrocefin and all enzymes failed to result in the detection of an anion intermediate of nitrocefin at 650 nm. These results suggest that Asp-120( 81) of IMP-1 is not a factor in decreasing the pKa for the water bridging two Zn( II) ions and is not a proton donor to the anionic intermediate. In the case of D120( 81) E, the nitrocefin hydrolysis product, which shows a maximum absorption at 460 nm, was bound to D120( 81) E in the protonated form. The three-dimensional structures of D120( 81) A and D120( 81) E were also determined at 2.0 and 3.0 angstrom resolutions, respectively. In the case of D120(81) E, the Zn-Zn distance was increased by 0.3 angstrom compared with WT, due to the change in the coordination mode of Glu-120(81)OE1 and the positional shift in the conserved His-263(197) at the active site.	Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Struct Funct Phys Chem, Kumamoto 8620973, Japan; Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Kumamoto 8620973, Japan; Natl Inst Infect Dis, Dept Bacterial Pathogenesis & Infect Control, Tokyo 2080011, Japan	Kumamoto University; Kumamoto University; National Institute of Infectious Diseases (NIID)	Yamaguchi, Y (corresponding author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Struct Funct Phys Chem, 5-1 Oe Honmachi, Kumamoto 8620973, Japan.	yyamagu@gpo.kumamoto-u.ac.jp	Yamagata, Yoshiki/T-6489-2019; jin, wanchun/B-8463-2016; Arakawa, Yoshichika/P-5997-2015					AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; ARAKAWA Y, 1995, ANTIMICROB AGENTS CH, V39, P1612, DOI 10.1128/AAC.39.7.1612; Bellais S, 2000, ANTIMICROB AGENTS CH, V44, P1878, DOI 10.1128/AAC.44.7.1878-1886.2000; BICKNELL R, 1985, BIOCHEMISTRY-US, V24, P6876, DOI 10.1021/bi00345a021; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bush K, 1998, CLIN INFECT DIS, V27, pS48, DOI 10.1086/514922; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Diaz N, 2000, J AM CHEM SOC, V122, P4197, DOI 10.1021/ja994462s; Docquier JD, 2002, ANTIMICROB AGENTS CH, V46, P1823, DOI 10.1128/AAC.46.6.1823-1830.2002; FELICI A, 1993, BIOCHEM J, V291, P151, DOI 10.1042/bj2910151; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Garrity JD, 2004, J BIOL CHEM, V279, P920, DOI 10.1074/jbc.M309852200; Goto M, 2003, BIOL PHARM BULL, V26, P589; Goto M, 1997, BIOL PHARM BULL, V20, P1136, DOI 10.1248/bpb.20.1136; Greenlee ML, 1999, BIOORG MED CHEM LETT, V9, P2549, DOI 10.1016/S0960-894X(99)00425-4; Haruta S, 2000, ANTIMICROB AGENTS CH, V44, P2304, DOI 10.1128/AAC.44.9.2304-2309.2000; HUSSAIN M, 1985, J BACTERIOL, V164, P223, DOI 10.1128/JB.164.1.223-229.1985; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaminskaia NV, 2000, J AM CHEM SOC, V122, P6411, DOI 10.1021/ja993704l; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Kurosaki H, 2003, ORG BIOMOL CHEM, V1, P17, DOI 10.1039/b209086d; Laraki N, 1999, ANTIMICROB AGENTS CH, V43, P902, DOI 10.1128/AAC.43.4.902; MASSIDDA O, 1991, J BACTERIOL, V173, P4611, DOI 10.1128/jb.173.15.4611-4617.1991; McManus-Munoz S, 1999, BIOCHEMISTRY-US, V38, P1547, DOI 10.1021/bi9826512; Mercuri PS, 2001, ANTIMICROB AGENTS CH, V45, P1254, DOI 10.1128/AAC.45.4.1254-1262.2001; Moali C, 2003, CHEM BIOL, V10, P319, DOI 10.1016/S1074-5521(03)00070-X; Mollard C, 2001, J BIOL CHEM, V276, P45015, DOI 10.1074/jbc.M107054200; Nagano R, 1999, ANTIMICROB AGENTS CH, V43, P2497, DOI 10.1128/AAC.43.10.2497; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Oelschlaeger P, 2003, PROTEIN ENG, V16, P341, DOI 10.1093/protein/gzg049; OSANO E, 1994, ANTIMICROB AGENTS CH, V38, P71, DOI 10.1128/AAC.38.1.71; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Payne DJ, 2002, ANTIMICROB AGENTS CH, V46, P1880, DOI 10.1128/AAC.46.6.1880-1886.2002; Poirel L, 2000, ANTIMICROB AGENTS CH, V44, P891, DOI 10.1128/AAC.44.4.891-897.2000; RASMUSSEN BA, 1990, ANTIMICROB AGENTS CH, V34, P1590, DOI 10.1128/AAC.34.8.1590; Rossolini GM, 1998, BIOCHEM J, V332, P145, DOI 10.1042/bj3320145; Rossolini GM, 2001, ANTIMICROB AGENTS CH, V45, P837, DOI 10.1128/AAC.45.3.837-844.2001; Siemann S, 2002, ANTIMICROB AGENTS CH, V46, P2450, DOI 10.1128/AAC.46.8.2450-2457.2002; Suarez D, 2002, BIOCHEMISTRY-US, V41, P6615, DOI 10.1021/bi0121860; Toney JH, 2001, J BIOL CHEM, V276, P31913, DOI 10.1074/jbc.M104742200; Toney JH, 1999, BIOORG MED CHEM LETT, V9, P2741, DOI 10.1016/S0960-894X(99)00458-8; Walsh TR, 1996, J ANTIMICROB CHEMOTH, V37, P423, DOI 10.1093/jac/37.3.423; Wang ZG, 1998, J AM CHEM SOC, V120, P10788, DOI 10.1021/ja982621m; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wang ZG, 1998, J BIOL CHEM, V273, P22402, DOI 10.1074/jbc.273.35.22402; Yanchak MP, 2000, BIOCHEMISTRY-US, V39, P11330, DOI 10.1021/bi0010524	47	51	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20824	20832		10.1074/jbc.M414314200	http://dx.doi.org/10.1074/jbc.M414314200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788415	hybrid			2022-12-27	WOS:000229242000080
J	Liu, GY; Kulasingam, V; Alexander, RT; Touret, N; Fong, AM; Patel, DD; Robinson, LA				Liu, GY; Kulasingam, V; Alexander, RT; Touret, N; Fong, AM; Patel, DD; Robinson, LA			Recycling of the membrane-anchored chemokine, CX(3)CL1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRACTALKINE RECEPTOR CX(3)CR1; TNF-ALPHA; CLEAVAGE; GLUT4; INSULIN; PH; ADHESION; CELLS; MECHANISMS; ADIPOCYTES	CX(3)CL1 ( fractalkine) plays an important role in inflammation by acting as both chemoattractant and as an adhesion molecule. As for other chemokines, expression of CX(3)CL1 is known to be regulated at the level of transcription and translation. The unique transmembrane structure of CX(3)CL1 raises the possibility of additional functional regulation by altering its abundance at the cell surface. This could be accomplished in principle by changes in traffic between subcellular compartments. To analyze this possibility we examined the subcellular distribution of CX(3)CL1 in human ECV-304 cells stably expressing untagged or green fluorescent protein-tagged forms of the chemokine. CX(3)CL1 was present in two distinct compartments, diffusely on the plasma membrane and in a punctate juxtanuclear compartment. The latter shared some features with, yet was distinct from the conventional endocytic pathway and may represent a specialized recycling subcompartment. Accordingly, surface CX(3)CL1 was found to be in dynamic equilibrium with the juxtanuclear vesicular compartment. Intracellular CX(3)CL1 co-localized with the SNARE (soluble N-ethylmaleimide factor attachment protein receptor) proteins syntaxin-13 and VAMP-3. Cleavage of VAMP-3 by tetanus toxin or impairment of syntaxin-13 function by expression of a dominant-negative allele inhibited the ability of internalized CX(3)CL1 to traffic back to the plasma membrane. These data demonstrate the existence of a dynamic, SNARE-mediated recycling of CX(3)CL1 from the cell surface to and from an endomembrane storage compartment. The intracellular storage depot may serve as a source of the chemokine that could be rapidly mobilized by stimuli.	Hosp Sick Children, Dept Paediat, Inst Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON M5G 1X8, Canada; Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC 27599 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of North Carolina; University of North Carolina Chapel Hill	Robinson, LA (corresponding author), Hosp Sick Children, Dept Paediat, Inst Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	lisa.robinson@sickkids.ca	Alexander, R. Todd/G-1373-2012	Kulasingam, Vathany/0000-0001-5610-873X				Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Brown D, 2003, AM J PHYSIOL-RENAL, V284, pF893, DOI 10.1152/ajprenal.00387.2002; Chao DS, 1999, J CELL BIOL, V144, P869, DOI 10.1083/jcb.144.5.869; Collins RF, 2002, J IMMUNOL, V169, P3250, DOI 10.4049/jimmunol.169.6.3250; Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Feng LL, 1999, KIDNEY INT, V56, P612, DOI 10.1046/j.1523-1755.1999.00604.x; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Fong AM, 2000, J BIOL CHEM, V275, P3781, DOI 10.1074/jbc.275.6.3781; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Gentzsch M, 2004, MOL BIOL CELL, V15, P2684, DOI 10.1091/mbc.E04-03-0176; Govers R, 2004, MOL CELL BIOL, V24, P6456, DOI 10.1128/MCB.24.14.6456-6466.2004; Haller C, 1998, EUR J CELL BIOL, V75, P353, DOI 10.1016/S0171-9335(98)80068-X; Harrison JK, 1999, J LEUKOCYTE BIOL, V66, P937, DOI 10.1002/jlb.66.6.937; Haskell CA, 2001, J CLIN INVEST, V108, P679, DOI 10.1172/JCI12976; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; Huang XH, 2001, AM J PHYSIOL-CELL PH, V281, pC740, DOI 10.1152/ajpcell.2001.281.3.C740; Hughes SE, 1996, EXP CELL RES, V225, P171, DOI 10.1006/excr.1996.0168; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Katsura T, 1996, AM J PHYSIOL-RENAL, V270, pF548, DOI 10.1152/ajprenal.1996.270.3.F548; Kerfoot SM, 2003, EUR J IMMUNOL, V33, P729, DOI 10.1002/eji.200323502; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; Kishibe J, 2000, J BIOL CHEM, V275, P15321, DOI 10.1074/jbc.275.20.15321; Lesnik P, 2003, J CLIN INVEST, V111, P333, DOI 10.1172/JCI200315555; Lidell ME, 2003, J BIOL CHEM, V278, P13944, DOI 10.1074/jbc.M210069200; Lippincott-Schwartz J, 1999, METHOD CELL BIOL, V58, P261; Liu LB, 2003, J BIOL CHEM, V278, P30157, DOI 10.1074/jbc.M301511200; Lucas AD, 2001, AM J PATHOL, V158, P855, DOI 10.1016/S0002-9440(10)64034-5; Ludwig A, 2002, J IMMUNOL, V168, P604, DOI 10.4049/jimmunol.168.2.604; Machen TE, 2003, AM J PHYSIOL-CELL PH, V285, pC205, DOI 10.1152/ajpcell.00008.2003; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; McCaffrey MW, 2001, FEBS LETT, V495, P21, DOI 10.1016/S0014-5793(01)02359-6; Muehlhoefer A, 2000, J IMMUNOL, V164, P3368, DOI 10.4049/jimmunol.164.6.3368; Olson TS, 2002, AM J PHYSIOL-REG I, V283, pR7, DOI 10.1152/ajpregu.00738.2001; Pastor-Soler N, 2003, J BIOL CHEM, V278, P49523, DOI 10.1074/jbc.M309543200; Randhawa VK, 2000, MOL BIOL CELL, V11, P2403, DOI 10.1091/mbc.11.7.2403; Reits EAJ, 2001, NAT CELL BIOL, V3, pE145, DOI 10.1038/35078615; Robinson LA, 2000, J IMMUNOL, V165, P6067, DOI 10.4049/jimmunol.165.11.6067; Rudich A, 2003, ACTA PHYSIOL SCAND, V178, P297, DOI 10.1046/j.1365-201X.2003.01163.x; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Sheff D, 2002, J CELL BIOL, V156, P797, DOI 10.1083/jcb.20111048; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; Su T, 1999, FEBS LETT, V453, P391, DOI 10.1016/S0014-5793(99)00763-2; Sun TX, 2002, AM J PHYSIOL-RENAL, V282, pF998, DOI 10.1152/ajprenal.00257.2001; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; TAKAHASI K, 1992, IN VITRO CELL DEV-AN, V28A, P380; Terebiznik MR, 2002, NAT CELL BIOL, V4, P766, DOI 10.1038/ncb854; Touret N, 2003, J BIOL CHEM, V278, P25548, DOI 10.1074/jbc.M212374200; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Umehara H, 2001, TRENDS IMMUNOL, V22, P602, DOI 10.1016/S1471-4906(01)02051-8; van Kerkhof P, 2001, J BIOL CHEM, V276, P3778, DOI 10.1074/jbc.M007326200; Volk R, 1999, J BIOL CHEM, V274, P24417, DOI 10.1074/jbc.274.34.24417; Ward ES, 2005, MOL BIOL CELL, V16, P2028, DOI 10.1091/mbc.E04-08-0735; Wu MM, 2001, J BIOL CHEM, V276, P33027, DOI 10.1074/jbc.M103917200; Yao XB, 2003, ANNU REV PHYSIOL, V65, P103, DOI 10.1146/annurev.physiol.65.072302.114200; YI Z, 1993, J BIOL CHEM, V268, P5615; Yoshikawa M, 2004, FEBS LETT, V561, P105, DOI 10.1016/S0014-5793(04)00132-2; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071; Zhang XM, 2004, J BIOL CHEM, V279, P43027, DOI 10.1074/jbc.M402264200	63	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19858	19866		10.1074/jbc.M413073200	http://dx.doi.org/10.1074/jbc.M413073200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774461	Green Published, hybrid			2022-12-27	WOS:000229113700054
J	Nagaike, T; Suzuki, T; Katoh, T; Ueda, T				Nagaike, T; Suzuki, T; Katoh, T; Ueda, T			Human mitochondrial mRNAs are stabilized with polyadenylation regulated by mitochondria-specific poly(A) polymerase and polynucleotide phosphorylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP SYNTHASE; DEVELOPMENTAL REGULATION; DEGRADATION; SEQUENCE; IDENTIFICATION; TRANSLATION; SUBUNIT-8; CHLOROPLAST; TRANSCRIPTS; EXONUCLEASE	Mammalian mitochondrial (mt) mRNAs have short poly(A) tails at their 3' termini that are post-transcriptionally synthesized by mt poly(A) polymerase (PAP). The polyadenylation of mt mRNAs is known to be a key process needed to create UAA stop codons that are not encoded in mtDNA. In some cases, polyadenylation is required for the tRNA maturation by editing of its 3' terminus. However, little is known about the functional roles the poly(A) tail of mt mRNAs plays in mt translation and RNA turnover. Here we show human mt PAP (hmtPAP) and human polynucleotide phosphorylase (hPNPase) control poly(A) synthesis in human mitochondria. Partial inactivation of hmtPAP by RNA interference using small interfering RNA in HeLa cells resulted in shortened poly(A) tails and decreased steady state levels of some mt mRNAs as well as their translational products. Moreover, knocking down hmtPAP generated markedly defective mt membrane potentials and reduced oxygen consumption. In contrast, knocking down hPNPase showed significantly extended poly(A) tails of mt mRNAs. These results demonstrate that the poly(A) length of human mt mRNAs is controlled by polyadenylation by hmtPAP and deadenylation by hPNPase, and polyadenylation is required for the stability of mt mRNAs.	Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Kashiwa, Chiba 2770882, Japan	University of Tokyo; University of Tokyo	Suzuki, T (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	ts@chembio.t.u-tokyo.ac.jp	Ueda, Takuya/K-5217-2014; Suzuki, Tsutomu/J-1776-2015	Ueda, Takuya/0000-0002-7760-8271; Suzuki, Tsutomu/0000-0002-9731-1731; Katoh, Takayuki/0000-0001-6550-6203				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BHAT GJ, 1992, MOL BIOCHEM PARASIT, V52, P231, DOI 10.1016/0166-6851(92)90055-O; BRADLEY P, 2003, MICROBIOLOGY, V149, P2173; BUTOW RA, 1989, GENOME, V31, P757, DOI 10.1139/g89-134; CAMOUGRAND N, 1995, J MOL BIOL, V247, P588, DOI 10.1006/jmbi.1995.0165; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; Chekanova JA, 2003, RNA, V9, P1476, DOI 10.1261/rna.5128903; Chrzanowska-Lightowlers ZMA, 2004, BIOCHEM J, V377, P725, DOI 10.1042/bj20031556; DIECKMANN CL, 1984, J BIOL CHEM, V259, P4722; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; Ellis TP, 2004, J BIOL CHEM, V279, P15728, DOI 10.1074/jbc.M314162200; Gagliardi D, 2004, TRENDS GENET, V20, P260, DOI 10.1016/j.tig.2004.04.006; Gagliardi D, 1999, EMBO J, V18, P3757, DOI 10.1093/emboj/18.13.3757; GROUDINSKY O, 1993, MOL GEN GENET, V240, P419, DOI 10.1007/BF00280396; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; Kadaba S, 2004, GENE DEV, V18, P1227, DOI 10.1101/gad.1183804; KATOH T, 2003, NUCL ACIDS RES S, V3, P249; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kuai L, 2004, P NATL ACAD SCI USA, V101, P8581, DOI 10.1073/pnas.0402888101; Kudla J, 1996, EMBO J, V15, P7137, DOI 10.1002/j.1460-2075.1996.tb01105.x; Leszczyniecka M, 2002, P NATL ACAD SCI USA, V99, P16636, DOI 10.1073/pnas.252643699; MANON S, 1989, BIOCHIM BIOPHYS ACTA, V985, P127, DOI 10.1016/0005-2736(89)90356-8; MANTHEY GM, 1995, EMBO J, V14, P4031, DOI 10.1002/j.1460-2075.1995.tb00074.x; Martin G, 2004, RNA, V10, P899, DOI 10.1261/rna.5242304; Mohanty BK, 2000, P NATL ACAD SCI USA, V97, P11966, DOI 10.1073/pnas.220295997; Nagaike T, 2001, J BIOL CHEM, V276, P40041, DOI 10.1074/jbc.M106202200; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; PELISSIER P, 1995, CURR GENET, V27, P409, DOI 10.1007/BF00311209; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; Perrin R, 2004, J BIOL CHEM, V279, P25440, DOI 10.1074/jbc.M401182200; Piwowarski J, 2003, J MOL BIOL, V329, P853, DOI 10.1016/S0022-2836(03)00528-X; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; READ LK, 1994, MOL BIOCHEM PARASIT, V68, P297, DOI 10.1016/0166-6851(94)90174-0; READ LK, 1992, J BIOL CHEM, V267, P1123; Read RL, 2002, P NATL ACAD SCI USA, V99, P12079, DOI 10.1073/pnas.192467799; Rott R, 2003, J BIOL CHEM, V278, P15771, DOI 10.1074/jbc.M211571200; Ryan CM, 2003, J BIOL CHEM, V278, P32753, DOI 10.1074/jbc.M303552200; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Saitoh S, 2002, CELL, V109, P563, DOI 10.1016/S0092-8674(02)00753-5; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; Temperley RJ, 2003, HUM MOL GENET, V12, P2341, DOI 10.1093/hmg/ddg238; Tomecki R, 2004, NUCLEIC ACIDS RES, V32, P6001, DOI 10.1093/nar/gkh923; Tomita K, 1996, NUCLEIC ACIDS RES, V24, P4987, DOI 10.1093/nar/24.24.4987; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Umeda N, 2005, J BIOL CHEM, V280, P1613, DOI 10.1074/jbc.M409306200; Walter M, 2002, EMBO J, V21, P6905, DOI 10.1093/emboj/cdf686; Wang LT, 2002, NATURE, V419, P312, DOI 10.1038/nature01039; Yehudai-Resheff S, 2001, MOL CELL BIOL, V21, P5408, DOI 10.1128/MCB.21.16.5408-5416.2001; Yokobori S, 1997, J MOL BIOL, V265, P95, DOI 10.1006/jmbi.1996.0728	50	154	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19721	19727		10.1074/jbc.M500804200	http://dx.doi.org/10.1074/jbc.M500804200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769737	hybrid			2022-12-27	WOS:000229113700038
J	Agoston, AT; Argani, P; Yegnasubramanian, S; De Marzo, AM; Ansari-Lari, MA; Hicks, JL; Davidson, NE; Nelson, WG				Agoston, AT; Argani, P; Yegnasubramanian, S; De Marzo, AM; Ansari-Lari, MA; Hicks, JL; Davidson, NE; Nelson, WG			Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG-ISLAND HYPERMETHYLATION; COLON-CANCER; 5-AZACYTIDINE NSC-102816; LUNG-CANCER; CELL-CYCLE; IN-VIVO; METHYLATION; EXPRESSION; TSG101; GENE	We report that DNA methyltransferase 1 (DNMT1) expression is dysregulated in breast cancer. The elevated protein levels are not a result of increased mRNA levels, but rather an increase in protein half-life. We found that DNMT1 protein levels were elevated in breast cancer tissues and in MCF-7 breast cancer cells relative to normal human mammary epithelial cells (HMECs) without a concomitant increase in DNMT1 mRNA or proliferative fraction. Although DNMT1 mRNA levels were properly S-phase-regulated in both cell types, DNMT1 protein levels did not follow S-phase fraction in MCF-7 cells. Rather, an increase in DNMT1 protein stability was found for MCF-7 cells relative to HMECs, and a destruction domain was mapped to the N-terminal 120 amino acids of DNMT1, which was required for its proper ubiquitination and degradation in HMECs. Furthermore, overexpression of DNMT1 with this deleted destruction domain in HMECs resulted in significantly increased genomic 5-methylcytosine levels relative to overexpression of the full-length protein. The regulation of DNMT1 destruction via this domain may be dysfunctional in cancer cells leading to subsequent cytosine hypermethylation in the genome.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Nelson, WG (corresponding author), Canc Res Bldg 151,1650 Orleans St, Baltimore, MD 21231 USA.	bnelson@jhmi.edu			NATIONAL CANCER INSTITUTE [R01CA070196, P50CA088843, P50CA058236] Funding Source: NIH RePORTER; NCI NIH HHS [CA88843, CA70196, CA58236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Belinsky SA, 2003, CANCER RES, V63, P7089; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BELLET RE, 1974, CANCER CHEMOTH REP 1, V58, P217; Bender CM, 1998, CANCER RES, V58, P95; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Burgdorf S, 2004, J BIOL CHEM, V279, P17524, DOI 10.1074/jbc.M313703200; Cardoso F, 2004, INT J ONCOL, V24, P201; Carney ME, 1998, J SOC GYNECOL INVEST, V5, P281, DOI 10.1016/s1071-5576(98)00018-5; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CUNNINGHAM TJ, 1974, CANCER CHEMOTH REP 1, V58, P677; De Marzo AM, 1999, CANCER RES, V59, P3855; Ding F, 2002, P NATL ACAD SCI USA, V99, P14861, DOI 10.1073/pnas.232565599; Eads CA, 1999, CANCER RES, V59, P2302; Eads CA, 2002, CANCER RES, V62, P1296; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Esteller M, 2001, CANCER RES, V61, P3225; Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; Gaudet F, 1998, J BIOL CHEM, V273, P32725, DOI 10.1074/jbc.273.49.32725; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Lo YF, 2000, BREAST CANCER RES TR, V60, P259, DOI 10.1023/A:1006426400524; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Muromoto R, 2004, J IMMUNOL, V172, P2985, DOI 10.4049/jimmunol.172.5.2985; Myers EL, 2002, J VIROL, V76, P11226, DOI 10.1128/JVI.76.22.11226-11235.2002; Nakagawa T, 2003, J UROLOGY, V170, P2463, DOI 10.1097/01.ju.0000095919.50869.c9; Nass SJ, 1999, ONCOGENE, V18, P7453, DOI 10.1038/sj.onc.1203138; Ponting CP, 1997, J MOL MED-JMM, V75, P467; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Trink B, 1998, ONCOGENE, V16, P2815, DOI 10.1038/sj.onc.1201795; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; WEISS AJ, 1977, CANCER TREAT REP, V61, P55; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115; Yegnasubramanian S, 2004, CANCER RES, V64, P1975, DOI 10.1158/0008-5472.CAN-03-3972; Zhong Q, 1998, CANCER RES, V58, P2699	47	102	106	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18302	18310		10.1074/jbc.M501675200	http://dx.doi.org/10.1074/jbc.M501675200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15755728	hybrid			2022-12-27	WOS:000228807200089
J	Sugita, H; Fujimoto, M; Yasukawa, T; Shimizu, N; Sugita, M; Yasuhara, S; Martyn, JAJ; Kaneki, M				Sugita, H; Fujimoto, M; Yasukawa, T; Shimizu, N; Sugita, M; Yasuhara, S; Martyn, JAJ; Kaneki, M			Inducible nitric-oxide synthase and NO donor induce insulin receptor substrate-1 degradation in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; OXIDATIVE STRESS; S-NITROSYLATION; TYROSINE PHOSPHORYLATION; ENDOTHELIAL DYSFUNCTION; TARGETED DISRUPTION; MURINE MACROPHAGES; NITROSATIVE STRESS; DIABETES-MELLITUS	Chronic inflammation plays an important role in insulin resistance. Inducible nitric- oxide synthase ( iNOS), a mediator of inflammation, has been implicated in many human diseases including insulin resistance. However, the molecular mechanisms by which iNOS mediates insulin resistance remain largely unknown. Here we demonstrate that exposure to NO donor or iNOS transfection reduced insulin receptor substrate ( IRS)- 1 protein expression without altering the mRNA level in cultured skeletal muscle cells. NO donor increased IRS- 1 ubiquitination, and proteasome inhibitors blocked NO donor- induced reduction in IRS- 1 expression in cultured skeletal muscle cells. The effect of NO donor on IRS- 1 expression was cGMP- independent and accentuated by concomitant oxidative stress, suggesting an involvement of nitrosative stress. Inhibitors for phosphatidylinositol- 3 kinase, mammalian target of rapamycin, and c- Jun amino- terminal kinase failed to block NO donor- induced IRS- 1 reduction, whereas these inhibitors prevented insulin- stimulated IRS- 1 decrease. Moreover iNOS expression was increased in skeletal muscle of diabetic ( ob/ ob) mice compared with lean wild- type mice. iNOS gene disruption or treatment with iNOS inhibitor ameliorated depressed IRS- 1 expression in skeletal muscle of diabetic ( ob/ ob) mice. These findings indicate that iNOS reduces IRS- 1 expression in skeletal muscle via proteasome- mediated degradation and thereby may contribute to obesity- related insulin resistance.	Harvard Univ, Sch Med, Shriners Hosp Children, Massachusetts Gen Hosp,Dept Anesthesia & Crit Car, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Kaneki, M (corresponding author), Harvard Univ, Sch Med, Shriners Hosp Children, Massachusetts Gen Hosp,Dept Anesthesia & Crit Car, 149 13th St,Rm 6604, Charlestown, MA 02129 USA.	mkaneki@partners.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM021700, R01GM031569, R01GM061411, R01GM055082] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK058127] Funding Source: Medline; NIGMS NIH HHS [R01GM061411, R01 GM055082, R01GM055082, GM21700, R01GM031569] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bedard S, 1997, BIOCHEM J, V325, P487, DOI 10.1042/bj3250487; Beltran B, 2000, BRIT J PHARMACOL, V129, P953, DOI 10.1038/sj.bjp.0703147; Blottner D, 1998, CELL TISSUE RES, V292, P293, DOI 10.1007/s004410051060; Brozinick JT, 2003, DIABETES, V52, P935, DOI 10.2337/diabetes.52.4.935; Buren J, 2003, EUR J ENDOCRINOL, V148, P157, DOI 10.1530/eje.0.1480157; Carvalho Eugenia, 2001, FASEB Journal, V15, P1101; Catalano PM, 2002, AM J PHYSIOL-ENDOC M, V282, pE522, DOI 10.1152/ajpendo.00124.2001; Ceriello A, 2002, DIABETES, V51, P1076, DOI 10.2337/diabetes.51.4.1076; De Vriese AS, 2000, BRIT J PHARMACOL, V130, P963, DOI 10.1038/sj.bjp.0703393; Detmers PA, 2000, J IMMUNOL, V165, P3430, DOI 10.4049/jimmunol.165.6.3430; Drew B, 2002, ANN NY ACAD SCI, V959, P66, DOI 10.1111/j.1749-6632.2002.tb02084.x; Elizalde M, 2000, J LIPID RES, V41, P1244; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Evans JL, 2003, DIABETES, V52, P1, DOI 10.2337/diabetes.52.1.1; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Friedman JE, 1997, AM J PHYSIOL-ENDOC M, V273, pE1014, DOI 10.1152/ajpendo.1997.273.5.E1014; Fujimoto M, 2003, BIOCHEM BIOPH RES CO, V305, P1002, DOI 10.1016/S0006-291X(03)00885-4; Fujiwara N, 2000, CIRCULATION, V101, P856, DOI 10.1161/01.CIR.101.8.856; Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383; Gaston Benjamin M, 2003, Mol Interv, V3, P253, DOI 10.1124/mi.3.5.253; Gath I, 1999, BIOCHEM J, V340, P723, DOI 10.1042/0264-6021:3400723; Gath I, 1996, FASEB J, V10, P1614, DOI 10.1096/fasebj.10.14.9002553; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Hamilton CA, 2001, HYPERTENSION, V37, P529, DOI 10.1161/01.HYP.37.2.529; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hirashima Y, 2003, J ENDOCRINOL, V179, P253, DOI 10.1677/joe.0.1790253; Hirose M, 2000, AM J PHYSIOL-ENDOC M, V279, pE1235, DOI 10.1152/ajpendo.2000.279.6.E1235; Honing MLH, 1998, DIABETES METAB REV, V14, P241, DOI 10.1002/(SICI)1099-0895(1998090)14:3<241::AID-DMR216>3.0.CO;2-R; Jansson PA, 2003, FASEB J, V17, P1434, DOI 10.1096/fj.02-1132com; Kaneki M, 1999, MOL CELL BIOL, V19, P461; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kido Y, 2001, J CLIN ENDOCR METAB, V86, P972, DOI 10.1210/jc.86.3.972; Kim YB, 1996, METABOLISM, V45, P1080, DOI 10.1016/S0026-0495(96)90006-2; Kisley LR, 2002, CANCER RES, V62, P6850; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Kuncewicz T, 2001, AM J PHYSIOL-RENAL, V281, pF326, DOI 10.1152/ajprenal.2001.281.2.F326; KUO PC, 1995, ANN SURG, V221, P220, DOI 10.1097/00000658-199503000-00003; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; Liberatore GT, 1999, NAT MED, V5, P1403; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Lyall F, 1998, DIABETES CARE, V21, P1753, DOI 10.2337/diacare.21.10.1753; Maccarrone M, 1997, FEBS LETT, V410, P470, DOI 10.1016/S0014-5793(97)00643-1; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Padron J, 2000, BIOCHEM BIOPH RES CO, V271, P217, DOI 10.1006/bbrc.2000.2617; Park CS, 1996, LIFE SCI, V59, P219, DOI 10.1016/0024-3205(96)00287-1; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Perreault M, 2001, NAT MED, V7, P1138, DOI 10.1038/nm1001-1138; Previs SF, 2000, J BIOL CHEM, V275, P38990, DOI 10.1074/jbc.M006490200; Rondinone CM, 2002, BIOCHEM BIOPH RES CO, V296, P1257, DOI 10.1016/S0006-291X(02)02083-1; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sesti G, 2001, FASEB J, V15, P2099, DOI 10.1096/fj.01-0009rev; SHARMA K, 1995, BIOCHEM BIOPH RES CO, V207, P80, DOI 10.1006/bbrc.1995.1156; Shimabukuro M, 1998, J BIOL CHEM, V273, P32487, DOI 10.1074/jbc.273.49.32487; Shirakami A, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740309; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209; Strand OA, 2000, CRIT CARE MED, V28, P2779, DOI 10.1097/00003246-200008000-00017; Sugita H, 2002, AM J PHYSIOL-ENDOC M, V282, pE386, DOI 10.1152/ajpendo.00087.2001; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; Takata M, 2001, AM J PHYSIOL-LUNG C, V280, pL272, DOI 10.1152/ajplung.2001.280.2.L272; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tannous M, 1999, DIABETOLOGIA, V42, P539, DOI 10.1007/s001250051192; Torres SH, 2004, J ENDOCRINOL, V181, P419, DOI 10.1677/joe.0.1810419; Warnholtz A, 2002, J AM COLL CARDIOL, V40, P1356, DOI 10.1016/S0735-1097(02)02133-2; Watanabe T, 2000, CLIN CHIM ACTA, V301, P169, DOI 10.1016/S0009-8981(00)00340-5; Wink DA, 2000, SEMIN PERINATOL, V24, P20, DOI 10.1016/S0146-0005(00)80049-X; Yoon Y, 2000, CLIN CHEM, V46, P1626; Young ME, 1998, BIOCHEM J, V329, P73; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002	77	89	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14203	14211		10.1074/jbc.M411226200	http://dx.doi.org/10.1074/jbc.M411226200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15805118	hybrid			2022-12-27	WOS:000228095500123
J	LaPointe, P; Wei, X; Gariepy, J				LaPointe, P; Wei, X; Gariepy, J			A role for the protease-sensitive loop region of shiga-like toxin 1 in the retrotranslocation of its A(1) domain from the endoplasmic reticulum lumen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI O157-H7; RICIN-A-CHAIN; DISULFIDE-ISOMERASE; SHIGELLA-DYSENTERIAE; PROTEOLYTIC CLEAVAGE; ANTIGEN DEGRADATION; BREFELDIN-A; C-TERMINUS; BINDING; CYTOTOXICITY	Shiga-like toxin I (Slt-I) is a ribosome-inactivating protein that undergoes retrograde transport to the endoplasmic reticulum to exert its cytotoxic effect on eukaryotic cells. Its catalytically active A(1) domain subsequently migrates from the endoplasmic reticulum ( ER) lumen to the cytoplasm. To study this final retrotrans-location event, a suicide assay was developed based on the cytoplasmic expression and ER-targeting of the cytotoxic Slt-I A1 fragment in Saccharomyces cerevisiae. Expression of the Slt-I A1 domain (residues 1-251) with and without an ER-targeting sequence was lethal to the host and demonstrated that this domain can efficiently migrate from the ER compartment to the cytosol. Deletion analyses revealed that residues 1-239 represent the minimal A1 segment displaying full enzymatic activity. This fragment, however, accumulates in the ER lumen when directed to this compartment. The addition of residues 240-251 restores the translocation property of the A1 chain in yeast. However, single mutations within this region do not significantly alter this function in the context of the 251-residue long A1 domain or affect the toxicity of the resulting Slt-I variants toward Vero cells in the context of the holotoxin. Since this mechanism of retrotranslocation is common to other protein toxins lacking a peptide motif similar in sequence to residues 240-251, the present results suggest that the ER export mechanism may involve the recognition of a more universal structural element, such as a misfolded or altered peptide domain localized at the C terminus of the A1 chain (residues 240-251) rather than a unique ER export signal sequence.	Univ Hlth Network, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Gariepy, J (corresponding author), Univ Hlth Network, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	gariepy@uhnres.utoronto.ca		LaPointe, Paul/0000-0002-5465-1795				BURGESS BJ, 1993, MOL MICROBIOL, V10, P171, DOI 10.1111/j.1365-2958.1993.tb00913.x; Day PJ, 2002, BIOCHEMISTRY-US, V41, P2836, DOI 10.1021/bi012012i; DONTA ST, 1993, INFECT IMMUN, V61, P3282, DOI 10.1128/IAI.61.8.3282-3286.1993; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; FRASER ME, 1994, NAT STRUCT BIOL, V1, P59, DOI 10.1038/nsb0194-59; GARRED O, 1995, J BIOL CHEM, V270, P10817; GARRED O, 1995, EXP CELL RES, V218, P39, DOI 10.1006/excr.1995.1128; GRANT EP, 1995, J IMMUNOL, V155, P3750; Gromme M, 2002, MOL IMMUNOL, V39, P181, DOI 10.1016/S0161-5890(02)00101-3; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hatsuzawa K, 1997, J BIOCHEM-TOKYO, V121, P270; Hazes B, 1997, BIOCHEMISTRY-US, V36, P11051, DOI 10.1021/bi971383p; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; Johannes L, 1998, TRENDS CELL BIOL, V8, P158, DOI 10.1016/S0962-8924(97)01209-9; Lea N, 1999, MICROBIOL-UK, V145, P999, DOI 10.1099/13500872-145-5-999; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; Menikh A, 1997, BIOCHEMISTRY-US, V36, P15865, DOI 10.1021/bi970944+; Pilon M, 1998, MOL BIOL CELL, V9, P3455, DOI 10.1091/mbc.9.12.3455; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; Saleh MT, 1996, BIOCHEMISTRY-US, V35, P9325, DOI 10.1021/bi960177z; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SELLECK SB, 1988, P NATL ACAD SCI USA, V85, P5399, DOI 10.1073/pnas.85.15.5399; SIMPSON JC, 1995, EUR J BIOCHEM, V232, P458; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Tsai M, 2002, J CELL BIOL, V159, P207, DOI 10.1083/jcb.200207120; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z; Zheng J, 2001, J BIOL CHEM, V276, P15747, DOI 10.1074/jbc.M011444200	34	47	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23310	23318		10.1074/JBC.m414193200	http://dx.doi.org/10.1074/JBC.m414193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15817449	hybrid			2022-12-27	WOS:000229741800090
J	Ueno, N; Takeya, R; Miyano, K; Kikuchi, H; Sumimoto, H				Ueno, N; Takeya, R; Miyano, K; Kikuchi, H; Sumimoto, H			The NADPH oxidase Nox3 constitutively produces superoxide in a p22(Phox)-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; SRC HOMOLOGY-3 DOMAINS; SH3 DOMAIN; P67(PHOX) PARTICIPATE; MOLECULAR-MECHANISM; NAD(P)H OXIDASE-1; ACTIVATION DOMAIN; P47(PHOX); PHOSPHORYLATION; PROTEINS	Nox3, a member of the superoxide-producing NADPH oxidase (Nox) family, participates in otoconia formation in mouse inner ears, which is required for perception of balance and gravity. The activity of other Nox enzymes such as gp91(phox/)Nox2 and Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) and an activator protein( p67(phox)orNoxa1); for the p47(phox)-dependent activation of these oxidases, treatment of cells with stimulants such as phorbol 12-myristate 13-acetate is also indispensable. Here we show that ectopic expression of Nox3 in various types of cells leads to phorbol 12-myristate 13-acetate-independent constitutive production of a substantial amount of superoxide under the conditions where gp91(phox) and Nox1 fail to generate superoxide, i.e. in the absence of the oxidase organizers and activators. Nox3 likely forms a functional complex with p22(phox); Nox3 physically interacts with and stabilizes p22(phox), and the Nox3-dependent superoxide production is totally dependent on p22phox. The organizers p47(phox) and Noxo1 are capable of enhancing the superoxide production by Nox3 in the absence of the activators, and the enhancement requires the interaction of the organizers with p22phox, further indicating a link between Nox3 and p22(phox). The p47(phox)-enhanced Nox3 activity is further facilitated by p67(phox) or Noxa1, whereas the activators cancel the Noxo1-induced enhancement. On the other hand, the small GTPase Rac, essential for the gp91(phox) activity, is likely dispensable to the Nox3 system. Thus Nox3 functions together with p22(phox) as an enzyme constitutively producing superoxide, which can be distinctly regulated by combinatorial use of the organizers and activators.	Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan; Hirosaki Univ, Fac Agr & Life Sci, Dept Biochem & Biotechnol, Hirosaki, Aomori 0368561, Japan	Kyushu University; Japan Science & Technology Agency (JST); Hirosaki University	Kikuchi, H (corresponding author), Kyushu Univ, Med Inst Bioregulat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	hsumi@bioreg.kyushu-u.ac.jp						Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Ago T, 2003, P NATL ACAD SCI USA, V100, P4474, DOI 10.1073/pnas.0735712100; Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Banfi B, 2004, J BIOL CHEM, V279, P46065, DOI 10.1074/jbc.M403046200; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Biberstine-Kinkade KJ, 2002, J BIOL CHEM, V277, P30368, DOI 10.1074/jbc.M203993200; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Brown GE, 2003, MOL CELL, V11, P35, DOI 10.1016/S1097-2765(03)00005-4; Cheng GJ, 2004, J BIOL CHEM, V279, P34250, DOI 10.1074/jbc.M400660200; Cheng GJ, 2004, J BIOL CHEM, V279, P4737, DOI 10.1074/jbc.M305968200; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; Cross AR, 1999, J BIOL CHEM, V274, P15519, DOI 10.1074/jbc.274.22.15519; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; DINAUER MC, 1991, P NATL ACAD SCI USA, V88, P11231, DOI 10.1073/pnas.88.24.11231; DINAUER MC, 1989, J CLIN INVEST, V84, P2012, DOI 10.1172/JCI114393; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FINAN P, 1994, J BIOL CHEM, V269, P13752; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200; Geiszt M, 2003, J IMMUNOL, V171, P299, DOI 10.4049/jimmunol.171.1.299; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Hashida S, 2004, J BIOL CHEM, V279, P26378, DOI 10.1074/jbc.M309724200; Hata K, 1997, BIOCHEM BIOPH RES CO, V241, P226, DOI 10.1006/bbrc.1997.7807; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; HURST JK, 1991, J BIOL CHEM, V266, P1627; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; Kami K, 2002, EMBO J, V21, P4268, DOI 10.1093/emboj/cdf428; Kawahara T, 2005, AM J PHYSIOL-CELL PH, V288, pC450, DOI 10.1152/ajpcell.00319.2004; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; Koshkin V, 1997, BBA-BIOENERGETICS, V1319, P139, DOI 10.1016/S0005-2728(96)00154-5; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lekstrom-Himes JA, 2000, NEW ENGL J MED, V343, P1703, DOI 10.1056/NEJM200012073432307; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Paffenholz R, 2004, GENE DEV, V18, P486, DOI 10.1101/gad.1172504; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Roos D, 1996, BLOOD, V87, P1663; Sarfstein R, 2004, J BIOL CHEM, V279, P16007, DOI 10.1074/jbc.M312394200; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Takeya R, 2003, MOL CELLS, V16, P271; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; Yuzawa S, 2004, J BIOL CHEM, V279, P29752, DOI 10.1074/jbc.M401457200; Yuzawa S, 2004, GENES CELLS, V9, P443, DOI 10.1111/j.1356-9597.2004.00733.x	61	147	157	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23328	23339		10.1074/jbc.M414548200	http://dx.doi.org/10.1074/jbc.M414548200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15824103	hybrid			2022-12-27	WOS:000229741800092
J	Wang, JB; Wu, WJ; Cerione, RA				Wang, JB; Wu, WJ; Cerione, RA			Cdc42 and Ras cooperate to mediate cellular transformation by intersectin-L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCYTIC PROTEIN INTERSECTIN; UBIQUITIN LIGASE ACTIVITY; ACTIN STRESS FIBERS; C-CBL; RHO; GROWTH; GTPASES; DBL; C-CBL/SLI-1; FILOPODIA	Cdc42, a Ras-related GTP-binding protein, has been implicated in the regulation of the actin cytoskeleton, membrane trafficking, cell-cycle progression, and malignant transformation. We have shown previously that a Cdc42 mutant (Cdc42(F28L)), capable of spontaneously exchanging GDP for GTP (referred to as "fastcycling"), transformed NIH 3T3 cells because of its ability to interfere with epidermal growth factor receptor (EGFR)-Cbl interactions and EGFR down-regulation. To further examine the link between the hyperactivation of Cdc42 and its ability to alter EGFR signaling and thereby cause cellular transformation, we examined the effects of expressing different forms of the Cdc42-specific guanine nucleotide exchange factor, intersectin-L, in fibroblasts. Full-length intersectin-L exhibited little ability to stimulate nucleotide exchange on Cdc42, whereas a truncated version that contained five Src homology 3 (SH3) domains, the Dbl and pleckstrin homology domains (DH and PH domains, respectively), and a C2 domain (designated as SH3A-C2) showed modest guanine nucleotide exchange factor activity, whereas a form containing just the DH, PH, and C2 domains (DH-C2) strongly activated Cdc42. However, DH-C2 showed little ability to stimulate growth in low serum or colony formation in soft agar, whereas SH3A-C2 gave rise to a much stronger stimulation of cell growth in low serum and was highly effective in stimulating colony formation. Moreover, although SH3A-C2 strongly transformed fibroblasts, it differed from the actions of the Cdc42(F28L) mutant, as SH3A-C2 showed little ability to alter EGFR levels or the lifetime of EGF-coupled signaling through ERK. Rather, we found that SH3A-C2 exhibited strong transforming activity through its ability to mediate cooperation between Ras and Cdc42.	Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Coll Vet Med, Dept Chem & Chem Biol, Baker Lab, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.	rac1@cornell.edu			NIGMS NIH HHS [GM47458] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 2000, J BIOL CHEM, V275, P27414; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Mohney RP, 2003, J BIOL CHEM, V278, P47038, DOI 10.1074/jbc.M303895200; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; Tu SS, 2002, BIOCHEMISTRY-US, V41, P12350, DOI 10.1021/bi026167h; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3; Zamanian JL, 2003, MOL BIOL CELL, V14, P1624, DOI 10.1091/mbc.E02-08-0494; Zhu KJ, 2000, J BIOL CHEM, V275, P25993, DOI 10.1074/jbc.M003780200	30	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22883	22891		10.1074/jbc.M414375200	http://dx.doi.org/10.1074/jbc.M414375200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15824104	hybrid			2022-12-27	WOS:000229741800041
J	Cheng, AX; McDonald, NA; Connolly, CN				Cheng, AX; McDonald, NA; Connolly, CN			Cell surface expression of 5-hydroxytryptamine type 3 receptors is promoted by RIC-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GABA(A) RECEPTORS; GLYCINE RECEPTOR; PLASMA-MEMBRANE; TRAFFICKING; GEPHYRIN; SUBUNIT; ASSOCIATION; CONDUCTANCE; REQUIREMENT	RIC-3 has been identified as a molecule essential for the recruitment of functional nicotinic acetylcholine receptors composed of a7, but it exhibits inhibitory effects on a4b2 or a3b4 receptors. In this study, we investigated the role of RIC-3 in the recruitment of 5-hydroxytryptamine type 3A (5-HT3A3A3A) receptors to the cell surface. Although RIC-3 is not essential for the surface transport of 5-HT3A receptors, we found that its presence enhances both receptor transport and function in a concentration-dependent manner. RIC-3 is localized to the endoplasmic reticulum, as evidenced by co-localization with the chaperone molecule, binding protein (BiP). RIC-3 is not detected at significant levels on the cell surface when expressed alone or in the presence of 5-HT. RIC-3 and 5-HT (show a low level interaction that is transient (< 4 h). That RIC-3 can interact with an endoplasmic reticulum-retained 5-HT)(3A) (construct, combined with the transient interaction observed and lack of significant surface-expressed RIC)(, suggests that RIC)(-3)(-3) (may play a role in 5-HT)(3A) receptor folding, assembly, or transport to the cell surface.	Univ Dundee, Ninewells Med Sch, Dept Pharmacol & Neurosci, Dundee DD1 9SY, Scotland	University of Dundee	Connolly, CN (corresponding author), Univ Dundee, Ninewells Med Sch, Dept Pharmacol & Neurosci, Dundee DD1 9SY, Scotland.	c.n.connolly@dundee.ac.uk		Connolly, Christopher/0000-0002-0445-8874				Banks GB, 2003, J NEUROCYTOL, V32, P709, DOI 10.1023/B:NEUR.0000020619.24681.2b; Bedford FK, 2001, NAT NEUROSCI, V4, P908, DOI 10.1038/nn0901-908; Bollan K, 2003, BIOCHEM SOC T, V31, P875, DOI 10.1042/bst0310875; Boyd GW, 2003, J BIOL CHEM, V278, P27681, DOI 10.1074/jbc.M304938200; Boyd GW, 2002, MOL CELL NEUROSCI, V21, P38, DOI 10.1006/mcne.2002.1160; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Christianson JC, 2004, EMBO J, V23, P4156, DOI 10.1038/sj.emboj.7600436; Collingridge GL, 2004, NAT REV NEUROSCI, V5, P952, DOI 10.1038/nrn1556; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Coyle JE, 2003, NEUROSCIENTIST, V9, P205, DOI 10.1177/1073858403009003013; Ernst M, 2003, NEUROSCIENCE, V119, P933, DOI 10.1016/S0306-4522(03)00288-4; Everitt AB, 2004, J BIOL CHEM, V279, P21701, DOI 10.1074/jbc.M312806200; Fritschy JM, 2003, BIOCHEM SOC T, V31, P889, DOI 10.1042/bst0310889; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Gunthorpe MJ, 2000, J PHYSIOL-LONDON, V522, P187, DOI 10.1111/j.1469-7793.2000.00187.x; Halevi S, 2003, J BIOL CHEM, V278, P34411, DOI 10.1074/jbc.M300170200; Halevi S, 2002, EMBO J, V21, P1012, DOI 10.1093/emboj/21.5.1012; Hanus C, 2004, J NEUROSCI, V24, P1119, DOI 10.1523/JNEUROSCI.4380-03.2004; Harvey K, 2004, J NEUROSCI, V24, P5816, DOI 10.1523/JNEUROSCI.1184-04.2004; HELEKAR SA, 1994, NEURON, V12, P179, DOI 10.1016/0896-6273(94)90162-7; Helekar SA, 1997, P NATL ACAD SCI USA, V94, P5432, DOI 10.1073/pnas.94.10.5432; Ilegems E, 2004, J BIOL CHEM, V279, P53346, DOI 10.1074/jbc.M407467200; Jeanclos EM, 2001, J BIOL CHEM, V276, P28281, DOI 10.1074/jbc.M011549200; Kittler JT, 2004, P NATL ACAD SCI USA, V101, P12736, DOI 10.1073/pnas.0401860101; Kneussel M, 2002, BRAIN RES REV, V39, P74, DOI 10.1016/S0165-0173(02)00159-5; Leil TA, 2004, J NEUROSCI, V24, P11429, DOI 10.1523/JNEUROSCI.3355-04.2004; Levi S, 2004, J NEUROSCI, V24, P207, DOI 10.1523/JNEUROSCI.1661-03.2004; Marchand S, 2002, J NEUROSCI, V22, P8891; Nevin ST, 2003, J BIOL CHEM, V278, P28985, DOI 10.1074/jbc.M300097200; Ngo ST, 2004, NEUROREPORT, V15, P2501, DOI 10.1097/00001756-200411150-00014; Rakhilin S, 1999, J CELL BIOL, V146, P203; Rangwala F, 1997, J NEUROSCI, V17, P8201; Reeves DC, 2003, BIOPHYS J, V84, P2338, DOI 10.1016/S0006-3495(03)75039-5; Wanamaker CP, 2003, ANN NY ACAD SCI, V998, P66, DOI 10.1196/annals.1254.009; Wang JM, 2002, NAT NEUROSCI, V5, P963, DOI 10.1038/nn918; Williams ME, 2005, J BIOL CHEM, V280, P1257, DOI 10.1074/jbc.M410039200	37	55	58	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22502	22507		10.1074/jbc.M414341200	http://dx.doi.org/10.1074/jbc.M414341200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15809299	hybrid			2022-12-27	WOS:000229557900097
J	Raymond, AC; Staker, BL; Burgin, AB				Raymond, AC; Staker, BL; Burgin, AB			Substrate specificity of tyrosyl-DNA phosphodiesterase I (Tdp1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TOPOISOMERASE-I; STRAND BREAK REPAIR; COVALENT COMPLEXES; SPINOCEREBELLAR ATAXIA; CRYSTAL-STRUCTURE; PHOSPHOLIPASE D1; CAMPTOTHECIN; PROTEIN; ENZYME; MECHANISM	Tyrosyl-DNA phosphodiesterase I (Tdp1) hydrolyzes 3'-phosphotyrosyl bonds to generate 3'-phosphate DNA and tyrosine in vitro. Tdp1 is involved in the repair of DNA lesions created by topoisomerase I, although the in vivo substrate is not known. Here we study the kinetic and binding properties of human Tdp1 (hTdp1) to identify appropriate 3'-phosphotyrosyl DNA substrates. Genetic studies argue that Tdp1 is involved in double and single strand break repair pathways; however, x-ray crystal structures suggest that Tdp1 can only bind single strand DNA. Separate kinetic and binding experiments show that hTdp1 has a preference for singlestranded and blunt-ended duplex substrates over nicked and tailed duplex substrate conformations. Based on these results, we present a new model to explain Tdp1/DNA binding properties. These results suggest that Tdp1 only acts upon double strand breaks in vivo, and the roles of Tdp1 in yeast and mammalian cells are discussed.	deCODE Biostruct, Bainbridge Isl, WA 98110 USA; San Diego State Univ, Dept Biol, San Diego, CA 92164 USA	California State University System; San Diego State University	Burgin, AB (corresponding author), deCODE Biostruct, 7869 NE Day Rd, Bainbridge Isl, WA 98110 USA.	aburgin@decode.com		Staker, Bart/0000-0001-9570-5086	NCI NIH HHS [CA 92079-01A2] Funding Source: Medline; NIGMS NIH HHS [GM 58596, 1F31 GM 66372-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM066372, R01GM058596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTHELMES HU, 2004, J BIOL CHEM, V19, P19; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Caldecott KW, 2003, CELL, V112, P7, DOI 10.1016/S0092-8674(02)01247-3; Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)00118-6; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Cheng TJ, 2002, EUR J BIOCHEM, V269, P3697, DOI 10.1046/j.1432-1033.2002.03059.x; Chreneik JE, 2003, J BIOL CHEM, V278, P12461, DOI 10.1074/jbc.M212930200; Connelly JC, 2004, MOL CELL, V13, P307, DOI 10.1016/S1097-2765(04)00056-5; Davies DR, 2004, J MED CHEM, V47, P829, DOI 10.1021/jm030487x; Davies DR, 2003, CHEM BIOL, V10, P139, DOI 10.1016/S1074-5521(03)00021-8; Davies DR, 2002, J MOL BIOL, V324, P917, DOI 10.1016/S0022-2836(02)01154-3; Davies DR, 2002, STRUCTURE, V10, P237, DOI 10.1016/S0969-2126(02)00707-4; Debethune L, 2002, NUCLEIC ACIDS RES, V30, P1198, DOI 10.1093/nar/30.5.1198; Dunlop J, 2004, CURR BIOL, V14, P2039, DOI 10.1016/j.cub.2004.10.048; Henrie MS, 2003, DNA REPAIR, V2, P151, DOI 10.1016/S1568-7864(02)00199-4; Hill JJ, 1997, METHOD ENZYMOL, V278, P390; HSIANG YH, 1989, CANCER RES, V49, P5077; Hughes WE, 2004, J BIOL CHEM, V279, P27534, DOI 10.1074/jbc.M403012200; Humeau Y, 2001, P NATL ACAD SCI USA, V98, P15300, DOI 10.1073/pnas.261358698; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; Inamdar KV, 2002, J BIOL CHEM, V277, P27162, DOI 10.1074/jbc.M204688200; Interthal H, 2001, P NATL ACAD SCI USA, V98, P12009, DOI 10.1073/pnas.211429198; KROEGER PE, 1989, NUCLEIC ACIDS RES, V17, P8495, DOI 10.1093/nar/17.21.8495; Lesher DTT, 2002, P NATL ACAD SCI USA, V99, P12102, DOI 10.1073/pnas.192282699; Liu CY, 2002, P NATL ACAD SCI USA, V99, P14970, DOI 10.1073/pnas.182557199; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Meng LH, 2003, CURR TOP MED CHEM, V3, P305; Park SY, 2002, CANCER RES, V62, P459; Pizzolato JF, 2003, LANCET, V361, P2235, DOI 10.1016/S0140-6736(03)13780-4; Plo I, 2003, DNA REPAIR, V2, P1087, DOI 10.1016/S1568-7864(03)00116-2; Pommier Yves, 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P429, DOI 10.2174/1568011043352777; Pouliot JJ, 2001, GENES CELLS, V6, P677, DOI 10.1046/j.1365-2443.2001.00452.x; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Raymond AC, 2004, J MOL BIOL, V338, P895, DOI 10.1016/j.jmb.2004.03.013; Rutledge SE, 2003, J AM CHEM SOC, V125, P14336, DOI 10.1021/ja034508o; Takashima H, 2002, NAT GENET, V32, P267, DOI 10.1038/ng987; Vance JR, 2002, P NATL ACAD SCI USA, V99, P13669, DOI 10.1073/pnas.202242599; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534	41	47	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22029	22035		10.1074/jbc.M502148200	http://dx.doi.org/10.1074/jbc.M502148200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15811850	hybrid			2022-12-27	WOS:000229557900046
J	Xie, B; Li, H; Wang, Q; Xie, SQ; Rahmeh, A; Dai, W; Lee, MYWT				Xie, B; Li, H; Wang, Q; Xie, SQ; Rahmeh, A; Dai, W; Lee, MYWT			Further characterization of human DNA polymerase delta interacting protein 38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; REPLICATION FORK; EUKARYOTIC CELLS; SIGNAL PEPTIDES; 3RD SUBUNIT; PCNA; BINDING; GENE; IDENTIFICATION; MITOCHONDRIA	Polymerase delta interacting protein 38 ( PDIP38) was identified as a human DNA polymerase (pol) delta interacting protein through a direct interaction with p50, the small subunit of human pol delta. PDIP38 was also found to interact with proliferating cell nuclear antigen, which suggested that it might play a role in vivo in the processes of DNA replication and DNA repair in the nucleus. In order to characterize further this novel protein, we have examined its subcellular localization by the use of immunochemical and cellular fractionation techniques. These studies show that PDIP38 is a novel mitochondrial protein and is localized mainly to the mitochondria. PDIP38 was shown to possess a functional mitochondrial targeting sequence that is located within the first 35 N-terminal amino acid residues. The mature PDIP38 protein is about 50 amino acid residues smaller than the full-length precursor PDIP38 protein, consistent with it being processed by cleavage of the mitochondrial targeting sequence during entry into the mitochondria. His-tagged mature PDIP38 inhibited pol delta activity in vitro and interacted with human papillomavirus 16 E7 oncoprotein, suggesting that PDIP38 might play a role in the pol delta-mediated viral DNA replication. Although the localization of PDIP38 to the mitochondria suggests that it serves functions within the mitochondria, we cannot eliminate the possibility that it may be involved in pol delta-mediated DNA replication or DNA repair under certain conditions such as viral infection.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	New York Medical College; New York Medical College	Lee, MYWT (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	Marietta_Lee@nymc.edu		Rahmeh, Amal/0000-0003-0985-7978	NATIONAL CANCER INSTITUTE [R13CA074299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER; NCI NIH HHS [CA 74299] Funding Source: Medline; NIGMS NIH HHS [GM 31973] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Bashir T, 2001, J VIROL, V75, P4394, DOI 10.1128/JVI.75.9.4394-4398.2001; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bereiter-Hahn J., 1990, International Review of Cytology, V122, P1, DOI 10.1016/S0074-7696(08)61205-X; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Christensen J, 2002, J VIROL, V76, P6518, DOI 10.1128/JVI.76.13.6518-6531.2002; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Coffey G, 2000, NUCLEIC ACIDS RES, V28, P3793, DOI 10.1093/nar/28.19.3793; Dell'Era P, 2005, ONCOGENE, V24, P1117, DOI 10.1038/sj.onc.1208359; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Eom CY, 2002, P NATL ACAD SCI USA, V99, P1894, DOI 10.1073/pnas.042689499; Feng WY, 2001, MOL CELL BIOL, V21, P4495, DOI 10.1128/MCB.21.14.4495-4504.2001; Frouin I, 2002, EMBO J, V21, P2485, DOI 10.1093/emboj/21.10.2485; Fukui T, 2004, GENES CELLS, V9, P179, DOI 10.1111/j.1356-9597.2004.00716.x; Gakh E, 2002, BBA-MOL CELL RES, V1592, P63, DOI 10.1016/S0167-4889(02)00265-3; Garg P, 2004, GENE DEV, V18, P2764, DOI 10.1101/gad.1252304; Garner-Hamrick PA, 2004, J VIROL, V78, P9041, DOI 10.1128/JVI.78.17.9041-9050.2004; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; He H, 2001, P NATL ACAD SCI USA, V98, P11979, DOI 10.1073/pnas.221452098; Henneke G, 2003, EMBO REP, V4, P252, DOI 10.1038/sj.embor.embor774; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kasamatsu H, 1998, ANNU REV MICROBIOL, V52, P627, DOI 10.1146/annurev.micro.52.1.627; Laquel-Robert P, 2003, BIOCHEM BIOPH RES CO, V303, P713, DOI 10.1016/S0006-291X(03)00410-8; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; Liao GL, 2005, J VIROL, V79, P245, DOI 10.1128/JVI.79.1.245-256.2005; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; Liu L, 2003, J BIOL CHEM, V278, P10041, DOI 10.1074/jbc.M208694200; Maga G, 2001, P NATL ACAD SCI USA, V98, P14298, DOI 10.1073/pnas.251193198; Mo JY, 2000, BIOCHEMISTRY-US, V39, P7245, DOI 10.1021/bi0000871; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; Raj K, 2004, J VIROL, V78, P7199, DOI 10.1128/JVI.78.13.7199-7207.2004; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; TAGUCHI T, 1995, BIOCHEM BIOPH RES CO, V216, P715, DOI 10.1006/bbrc.1995.2680; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; Tsuchimoto D, 2001, NUCLEIC ACIDS RES, V29, P2349, DOI 10.1093/nar/29.11.2349; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wang Y, 2002, P NATL ACAD SCI USA, V99, P12114, DOI 10.1073/pnas.192449499; Willer M, 1999, CURR BIOL, V9, P1085, DOI 10.1016/S0960-9822(99)80477-1; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561; Xie B, 2002, BIOCHEMISTRY-US, V41, P13133, DOI 10.1021/bi0262707; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; ZENG XR, 1994, J BIOL CHEM, V269, P24027; ZENG XR, 1994, J BIOL CHEM, V269, P13748; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647; ZHANG SJ, 1995, J BIOL CHEM, V270, P7988, DOI 10.1074/jbc.270.14.7988; Zhang XP, 2001, PLANT J, V27, P427, DOI 10.1046/j.1365-313X.2001.01108.x	61	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22375	22384		10.1074/jbc.M414597200	http://dx.doi.org/10.1074/jbc.M414597200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15811854	hybrid			2022-12-27	WOS:000229557900083
J	Lee, YH; Kolade, OO; Nomura, K; Arvidson, DN; He, SY				Lee, YH; Kolade, OO; Nomura, K; Arvidson, DN; He, SY			Use of dominant-negative HrpA mutants to dissect Hrp pilus assembly and type III secretion in Pseudomonas syringae pv. tomato	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUPRAMOLECULAR STRUCTURE; PROTEIN SECRETION; NEEDLE COMPLEX; AVR PROTEINS; X-RAY; SYSTEM; PILIN; AERUGINOSA; TRANSLOCATION	The Hrp pilus plays an essential role in the long-distance type III translocation of effector proteins from bacteria into plant cells. HrpA is the structural subunit of the Hrp pilus in Pseudomonas syringae pv. tomato (Pst) DC3000. Little is known about the molecular features in the HrpA protein for pilus assembly or for transporting effector proteins. From previous collections of nonfunctional HrpA derivatives that carry random pentapeptide insertions or single amino acid mutations, we identified several dominant-negative mutants that blocked the ability of wild-type Pst DC3000 to elicit host responses. The dominant-negative phenotype was correlated with the disappearance of the Hrp pilus in culture and inhibition of wild-type HrpA protein self-assembly in vitro. Dominant- negative HrpA mutants can be grouped into two functional classes: one class exerted a strong dominant- negative effect on the secretion of effector proteins AvrPto and HopPtoM in culture, and the other did not. The two classes of mutant HrpA proteins carry pentapeptide insertions in discrete regions, which are interrupted by insertions without a dominant- negative effect. These results enable prediction of possible subunit-subunit interaction sites in the assembly of the Hrp pilus and suggest the usefulness of dominant-negative mutants in dissection of the role of the wild- type HrpA protein in various stages of type III translocation: protein exit across the bacterial cell wall, the assembly and/ or stabilization of the Hrp pilus in the extracellular space, and Hrp pilus-mediated long-distance transport beyond the bacterial cell wall.	Michigan State Univ, Dept Energy Plant Res Lab, E Lansing, MI 48824 USA; Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA; Natl Inst Agr Sci & Technol, Dept Plant Biol, Rural Dev Adm, Suwon 441707, South Korea	Michigan State University; Michigan State University; Michigan State University; Rural Development Administration (RDA), Republic of Korea	He, SY (corresponding author), Michigan State Univ, Dept Energy Plant Res Lab, 206 Plant Biol Bldg, E Lansing, MI 48824 USA.	hes@msu.edu	Lee, Yong Hoon/S-8079-2016	Lee, Yong Hoon/0000-0001-9921-3871; He, Sheng Yang/0000-0003-1308-498X				Badel JL, 2003, MOL MICROBIOL, V49, P1239, DOI 10.1046/j.1365-2958.2003.03647.x; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; Buttner D, 2002, EMBO J, V21, P5313, DOI 10.1093/emboj/cdf536; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Cordes FS, 2003, J BIOL CHEM, V278, P17103, DOI 10.1074/jbc.M300091200; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Craig L, 2003, MOL CELL, V11, P1139, DOI 10.1016/S1097-2765(03)00170-9; Daniell SJ, 2003, MOL MICROBIOL, V49, P301, DOI 10.1046/j.1365-2958.2003.03555.x; Ebel F, 1998, MOL MICROBIOL, V30, P147, DOI 10.1046/j.1365-2958.1998.01046.x; FLEGLER SL, 1993, SCANNING TRANSMISSIO, P43; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Guttman DS, 2001, MOL PLANT MICROBE IN, V14, P145, DOI 10.1094/MPMI.2001.14.2.145; Hazes B, 2000, J MOL BIOL, V299, P1005, DOI 10.1006/jmbi.2000.3801; He SY, 2003, CURR OPIN MICROBIOL, V6, P15, DOI 10.1016/S1369-5274(02)00007-3; He SY, 1997, TRENDS MICROBIOL, V5, P489, DOI 10.1016/S0966-842X(97)01163-3; Hoiczyk E, 2001, P NATL ACAD SCI USA, V98, P4669, DOI 10.1073/pnas.071065798; HUYNH TV, 1989, SCIENCE, V245, P1374, DOI 10.1126/science.2781284; Jin QL, 2001, SCIENCE, V294, P2556, DOI 10.1126/science.1066397; Jin QL, 2001, MOL MICROBIOL, V40, P1129, DOI 10.1046/j.1365-2958.2001.02455.x; Journet L, 2003, SCIENCE, V302, P1757, DOI 10.1126/science.1091422; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Keizer DW, 2001, J BIOL CHEM, V276, P24186, DOI 10.1074/jbc.M100659200; Kimbrough TG, 2000, P NATL ACAD SCI USA, V97, P11008, DOI 10.1073/pnas.200209497; Knutton S, 1998, EMBO J, V17, P2166, DOI 10.1093/emboj/17.8.2166; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li CM, 2002, EMBO J, V21, P1909, DOI 10.1093/emboj/21.8.1909; Marlovits TC, 2004, SCIENCE, V306, P1040, DOI 10.1126/science.1102610; Mudgett MB, 2000, P NATL ACAD SCI USA, V97, P13324, DOI 10.1073/pnas.230450797; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; Roine E, 1997, FEBS LETT, V417, P168, DOI 10.1016/S0014-5793(97)01276-3; Roine E, 1997, P NATL ACAD SCI USA, V94, P3459, DOI 10.1073/pnas.94.7.3459; Romantschuk M, 2001, EUR J PLANT PATHOL, V107, P153, DOI 10.1023/A:1011235101437; Samatey FA, 2001, NATURE, V410, P331, DOI 10.1038/35066504; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sauer FG, 2002, CELL, V111, P543, DOI 10.1016/S0092-8674(02)01050-4; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; SCHWEIZER HP, 1991, GENE, V97, P109, DOI 10.1016/0378-1119(91)90016-5; Sekiya K, 2001, P NATL ACAD SCI USA, V98, P11638, DOI 10.1073/pnas.191378598; Taira S, 1999, MOL MICROBIOL, V34, P736, DOI 10.1046/j.1365-2958.1999.01635.x; Tamano K, 2000, EMBO J, V19, P3876, DOI 10.1093/emboj/19.15.3876; Van Gijsegem F, 2000, MOL MICROBIOL, V36, P249, DOI 10.1046/j.1365-2958.2000.01851.x; Van Gijsegem F, 2002, MOL MICROBIOL, V44, P935, DOI 10.1046/j.1365-2958.2002.02936.x; Wei WS, 2000, P NATL ACAD SCI USA, V97, P2247, DOI 10.1073/pnas.040570097; Yip CK, 2005, NAT STRUCT MOL BIOL, V12, P75, DOI 10.1038/nsmb879; Yonekura K, 2003, NATURE, V424, P643, DOI 10.1038/nature01830; Zwiesler-Vollick J, 2002, MOL MICROBIOL, V45, P1207, DOI 10.1046/j.1365-2958.2002.02964.x	47	12	15	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21409	21417		10.1074/jbc.M500972200	http://dx.doi.org/10.1074/jbc.M500972200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797867	hybrid			2022-12-27	WOS:000229438800061
J	Liszt, G; Ford, E; Kurtev, M; Guarente, L				Liszt, G; Ford, E; Kurtev, M; Guarente, L			Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; LIFE-SPAN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HISTONE DEACETYLATION; TRANSCRIPTION FACTORS; PROTEIN DEACETYLASES; SIR2-LIKE PROTEINS; NAD; RIBOSYLATION	Members of the Sir2 family of NAD-dependent protein deacetylases regulate diverse cellular processes including aging, gene silencing, and cellular differentiation. Here, we report that the distant mammalian Sir2 homolog SIRT6 is a broadly expressed, predominantly nuclear protein. Northern analysis of embryonic samples and multiple adult tissues revealed mouse SIRT6 (mSIRT6) mRNA peaks at day E11, persisting into adulthood in all eight tissues examined. At the protein level, mSIRT6 was readily detectable in the same eight tissue types, with the highest levels in muscle, brain, and heart. Subcellular localization studies using both C- and N- terminal green fluorescent protein fusion proteins showed mSIRT6- green fluorescent protein to be a predominantly nuclear protein. Indirect immunofluorescence using antibodies to two different mSIRT6 epitopes confirmed that endogenous mSIRT6 is also largely nuclear. Consistent with previous findings, we did not observe any NAD(+)- dependent protein deacetylase activity in preparations of mSIRT6. However, purified recombinant mSIRT6 did catalyze the robust transfer of radio-label from [P-32] NAD to mSIRT6. Two highly conserved residues within the catalytic core of the protein were required for this reaction. This reaction is most likely mono-ADP-ribosylation because only the modified form of the protein was recognized by an antibody specific to mono- ADP- ribose. Surprisingly, we observed that the catalytic mechanism of this reaction is intra-molecular, with individual molecules of mSIRT6 directing their own modification. These results provide the first characterization of a Sir2 protein from phylogenetic class IV.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave,Rm 68-280, Cambridge, MA 02139 USA.	leng@mit.edu						Armstrong CM, 2002, MOL BIOL CELL, V13, P1427, DOI 10.1091/mbc.01-10-0482; Bitterman KJ, 2003, MICROBIOL MOL BIOL R, V67, P376, DOI 10.1128/MMBR.67.3.376-399.2003; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Corda D, 2003, EMBO J, V22, P1953, DOI 10.1093/emboj/cdg209; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Itoga M, 1997, J BIOCHEM-TOKYO, V121, P1041; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; KAIN SR, 1994, BIOTECHNIQUES, V17, P982; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; MEYER T, 1986, EUR J BIOCHEM, V155, P157, DOI 10.1111/j.1432-1033.1986.tb09471.x; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Riese MJ, 2002, J BIOL CHEM, V277, P12082, DOI 10.1074/jbc.M109039200; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Sauve AA, 2004, CURR MED CHEM, V11, P807, DOI 10.2174/0929867043455675; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Weng BY, 1999, J BIOL CHEM, V274, P31797, DOI 10.1074/jbc.274.45.31797; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382	31	419	439	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21313	21320		10.1074/jbc.M413296200	http://dx.doi.org/10.1074/jbc.M413296200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15795229	hybrid			2022-12-27	WOS:000229438800049
J	Hausmann, S; Zheng, SS; Fabrega, C; Schneller, SW; Lima, CD; Shuman, S				Hausmann, S; Zheng, SS; Fabrega, C; Schneller, SW; Lima, CD; Shuman, S			Encephalitozoon cuniculi mRNA cap (guanine N-7) methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; STABLE NITROGEN ANALOGS; METHYL ACCEPTOR SITE; VACCINIA VIRUS; CAPPING ENZYME; SACCHAROMYCES-CEREVISIAE; SUBUNIT ASSOCIATION; ESCHERICHIA-COLI; (GUANINE-7-)METHYLTRANSFERASE; APPARATUS	The Encephalitozoon cuniculi mRNA cap ( guanine N-7) methyltransferase Ecm1 has been characterized structurally but not biochemically. Here we show that purified Ecm1 is a monomeric protein that catalyzes methyl transfer from S-adenosylmethionine ( AdoMet) to GTP. The reaction is cofactor-independent and optimal at pH 7.5. Ecm1 also methylates GpppA, GDP, and dGTP but not ATP, CTP, UTP, ITP, or m(7)GTP. The affinity of Ecm1 for the cap dinucleotide GpppA (K-m 0.1 mM) is higher than that for GTP ( Km 1 mM) or GDP (K-m 2.4 mM). Methylation of GTP by Ecm1 in the presence of 5 mu M AdoMet is inhibited by the reaction product AdoHcy (IC50 4 mu M) and by substrate analogs sinefungin (IC50 1.5 mu M), aza-AdoMet (IC50 100 mu M), and carbocyclic aza-AdoMet (IC50 35 mu M). The crystal structure of an Ecm1(.)aza-AdoMet binary complex reveals that the inhibitor occupies the same site as AdoMet. Structure-function analysis of Ecm1 by alanine scanning and conservative substitutions identified functional groups necessary for methyltransferase activity in vivo. Amino acids Lys-54, Asp-70, Asp-78, and Asp-94, which comprise the AdoMet-binding site, and Phe-141, which contacts the cap guanosine, are essential for cap methyltransferase activity in vitro.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10021 USA; Auburn Univ, Dept Chem & Biochem, Auburn, AL 36849 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Auburn University System; Auburn University	Shuman, S (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Fabrega, Carme/AAZ-5469-2021; Fàbrega, MCarme/K-9847-2014	Fàbrega, MCarme/0000-0003-3816-7634; Lima, Christopher/0000-0002-9163-6092	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI056540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470, R01GM061906] Funding Source: NIH RePORTER; NIAID NIH HHS [AI56540] Funding Source: Medline; NIGMS NIH HHS [GM61906, GM52470] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBOSA E, 1978, J BIOL CHEM, V253, P7692; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; CONG PJ, 1992, J BIOL CHEM, V267, P16424; Fabrega C, 2004, MOL CELL, V13, P77, DOI 10.1016/S1097-2765(03)00522-7; Ghosh AK, 1996, J ORG CHEM, V61, P6175, DOI 10.1021/jo960670g; Hausmann S, 2002, J BIOL CHEM, V277, P96, DOI 10.1074/jbc.M109649200; HIGMAN MA, 1994, J BIOL CHEM, V269, P14974; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; HIGMAN MA, 1994, J BIOL CHEM, V269, P14982; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LIU S, 1992, ANTIVIR RES, V19, P247, DOI 10.1016/0166-3542(92)90083-H; MAO XD, 1994, J BIOL CHEM, V269, P24472; Mao XD, 1996, BIOCHEMISTRY-US, V35, P6900, DOI 10.1021/bi960221a; MAO XD, 1995, MOL CELL BIOL, V15, P4167; Mao XD, 1996, MOL CELL BIOL, V16, P475; MARTIN SA, 1975, J BIOL CHEM, V250, P9330; MARTIN SA, 1976, J BIOL CHEM, V251, P7313; MINNICK AA, 1988, J ORG CHEM, V53, P4952, DOI 10.1021/jo00256a010; NILES EG, 1994, BIOCHEMISTRY-US, V33, P9898, DOI 10.1021/bi00199a011; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pillutla RC, 1998, J BIOL CHEM, V273, P21443, DOI 10.1074/jbc.273.34.21443; PUGH CSG, 1978, J BIOL CHEM, V253, P4075; REICH NO, 1990, J BIOL CHEM, V265, P8966; Saha N, 1999, J BIOL CHEM, V274, P16553, DOI 10.1074/jbc.274.23.16553; Schwer B, 2000, GENETICS, V155, P1561; Shuman S, 2001, COLD SPRING HARB SYM, V66, P301, DOI 10.1101/sqb.2001.66.301; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; Takata Y, 2003, BIOCHEMISTRY-US, V42, P8394, DOI 10.1021/bi034245a; Thompson MJ, 1996, CHEM COMMUN, P791, DOI 10.1039/cc9960000791; Thompson MJ, 1999, J ORG CHEM, V64, P7467, DOI 10.1021/jo9907742; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V251, P27, DOI 10.1006/bbrc.1998.9402; Wang SP, 1997, J BIOL CHEM, V272, P14683, DOI 10.1074/jbc.272.23.14683; Yamada-Okabe T, 1999, MICROBIOL-UK, V145, P3023, DOI 10.1099/00221287-145-11-3023; Yang MM, 2004, J ORG CHEM, V69, P3993, DOI 10.1021/jo040119g	35	31	33	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20404	20412		10.1074/jbc.M501073200	http://dx.doi.org/10.1074/jbc.M501073200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15760890	hybrid			2022-12-27	WOS:000229242000032
J	Pyo, JO; Jang, MH; Kwon, YK; Lee, HJ; Jun, JIL; Woo, HN; Cho, DH; Choi, B; Lee, H; Kim, JH; Mizushima, N; Oshumi, Y; Jung, YK				Pyo, JO; Jang, MH; Kwon, YK; Lee, HJ; Jun, JIL; Woo, HN; Cho, DH; Choi, B; Lee, H; Kim, JH; Mizushima, N; Oshumi, Y; Jung, YK			Essential roles of Atg5 and FADD in autophagic cell death - Dissection of autophagic cell death into vacuole formation and cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; CARDIOMYOPATHY; MYOPATHY	Autophagic cell death is characterized by the accumulation of vacuoles in physiological and pathological conditions. However, its molecular event is unknown. Here, we show that Atg5, which is known to function in autophagy, contributes to autophagic cell death by interacting with Fas-associated protein with death domain ( FADD). Down-regulation of Atg5 expression in HeLa cells suppresses cell death and vacuole formation induced by IFN-gamma. Inversely, ectopic expression of Atg5 using adenoviral delivery induces autophagic cell death. Deletion mapping analysis indicates that procell death activity resides in the middle and C-terminal region of Atg5. Cells harboring the accumulated vacuoles triggered by IFN-gamma or Atg5 expression become dead, and vacuole formation precedes cell death. 3-Methyladenine or expression of Atg5(K130R) mutant blocks both cell death and vacuole formation triggered by IFN-gamma, whereas benzyloxycarbonyl-VAD-fluoromethyl ketone (Z-VAD-fmk) inhibits only cell death but not vacuole formation. Atg5 interacts with FADD via death domain in vitro and in vivo, and the Atg5-mediated cell death, but not vacuole formation, is blocked in FADD-deficient cells. These results suggest that Atg5 plays a crucial role in IFN-gamma-induced autophagic cell death by interacting with FADD.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Ulsan Med Sch, Seoul 138736, South Korea; Yonsei Med Sch, Seoul 120749, South Korea; Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan	Gwangju Institute of Science & Technology (GIST); University of Ulsan; Yonsei University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Jung, YK (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Kwangju 500712, South Korea.	ykjung@gist.ac.kr	Ohsumi, Yoshinori/C-6449-2009; Mizushima, Noboru/C-3635-2009; Lee, Ho-June/D-8855-2014	Ohsumi, Yoshinori/0000-0003-2384-2166; Mizushima, Noboru/0000-0002-6258-6444; Lee, Ho-June/0000-0002-7019-2533; Woo, Ha-Na/0000-0002-6771-8151; Jung, Yong-Keun/0000-0002-9686-3120				Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Bursch W, 2000, J CELL SCI, V113, P1189; CATALSO AM, 1995, NEURON, V3, P671; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Choi YH, 2001, J BIOL CHEM, V276, P25073, DOI 10.1074/jbc.M102941200; Cohen O, 1999, J CELL BIOL, V146, P141; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Lee CY, 2003, CURR BIOL, V13, P350, DOI 10.1016/S0960-9822(03)00085-X; Lee CY, 2002, DEV BIOL, V250, P101, DOI 10.1006/dbio.2002.0784; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; SELGEN PO, 1982, P NATL ACAD SCI USA, V79, P1889; Song S, 2003, MOL CELL, V12, P553, DOI 10.1016/j.molcel.2003.08.005; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Yamamoto A, 2001, NEUROLOGY, V57, P903, DOI 10.1212/WNL.57.5.903; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; ZAKERI Z, 1995, CELL DEATH DIFFER, V2, P87	29	449	471	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20722	20729		10.1074/jbc.M413934200	http://dx.doi.org/10.1074/jbc.M413934200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15778222	hybrid			2022-12-27	WOS:000229242000070
J	Roybal, CN; Hunsaker, LA; Barbash, O; Jagt, DLV; Abcouwer, SF				Roybal, CN; Hunsaker, LA; Barbash, O; Jagt, DLV; Abcouwer, SF			The oxidative stressor arsenite activates vascular endothelial growth factor mRNA transcription by an ATF4-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; CHOROIDAL NEOVASCULAR MEMBRANES; ENDOPLASMIC-RETICULUM STRESS; FACTOR EXPRESSION; MACULAR DEGENERATION; MAMMALIAN-CELLS; SODIUM ARSENITE; HEME OXYGENASE; KINASE; ATF4	Aberrant retinal expression of vascular endothelial growth factor (VEGF) leading to neovascularization is a central feature of age-related macular degeneration and diabetic retinopathy, two leading causes of vision loss. Oxidative stress is suggested to occur in retinal tissue during age-related macular degeneration and diabetic retinopathy and is suspected in the mechanism of VEGF expression in these diseases. Arsenite, a thiol-reactive oxidative stressor, induces VEGF expression by a HIF-1 alpha-independent mechanism. Previously, we demonstrated that homocysteine, an endoplasmic reticulum stressor, increases VEGF transcription by a mechanism dependent upon activating transcription factor ATF4. Because ATF4 is expressed in response to oxidative stress, we hypothesized that ATF4 was also responsible for increased VEGF transcription in response to arsenite. We now show that arsenite increased steady state levels of VEGF mRNA and activated transcription from a VEGF promoter construct. Arsenite induced eIF2 alpha phosphorylation, resulting in increased ATF4 protein levels. Inactivation or loss of ATF4 greatly diminished the VEGF response to arsenite treatment. Overexpression of ATF4 was sufficient to activate the VEGF promoter, and arsenite cooperated with exogenous ATF4 to further activate the promoter. A complex containing ATF4 binds a DNA element at +1767 bp relative to the VEGF transcription start site, and DNA binding activity is increased by arsenite treatment. In addition, the ability of a thiol antioxidant, N-acetylcysteine, to inhibit the effect of arsenite on VEGF expression coincided with its ability to inhibit phosphorylation of eIF2 alpha and ATF4 protein expression. Thus, arsenite-induced up-regulation of VEGF gene transcription occurs by an ATF4-dependent mechanism.	Univ New Mexico, Dept Biochem & Mol Biol, Sch Med, Albuquerque, NM 87131 USA	University of New Mexico	Abcouwer, SF (corresponding author), Univ New Mexico, Dept Biochem & Mol Biol, Sch Med, MSC08-4670,1, Albuquerque, NM 87131 USA.	sabcouwer@salud.unm.edu		Abcouwer, Steven F/0000-0003-2580-1288	NATIONAL EYE INSTITUTE [R03EY013695, F31EY014535] Funding Source: NIH RePORTER; NEI NIH HHS [EY13695, EY014535] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abcouwer SF, 1999, J BIOL CHEM, V274, P28645, DOI 10.1074/jbc.274.40.28645; Brostrom CO, 1996, J BIOL CHEM, V271, P24995, DOI 10.1074/jbc.271.40.24995; CHANG LS, 1984, VIROLOGY, V133, P341, DOI 10.1016/0042-6822(84)90400-8; DUNCAN RF, 1987, ARCH BIOCHEM BIOPHYS, V256, P651, DOI 10.1016/0003-9861(87)90622-9; Duyndam MCA, 2003, J BIOL CHEM, V278, P6885, DOI 10.1074/jbc.M206320200; Duyndam MCA, 2001, J BIOL CHEM, V276, P48066, DOI 10.1074/jbc.M106282200; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Goldstein M, 2004, EYE, V18, P460, DOI 10.1038/sj.eye.6700702; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; Ji C, 2004, WORLD J GASTROENTERO, V10, P1699; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kevil CG, 1997, BIOCHEM BIOPH RES CO, V238, P277, DOI 10.1006/bbrc.1997.7284; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; Li WY, 1999, CELL MOL BIOL, V45, P59; Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466; McEwen E, 2005, J BIOL CHEM, V280, P16925, DOI 10.1074/jbc.M412882200; Obrosova IG, 2001, DIABETOLOGIA, V44, P1102, DOI 10.1007/s001250100631; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Ord D, 2003, EXP CELL RES, V286, P308, DOI 10.1016/S0014-4827(03)00070-3; Roybal CN, 2004, J BIOL CHEM, V279, P14844, DOI 10.1074/jbc.M312948200; SARDANA MK, 1981, PHARMACOLOGY, V23, P247, DOI 10.1159/000137557; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7	36	100	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20331	20339		10.1074/jbc.M411275200	http://dx.doi.org/10.1074/jbc.M411275200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788408	hybrid			2022-12-27	WOS:000229242000023
J	van den Born, J; Salmivirta, K; Henttinen, T; Ostman, N; Ishimaru, T; Miyaura, S; Yoshida, K; Salmivirta, M				van den Born, J; Salmivirta, K; Henttinen, T; Ostman, N; Ishimaru, T; Miyaura, S; Yoshida, K; Salmivirta, M			Novel heparan sulfate structures revealed by monoclonal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; SEQUENCE-ANALYSIS; DOMAIN-STRUCTURE; PROTEOGLYCANS; EXPRESSION; BINDING; GROWTH-FACTOR-2; 2-O-SULFATION; GLYPICAN-1; DIVERSITY	The sulfated glycosaminoglycan heparan sulfate (HS) is found ubiquitously on cell surfaces, in the extracellular matrix, and intracellularly as HS proteoglycans. Because of the structural heterogeneity of HS, tissue-derived HS preparations represent a mixture of HS chains originating from different cell types and tissue loci. Monoclonal anti-HS antibodies have been employed to detect the localization of specific HS epitopes in tissues, but limited information has been available on the saccharide structures recognized by the antibodies. We have studied the saccharide epitope structures of four anti-HS antibodies, HepSS1, JM13, JM403, and 10E4, which all recognize distinct HS species as demonstrated by different patterns of immunoreactivity upon staining of embryonic rat and adult human tissues. The epitopes recognized by JM13 and HepSS1 were found almost exclusively in basement membrane HS, whereas JM403 and 10E4 reacted also with cell-associated HS species. The binding of HepSS1, JM403, and 10E4 to HS was dependent on the GlcN N-substitution of the polysaccharide rather than O-sulfation. HepSS1 thus interacted with N-sulfated HS domains, JM403 binding was critically dependent on N-unsubstituted GlcN residues, and 10E4 bound to "mixed" HS domains containing both N-acetylated and N-sulfated disaccharide units. By contrast, JM13 binding seemed to require the presence of 2-O-sulfated glucuronic acid residues.	Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Seikagaku Corp, Cent Res Labs, Tokyo 2070021, Japan; Vrije Univ Amsterdam, Med Ctr, Dept Mol Cell Biol & Immunol, NL-1007 MB Amsterdam, Netherlands; Uppsala Univ, Dept Anim Physiol, SE-75123 Uppsala, Sweden; Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; Natl Publ Hlth Inst, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University; Seikagaku Corporation; Vrije Universiteit Amsterdam; Uppsala University; University of Turku; Finland National Institute for Health & Welfare	Salmivirta, M (corresponding author), Univ Turku, Turku Ctr Biotechnol, Tykistokatu 6, FIN-20520 Turku, Finland.	markku.salmivirta@btk.fi						Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Cheng F, 2002, J BIOL CHEM, V277, P44431, DOI 10.1074/jbc.M205241200; Conrad H. E., 1998, HEPARIN BINDING PROT; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; Friedl A, 1997, AM J PATHOL, V150, P1443; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; IVERIUS PH, 1971, BIOCHEM J, V124, P677, DOI 10.1042/bj1240677; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; KURE S, 1986, J IMMUNOL, V137, P3900; Leteux C, 2001, J BIOL CHEM, V276, P12539, DOI 10.1074/jbc.M010291200; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Loo BM, 2001, J BIOL CHEM, V276, P16868, DOI 10.1074/jbc.M011226200; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Mani K, 2004, GLYCOBIOLOGY, V14, P599, DOI 10.1093/glycob/cwh067; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; Pikas DS, 2000, BIOCHEMISTRY-US, V39, P4552, DOI 10.1021/bi992524l; Rong JH, 2000, BIOCHEM J, V346, P463, DOI 10.1042/0264-6021:3460463; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Safaiyan F, 1999, J BIOL CHEM, V274, P36267, DOI 10.1074/jbc.274.51.36267; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Thesleff I, 2003, J CELL SCI, V116, P1647, DOI 10.1242/jcs.00410; Thesleff I, 2001, Adv Dent Res, V15, P14; Thesleff I, 2002, INT REV CYTOL, V217, P93; Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499; Turnbull JE, 1999, P NATL ACAD SCI USA, V96, P2698, DOI 10.1073/pnas.96.6.2698; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; VANDENBORN J, 1992, KIDNEY INT, V41, P115, DOI 10.1038/ki.1992.15; VANDENBORN J, 1991, LAB INVEST, V65, P287; Vives RR, 1999, BIOCHEM J, V339, P767, DOI 10.1042/0264-6021:3390767; Westling C, 2002, J BIOL CHEM, V277, P49247, DOI 10.1074/jbc.M209139200; Yip GW, 2002, DEVELOPMENT, V129, P2109	37	97	98	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20516	20523		10.1074/jbc.M502065200	http://dx.doi.org/10.1074/jbc.M502065200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15778504	hybrid, Green Published			2022-12-27	WOS:000229242000045
J	Bazzini, C; Vezzoli, V; Sironi, C; Dossena, S; Ravasio, A; De Biasi, S; Garavaglia, ML; Rodighiero, S; Meyer, G; Fascio, U; Furst, J; Ritter, M; Botta, G; Paulmichl, M				Bazzini, C; Vezzoli, V; Sironi, C; Dossena, S; Ravasio, A; De Biasi, S; Garavaglia, ML; Rodighiero, S; Meyer, G; Fascio, U; Furst, J; Ritter, M; Botta, G; Paulmichl, M			Thiazide-sensitive NaCl-cotransporter in the intestine possible role of hydrochlorothiazide in the intestinal Ca2+ uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT GALLBLADDER EPITHELIUM; SODIUM-CHLORIDE COTRANSPORTER; MONOVALENT CATION CURRENTS; CL-COTRANSPORTER; STRONTIUM TRANSPORT; CALCIUM-ABSORPTION; GITELMANS-SYNDROME; GENE-EXPRESSION; N-GLYCOSYLATION; MESSENGER-RNA	Thiazides, such as hydrochlorothiazide (HCTZ), are used to control blood pressure and to reduce renal calcium excretion. These effects are a result of interactions with the NaCl-cotransporter (NCC). This is demonstrated by the fact that mutations within the NCC protein lead to salt-resistant hypotension and hypocalciuria, paralleled by an increase in bone mineral density. These symptoms are also known as Gitelman syndrome. It has become increasingly evident that the effect of HCTZ on blood pressure and calcium homeostasis cannot be attributed exclusively to kidney functions, where the primary action of HCTZ on NCC is postulated to occur. We demonstrated the presence of the NCC transporter in the rat small intestine (ileum and jejunum) and human HT-29 cells, by using reverse transcription-PCR, Northern blot, Western blot, and immunofluorescence. Furthermore, we show that HCTZ modulates Ca2+ uptake by intestinal cells, while affecting the electrical parameters of the cellular membrane, thus suggesting a functional interaction between NCC and the epithelial voltage-dependent calcium channel. The experiments presented here support the hypothesis of a direct involvement of the intestinal cells in the interaction between HCTZ and NaCl, as well as calcium homeostasis.	Univ Milan, Dept Biomol Sci & Biotechnol, I-20133 Milan, Italy; Innsbruck Med Univ, Dept Physiol & Med Phys, A-6020 Innsbruck, Austria; Ctr Interdipartimentale Microscopia Aranzata, I-20133 Milan, Italy; Ctr Interdisciplinare Mat & Interface Nanostrutur, I-20133 Milan, Italy; Paracelsus Private Med Univ, A-5020 Salzburg, Austria	University of Milan; Medical University of Innsbruck; Paracelsus Private Medical University	Botta, G (corresponding author), Univ Milan, Dept Biomol Sci & Biotechnol, Via Celoria 26, I-20133 Milan, Italy.	guido.botta@unimi.it; markus.paulmichl@unimi.it	Rodighiero, Simona/AAP-9816-2020; Ritter, Markus/AAG-4987-2020; Ravasio, Andrea/H-6722-2012; Ravasio, Andrea/G-6167-2011; Dossena, Silvia/G-1437-2018; Garavaglia, Maria Lisa/AFV-3214-2022; Bazzini, Claudia/G-8214-2011; Meyer, Giuliano/G-8062-2011	Ritter, Markus/0000-0001-7346-7750; Ravasio, Andrea/0000-0001-7835-5133; Rodighiero, Simona/0000-0003-4236-7823; Vezzoli, Valeria/0000-0001-6396-7284				Abuladze N, 1998, J AM SOC NEPHROL, V9, P819; Aubin R, 1996, KIDNEY INT, V50, P1476, DOI 10.1038/ki.1996.461; Barley NF, 2001, AM J PHYSIOL-GASTR L, V280, pG285, DOI 10.1152/ajpgi.2001.280.2.G285; Barry ELR, 1998, J MEMBRANE BIOL, V161, P55, DOI 10.1007/s002329900314; Barry ELR, 1997, AM J PHYSIOL-CELL PH, V272, pC109, DOI 10.1152/ajpcell.1997.272.1.C109; BERNSTEIN PL, 1995, J AM SOC NEPHROL, V6, P732; Bostonjoglo M, 1998, J AM SOC NEPHROL, V9, P1347; Bouillon R, 2003, J CELL BIOCHEM, V88, P332, DOI 10.1002/jcb.10360; Bronner F, 1998, J NUTR, V128, P917, DOI 10.1093/jn/128.5.917; Chang HI, 1996, BIOCHEM BIOPH RES CO, V223, P324, DOI 10.1006/bbrc.1996.0893; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; CREMASCHI D, 1994, J MEMBRANE BIOL, V141, P29; CREMASCHI D, 1995, J MEMBRANE BIOL, V147, P159; Cremaschi D, 2000, J MEMBRANE BIOL, V176, P53, DOI 10.1007/s002320001075; De Jong JC, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017904.77985.03; Delpire E, 2002, ANNU REV PHYSIOL, V64, P803, DOI 10.1146/annurev.physiol.64.081501.155847; DONATH A, 1970, HELV PAEDIATR ACTA, V25, P293; DONATH A, 1971, ISRAEL J MED SCI, V7, P393; Ellison DH, 2000, AM J PHYSIOL-RENAL, V279, pF616, DOI 10.1152/ajprenal.2000.279.4.F616; Friedman PA, 2000, EXP NEPHROL, V8, P343; GALL MA, 1992, AM J HYPERTENS, V5, P257, DOI 10.1093/ajh/5.5.257; Gamba G, 2001, AM J PHYSIOL-RENAL, V281, pF781, DOI 10.1152/ajprenal.2001.281.5.F781; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gawenis LR, 2002, AM J PHYSIOL-GASTR L, V282, pG776, DOI 10.1152/ajpgi.00297.2001; GESEK FA, 1992, J CLIN INVEST, V90, P429, DOI 10.1172/JCI115878; Hodin RA, 1996, CELL GROWTH DIFFER, V7, P647; Hoenderop JGJ, 2000, J AM SOC NEPHROL, V11, P1171, DOI 10.1681/ASN.V1171171; Hoenderop JGJ, 2002, BBA-PROTEINS PROTEOM, V1600, P6, DOI 10.1016/S1570-9639(02)00438-7; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hoenderop JGJ, 2002, ANNU REV PHYSIOL, V64, P529, DOI 10.1146/annurev.physiol.64.081501.155921; Hoover RS, 2003, J AM SOC NEPHROL, V14, P271, DOI 10.1097/01.ASN.0000043903.93452.D0; JORGENSEN FS, 1974, ACTA MED SCAND, V195, P33; Kumar V, 2003, BBA-MOL BASIS DIS, V1639, P185, DOI 10.1016/j.bbadis.2003.09.006; LaCroix AZ, 2000, ANN INTERN MED, V133, P516, DOI 10.7326/0003-4819-133-7-200010030-00010; Loffing J, 2001, AM J PHYSIOL-RENAL, V281, pF1021, DOI 10.1152/ajprenal.0085.2001; MacKenzie S, 2001, BIOCHEM BIOPH RES CO, V282, P991, DOI 10.1006/bbrc.2001.4673; Matthews JB, 1998, J CLIN INVEST, V101, P2072, DOI 10.1172/JCI1042; Meyer G, 1997, CELL MOL LIFE SCI, V53, P769, DOI 10.1007/s000180050097; Musch MW, 1998, PFLUG ARCH EUR J PHY, V436, P415, DOI 10.1007/s004240050651; Nijenhuis T, 2003, KIDNEY INT, V64, P555, DOI 10.1046/j.1523-1755.2003.00128.x; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; Nilius B, 2001, BRIT J PHARMACOL, V134, P453, DOI 10.1038/sj.bjp.0704272; Orsenigo MN, 1997, J MEMBRANE BIOL, V158, P257, DOI 10.1007/s002329900262; Peng JB, 2003, NEWS PHYSIOL SCI, V18, P158, DOI 10.1152/nips.01440.2003; Pickkers P, 1999, HYPERTENSION, V33, P1043, DOI 10.1161/01.HYP.33.4.1043; Plotkin MD, 1996, KIDNEY INT, V50, P174, DOI 10.1038/ki.1996.300; Reilly RF, 2000, PHYSIOL REV, V80, P277, DOI 10.1152/physrev.2000.80.1.277; Rejnmark L, 2001, J INTERN MED, V250, P144, DOI 10.1046/j.1365-2796.2001.00868.x; Rottingen JA, 2000, ACTA PHYSIOL SCAND, V169, P203; Schmieder S, 2001, BIOCHEM BIOPH RES CO, V286, P635, DOI 10.1006/bbrc.2001.5407; Schultheis PJ, 1998, J BIOL CHEM, V273, P29150, DOI 10.1074/jbc.273.44.29150; Sebastian A, 2000, AM J MED, V109, P429, DOI 10.1016/S0002-9343(00)00582-9; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; SUNDARAM U, 1991, AM J PHYSIOL, V260, pG440, DOI 10.1152/ajpgi.1991.260.3.G440; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; Tosco M, 2002, CELL PHYSIOL BIOCHEM, V12, P9, DOI 10.1159/000047822; TSIEN RY, 1985, CELL CALCIUM, V6, P145, DOI 10.1016/0143-4160(85)90041-7; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Vidyasagar S, 2002, J PHYSIOL-LONDON, V539, P163, DOI 10.1113/jphysiol.2001.013056; YENDT ER, 1965, T AM CLIN CLIMAT ASS, V77, P96; Zhuang LY, 2002, LAB INVEST, V82, P1755, DOI 10.1097/01.LAB.0000043910.41414.E7	61	33	35	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19902	19910		10.1074/jbc.M411961200	http://dx.doi.org/10.1074/jbc.M411961200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15781471	hybrid			2022-12-27	WOS:000229113700060
J	Lu, T; Hong, MP; Lee, HC				Lu, T; Hong, MP; Lee, HC			Molecular determinants of cardiac K-ATP channel activation by epoxyeicosatrienoic acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; BINDING-SITE; 11,12-EPOXYEICOSATRIENOIC ACID; ARACHIDONIC-ACID; SMOOTH-MUSCLE; C-TERMINUS; INHIBITION; KIR6.2; CYTOCHROME-P450; IDENTIFICATION	We have previously reported that epoxyeicosatrienoic acids (EETs), the cytochrome P450 epoxygenase metabolites of arachidonic acid, are potent stereospecific activators of the cardiac K-ATP channel. The epoxide group in EET is critical for reducing channel sensitivity to ATP, thereby activating the channel. This study is to identify the molecular sites on the K-ATP channels for EET-mediated activation. We investigated the effects of EETs on Kir6.2 Delta C26 with or without the coexpression of SUR2A and on Kir6.2 mutants of positively charged residues known to affect channel activity coexpressed with SUR2A in HEK293 cells. The ATP IC50 values were significantly increased in Kir6.2 R27A, R50A, K185A, and R201A but not in R16A, K47A, R54A, K67A, R192A, R195A, K207A, K222A, and R314A mutants. Similar to native cardiac KATP channel, 5 mu M 11,12-EET increased the ATP IC50 by 9.6-fold in Kir6.2/SUR2A wild type and 8.4-fold in Kir6.2 Delta C26. 8,9- and 14,15-EET regioisomers activated the Kir6.2 channel as potently as 11,12-EET. 8,9- and 11,12-EET failed to change the ATP sensitivity of Kir6.2 K185A, R195A, and R201A, whereas their effects were intact in the other mutants. 14,15-EET had a similar effect with K185A and R201A mutants, but instead of R195A, it failed to activate Kir6.2R192A. These results indicate that activation of Kir6.2 by EETs does not require the SUR2A subunit, and the region in the Kir6.2 C terminus from Lys-185 to Arg-201 plays a critical role in EET-mediated Kir6.2 channel activation. Based on computer modeling of the Kir6.2 structure, we infer that the EET-Kir6.2 interaction may allosterically change the ATP binding site on Kir6.2, reducing the channel sensitivity to ATP.	Mayo Clin, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN 55905 USA	Mayo Clinic	Lu, T (corresponding author), Mayo Clin, Dept Med, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.	Lu.tong@mayo.edu	Hong, Min Pyo/B-5337-2008; Lu, Tong/A-7745-2009	Lu, Tong/0000-0002-2393-7643	NHLBI NIH HHS [HL-63754, R01 HL063754, HL-74180] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063754, R56HL074180, R01HL074180] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; Antcliff JF, 2005, EMBO J, V24, P229, DOI 10.1038/sj.emboj.7600487; Archer SL, 2003, CIRCULATION, V107, P769, DOI 10.1161/01.CIR.0000047278.28407.C2; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; Bienengraeber M, 2004, NAT GENET, V36, P382, DOI 10.1038/ng1329; Campbell WB, 2000, TRENDS PHARMACOL SCI, V21, P125, DOI 10.1016/S0165-6147(00)01472-3; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; Cukras CA, 2002, J GEN PHYSIOL, V119, P581, DOI 10.1085/jgp.20028562; Cukras CA, 2002, J GEN PHYSIOL, V120, P437, DOI 10.1085/jgp.20028621; Dabrowski M, 2004, J PHYSIOL-LONDON, V557, P347, DOI 10.1113/jphysiol.2003.059105; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Fox JEM, 2004, MOL ENDOCRINOL, V18, P679, DOI 10.1210/me.2003-0431; Gross GJ, 2003, AM J PHYSIOL-HEART C, V285, pH921, DOI 10.1152/ajpheart.00421.2003; Haruna T, 2000, PFLUG ARCH EUR J PHY, V441, P200, DOI 10.1007/s004240000428; Hodgson DM, 2003, EMBO J, V22, P1732, DOI 10.1093/emboj/cdg192; John SA, 2003, J PHYSIOL-LONDON, V552, P23, DOI 10.1113/jphysiol.2003.048843; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Lee HC, 1999, J PHYSIOL-LONDON, V519, P153, DOI 10.1111/j.1469-7793.1999.0153o.x; Li PL, 1997, CIRC RES, V80, P877; Lu T, 2002, MOL PHARMACOL, V62, P1076, DOI 10.1124/mol.62.5.1076; Lu T, 2001, J PHYSIOL-LONDON, V537, P811; Lu T, 2001, J PHYSIOL-LONDON, V534, P651, DOI 10.1111/j.1469-7793.2001.t01-1-00651.x; MacGregor GG, 2002, P NATL ACAD SCI USA, V99, P2726, DOI 10.1073/pnas.042688899; Nithipatikom K, 2001, ANAL BIOCHEM, V292, P115, DOI 10.1006/abio.2001.5044; Potente M, 2003, J BIOL CHEM, V278, P29619, DOI 10.1074/jbc.M305385200; Potente M, 2002, J BIOL CHEM, V277, P15671, DOI 10.1074/jbc.M110806200; Proks P, 1999, J PHYSIOL-LONDON, V514, P19, DOI 10.1111/j.1469-7793.1999.019af.x; Reimann F, 1999, J PHYSIOL-LONDON, V520, P661, DOI 10.1111/j.1469-7793.1999.00661.x; Ribalet B, 2003, BIOPHYS J, V84, P266, DOI 10.1016/S0006-3495(03)74847-4; Schulze D, 2003, J BIOL CHEM, V278, P10500, DOI 10.1074/jbc.M208413200; Schulze D, 2003, J PHYSIOL-LONDON, V552, P357, DOI 10.1113/jphysiol.2003.047035; Seino S, 2003, J DIABETES COMPLICAT, V17, P2, DOI 10.1016/S1056-8727(02)00274-X; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Suzuki M, 2003, CIRCULATION, V107, P682, DOI 10.1161/01.CIR.0000055187.67365.81; Suzuki M, 2001, CIRC RES, V88, P570, DOI 10.1161/01.RES.88.6.570; Trapp S, 2003, EMBO J, V22, P2903, DOI 10.1093/emboj/cdg282; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Vanoye CG, 2002, J BIOL CHEM, V277, P23260, DOI 10.1074/jbc.M112004200; Wu S, 1997, J BIOL CHEM, V272, P12551, DOI 10.1074/jbc.272.19.12551; Xiao YF, 1998, J PHYSIOL-LONDON, V508, P777, DOI 10.1111/j.1469-7793.1998.777bp.x; Zeldin DC, 2001, J BIOL CHEM, V276, P36059, DOI 10.1074/jbc.R100030200; Zhang YD, 2001, AM J PHYSIOL-HEART C, V280, pH2430, DOI 10.1152/ajpheart.2001.280.6.H2430; ZHU Y, 1995, HYPERTENSION, V25, P854, DOI 10.1161/01.HYP.25.4.854; Zingman LV, 2002, P NATL ACAD SCI USA, V99, P13278, DOI 10.1073/pnas.212315199	46	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19097	19104		10.1074/jbc.M414065200	http://dx.doi.org/10.1074/jbc.M414065200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15760904	hybrid			2022-12-27	WOS:000228932300066
J	Smith, D; Gray, J; Mitchell, L; Antholine, WE; Hosler, JP				Smith, D; Gray, J; Mitchell, L; Antholine, WE; Hosler, JP			Assembly of cytochrome-c oxidase in the absence of assembly protein Surf1p leads to loss of the active site heme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOBACTER-SPHAEROIDES; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL COX1P; PROTON UPTAKE; SUBUNIT-III; WILD-TYPE; YEAST; PURIFICATION; EXPRESSION	Surf1p is a protein of the inner membrane of mitochondria that functions in the assembly of cytochrome-c oxidase. The specifics of the role of Surf1p have remained unresolved. Numerous mutations in human Surf1p lead to severe mitochondrial disease. A homolog of human Surf1p is encoded by the genome of the alpha-proteobacterium Rhodobacter sphaeroides, which synthesizes a mitochondria-llike aa(3)-type cytochrome-c oxidase. The gene for Surf1p was deleted from the genome of R. sphaeroides. The resulting aa(3)-type oxidase was purified and analyzed by biochemical methods plus optical and EPR spectroscopy. The oxidase that assembled in the absence of Surf1p was composed of three subpopulations with structurally distinct heme a(3)-Cu-B active sites. 50% of the oxidase lacked heme a(3), 10-15% contained heme a3 but lacked Cu-B, and 35-40% had a normal heme (3)-Cu-B active site with normal activity. Cu-A assembly was unaffected. All of the oxidase contained low-spin heme a, but the environment of the heme a center was slightly altered in the 50% of the enzyme that lacked heme a3. Introduction of a normal copy of the gene for Surf1p on an exogenous plasmid resulted in a single population of normally assembled, highly active enzyme. The data indicate that Surf1p plays a role in facilitating the insertion of heme a3 into the active site of cytochrome-c oxidase. The results suggest that maturation of the heme a(3)-Cu-B center is a step that limits the association of subunits I and II in the assembly of mitochondrial cytochrome oxidase.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; Med Coll Wisconsin, Natl Biomed Esr Ctr, Dept Biophys, Milwaukee, WI 53226 USA	University of Mississippi; University of Mississippi Medical Center; Medical College of Wisconsin	Hosler, JP (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, 2500 N State St, Jackson, MS 39216 USA.	jhosler@biochem.umsmed.edu			NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB001980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056824] Funding Source: NIH RePORTER; NIBIB NIH HHS [EB001980] Funding Source: Medline; NIGMS NIH HHS [GM56824] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1976, BIOCHIM BIOPHYS ACTA, V422, P260, DOI 10.1016/0005-2744(76)90137-6; Agostino A, 2003, HUM MOL GENET, V12, P399, DOI 10.1093/hmg/ddg038; Barrientos A, 2004, EMBO J, V23, P3472, DOI 10.1038/sj.emboj.7600358; Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; Bratton MR, 1999, BIOCHEMISTRY-US, V38, P16236, DOI 10.1021/bi9914107; Bratton MR, 2000, BIOCHEMISTRY-US, V39, P12989, DOI 10.1021/bi0003083; Brown BM, 2004, BIOCHEMISTRY-US, V43, P13541, DOI 10.1021/bi048469k; CAO J, 1992, J BIOL CHEM, V267, P24273; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Choudhary M, 2004, J BACTERIOL, V186, P2019, DOI 10.1128/JB.186.7.2019-2027.2004; DONOHUE TJ, 1991, METHOD ENZYMOL, V204, P459; ERASO JM, 1994, J BACTERIOL, V176, P32, DOI 10.1128/JB.176.1.32-43.1994; GARCIAHORSMAN JA, 1994, BIOCHEMISTRY-US, V33, P3113, DOI 10.1021/bi00176a046; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Hiser L, 2001, J BIOL CHEM, V276, P45403, DOI 10.1074/jbc.M107016200; HOSLER JP, 1992, J BIOL CHEM, V267, P24264; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; Hunter DJB, 1997, FEBS LETT, V412, P43, DOI 10.1016/S0014-5793(97)00735-7; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Mashkevich G, 1997, J BIOL CHEM, V272, P14356, DOI 10.1074/jbc.272.22.14356; McEwan AG, 2002, FEBS LETT, V518, P10, DOI 10.1016/S0014-5793(02)02532-2; Mills DA, 2003, BIOCHEMISTRY-US, V42, P7410, DOI 10.1021/bi0341307; MITCHELL DM, 1995, FEBS LETT, V368, P148, DOI 10.1016/0014-5793(95)00626-K; MITCHELL DM, 1995, FEBS LETT, V374, P371, DOI 10.1016/0014-5793(95)01149-9; MITCHELL R, 1994, BBA-BIOENERGETICS, V1186, P19, DOI 10.1016/0005-2728(94)90130-9; MITCHELL R, 1995, BIOCHEMISTRY-US, V34, P7576, DOI 10.1021/bi00023a003; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; Nijtmans LGJ, 2001, FEBS LETT, V498, P46, DOI 10.1016/S0014-5793(01)02447-4; Pecina P, 2004, PHYSIOL RES, V53, pS213; Perez-Martinez X, 2003, EMBO J, V22, P5951, DOI 10.1093/emboj/cdg566; Rich P. R., 1997, BIOENERGETICS, P418, DOI [10.1007/978-3-0348-8994-0_10, DOI 10.1007/978-3-0348-8994-0_10]; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SHAPLEIGH JP, 1992, MOL MICROBIOL, V6, P635, DOI 10.1111/j.1365-2958.1992.tb01511.x; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STEVENS TH, 1982, J BIOL CHEM, V257, P2106; Svensson-Ek M, 2002, J MOL BIOL, V321, P329, DOI 10.1016/S0022-2836(02)00619-8; TWEEDLE MF, 1978, J BIOL CHEM, V253, P8065; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; VANNESTE WH, 1966, BIOCHEMISTRY-US, V5, P838, DOI 10.1021/bi00867a005; Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200; Zhen Y, 1998, PROTEIN EXPRES PURIF, V13, P326, DOI 10.1006/prep.1998.0903	42	75	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17652	17656		10.1074/jbc.C500061200	http://dx.doi.org/10.1074/jbc.C500061200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15764605	hybrid			2022-12-27	WOS:000228807200012
J	Williams, TM; Hassan, GS; Li, JW; Cohen, AW; Medina, F; Frank, PG; Pestell, RG; Di Vizio, D; Loda, M; Lisanti, MP				Williams, TM; Hassan, GS; Li, JW; Cohen, AW; Medina, F; Frank, PG; Pestell, RG; Di Vizio, D; Loda, M; Lisanti, MP			Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer - Genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; ANCHORAGE-INDEPENDENT GROWTH; BREAST-CANCER; TRANSGENIC MOUSE; EXPRESSION; CARCINOMA; METASTASIS; DIFFERENTIATION; ADENOCARCINOMA; OVEREXPRESSION	Caveolin-1 (Cav-1) is the primary structural component of caveolae and is implicated in the processes of vesicular transport, cholesterol balance, transformation, and tumorigenesis. Despite an abundance of data suggesting that Cav-1 has transformation suppressor properties both in vitro and in vivo, Cav-1 is expressed at increased levels in human prostate cancer. To investigate the role of Cav-1 in prostate cancer onset and progression, we interbred Cav-1(-/-) null mice with a TRAMP (transgenic adenocarcinoma of mouse prostate) model that spontaneously develops advanced prostate cancer and metastatic disease. We found that, although the loss of Cav-1 did not affect the appearance of minimally invasive prostate cancer, its absence significantly impeded progression to highly invasive and metastatic disease. Inactivation of one (+/-) or both (-/-) alleles of Cav-1 resulted in significant reductions in prostate tumor burden, as well as decreases in regional lymph node metastases. Moreover, further examination revealed decreased metastasis to distant organs, such as the lungs, in TRAMP/Cav-1(-/-) mice. Utilizing prostate carcinoma cell lines (C1, C2, and C3) derived from TRAMP tumors, we also showed a positive correlation between Cav-1 expression and the ability of these cells to form tumors in vivo. Furthermore, down-regulation of Cav-1 expression in these cells, using a small interfering RNA approach, significantly reduced their tumorigenic and metastatic potential. Mechanistically, we showed that loss or down-regulation of Cav-1 expression results in increased apoptosis, with increased prostate apoptosis response factor-4 and PTEN levels in Cav-1(-/-) null prostate tumors. Our current findings provide the first in vivo molecular genetic evidence that Cav-1 does indeed function as a tumor promoter during prostate carcinogenesis, rather than as a tumor suppressor.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Urol, Bronx, NY 10461 USA; Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Georgetown University; Harvard University; Dana-Farber Cancer Institute	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael/B-6131-2018; Williams, Terence M/I-9614-2014; Lisanti, Michael P/C-6866-2013; Frank, Philippe G/A-3463-2011	Lisanti, Michael/0000-0003-2034-1382; Frank, Philippe G/0000-0003-4857-5279; Hassan, Ghada S./0000-0002-1391-5248	NIDDK NIH HHS [T32-DK07513] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007513] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Capozza F, 2003, AM J PATHOL, V162, P2029, DOI 10.1016/S0002-9440(10)64335-0; Chakraborty M, 2001, CANCER RES, V61, P7255; Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Fong A, 2003, AM J CLIN PATHOL, V120, P93, DOI 10.1309/292NHAYNWAVREJ37; Foster BA, 1997, CANCER RES, V57, P3325; Gingrich JR, 1996, CANCER RES, V56, P4096; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Gurumurthy S, 2001, CANCER METAST REV, V20, P225, DOI 10.1023/A:1015583310759; Han SE, 2004, INT J ONCOL, V24, P435; Hayashi K, 2001, CANCER RES, V61, P2361; Hu YC, 2001, CLIN CANCER RES, V7, P3519; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kato K, 2002, CANCER, V94, P929, DOI 10.1002/cncr.10329.abs; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Li LK, 2001, CANCER RES, V61, P4386; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Rajjayabun PH, 2001, UROLOGY, V58, P811, DOI 10.1016/S0090-4295(01)01337-1; Razani B, 2001, J BIOL CHEM, V276, P38121; Razani B, 2001, J CLIN INVEST, V108, P1553, DOI 10.1172/JCI14611; Satoh T, 2003, CANCER-AM CANCER SOC, V97, P1225, DOI 10.1002/cncr.11198; Sloan EK, 2004, ONCOGENE, V23, P7893, DOI 10.1038/sj.onc.1208062; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Williams TM, 2004, J BIOL CHEM, V279, P24745, DOI 10.1074/jbc.M402064200; Williams TM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-214; Williams TM, 2003, MOL BIOL CELL, V14, P1027, DOI 10.1091/mbc.E02-08-0503; Williams TM, 2004, J BIOL CHEM, V279, P51630, DOI 10.1074/jbc.M409214200; Yang G, 1999, CANCER RES, V59, P5719; Yang G, 1998, CLIN CANCER RES, V4, P1873; Zhang W, 2000, J BIOL CHEM, V275, P20717, DOI 10.1074/jbc.M909895199	34	147	151	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25134	25145		10.1074/jbc.M501186200	http://dx.doi.org/10.1074/jbc.M501186200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15802273	hybrid			2022-12-27	WOS:000230114000098
J	Bhide, VM; Laschinger, CA; Arora, PD; Lee, W; Hakkinen, L; Larjava, H; Sodek, J; McCulloch, CA				Bhide, VM; Laschinger, CA; Arora, PD; Lee, W; Hakkinen, L; Larjava, H; Sodek, J; McCulloch, CA			Collagen phagocytosis by fibroblasts is regulated by decorin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEAT; GROWTH-FACTOR-BETA; I COLLAGEN; CORE PROTEIN; PERIODONTAL-LIGAMENT; PROTEOGLYCAN DECORIN; BINDING-SITES; FIBRILLOGENESIS; MATRIX; DEGRADATION	Decorin is a small, leucine-rich proteoglycan that binds to collagen and regulates fibrillogenesis. We hypothesized that decorin binding to collagen inhibits phagocytosis of collagen fibrils. To determine the effects of decorin on collagen degradation, we analyzed phagocytosis of collagen and collagen/decorin-coated fluorescent beads by Rat-2 and gingival fibroblasts. Collagen beads bound to gingival cells by alpha 2 beta 1 integrins. Binding and internalization of decorin/collagen-coated beads decreased dose-dependently with increasing decorin concentration (p < 0.001). Inhibition of binding was sustained over 5 h (p < 0.001) and was attributed to interactions between decorin and collagen and not to decorin-collagen receptor interactions. Both the nonglycosylated decorin core protein and the thermally denatured decorin significantly inhibited collagen bead binding (similar to 50 and 89%, respectively; p < 0.05). Mimetic peptides corresponding to leucine-rich repeats 1-3, encompassed by a collagen-binding similar to 11-kDa cyanogen bromide fragment of decorin and leucine-rich repeats 4 and 5, previously shown to bind to collagen, were tested for their ability to inhibit collagen bead binding. Although the synthetic peptide 3 alone exhibited saturable binding to collagen, neither peptides 3 nor 1 and 2 markedly inhibited phagocytosis. Leucine-rich repeat 3 bound to a triple helical peptide containing the alpha 2 integrin-binding site of collagen. When collagen beads were co-incubated with peptides 3 and 4, inhibition of collagen phagocytosis (55%) was equivalent to intact native/recombinant core protein. Thus a novel collagen binding domain in decorin acts cooperatively with leucine-rich repeat 4 to mask the alpha 2 beta 1 integrin-binding site on collagen, an important sequence for the phagocytosis of collagen fibrils.	Univ Toronto, Canadian Inst Hlth, Res Grp Matrix Dynam, Fac Dent, Toronto, ON M5S 3E2, Canada; Univ British Columbia, Fac Dent, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada	University of Toronto; University of British Columbia	McCulloch, CA (corresponding author), Univ Toronto, Canadian Inst Hlth, Res Grp Matrix Dynam, Fac Dent, Rm 239,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	christopher.mcculloch@utoronto.ca	Larjava, Hannu/GRO-4325-2022; Hakkinen, Lari/B-2228-2016					Arora PD, 2001, J BIOL CHEM, V276, P14100, DOI 10.1074/jbc.M010298200; Arora PD, 2000, J BIOL CHEM, V275, P35432, DOI 10.1074/jbc.M003221200; Baronas-Lowell D, 2004, J BIOL CHEM, V279, P952, DOI 10.1074/jbc.M305989200; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; Bittner K, 1996, BIOCHEM J, V314, P159, DOI 10.1042/bj3140159; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DINGEMANS KP, 1994, ULTRASTRUCT PATHOL, V18, P539, DOI 10.3109/01913129409021896; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Everts V, 1996, HISTOCHEM J, V28, P229, DOI 10.1007/BF02409011; Hakkinen L, 2000, LAB INVEST, V80, P1869, DOI 10.1038/labinvest.3780197; HAKKINEN L, 1993, J HISTOCHEM CYTOCHEM, V41, P1689, DOI 10.1177/41.11.8409375; Hausser H, 1998, ARCH BIOCHEM BIOPHYS, V349, P363, DOI 10.1006/abbi.1997.0471; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; KLEOVITCH O, 1998, J BIOL CHEM, V273, P23856; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; Lauer-Fields JL, 2000, J CHROMATOGR A, V890, P117, DOI 10.1016/S0021-9673(00)00396-4; Lee W, 1996, J CELL PHYSIOL, V168, P695, DOI 10.1002/(SICI)1097-4652(199609)168:3<695::AID-JCP22>3.0.CO;2-X; MCCULLOCH CAG, 1993, J CELL PHYSIOL, V155, P461, DOI 10.1002/jcp.1041550305; MCKEOWN M, 1990, CELL TISSUE RES, V262, P523, DOI 10.1007/BF00305249; MELCHER AH, 1981, J ULTRA MOL STRUCT R, V77, P1, DOI 10.1016/S0022-5320(81)80064-0; Neame PJ, 2000, CELL MOL LIFE SCI, V57, P859, DOI 10.1007/s000180050048; POGANY G, 1992, BIOCHEM BIOPH RES CO, V189, P165, DOI 10.1016/0006-291X(92)91539-3; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; Schaefer L, 2002, AM J PATHOL, V160, P1181, DOI 10.1016/S0002-9440(10)64937-1; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; Scott PG, 2003, J BIOL CHEM, V278, P18353, DOI 10.1074/jbc.M211936200; Segal G, 2001, J CELL SCI, V114, P119; Sini P, 1997, GLYCOCONJUGATE J, V14, P871, DOI 10.1023/A:1018550307649; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; SVOBODA ELA, 1981, ANAT REC, V199, P473, DOI 10.1002/ar.1091990404; TENCATE AR, 1974, ARCH ORAL BIOL, V19, P339; Tenni R, 2002, EUR J BIOCHEM, V269, P1428, DOI 10.1046/j.1432-1033.2002.02784.x; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	46	38	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23103	23113		10.1074/jbc.M410060200	http://dx.doi.org/10.1074/jbc.M410060200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15811857	hybrid			2022-12-27	WOS:000229741800067
J	De Cristofaro, R; Peyvandi, F; Palla, R; Lavoretano, S; Lombardi, R; Merati, G; Romitelli, F; Di Stasio, E; Mannucci, PM				De Cristofaro, R; Peyvandi, F; Palla, R; Lavoretano, S; Lombardi, R; Merati, G; Romitelli, F; Di Stasio, E; Mannucci, PM			Role of chloride ions in modulation of the interaction between von Willebrand factor and ADAMTS-13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; FACTOR-CLEAVING PROTEASE; PLATELET GLYCOPROTEIN IB; FACTOR A1 DOMAIN; HEMOLYTIC-UREMIC SYNDROME; HOFMEISTER SERIES; BINDING; DISEASE; ALPHA; WATER	The degradation of von Willebrand factor (VWF) depends on the activity of a zinc protease ( referred to as ADAMTS-13), which cleaves VWF at the Tyr(1605)-Met(1606) peptide bond. Little information is available on the physiological mechanisms involved in regulation of ADAMTS-13 activity. In this study, the role of ions on the ADAMTS-13/VWF interaction was investigated. In the presence of 1.5 M urea, the protease cleaved multimeric VWF in the absence of NaCl at pH 8.00 and 37 degrees C, with an apparent k(cat)/K-m congruent to 3.4 x 10(4) m(-1) s-(1,) but this value decreased by similar to 10-fold in the presence of 0.15 M NaCl. Using several monovalent salts, the inhibitory effect was attributed mostly to anions, whose potency was inversely related to the corresponding Jones-Dole viscosity B coefficients (ClO4- > Cl- > F-). The specific inhibitory effect of anions was due to their binding to VWF, which caused a conformational change responsible for quenching the intrinsic fluorescence of the protein and reducing tyrosine exposition to bulk solvent. Ristocetin binding to VWF could reduce the apparent affinity and reverse the inhibitory effect of chloride. We hypothesize that, after secretion into the extracellular compartment, VWF is bound by chloride ions abundantly present in this milieu, becoming unavailable to proteolysis by ADAMTS-13. Shear forces, which facilitate GpIb alpha binding ( this effect being artificially obtained by ristocetin), can reverse the inhibitory effect of chloride, whose concentration gradient across the cell membrane may represent a simple but efficient strategy to regulate the enzymatic activity of ADAMTS-13.	Univ Sacred Heart, Sch Med, Hemostasis Res Ctr, Inst Internal Med & Geriatr, I-00168 Rome, Italy; Univ Sacred Heart, Sch Med, Inst Biochem & Clin Biochem, I-00168 Rome, Italy; Regina Elena & Univ Milan, IRCCS, Fdn Maggiore Hosp, Angelo Bianchi Bonomi Hemphilia & Thrombosis Ctr, I-20121 Milan, Italy; Regina Elena & Univ Milan, IRCCS, Fdn Maggiore Hosp, Fdn Luigi Villa, I-20121 Milan, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Milan; University of Milan	De Cristofaro, R (corresponding author), Univ Sacred Heart, Sch Med, Hemostasis Res Ctr, Inst Internal Med & Geriatr, Largo F Vito 1, I-00168 Rome, Italy.	rdecristofaro@rm.unicatt.it	Merati, Giuliana/B-4706-2009; Peyvandi, Flora/AAK-7437-2020; De Cristofaro, Raimondo/K-3942-2018; di stasio, enrico/AAL-3082-2020; Merati, Giampiero/J-9713-2018	Merati, Giuliana/0000-0002-6185-5294; Peyvandi, Flora/0000-0001-7423-9864; De Cristofaro, Raimondo/0000-0002-8066-8849; Merati, Giampiero/0000-0002-1389-7596; Palla, Roberta/0000-0001-8837-2367				Baerga-Ortiz A, 2000, J MOL BIOL, V296, P651, DOI 10.1006/jmbi.1999.3447; Cacace MG, 1997, Q REV BIOPHYS, V30, P241, DOI 10.1017/S0033583597003363; Celikel R, 2000, NAT STRUCT BIOL, V7, P881; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; Chung DW, 2002, BIOCHEMISTRY-US, V41, P11065, DOI 10.1021/bi0204692; Collins KD, 2004, METHODS, V34, P300, DOI 10.1016/j.ymeth.2004.03.021; COLLINS KD, 1985, Q REV BIOPHYS, V18, P323, DOI 10.1017/S0033583500005369; COLLINS KD, 1995, P NATL ACAD SCI USA, V92, P5553, DOI 10.1073/pnas.92.12.5553; Di Stasio E, 2004, BIOPHYS CHEM, V107, P197, DOI 10.1016/j.bpc.2003.09.005; Dumas JJ, 2004, J BIOL CHEM, V279, P23327, DOI 10.1074/jbc.M401659200; Favaloro EJ, 2000, AM J CLIN PATHOL, V114, P608, DOI 10.1309/2PMF-3HK9-V8TT-VFUN; Fersht A, 1985, ENZYME STRUCTURE MEC, P105; Fujikawa K, 2001, BLOOD, V98, P1662, DOI 10.1182/blood.V98.6.1662; Furlan M, 1998, NEW ENGL J MED, V339, P1578, DOI 10.1056/NEJM199811263392202; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Galla JH, 2002, ACID BASE ELECTROLYT, P109; Gerritsen HE, 1999, THROMB HAEMOSTASIS, V82, P1386; Griffon N, 2001, BIOPHYS CHEM, V90, P89, DOI 10.1016/S0301-4622(01)00129-6; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Jenkins PV, 1998, BLOOD, V91, P2032, DOI 10.1182/blood.V91.6.2032.2032_2032_2044; Ledvina PS, 1996, P NATL ACAD SCI USA, V93, P6786, DOI 10.1073/pnas.93.13.6786; Lo Nostro P, 2002, BIOMACROMOLECULES, V3, P1217, DOI 10.1021/bm0255692; Matsushita T, 2000, J BIOL CHEM, V275, P11044, DOI 10.1074/jbc.275.15.11044; Miyata S, 1999, J BIOL CHEM, V274, P6586, DOI 10.1074/jbc.274.10.6586; Nishio K, 2004, P NATL ACAD SCI USA, V101, P10578, DOI 10.1073/pnas.0402041101; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; RAINES G, 1990, THROMB RES, V60, P201, DOI 10.1016/0049-3848(90)90181-B; Rastegar-Lari G, 2002, BIOCHEMISTRY-US, V41, P6668, DOI 10.1021/bi020044f; Remuzzi G, 2002, BLOOD, V100, P778, DOI 10.1182/blood-2001-12-0166; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Schneppenheim R, 2004, THROMB HAEMOSTASIS, V92, P36, DOI 10.1160/th04-02-0084; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; Tsai HM, 2004, SEMIN THROMB HEMOST, V30, P549, DOI 10.1055/s-2004-835675; Tsai HM, 2003, SEMIN THROMB HEMOST, V29, P479; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203; Uchida T, 2004, BLOOD, V104, P2081, DOI 10.1182/blood-2004-02-0715; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; WYMAN J, 1990, BINDING LINKAGE FUNC, P33; Zavitsas AA, 2001, J PHYS CHEM B, V105, P7805, DOI 10.1021/jp011053l	39	40	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23295	23302		10.1074/jbc.M501143200	http://dx.doi.org/10.1074/jbc.M501143200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15809291	hybrid			2022-12-27	WOS:000229741800088
J	Chaudhary, K; Donald, RGK; Nishi, M; Carter, D; Ullman, B; Roos, DS				Chaudhary, K; Donald, RGK; Nishi, M; Carter, D; Ullman, B; Roos, DS			Differential localization of alternatively spliced hypoxanthine-xanthine-guanine phosphoribosyltransferase isoforms in Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTABLE MARKER; CRYSTAL-STRUCTURES; ADENOSINE KINASE; APICOMPLEXAN PARASITES; PROTEIN PALMITOYLATION; EXPRESSION; GENE; TRANSFORMATION; CYTOSKELETON; INHIBITION	A unique feature of the Toxoplasma gondii purine salvage pathway is the expression of two isoforms of the hypoxanthine-xanthine-guanine phosophoribosyltransferase (HXGPRT) of the parasite encoded by a single genetic locus. These isoforms differ in the presence or absence of a 49-amino acid insertion (which is specified by a single differentially spliced exon) but exhibit similar substrate specificity, kinetic characteristics, and temporal expression patterns. To examine possible functional differences between the two HXGPRT isoforms, fluorescent protein fusions were expressed in parasites lacking the endogenous hxgprt gene. Immunoblot analysis of fractionated cell extracts and fluorescence microscopy indicated that HXGPRT-I (which lacks the 49-amino acid insertion) is found in the cytosol, whereas HXGPRT-II (which contains the insertion) localizes to the inner membrane complex (IMC) of the parasite. Simultaneous expression of both isoforms resulted in the formation of hetero-oligomers, which distributed between the cytosol and IMC. Chimeric constructs expressing N-terminal peptides from either isoform I (11 amino acids) or isoform II (60 amino acids) fused to a chloramphenicol acetyl transferase ( CAT) reporter demonstrated that the N-terminal domain of isoform II is both necessary and sufficient for membrane association. Metabolic labeling experiments with transgenic parasites showed that isoform II or an isoform II-CAT fusion protein (but not isoform I or isoform I-CAT) incorporate [H-3] palmitate. Mutation of three adjacent cysteine residues within the isoform II-targeting domain to serines blocked both palmitate incorporation and IMC attachment without affecting enzyme activity, demonstrating that acylation of N-terminal isoform II cysteine residues is responsible for the association of HXGPRT-II with the IMC.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	University of Pennsylvania; Oregon Health & Science University	Roos, DS (corresponding author), Univ Penn, Dept Biol, 415 S Univ Ave, Philadelphia, PA 19104 USA.	droos@sas.upenn.edu	Donald, Robert George Konrad/GNP-4958-2022; Carter, Darrick/N-3304-2016	Roos, David Siker/0000-0001-6725-4089; Carter, Darrick/0000-0001-5901-3402				Berens R. I., 1995, BIOCH MOL BIOL PARAS, P323; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Bohne W, 1997, MOL BIOCHEM PARASIT, V88, P115, DOI 10.1016/S0166-6851(97)00087-X; CARTER NS, 2003, MOL MED PARASITOLOGY, P197; Chaudhary K, 2004, J BIOL CHEM, V279, P31221, DOI 10.1074/jbc.M404232200; Darling JA, 1999, MOL BIOCHEM PARASIT, V103, P15, DOI 10.1016/S0166-6851(99)00109-7; Donald RGK, 1998, MOL BIOCHEM PARASIT, V91, P295, DOI 10.1016/S0166-6851(97)00210-7; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; DONALD RGK, 1993, P NATL ACAD SCI USA, V90, P11703, DOI 10.1073/pnas.90.24.11703; Gaskins E, 2004, J CELL BIOL, V165, P383, DOI 10.1083/jcb.200311137; Heroux A, 1999, BIOCHEMISTRY-US, V38, P14485, DOI 10.1021/bi990507q; HOWE DK, 1995, J INFECT DIS, V172, P1561, DOI 10.1093/infdis/172.6.1561; Hu K, 2002, MOL BIOL CELL, V13, P593, DOI 10.1091/mbc.01-06-0309; Jewett TJ, 2003, MOL CELL, V11, P885, DOI 10.1016/S1097-2765(03)00113-8; KIM K, 1993, SCIENCE, V262, P911, DOI 10.1126/science.8235614; Knoll LJ, 1998, MOL CELL BIOL, V18, P807, DOI 10.1128/MCB.18.2.807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; Mann T, 2001, MOL BIOCHEM PARASIT, V115, P257, DOI 10.1016/S0166-6851(01)00289-4; Morrissette NS, 2002, MICROBIOL MOL BIOL R, V66, P21, DOI 10.1128/MMBR.66.1.21-38.2002; Morrissette NS, 1997, J CELL SCI, V110, P35; Opitz C, 2002, MOL MICROBIOL, V45, P597, DOI 10.1046/j.1365-2958.2002.03056.x; PFEFFERKORN ER, 1994, EXP PARASITOL, V79, P374, DOI 10.1006/expr.1994.1099; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; Schumacher MA, 2000, J MOL BIOL, V296, P549, DOI 10.1006/jmbi.1999.3474; Schumacher MA, 1996, NAT STRUCT BIOL, V3, P881, DOI 10.1038/nsb1096-881; SHAHABUDDIN M, 1992, EXP PARASITOL, V74, P11, DOI 10.1016/0014-4894(92)90134-V; Stokkermans TJW, 1996, EXP PARASITOL, V84, P355, DOI 10.1006/expr.1996.0124; Sullivan WJ, 1999, MOL BIOCHEM PARASIT, V103, P1, DOI 10.1016/S0166-6851(99)00114-0; Tomavo S, 2001, INT J PARASITOL, V31, P1023, DOI 10.1016/S0020-7519(01)00193-X; ULLMAN B, 1995, INFECT AGENT DIS, V4, P29; White EL, 2000, J BIOL CHEM, V275, P19218, DOI 10.1074/jbc.M908879199; WILSON CB, 1980, AM J OBSTET GYNECOL, V138, P357, DOI 10.1016/0002-9378(80)90129-5	34	27	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22053	22059		10.1074/jbc.M503178200	http://dx.doi.org/10.1074/jbc.M503178200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15814612	hybrid			2022-12-27	WOS:000229557900049
J	Rangone, H; Pardo, R; Colin, E; Girault, JA; Saudou, F; Humbert, S				Rangone, H; Pardo, R; Colin, E; Girault, JA; Saudou, F; Humbert, S			Phosphorylation of arfaptin 2 at Ser(260) by Akt inhibits poly-Q-huntingtin-induced toxicity by rescuing proteasome impairment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT HUNTINGTIN; RAC1-INTERACTING PROTEIN; AGGREGATE FORMATION; REDUCES TOXICITY; WILD-TYPE; DEGRADATION; CLEAVAGE; DISEASE; DEATH; STABILIZATION	Huntington disease (HD) is caused by an abnormal expanded polyglutamine repeat in the huntingtin protein. Insulin-like growth factor-1 is of particular interest in HD because it strongly inhibits polyQ-huntingtin-induced neurotoxicity. This neuroprotective effect involves the phosphorylation of huntingtin at Ser(421) by the prosurvival kinase Akt (Humbert, S., Bryson, E. A., Cordelieres, F. P., Connors, N. C., Datta, S. R., Finkbeiner, S., Greenberg, M. E., and Saudou, F. ( 2002) Dev. Cell 2, 831 - 837). Here, we report that Akt inhibits polyQ-huntingtin-induced toxicity in the absence of phosphorylation of huntingtin at Ser421, suggesting that Akt also acts on other downstream effector(s) to prevent neuronal death in HD. We show that this survival effect involves the ADP-ribosylation factorinteracting protein arfaptin 2, the levels of which are increased in HD patients. Akt phosphorylated arfaptin 2 at Ser260. Lack of phosphorylation of arfaptin 2 at this site substantially modified its subcellular distribution and increased neuronal death and intranuclear inclusions caused by polyQ-huntingtin. In contrast, arfaptin 2 had a neuroprotective effect on striatal neurons when phosphorylated by Akt. This effect is mediated through the proteasome, as phosphorylated arfaptin 2 inhibited the blockade of the proteasome induced by polyQ-huntingtin. This study points out a new mechanism by which Akt promotes neuroprotection in HD, emphasizing the potential therapeutic interest of this pathway in the disease.	Ctr Univ Orsay, CNRS, UMR 146, Inst Curie, F-91405 Orsay, France; Univ Paris 06, INSERM, U536, Inst Fer Moulin, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Saudou, F (corresponding author), Ctr Univ Orsay, CNRS, UMR 146, Inst Curie, Bldg 110, F-91405 Orsay, France.	frederic.saudou@curie.u-psud.fr	Girault, Jean-Antoine/F-7518-2013; SAUDOU, Frédéric/L-3454-2014; Humbert, Sandrine/S-2981-2016	Girault, Jean-Antoine/0000-0002-7900-1705; SAUDOU, Frédéric/0000-0001-6107-1046; Humbert, Sandrine/0000-0002-9501-2658	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH031862] Funding Source: NIH RePORTER; NIMH NIH HHS [MH.NS 31862] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Berke SJS, 2003, CURR OPIN GENET DEV, V13, P253, DOI 10.1016/S0959-437X(03)00053-4; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Gafni J, 2004, J BIOL CHEM, V279, P20211, DOI 10.1074/jbc.M401267200; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; Goffredo D, 2002, J BIOL CHEM, V277, P39594, DOI 10.1074/jbc.C200353200; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Li SH, 2004, TRENDS GENET, V20, P146, DOI 10.1016/j.tig.2004.01.008; Ligon LA, 2003, MOL BIOL CELL, V14, P1405, DOI 10.1091/mbc.E02-03-0155; Lunkes A, 2002, MOL CELL, V10, P259, DOI 10.1016/S1097-2765(02)00602-0; Martin-Aparicio E, 2001, J NEUROSCI, V21, P8772, DOI 10.1523/JNEUROSCI.21-22-08772.2001; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Peters PJ, 2002, NAT CELL BIOL, V4, P240, DOI 10.1038/ncb761; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Rangone H, 2004, EUR J NEUROSCI, V19, P273, DOI 10.1111/j.0953-816X.2003.03131.x; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Shin OH, 2001, BIOCHEM BIOPH RES CO, V285, P1267, DOI 10.1006/bbrc.2001.5330; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Verhoef LGGC, 2002, HUM MOL GENET, V11, P2689, DOI 10.1093/hmg/11.22.2689; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Young AB, 2003, J CLIN INVEST, V111, P299, DOI 10.1172/JCI200317742; Zhou H, 2003, J CELL BIOL, V163, P109, DOI 10.1083/jcb.200306038	34	38	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22021	22028		10.1074/jbc.M407528200	http://dx.doi.org/10.1074/jbc.M407528200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15809304	hybrid			2022-12-27	WOS:000229557900045
J	Chen, HB; Rud, JG; Lin, K; Xu, L				Chen, HB; Rud, JG; Lin, K; Xu, L			Nuclear targeting of transforming growth factor-b-activated smad complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA RECEPTOR; NUCLEOCYTOPLASMIC TRANSPORT; LOCALIZATION SIGNAL; CRYSTAL-STRUCTURE; TUMOR-SUPPRESSOR; PORE COMPLEX; CANCER-CELLS; IMPORT; EXPORT; PHOSPHORYLATION	Upon stimulation by the transforming growth factor b (TGF-b), Smad2 and Smad3 are phosphorylated at their C termini and assemble into stable heteromeric complexes with Smad4. These complexes are the functional entities that translocate into the nucleus and regulate the expression of TGF-b target genes. Here we report that the TGF-b- activated phospho-Smad3/ Smad4 complex utilizes an importin-independent mechanism for nuclear import and engages different nucleoporins for nuclear import compared with the monomeric Smad4. Within the heteromeric complex, phospho-Smad3 appears to dominate over Smad4 in the nuclear import process and guides the complex to its nuclear destination. We also demonstrate that the binding of phospho-Smad3 to Smad4 prevents Smad4 from interacting with the nuclear export receptor chromosome region maintenance 1. In this way, TGF-b signaling suppresses nuclear export of Smad4 by chromosome region maintenance 1 and thereby targets Smad4 into the nucleus. Indeed tumorigenic mutations in Smad4 that affect its interaction with Smad2 or Smad3 impair nuclear accumulation of Smad4 in response to TGF-b.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Xu, L (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St,Rm 308, Worcester, MA 01605 USA.	lan.xu@umassmed.edu		Rud, Jonathan/0000-0003-0295-7714	NATIONAL CANCER INSTITUTE [R01CA108509] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA108509] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM SA, 1992, METHOD ENZYMOL, V219, P97; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Chacko BM, 2004, MOL CELL, V15, P813, DOI 10.1016/j.molcel.2004.07.016; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Dai JL, 1998, CANCER RES, V58, P4592; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Iacobuzio-Donahue CA, 2004, CLIN CANCER RES, V10, P1597, DOI 10.1158/1078-0432.CCR-1121-3; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Nicolas FJ, 2004, J CELL SCI, V117, P4113, DOI 10.1242/jcs.01289; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Souchelnytskyi S, 2002, TRENDS CELL BIOL, V12, P304, DOI 10.1016/S0962-8924(02)02300-0; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Watanabe M, 2000, EMBO REP, V1, P176, DOI 10.1093/embo-reports/kvd029; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Xiao Z, 2003, ONCOGENE, V22, P1057, DOI 10.1038/sj.onc.1206212; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Xu L, 2003, J BIOL CHEM, V278, P42569, DOI 10.1074/jbc.M307601200; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	44	51	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21329	21336		10.1074/jbc.M500362200	http://dx.doi.org/10.1074/jbc.M500362200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799969	hybrid			2022-12-27	WOS:000229438800051
J	Holmen, SL; Zylstra, CR; Mukherjee, A; Sigler, RE; Faugere, MC; Bouxsein, ML; Deng, LF; Clemens, TL; Williams, BO				Holmen, SL; Zylstra, CR; Mukherjee, A; Sigler, RE; Faugere, MC; Bouxsein, ML; Deng, LF; Clemens, TL; Williams, BO			Essential role of beta-catenin in postnatal bone acquisition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN-5; OSTEOPOROSIS-PSEUDOGLIOMA SYNDROME; OSTEOBLAST PROLIFERATION; PROGRESSIVE DEVELOPMENT; MOUSE DEVELOPMENT; LRP5 GENE; APC GENE; MICE; GASTRULATION; MUTATION	Mutations in the Wnt co-receptor LRP5 alter bone mass in humans, but the mechanisms responsible for Wnts actions in bone are unclear. To investigate the role of the classical Wnt signaling pathway in osteogenesis, we generated mice lacking the beta-catenin or adenomatous polyposis coli (Apc) genes in osteoblasts. Loss of beta-catenin produced severe osteopenia with striking increases in osteoclasts, whereas constitutive activation of beta-catenin in the conditional Apc mutants resulted in dramatically increased bone deposition and a disappearance of osteoclasts. In vitro, osteoblasts lacking the beta-catenin gene exhibited impaired maturation and mineralization with elevated expression of the osteoclast differentiation factor, receptor activated by nuclear factor-kappa B ligand (RANKL), and diminished expression of the RANKL decoy receptor, osteoprotegerin. By contrast, Apc-deficient osteoblasts matured normally but demonstrated decreased expression of RANKL and increased osteoprotegerin. These findings suggest that Wnt/beta-catenin signaling in osteoblasts coordinates postnatal bone acquisition by controlling the differentiation and activity of both osteoblasts and osteoclasts.	Van Andel Res Inst, Lab Cell Signaling & Carcinnogenesis, Grand Rapids, MI 49503 USA; Van Andel Res Inst, Lab Analyt Cellular & Mol Microscopy, Grand Rapids, MI 49503 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Kentucky, Dept Med, Lexington, KY 40536 USA; Beth Israel Deaconess Med Ctr, Orthoped Biomech Lab, Boston, MA 02215 USA	Van Andel Institute; Van Andel Institute; University of Alabama System; University of Alabama Birmingham; University of Kentucky; Harvard University; Beth Israel Deaconess Medical Center	Williams, BO (corresponding author), Van Andel Res Inst, Lab Cell Signaling & Carcinnogenesis, Grand Rapids, MI 49503 USA.	bart.williams@vai.org	Williams, Bart/A-3539-2013	Williams, Bart/0000-0002-5261-5301; Diegel, Cassandra/0000-0002-6526-9372	NIAMS NIH HHS [AR44410] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brault V, 2001, DEVELOPMENT, V128, P1253; DEPAEPE A, 1993, AM J MED GENET, V45, P30, DOI 10.1002/ajmg.1320450110; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Fujino T, 2003, P NATL ACAD SCI USA, V100, P229, DOI 10.1073/pnas.0133792100; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gong YQ, 1996, AM J HUM GENET, V59, P146; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hofbauer LC, 2004, JAMA-J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490; Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Jackson A, 2005, BONE, V36, P585, DOI 10.1016/j.bone.2005.01.007; Karsenty G, 2001, ENDOCRINOLOGY, V142, P2731, DOI 10.1210/en.142.7.2731; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kelly OG, 2004, DEVELOPMENT, V131, P2803, DOI 10.1242/dev.01137; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; MOSER AR, 1995, DEV DYNAM, V203, P422, DOI 10.1002/aja.1002030405; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200	28	477	519	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21162	21168		10.1074/jbc.M501900200	http://dx.doi.org/10.1074/jbc.M501900200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802266	hybrid			2022-12-27	WOS:000229438800033
J	Zhuang, SG; Yan, Y; Han, JH; Schnellmann, RG				Zhuang, SG; Yan, Y; Han, JH; Schnellmann, RG			P38 kinase-mediated transactivation of the epidermal growth factor receptor is required for dedifferentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ACUTE-RENAL-FAILURE; MUSCLE-CELL-MIGRATION; BETA-CATENIN; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; CANCER-CELLS; E-CADHERIN; IN-VITRO; GENE-EXPRESSION	Renal proximal tubular cell (RPTC) dedifferentiation is thought to be a prerequisite for regenerative proliferation and migration after renal injury. However, the specific mediators and the mechanisms that regulate RPTC dedifferentiation have not been elucidated. Because epidermal growth factor (EGF) receptor activity is required for recovery from acute renal failure, we examined the role of the EGF receptor in dedifferentiation and the mechanisms of EGF receptor transactivation in primary cultures of RPTCs after oxidant injury. Exposure of confluent RPTCs to H2O2 resulted in 40 % cell death, and surviving RPTCs acquired a dedifferentiated phenotype ( e. g. elongated morphology and vimetin expression). The EGF receptor, p38, Src, and MKK3 were activated after oxidant injury and inhibition of the EGF receptor or p38 with specific inhibitors (AG1478 and SB203580, respectively) blocked RPTC dedifferentiation. Treatment with SB203580 or adenoviral overexpression of dominant negative p38 alpha or its upstream activator, MKK3, inhibited EGF receptor phosphorylation induced by oxidant injury, whereas AG1478 had no effect on p38 phosphorylation. Inhibition of Src with 4amino-5-( 4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP1) blocked MKK3 and p38 activation, and inhibition of MKK3 blocked p38 activation. In addition, inactivation of Src, MKK3, p38, or the EGF receptor blocked tyrosine phosphorylation of beta-catenin, a key signaling intermediate that is involved in the epithelial-mesenchymal transition and vimentin expression. These results reveal that p38 mediates EGF receptor activation after oxidant injury; that Src activates MMK3, which, in turn, activates p38; and that the EGF receptor signaling pathway plays a critical role in RPTC dedifferentiation.	Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Medical University of South Carolina; Medical University of South Carolina; Scripps Research Institute	Schnellmann, RG (corresponding author), Med Univ S Carolina, Dept Pharmaceut Sci, 280 Calhoun St,POB 250140, Charleston, SC 29425 USA.	schnell@musc.edu	Han, J/G-4671-2010					ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Awazu M, 2002, NEPHROL DIAL TRANSPL, V17, P5, DOI 10.1093/ndt/17.suppl_9.5; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; Bakin AV, 2002, J CELL SCI, V115, P3193; Bonventre JV, 2003, J AM SOC NEPHROL, V14, pS55, DOI 10.1097/01.ASN.0000067652.51441.21; Cheng H, 2002, J CELL PHYSIOL, V192, P234, DOI 10.1002/jcp.10134; COFFER PJ, 1995, ONCOGENE, V11, P561; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; COUNTS RS, 1995, AM J PHYSIOL-RENAL, V269, pF274, DOI 10.1152/ajprenal.1995.269.2.F274; Cummings BS, 2000, TOXICOLOGY, V150, P83, DOI 10.1016/S0300-483X(00)00252-3; CYBULSKY AV, 1994, AM J PHYSIOL, V267, pF428, DOI 10.1152/ajprenal.1994.267.3.F428; Devarajan P, 2003, MOL GENET METAB, V80, P365, DOI 10.1016/j.ymgme.2003.09.012; Eckert RL, 2003, J INVEST DERMATOL, V120, P823, DOI 10.1046/j.1523-1747.2003.12120.x; Eguchi S, 2003, BIOCHEM SOC T, V31, P1198; FINI ME, 1992, ACTA OPHTHALMOL, V70, P26; Fischer OM, 2004, MOL CELL BIOL, V24, P5172, DOI 10.1128/MCB.24.12.5172-5183.2004; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Frank GD, 2003, MOL CELL BIOL, V23, P1581, DOI 10.1128/MCB.23.5.1581-1589.2003; Gilles C, 2003, CANCER RES, V63, P2658; GOODYER PR, 1991, MOL CELL ENDOCRINOL, V77, P199, DOI 10.1016/0303-7207(91)90075-4; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Hay ED, 1995, ACTA ANAT, V154, P8; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Iijima K, 2002, CIRCULATION, V105, P2404, DOI 10.1161/01.CIR.0000016349.36385.FB; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; KAYS SE, 1995, TOXICOL APPL PHARM, V132, P273, DOI 10.1006/taap.1995.1108; Kim K, 2002, CELL BIOL INT, V26, P463, DOI 10.1006/cbir.2002.0901; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Li XJ, 2004, J BIOL CHEM, V279, P27365, DOI 10.1074/jbc.M401690200; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Lui VWY, 2003, ONCOGENE, V22, P6183, DOI 10.1038/sj.onc.1206720; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Nony PA, 2003, J PHARMACOL EXP THER, V304, P905, DOI 10.1124/jpet.102.035022; NOWAK G, 1996, AM J PHYSIOL, V271, pC2080; Omori S, 2000, KIDNEY INT, V58, P27, DOI 10.1046/j.1523-1755.2000.00137.x; Pargellis Christopher, 2003, Curr Opin Investig Drugs, V4, P566; Partik G, 1999, J CANCER RES CLIN, V125, P379, DOI 10.1007/s004320050290; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Price VR, 2002, J AM SOC NEPHROL, V13, P1152, DOI 10.1097/01.ASN.0000012609.22035.44; PUGH JL, 1995, KIDNEY INT, V47, P774, DOI 10.1038/ki.1995.118; Rao RK, 2002, BIOCHEM J, V368, P471, DOI 10.1042/BJ20011804; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SAFIRSTEIN R, 1990, KIDNEY INT, V37, P1515, DOI 10.1038/ki.1990.143; Sato K, 2003, GENES CELLS, V8, P995, DOI 10.1046/j.1356-9597.2003.00691.x; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schramek H, 2003, AM J PHYSIOL-CELL PH, V285, pC652, DOI 10.1152/ajpcell.00463.2002; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Simon C, 1998, CANCER RES, V58, P1135; Strniskova M, 2002, GEN PHYSIOL BIOPHYS, V21, P231; Taira T, 1996, VIRCHOWS ARCH, V427, P583; Takahashi K, 1997, ONCOGENE, V15, P71, DOI 10.1038/sj.onc.1201160; Takahashi M, 2003, CIRCULATION, V108, P2524, DOI 10.1161/01.CIR.0000096482.02567.8C; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214; Yano T, 1999, NEPHRON, V81, P230, DOI 10.1159/000045281; Zhougang SG, 2004, AM J PHYSIOL-RENAL, V286, pF858, DOI 10.1152/ajprenal.00282.2003; Zhuang SG, 2004, AM J PHYSIOL-RENAL, V287, pF365, DOI 10.1152/ajprenal.00035.2004	62	58	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21036	21042		10.1074/jbc.M413300200	http://dx.doi.org/10.1074/jbc.M413300200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797859	hybrid			2022-12-27	WOS:000229438800018
J	Hutt, DM; Baltz, JM; Ngsee, JK				Hutt, DM; Baltz, JM; Ngsee, JK			Synaptotagmin VI and VIII and syntaxin 2 are essential for the mouse sperm acrosome reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZONA-PELLUCIDA; PHOSPHOLIPID-BINDING; TRANSMITTER RELEASE; INTRACELLULAR CA2+; MOLECULAR-CLONING; CALCIUM-CHANNELS; SNARE COMPLEXES; C2B DOMAIN; PROTEIN; EXOCYTOSIS	The sperm acrosome is a large secretory granule that undergoes calcium-stimulated exocytosis by a mechanism analogous to neuronal secretion. In neurons the core SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex, composed of syntaxin (Stx), SNAP-25, and VAMP2, mediates vesicle fusion, whereas calcium regulation is thought to be accomplished by the synaptotagmin (Syt) family, some of which exhibit calcium-dependent binding to syntaxin and SNAP-25. Sperm express Syt VI and VIII and Stx2, which are co-localized to the acrosomal compartment where they might mediate exocytosis in response to calcium influx. Therefore, we examined the calcium dependence and isoform-specific interaction of Syt and Stx. We found that Stx2 binds to Syt I, VI, and VIII in a calcium-dependent manner with EC50 values of 175, 233, and 96 mu M calcium, respectively. We also determined that the EC50 for calcium of the acrosome reaction in streptolysin O-permeabilized sperm is 87 mu M, which closely coincides with the calcium sensitivity of Stx2 and Syt VIII interaction. Consistent with this is the greater potency of recombinant Syt VIII, VI, and Stx2 compared with other isoforms in inhibiting the acrosome reaction in streptolysin O-permeabilized sperm. Similarly, introduction of Syt VIII-specific antibodies was equally effective in inhibiting the acrosome fusion. Taken together, our data suggest a critical role for Syt VIII and Stx2 in membrane fusion and acrosome reaction in the sperm.	Univ Ottawa, Ottawa Hlth Res Inst, Dept Cellular & Mol Med, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Obstet & Gynecol, Div Reprod Med, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Ngsee, JK (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Dept Cellular & Mol Med, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	jngsee@ohri.ca		Baltz, Jay/0000-0002-9749-2480				Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Arnoult C, 1996, P NATL ACAD SCI USA, V93, P13004, DOI 10.1073/pnas.93.23.13004; Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; BAILEY JL, 1994, MOL REPROD DEV, V39, P297, DOI 10.1002/mrd.1080390307; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Brahmaraju M, 2004, BIOCHEM BIOPH RES CO, V318, P148, DOI 10.1016/j.bbrc.2004.04.006; BROADIE K, 1994, P NATL ACAD SCI USA, V91, P10727, DOI 10.1073/pnas.91.22.10727; Butz S, 1999, J BIOL CHEM, V274, P18290, DOI 10.1074/jbc.274.26.18290; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Charvin N, 1997, EMBO J, V16, P4591, DOI 10.1093/emboj/16.15.4591; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FLORMAN HM, 1994, DEV BIOL, V165, P152, DOI 10.1006/dbio.1994.1242; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; Fukuda M, 2003, BIOCHEM BIOPH RES CO, V306, P64, DOI 10.1016/S0006-291X(03)00911-2; Fukuda M, 2003, J BIOCHEM, V133, P641, DOI 10.1093/jb/mvg082; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; GREEN DPL, 1978, J CELL SCI, V32, P165; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; Hutt DM, 2002, BIOL REPROD, V66, P50, DOI 10.1095/biolreprod66.1.50; Irion U, 1999, CURR BIOL, V9, P1373, DOI 10.1016/S0960-9822(00)80082-2; Katafuchi K, 2000, MOL REPROD DEV, V57, P375, DOI 10.1002/1098-2795(200012)57:4&lt;375::AID-MRD10&gt;3.0.CO;2-Z; Kierszenbaum AL, 2000, MOL REPROD DEV, V57, P309, DOI 10.1002/1098-2795(200012)57:4&lt;309::AID-MRD1&gt;3.0.CO;2-W; Kobori H, 2000, BIOL REPROD, V63, P113, DOI 10.1095/biolreprod63.1.113; Larson JL, 1999, MOL REPROD DEV, V52, P445, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;445::AID-MRD14&gt;3.0.CO;2-6; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; MartinMoutot N, 1996, J BIOL CHEM, V271, P6567, DOI 10.1074/jbc.271.12.6567; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; Meizel S, 1997, DEV BIOL, V182, P67, DOI 10.1006/dbio.1997.8477; Michaut M, 2000, P NATL ACAD SCI USA, V97, P9996, DOI 10.1073/pnas.180206197; Michaut M, 2001, DEV BIOL, V235, P521, DOI 10.1006/dbio.2001.0316; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; Murase T, 1996, BIOCHEM J, V320, P1017, DOI 10.1042/bj3201017; O'Toole CMB, 2000, MOL BIOL CELL, V11, P1571, DOI 10.1091/mbc.11.5.1571; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Ramalho-Santos J, 2000, DEV BIOL, V223, P54, DOI 10.1006/dbio.2000.9745; Ramalho-Santos J, 2001, EXP CELL RES, V267, P45, DOI 10.1006/excr.2000.5119; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rickman C, 2004, BIOCHEM J, V378, P681, DOI 10.1042/BJ20031407; ROLDAN ERS, 1994, SCIENCE, V266, P1578, DOI 10.1126/science.7985030; Schulz JR, 1997, DEV BIOL, V191, P80, DOI 10.1006/dbio.1997.8712; Schulz JR, 1998, J BIOL CHEM, V273, P24355, DOI 10.1074/jbc.273.38.24355; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; SHI QX, 1995, BIOL REPROD, V52, P373, DOI 10.1095/biolreprod52.2.373; SPUNGIN B, 1995, J CELL SCI, V108, P2525; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Teng FYH, 2001, GENOME BIOL, V2; Terrian DM, 1997, EUR J CELL BIOL, V73, P198; Thompson CC, 1996, J NEUROSCI, V16, P7832; Tomes CN, 2002, DEV BIOL, V243, P326, DOI 10.1006/dbio.2002.0567; von Poser C, 2001, EUR J CELL BIOL, V80, P41; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Yunes R, 2000, BIOL REPROD, V62, P1084, DOI 10.1095/biolreprod62.4.1084	67	43	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20197	20203		10.1074/jbc.M412920200	http://dx.doi.org/10.1074/jbc.M412920200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15774481	hybrid			2022-12-27	WOS:000229242000006
J	Claudet, C; Angelov, D; Bouvet, P; Dimitrov, S; Bednar, J				Claudet, C; Angelov, D; Bouvet, P; Dimitrov, S; Bednar, J			Histone octamer instability under single molecule experiment conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME CORE PARTICLE; INDIVIDUAL NUCLEOSOMES; CHROMATIN FIBER; DNA; TRANSCRIPTION; BINDING; DISSOCIATION; DISRUPTION; REVEALS; RELEASE	We have studied the sample concentration-dependent and external stress-dependent stability of native and reconstituted nucleosomal arrays. Whereas upon stretching a single chromatin fiber in a solution of very low chromatin concentration the statistical distribution of DNA length released upon nucleosome unfolding shows only one population centered around similar to 25 nm, in nucleosome stabilizing conditions a second population with average length of similar to 50 nm was observed. Using radioactively labeled histone H3 and H2B, we demonstrate that upon lowering the chromatin concentration to very low values, first the linker histones are released, followed by the H2A-H2B dimer, whereas the H3-H4 tetramer remains stably attached to DNA even at the lowest concentration studied. The nucleosomal arrays reconstituted on a 5 S rDNA tandem repeat exhibited similar behavior. This suggests that the 25-nm disruption length is a consequence of the histone H2A-H2B dimer dissociation from the histone octamer. In nucleosome stabilizing conditions, a full similar to 145 bp is constrained in the nucleosome. Our data demonstrate that the nucleosome stability and histone octamer integrity can be severely degraded in experiments where the sample concentration is low.	CNRS, Spectrometrie Phys Lab, UMR 5588, F-38402 St Martin Dheres, France; Ecole Normale Super Lyon, CNRS, UMR 5161, F-69007 Lyon, France; Inst Albert Bonniot, Lab Biol Mol & Cellulaire Differenciat, U309, F-38706 La Tronche, France; Ecole Normale Super Lyon, Lab Rech Joliot Curie, F-69007 Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Ecole Normale Superieure de Lyon (ENS de LYON)	Bednar, J (corresponding author), CNRS, Spectrometrie Phys Lab, UMR 5588, BP87,140 Av Phys, F-38402 St Martin Dheres, France.	jbednar@spectro.ujf-grenoble.fr	Bednar, Jan/H-3648-2017; Angelov, Dimitar/K-2004-2017; , Bouvet/AAC-8779-2020; Bednar, Jan/K-2162-2012; dimitrov, stefan/M-7697-2013	Bednar, Jan/0000-0003-0879-6405; Angelov, Dimitar/0000-0002-5511-6647; dimitrov, stefan/0000-0002-1326-3630; Bouvet, Philippe/0000-0003-4524-2233; Claudet, Cyrille/0000-0002-7733-8283				Angelov D, 2004, EMBO J, V23, P3815, DOI 10.1038/sj.emboj.7600400; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; AUSIO J, 1984, J MOL BIOL, V176, P77, DOI 10.1016/0022-2836(84)90383-8; AUSIO J, 1984, J MOL BIOL, V177, P373, DOI 10.1016/0022-2836(84)90291-2; Bennink ML, 2001, NAT STRUCT BIOL, V8, P606, DOI 10.1038/89646; Brower-Toland BD, 2002, P NATL ACAD SCI USA, V99, P1960, DOI 10.1073/pnas.022638399; BURTON DR, 1978, NUCLEIC ACIDS RES, V5, P3643, DOI 10.1093/nar/5.10.3643; COTTON RW, 1981, NUCLEIC ACIDS RES, V9, P445, DOI 10.1093/nar/9.2.445; Cui Y, 2000, P NATL ACAD SCI USA, V97, P127, DOI 10.1073/pnas.97.1.127; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; Hayes JJ, 2001, CURR OPIN GENET DEV, V11, P124, DOI 10.1016/S0959-437X(00)00168-4; Kagalwala MN, 2004, EMBO J, V23, P2092, DOI 10.1038/sj.emboj.7600220; Katsani KR, 2003, CURR TOP MICROBIOL, V274, P113; Kulic IM, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.228101; LIBERTINI LJ, 1980, NUCLEIC ACIDS RES, V8, P3517, DOI 10.1093/nar/8.16.3517; LILLEY DMJ, 1979, NUCLEIC ACIDS RES, V7, P377, DOI 10.1093/nar/7.2.377; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1999, METH MOL B, V119, P1; Marko JF, 2003, BIOCHEM CELL BIOL, V81, P209, DOI 10.1139/o03-047; Marko JF, 1997, BIOPHYS J, V73, P2173, DOI 10.1016/S0006-3495(97)78248-1; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Scrittori L, 2001, J BIOL CHEM, V276, P30002, DOI 10.1074/jbc.M102701200; Thastrom A, 2004, BIOCHEMISTRY-US, V43, P736, DOI 10.1021/bi0302043; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; van Holde K.E., 1988, CHROMATIN; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; Wuite GJL, 2000, BIOPHYS J, V79, P1155, DOI 10.1016/S0006-3495(00)76369-7; YAGER TD, 1989, BIOCHEMISTRY-US, V28, P2271, DOI 10.1021/bi00431a045; Zlatanova J, 2002, J MUSCLE RES CELL M, V23, P377, DOI 10.1023/A:1023498120458	32	76	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19958	19965		10.1074/jbc.M500121200	http://dx.doi.org/10.1074/jbc.M500121200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772075	Green Submitted, Green Published, hybrid			2022-12-27	WOS:000229113700065
J	Matsuda, S; Kamiya, Y; Yuzaki, M				Matsuda, S; Kamiya, Y; Yuzaki, M			Roles of the N-terminal domain on the function and quaternary structure of the ionotropic glutamate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-GATED CHANNELS; ION CHANNELS; SUBUNIT STOICHIOMETRY; KAINATE RECEPTORS; NMDA RECEPTORS; AMPA; DESENSITIZATION; TETRAMERIZATION; OLIGOMERIZATION; DETERMINANTS	The alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionic acid (AMPA) subtype of ionotropic glutamate receptors (iGluRs) mediates fast excitatory neurotransmission in the mammalian brain. Although the most N-terminal leucine/isoleucine/valine-binding protein (LIVBP) domain is suggested to play a role in the initial assembly of iGluR subunits, it is unclear how this domain is arranged and functions in intact iGluRs. Similarly, although recent crystallographic analyses indicate that the isolated ligand-binding lysine/arginine/ornithine-binding protein domain forms a 2-fold symmetric dimer, the subunit stoichiometry of intact iGluRs remains elusive. Here, we developed a new approach to address these issues. The LIVBP domain of the GluR1 subunit of AMPA receptors was replaced by leucine-zipper peptides designed to form stable symmetric dimers, trimers, tetramers, or pentamers. All these mutant GluR1s were expressed in human embryonic kidney 293 cells and were transported to the cell surface as well as wild type GluR1. Functional and biochemical analyses indicated that these oligomerizing peptides specifically controlled the formation of the expected number of subunits in a channel complex. However, the channel function was only restored by the tetramer-forming peptide. Although the purified LIVBP domain of GluR1 formed a dimmer in solution, a dimer-forming peptide could not restore the function of GluR1. Moreover, a cross-linking assay indicated that four LIVBP domains are located in proximity to each other. These results suggest that the function of the LIVBP domain is not simply to form initial dimers but to adopt a conformation compatible with the overall tetrameric arrangement of subunits in intact AMPA receptors.	Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1608582, Japan; Yokohama City Univ, Sch Med, Dept Anesthesiol, Kanagawa 2360004, Japan	Keio University; Yokohama City University	Yuzaki, M (corresponding author), Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.	myuzaki@sc.itc.keio.ac.jp	Yuzaki, Michisuke/K-5328-2013; Matsuda, Shinji/GRR-5226-2022; Matsuda, Shinji/L-4727-2013	Yuzaki, Michisuke/0000-0002-5750-3544; Kamiya, Yoshinori/0000-0001-9790-9867				Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Ayalon G, 2005, J BIOL CHEM, V280, P15053, DOI 10.1074/jbc.M408413200; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; Bowie D, 2002, J NEUROSCI, V22, P3392; BROSE N, 1993, J BIOL CHEM, V268, P22663; Chen GQ, 1999, NATURE, V402, P817, DOI 10.1038/45568; Dingledine R, 1999, PHARMACOL REV, V51, P7; FerrerMontiel AV, 1996, P NATL ACAD SCI USA, V93, P2741, DOI 10.1073/pnas.93.7.2741; Greger IH, 2003, NEURON, V40, P763, DOI 10.1016/S0896-6273(03)00668-8; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hawkins LM, 1999, J BIOL CHEM, V274, P27211, DOI 10.1074/jbc.274.38.27211; He YJ, 2000, P NATL ACAD SCI USA, V97, P895, DOI 10.1073/pnas.97.2.895; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; Kohda K, 2000, NAT NEUROSCI, V3, P315, DOI 10.1038/73877; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Kuusinen A, 1999, J BIOL CHEM, V274, P28937, DOI 10.1074/jbc.274.41.28937; Leuschner WD, 1999, J BIOL CHEM, V274, P16907, DOI 10.1074/jbc.274.24.16907; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; Mansour M, 2001, NEURON, V32, P841, DOI 10.1016/S0896-6273(01)00520-7; Matsuda S, 2002, EUR J NEUROSCI, V16, P1507, DOI 10.1046/j.1460-9568.2002.02219.x; Meddows E, 2001, J BIOL CHEM, V276, P18795, DOI 10.1074/jbc.M101382200; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; Nakagawa T, 2005, NATURE, V433, P545, DOI 10.1038/nature03328; Opella SJ, 1999, NAT STRUCT BIOL, V6, P374, DOI 10.1038/7610; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; Pasternack A, 2002, J BIOL CHEM, V277, P49662, DOI 10.1074/jbc.M208349200; Robbins MJ, 1999, J NEUROCHEM, V72, P2539, DOI 10.1046/j.1471-4159.1999.0722539.x; Robert A, 2001, J NEUROSCI, V21, P5574, DOI 10.1523/JNEUROSCI.21-15-05574.2001; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Rothberg BS, 2003, J GEN PHYSIOL, V122, P501, DOI 10.1085/jgp.200308928; Safferling M, 2001, BIOCHEMISTRY-US, V40, P13948, DOI 10.1021/bi011143g; Shammat IM, 1999, NEURON, V23, P809, DOI 10.1016/S0896-6273(01)80038-6; Sobolevsky AI, 2004, NEURON, V41, P367, DOI 10.1016/S0896-6273(04)00008-X; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; Wang Y, 2003, EUR J NEUROSCI, V17, P1581, DOI 10.1046/j.1460-9568.2003.02595.x; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; Xia HH, 2002, J BIOL CHEM, V277, P47765, DOI 10.1074/jbc.M207122200; Zerangue N, 2000, P NATL ACAD SCI USA, V97, P3591, DOI 10.1073/pnas.060016797; Zhong HM, 2002, NATURE, V420, P193, DOI 10.1038/nature01201	43	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20021	20029		10.1074/jbc.M410513200	http://dx.doi.org/10.1074/jbc.M410513200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15781472	hybrid			2022-12-27	WOS:000229113700072
J	Novi, F; Stanasila, L; Giorgi, F; Corsini, GU; Cotecchia, S; Maggio, R				Novi, F; Stanasila, L; Giorgi, F; Corsini, GU; Cotecchia, S; Maggio, R			Paired activation of two components within muscarinic M-3 receptor dimers is required for recruitment of beta-arrestin-1 to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; CRYSTAL-STRUCTURE; VISUAL ARRESTIN; BETA-ARRESTIN; CROSS-TALK; BINDING; PHOSPHORYLATION; INTERNALIZATION; DOPAMINE; DIMERIZATION	beta-Arrestins regulate the functioning of G protein-coupled receptors in a variety of cellular processes including receptor-mediated endocytosis and activation of signaling molecules such as ERK. A key event in these processes is the G protein-coupled receptor-mediated recruitment of beta-arrestins to the plasma membrane. However, despite extensive knowledge in this field, it is still disputable whether activation of signaling pathways via beta-arrestin recruitment entails paired activation of receptor dimers. To address this question, we investigated the ability of different muscarinic receptor dimers to recruit beta-arrestin-1 using both co-immunoprecipitation and fluorescence microscopy in COS-7 cells. Experimentally, we first made use of a mutated muscarinic M-3 receptor, which is deleted in most of the third intracellular loop (M-3-short). Although still capable of activating phospholipase C, this receptor loses almost completely the ability to recruit beta-arrestin- 1 following carbachol stimulation in COS-7 cells. Subsequently, M-3-short was co-expressed with the M-3 receptor. Under these conditions, the M-3/M-3-short heterodimer could not recruit beta-arrestin- 1 to the plasma membrane, even though the control M-3/M-3 homodimer could. We next tested the ability of chimeric adrenergic muscarinic alpha(2)/M-3 and M-3/alpha(2) heterodimeric receptors to co-immunoprecipitate with beta-arrestin- 1 following stimulation with adrenergic and muscarinic agonists. beta-Arrestin-1 co-immunoprecipitation could be induced only when carbachol or clonidine were given together and not when the two agonists were supplied separately. Finally, we tested the reciprocal influence that each receptor may exert on the M-2/M-3 heterodimer to recruit beta-arrestin-1. Remarkably, we observed that M-2/M-3 heterodimers recruit significantly greater amounts of beta-arrestin-1 than their respective M-3/M-3 or M-2/M-2 homodimers. Altogether, these findings provide strong evidence in favor of the view that binding of beta-arrestin-1 to muscarinic M-3 receptors requires paired stimulation of two receptor components within the same receptor dimer.	Univ Pisa, Dept Neurosci, I-56100 Pisa, Italy; Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Pisa; University of Lausanne	Maggio, R (corresponding author), Univ Pisa, Dept Neurosci, Via Roma 55, I-56100 Pisa, Italy.	r.maggio@drugs.med.unipi.it	maggio, Roberto/Q-2032-2015	Maggio, Roberto/0000-0003-4436-2356				Agnati LF, 2003, PHARMACOL REV, V55, P509, DOI 10.1124/pr.55.3.2; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; Budd DC, 2001, J BIOL CHEM, V276, P4581, DOI 10.1074/jbc.M008827200; Chinault SL, 2004, J BIOL CHEM, V279, P16091, DOI 10.1074/jbc.M311099200; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dessy C, 2000, EMBO J, V19, P4272, DOI 10.1093/emboj/19.16.4272; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hillion J, 2002, J BIOL CHEM, V277, P18091, DOI 10.1074/jbc.M107731200; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Hornigold DC, 2003, BRIT J PHARMACOL, V138, P1340, DOI 10.1038/sj.bjp.0705178; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Maggio R, 1999, J PHARMACOL EXP THER, V291, P251; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MAGGIO R, 1994, EUR J PHARM-MOLEC PH, V268, P459, DOI 10.1016/0922-4106(94)90075-2; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Mhaouty-Kodja S, 1999, MOL PHARMACOL, V55, P339, DOI 10.1124/mol.55.2.339; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Novi F, 2004, J BIOL CHEM, V279, P7476, DOI 10.1074/jbc.M306818200; OHGURO H, 1994, PROTEIN SCI, V3, P2428, DOI 10.1002/pro.5560031226; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Scarselli M, 2001, J BIOL CHEM, V276, P30308, DOI 10.1074/jbc.M102297200; Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	35	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19768	19776		10.1074/jbc.M411281200	http://dx.doi.org/10.1074/jbc.M411281200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769745	hybrid			2022-12-27	WOS:000229113700043
J	Bai, Y; Onuma, H; Bai, X; Medvedev, AV; Misukonis, M; Weinberg, JB; Cao, WH; Robidoux, J; Floering, LM; Daniel, KW; Collins, S				Bai, Y; Onuma, H; Bai, X; Medvedev, AV; Misukonis, M; Weinberg, JB; Cao, WH; Robidoux, J; Floering, LM; Daniel, KW; Collins, S			Persistent nuclear factor-kappa B activation in UCP2-/- mice leads to enhanced nitric oxide and inflammatory cytokine production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL UNCOUPLING PROTEINS; NADPH PHAGOCYTE OXIDASE; BETA-CELL DYSFUNCTION; MACROPHAGES IN-VITRO; BACTERIAL LIPOPOLYSACCHARIDE; EXPERIMENTAL SALMONELLOSIS; ANTIMICROBIAL ACTIONS; TRANSCRIPTION FACTOR; INSULIN-RESISTANCE; P50 HOMODIMERS	One of the phenotypes of mice with targeted disruption of the uncoupling protein-2 gene (Ucp2-/-) is greater macrophage phagocytic activity and free radical production, resulting in a striking resistance to infectious microorganisms. In this study, the molecular mechanisms of this enhanced immune response were investigated. We found that levels of nitric oxide measured in either plasma or isolated macrophages from Ucp2-/- mice are significantly elevated in response to bacterial lipopolysaccharide challenge compared with similarly treated Ucp2+/+ mice. Likewise, expression of inducible nitric-oxide synthase and inflammatory cytokines is higher in Ucp2-/- mice in vivo and in vitro. Key steps in the activation cascade of nuclear factor (NF)-kappa B, including I kappa B kinase and nuclear translocation of NF-kappa B subunits, are all remarkably enhanced in Ucp2-/- mice, most notably even under basal conditions. The elevated basal activity of I kappa B kinase in macrophages from Ucp2-/- mice can be blocked by cell-permeable inhibitors of superoxide and hydrogen peroxide generation, but not by a specific inhibitor for inducible nitric-oxide synthase. Isolated mitochondria from Ucp2-/- cells produced more superoxide/hydrogen peroxide. We conclude that mitochrondrially derived reactive oxygen from Ucp2-/- cells constitutively activates NF-kappa B, resulting in a "primed" state to both potentiate and amplify the inflammatory response upon subsequent stimulation.	CIIT Ctr Hlth Res, Endocrine Biol Program, Div Biol Sci, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Vet Adm Med Ctr, Div Hematol Oncol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Vet Adm Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Collins, S (corresponding author), CIIT Ctr Hlth Res, Endocrine Biol Program, Div Biol Sci, 6 Davis Dr,POB 12137, Res Triangle Pk, NC 27709 USA.	scollins@ciit.org		Robidoux, JAcques/0000-0002-4809-4734; Medvedev, Alexander/0000-0001-6983-1687	NIDDK NIH HHS [R01-DK54024, R01 DK054024] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054024] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bayon Y, 2003, MOL CELL BIOL, V23, P1061, DOI 10.1128/MCB.23.3.1061-1074.2003; Blanc J, 2003, CIRCULATION, V107, P388, DOI 10.1161/01.CIR.0000051722.66074.60; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Bonetta L, 2004, NAT METHODS, V1, P169, DOI 10.1038/nmeth1104-169; Bourke E, 2000, J BIOL CHEM, V275, P39996, DOI 10.1074/jbc.M007693200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bureau F, 2000, J IMMUNOL, V165, P5822, DOI 10.4049/jimmunol.165.10.5822; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Chase AJ, 2002, ARTERIOSCL THROM VAS, V22, P765, DOI 10.1161/01.ATV.0000015078.09208.92; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; Couplan E, 2002, J BIOL CHEM, V277, P26268, DOI 10.1074/jbc.M202535200; Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013; De Plaen IG, 1998, BBA-LIPID LIPID MET, V1392, P185, DOI 10.1016/S0005-2760(98)00024-1; Dulloo AG, 2001, BRIT J NUTR, V86, P123, DOI 10.1079/BJN2001412; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Jaburek M, 2004, J BIOL CHEM, V279, P53097, DOI 10.1074/jbc.M405339200; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jezek P, 2004, PHYSIOL RES, V53, pS199; Kim SH, 2002, J CELL BIOL, V159, P821, DOI 10.1083/jcb.200112131; Kizaki T, 2002, P NATL ACAD SCI USA, V99, P9392, DOI 10.1073/pnas.142206299; Krauss S, 2003, J CLIN INVEST, V112, P1831, DOI 10.1172/JCI200319774; Krauss S, 2002, P NATL ACAD SCI USA, V99, P118, DOI 10.1073/pnas.012410699; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Lembertas AV, 1997, J CLIN INVEST, V100, P1240, DOI 10.1172/JCI119637; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; LIEW FY, 1990, J IMMUNOL, V144, P4794; LIOCHEV SI, 1995, ARCH BIOCHEM BIOPHYS, V318, P408, DOI 10.1006/abbi.1995.1247; Mastroeni P, 2000, J EXP MED, V192, P237, DOI 10.1084/jem.192.2.237; Matsuura M, 2003, EUR J BIOCHEM, V270, P4016, DOI 10.1046/j.1432-1033.2003.03792.x; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741; Nedergaard J, 1999, J BIOENERG BIOMEMBR, V31, P475, DOI 10.1023/A:1005400507802; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Oberkofler H, 2005, ARTERIOSCL THROM VAS, V25, P604, DOI 10.1161/01.ATV.0000153141.42033.22; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Pecqueur C, 2001, J MOL MED, V79, P48, DOI 10.1007/s001090000150; Pi JB, 2003, FREE RADICAL BIO MED, V35, P102, DOI 10.1016/S0891-5849(03)00269-7; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; Shoelson SE, 2003, INT J OBESITY, V27, pS49, DOI 10.1038/sj.ijo.0802501; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; Vancurova I, 2002, J VIROL, V76, P1533, DOI 10.1128/JVI.76.3.1533-1536.2002; Vazquez-Torres A, 2000, J EXP MED, V192, P227, DOI 10.1084/jem.192.2.227; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; Werner ER, 2002, J BIOL CHEM, V277, P10129, DOI 10.1074/jbc.M107326200; Willerson JT, 2004, CIRCULATION, V109, P2, DOI 10.1161/01.CIR.0000129535.04194.38; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	61	107	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19062	19069		10.1074/jbc.M500566200	http://dx.doi.org/10.1074/jbc.M500566200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757894	Green Accepted, hybrid			2022-12-27	WOS:000228932300062
J	Chen, HX; Rubin, E; Zhang, HP; Chung, S; Jie, CC; Garrett, E; Biswal, S; Sukumar, S				Chen, HX; Rubin, E; Zhang, HP; Chung, S; Jie, CC; Garrett, E; Biswal, S; Sukumar, S			Identification of transcriptional targets of HOXA5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PLEIOTROPHIN GENE-EXPRESSION; MAMMARY-GLAND DEVELOPMENT; DNA-BINDING; HOMEODOMAIN PROTEINS; HOMEOBOX GENES; MESSENGER-RNA; SPECIFICITY; ACTIVATION; CANCER	The homeobox gene HOXA5 encodes a transcription factor that has been shown to play important roles in embryogenesis, hematopoiesis, and tumorigenesis. In order to decipher downstream signaling pathways of HOXA5, we utilized oligonucleotide microarray analysis to identify genes that are differentially expressed in HOXA5-induced cells compared with uninduced cells. Comparative analysis of gene expression changes after 9 h of HOXA5 induction in Hs578T breast cancer cells identified 306 genes whose expression was modulated at least 2-fold. Ten of these 306 genes were also up-regulated by at least 2-fold at 6 h post-induction. The expression of all of these 10 genes was confirmed by semi-quantitative reverse transcription-PCR. Among these 10 genes, which are most likely to be direct targets of HOXA5, we initiated an investigation into the pleiotrophin gene by first cloning its promoter. Transient transfection assays indicated that HOXA5 can specifically activate the pleiotrophin promoter. Promoter deletion, chromatin immunoprecipitation assay, and gel-shift assays were performed to show that HOXA5 can directly bind to one binding site on the pleiotrophin promoter. These data strongly suggest that microarray analysis can successfully identify many potential direct downstream genes of HOXA5. Further functional analysis of these targets will allow us to better understand the diverse functions of HOXA5 in embryonic development and tumorigenesis.	Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Breast Canc Program, Baltimore, MD 21231 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat & Clin Trials, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Sukumar, S (corresponding author), Johns Hopkins Univ Hosp, Ctr Comprehens Canc, 1650 Orleans St,CRB410, Baltimore, MD 21231 USA.	saras@jhmi.edu			NATIONAL CANCER INSTITUTE [P50CA088843] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA88843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Aubin J, 1997, DEV BIOL, V192, P432, DOI 10.1006/dbio.1997.8746; Aubin J, 2002, DEVELOPMENT, V129, P4075; Aubin J, 1999, AM J PHYSIOL-CELL PH, V277, pC965, DOI 10.1152/ajpcell.1999.277.5.C965; Ausubel FM, 1988, MOL REPROD DEV; Chen HX, 2003, CANCER BIOL THER, V2, P524, DOI 10.4161/cbt.2.5.525; Chen HX, 2004, MOL CELL BIOL, V24, P924, DOI 10.1128/MCB.24.2.924-935.2004; Chen HX, 2003, J MAMMARY GLAND BIOL, V8, P159, DOI 10.1023/A:1025996707117; Crooks GM, 1999, BLOOD, V94, P519, DOI 10.1182/blood.V94.2.519.414k20_519_528; Deuel TF, 2002, ARCH BIOCHEM BIOPHYS, V397, P162, DOI 10.1006/abbi.2001.2705; DONY C, 1987, EMBO J, V6, P2965, DOI 10.1002/j.1460-2075.1987.tb02602.x; Dorsam ST, 2004, BLOOD, V103, P1676, DOI 10.1182/blood-2003-07-2202; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Fuller JF, 1999, BLOOD, V93, P3391, DOI 10.1182/blood.V93.10.3391.410k26_3391_3400; Ghannam G, 2004, J BIOL CHEM, V279, P866, DOI 10.1074/jbc.M307280200; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Goodwin RG, 1998, APOPTOSIS, V3, P83, DOI 10.1023/A:1009640823621; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; Hedlund E, 2004, J NEUROSCI RES, V75, P307, DOI 10.1002/jnr.10844; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Lewis MT, 2000, BREAST CANCER RES, V2, P158, DOI 10.1186/bcr49; LI YS, 1992, J BIOL CHEM, V267, P26011; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LI YS, 1992, BIOCHEM BIOPH RES CO, V184, P427, DOI 10.1016/0006-291X(92)91211-8; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Mannervik M, 1999, BIOESSAYS, V21, P267, DOI 10.1002/(SICI)1521-1878(199904)21:4<267::AID-BIES1>3.3.CO;2-3; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; ODENWALD WF, 1989, GENE DEV, V3, P158, DOI 10.1101/gad.3.2.158; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; PELLERIN I, 1994, MOL CELL BIOL, V14, P4532, DOI 10.1128/MCB.14.7.4532; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Phelan ML, 1997, J BIOL CHEM, V272, P8635, DOI 10.1074/jbc.272.13.8635; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Raman V, 2000, J BIOL CHEM, V275, P26551, DOI 10.1074/jbc.C000324200; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866; Sanlioglu S, 1998, J NEUROBIOL, V36, P559, DOI 10.1002/(SICI)1097-4695(19980915)36:4<559::AID-NEU9>3.0.CO;2-V; Sharkey M, 1997, TRENDS GENET, V13, P145, DOI 10.1016/S0168-9525(97)01096-2; Shen J, 2000, EXP CELL RES, V259, P274, DOI 10.1006/excr.2000.4963; Shen WF, 1996, NUCLEIC ACIDS RES, V24, P898, DOI 10.1093/nar/24.5.898; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; SilosSantiago I, 1996, J NEUROBIOL, V31, P283, DOI 10.1002/(SICI)1097-4695(199611)31:3<283::AID-NEU2>3.0.CO;2-6; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Suzuki M, 2003, J BIOL CHEM, V278, P30148, DOI 10.1074/jbc.M303932200; TANI M, 1989, J NEUROSCI RES, V24, P457, DOI 10.1002/jnr.490240402; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Tkatchenko AV, 2001, DEVELOPMENT, V128, P1547; VANDERWINDEN JM, 1992, ANAT EMBRYOL, V186, P387; Vigano MA, 1998, MOL CELL BIOL, V18, P6201, DOI 10.1128/MCB.18.11.6201; Yeh HJ, 1998, J NEUROSCI, V18, P3699; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732; Zhao YX, 2001, DEVELOPMENT, V128, P3197	56	45	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19373	19380		10.1074/jbc.M413528200	http://dx.doi.org/10.1074/jbc.M413528200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757903	hybrid			2022-12-27	WOS:000228932300095
J	Lee, CC; Huang, CC; Wu, MY; Hsu, KS				Lee, CC; Huang, CC; Wu, MY; Hsu, KS			Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; ER RETENTION SIGNAL; MESSENGER-RNA TRANSLATION; KINASE-B; MAMMALIAN TARGET; RECEPTOR; NMDA; PHOSPHORYLATION; DEPRESSION; PSD-95	Insulin receptors are highly enriched at neuronal synapses, but whose function remains unclear. Here we present evidence that brief incubations of rat hippocampal slices with insulin resulted in an increased protein expression of dendritic scaffolding protein postsynaptic density-95 (PSD-95) in area CA1. This insulin-induced increase in the PSD-95 protein expression was inhibited by the tyrosine kinase inhibitor, AG1024, phosphatidylinositol 3-kinase (PI3K) inhibitors, LY294002 and wortmannin, translational inhibitors, anisomycin and rapamycin, but not by LY303511 ( an inactive analogue of LY294002), and transcriptional inhibitor, actinomycin D, suggesting that insulin regulates the translation of PSD-95 by activating the receptor tyrosine kinase-PI3K-mammalian target of rapamycin ( mTOR) signaling pathway. A similar insulin-induced increase in the PSD-95 protein expression was detected after stimulation of the synaptic fractions isolated from the hippocampal neurons. Furthermore, insulin treatment did not affect the PSD-95 mRNA levels. In agreement, insulin rapidly induced the phosphorylation of 3-phosphoinositide-dependent protein kinase-1 (PDK1), protein kinase B (Akt), and mTOR, effects that were prevented by the AG1024 and LY294002. We also show that insulin stimulated the phosphorylation of 4E-binding protein 1 (4E-BP1) and p70S6 kinase (p70S6K) in a mTOR-dependent manner. Finally, we demonstrate the constitutive expression of PSD-95 mRNA in the synaptic fractions isolated from hippocampal neurons. Taken together, these findings suggest that activation of the PI3K-Akt-mTOR signaling pathway is essential for the insulin-induced up-regulation of local PSD-95 protein synthesis in neuronal dendrites and indicate a new molecular mechanism that may contribute to the modulation of synaptic function by insulin in hippocampal area CA1.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 701, Taiwan	National Cheng Kung University; National Cheng Kung University	Hsu, KS (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, 1 Univ Rd, Tainan 701, Taiwan.	richard@mail.ncku.edu.tw	Hsu, Kuei-Sen/AAV-8386-2021					Aakalu G, 2001, NEURON, V30, P489, DOI 10.1016/S0896-6273(01)00295-1; Abbott MA, 1999, J NEUROSCI, V19, P7300, DOI 10.1523/JNEUROSCI.19-17-07300.1999; Akama KT, 2003, J NEUROSCI, V23, P2333; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Asaki C, 2003, BRAIN RES, V972, P168, DOI 10.1016/S0006-8993(03)02523-X; BASKIN DG, 1983, ENDOCRINOLOGY, V113, P1818, DOI 10.1210/endo-113-5-1818; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Ehlers MD, 1996, CURR OPIN CELL BIOL, V8, P484, DOI 10.1016/S0955-0674(96)80024-X; Ehrlich I, 2004, J NEUROSCI, V24, P916, DOI 10.1523/JNEUROSCI.4733-03.2004; El-Hussein AE, 2000, SCIENCE, V290, P1364; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HEIDENREICH KA, 1993, ANN NY ACAD SCI, V692, P72; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; HILL JM, 1986, NEUROSCIENCE, V17, P1127, DOI 10.1016/0306-4522(86)90082-5; HOLLINGSWORTH EB, 1985, J NEUROSCI, V5, P2240; Huang CC, 2004, J NEUROCHEM, V89, P217, DOI 10.1111/j.1471-4159.2003.02307.x; Huang CC, 1999, J NEUROSCI, V19, P9728; Huang CC, 2003, MOL CELL NEUROSCI, V24, P831, DOI 10.1016/S1044-7431(03)00238-0; Ju W, 2004, NAT NEUROSCI, V7, P244, DOI 10.1038/nn1189; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Klann E, 2004, NAT REV NEUROSCI, V5, P931, DOI 10.1038/nrn1557; KULL FC, 1983, J BIOL CHEM, V258, P6561; Liao GY, 1999, J NEUROCHEM, V73, P1510, DOI 10.1046/j.1471-4159.1999.0731510.x; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIU LF, 1995, NEUROSCI LETT, V192, P5, DOI 10.1016/0304-3940(95)11593-L; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; MARKS JL, 1988, J NEUROCHEM, V50, P774, DOI 10.1111/j.1471-4159.1988.tb02981.x; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Niethammer M, 1996, J NEUROSCI, V16, P2157; Ouyang Y, 1999, J NEUROSCI, V19, P7823; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; Schechter R, 1996, BRAIN RES, V736, P16, DOI 10.1016/S0006-8993(96)00664-6; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Stein V, 2003, J NEUROSCI, V23, P5503; Stockhorst U, 2004, PHYSIOL BEHAV, V83, P47, DOI 10.1016/j.physbeh.2004.07.022; Sutton MA, 2004, SCIENCE, V304, P1979, DOI 10.1126/science.1096202; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; UNGER J, 1989, NEUROSCIENCE, V31, P143, DOI 10.1016/0306-4522(89)90036-5; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; Wells DG, 2001, J NEUROSCI, V21, P9541, DOI 10.1523/JNEUROSCI.21-24-09541.2001; Wickelgren I, 1998, SCIENCE, V280, P517, DOI 10.1126/science.280.5363.517; WOZNIAK M, 1993, NEUROCHEM INT, V22, P1, DOI 10.1016/0197-0186(93)90062-A; Xia H, 2001, NEUROPHARMACOLOGY, V41, P714, DOI 10.1016/S0028-3908(01)00103-4; Yao WD, 2004, NEURON, V41, P625, DOI 10.1016/S0896-6273(04)00048-0; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	56	142	150	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18543	18550		10.1074/jbc.M414112200	http://dx.doi.org/10.1074/jbc.M414112200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15755733	hybrid			2022-12-27	WOS:000228807200119
J	Ghosh, AK; Steele, R; Ray, RB				Ghosh, AK; Steele, R; Ray, RB			c-myc promoter-binding protein 1 (MBP-1) regulates prostate cancer cell growth by inhibiting MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; CARCINOMA-CELLS; CONSTITUTIVE ACTIVATION; SIGNAL-TRANSDUCTION; FUNCTIONAL DOMAINS; ALPHA-ENOLASE; NUDE-MICE; CYCLIN D1; EXPRESSION	Prostate cancer is the most common and invasive type of cancer among American men, and the second leading cause of cancer-elated deaths in the United States. Unfortunately, an effective therapeutic regimen is still lacking for advance stages of the disease. Recently, MEK5 has been shown to overexpress in prostate cancer and is associated with poor survival outcome. MEK5 exists as alpha- and beta-isoforms. MEK5 alpha induces cell proliferation by activating its downstream molecules, whereas MEK5 beta expression is associated with inhibition of cell growth. We have recently shown that exogenous expression of c-myc promoter-binding protein 1 (MBP-1) induces prostate cancer cell death (Ghosh, A. K., Steele, R., and Ray, R. B. (2005) Cancer Res. 65, 718-721). In this study, we have investigated whether inhibition of MEK5 signaling pathway can modulate prostate cancer cell growth. MBP-1 is a general transcriptional repressor and modulates a number of cellular genes. Therefore, we examined the endogenous expression status of MEK5 in androgen-independent prostate cancer cells upon recombinant adenovirus-mediated introduction of MBP-1. Our results demonstrated that MBP-1 expression reduced the endogenous MEK5 alpha protein level; on the other hand, MEK5 beta expression was enhanced significantly. Transduction of MBP-1 modulates the downstream signaling molecules of MEK5, such as activation of the cyclin D1 promoter and MEF2C transcriptional activities in androgen-independent prostate cancer cells. MBP-1 expression also modulates MEK5-mediated activation of NF-kappa B. Further analysis suggested that MBP-1 physically associates with MEK5 and induces proteasome-mediated degradation of the MEK5 protein, which appears to occur independently of ubiquitination. Together, our results suggested a novel role of MBP-1 for suppression of prostate cancer cell growth by regulating the MEK5-mediated signaling pathway.	St Louis Univ, Dept Pathol, St Louis, MO 63104 USA	Saint Louis University	Ray, RB (corresponding author), St Louis Univ, Dept Pathol, 1402 S Grand Blvd,4th Floor, St Louis, MO 63104 USA.	rayrb@slu.edu			NATIONAL CANCER INSTITUTE [R01CA052799, R29CA052799] Funding Source: NIH RePORTER; NCI NIH HHS [CA52799] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; American Cancer Society, 2002, SURV RES CANC FACTS; Cameron SJ, 2004, J BIOL CHEM, V279, P1506, DOI 10.1074/jbc.M308755200; CHAUDHARY D, 1995, BIOCHEMISTRY-US, V34, P3438, DOI 10.1021/bi00010a036; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Feo S, 2000, FEBS LETT, V473, P47, DOI 10.1016/S0014-5793(00)01494-0; Gasparian AV, 2002, J CELL SCI, V115, P141; Ghosh AK, 2000, J BIOL CHEM, V275, P7184, DOI 10.1074/jbc.275.10.7184; Ghosh AK, 2005, CANCER RES, V65, P718; Ghosh AK, 1999, MOL CELL BIOL, V19, P2880; Ghosh AK, 2002, ONCOGENE, V21, P2775, DOI 10.1038/sj.onc.1205384; GIALLONGO A, 1986, P NATL ACAD SCI USA, V83, P6741, DOI 10.1073/pnas.83.18.6741; Isaacs WB, 1995, CANCER SURV, V25, P357; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Mehta PB, 2003, ONCOGENE, V22, P1381, DOI 10.1038/sj.onc.1206154; Mulloy R, 2003, ONCOGENE, V22, P5387, DOI 10.1038/sj.onc.1206839; Newman RM, 2004, J BIOL CHEM, V279, P41504, DOI 10.1074/jbc.M407349200; Orlowski M, 2003, ARCH BIOCHEM BIOPHYS, V415, P1, DOI 10.1016/S0003-9861(03)00197-8; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; RAY RB, 1995, CELL GROWTH DIFFER, V6, P1089; RAY RB, 1995, CANCER RES, V55, P3747; RAY RB, 1994, INT J ONCOL, V5, P1433; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sohn SJ, 2002, J BIOL CHEM, V277, P43344, DOI 10.1074/jbc.M207573200; Song H, 2004, ONCOGENE, V23, P8301, DOI 10.1038/sj.onc.1208026; Subramanian A, 2000, J BIOL CHEM, V275, P5958, DOI 10.1074/jbc.275.8.5958; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; White RA, 1997, GENOMICS, V39, P406, DOI 10.1006/geno.1996.4499; Yang RM, 1998, J UROLOGY, V159, P941, DOI 10.1016/S0022-5347(01)63776-5; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	40	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					14325	14330		10.1074/jbc.M413313200	http://dx.doi.org/10.1074/jbc.M413313200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	15805119	hybrid			2022-12-27	WOS:000228095500137
J	Lesne, S; Gabriel, C; Nelson, DA; White, E; MacKenzie, ET; Vivien, D; Buisson, A				Lesne, S; Gabriel, C; Nelson, DA; White, E; MacKenzie, ET; Vivien, D; Buisson, A			Akt-dependent expression of NAIP-1 protects neurons against amyloid-beta toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NEUROTROPHIN SIGNAL-TRANSDUCTION; APOPTOSIS-INHIBITORY PROTEIN; NERVE GROWTH-FACTOR; FACTOR GENE-THERAPY; ALZHEIMERS-DISEASE; CELL-DEATH; DIFFERENTIAL REGULATION; ENDOTHELIAL-CELLS; CORTICAL-NEURONS	Neurotrophins are a family of growth factors that attenuate several forms of pathological neuronal cell death and may represent a putative therapeutic approach to neurodegenerative diseases. In Alzheimer disease, amyloid-beta (A beta) is thought to play a central role in the neuronal death occurring in brains of patients. In the present study, we evaluate the ability of neurotrophin-3 (NT-3) to protect neurons against the toxicity induced by aggregated A beta. We showed that in primary cultures of cortical neurons, NT-3 reduces A beta-induced apoptosis by limiting caspase-8, caspase-9, and caspase-3 cleavage. This neuroprotective effect of NT-3 was concomitant to an increased level of Akt phosphorylation and was abolished by an inhibitor of the phosphatidylinositol-3 kinase (PI-3K), LY294002. In parallel, NT-3 treatment reduced A beta induced caspase-3 processing to control levels. In an attempt to link PI-3K/Akt to caspase inhibition, we evaluated the influence of the PI-3K/Akt axis on the expression of a member of the inhibitors of apoptosis proteins (IAPs), the neuronal apoptosis inhibitory protein-1. We demonstrated that NT-3 induces an up-regulation of neuronal apoptosis inhibitory protein-1 expression in neurons that promotes the inhibition of A beta-induced neuronal apoptosis. Together, these findings demonstrate that NT-3 signaling counters A beta-dependent neuronal cell death and may represent an innovative therapeutic intervention to limit neuronal death in Alzheimer disease.	Univ Caen, UMR CNRS 6185, F-14074 Caen, France; Rutgers State Univ, Howard Hughes Med Inst, Piscataway, NJ 08854 USA	Universite de Caen Normandie; Howard Hughes Medical Institute; Rutgers State University New Brunswick	Buisson, A (corresponding author), Univ Caen, UMR CNRS 6185, Bd H Becquerel,BP5229, F-14074 Caen, France.	a.buisson@neuro.unicaen.fr	Mackenzie, Eric Thomson/L-1938-2015; White, Eileen/ABD-6745-2021; buisson, alain/AAI-8218-2020	White, Eileen/0000-0003-2961-3065; buisson, alain/0000-0002-4281-7911; MacKenzie, Eric T/0000-0003-1057-7033; Lesne, Sylvain/0000-0001-9411-1868; Nelson, Deirdre/0000-0001-5527-2570; VIVIEN, DENIS/0000-0002-7636-2185				Berhow MT, 1996, J NEUROSCI, V16, P4707; BRION JP, 1985, J SUBMICR CYTOL PATH, V17, P89; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cavanaugh JE, 2001, J NEUROSCI, V21, P434, DOI 10.1523/JNEUROSCI.21-02-00434.2001; Chao MV, 2002, NEURON, V33, P9, DOI 10.1016/S0896-6273(01)00573-6; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Das KP, 2001, NEUROSCIENCE, V103, P739, DOI 10.1016/S0306-4522(01)00011-2; Davoodi J, 2004, J BIOL CHEM, V279, P40622, DOI 10.1074/jbc.M405963200; Durany N, 2000, INT J DEV NEUROSCI, V18, P807, DOI 10.1016/S0736-5748(00)00046-0; FRIEDMAN WJ, 1991, J NEUROSCI, V11, P1577; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Harada J, 1999, BRAIN RES, V842, P311, DOI 10.1016/S0006-8993(99)01808-9; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hock C, 2000, ARCH NEUROL-CHICAGO, V57, P846, DOI 10.1001/archneur.57.6.846; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Hu YQ, 1998, J NEUROCHEM, V71, P213; Hugon J, 2000, J NEURAL TRANSM-SUPP, P125; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; Martin D, 2001, J NEUROCHEM, V78, P1000, DOI 10.1046/j.1471-4159.2001.00472.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; NarisawaSaito M, 1996, J NEUROCHEM, V67, P1124; Rose Kamala, 1993, P46; Roth KA, 2001, J NEUROPATH EXP NEUR, V60, P829, DOI 10.1093/jnen/60.9.829; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Smith DE, 1999, P NATL ACAD SCI USA, V96, P10893, DOI 10.1073/pnas.96.19.10893; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.00218.x; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Troy CM, 2000, J NEUROSCI, V20, P1386; Tuszynski MH, 2002, LANCET NEUROL, V1, P51, DOI 10.1016/S1474-4422(02)00006-6; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Wei WL, 2002, J BIOL CHEM, V277, P17649, DOI 10.1074/jbc.M111704200; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; Wiese S, 1999, NAT NEUROSCI, V2, P978, DOI 10.1038/14777; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang Y, 2003, J NEUROSCI, V23, P7385	57	55	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24941	24947		10.1074/jbc.M413495200	http://dx.doi.org/10.1074/jbc.M413495200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15797869	hybrid			2022-12-27	WOS:000230114000078
J	Wang, DQ; Guo, M; Liang, Z; Fan, J; Zhu, ZQ; Zang, JY; Zhu, ZG; Li, XW; Teng, MK; Niu, LW; Dong, YH; Liu, P				Wang, DQ; Guo, M; Liang, Z; Fan, J; Zhu, ZQ; Zang, JY; Zhu, ZG; Li, XW; Teng, MK; Niu, LW; Dong, YH; Liu, P			Crystal structure of human vacuolar protein sorting protein 29 reveals a phosphodiesterase/nuclease-like fold and two protein-protein interaction sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI RETROGRADE TRANSPORT; MEMBRANE-PROTEINS; YEAST; ENDOSOME; ASSOCIATION; RETRIEVAL; RETROMER; RECEPTOR; MUTANTS; NEXIN-1	Vacuolar protein sorting protein 29 (Vps29p), which is involved in retrograde trafficking from prevacuolar endosomes to the trans-Golgi network, performs its biological functions by participating in the formation of a "retromer complex." In human cells, this complex comprises four conserved proteins: hVps35p, hVps29p, hVps26p, and sorting nexin 1 protein (SNX1). Here, we report the crystal structure of hVps29p at 2.1 angstrom resolution, the first three-dimensional structure of the retromer subunits. This novel structure adopts a four-layered alpha-beta-beta-alpha sandwich fold. hVps29p contains a metal-binding site that is very similar to the active sites of some proteins of the phosphodiesterase/nuclease protein family, indicating that hVps29p may carry out chemically similar functions. Structure and sequence conservation analysis suggests that hVps29p contains two protein-protein interaction sites. One site, which potentially serves as the interface between hVps29p and hVps35p, comprises 5 conserved hydrophobic and 8 hydrophilic residues. The other site is relatively more hydrophilic and may serve as a binding interface with hVps26p, SNX1, or other target proteins.	Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China; Univ Sci & Technol China, Chinese Acad Sci, Key Lab Struct Biol, Hefei 230026, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Dept Mol & Cell Biol, Hefei 230026, Anhui, Peoples R China; Chinese Acad Sci, Inst High Energy Phys, Beijing Synchrotron Radiat Facil, Beijing 100039, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; Institute of High Energy Physics, CAS	Teng, MK (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, 96 Jinzhai Rd, Hefei 230026, Anhui, Peoples R China.	mkteng@ustc.edu.cn; lwniu@ustc.edu.cn	Zang, Jianye/E-5228-2013; Zhu, Zhiqiang/J-6210-2016	Dong, Yuhui/0000-0002-4422-4685				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Bryant NJ, 1997, J CELL BIOL, V136, P287, DOI 10.1083/jcb.136.2.287; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Burda P, 2002, J CELL SCI, V115, P3889, DOI 10.1242/jcs.00090; Chen SF, 2004, J BIOL CHEM, V279, P31854, DOI 10.1074/jbc.M401059200; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Cozier GE, 2002, J BIOL CHEM, V277, P48730, DOI 10.1074/jbc.M206986200; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Edgar AJ, 2000, BIOCHEM BIOPH RES CO, V277, P622, DOI 10.1006/bbrc.2000.3727; Glaser F, 2001, PROTEINS, V43, P89, DOI 10.1002/1097-0134(20010501)43:2<89::AID-PROT1021>3.3.CO;2-8; GOTO K, 1995, BIOCHEM BIOPH RES CO, V206, P497, DOI 10.1006/bbrc.1995.1071; Guddat LW, 1999, STRUCT FOLD DES, V7, P757, DOI 10.1016/S0969-2126(99)80100-2; Gullapalli A, 2004, MOL BIOL CELL, V15, P2143, DOI 10.1091/mbc.E03-09-0711; Haft CR, 2000, MOL BIOL CELL, V11, P4105, DOI 10.1091/mbc.11.12.4105; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; HORTON N, 1992, PROTEIN SCI, V1, P169; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Klabunde T, 1996, J MOL BIOL, V259, P737, DOI 10.1006/jmbi.1996.0354; Knofel T, 1999, NAT STRUCT BIOL, V6, P448; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nothwehr SF, 2000, J CELL BIOL, V151, P297, DOI 10.1083/jcb.151.2.297; Nothwehr SF, 1997, J CELL SCI, V110, P1063; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pfeffer SR, 2001, CURR BIOL, V11, pR109, DOI 10.1016/S0960-9822(01)00042-2; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Reddy JV, 2001, MOL BIOL CELL, V12, P3242, DOI 10.1091/mbc.12.10.3242; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; Seaman MNJ, 2004, J CELL BIOL, V165, P111, DOI 10.1083/jcb.200312034; Seaman MNJ, 2002, MOL BIOL CELL, V13, P2826, DOI 10.1091/mbc.02-05-0064; Sheinerman FB, 2000, CURR OPIN STRUC BIOL, V10, P153, DOI 10.1016/S0959-440X(00)00065-8; van Vliet C, 2003, PROG BIOPHYS MOL BIO, V83, P1, DOI 10.1016/S0079-6107(03)00019-1; Verges M, 2004, NAT CELL BIOL, V6, P763, DOI 10.1038/ncb1153; Voegtli WC, 2000, BIOCHEMISTRY-US, V39, P15365, DOI 10.1021/bi0021030; Xu D, 1997, J MOL BIOL, V265, P68, DOI 10.1006/jmbi.1996.0712; Zhong Q, 2002, P NATL ACAD SCI USA, V99, P6767, DOI 10.1073/pnas.092142699	52	53	54	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22962	22967		10.1074/jbc.M500464200	http://dx.doi.org/10.1074/jbc.M500464200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15788412	hybrid			2022-12-27	WOS:000229741800050
J	Weber, ANR; Moncrieffe, MC; Gangloff, M; Imler, JL; Gay, NJ				Weber, ANR; Moncrieffe, MC; Gangloff, M; Imler, JL; Gay, NJ			Ligand-receptor and receptor-receptor interactions act in concert to activate signaling in the Drosophila toll pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DORSAL-VENTRAL POLARITY; CRYSTAL-STRUCTURE; PROTEIN; LIPOPOLYSACCHARIDE; RECOGNITION; COMPLEX; SPATZLE; MD-2; OLIGOMERIZATION	In Drosophila, the signaling pathway mediated by the Toll receptor is critical for the establishment of embryonic dorso-ventral pattern and for innate immune responses to bacterial and fungal pathogens. Toll is activated by high affinity binding of the cytokine Spatzle, a dimeric ligand of the cystine knot family. In vertebrates, a related family of Toll-like receptors play a critical role in innate immune responses. Despite the importance of this family of receptors, little is known about the biochemical events that lead to receptor activation and signaling. Here, we show that Spatzle binds to the N-terminal region of Toll and, using biophysical methods, that the binding is complex. The two binding events that cause formation of the cross-linked complex are non-equivalent: the first Toll ectodomain binds Spatzle with an affinity 3-fold higher than the second molecule suggesting that pathway activation involves negative cooperativity. We further show that the Toll ectodomains are able to form low affinity dimers in solution and that juxtamembrane sequences of Toll are critical for the activation or derepression of the pathway. These results, taken together, suggest a mechanism of signal transduction that requires both ligand-receptor and receptor-receptor interactions.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; CNRS, Inst Biol Mol & Cellulaire, UPR 9022, F-67084 Strasbourg, France	University of Cambridge; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gay, NJ (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	njg11@mole.bio.cam.ac.uk	Imler, Jean-Luc/GXH-4323-2022	Gangloff, Monique/0000-0001-6131-0115; Weber, Alexander/0000-0002-8627-7056				Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bischoff V, 2004, NAT IMMUNOL, V5, P1175, DOI 10.1038/ni1123; DeLotto Y, 1998, MECH DEVELOP, V72, P141, DOI 10.1016/S0925-4773(98)00024-0; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Harmer NJ, 2003, BIOPHYS CHEM, V100, P545, DOI 10.1016/S0301-4622(02)00305-8; He XL, 2004, SCIENCE, V304, P870, DOI 10.1126/science.1095190; He XLL, 2003, NEURON, V38, P177, DOI 10.1016/S0896-6273(03)00232-0; Hu XD, 2004, P NATL ACAD SCI USA, V101, P9369, DOI 10.1073/pnas.0307062101; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Imler JL, 2001, TRENDS CELL BIOL, V11, P304, DOI 10.1016/S0962-8924(01)02004-9; Kennedy MN, 2004, J BIOL CHEM, V279, P34698, DOI 10.1074/jbc.M405444200; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Miyake K, 2004, TRENDS MICROBIOL, V12, P186, DOI 10.1016/j.tim.2004.02.009; Mizuguchi K, 1998, BIOINFORMATICS, V14, P617, DOI 10.1093/bioinformatics/14.7.617; Mizuguchi K, 1998, TRENDS BIOCHEM SCI, V23, P239, DOI 10.1016/S0968-0004(98)01216-X; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; Tauszig S, 2000, P NATL ACAD SCI USA, V97, P10520, DOI 10.1073/pnas.180130797; Vistica J, 2004, ANAL BIOCHEM, V326, P234, DOI 10.1016/j.ab.2003.12.014; Weber ANR, 2004, J BIOL CHEM, V279, P34589, DOI 10.1074/jbc.M403830200; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; WINANS KA, 1995, MOL BIOL CELL, V6, P587, DOI 10.1091/mbc.6.5.587	35	52	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22793	22799		10.1074/jbc.M502074200	http://dx.doi.org/10.1074/jbc.M502074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15795223	hybrid			2022-12-27	WOS:000229741800030
J	Swaminath, G; Deupi, X; Lee, TW; Zhu, W; Thian, FS; Kobilka, TS; Kobilka, B				Swaminath, G; Deupi, X; Lee, TW; Zhu, W; Thian, FS; Kobilka, TS; Kobilka, B			Probing the beta(2) adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PROTEIN-COUPLED RECEPTORS; CONFORMATIONAL STATES; SERINE; DOMAIN	The beta(2) adrenergic receptor (beta(2)AR) is a prototypical family A G protein-coupled receptor (GPCR) and an excellent model system for studying the mechanism of GPCR activation. The beta(2)AR agonist binding site is well characterized, and there is a wealth of structurally related ligands with functionally diverse properties. In the present study, we use catechol (1,2-benzenediol, a structural component of catecholamine agonists) as a molecular probe to identify mechanistic differences between beta(2)AR activation by catecholamine agonists, such as isoproterenol, and by the structurally related non-catechol partial agonist salbutamol. Using biophysical and pharmacologic approaches, we show that the aromatic ring of salbutamol binds to a different site on the beta(2)AR than the aromatic ring of catecholamines. This difference is important in receptor activation as it has been hypothesized that the aromatic ring of catecholamines plays a role in triggering receptor activation through interactions with a conserved cluster of aromatic residues in the sixth transmembrane segment by a rotamer toggle switch mechanism. Our experiments indicate that the aromatic ring of salbutamol does not activate this mechanism either directly or indirectly. Moreover, the non-catechol ring of partial agonists does not interact optimally with serine residues in the fifth transmembrane helix that have been shown to play an important role in activation by catecholamines. These results demonstrate unexpected differences in binding and activation by structurally similar agonists and partial agonists. Moreover, they provide evidence that activation of a GPCR is a multistep process that can be dissected into its component parts using agonist fragments.	Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Palo Alto, CA 94305 USA	Stanford University	Kobilka, B (corresponding author), Stanford Univ, Sch Med, 157 Beckman Ctr,279 Campus Dr, Stanford, CA 94305 USA.	kobilka@cmgm.stanford.edu	Centeno, Patricia Pacios/O-8368-2016; Deupi, Xavier/B-2424-2009	Deupi, Xavier/0000-0003-4572-9316; Kobilka, Brian/0000-0001-5958-3990	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028471] Funding Source: NIH RePORTER; NINDS NIH HHS [5R01 NS 28471] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; CASE DA, 2004, AMBER 8; Chen SH, 2002, BIOCHEMISTRY-US, V41, P6045, DOI 10.1021/bi012189c; Del Carmine R, 2004, MOL PHARMACOL, V66, P356, DOI 10.1124/mol.66.2.356; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Kobilka B, 2004, MOL PHARMACOL, V65, P1060, DOI 10.1124/mol.65.5.1060; KOBILKA BK, 1995, ANAL BIOCHEM, V231, P269, DOI 10.1006/abio.1995.1533; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee TW, 1999, BIOCHEMISTRY-US, V38, P13801, DOI 10.1021/bi9908282; Liapakis G, 2000, J BIOL CHEM, V275, P37779, DOI 10.1074/jbc.M002092200; Liapakis G, 2004, MOL PHARMACOL, V65, P1181, DOI 10.1124/mol.65.5.1181; Luttrell LM, 2002, J CELL SCI, V115, P455; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Palanche T, 2001, J BIOL CHEM, V276, P34853, DOI 10.1074/jbc.M104363200; Rees DC, 2004, NAT REV DRUG DISCOV, V3, P660, DOI 10.1038/nrd1467; Shi L, 2002, J BIOL CHEM, V277, P14777, DOI 10.1074/jbc.M108967200; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1989, TRENDS PHARM SCI S, V10, P26; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Wieland K, 1996, P NATL ACAD SCI USA, V93, P9276, DOI 10.1073/pnas.93.17.9276; Wu ZR, 2001, BIOCHEM J, V354, P485, DOI 10.1042/0264-6021:3540485	30	227	234	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22165	22171		10.1074/jbc.M502352200	http://dx.doi.org/10.1074/jbc.M502352200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817484	hybrid			2022-12-27	WOS:000229557900061
J	Benn, M; Nordestgaard, BG; Jensen, JS; Nilausen, K; Meinertz, H; Tybjaerg-Hansen, A				Benn, M; Nordestgaard, BG; Jensen, JS; Nilausen, K; Meinertz, H; Tybjaerg-Hansen, A			Mutation in apolipoprotein B associated with hypobetalipoproteinemia despite decreased binding to the low density lipoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRUNCATED APOLIPOPROTEIN; PLASMA; IDENTIFICATION; GENE; CODON-3500; SEQUENCE; B-100	Mutations in apolipoprotein B (APOB) may reduce binding of low density lipoprotein (LDL) to the LDL receptor and cause hypercholesterolemia. We showed that heterozygotes for a new mutation in APOB have hypobetalipoproteinemia, despite a reduced binding of LDL to the LDL receptor. APOB R3480P heterozygotes were identified among 9,255 individuals from the general population and had reduced levels of apoB-containing lipoproteins. Most surprisingly, R3480P LDL bound with lower affinity to the LDL receptor than non- carrier LDL in vitro, and these results were confirmed by turnover studies of LDL in vivo. In very low density lipoprotein (VLDL) turnover studies, the amount of VLDL converted to LDL in R3480P heterozygotes was substantially reduced, suggesting that this was the explanation for the hypobetalipoproteinemia observed in these individuals. Our findings emphasized the importance of combining in vitro studies with both human in vivo and population- based studies, as in vitro studies often have focused on very limited aspects of complex mechanisms taken out of their natural context.	Univ Copenhagen Hosp, Rigshosp, Dept Clin Biochem, Sect Mol Genet, DK-2100 Copenhagen, Denmark; Herlev Univ Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark; Bispebjerg Hosp, Copenhagen City Heart Study, DK-2400 Copenhagen, Denmark; Panum Inst, Dept Med Anat, DK-2200 Copenhagen, Denmark; Univ Copenhagen Hosp, Rigshosp, Dept Med B, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Bispebjerg Hospital; Rigshospitalet; University of Copenhagen	Tybjaerg-Hansen, A (corresponding author), Univ Copenhagen Hosp, Rigshosp, Dept Clin Biochem, Sect Mol Genet, KB3011,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	at-h@rh.dk	Benn, Marianne/O-4164-2019; Nordestgaard, Borge Gronne/ABF-1310-2020	Benn, Marianne/0000-0002-1701-595X; Nordestgaard, Borge/0000-0002-1954-7220				APPLEYARD M, 1989, SCAND J SOC MED S, V41, P1; ARMITAGE P, 2002, STAT METHODS MED RES, P1; ARNOLD KS, 1992, LIPOPROTEIN ANAL PRA, P145; Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; Boren J, 2001, J BIOL CHEM, V276, P9214, DOI 10.1074/jbc.M008890200; CHATTERTON JE, 1995, J LIPID RES, V36, P2027; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; EGUSA G, 1983, J LIPID RES, V24, P1261; Frikke-Schmidt R, 2000, J LIPID RES, V41, P1812; Gabelli C, 1996, ARTERIOSCL THROM VAS, V16, P1189, DOI 10.1161/01.ATV.16.9.1189; GAFFNEY D, 1995, ARTERIOSCL THROM VAS, V15, P1025, DOI 10.1161/01.ATV.15.8.1025; Goldstein JL, 2001, METABOLIC MOL BASES, V8th, P2863; HAVEL RJ, 2001, METABOLIC MOL BASES, P2717; Kornerup K, 2002, ARTERIOSCL THROM VAS, V22, P1168, DOI 10.1161/01.ATV.0000022849.26083.FA; KRAUSS RM, 1982, J LIPID RES, V23, P97; LINTON MF, 1993, J LIPID RES, V34, P521; LUDWIG EH, 1987, DNA-J MOLEC CELL BIO, V6, P363, DOI 10.1089/dna.1987.6.363; MATTHEWS CME, 1957, PHYS MED BIOL, V2, P36, DOI 10.1088/0031-9155/2/1/305; *MIN INC, 1995, MIN WIND MIN REL 10; NISSEN H, 1995, CLIN CHEM, V41, P419; NORDESTGAARD BG, 1992, ARTERIOSCLER THROMB, V12, P6, DOI 10.1161/01.ATV.12.1.6; PARHOFER KG, 1992, J CLIN INVEST, V89, P1931, DOI 10.1172/JCI115799; PULLINGER CR, 1995, J CLIN INVEST, V95, P1225, DOI 10.1172/JCI117772; *SAAM I, 2002, SAAM 2 VERS 1 2; Schnohr P, 2001, EUR HEART J SUPPL, V3, pH1; SORIA LF, 1989, P NATL ACAD SCI USA, V86, P587, DOI 10.1073/pnas.86.2.587; Sparks JD, 1996, METHOD ENZYMOL, V263, P104; *SPSS INC, 1999, SPSS WIND REL 11 5 0; Tybjaerg-Hansen A, 1998, NEW ENGL J MED, V338, P1577, DOI 10.1056/NEJM199805283382203	29	16	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21052	21060		10.1074/jbc.M413877200	http://dx.doi.org/10.1074/jbc.M413877200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797858	hybrid			2022-12-27	WOS:000229438800020
J	Norris, EH; Giasson, BI; Hodara, R; Xu, SH; Trojanowski, JQ; Ischiropoulos, H; Lee, VMY				Norris, EH; Giasson, BI; Hodara, R; Xu, SH; Trojanowski, JQ; Ischiropoulos, H; Lee, VMY			Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; LEWY BODY DISEASE; PARKINSONS-DISEASE; IN-VITRO; ALZHEIMERS-DISEASE; SUBSTANTIA-NIGRA; NEURODEGENERATIVE DISEASES; FIBRIL FORMATION; HUMAN BRAIN; BODIES	Previous studies demonstrated that alpha-synuclein (alpha-syn) fibrillization is inhibited by dopamine, and studies to understand the molecular basis of this process were conducted (Conway, K. A., Rochet, J. C., Bieganski, R. M., and Lansbury, P. T., Jr. ( 2001) Science 294, 1346-1349). Dopamine inhibition of alpha-syn fibrillization generated exclusively spherical oligomers that depended on dopamine autoxidation but not alpha-syn oxidation, because mutagenesis of Met, His, and Tyr residues in alpha-syn did not abrogate this inhibition. However, truncation of alpha-syn at residue 125 restored the ability of alpha-syn to fibrillize in the presence of dopamine. Mutagenesis and competition studies with specific synthetic peptides identified alpha-syn residues 125-129 (i.e. YEMPS) as an important region in the dopamine-induced inhibition of alpha-syn fibrillization. Significantly, the dopamine oxidation product dopaminochrome was identified as a specific inhibitor of alpha-syn fibrillization. Dopaminochrome promotes the formation of spherical oligomers by inducing conformational changes, as these oligomers regained the ability to fibrillize by simple denaturation/ renaturation. Taken together, these data indicate that dopamine inhibits alpha-syn fibrillization by inducing structural changes in alpha-syn that can occur through the interaction of dopaminochrome with the (YEMPS129)-Y-125 motif of alpha-syn. These results suggest that the dopamine autoxidation can prevent alpha-syn fibrillization in dopaminergic neurons through a novel mechanism. Thus, decreased dopamine levels in substantia nigra neurons might promote alpha-syn aggregation in Parkinson's disease.	Univ Penn, Inst Aging, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Stokes Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Lee, VMY (corresponding author), Univ Penn, Inst Aging, Ctr Neurodegenerat Dis Res, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.	vmylee@mail.med.upenn.edu		Norris, Erin/0000-0002-4522-3537	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS044233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009215] Funding Source: NIH RePORTER; NIA NIH HHS [AG09215] Funding Source: Medline; NINDS NIH HHS [NS044233] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Cabin DE, 2002, J NEUROSCI, V22, P8797; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Crowther RA, 2000, NEUROSCI LETT, V292, P128, DOI 10.1016/S0304-3940(00)01440-3; Crystal AS, 2003, J NEUROCHEM, V86, P1359, DOI 10.1046/j.1471-4159.2003.01949.x; Damier P, 1999, BRAIN, V122, P1437, DOI 10.1093/brain/122.8.1437; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; Duda JE, 2002, ANN NEUROL, V52, P205, DOI 10.1002/ana.10279; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Kosaka K, 1996, CURR OPIN NEUROL, V9, P271, DOI 10.1097/00019052-199608000-00005; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Li J, 2004, FASEB J, V18, P962, DOI 10.1096/fj.03-0770fje; Louis ED, 1996, ADV NEUROL, V69, P311; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Murray IVJ, 2003, BIOCHEMISTRY-US, V42, P8530, DOI 10.1021/bi027363r; Norris EH, 2003, J BIOL CHEM, V278, P27230, DOI 10.1074/jbc.M212436200; PAKKENBERG B, 1991, J NEUROL NEUROSUR PS, V54, P30, DOI 10.1136/jnnp.54.1.30; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Takeda A, 1998, AM J PATHOL, V152, P367; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wersinger C, 2003, NEUROSCI LETT, V340, P189, DOI 10.1016/S0304-3940(03)00097-1; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600	48	216	221	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21212	21219		10.1074/jbc.M412621200	http://dx.doi.org/10.1074/jbc.M412621200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15817478	hybrid			2022-12-27	WOS:000229438800039
J	Torres, VJ; Ivie, SE; McClain, MS; Cover, TL				Torres, VJ; Ivie, SE; McClain, MS; Cover, TL			Functional properties of the p33 and p55 domains of the Helicobacter pylori vacuolating cytotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIN VACA; CELLULAR VACUOLATION; ACID ACTIVATION; PLASMA-MEMBRANE; BINDING; RECEPTOR; INDUCTION; REVEALS; INTERNALIZATION; IDENTIFICATION	Helicobacter pylori secretes an 88-kDa vacuolating cytotoxin (VacA) that may contribute to the pathogenesis of peptic ulcer disease and gastric cancer. VacA cytotoxic activity requires assembly of VacA monomers into oligomeric structures, formation of anion-selective membrane channels, and entry of VacA into host cells. In this study, we analyzed the functional properties of recombinant VacA fragments corresponding to two putative VacA domains ( designated p33 and p55). Immunoprecipitation experiments indicated that these two domains can interact with each other to form protein complexes. In comparison to the individual VacA domains, a mixture of the p33 and p55 proteins exhibited markedly enhanced binding to the plasma membrane of mammalian cells. Furthermore, internalization of the VacA domains was detected when cells were incubated with the p33/ p55 mixture but not when the p33 and p55 proteins were tested individually. Incubation of cells with the p33/ p55 mixture resulted in cell vacuolation, whereas the individual domains lacked detectable cytotoxic activity. Interestingly, sequential addition of p55 followed by p33 resulted in VacA internalization and cell vacuolation, whereas sequential addition in the reverse order was ineffective. These results indicate that both the p33 and p55 domains contribute to the binding and internalization of VacA and that both domains are required for vacuolating cytotoxic activity. Reconstitution of toxin activity from two separate domains, as described here for VacA, has rarely been described for pore-forming bacterial toxins, which suggests that VacA is a pore-forming toxin with unique structural properties.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Div Infect Dis, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Torres, VJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Div Infect Dis, A2200 MCN, Nashville, TN 37232 USA.	timothy.L.cover@vanderbilt.edu	Cover, Timothy/I-3814-2015; McClain, Mark S/A-6942-2009	Cover, Timothy/0000-0001-8503-002X; McClain, Mark S/0000-0002-9857-4883; Torres, Victor/0000-0002-7126-0489	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053623] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM070061] Funding Source: NIH RePORTER; NIAID NIH HHS [AI39657] Funding Source: Medline; NIDDK NIH HHS [DK53623] Funding Source: Medline; NIGMS NIH HHS [GM070061-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adrian M, 2002, J MOL BIOL, V318, P121, DOI 10.1016/S0022-2836(02)00047-5; ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; Boncristiano M, 2003, J EXP MED, V198, P1887, DOI 10.1084/jem.20030621; Cover TL, 2005, NAT REV MICROBIOL, V3, P320, DOI 10.1038/nrmicro1095; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; Cover TL, 2003, CANCER RES, V63, P951; COVER TL, 1992, J BIOL CHEM, V267, P10570; COVER TL, 1994, J BIOL CHEM, V269, P10566; Cover TL, 1997, J CELL BIOL, V138, P759, DOI 10.1083/jcb.138.4.759; Czajkowsky DM, 1999, P NATL ACAD SCI USA, V96, P2001, DOI 10.1073/pnas.96.5.2001; DEBERNARD M, 1995, J BIOL CHEM, V270, P23937, DOI 10.1074/jbc.270.41.23937; Diep DB, 1998, MOL MICROBIOL, V30, P341, DOI 10.1046/j.1365-2958.1998.01068.x; Dubail I, 2001, MICROBIOL-SGM, V147, P2679, DOI 10.1099/00221287-147-10-2679; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; Figueiredo C, 2002, J NATL CANCER I, V94, P1680, DOI 10.1093/jnci/94.22.1680; Fujikawa A, 2003, NAT GENET, V33, P375, DOI 10.1038/ng1112; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; Gebert B, 2005, REV PHYSIOL BIOCH P, V152, P205, DOI 10.1007/s10254-004-0027-3; Gebert B, 2003, SCIENCE, V301, P1099, DOI 10.1126/science.1086871; Geisse NA, 2004, BIOCHEM J, V381, P911, DOI 10.1042/BJ20031719; HAWRYLIK SJ, 1994, J CLIN MICROBIOL, V32, P790, DOI 10.1128/JCM.32.3.790-792.1994; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; Li Y, 2004, MOL BIOL CELL, V15, P1946, DOI 10.1091/mbc.e03-08-0618; Lupetti P, 1996, J CELL BIOL, V133, P801, DOI 10.1083/jcb.133.4.801; MARSHALL BJ, 1984, LANCET, V1, P1311; McClain MS, 2000, MOL MICROBIOL, V37, P433, DOI 10.1046/j.1365-2958.2000.02013.x; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; McClain MS, 2003, INFECT IMMUN, V71, P2266, DOI 10.1128/IAI.71.4.2266-2271.2003; McClain MS, 2001, J BACTERIOL, V183, P6499, DOI 10.1128/JB.183.22.6499-6508.2001; McClain MS, 2001, INFECT IMMUN, V69, P1181, DOI 10.1128/IAI.69.2.1181-1184.2001; Molinari M, 1998, BIOCHEM BIOPH RES CO, V248, P334, DOI 10.1006/bbrc.1998.8808; Molinari M, 1998, J EXP MED, V187, P135, DOI 10.1084/jem.187.1.135; Moll G, 1995, EUR J BIOCHEM, V234, P947, DOI 10.1111/j.1432-1033.1995.947_a.x; Montecucco C, 2003, J EXP MED, V198, P1767, DOI 10.1084/jem.20031839; Nakayama M, 2004, J BIOL CHEM, V279, P7024, DOI 10.1074/jbc.M308898200; Nguyen VQ, 2001, INFECT IMMUN, V69, P543, DOI 10.1128/IAI.69.1.543-546.2001; Padilla PI, 2000, J BIOL CHEM, V275, P15200, DOI 10.1074/jbc.275.20.15200; Patel HK, 2002, INFECT IMMUN, V70, P4112, DOI 10.1128/IAI.70.8.4112-4123.2002; Reyrat JM, 1999, J MOL BIOL, V290, P459, DOI 10.1006/jmbi.1999.2877; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; Schraw W, 2002, J BIOL CHEM, V277, P34642, DOI 10.1074/jbc.M203466200; Seto K, 1998, FEBS LETT, V431, P347, DOI 10.1016/S0014-5793(98)00788-1; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Sundrud MS, 2004, P NATL ACAD SCI USA, V101, P7727, DOI 10.1073/pnas.0401528101; Szabo I, 1999, EMBO J, V18, P5517, DOI 10.1093/emboj/18.20.5517; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Torres VJ, 2004, J BIOL CHEM, V279, P2324, DOI 10.1074/jbc.M310159200; Utt M, 2001, FEMS IMMUNOL MED MIC, V30, P109, DOI 10.1111/j.1574-695X.2001.tb01557.x; Vinion-Dubiel AD, 1999, J BIOL CHEM, V274, P37736, DOI 10.1074/jbc.274.53.37736; Wang HJ, 2000, BIOCHEM BIOPH RES CO, V278, P449, DOI 10.1006/bbrc.2000.3820; Wang WC, 2001, BIOCHEMISTRY-US, V40, P11887, DOI 10.1021/bi010065u; Willhite DC, 2004, CELL MICROBIOL, V6, P143, DOI 10.1046/j.1462-5822.2003.00347.x; Willhite DC, 2003, J BIOL CHEM, V278, P48204, DOI 10.1074/jbc.M304131200; Willhite DC, 2002, INFECT IMMUN, V70, P3824, DOI 10.1128/IAI.70.7.3824-3832.2002; Yahiro K, 1999, J BIOL CHEM, V274, P36693, DOI 10.1074/jbc.274.51.36693; Yahiro K, 2003, J BIOL CHEM, V278, P19183, DOI 10.1074/jbc.M300117200; Ye D, 2000, INFECT IMMUN, V68, P4354, DOI 10.1128/IAI.68.7.4354-4357.2000; Ye D, 2002, MOL MICROBIOL, V43, P1243, DOI 10.1046/j.1365-2958.2002.02818.x; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277	59	59	64	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21107	21114		10.1074/jbc.M501042200	http://dx.doi.org/10.1074/jbc.M501042200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15817461	hybrid			2022-12-27	WOS:000229438800026
J	Kellenberger, E; Dominguez, C; Fribourg, S; Wasielewski, E; Moras, D; Poterszman, A; Boelens, R; Kieffer, B				Kellenberger, E; Dominguez, C; Fribourg, S; Wasielewski, E; Moras, D; Poterszman, A; Boelens, R; Kieffer, B			Solution structure of the C-terminal domain of TFIIH p44 subunit reveals a novel type of C4C4 ring domain involved in protein-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; MOLECULAR-STRUCTURE; COCKAYNE-SYNDROME; REPAIR COMPLEX; NMR; FINGER; INSIGHTS; HELICASE; DATABASE; QUALITY	The human general transcription factor TFIIH is involved in both transcription and DNA nucleotide excision repair. Among the 10 subunits of the complex, p44 subunit plays a crucial role in both mechanisms. Its N-terminal domain interacts with the XPD helicase, whereas its C-terminal domain is involved specifically in the promoter escape activity. By mutating an exposed and non-conserved cysteine residue into a serine, we produced a soluble mutant of p44-( 321 - 395) suitable for solution structure determination. The domain adopts a C4C4 RING domain structure with sequential organization of beta-strands that is related to canonical RING domains by a circular permutation of the beta-sheet elements. Analysis of the molecular surface and mutagenesis experiments suggests that the binding of p44-( 321 - 395) to TFIIH p34 subunit is not mediated by electrostatic interactions and, thus, differs from previously reported interaction mechanisms involving RING domains.	Inst Genet & Biol Mol & Cellulaire, UMR 7104, Dept Biol & Genom Struct, F-67404 Illkirch Graffenstaden, France; Univ Utrecht, Bijvoet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Utrecht University	Kieffer, B (corresponding author), ETH Honggerberg, Swiss Fed Inst Technol, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland.	kieffer@esbs.u-strasbg.fr	Fribourg, Sebastien/M-7418-2014; Boelens, Rolf/B-4702-2009; Kellenberger, Esther/AFN-2081-2022; Dominguez, Cyril/H-3347-2019; Wasielewski, Emeric/L-4424-2013; Kieffer, Bruno/AAE-8999-2019	Fribourg, Sebastien/0000-0003-4112-7510; Boelens, Rolf/0000-0002-6939-8913; Kellenberger, Esther/0000-0002-9320-4840; Dominguez, Cyril/0000-0003-3575-8922; Wasielewski, Emeric/0000-0001-9656-4764; POTERSZMAN, Arnaud/0000-0002-6702-5777; Kieffer, Bruno/0000-0002-2033-4679				Albert TK, 2002, EMBO J, V21, P355, DOI 10.1093/emboj/21.3.355; Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BERNSTEIN BE, 1994, BIOCHEMISTRY-US, V33, P4460, DOI 10.1021/bi00181a005; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang WH, 2000, CELL, V102, P609, DOI 10.1016/S0092-8674(00)00083-0; Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491; COLEMAN JE, 1993, METHOD ENZYMOL, V227, P16; Crowley P, 2000, J AM CHEM SOC, V122, P2968, DOI 10.1021/ja9942787; Dominguez C, 2004, STRUCTURE, V12, P633, DOI 10.1016/j.str.2004.03.004; Dominguez C, 2004, HDB METALLOPROTEINS, V3, P338; Donate LE, 1996, PROTEIN SCI, V5, P2600, DOI 10.1002/pro.5560051223; Egly JM, 2001, FEBS LETT, V498, P124, DOI 10.1016/S0014-5793(01)02458-9; Fribourg S, 2000, J BIOL CHEM, V275, P31963, DOI 10.1074/jbc.M004960200; Fribourg S, 2001, J MOL BIOL, V306, P363, DOI 10.1006/jmbi.2000.4376; Frit P, 1999, BIOCHIMIE, V81, P27, DOI 10.1016/S0300-9084(99)80035-2; Gervais V, 2004, NAT STRUCT MOL BIOL, V11, P616, DOI 10.1038/nsmb782; Gervais V, 2001, J BIOL CHEM, V276, P7457, DOI 10.1074/jbc.M007963200; Giglia-Mari G, 2004, NAT GENET, V36, P714, DOI 10.1038/ng1387; Hanzawa H, 2001, J BIOL CHEM, V276, P10185, DOI 10.1074/jbc.M009298200; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuszewski J, 1996, PROTEIN SCI, V5, P1067; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lehmann AR, 2003, BIOCHIMIE, V85, P1101, DOI 10.1016/j.biochi.2003.09.010; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Ohi MD, 2003, NAT STRUCT BIOL, V10, P250, DOI 10.1038/nsb906; PELTON JG, 1993, PROTEIN SCI, V2, P543; Schultz P, 2000, CELL, V102, P599, DOI 10.1016/S0092-8674(00)00082-9; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Seroz T, 2000, J BIOL CHEM, V275, P33260, DOI 10.1074/jbc.M004764200; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; Tremeau-Bravard A, 2001, J BIOL CHEM, V276, P27693, DOI 10.1074/jbc.M102457200; VanDemark AP, 2002, CURR OPIN STRUC BIOL, V12, P822, DOI 10.1016/S0959-440X(02)00389-5; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; VUISTER GW, 1993, J BIOMOL NMR, V3, P67; Winkler GS, 2004, J MOL BIOL, V337, P157, DOI 10.1016/j.jmb.2004.01.031; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; Zurita M, 2003, TRENDS GENET, V19, P578, DOI 10.1016/j.tig.2003.08.005	42	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20785	20792		10.1074/jbc.M412999200	http://dx.doi.org/10.1074/jbc.M412999200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15790571	hybrid, Green Published			2022-12-27	WOS:000229242000076
J	McDonald, C; Inohara, N; Nunez, G				McDonald, C; Inohara, N; Nunez, G			Peptidoglycan signaling in innate immunity and inflammatory disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							BACTERIAL MURAMYL DIPEPTIDE; KAPPA-B ACTIVATION; L-ALANINE AMIDASE; RECOGNITION PROTEINS; CROHNS-DISEASE; HOST RECOGNITION; CARD15 MUTATIONS; NOD2; SUSCEPTIBILITY; PURIFICATION		Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	McDonald, C (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.	bclx@umich.edu	Nuñez, Gabriel/A-7160-2014	McDonald, Christine/0000-0002-6745-9487	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI054053] Funding Source: NIH RePORTER; NIAID NIH HHS [F32 AI054053] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032; Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Albrecht M, 2003, FEBS LETT, V554, P520, DOI 10.1016/S0014-5793(03)01222-5; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Dowds TA, 2004, J BIOL CHEM, V279, P21924, DOI 10.1074/jbc.M401178200; Dziarski R, 2003, BLOOD, V102, P689, DOI 10.1182/blood-2002-12-3853; Dziarski R, 2004, MOL IMMUNOL, V40, P877, DOI 10.1016/j.molimm.2003.10.011; Ferrandon D, 2004, SEMIN IMMUNOL, V16, P43, DOI 10.1016/j.smim.2003.10.008; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; Hoijer MA, 1996, BBA-GEN SUBJECTS, V1289, P57, DOI 10.1016/0304-4165(95)00136-0; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; KANAZAWA M, 2004, BLOOD J, V105, P1195; Kiselev SL, 1998, J BIOL CHEM, V273, P18633, DOI 10.1074/jbc.273.29.18633; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Lala S, 2003, GASTROENTEROLOGY, V125, P47, DOI 10.1016/S0016-5085(03)00661-9; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Martinon F, 2004, CURR BIOL, V14, P1929, DOI 10.1016/j.cub.2004.10.027; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Ogura Y, 2003, GUT, V52, P1591, DOI 10.1136/gut.52.11.1591; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Otte JM, 2003, GASTROENTEROLOGY, V124, P1866, DOI 10.1016/S0016-5085(03)00403-7; Pauleau AL, 2003, MOL CELL BIOL, V23, P7531, DOI 10.1128/MCB.23.21.7531-7539.2003; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Schorey JS, 2003, CELL MICROBIOL, V5, P133, DOI 10.1046/j.1462-5822.2003.00263.x; Steiner H, 2004, IMMUNOL REV, V198, P83, DOI 10.1111/j.0105-2896.2004.0120.x; STEWARTTULL DES, 1980, ANNU REV MICROBIOL, V34, P311, DOI 10.1146/annurev.mi.34.100180.001523; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tanabe T, 2004, EMBO J, V23, P1587, DOI 10.1038/sj.emboj.7600175; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; VALINGER Z, 1982, BIOCHIM BIOPHYS ACTA, V701, P63, DOI 10.1016/0167-4838(82)90313-2; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092; Wehkamp J, 2004, GUT, V53, P1658, DOI 10.1136/gut.2003.032805; Xu M, 2004, MOL CELL BIOL, V24, P7949, DOI 10.1128/MCB.24.18.7949-7957.2004; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	46	105	111	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20177	20180		10.1074/jbc.R500001200	http://dx.doi.org/10.1074/jbc.R500001200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15802263	hybrid			2022-12-27	WOS:000229242000002
J	Rathore, D; Nagarkatti, R; Jani, D; Chattopadhyay, R; de la Vega, P; Kumar, S; McCutchan, TF				Rathore, D; Nagarkatti, R; Jani, D; Chattopadhyay, R; de la Vega, P; Kumar, S; McCutchan, TF			An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; VACCINE; HEPARIN; ANTIGEN; REGION; SPOROZOITE; RECEPTORS; INFECTION; MEMBRANE; BINDING	Circumsporozoite, a predominant surface protein, is involved in invasion of liver cells by Plasmodium sporozoites, which leads to malaria. We have previously reported that the amino terminus region ( amino acids 27 117) of P. falciparum circumsporozoite protein plays a critical role in the invasion of liver cells by the parasite. Here we show that invasion-blocking antibodies are induced by a polypeptide encoding these 91 amino acids, only when it is presented in the absence of the rest of the protein. This suggests that when present in the whole protein, the amino terminus remains immunologically cryptic. A single reactive epitope was identified and mapped to a stretch of 21 amino acids from position 93 to 113. The epitope is configurational in nature, since its recognition was affected by deleting as little as 3 amino acids from either end of the 21-residue peptide. Lysine 104, the only known polymorphic position in the epitope, affected its recognition by the antibodies, and its conversion to leucine in the protein led to a substantial loss of binding activity of the protein to the hepatocytes. This indicated that in the protein, the epitope serves as a binding ligand and facilitates the interaction between sporozoite and hepatic cells. When considered along with the observation that in its native state this motif is immunologically unresponsive, we suggest that hiding functional moieties of the protein from the immune system is an evasion strategy to preserve liver cell binding function and may be of importance in designing anti-sporozoite vaccines.	Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA; NIAID, Growth & Dev Sect, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA; USN, Med Res Ctr, Malaria Program, Silver Spring, MD 20910 USA; US FDA, Div Emerging & Transfus Transmitted Dis, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA	Virginia Polytechnic Institute & State University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); United States Department of Defense; United States Navy; US Food & Drug Administration (FDA)	McCutchan, TF (corresponding author), Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA.	Tmccutchan@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000208, ZIAAI000208] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; ANDERS RF, 1986, CIBA F SYMP, V119, P164; CALLE JMC, 1992, J IMMUNOL, V149, P2695; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; Chattopadhyay R, 2003, J BIOL CHEM, V278, P25977, DOI 10.1074/jbc.M300865200; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DELACRUZ VF, 1989, J IMMUNOL, V142, P3568; DELPORTILLO HA, 1987, MOL BIOCHEM PARASIT, V24, P289, DOI 10.1016/0166-6851(87)90161-7; Escalante AA, 2002, MOL BIOCHEM PARASIT, V125, P83, DOI 10.1016/S0166-6851(02)00216-5; Frevert U, 1998, EMBO J, V17, P3816, DOI 10.1093/emboj/17.14.3816; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; KUMAR S, 1988, NATURE, V334, P258, DOI 10.1038/334258a0; Lally KM, 2001, INT J CANCER, V93, P841, DOI 10.1002/ijc.1420; LOCKYER MJ, 1988, NUCLEIC ACIDS RES, V16, P9041, DOI 10.1093/nar/16.18.9041; Nardin EH, 2000, J INFECT DIS, V182, P1486, DOI 10.1086/315871; OZAKI LS, 1983, CELL, V34, P815, DOI 10.1016/0092-8674(83)90538-X; Rathore D, 2000, P NATL ACAD SCI USA, V97, P8530, DOI 10.1073/pnas.140224597; Rathore D, 2003, J BIOL CHEM, V278, P40905, DOI 10.1074/jbc.M306250200; Rathore D, 2000, INFECT IMMUN, V68, P740, DOI 10.1128/IAI.68.2.740-743.2000; Rathore D, 2002, J BIOL CHEM, V277, P7092, DOI 10.1074/jbc.M106862200; Rathore D, 2001, MOL BIOCHEM PARASIT, V118, P75, DOI 10.1016/S0166-6851(01)00369-3; Rathore D, 2001, BIOCHEMISTRY-US, V40, P11518, DOI 10.1021/bi0105476; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Sidjanski SP, 1997, MOL BIOCHEM PARASIT, V90, P33, DOI 10.1016/S0166-6851(97)00124-2; SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; ZAVALA F, 1985, SCIENCE, V228, P1436, DOI 10.1126/science.2409595	28	52	60	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20524	20529		10.1074/jbc.M414254200	http://dx.doi.org/10.1074/jbc.M414254200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781464	hybrid			2022-12-27	WOS:000229242000046
J	Shen, C; Nettleton, D; Jiang, M; Kim, SK; Powell-Coffman, JA				Shen, C; Nettleton, D; Jiang, M; Kim, SK; Powell-Coffman, JA			Roles of the HIF-1 hypoxia-inducible factor during hypoxia response in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED SUSPENDED ANIMATION; C-ELEGANS; PROLYL 4-HYDROXYLASE; GENE-EXPRESSION; STRUCTURAL BASIS; PROTEIN; HIF-1-ALPHA; DISEASE; MUTANTS; MAINTENANCE	The human hypoxia-inducible transcription factor HIF-1 is a critical regulator of cellular and systemic responses to low oxygen levels. When oxygen levels are high, the HIF-1 alpha subunit is hydroxylated and is targeted for degradation by the von Hippel-Lindau tumor suppressor protein (VHL). This regulatory pathway is evolutionarily conserved, and the Caenorhabditis elegans hif-1 and vhl-1 genes encode homologs of the HIF-1 alpha subunit and VHL. To understand and describe more fully the molecular basis for hypoxia response in this important genetic model system, we compared hypoxia-induced changes in mRNA expression in wild-type, hif-1-deficient, and vhl-1-deficient C. elegans using whole genome microarrays. These studies identified 110 hypoxia-regulated gene expression changes, 63 of which require hif- 1 function. Mutation of vhl- 1 abrogates most hif-1-dependent changes in mRNA expression. Genes regulated by C. elegans hif- 1 have predicted functions in signal transduction, metabolism, transport, and extracellular matrix remodeling. We examined the in vivo requirement for 16 HIF-1 target genes and discovered that the phy-2 prolyl 4-hydroxylase alpha subunit is critical for survival in hypoxic conditions. Some HIF-1 target genes negatively regulate formation of stress-resistant dauer larvae. The microarray data presented herein also provide clear evidence for an HIF-1-independent pathway for hypoxia response, and this pathway regulates the expression of multiple heat shock proteins and several transcription factors.	Iowa State Univ, Dept Genet Dev & Cell Biol, Ames, IA 50011 USA; Iowa State Univ, Dept Stat, Ames, IA 50011 USA; Stanford Univ, Dept Dev Biol, Stanford, CA 94305 USA	Iowa State University; Iowa State University; Stanford University	Powell-Coffman, JA (corresponding author), Iowa State Univ, Dept Genet Dev & Cell Biol, 2108 Mol Biol Bldg, Ames, IA 50011 USA.	japc@iastate.edu		Nettleton, Dan/0000-0002-6045-1036; Powell-Coffman, Jo Anne/0000-0001-9164-7499				Ailion M, 2003, GENETICS, V165, P127; Bishop T, 2004, PLOS BIOL, V2, P1549, DOI 10.1371/journal.pbio.0020289; BRENNER S, 1974, GENETICS, V77, P71; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Dong QF, 2004, NUCLEIC ACIDS RES, V32, pD354, DOI 10.1093/nar/gkh046; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Friedman L, 2000, P NATL ACAD SCI USA, V97, P4736, DOI 10.1073/pnas.97.9.4736; Gray JM, 2004, NATURE, V430, P317, DOI 10.1038/nature02714; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hong M, 2004, J MOL BIOL, V344, P369, DOI 10.1016/j.jmb.2004.09.077; Hopfl G, 2004, AM J PHYSIOL-REG I, V286, pR608, DOI 10.1152/ajpregu.00538.2003; Horman S, 2003, J BIOL CHEM, V278, P41970, DOI 10.1074/jbc.M302403200; Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Jiang HQ, 2001, P NATL ACAD SCI USA, V98, P7916, DOI 10.1073/pnas.141234698; Jiang M, 2001, P NATL ACAD SCI USA, V98, P218, DOI 10.1073/pnas.011520898; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; LARSEN PL, 1995, GENETICS, V139, P1567; McElwee JJ, 2004, J BIOL CHEM, V279, P44533, DOI 10.1074/jbc.M406207200; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; Nystul TG, 2004, P NATL ACAD SCI USA, V101, P9133, DOI 10.1073/pnas.0403312101; Padilla PA, 2002, MOL BIOL CELL, V13, P1473, DOI 10.1091/mbc.01-12-0594; Reinke V, 2000, MOL CELL, V6, P605, DOI 10.1016/S1097-2765(00)00059-9; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Riihimaa P, 2002, J BIOL CHEM, V277, P18238, DOI 10.1074/jbc.M200895200; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Scott BA, 2002, SCIENCE, V296, P2388, DOI 10.1126/science.1072302; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sym M, 2000, CURR BIOL, V10, P527, DOI 10.1016/S0960-9822(00)00468-1; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Treinin M, 2003, PHYSIOL GENOMICS, V14, P17, DOI 10.1152/physiolgenomics.00179.2002; Van Voorhies WA, 2000, J EXP BIOL, V203, P2467; WANG GL, 1993, J BIOL CHEM, V268, P21513; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Winter AD, 2000, MOL CELL BIOL, V20, P4084, DOI 10.1128/MCB.20.11.4084-4093.2000; Zhang M, 2004, AM J PATHOL, V165, P843, DOI 10.1016/S0002-9440(10)63347-0	52	155	202	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20580	20588		10.1074/jbc.M501894200	http://dx.doi.org/10.1074/jbc.M501894200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781453	hybrid			2022-12-27	WOS:000229242000053
J	Aertgeerts, K; Levin, I; Shi, LH; Snell, GP; Jennings, A; Prasad, GS; Zhang, YM; Kraus, ML; Salakian, S; Sridhar, V; Wijnands, R; Tennant, MG				Aertgeerts, K; Levin, I; Shi, LH; Snell, GP; Jennings, A; Prasad, GS; Zhang, YM; Kraus, ML; Salakian, S; Sridhar, V; Wijnands, R; Tennant, MG			Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL-PEPTIDASE-IV; REACTIVE STROMAL FIBROBLASTS; SERINE-PROTEASE; DIFFERENTIAL EXPRESSION; EPITHELIAL CANCERS; PROGRAM; CELLS; TRUNCATION; INHIBITORS; REVEALS	Fibroblast activation protein alpha (FAP alpha) is highly expressed in epithelial cancers and has been implicated in extracellular matrix remodeling, tumor growth, and metastasis. We present the first high resolution structure for the apoenzyme as well as kinetic data toward small dipeptide substrates. FAP alpha exhibits a dipeptidyl peptidase IV (DPPIV)-like fold, featuring an alpha/beta-hydrolase domain and an eight-bladed beta-propeller domain. Known DPPIV dipeptides are cleaved by FAP alpha with an similar to 100-fold decrease in catalytic efficiency compared with DPPIV. Moreover, FAP alpha, but not DPPIV, possesses endopeptidase activity toward N- terminal benzyloxycarbonyl (Z)-blocked peptides. Comparison of the crystal structures of FAP alpha and DPPIV revealed one major difference in the vicinity of the Glu motif (Glu(203)-Glu(204) for FAP alpha; Glu(205)-Glu(206) for DPPIV) within the active site of the enzyme. Ala(657) in FAP alpha, instead of Asp(663) as in DPPIV, reduces the acidity in this pocket, and this change could explain the lower affinity for N- terminal amines by FAP alpha. This hypothesis was tested by kinetic analysis of the mutant FAP alpha/A657D, which shows on average an similar to 60-fold increase in the catalytic efficiency, as measured by k(cat)/K-m, for the cleavage of dipeptide substrates. Furthermore, the catalytic efficiency of the mutant is reduced by similar to 350-fold for cleavage of Z-Gly-Pro-7-amino-4-methylcoumarin. Our data provide a clear understanding of the molecular determinants responsible for the substrate specificity and endopeptidase activity of FAP alpha.	Takeda San Diego Inc, San Diego, CA 92121 USA	Takeda Pharmaceutical Company Ltd; Takeda Pharmaceuticals USA Inc. (TPUSA); Takeda California Inc	Aertgeerts, K (corresponding author), Takeda San Diego Inc, 10410 Sci Ctr Dr, San Diego, CA 92121 USA.	kaertgeerts@takedasd.com		Tennant, Mike/0000-0001-6083-3109				Abbott CA, 1999, FEBS LETT, V458, P278, DOI 10.1016/S0014-5793(99)01166-7; Aertgeerts K, 2004, PROTEIN SCI, V13, P412, DOI 10.1110/ps.03460604; BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; Cheng JD, 2002, CANCER RES, V62, P4767; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; Drucker DJ, 2003, EXPERT OPIN INV DRUG, V12, P87, DOI 10.1517/13543784.12.1.87; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Ghersi G, 2002, J BIOL CHEM, V277, P29231, DOI 10.1074/jbc.M202770200; Hosfield D, 2003, J STRUCT BIOL, V142, P207, DOI 10.1016/S1047-8477(03)00051-0; Huber MA, 2003, J INVEST DERMATOL, V120, P182, DOI 10.1046/j.1523-1747.2003.12035.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambeir AM, 2002, BIOCHEM PHARMACOL, V64, P1753, DOI 10.1016/S0006-2952(02)01415-6; Lambeir AM, 2001, FEBS LETT, V507, P327, DOI 10.1016/S0014-5793(01)02982-9; Lambeir AM, 2001, J BIOL CHEM, V276, P29839, DOI 10.1074/jbc.M103106200; Levy MT, 1999, HEPATOLOGY, V29, P1768, DOI 10.1002/hep.510290631; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Niedermeyer J, 1998, EUR J BIOCHEM, V254, P650, DOI 10.1046/j.1432-1327.1998.2540650.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505; Ramirez-Montagut T, 2004, ONCOGENE, V23, P5435, DOI 10.1038/sj.onc.1207730; RETTIG WJ, 1988, P NATL ACAD SCI USA, V85, P3110, DOI 10.1073/pnas.85.9.3110; RETTIG WJ, 1994, CANCER RES, V53, P385; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; Snell G, 2004, STRUCTURE, V12, P537, DOI 10.1016/j.str.2004.03.011; Tsujimoto H, 1999, MOL CARCINOGEN, V26, P298, DOI 10.1002/(SICI)1098-2744(199912)26:4<298::AID-MC8>3.0.CO;2-M; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Zhu L, 2003, J BIOL CHEM, V278, P22418, DOI 10.1074/jbc.M212355200	29	186	201	1	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19441	19444		10.1074/jbc.C500092200	http://dx.doi.org/10.1074/jbc.C500092200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15809306	hybrid			2022-12-27	WOS:000229113700003
J	Yi-Brunozzi, HY; Le Grice, SFJ				Yi-Brunozzi, HY; Le Grice, SFJ			Investigating HIV-1 polypurine tract geometry via targeted insertion of abasic lesions in the (-)-DNA template and (+)-RNA primer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 REVERSE-TRANSCRIPTASE; COLI RIBONUCLEASE HI; SEQUENCE FEATURES IMPORTANT; MURINE LEUKEMIA-VIRUS; RNASE-H; DNA-TEMPLATE; RECOGNITION; SUBSTRATE; COMPLEX	A variety of biochemical and structural studies indicate that two regions of the human immunodeficiency virus type 1 (HIV-1) polypurine tract ( PPT)-containing RNA/DNA hybrid deviate from standard Watson-Crick geometry. However, it is unclear whether and how these regions cooperate to ensure PPT primer selection by reverse transcriptase-associated ribonuclease H and subsequent removal from nascent (+)-DNA. To address these issues, we synthesized oligonucleotides containing abasic lesions in either the PPT (+)-RNA primer or (-)-DNA template to locally remove nucleobases, although retaining the sugar-phosphate backbone. KMnO4 footprinting indicates such lesions locally alter duplex structure, whereas thermal melting studies show significantly reduced stability when lesions are positioned around the scissile bond. Substituting the (-)DNA template between positions -15 and -13 altered cleavage specificity, whereas equivalent substitutions of the (+)- RNA had almost no effect. The unpaired base of the DNA template observed crystallographically (-11C) could also be removed without significant loss of cleavage specificity. With respect to the scissile -1/+1 phosphodiester bond, template nucleobases could be removed without loss of cleavage specificity, whereas equivalent lesions in the RNA primer were inhibitory. Our data suggest an interaction between the p66 thumb subdomain of HIV-1 reverse transcriptase, and the DNA template in the "unzipped" portion of the RNA/DNA hybrid could aid in positioning the ribonuclease H catalytic center at the PPT/U3 junction and also provides insights into nucleic acid geometry around the scissile bond required for hydrolysis.	NCI, Reverse Transcriptase Biochem Sect, Resistance Mech Lab, HIV Drug Resistance Program,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Le Grice, SFJ (corresponding author), NCI, Reverse Transcriptase Biochem Sect, Resistance Mech Lab, HIV Drug Resistance Program,NIH, Frederick, MD 21702 USA.	slegrice@nciferf.gov			DIVISION OF BASIC SCIENCES - NCI [Z01BC010492] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Coppel Y, 1997, BIOCHEMISTRY-US, V36, P4817, DOI 10.1021/bi962677y; Dash C, 2004, J BIOL CHEM, V279, P37095, DOI 10.1074/jbc.M403306200; Farah JA, 1997, J MOL BIOL, V272, P699, DOI 10.1006/jmbi.1997.1259; Fedoroff OY, 1997, J MOL BIOL, V269, P225, DOI 10.1006/jmbi.1997.1024; Forgacs E, 1997, J BIOL CHEM, V272, P8525, DOI 10.1074/jbc.272.13.8525; GOLJER I, 1995, J BIOL CHEM, V270, P22980, DOI 10.1074/jbc.270.39.22980; Haruki M, 2000, BIOCHEMISTRY-US, V39, P13939, DOI 10.1021/bi001469+; Horton NC, 1998, P NATL ACAD SCI USA, V95, P13489, DOI 10.1073/pnas.95.23.13489; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; IWAI S, 1995, FEBS LETT, V368, P315, DOI 10.1016/0014-5793(95)00683-Z; JACOBOMOLINA A, 1991, P NATL ACAD SCI USA, V88, P10895, DOI 10.1073/pnas.88.23.10895; Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453; Kopka ML, 2003, J MOL BIOL, V334, P653, DOI 10.1016/j.jmb.2003.09.057; Kvaratskhelia M, 2002, J BIOL CHEM, V277, P16689, DOI 10.1074/jbc.M109914200; LATHAM GJ, 1994, J BIOL CHEM, V269, P28527; Latham GJ, 2000, J BIOL CHEM, V275, P15025, DOI 10.1074/jbc.M000279200; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; Lener D, 2003, J BIOL CHEM, V278, P26526, DOI 10.1074/jbc.M302374200; Lhomme J, 1999, BIOPOLYMERS, V52, P65, DOI 10.1002/1097-0282(1999)52:2<65::AID-BIP1>3.0.CO;2-U; Lima WF, 2004, J BIOL CHEM, V279, P36317, DOI 10.1074/jbc.M405035200; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; Nielsen KE, 2000, BIOCONJUGATE CHEM, V11, P228, DOI 10.1021/bc990121s; Petersen M, 2002, J AM CHEM SOC, V124, P5974, DOI 10.1021/ja012288d; Petersen M, 2000, J MOL RECOGNIT, V13, P44, DOI 10.1002/(SICI)1099-1352(200001/02)13:1<44::AID-JMR486>3.0.CO;2-6; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; Rausch JW, 1997, J BIOL CHEM, V272, P8602, DOI 10.1074/jbc.272.13.8602; Rausch JW, 2004, INT J BIOCHEM CELL B, V36, P1752, DOI 10.1016/j.biocel.2004.02.016; Rausch JW, 2003, P NATL ACAD SCI USA, V100, P11279, DOI 10.1073/pnas.1932546100; Reddy YVR, 2000, J MOL BIOL, V298, P597, DOI 10.1006/jmbi.2000.3673; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Schultz SJ, 2000, J BIOL CHEM, V275, P32299, DOI 10.1074/jbc.M000021200; Schultz SJ, 2003, J VIROL, V77, P5275, DOI 10.1128/JVI.77.9.5275-5285.2003; UCHIYAMA Y, 1994, J MOL BIOL, V243, P782, DOI 10.1016/0022-2836(94)90047-7; Wilhelm M, 2001, J BIOL CHEM, V276, P47695, DOI 10.1074/jbc.M106067200; Zou Y, 1999, EMBO J, V18, P4889, DOI 10.1093/emboj/18.17.4889	36	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20154	20162		10.1074/jbc.M411228200	http://dx.doi.org/10.1074/jbc.M411228200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15778225	hybrid			2022-12-27	WOS:000229113700088
J	Nakaya, Y; Yamane, T; Shiraishi, H; Wang, HQ; Matsubara, E; Sato, T; Dolios, G; Wang, R; De Strooper, B; Shoji, M; Komano, H; Yanagisawa, K; Ihara, Y; Fraser, P; St George-Hyslop, P; Nishimura, M				Nakaya, Y; Yamane, T; Shiraishi, H; Wang, HQ; Matsubara, E; Sato, T; Dolios, G; Wang, R; De Strooper, B; Shoji, M; Komano, H; Yanagisawa, K; Ihara, Y; Fraser, P; St George-Hyslop, P; Nishimura, M			Random mutagenesis of presenilin-1 identifies novel mutants exclusively generating long amyloid beta-peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ALZHEIMERS-DISEASE; ASPARTYL PROTEASE; PRECURSOR PROTEIN; ACTIVE-SITE; ENDOPROTEOLYSIS; COMPLEX; INHIBITOR; APP	Familial Alzheimer disease-causing mutations in the presenilins increase production of longer pathogenic amyloid beta-peptides (A beta(42/43)) by altering gamma-secretase activity. The mechanism underlying this effect remains unknown, although it has been proposed that heteromeric macromolecular complexes containing presenilins mediate gamma-secretase cleavage of the amyloid beta-precursor protein. Using a random mutagenesis screen of presenilin-1 (PS1) for PS1 endoproteolysis-impairing mutations, we identified five unique mutants, including R278I-PS1 and L435H-PS1, that exclusively generated a high level of A beta(43), but did not support physiological PS1 endoproteolysis or A beta(40) generation. These mutants did not measurably alter the molecular size or subcellular localization of PS1 complexes. Pharmacological studies indicated that the up-regulation of activity for A beta(43) generation by these mutations was not further enhanced by the difluoroketone inhibitor DFK167 and was refractory to inhibition by sulindac sulfide. These results suggest that PS1 mutations can lead to a wide spectrum of changes in the activity and specificity of gamma-secretase and that the effects of PS1 mutations and gamma-secretase inhibitors on the specificity are mediated through a common mechanism.	Shiga Univ Med Sci, Mol Neurosci Res Ctr, Shiga 5202192, Japan; Kyoto Univ, Grad Sch Med, Dept Neurol, Kyoto 6068507, Japan; Natl Inst Logev Sci, Dept Dementia Res, Aichi 4748522, Japan; Okayama Univ, Grad Sch Med & Dens, Dept Neurol, Okayama 7008558, Japan; Univ Tokyo, Fac Med, Dept Neuropathol, Tokyo 1130033, Japan; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Katholieke Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium; Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada	Shiga University of Medical Science; Kyoto University; Okayama University; University of Tokyo; Icahn School of Medicine at Mount Sinai; KU Leuven; University of Toronto	Nishimura, M (corresponding author), Shiga Univ Med Sci, Mol Neurosci Res Ctr, Shiga 5202192, Japan.	mnishimu@belle.shiga-med.ac.jp	De Strooper, Bart/F-6507-2012; de+Strooper, Bart/Z-1638-2019; Wang, Rong/A-8721-2009	De Strooper, Bart/0000-0001-5455-5819; Shoji, Mikio/0000-0003-1027-1712	NIA NIH HHS [AG10491] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG010491] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beher D, 2004, J BIOL CHEM, V279, P43419, DOI 10.1074/jbc.M404937200; Beher D, 2002, J NEUROCHEM, V82, P563, DOI 10.1046/j.1471-4159.2002.00985.x; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Campbell WA, 2003, J NEUROCHEM, V85, P1563, DOI 10.1046/j.1471-4159.2003.01799.x; Campbell WA, 2002, BIOCHEMISTRY-US, V41, P3372, DOI 10.1021/bi015810h; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Godbolt AK, 2004, NEUROLOGY, V63, P1702, DOI 10.1212/01.WNL.0000143060.98164.1A; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Ikeuchi T, 2003, J BIOL CHEM, V278, P7010, DOI 10.1074/jbc.M209252200; Jacobsen H, 1999, J BIOL CHEM, V274, P35233, DOI 10.1074/jbc.274.49.35233; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Komano H, 2002, J BIOL CHEM, V277, P39627, DOI 10.1074/jbc.M205255200; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lleo A, 2004, NAT MED, V10, P1065, DOI 10.1038/nm1112; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; Shirotani K, 2000, J BIOL CHEM, V275, P3681, DOI 10.1074/jbc.275.5.3681; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Tomita T, 2001, J BIOL CHEM, V276, P33273, DOI 10.1074/jbc.M011152200; Wang J, 2004, NEUROBIOL DIS, V15, P654, DOI 10.1016/j.nbd.2003.12.008; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weggen S, 2003, J BIOL CHEM, V278, P31831, DOI 10.1074/jbc.M303592200; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wrigley JDJ, 2004, J NEUROCHEM, V90, P1312, DOI 10.1111/j.1471-4159.2004.02596.x; Xia WM, 2000, NEUROBIOL DIS, V7, P673, DOI 10.1006/nbdi.2000.0322; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang LL, 2001, BIOCHEMISTRY-US, V40, P5049, DOI 10.1021/bi0028800	52	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19070	19077		10.1074/jbc.M501130200	http://dx.doi.org/10.1074/jbc.M501130200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15764596	Green Published, hybrid, Green Submitted			2022-12-27	WOS:000228932300063
J	Picard, M; Toyoshima, C; Champeil, P				Picard, M; Toyoshima, C; Champeil, P			The average conformation at micromolar [Ca2+] of Ca2+-ATPase with bound nucleotide differs from that adopted with the transition state analog ADP center dot AlFx or with AMPPCP under crystallization conditions at millimolar [Ca2+]	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; CALCIUM ADENOSINE-TRIPHOSPHATASE; TRANSPORT SITES; BINDING; ATPASE; DISSOCIATION; OCCLUSION; KINETICS; CA-2+; PHOSPHOENZYME	Crystalline forms of detergent-solubilized sarcoplasmic reticulum Ca2+-ATPase, obtained in the presence of either a substrate analog, AMPPCP, or a transition state complex, ADP.fluoroaluminate, were recently described to share the same general architecture despite the fact that, when studied in a test tube, these forms show different functional properties. Here, we show that the differences in the properties of the E1.AMPPCP and the E1.ADP.AlFx membraneous (or solubilized) forms are much less pronounced when these properties are examined in the presence of 10 mM Ca2+ (the concentration prevailing in the crystallization media) than when they are examined in the presence of the few micromolar of Ca2+ known to be sufficient to saturate the transport sites. This concerns various properties, including ATPase susceptibility to proteolytic cleavage by proteinase K, ATPase reactivity toward SH-directed Ellman's reagent, ATPase intrinsic fluorescence properties ( here described for the E1.ADP.AlFx complex for the first time), and also the rates of Ca-45(2+)-Ca-40(2+) exchange at site "II." These results solve the above paradox at least partially and suggest that the presence of a previously unrecognized Ca2+ ion in the E1.AMPPCP crystals should be re-investigated. A contrario, they emphasize the fact that the average conformation of the E1.AMPPCP complex under usual conditions in the test tube differs from that found in the crystalline form. The extended conformation of nucleotide revealed by the E1.AMPPCP crystalline form might be only indicative of the requirements for further processing of the complex, toward the transition state leading to phosphorylation and Ca2+ occlusion.	CEA, Dept Biol Joliot Curie, Serv Biophys Fonct Membranaires, CNRS,Unite Rech Associee 2096, F-91191 Gif Sur Yvette, France; Univ Paris Sud, CEA Saclay, IFR46, F-91191 Gif Sur Yvette, France; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo, Japan	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Tokyo	Champeil, P (corresponding author), CEA, Dept Biol Joliot Curie, Serv Biophys Fonct Membranaires, CNRS,Unite Rech Associee 2096, F-91191 Gif Sur Yvette, France.	champeil@dsvidf.cea.fr	Toyoshima, Chikashi/R-4153-2019; Picard, Martin/A-3236-2016	Picard, Martin/0000-0002-6518-8900; Toyoshima, Chikashi/0000-0001-9640-0778				BAYLEY P, 1984, BIOCHEM BIOPH RES CO, V120, P185, DOI 10.1016/0006-291X(84)91431-1; Champeil P, 1997, BIOCHEMISTRY-US, V36, P12383, DOI 10.1021/bi9709699; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; CHAMPEIL P, 1986, FEBS LETT, V206, P93, DOI 10.1016/0014-5793(86)81347-3; Champeil P, 2001, J BIOL CHEM, V276, P5795, DOI 10.1074/jbc.M006980200; CHAMPEIL P, 1978, J BIOL CHEM, V253, P1179; COAN C, 1982, BIOCHEMISTRY-US, V21, P3214, DOI 10.1021/bi00256a028; COAN CR, 1977, J BIOL CHEM, V252, P3044; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; DEFORESTA B, 1990, EUR J BIOCHEM, V194, P383; DEFORESTA B, 1990, ANAL BIOCHEM, V189, P59, DOI 10.1016/0003-2697(90)90044-A; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; FORGE V, 1993, J BIOL CHEM, V268, P10961; FROEHLICH JP, 1985, BIOCHEMISTRY-US, V24, P126, DOI 10.1021/bi00322a018; HENAO F, 1992, J BIOL CHEM, V267, P10302; Hua SM, 2002, BIOCHEMISTRY-US, V41, P11405, DOI 10.1021/bi026181u; Inesi G, 2004, J BIOL CHEM, V279, P31629, DOI 10.1074/jbc.M403211200; INESI G, 1987, J BIOL CHEM, V262, P16338; Kim HY, 2002, J BIOL CHEM, V277, P46651, DOI 10.1074/jbc.M204866200; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; Ma HL, 2003, J BIOL CHEM, V278, P28938, DOI 10.1074/jbc.M304120200; MAHANEY JE, 1995, BIOCHEMISTRY-US, V34, P4864, DOI 10.1021/bi00014a044; MINTZ E, 1995, J BIOL CHEM, V270, P27160, DOI 10.1074/jbc.270.45.27160; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; Montigny C, 2004, J BIOL CHEM, V279, P43971, DOI 10.1074/jbc.M407142200; Ogawa H, 1998, BIOPHYS J, V75, P41, DOI 10.1016/S0006-3495(98)77493-4; OGAWA Y, 1986, J BIOCHEM-TOKYO, V100, P1305, DOI 10.1093/oxfordjournals.jbchem.a121837; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PANG DC, 1977, J BIOL CHEM, V252, P3262; Peeraer Y, 2004, EUR J BIOCHEM, V271, P3421, DOI 10.1111/j.0014-2956.2004.04277.x; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; ROSS DC, 1987, J BIOL CHEM, V262, P12977; SHIGEKAWA M, 1982, J BIOL CHEM, V257, P7657; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; STEWART JMM, 1989, BIOCHEMISTRY-US, V28, P4695, DOI 10.1021/bi00437a028; SUZUKI H, 1994, BIOCHEMISTRY-US, V33, P8240, DOI 10.1021/bi00193a010; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2003, FEBS LETT, V555, P106, DOI 10.1016/S0014-5793(03)01086-X; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; TROULLIER A, 1992, J BIOL CHEM, V267, P22821; VERJOVSKIALMEIDA S, 1978, BIOCHEMISTRY-US, V17, P5006, DOI 10.1021/bi00616a023; VILSEN B, 1992, J BIOL CHEM, V267, P3539; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1986, BIOCHIM BIOPHYS ACTA, V855, P429, DOI 10.1016/0005-2736(86)90089-1; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P7309, DOI 10.1021/bi00483a022; YASUOKA K, 1982, J BIOCHEM-TOKYO, V91, P1629, DOI 10.1093/oxfordjournals.jbchem.a133854; YATES DW, 1978, BIOCHEM J, V159, P719	51	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18745	18754		10.1074/jbc.M501596200	http://dx.doi.org/10.1074/jbc.M501596200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757892	Green Submitted, hybrid			2022-12-27	WOS:000228932300026
J	Volk, KA; Husted, RF; Sigmund, RD; Stokes, JB				Volk, KA; Husted, RF; Sigmund, RD; Stokes, JB			Overexpression of the epithelial Na+ channel gamma subunit in collecting duct cells - Interactions of Liddle's mutations and steroids on expression and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; ALPHA-SUBUNIT; SURFACE EXPRESSION; APICAL MEMBRANE; BLOOD-PRESSURE; BETA-SUBUNIT; MOUSE MODEL; ENAC; TRANSPORT; DISEASE	The epithelial Na+ channel (ENaC) has three subunits; the expression of each can be regulated. Liddle's syndrome is caused by an activating mutation in the C terminus of either the beta or gamma subunit. We used a doxycycline-regulated adenovirus system to express varying levels of human gamma ENaC in renal collecting duct (M1 cell) monolayers. Increasing levels of wild type human gamma ENaC (gamma hENaC) produced a 2.5-fold enhancement of Na+ transport. Expression of a truncated C terminus produced less protein than wild type or a gamma Y627A missense mutation. However, either of these mutations produced a similar to 4-fold increase in Na+ transport despite the different levels of protein expression. Unexpectedly, overexpression of a marginally detectable amount of gamma hENaC was sufficient to produce a full increase in Na+ transport; a further increase in protein expression produced no further increase in Na+ transport. Steroid treatment increased Na+ transport to a similar absolute magnitude in control monolayers and in monolayers expressing all types of gamma hENaC. Withdrawal of steroids after 24 h produced a decline in Na+ transport over 8 h in monolayers expressing wild type but not the Liddle's mutation. Using treatment with brefeldin A to estimate the disappearance rate constants, we found progressively slower disappearance rates in monolayers over-expressing gamma hENaC and the Liddle's mutant. Calculated insertion rates were slower for the Liddle's mutant than for wild type despite increasing rates of Na+ transport. These results raise questions regarding previously held assumptions about the behavior of ENaC.	Univ Iowa, Dept Internal Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; Iowa City Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Stokes, JB (corresponding author), Univ Iowa, Dept Internal Med, Roy J & Lucille A Carver Coll Med, E300 GH,200 Hawkins Dr, Iowa City, IA 52242 USA.	john-stokes@uiowa.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK052617, P30DK054759] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-55066, P50 HL055006] Funding Source: Medline; NIDDK NIH HHS [P50 DK052617, P30 DK054759, DK-52617] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auberson M, 2003, AM J PHYSIOL-RENAL, V285, pF459, DOI 10.1152/ajprenal.00071.2003; AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; Blazer-Yost BL, 2001, AM J PHYSIOL-CELL PH, V281, pC624, DOI 10.1152/ajpcell.2001.281.2.C624; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Carattino MD, 2003, J BIOL CHEM, V278, P36202, DOI 10.1074/jbc.M300312200; Chalfant ML, 1996, AM J PHYSIOL-CELL PH, V270, pC998, DOI 10.1152/ajpcell.1996.270.4.C998; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Drummond HA, 2000, BRAIN RES, V884, P1, DOI 10.1016/S0006-8993(00)02831-6; Fisher RS, 1996, AM J PHYSIOL-CELL PH, V270, pC138, DOI 10.1152/ajpcell.1996.270.1.C138; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; HUSTED RF, 1990, J CLIN INVEST, V86, P498, DOI 10.1172/JCI114736; HUSTED RF, 1988, AM J PHYSIOL, V255, pF1160, DOI 10.1152/ajprenal.1988.255.6.F1160; HUSTED RF, 1994, AM J PHYSIOL-RENAL, V267, pF767, DOI 10.1152/ajprenal.1994.267.5.F767; Husted RF, 2000, AM J PHYSIOL-RENAL, V278, pF425, DOI 10.1152/ajprenal.2000.278.3.F425; Itani OA, 2002, AM J PHYSIOL-LUNG C, V282, pL631, DOI 10.1152/ajplung.00085.2001; LETZ B, 1995, J MEMBRANE BIOL, V148, P127; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; Ma HP, 2004, J BIOL CHEM, V279, P33206, DOI 10.1074/jbc.M405455200; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; Mohan S, 2004, J BIOL CHEM, V279, P32071, DOI 10.1074/jbc.M405091200; Nakhoul NL, 1998, AM J PHYSIOL-RENAL, V275, pF998, DOI 10.1152/ajprenal.1998.275.6.F998; Pradervand S, 2003, J AM SOC NEPHROL, V14, P2219, DOI 10.1097/01.ASN.0000080204.65527.E6; Pradervand S, 1999, J AM SOC NEPHROL, V10, P2527; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Sayegh R, 1999, J BIOL CHEM, V274, P12431, DOI 10.1074/jbc.274.18.12431; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Staub O, 2000, KIDNEY INT, V57, P809, DOI 10.1046/j.1523-1755.2000.00919.x; Stokes JB, 1999, KIDNEY INT, V56, P2318, DOI 10.1046/j.1523-1755.1999.00803.x; STOOS BA, 1991, KIDNEY INT, V39, P1168, DOI 10.1038/ki.1991.148; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; Volk KA, 1995, J CLIN INVEST, V96, P2748, DOI 10.1172/JCI118344; Volk KA, 2000, AM J PHYSIOL-CELL PH, V278, pC1047, DOI 10.1152/ajpcell.2000.278.5.C1047; Wang GS, 2000, AM J RESP CELL MOL, V22, P129, DOI 10.1165/ajrcmb.22.2.3938; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; Zabner J, 1997, J CLIN INVEST, V100, P1144, DOI 10.1172/JCI119625	47	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					18348	18354		10.1074/jbc.M413689200	http://dx.doi.org/10.1074/jbc.M413689200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15755736	Green Accepted, hybrid			2022-12-27	WOS:000228807200095
J	Colletti, KS; Xu, YY; Yamboliev, I; Pari, GS				Colletti, KS; Xu, YY; Yamboliev, I; Pari, GS			Human cytomegalovirus UL84 is a phosphoprotein that exhibits UTPase activity and is a putative member of the DExD/H box family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN-BINDING-PROTEIN; EPSTEIN-BARR-VIRUS; NUCLEAR-LOCALIZATION SIGNAL; DEPENDENT DNA-REPLICATION; HERPES-SIMPLEX VIRUS-1; LARGE-T-ANTIGEN; TYPE-1 ORIGIN; LYTIC ORIGIN; HELICASE ACTIVITY; VIRAL ORIGIN	Human cytomegalovirus (HCMV) UL84 is required for lytic DNA replication and is proposed to be the key factor in initiation of viral DNA synthesis. We now show that UL84 has a high degree of homology to the DExD/H (where x can be any amino acid) box family of helicases, displays UTPase activity, and is phosphorylated at serine residues. Affinity column-purified UL84-FLAG fusion protein was used in an in vitro nucleoside triphosphatase (NTPase) assay to show that UL84 has NTPase activity, preferring UTP. This UTPase activity was linear with respect to enzyme concentration and slightly enhanced by the addition of nucleic acid substrates. UL84 UTPase was the highest at low salt concentrations, a pH of 7.5, and a temperature of 45 degrees C. The enzyme preferred Mg2+ as the divalent cation but was also able to catalyze the UTPase reaction in the presence of Mn2+, Ca2+, and Zn2+ albeit at lower levels. The evidence presented here suggests that the UL84 UTPase activity may be part of an energy-generating system for helicase activity associated with the initiation of HCMV DNA replication.	Univ Nevada, Dept Microbiol & Immunol, Reno, NV 89557 USA; Univ Nevada, Cell & Mol Biol Program, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno	Pari, GS (corresponding author), Univ Nevada, Dept Microbiol, Sch Med, Howard Bldg, Reno, NV 89557 USA.	gpari@med.unr.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045096] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45096] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbate EA, 2004, GENE DEV, V18, P1981, DOI 10.1101/gad.1220104; AuCoin DP, 2004, VIROLOGY, V318, P542, DOI 10.1016/j.virol.2003.10.016; AuCoin DP, 2002, J VIROL, V76, P7890, DOI 10.1128/JVI.76.15.7890-7896.2002; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; Bronstein JC, 2001, PROTEIN EXPRES PURIF, V22, P276, DOI 10.1006/prep.2001.1446; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; Colletti KS, 2004, J VIROL, V78, P9203, DOI 10.1128/JVI.78.17.9203-9214.2004; DODSON MS, 1993, J BIOL CHEM, V268, P1213; El-Guindy AS, 2004, J VIROL, V78, P7634, DOI 10.1128/JVI.78.14.7634-7644.2004; El-Guindy AS, 2002, J VIROL, V76, P11199, DOI 10.1128/JVI.76.22.11199-11208.2002; FIERER DS, 1995, J BIOL CHEM, V270, P7330, DOI 10.1074/jbc.270.13.7330; FIXMAN ED, 1995, J VIROL, V69, P2998, DOI 10.1128/JVI.69.5.2998-3006.1995; Gao ZG, 1998, J VIROL, V72, P8559, DOI 10.1128/JVI.72.11.8559-8567.1998; Gebert S, 1997, J VIROL, V71, P7048, DOI 10.1128/JVI.71.9.7048-7060.1997; HAMMERSCHMIDT W, 1988, CELL, V55, P427, DOI 10.1016/0092-8674(88)90028-1; He XD, 2000, J VIROL, V74, P5726, DOI 10.1128/JVI.74.12.5726-5728.2000; He XD, 2001, P NATL ACAD SCI USA, V98, P3024, DOI 10.1073/pnas.061028298; Isler JA, 2001, J VIROL, V75, P628, DOI 10.1128/JVI.75.2.628-637.2001; Joo WS, 1998, MOL CELL BIOL, V18, P2677, DOI 10.1128/MCB.18.5.2677; Kim J, 2004, J BIOL CHEM, V279, P4394, DOI 10.1074/jbc.M308637200; Kim RJ, 2002, J VIROL, V76, P11785, DOI 10.1128/JVI.76.23.11785-11792.2002; KOLMAN JL, 1993, P NATL ACAD SCI USA, V90, P10115, DOI 10.1073/pnas.90.21.10115; Lentz MR, 2002, VIRUS RES, V83, P213, DOI 10.1016/S0168-1702(02)00003-5; Liao GL, 2001, J VIROL, V75, P8792, DOI 10.1128/JVI.75.18.8792-8802.2001; LIEBERMAN PM, 1990, J VIROL, V64, P1143, DOI 10.1128/JVI.64.3.1143-1155.1990; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; Macao B, 2004, J BIOL CHEM, V279, P29211, DOI 10.1074/jbc.M400371200; Makhov AM, 1996, EMBO J, V15, P1742, DOI 10.1002/j.1460-2075.1996.tb00520.x; Marintcheva B, 2001, J BIOL CHEM, V276, P6605, DOI 10.1074/jbc.M007743200; Mitchell MS, 2004, VIROLOGY, V321, P217, DOI 10.1016/j.virol.2003.11.006; Murata LB, 1999, J BIOL CHEM, V274, P37079, DOI 10.1074/jbc.274.52.37079; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; Prichard MN, 1998, J VIROL, V72, P6997, DOI 10.1128/JVI.72.9.6997-7004.1998; Reese DK, 2004, J VIROL, V78, P2921, DOI 10.1128/JVI.78.6.2921-2934.2004; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; SCHEFFNER M, 1991, EUR J BIOCHEM, V195, P49, DOI 10.1111/j.1432-1033.1991.tb15674.x; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SCHEPERS A, 1993, J VIROL, V67, P4237, DOI 10.1128/JVI.67.7.4237-4245.1993; Schepers A, 1996, VIROLOGY, V220, P367, DOI 10.1006/viro.1996.0325; Sheikh S, 2003, J GEN VIROL, V84, P277, DOI 10.1099/vir.0.18527-0; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Trego KS, 2003, J VIROL, V77, P12646, DOI 10.1128/JVI.77.23.12646-12659.2003; Tuteja N, 2004, EUR J BIOCHEM, V271, P1849, DOI 10.1111/j.1432-1033.2004.04094.x; Wang Y, 2004, J VIROL, V78, P8615, DOI 10.1128/JVI.78.16.8615-8629.2004; WEIR HM, 1990, J GEN VIROL, V71, P1379, DOI 10.1099/0022-1317-71-6-1379; Xu YY, 2004, J VIROL, V78, P11664, DOI 10.1128/JVI.78.21.11664-11677.2004; Xu YY, 2004, J VIROL, V78, P10360, DOI 10.1128/JVI.78.19.10360-10369.2004; Xu YY, 2002, J VIROL, V76, P8931, DOI 10.1128/JVI.76.17.8931-8938.2002; Zhi Y, 1999, J VIROL, V73, P3246, DOI 10.1128/JVI.73.4.3246-3257.1999	50	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	2005	280	12					11955	11960		10.1074/jbc.C400603200	http://dx.doi.org/10.1074/jbc.C400603200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	908BI	15778228	hybrid			2022-12-27	WOS:000227761800127
J	Youn, CK; Kim, SH; Lee, DY; Song, SH; Chang, IY; Hyun, JW; Chung, MH; You, HJ				Youn, CK; Kim, SH; Lee, DY; Song, SH; Chang, IY; Hyun, JW; Chung, MH; You, HJ			Cadmium down-regulates human OGG1 through suppression of Sp1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							8-OXOGUANINE DNA GLYCOSYLASE; ALVEOLAR EPITHELIAL-CELLS; ZINC-FINGER PROTEINS; HAMSTER OVARY CELLS; TRANSCRIPTION FACTORS; SACCHAROMYCES-CEREVISIAE; 8-HYDROXYGUANINE REPAIR; MUTATIONAL SPECTRUM; MAMMALIAN-CELLS; REACTIVE OXYGEN	Cadmium is a well known human and animal carcinogen and is a ubiquitous contaminant in the environment. Although the carcinogenic mechanism of cadmium is a multifactorial process, oxidative DNA damage is believed to be of prime importance. In particular, cadmium suppresses the capacity of cells to repair oxidative DNA damage. In this study, cadmium treatment led to a significant increase in gamma-ray-induced 8-oxoguanine (8-oxoG) formation. Western blotting and semi-quantitative reverse transcription-PCR revealed that cadmium treatment caused a decrease in the expression level of human OGG1 (8-oxoguanine-DNA glycosylase-1; hOGG1) in human fibroblast GM00637 and HeLa S3 cells. In addition, the cadmium-mediated decrease in hOGG1 transcription was the result of decreased binding of the transcription factor Sp1 to the hOGG1 promoter. Finally, we show that an increase in the functional hOGG1 expression level could inhibit the cadmium-mediated increase in gamma-ray-induced 8-oxoG accumulation as well as in gamma-radiation-induced mutation frequency at the HPRT (hypoxanthine-guanine phosphoribosyltransferase) gene locus. These results suggest that cadmium attenuates removal of gamma-ray-induced 8-oxoG adducts, which in turn increases the mutation frequency, and that this effect might, at least in part, result from suppression of hOGG1 transcription via inactivation of Sp1 as a result of cadmium treatment.	Chosun Univ, Sch Med, Dept Pharmacol, Kwangju 501759, South Korea; Chosun Univ, Sch Med, Dept Anat, Kwangju 501759, South Korea; Chosun Univ, Res Ctr Prot Mat, Kwangju 501759, South Korea; Jeju Natl Univ, Coll Med, Dept Biochem, Cheju 690756, South Korea; Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea	Chosun University; Chosun University; Chosun University; Jeju National University; Seoul National University (SNU)	You, HJ (corresponding author), Chosun Univ, Sch Med, Dept Pharmacol, 375 Seosuk Dong, Kwangju 501759, South Korea.	hjyou@mail.chosun.ac.kr		Chang, In-Youb/0000-0002-8911-7541; You, Ho Jin/0000-0002-0530-4017				Arai T, 2003, CANCER RES, V63, P4287; AYLETT BJ, 1979, CHEM BIOCH BIOL CADM, P267; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Blons H, 1999, MOL CARCINOGEN, V26, P254; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Chao JI, 2001, MUTAT RES-GEN TOX EN, V498, P7, DOI 10.1016/S1383-5718(01)00249-2; CHENG KC, 1992, J BIOL CHEM, V267, P166; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; Dally H, 1997, CARCINOGENESIS, V18, P1021, DOI 10.1093/carcin/18.5.1021; Dhenaut A, 2000, MUTAT RES-DNA REPAIR, V461, P109, DOI 10.1016/S0921-8777(00)00042-2; Emami KH, 1998, NUCLEIC ACIDS RES, V26, P839, DOI 10.1093/nar/26.3.839; Fatur T, 2003, MUTAT RES-FUND MOL M, V529, P109, DOI 10.1016/S0027-5107(03)00112-X; Fatur T, 2002, FOOD CHEM TOXICOL, V40, P1069, DOI 10.1016/S0278-6915(02)00058-3; Filipic M, 2004, MUTAT RES-FUND MOL M, V546, P81, DOI 10.1016/j.mrfmmm.2003.11.006; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; Goering PL, 1994, HDB EXPT PHARM TOXIC, V115, P189, DOI DOI 10.1007/978-3-642-79162-8_9; Gong PF, 2000, IND HEALTH, V38, P224, DOI 10.2486/indhealth.38.224; HARTMANN A, 1994, ENVIRON MOL MUTAGEN, V23, P299, DOI 10.1002/em.2850230407; HARTWIG A, 1994, ENVIRON HEALTH PERSP, V102, P45, DOI 10.2307/3431762; Hartwig A, 2002, TOXICOL LETT, V127, P47, DOI 10.1016/S0378-4274(01)00482-9; Hartwig A, 2001, ANTIOXID REDOX SIGN, V3, P625, DOI 10.1089/15230860152542970; Hartwig A, 1998, TOXICOL LETT, V103, P235, DOI 10.1016/S0378-4274(98)00312-9; Hirano T, 1997, TOXICOL APPL PHARM, V147, P9, DOI 10.1006/taap.1997.8260; Hodges NJ, 2002, CARCINOGENESIS, V23, P55, DOI 10.1093/carcin/23.1.55; Hwua YS, 1998, CARCINOGENESIS, V19, P881, DOI 10.1093/carcin/19.5.881; International Agency for Research on Cancer, 1993, IARC MON EV CARC RIS, V58, P41; Jeong HG, 2004, J BIOL CHEM, V279, P34138, DOI 10.1074/jbc.M402530200; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; Kim HN, 2001, CARCINOGENESIS, V22, P265, DOI 10.1093/carcin/22.2.265; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Kuipers GK, 2000, MUTAT RES-DNA REPAIR, V461, P189, DOI 10.1016/S0921-8777(00)00050-1; Kuo FC, 1997, J EXP MED, V186, P1547, DOI 10.1084/jem.186.9.1547; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lee MR, 2004, J BIOL CHEM, V279, P9857, DOI 10.1074/jbc.M311132200; LIN RH, 1994, ENVIRON MOL MUTAGEN, V23, P143, DOI 10.1002/em.2850230212; Liu F, 2000, FREE RADICAL BIO MED, V28, P55, DOI 10.1016/S0891-5849(99)00196-3; Lloyd DR, 1997, CHEM RES TOXICOL, V10, P393, DOI 10.1021/tx960158q; Lloyd DR, 1998, CHEM RES TOXICOL, V11, P420, DOI 10.1021/tx970156l; LOEB LA, 1991, CANCER RES, V51, P3075; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; Misra RR, 1998, TOXICOLOGY, V126, P103, DOI 10.1016/S0300-483X(98)00003-1; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; OCHI T, 1985, MUTAT RES, V143, P137, DOI 10.1016/S0165-7992(85)80024-5; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Potts RJ, 2003, TOXICOLOGY, V184, P189, DOI 10.1016/S0300-483X(02)00579-6; Potts RJ, 2001, TOXICOLOGY, V161, P25, DOI 10.1016/S0300-483X(00)00419-4; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; ROSSMAN TG, 1992, TOXICITY CARCINOGENI, P367; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; Shinmura K, 2001, ANTIOXID REDOX SIGN, V3, P597, DOI 10.1089/15230860152542952; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; TAKENAKA S, 1983, J NATL CANCER I, V70, P367; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; Tsurudome Y, 1999, CARCINOGENESIS, V20, P1573, DOI 10.1093/carcin/20.8.1573; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; WAALKES MP, 1994, REGUL TOXICOL PHARM, V20, P119, DOI 10.1006/rtph.1994.1040; Waalkes MP, 2000, J INORG BIOCHEM, V79, P241, DOI 10.1016/S0162-0134(00)00009-X; WAALKES MP, 1984, TOXICOL APPL PHARM, V75, P539, DOI 10.1016/0041-008X(84)90190-X; WAALKES MP, 1992, CRIT REV TOXICOL, V22, P175, DOI 10.3109/10408449209145323; Watkin RD, 2003, TOXICOLOGY, V184, P157, DOI 10.1016/S0300-483X(02)00577-2; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yamane A, 2004, CARCINOGENESIS, V25, P1689, DOI 10.1093/carcin/bgh166; Yang JL, 1996, CHEM RES TOXICOL, V9, P1360, DOI 10.1021/tx960122y; Youn CK, 2004, CANCER RES, V64, P4849, DOI 10.1158/0008-5472.CAN-04-0348; Zawia NH, 2000, NEUROTOXICOLOGY, V21, P1069	79	67	70	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25185	25195		10.1074/jbc.M412793200	http://dx.doi.org/10.1074/jbc.M412793200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15760895	hybrid			2022-12-27	WOS:000230114000103
J	Lu, XF; Jiang, XG; Lu, YB; Bai, JH; Mao, ZB				Lu, XF; Jiang, XG; Lu, YB; Bai, JH; Mao, ZB			Characterization of a novel positive transcription regulatory element that differentially regulates the insulin-like growth factor binding protein-3 (IGFBP-3) gene in senescent cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; I IGF-I; HUMAN FIBROBLASTS; APOPTOSIS; P53; INHIBITION; EXPRESSION; RECEPTOR; DEATH; OVEREXPRESSION	Insulin-like growth factor binding protein-3 (IGFBP-3) is a well documented growth inhibitor and proapoptotic factor. IGFBP-3 mRNA and its protein are overexpressed by senescent human diploid fibroblasts. However, the mechanism responsible for the up-regulation of its expression is still unclear. This report describes a novel transcriptional regulatory element, IGFBP-3 enhancer element (IEE), identified in the 5' untranslated region of the IGFBP-3 gene. This element differentially activates IGFBP-3 expression in senescent versus young fibroblasts. Electrophoretic mobility shift assays revealed abundant complexes in senescent cell nuclear extracts compared with young cell nuclear extracts. Similar to young proliferative cells, young quiescent cells showed reduced binding activity; enhancement of this activity was specific to senescent cells and not an effect of cell cycle arrest. The DNase I footprint revealed the protein-binding core sequence within the IEE through which the protein binds the IEE. Site-directed mutagenesis within IEE abolished binding activity and selectively decreased IGFBP-3 promoter activity in senescent ( but not young) cells. Furthermore, introduction of an IEE decoy suppressed the endogenous IGFBP-3 gene expression specifically in senescent cells. These results point to the IEE as being a positive transcription regulatory element that contributes to the up-regulation of IGFBP-3 during cellular senescence.	Peking Univ, Ctr Hlth Sci, Dept Biochem & Mol Biol, Beijing 100871, Peoples R China; Xi An Jiao Tong Univ, Dept Biochem & Mol Biol, Sch Med, Xian 710061, Peoples R China	Peking University; Xi'an Jiaotong University	Mao, ZB (corresponding author), Peking Univ, Ctr Hlth Sci, Dept Biochem & Mol Biol, 38 Xueyuan Rd, Beijing 100871, Peoples R China.	zbmao@bjmu.edu.cn						ARANY E, 1994, J CLIN ENDOCR METAB, V79, P1871, DOI 10.1210/jc.79.6.1871; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BALLARD FJ, 1991, J ENDOCRINOL, V128, P197, DOI 10.1677/joe.0.1280197; Barreca A, 1996, J ENDOCRINOL INVEST, V19, P35, DOI 10.1007/BF03347856; Baxter RC, 1997, ADV MOL CELL ENDOCRI, V1, P123, DOI [10.1016/S1569-2566(97)80036-1, DOI 10.1016/S1569-2566(97)80036-1]; Berardi P, 2003, J BIOL CHEM, V278, P7510, DOI 10.1074/jbc.M210864200; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; CHIN E, 1994, ENDOCRINOLOGY, V134, P2498, DOI 10.1210/en.134.6.2498; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; COHEN P, 1993, GROWTH REGULAT, V3, P23; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DIMRI GP, 1994, EXP CELL RES, V212, P132, DOI 10.1006/excr.1994.1127; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Firth SM, 1998, BIOCHEM BIOPH RES CO, V246, P325, DOI 10.1006/bbrc.1998.8615; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; GOLDSTEIN S, 1993, J CELL PHYSIOL, V156, P294, DOI 10.1002/jcp.1041560211; GOLDSTEIN S, 1991, P NATL ACAD SCI USA, V88, P9680, DOI 10.1073/pnas.88.21.9680; GRIGORIEV VG, 1995, EXP CELL RES, V219, P315, DOI 10.1006/excr.1995.1234; GROSSMANN ME, 1994, MOL ENDOCRINOL, V8, P448, DOI 10.1210/me.8.4.448; Gucev ZS, 1996, CANCER RES, V56, P1545; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; Karas M, 1997, J BIOL CHEM, V272, P16514, DOI 10.1074/jbc.272.26.16514; Li YM, 1997, ENDOCRINOLOGY, V138, P362, DOI 10.1210/en.138.1.362; Mao ZB, 2003, ONCOGENE, V22, P4434, DOI 10.1038/sj.onc.1206508; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MIYASHITA T, 1994, CANCER RES, V54, P3131; MOERMAN EJ, 1993, EXP GERONTOL, V28, P361, DOI 10.1016/0531-5565(93)90063-J; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; Nickerson T, 1998, ENDOCRINOLOGY, V139, P807, DOI 10.1210/en.139.2.807; Nickerson T, 1997, BIOCHEM BIOPH RES CO, V237, P690, DOI 10.1006/bbrc.1997.7089; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Rozen F, 1998, INT J ONCOL, V13, P865; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Shen L, 1998, BIOCHEM PHARMACOL, V55, P1711, DOI 10.1016/S0006-2952(98)00045-8; TANG ZQ, 1994, MECH AGEING DEV, V73, P57, DOI 10.1016/0047-6374(94)90038-8; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Wang W, 2001, J BIOL CHEM, V276, P48655, DOI 10.1074/jbc.M108278200; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; YATEMAN ME, 1993, J ENDOCRINOL, V137, P151, DOI 10.1677/joe.0.1370151; Yeo EJ, 2000, MOL CELLS, V10, P415	42	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22606	22615		10.1074/jbc.M412073200	http://dx.doi.org/10.1074/jbc.M412073200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15817480	hybrid			2022-12-27	WOS:000229741800009
J	Gaigg, B; Timischl, B; Corbino, L; Schneiter, R				Gaigg, B; Timischl, B; Corbino, L; Schneiter, R			Synthesis of sphingolipids with very long chain fatty acids but not ergosterol is required for routing of newly synthesized plasma membrane ATPase to the cell surface of yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; INOSITOL PHOSPHORYLCERAMIDE SYNTHASE; SACCHAROMYCES-CEREVISIAE; CERAMIDE SYNTHESIS; GOLGI-APPARATUS; ENDOPLASMIC-RETICULUM; H+-ATPASE; MUTANT; GENE; TRANSPORT	The proton pumping H+- ATPase, Pma1p, is an abundant and very long-lived polytopic protein of the Saccharomyces cerevisiae plasma membrane. Pma1p constitutes a major cargo of the secretory pathway and thus serves as an excellent model to study plasma membrane biogenesis. We have previously shown that newly synthesized Pma1p is mistargeted to the vacuole in an elo3 Delta mutant that affects the synthesis of the ceramide-bound C26 very long chain fatty acid (Eisenkolb, M., Zenzmaier, C., Leitner, E., and Schneiter, R. ( 2002) Mol. Biol. Cell 13, 4414-4428) and now describe a more detailed analysis of the role of lipids in Pma1p biogenesis. Remarkably, a block at various steps of sterol biosynthesis, a complete block in sterol synthesis, or the substitution of internally synthesized ergosterol by externally supplied ergosterol or even by cholesterol does not affect Pma1p biogenesis or its association with detergent-resistant membrane domains (lipid "rafts"). However, a block in sphingolipid synthesis or any perturbation in the synthesis of the ceramide-bound C26 very long chain fatty acid results in mistargeting of newly synthesized Pma1p to the vacuole. Mistargeting correlates with a lack of newly synthesized Pma1p to acquire detergent resistance, suggesting that sphingolipids with very long acyl chains affect sorting of Pma1p to the cell surface.	Univ Fribourg, Dept Med, Div Biochem, CH-1700 Fribourg, Switzerland	University of Fribourg	Schneiter, R (corresponding author), Univ Fribourg, Dept Med, Div Biochem, Chemin Musee 5, CH-1700 Fribourg, Switzerland.	roger.schneiter@unifr.ch		Schneiter, Roger/0000-0002-9102-8396				Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; Balguerie A, 2002, EUKARYOT CELL, V1, P1021, DOI 10.1128/EC.1.6.1021-1031.2002; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chung JH, 2003, J BIOL CHEM, V278, P28872, DOI 10.1074/jbc.M300943200; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Chung NJ, 2001, J BIOL CHEM, V276, P35614, DOI 10.1074/jbc.M105653200; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Eisenkolb M, 2002, MOL BIOL CELL, V13, P4414, DOI 10.1091/mbc.E02-02-0116; Ferreira T, 2001, J BIOL CHEM, V276, P29613, DOI 10.1074/jbc.R100022200; Funato K, 2002, BIOCHEMISTRY-US, V41, P15105, DOI 10.1021/bi026616d; Funato K, 2001, J CELL BIOL, V155, P949, DOI 10.1083/jcb.200105033; Gaigg B, 2001, MOL BIOL CELL, V12, P1147, DOI 10.1091/mbc.12.4.1147; GOLLUB EG, 1977, J BIOL CHEM, V252, P2846; Gong XH, 2001, P NATL ACAD SCI USA, V98, P9104, DOI 10.1073/pnas.161282998; Guillas I, 2003, J BIOL CHEM, V278, P37083, DOI 10.1074/jbc.M307554200; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Gurunathan S, 2002, EMBO J, V21, P602, DOI 10.1093/emboj/21.4.602; Han GS, 2002, J BIOL CHEM, V277, P35440, DOI 10.1074/jbc.M205620200; Harsay E, 2002, J CELL BIOL, V156, P271, DOI 10.1083/jcb.200109077; Hettema EH, 2004, EMBO J, V23, P1279, DOI 10.1038/sj.emboj.7600137; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; JANDROSITZ A, 1991, GENE, V107, P155, DOI 10.1016/0378-1119(91)90310-8; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Kobayashi SD, 2003, EUKARYOT CELL, V2, P284, DOI 10.1128/EC.2.2.284-294.2003; Koffel R, 2005, MOL CELL BIOL, V25, P1655, DOI 10.1128/MCB.25.5.1655-1668.2005; Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001; Lee MCS, 2002, J BIOL CHEM, V277, P22395, DOI 10.1074/jbc.M200450200; Lees ND, 1999, CRIT REV BIOCHEM MOL, V34, P33; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; Lisman Q, 2004, J BIOL CHEM, V279, P1020, DOI 10.1074/jbc.M306119200; LORENZ RT, 1991, LIPIDS, V26, P598, DOI 10.1007/BF02536423; Luo WJ, 1997, J CELL BIOL, V138, P731, DOI 10.1083/jcb.138.4.731; Luo WJ, 2000, MOL BIOL CELL, V11, P579, DOI 10.1091/mbc.11.2.579; Malinska K, 2003, MOL BIOL CELL, V14, P4427, DOI 10.1091/mbc.E03-04-0221; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; Morsomme P, 2000, BBA-REV BIOMEMBRANES, V1469, P133, DOI 10.1016/S0304-4157(00)00015-0; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Obeid LA, 2002, BBA-MOL CELL BIOL L, V1585, P163, DOI 10.1016/S1388-1981(02)00337-2; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Opekarova M, 2002, BBA-BIOMEMBRANES, V1564, P9, DOI 10.1016/S0005-2736(02)00455-8; Pizzirusso M, 2004, MOL BIOL CELL, V15, P2401, DOI 10.1091/mbc.E03-10-0727; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; Schneiter R, 2000, J BACTERIOL, V182, P3655, DOI 10.1128/JB.182.13.3655-3660.2000; Schneiter R, 1996, MOL CELL BIOL, V16, P7161; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Skrzypek MS, 1998, J BIOL CHEM, V273, P2829, DOI 10.1074/jbc.273.5.2829; Sutterlin C, 1997, J CELL SCI, V110, P2703; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Umebayashi K, 2003, J CELL BIOL, V161, P1117, DOI 10.1083/jcb.200303088; Vallee B, 2005, EMBO J, V24, P730, DOI 10.1038/sj.emboj.7600562; Wang QQ, 2002, P NATL ACAD SCI USA, V99, P12853, DOI 10.1073/pnas.202115499; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353	56	79	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22515	22522		10.1074/jbc.M413472200	http://dx.doi.org/10.1074/jbc.M413472200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817474	Green Submitted, hybrid			2022-12-27	WOS:000229557900099
J	Law, RHP; Irving, JA; Buckle, AM; Ruzyla, K; Buzza, M; Bashtannyk-Puhalovich, TA; Beddoe, TC; Nguyen, K; Worrall, DM; Bottomley, SP; Bird, PI; Rossjohn, J; Whisstock, JC				Law, RHP; Irving, JA; Buckle, AM; Ruzyla, K; Buzza, M; Bashtannyk-Puhalovich, TA; Beddoe, TC; Nguyen, K; Worrall, DM; Bottomley, SP; Bird, PI; Rossjohn, J; Whisstock, JC			The high resolution crystal structure of the human tumor suppressor maspin reveals a novel conformational switch in the G-helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIUM-DERIVED FACTOR; REACTIVE CENTER LOOP; CANCER CELLS; SERPIN; OVALBUMIN; ALPHA(1)-ANTITRYPSIN; PROTEASE; INHIBITION; MECHANISM; PROTEINS	Maspin is a serpin that acts as a tumor suppressor in a range of human cancers, including tumors of the breast and lung. Maspin is crucial for development, because homozygous loss of the gene is lethal; however, the precise physiological role of the molecule is unclear. To gain insight into the function of human maspin, we have determined its crystal structure in two similar, but nonisomorphous crystal forms, to 2.1- and 2.8-angstrom resolution, respectively. The structure reveals that maspin adopts the native serpin fold in which the reactive center loop is expelled fully from the A beta- sheet, makes minimal contacts with the core of the molecule, and exhibits a high degree of flexibility. A buried salt bridge unique to maspin orthologues causes an unusual bulge in the region around the D and E alpha- helices, an area of the molecule demonstrated in other serpins to be important for cofactor recognition. Strikingly, the structural data reveal that maspin is able to undergo conformational change in and around the G alpha- helix, switching between an open and a closed form. This change dictates the electrostatic character of a putative cofactor binding surface and highlights this region as a likely determinant of maspin function. The high resolution crystal structure of maspin provides a detailed molecular framework to elucidate the mechanism of function of this important tumor suppressor.	Monash Univ, Fac Med, Sch Biomed Sci, Monash Ctr Synchrotron Sci,Prot Crystallog Unit, Clayton, Vic 3800, Australia; Monash Univ, Fac Med, Sch Biomed Sci, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Monash Univ, Victorian Bioinformat Consortium, Clayton, Vic 3800, Australia; Monash Univ, ARC Ctr Struct & Funct Microbial Genom, Clayton, Vic 3800, Australia; Univ Coll Dublin, Conway Inst, Dublin 2, Ireland	Monash University; Monash University; Monash University; Monash University; University College Dublin	Whisstock, JC (corresponding author), Monash Univ, Fac Med, Sch Biomed Sci, Monash Ctr Synchrotron Sci,Prot Crystallog Unit, Clayton, Vic 3800, Australia.	James.Whisstock@med.monash.edu.au	Beddoe, Travis/F-3415-2014; Rossjohn, Jamie/F-9032-2013; Buckle, Ashley/P-8366-2016; Irving, James/P-3860-2019; Irving, James A/I-8467-2015	Beddoe, Travis/0000-0003-4550-2277; Rossjohn, Jamie/0000-0002-2020-7522; Buckle, Ashley/0000-0003-2943-9044; Irving, James/0000-0003-3204-6356; Whisstock, James/0000-0003-4200-5611; law, ruby/0000-0001-5432-5781; Bird, Phillip/0000-0002-6695-606X				Al-Ayyoubi M, 2004, J BIOL CHEM, V279, P55540, DOI 10.1074/jbc.M409957200; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bass R, 2002, J BIOL CHEM, V277, P46845, DOI 10.1074/jbc.C200532200; Blacque OE, 2002, J BIOL CHEM, V277, P10783, DOI 10.1074/jbc.M110992200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabrita LD, 2004, BIOCHEMISTRY-US, V43, P9834, DOI 10.1021/bi0491346; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; Clements CS, 2003, P NATL ACAD SCI USA, V100, P11059, DOI 10.1073/pnas.1833158100; Gao F, 2004, DEVELOPMENT, V131, P1479, DOI 10.1242/dev.01048; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033; HOPKINS PCR, 1994, SCIENCE, V265, P1893; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; James EL, 1999, J BIOL CHEM, V274, P9482, DOI 10.1074/jbc.274.14.9482; Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kapust RB, 2001, PROTEIN ENG, V14, P993, DOI 10.1093/protein/14.12.993; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESK AM, 1986, BIOSEQUENCES PERSPEC, P23; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Meyer C, 2002, J BIOL CHEM, V277, P45400, DOI 10.1074/jbc.M208339200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakamura H, 1996, Q REV BIOPHYS, V29, P1, DOI 10.1017/S0033583500005746; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Ngamkitidechakul C, 2003, J BIOL CHEM, V278, P31796, DOI 10.1074/jbc.M302408200; Nicholls A., 1992, GRASP GRAPHICAL REPR; Odero-Marah VA, 2002, BIOCHEM BIOPH RES CO, V295, P800, DOI 10.1016/S0006-291X(02)00764-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; Reis JS, 2001, PATHOL RES PRACT, V197, P817, DOI 10.1078/0344-0338-00165; Rodriguez R, 1998, BIOINFORMATICS, V14, P523, DOI 10.1093/bioinformatics/14.6.523; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Simonovic M, 2001, P NATL ACAD SCI USA, V98, P11131, DOI 10.1073/pnas.211268598; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Stratikos E, 1996, PROTEIN SCI, V5, P2575, DOI 10.1002/pro.5560051220; Tew DJ, 2001, J MOL BIOL, V313, P1161, DOI 10.1006/jmbi.2001.5104; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; Whisstock JC, 2000, J MOL BIOL, V301, P1287, DOI 10.1006/jmbi.2000.3982; Whisstock JC, 2000, J MOL BIOL, V296, P685, DOI 10.1006/jmbi.1999.3520; Yamasaki M, 2003, J BIOL CHEM, V278, P35524, DOI 10.1074/jbc.M305926200; Zhang M, 2004, FRONT BIOSCI-LANDMRK, V9, P2218, DOI 10.2741/1392; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	54	51	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22356	22364		10.1074/jbc.M412043200	http://dx.doi.org/10.1074/jbc.M412043200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15760906	hybrid			2022-12-27	WOS:000229557900081
J	Lolkema, MP; Gervais, ML; Snijckers, CM; Hill, RP; Giles, RH; Voest, EE; Ohh, M				Lolkema, MP; Gervais, ML; Snijckers, CM; Hill, RP; Giles, RH; Voest, EE; Ohh, M			Tumor suppression by the von hippel-lindau protein requires phosphorylation of the acidic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR; BIOLOGICALLY-ACTIVE PRODUCT; KINASE CK2; FIBRONECTIN MATRIX; CELL-SURFACE; REGULATE HIF; GENE-PRODUCT; VHL; BINDING; EXPRESSION	The tumor suppressor function of the von Hippel-Lindau protein (pVHL) has previously been linked to its role in regulating hypoxia-inducible factor levels. However, VHL gene mutations suggest a hypoxia-inducible factor-independent function for the N-terminal acidic domain in tumor suppression. Here, we report that phosphorylation of the N-terminal acidic domain of pVHL by casein kinase-2 is essential for its tumor suppressor function. This post-translational modification did not affect the levels of hypoxia-inducible factor; however, it did change the binding of pVHL to another known binding partner, fibronectin. Cells expressing phospho-defective mutants caused improper fibronectin matrix deposition and demonstrated retarded tumor formation in mice. We propose that phosphorylation of the acidic domain plays a role in the regulation of proper fibronectin matrix deposition and that this may be relevant for the development of VHL-associated malignancies.	Univ Utrecht, Med Ctr, Dept Med Oncol, NL-3584 CX Utrecht, Netherlands; Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Princess Margaret Hosp, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	Utrecht University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Voest, EE (corresponding author), Univ Utrecht, Med Ctr, Dept Med Oncol, F02-126,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	michael.ohh@utoronto.ca	Lolkema, M.P./AAE-2906-2019	Lolkema, M.P./0000-0003-0466-2928; Giles, Rachel/0000-0001-9133-2008; Hill, Richard Peter/0000-0001-5331-8045				AVILA J, 1994, CELL MOL BIOL RES, V40, P573; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Bluyssen HAR, 2004, FEBS LETT, V556, P137, DOI 10.1016/S0014-5793(03)01392-9; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; KONDO K, 2003, PLOS BIOL; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Lim ACB, 2004, J BIOL CHEM, V279, P4433, DOI 10.1074/jbc.M310563200; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Marsden M, 2001, DEVELOPMENT, V128, P3635; Maynard MA, 2004, AM J NEPHROL, V24, P1, DOI 10.1159/000075346; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Moreno FJ, 1999, MOL CELL BIOCHEM, V191, P201, DOI 10.1023/A:1006836211318; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pasqualini R, 1996, NAT MED, V2, P1197, DOI 10.1038/nm1196-1197; Patel SK, 2003, MOL CARCINOGEN, V38, P141, DOI 10.1002/mc.10153; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Zimmer M, 2004, MOL CANCER RES, V2, P89	34	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22205	22211		10.1074/jbc.M503220200	http://dx.doi.org/10.1074/jbc.M503220200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824109	hybrid			2022-12-27	WOS:000229557900066
J	James, AM; Cocheme, HM; Smith, RAJ; Murphy, MP				James, AM; Cocheme, HM; Smith, RAJ; Murphy, MP			Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species - Implications for the use of exogenous ubiquinones as therapies and experimental tools	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MANGANOUS SUPEROXIDE-DISMUTASE; BOVINE HEART-MITOCHONDRIA; COENZYME-Q; FRIEDREICHS-ATAXIA; OXIDATIVE STRESS; NITRIC-OXIDE; SACCHAROMYCES-CEREVISIAE; BC(1) COMPLEX; CYTOCHROME-C	Antioxidants, such as ubiquinones, are widely used in mitochondrial studies as both potential therapies and useful research tools. However, the effects of exogenous ubiquinones can be difficult to interpret because they can also be pro-oxidants or electron carriers that facilitate respiration. Recently we developed a mitochondria-targeted ubiquinone (MitoQ(10)(10)() that accumulates within mitochondria. MitoQ) (has been used to prevent mitochondrial oxidative damage and to infer the involvement of mitochondrial reactive oxygen species in signaling pathways. However, uncertainties remain about the mitochondrial reduction of MitoQ)(, its oxidation by the respiratory chain, and its pro-oxidant potential. Therefore, we compared MitoQ analogs of varying alkyl chain lengths (MitoQ)(, n = 3-15) with untargeted exogenous ubiquinones. We found that MitoQ)(10)(n)(10) (could not restore respiration in ubiquinone-deficient mitochondria because oxidation of MitoQ analogs by complex III was minimal. Complex II and glycerol 3-phosphate dehydrogenase reduced MitoQ analogs, and the rate depended on chain length. Because of its rapid reduction and negligible oxidation, MitoQ)(10) (is a more effective antioxidant against lipid peroxidation, peroxynitrite and superoxide. Paradoxically, exogenous ubiquinols also autoxidize to generate superoxide, but this requires their deprotonation in the aqueous phase. Consequently, in the presence of phospholipid bilayers, the rate of autoxidation is proportional to ubiquinol hydrophilicity. Superoxide production by MitoQ)(10) was insufficient to damage aconitase but did lead to hydrogen peroxide production and nitric oxide consumption, both of which may affect cell signaling pathways. Our results comprehensively describe the interaction of exogenous ubiquinones with mitochondria and have implications for their rational design and use as therapies and as research tools to probe mitochondrial function.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Otago, Dept Chem, Dunedin, New Zealand	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Otago	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	mpm@mrc-dunn.cam.ac.uk	James, Andrew M/A-2639-2015; Murphy, Michael P/C-2120-2009	James, Andrew M/0000-0002-0515-9649; Murphy, Michael P/0000-0003-1115-9618; Cocheme, Helena/0000-0001-8637-0042				Abe K, 1999, J NEUROL SCI, V162, P65, DOI 10.1016/S0022-510X(98)00296-2; Asin-Cayuela J, 2004, FEBS LETT, V571, P9, DOI 10.1016/j.febslet.2004.06.045; Aure K, 2004, NEUROLOGY, V63, P727, DOI 10.1212/01.WNL.0000134607.76780.B2; AZZI A, 1975, BIOCHEM BIOPH RES CO, V65, P597, DOI 10.1016/S0006-291X(75)80188-4; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bedogni B, 2003, J BIOL CHEM, V278, P16510, DOI 10.1074/jbc.M301089200; Borrello S, 1997, ARCH BIOCHEM BIOPHYS, V348, P289, DOI 10.1006/abbi.1997.0355; Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; Buyse G, 2003, NEUROLOGY, V60, P1679, DOI 10.1212/01.WNL.0000068549.52812.0F; Calabrese EJ, 2004, EMBO REP, V5, pS37, DOI 10.1038/sj.embor.7400222; Carreras Maria C., 2004, Molecular Aspects of Medicine, V25, P125, DOI 10.1016/j.mam.2004.02.014; Chappell J. B., 1972, SUBCELLULAR COMPONEN, P77; Chen K, 2004, J BIOL CHEM, V279, P35079, DOI 10.1074/jbc.M404859200; CRANE F. L., 1971, Methods in Enzymology, V18C, P137, DOI 10.1016/S0076-6879(71)18022-6; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Dallner G, 2000, FREE RADICAL BIO MED, V29, P285, DOI 10.1016/S0891-5849(00)00307-5; Dhanasekaran A, 2004, J BIOL CHEM, V279, P37575, DOI 10.1074/jbc.M404003200; Di Giovanni S, 2001, NEUROLOGY, V57, P515, DOI 10.1212/WNL.57.3.515; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Duchen Michael R., 2004, Molecular Aspects of Medicine, V25, P365, DOI 10.1016/j.mam.2004.03.001; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; FLEWELLING RF, 1986, BIOPHYS J, V49, P531, DOI 10.1016/S0006-3495(86)83663-3; FREI B, 1990, P NATL ACAD SCI USA, V87, P4879, DOI 10.1073/pnas.87.12.4879; Gao XG, 2003, BIOCHEMISTRY-US, V42, P9067, DOI 10.1021/bi0341814; Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076-6879(02)49317-2; GARRIB A, 1986, J BIOL CHEM, V261, P8042; Genova MW, 2003, EXP BIOL MED, V228, P506, DOI 10.1177/15353702-0322805-14; GILLIS JC, 1994, DRUG AGING, V5, P133, DOI 10.2165/00002512-199405020-00007; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; Hausse AO, 2002, HEART, V87, P346, DOI 10.1136/heart.87.4.346; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; James AM, 2004, ARCH BIOCHEM BIOPHYS, V423, P47, DOI 10.1016/j.abb.2003.12.025; James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; Kaiser J, 2003, SCIENCE, V302, P376, DOI 10.1126/science.302.5644.376; Kamzalov S, 2003, J NUTR, V133, P3175, DOI 10.1093/jn/133.10.3175; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; KETTERER B, 1971, J MEMBRANE BIOL, V5, P225, DOI 10.1007/BF01870551; Kwong LK, 2002, FREE RADICAL BIO MED, V33, P627, DOI 10.1016/S0891-5849(02)00916-4; Lambert AJ, 2004, BIOCHEM J, V382, P511, DOI 10.1042/BJ20040485; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; Mariotti C, 2003, NEUROLOGY, V60, P1676, DOI 10.1212/01.WNL.0000055872.50364.FC; Marriage BJ, 2004, MOL GENET METAB, V81, P263, DOI 10.1016/j.ymgme.2003.12.008; Matthews RT, 1998, P NATL ACAD SCI USA, V95, P8892, DOI 10.1073/pnas.95.15.8892; McKenzie M, 2004, NEUROCHEM RES, V29, P589, DOI 10.1023/B:NERE.0000014829.42364.dd; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Muller T, 2003, NEUROSCI LETT, V341, P201, DOI 10.1016/S0304-3940(03)00185-X; Murphy MP, 2000, ADV DRUG DELIVER REV, V41, P235, DOI 10.1016/S0169-409X(99)00069-1; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; Murphy MP, 2001, EXPERT OPIN BIOL TH, V1, P753, DOI 10.1517/14712598.1.5.753; Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101; Nohl H, 1998, FREE RADICAL BIO MED, V25, P666, DOI 10.1016/S0891-5849(98)00105-1; Okada K, 1998, FEBS LETT, V431, P241, DOI 10.1016/S0014-5793(98)00753-4; ONO A, 1994, BIOCHEMISTRY-US, V33, P4312, DOI 10.1021/bi00180a027; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Petersen DR, 2004, FREE RADICAL BIO MED, V37, P937, DOI 10.1016/j.freeradbiomed.2004.06.012; Poderoso JJ, 1999, FREE RADICAL BIO MED, V26, P925, DOI 10.1016/S0891-5849(98)00277-9; Quiles JL, 2004, EXP GERONTOL, V39, P189, DOI 10.1016/j.exger.2003.10.002; RICH PR, 1980, BIOCHIM BIOPHYS ACTA, V592, P506, DOI 10.1016/0005-2728(80)90095-X; RICH PR, 1979, FEBS LETT, V105, P189, DOI 10.1016/0014-5793(79)80608-0; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; ROSE IA, 1967, J BIOL CHEM, V242, P1870; Rustin P, 1999, LANCET, V354, P477, DOI 10.1016/S0140-6736(99)01341-0; Rustin P, 2002, FREE RADICAL RES, V36, P467, DOI 10.1080/10715760290021333; Santos-Ocana C, 2002, J BIOL CHEM, V277, P10973, DOI 10.1074/jbc.M112222200; Saretzki G, 2003, AGING CELL, V2, P141, DOI 10.1046/j.1474-9728.2003.00040.x; Schafer M, 2003, CIRC RES, V92, P1010, DOI 10.1161/01.RES.0000070882.81508.FC; Schopfer F, 2000, BIOCHEM J, V349, P35, DOI 10.1042/0264-6021:3490035; Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smith RAJ, 2003, BIOCHEM SOC T, V31, P1295; Smith RAJ, 2004, METHOD ENZYMOL, V382, P45; Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; SUNO M, 1984, JPN J PHARMACOL, V35, P196, DOI 10.1254/jjp.35.196; Svensson M, 1999, INT J SPORT NUTR, V9, P166, DOI 10.1123/ijsn.9.2.166; TAKADA M, 1984, METHOD ENZYMOL, V105, P147; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Turunen M, 2004, BBA-BIOMEMBRANES, V1660, P171, DOI 10.1016/j.bbamem.2003.11.012; TYLER DD, 1992, MITOCHONDRION HLTH D, P41; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; WINTERBOURN CC, 1981, ARCH BIOCHEM BIOPHYS, V209, P159, DOI 10.1016/0003-9861(81)90268-X; Wright AF, 2004, NAT GENET, V36, P1153, DOI 10.1038/ng1448; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Yokoo S, 2004, J CELL BIOCHEM, V93, P588, DOI 10.1002/jcb.20208; Zhang YY, 1996, J NUTR, V126, P2089, DOI 10.1093/jn/126.9.2089	95	287	314	2	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21295	21312		10.1074/jbc.M501527200	http://dx.doi.org/10.1074/jbc.M501527200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15788391	hybrid			2022-12-27	WOS:000229438800048
J	Ioannidis, P; Mahaira, LG; Perez, SA; Gritzapis, AD; Sotiropoulou, PA; Kavalakis, GJ; Antsaklis, AI; Baxevanis, CN; Papamichail, M				Ioannidis, P; Mahaira, LG; Perez, SA; Gritzapis, AD; Sotiropoulou, PA; Kavalakis, GJ; Antsaklis, AI; Baxevanis, CN; Papamichail, M			CRD-BP/IMP1 expression characterizes cord blood CD34(+) stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING-PROTEIN; HUMAN-BREAST-CANCER; MESSENGER-RNA; GROWTH-FACTOR; CRD-BP; GENE-EXPRESSION; SELF-RENEWAL; PROGENITOR CELLS; CODING REGION; BONE-MARROW	The coding region determinant-binding protein/insulin-like growth factor II mRNA-binding protein (CRDBP/IMP1) is an RNA-binding protein specifically recognizing c-myc, leader 3' IGF-II and tau mRNAs, and the H19 RNA. CRD-BP/IMP1 is predominantly expressed in embryonal tissues but is de novo activated and/or over-expressed in various human neoplasias. To address the question of whether CRD-BP/IMP1 expression characterizes certain cell types displaying distinct proliferation and/or differentiation properties (i.e. stem cells), we isolated cell subpopulations from human bone marrow, mobilized peripheral blood, and cord blood, all sources known to contain stem cells, and monitored for its expression. CRD-BP/IMP1 was detected only in cord blood-derived CD34(+) stem cells and not in any other cell type of either adult or cord blood origin. Adult BM CD34(+) cells cultured in the presence of 5'-azacytidine expressed de novo CRD-BP/IMP1, suggesting that epigenetic modifications may be responsible for its silencing in adult non-expressing cells. Furthermore, by applying the short interfering RNA methodology in MCF-7 cells, we observed, subsequent to knocking down CRD-BP/IMP1, decreased c-myc expression, increased IGF-II mRNA levels, and reduced cell proliferation rates. These data 1) suggest a normal role for CRD-BP/IMP1 in pluripotent stem cells with high renewal capacity, like the CB CD34(+) cells, 2) indicate that altered methylation may directly or indirectly affect its expression in adult cells, 3) imply that its de novo activation in cancer cells may affect the expression of c-Myc and insulin-like growth factor II, and 4) indicate that the inhibition of CRD-BP/IMP1 expression might affect cancer cell proliferation.	St Savas Hosp, Canc Immunol Immunotherapy Ctr, Athens 11522, Greece; Obstet & Gynecol Univ Clin 1st, Alexandras Matern Hosp, Athens 11521, Greece	Alexandra Hospital	Perez, SA (corresponding author), St Savas Hosp, Canc Immunol Immunotherapy Ctr, 171,Alexandras Ave, Athens 11522, Greece.	perez@ciic.gr		GRITZAPIS, ANGELOS/0000-0003-3031-2710				ARANDAABREU GE, 1999, J NEUROCHEM, V22, P8827; Atlas R, 2004, J NEUROCHEM, V89, P613, DOI 10.1111/j.1471-4159.2004.02371.x; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; Doyle GA, 2000, CANCER RES, V60, P2756; El-Osta A, 2004, LEUKEMIA, V18, P233, DOI 10.1038/sj.leu.2403218; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gu LJ, 2004, INT J ONCOL, V24, P671; Hansen TVO, 2004, MOL CELL BIOL, V24, P4448, DOI 10.1128/MCB.24.10.4448-4464.2004; Ioannidis P, 2004, CANCER LETT, V209, P245, DOI 10.1016/j.canlet.2003.12.015; Ioannidis P, 2003, INT J CANCER, V104, P54, DOI 10.1002/ijc.10794; Ioannidis P, 2001, INT J CANCER, V94, P480, DOI 10.1002/ijc.1512; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; KARN J, 1989, ONCOGENE, V4, P773; Kim DK, 1999, STEM CELLS, V17, P286, DOI 10.1002/stem.170286; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; LEROITH D, 1995, ANN INTERN MED, V122, P54, DOI 10.7326/0003-4819-122-1-199501010-00009; Liao BS, 2004, J BIOL CHEM, V279, P48716, DOI 10.1074/jbc.M405853200; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ng YY, 2004, J LEUKOCYTE BIOL, V75, P314, DOI 10.1189/jlb.0603287; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Nielsen J, 2003, BIOCHEM J, V376, P383, DOI 10.1042/BJ20030943; Oh IH, 2000, BLOOD, V96, P4160, DOI 10.1182/blood.V96.13.4160.h8004160_4160_4168; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; Piacibello W, 1999, BLOOD, V93, P3736, DOI 10.1182/blood.V93.11.3736.411k01_3736_3749; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; Puri MC, 2003, P NATL ACAD SCI USA, V100, P12753, DOI 10.1073/pnas.2133552100; Ross J, 2001, ONCOGENE, V20, P6544, DOI 10.1038/sj.onc.1204838; Rummukainen J, 2001, CANCER GENET CYTOGEN, V126, P1, DOI 10.1016/S0165-4608(00)00387-3; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; Satoh Y, 2004, J BIOL CHEM, V279, P24986, DOI 10.1074/jbc.M400407200; Schwartz GN, 1996, STEM CELLS, V14, P337, DOI 10.1002/stem.140337; Shojaei F, 2004, BLOOD, V103, P2530, DOI 10.1182/blood-2003-09-3209; Steidl U, 2002, BLOOD, V99, P2037, DOI 10.1182/blood.V99.6.2037; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Tanavde VM, 2002, EXP HEMATOL, V30, P816, DOI 10.1016/S0301-472X(02)00818-4; Tessier CR, 2004, CANCER RES, V64, P209, DOI 10.1158/0008-5472.CAN-03-2927; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; YEE D, 1988, CANCER RES, V48, P6691; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zhang JY, 2003, CANCER EPIDEM BIOMAR, V12, P136	44	58	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20086	20093		10.1074/jbc.M410036200	http://dx.doi.org/10.1074/jbc.M410036200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769738	hybrid			2022-12-27	WOS:000229113700079
J	Liu, G; Chen, XB				Liu, G; Chen, XB			The C-terminal sterile alpha motif and the extreme C terminus regulate the transcriptional activity of the alpha isoform of p73	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; PHYSICAL INTERACTION; APOPTOTIC RESPONSE; BINDING-PROTEIN; SAM DOMAIN; P53 FAMILY; ACETYLATION; P63; ACTIVATION; GENE	p73, a member of the p53 family, is expressed from two separate promoters, generating TA and Delta N variants. Each variant potentially encodes at least seven alternatively spliced isoforms (alpha-eta). Interestingly, we and others have shown that the alpha isoform of p73 has a weaker transcriptional activity than the beta isoform. Because the alpha isoform has an extended C terminus consisting of a sterile alpha motif (SAM) and an extreme C terminus, it appears that the C terminus is inhibitory. However, how the C terminus inhibits the transcriptional activity of p73 has not been determined. Here, we found that both the SAM and the extreme C terminus exert their inhibitory activity by preventing the accessibility of p300/CBP to the activation domain in p73. Specifically, we showed that the SAM and the extreme C terminus together or individually are capable of repressing the function of p73 activation domain, but neither interacts directly with the activation domain, or suppresses the DNA-binding activity, of the p73 protein. We also showed that the intact state of the SAM and the extreme C terminus is essential for their inhibitory functions such that a small deletion of either the SAM or the extreme C terminus abolishes its inhibitory activity. Furthermore, we showed that both inhibitory domains in the C terminus are capable of suppressing the function of a cis heterologous activation domain from p53 or Gal4. Finally, we showed that both inhibitory domains suppress the ability of p73 to interact with the transcriptional coactivators p300/CBP that are necessary for the initiation of transcription.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, MCLM 660,1918 Univ Blvd, Birmingham, AL 35294 USA.	xchen@uab.edu		, Gang/0000-0002-6999-7633; Liu, Gang/0000-0003-2615-131X	NATIONAL CANCER INSTITUTE [R01CA081237] Funding Source: NIH RePORTER; NCI NIH HHS [CA081237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Bork P, 1998, NAT GENET, V18, P313, DOI 10.1038/ng0498-313; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Gong JG, 1999, NATURE, V399, P806; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Ishimoto O, 2002, CANCER RES, V62, P636; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Liu L, 1999, MOL CELL BIOL, V19, P1202; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Nimura Y, 1998, INT J CANCER, V78, P437, DOI 10.1002/(SICI)1097-0215(19981109)78:4<437::AID-IJC8>3.0.CO;2-V; Nomoto S, 1998, CANCER RES, V58, P1380; Ozaki T, 2003, ONCOGENE, V22, P3231, DOI 10.1038/sj.onc.1206382; Park EK, 2004, MOL BIOL CELL, V15, P1647, DOI 10.1091/mbc.E03-09-0674; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Tsao H, 1999, CANCER RES, V59, P172; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wang WK, 2000, ACTA CRYSTALLOGR D, V56, P769, DOI 10.1107/S0907444900005059; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zhu JH, 1998, CANCER RES, V58, P5061	61	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20111	20119		10.1074/jbc.M413889200	http://dx.doi.org/10.1074/jbc.M413889200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769743	hybrid			2022-12-27	WOS:000229113700082
J	Aranyi, T; Ratajewski, M; Bardoczy, V; Pulaski, L; Bors, A; Tordai, A; Varadi, A				Aranyi, T; Ratajewski, M; Bardoczy, V; Pulaski, L; Bors, A; Tordai, A; Varadi, A			Identification of a DNA methylation-dependent activator sequence in the pseudoxanthoma elasticum gene, ABCC6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER-CELLS; MRP6 GENE; MUTATIONS; TRANSPORTER; RESISTANCE; SENSITIVITY; ALIGNMENT; PROMOTER; ISLANDS; TISSUES	ABCC6 encodes MRP6, a member of the ABC protein family with an unknown physiological role. The human ABCC6 and its two pseudogenes share 99% identical DNA sequence. Loss-of-function mutations of ABCC6 are associated with the development of pseudoxanthoma elasticum (PXE), a recessive hereditary disorder affecting the elastic tissues. Various disease-causing mutations were found in the coding region; however, the mutation detection rate in the ABCC6 coding region of bona fide PXE patients is only similar to 80%. This suggests that polymorphisms or mutations in the regulatory regions may contribute to the development of the disease. Here, we report the first characterization of the ABCC6 gene promoter. Phylogenetic in silico analysis of the 5' regulatory regions revealed the presence of two evolutionarily conserved sequence elements embedded in CpG islands. The study of DNA methylation of ABCC6 and the pseudogenes identified a correlation between the methylation of the CpG island in the proximal promoter and the ABCC6 expression level in cell lines. Both activator and repressor sequences were uncovered in the proximal promoter by reporter gene assays. The most potent activator sequence was one of the conserved elements protected by DNA methylation on the endogenous gene in non-expressing cells. Finally, in vitro methylation of this sequence inhibits the transcriptional activity of the luciferase promoter constructs. Altogether these results identify a DNA methylation-dependent activator sequence in the ABCC6 promoter.	Hungarian Acad Sci, Inst Enzymol, H-1113 Budapest, Hungary; Polish Acad Sci, Ctr Med Biol, PL-93232 Lodz, Poland; Natl Med Ctr, Inst Hematol & Immunol, Dept Mol Diagnost, H-1113 Budapest, Hungary	Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; Polish Academy of Sciences	Aranyi, T (corresponding author), Hungarian Acad Sci, Inst Enzymol, Karolina Ut 29, H-1113 Budapest, Hungary.	aranyi@enzim.hu; varadi@enzim.hu	Aranyi, Tamas/AAJ-9629-2021; Ratajewski, Marcin/I-4657-2019; Varadi, Andras/A-2055-2012	Aranyi, Tamas/0000-0002-2087-6275; Ratajewski, Marcin/0000-0001-5391-5843; Pulaski, Lukasz/0000-0001-8063-801X				Aessopos A, 2002, BLOOD, V99, P30, DOI 10.1182/blood.V99.1.30; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Beck K, 2003, J HISTOCHEM CYTOCHEM, V51, P887, DOI 10.1177/002215540305100704; Bergen AAB, 2000, NAT GENET, V25, P228, DOI 10.1038/76109; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; Chassaing N, 2004, J INVEST DERMATOL, V122, P608, DOI 10.1111/j.0022-202X.2004.22312.x; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; De Smet C, 1999, MOL CELL BIOL, V19, P7327; DEAN M, 2002, HUMAN ATP BINDING CA; Down TA, 2002, GENOME RES, V12, P458, DOI 10.1101/gr.216102; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gheduzzi Dealba, 2004, Hum Mutat, V24, P438, DOI 10.1002/humu.9284; GOODMAN RM, 1963, MEDICINE, V42, P297, DOI 10.1097/00005792-196309000-00001; Grant CE, 1997, GENOMICS, V45, P368, DOI 10.1006/geno.1997.4950; Hu XF, 2003, EUR J HUM GENET, V11, P215, DOI 10.1038/sj.ejhg.5200953; Hubbard T, 2005, NUCLEIC ACIDS RES, V33, pD447, DOI 10.1093/nar/gki138; Ilias A, 2002, J BIOL CHEM, V277, P16860, DOI 10.1074/jbc.M110918200; Imamura T, 2001, GENOMICS, V76, P117, DOI 10.1006/geno.2001.6607; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Knudsen S, 1999, BIOINFORMATICS, V15, P356, DOI 10.1093/bioinformatics/15.5.356; Kool M, 1999, CANCER RES, V59, P175; Le Saux O, 1999, GENOMICS, V62, P1, DOI 10.1006/geno.1999.5925; Le Saux O, 2000, NAT GENET, V25, P223, DOI 10.1038/76102; LEBWOHL M, 1994, J AM ACAD DERMATOL, V30, P103, DOI 10.1016/S0190-9622(08)81894-4; LEBWOHL M, 1987, NEW ENGL J MED, V317, P347, DOI 10.1056/NEJM198708063170604; Lian ZR, 2001, HEPATOLOGY, V34, P146, DOI 10.1053/jhep.2001.25545; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Madon J, 2000, MOL PHARMACOL, V57, P634, DOI 10.1124/mol.57.3.634; MCCREEDY CA, 1989, SURGERY, V105, P170; Morgenstern B, 2004, NUCLEIC ACIDS RES, V32, pW33, DOI 10.1093/nar/gkh373; Noji Y, 2004, INTERNAL MED, V43, P1171, DOI 10.2169/internalmedicine.43.1171; Pulkkinen L, 2001, HUM GENET, V109, P356, DOI 10.1007/s004390100582; Ringpfeil F, 2000, P NATL ACAD SCI USA, V97, P6001, DOI 10.1073/pnas.100041297; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pW249, DOI 10.1093/nar/gkh372; SCHORDERET DF, 1992, P NATL ACAD SCI USA, V89, P957, DOI 10.1073/pnas.89.3.957; SCHUG J, 1997, ISMB, V5, P268; Shiota K, 2002, GENES CELLS, V7, P961, DOI 10.1046/j.1365-2443.2002.00574.x; Spinzi G, 1996, AM J GASTROENTEROL, V91, P1631; Struk B, 2000, J MOL MED, V78, P282, DOI 10.1007/s001090000114; Struk B, 1997, HUM MOL GENET, V6, P1823, DOI 10.1093/hmg/6.11.1823; Szakacs G, 2004, CANCER CELL, V6, P129, DOI 10.1016/j.ccr.2004.06.026; Trip MD, 2002, CIRCULATION, V106, P773, DOI 10.1161/01.CIR.0000028420.27813.C0; Tusnady GE, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni012; Uitto J, 2001, TRENDS MOL MED, V7, P13, DOI 10.1016/S1471-4914(00)01869-4; VILJOEN DL, 1987, CLIN GENET, V32, P100; Wang J, 2001, J HUM GENET, V46, P699, DOI 10.1007/s100380170003; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; YOSHIDA S, 2004, EYE, V19, P215	50	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18643	18650		10.1074/jbc.M501139200	http://dx.doi.org/10.1074/jbc.M501139200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15760889	hybrid			2022-12-27	WOS:000228932300014
J	Schopfer, FJ; Baker, PRS; Giles, G; Chumley, P; Batthyany, C; Crawford, J; Patel, RP; Hogg, N; Branchaud, BP; Lancaster, JR; Freeman, BA				Schopfer, FJ; Baker, PRS; Giles, G; Chumley, P; Batthyany, C; Crawford, J; Patel, RP; Hogg, N; Branchaud, BP; Lancaster, JR; Freeman, BA			Fatty acid transduction of nitric oxide signaling - Nitrolinoleic acid is a hydrophobically stabilized nitric oxide donor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID PEROXYL RADICALS; NEF REACTION; GUANYLATE-CYCLASE; CATALYTIC CONSUMPTION; ALPHA-TOCOPHEROL; RELAXING FACTOR; IN-VIVO; NO; CELL; ACTIVATION	The aqueous decay and concomitant release of nitric oxide ((NO)-N-center dot) by nitrolinoleic acid (10-nitro-9,12-octadecadienoic acid and 12-nitro-9,12-octadecadienoic acid; LNO2) are reported. Mass spectrometric analysis of reaction products supports a modified Nef reaction as the mechanism accounting for the generation of (NO)-N-center dot by the aqueous reactions of fatty acid nitroalkene derivatives. Nitrolinoleic acid is stabilized by an aprotic milieu, with LNO2 decay and (NO)-N-center dot release strongly inhibited by phosphatidylcholine/cholesterol liposome membranes and detergents when present at levels above their critical micellar concentrations. The release of (NO)-N-center dot from LNO2 was induced by UV photolysis and triiodide-based ozone chemiluminescence reactions currently used to quantify putative protein nitrosothiol and N-nitrosamine derivatives. This reactivity of LNO2 complicates the qualitative and quantitative analysis of biological oxides of nitrogen when applying UV photolysis and triiodide-based analytical systems to biological preparations typically abundant in nitrated fatty acids. The results reveal that nitroalkene derivatives of linoleic acid are pluripotent signaling mediators that act not only via receptor-dependent mechanisms, but also by transducing the signaling actions of (NO)-N-center dot via pathways subject to regulation by the relative distribution of LNO2 to hydrophobic versus aqueous microenvironments.	Univ Alabama, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35233 USA; Univ Alabama, Ctr Free Rad Biol, Birmingham, AL 35233 USA; Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Univ Oregon, Dept Chem, Eugene, OR 97403 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Medical College of Wisconsin; University of Oregon	Freeman, BA (corresponding author), Univ Alabama, Dept Anesthesiol, 304-8 Biomed Res Bldg 2,901 19th St S, Birmingham, AL 35233 USA.	freerad@uab.edu	Giles, Gregory/C-6368-2009; Schopfer, Francisco Jose/AAE-8125-2020; Schopfer, Francisco/AAW-6505-2021; Freeman, Bruce A/H-9342-2012; Batthyany, Carlos I./A-6478-2009; Giles, Gregory/X-7155-2019	Giles, Gregory/0000-0002-8225-0462; Schopfer, Francisco Jose/0000-0001-9526-695X; Giles, Gregory/0000-0002-8225-0462; Batthyany, Carlos/0000-0002-0627-1982; Patel, Rakesh/0000-0002-1526-4303	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007457, R01HL074391, R01HL058115, R01HL064937, R01HL070146, R01HL071189, R37HL058115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055792, R01GM055792] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58115, HL074391, T32HL07457, HL71189, HL70146, HL64937] Funding Source: Medline; NIDDK NIH HHS [DK46935] Funding Source: Medline; NIGMS NIH HHS [GM55792] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; ARMAND J, 1965, B SOC CHIM FR, P3246; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; Baker PRS, 2004, P NATL ACAD SCI USA, V101, P11577, DOI 10.1073/pnas.0402587101; Balazy M, 2001, J PHARMACOL EXP THER, V299, P611; Ballini R, 2004, TETRAHEDRON, V60, P1017, DOI 10.1016/j.tet.2003.11.016; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Coffey MJ, 2001, P NATL ACAD SCI USA, V98, P8006, DOI 10.1073/pnas.141136098; Coles B, 2002, CIRC RES, V91, P375, DOI 10.1161/01.RES.0000032114.68919.EF; Coles B, 2002, J BIOL CHEM, V277, P5832, DOI 10.1074/jbc.M105209200; Crawford JH, 2004, BLOOD, V104, P1375, DOI 10.1182/blood-2004-03-0880; CUNDALL RB, 1968, J CHEM SOC B, P98, DOI 10.1039/j29680000098; Denicola A, 1998, P NATL ACAD SCI USA, V95, P3566, DOI 10.1073/pnas.95.7.3566; Denicola A, 2002, J BIOL CHEM, V277, P932, DOI 10.1074/jbc.M106589200; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; FEUER H, 1962, J AM CHEM SOC, V84, P688, DOI 10.1021/ja00863a048; Gladwin MT, 2002, J BIOL CHEM, V277, P27818, DOI 10.1074/jbc.M203236200; HAWTHORNE MF, 1957, J AM CHEM SOC, V79, P2510, DOI 10.1021/ja01567a042; HOGG N, 1995, FREE RADICAL RES, V22, P47, DOI 10.3109/10715769509147527; Hogg N, 2002, ANNU REV PHARMACOL, V42, P585, DOI 10.1146/annurev.pharmtox.42.092501.104328; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; Janero DR, 2004, P NATL ACAD SCI USA, V101, P16958, DOI 10.1073/pnas.0406075101; KORNBLUM N, 1965, J AM CHEM SOC, V87, P1742, DOI 10.1021/ja01086a023; LEITCH LC, 1955, CAN J CHEM, V33, P400, DOI 10.1139/v55-047; Lim DG, 2002, P NATL ACAD SCI USA, V99, P15941, DOI 10.1073/pnas.232409599; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; Nef J., 1894, LIEBIGS ANN CHEM, V280, P263; NOLAND WE, 1955, CHEM REV, V55, P137, DOI 10.1021/cr50001a003; O'Donnell VB, 2000, J BIOL CHEM, V275, P38239, DOI 10.1074/jbc.M001802200; O'Donnell VB, 1999, J BIOL CHEM, V274, P20083, DOI 10.1074/jbc.274.29.20083; ODonnell VB, 1997, BIOCHEMISTRY-US, V36, P15216, DOI 10.1021/bi971891z; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; Pinnick H. W., 1990, ORG REACT, V38, P655, DOI [10.1002/0471264180.or038.03, DOI 10.1002/0471264180.0R038.03]; Rubbo H, 2000, J BIOL CHEM, V275, P10812, DOI 10.1074/jbc.275.15.10812; Schopfer FJ, 2003, TRENDS BIOCHEM SCI, V28, P646, DOI 10.1016/j.tibs.2003.10.006; Schopfer FJ, 2005, P NATL ACAD SCI USA, V102, P2340, DOI 10.1073/pnas.0408384102; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; SZOKA F, 1980, ANNU REV BIOPHYS BIO, V9, P467, DOI 10.1146/annurev.bb.09.060180.002343; Thatcher GRJ, 2004, FREE RADICAL BIO MED, V37, P1122, DOI 10.1016/j.freeradbiomed.2004.06.013; VANTAMELEN EE, 1952, J AM CHEM SOC, V74, P2615, DOI 10.1021/ja01130a044; WILSON H, 1972, J AM CHEM SOC, V94, P2283, DOI 10.1021/ja00762a019	43	143	157	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19289	19297		10.1074/jbc.M414689200	http://dx.doi.org/10.1074/jbc.M414689200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15764811	hybrid			2022-12-27	WOS:000228932300086
J	Yagur-Kroll, S; Amster-Choder, O				Yagur-Kroll, S; Amster-Choder, O			Dynamic membrane topology of the Escherichia coli beta-glucoside transporter BglF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; MANNITOL PERMEASE; TRANSCRIPTIONAL ANTITERMINATOR; PROTEIN-STRUCTURE; LACTOSE PERMEASE; CARBOHYDRATE TRANSPORTERS; SULFHYDRYL-REAGENTS; BACILLUS-SUBTILIS; SUBSTRATE-BINDING; CHANNEL STRUCTURE	The Escherichia coli BglF protein, a permease of the phosphoenolpyruvate-dependent phosphotransferase system, catalyzes transport and phosphorylation of beta-glucosides. In addition, BglF regulates bgl operon expression by controlling the activity of the transcriptional regulator BglG via reversible phosphorylation. BglF is composed of three domains; one is hydrophobic, which presumably forms the sugar translocation channel. We studied the topology of this domain by Cys-replacement mutagenesis and chemical modification by thiol reagents. Most Cys substitutions were well tolerated, as demonstrated by the ability of the mutant proteins to catalyze BglF activities. Our results suggest that the membrane domain contains eight transmembrane helices and an alleged cytoplasmic loop that contains two additional helices. The latter region forms a dynamic structure, as evidenced by the alternation of residues near its ends between faced-in and faced-out states. We suggest that this region, together with the two transmembrane helices encompassing it, forms the sugar translocation channel. BglF periplasmic loops are close to the membrane, the first being a reentrant loop. This is the first systematic topological study carried out with an intact phosphotransferase system permease and the first demonstration of a reentrant loop in this group of proteins.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Amster-Choder, O (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, POB 12272, IL-91120 Jerusalem, Israel.	amster@cc.huji.ac.il						Aboulwafa M, 2003, MICROBIOL-SGM, V149, P763, DOI 10.1099/mic.0.25731-0; Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; AMSTERCHODER O, 1990, SCIENCE, V249, P540, DOI 10.1126/science.2200123; AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; Beutler R, 2000, BIOCHEMISTRY-US, V39, P3745, DOI 10.1021/bi992679t; BRIGGS CE, 1992, RES MICROBIOL, V143, P139, DOI 10.1016/0923-2508(92)90003-7; BUHR A, 1993, J BIOL CHEM, V268, P11599; Chen Q, 1998, BIOCHEMISTRY-US, V37, P17040, DOI 10.1021/bi980067n; Chen Q, 1999, J BACTERIOL, V181, P462, DOI 10.1128/JB.181.2.462-468.1999; Chen Q, 1997, EMBO J, V16, P4617, DOI 10.1093/emboj/16.15.4617; Chen Q, 2001, J BIOL CHEM, V276, P44751, DOI 10.1074/jbc.M108729200; Chen Q, 2000, J BACTERIOL, V182, P2033, DOI 10.1128/JB.182.7.2033-2036.2000; Chen Q, 1998, BIOCHEMISTRY-US, V37, P8714, DOI 10.1021/bi9731652; CRUTZ AM, 1990, J BACTERIOL, V172, P1043, DOI 10.1128/jb.172.2.1043-1050.1990; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FOX CF, 1968, P NATL ACAD SCI USA, V59, P988, DOI 10.1073/pnas.59.3.988; Gasol E, 2004, J BIOL CHEM, V279, P31228, DOI 10.1074/jbc.M402428200; Getz EB, 1999, ANAL BIOCHEM, V273, P73, DOI 10.1006/abio.1999.4203; Grunewald M, 2002, J BIOL CHEM, V277, P26074, DOI 10.1074/jbc.M202248200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Idelson M, 1998, J BACTERIOL, V180, P660, DOI 10.1128/JB.180.3.660-666.1998; JACOBSON GR, 1993, J BIOENERG BIOMEMBR, V25, P621; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Koning RI, 1999, J MOL BIOL, V287, P845, DOI 10.1006/jmbi.1999.2650; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lee SJ, 2000, EMBO J, V19, P5353, DOI 10.1093/emboj/19.20.5353; LENGELER JW, 1994, BBA-BIOENERGETICS, V1188, P1, DOI 10.1016/0005-2728(94)90017-5; LENGELER JW, 1990, BIOCHIM BIOPHYS ACTA, V1018, P155, DOI 10.1016/0005-2728(90)90238-Y; LENGELER JW, 1990, PHILOS T ROY SOC B, V326, P489, DOI 10.1098/rstb.1990.0027; LOLKEMA JS, 1992, BIOCHEMISTRY-US, V31, P5514, DOI 10.1021/bi00139a013; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MAHADEVAN S, 1987, J BACTERIOL, V169, P2570, DOI 10.1128/jb.169.6.2570-2578.1987; Nilsson J, 2002, PROTEIN SCI, V11, P2974, DOI 10.1110/ps.0226702; Nilsson J, 2000, FEBS LETT, V486, P267, DOI 10.1016/S0014-5793(00)02321-8; Ninio S, 2004, FEBS LETT, V562, P193, DOI 10.1016/S0014-5793(04)00240-6; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Ren XY, 2001, J BIOL CHEM, V276, P9572, DOI 10.1074/jbc.M007823200; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Robillard GT, 1999, BBA-REV BIOMEMBRANES, V1422, P73, DOI 10.1016/S0304-4157(99)00002-7; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; SaraceniRichards CA, 1997, J BACTERIOL, V179, P1135, DOI 10.1128/jb.179.4.1135-1142.1997; SCHAEFLER S, 1967, J BACTERIOL, V93, P254, DOI 10.1128/JB.93.1.254-263.1967; SCHNETZ K, 1990, P NATL ACAD SCI USA, V87, P5074, DOI 10.1073/pnas.87.13.5074; Siebold C, 2001, FEBS LETT, V504, P104, DOI 10.1016/S0014-5793(01)02705-3; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Tusnady GE, 2001, J CHEM INF COMP SCI, V41, P364, DOI 10.1021/ci0001280; Venkatesan P, 2000, BIOCHEMISTRY-US, V39, P10649, DOI 10.1021/bi0004394; Vervoort EB, 2005, J MOL BIOL, V346, P733, DOI 10.1016/j.jmb.2004.12.011; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; VonHeijne G, 1996, PROG BIOPHYS MOL BIO, V66, P113, DOI 10.1016/S0079-6107(97)85627-1; White SH, 2001, J BIOL CHEM, V276, P32395, DOI 10.1074/jbc.R100008200; YAMADA Y, 1991, J BIOL CHEM, V266, P17863; Zhang W, 2003, BIOCHEMISTRY-US, V42, P4904, DOI 10.1021/bi034078e; Zhuang JP, 1999, ARCH BIOCHEM BIOPHYS, V372, P89, DOI 10.1006/abbi.1999.1458	65	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19306	19318		10.1074/jbc.M410896200	http://dx.doi.org/10.1074/jbc.M410896200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755739	hybrid			2022-12-27	WOS:000228932300088
J	Masuda, S; Murakami, M; Takanezawa, Y; Aoki, J; Arai, H; Ishikawa, Y; Ishii, T; Arioka, M; Kudo, I				Masuda, S; Murakami, M; Takanezawa, Y; Aoki, J; Arai, H; Ishikawa, Y; Ishii, T; Arioka, M; Kudo, I			Neuronal expression and neuritogenic action of group X secreted phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; HUMAN GROUP-IIA; GROUP-V; NEURITE OUTGROWTH; A(2) ENZYMES; PC12 CELLS; RECEPTOR-BINDING; PROSTAGLANDIN PRODUCTION; MAMMALIAN-CELLS; N-CADHERIN	Although individual mammalian secreted phospholipase A(2) (sPLA(2)) enzymes exhibit unique tissue and cellular distributions, the cell type-specific functions of each enzyme remain largely unknown. In this study, we found by immunohistochemistry that group X sPLA(2) (sPLA(2)-X) is uniquely located in the peripheral neuronal fibers, an observation that was supported by detection of its transcript and protein in the neuronal cell line PC12 and in primary dorsal root ganglia neurons. Adenoviral expression of sPLA(2)-X in PC12 cells facilitated neurite outgrowth, particularly when combined with a suboptimal concentration of nerve growth factor. In neuronally differentiated PC12 cells, sPLA(2)-X was preferentially localized in the Golgi apparatus and growth cones, and proteolytic conversion of the proenzyme to mature enzyme mainly occurred after the secretion process. The neurite-extending ability of sPLA(2)-X depended on the production of its catalytic product, lysophosphatidylcholine. Moreover, nerve growth factor-induced neurite extension of PC12 cells was modestly but significantly attenuated by an anti-sPLA(2)-X antibody or by a small interfering RNA for sPLA(2)-X. These observations suggest the potential contribution of sPLA(2)-X to neuronal differentiation, and possibly repair, under certain conditions.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1138613, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Toho Univ, Sch Med, Dept Pathol, Ohta Ku, Tokyo 1438540, Japan	Showa University; Tokyo Metropolitan Institute of Medical Science; University of Tokyo	Murakami, M (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	mako@pharm.showa-u.ac.jp		Takanezawa, Yasukazu/0000-0002-9220-5825; Aoki, Junken/0000-0001-9435-1896				Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; de Turco EBR, 2002, J NEUROSCI RES, V68, P558, DOI 10.1002/jnr.10239; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DOHERTY P, 1992, J CELL BIOL, V117, P1093, DOI 10.1083/jcb.117.5.1093; Garcia-Pastor P, 1999, J PHARMACOL EXP THER, V289, P166; Hamaguchi K, 2003, BBA-MOL CELL BIOL L, V1635, P37, DOI 10.1016/j.bbalip.2003.10.004; Hanasaki K, 2002, J BIOL CHEM, V277, P29116, DOI 10.1074/jbc.M202867200; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; KATER SB, 1991, J NEUROSCI, V11, P891; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Kishimoto T, 2002, CLIN BIOCHEM, V35, P411, DOI 10.1016/S0009-9120(02)00327-2; Kolko M, 1996, J BIOL CHEM, V271, P32722, DOI 10.1074/jbc.271.51.32722; Kolko M, 2003, NEUROSCI LETT, V338, P164, DOI 10.1016/S0304-3940(02)01385-X; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LAURITZEN I, 1994, BRAIN RES, V651, P353, DOI 10.1016/0006-8993(94)90719-6; Lu WG, 2004, CELL, V119, P97, DOI 10.1016/j.cell.2004.09.019; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MARSHALL LA, 1995, J PHARMACOL EXP THER, V274, P1254; Masuda S, 2005, BIOCHEM J, V387, P27, DOI 10.1042/BJ20041307; Masuda S, 2005, FEBS J, V272, P655, DOI 10.1111/j.1742-4658.2004.04489.x; Masuda S, 2004, BBA-MOL CELL BIOL L, V1686, P61, DOI 10.1016/j.bbalip.2004.08.017; Matsuzawa A, 1996, BIOCHEM J, V318, P701, DOI 10.1042/bj3180701; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; Munoz NM, 2003, J BIOL CHEM, V278, P38813, DOI 10.1074/jbc.M302476200; MURAKAMI M, 1992, BIOCHIM BIOPHYS ACTA, V1124, P17, DOI 10.1016/0005-2760(92)90120-K; Murakami M, 2003, J BIOL CHEM, V278, P10657, DOI 10.1074/jbc.M211325200; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; NAKANO T, 1994, BIOCHEM BIOPH RES CO, V198, P10, DOI 10.1006/bbrc.1994.1002; Nakashima S, 2004, BRAIN RES, V1015, P207, DOI 10.1016/j.brainres.2004.04.069; Nakashima S, 2003, BIOCHEM J, V376, P655, DOI 10.1042/BJ20030830; Nicolas JP, 1997, J BIOL CHEM, V272, P7173, DOI 10.1074/jbc.272.11.7173; Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; Seeds MC, 2000, AM J RESP CELL MOL, V23, P37, DOI 10.1165/ajrcmb.23.1.4034; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Tanaka M, 2004, FEBS LETT, V571, P197, DOI 10.1016/j.febslet.2004.06.083; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 2000, J BIOL CHEM, V275, P7492, DOI 10.1074/jbc.275.11.7492; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Wakatsuki S, 1999, J BIOCHEM-TOKYO, V126, P1151, DOI 10.1093/oxfordjournals.jbchem.a022561; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; Wei S, 2003, NEUROSCIENCE, V121, P891, DOI 10.1016/S0306-4522(03)00525-6; Xu Y, 2002, BBA-MOL CELL BIOL L, V1582, P81, DOI 10.1016/S1388-1981(02)00140-3; Yagami T, 2002, BRAIN RES, V949, P197, DOI 10.1016/S0006-8993(02)03144-X; Yagami T, 2002, MOL PHARMACOL, V61, P114, DOI 10.1124/mol.61.1.114; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	58	50	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23203	23214		10.1074/jbc.M500985200	http://dx.doi.org/10.1074/jbc.M500985200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15781456	hybrid			2022-12-27	WOS:000229741800078
J	Galibert, L; Diemer, GS; Liu, Z; Johnson, RS; Smith, JL; Walzer, T; Comeau, MR; Rauch, CT; Wolfson, MF; Sorensen, RA; de Vries, ARV; Branstetter, DG; Koelling, RM; Scholler, J; Fanslow, WC; Baum, PR; Derry, JM; Yan, W				Galibert, L; Diemer, GS; Liu, Z; Johnson, RS; Smith, JL; Walzer, T; Comeau, MR; Rauch, CT; Wolfson, MF; Sorensen, RA; de Vries, ARV; Branstetter, DG; Koelling, RM; Scholler, J; Fanslow, WC; Baum, PR; Derry, JM; Yan, W			Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-I-restricted T-cell-associated molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR TSLC1; SINGLE-CHAIN FV; CUTTING EDGE; IMMUNOGLOBULIN SUPERFAMILY; ADHESION MOLECULE; PHAGE; ANTIBODIES; EXPRESSION; GENE; IDENTIFICATION	Dendritic cells (DCs) are a phenotypically and functionally heterogenous population of leukocytes with distinct subsets serving a different set of specialized immune functions. Here we applied an in vitro whole cell panning approach using antibody phage display technology to identify cell-surface epitopes specifically expressed on human blood BDCA3(+) DCs. A single- chain antibody fragment (anti-1F12 scFv) was isolated that recognizes a conserved surface antigen expressed on both human BDCA3(+) DCs and mouse CD8 alpha(+) DCs. We demonstrate that anti-1F12 scFv binds Nectin-like protein 2 (Necl2, Tslc1, SynCaM, SgIGSF, or Igsf4), an adhesion molecule involved in tumor suppression, synapse formation, and spermatogenesis. Thus, Necl2 defines a specialized subset of DCs in both mouse and human. We further show that Necl2 binds Class-I-restricted T-cell-associated molecule ( CRTAM), a receptor primarily expressed on activated cytotoxic lymphocytes. When present on antigen presenting cells, Necl2 regulates IL-22 expression by activated CD8(+) T-cells. We propose that Necl2/CRTAM molecular pair could regulate a large panel of cell/cell interactions both within and outside of the immune system.	Amgen Inc, Dept Mol Sci, Seattle, WA 98119 USA; Amgen Inc, Dept Prot Sci, Seattle, WA 98119 USA; Amgen Inc, Dept Inflammat, Seattle, WA 98119 USA; Amgen Inc, Dept Oncol, Seattle, WA 98119 USA; Amgen Inc, Dept Pathol, Seattle, WA 98119 USA	Amgen; Amgen; Amgen; Amgen; Amgen	Yan, W (corresponding author), Amgen Inc, Dept Mol Sci, AW2-D-3291,1201 Amgen Ct, Seattle, WA 98119 USA.	ywei@amgen.com	Walzer, Thierry/L-9418-2014	Walzer, Thierry/0000-0002-0857-8179				Aliberti J, 2003, BLOOD, V101, P305, DOI 10.1182/blood-2002-04-1088; Andrews DM, 2003, NAT IMMUNOL, V4, P175, DOI 10.1038/ni880; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Barry SC, 2001, HUM GENE THER, V12, P1103, DOI 10.1089/104303401750214311; Belz GT, 2004, J IMMUNOL, V172, P1996, DOI 10.4049/jimmunol.172.4.1996; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; Bjorck P, 2002, HUM IMMUNOL, V63, P1094, DOI 10.1016/S0198-8859(02)00747-4; Brasel K, 2000, BLOOD, V96, P3029, DOI 10.1182/blood.V96.9.3029.h8003029_3029_3039; Caux C, 2000, SPRINGER SEMIN IMMUN, V22, P345, DOI 10.1007/s002810000053; de Vries ARV, 1999, EUR J IMMUNOL, V29, P3898, DOI 10.1002/(SICI)1521-4141(199912)29:12<3898::AID-IMMU3898>3.0.CO;2-2; De Vries ARV, 1999, IMMUNOLOGY, V98, P55; DEKRUIF J, 1995, P NATL ACAD SCI USA, V92, P3938, DOI 10.1073/pnas.92.9.3938; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Donskoy E, 2003, J IMMUNOL, V170, P3514, DOI 10.4049/jimmunol.170.7.3514; Du Pasquier L, 2000, Curr Top Microbiol Immunol, V248, P160; Dumoutier L, 2000, J IMMUNOL, V164, P1814, DOI 10.4049/jimmunol.164.4.1814; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Edwards AD, 2003, J IMMUNOL, V171, P47, DOI 10.4049/jimmunol.171.1.47; Ettehadieh E, 2002, CYTOTECHNOLOGY, V38, P11, DOI 10.1023/A:1021121107801; Fernandez NC, 1999, NAT MED, V5, P405, DOI 10.1038/7403; Fredericks ZL, 2004, PROTEIN ENG DES SEL, V17, P95, DOI 10.1093/protein/gzh012; Fukuda M, 1999, J CELL BIOL, V147, P467, DOI 10.1083/jcb.147.3.467; Fukuhara H, 2003, ONCOGENE, V22, P6160, DOI 10.1038/sj.onc.1206744; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Hubert FX, 2004, J IMMUNOL, V172, P7485, DOI 10.4049/jimmunol.172.12.7485; Huls GA, 1999, NAT BIOTECHNOL, V17, P276, DOI 10.1038/7023; Ito T, 2003, CANCER RES, V63, P6320; Iyoda T, 2002, J EXP MED, V195, P1289, DOI 10.1084/jem.20020161; Jego Gaetan, 2005, V8, P124; Kamath AT, 2000, J IMMUNOL, V165, P6762, DOI 10.4049/jimmunol.165.12.6762; Kamath AT, 2002, BLOOD, V100, P1734, DOI 10.1182/blood.V100.5.1734.h81702001734_1734_1741; Kennedy J, 2000, J LEUKOCYTE BIOL, V67, P725, DOI 10.1002/jlb.67.5.725; Koenderman L, 2000, J LEUKOCYTE BIOL, V68, P58; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Lekkerkerker A, 1999, J IMMUNOL METHODS, V231, P53, DOI 10.1016/S0022-1759(99)00140-4; Maldonado-Lopez R, 1999, J EXP MED, V189, P587, DOI 10.1084/jem.189.3.587; Mao XL, 2004, ONCOGENE, V23, P5632, DOI 10.1038/sj.onc.1207756; Mao XL, 2003, CANCER RES, V63, P7979; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pulendran B, 1997, J IMMUNOL, V159, P2222; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Ridgway JBB, 1999, CANCER RES, V59, P2718; Rondot S, 2001, NAT BIOTECHNOL, V19, P75, DOI 10.1038/83567; Sakisaka T, 2004, CURR OPIN CELL BIOL, V16, P513, DOI 10.1016/j.ceb.2004.07.007; Schiavoni G, 2002, J EXP MED, V196, P1415, DOI 10.1084/jem.20021263; Schultz N, 2003, P NATL ACAD SCI USA, V100, P12201, DOI 10.1073/pnas.1635054100; Shadidi M, 2001, BIOCHEM BIOPH RES CO, V280, P548, DOI 10.1006/bbrc.2000.4158; Sheehy ME, 2001, J IMMUNOL METHODS, V249, P99, DOI 10.1016/S0022-1759(00)00329-X; Shingai T, 2003, J BIOL CHEM, V278, P35421, DOI 10.1074/jbc.M305387200; Steenbergen RDM, 2004, JNCI-J NATL CANCER I, V96, P294, DOI 10.1093/jnci/djh031; Sundberg JP, 2003, J INVEST DERMATOL, V120, P771, DOI 10.1046/j.1523-1747.2003.12135.x; Suzuki S, 2004, P NATL ACAD SCI USA, V101, P8981, DOI 10.1073/pnas.0402139101; Taylor JA, 1997, RAPID COMMUN MASS SP, V11, P1067, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1067::AID-RCM953>3.0.CO;2-L; Topping KP, 2000, INT J ONCOL, V16, P187; Tsujimura H, 2003, J IMMUNOL, V170, P1131, DOI 10.4049/jimmunol.170.3.1131; Uchino K, 2003, CANCER-AM CANCER SOC, V98, P1002, DOI 10.1002/cncr.11599; VanEwijk W, 1997, P NATL ACAD SCI USA, V94, P3903, DOI 10.1073/pnas.94.8.3903; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; Wakayama T, 2003, BIOL REPROD, V68, P1755, DOI 10.1095/biolreprod.102.012344; Wakayama T, 2001, MOL REPROD DEV, V60, P158, DOI 10.1002/mrd.1072; Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Yrlid U, 2003, APMIS, V111, P756, DOI 10.1034/j.1600-0463.2003.11107807.x	66	139	159	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21955	21964		10.1074/jbc.M502095200	http://dx.doi.org/10.1074/jbc.M502095200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15781451	hybrid			2022-12-27	WOS:000229557900037
J	Gould, PS; Easton, AJ				Gould, PS; Easton, AJ			Coupled translation of the respiratory syncytial virus M2 open reading frames requires upstream sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT REINITIATION MECHANISM; RIBOSOME ENTRY SITES; MESSENGER-RNA; INITIATION; PROTEIN; TRANSCRIPTION; ELONGATION; EXPRESSION; COMPLEXES; GENE	We have investigated the mechanism of the translation of the second open reading frame (ORF) of the respiratory syncytial virus M2 transcript that uses a novel coupled translation process requiring prior translation of the upstream ORF. The second M2-2 ORF sequences play no role in the coupling process and can be replaced with other gene sequences. Surprisingly, the overlap region of the two ORFs alone was not sufficient for coupled translation to occur. An analysis of the sequences required for the coupling process showed that portions of the transcript located along the length of the first ORF M2-1, upstream of the ORF overlap region, were essential for coupled translation to occur. A critically important region for this process was centered similar to 150 nucleotides upstream of the ORF2 initiation codons. This region was shown to contain a significant degree of secondary structure, and mutation of this sequence to remove predicted areas of base pairing significantly reduced coupled translation, confirming that the secondary structure was important for the coupling process. Additional sequences further upstream increased the efficiency of the coupled translation process. These data indicate that upstream sequences act in conjunction with the M2-1/M2-2 overlap region to promote coupled translation.	Univ Warwick, Dept Biol Sci, Warwick CV4 7AL, W Midlands, England	University of Warwick	Easton, AJ (corresponding author), Univ Warwick, Dept Biol Sci, Gibbet Hill Rd, Warwick CV4 7AL, W Midlands, England.	a.j.easton@warwick.ac.uk		Gould, Phillip/0000-0003-1230-6771				Ahmadian G, 1999, J GEN VIROL, V80, P2011, DOI 10.1099/0022-1317-80-8-2011; Ahmadian G, 2000, EMBO J, V19, P2681, DOI 10.1093/emboj/19.11.2681; ANTHONY DD, 1992, J BIOL CHEM, V267, P1554; BALTIMORE D, 1971, BACTERIOL REV, V35, P235, DOI 10.1128/MMBR.35.3.235-241.1971; Bermingham A, 1999, P NATL ACAD SCI USA, V96, P11259, DOI 10.1073/pnas.96.20.11259; Collins PL, 1996, P NATL ACAD SCI USA, V93, P81, DOI 10.1073/pnas.93.1.81; GARDNER PS, 1973, POSTGRAD MED J, V49, P788, DOI 10.1136/pgmj.49.577.788; Gould PS, 2005, BIOTECHNIQUES, V38, P397, DOI 10.2144/05383ST02; Green KY, 2000, J INFECT DIS, V181, pS322, DOI 10.1086/315591; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; HOLBERG CJ, 1991, AM J EPIDEMIOL, V133, P1135, DOI 10.1093/oxfordjournals.aje.a115826; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Jin H, 2000, VIROLOGY, V273, P210, DOI 10.1006/viro.2000.0393; Kozak M, 1998, NUCLEIC ACIDS RES, V26, P4853, DOI 10.1093/nar/26.21.4853; Latorre P, 1998, MOL CELL BIOL, V18, P5021, DOI 10.1128/MCB.18.9.5021; Meyers G, 2003, J BIOL CHEM, V278, P34051, DOI 10.1074/jbc.M304874200; PARROTT RH, 1973, AM J EPIDEMIOL, V98, P289, DOI 10.1093/oxfordjournals.aje.a121558; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pestova TV, 2003, GENE DEV, V17, P181, DOI 10.1101/gad.1040803; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Pisarev AV, 2004, J VIROL, V78, P4487, DOI 10.1128/JVI.78.9.4487-4497.2004; Plant EP, 2003, RNA, V9, P168, DOI 10.1261/rna.2132503; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	24	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21972	21980		10.1074/jbc.M502276200	http://dx.doi.org/10.1074/jbc.M502276200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15784616	hybrid			2022-12-27	WOS:000229557900039
J	Kallen, J; Sedrani, R; Zenke, G; Wagner, J				Kallen, J; Sedrani, R; Zenke, G; Wagner, J			Structure of human cyclophilin a in complex with the novel immunosuppressant sanglifehrin a at 1.6 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES SP A92-308110; X-RAY-STRUCTURE; CYCLOSPORINE-A; CRYSTAL-STRUCTURE; BINDING IMMUNOSUPPRESSANT; CALCINEURIN; IMMUNOPHILIN; DEGRADATION; REFINEMENT; MECHANISM	Sanglifehrin A (SFA) is a novel immunosuppressant isolated from Streptomyces sp. that binds strongly to the human immunophilin cyclophilin A ( CypA). SFA exerts its immunosuppressive activity through a mode of action different from that of all other known immunophilin-binding substances, namely cyclosporine A (CsA), FK506, and rapamycin. We have determined the crystal structure of human CypA in complex with SFA at 1.6 angstrom resolution. The high resolution of the structure revealed the absolute configuration at all 17 chiral centers of SFA as well as the details of the CypA/SFA interactions. In particular, it was shown that the 22-membered macrocycle of SFA is deeply embedded in the same binding site as CsA and forms six direct hydrogen bonds with CypA. The effector domain of SFA, on the other hand, has a chemical and three-dimensional structure very different from CsA, already strongly suggesting different immunosuppressive mechanisms. Furthermore, two CypA center dot SFA complexes form a dimer in the crystal as well as in solution as shown by light scattering and size exclusion chromatography experiments. This observation raises the possibility that the dimer of CypA center dot SFA complexes is the molecular species mediating the immunosuppressive effect.	Novartis Inst BioMed Res, Prot Struct Unit, CH-4002 Basel, Switzerland; Novartis Inst BioMed Res, Protease Platform, CH-4002 Basel, Switzerland; Novartis Inst BioMed Res, Transplantat Res, CH-4002 Basel, Switzerland	Novartis; Novartis; Novartis	Kallen, J (corresponding author), Novartis Inst BioMed Res, Prot Struct Unit, CH-4002 Basel, Switzerland.	joerg.kallen@pharma.novartis.com						Allen A, 2004, J IMMUNOL, V172, P4797, DOI 10.4049/jimmunol.172.8.4797; ANDERSON PS, 1994, PERSPECT DRUG DISCOV, V2, P3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banteli R, 2001, BIOORG MED CHEM LETT, V11, P1609, DOI 10.1016/S0960-894X(01)00293-1; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BRUENGER AT, 1993, XPLOR VERSION 3 1 SY; Fehr T, 1999, J ANTIBIOT, V52, P474, DOI 10.7164/antibiotics.52.474; Huai Q, 2002, P NATL ACAD SCI USA, V99, P12037, DOI 10.1073/pnas.192206699; Jin L, 2002, P NATL ACAD SCI USA, V99, P13522, DOI 10.1073/pnas.212504399; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALLEN J, 1992, FEBS LETT, V300, P286, DOI 10.1016/0014-5793(92)80865-E; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KALLEN J, 1997, BIOTECHNOLOGY, V7, P536; KE HM, 1992, J MOL BIOL, V228, P539, DOI 10.1016/0022-2836(92)90841-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Metternich R, 1999, J ORG CHEM, V64, P9632, DOI 10.1021/jo9912395; MIKOL V, 1993, J MOL BIOL, V234, P1119, DOI 10.1006/jmbi.1993.1664; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nicolaou KC, 2000, J AM CHEM SOC, V122, P3830, DOI 10.1021/ja994285v; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paquette LA, 2002, J AM CHEM SOC, V124, P4257, DOI 10.1021/ja020091v; Pemberton TJ, 2003, FEBS LETT, V555, P335, DOI 10.1016/S0014-5793(03)01270-5; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Sanglier JJ, 1999, J ANTIBIOT, V52, P466, DOI 10.7164/antibiotics.52.466; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Sedrani R, 2003, J AM CHEM SOC, V125, P3849, DOI 10.1021/ja021327y; Steinschulte C, 2003, J IMMUNOL, V171, P542, DOI 10.4049/jimmunol.171.2.542; Woltman AM, 2004, J IMMUNOL, V172, P6482, DOI 10.4049/jimmunol.172.10.6482; Zenke G, 2001, J IMMUNOL, V166, P7165, DOI 10.4049/jimmunol.166.12.7165; Zhang LH, 2001, J BIOL CHEM, V276, P43534, DOI 10.1074/jbc.M104257200; Zhang LH, 2001, J IMMUNOL, V166, P5611, DOI 10.4049/jimmunol.166.9.5611; Zhao YD, 1996, BIOCHEMISTRY-US, V35, P7362, DOI 10.1021/bi960278x	34	30	40	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21965	21971		10.1074/jbc.M501623200	http://dx.doi.org/10.1074/jbc.M501623200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15772070	hybrid			2022-12-27	WOS:000229557900038
J	Honda, K; Smith, MA; Zhu, XW; Baus, D; Merrick, WC; Tartakoff, AM; Hattier, T; Harris, PL; Siedlak, SL; Fujioka, H; Liu, Q; Moreira, PI; Miller, FP; Nunomura, A; Shimohama, S; Perry, G				Honda, K; Smith, MA; Zhu, XW; Baus, D; Merrick, WC; Tartakoff, AM; Hattier, T; Harris, PL; Siedlak, SL; Fujioka, H; Liu, Q; Moreira, PI; Miller, FP; Nunomura, A; Shimohama, S; Perry, G			Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED FENTON REACTIONS; ION-BINDING-SITES; OXIDATIVE DAMAGE; AMYLOID-BETA; HYDROGEN-PEROXIDE; PROMINENT FEATURE; DNA CONSTITUENTS; HEME OXYGENASE-1; SENILE PLAQUES; METAL-BINDING	Oxidative modification of cytoplasmic RNA in vulnerable neurons is an important, well documented feature of the pathophysiology of Alzheimer disease. Here we report that RNA-bound iron plays a pivotal role for RNA oxidation in vulnerable neurons in Alzheimer disease brain. The cytoplasm of hippocampal neurons showed significantly higher redox activity and iron(II) staining than age-matched controls. Notably, both were susceptible to RNase, suggesting a physical association of iron( II) with RNA. Ultrastructural analysis further suggested an endoplasmic reticulum association. Both rRNA and mRNA showed twice the iron binding as tRNA. rRNA, extremely abundant in neurons, was considered to provide the greatest number of iron binding sites among cytoplasmic RNA species. Interestingly, the difference of iron binding capacity disappeared after denaturation of RNA, suggesting that the higher order structure may contribute to the greater iron binding of rRNA. Reflecting the difference of iron binding capacity, oxidation of rRNA by the Fenton reaction formed 13 times more 8-hydroxyguanosine than tRNA. Consistent with in situ findings, ribosomes purified from Alzheimer hippocampus contained significantly higher levels of RNase-sensitive iron( II) and redox activity than control. Furthermore, only Alzheimer rRNA contains 8-hydroxyguanosine in reverse transcriptase-PCR. Addressing the biological significance of ribosome oxidation by redox-active iron, in vitro translation with oxidized ribosomes from rabbit reticulocyte showed a significant reduction of protein synthesis. In conclusion these results suggest that rRNA provides a binding site for redoxactive iron and serves as a redox center within the cytoplasm of vulnerable neurons in Alzheimer disease in advance of the appearance of morphological change indicating neurodegeneration.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Univ Coimbra, Ctr Neurosci & Cell Biol Coimbra, P-3004517 Coimbra, Portugal; Asahikawa Med Coll, Dept Psychiat & Neurol, Asahikawa, Hokkaido 0788510, Japan; Kyoto Univ, Grad Sch Med, Dept Neurol, Kyoto 6068507, Japan	Case Western Reserve University; Case Western Reserve University; Universidade de Coimbra; Asahikawa Medical College; Kyoto University	Perry, G (corresponding author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.	george.perry@case.edu	Moreira, Paula/B-3608-2009; Zhu, Xiongwei/A-9629-2009; Perry, George/A-8611-2009; Smith, Mark A/A-9053-2009	Moreira, Paula/0000-0001-5177-6747; Zhu, Xiongwei/0000-0003-2092-6508; Perry, George/0000-0002-6547-0172; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026796] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038648] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26796] Funding Source: Medline; NINDS NIH HHS [NS38648] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alberts B., 1994, MOL BIOL CELL; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Bayer TA, 2003, P NATL ACAD SCI USA, V100, P14187, DOI 10.1073/pnas.2332818100; Berens C, 1998, CHEM BIOL, V5, P163, DOI 10.1016/S1074-5521(98)90061-8; Castegna A, 2002, FREE RADICAL BIO MED, V33, P562, DOI 10.1016/S0891-5849(02)00914-0; Cate JH, 1996, STRUCTURE, V4, P1221, DOI 10.1016/S0969-2126(96)00129-3; Chen BX, 1996, J HISTOCHEM CYTOCHEM, V44, P819, DOI 10.1177/44.8.8756754; Colwell BA, 2003, J INORG BIOCHEM, V94, P100, DOI 10.1016/S0162-0134(02)00626-8; CONNOR JR, 1992, J NEUROSCI RES, V31, P327, DOI 10.1002/jnr.490310214; CONNOR JR, 1992, J NEUROSCI RES, V31, P75, DOI 10.1002/jnr.490310111; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Deibel MA, 1996, J NEUROL SCI, V143, P137, DOI 10.1016/S0022-510X(96)00203-1; Ding QX, 2004, J NEUROCHEM, V91, P1211, DOI 10.1111/j.1471-4159.2004.02802.x; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; Gabbita SP, 1998, J NEUROCHEM, V71, P2034, DOI 10.1046/j.1471-4159.1998.71052034.x; Gonzalez RL, 2001, METHOD ENZYMOL, V338, P421; Henle ES, 1996, J BIOL CHEM, V271, P21177, DOI 10.1074/jbc.271.35.21177; Henle ES, 1999, J BIOL CHEM, V274, P962, DOI 10.1074/jbc.274.2.962; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; JOHNSON G, 1992, MOL BRAIN RES, V15, P319; Kemper W M, 1979, Methods Enzymol, V60, P638; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; LANGSTROM NS, 1989, MOL BRAIN RES, V5, P259, DOI 10.1016/0169-328X(89)90060-0; Lloyd DR, 1999, MUTAT RES-FUND MOL M, V424, P23, DOI 10.1016/S0027-5107(99)00005-6; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Lovell MA, 2001, ARCH NEUROL-CHICAGO, V58, P392, DOI 10.1001/archneur.58.3.392; Luo YZ, 1996, J BIOL CHEM, V271, P21167, DOI 10.1074/jbc.271.35.21167; LUO YZ, 1994, P NATL ACAD SCI USA, V91, P12438, DOI 10.1073/pnas.91.26.12438; MANN DMA, 1981, J NEUROL NEUROSUR PS, V44, P97, DOI 10.1136/jnnp.44.2.97; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MORRIS CM, 1994, NEURODEGENERATION, V3, P267; Nunomura A, 2004, NEUROBIOL DIS, V17, P108, DOI 10.1016/j.nbd.2004.06.003; Nunomura A, 1999, J NEUROSCI, V19, P1959; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Polacek N, 1998, RNA, V4, P1282, DOI 10.1017/S1355838298980347; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Pyle AM, 2002, J BIOL INORG CHEM, V7, P679, DOI 10.1007/s00775-002-0387-6; Quintana C, 2000, CELL MOL BIOL, V46, P807; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Rottkamp CA, 2001, FREE RADICAL BIO MED, V30, P447, DOI 10.1016/S0891-5849(00)00494-9; SAJDELSULKOWSKA EM, 1984, SCIENCE, V225, P947, DOI 10.1126/science.6206567; Sayre LM, 2000, J NEUROCHEM, V74, P270, DOI 10.1046/j.1471-4159.2000.0740270.x; SCHIPPER HM, 1995, ANN NEUROL, V37, P758, DOI 10.1002/ana.410370609; Shan X, 2003, J NEUROSCI, V23, P4913; Shiman R, 2000, J MOL BIOL, V302, P79, DOI 10.1006/jmbi.2000.4031; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; SMITH MA, 1994, AM J PATHOL, V145, P42; Smith MA, 2000, ANTIOXID REDOX SIGN, V2, P413, DOI 10.1089/15230860050192198; van Rensburg SJ, 2004, METAB BRAIN DIS, V19, P89, DOI 10.1023/B:MEBR.0000027420.50736.62	52	217	239	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20978	20986		10.1074/jbc.M500526200	http://dx.doi.org/10.1074/jbc.M500526200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15767256	hybrid			2022-12-27	WOS:000229438800011
J	Maza, J; Das Sarma, J; Koval, M				Maza, J; Das Sarma, J; Koval, M			Defining a minimal motif required to prevent connexin oligomerization in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION CHANNELS; VASCULAR SMOOTH-MUSCLE; AMINO-ACID-RESIDUES; INTRACELLULAR-TRANSPORT; MEMBRANE CHANNEL; CELL-LINES; PROTEINS; TRAFFICKING; DISEASE; EXPRESSION	In contrast to most multimeric transmembrane complexes that oligomerize in the endoplasmic reticulum (ER), the gap junction protein connexin43 (Cx43) oligomerizes in an aspect of the Golgi apparatus. The mechanisms that prevent oligomerization of Cx43 and related connexins in the ER are not well understood. Also, some studies suggest that connexins can oligomerize in the ER. We used connexin constructs containing a C-terminal dilysine-based ER retention/ retrieval signal (HKKSL) transfected into HeLa cells to study early events in connexin oligomerization. Using this approach, Cx43- HKKSL was retained in the ER and prevented from oligomerization. However, another ER-retained HKKSL-tagged connexin, Cx32-HKKSL, had the capacity to oligomerize. Because this suggested that Cx43 contains a motif that prevented oligomerization in the ER, a series of HKKSL-tagged and untagged Cx32/ Cx43 chimeras was screened to define this motif. The minimal motif, which prevented ER oligomerization, consisted of the complete third transmembrane domain and the second extracellular loop from Cx43 on a Cx32 backbone. We propose that charged residues present in Cx43 and related connexins help prevent ER oligomerization by stabilizing the third transmembrane domain in the membrane bilayer.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Koval, M (corresponding author), Emory Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Whitehead Biomed Res Bldg,615 Micheale St,Suite 2, Atlanta, GA 30322 USA.		Sarma, Jayasri Das/AAS-3837-2020; Koval, Michael/C-6366-2015	Koval, Michael/0000-0002-5422-5614	NHLBI NIH HHS [P01 HL019737, P01 HL019737-300018, P01-HL019737-26] Funding Source: Medline; NIGMS NIH HHS [R01 GM061012-06, GM61012, R01 GM061012] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061012] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad S, 2001, EUR J BIOCHEM, V268, P4544, DOI 10.1046/j.1432-1327.2001.02380.x; Bennett MVL, 2004, NEURON, V41, P495, DOI 10.1016/S0896-6273(04)00043-1; Berthoud VM, 2003, EUR J CELL BIOL, V82, P209, DOI 10.1078/0171-9335-00316; Beyer EC, 2001, CELL COMMUN ADHES, V8, P199, DOI 10.3109/15419060109080723; Brink PR, 1998, ACTA PHYSIOL SCAND, V164, P349; BRUZZONE R, 1994, J CELL SCI, V107, P955; CIVITELLI R, 1993, J CLIN INVEST, V91, P1888, DOI 10.1172/JCI116406; Cottrell GT, 2002, AM J PHYSIOL-CELL PH, V282, pC1469, DOI 10.1152/ajpcell.00484.2001; Das Sarma J, 2002, J BIOL CHEM, V277, P20911, DOI 10.1074/jbc.M111498200; Das Sarma J, 2001, J CELL SCI, V114, P4013; Delmar M, 2004, CARDIOVASC RES, V62, P268, DOI 10.1016/j.cardiores.2003.12.030; Deschenes SM, 1997, J NEUROSCI, V17, P9077; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Figueroa XF, 2004, PHYSIOLOGY, V19, P277, DOI 10.1152/physiol.00008.2004; Fleishman SJ, 2004, MOL CELL, V15, P879, DOI 10.1016/j.molcel.2004.08.016; Gemel J, 2004, J CELL SCI, V117, P2469, DOI 10.1242/jcs.01084; George CH, 1999, J BIOL CHEM, V274, P8678, DOI 10.1074/jbc.274.13.8678; Govindarajan R, 2002, J BIOL CHEM, V277, P50087, DOI 10.1074/jbc.M202652200; He DS, 1999, P NATL ACAD SCI USA, V96, P6495, DOI 10.1073/pnas.96.11.6495; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kelsell DP, 2001, TRENDS CELL BIOL, V11, P2, DOI 10.1016/S0962-8924(00)01866-3; KOVAL M, 1995, J CELL BIOL, V130, P987, DOI 10.1083/jcb.130.4.987; Koval M, 1997, J CELL BIOL, V137, P847, DOI 10.1083/jcb.137.4.847; KUMAR NM, 1995, J CELL SCI, V108, P3725; Lagree V, 2003, J CELL SCI, V116, P3189, DOI 10.1242/jcs.00604; Larson D. M., 2000, Molecular Cell Biology Research Communications, V3, P115, DOI 10.1006/mcbr.2000.0200; Lauf U, 2001, FEBS LETT, V498, P11, DOI 10.1016/S0014-5793(01)02462-0; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Martin PEM, 2000, BIOCHEM J, V349, P281, DOI 10.1042/0264-6021:3490281; Martin PEM, 2004, CARDIOVASC RES, V62, P378, DOI 10.1016/j.cardiores.2004.01.016; Martin PEM, 2000, J NEUROCHEM, V74, P711, DOI 10.1046/j.1471-4159.2000.740711.x; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; Rouan F, 2001, J CELL SCI, V114, P2105; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; Segretain D, 2004, BBA-BIOMEMBRANES, V1662, P3, DOI 10.1016/j.bbamem.2004.01.007; Simon AM, 2003, J CELL SCI, V116, P2223, DOI 10.1242/jcs.00429; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; Simon AM, 2002, DEV BIOL, V251, P206, DOI 10.1006/dbio.2002.0826; Skerrett IM, 2002, J CELL BIOL, V159, P349, DOI 10.1083/jcb.200207060; Stergiopoulos K, 1999, CIRC RES, V84, P1144, DOI 10.1161/01.RES.84.10.1144; Thomas T, 2004, J BIOL CHEM, V279, P19157, DOI 10.1074/jbc.M314117200; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; Valiunas V, 2001, AM J PHYSIOL-HEART C, V281, pH1675, DOI 10.1152/ajpheart.2001.281.4.H1675; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; Wang HL, 2004, NEUROBIOL DIS, V15, P361, DOI 10.1016/j.nbd.2003.11.005; WILLECKE K, 1991, EUR J CELL BIOL, V56, P1; Yum SW, 2002, NEUROBIOL DIS, V11, P43, DOI 10.1006/nbdi.2002.0545	50	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21115	21121		10.1074/jbc.M412612200	http://dx.doi.org/10.1074/jbc.M412612200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15817491	hybrid			2022-12-27	WOS:000229438800027
J	Kasus-Jacobi, A; Ou, JF; Birch, DG; Locke, KG; Shelton, JM; Richardson, JA; Murphy, AJ; Valenzuela, DM; Yancopoulos, GD; Edwards, AO				Kasus-Jacobi, A; Ou, JF; Birch, DG; Locke, KG; Shelton, JM; Richardson, JA; Murphy, AJ; Valenzuela, DM; Yancopoulos, GD; Edwards, AO			Functional characterization of mouse RDH11 as a retinol dehydrogenase involved in dark adaptation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT-CHAIN DEHYDROGENASE/REDUCTASE; ALL-TRANS-RETINOL; SUBSTRATE-SPECIFICITY; RETINITIS-PIGMENTOSA; OUTER SEGMENTS; A-WAVE; MUTATIONS; FAMILY; ENZYME; GENE	We previously cloned mouse RDH11 ( mRDH11) as a gene regulated by the transcription factor sterol regulatory element-binding proteins and showed that it is a retinol dehydrogenase expressed in non-ocular tissues such as the liver and testis and in the retina (Kasus-Jacobi, A., Ou, J., Bashmakov, Y. K., Shelton, J. M., Richardson, J. A., Goldstein, J. L., and Brown, M. S. ( 2003) J. Biol. Chem. 278, 32380-32389). It was proposed to function in the recycling of the visual chromophore 11-cis-retinal after photoisomerization by a bleaching light, a pathway referred to as the visual cycle. In this work, we describe our studies on the ocular function of mRDH11. We created a knockout mouse by replacing the mrdh11 coding sequence with the lacZ reporter gene for expression profiling. 5-Bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal) staining demonstrated active transcription of this gene in photoreceptor cells. We show by immunoblot analysis that mRDH11 is associated with retinal membranes purified from a non-outer segment fraction of the retina. No obvious retinal defect was found during development and aging of RDH11-deficient mice. The functional consequences of mRDH11 disruption were investigated by electroretinography. Dark adaptation was delayed by a factor of 2.5-3 compared with wild-type mice. However, the kinetics of 11-cis-retinal recycling during dark adaptation was not affected, suggesting that mRDH11 is not involved in the visual cycle. We propose that mRDH11 disruption affects retinoid metabolism in photoreceptor inner segments and delays the kinetics of dark adaptation through modulation of calcium homeostasis.	Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73104 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Ophthalmol, Dallas, TX 75390 USA; Retina Fdn SW, Dallas, TX 75231 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Retina Foundation of the Southwest; Regeneron	Kasus-Jacobi, A (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Dean A McGee Eye Inst,608 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	anne-kasus-jacobi@ouhsc.edu	KASUS-JACOBI, Anne/V-7799-2019	KASUS-JACOBI, Anne/0000-0003-3844-0450; Birch, David/0000-0002-6594-2897; Murphy, Andrew/0000-0003-4152-4081	NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belyaeva OV, 2003, BIOCHEMISTRY-US, V42, P14838, DOI 10.1021/bi035288u; BIRCH DG, 1995, INVEST OPHTH VIS SCI, V36, P1603; BRETON ME, 1994, INVEST OPHTH VIS SCI, V35, P295; Dean DM, 2002, P NATL ACAD SCI USA, V99, P8372, DOI 10.1073/pnas.122681899; Garwin GG, 2000, METHOD ENZYMOL, V316, P313; Haeseleer F, 2002, J BIOL CHEM, V277, P45537, DOI 10.1074/jbc.M208882200; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; HOOD DC, 1993, VISION RES, V33, P1605, DOI 10.1016/0042-6989(93)90027-T; HOOD DC, 1994, INVEST OPHTH VIS SCI, V35, P2948; Janecke AR, 2004, NAT GENET, V36, P850, DOI 10.1038/ng1394; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; Kasus-Jacobi A, 2003, J BIOL CHEM, V278, P32380, DOI 10.1074/jbc.M304969200; Kedishvili NY, 2002, J BIOL CHEM, V277, P28909, DOI 10.1074/jbc.M202588200; Kim TS, 2005, J BIOL CHEM, V280, P8694, DOI 10.1074/jbc.M413172200; Krizaj D, 2002, FRONT BIOSCI-LANDMRK, V7, pD2023, DOI 10.2741/krizaj; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; Lin BY, 2001, CANCER RES, V61, P1611; Martin RE, 2004, MOL VIS, V10, P199; McCabe SL, 2004, J GEN PHYSIOL, V123, P521, DOI 10.1085/jgp.200409011; Oppermann UCT, 2001, CHEM-BIOL INTERACT, V130, P699, DOI 10.1016/S0009-2797(00)00301-X; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; Perrault I, 2004, AM J HUM GENET, V75, P639, DOI 10.1086/424889; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337; Shang EY, 2002, J LIPID RES, V43, P590; Sheehan D.C., 1980, THEORY PRACTICE HIST; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; Vellani V, 2000, J PHYSIOL-LONDON, V529, P333, DOI 10.1111/j.1469-7793.2000.00333.x; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; Woods A, 1994, LAB HISTOPATHOLOGY C; Wu BX, 2004, INVEST OPHTH VIS SCI, V45, P3857, DOI 10.1167/iovs.03-1302; Wu BX, 2002, INVEST OPHTH VIS SCI, V43, P3365; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707; Zhao XY, 1998, J BIOL CHEM, V273, P5124, DOI 10.1074/jbc.273.9.5124	39	33	34	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20413	20420		10.1074/jbc.M413789200	http://dx.doi.org/10.1074/jbc.M413789200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15790565	hybrid			2022-12-27	WOS:000229242000033
J	Skurk, C; Izumiya, Y; Maatz, H; Razeghi, P; Shiojima, I; Sandri, M; Sato, K; Zeng, L; Schiekofer, S; Pimentel, D; Lecker, S; Taegtmeyer, H; Goldberg, AL; Walsh, K				Skurk, C; Izumiya, Y; Maatz, H; Razeghi, P; Shiojima, I; Sandri, M; Sato, K; Zeng, L; Schiekofer, S; Pimentel, D; Lecker, S; Taegtmeyer, H; Goldberg, AL; Walsh, K			The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE ATROPHY; LEFT-VENTRICULAR MASS; GLYCOGEN-SYNTHASE KINASE-3-BETA; UBIQUITIN LIGASE COMPLEX; GENE-EXPRESSION; TRANSGENIC MICE; IN-VIVO; F-BOX; MYOCARDIAL-CONTRACTILITY; PROTEIN-SYNTHESIS	Although signaling mechanisms inducing cardiac hypertrophy have been extensively studied, little is known about the mechanisms that reverse cardiac hypertrophy. Here, we describe the existence of a similar Akt/forkhead signaling axis in cardiac myocytes in vitro and in vivo, which is regulated by insulin, insulin-like growth factor (IGF), stretch, pressure overload, and angiotensin II stimulation. FOXO3a gene transfer prevented both IGF and stretch-induced hypertrophy in rat neonatal cardiac myocyte cultures in vitro. Transduction with FOXO3a also caused a significant reduction in cardiomyocyte size in mouse hearts in vivo. Akt/FOXO signaling regulated the expression of multiple atrophy-related genes "atrogenes," including the ubiquitin ligase atrogin-1 ( MAFbx). In cardiac myocyte cultures, transduction with constitutively active Akt or treatment with IGF suppressed atrogin-1 mRNA expression, whereas transduction with FOXO3a stimulated its expression. FOXO3a transduction activated the atrogin-1 promoter in both cultured myocytes and mouse heart. Thus, in cardiomyocytes, as in skeletal muscle, FOXO3a activates an atrogene transcriptional program, which retards or prevents hypertrophy and is down-regulated by multiple physiological and pathological stimuli of myocyte growth.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Renal Unit, Boston, MA 02115 USA; Univ Texas, Sch Med, Houston, TX 77030 USA	Boston University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Texas System	Walsh, K (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W611, Boston, MA 02118 USA.	kxwalsh@bu.edu		Walsh, Kenneth/0000-0001-7580-2276; Pimentel, David/0000-0002-0537-7195	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015052, R37AG015052, R01AG017241] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66957, P01 HL066957] Funding Source: Medline; NIAMS NIH HHS [AR40197, R01 AR040197] Funding Source: Medline; NIA NIH HHS [R01 AG017241, AG15052, R01 AG015052, AG17241, R37 AG015052] Funding Source: Medline; NIDDK NIH HHS [R01 DK062307, DK062307] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BENES AJ, 1985, J CELL SCI, V75, P35; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Brancaccio M, 2003, NAT MED, V9, P68, DOI 10.1038/nm805; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Condorelli G, 2002, P NATL ACAD SCI USA, V99, P12333, DOI 10.1073/pnas.172376399; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; DESIMONE GD, 1994, BRIT HEART J, V71, P287; Deval C, 2001, BIOCHEM J, V360, P143, DOI 10.1042/0264-6021:3600143; Devereux RB, 2004, JAMA-J AM MED ASSOC, V292, P2350, DOI 10.1001/jama.292.19.2350; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Himeno E, 1996, AM HEART J, V131, P313, DOI 10.1016/S0002-8703(96)90360-9; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Jagoe RT, 2002, FASEB J, V16, P1697, DOI 10.1096/fj.02-0312com; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200; Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Li HH, 2004, J CLIN INVEST, V114, P1058, DOI 10.1172/JCl200422220; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; McMullen JR, 2004, J BIOL CHEM, V279, P4782, DOI 10.1074/jbc.M310405200; McMullen JR, 2003, P NATL ACAD SCI USA, V100, P12355, DOI 10.1073/pnas.1934654100; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; PAPADIMITRIOU JM, 1974, CIRC RES, V35, P127, DOI 10.1161/01.RES.35.1.127; Petroff MGV, 2001, NAT CELL BIOL, V3, P867, DOI 10.1038/ncb1001-867; Pham FH, 2001, ADV ENZYME REGUL, V41, P73, DOI 10.1016/S0065-2571(00)00007-8; Razeghi P, 2003, CIRCULATION, V108, P2536, DOI 10.1161/01.CIR.0000096481.45105.13; SAAD MJA, 1995, BIOCHEM J, V310, P741, DOI 10.1042/bj3100741; Sacheck JM, 2004, AM J PHYSIOL-ENDOC M, V287, pE591, DOI 10.1152/ajpendo.00073.2004; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Schneider MR, 2002, J ENDOCRINOL, V172, P423, DOI 10.1677/joe.0.1720423; Shibata R, 2004, NAT MED, V10, P1384, DOI 10.1038/nm1137; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shiojima I, 2002, J BIOL CHEM, V277, P37670, DOI 10.1074/jbc.M204572200; Shiraishi I, 2004, CIRC RES, V94, P884, DOI 10.1161/01.RES.0000124394.01180.BE; Skurk C, 2004, J BIOL CHEM, V279, P1513, DOI 10.1074/jbc.M304736200; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Sugden PH, 2003, CIRC RES, V93, P1179, DOI 10.1161/01.RES.0000106132.04301.F5; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; THAIK CM, 1995, J CLIN INVEST, V96, P1093, DOI 10.1172/JCI118095; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; TOMANEK RJ, 1982, CIRC RES, V51, P295, DOI 10.1161/01.RES.51.3.295; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Wilkins BJ, 2002, J PHYSIOL-LONDON, V541, P1, DOI 10.1113/jphysiol.2002.017129; Wray CJ, 2003, INT J BIOCHEM CELL B, V35, P698, DOI 10.1016/S1357-2725(02)00341-2; Yang HL, 2005, ONCOGENE, V24, P1924, DOI 10.1038/sj.onc.1208352; Yu ZH, 1996, CIRC RES, V79, P691, DOI 10.1161/01.RES.79.4.691; Zafeiridis A, 1998, CIRCULATION, V98, P656, DOI 10.1161/01.CIR.98.7.656; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	60	255	265	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20814	20823		10.1074/jbc.M500528200	http://dx.doi.org/10.1074/jbc.M500528200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781459	hybrid, Green Accepted			2022-12-27	WOS:000229242000079
J	Martins, AHB; Resende, RR; Majumder, P; Faria, M; Casarini, DE; Tarnok, A; Colli, W; Pesquero, JB; Ulrich, H				Martins, AHB; Resende, RR; Majumder, P; Faria, M; Casarini, DE; Tarnok, A; Colli, W; Pesquero, JB; Ulrich, H			Neuronal differentiation of P19 embryonal carcinoma cells modulates kinin B2 receptor gene expression and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORADRENALINE RELEASE; BRADYKININ RECEPTORS; TISSUE KALLIKREIN; CALCIUM WAVES; PC-12 CELLS; CROSS-TALK; IDENTIFICATION; CA2+; STIMULATION; ACTIVATION	Kinins are vasoactive oligopeptides generated upon proteolytic cleavage of low and high molecular weight kininogens by kallikreins. These peptides have a well established signaling role in inflammation and homeostasis. Nevertheless, emerging evidence suggests that bradykinin and other kinins are stored in the central nervous system and may act as neuromediators in the control of nociceptive response. Here we show that the kinin-B2 receptor (B2BKR) is differentially expressed during in vitro neuronal differentiation of P19 cells. Following induction by retinoic acid, cells form embryonic bodies and then undergo neuronal differentiation, which is complete after 8 and 9 days. Immunochemical staining revealed that B2BKR protein expression was below detection limits in nondifferentiated P19 cells but increased during the course of neuronal differentiation and peaked on days 8 and 9. Measurement of [Ca2+](i) in the absence and presence of bradykinin showed that most undifferentiated cells are unresponsive to bradykinin application, but following differentiation, P19 cells express high molecular weight neurofilaments, secrete bradykinin into the culture medium, and respond to bradykinin application with a transient increase in [Ca2+](i). However, inhibition of B2BKR activity with HOE-140 during early differentiation led to a decrease in the size of embryonic bodies formed. Pretreatment of differentiating P19 cells with HOE-140 on day 5 resulted in a reduction of the calcium response induced by the cholinergic agonist carbamoylcholine and decreased expression levels of M1-M3 muscarinic acetylcholine receptors, indicating crucial functions of the B2BKR during neuronal differentiation.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05513970 Sao Paulo, Brazil; Univ Fed Sao Paulo, Dept Biofis, BR-04023062 Sao Paulo, Brazil; Univ Fed Sao Paulo, Dept Nefrol, BR-04044020 Sao Paulo, Brazil; Univ Leipzig, Cardiac Ctr Leipzig, D-04280 Leipzig, Germany	Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP); Leipzig University	Ulrich, H (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, Caixa Postal 26077, BR-05513970 Sao Paulo, Brazil.	henning@iq.usp.br	Ulrich, Henning/AAX-8586-2021; Colli, Walter/G-1188-2012; Colli, Walter/AAW-7649-2021; Pesquero, Joao/C-1470-2012; Colli, Walter/ABA-5440-2021; Majumder, Paromita/AAK-9704-2020; Ulrich, Henning/C-5245-2013	Ulrich, Henning/0000-0002-2114-3815; Colli, Walter/0000-0001-7305-4673; Pesquero, Joao/0000-0002-4507-632X; Majumder, Paromita/0000-0002-1340-2290; Ulrich, Henning/0000-0002-2114-3815; Casarini, Dulce/0000-0003-1912-4292; Resende, Rodrigo/0000-0002-2003-0739				Arganaraz GA, 2004, BRAIN RES, V1006, P114, DOI 10.1016/j.brainres.2003.12.050; Baptista HA, 2002, MOL PHARMACOL, V62, P1344, DOI 10.1124/mol.62.6.1344; BAUMGARTNER MK, 1993, DEV BRAIN RES, V72, P305, DOI 10.1016/0165-3806(93)90197-I; BHOOLA KD, 1992, BRIT J RHEUMATOL, V31, P509; Burke MA, 2003, J NEUROBIOL, V55, P191, DOI 10.1002/neu.10174; BUSH AB, 1991, J NEUROCHEM, V57, P562, DOI 10.1111/j.1471-4159.1991.tb03787.x; Calixto JB, 2000, PAIN, V87, P1, DOI 10.1016/S0304-3959(00)00335-3; Canzoniero LMT, 1996, J NEUROSCI RES, V45, P226; Cardoso CC, 2004, BIOL CHEM, V385, P295, DOI 10.1515/BC.2004.025; Casarini DE, 1999, AM J PHYSIOL-RENAL, V277, pF66, DOI 10.1152/ajprenal.1999.277.1.F66; CHAU LY, 1993, J NEUROCHEM, V60, P454, DOI 10.1111/j.1471-4159.1993.tb03172.x; De Jaco A, 2002, J NEUROSCI RES, V70, P756, DOI 10.1002/jnr.10436; Dendorfer A, 1996, PFLUG ARCH EUR J PHY, V432, pR99; DIXON BS, 1997, KIDNEY INT S, V61, P514; Drube S, 2000, BRIT J PHARMACOL, V131, P1553, DOI 10.1038/sj.bjp.0703764; El-Dahr SS, 2000, PEDIATR NEPHROL, V14, P288, DOI 10.1007/s004670050761; ElDahr SS, 1997, MICROSC RES TECHNIQ, V39, P222, DOI 10.1002/(SICI)1097-0029(19971101)39:3<222::AID-JEMT3>3.0.CO;2-M; Eurin J, 2002, NEUROPEPTIDES, V36, P257, DOI 10.1016/S0143-4179(02)00025-2; Fink CC, 2000, BIOPHYS J, V79, P163, DOI 10.1016/S0006-3495(00)76281-3; Gomez TM, 2003, METHOD ENZYMOL, V361, P407; Graness A, 1997, BIOCHEM J, V327, P147, DOI 10.1042/bj3270147; Green BT, 2003, J PHARMACOL EXP THER, V305, P733, DOI 10.1124/jpet.102.047829; HALLETT MB, 1990, PEPTIDE HORMONE ACTI, P115; HOCK FJ, 1991, BRIT J PHARMACOL, V103, P774; IRVING AJ, 1992, CELL CALCIUM, V13, P293, DOI 10.1016/0143-4160(92)90064-Y; Iwadate H, 2002, CAN J PHYSIOL PHARM, V80, P245, DOI 10.1139/Y02-026; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Jong YJI, 2002, INT IMMUNOPHARMACOL, V2, P1833, DOI 10.1016/S1567-5769(02)00168-6; Kansui Y, 2002, HYPERTENSION, V39, P29, DOI 10.1161/hy0102.098309; KOZLOWSKI MR, 1988, NEUROPEPTIDES, V12, P207, DOI 10.1016/0143-4179(88)90056-X; Kurz T, 1997, J MOL CELL CARDIOL, V29, P2561, DOI 10.1006/jmcc.1997.0492; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SD, 2000, NEUROSCI LETT, V294, P130, DOI 10.1016/S0304-3940(00)01563-9; Lee YJ, 2002, MOL CELL NEUROSCI, V19, P186, DOI 10.1006/mcne.2001.1073; Lin PX, 1996, J NEUROCHEM, V66, P233; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma QP, 2001, NEUROREPORT, V12, P2311, DOI 10.1097/00001756-200108080-00006; Mahabeer R, 2000, METAB BRAIN DIS, V15, P325, DOI 10.1023/A:1011131510491; Marceau F, 1998, PHARMACOL REV, V50, P357; Martin AK, 1999, BRIT J PHARMACOL, V126, P1559, DOI 10.1038/sj.bjp.0702464; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MONGE JC, 1995, J BIOL CHEM, V270, P15385, DOI 10.1074/jbc.270.25.15385; Morinelli TA, 2001, PEPTIDES, V22, P2169, DOI 10.1016/S0196-9781(01)00545-9; Niemann S, 1996, NEUROSCI LETT, V207, P49, DOI 10.1016/0304-3940(96)12485-X; Parnas D, 1998, J MOL NEUROSCI, V10, P17, DOI 10.1007/BF02737082; Parnas D, 1995, INT J DEV NEUROSCI, V13, P767, DOI 10.1016/0736-5748(95)00052-6; Pizard A, 2001, BIOCHEMISTRY-US, V40, P15743, DOI 10.1021/bi011600t; PURKISS JR, 1995, J NEUROCHEM, V64, P1175; Pyle SJ, 2001, DEV BRAIN RES, V132, P103, DOI 10.1016/S0165-3806(01)00289-9; Reber BFX, 1996, PFLUG ARCH EUR J PHY, V432, P893, DOI 10.1007/s004240050213; REETZ G, 1994, J NEUROCHEM, V62, P890; Regoli D, 1998, EUR J PHARMACOL, V348, P1, DOI 10.1016/S0014-2999(98)00165-4; Schelb V, 2001, N-S ARCH PHARMACOL, V364, P359; STAINES WA, 1994, NEUROSCIENCE, V58, P735, DOI 10.1016/0306-4522(94)90451-0; STEPHENS GJ, 1993, GLIA, V9, P269, DOI 10.1002/glia.440090405; Tarnok A, 1997, CYTOMETRY, V27, P65, DOI 10.1002/(SICI)1097-0320(19970101)27:1<65::AID-CYTO8>3.0.CO;2-K; Taub JS, 2003, CANCER RES, V63, P2037; THAYER SA, 1988, J NEUROSCI, V8, P4089; Wu J, 2002, INT J CANCER, V98, P29, DOI 10.1002/ijc.10142; YANO K, 1984, J BIOL CHEM, V259, P201; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0	65	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19576	19586		10.1074/jbc.M502513200	http://dx.doi.org/10.1074/jbc.M502513200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15767251	hybrid			2022-12-27	WOS:000229113700020
J	Yang, X; Li, JF; Qin, HY; Yang, H; Li, JL; Zhou, P; Liang, YM; Han, H				Yang, X; Li, JF; Qin, HY; Yang, H; Li, JL; Zhou, P; Liang, YM; Han, H			Mint represses transactivation of the type II collagen gene enhancer through interaction with alpha A-crystallin-binding protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROCYTE-SPECIFIC ENHANCER; AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; BINDING-PROTEIN; CAMPOMELIC DYSPLASIA; TRANSCRIPTION FACTOR; SIGNALING PATHWAY; CARTILAGE FORMATION; NUCLEAR PROTEINS; CELL-DEVELOPMENT	Collagen type II is an extracellular matrix protein important for cartilage and bone formation, and its expression is controlled by multiple cis- and trans-acting elements, including the zinc finger transcription factor alpha A-crystallin-binding protein 1 (CRYBP1). Here we show that MSX2-interacting nuclear target protein ( MINT), a conserved transcriptional repressor, associates with CRYBP1 and negatively regulates the transactivation of the collagen type II gene (Col2a1) enhancer. We identified CRYBP1 as a binding partner of MINT by screening a mouse embryonic cDNA library using the yeast two-hybrid system. We demonstrated that the C terminus of MINT interacts with the C terminus of CRYBP1 using the mammalian cell two-hybrid assay, glutathione S-transferase pull-down, and co-immunoprecipitation analyses. Furthermore, MINT and CRYBP1 form a complex on the Col2a1 enhancer, as shown by chromatin immunoprecipitation and gel shift assays. In the presence of CRYBP1, overexpression of MINT or its C-terminal fragment in cells repressed a reporter construct driven by the Col2a1 enhancer elements. This transcription repression is dependent on histone deacetylase, the main co-repressor recruited by MINT. The present study shows that MINT is involved in CRYBP1-mediated Col2a1 gene repression and may play a role in regulation of cartilage development.	Fourth Mil Med Univ, Dept Med Genet & Dev Biol, State Key Lab Canc Biol, Xian 710032, Peoples R China	Air Force Military Medical University	Han, H (corresponding author), Fourth Mil Med Univ, Dept Med Genet & Dev Biol, State Key Lab Canc Biol, Changle Xi St 17, Xian 710032, Peoples R China.	huahan@fmmu.edu.cn		han, hua/0000-0002-1872-9700				Ariyoshi M, 2003, GENE DEV, V17, P1909, DOI 10.1101/gad.266203; ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Bassett JHD, 2003, TRENDS ENDOCRIN MET, V14, P356, DOI 10.1016/S1043-2760(03)00144-90; Basson M, 1996, GENE DEV, V10, P1953, DOI 10.1101/gad.10.15.1953; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bi WM, 2001, P NATL ACAD SCI USA, V98, P6698, DOI 10.1073/pnas.111092198; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BRADY JP, 1995, J BIOL CHEM, V270, P1221, DOI 10.1074/jbc.270.3.1221; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; CHEAH KSE, 1991, DEVELOPMENT, V111, P945; Chen FL, 2000, CURR BIOL, V10, P943, DOI 10.1016/S0960-9822(00)00625-4; de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945-053X(00)00094-9; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Huang WD, 2000, MOL CELL BIOL, V20, P4149, DOI 10.1128/MCB.20.11.4149-4158.2000; KANTOROW M, 1993, GENE, V131, P159, DOI 10.1016/0378-1119(93)90289-F; Krebsbach PH, 1996, J BIOL CHEM, V271, P4298, DOI 10.1074/jbc.271.8.4298; Kuang B, 2000, DEVELOPMENT, V127, P1517; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; Kuroda K, 2003, IMMUNITY, V18, P301, DOI 10.1016/S1074-7613(03)00029-3; KWOK C, 1995, AM J HUM GENET, V57, P1028; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Lefebvre W, 2002, J BONE MINER METAB, V20, P121, DOI 10.1007/s007740200017; MAEKAWA T, 1989, J BIOL CHEM, V264, P14591; MANINA E, 2001, DEVELOPMENT, V128, P5423; MITCHELMORE C, 1991, NUCLEIC ACIDS RES, V19, P141, DOI 10.1093/nar/19.1.141; MUCHARDT C, 1992, J VIROL, V66, P244, DOI 10.1128/JVI.66.1.244-250.1992; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; NAKAMURA T, 1990, MOL CELL BIOL, V10, P3700, DOI 10.1128/MCB.10.7.3700; Newberry EP, 1999, BIOCHEMISTRY-US, V38, P10678, DOI 10.1021/bi990967j; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; Oswald F, 2002, EMBO J, V21, P5417, DOI 10.1093/emboj/cdf549; Qin HY, 2004, NUCLEIC ACIDS RES, V32, P1492, DOI 10.1093/nar/gkh295; Robson H, 2000, ENDOCRINOLOGY, V141, P3887, DOI 10.1210/en.141.10.3887; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Sierra OL, 2004, J BIOL CHEM, V279, P32913, DOI 10.1074/jbc.M314098200; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; Stevens DA, 2000, J BONE MINER RES, V15, P2431, DOI 10.1359/jbmr.2000.15.12.2431; Tanaka K, 2002, MOL CELL BIOL, V22, P4256, DOI 10.1128/MCB.22.12.4256-4267.2002; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Wiellette EL, 1999, DEVELOPMENT, V126, P5373; Wirth J, 1996, HUM GENET, V97, P186, DOI 10.1007/BF02265263; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; Yamagiwa H, 2004, MOL BIOTECHNOL, V28, P1, DOI 10.1385/MB:28:1:01; Yoon BS, 2004, J CELL BIOCHEM, V93, P93, DOI 10.1002/jcb.20211; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989; ZHOU G, 1995, J CELL SCI, V108, P3677	50	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18710	18716		10.1074/jbc.M500859200	http://dx.doi.org/10.1074/jbc.M500859200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15778499	hybrid			2022-12-27	WOS:000228932300022
J	Burstein, E; Hoberg, JE; Wilkinson, AS; Rumble, JM; Csomos, RA; Komarck, CM; Maine, GN; Wilkinson, JC; Mayo, MW; Duckett, CS				Burstein, E; Hoberg, JE; Wilkinson, AS; Rumble, JM; Csomos, RA; Komarck, CM; Maine, GN; Wilkinson, JC; Mayo, MW; Duckett, CS			COMMD proteins, a novel family of structural and functional homologs of MURR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; T-CELLS; GENE; TRANSCRIPTION; ALPHA; ACTIVATION; APOPTOSIS; BINDING; HIV; DNA	MURR1 is a multifunctional protein that inhibits nuclear factor kB (NF-kB), a transcription factor with pleiotropic functions affecting innate and adaptive immunity, apoptosis, cell cycle regulation, and oncogenesis. Here we report the discovery of a new family of proteins with homology to MURR1. These proteins form multimeric complexes and were identified in a biochemical screen for MURR1-associated factors. The family is defined by the presence of a conserved and unique motif termed the COMM ( copper metabolism gene MURR1) domain, which functions as an interface for protein-protein interactions. Like MURR1, several of these factors also associate with and inhibit NF-kB. The proteins designated as COMMD or COMM domain containing 1-10 are extensively conserved in multicellular eukaryotic organisms and define a novel family of structural and functional homologs of MURR1. The prototype of this family, MURR1/COMMD1, suppresses NF-kB not by affecting nuclear translocation or binding of NF-kB to cognate motifs; rather, it functions in the nucleus by affecting the association of NF-kB with chromatin.	Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Virginia, Dept Mol Genet & Biochem, Charlottesville, VA 22908 USA; Ann Arbor Vet Affairs MEd Ctr, Gastroenterol Sect, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Virginia; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System	Duckett, CS (corresponding author), Med Sci 1,Rm 5315,1301 Catherine, Ann Arbor, MI 48109 USA.	colind@umich.edu	Burstein, Ezra/B-7247-2016; Martinez, Octavio/B-7375-2009	Burstein, Ezra/0000-0003-4341-6367; Duckett, Colin/0000-0001-9413-2263	NCI NIH HHS [T32 CA 09676, R01 CA 104397, R01 CA 095644, K01 CA 78595] Funding Source: Medline; NIGMS NIH HHS [GM 067287] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009676, R01CA095644, R01CA104397, K01CA078595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Burstein E, 2004, EMBO J, V23, P244, DOI 10.1038/sj.emboj.7600031; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; Ganesh L, 2003, NATURE, V426, P853, DOI 10.1038/nature02171; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Greene WC, 2004, NAT IMMUNOL, V5, P18, DOI 10.1038/ni0104-18; HAUPT Y, 1992, MOL BIOL REP, V17, P17, DOI 10.1007/BF01006395; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Mir SS, 2000, BLOOD, V96, P4307; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nabetani A, 1997, MOL CELL BIOL, V17, P789, DOI 10.1128/MCB.17.2.789; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Reffey SB, 2001, J BIOL CHEM, V276, P26542, DOI 10.1074/jbc.M100331200; Richter BWM, 2001, MOL CELL BIOL, V21, P4292, DOI 10.1128/MCB.21.13.4292-4301.2001; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Schmid JA, 2000, J BIOL CHEM, V275, P17035, DOI 10.1074/jbc.M000291200; Semenova E, 2003, HUM MOL GENET, V12, P1301, DOI 10.1093/hmg/ddg140; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Solban N, 2000, J BIOL CHEM, V275, P32234, DOI 10.1074/jbc.M001352200; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tao TY, 2003, J BIOL CHEM, V278, P41593, DOI 10.1074/jbc.C300391200; van de Sluis B, 2002, HUM MOL GENET, V11, P165, DOI 10.1093/hmg/11.2.165; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	40	198	225	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22222	22232		10.1074/jbc.M501928200	http://dx.doi.org/10.1074/jbc.M501928200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15799966	hybrid			2022-12-27	WOS:000229557900068
J	Kane, LP; Watkins, SC				Kane, LP; Watkins, SC			Dynamic regulation of tec kinase localization in membraneproximal vesicles of a T cell clone revealed by total internal reflection fluorescence and confocal microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY TYROSINE KINASES; PLECKSTRIN HOMOLOGY DOMAIN; IMMUNE-SYSTEM; IMMUNOLOGICAL SYNAPSE; SIGNAL-TRANSDUCTION; NEGATIVE REGULATION; ITK; ACTIVATION; PATHWAYS; 3-KINASE	Tec family tyrosine kinases are key regulators of lymphocyte activation and effector function. Several Tec family kinases ( Tec, Itk, Rlk/Txk) are expressed in T cells, but it is still not clear to what degree these are redundant or have unique functions. We recently demonstrated that Tec alone, among the Tec kinase family members examined, can induce nuclear factor of activated T cell-dependent transcription. This unique functional characteristic correlated with a unique pattern of subcellular localization, as Tec ( but not other family members) was found in small vesicles, the appearance of which requires signaling through the T cell receptor for antigen. Here we report on our studies of these Tec-containing structures in live T cells, using total internal reflection fluorescence microscopy. With this technique, we showed that, in live T cells, the Tec vesicles are located at the plasma membrane, the vesicles are unique to Tec ( and not the related kinase Itk), and their formation and maintenance require T cell receptor signaling through Src family kinases and PI 3-kinase. Finally, we have imaged isolated T cell membranes by confocal microscopy, confirming the membrane-proximal location of Tec vesicles, as well as demonstrating overlap of these vesicles with the tyrosine kinase Lck, the Tec substrate PLC-gamma 1, and the early endosomal antigen 1 marker EEA1.	Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kane, LP (corresponding author), Univ Pittsburgh, Dept Immunol, BST E-1056, Pittsburgh, PA 15261 USA.	lkane@pitt.edu	Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552; Kane, Lawrence/0000-0001-5198-516X	NATIONAL CANCER INSTITUTE [P01CA073743] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 73743] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcover A, 2000, CRIT REV IMMUNOL, V20, P325; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; Astoul E, 2001, TRENDS IMMUNOL, V22, P490, DOI 10.1016/S1471-4906(01)01973-1; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Das V, 2004, IMMUNITY, V20, P577, DOI 10.1016/S1074-7613(04)00106-2; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; Garcon F, 2004, EUR J IMMUNOL, V34, P1972, DOI 10.1002/eji.200324777; Garcon F, 2004, J IMMUNOL, V173, P770, DOI 10.4049/jimmunol.173.2.770; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kane LP, 2004, J IMMUNOL, V172, P5441, DOI 10.4049/jimmunol.172.9.5441; Kashiwakura J, 1999, J EXP MED, V190, P1147, DOI 10.1084/jem.190.8.1147; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; Keyel PA, 2004, J BIOL CHEM, V279, P13190, DOI 10.1074/jbc.M312717200; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Lewis CM, 2001, CURR OPIN IMMUNOL, V13, P317, DOI 10.1016/S0952-7915(00)00221-1; Lucas JA, 2003, IMMUNOL REV, V191, P119, DOI 10.1034/j.1600-065X.2003.00029.x; Miller AT, 2002, CURR OPIN IMMUNOL, V14, P331, DOI 10.1016/S0952-7915(02)00345-X; Miller AT, 2004, IMMUNITY, V21, P67, DOI 10.1016/j.immuni.2004.06.009; Schwartzberg PL, 2003, IMMUNOL RES, V27, P481, DOI 10.1385/IR:27:2-3:481; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Stefanova I, 2003, NAT IMMUNOL, V4, P248, DOI 10.1038/ni895; Takeno M, 2004, CLIN EXP ALLERGY, V34, P965, DOI 10.1111/j.1365-2222.2004.01981.x; Takesono A, 2002, J CELL SCI, V115, P3039; Tomlinson MG, 2004, J BIOL CHEM, V279, P55089, DOI 10.1074/jbc.M408141200; Tomlinson MG, 2004, MOL CELL BIOL, V24, P2455, DOI 10.1128/MCB.24.6.2455-2466.2004; Tomlinson MG, 1999, J BIOL CHEM, V274, P13577, DOI 10.1074/jbc.274.19.13577; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Yang WC, 2000, INT IMMUNOL, V12, P1547, DOI 10.1093/intimm/12.11.1547; Yang WC, 2001, J IMMUNOL, V166, P387, DOI 10.4049/jimmunol.166.1.387; Yang WC, 1999, EUR J IMMUNOL, V29, P1842, DOI 10.1002/(SICI)1521-4141(199906)29:06<1842::AID-IMMU1842>3.0.CO;2-D; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223	37	7	9	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21949	21954		10.1074/jbc.M412913200	http://dx.doi.org/10.1074/jbc.M412913200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817477	hybrid			2022-12-27	WOS:000229557900036
J	Majerus, EM; Anderson, PJ; Sadler, JE				Majerus, EM; Anderson, PJ; Sadler, JE			Binding of ADAMTS13 to von Willebrand factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; FACTOR-CLEAVING PROTEASE; FACTOR MULTIMERS; SPACER DOMAIN; CLEAVAGE; PROTEOLYSIS; SURFACE; PLASMA; FAMILY; AGGRECANASE-1	ADAMTS13, a metalloprotease, cleaves von Willebrand factor (VWF) in plasma to generate smaller, less thrombogenic fragments. The interaction of von Willebrand factor with specific ADAMTS13 domains was characterized with a binding assay employing von Willebrand factor immobilized on a plastic surface. ADAMTS13 binding was saturable and reversible. Equilibrium binding occurred within 2 h and the half-time for dissociation was similar to 4 h. Binding to von Willebrand factor was similar with either recombinant ADAMTS13 or normal plasma ADAMTS13; plasma from a patient who lacked ADAMTS13 activity showed no binding. The stoichiometry of binding was one ADAMTS13 per two von Willebrand factor monomers, and the K-d was 14 nM. The ADAMTS13 metalloprotease and disintegrin domains did not bind VWF detectably. ADAMTS13 truncated after the first thrombospondin type 1 repeat bound VWF with a K-d of 206 nM, whereas ADAMTS13 truncated after the spacer domain had a K-d of 23 nM, which is comparable with that of full-length ADAMTS13. Truncation after the eighth thrombospondin type 1 repeat reduced the binding affinity by similar to 3-fold and truncation after the seventh thrombospondin type 1 repeat in addition to the CUB domains increased the affinity for von Willebrand factor by similar to 2-fold. Therefore, the spacer domain is required for ADAMTS13 binding to von Willebrand factor. The first thrombospondin repeat also affects binding, and the C-terminal thrombospondin type 1 and CUB domains of ADAMTS13 may modulate this interaction.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Sadler, JE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, 660 S Euclid Ave,Box 8022, St Louis, MO 63110 USA.	esadler@im.wustl	Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X	NHLBI NIH HHS [HL 72917] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072917] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Dong JF, 2003, J BIOL CHEM, V278, P29633, DOI 10.1074/jbc.M301385200; Dong JF, 2002, BLOOD, V100, P4033, DOI 10.1182/blood-2002-05-1401; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Furian M, 1999, THROMB HAEMOSTASIS, V82, P592; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Gerritsen HE, 2001, BLOOD, V98, P1654, DOI 10.1182/blood.V98.6.1654; Hartigan N, 2003, J BIOL CHEM, V278, P18045, DOI 10.1074/jbc.M211448200; Klaus C, 2004, BLOOD, V103, P4514, DOI 10.1182/blood-2003-12-4165; Kokame K, 2004, BLOOD, V103, P607, DOI 10.1182/blood-2003-08-2861; Kristiansen M, 1999, J BIOL CHEM, V274, P20540, DOI 10.1074/jbc.274.29.20540; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Luken BM, 2005, THROMB HAEMOSTASIS, V93, P267, DOI 10.1160/TH04-05-0301; Moake JL, 2002, NEW ENGL J MED, V347, P589, DOI 10.1056/NEJMra020528; Nishio K, 2004, P NATL ACAD SCI USA, V101, P10578, DOI 10.1073/pnas.0402041101; Padilla A, 2004, BLOOD, V103, P2150, DOI 10.1182/blood-2003-08-2956; Raghavachari M, 2000, COLLOID SURFACE B, V19, P315, DOI 10.1016/S0927-7765(00)00140-5; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Sadler JE, 2002, P NATL ACAD SCI USA, V99, P11552, DOI 10.1073/pnas.192448999; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Soejima K, 2001, J BIOCHEM-TOKYO, V130, P475, DOI 10.1093/oxfordjournals.jbchem.a003009; Soejima K, 2003, BLOOD, V102, P3232, DOI 10.1182/blood-2003-03-0908; STECK TL, 1965, BIOCHIM BIOPHYS ACTA, V97, P510; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; TSAI HM, 1994, BLOOD, V83, P2171; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; Vankemmelbeke MN, 2001, EUR J BIOCHEM, V268, P1259, DOI 10.1046/j.1432-1327.2001.01990.x; Zhang WR, 2004, BLOOD, V104, p39A; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200; Zheng XL, 2003, J BIOL CHEM, V278, P30136, DOI 10.1074/jbc.M305331200	36	95	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21773	21778		10.1074/jbc.M502529200	http://dx.doi.org/10.1074/jbc.M502529200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824096	hybrid			2022-12-27	WOS:000229557900014
J	Parakati, R; DiMario, JX				Parakati, R; DiMario, JX			Dynamic transcriptional regulatory complexes, including E2F4, p107, p130, and Sp1, control fibroblast growth factor receptor 1 gene expression during myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE CELLS; HISTONE DEACETYLASE; CHROMATIN IMMUNOPRECIPITATION; NEURONAL DIFFERENTIATION; REPRESS TRANSCRIPTION; IN-VIVO; CYCLE; PROTEIN; FAMILY; PRB	Developmentally controlled transcriptional regulation of myogenic cell proliferation and differentiation via expression of the fibroblast growth factor receptor 1 (FGFR1) gene is positively regulated by Sp1 and negatively regulated by E2F4-based transcriptional complexes. We report that p107 and p130 formed transcriptional complexes with E2F4 on the FGFR1 promoter and repressed FGFR1 gene transcription in myogenic cells. However, in Drosophila melanogaster SL2 cells, only p107 was able to repress Sp1-mediated transactivation of the FGFR1 promoter. Gel shift assays using transfected myoblast nuclear extracts showed that ectopic p107 reduced Sp1 occupancy of the proximal Sp binding site of the FGFR1 promoter, and coimmunoprecipitation studies indicated that Sp1 interacts with p107 but not with p130. Gel shift assays also demonstrated that Sp1 interacted with p107 in E2F4-p107 transcriptional complexes in myoblasts. The nature of the repressor transcriptional complex was altered in differentiated muscle fibers by the relative loss of the E2F4-p107-Sp1 transcription complex and replacement by the repressor E2F4-p130 complex. These findings demonstrate that activation and repression of FGFR1 gene transcription is governed by interplay between Sp1, p107, p130, and E2F4 in distinct transcriptional complexes during skeletal muscle development.	Univ Chicago, Sch Med, Dept Cell Biol & Anat, N Chicago, IL 60064 USA	University of Chicago	DiMario, JX (corresponding author), Univ Chicago, Sch Med, Dept Cell Biol & Anat, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	joseph.dimario@rosalindfranklin.edu						Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; Callaghan DA, 1999, DEV BIOL, V207, P257, DOI 10.1006/dbio.1998.9162; Chang YC, 2001, MOL CELL BIOL, V21, P1121, DOI 10.1128/MCB.21.4.1121-1131.2001; CORBEIL HB, 1995, ONCOGENE, V11, P909; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIMARIO JX, 1995, EXP CELL RES, V216, P431, DOI 10.1006/excr.1995.1054; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Flanagan-Steet H, 2000, DEV BIOL, V218, P21, DOI 10.1006/dbio.1999.9535; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Huet X, 1996, MOL CELL BIOL, V16, P3789; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Itoh N, 1996, DEVELOPMENT, V122, P291; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kastner A, 1998, CELL GROWTH DIFFER, V9, P857; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lavrrar JL, 2004, J BIOL CHEM, V279, P46343, DOI 10.1074/jbc.M402692200; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; ONEILL MC, 1972, J CELL BIOL, V52, P52, DOI 10.1083/jcb.52.1.52; Parakati R, 2005, DEV DYNAM, V232, P119, DOI 10.1002/dvdy.20214; Parakati R, 2002, J BIOL CHEM, V277, P9278, DOI 10.1074/jbc.M108411200; Patel SG, 2001, GENE, V270, P171, DOI 10.1016/S0378-1119(01)00478-4; Patel SG, 1999, GENE, V237, P265, DOI 10.1016/S0378-1119(99)00278-4; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; Sambrook J., 2002, MOL CLONING LAB MANU; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; Takahashi Y, 2000, GENE DEV, V14, P804; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001	46	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21284	21294		10.1074/jbc.M410744200	http://dx.doi.org/10.1074/jbc.M410744200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15811856	hybrid			2022-12-27	WOS:000229438800047
J	Xiao, RY; Lundstrom-Ljung, J; Holmgren, A; Gilbert, HF				Xiao, RY; Lundstrom-Ljung, J; Holmgren, A; Gilbert, HF			Catalysis of thiol/disulfide exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; THIOREDOXIN-LIKE DOMAINS; ESCHERICHIA-COLI; ACTIVE-SITE; RIBONUCLEASE-A; MIXED DISULFIDE; BOND FORMATION; GLUTAREDOXIN; ISOMERIZATION; GLUTATHIONE	Glutaredoxin (Grx) and protein-disulfide isomerase (PDI) are members of the thioredoxin superfamily of thiol/disulfide exchange catalysts. Thermodynamically, rat PDI is a 600-fold better oxidizing agent than Grx1 from Escherichia coli. Despite that, Grx1 is a surprisingly good protein oxidase. It catalyzes protein disulfide formation in a redox buffer with an initial velocity that is 30-fold faster than PDI. Catalysis of protein and peptide oxidation by the individual catalytic domains of PDI and by a Grx1-PDI chimera show that differences in active site chemistry are fundamental to their oxidase activity. Mutations in the active site cysteines reveal that Grx1 needs only one cysteine to catalyze rapid substrate oxidation, whereas PDI requires both cysteines. Grx1 is a good oxidase because of the high reactivity of a Grx1-glutathione mixed disulfide, and PDI is a good oxidase because of the high reactivity of the disulfide between the two active site cysteines. As a protein disulfide reductase, Grx1 is also superior to PDI. It catalyzes the reduction of nonnative disulfides in scrambled ribonuclease and protein-glutathione mixed disulfides 30-180 times faster than PDI. A multidomain structure is necessary for PDI to catalyze effective protein reduction; however, placing Grx1 into the PDI multidomain structure does not enhance its already high reductase activity. Grx1 and PDI have both found mechanisms to enhance active site reactivity toward proteins, particularly in the kinetically difficult direction: Grx1 by providing a reactive glutathione mixed disulfide to supplement its oxidase activity and PDI by utilizing its multidomain structure to supplement its reductase activity.	Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, Stockholm, Sweden	Baylor College of Medicine; Karolinska Institutet	Gilbert, HF (corresponding author), Baylor Coll Med, Dept Biochem, 1 Baylor Pl, Houston, TX 77030 USA.	hgilbert@bcm.tmc.edu			NIGMS NIH HHS [GM-40379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; ASLUND F, 1996, GLUTAREDOXINS STRUCT; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BUSHWELLER JH, 1994, J MOL BIOL, V235, P1585, DOI 10.1006/jmbi.1994.1108; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Darby NJ, 1995, BIOCHEMISTRY-US, V34, P16770, DOI 10.1021/bi00051a027; Foloppe N, 2004, STRUCTURE, V12, P289, DOI 10.1016/j.str.2004.01.009; Foloppe N, 2001, J MOL BIOL, V310, P449, DOI 10.1006/jmbi.2001.4767; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; GILBERT HF, 1989, BIOCHEMISTRY-US, V28, P7298, DOI 10.1021/bi00444a023; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; JENG MF, 1995, BIOCHEMISTRY-US, V34, P10101, DOI 10.1021/bi00032a001; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kortemme T, 1996, BIOCHEMISTRY-US, V35, P14503, DOI 10.1021/bi9617724; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; Lundstrom-Ljung J, 1999, FEBS LETT, V443, P85, DOI 10.1016/S0014-5793(98)01698-6; LUNDSTROMLJUNG J, 1995, J BIOL CHEM, V270, P7822, DOI 10.1074/jbc.270.14.7822; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; Marino G, 2000, METH MOL B, V160, P227; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P8883, DOI 10.1021/bi00100a023; Nordstrand K, 1999, FEBS LETT, V449, P196, DOI 10.1016/S0014-5793(99)00401-9; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Ruoppolo M, 1997, BIOCHEMISTRY-US, V36, P12259, DOI 10.1021/bi970851s; Sahlin L, 2000, MOL HUM REPROD, V6, P1147, DOI 10.1093/molehr/6.12.1147; Schwaller M, 2003, J BIOL CHEM, V278, P7154, DOI 10.1074/jbc.M211036200; Solovyov A, 2004, J BIOL CHEM, V279, P34095, DOI 10.1074/jbc.M405640200; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; WILSON JM, 1977, J AM CHEM SOC, V99, P7922, DOI 10.1021/ja00466a027; Xiao R, 2001, J BIOL CHEM, V276, P27975, DOI 10.1074/jbc.M104203200; YANG YF, 1991, J BIOL CHEM, V266, P12759	43	49	56	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21099	21106		10.1074/jbc.M411476200	http://dx.doi.org/10.1074/jbc.M411476200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15814611	hybrid			2022-12-27	WOS:000229438800025
J	Guazzaroni, MAE; Krell, T; Felipe, A; Ruiz, R; Meng, CX; Zhang, XD; Gallegos, MT; Ramos, JL				Guazzaroni, MAE; Krell, T; Felipe, A; Ruiz, R; Meng, CX; Zhang, XD; Gallegos, MT; Ramos, JL			The multidrug efflux regulator TtgV recognizes a wide range of structurally different effectors in solution and complexed with target DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA DOT-T1E; GRAM-NEGATIVE BACTERIA; TRANSCRIPTIONAL REGULATOR; ESCHERICHIA-COLI; BINDING PROTEIN; PUMP; REPRESSOR; QACR; MECHANISM; TOLERANCE	TtgV modulates the expression of the ttgGHI operon, which encodes an efflux pump that extrudes a wide variety of chemicals including mono- and binuclear aromatic hydrocarbons, aliphatic alcohols, and antibiotics of dissimilar chemical structure. Using a 'lacZ fusion to the ttgG promoter, we show that the most efficient in vivo inducers were 1-naphthol, 2,3-dihydroxynaphthalene, 4-nitrotoluene, benzonitrile, and indole. The thermodynamic parameters for the binding of different effector molecules to purified TtgV were determined by isothermal titration calorimetry. For the majority of effectors, the interaction was enthalpy-driven and counterbalance by unfavorable entropy changes. The TtgV-effector dissociation constants were found to vary between 2 and 890 mu M. There was a relationship between TtgV affinity for the different effectors and their potential to induce gene expression in vivo, indicating that the effector binding constant is a major determinant for efficient efflux pump gene expression. Equilibrium dialysis and isothermal titration calorimetry studies indicated that a TtgV dimer binds one effector molecule. No evidence for the simultaneous binding of multiple effectors to TtgV was obtained. The binding of TtgV to a 63-bp DNA fragment containing its cognate operator was tight and entropy-driven (K-D = 2.4 +/- 0.35 nM, Delta H = 5.5 +/- 0.04 kcal/mol). The TtgV-DNA complex was shown to bind 1-napthol with an affinity comparable with the free soluble TtgV protein, K-D = 4.8 +/- 0.19 and 3.0 +/- 0.15 mu M, respectively. The biological relevance of this finding is discussed.	CSIC, Dept Biochem & Mol & Cellular Biol Plants, Estac Expt Zaidin, E-18008 Granada, Spain; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Ctr Struct Biol, London SW7 2AZ, England	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ); Imperial College London; University of London; Institute of Cancer Research - UK	Ramos, JL (corresponding author), CSIC, Dept Biochem & Mol & Cellular Biol Plants, Estac Expt Zaidin, Prof Albareda,1, E-18008 Granada, Spain.	jlramos@eez.csic.es	Krell, Tino/G-7296-2015; Guazzaroni, María Eugenia MEG/E-2599-2013; Gallegos, María-Trinidad M.T./K-6501-2014; Guazzaroni, María-Eugenia/Y-9268-2019	Krell, Tino/0000-0002-9040-3166; Guazzaroni, María Eugenia MEG/0000-0002-4657-3731; Gallegos, María-Trinidad M.T./0000-0001-7633-8807; Guazzaroni, María-Eugenia/0000-0002-4657-3731; Zhang, Xiaodong/0000-0001-9786-7038; Ramos, Juan L./0000-0002-8731-7435				Ausubel FM, 1991, CURRENT PROTOCOLS MO; Berens C, 2003, EUR J BIOCHEM, V270, P3109, DOI 10.1046/j.1432-1033.2003.03694.x; Chatterjee A, 2004, J BACTERIOL, V186, P6809, DOI 10.1128/JB.186.20.6809-6814.2004; DiRusso CC, 1998, J BIOL CHEM, V273, P33652, DOI 10.1074/jbc.273.50.33652; Gallegos MT, 1996, J BACTERIOL, V178, P2356, DOI 10.1128/jb.178.8.2356-2361.1996; Gerischer U, 1998, J BACTERIOL, V180, P1512, DOI 10.1128/JB.180.6.1512-1524.1998; Grkovic S, 2003, BIOCHEMISTRY-US, V42, P15226, DOI 10.1021/bi035447+; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; Grkovic S, 2001, J BACTERIOL, V183, P7102, DOI 10.1128/JB.183.24.7102-7109.2001; Guazzaroni ME, 2004, J BACTERIOL, V186, P2921, DOI 10.1128/JB.186.10.2921-2927.2004; Heldwein EEZ, 2001, NATURE, V409, P378, DOI 10.1038/35053138; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; Kavanoor M, 1997, BIOPHYS CHEM, V66, P43, DOI 10.1016/S0301-4622(97)00002-1; Kok RG, 1998, J BACTERIOL, V180, P5058, DOI 10.1128/JB.180.19.5058-5069.1998; Lee EH, 2003, J BACTERIOL, V185, P7145, DOI 10.1128/JB.185.24.7145-7152.2003; Lee EW, 2003, ANTIMICROB AGENTS CH, V47, P3733, DOI 10.1128/AAC.47.12.3733-3738.2003; Middlemiss JK, 2004, J BACTERIOL, V186, P1258, DOI 10.1128/JB.186.5.1258-1269.2004; Murray DS, 2004, J BIOL CHEM, V279, P14365, DOI 10.1074/jbc.M313870200; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; Ramos JL, 2002, ANNU REV MICROBIOL, V56, P743, DOI 10.1146/annurev.micro.56.012302.161038; Ramos JL, 1998, J BACTERIOL, V180, P3323, DOI 10.1128/JB.180.13.3323-3329.1998; RAMOS JL, 1995, J BACTERIOL, V177, P3911, DOI 10.1128/jb.177.14.3911-3916.1995; Rojas A, 2004, APPL ENVIRON MICROB, V70, P3637, DOI 10.1128/aem.70.6.3637-3643.2004; Rojas A, 2003, J BACTERIOL, V185, P4755, DOI 10.1128/JB.185.16.4755-4763.2003; Rojas A, 2001, J BACTERIOL, V183, P3967, DOI 10.1128/JB.183.13.3967-3973.2001; Schnappinger D, 1999, J BIOL CHEM, V274, P6405, DOI 10.1074/jbc.274.10.6405; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Schumacher MA, 2004, EMBO J, V23, P2923, DOI 10.1038/sj.emboj.7600288; SIKKEMA J, 1995, MICROBIOL REV, V59, P201, DOI 10.1128/MMBR.59.2.201-222.1995; SPAINK HP, 1987, PLANT MOL BIOL, V9, P27, DOI 10.1007/BF00017984; Teran W, 2003, ANTIMICROB AGENTS CH, V47, P3067, DOI 10.1128/AAC.47.10.3067-3072.2003; Trautwein G, 2001, J BACTERIOL, V183, P873, DOI 10.1128/JB.183.3.873-881.2001; Vazquez-Laslop N, 1999, BIOCHEMISTRY-US, V38, P16925, DOI 10.1021/bi991988g; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yoshida K, 2004, J BACTERIOL, V186, P5640, DOI 10.1128/JB.186.17.5640-5648.2004; Yu EW, 2003, J BACTERIOL, V185, P5657, DOI 10.1128/JB.185.19.5657-5664.2003	37	51	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20887	20893		10.1074/jbc.M500783200	http://dx.doi.org/10.1074/jbc.M500783200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15767250	hybrid			2022-12-27	WOS:000229242000087
J	Jiang, H; Luo, SQ; Li, HL				Jiang, H; Luo, SQ; Li, HL			Cdk5 activator-binding protein C53 regulates apoptosis induced by genotoxic stress via modulating the G(2)/M DNA damage checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; NUCLEAR-LOCALIZATION; P34(CDC2) KINASE; CELL-CYCLE; B1; PHOSPHORYLATION; MECHANISMS; PATHWAY; CDC25C; EXPORT	In response to DNA damage, the cellular decision of life versus death involves an intricate network of multiple factors that play critical roles in regulation of DNA repair, cell cycle, and cell death. DNA damage checkpoint proteins are crucial for maintaining DNA integrity and normal cellular functions, but they may also reduce the effectiveness of cancer treatment. Here we report the involvement of Cdk5 activator p35-binding protein C53 in regulation of apoptosis induced by genotoxic stress through modulating Cdk1-cyclin B1 function. C53 was originally identified as a Cdk5 activator p35-binding protein and a caspase substrate. Importantly, our results demonstrated that C53 deficiency conferred partial resistance to genotoxic agents such as etoposide and x-ray irradiation, whereas ectopic expression of C53 rendered cells susceptible to multiple genotoxins that usually trigger G(2)/M arrest. Furthermore, we found that Cdk1 activity was required for etoposide-induced apoptosis of HeLa cells. Overexpression of C53 promoted Cdk1 activity and nuclear accumulation of cyclin B1, whereas C53 deficiency led to more cytoplasmic retention of cyclin B1, suggesting that C53 acts as a pivotal player in modulating the G(2)/M DNA damage checkpoint. Finally, C53 and cyclin B1 co-localize and associate in vivo, indicating a direct role of C53 in regulating the Cdk1-cyclin B1 complex. Taken together, our results strongly indicate that in response to genotoxic stress, C53 serves as an important regulatory component of the G(2)/M DNA damage checkpoint. By overriding the G(2)/M checkpoint-mediated inhibition of Cdk1-cyclin B1 function, ectopic expression of C53 may represent a novel approach for chemo- and radio-sensitization of cancer cells.	Northwestern Univ, Childrens Mem Res Ctr, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60614 USA; Northwestern Univ, IGP Grad Program, Chicago, IL 60614 USA; Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Cambridge CB2 2XY, England	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; University of Cambridge	Li, HL (corresponding author), Northwestern Univ, Childrens Mem Res Ctr, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, 2430 N Halsted St, Chicago, IL 60614 USA.	h-li2@northwestern.edu		jiang, hai/0000-0002-2508-5413				Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Ching YP, 2000, GENE, V242, P285, DOI 10.1016/S0378-1119(99)00499-0; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Erenpreisa Jekaterina, 2001, Cancer Cell Int, V1, P1, DOI 10.1186/1475-2867-1-1; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Okada S., 1970, RAD BIOCH, VI; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Porter LA, 2003, BLOOD, V101, P1928, DOI 10.1182/blood-2002-04-1103; Porter LA, 2000, BLOOD, V95, P2645; Porter Lisa A, 2003, Prog Cell Cycle Res, V5, P335; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	28	61	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20651	20659		10.1074/jbc.M413431200	http://dx.doi.org/10.1074/jbc.M413431200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15790566	hybrid			2022-12-27	WOS:000229242000062
J	Madsen, KL; Beuming, T; Niv, MY; Chang, CW; Dev, KK; Weinstein, H; Gether, U				Madsen, KL; Beuming, T; Niv, MY; Chang, CW; Dev, KK; Weinstein, H; Gether, U			Molecular determinants for the complex binding specificity of the PDZ domain in PICK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ALPHA; PROTEIN PICK1; CARBOXYL-TERMINUS; CRYSTAL-STRUCTURE; RECOGNITION; INTERACTS; AMPA; RECEPTORS; DYNAMICS; ERBIN	PICK1 ( protein interacting with C kinase 1) contains a single PDZ domain known to mediate interaction with the C termini of several receptors, transporters, ion channels, and kinases. In contrast to most PDZ domains, the PICK1 PDZ domain interacts with binding sequences classifiable as type I ( terminating in (S/T) X Phi; X, any residue) as well as type II (Phi X Phi; Phi, any hydrophobic residue). To enable direct assessment of the affinity of the PICK1 PDZ domain for its binding partners we developed a purification scheme for PICK1 and a novel quantitative binding assay based on fluorescence polarization. Our results showed that the PICK1 PDZ domain binds the type II sequence presented by the human dopamine transporter (-WLKV) with an almost 15-fold and > 100-fold higher affinity than the type I sequences presented by protein kinase C alpha (-QSAV) and the beta(2)-adrenergic receptor (-DSLL), respectively. Mutational analysis of Lys(83) in the alpha B1 position of the PDZ domain suggested that this residue mimics the function of hydrophobic residues present in this position in regular type II PDZ domains. The PICK1 PDZ domain was moreover found to prefer small hydrophobic residues in the C-terminal P( 0) position of the ligand. Molecular modeling predicted a rank order of (Val > Ile > Leu) that was verified experimentally with up to a similar to 16-fold difference in binding affinity between a valine and a leucine in P(0). The results define the structural basis for the unusual binding pattern of the PICK1 PDZ domain by substantiating the critical role of the alpha B1 position (Lys83) and of discrete side chain differences in position P(0) of the ligands.	Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Neuropharmacol Grp, DK-2200 Copenhagen, Denmark; Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA; Novartis Inst BioMed Res, Dept Neurosci Res, CH-4002 Basel, Switzerland	University of Copenhagen; Cornell University; Novartis	Gether, U (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Neuropharmacol Grp, DK-2200 Copenhagen, Denmark.	gether@neuropharm.ku.dk	Niv, Masha Y/E-3148-2010; Niv, Masha/AAL-1123-2020; Madsen, Kenneth/C-7778-2012; WEINSTEIN, HAREL/O-8245-2019	Madsen, Kenneth/0000-0001-9274-6691; WEINSTEIN, HAREL/0000-0003-3473-9818; Gether, Ulrik/0000-0002-0020-3807; Dev, Kumlesh/0000-0003-4274-9119; Niv, Masha/0000-0001-8275-8795	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA012408] Funding Source: NIH RePORTER; NIDA NIH HHS [P01 DA 12408] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Baron A, 2002, J BIOL CHEM, V277, P50463, DOI 10.1074/jbc.M208848200; Beuming T, 2005, BIOINFORMATICS, V21, P827, DOI 10.1093/bioinformatics/bti098; Bezprozvanny I, 2001, FEBS LETT, V509, P457, DOI 10.1016/S0014-5793(01)03214-8; Birrane G, 2003, J BIOL CHEM, V278, P1399, DOI 10.1074/jbc.C200571200; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Boudin H, 2000, NEURON, V28, P485, DOI 10.1016/S0896-6273(00)00127-6; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; Chung HJ, 2000, J NEUROSCI, V20, P7258; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Dev KK, 2004, J BIOL CHEM, V279, P41393, DOI 10.1074/jbc.M404499200; Dev KK, 1999, NEUROPHARMACOLOGY, V38, P635, DOI 10.1016/S0028-3908(98)00230-5; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Duggan A, 2002, J BIOL CHEM, V277, P5203, DOI 10.1074/jbc.M104748200; El Far O, 2000, EUR J NEUROSCI, V12, P4215, DOI 10.1046/j.1460-9568.2000.01309.x; Excoffon KJDA, 2004, J CELL SCI, V117, P4401, DOI 10.1242/jcs.01300; Fiser A, 2003, BIOINFORMATICS, V19, P2500, DOI 10.1093/bioinformatics/btg362; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Hassan SA, 2003, PROTEINS, V51, P109, DOI 10.1002/prot.10330; Hassan SA, 2002, PROTEINS, V47, P45, DOI 10.1002/prot.10059; Hirbec H, 2002, J BIOL CHEM, V277, P15221, DOI 10.1074/jbc.C200112200; Hirbec H, 2003, NEURON, V37, P625, DOI 10.1016/S0896-6273(02)01191-1; Hruska-Hageman AM, 2002, BIOCHEM J, V361, P443, DOI 10.1042/0264-6021:3610443; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Jaulin-Bastard F, 2001, J BIOL CHEM, V276, P15256, DOI 10.1074/jbc.M010032200; Kang BS, 2003, STRUCTURE, V11, P845, DOI 10.1016/S0969-2126(03)00125-4; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kurschner C, 1998, MOL CELL NEUROSCI, V11, P161, DOI 10.1006/mcne.1998.0679; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; Lim IA, 2002, J BIOL CHEM, V277, P21697, DOI 10.1074/jbc.M112339200; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Lin SHS, 2001, MOL PHARMACOL, V60, P916, DOI 10.1124/mol.60.5.916; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Nieba L, 1996, ANAL BIOCHEM, V234, P155, DOI 10.1006/abio.1996.0067; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Novak KAP, 2002, BIOORG MED CHEM LETT, V12, P2471, DOI 10.1016/S0960-894X(02)00345-1; Perez JL, 2001, J NEUROSCI, V21, P5417, DOI 10.1523/JNEUROSCI.21-15-05417.2001; Piserchio A, 2002, J BIOL CHEM, V277, P6967, DOI 10.1074/jbc.M109453200; Reina J, 2002, NAT STRUCT BIOL, V9, P621, DOI 10.1038/nsb815; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; STRICKER NL, 1997, NAT STRUCT BIOL, V4, P336; Takeya R, 2000, BIOCHEM BIOPH RES CO, V267, P149, DOI 10.1006/bbrc.1999.1932; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; van Ham M, 2003, MOL BIOL REP, V30, P69, DOI 10.1023/A:1023941703493; Wang WL, 2003, J BIOL CHEM, V278, P37705, DOI 10.1074/jbc.M304619200; Williams ME, 2003, J NEUROSCI, V23, P11279; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3	54	65	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20539	20548		10.1074/jbc.M500577200	http://dx.doi.org/10.1074/jbc.M500577200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15774468	hybrid			2022-12-27	WOS:000229242000048
J	Okada, K; Hase, T				Okada, K; Hase, T			Cyanobacterial non-mevalonate pathway - (E)-4-hydroxy-3-methylbut-2-enyl diphosphate synthase interacts with ferredoxin in Thermosynechococcus elongatus Bp-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLERYTHRITOL PHOSPHATE-PATHWAY; COMPLETE GENOME STRUCTURE; ISOPRENOID BIOSYNTHESIS; ESCHERICHIA-COLI; GCPE; PERSPECTIVES; ACTIVATION; STEPS; CELLS; LYTB	E)-4-Hydroxy-3-methylbut-2-enyl diphosphate synthase (GcpE), which catalyzes the conversion of 2-C-methyl-D-erythritol cyclodiphosphate (MEcPP) into (E)4-hydroxy-3-methylbut-2-enyl diphosphate (HMBPP), is an essential enzyme of the non-mevalonate (2-C-methyl-D-erythritol-4-phosphate (MEP)) pathway for isoprenoid biosynthesis. The terminal steps of the MEP pathway are still not fully understood, although this pathway is necessary for survival in various organisms such as cyanobacteria, plastids of algae and higher plants, and the apicoplast of human malaria parasites. To determine the efficient redox partner for thermophilic cyanobacterial GcpE, We have expressed the gcpE and petF genes in Escherichia coli and studied the protein-protein interaction of GcpE protein with ferredoxin I (PetF) from the thermophilic cyanobacterium Thermosynechococcus elongatus BP-1. Recombinant GcpE protein was purified by an N-terminal His(6) tag and reconstituted as a [4Fe-4S](2+) metalloprotein. GcpE was shown to interact strongly with PetF via the bacterial two-hybrid system designed to detect protein-protein interactions. Moreover, a direct protein-protein interaction between PetF and GcpE was confirmed in an in vitro glutathione S-transferase (GST) pull-down assay. To investigate electron transfer activity from PetF to GcpE, we also constructed a NADPH-dependent reducing shuttle system with purified recombinant ferredoxin-NADP(+) oxidoreductase (PetH) and PetF. The result demonstrated that PetF has the ability to transfer electrons to GcpE. Thus, the combined data provide the first evidence that GcpE is a ferredoxin-dependent enzyme in T. elongatus BP-1.	Osaka Univ, Inst Prot Res, Div Enzymol, Suita, Osaka 5650871, Japan	Osaka University	Okada, K (corresponding author), Osaka Univ, Inst Prot Res, Div Enzymol, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	okadak@protein.osaka-u.ac.jp	Hase, Toshiharu/H-9271-2013					Altincicek B, 2002, FEBS LETT, V532, P437, DOI 10.1016/S0014-5793(02)03726-2; Altincicek B, 2001, J BACTERIOL, V183, P2411, DOI 10.1128/JB.183.8.2411-2416.2001; Cunningham FX, 2000, J BACTERIOL, V182, P5841, DOI 10.1128/JB.182.20.5841-5848.2000; Dove SL, 1997, NATURE, V386, P627, DOI 10.1038/386627a0; Dove SL, 1998, GENE DEV, V12, P745, DOI 10.1101/gad.12.5.745; Eisenreich W, 2001, TRENDS PLANT SCI, V6, P78, DOI 10.1016/S1360-1385(00)01812-4; Ershov YV, 2002, J BACTERIOL, V184, P5045, DOI 10.1128/JB.184.18.5045-5051.2002; Gabrielsen M, 2004, J BIOL CHEM, V279, P52753, DOI 10.1074/jbc.M408895200; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P199; Itoh D, 2003, J NAT PROD, V66, P332, DOI 10.1021/np0204141; Joung JK, 2000, P NATL ACAD SCI USA, V97, P7382, DOI 10.1073/pnas.110149297; Kollas AK, 2002, FEBS LETT, V532, P432, DOI 10.1016/S0014-5793(02)03725-0; Matsumura T, 1999, PLANT PHYSIOL, V119, P481, DOI 10.1104/pp.119.2.481; Nakajima M, 2002, PLANT CELL PHYSIOL, V43, P484, DOI 10.1093/pcp/pcf058; Nakamura Y, 2002, DNA RES, V9, P123, DOI 10.1093/dnares/9.4.123; Nakamura Y, 2002, DNA RES, V9, P135, DOI 10.1093/dnares/9.4.135; Page JE, 2004, PLANT PHYSIOL, V134, P1401, DOI 10.1104/pp.103.038133; Ralph SA, 2004, NAT REV MICROBIOL, V2, P203, DOI 10.1038/nrmicro843; Rodriguez-Concepcion M, 2002, PLANT PHYSIOL, V130, P1079, DOI 10.1104/pp.007138; Rohdich F, 2004, BIOORG CHEM, V32, P292, DOI 10.1016/j.bioorg.2004.05.012; Rohdich F, 2003, P NATL ACAD SCI USA, V100, P1586, DOI 10.1073/pnas.0337742100; Rohdich F, 2001, CURR OPIN CHEM BIOL, V5, P535, DOI 10.1016/S1367-5931(00)00240-4; Seemann M, 2005, J BIOL INORG CHEM, V10, P131, DOI 10.1007/s00775-004-0619-z; Seemann M, 2002, ANGEW CHEM INT EDIT, V41, P4337, DOI 10.1002/1521-3773(20021115)41:22<4337::AID-ANIE4337>3.0.CO;2-K; Wolff M, 2003, FEBS LETT, V541, P115, DOI 10.1016/S0014-5793(03)00317-X	26	59	67	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20672	20679		10.1074/jbc.M500865200	http://dx.doi.org/10.1074/jbc.M500865200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15792953	hybrid			2022-12-27	WOS:000229242000065
J	Yin, QY; de Groot, PWJ; Dekker, HL; de Jong, L; Klis, FM; de Koster, CG				Yin, QY; de Groot, PWJ; Dekker, HL; de Jong, L; Klis, FM; de Koster, CG			Comprehensive proteomic analysis of Saccharomyces cerevisiae cell walls	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEINS; CARBOHYDRATE-ACTIVE ENZYMES; WILD-TYPE CELLS; CANDIDA-ALBICANS; PLASMA-MEMBRANE; TRANSCRIPTIONAL RESPONSE; GENE-EXPRESSION; YEAST-CELLS; IDENTIFICATION; SEQUENCE	The cell wall of yeast contains proteins that are covalently bound to the glycan network. These cell wall proteins (CWPs) mediate cell-cell interactions and may be involved in cell wall biosynthesis. Using tandem mass spectrometry, we have identified 19 covalently bound CWPs of Saccharomyces cerevisiae. Twelve of them are shown for the first time to be covalently incorporated into the cell wall. The identified proteins include 12 predicted glycosylphosphatidylinositol-modified CWPs, all four members of the Pir protein family, and three additional proteins (Scw4p, Scw10p, and Tos1p) that are, like Pir proteins, connected to the cell wall glycan network via an alkali-sensitive linkage. However, Scw4p, Scw10p, and Tos1p do not contain internal repeat sequences shown to be essential for Pir protein incorporation and may represent a separate class of CWPs. Strikingly, seven of the identified proteins (Gas1p, Gas3p, Gas5p, Crh1p, Utr2p, Scw4p, and Scw10p) are classified as glycoside hydrolases. Phenotypic analysis of deletion mutants lacking the corresponding CWP-encoding genes indicated that most of them have altered cell wall properties, which reinforces the importance of the identified proteins for proper cell wall formation. In particular, gas1 Delta and ecm33 Delta were highly sensitive to Calcofluor White and high temperature, whereas gas1 Delta, scw4 Delta, and tos1 Delta were highly resistant to incubation with beta-1,3-glucanase. The CWP identification method developed here relies on directly generating tryptic peptides from isolated cell walls and is independent of the nature of the covalent linkages between CWPs and cell wall glycans. Therefore, it will probably be equally effective in many other fungi.	Univ Amsterdam, Swammerdam Inst Life Sci, Lab Mass Spectrometry Biomacromol, NL-1018 WV Amsterdam, Netherlands	University of Amsterdam	de Groot, PWJ (corresponding author), Univ Amsterdam, Swammerdam Inst Life Sci, Lab Mass Spectrometry Biomacromol, Nieuwe Achtergracht 166, NL-1018 WV Amsterdam, Netherlands.	pgroot@science.uva.nl	De Groot, Piet/L-7737-2014; de Jong, Luitzen/E-7882-2011; Klis, Frans M/B-9085-2008	De Groot, Piet/0000-0002-3112-6947; Klis, Frans M/0000-0003-0079-9492; de Koster, Chris/0000-0003-2872-2796				Abramova N, 2001, J BACTERIOL, V183, P2881, DOI 10.1128/JB.183.9.2881-2887.2001; Boorsma A, 2004, YEAST, V21, P413, DOI 10.1002/yea.1109; Bruneau JM, 2001, ELECTROPHORESIS, V22, P2812, DOI 10.1002/1522-2683(200108)22:13&lt;2812::AID-ELPS2812&gt;3.0.CO;2-Q; Cappellaro C, 1998, J BACTERIOL, V180, P5030, DOI 10.1128/JB.180.19.5030-5037.1998; Caro LHP, 1997, YEAST, V13, P1477, DOI 10.1002/(SICI)1097-0061(199712)13:15<1477::AID-YEA184>3.0.CO;2-L; Carotti C, 2004, EUR J BIOCHEM, V271, P3635, DOI 10.1111/j.1432-1033.2004.04297.x; Castillo L, 2003, YEAST, V20, P973, DOI 10.1002/yea.1016; Chaffin WL, 1998, MICROBIOL MOL BIOL R, V62, P130, DOI 10.1128/MMBR.62.1.130-180.1998; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; Cormack BP, 1999, SCIENCE, V285, P578, DOI 10.1126/science.285.5427.578; Coutinho PM, 1999, ROY SOC CH, P3; de Groot PWJ, 2004, EUKARYOT CELL, V3, P955, DOI 10.1128/EC.3.4.955-965.2004; de Groot PWJ, 2003, YEAST, V20, P781, DOI 10.1002/yea.1007; de Groot PWJ, 2001, COMP FUNCT GENOM, V2, P124, DOI 10.1002/cfg.85; de Sampaio G, 1999, MOL MICROBIOL, V34, P247, DOI 10.1046/j.1365-2958.1999.01585.x; Douglas LJ, 2003, TRENDS MICROBIOL, V11, P30, DOI 10.1016/S0966-842X(02)00002-1; Fradin C, 2005, MOL MICROBIOL, V56, P397, DOI 10.1111/j.1365-2958.2005.04557.x; Frieman MB, 2004, MICROBIOL-SGM, V150, P3105, DOI 10.1099/mic.0.27420-0; Frieman MB, 2003, MOL MICROBIOL, V50, P883, DOI 10.1046/j.1365-2958.2003.03722.x; Frieman MB, 2002, MOL MICROBIOL, V46, P479, DOI 10.1046/j.1365-2958.2002.03166.x; Garcia R, 2004, J BIOL CHEM, V279, P15183, DOI 10.1074/jbc.M312954200; Garcia-Sanchez S, 2004, EUKARYOT CELL, V3, P536, DOI 10.1128/EC.3.2.536-545.2004; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Hamada K, 1999, J BACTERIOL, V181, P3886, DOI 10.1128/JB.181.13.3886-3889.1999; Hamada K, 1998, MOL GEN GENET, V258, P53, DOI 10.1007/s004380050706; HARTLAND RP, 1994, YEAST, V10, P1591, DOI 10.1002/yea.320101208; Hoyer LL, 2001, TRENDS MICROBIOL, V9, P176, DOI 10.1016/S0966-842X(01)01984-9; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Kapteyn JC, 2000, MOL MICROBIOL, V35, P601, DOI 10.1046/j.1365-2958.2000.01729.x; Kapteyn JC, 2001, MOL MICROBIOL, V39, P469, DOI 10.1046/j.1365-2958.2001.02242.x; Kapteyn JC, 1999, MOL MICROBIOL, V31, P1835, DOI 10.1046/j.1365-2958.1999.01320.x; Kapteyn JC, 1996, GLYCOBIOLOGY, V6, P337, DOI 10.1093/glycob/6.3.337; Klis FM, 2001, MED MYCOL, V39, P1, DOI 10.1080/744118876; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1016/S0168-6445(02)00087-6; Klotz SA, 2004, INFECT IMMUN, V72, P2029, DOI 10.1128/IAI.72.4.2029-2034.2004; KOPECKA M, 1974, J CELL BIOL, V62, P66, DOI 10.1083/jcb.62.1.66; Kumamoto CA, 2002, CURR OPIN MICROBIOL, V5, P608, DOI 10.1016/S1369-5274(02)00371-5; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Lussier M, 1997, GENETICS, V147, P435; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; Moukadiri I, 1997, J BACTERIOL, V179, P2154, DOI 10.1128/jb.179.7.2154-2162.1997; Mouyna I, 2000, J BIOL CHEM, V275, P14882, DOI 10.1074/jbc.275.20.14882; Mouyna I, 2000, BIOCHEM J, V347, P741, DOI 10.1042/0264-6021:3470741; Mrsa V, 1997, YEAST, V13, P1145; MRSA V, 1993, J BACTERIOL, V175, P2102, DOI 10.1128/JB.175.7.2102-2106.1993; Mrsa V, 1999, YEAST, V15, P813, DOI 10.1002/(SICI)1097-0061(199907)15:10A<813::AID-YEA421>3.0.CO;2-Y; Mrsa V, 1999, J BACTERIOL, V181, P3076, DOI 10.1128/JB.181.10.3076-3086.1999; Osumi M, 1998, MICRON, V29, P207; Pardo M, 2004, MICROBIOL-SGM, V150, P4157, DOI 10.1099/mic.0.26924-0; Ram AFJ, 1998, J BACTERIOL, V180, P1418, DOI 10.1128/JB.180.6.1418-1424.1998; Ram AFJ, 1998, FEMS MICROBIOL LETT, V162, P249, DOI 10.1111/j.1574-6968.1998.tb13006.x; Reynolds TB, 2001, SCIENCE, V291, P878, DOI 10.1126/science.291.5505.878; Rodriguez-Pena JM, 2002, J CELL SCI, V115, P2549; Rodriguez-Pena JM, 2000, MOL CELL BIOL, V20, P3245, DOI 10.1128/MCB.20.9.3245-3255.2000; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimoi H, 1998, J BACTERIOL, V180, P3381, DOI 10.1128/JB.180.13.3381-3387.1998; Staab JF, 1998, YEAST, V14, P681, DOI 10.1002/(SICI)1097-0061(199805)14:7&lt;681::AID-YEA256&gt;3.0.CO;2-8; Terashima H, 2003, FEMS MICROBIOL LETT, V218, P175, DOI 10.1016/S0378-1097(02)01124-2; Terashima H, 2002, CURR GENET, V40, P311, DOI 10.1007/s00294-001-0264-9; TOKUNAGA M, 1986, J ELECTRON MICROSC, V35, P237; VANDERVAART JM, 1995, J BACTERIOL, V177, P3104, DOI 10.1128/jb.177.11.3104-3110.1995; Vossen JH, 1997, J BACTERIOL, V179, P2202, DOI 10.1128/jb.179.7.2202-2209.1997; Weig M, 2004, MICROBIOL-SGM, V150, P3129, DOI 10.1099/mic.0.27256-0; Weissman Z, 2004, MOL MICROBIOL, V53, P1209, DOI 10.1111/j.1365-2958.2004.04199.x	64	150	170	0	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20894	20901		10.1074/jbc.M500334200	http://dx.doi.org/10.1074/jbc.M500334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781460	hybrid			2022-12-27	WOS:000229242000088
J	Zhou, YG; Kanner, BI				Zhou, YG; Kanner, BI			Transporter-associated currents in the gamma-aminobutyric acid transporter GAT-1 are conditionally impaired by mutations of a conserved glycine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CL-COTRANSPORT FUNCTION; OOCYTE-MEMBRANE-PATCHES; TRANSMEMBRANE DOMAIN-I; CONFORMATIONAL-CHANGES; SCANNING MUTAGENESIS; XENOPUS OOCYTES; NEUROTRANSMITTER; SODIUM; EXPRESSION; STATES	To determine whether glycine residues play a role in the conformational changes during neurotransmitter transport, we have analyzed site-directed mutants of the gamma-aminobutyric acid ( GABA) transporter GAT-1 in a domain containing three consecutive glycines conserved throughout the sodium- and chloride-dependent neurotransmitter transporter family. Only cysteine replacement of glycine 80 resulted in the complete loss of [H-3] GABA uptake, but oocytes expressing this mutant exhibited the sodium- dependent transient currents thought to reflect a charge-moving conformational change. When sodium was removed and subsequently added back, the transients by G80C did not recover, as opposed to wild type, where recovery was almost complete. Remarkably, the transients by G80C could be restored after exposure of the oocytes to either GABA or a depolarizing pre-pulse. These treatments also resulted in a full recovery of the transients by the wild type. Whereas in wild type lithium leak currents are observed after prior sodium depletion, this was not the case for the glycine 80 mutants unless GABA was added or the oocytes were subjected to a depolarizing pre-pulse. Thus, glycine 80 appears essential for conformational transitions in GAT-1. When this residue is mutated, removal of sodium results in "freezing" the transporter in one conformation from which it can only exit by compensatory changes induced by GABA or depolarization. Our results can be explained by a model invoking two outward-facing states of the empty transporter and a defective transition between these states in the glycine 80 mutants.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel.	kannerb@cc.huji.ac.il						Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRUNEWALD M, 1995, J BIOL CHEM, V270, P17017, DOI 10.1074/jbc.270.28.17017; Grunewald M, 2002, J BIOL CHEM, V277, P26074, DOI 10.1074/jbc.M202248200; Hilgemann DW, 1999, J GEN PHYSIOL, V114, P459, DOI 10.1085/jgp.114.3.459; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Kanner BI, 2003, J BIOL CHEM, V278, P3705, DOI 10.1074/jbc.M210525200; KANNER BI, 1994, J EXP BIOL, V196, P237; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Larsson HP, 2004, P NATL ACAD SCI USA, V101, P3951, DOI 10.1073/pnas.0306737101; Loo DDF, 2000, J BIOL CHEM, V275, P37414, DOI 10.1074/jbc.M007241200; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; Lu CC, 1999, J GEN PHYSIOL, V114, P445, DOI 10.1085/jgp.114.3.445; MABJEESH NJ, 1993, BIOCHEMISTRY-US, V32, P8540, DOI 10.1021/bi00084a021; MacAulay N, 2002, J PHYSIOL-LONDON, V544, P447, DOI 10.1113/jphysiol.2002.022897; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Nelson N, 1998, J NEUROCHEM, V71, P1785; Weinglass AB, 2001, BIOCHEMISTRY-US, V40, P769, DOI 10.1021/bi002171m; Zhou YG, 2004, J BIOL CHEM, V279, P13800, DOI 10.1074/jbc.M311579200; Zomot E, 2003, J BIOL CHEM, V278, P42950, DOI 10.1074/jbc.M209307200	25	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20316	20324		10.1074/jbc.M412937200	http://dx.doi.org/10.1074/jbc.M412937200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15784623	hybrid			2022-12-27	WOS:000229242000021
J	Kawamura, T; Ono, K; Morimoto, T; Wada, H; Hirai, M; Hidaka, K; Morisaki, T; Heike, T; Nakahata, T; Kita, T; Hasegawa, K				Kawamura, T; Ono, K; Morimoto, T; Wada, H; Hirai, M; Hidaka, K; Morisaki, T; Heike, T; Nakahata, T; Kita, T; Hasegawa, K			Acetylation of GATA-4 is involved in the differentiation of embryonic stem cells into cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE ACTIVITY; TRANSCRIPTION FACTOR GATA-4; P300; HEART; HATS; COACTIVATOR; RECRUITMENT; INHIBITION; ACTIVATION; PATHWAY	Differentiation of embryonic stem (ES) cells into cardiac myocytes requires activation of a cardiac-specific gene program. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) govern gene expression patterns by being recruited to target genes through association with specific transcription factors. One of the HATs, p300, serves as a coactivator of cardiac-specific transcription factors such as GATA-4. The HAT activity of p300 is required for acetylation and DNA binding of GATA-4 and its full transcriptional activity as well as for promotion of a transcriptionally active chromatin configuration. However, the roles of HATs and HDACs in post-translational modification of GATA-4 during the differentiation of ES cells into cardiac myocytes remain unknown. In an ES cell model of developing embryoid bodies, an acetylated form of GATA-4 and its DNA binding increased concomitantly with the expression of p300 during the differentiation of ES cells into cardiac myocytes. Treatment of ES cells with trichostatin A (TSA), a specific HDAC inhibitor, induced acetylation of histone-3/4 near GATA sites within the atrial natriuretic factor promoter. In addition, TSA augmented the increase in an acetylated form of GATA-4 and its DNA binding during the ES cell differentiation. Finally, TSA facilitated the expression of green fluorescence protein under the control of the cardiac-specific Nkx-2.5 promoter and of endogenous cardiac beta- myosin heavy chain during the differentiation. These findings demonstrate that acetylation of GATA-4 as well as of histones is involved in the differentiation of ES cells into cardiac myocytes.	Natl Hosp Org, Kyoto Med Ctr, Div Translat Res, Fushimi Ku, Kyoto 6128555, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, Kyoto 6068507, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Biosci, Suita, Osaka 5658565, Japan	Kyoto University; Kyoto University; National Cerebral & Cardiovascular Center - Japan	Hasegawa, K (corresponding author), Natl Hosp Org, Kyoto Med Ctr, Div Translat Res, Fushimi Ku, 1-1 Mukaihata Cho, Kyoto 6128555, Japan.	koj@kuhp.kyoto-u.ac.jp		Wada, Hiromichi/0000-0002-8980-224X				Chan HM, 2001, J CELL SCI, V114, P2363; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Grepin C, 1997, DEVELOPMENT, V124, P2387; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hamamori Y, 2003, J CLIN INVEST, V112, P824, DOI 10.1172/JC1200319834; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; Hidaka K, 2003, FASEB J, V17, P740, DOI 10.1096/fj.02-0104fje; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; Kakita T, 1999, J BIOL CHEM, V274, P34096, DOI 10.1074/jbc.274.48.34096; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kook H, 2003, J CLIN INVEST, V112, P863, DOI 10.1172/JCI200319137; Lagace DC, 2004, J BIOL CHEM, V279, P18851, DOI 10.1074/jbc.M312795200; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Lezzi Simona, 2002, Proceedings of the National Academy of Sciences of the United States of America, V99, P7757; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Marin-Husstege M, 2002, J NEUROSCI, V22, P10333; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Partanen M, 1999, INT J DEV BIOL, V43, P487; Sachinidis A, 2003, CARDIOVASC RES, V58, P278, DOI 10.1016/S0008-6363(03)00248-7; Shikama N, 2003, EMBO J, V22, P5175, DOI 10.1093/emboj/cdg502; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Viger RS, 1998, DEVELOPMENT, V125, P2665; Yanazume T, 2003, MOL CELL BIOL, V23, P3593, DOI 10.1128/MCB.23.10.3593-3606.2003; Yanazume T, 2002, J BIOL CHEM, V277, P8618, DOI 10.1074/jbc.M107924200; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	30	104	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19682	19688		10.1074/jbc.M412428200	http://dx.doi.org/10.1074/jbc.M412428200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15764815	hybrid			2022-12-27	WOS:000229113700033
J	Milhas, D; Cuvillier, O; Therville, N; Clave, P; Thomsen, M; Levade, T; Benoist, H; Segui, B				Milhas, D; Cuvillier, O; Therville, N; Clave, P; Thomsen, M; Levade, T; Benoist, H; Segui, B			Caspase-10 triggers bid cleavage and caspase cascade activation in FasL-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT CELL-DEATH; CYTOCHROME-C RELEASE; SIGNALING COMPLEX; T-LYMPHOCYTES; RECEPTOR; PATHWAY; PROTEASE; DISEASE; MITOCHONDRIA; INITIATION	In contrast to caspase-8, controversy exists as to the ability of caspase-10 to mediate apoptosis in response to FasL. Herein, we have shown activation of caspase-10, -3, and -7 as well as B cell lymphoma-2-interacting domain ( Bid) cleavage and cytochrome c release in caspase-8-deficient Jurkat (I9-2) cells treated with FasL. Apoptosis was clearly induced as illustrated by nuclear and DNA fragmentation. These events were inhibited by benzyloxycarbonyl-VAD-fluoromethyl ketone, a broad spectrum caspase inhibitor, indicating that caspases were functionally and actively involved. Benzyloxycarbonyl-AEVD-fluoromethyl ketone, a caspase-10 inhibitor, had a comparable effect. FasL-induced cell death was not completely abolished by caspase inhibitors in agreement with the existence of a cytotoxic caspase-independent pathway. In subpopulations of I9-2 cells displaying distinct caspase-10 expression levels, cell sensitivity to FasL correlated with caspase-10 expression. A robust caspase activation, Bid cleavage, and DNA fragmentation were observed in cells with high caspase-10 levels but not in those with low levels. In vitro, caspase-10, as well as caspase-8, could cleave Bid to generate active truncated Bid (p15). Altogether, our data strongly suggest that caspase-10 can serve as an initiator caspase in Fas signaling leading to Bid processing, caspase cascade activation, and apoptosis.	INSERM, Inst Louis Bugnard, U466, F-31432 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Segui, B (corresponding author), INSERM, Inst Louis Bugnard, U466, BP 84225, F-31432 Toulouse, France.	bruno.segui@toulouse.inserm.fr	Levade, Thierry/O-8948-2014; Clave, Pere/P-9070-2016; Ségui, Bruno/O-8957-2014; Thomsen, Mogens/B-7651-2011; CUVILLIER, Olivier/S-1631-2019; CUVILLIER, Olivier/B-2567-2009; Benoist, Hervé/P-2927-2014; Therville, Nicole/P-2371-2014	Clave, Pere/0000-0002-0696-8560; Ségui, Bruno/0000-0002-6119-1889; Thomsen, Mogens/0000-0002-4546-0129; CUVILLIER, Olivier/0000-0003-3346-375X; CUVILLIER, Olivier/0000-0003-3346-375X; Therville, Nicole/0000-0002-7068-1361				BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cuvillier O, 2000, J BIOL CHEM, V275, P15691, DOI 10.1074/jbc.M000280200; Davidson WF, 2002, J IMMUNOL, V169, P6218, DOI 10.4049/jimmunol.169.11.6218; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P699, DOI 10.1006/bbrc.1999.1888; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; Park SJ, 2004, J BIOL CHEM, V279, P51057, DOI 10.1074/jbc.M406543200; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Segui B, 1999, J BIOL CHEM, V274, P37251, DOI 10.1074/jbc.274.52.37251; Shimizu M, 1999, J IMMUNOL, V162, P7350; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Vonarbourg C, 2002, EUR J IMMUNOL, V32, P2376, DOI 10.1002/1521-4141(200208)32:8<2376::AID-IMMU2376>3.0.CO;2-V; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wyllie A, 1998, NATURE, V391, P20, DOI 10.1038/34040	33	99	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19836	19842		10.1074/jbc.M414358200	http://dx.doi.org/10.1074/jbc.M414358200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772077	hybrid			2022-12-27	WOS:000229113700051
J	Stahelin, RV; Digman, MA; Medkova, M; Ananthanarayanan, B; Melowic, HR; Rafter, JD; Cho, W				Stahelin, RV; Digman, MA; Medkova, M; Ananthanarayanan, B; Melowic, HR; Rafter, JD; Cho, W			Diacylglycerol-induced membrane targeting and activation of protein kinase C epsilon - Mechanistic differences between protein kinases C delta and C epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; PHORBOL ESTER BINDING; SUBCELLULAR-LOCALIZATION; SELECTIVE BINDING; MOLECULAR-BASIS; PKC-EPSILON; DOMAINS; ALPHA; PHOSPHORYLATION; TRANSLOCATION	Two novel protein kinases C (PKC), PKC delta and PKC epsilon, have been reported to have opposing functions in some mammalian cells. To understand the basis of their distinct cellular functions and regulation, we investigated the mechanism of in vitro and cellular sn-1,2-diacylglycerol (DAG)- mediated membrane binding of PKC epsilon and compared it with that of PKC delta. The regulatory domains of novel PKC contain a C2 domain and a tandem repeat of C1 domains (C1A and C1B), which have been identified as the interaction site for DAG and phorbol ester. Isothermal titration calorimetry and surface plasmon resonance measurements showed that isolated C1A and C1B domains of PKC epsilon have comparably high affinities for DAG and phorbol ester. Furthermore, in vitro activity and membrane binding analyses of PKC epsilon mutants showed that both the C1A and C1B domains play a role in the DAG-induced membrane binding and activation of PKC epsilon. The C1 domains of PKC epsilon are not conformationally restricted and readily accessible for DAG binding unlike those of PKC delta. Consequently, phosphatidylserine-dependent unleashing of C1 domains seen with PKC delta was not necessary for PKC epsilon. Cell studies with fluorescent protein-tagged PKCs showed that, due to the lack of lipid headgroup selectivity, PKC epsilon translocated to both the plasma membrane and the nuclear membrane, whereas PKC delta migrates specifically to the plasma membrane under the conditions in which DAG is evenly distributed among intracellular membranes of HEK293 cells. Also, PKC epsilon translocated much faster than PKC delta due to conformational flexibility of its C1 domains. Collectively, these results provide new insight into the differential activation mechanisms of PKC delta and PKC epsilon based on different structural and functional properties of their C1 domains.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, W (corresponding author), Univ Illinois, Dept Chem, MC 111,845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu	Stahelin, Robert/L-3567-2019	Stahelin, Robert/0000-0001-5443-7863	NIGMS NIH HHS [GM52598, GM68849, GM53987] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068849, R01GM053987, R01GM052598] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akita Y, 2002, J BIOCHEM, V132, P847, DOI 10.1093/oxfordjournals.jbchem.a003296; Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P6776, DOI 10.1021/bi00418a020; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; Bogi K, 1998, CANCER RES, V58, P1423; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cho Wonhwa, 2003, Methods Mol Biol, V233, P291; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Csukai M, 1999, PHARMACOL RES, V39, P253, DOI 10.1006/phrs.1998.0418; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; Liu HP, 2001, AM J PHYSIOL-HEART C, V281, pH404, DOI 10.1152/ajpheart.2001.281.1.H404; Lopez-Andreo MJ, 2003, MOL BIOL CELL, V14, P4885, DOI 10.1091/mbc.E03-05-0295; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mozsolits H, 2003, J PEPT SCI, V9, P77, DOI 10.1002/psc.439; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Ochoa WF, 2001, J MOL BIOL, V311, P837, DOI 10.1006/jmbi.2001.4910; Pappa H, 1998, STRUCT FOLD DES, V6, P885, DOI 10.1016/S0969-2126(98)00090-2; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Pepio AM, 2001, J BIOL CHEM, V276, P3846, DOI 10.1074/jbc.M006339200; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Rodriguez MM, 1999, FEBS LETT, V454, P240, DOI 10.1016/S0014-5793(99)00697-3; Schechtman D, 2004, J BIOL CHEM, V279, P15831, DOI 10.1074/jbc.M310696200; Shirai Y, 2002, J BIOCHEM, V132, P663, DOI 10.1093/oxfordjournals.jbchem.a003271; Slater SJ, 1996, J BIOL CHEM, V271, P4627; Stahelin RV, 2004, J BIOL CHEM, V279, P29501, DOI 10.1074/jbc.M403191200; Stahelin RV, 2003, J BIOL CHEM, V278, P12452, DOI 10.1074/jbc.M212864200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; SUNAMOTO J, 1980, J AM CHEM SOC, V102, P1146, DOI 10.1021/ja00523a035; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; Yang CF, 2003, TRENDS PHARMACOL SCI, V24, P602, DOI 10.1016/j.tips.2003.09.003	47	95	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19784	19793		10.1074/jbc.M411285200	http://dx.doi.org/10.1074/jbc.M411285200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769752	hybrid			2022-12-27	WOS:000229113700045
J	Wang, Y; Ko, BCB; Yang, JY; Lam, TTL; Jiang, ZR; Zhang, JS; Chung, SK; Chung, SSM				Wang, Y; Ko, BCB; Yang, JY; Lam, TTL; Jiang, ZR; Zhang, JS; Chung, SK; Chung, SSM			Transgenic mice expressing dominant-negative osmotic-response element-binding protein (OREBP) in lens exhibit fiber cell elongation defect associated with increased DNA breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDOSE REDUCTASE GENE; STIMULATES TRANSCRIPTION; CYCLE DELAY; HYPERTONICITY; P53; APOPTOSIS; STRESS; MOUSE; NFAT5; SPERMIOGENESIS	Osmotic-response element-binding protein (OREBP), also known as TonEBP or NFAT5, is thought to be responsible for the induction of osmolyte-accumulating genes when cells are under hypertonic stress. Recent studies suggest that OREBP also plays a role in water reabsorption in the kidney, T-cell proliferation, and embryonic development. We developed transgenic mice that express the dominant-negative OREBP (OREBPdn) specifically in the lens because our earlier studies showed that it is particularly sensitive to osmotic stress. The transgenic mice developed nuclear cataract soon after birth, suggesting defects in lens development. The developing transgenic lenses showed incomplete elongation of fiber cells and formation of vacuoles. This is accompanied by evidence of DNA strand breaks, activation of p53, and induction of checkpoint kinase, suggesting that the developing fiber cells lacking OREBP are in a similar physiological state as cells experiencing hypertonic stress. These results indicate that OREBP-mediated accumulation of osmolytes is essential during elongation of the lens fiber cells.	Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Open Lab Chem Biol, Inst Mol Technol Drug Discovery & Synth, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; China Med Univ, Affiliated Hosp 4, Dept Ophthalmol, Shenyang, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; China Medical University	Ko, BCB (corresponding author), Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China.	cbko@hkucc.hku.hk; yyang@hkucc.hku.hk	Ko, Chi-bun/ACH-7514-2022	Ko, Ben Chi Bun/0000-0003-2027-5899				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Dmitrieva N, 2000, J BIOL CHEM, V275, P18243, DOI 10.1074/jbc.M000522200; Dmitrieva NI, 2004, P NATL ACAD SCI USA, V101, P2317, DOI 10.1073/pnas.0308463100; Dmitrieva NI, 2001, COMP BIOCHEM PHYS A, V130, P411, DOI 10.1016/S1095-6433(01)00439-1; Go WY, 2004, P NATL ACAD SCI USA, V101, P10673, DOI 10.1073/pnas.0403139101; Ho SN, 2003, ARCH BIOCHEM BIOPHYS, V413, P151, DOI 10.1016/S0003-9861(03)00130-9; Huang AM, 2000, GENETICS, V156, P1219; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jiang ZR, 2000, INVEST OPHTH VIS SCI, V41, P1467; Kishi H, 2001, J BIOL CHEM, V276, P39115, DOI 10.1074/jbc.M105134200; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; Kultz D, 2001, P NATL ACAD SCI USA, V98, P1999, DOI 10.1073/pnas.98.4.1999; KUSZAK J, 2000, PRINCIPLES PRACTICE, V2, P1355; Lam AKM, 2004, J BIOL CHEM, V279, P48048, DOI 10.1074/jbc.M407224200; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; LIN LR, 1993, INVEST OPHTH VIS SCI, V34, P2352; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lopez-Rodriguez C, 2004, P NATL ACAD SCI USA, V101, P2392, DOI 10.1073/pnas.0308703100; Maouyo D, 2002, AM J PHYSIOL-RENAL, V282, pF802, DOI 10.1152/ajprenal.00123.2001; Marcon L, 2004, BIOL REPROD, V70, P910, DOI 10.1095/biolreprod.103.022541; Michea L, 2000, AM J PHYSIOL-RENAL, V278, pF209, DOI 10.1152/ajprenal.2000.278.2.F209; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Miyakawa H, 1998, AM J PHYSIOL-RENAL, V274, pF753, DOI 10.1152/ajprenal.1998.274.4.F753; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; O'Neill WC, 1999, AM J PHYSIOL-CELL PH, V276, pC995, DOI 10.1152/ajpcell.1999.276.5.C995; PARMELEE JT, 1988, J CELL PHYSIOL, V134, P491, DOI 10.1002/jcp.1041340323; Pokroy R, 2002, INVEST OPHTH VIS SCI, V43, P1736; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shim EH, 2002, EMBO REP, V3, P857, DOI 10.1093/embo-reports/kvf175; Smith A, 1998, BIOTECHNIQUES, V25, P496, DOI 10.2144/98253rr05; Trama J, 2002, J IMMUNOL, V169, P5477, DOI 10.4049/jimmunol.169.10.5477; Woo SK, 2002, INT REV CYTOL, V215, P189; Woo SK, 2002, MOL CELL BIOL, V22, P5753, DOI 10.1128/MCB.22.16.5753-5760.2002	36	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19986	19991		10.1074/jbc.M501689200	http://dx.doi.org/10.1074/jbc.M501689200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774462	hybrid			2022-12-27	WOS:000229113700068
J	Yoon, IS; Pietrzik, CU; Kang, DE; Koo, EH				Yoon, IS; Pietrzik, CU; Kang, DE; Koo, EH			Sequences from the low density lipoprotein receptor-related protein (LRP) cytoplasmic domain enhance amyloid beta protein production via the beta-secretase pathway without altering amyloid precursor protein/LRP nuclear signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E RECEPTOR; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; CYTOSOLIC ADAPTER; SCAFFOLD PROTEINS; PEPTIDE; FE65; METABOLISM; MODULATION; CLEARANCE	Increasing evidence suggests that the low density lipoprotein receptor-related protein (LRP) affects the processing of amyloid precursor protein (APP) and amyloid beta (A beta) protein production as well as mediates the clearance of A beta from the brain. Recent studies indicate that the cytoplasmic domain of LRP is critical for this modulation of APP processing requiring perhaps a complex between APP, the adaptor protein FE65, and LRP. In this study, we expressed a small LRP domain consisting of the C-terminal 97 amino acids of the cytoplasmic domain, or LRP-soluble tail (LRP-ST), in CHO cells to test the hypothesis that the APP(.)LRP complex can be disrupted. We anticipated that LRP-ST would inhibit the normal interaction between LRP and APP and therefore perturb APP processing to resemble a LRP-deficient state. Surprisingly, CHO cells expressing LRP-ST demonstrated an increase in both sAPP secretion and A beta production compared with control CHO cells in a manner reminiscent of the cellular effects of the APP "Swedish mutation." The increase in sAPP secretion consisted mainly of sAPP beta, consistent with the increase in A beta release. Further, this effect is LRP-independent, as the same alterations remained when LRP-ST was expressed in LRP-deficient cells but not when the construct was membrane-anchored. Finally, deletion experiments suggested that the last 50 amino acid residues of LRP-ST contain the important domain for altering APP processing and A beta production. These observations indicate that there are cellular pathways that may suppress A beta generation but that can be altered to facilitate A beta production.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Koo, EH (corresponding author), Univ Calif San Diego, Dept Neurosci, 9500 Gilman Dr,Mail Code 0691, La Jolla, CA 92093 USA.	edkoo@ucsd.edu	Kang, David E./E-5234-2012	Kang, David E./0000-0002-7132-821X	NATIONAL INSTITUTE ON AGING [R01AG012376] Funding Source: NIH RePORTER; NIA NIH HHS [AG12376] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017; EMI N, 1991, J VIROL, V65, P1202, DOI 10.1128/JVI.65.3.1202-1207.1991; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Ho CS, 2002, J BIOL CHEM, V277, P27021, DOI 10.1074/jbc.M201823200; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; King GD, 2003, NEUROSCIENCE, V120, P143, DOI 10.1016/S0306-4522(03)00284-7; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Mueller HT, 2000, J BIOL CHEM, V275, P39302, DOI 10.1074/jbc.M008453200; Narita M, 1997, J NEUROCHEM, V69, P1904; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Qiu ZH, 1999, J NEUROCHEM, V73, P1393, DOI 10.1046/j.1471-4159.1999.0731393.x; Rebeck GW, 2001, MOL BRAIN RES, V87, P238, DOI 10.1016/S0169-328X(01)00006-7; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; SISODIA SS, 1993, J NEUROSCI, V13, P3136; Strickland DK, 2003, J THROMB HAEMOST, V1, P1663, DOI 10.1046/j.1538-7836.2003.00330.x; Tanahashi H, 1999, BIOCHEM BIOPH RES CO, V258, P385, DOI 10.1006/bbrc.1999.0639; Taru H, 2002, J BIOL CHEM, V277, P27567, DOI 10.1074/jbc.M203713200; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Zerbinatti CV, 2004, P NATL ACAD SCI USA, V101, P1075, DOI 10.1073/pnas.0305803101	43	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20140	20147		10.1074/jbc.M413729200	http://dx.doi.org/10.1074/jbc.M413729200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772078	hybrid			2022-12-27	WOS:000229113700086
J	Muro, I; Means, JC; Clem, RJ				Muro, I; Means, JC; Clem, RJ			Cleavage of the apoptosis inhibitor DIAP1 by the apical caspase DRONC in both normal and apoptotic Drosophila cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; CYTOCHROME-C; DEATH; ACTIVATION; HID; REAPER; DEGRADATION; MECHANISMS; DARK; IAP	In Drosophila S2 cells, the apical caspase DRONC undergoes a low level of spontaneous autoprocessing. Unintended apoptosis is prevented by the inhibitor of apoptosis DIAP1, which targets the processed form of DRONC for degradation through its E3 ubiquitin protein ligase activity. Recent reports have demonstrated that shortly after the initiation of apoptosis in S2 cells, DIAP1 is cleaved following aspartate residue Asp-20 by the effector caspase DrICE. Here we report a novel caspase-mediated cleavage of DIAP1 in S2 cells. In both living and dying S2 cells, DIAP1 is cleaved by DRONC after glutamate residue Glu-205, located between the first and second BIR domains. The mutation of Glu-205 prevented the interaction of DIAP1 and processed DRONC but had no effect on the interaction with full-length DRONC. The mutation of Glu-205 also had a negative effect on the ability of overexpressed DIAP1 to prevent apoptosis stimulated by the proapoptotic protein Reaper or by UV light. These results expand our knowledge of the events that occur in the Drosophila apoptosome prior to and after receiving an apoptotic signal.	Kansas State Univ, Div Biol, Manhattan, KS 66506 USA	Kansas State University	Clem, RJ (corresponding author), Kansas State Univ, Div Biol, Ackert Hall, Manhattan, KS 66506 USA.	rclem@ksu.edu		Clem, Rollie/0000-0002-2368-720X	NCI NIH HHS [R29 CA78602] Funding Source: Medline; NCRR NIH HHS [P20 RR16475, P20 RR107686] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078602] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016475] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Chai JJ, 2003, NAT STRUCT BIOL, V10, P892, DOI 10.1038/nsb989; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Dorstyn L, 2004, J CELL BIOL, V167, P405, DOI 10.1083/jcb.200408054; Green MC, 2004, VIRUS RES, V105, P89, DOI 10.1016/j.virusres.2004.04.017; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Huang HK, 2000, J BIOL CHEM, V275, P26661; Igaki T, 2002, J BIOL CHEM, V277, P23103, DOI 10.1074/jbc.C200222200; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Muro I, 2002, J BIOL CHEM, V277, P49644, DOI 10.1074/jbc.M203464200; Muro I, 2004, J CELL SCI, V117, P5035, DOI 10.1242/jcs.01376; Olson MR, 2003, J BIOL CHEM, V278, P4028, DOI 10.1074/jbc.M209734200; Quinn LM, 2000, J BIOL CHEM, V275, P40416, DOI 10.1074/jbc.M002935200; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Varkey J, 1999, J CELL BIOL, V144, P701, DOI 10.1083/jcb.144.4.701; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Yan N, 2004, NAT STRUCT MOL BIOL, V11, P420, DOI 10.1038/nsmb764; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yokokura T, 2004, J BIOL CHEM, V279, P52603, DOI 10.1074/jbc.M409691200; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068	33	30	30	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18683	18688		10.1074/jbc.M501206200	http://dx.doi.org/10.1074/jbc.M501206200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15774476	Green Accepted, hybrid			2022-12-27	WOS:000228932300018
J	Tamamura, Y; Otani, T; Kanatani, N; Koyama, E; Kitagaki, J; Komori, T; Yamada, Y; Costantini, F; Wakisaka, S; Pacifici, M; Iwamoto, M; Enomoto-Iwamoto, M				Tamamura, Y; Otani, T; Kanatani, N; Koyama, E; Kitagaki, J; Komori, T; Yamada, Y; Costantini, F; Wakisaka, S; Pacifici, M; Iwamoto, M; Enomoto-Iwamoto, M			Developmental regulation of Wnt/beta-catenin signals is required for growth plate assembly, cartilage integrity, and endochondral ossification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; ARTICULAR-CARTILAGE; NEGATIVE REGULATOR; PATTERN-FORMATION; JOINT FORMATION; WNT; EXPRESSION; BONE; PATHWAY; GENE	Studies have suggested that continuous Wnt/beta-catenin signaling in nascent cartilaginous skeletal elements blocks chondrocyte hypertrophy and endochondral ossification, whereas signaling starting at later stages stimulates hypertrophy and ossification, indicating that Wnt/beta-catenin roles are developmentally regulated. To test this conclusion further, we created transgenic mice expressing a fusion mutant protein of beta-catenin and LEF (CA-LEF) in nascent chondrocytes. Transgenic mice had severe skeletal defects, particularly in limbs. Growth plates were totally disorganized, lacked maturing chondrocytes expressing Indian hedgehog and collagen X, and failed to undergo endochondral ossification. Interestingly, the transgenic cartilaginous elements were ill defined, intermingled with surrounding connective and vascular tissues, and even displayed abnormal joints. However, when activated beta-catenin mutant (Delta-beta-catenin) was expressed in chondrocytes already engaged in maturation such as those present in chick limbs, chondrocyte maturation and bone formation were greatly enhanced. Differential responses to Wnt/beta-catenin signaling were confirmed in cultured chondrocytes. Activation in immature cells blocked maturation and actually de-stabilized their phenotype, as revealed by reduced expression of chondrocyte markers, abnormal cytoarchitecture, and loss of proteoglycan matrix. Activation in mature cells instead stimulated hypertrophy, matrix mineralization, and expression of terminal markers such as metalloprotease (MMP)-13 and vascular endothelial growth factor. Because proteoglycans are crucial for cartilage function, we tested possible mechanisms for matrix loss. Delta-beta-Catenin expression markedly increased expression of MMP-2, MMP-3, MMP-7, MMP-9, MT3-MMP, and ADAMTS5. In conclusion, Wnt/beta-catenin signaling regulates chondrocyte phenotype, maturation, and function in a developmentally regulated manner, and regulated action by this pathway is critical for growth plate organization, cartilage boundary definition, and endochondral ossification.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Orthopaed Surg, Philadelphia, PA 19107 USA; Nagasaki Univ, Sch Dent, Dept Oral Cytol & Cell Biol, Nagasaki 8528501, Japan; Osaka Univ, Fac Dent, Suita, Osaka 5650871, Japan; NIDCR, Mol Biol Sect, NIH, Bethesda, MD 20892 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Jefferson University; Nagasaki University; Osaka University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Columbia University	Iwamoto, M (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Orthoped Surg, 1015 Walnut St,Curtis Bldg,Suite 501, Philadelphia, PA 19107 USA.	Motomi.Iwamoto@jefferson.edu			NIAMS NIH HHS [AR47543, AR46000, AR050507] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047543, R01AR046000, R01AR050507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000483] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Caterson B, 2000, MATRIX BIOL, V19, P333, DOI 10.1016/S0945-053X(00)00078-0; Cawston T, 1999, ANN NY ACAD SCI, V878, P120, DOI 10.1111/j.1749-6632.1999.tb07678.x; Church V, 2002, J CELL SCI, V115, P4809, DOI 10.1242/jcs.00152; de Crombrugghe B, 2001, CURR OPIN CELL BIOL, V13, P721, DOI 10.1016/S0955-0674(00)00276-3; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; EDWARDS JCW, 1994, J ANAT, V185, P355; Enomoto-Iwamoto M, 2002, DEV BIOL, V251, P142, DOI 10.1006/dbio.2002.0802; Enomoto-Iwamoto M, 1998, J CELL BIOL, V140, P409, DOI 10.1083/jcb.140.2.409; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Guo XZ, 2004, GENE DEV, V18, P2404, DOI 10.1101/gad.1230704; Hartmann C, 2001, CELL, V104, P341, DOI 10.1016/S0092-8674(01)00222-7; Hartmann C, 2000, DEVELOPMENT, V127, P3141; HIRAKI Y, 1991, BIOCHEM BIOPH RES CO, V175, P971, DOI 10.1016/0006-291X(91)91660-5; Hoang BH, 1998, DEV DYNAM, V212, P364, DOI 10.1002/(SICI)1097-0177(199807)212:3<364::AID-AJA4>3.0.CO;2-F; Horton William A., 1993, P641; Horton William A., 1993, P73; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Iwamoto M, 2000, J CELL BIOL, V150, P27, DOI 10.1083/jcb.150.1.27; Iwamoto M, 2003, OSTEOARTHR CARTILAGE, V11, P6, DOI 10.1053/joca.2002.0860; IWAMOTO M, 1993, EXP CELL RES, V207, P413, DOI 10.1006/excr.1993.1209; Iwasaki M, 1997, MECH DEVELOP, V69, P197, DOI 10.1016/S0925-4773(97)00145-7; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kalembeyi I, 1997, INT J DEV BIOL, V41, P569; Kanda S, 2003, J BIOL CHEM, V278, P8244, DOI 10.1074/jbc.M210635200; Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654; Kawakami Y, 2001, CELL, V104, P891, DOI 10.1016/S0092-8674(01)00285-9; Kawakami Y, 1999, DEV GROWTH DIFFER, V41, P29; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagaki J, 2003, OSTEOARTHR CARTILAGE, V11, P36, DOI 10.1053/joca.2002.0863; Lee KKH, 2001, DEV BIOL, V234, P188, DOI 10.1006/dbio.2001.0249; Loughlin J, 2004, P NATL ACAD SCI USA, V101, P9757, DOI 10.1073/pnas.0403456101; Maes C, 2004, J CLIN INVEST, V113, P188, DOI 10.1172/JCI200419383; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PACIFICI M, 1993, DEV DYNAM, V198, P123, DOI 10.1002/aja.1001980206; PACIFICI M, 1991, EXP CELL RES, V192, P266, DOI 10.1016/0014-4827(91)90185-W; Pacifici M, 2000, CONNECT TISSUE RES, V41, P175, DOI 10.3109/03008200009005288; Rudnicki JA, 1997, DEV BIOL, V185, P104, DOI 10.1006/dbio.1997.8536; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Sen M, 2000, P NATL ACAD SCI USA, V97, P2791, DOI 10.1073/pnas.050574297; Storm EE, 1999, DEV BIOL, V209, P11, DOI 10.1006/dbio.1999.9241; Surendran K, 2002, AM J PHYSIOL-RENAL, V282, pF431, DOI 10.1152/ajprenal.0009.2001; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Vleminckx K, 1999, MECH DEVELOP, V81, P65, DOI 10.1016/S0925-4773(98)00225-1; Wada N, 1999, INT J DEV BIOL, V43, P495; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Yang YZ, 2003, DEVELOPMENT, V130, P1003, DOI 10.1242/dev.00324	62	261	317	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19185	19195		10.1074/jbc.M414275200	http://dx.doi.org/10.1074/jbc.M414275200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15760903	hybrid			2022-12-27	WOS:000228932300075
J	Boni, S; Lavergne, JP; Boulant, S; Cahour, A				Boni, S; Lavergne, JP; Boulant, S; Cahour, A			Hepatitis C virus core protein acts as a trans-modulating factor on internal translation initiation of the viral RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-ENTRY SITE; 5' NONTRANSLATED REGION; QUASI-SPECIES PRESENT; MEDIATED TRANSLATION; CODING SEQUENCES; IN-VITRO; DEPENDENT TRANSLATION; UNTRANSLATED REGION; NONCODING REGION; REPLICATION	Translation initiation of hepatitis C virus (HCV) RNA occurs through an internal ribosome entry site (IRES) located at its 5' end. As a positive-stranded virus, HCV uses the genomic RNA template for translation and replication, but the transition between these two processes remains poorly understood. HCV core protein (HCV-C) has been proposed as a good candidate to modulate such a regulation. However, current data are still the subject of controversy in attributing any potential role in HCV translation to the HCV core protein. Here we demonstrate that HCV-C displays binding activities toward both HCV IRES and the 40 S ribosomal subunit by using centrifugation on sucrose gradients. To gain further insight into these interactions, we investigated the effect of exogenous addition of purified HCV-C on HCV IRES activity by using an in vitro reporter assay. We found that HCV IRES-mediated translation was specifically modulated by HCV-C provided in trans, in a dose-dependent manner, with up to a 5-fold stimulation of the IRES efficiency upon addition of low amounts of HCV-C, followed by a decrease at high doses. Interestingly, mutations within some domains of the IRES as well as the presence of an upstream reporter gene both lead to changes in the expected effects, consistent with the high dependence of HCV IRES function on its overall structure. Collectively, these results indicate that the HCV core protein is involved in a tight modulation of HCV translation initiation, depending on its concentration, and they suggest an important biological role of this protein in viral gene expression.	Grp Hosp Pitie Salpetriere, Unite Propre Rech & Enseignement Super EA 2387, Ctr Europeen Rech Virol & Immunol, Lab Virol,IFR 113 Immun & Infect, F-75651 Paris, France; Univ Lyon 1, Lab Bioinformat & RMN Struct, Inst Biol & Chim Prot, CNRS,IFR 128 Biosci Lyon Gerland,UMR5086, F-69367 Lyon, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Cahour, A (corresponding author), Grp Hosp Pitie Salpetriere, Unite Propre Rech & Enseignement Super EA 2387, Ctr Europeen Rech Virol & Immunol, Lab Virol,IFR 113 Immun & Infect, 83 Bd Hop, F-75651 Paris, France.	cahour@idf.ext.jussieu.fr	Boulant, Steeve/W-3754-2019	Boulant, Steeve/0000-0001-8614-4993				Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Bergqvist A, 2001, J VIROL, V75, P772, DOI 10.1128/JVI.75.2.772-781.2001; Boulant S, 2003, J BIOL CHEM, V278, P45785, DOI 10.1074/jbc.M307174200; BROWN EA, 1992, NUCLEIC ACIDS RES, V20, P5041, DOI 10.1093/nar/20.19.5041; Bukh J, 1999, VIROLOGY, V262, P470, DOI 10.1006/viro.1999.9941; Chang M, 2003, AM J PATHOL, V163, P433, DOI 10.1016/S0002-9440(10)63673-5; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CORTAY JC, 1994, J BIOL CHEM, V269, P14885; Cristofari G, 2004, NUCLEIC ACIDS RES, V32, P2623, DOI 10.1093/nar/gkh579; Dumas E, 2003, NUCLEIC ACIDS RES, V31, P1275, DOI 10.1093/nar/gkg199; Fan ZY, 1999, J MED VIROL, V59, P131, DOI 10.1002/(SICI)1096-9071(199910)59:2<131::AID-JMV1>3.3.CO;2-3; Fletcher SP, 2002, RNA, V8, P1558, DOI 10.1017/S1355838202023038; Gamarnik AV, 1998, GENE DEV, V12, P2293, DOI 10.1101/gad.12.15.2293; HAMBIDGE SJ, 1992, P NATL ACAD SCI USA, V89, P10272, DOI 10.1073/pnas.89.21.10272; He YP, 2003, J GEN VIROL, V84, P535, DOI 10.1099/vir.0.18658-0; Honda M, 2000, GASTROENTEROLOGY, V118, P152, DOI 10.1016/S0016-5085(00)70424-0; Honda M, 1999, J VIROL, V73, P4941, DOI 10.1128/JVI.73.6.4941-4951.1999; Honda M, 1999, J VIROL, V73, P1165, DOI 10.1128/JVI.73.2.1165-1174.1999; Honda M, 1996, RNA, V2, P955; HOOFNAGLE JH, 1997, HEPATOLOGY S1, V26, P15; HUNT SL, 1993, VIROLOGY, V197, P801, DOI 10.1006/viro.1993.1661; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Ji H, 2004, P NATL ACAD SCI USA, V101, P16990, DOI 10.1073/pnas.0407402101; Jubin Ronald, 2003, Curr Opin Investig Drugs, V4, P162; Kato J, 2002, J MED VIROL, V66, P187, DOI 10.1002/jmv.2129; Kieft JS, 1999, J MOL BIOL, V292, P513, DOI 10.1006/jmbi.1999.3095; Kieft JS, 2001, RNA, V7, P194, DOI 10.1017/S1355838201001790; Kim YK, 2003, RNA, V9, P599, DOI 10.1261/rna.2185603; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; Laporte J, 2000, J VIROL, V74, P10827, DOI 10.1128/JVI.74.22.10827-10833.2000; Laporte J, 2003, BLOOD, V101, P52, DOI 10.1182/blood-2002-03-0818; Large MK, 1999, J IMMUNOL, V162, P931; Li DS, 2003, J GEN VIROL, V84, P815, DOI 10.1099/vir.0.18697-0; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Malet I, 1998, BIOCHEM BIOPH RES CO, V253, P257, DOI 10.1006/bbrc.1998.9740; Malet I, 2003, J VIROL METHODS, V109, P161, DOI 10.1016/S0166-0934(03)00067-3; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Matsumoto M, 1996, VIROLOGY, V218, P43, DOI 10.1006/viro.1996.0164; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; Nolandt O, 1997, J GEN VIROL, V78, P1331, DOI 10.1099/0022-1317-78-6-1331; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Ray PS, 2004, NUCLEIC ACIDS RES, V32, P1678, DOI 10.1093/nar/gkh328; RAY RB, 1995, VIRUS RES, V37, P209, DOI 10.1016/0168-1702(95)00034-N; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; REBOUD AM, 1980, J BIOL CHEM, V255, P6954; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; Rijnbrand RCA, 2000, CURR TOP MICROBIOL, V242, P85; Ruggli N, 1996, J VIROL, V70, P3478, DOI 10.1128/JVI.70.6.3478-3487.1996; Sansonno D, 2004, J VIRAL HEPATITIS, V11, P27, DOI 10.1046/j.1365-2893.2003.00474.x; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; SCHEPER GC, 1991, BIOCHIM BIOPHYS ACTA, V1089, P220, DOI 10.1016/0167-4781(91)90011-A; Shimoike T, 1999, J VIROL, V73, P9718, DOI 10.1128/JVI.73.12.9718-9725.1999; TANAKA T, 1992, VIRUS RES, V23, P39; Tanaka Y, 2000, VIROLOGY, V270, P229, DOI 10.1006/viro.2000.0252; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; Wang TH, 2000, J VIROL, V74, P11347, DOI 10.1128/JVI.74.23.11347-11358.2000; Zhang J, 2002, VIROLOGY, V293, P141, DOI 10.1006/viro.2001.1270; Zhao WD, 2000, J VIROL, V74, P6223, DOI 10.1128/JVI.74.13.6223-6226.2000	62	39	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17737	17748		10.1074/jbc.M501826200	http://dx.doi.org/10.1074/jbc.M501826200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15760888	hybrid			2022-12-27	WOS:000228807200024
J	Flint, J; Bolam, DN; Nurizzo, D; Taylor, EJ; Williamson, MP; Walters, C; Davies, GJ; Gilbert, HJ				Flint, J; Bolam, DN; Nurizzo, D; Taylor, EJ; Williamson, MP; Walters, C; Davies, GJ; Gilbert, HJ			Probing the mechanism of ligand recognition in family 29 carbohydrate-binding modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULOMONAS-FIMI; XYLANASE 10A; PSEUDOMONAS XYLANASE; TRICHODERMA-REESEI; CRYSTAL-STRUCTURES; ENDOGLUCANASE Z; PEANUT LECTIN; AMINO-ACIDS; DOMAIN; COMPLEX	The recycling of photosynthetically fixed carbon, by the action of microbial plant cell wall hydrolases, is integral to one of the major geochemical cycles and is of considerable industrial importance. Non-catalytic carbohydrate-binding modules (CBMs) play a key role in this degradative process by targeting hydrolytic enzymes to their cognate substrate within the complex milieu of polysaccharides that comprise the plant cell wall. Family 29 CBMs have, thus far, only been found in an extracellular multienzyme plant cell wall-degrading complex from the anaerobic fungus Piromyces equi, where they exist as a CBM29-1:CBM29-2 tandem. Here we present both the structure of the CBM29-1 partner, at 1.5 angstrom resolution, and examine the importance of hydrophobic stacking interactions as well as direct and solvent-mediated hydrogen bonds in the binding of CBM29-2 to different polysaccharides. CBM29 domains display unusual binding properties, exhibiting specificity for both beta-manno- and beta-gluco-configured ligands such as mannan, cellulose, and glucomannan. Mutagenesis reveals that "stacking" of tryptophan residues in the n and n + 2 subsites plays a critical role in ligand binding, whereas the loss of tyrosine-mediated stacking in the n + 4 subsite reduces, but does not abrogate, polysaccharide recognition. Direct hydrogen bonds to ligand, such as those provided by Arg-112 and Glu-78, play a pivotal role in the interaction with both mannan and cellulose, whereas removal of water-mediated interactions has comparatively little effect on carbohydrate binding. The interactions of CBM29-2 with the O2 of glucose or mannose contribute little to binding affinity, explaining why this CBM displays dual gluco/manno specificity.	Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2UH, S Yorkshire, England	Newcastle University - UK; University of York - UK; University of Sheffield	Gilbert, HJ (corresponding author), Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	H.J.Gilbert@ncl.ac.uk	Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X; Williamson, Mike/0000-0001-5572-1903; Flint, James/0000-0003-2923-7813; Taylor, Edward/0000-0003-4024-0976; Bolam, David/0000-0003-0314-3122				Abou Hachem M, 2000, BIOCHEM J, V345, P53, DOI 10.1042/0264-6021:3450053; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 2003, STRUCTURE, V11, P665, DOI 10.1016/S0969-2126(03)00100-X; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Boraston AB, 1999, ROY SOC CH, P202; Bray MR, 1996, PROTEIN SCI, V5, P2311, DOI 10.1002/pro.5560051117; Brett CT, 1996, PHYSL BIOCH PLANT CE, P4; Brun E, 1997, BIOCHEMISTRY-US, V36, P16074, DOI 10.1021/bi9718494; Brzozowski AM, 2001, J APPL CRYSTALLOGR, V34, P97, DOI 10.1107/S0021889800017362; Carvalho AL, 2004, J BIOL CHEM, V279, P34785, DOI 10.1074/jbc.M405867200; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P14077, DOI 10.1073/pnas.212516199; Coutinho PM, 1999, ROY SOC CH, P3; Creagh AL, 1996, P NATL ACAD SCI USA, V93, P12229, DOI 10.1073/pnas.93.22.12229; Czjzek M, 2001, J BIOL CHEM, V276, P48580, DOI 10.1074/jbc.M109142200; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Elgavish S, 1998, J MOL BIOL, V277, P917, DOI 10.1006/jmbi.1998.1664; Flint J, 2004, J MOL BIOL, V337, P417, DOI 10.1016/j.jmb.2003.12.081; Freelove ACJ, 2001, J BIOL CHEM, V276, P43010, DOI 10.1074/jbc.M107143200; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; Henshaw JL, 2004, J BIOL CHEM, V279, P21552, DOI 10.1074/jbc.M401620200; Hogg D, 2003, BIOCHEM J, V371, P1027, DOI 10.1042/BJ20021860; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LINDER M, 1995, PROTEIN SCI, V4, P1056, DOI 10.1002/pro.5560040604; LINDER M, 1995, FEBS LETT, V372, P96, DOI 10.1016/0014-5793(95)00961-8; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; McLean BW, 2000, PROTEIN ENG, V13, P801, DOI 10.1093/protein/13.11.801; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Notenboom V, 2001, J MOL BIOL, V314, P797, DOI 10.1006/jmbi.2001.5153; Notenboom V, 2002, BIOCHEMISTRY-US, V41, P4246, DOI 10.1021/bi015865j; Notenboom V, 2001, BIOCHEMISTRY-US, V40, P6248, DOI 10.1021/bi0101704; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pell G, 2003, BIOCHEMISTRY-US, V42, P9316, DOI 10.1021/bi0347510; Ponyi T, 2000, BIOCHEMISTRY-US, V39, P985, DOI 10.1021/bi9921642; Raghothama S, 2000, BIOCHEMISTRY-US, V39, P978, DOI 10.1021/bi992163+; Ravishankar R, 1999, ACTA CRYSTALLOGR D, V55, P1375, DOI 10.1107/S0907444999006587; Ravishankar R, 1997, CURR SCI INDIA, V72, P855; Simpson HD, 1999, J BACTERIOL, V181, P4611, DOI 10.1128/JB.181.15.4611-4616.1999; Simpson PJ, 2000, J BIOL CHEM, V275, P41137, DOI 10.1074/jbc.M006948200; Szabo L, 2001, J BIOL CHEM, V276, P49061, DOI 10.1074/jbc.M109558200; TAKEO K, 1984, ELECTROPHORESIS, V5, P187, DOI 10.1002/elps.1150050402; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; Xie HF, 2001, BIOCHEMISTRY-US, V40, P5700, DOI 10.1021/bi010034z; Xie HF, 2001, BIOCHEMISTRY-US, V40, P9167, DOI 10.1021/bi0106742; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	48	33	33	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23718	23726		10.1074/jbc.M501551200	http://dx.doi.org/10.1074/jbc.M501551200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15784618	hybrid			2022-12-27	WOS:000229880000040
J	Saslowsky, DE; Warek, U; Winkel, BSJ				Saslowsky, DE; Warek, U; Winkel, BSJ			Nuclear localization of flavonoid enzymes in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOKINASE REGULATORY PROTEIN; TRANSPARENT TESTA MUTANTS; DNA-POLYMERASE-ALPHA; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; TISSUE LOCALIZATION; PHENOLIC-COMPOUNDS; CHALCONE SYNTHASE; AUXIN TRANSPORT; BINDING; EXPRESSION	Flavonoids represent one of the oldest, largest, and most diverse families of plant secondary metabolites. These compounds serve a wide range of functions in plants, from pigmentation and UV protection to the regulation of hormone transport. Flavonoids also have interesting pharmacological activities in animals that are increasingly being characterized in terms of effects on specific proteins or other macromolecules. Although flavonoids are found in many different locations both inside and outside the cell, biosynthesis has long been believed to take place exclusively in the cytoplasm. Recent reports from a number of different plant species have documented the presence of flavonoids in nuclei, raising the possibility of novel mechanisms of action for these compounds. Here we present evidence that not only flavonoids, but also at least two of the biosynthetic enzymes, are located in the nucleus in several cell types in Arabidopsis. This is the first indication that differential targeting of the biosynthetic machinery may be used to regulate the deposition of plant secondary products at diverse sites of action within the cell.	Virginia Tech, Dept Biol, W Campus Dr, VA 24061 USA; Virginia Tech, Franklin Ctr Biotechnol, W Campus Dr, VA 24061 USA	Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University	Winkel, BSJ (corresponding author), Virginia Tech, Dept Biol, W Campus Dr, VA 24061 USA.	winkel@vt.edu	Winkel, Brenda S.J./A-6602-2008	Winkel, Brenda S.J./0000-0003-3481-024X				Agius L, 1997, BIOCHEM SOC T, V25, P145, DOI 10.1042/bst0250145; Anderson LE, 2004, PROTOPLASMA, V223, P103, DOI 10.1007/s00709-004-0041-y; ANDERSON LE, 1995, PLANT PHYSIOL, V108, P659, DOI 10.1104/pp.108.2.659; Audhya A, 2003, EMBO J, V22, P4223, DOI 10.1093/emboj/cdg397; BECKER D, 1990, NUCLEIC ACIDS RES, V18, P203, DOI 10.1093/nar/18.1.203; Ben-Efraim I, 2004, BIOCHEMISTRY-US, V43, P3518, DOI 10.1021/bi0356911; Bosco D, 2000, BIOCHEM J, V348, P215, DOI 10.1042/0264-6021:3480215; Bovy A, 2002, PLANT CELL, V14, P2509, DOI 10.1105/tpc.004218; Bravo L, 1998, NUTR REV, V56, P317, DOI 10.1111/j.1753-4887.1998.tb01670.x; Bryant JA, 2000, J EXP BOT, V51, P1945, DOI 10.1093/jexbot/51.352.1945; Buer CS, 2004, PLANT CELL, V16, P1191, DOI 10.1105/tpc.020313; Burbulis IE, 1999, P NATL ACAD SCI USA, V96, P12929, DOI 10.1073/pnas.96.22.12929; CHEN H, 1994, BIOTECHNIQUES, V16, P664; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Cuadra P, 1996, Z NATURFORSCH C, V51, P671; DANA CD, 2005, IN PRESS J MOL MODEL; Debeaujon I, 2001, PLANT CELL, V13, P853, DOI 10.1105/tpc.13.4.853; DeLong A, 2002, PLANT MOL BIOL, V49, P285, DOI 10.1023/A:1015246828230; Dixon RA, 1999, TRENDS PLANT SCI, V4, P394, DOI 10.1016/S1360-1385(99)01471-5; Endt DV, 2002, PHYTOCHEMISTRY, V61, P107, DOI 10.1016/S0031-9422(02)00185-1; Farrelly D, 1999, P NATL ACAD SCI USA, V96, P14511, DOI 10.1073/pnas.96.25.14511; Feucht W, 2004, PLANT CELL REP, V22, P430, DOI 10.1007/s00299-003-0705-7; Goodman CD, 2004, PLANT CELL, V16, P1812, DOI 10.1105/tpc.022574; Grandmaison J, 1996, J PLANT PHYSIOL, V147, P653, DOI 10.1016/S0176-1617(11)81474-4; Grotewold E, 1998, PLANT CELL, V10, P721, DOI 10.1105/tpc.10.5.721; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gutzeit HO, 2004, BIOCHEM BIOPH RES CO, V318, P490, DOI 10.1016/j.bbrc.2004.04.078; Hanaka H, 2002, BIOCHEM J, V361, P505, DOI 10.1042/0264-6021:3610505; Harborne JB, 2000, PHYTOCHEMISTRY, V55, P481, DOI 10.1016/S0031-9422(00)00235-1; Havsteen BH, 2002, PHARMACOL THERAPEUT, V96, P67, DOI 10.1016/S0163-7258(02)00298-X; Herrero P, 1998, FEBS LETT, V434, P71, DOI 10.1016/S0014-5793(98)00872-2; Hodek P, 2002, CHEM-BIOL INTERACT, V139, P1, DOI 10.1016/S0009-2797(01)00285-X; HRAZDINA G, 1992, ANNU REV PLANT PHYS, V43, P241, DOI 10.1146/annurev.pp.43.060192.001325; HRAZDINA G, 1985, ANN P PHYTOCHEM SOC, V25, P120; Hutzler P, 1998, J EXP BOT, V49, P953, DOI 10.1093/jexbot/49.323.953; Keminer O, 1999, BIOPHYS J, V77, P217, DOI 10.1016/S0006-3495(99)76883-9; Kuras M, 1999, ANN BOT-LONDON, V84, P135, DOI 10.1006/anbo.1999.0884; Lin Yakang, 2003, BMC Plant Biology, V3, P10, DOI 10.1186/1471-2229-3-10; Mamczur P, 2004, HISTOL HISTOPATHOL, V19, P753, DOI 10.14670/HH-19.753; MARCHAND L, 1987, J PLANT PHYSIOL, V131, P339, DOI 10.1016/S0176-1617(87)80173-6; Markham KR, 2001, PHYTOCHEMISTRY, V58, P403, DOI 10.1016/S0031-9422(01)00276-X; Mathews H, 2003, PLANT CELL, V15, P1689, DOI 10.1105/tpc.012963; Mazzola JL, 2003, BBA-GEN SUBJECTS, V1622, P50, DOI 10.1016/S0304-4165(03)00117-X; Mizushina Y, 2003, BIOCHEM BIOPH RES CO, V301, P480, DOI 10.1016/S0006-291X(02)03083-8; MOSKALEWSKI S, 1980, CELL TISSUE RES, V210, P403; Murphy A, 2000, PLANTA, V211, P315, DOI 10.1007/s004250000300; Nijveldt RJ, 2001, AM J CLIN NUTR, V74, P418; Peer WA, 2001, PLANT PHYSIOL, V126, P536, DOI 10.1104/pp.126.2.536; Pelletier MK, 1996, PLANT PHYSIOL, V111, P339, DOI 10.1104/pp.111.1.339; Popanda O, 1998, BBA-GENE STRUCT EXPR, V1397, P102, DOI 10.1016/S0167-4781(97)00229-7; Ramadass P, 2003, TOXICOL SCI, V76, P212, DOI 10.1093/toxsci/kfg227; Rice-Evans C, 2001, CURR MED CHEM, V8, P797, DOI 10.2174/0929867013373011; Sarma AD, 1999, PHYTOCHEMISTRY, V52, P1313, DOI 10.1016/S0031-9422(99)00427-6; Saslowsky D, 2001, PLANT J, V27, P37, DOI 10.1046/j.1365-313x.2001.01073.x; Schnitzler JP, 1996, NEW PHYTOL, V132, P247, DOI 10.1111/j.1469-8137.1996.tb01844.x; SHEAHAN JJ, 1993, ANAL CHEM, V65, P961, DOI 10.1021/ac00055a022; SHIRLEY BW, 1992, PLANT CELL, V4, P333, DOI 10.1105/tpc.4.3.333; SNYDER BA, 1990, SCIENCE, V248, P1637, DOI 10.1126/science.248.4963.1637; STAFFORD HA, 1974, RECENT ADV PHYTOCHEM, V8, P53, DOI DOI 10.1016/B978-0-12-612408-8.50009-3; Stevens JF, 2004, PHYTOCHEMISTRY, V65, P1317, DOI 10.1016/j.phytochem.2004.04.025; Suetsugu S, 2003, J BIOL CHEM, V278, P42515, DOI 10.1074/jbc.M302177200; Verhoeyen ME, 2002, J EXP BOT, V53, P2099, DOI 10.1093/jxb/erf044; von Arnim AG, 1998, GENE, V221, P35, DOI 10.1016/S0378-1119(98)00433-8; Walle T, 2003, BIOCHEM PHARMACOL, V65, P1603, DOI 10.1016/S0006-2952(03)00151-5; Wang XW, 1999, ARCH BIOCHEM BIOPHYS, V367, P348, DOI 10.1006/abbi.1999.1261; Wietzke JA, 2003, J STEROID BIOCHEM, V84, P149, DOI 10.1016/S0960-0760(03)00024-4; Winkel BSJ, 2004, ANNU REV PLANT BIOL, V55, P85, DOI 10.1146/annurev.arplant.55.031903.141714; Winkel-Shirley B, 1999, PHYSIOL PLANTARUM, V107, P142, DOI 10.1034/j.1399-3054.1999.100119.x; Winkel-Shirley B, 2001, PLANT PHYSIOL, V126, P485, DOI 10.1104/pp.126.2.485; WOLLENWEBER E, 1981, PHYTOCHEMISTRY, V20, P869, DOI 10.1016/0031-9422(81)83001-4; Yoshizumi M, 2002, BIOCHEM BIOPH RES CO, V293, P1458, DOI 10.1016/S0006-291X(02)00407-2; Yu O, 2003, PHYTOCHEMISTRY, V63, P753, DOI 10.1016/S0031-9422(03)00345-5	72	165	178	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23735	23740		10.1074/jbc.M413506200	http://dx.doi.org/10.1074/jbc.M413506200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15817473	hybrid			2022-12-27	WOS:000229880000042
J	Gokhale, KC; Newnam, GP; Sherman, MY; Chernoff, YO				Gokhale, KC; Newnam, GP; Sherman, MY; Chernoff, YO			Modulation of prion-dependent polyglutamine aggregation and toxicity by chaperone proteins in the yeast model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTAGONISTIC INTERACTIONS; SACCHAROMYCES-CEREVISIAE; CYTOSOLIC HSP70; PSI+ PRION; HUNTINGTIN; HSP104; PROPAGATION; SUPPRESSION; EXPRESSION; DOMAIN	In yeast, aggregation and toxicity of the expanded polyglutamine fragment of human huntingtin strictly depend on the presence of the endogenous self-perpetuating aggregated proteins (prions), which contain glutamine/asparagine-rich domains. Some chaperones of the Hsp100/70/40 complex, modulating propagation of yeast prions, were also reported to influence polyglutamine aggregation in yeast, but it was not clear whether they do it directly or via affecting prions. Our data show that although some chaperone alterations indeed act on polyglutamines via curing endogenous prions, other alterations decrease size and ameliorate toxicity of polyglutamine aggregates without affecting prion propagation. Therefore, the role of yeast chaperones in polyglutamine aggregation and toxicity is not restricted only to their effects on the endogenous prions. Moreover, chaperone interactions with prion and polyglutamine aggregates appear to be of a highly specific nature. One and the same chaperone alteration, substitution A503V in the middle region of the chaperone Hsp104, exhibited opposite effects on one of the endogenous prions ([PSI+], the prion form of Sup35) and on polyglutamines, increasing aggregate size and toxicity in the former case and decreasing them in the latter case. On the other hand, different members of a single chaperone family exhibited opposite effects on one and the same type of aggregates: excess of the Hsp40 chaperone Ydj1 increased polyglutamine aggregate size and toxicity, whereas excess of the other Hsp40 chaperone, Sis1, decreased them. As many stress-defense proteins are conserved between yeast and mammals, these data shed light on possible mechanisms modulating polyglutamine aggregation and toxicity in mammalian cells.	Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; Georgia Inst Technol, Inst Bioengn & Biosci, Atlanta, GA 30332 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; Boston University	Chernoff, YO (corresponding author), Georgia Inst Technol, Sch Biol, 310 Ferst Dr, Atlanta, GA 30332 USA.	yury.chernoff@biology.gatech.edu	Chernoff, Yury O/J-2833-2014	Chernoff, Yury/0000-0002-8934-9051; Sherman, Michael/0000-0003-3345-073X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058763] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM58763] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen KD, 2005, GENETICS, V169, P1227, DOI 10.1534/genetics.104.037168; Bailleul PA, 1999, GENETICS, V153, P81; Bailleul-Winslett PA, 2000, GENE EXPRESSION, V9, P145; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cao F, 2001, BBA-MOL BASIS DIS, V1537, P158, DOI 10.1016/S0925-4439(01)00068-0; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; Chacinska A, 2001, CURR GENET, V39, P62, DOI 10.1007/s002940000180; Chan HYE, 2000, HUM MOL GENET, V9, P2811, DOI 10.1093/hmg/9.19.2811; Chernoff YO, 2004, TRENDS BIOTECHNOL, V22, P549, DOI 10.1016/j.tibtech.2004.09.001; CHERNOFF YO, 1992, YEAST, V8, P489, DOI 10.1002/yea.320080702; Chernoff YO, 1999, MOL CELL BIOL, V19, P8103; Chernoff YO, 2002, METHOD ENZYMOL, V351, P499; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Chernoff YO, 2001, MUTAT RES-REV MUTAT, V488, P39, DOI 10.1016/S1383-5742(00)00060-0; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Derkatch IL, 1997, GENETICS, V147, P507; Derkatch IL, 1996, GENETICS, V144, P1375; Faber PW, 1999, P NATL ACAD SCI USA, V96, P179, DOI 10.1073/pnas.96.1.179; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Jung G, 2000, GENETICS, V156, P559; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Kimura Y, 2001, GENES CELLS, V6, P887, DOI 10.1046/j.1365-2443.2001.00472.x; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Li SH, 2004, TRENDS GENET, V20, P146, DOI 10.1016/j.tig.2004.01.008; LIU HP, 1992, GENETICS, V132, P665; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Meriin AB, 2003, MOL CELL BIOL, V23, P7554, DOI 10.1128/MCB.23.21.7554-7565.2003; Meriin AB, 2002, J CELL BIOL, V157, P997, DOI 10.1083/jcb.200112104; Michelitsch MD, 2000, P NATL ACAD SCI USA, V97, P11910, DOI 10.1073/pnas.97.22.11910; Moriyama H, 2000, MOL CELL BIOL, V20, P8916, DOI 10.1128/MCB.20.23.8916-8922.2000; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Newnam GP, 1999, MOL CELL BIOL, V19, P1325; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Osherovich LZ, 2004, PLOS BIOL, V2, P442, DOI 10.1371/journal.pbio.0020086; Osherovich LZ, 2001, CELL, V106, P183, DOI 10.1016/S0092-8674(01)00440-8; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Perez MK, 1998, J CELL BIOL, V143, P1457, DOI 10.1083/jcb.143.6.1457; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Roberts BT, 2004, YEAST, V21, P107, DOI 10.1002/yea.1062; Satyal SH, 2000, P NATL ACAD SCI USA, V97, P5750, DOI 10.1073/pnas.100107297; Schirmer EC, 2004, MOL BIOL CELL, V15, P2061, DOI 10.1091/mbc.E02-08-0502; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schwimmer C, 2002, MOL CELL BIOL, V22, P3590, DOI 10.1128/MCB.22.11.3590-3598.2002; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shorter J, 2004, SCIENCE, V304, P1793, DOI 10.1126/science.1098007; Sondheimer N, 2001, EMBO J, V20, P2435, DOI 10.1093/emboj/20.10.2435; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; Velier J, 1998, EXP NEUROL, V152, P34, DOI 10.1006/exnr.1998.6832; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wegrzyn RD, 2001, MOL CELL BIOL, V21, P4656, DOI 10.1128/MCB.21.14.4656-4669.2001; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898	58	110	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22809	22818		10.1074/jbc.M500390200	http://dx.doi.org/10.1074/jbc.M500390200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15824100	hybrid			2022-12-27	WOS:000229741800032
J	Brown, ST; Scragg, JL; Boyle, JP; Hudasek, K; Peers, C; Fearon, IM				Brown, ST; Scragg, JL; Boyle, JP; Hudasek, K; Peers, C; Fearon, IM			Hypoxic augmentation of Ca2+channel currents requires a functional electron transport chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; MITOCHONDRIAL DYSFUNCTION; CALCIUM HOMEOSTASIS; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; BETA; CELLS; MODEL; SUPEROXIDE; ASTROCYTES	The incidence of Alzheimer disease is increased following ischemic episodes, and we previously demonstrated that following chronic hypoxia (CH), amyloid b (Ab) peptide-mediated increases in voltage-gated L-type Ca-2(2+ channel activity contribute to the Ca2+ dyshomeostasis seen in Alzheimer disease. Because in certain cell types mitochondria are responsible for detecting altered O) (levels we examined the role of mitochondrial oxidant production in the regulation of recombinant Ca2+ channel a)(1C) (subunits during CH and exposure to Ab-(1-40). In wild-type (r+) HEK 293 cells expressing recombinant L-type a)(1C) (subunits, Ca2+ currents were enhanced by prolonged (24 h) exposure to either CH (6% O)() or Ab-(1-40) (50 nM). By contrast the response to CH was absent in r0 cells in which the mitochondrial electron transport chain (ETC) was depleted following long term treatment with ethidium bromide or in r+ cells cultured in the presence of 1 mM rotenone. CH was mimicked in r0 cells by the exogenous production of O)(2)(2). by xanthine/xanthine oxidase. Furthermore Ab-(1-40) enhanced currents in r0 cells to a degree similar to that seen in cells with an intact ETC. The antioxidants ascorbate (200 mM) and Trolox (500 mM) ablated the effect of CH in r+ cells but were without effect on Ab-(1-40)-mediated augmentation of Ca2+ current in r0 cells. Thus oxidant production in the mitochondrial ETC is a critical factor, acting upstream of amyloid b peptide production in the up-regulation of Ca2+ channels in response to CH.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England; Univ Leeds, Sch Med, Leeds LS2 9JT, W Yorkshire, England; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada	University of Manchester; University of Leeds; McMaster University	Fearon, IM (corresponding author), Univ Manchester, Fac Life Sci, G38 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	ian.fearon@manchester.ac.uk	Boyle, John/N-4868-2016	Peers, Chris/0000-0002-8354-346X				Abramov AY, 2004, J NEUROSCI, V24, P565, DOI 10.1523/JNEUROSCI.4042-03.2004; Fearon IM, 1997, J PHYSIOL-LONDON, V500, P551, DOI 10.1113/jphysiol.1997.sp022041; Green KN, 2002, J NEUROCHEM, V81, P1043, DOI 10.1046/j.1471-4159.2002.00907.x; Green KN, 2002, J PHYSIOL-LONDON, V541, P1013, DOI 10.1113/jphysiol.2002.017582; Green KN, 2001, J NEUROCHEM, V77, P953, DOI 10.1046/j.1471-4159.2001.00338.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hartness ME, 2003, J BIOL CHEM, V278, P51422, DOI 10.1074/jbc.M309463200; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kim SH, 2001, LIFE SCI, V68, P2741, DOI 10.1016/S0024-3205(01)01074-8; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Lambert AJ, 2004, J BIOL CHEM, V279, P39414, DOI 10.1074/jbc.M406576200; Li F, 2004, J NEUROCHEM, V89, P1308, DOI 10.1111/j.1471-4159.2004.02455.x; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; Mattson MP, 2002, J NEUROVIROL, V8, P539, DOI 10.1080/13550280290100978; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Mattson MP, 2001, J MOL NEUROSCI, V17, P205, DOI 10.1385/JMN:17:2:205; Moroney JT, 1996, STROKE, V27, P1283, DOI 10.1161/01.STR.27.8.1283; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Schroedl C, 2002, AM J PHYSIOL-LUNG C, V283, pL922, DOI 10.1152/ajplung.00014.2002; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; Scragg JL, 2004, FASEB J, V18, P150, DOI 10.1096/fj.04-2659fje; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sharp FR, 2004, NAT REV NEUROSCI, V5, P437, DOI 10.1038/nrn1408; Smith IF, 2004, J NEUROCHEM, V88, P869, DOI 10.1016/j.1471-4159.2003.02212.x; Smith MA, 2002, NEUROCHEM INT, V40, P527, DOI 10.1016/S0197-0186(01)00123-1; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Valencia A, 2004, FREE RADICAL BIO MED, V36, P1112, DOI 10.1016/j.freeradbiomed.2004.02.013; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Walter J, 2001, CURR OPIN NEUROBIOL, V11, P585, DOI 10.1016/S0959-4388(00)00253-1; Waypa GB, 2001, CIRC RES, V88, P1259, DOI 10.1161/hh1201.091960; Wen Y, 2004, BRAIN RES, V1009, P1, DOI 10.1016/j.brainres.2003.09.086; Wolfe MS, 2003, CURR TOP DEV BIOL, V54, P233, DOI 10.1016/S0070-2153(03)54011-X; Wyatt CN, 2004, J PHYSIOL-LONDON, V556, P175, DOI 10.1113/jphysiol.2003.058131	35	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21706	21712		10.1074/jbc.M503144200	http://dx.doi.org/10.1074/jbc.M503144200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15824110	hybrid			2022-12-27	WOS:000229557900005
J	Phillips, RJ; Mestas, J; Gharee-Kermani, M; Burdick, MD; Sica, A; Belperio, JA; Keane, MP; Strieter, RM				Phillips, RJ; Mestas, J; Gharee-Kermani, M; Burdick, MD; Sica, A; Belperio, JA; Keane, MP; Strieter, RM			Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; HIF-ALPHA; PTEN; HIF-1-ALPHA; ANGIOGENESIS; METASTASIS; PROMOTER; BIOLOGY; KINASE	Non-small cell lung cancer (NSCLC) expresses a particularly aggressive metastatic phenotype, and patients with this disease have a poor prognosis. CXC chemokine receptor 4 (CXCR4) is a cell surface receptor that has been shown to mediate the metastasis of many solid tumors including lung, breast, kidney, and prostate. In addition, overexpression of the epidermal growth factor receptor ( EGFR) is associated with the majority of NSCLC and has been implicated in the process of malignant transformation by promoting cell proliferation, cell survival, and motility. Here we show for the first time that activation of the EGFR by EGF increases CXCR4 expression and the migratory capacity of NSCLC cells. Furthermore, many solid tumors are associated with low oxygen tension, and when NSCLC cells were cultured with EGF under hypoxic conditions, CXCR4 expression was dramatically enhanced. A molecular analysis of these events indicated that augmented CXCR4 expression was regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/ mammalian target of rapamycin signal transduction pathway, activation of hypoxia inducible factor (HIF) 1 alpha, and ultimately HIF-1-dependent transcription of the CXCR4 gene. Thus, a combination of low oxygen tension and overexpression of EGFR within the primary tumor of NSCLC may provide the microenvironmental signals necessary to upregulate CXCR4 expression and promote metastasis.	Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA; Ist Ric Farmacol Mario Negri, I-20157 Milan, Italy	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Strieter, RM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, 900 Vet Ave,14-154 Warren Hall, Los Angeles, CA 90095 USA.	rstrieter@mednet.ucla.edu	Sica, Antonio/AAB-9546-2020		NCI NIH HHS [P50 CA 90388, CA 87879] Funding Source: Medline; NHLBI NIH HHS [HL 66027] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087879, P50CA090388] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066027] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belperio JA, 2004, CHEST, V125, p156S, DOI 10.1378/chest.125.5_suppl.156S; Belperio JA, 2002, AM J RESP CELL MOL, V27, P419, DOI 10.1165/rcmb.2002-0009OC; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Brognard J, 2001, CANCER RES, V61, P3986; Caruz A, 1998, FEBS LETT, V426, P271, DOI 10.1016/S0014-5793(98)00359-7; DEVESA SS, 1995, JNCI-J NATL CANCER I, V87, P175, DOI 10.1093/jnci/87.3.175; FIDLER IJ, 1990, CANCER RES, V50, P6130; Franklin WA, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.31520; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Goberdhan DCI, 2003, HUM MOL GENET, V12, pR239, DOI 10.1093/hmg/ddg288; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HENDLER FJ, 1984, J CLIN INVEST, V74, P647, DOI 10.1172/JCI111463; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Jung YJ, 2003, BIOCHEM J, V370, P1011, DOI 10.1042/BJ20021279; Krishnamachary B, 2003, CANCER RES, V63, P1138; KUZMIN I, 1995, ONCOGENE, V10, P2185; Leung Sherri K., 2002, Journal of Biomedicine & Biotechnology, V2, P131, DOI 10.1155/S1110724302205057; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Scotton CJ, 2001, CANCER RES, V61, P4961; Semenza G L, 2000, Respir Res, V1, P159, DOI 10.1186/rr27; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Smith W, 2004, SEMIN ONCOL, V31, P11, DOI 10.1053/j.seminoncol.2004.02.012; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Strieter RM, 2004, SEMIN CANCER BIOL, V14, P195, DOI 10.1016/j.semcancer.2003.10.006; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Taichman RS, 2002, CANCER RES, V62, P1832; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Zatyka M, 2002, J MED GENET, V39, P463, DOI 10.1136/jmg.39.7.463; Zhong H, 2000, CANCER RES, V60, P1541; Zlotnik A, 2004, SEMIN CANCER BIOL, V14, P181, DOI 10.1016/j.semcancer.2003.10.004; Zundel W, 2000, GENE DEV, V14, P391	45	271	294	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22473	22481		10.1074/jbc.M500963200	http://dx.doi.org/10.1074/jbc.M500963200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15802268	hybrid			2022-12-27	WOS:000229557900093
J	Sidhu, RS; Clough, RR; Bhullar, RP				Sidhu, RS; Clough, RR; Bhullar, RP			Regulation of phospholipase C-delta 1 through direct interactions with the small GTPase Ral and calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEINS; C-DELTA; CA2+ OSCILLATIONS; HUMAN PLATELETS; ACTIVATION; EFFECTOR; IDENTIFICATION; PATHWAY; COMPLEX; MEMBRANE	Second messengers generated from membrane lipids play a critical role in signaling and control diverse cellular processes. Despite being one of the most evolutionarily conserved of all the phosphoinositide-specific phospholipase C (PLC) isoforms, a family of enzymes responsible for hydrolysis of the membrane lipid phosphatidylinositol bisphosphate, the mechanism of PLC-delta 1 activation is still poorly understood. Here we report a novel regulatory mechanism for PLC-delta 1 activation that involves direct interaction of the small GTPase Ral and the universal calcium-signaling molecule calmodulin (CaM) with PLC-delta 1. In addition, we have identified a novel IQ type CaM binding motif within the catalytic region of PLC-delta 1 that is not found in other PLC isoforms. Binding of CaM at the IQ motif inhibits PLC-delta 1 activity, while addition of Ral reverses the inhibition. The overexpression of various Ral mutants in cells potentiates PLC-delta 1 activity. Thus, the Ral-CaM complex defines a multifaceted regulatory mechanism for PLC-delta 1 activation.	Univ Manitoba, Fac Dent, Dept Oral Biol, Winnipeg, MB R3E 0W2, Canada; Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3E 0W2, Canada	University of Manitoba; University of Manitoba	Bhullar, RP (corresponding author), Univ Manitoba, Fac Dent, Dept Oral Biol, Winnipeg, MB R3E 0W2, Canada.	bhullar@MS.Umanitoba.CA						Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; Bauer B, 1999, J BIOL CHEM, V274, P17763, DOI 10.1074/jbc.274.25.17763; Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Clough RR, 2002, J BIOL CHEM, V277, P28972, DOI 10.1074/jbc.M201504200; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; ELLIS MV, 1993, EUR J BIOCHEM, V213, P339, DOI 10.1111/j.1432-1033.1993.tb17767.x; Ellis MV, 1998, J BIOL CHEM, V273, P11650, DOI 10.1074/jbc.273.19.11650; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; Gildea JJ, 2002, CANCER RES, V62, P982; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; HWANG JI, 2005, UNPUB BIOCH J; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Jilkina O, 1996, BBA-MOL CELL RES, V1314, P157, DOI 10.1016/S0167-4889(96)00073-0; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; Katan M, 1999, FEBS LETT, V452, P36, DOI 10.1016/S0014-5793(99)00531-1; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Kouchi Z, 2004, J BIOL CHEM, V279, P10408, DOI 10.1074/jbc.M313801200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; McCullar JS, 2003, J BIOL CHEM, V278, P33708, DOI 10.1074/jbc.M301940200; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Nakamura Y, 2003, EMBO J, V22, P2981, DOI 10.1093/emboj/cdg302; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; PARK DG, 1993, J BIOL CHEM, V268, P4573; Polzin A, 2002, MOL CELL BIOL, V22, P1714, DOI 10.1128/MCB.22.6.1714-1722.2002; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Richard EA, 1997, P NATL ACAD SCI USA, V94, P14095, DOI 10.1073/pnas.94.25.14095; Saunders CM, 2002, DEVELOPMENT, V129, P3533; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Stewart AJ, 2005, INT J MOL MED, V15, P117; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; WAHL MI, 1992, J BIOL CHEM, V267, P10447; Wang KL, 1997, J BIOL CHEM, V272, P16002, DOI 10.1074/jbc.272.25.16002; Williams RL, 1999, BBA-MOL CELL BIOL L, V1441, P255, DOI 10.1016/S1388-1981(99)00150-X; Wing MR, 2003, J BIOL CHEM, V278, P41253, DOI 10.1074/jbc.M306904200; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; WU DQ, 1993, J BIOL CHEM, V268, P3704; Xu LZ, 2003, MOL CELL BIOL, V23, P645, DOI 10.1128/MCB.23.2.645-654.2003; Yamniuk AP, 2004, MOL BIOTECHNOL, V27, P33, DOI 10.1385/MB:27:1:33; Ziegelhoffer A, 2001, CARDIOVASC RES, V49, P118, DOI 10.1016/S0008-6363(00)00209-1	55	51	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21933	21941		10.1074/jbc.M412966200	http://dx.doi.org/10.1074/jbc.M412966200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817490	hybrid			2022-12-27	WOS:000229557900034
J	Kamalakaran, S; Radhakrishnan, SK; Beck, WT				Kamalakaran, S; Radhakrishnan, SK; Beck, WT			Identification of estrogen-responsive genes using a genome-wide analysis of promoter elements for transcription factor binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							START SITES; DATABASE; DNA; SEQUENCE; TRANSFAC; SYSTEM; DBTSS; TOOL	We developed a pipeline to identify novel genes regulated by the steroid hormone-dependent transcription factor, estrogen receptor, through a systematic analysis of upstream regions of all human and mouse genes. We built a data base of putative promoter regions for 23,077 human and 19,984 mouse transcripts from National Center for Biotechnology Information annotation and 8793 human and 6785 mouse promoters from the Data Base of Transcriptional Start Sites. We used this data base of putative promoters to identify potential targets of estrogen receptor by identifying estrogen response elements ( EREs) in their promoters. Our program correctly identified EREs in genes known to be regulated by estrogen in addition to several new genes whose putative promoters contained EREs. We validated six genes (KIAA1243, NRIP1, MADH9, NME3, TPD52L, and ABCG2) to be estrogen-responsive in MCF7 cells using reverse transcription PCR. To allow for extensibility of our program in identifying targets of other transcription factors, we have built a Web interface to access our data base and programs. Our Web-based program for Promoter Analysis of Genome, PAGen@UIC, allows a user to identify putative target genes for vertebrate transcription factors through the analysis of their upstream sequences. The interface allows the user to search the human and mouse promoter data bases for potential target genes containing one or more listed transcription factor binding sites (TFBSs) in their upstream elements, using either regular expression-based consensus or position weight matrices. The data base can also be searched for promoters harboring user-defined TFBSs given as a consensus or a position weight matrix. Furthermore, the user can retrieve putative promoter sequences for any given gene together with identified TFBSs located on its promoter. Orthologous promoters are also analyzed to determine conserved elements.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60612 USA; Univ Illinois, Dept Med Microbiol & Immunol, Chicago, IL 60612 USA; Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL 60612 USA; Univ Illinois, Ctr Canc, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Beck, WT (corresponding author), Univ Illinois, Dept Biopharmaceut Sci MC 865, 833 S Wood St, Chicago, IL 60612 USA.	wtbeck@uic.edu		Radhakrishnan, Senthil/0000-0002-5211-9498	NATIONAL CANCER INSTITUTE [R01CA030103, R01CA040570] Funding Source: NIH RePORTER; NCI NIH HHS [CA30103, CA40570] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bajic VB, 2003, NUCLEIC ACIDS RES, V31, P3605, DOI 10.1093/nar/gkg517; Benos PV, 2002, NUCLEIC ACIDS RES, V30, P4442, DOI 10.1093/nar/gkf578; Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441; Bulyk ML, 2004, GENOME BIOL, V5; Ee PLR, 2004, CANCER RES, V64, P1247, DOI 10.1158/0008-5472.CAN-03-3583; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Friedl JEF, 2002, MASTERING REGULAR EX; Halees AS, 2003, NUCLEIC ACIDS RES, V31, P3554, DOI 10.1093/nar/gkg549; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Kasprzyk A, 2004, GENOME RES, V14, P160, DOI 10.1101/gr.1645104; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Perier RC, 2000, NUCLEIC ACIDS RES, V28, P302, DOI 10.1093/nar/28.1.302; Perier RC, 1998, NUCLEIC ACIDS RES, V26, P353, DOI 10.1093/nar/26.1.353; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Rosenfeld CS, 2001, REPRODUCTION, V122, P215, DOI 10.1530/rep.0.1220215; Sanchez R, 2002, BIOESSAYS, V24, P244, DOI 10.1002/bies.10066; Schmid CD, 2004, NUCLEIC ACIDS RES, V32, pD82, DOI 10.1093/nar/gkh122; Schuldiner O, 2002, GENE, V292, P91, DOI 10.1016/S0378-1119(02)00668-6; SCHWABE JW, 2004, SCI STKE, pPE4; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stormo GD, 2000, BIOINFORMATICS, V16, P16, DOI 10.1093/bioinformatics/16.1.16; Sun H, 2004, BIOINFORMATICS, V20, P727, DOI 10.1093/bioinformatics/btg476; Suzuki Y, 2004, NUCLEIC ACIDS RES, V32, pD78, DOI 10.1093/nar/gkh076; Suzuki Y, 2002, NUCLEIC ACIDS RES, V30, P328, DOI 10.1093/nar/30.1.328; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281	33	45	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21491	21497		10.1074/jbc.M409176200	http://dx.doi.org/10.1074/jbc.M409176200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15790569	hybrid			2022-12-27	WOS:000229438800070
J	Klamt, F; Shacter, E				Klamt, F; Shacter, E			Taurine chloramine, an oxidant derived from neutrophils, induces apoptosis in human B lymphoma cells through mitochondrial damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; HYPOCHLOROUS ACID; OXIDATIVE STRESS; AMINO-ACID; LEUKEMIA-CELLS; CYCLOSPORINE-A; DEATH; RECEPTOR; PHOSPHATIDYLSERINE	Taurine chloramine (TN-Cl) is one of the most abundant compounds generated by activated neutrophils. In contrast to HOCl, which causes necrosis, TN-Cl is a potent inducer of apoptosis in tumor cells. Here we show that the apoptosis induced by TN-Cl in human B lymphoma cells is dependent upon oxidant-mediated mitochondrial damage, a decrease in mitochondrial membrane potential, and caspase-9 activation. Further, we show that TN-Cl is taken up into the cells and is concentrated in the mitochondria, where it induces opening of the permeability transition pore and mitochondrial swelling. Identical activity is seen upon treatment of isolated mitochondria with TN-Cl and is blocked by the permeability transition pore inhibitors bongkrekic acid and cyclosporin A, as well as by the sulfhydryl-reducing agent tris(2-carboxyethyl)-phosphine. The data suggest that TN-Cl causes apoptosis through direct damage to the mitochondria.	US FDA, Biochem Lab, Div Therapeut Prot, CDER, Bethesda, MD 20892 USA; Lutheran Univ Brazil ULBRA, Dept Biol, BR-92450900 Canoas, RS, Brazil	US Food & Drug Administration (FDA); Universidade Luterana do Brasil	Shacter, E (corresponding author), US FDA, Biochem Lab, Div Therapeut Prot, CDER, 29 Lincoln Dr,Bldg 29A,Rm 2A-11, Bethesda, MD 20892 USA.	emily.shacter@fda.gov						Anderson HA, 2002, CELL DEATH DIFFER, V9, P616, DOI 10.1038/sj.cdd.4401013; Anderson HA, 2003, NAT IMMUNOL, V4, P87, DOI 10.1038/ni871; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; de Graaf AO, 2004, EXP CELL RES, V299, P533, DOI 10.1016/j.yexcr.2004.06.024; Elamiri A, 2003, PHARMACOL RES, V48, P467, DOI 10.1016/S1043-6618(03)00187-7; Emerson DK, 2005, J BIOL CHEM, V280, P3233, DOI 10.1074/jbc.M411672200; Englert RP, 2002, J BIOL CHEM, V277, P20518, DOI 10.1074/jbc.M200212200; Fadok VA, 2003, CURR BIOL, V13, pR655, DOI 10.1016/S0960-9822(03)00575-X; FUKUDA K, 1982, CLIN CHEM, V28, P1758; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Garg Tarun K., 2004, BMC Pharmacology, V4, P6, DOI 10.1186/1471-2210-4-6; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; GRISHAM MB, 1984, J BIOL CHEM, V259, P404; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Illmer T, 2004, LEUKEMIA, V18, P401, DOI 10.1038/sj.leu.2403257; Kanayama A, 2002, J BIOL CHEM, V277, P24049, DOI 10.1074/jbc.M110832200; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Kontny E, 2003, ADV EXP MED BIOL, V526, P329; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Lauber K, 2004, MOL CELL, V14, P277, DOI 10.1016/S1097-2765(04)00237-0; Lee Y, 1999, J BIOL CHEM, V274, P19792, DOI 10.1074/jbc.274.28.19792; Lee YJ, 1997, BLOOD, V89, P4480, DOI 10.1182/blood.V89.12.4480; Midwinter RG, 2004, J BIOL CHEM, V279, P32205, DOI 10.1074/jbc.M402070200; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Ogino T, 1997, FREE RADICAL BIO MED, V23, P445, DOI 10.1016/S0891-5849(97)00115-9; PARK E, 1993, J LEUKOCYTE BIOL, V54, P119, DOI 10.1002/jlb.54.2.119; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; Peskin AV, 2004, FREE RADICAL BIO MED, V37, P1622, DOI 10.1016/j.freeradbiomed.2004.08.010; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Pullar JM, 2000, IUBMB LIFE, V50, P259, DOI 10.1080/15216540051080958; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Schuller-Levis GB, 2004, NEUROCHEM RES, V29, P117, DOI 10.1023/B:NERE.0000010440.37629.17; Schuller-Levis GB, 2003, FEMS MICROBIOL LETT, V226, P195, DOI 10.1016/S0378-1097(03)00611-6; Shacter E, 2000, BLOOD, V96, P307, DOI 10.1182/blood.V96.1.307.013k47_307_313; Shacter E, 2002, ONCOLOGY-NY, V16, P217; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1985, J BIOL CHEM, V260, P3321; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wagner BA, 2002, ARCH BIOCHEM BIOPHYS, V401, P223, DOI 10.1016/S0003-9861(02)00053-X; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652	48	57	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21346	21352		10.1074/jbc.M501170200	http://dx.doi.org/10.1074/jbc.M501170200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799967	hybrid			2022-12-27	WOS:000229438800053
J	Kreiling, JL; Byrd, JC; MacDonald, RG				Kreiling, JL; Byrd, JC; MacDonald, RG			Domain interactions of the mannose 6-phosphate/insulin-like growth factor II receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II/MANNOSE 6-PHOSPHATE RECEPTOR; LIGAND-BINDING; CARBOHYDRATE-RECOGNITION; TRANSFORMING GROWTH-FACTOR-BETA-1; EXTRACYTOPLASMIC REGION; UROKINASE RECEPTOR; FULL-LENGTH; SITE; LOCALIZATION; IDENTIFICATION	The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) forms oligomeric structures important for optimal function in binding and internalization of Man-6-P-bearing extracellular ligands as well as lysosomal biogenesis and growth regulation. However, neither the mechanism of inter-receptor interaction nor the dimerization domain has yet been identified. We hypothesized that areas near the ligand binding domains of the receptor would contribute preferentially to oligomerization. Two panels of minireceptors were constructed that involved truncations of either the N- or C-terminal regions of the M6P/IGF2R encompassing deletions of various ligand binding domains. alpha-FLAG or alpha-Myc-based immunoprecipitation assays showed that all of the minireceptors tested were able to associate with a full-length, Myc-tagged M6P/IGF2R (WT-M). In the alpha-FLAG but not alpha-Myc immunoprecipitation assays, the degree of association of a series of C- terminally truncated minireceptors with WT-M showed a positive trend with length of the minireceptor. In contrast, length did not seem to affect the association of the N- terminally truncated minireceptors with WT-M, except that the 12th extracytoplasmic repeat appeared exceptionally important in dimerization in the alpha-FLAG assays. The presence of mutations in the ligand-binding sites of the minireceptors had no effect on their ability to associate with WT-M. Thus, association within the heterodimers was not dependent on the presence of functional ligand binding domains. Heterodimers formed between WT-M and the minireceptors demonstrated high affinity IGF-II and Man-6-P-ligand binding, suggesting a functional association. We conclude that there is no finite M6P/IGF2R dimerization domain, but rather that interactions between dimer partners occur all along the extracytoplasmic region of the receptor.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	MacDonald, RG (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.	rgmacdon@unmc.edu			NATIONAL CANCER INSTITUTE [R01CA091885] Funding Source: NIH RePORTER; NCI NIH HHS [5R01CA91885] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Braulke T, 1999, HORM METAB RES, V31, P242, DOI 10.1055/s-2007-978725; Brown J, 2002, EMBO J, V21, P1054, DOI 10.1093/emboj/21.5.1054; Byrd JC, 2000, J BIOL CHEM, V275, P18638, DOI 10.1074/jbc.M000010200; Byrd JC, 1999, J BIOL CHEM, V274, P24408, DOI 10.1074/jbc.274.34.24408; Byrd JC, 2000, J BIOL CHEM, V275, P18647, DOI 10.1074/jbc.M001273200; Dahms NM, 1996, BIOCHEM SOC T, V24, P136, DOI 10.1042/bst0240136; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; Dahms NM, 2002, BBA-GEN SUBJECTS, V1572, P317, DOI 10.1016/S0304-4165(02)00317-3; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; Devi GR, 1998, MOL ENDOCRINOL, V12, P1661, DOI 10.1210/me.12.11.1661; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Garmroudi F, 1996, MOL ENDOCRINOL, V10, P642, DOI 10.1210/me.10.6.642; GARMROUDI F, 1994, J BIOL CHEM, V269, P26944; Ghahary A, 1999, J CELL PHYSIOL, V180, P61, DOI 10.1002/(SICI)1097-4652(199907)180:1<61::AID-JCP7>3.0.CO;2-R; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; Groskopf JC, 1997, ENDOCRINOLOGY, V138, P2835, DOI 10.1210/en.138.7.2835; Hancock MK, 2002, J BIOL CHEM, V277, P47205, DOI 10.1074/jbc.M208534200; Hancock MK, 2002, J BIOL CHEM, V277, P11255, DOI 10.1074/jbc.M109855200; Hassan AB, 2003, AM J PATHOL, V162, P3, DOI 10.1016/S0002-9440(10)63791-1; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Kreiling JL, 2003, J BIOL CHEM, V278, P20628, DOI 10.1074/jbc.M302249200; Leksa V, 2002, J BIOL CHEM, V277, P40575, DOI 10.1074/jbc.M207979200; Linnell J, 2001, J BIOL CHEM, V276, P23986, DOI 10.1074/jbc.M100700200; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MACDONALD RG, 1989, J BIOL CHEM, V264, P3256; Marron-Terada PG, 2000, BIOCHEMISTRY-US, V39, P2243, DOI 10.1021/bi992226o; Marron-Terada PG, 1998, J BIOL CHEM, V273, P22358, DOI 10.1074/jbc.273.35.22358; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; Olson LJ, 1999, J BIOL CHEM, V274, P29889, DOI 10.1074/jbc.274.42.29889; Olson LJ, 2004, J BIOL CHEM, V279, P34000, DOI 10.1074/jbc.M404588200; Olson LJ, 2004, EMBO J, V23, P2019, DOI 10.1038/sj.emboj.7600215; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERDUE JF, 1983, J BIOL CHEM, V258, P7800; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; Reddy ST, 2004, J BIOL CHEM, V279, P38658, DOI 10.1074/jbc.M407474200; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; TONG PY, 1989, J BIOL CHEM, V264, P7962; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; York SJ, 1999, J BIOL CHEM, V274, P1164, DOI 10.1074/jbc.274.2.1164	48	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21067	21077		10.1074/jbc.M412971200	http://dx.doi.org/10.1074/jbc.M412971200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799974	hybrid			2022-12-27	WOS:000229438800022
J	Frescas, D; Valenti, L; Accili, D				Frescas, D; Valenti, L; Accili, D			Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN ACTION; CELL-SURVIVAL; FAMILY-MEMBER; FACTOR AFX; LIFE-SPAN; PHOSPHORYLATION; KINASE; FKHR; P53; RESTRICTION	Activation of NAD-dependent deacetylases, or Sirtuins, prolongs life span and mimics the effects of caloric restriction in yeast. The FoxO subfamily of forkhead transcription factors has been shown to mediate some of the effects of Sirtuins. Here we have shown that Sirtuin activation or hydrogen peroxide treatment overrides the phosphorylation-dependent nuclear exclusion of FoxO1 caused by growth factors and causes nuclear translocation of FoxO1 in hepatocytes. Kinetic measurements of nuclear fluorescence recovery after photo-bleaching show that FoxO1 is readily diffusible within the nucleus under normal conditions but becomes restricted within a nuclear subdomain following treatment with the prototypical Sirtuin agonist resveratrol or oxidative stress. Expression of FoxO1 target genes is accordingly increased, leading to activation of gluconeogenesis and increased glucose release from hepatocytes. Selective modulation of the FoxO/Sirtuin interaction represents a promising therapeutic modality for metabolic disorders.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University	Accili, D (corresponding author), 1150 St Nicholas Ave, New York, NY 10032 USA.	da230@columbia.edu	Valenti, Luca/B-3695-2009	Valenti, Luca/0000-0001-8909-0345	NIDDK NIH HHS [DK57539, DK63608] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK063608, R01DK057539] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Fukuoka M, 2003, INT J MOL MED, V12, P503; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lippincott-Schwartz J, 2003, NAT CELL BIOL, pS7, DOI 10.1038/ncb1032; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789	38	423	446	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20589	20595		10.1074/jbc.M412357200	http://dx.doi.org/10.1074/jbc.M412357200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788402	hybrid			2022-12-27	WOS:000229242000054
J	McCullough, LD; Zeng, ZY; Li, H; Landree, LE; McFadden, J; Ronnett, GV				McCullough, LD; Zeng, ZY; Li, H; Landree, LE; McFadden, J; Ronnett, GV			Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SYNTHASE INHIBITOR; FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE; CELL-DEATH; GLUCOSE-TRANSPORT; NEURONAL-ACTIVITY; GENE-EXPRESSION; AICA RIBOSIDE; FOOD-INTAKE; APOPTOSIS	The restoration of energy balance during ischemia is critical to cellular survival; however, relatively little is known concerning the regulation of neuronal metabolic pathways in response to central nervous system ischemia. AMP-activated protein kinase ( AMPK), a master sensor of energy balance in peripheral tissues, is phosphorylated and activated when energy balance is low. We investigated whether AMPK might also modulate neuronal energy homeostasis during ischemia. We utilized two model systems of ischemia, middle cerebral artery occlusion in vivo and oxygen-glucose deprivation in vitro, to delineate changes in AMPK activity incurred from a metabolic stress. AMPK is highly expressed in cortical and hippocampal neurons under both normal and ischemic conditions. AMPK activity, as assessed by phosphorylation status, is increased following both middle cerebral artery occlusion and oxygen-glucose deprivation. Pharmacological inhibition of AMPK by either C75, a known modulator of neuronal ATP levels, or compound C reduced stroke damage. In contrast, activation of AMPK by 5-aminoimidazole-4-carboxamide ribonucleoside exacerbated damage. Mice deficient in neuronal nitric-oxide synthase demonstrated a decrease in both stroke damage and AMPK activation compared with wild type, suggesting a possible interaction between NO and AMPK activation in stroke. These data demonstrate a role for AMPK in the response of neurons during metabolic stress and suggest that in ischemia the activation of AMPK is deleterious. The ability to manipulate pharmacologically neuronal energy balance during ischemia represents an innovative approach to neuroprotection.	Univ Connecticut, Ctr Hlth, Dept Neurol & Neurosci, Farmington, CT 06030 USA; FASgen Inc, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA	University of Connecticut; Johns Hopkins University; Johns Hopkins University	McCullough, LD (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurol & Neurosci, 263 Farmington Ave, Farmington, CT 06030 USA.	lmcculllough@uchc.edu; gronnett@jhmi.edu	McCullough, Louise/R-2824-2019					Almeida A, 2001, P NATL ACAD SCI USA, V98, P15294, DOI 10.1073/pnas.261560998; Almeida A, 2004, NAT CELL BIOL, V6, P45, DOI 10.1038/ncb1080; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; Blazquez C, 2001, FEBS LETT, V489, P149, DOI 10.1016/S0014-5793(01)02089-0; Blazquez C, 1999, J NEUROCHEM, V73, P1674, DOI 10.1046/j.1471-4159.1999.731674.x; Bolanos Juan P., 2004, Molecular Aspects of Medicine, V25, P61, DOI 10.1016/j.mam.2004.02.009; Bouzier-Sore AK, 2002, J PHYSIOL-PARIS, V96, P273, DOI 10.1016/S0928-4257(02)00016-5; Brorson JR, 1999, J NEUROSCI, V19, P147, DOI 10.1523/JNEUROSCI.19-01-00147.1999; Brucklacher RM, 2002, DEV NEUROSCI-BASEL, V24, P411, DOI 10.1159/000069051; Carling D, 2004, CURR BIOL, V14, pR220, DOI 10.1016/j.cub.2004.02.048; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Choi SL, 2001, BIOCHEM BIOPH RES CO, V287, P92, DOI 10.1006/bbrc.2001.5544; CLOUGHHELFMAN C, 1990, BRAIN RES BULL, V25, P203, DOI 10.1016/0361-9230(90)90277-7; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Cox SE, 1997, BIOCHEM SOC T, V25, pS583, DOI 10.1042/bst025s583; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Fryer LGD, 2000, DIABETES, V49, P1978, DOI 10.2337/diabetes.49.12.1978; Gadalla AE, 2004, J NEUROCHEM, V88, P1272, DOI 10.1046/j.1471-4159.2003.02253.x; Gao S, 2003, P NATL ACAD SCI USA, V100, P5628, DOI 10.1073/pnas.1031698100; Garcia-Gil M, 2003, NEUROSCIENCE, V117, P811, DOI 10.1016/S0306-4522(02)00836-9; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Hardie DG, 2002, BIOCHEM SOC T, V30, P1064, DOI 10.1042/BST0301064; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Jung JE, 2004, NEUROSCI LETT, V354, P197, DOI 10.1016/j.neulet.2003.10.012; Kefas BA, 2003, J MOL ENDOCRINOL, V30, P151, DOI 10.1677/jme.0.0300151; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kim EK, 2004, J BIOL CHEM, V279, P19970, DOI 10.1074/jbc.M402165200; Kim MS, 2004, NAT MED, V10, P727, DOI 10.1038/nm1061; KINGMA JG, 1994, CARDIOVASC RES, V28, P1003, DOI 10.1093/cvr/28.7.1003; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Kury P, 2004, EUR J NEUROSCI, V19, P1708, DOI 10.1111/j.1460-9568.2004.03226.x; Landree LE, 2004, J BIOL CHEM, V279, P3817, DOI 10.1074/jbc.M310991200; Lee M, 2003, J BIOL CHEM, V278, P39653, DOI 10.1074/jbc.M306104200; Leon H, 2004, CAN J PHYSIOL PHARM, V82, P409, DOI 10.1139/Y04-050; Love S, 2003, PROG NEURO-PSYCHOPH, V27, P267, DOI 10.1016/S0278-5846(03)00022-8; Luo HR, 2003, P NATL ACAD SCI USA, V100, P11712, DOI 10.1073/pnas.1634990100; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Marsin AS, 2002, J BIOL CHEM, V277, P30778, DOI 10.1074/jbc.M205213200; McCullough L, 2004, J NEUROSCI, V24, P257, DOI 10.1523/JNEUROSCI.4485-03.2004; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; McCullough LD, 2005, J CEREBR BLOOD F MET, V25, P502, DOI 10.1038/sj.jcbfm.9600059; Meisse D, 2002, FEBS LETT, V526, P38, DOI 10.1016/S0014-5793(02)03110-1; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Morrow VA, 2003, J BIOL CHEM, V278, P31629, DOI 10.1074/jbc.M212831200; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Nicotera P, 1998, TOXICOL LETT, V103, P139; OBRIEN MD, 1974, ARCH NEUROL-CHICAGO, V30, P456, DOI 10.1001/archneur.1974.00490360032007; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Snider BJ, 1999, ANN NY ACAD SCI, V893, P243, DOI 10.1111/j.1749-6632.1999.tb07829.x; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo C, 1996, BRAIN RES BULL, V41, P131, DOI 10.1016/S0361-9230(96)00159-1; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Toung TJK, 2002, CRIT CARE MED, V30, P644, DOI 10.1097/00003246-200203000-00025; Turnley AM, 1999, J NEUROCHEM, V72, P1707, DOI 10.1046/j.1471-4159.1999.721707.x; Virag L, 2003, TOXICOL LETT, V140, P113, DOI 10.1016/S0378-4274(02)00508-8; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; WOJTASZEWSKI JF, 2003, AM J PHYSIOL, V284, pC813; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 2003, J BIOL CHEM, V278, P28434, DOI 10.1074/jbc.M303946200; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zhou M, 2000, AM J PHYSIOL-ENDOC M, V279, pE622, DOI 10.1152/ajpendo.2000.279.3.E622; Zou MH, 2004, J BIOL CHEM, V279, P43940, DOI 10.1074/jbc.M404421200; Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442; Zou MH, 2002, J BIOL CHEM, V277, P32552, DOI 10.1074/jbc.M204512200	81	285	306	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20493	20502		10.1074/jbc.M409985200	http://dx.doi.org/10.1074/jbc.M409985200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15772080	hybrid			2022-12-27	WOS:000229242000042
J	Schumacher, M; Mizuno, K; Bachinger, HP				Schumacher, M; Mizuno, K; Bachinger, HP			The crystal structure of the collagen-like polypeptide (Glycyl-4(R)-hydroxyprolyl-4(R)-hydroxyprolyl)(9) at 1.55 angstrom resolution shows up-puckering of the proline ring in the Xaa position	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYLATION-INDUCED STABILIZATION; TRIPLE-HELIX; MODEL PEPTIDES; MOLECULAR-STRUCTURE; REPEATING SEQUENCE; X-RAY; STABILITY; NMR; 4-HYDROXYPROLINE; HYDROXYPROLINE	The collagen triple helix is characterized by the repeating sequence motif Gly-Xaa-Yaa, where Xaa and Yaa are typically proline and (2S, 4R)-4-hydroxyproline (4(R)Hyp), respectively. Previous analyses have revealed that H-(Pro-4(R)Hyp-Gly)(10)-OH forms a stable triple helix, whereas H-(4(R)Hyp-Pro-Gly)(10)-OH does not. Several theories have been put forth to explain the importance of proline puckering and conformation in triple helix formation; however, the details of how they affect triple helix stability are unknown. Underscoring this, we recently demonstrated that the polypeptide Ac(Gly-4(R)Hyp-4(R)Hyp)(10)-NH2 forms a triple helix that is more stable than Ac-(Gly-Pro-4(R)Hyp)(10)-NH2. Here we report the crystal structure of the H-(Gly-4(R)Hyp4(R)Hyp)(9)-OH peptide at 1.55 angstrom resolution. The puckering of the Yaa position 4(R)Hyp in this structure is up (C gamma exo), as has been found in other collagen peptide structures. Notably, however, the 4(R)Hyp in the Xaa position also takes the up pucker, which is distinct from all other collagen structures. Regardless of the notable difference in the Xaa proline puckering, our structure still adopts a 7/2 superhelical symmetry similar to that observed in other collagen structures. Thus, the basis for the observed differences in the thermodynamic data of the triple helix <-> coil transition between our peptide and other triple helical peptides likely results from contributions from the unfolded state. Indeed, the unfolded state of the H-(Gly-4(R)Hyp-4(R)Hyp)(9)-OH peptide seems to be stabilized by a preformed polyproline II helix in each strand, which could be explained by the presence of a unique repeating intra-strand water-mediated bridge observed in the H-(Gly-4(R)Hyp-4(R)Hyp)(9)-OH structure, as well as a higher amount of trans peptide bonds.	Shriners Hosp Children, Res Dept, Portland, OR 97239 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Bachinger, HP (corresponding author), Shriners Hosp Children, Res Dept, 3101 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	hpb@shcc.org	Mizuno, Kazunori/AAY-7613-2021	Mizuno, Kazunori/0000-0003-3354-6264				Bann JG, 2000, J BIOL CHEM, V275, P24466, DOI 10.1074/jbc.M003336200; BELLA J, 1995, STRUCTURE, V3, P893, DOI 10.1016/S0969-2126(01)00224-6; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Berisio R, 2002, PROTEIN SCI, V11, P262, DOI 10.1110/ps.32602; BRAHMACHARI SK, 1979, MACROMOLECULES, V12, P23, DOI 10.1021/ma60067a006; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; DeRider ML, 2002, J AM CHEM SOC, V124, P2497, DOI 10.1021/ja0166904; Engel J, 1998, MATRIX BIOL, V17, P679, DOI 10.1016/S0945-053X(98)90119-6; Fields GB, 1996, BIOPOLYMERS, V40, P345, DOI 10.1002/(SICI)1097-0282(1996)40:4<345::AID-BIP1>3.0.CO;2-W; FRASER RDB, 1979, J MOL BIOL, V129, P463, DOI 10.1016/0022-2836(79)90507-2; GAILL F, 1995, J MOL BIOL, V246, P284, DOI 10.1006/jmbi.1994.0084; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; Holmgren SK, 1998, NATURE, V392, P666, DOI 10.1038/33573; Hongo C, 2001, POLYM J, V33, P812; Improta R, 2002, J AM CHEM SOC, V124, P7857, DOI 10.1021/ja020187p; Improta R, 2001, J AM CHEM SOC, V123, P12568, DOI 10.1021/ja010599i; INOUYE K, 1976, BIOCHIM BIOPHYS ACTA, V420, P133, DOI 10.1016/0005-2795(76)90352-4; INOUYE K, 1982, ARCH BIOCHEM BIOPHYS, V219, P198, DOI 10.1016/0003-9861(82)90149-7; Jenkins CL, 2002, NAT PROD REP, V19, P49, DOI 10.1039/a903001h; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kivirikko KI, 1998, MATRIX BIOL, V16, P355, DOI 10.1016/S0945-053X(98)90008-7; Kramer RZ, 2000, J MOL BIOL, V301, P1191, DOI 10.1006/jmbi.2000.4017; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Kramer RZ, 1998, J MOL BIOL, V280, P623, DOI 10.1006/jmbi.1998.1881; Kramer RZ, 2001, J MOL BIOL, V311, P131, DOI 10.1006/jmbi.2001.4849; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; LESLI AGW, 1992, JOINT CCP4 ESF EAMCB; LI MH, 1993, BIOCHEMISTRY-US, V32, P7377, DOI 10.1021/bi00080a007; Mann K, 1996, J MOL BIOL, V261, P255, DOI 10.1006/jmbi.1996.0457; Mayo KH, 1996, BIOPOLYMERS, V40, P359, DOI 10.1002/(SICI)1097-0282(1996)40:4<359::AID-BIP2>3.0.CO;2-V; Mizuno K, 2004, J BIOL CHEM, V279, P38072, DOI 10.1074/jbc.M402953200; Mizuno K, 2004, J BIOL CHEM, V279, P282, DOI 10.1074/jbc.M308181200; Mizuno K, 2003, J BIOL CHEM, V278, P32373, DOI 10.1074/jbc.M304741200; Mogilner IG, 2002, J MOL GRAPH MODEL, V21, P209, DOI 10.1016/S1093-3263(02)00145-6; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nagarajan V, 1998, J BIOCHEM-TOKYO, V124, P1117, DOI 10.1093/oxfordjournals.jbchem.a022229; Nagarajan V, 1999, J BIOCHEM-TOKYO, V125, P310, DOI 10.1093/oxfordjournals.jbchem.a022288; Okuyama K, 2004, BIOPOLYMERS, V76, P367, DOI 10.1002/bip.20107; OKUYAMA K, 1981, J MOL BIOL, V152, P427, DOI 10.1016/0022-2836(81)90252-7; PANASIK N, 1994, INT J PEPT PROT RES, V44, P262; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Vitagliano L, 2001, BIOPOLYMERS, V58, P459, DOI 10.1002/1097-0282(20010415)58:5<459::AID-BIP1021>3.0.CO;2-V	46	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20397	20403		10.1074/jbc.M501453200	http://dx.doi.org/10.1074/jbc.M501453200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15784619	hybrid			2022-12-27	WOS:000229242000031
J	Spolitak, T; Dawson, JH; Ballou, DP				Spolitak, T; Dawson, JH; Ballou, DP			Reaction of ferric cytochrome P450cam with peracids - Kinetic characterization of intermediates on the reaction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; COMPOUND-I FORMATION; TYROSYL RADICAL FORMATION; C PEROXIDASE; HORSERADISH-PEROXIDASE; MYCOBACTERIUM-TUBERCULOSIS; CATALASE-PEROXIDASE; HYDROGEN-PEROXIDE; WILD-TYPE; MULTIFREQUENCY EPR	Reactions of substrate-free ferric cytochrome P450cam with peracids to generate Fe = O intermediates have previously been investigated with contradictory results. Using stopped-flow spectrophotometry, the reaction with m-chloroperoxybenzoic acid demonstrated an Fe-IV = O + porphyrin pi-cation radical (Cpd I) (Egawa, T., Shimada, H., and Ishimura, Y. ( 1994) Biochem. Biophys. Res. Commun. 201, 1464-1469). By contrast, with peracetic acid, Fe-IV = O plus a tyrosyl radical were observed by freeze-quench Mossbauer and EPR spectroscopy (Schunemann, V., Jung, C., Trautwein, A. X., Mandon, D., and Weiss, R. ( 2000) FEBS Lett. 479, 149-154). Our detailed kinetic studies have resolved these contradictory results. At pH > 7, a significant fraction of Cpd I is formed transiently, whereas at low pH only a species with a Soret band at 406 nm, presumably Fe-IV = O + tyrosyl radical, is observed. Evidence for formation of an acylperoxo complex en route to Cpd I was obtained. Because of rapid heme destruction, steps subsequent to formation of the highly oxidized forms could not be fully characterized. Heme destruction was avoided by including peroxidase substrates ( e. g. guaiacol), which were oxidized to characteristic peroxidase products as the Fe-III-P450 was regenerated. Addition of ascorbate to either of the high valent species also reforms the FeIII state with only a small loss of heme absorbance. These results indicate that typical peroxidase chemistry occurs with P450cam and offer an explanation for the contrasting results reported earlier. The delineation of improved conditions (pH, temperature, choice of peracid) for generating highly oxidized species with P450cam should be valuable for their further characterization.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; Univ S Carolina, Sch Med, Columbia, SC 29208 USA	University of Michigan System; University of Michigan; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Dawson, JH (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.	dawson@sc.edu	dballou@umich.edu, David P/A-1298-2007; Dawson, John/HDM-6702-2022	Dawson, John H/0000-0002-4902-4295	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026730, R37GM020877, R01GM020877] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26730, GM20877] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENECKY MJ, 1993, BIOCHEMISTRY-US, V32, P11929, DOI 10.1021/bi00095a024; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; Bonagura CA, 2003, BIOCHEMISTRY-US, V42, P5600, DOI 10.1021/bi034058c; BRUICE TC, 1983, J CHEM SOC CHEM COMM, P14, DOI 10.1039/c39830000014; Chouchane S, 2000, BIOCHEMISTRY-US, V39, P9975, DOI 10.1021/bi0005815; Chouchane S, 2002, J BIOL CHEM, V277, P42633, DOI 10.1074/jbc.M207916200; COTTON ML, 1973, CAN J BIOCHEM CELL B, V51, P627, DOI 10.1139/o73-078; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; Dorlet P, 2002, BIOCHEMISTRY-US, V41, P6107, DOI 10.1021/bi015871f; Dunford H. B., 1999, HEME PEROXIDASES; EGAWA T, 1991, J BIOL CHEM, V266, P10246; EGAWA T, 1994, BIOCHEM BIOPH RES CO, V201, P1464, DOI 10.1006/bbrc.1994.1868; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; Erman JE, 2002, BBA-PROTEIN STRUCT M, V1597, P193, DOI 10.1016/S0167-4838(02)00317-5; FISHEL LA, 1991, BIOCHEMISTRY-US, V30, P1986, DOI 10.1021/bi00221a036; Goodin DB, 1996, J BIOL INORG CHEM, V1, P360, DOI 10.1007/s007750050065; Green MT, 2004, SCIENCE, V304, P1653, DOI 10.1126/science.1096897; Groves JT, 2003, P NATL ACAD SCI USA, V100, P3569, DOI 10.1073/pnas.0830019100; GROVES JT, 1988, J AM CHEM SOC, V110, P8443, DOI 10.1021/ja00233a021; Gunther MR, 2000, FREE RADICAL BIO MED, V28, P709, DOI 10.1016/S0891-5849(00)00164-7; Harris D, 2001, J INORG BIOCHEM, V83, P309, DOI 10.1016/S0162-0134(00)00177-X; Hersleth HP, 2002, J BIOL INORG CHEM, V7, P299, DOI 10.1007/s007750100296; HORI H, 1985, J BIOL CHEM, V260, P349; HOUSEMAN ALP, 1993, BIOCHEMISTRY-US, V32, P4430, DOI 10.1021/bi00067a036; HUYETT JE, 1995, J AM CHEM SOC, V117, P9033, DOI 10.1021/ja00140a021; Isaac IS, 1999, ESSAYS BIOCHEM, V34, P51, DOI 10.1042/bse0340051; Ivancich A, 2001, BIOCHEMISTRY-US, V40, P6860, DOI 10.1021/bi002826j; Ivancich A, 2003, J AM CHEM SOC, V125, P14093, DOI 10.1021/ja035582+; Ivancich A, 1997, BIOCHEMISTRY-US, V36, P9356, DOI 10.1021/bi970886s; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; Kellner DG, 2002, J BIOL CHEM, V277, P9641, DOI 10.1074/jbc.C100745200; LANG G, 1976, BIOCHIM BIOPHYS ACTA, V451, P250, DOI 10.1016/0304-4165(76)90275-0; Liu A, 1998, BIOCHEMISTRY-US, V37, P16369, DOI 10.1021/bi981471p; MILLER VP, 1995, J BIOL CHEM, V270, P18413, DOI 10.1074/jbc.270.31.18413; Palamakumbura AH, 1999, BIOCHEMISTRY-US, V38, P15647, DOI 10.1021/bi991497w; PALCIC MM, 1980, BIOCHEM BIOPH RES CO, V94, P1123, DOI 10.1016/0006-291X(80)90535-5; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4342, DOI 10.1021/bi00013a024; Pfister TD, 2001, BIOCHEMISTRY-US, V40, P14942, DOI 10.1021/bi011400h; Pond AE, 1998, INORG CHIM ACTA, V276, P250; Prasad S, 2004, BIOCHEM BIOPH RES CO, V314, P610, DOI 10.1016/j.bbrc.2003.12.141; Rodriguez-Lopez JN, 2000, BIOCHEMISTRY-US, V39, P13201, DOI 10.1021/bi001150p; RodriguezLopez JN, 1997, J BIOL CHEM, V272, P5469, DOI 10.1074/jbc.272.9.5469; ROE JA, 1993, J BIOL CHEM, V268, P20037; SCHULZ CE, 1984, BIOCHEMISTRY-US, V23, P4743, DOI 10.1021/bi00315a033; Schunemann V, 2002, J INORG BIOCHEM, V91, P586, DOI 10.1016/S0162-0134(02)00476-2; Schunemann V, 2000, FEBS LETT, V479, P149, DOI 10.1016/S0014-5793(00)01886-X; Schunemann V, 2004, J BIOL CHEM, V279, P10919, DOI 10.1074/jbc.M307884200; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SLIGAR SG, 1999, ESSAYS BIOCHEM, P71; SLIGAR SG, 1977, MICROSOMES DRUG OXID; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; Tsaprailis G., 1995, ADV INORG CHEM, V43, P79; vanDeurzen MPJ, 1997, TETRAHEDRON, V53, P13183, DOI 10.1016/S0040-4020(97)00477-8; VITELLO LB, 1990, BIOCHIM BIOPHYS ACTA, V1038, P90, DOI 10.1016/0167-4838(90)90015-8; WAGNER GC, 1983, FEBS LETT, V156, P244, DOI 10.1016/0014-5793(83)80505-5; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; Zhao XB, 2004, J BIOL CHEM, V279, P7606, DOI 10.1074/jbc.M311884200	60	106	106	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20300	20309		10.1074/jbc.M501761200	http://dx.doi.org/10.1074/jbc.M501761200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781454	hybrid			2022-12-27	WOS:000229242000019
J	Kaplan-Albuquerque, N; Bogaert, YE; Van Putten, V; Weiser-Evans, MC; Nemenoff, RA				Kaplan-Albuquerque, N; Bogaert, YE; Van Putten, V; Weiser-Evans, MC; Nemenoff, RA			Patterns of gene expression differentially regulated by platelet-derived growth factor and hypertrophic stimuli in vascular smooth muscle cells - Markers for phenotypic modulation and response to injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE-VASOPRESSIN; ALPHA-ACTIN; EXTRACELLULAR-MATRIX; ANGIOTENSIN-II; PROTEOGLYCANS; LOCALIZATION; MECHANISM; COLLAGEN; UNIQUE; PDGF	In vascular smooth muscle cells (VSMC), platelet-derived growth factor ( PDGF) suppresses expression of multiple smooth muscle contractile proteins, useful markers of differentiation. Conversely, hypertrophic agents induce expression of these genes. The goal of this study was to employ genomic approaches to identify classes of genes differentially regulated by PDGF and hypertrophic stimuli. Changes in gene expression were determined using Affymetrix RAE-230 GeneChips in rat aortic VSMC stimulated with PDGF. For comparison with a model hypertrophic stimulus, a microarray was performed with VSMC stably expressing constitutively active G alpha(16), which strongly induces smooth muscle marker expression. We identified 75 genes whose expression was increased by exposure to PDGF and decreased by expression of G alpha(16) and 97 genes whose expression was decreased by PDGF and increased by G alpha(16). These genes included many smooth muscle-specific proteins; several extracellular matrix, cytoskeletal, and chemotaxis-related proteins; cell signaling molecules; and transcription factors. Changes in gene expression for many of these were confirmed by PCR or immuno-blotting. The contribution of signaling pathways activated by PDGF to the gene expression profile was examined in VSMC stably expressing gain-of-function H-Ras or myristoylated Akt. Among the genes that were confirmed to be differentially regulated were CCAAT/enhancer-binding protein delta, versican, and nexilin. All of these genes also had altered expression in injured aortas, consistent with a role for PDGF in the response of injured VSMC. These data indicate that genes that are differentially regulated by PDGF and hypertrophic stimuli may represent families of genes and potentially be biomarkers for vascular injury.	Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nemenoff, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Med, 4200 E 9th Ave,Box C-281, Denver, CO 80262 USA.	Raphael.Nemenoff@UCHSC.edu			NCI NIH HHS [CA103618] Funding Source: Medline; NIDDK NIH HHS [DK 19928] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA103618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams LD, 2000, CIRC RES, V87, P623, DOI 10.1161/01.RES.87.7.623; Akai J, 2002, MECH DEVELOP, V119, pS191, DOI 10.1016/S0925-4773(03)00115-1; Arai A, 2002, J BIOL CHEM, V277, P24453, DOI 10.1074/jbc.M202216200; Barber RE, 1996, BIOCHEM J, V320, P479, DOI 10.1042/bj3200479; Campos AH, 2003, CIRC RES, V92, P111, DOI 10.1161/01.RES.0000049100.22673.F6; CARAMELO C, 1988, BIOCHEM J, V254, P625, DOI 10.1042/bj2540625; Cen B, 2004, J CELL BIOCHEM, V93, P74, DOI 10.1002/jcb.20199; CHAMLEYCAMPBELL JH, 1981, ATHEROSCLEROSIS, V40, P347, DOI 10.1016/0021-9150(81)90145-3; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Evanko SP, 1999, J HISTOCHEM CYTOCHEM, V47, P1331, DOI 10.1177/002215549904701013; Franco CD, 2002, TRENDS CARDIOVAS MED, V12, P143, DOI 10.1016/S1050-1738(01)00165-7; Garat C, 2000, J BIOL CHEM, V275, P22537, DOI 10.1074/jbc.M003000200; Geary RL, 2002, ARTERIOSCL THROM VAS, V22, P2010, DOI 10.1161/01.ATV.0000038147.93527.35; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GEISTERFER AAT, 1989, HYPERTENSION, V14, P413, DOI 10.1161/01.HYP.14.4.413; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; Grabe Niels, 2002, In Silico Biology, V2, pS1; Han SY, 2002, J BIOL CHEM, V277, P47167, DOI 10.1074/jbc.M204270200; Higashita R, 1997, J BIOL CHEM, V272, P25845, DOI 10.1074/jbc.272.41.25845; Hou GP, 2002, CIRC RES, V90, P1147, DOI 10.1161/01.RES.0000022166.74073.F8; Kaplan-Albuquerque N, 2003, J BIOL CHEM, V278, P39830, DOI 10.1074/jbc.M305991200; Kaplan-Albuquerque N, 2003, AM J PHYSIOL-HEART C, V285, pH1444, DOI 10.1152/ajpheart.00306.2003; Kenagy RD, 2005, J HISTOCHEM CYTOCHEM, V53, P131, DOI 10.1369/jhc.4A6493.2005; KIELTY CM, 1985, BIOCHEM J, V227, P545, DOI 10.1042/bj2270545; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; Lee RT, 2001, J BIOL CHEM, V276, P13847, DOI 10.1074/jbc.M010556200; Li XM, 1997, BIOCHEM J, V327, P709, DOI 10.1042/bj3270709; Liu HW, 2003, AM J RESP CELL MOL, V29, P39, DOI 10.1165/rcmb.2002-0206OC; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Mourani PM, 2004, CIRCULATION, V109, P1299, DOI 10.1161/01.CIR.0000118462.22970.BE; Ohtsuka T, 1998, J CELL BIOL, V143, P1227, DOI 10.1083/jcb.143.5.1227; Owens GK, 1997, AGENT ACTION SUPPL, V48, P3; Owens GK, 1996, J HYPERTENS, V14, pS55; OWENS GK, 1991, ADV EXP MED BIOL, V308, P71; Owens GK, 1998, ACTA PHYSIOL SCAND, V164, P623, DOI 10.1111/j.1365-201X.1998.tb10706.x; OWENS GK, 1995, PHYSIOL REV, V75, P487; Psichari E, 2002, J BIOL CHEM, V277, P29490, DOI 10.1074/jbc.M112368200; Raines EW, 2004, CYTOKINE GROWTH F R, V15, P237, DOI 10.1016/j.cytogfr.2004.03.004; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; Sobue K, 1999, MOL CELL BIOCHEM, V190, P105, DOI 10.1023/A:1006941621170; Sobue K, 1998, HORM RES, V50, P15, DOI 10.1159/000053119; Treisman R, 1998, COLD SPRING HARB SYM, V63, P643, DOI 10.1101/sqb.1998.63.643; VANPUTTEN V, 1994, CIRC RES, V75, P1126, DOI 10.1161/01.RES.75.6.1126; Weissberg P L, 1995, Blood Press Suppl, V2, P68; Wight TN, 2004, CIRC RES, V94, P1158, DOI 10.1161/01.RES.0000126921.29919.51; Yang ZH, 2001, CIRC RES, V89, P503, DOI 10.1161/hh1801.096265	48	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19966	19976		10.1074/jbc.M500917200	http://dx.doi.org/10.1074/jbc.M500917200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774477	hybrid			2022-12-27	WOS:000229113700066
J	Merighi, S; Benini, A; Mirandola, P; Gessi, S; Varani, K; Leung, E; Maclennan, S; Borea, PA				Merighi, S; Benini, A; Mirandola, P; Gessi, S; Varani, K; Leung, E; Maclennan, S; Borea, PA			A(3) adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; PROTEIN-COUPLED RECEPTORS; COLON-CARCINOMA GROWTH; SMOOTH-MUSCLE-CELLS; BIOCHEMICAL-CHARACTERIZATION; PATHWAY; RAF; AKT; EXPRESSION; DIFFERENTIATION	Adenosine exerts its effects through four subtypes of G-protein-coupled receptors: A(1), A(2A), A(2B), and A(3). Stimulation of the human A(3) receptor has been suggested to influence cell death and proliferation. The phosphatidylinositide-3-OH kinase (PI3K)/Akt and the Raf/mitogen-activated protein kinase (MAPK/ERK) kinase (MEK)/mitogen-activated protein kinase (MAPK) pathways have central roles in the regulation of cell survival and proliferation. Due to their importance, the cross-talk between these two pathways has been investigated. Here, we show that the A(3) adenosine receptor agonist Cl-IB-MECA stimulates PI3K-dependent phosphorylation of Akt leading to the reduction of basal levels of ERK1/2 phosphorylation, which in turn inhibits cell proliferation. The response to Cl-IB-MECA was not blocked by A(1), A(2A), or A(2B) receptor antagonists, although it was abolished by A(3) receptor antagonists. Furthermore, the response to Cl-IB-MECA was generated at the cell surface, since the inhibition of A(3) receptor expression, by using small interfering RNA, abolished agonist effects. Using A375 cells, we show that A(3) adenosine receptor stimulation results in PI3K-dependent phosphorylation of Akt, leading to the reduction of basal levels of ERK1/2 phosphorylation, which in turn inhibits cell proliferation.	Univ Ferrara, Dept Clin & Expt Med, Pharmacol Unit, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Nazl Eccellenza Sviluppo Metodol Innovat Stud, I-44100 Ferrara, Italy; Univ Parma, Osped Maggiore, Inst Normal Human Anat, Dept Human Anat Pharmacol & Forens Med, I-43100 Parma, Italy; King Pharmaceut, Cary, NC 27513 USA	University of Ferrara; University of Ferrara; University of Parma; University Hospital of Parma; Pfizer	Borea, PA (corresponding author), Univ Ferrara, Dept Clin & Expt Med, Pharmacol Unit, 17-19 Via Fossato Mortara, I-44100 Ferrara, Italy.	bpa@dns.unife.it	Gessi, Stefania/AAS-3844-2020; Mirandola, Prisco/L-3137-2015	Mirandola, Prisco/0000-0002-5058-3924; Gessi, Stefania/0000-0002-2197-5611; MERIGHI, STEFANIA/0000-0003-0839-6671				Bar-Yehuda S, 2001, NEOPLASIA, V3, P125, DOI 10.1038/sj.neo.7900138; Baraldi PG, 2004, J MED CHEM, V47, P1434, DOI 10.1021/jm0309654; Begum N, 2000, AM J PHYSIOL-CELL PH, V278, pC81, DOI 10.1152/ajpcell.2000.278.1.C81; Brambilla R, 2000, N-S ARCH PHARMACOL, V361, P225, DOI 10.1007/s002109900186; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Feoktistov I, 2004, HYPERTENSION, V44, P649, DOI 10.1161/01.HYP.0000144800.21037.a5; Fishman P, 2000, J CELL PHYSIOL, V183, P393, DOI 10.1002/(SICI)1097-4652(200006)183:3<393::AID-JCP12>3.0.CO;2-G; Fishman P, 2004, ONCOGENE, V23, P2465, DOI 10.1038/sj.onc.1207355; Fishman P, 1998, CANCER RES, V58, P3181; Fishman P, 2002, ONCOGENE, V21, P4060, DOI 10.1038/sj.onc.1205531; Fishman P, 2001, EXP CELL RES, V269, P230, DOI 10.1006/excr.2001.5327; Fredholm BB, 2001, BIOCHEM PHARMACOL, V61, P443, DOI 10.1016/S0006-2952(00)00570-0; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Gao ZH, 2001, MOL PHARMACOL, V59, P76, DOI 10.1124/mol.59.1.76; Gessi S, 2004, CLIN CANCER RES, V10, P5895, DOI 10.1158/1078-0432.CCR-1134-03; Guan KL, 2000, J BIOL CHEM, V275, P27354; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Haberberger RV, 2002, J INVEST DERMATOL, V119, P943, DOI 10.1046/j.1523-1747.2002.00182.x; Hammarberg C, 2004, BIOCHEM PHARMACOL, V67, P129, DOI 10.1016/j.bcp.2003.08.031; Hammarberg C, 2003, J NEUROCHEM, V86, P1051, DOI 10.1046/j.1471-4159.2003.01919.x; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; Klotz KN, 1999, N-S ARCH PHARMACOL, V360, P103, DOI 10.1007/s002109900044; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Merighi S, 2003, PHARMACOL THERAPEUT, V100, P31, DOI 10.1016/S0163-7258(03)00084-6; Merighi S, 2003, DRUG DEVELOP RES, V58, P377, DOI 10.1002/ddr.10181; Merighi S, 2003, BIOCHEM PHARMACOL, V66, P739, DOI 10.1016/S0006-2952(03)00400-3; Merighi S, 2002, J INVEST DERMATOL, V119, P923, DOI 10.1046/j.1523-1747.2002.00111.x; Merighi S, 2001, BRIT J PHARMACOL, V134, P1215, DOI 10.1038/sj.bjp.0704352; Mirandola P, 2004, BLOOD, V104, P2418, DOI 10.1182/blood-2004-04-1294; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Ohana G, 2003, BRIT J CANCER, V89, P1552, DOI 10.1038/sj.bjc.6601315; Ohana G, 2001, J CELL PHYSIOL, V186, P19, DOI 10.1002/1097-4652(200101)186:1<19::AID-JCP1011>3.0.CO;2-3; Ralevic V, 1998, PHARMACOL REV, V50, P413; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Ruiz-Hidalgo MJ, 2002, EXP CELL RES, V274, P178, DOI 10.1006/excr.2001.5464; Schulte G, 2000, MOL PHARMACOL, V58, P477, DOI 10.1124/mol.58.3.477; Schulte G, 2003, CELL SIGNAL, V15, P813, DOI 10.1016/S0898-6568(03)00058-5; Schulte G, 2002, MOL PHARMACOL, V62, P1137, DOI 10.1124/mol.62.5.1137; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; Slominski A, 2002, J INVEST DERMATOL, V119, P1449, DOI 10.1046/j.1523-1747.2002.19617.x; Slominski A, 2002, J INVEST DERMATOL, V119, P934, DOI 10.1046/j.1523-1747.2002.00156.x; Varani K, 2000, MOL PHARMACOL, V57, P968; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	52	97	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19516	19526		10.1074/jbc.M413772200	http://dx.doi.org/10.1074/jbc.M413772200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774470	hybrid			2022-12-27	WOS:000229113700013
J	Prabhu, KS; Arner, RJ; Vunta, H; Reddy, CC				Prabhu, KS; Arner, RJ; Vunta, H; Reddy, CC			Up-regulation of human myo-inositol oxygenase by hyperosmotic stress in renal proximal tubular epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDOSE REDUCTASE INHIBITOR; D-GLUCURONATE REDUCTASE; BINDING PROTEIN; PERIPHERAL-NERVE; DIABETIC-RATS; INOSITOL; GENE; TRANSCRIPTION; PURIFICATION; GLUCOSE	myo-Inositol oxygenase (MIOX) catalyzes the oxidative cleavage of myo-inositol (MI) to give D-glucuronic acid, a committed step in MI catabolism. D-Glucuronic acid is further metabolized to xylitol via the glucuronate-xylulose pathway. Although accumulation of polyols such as xylitol and sorbitol is associated with MI depletion in diabetic complications, no causal relationship has been established. Therefore we are examining the role of MIOX in diabetic nephropathy. Here we present evidence that the basis for the depletion of MI in diabetes is likely to be mediated by the increased expression of MIOX, which is induced by sorbitol, mannitol, and xylitol in a porcine renal proximal tubular epithelial cell line, LLC-PK1. To understand the molecular mechanism of regulation of MIOX expression by polyols, we have cloned the human MIOX gene locus of 10 kb containing 5.6 kb of the 5' upstream sequence. Analysis of the 5' upstream sequence led to the identification of an osmotic response element (ORE) in the promoter region, which is present similar to 2 kb upstream of the translation start site. Based on luciferase reporter and electrophoretic mobility shift assays, polyols increased the ORE-dependent expression of MIOX. In addition, we demonstrate that the activity of the promoter is dependent on the binding of the transcription factor, tonicity element-binding protein, or osmotic response element-binding protein, to the ORE site. These results suggest that the expression of MIOX is up-regulated by a positive feedback mechanism where xylitol, one of the products of MI catabolism via the glucuronate-xylulose pathway, induces an overexpression of MIOX.	Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Reddy, CC (corresponding author), Penn State Univ, Dept Vet Sci, 115 William L Henning Bldg, University Pk, PA 16802 USA.	ccr1@psu.edu						Arner RJ, 2001, BIOCHEM J, V360, P313, DOI 10.1042/bj3600313; BertiMattera L, 1996, METABOLISM, V45, P320, DOI 10.1016/S0026-0495(96)90285-1; BHATNAGAR A, 1992, BIOCHEM MED METAB B, V48, P91, DOI 10.1016/0885-4505(92)90055-4; BURG MB, 1995, AM J PHYSIOL, V268, P983; CHARALAMPOUS FC, 1959, J BIOL CHEM, V234, P220; COHEN AM, 1995, DIABETOLOGIA, V38, P899; DELMONTE MA, 1991, DIABETES, V40, P1335, DOI 10.2337/diabetes.40.10.1335; Ferraris JD, 1999, AM J PHYSIOL-CELL PH, V276, pC667, DOI 10.1152/ajpcell.1999.276.3.C667; FINEGOLD D, 1983, DIABETES, V32, P988, DOI 10.2337/diabetes.32.11.988; GREENE DA, 1987, J CLIN INVEST, V79, P1479, DOI 10.1172/JCI112977; HANKES LV, 1969, ANN NY ACAD SCI, V165, P564; HOLUB BJ, 1986, ANNU REV NUTR, V6, P563, DOI 10.1146/annurev.nu.06.070186.003023; Hu E, 2000, AM J PHYSIOL-RENAL, V279, pF426, DOI 10.1152/ajprenal.2000.279.3.F426; Irarrazabal CE, 2004, P NATL ACAD SCI USA, V101, P8809, DOI 10.1073/pnas.0403062101; Ito T, 2004, BIOCHEM J, V382, P177, DOI 10.1042/BJ20031838; Kabashima T, 2003, P NATL ACAD SCI USA, V100, P5107, DOI 10.1073/pnas.0730817100; Ko BCB, 2000, BIOCHEM BIOPH RES CO, V270, P52, DOI 10.1006/bbrc.2000.2376; Ko BCB, 2002, J BIOL CHEM, V277, P46085, DOI 10.1074/jbc.M208138200; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; KOLLER F, 1979, H-S Z PHYSIOL CHEM, V360, P507, DOI 10.1515/bchm2.1979.360.1.507; Larner Joseph, 2002, Int J Exp Diabetes Res, V3, P47, DOI 10.1080/15604280212528; LIN LR, 1991, EXP EYE RES, V52, P93, DOI 10.1016/0014-4835(91)90132-X; LUCAS VA, 1986, EXP EYE RES, V42, P151, DOI 10.1016/0014-4835(86)90039-4; NABER NI, 1987, BIOCHIM BIOPHYS ACTA, V911, P365, DOI 10.1016/0167-4838(87)90078-1; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Raccah D, 1998, J DIABETES COMPLICAT, V12, P154, DOI 10.1016/S1056-8727(97)00093-7; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rauchman MI, 1997, AM J PHYSIOL-RENAL, V273, pF9, DOI 10.1152/ajprenal.1997.273.1.F9; REDDY CC, 1981, J BIOL CHEM, V256, P8510; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; STEVENS MJ, 1993, AM J PHYSIOL, V265, pE428, DOI 10.1152/ajpendo.1993.265.3.E428; Sundkvist G, 2000, DIABETIC MED, V17, P259, DOI 10.1046/j.1464-5491.2000.00261.x; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; WINEGRAD AI, 1987, DIABETES, V36, P396, DOI 10.2337/diab.36.3.396; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298	35	42	45	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19895	19901		10.1074/jbc.M502621200	http://dx.doi.org/10.1074/jbc.M502621200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15778219	hybrid			2022-12-27	WOS:000229113700059
J	Slagsvold, T; Aasland, R; Hirano, S; Bache, KG; Raiborg, C; Trambaiolo, D; Wakatsuki, S; Stenmark, H				Slagsvold, T; Aasland, R; Hirano, S; Bache, KG; Raiborg, C; Trambaiolo, D; Wakatsuki, S; Stenmark, H			Eap45 in mammalian ESCRT-II binds ubiquitin via a phosphoinositide-interacting GLUE domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOSOME-ASSOCIATED COMPLEX; RECEPTOR DOWN-REGULATION; MULTIVESICULAR-BODY; CRYSTAL-STRUCTURE; GRAM DOMAIN; CUE DOMAIN; PROTEIN; HRS; ENDOCYTOSIS; TRANSPORT	Ubiquitination serves as a key sorting signal in the lysosomal degradation of endocytosed receptors through the ability of ubiquitinated membrane proteins to be recognized and sorted by ubiquitin-binding proteins along the endocytic route. The ESCRT-II complex in yeast contains one such protein, Vps36, which harbors a ubiquitin-binding NZF domain and is required for vacuolar sorting of ubiquitinated membrane proteins. Surprisingly, the presumptive mammalian ortholog Eap45 lacks the ubiquitin-binding module of Vps36, and it is thus not clear whether mammalian ESCRT-II functions to bind ubiquitinated cargo. In this paper, we provide evidence that Eap45 contains a novel ubiquitin-binding domain, GLUE (GRAM-like ubiquitin-binding in Eap45), which binds ubiquitin with similar affinity and specificity as other ubiquitin-binding domains. The GLUE domain shares similarities in its primary and predicted secondary structures to phosphoinositide-binding GRAM and PH domains. Accordingly, we find that Eap45 binds to a subset of 3-phosphoinositides, suggesting that ubiquitin recognition could be coordinated with phosphoinositide binding. Furthermore, we show that Eap45 colocalizes with ubiquitinated proteins on late endosomes. These results are consistent with a role for Eap45 in endosomal sorting of ubiquitinated cargo.	Norwegian Radium Hosp, Dept Biochem, N-0310 Oslo, Norway; Univ Bergen, Dept Mol Biol, HIB, N-5020 Bergen, Norway; KEK, IMSS, Struct Biol Res Ctr, Photon Factory, Tsukuba, Ibaraki 3050801, Japan	University of Oslo; University of Bergen; High Energy Accelerator Research Organization (KEK)	Stenmark, H (corresponding author), Norwegian Radium Hosp, Dept Biochem, N-0310 Oslo, Norway.	stenmark@ulrik.uio.no	Bache, Kristi G./AAD-9335-2020; Stenmark, Harald/B-8868-2008	Wakatsuki, Soichi/0000-0001-5896-7968				Alam SL, 2004, EMBO J, V23, P1411, DOI 10.1038/sj.emboj.7600114; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Begley MJ, 2003, MOL CELL, V12, P1391, DOI 10.1016/S1097-2765(03)00486-6; Berger P, 2003, P NATL ACAD SCI USA, V100, P12177, DOI 10.1073/pnas.2132732100; Bilodeau PS, 2003, J CELL BIOL, V163, P237, DOI 10.1083/jcb.200305007; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P483, DOI 10.1016/S0968-0004(00)01664-9; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hierro A, 2004, NATURE, V431, P221, DOI 10.1038/nature02914; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350; Mueller TD, 2004, J BIOL CHEM, V279, P11926, DOI 10.1074/jbc.M312865200; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Raiborg C, 2002, CELL STRUCT FUNCT, V27, P403, DOI 10.1247/csf.27.403; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, J CELL SCI, V114, P2255; Sato M, 2003, NAT CELL BIOL, V5, P1016, DOI 10.1038/ncb1054; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Simonsen A, 1998, EUR J CELL BIOL, V75, P223, DOI 10.1016/S0171-9335(98)80116-7; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Slagsvold T, 2004, DEV CELL, V7, P457, DOI 10.1016/j.devcel.2004.09.007; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Stang E, 2004, MOL BIOL CELL, V15, P3591, DOI 10.1091/mbc.E04-01-0041; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Teo H, 2004, DEV CELL, V7, P559, DOI 10.1016/j.devcel.2004.09.003; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tsujita K, 2004, J BIOL CHEM, V279, P13817, DOI 10.1074/jbc.M312294200; Urbe S, 2003, J CELL SCI, V116, P4169, DOI 10.1242/jcs.00723; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200; Yu JW, 2004, MOL CELL, V13, P677, DOI 10.1016/S1097-2765(04)00083-8	48	128	133	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19600	19606		10.1074/jbc.M501510200	http://dx.doi.org/10.1074/jbc.M501510200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15755741	hybrid			2022-12-27	WOS:000229113700023
J	Zeugner, A; Byrdin, M; Bouly, JP; Bakrim, N; Giovani, B; Brettel, K; Ahmad, M				Zeugner, A; Byrdin, M; Bouly, JP; Bakrim, N; Giovani, B; Brettel, K; Ahmad, M			Light-induced electron transfer in Arabidopsis cryptochrome-1 correlates with in vivo function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DNA PHOTOLYASE; ESCHERICHIA-COLI; PHOTOACTIVATION; DYNAMICS; PROTEIN; CRY1; PHOTORECEPTORS; FLAVOPROTEINS; INHIBITION; BINDING	Cryptochromes are blue light-activated photoreceptors found in multiple organisms with significant similarity to photolyases, a class of light-dependent DNA repair enzymes. Unlike photolyases, cryptochromes do not repair DNA and instead mediate blue light-dependent developmental, growth, and/or circadian responses by an as yet unknown mechanism of action. It has recently been shown that Arabidopsis cryptochrome-1 retains photolyase-like photoreduction of its flavin cofactor FAD by intraprotein electron transfer from tryptophan and tyrosine residues. Here we demonstrate that substitution of two conserved tryptophans that are constituents of the flavin-reducing electron transfer chain in Escherichia coli photolyase impairs light-induced electron transfer in the Arabidopsis cryptochrome-1 photoreceptor in vitro. Furthermore, we show that these substitutions result in marked reduction of light-activated autophosphorylation of cryptochrome-1 in vitro and of its photoreceptor function in vivo, consistent with biological relevance of the electron transfer reaction. These data support the possibility that light-induced flavin reduction via the tryptophan chain is the primary step in the signaling pathway of plant cryptochrome.	Univ Paris 06, F-75252 Paris, France; CEA, Serv Bioengn, F-91191 Gif Sur Yvette, France; CNRS, URA 2096, F-91191 Gif Sur Yvette, France; Penn State Univ, Media, PA 19063 USA	UDICE-French Research Universities; Sorbonne Universite; CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	Zeugner, A (corresponding author), Univ Paris 06, Casier 156,4 Pl Jussieu, F-75252 Paris, France.	ahmad@ccr.jussieu.fr		Ahmad, Margaret/0000-0003-4524-5813; byrdin, martin/0000-0002-6389-8714				AHMAD M, 1995, PLANT J, V8, P653, DOI 10.1046/j.1365-313X.1995.08050653.x; Ahmad M, 2002, PLANT PHYSIOL, V129, P774, DOI 10.1104/pp.010969; Ahmad M, 1998, PLANT CELL, V10, P197, DOI 10.1105/tpc.10.2.197; Bouly JP, 2003, EUR J BIOCHEM, V270, P2921, DOI 10.1046/j.1432-1033.2003.03691.x; Brautigam CA, 2004, P NATL ACAD SCI USA, V101, P12142, DOI 10.1073/pnas.0404851101; Brudler R, 2003, MOL CELL, V11, P59, DOI 10.1016/S1097-2765(03)00008-X; Byrdin M, 2004, BBA-BIOENERGETICS, V1655, P64, DOI 10.1016/j.bbabio.2003.07.001; Byrdin M, 2003, P NATL ACAD SCI USA, V100, P8676, DOI 10.1073/pnas.1531645100; Carell T, 2001, CURR OPIN CHEM BIOL, V5, P491, DOI 10.1016/S1367-5931(00)00239-8; Cheung MS, 1999, BIOPHYS J, V76, P1241, DOI 10.1016/S0006-3495(99)77287-5; Christie JM, 2001, J BIOL CHEM, V276, P11457, DOI 10.1074/jbc.R100004200; Froy O, 2002, CURR BIOL, V12, P147, DOI 10.1016/S0960-9822(01)00656-X; Giovani B, 2003, NAT STRUCT BIOL, V10, P489, DOI 10.1038/nsb933; Green CB, 2004, CURR BIOL, V14, pR847, DOI 10.1016/j.cub.2004.09.040; HEELIS PF, 1982, CHEM SOC REV, V11, P15, DOI 10.1039/cs9821100015; LI YF, 1991, BIOCHEMISTRY-US, V30, P6322, DOI 10.1021/bi00239a034; Lin CT, 2003, ANNU REV PLANT BIOL, V54, P469, DOI 10.1146/annurev.arplant.54.110901.160901; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; Mataga N, 2002, J PHYS CHEM B, V106, P8917, DOI 10.1021/jp0205741; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; Shalitin D, 2003, PLANT CELL, V15, P2421, DOI 10.1105/tpc.013011; Weber S, 2002, P NATL ACAD SCI USA, V99, P1319, DOI 10.1073/pnas.032469399; Yang HQ, 2000, CELL, V103, P815, DOI 10.1016/S0092-8674(00)00184-7; Zhong DP, 2001, P NATL ACAD SCI USA, V98, P11867, DOI 10.1073/pnas.211440398; Zhu HS, 2001, CURR BIOL, V11, P1945, DOI 10.1016/S0960-9822(01)00601-7	29	134	139	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19437	19440		10.1074/jbc.C500077200	http://dx.doi.org/10.1074/jbc.C500077200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774475	hybrid			2022-12-27	WOS:000229113700002
J	Jeschke, G; Bender, A; Schweikardt, T; Panek, G; Decker, H; Paulsen, H				Jeschke, G; Bender, A; Schweikardt, T; Panek, G; Decker, H; Paulsen, H			Localization of the N-terminal domain in light-harvesting chlorophyll a/b protein by EPR measurements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX-II LHCII; BINDING PROTEIN; CONFORMATIONAL-CHANGES; PHOSPHORYLATION SITE; MEMBRANE-PROTEIN; DISTANCE; RESONANCE; STATE; TRIMERIZATION; TRANSITION	The conformational distribution of the N-terminal domain of the major light-harvesting chlorophyll a/b protein ( LHCIIb) has been characterized by electron-electron double resonance yielding distances between spin labels placed in various domains of the protein. Distance distributions involving residue 3 near the N terminus turned out to be bimodal, revealing that this domain, which is involved in regulatory functions such as balancing the energy flow through photosystems ( PS) I and II, exists in at least two conformational states. Models of the conformational sub-ensembles were generated on the basis of experimental distance restraints from measurements on LHCIIb monomers and then checked for consistency with the experimental distance distribution between residues 3 in trimers. Only models where residue 3 is located above the core of the protein and extends into the aqueous phase on the stromal side fit the trimer data. In the other state, which consequently is populated only in monomers, the N-terminal domain extends sideways from the protein core. The two conformational states may correspond to two functional states of LHCIIb, namely trimeric LHCIIb associated with PSII in stacked thylakoid membranes and presumably monomeric LHCIIb associated with PSI in nonstacked thylakoids. The switch between these two is known to be triggered by phosphorylation of Thr-6. A similar phosphorylation-induced conformational change of the N-terminal domain has been observed by others in bovine annexin IV which, due to the conformational switch, also loses its membrane-aggregating property.	Johannes Gutenberg Univ Mainz, Inst Allgemeine Bot, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Mol Biophys, D-55128 Mainz, Germany; Max Planck Inst Polymer Res, D-55021 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Max Planck Society	Paulsen, H (corresponding author), Johannes Gutenberg Univ Mainz, Inst Allgemeine Bot, Mullerweg 6, D-55099 Mainz, Germany.	paulsen@mail.uni-mainz.de	Paulsen, Harald/D-3742-2011	Schweikardt, Thorsten/0000-0002-1304-7970; Jeschke, Gunnar/0000-0001-6853-8585				Allen JF, 2001, TRENDS PLANT SCI, V6, P317, DOI 10.1016/S1360-1385(01)02010-6; Allen JF, 2003, SCIENCE, V299, P1530, DOI 10.1126/science.1082833; Booth PJ, 1996, BIOCHEMISTRY-US, V35, P5103, DOI 10.1021/bi953053f; Borbat PP, 2002, J AM CHEM SOC, V124, P5304, DOI 10.1021/ja020040y; Borbat PP, 1999, CHEM PHYS LETT, V313, P145, DOI 10.1016/S0009-2614(99)00972-0; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Garab G, 2002, BIOCHEMISTRY-US, V41, P15121, DOI 10.1021/bi026157g; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOBE S, 1995, BIOCHEMISTRY-US, V34, P10224, DOI 10.1021/bi00032a016; HOBE S, 1994, EMBO J, V13, P3423, DOI 10.1002/j.1460-2075.1994.tb06647.x; Holt NE, 2005, SCIENCE, V307, P433, DOI 10.1126/science.1105833; Horton P, 2000, PHILOS T R SOC B, V355, P1361, DOI 10.1098/rstb.2000.0698; HUBBELL WL, 1994, CURR OPIN STRUC BIOL, V4, P566, DOI 10.1016/S0959-440X(94)90219-4; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; Jeschke G, 2004, APPL MAGN RESON, V26, P223, DOI 10.1007/BF03166574; Jeschke G, 2004, J MAGN RESON, V169, P1, DOI 10.1016/j.jmr.2004.03.024; Jeschke G, 2004, BIOPHYS J, V86, P2551, DOI 10.1016/S0006-3495(04)74310-6; Jeschke G, 2002, J MAGN RESON, V155, P72, DOI 10.1006/jmre.2001.2498; Johnson AE, 2005, FEBS LETT, V579, P916, DOI 10.1016/j.febslet.2004.11.046; Kaetzel MA, 2001, BIOCHEMISTRY-US, V40, P4192, DOI 10.1021/bi002507s; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; MILOV AD, 1981, FIZ TVERD TELA+, V23, P975; Nilsson A, 1997, J BIOL CHEM, V272, P18350, DOI 10.1074/jbc.272.29.18350; Pannier M, 2000, J MAGN RESON, V142, P331, DOI 10.1006/jmre.1999.1944; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; ROTH M, 1989, NATURE, V340, P659, DOI 10.1038/340659a0; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Steinhoff HJ, 2002, FRONT BIOSCI-LANDMRK, V7, pC97, DOI 10.2741/stein; Tucker MJ, 2005, J PHYS CHEM B, V109, P4788, DOI 10.1021/jp044347q; Vink M, 2004, BIOCHEMISTRY-US, V43, P7824, DOI 10.1021/bi030267l; Wentworth M, 2004, BIOCHEMISTRY-US, V43, P501, DOI 10.1021/bi034975i; Zer H, 2003, TRENDS BIOCHEM SCI, V28, P467, DOI 10.1016/S0968-0004(03)00173-7; Zer H, 1999, P NATL ACAD SCI USA, V96, P8277, DOI 10.1073/pnas.96.14.8277; Zer H, 2003, BIOCHEMISTRY-US, V42, P728, DOI 10.1021/bi020451r	41	55	58	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18623	18630		10.1074/jbc.M501171200	http://dx.doi.org/10.1074/jbc.M501171200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755729	hybrid			2022-12-27	WOS:000228932300011
J	Pajor, AM; Randolph, KM				Pajor, AM; Randolph, KM			Conformationally sensitive residues in extracellular loop 5 of the Na+/dicarboxylate co-transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE RESIDUES; SUBSTRATE-BINDING; DOMAIN; TRANSPORTER; MUTAGENESIS; SEROTONIN; SITE; REVEALS; HELIX	The Na+/dicarboxylate co-transporter, NaDC-1, from the kidney and small intestine, transports three sodium ions together with one divalent anion substrate, such as succinate(2-). A previous study (Pajor, A. M. (2001) J. Biol. Chem. 276, 29961-29968), identified four amino acids, Ser-478, Ala-480, Ala-481, and Thr-482, near the extracellular end of transmembrane helix (TM) 9 that are likely to form part of the permeation pathway of the transporter. All four cysteine-substituted mutants were sensitive to inhibition by the membrane-impermeant reagent [2-(trimethylammonium) ethyl]-methanethiosulfonate ( MTSET) and protected by substrate. In the present study, we continued the cysteine scan through extracellular loop 5 and TM10, from Thr-483 to Val-528. Most cysteine substitutions were well tolerated, although cysteine mutations of some residues, particularly within the TM, produced proteins that were not expressed on the plasma membrane. Six residues in the extracellular loop (Thr-483, Thr-484, Leu-485, Leu-487, Ile-489, and Met-493) were sensitive to chemical labeling by MTSET, depending on the conformational state of the protein. Transport inhibition by MTSET could be prevented by substrate regardless of temperature, suggesting that the likely mechanism of substrate protection is steric hindrance rather than large-scale conformational changes associated with translocation. We conclude that extracellular loop 5 in NaDC-1 appears to have a functional role, and it is likely to be located in or near the substrate translocation pore in the protein. Conformational changes in the protein affect the accessibility of the residues in extracellular loop 5 and provide further evidence of large-scale changes in the structure of NaDC-1 during the transport cycle.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Pajor, AM (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 301 Univ Blvd, Galveston, TX 77555 USA.	ampajor@utmb.edu		Randolph, Kathleen/0000-0003-4394-0978	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046269] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46269, R01 DK046269] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; Emmerlich V, 2003, P NATL ACAD SCI USA, V100, P11122, DOI 10.1073/pnas.1832002100; Grunewald M, 2002, J BIOL CHEM, V277, P26074, DOI 10.1074/jbc.M202248200; Hamasaki N, 2002, BIOCHEMISTRY-US, V41, P3852, DOI 10.1021/bi011918l; He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488; Henry LK, 2003, J BIOL CHEM, V278, P37052, DOI 10.1074/jbc.M305514200; Kahn ES, 1999, BIOCHEMISTRY-US, V38, P6151, DOI 10.1021/bi9827722; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Leighton BH, 2002, J BIOL CHEM, V277, P29847, DOI 10.1074/jbc.M202508200; Li HY, 2003, AM J PHYSIOL-CELL PH, V285, pC1188, DOI 10.1152/ajpcell.00162.2003; Markovich D, 2004, PFLUG ARCH EUR J PHY, V447, P594, DOI 10.1007/s00424-003-1128-6; Pajor AM, 1999, BIOCHEM J, V344, P205, DOI 10.1042/0264-6021:3440205; Pajor AM, 1998, BBA-BIOMEMBRANES, V1370, P98, DOI 10.1016/S0005-2736(97)00249-6; Pajor AM, 1999, SEMIN NEPHROL, V19, P195; Pajor AM, 2000, J MEMBRANE BIOL, V175, P1, DOI 10.1007/s002320001049; Pajor AM, 1998, BIOCHEM J, V331, P257, DOI 10.1042/bj3310257; Pajor AM, 2001, J BIOL CHEM, V276, P29961, DOI 10.1074/jbc.M011387200; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; Segel I.H., 1975, ENZYME KINETICS; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; TAMURA S, 1995, J BIOL CHEM, V270, P28712, DOI 10.1074/jbc.270.48.28712; Wang HP, 2000, AM J PHYSIOL-CELL PH, V278, pC1019, DOI 10.1152/ajpcell.2000.278.5.C1019; Yao XZ, 2002, BIOCHEMISTRY-US, V41, P1083, DOI 10.1021/bi0156761; Yao XZ, 2000, AM J PHYSIOL-RENAL, V279, pF54, DOI 10.1152/ajprenal.2000.279.1.F54; Zhang FF, 2001, BBA-BIOMEMBRANES, V1511, P80, DOI 10.1016/S0005-2736(00)00385-0; Zomot E, 2003, J BIOL CHEM, V278, P42950, DOI 10.1074/jbc.M209307200	29	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18728	18735		10.1074/jbc.M501265200	http://dx.doi.org/10.1074/jbc.M501265200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15774465	Green Accepted, hybrid			2022-12-27	WOS:000228932300024
J	Katsumi, A; Naoe, T; Matsushita, T; Kaibuchi, K; Schwartz, MA				Katsumi, A; Naoe, T; Matsushita, T; Kaibuchi, K; Schwartz, MA			Integrin activation and matrix binding mediate cellular responses to mechanical stretch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; MECHANOTRANSDUCTION; TENSION; STRESS; FIBROBLASTS; MODULATION; GROWTH; RAC	Mechanical tension is a critical determinant of cell growth, differentiation, apoptosis, migration, and development. Integrins have been implicated in sensing force but little is known about how forces are transduced to biochemical signals. We now show that mechanical strain stimulates conformational activation of integrin alpha v beta 3 in NIH3T3 cells. Integrin activation is mediated by phosphoinositol 3-kinase and is followed by an increase in integrin binding to extracellular matrix proteins. Mechanical stretch stimulation of JNK was dependent on new integrin binding to extracellular matrix. These data define a molecular mechanism for the role of integrins in mechanotransduction.	Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Mellon Prostate Res Inst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Mellon Prostate Res Inst, Dept Biomed Engn, Charlottesville, VA 22908 USA; Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Showa Ku, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Hematol, Showa Ku, Aichi 4668550, Japan	University of Virginia; University of Virginia; University of Virginia; Nagoya University; Nagoya University	Schwartz, MA (corresponding author), Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA.	maschwartz@virginia.edu	Naoe, Tomoki/I-1888-2012; Matsushita, Tadadshi/I-7349-2014	schwartz, martin/0000-0002-2071-1243	NHLBI NIH HHS [R01 HL075092] Funding Source: Medline; NIGMS NIH HHS [R01GM47214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAY D, 1984, DEV BIOL, V102, P379, DOI 10.1016/0012-1606(84)90202-1; Chicurel ME, 1998, NATURE, V392, P730, DOI 10.1038/33719; Davis MJ, 2001, AM J PHYSIOL-HEART C, V280, pH1427, DOI 10.1152/ajpheart.2001.280.4.H1427; Farge E, 2003, CURR BIOL, V13, P1365, DOI 10.1016/S0960-9822(03)00576-1; HASTON WS, 1983, EXP CELL RES, V146, P117, DOI 10.1016/0014-4827(83)90330-0; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200; Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; KOLEGA J, 1986, J CELL BIOL, V102, P1400, DOI 10.1083/jcb.102.4.1400; Lee AA, 1996, AM J PHYSIOL-CELL PH, V271, pC1400, DOI 10.1152/ajpcell.1996.271.4.C1400; MacKenna DA, 1998, J CLIN INVEST, V101, P301, DOI 10.1172/JCI1026; Ozaki S, 2000, P NATL ACAD SCI USA, V97, P11286, DOI 10.1073/pnas.210197897; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Sawada Y, 2001, J CELL SCI, V114, P1221; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; Shimizu Y, 1999, ADV IMMUNOL, V72, P325, DOI 10.1016/S0065-2776(08)60024-3; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; Suzuma I, 2002, J BIOL CHEM, V277, P1047, DOI 10.1074/jbc.M105336200; TERRACIO L, 1988, IN VITRO CELL DEV B, V24, P53; THUBRIKAR MJ, 1995, ANN THORAC SURG, V59, P1594, DOI 10.1016/0003-4975(94)01037-D; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200	26	177	187	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	2005	280	17					16546	16549		10.1074/jbc.C400455200	http://dx.doi.org/10.1074/jbc.C400455200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	919JY	15760908	hybrid			2022-12-27	WOS:000228615500003
J	Chen, YH; Wang, CC; Greenwell, L; Rix, U; Hoffmeister, D; Vining, LC; Rohr, JR; Yang, KQ				Chen, YH; Wang, CC; Greenwell, L; Rix, U; Hoffmeister, D; Vining, LC; Rohr, JR; Yang, KQ			Functional analyses of oxygenases in jadomycin biosynthesis and identification of JadH as a bifunctional oxygenase/dehydrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-VENEZUELAE ISP5230; ANTITUMOR DRUG MITHRAMYCIN; GENE-CLUSTER; RATIONAL DESIGN; GILVOCARCIN-V; CLONING; MONOOXYGENASE; POLYKETIDES; PURIFICATION; MANIPULATION	A novel angucycline metabolite, 2,3-dehydro-UWM6, was identified in a jadH mutant of Streptomyces venezuelae ISP5230. Both UWM6 and 2,3-dehydro- UWM6 could be converted to jadomycin A or B by a ketosynthase alpha (jadA) mutant of S. venezuelae. These angucycline intermediates were also converted to jadomycin A by trans-formant of the heterologous host Streptomyces lividans expressing the jadFGH oxygenases in vivo and by its cell-free extracts in vitro; thus the three gene products JadFGH are implicated in catalysis of the post-polyketide synthase biosynthetic reactions converting UWM6 to jadomycin aglycone. Genetic and biochemical analyses indicate that JadH possesses dehydrase activity, not previously associated with polyketide-modifying oxygenase. Since the formation of aromatic polyketides often requires multiple dehydration steps, bifunctionality of oxygenases modifying aromatic polyketides may be a general phenomenon.	Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA; Chinese Acad Sci, Inst Microbiol, State Key Lab Microbial Resources, Beijing 100080, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing 100080, Peoples R China; Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada	University of Kentucky; Chinese Academy of Sciences; Institute of Microbiology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Dalhousie University	Rohr, JR (corresponding author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, 725 Rose St, Lexington, KY 40536 USA.	jrohr2@uky.edu; yangkq@im.ac.cn	Wang, Chenchen/F-1061-2011; Rohr, Jason R./AAJ-5856-2021		NCI NIH HHS [R01 CA102102-01A2, R01 CA102102, R01 CA091901, CA 91901] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102102, R01CA091901] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AYER SW, 1991, TETRAHEDRON LETT, V32, P6301, DOI 10.1016/0040-4039(91)80152-V; Bak S, 1998, PLANT MOL BIOL, V36, P393, DOI 10.1023/A:1005915507497; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DOULL JL, 1994, J IND MICROBIOL, V13, P120, DOI 10.1007/BF01584109; Doumith M, 2000, MOL GEN GENET, V264, P477, DOI 10.1007/s004380000329; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; Eppink MHM, 1997, PROTEIN SCI, V6, P2454; Fischer C, 2003, J AM CHEM SOC, V125, P7818, DOI 10.1021/ja034781q; Gould SJ, 1997, CHEM REV, V97, P2499, DOI 10.1021/cr9600215; Gould SJ, 1998, J ANTIBIOT, V51, P50, DOI 10.7164/antibiotics.51.50; HAN L, 1994, MICROBIOL-SGM, V140, P3379, DOI 10.1099/13500872-140-12-3379; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P2257; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; Kendrew SG, 1997, J BACTERIOL, V179, P4305, DOI 10.1128/jb.179.13.4305-4310.1997; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; Kulowski K, 1999, J AM CHEM SOC, V121, P1786, DOI 10.1021/ja982707f; Li AY, 2002, CHEM BIOL, V9, P1017, DOI 10.1016/S1074-5521(02)00223-5; Liu T, 2004, J AM CHEM SOC, V126, P12262, DOI 10.1021/ja0467521; MACNEIL DJ, 1992, GENE, V111, P61, DOI 10.1016/0378-1119(92)90603-M; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; MCVEY J, 1998, THESIS DALHOUSIE U C; Menendez N, 2004, CHEM BIOL, V11, P21, DOI 10.1016/j.chembiol.2003.12.011; Ostash B, 2004, CHEM BIOL, V11, P547, DOI 10.1016/j.chembiol.2004.03.011; Prado L, 1999, CHEM BIOL, V6, P19, DOI 10.1016/S1074-5521(99)80017-9; Rawlings BJ, 1999, NAT PROD REP, V16, P425, DOI 10.1039/a900566h; Rix U, 2005, CHEMBIOCHEM, V6, P838, DOI 10.1002/cbic.200400395; Rix U, 2004, J AM CHEM SOC, V126, P4496, DOI 10.1021/ja031724o; Rix U, 2002, NAT PROD REP, V19, P542, DOI 10.1039/b103920m; Rodriguez D, 2003, J BACTERIOL, V185, P3962, DOI 10.1128/JB.185.13.3962-3965.2003; Sambrook J., 2001, MOL CLONING LAB MANU; Sciara G, 2003, EMBO J, V22, P205, DOI 10.1093/emboj/cdg031; SEATON PJ, 1987, J AM CHEM SOC, V109, P5282, DOI 10.1021/ja00251a045; Shen B, 2000, TOP CURR CHEM, V209, P1; SHEN B, 1993, BIOCHEMISTRY-US, V32, P6656, DOI 10.1021/bi00077a019; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vallon O, 2000, PROTEINS, V38, P95, DOI 10.1002/(SICI)1097-0134(20000101)38:1<95::AID-PROT10>3.0.CO;2-A; WEBER S, 1994, J ORG CHEM, V59, P4211, DOI 10.1021/jo00094a037; Westrich L, 1999, FEMS MICROBIOL LETT, V170, P381, DOI 10.1111/j.1574-6968.1999.tb13398.x; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YANG KQ, 1995, J BACTERIOL, V177, P6111, DOI 10.1128/jb.177.21.6111-6117.1995; Yang KQ, 1996, MICROBIOL-UK, V142, P123, DOI 10.1099/13500872-142-1-123	43	60	63	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22508	22514		10.1074/jbc.M414229200	http://dx.doi.org/10.1074/jbc.M414229200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817470	Green Accepted, hybrid			2022-12-27	WOS:000229557900098
J	Kimura, T; Ohno, N; Terada, N; Rokuhara, A; Matsumoto, A; Yagi, S; Tanaka, E; Kiyosawa, K; Ohno, S; Maki, N				Kimura, T; Ohno, N; Terada, N; Rokuhara, A; Matsumoto, A; Yagi, S; Tanaka, E; Kiyosawa, K; Ohno, S; Maki, N			Hepatitis B virus DNA-negative Dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-ANTIGEN; SIGNAL PEPTIDE; ENZYME-IMMUNOASSAY; ELECTRON CRYOMICROSCOPY; AUSTRALIA-ANTIGEN; ESCHERICHIA-COLI; XENOPUS OOCYTES; GENE; EXPRESSION; STABILITY	DNA-negative Dane particles have been observed in hepatitis B virus (HBV)-infected sera. The capsids of the empty particles are thought to be composed of core protein but have not been studied in detail. In the present study, the protein composition of the particles was examined using new enzyme immunoassays for the HBV core antigen (HBcAg) and for the HBV precore/core proteins (core-related antigens, HBcrAg). HBcrAg were abundant in fractions slightly less dense than HBcAg and HBV DNA. Three times more Dane-like particles were observed in the HBcrAg-rich fraction than in the HBV DNA-rich fraction by electron microscopy. Western blots and mass spectrometry identified the HBcrAg as a 22-kDa precore protein (p22cr) containing the un-cleaved signal peptide and lacking the arginine-rich domain that is involved in binding the RNA pregenome or the DNA genome. In sera from 30 HBV-infected patients, HBcAg represented only a median 10.5% of the precore/core proteins in enveloped particles. These data suggest that most of the Dane particles lack viral DNA and core capsid but contain p22cr. This study provides a model for the formation of the DNA-negative Dane particles. The precore proteins, which lack the arginine-rich nucleotide-binding domain, form viral RNA/DNA-negative capsid-like particles and are enveloped and released as empty particles.	Adv Life Sci Inst Inc, Div Res & Dev, Wako, Saitama 3510112, Japan; Univ Yamanashi, Dept Anat, Interdisciplinary Grad Sch Med & Engn, Yamanashi 4093898, Japan; Shinshu Univ, Sch Med, Dept Internal Med, Matsumoto, Nagano 3908621, Japan	University of Yamanashi; Shinshu University	Kimura, T (corresponding author), Adv Life Sci Inst Inc, Div Res & Dev, 2-10-23 Maruyamadai, Wako, Saitama 3510112, Japan.	tkimura@alsi-i.co.jp						ALBERTI A, 1978, GASTROENTEROLOGY, V75, P869; BEAMES B, 1993, VIROLOGY, V194, P597, DOI 10.1006/viro.1993.1299; BIRNBAUM F, 1990, J VIROL, V64, P3319, DOI 10.1128/JVI.64.7.3319-3330.1990; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; Conway JF, 1997, NATURE, V386, P91, DOI 10.1038/386091a0; CROWTHER RA, 1994, CELL, V77, P943, DOI 10.1016/0092-8674(94)90142-2; DANE DS, 1970, LANCET, V1, P695; GALLINA A, 1989, J VIROL, V63, P4645, DOI 10.1128/JVI.63.11.4645-4652.1989; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GERIN JL, 1975, AM J PATHOL, V81, P651; Guidotti LG, 1996, J VIROL, V70, P7056, DOI 10.1128/JVI.70.10.7056-7061.1996; Kimura T, 2003, J CLIN MICROBIOL, V41, P1901, DOI 10.1128/JCM.41.5.1901-1906.2003; Kimura T, 2002, J CLIN MICROBIOL, V40, P439, DOI 10.1128/JCM.40.2.439-445.2002; LOK ASF, 1994, P NATL ACAD SCI USA, V91, P4077, DOI 10.1073/pnas.91.9.4077; MAASSEN A, 1994, ARCH VIROL, V135, P131, DOI 10.1007/BF01309770; Messageot F, 2003, J BIOL CHEM, V278, P891, DOI 10.1074/jbc.M207634200; MIYANOHARA A, 1986, J VIROL, V59, P176, DOI 10.1128/JVI.59.1.176-180.1986; Mukaide M, 2003, J GASTROEN HEPATOL, V18, P1264, DOI 10.1046/j.1440-1746.2003.03204.x; NASSAL M, 1993, J VIROL, V67, P4307, DOI 10.1128/JVI.67.7.4307-4315.1993; Newman M, 2003, J VIROL, V77, P12950, DOI 10.1128/JVI.77.24.12950-12960.2003; OU JH, 1990, VIROLOGY, V174, P185, DOI 10.1016/0042-6822(90)90067-2; OU JH, 1986, P NATL ACAD SCI USA, V83, P1578, DOI 10.1073/pnas.83.6.1578; OU JH, 1989, J VIROL, V63, P5238, DOI 10.1128/JVI.63.12.5238-5243.1989; Rokuhara A, 2003, J VIRAL HEPATITIS, V10, P324, DOI 10.1046/j.1365-2893.2003.00437.x; SAKAMOTO Y, 1983, LAB INVEST, V48, P678; Scaglioni PP, 1997, J VIROL, V71, P345, DOI 10.1128/JVI.71.1.345-353.1997; SCHLICHT HJ, 1991, J VIROL, V65, P3489, DOI 10.1128/JVI.65.7.3489-3495.1991; SCHLICHT HJ, 1991, J VIROL, V65, P6817, DOI 10.1128/JVI.65.12.6817-6825.1991; SCHODEL F, 1993, J BIOL CHEM, V268, P1332; Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000; STANDRING DN, 1988, P NATL ACAD SCI USA, V85, P8405, DOI 10.1073/pnas.85.22.8405; TAKAHASHI K, 1991, J IMMUNOL, V147, P3156; TAKAHASHI K, 1983, J IMMUNOL, V130, P2903; TAKAHASHI T, 1980, J MED MICROBIOL, V13, P163, DOI 10.1099/00222615-13-1-163; WASENAUER G, 1992, J VIROL, V66, P5338, DOI 10.1128/JVI.66.9.5338-5346.1992; WEIMER T, 1987, J VIROL, V61, P3109, DOI 10.1128/JVI.61.10.3109-3113.1987; WINGFIELD PT, 1995, BIOCHEMISTRY-US, V34, P4919, DOI 10.1021/bi00015a003; YANG SQ, 1992, J VIROL, V66, P37, DOI 10.1128/JVI.66.1.37-45.1992; ZHOU SL, 1992, J VIROL, V66, P5393, DOI 10.1128/JVI.66.9.5393-5398.1992	39	105	111	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21713	21719		10.1074/jbc.M501564200	http://dx.doi.org/10.1074/jbc.M501564200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15814524	hybrid			2022-12-27	WOS:000229557900006
J	McLaughlin, JN; Mazzoni, MR; Cleator, JH; Earls, L; Perdigoto, AL; Brooks, JD; Muldowney, JAS; Vaughan, DE; Hamm, HE				McLaughlin, JN; Mazzoni, MR; Cleator, JH; Earls, L; Perdigoto, AL; Brooks, JD; Muldowney, JAS; Vaughan, DE; Hamm, HE			Thrombin modulates the expression of a set of genes including thrombospondin-1 in human microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; PROTEASE-ACTIVATED RECEPTOR-1; COLONY-STIMULATING FACTOR; TERNARY COMPLEX FACTORS; SERUM RESPONSE ELEMENT; DIFFERENTIAL EXPRESSION; MOLECULAR-CLONING; G-PROTEINS; REAL-TIME; KINASE-C	Thrombospondin-1 (THBS1) is a large extracellular matrix glycoprotein that affects vasculature systems such as platelet activation, angiogenesis, and wound healing. Increases in THBS1 expression have been liked to disease states including tumor progression, atherosclerosis, and arthritis. The present study focuses on the effects of thrombin activation of the G-protein-coupled, protease-activated receptor-1 (PAR-1) on THBS1 gene expression in the microvascular endothelium. Thrombin-induced changes in gene expression were characterized by microarray analysis of similar to 11,000 different human genes in human microvascular endothelial cells (HMEC-1). Thrombin induced the expression of a set of at least 65 genes including THBS1. Changes in THBS1 mRNA correlated with an increase in the extracellular THBS1 protein concentration. The PAR-1-specific agonist peptide (TFLLRNK-PDK) mimicked thrombin stimulation of THBS1 expression, suggesting that thrombin signaling is through PAR-1. Further studies showed THBS1 expression was sensitive to pertussis toxin and protein kinase C inhibition indicating G(i/o)- and G(q)-mediated pathways. THBS1 up-regulation was also confirmed in human umbilical vein endothelial cells stimulated with thrombin. Analysis of the promoter region of THBS1 and other genes of similar expression profile identified from the microarray predicted an EBOX/EGRF transcription model. Expression of members of each family, MYC and EGR1, respectively, correlated with THBS1 expression. These results suggest thrombin formed at sites of vascular injury increases THBS1 expression into the extracellular matrix via activation of a PAR-1, G(i/o), G(q), EBOX/EGRF-signaling cascade, elucidating regulatory points that may play a role in increased THBS1 expression in disease states.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Div Cardiovasc Med, Nashville, TN 37232 USA; Univ Pisa, Dept Psychiat Neurobiol Pharmacol & Biotechnol, I-56126 Pisa, Italy	Vanderbilt University; Vanderbilt University; University of Pisa	McLaughlin, JN (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 444 Robinson Res Bldg,23rd Ave S Pierce, Nashville, TN 37232 USA.	mclaughlin@vanderbilt.edu	Hamm, Heidi E/G-2374-2014; Mazzoni, Maria Rosa/AAA-2366-2022	Mazzoni, Maria Rosa/0000-0003-2612-432X	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060906, T32HL007751, T32HL007411] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK058404] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 68485] Funding Source: Medline; NHLBI NIH HHS [5R01 HL 60906-04, 5T32 HL 07411-23, 5T32 HL 07751-11, P01 HL 6744-01] Funding Source: Medline; NIDDK NIH HHS [P30 DK 58404, P60 DK 20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anrather D, 1997, J IMMUNOL, V159, P5620; BAENZIGE.NL, 1971, P NATL ACAD SCI USA, V68, P240, DOI 10.1073/pnas.68.1.240; Bartoli M, 2003, FASEB J, V17, P1562, DOI 10.1096/fj.02-1084fje; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Blackhart BD, 1996, J BIOL CHEM, V271, P16466, DOI 10.1074/jbc.271.28.16466; Bochkov VN, 2002, BLOOD, V99, P199, DOI 10.1182/blood.V99.1.199; Bogatcheva NV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P75, DOI 10.1023/A:1013904231324; Bonnefoy A, 2001, THROMB HAEMOSTASIS, V85, P552, DOI 10.1055/s-0037-1615620; Bonnefoy A, 2001, J BIOL CHEM, V276, P5605, DOI 10.1074/jbc.M010091200; BOTNEY MD, 1992, AM J PATHOL, V140, P357; Cesari F, 2004, GENESIS, V38, P87, DOI 10.1002/gene.20003; Chandrasekharan UM, 2004, J BIOL CHEM, V279, P46678, DOI 10.1074/jbc.M406441200; Chapman NR, 2002, BIOCHEM J, V366, P459, DOI 10.1042/BJ20020444; CHEN J, 1994, J BIOL CHEM, V269, P16041; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Coughlin SR, 2003, J CLIN INVEST, V111, P25, DOI 10.1172/JCI200317564; DaSilva L, 2003, TOXICON, V41, P813, DOI 10.1016/S0041-0101(03)00035-7; Dejong V, 1999, ONCOGENE, V18, P3143, DOI 10.1038/sj.onc.1202654; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; DORN GW, 1992, J PHARMACOL EXP THER, V262, P1242; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; Esemuede N, 2004, J SURG RES, V122, P135, DOI 10.1016/j.jss.2004.05.015; Feoktistov I, 2002, CIRC RES, V90, P531, DOI 10.1161/01.RES.0000012203.21416.14; Fishman P, 2003, ANTICANCER RES, V23, P2077; Gilchrist A, 2001, J BIOL CHEM, V276, P25672, DOI 10.1074/jbc.M100914200; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Hanlon M, 1999, J BIOL CHEM, V274, P14224, DOI 10.1074/jbc.274.20.14224; Hirota Y, 2003, J CLIN ENDOCR METAB, V88, P3952, DOI 10.1210/jc.2002-021785; Hollenberg MD, 2002, PHARMACOL REV, V54, P203, DOI 10.1124/pr.54.2.203; Hoshi S, 2000, J BIOL CHEM, V275, P883, DOI 10.1074/jbc.275.2.883; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Inuzuka H, 1999, BIOCHEM BIOPH RES CO, V265, P664, DOI 10.1006/bbrc.1999.1734; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1993, J BIOL CHEM, V268, P9780; Jurk K, 2003, FASEB J, V17, P1490, DOI 10.1096/fj.02-0830fje; Kim JA, 2001, J CELL BIOCHEM, V81, P93, DOI 10.1002/1097-4644(20010401)81:1<93::AID-JCB1026>3.0.CO;2-I; Kuhn I, 2001, PHYSIOL GENOMICS, V7, P105, DOI 10.1152/physiolgenomics.00052.2001; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; Lidington EA, 2000, BLOOD, V96, P2784; Lidington EA, 1999, TRANSPL IMMUNOL, V7, P239, DOI 10.1016/S0966-3274(99)80008-2; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lum H, 1996, CAN J PHYSIOL PHARM, V74, P787, DOI 10.1139/cjpp-74-7-787; MALIK AB, 1992, SEMIN THROMB HEMOST, V18, P193, DOI 10.1055/s-2007-1002425; Martin TA, 2002, J CELL PHYSIOL, V192, P268, DOI 10.1002/jcp.10133; Maruyama I, 1998, LUPUS, V7, pS41, DOI 10.1177/096120339800700210; MCCARTHY SA, 1992, J BIOL CHEM, V267, P21617; MCCREATH G, 1994, BRIT J PHARMACOL, V113, P823, DOI 10.1111/j.1476-5381.1994.tb17067.x; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; Mora-Garcia P, 2000, J BIOL CHEM, V275, P22418, DOI 10.1074/jbc.M001731200; MORANDI V, 1993, IN VITRO CELL DEV-AN, V29A, P585; Nasi S, 2001, FEBS LETT, V490, P153, DOI 10.1016/S0014-5793(01)02118-4; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Park JK, 2002, MOL PHARMACOL, V62, P1400, DOI 10.1124/mol.62.6.1400; Park SW, 2003, J BIOL CHEM, V278, P29776, DOI 10.1074/jbc.M303306200; Rahman A, 1999, J IMMUNOL, V162, P5466; RajagopalanGupta RM, 1997, MOL ENDOCRINOL, V11, P538, DOI 10.1210/me.11.5.538; RAUGI GJ, 1990, AM J PATHOL, V137, P179; RAUGI GJ, 1982, J CELL BIOL, V95, P351, DOI 10.1083/jcb.95.1.351; REED MJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1467, DOI 10.1177/41.10.8245406; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Ryu J, 2000, J BIOL CHEM, V275, P29955, DOI 10.1074/jbc.M001220200; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; Schmidt VA, 1998, J BIOL CHEM, V273, P15061, DOI 10.1074/jbc.273.24.15061; Shimizu T, 2004, J BIOL CHEM, V279, P13729, DOI 10.1074/jbc.M400150200; Shin H, 1999, ANN RHEUM DIS, V58, P55, DOI 10.1136/ard.58.1.55; SHINGU T, 1994, J BIOL CHEM, V269, P32551; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Stenina OI, 2003, CIRCULATION, V107, P3209, DOI 10.1161/01.CIR.0000074223.56882.97; Stenina OI, 2001, P NATL ACAD SCI USA, V98, P7277, DOI 10.1073/pnas.121592298; Stepien O, 1998, J CARDIOVASC PHARM, V31, P786, DOI 10.1097/00005344-199805000-00019; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Tolsma SS, 1997, MICROVASC RES, V54, P13, DOI 10.1006/mvre.1997.2015; Trumel C, 2003, J THROMB HAEMOST, V1, P320, DOI 10.1046/j.1538-7836.2003.00068.x; TUSZYNSKI GP, 1992, THROMB HAEMOSTASIS, V67, P607; Unger RE, 2002, MICROVASC RES, V64, P384, DOI 10.1006/mvre.2002.2434; Vallejo AN, 2000, J IMMUNOL, V164, P2947, DOI 10.4049/jimmunol.164.6.2947; Vanhauwe JF, 2002, J BIOL CHEM, V277, P34143, DOI 10.1074/jbc.M204477200; VARANI J, 1989, CLIN EXP METASTAS, V7, P265, DOI 10.1007/BF01753679; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; WIGHT TN, 1985, J HISTOCHEM CYTOCHEM, V33, P295, DOI 10.1177/33.4.3884704; Wu SQ, 2002, BLOOD, V100, P4454, DOI 10.1182/blood-2002-02-0415; Yang GF, 2004, WORLD J GASTROENTERO, V10, P491, DOI 10.3748/wjg.v10.i4.491	92	50	57	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22172	22180		10.1074/jbc.M500721200	http://dx.doi.org/10.1074/jbc.M500721200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817447	hybrid			2022-12-27	WOS:000229557900062
J	Pan, XQ; Ohnedal, O; Ohneda, K; Lindeboom, F; Iwata, F; Shimizu, R; Nagano, M; Suwabe, N; Philipsen, S; Lim, KC; Engel, JD; Yamamoto, M				Pan, XQ; Ohnedal, O; Ohneda, K; Lindeboom, F; Iwata, F; Shimizu, R; Nagano, M; Suwabe, N; Philipsen, S; Lim, KC; Engel, JD; Yamamoto, M			Graded levels of GATA-1 expression modulate survival, proliferation, and differentiation of erythroid progenitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; TRANSIENT MYELOPROLIFERATIVE DISORDER; EMBRYONIC STEM-CELLS; DOWN-SYNDROME; MEGAKARYOBLASTIC LEUKEMIA; DEFINITIVE ERYTHROCYTES; IN-VIVO; MICE; LEUKEMOGENESIS; PRECURSORS	Transcription factor GATA-1 plays an important role in gene regulation during the development of erythroid cells. Several reports suggest that GATA-1 plays multiple roles in survival, proliferation, and differentiation of erythroid cells. However, little is known about the relationship between the level of GATA-1 expression and its nature of multifunction to affect erythroid cell fate. To address this issue, we developed in vitro embryonic stem (ES) culture system by using OP9 stromal cells (OP9/ ES cell co-culture system), and cultured the mutant (GATA-1.05 and GATA-1-null) and wild type (WT) ES cells, respectively. By using this OP9/ ES cell co-culture system, primitive and definitive erythroid cells were developed individually, and we examined how expression level of GATA-1 affects the development of erythroid cells. GATA-1.05 ES-derived definitive erythroid cells were immature with the appearance of proerythroblasts, and highly proliferated, compared with WT and GATA-1-null ES- derived erythroid cells. Extensive studies of cell cycle kinetics revealed that the GATA-1.05 proerythroblasts accumulated in S phase and expressed lower levels of p16(INK4A) than WT ES cell-derived proerythroblasts. We concluded that GATA-1 must achieve a critical threshold activity to achieve selective activation of specific target genes, thereby influencing the developmental decision of an erythroid progenitor cell to undergo apoptosis, proliferation, or terminal differentiation.	Univ Tsukuba, Dept Regenerat Med & Stem Cell Biol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr TARA, ERATO, Environm Res Project,Dept Mol & Dev Biol, Tsukuba, Ibaraki 3058577, Japan; Erasmus MC, Med Genet Cluster, Dept Cell Biol, NL-3000 DR Rotterdam, Netherlands; Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	University of Tsukuba; Japan Science & Technology Agency (JST); University of Tsukuba; Erasmus University Rotterdam; Erasmus MC; University of Michigan System; University of Michigan	Pan, XQ (corresponding author), Univ Tsukuba, Dept Regenerat Med & Stem Cell Biol, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan.	oohneda@md.tsukuba.ac.jp; masi@tara.tsukuba.ac.jp	Yamamoto, Masayuki/A-4873-2010; Shimizu, Ritsuko/A-4877-2010; Ohneda, Kinuko/AAC-8822-2019	Yamamoto, Masayuki/0000-0002-9073-9436; Shimizu, Ritsuko/0000-0001-6672-7606; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028896] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28896] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Briegel K, 1996, DEVELOPMENT, V122, P3839; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Cullen ME, 1997, J BIOL CHEM, V272, P2464; Dubart A, 1996, BLOOD, V87, P3711, DOI 10.1182/blood.V87.9.3711.bloodjournal8793711; Ferreira R, 2005, MOL CELL BIOL, V25, P1215, DOI 10.1128/MCB.25.4.1215-1227.2005; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Gurbuxani S, 2004, BLOOD, V103, P399, DOI 10.1182/blood-2003-05-1556; Ikonomi P, 2000, EXP HEMATOL, V28, P1423, DOI 10.1016/S0301-472X(00)00553-1; Lacronique V, 1997, BLOOD, V90, P3050, DOI 10.1182/blood.V90.8.3050; LEONARD M, 1993, BLOOD, V82, P1071; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; Mundschau G, 2003, BLOOD, V101, P4298, DOI 10.1182/blood-2002-12-3904; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Nakano T, 1996, SCIENCE, V272, P722, DOI 10.1126/science.272.5262.722; Ohneda K, 2002, ACTA HAEMATOL-BASEL, V108, P237, DOI 10.1159/000065660; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Rainis L, 2003, BLOOD, V102, P981, DOI 10.1182/blood-2002-11-3599; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimada A, 2004, BLOOD, V103, P366, DOI 10.1182/blood-2003-09-3219; Shimizu R, 2004, MOL CELL BIOL, V24, P10814, DOI 10.1128/MCB.24.24.10814-10825.2004; Shimizu R, 2001, EMBO J, V20, P5250, DOI 10.1093/emboj/20.18.5250; Suwabe N, 1998, BLOOD, V92, P4108, DOI 10.1182/blood.V92.11.4108.423k29_4108_4118; Suzuki N, 2003, BLOOD, V102, P3575, DOI 10.1182/blood-2003-04-1154; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Whyatt David J., 1997, Genes and Function, V1, P11; Xu G, 2003, BLOOD, V102, P2960, DOI 10.1182/blood-2003-02-0390; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	40	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22385	22394		10.1074/jbc.M500081200	http://dx.doi.org/10.1074/jbc.M500081200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817467	hybrid			2022-12-27	WOS:000229557900084
J	Zang, Y; Wang, WH; Wu, SW; Ealick, SE; Wang, CC				Zang, Y; Wang, WH; Wu, SW; Ealick, SE; Wang, CC			Identification of a subversive substrate of Trichomonas vaginalis purine nucleoside phosphorylase and the crystal structure of the enzyme-substrate complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEXUALLY-TRANSMITTED DISEASES; ELECTRON-DENSITY MAPS; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE; GUANINE PHOSPHORIBOSYLTRANSFERASE; 3-DIMENSIONAL STRUCTURE; URIDINE PHOSPHORYLASE; REVEALS SIMILARITY; RATIONAL DESIGN	Trichomonas vaginalis is an anaerobic protozoan parasite that causes trichomoniasis, a common sexually transmitted disease with worldwide impact. One of the pivotal enzymes in its purine salvage pathway, purine nucleoside phosphorylase (PNP), shows physical properties and substrate specificities similar to those of the high molecular mass bacterial PNPs but differing from those of human PNP. While carrying out studies to identify inhibitors of T. vaginalis PNP (TvPNP), we discovered that the nontoxic nucleoside analogue 2-fluoro-2'-deoxyadenosine (F-dAdo) is a "subversive substrate." Phosphorolysis by TvPNP of F-dAdo, which is not a substrate for human PNP, releases highly cytotoxic 2-fluoroadenine (F-Ade). In vitro studies showed that both F-dAdo and F-Ade exert strong inhibition of T. vaginalis growth with estimated IC50 values of 106 and 84 nM, respectively, suggesting that F-dAdo might be useful as a potential chemotherapeutic agent against T. vaginalis. To understand the basis of TvPNP specificity, the structures of TvPNP complexed with F-dAdo, 2-fluoroadenosine, formycin A, adenosine, inosine, or 2'-deoxyinosine were determined by x-ray crystallography with resolutions ranging from 2.4 to 2.9 . These studies showed that the quaternary structure, monomer fold, and active site are similar to those of Escherichia coli PNP. The principal active site difference is at Thr-156, which is alanine in E. coli PNP. In the complex of TvPNP with F-dAdo, Thr-156 causes the purine base to tilt and shift by 0.5 as compared with the binding scheme of F-dAdo in E. coli PNP. The structures of the TvPNP complexes suggest opportunities for further improved subversive substrates beyond F-dAdo.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	University of California System; University of California San Francisco; Cornell University	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ccwang@cgl.ucsf.edu			NATIONAL CANCER INSTITUTE [U19CA067763] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR015301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060660] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67763] Funding Source: Medline; NCRR NIH HHS [RR 15301] Funding Source: Medline; NIAID NIH HHS [AI 60660] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Appleby TC, 2001, J BIOL CHEM, V276, P39232, DOI 10.1074/jbc.M105694200; Appleby TC, 1999, STRUCTURE, V7, P629, DOI 10.1016/S0969-2126(99)80084-7; Aronov A.M., 2001, Patent No. [6221877, US 6221877 B1]; Aronov AM, 2001, ANTIMICROB AGENTS CH, V45, P2571, DOI 10.1128/AAC.45.9.2571-2576.2001; Aronov AM, 2000, BIOCHEMISTRY-US, V39, P4684, DOI 10.1021/bi992555g; Bennett EM, 2003, J BIOL CHEM, V278, P47110, DOI 10.1074/jbc.M304622200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BZOWSKA A, 1992, BIOCHIM BIOPHYS ACTA, V1120, P239, DOI 10.1016/0167-4838(92)90243-7; BZOWSKA A, 1990, Z NATURFORSCH C, V45, P59; BZOWSKA A, 1995, FEBS LETT, V367, P214, DOI 10.1016/0014-5793(95)00540-P; CAMERON D W, 1990, AIDS (London), V4, pS99; Craig SP, 2000, J BIOL CHEM, V275, P20231, DOI 10.1074/jbc.R000002200; EALICK SE, 1990, J BIOL CHEM, V265, P1812; Erion MD, 1997, BIOCHEMISTRY-US, V36, P11725, DOI 10.1021/bi961969w; Erion MD, 1997, BIOCHEMISTRY-US, V36, P11735, DOI 10.1021/bi961970v; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HARRIS DI, 1988, MOL BIOCHEM PARASIT, V29, P105, DOI 10.1016/0166-6851(88)90065-5; HEYWORTH PG, 1982, FEBS LETT, V141, P106, DOI 10.1016/0014-5793(82)80026-4; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; JENSEN KF, 1975, EUR J BIOCHEM, V51, P253, DOI 10.1111/j.1432-1033.1975.tb03925.x; JOHNSON PJ, 1993, PARASITOL TODAY, V9, P183, DOI 10.1016/0169-4758(93)90143-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koellner G, 1998, J MOL BIOL, V280, P153, DOI 10.1006/jmbi.1998.1799; Koellner G, 1997, J MOL BIOL, V265, P202, DOI 10.1006/jmbi.1996.0730; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; Lee JE, 2001, STRUCTURE, V9, P941, DOI 10.1016/S0969-2126(01)00656-6; Mao C, 1997, STRUCTURE, V5, P1373, DOI 10.1016/S0969-2126(97)00287-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miller R L, 1986, Adv Exp Med Biol, V195 Pt B, P573; MILLER RL, 1983, MOL BIOCHEM PARASIT, V7, P41, DOI 10.1016/0166-6851(83)90115-9; MORGUNOVA EY, 1995, FEBS LETT, V367, P183, DOI 10.1016/0014-5793(95)00489-V; Munagala N, 2002, BIOCHEMISTRY-US, V41, P10382, DOI 10.1021/bi026025n; Munagala N, 2002, MOL MICROBIOL, V44, P1073, DOI 10.1046/j.1365-2958.2002.02942.x; Munagala NR, 2003, MOL BIOCHEM PARASIT, V127, P143, DOI 10.1016/S0166-6851(02)00330-4; NELSON DJ, 1979, J BIOL CHEM, V254, P1544; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parker WB, 1998, BIOCHEM PHARMACOL, V55, P1673, DOI 10.1016/S0006-2952(98)00034-3; Parker WB, 2003, CANCER GENE THER, V10, P23, DOI 10.1038/sj.cgt.7700520; Parker WB, 1997, HUM GENE THER, V8, P1637, DOI 10.1089/hum.1997.8.14-1637; Petrin D, 1998, CLIN MICROBIOL REV, V11, P300, DOI 10.1128/CMR.11.2.300; Pugmire MJ, 2002, BIOCHEM J, V361, P1, DOI 10.1042/0264-6021:3610001; Secrist JA, 1999, NUCLEOS NUCLEOT, V18, P745, DOI 10.1080/15257779908041562; Shi WX, 2004, J BIOL CHEM, V279, P18103, DOI 10.1074/jbc.C400068200; Somoza JR, 1998, BIOCHEMISTRY-US, V37, P5344, DOI 10.1021/bi973095z; TAKEHARA M, 1995, BIOSCI BIOTECH BIOCH, V59, P1987, DOI 10.1271/bbb.59.1987; Upcroft P, 2001, CLIN MICROBIOL REV, V14, P150, DOI 10.1128/CMR.14.1.150-164.2001; Wang C.C., 2000, Heterocyclic derivatives as inhibitors of purine salvage phosphoribosyltransferases, Patent No. [US006075044A, 006075044, 6075044]; WANG CC, 1984, J MED CHEM, V27, P1, DOI 10.1021/jm00367a001; WANG CC, 1984, EXP PARASITOL, V57, P68, DOI 10.1016/0014-4894(84)90064-X; Zhang Y, 2004, STRUCTURE, V12, P1383, DOI 10.1016/j.str.2004.05.015	53	17	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22318	22325		10.1074/jbc.M501843200	http://dx.doi.org/10.1074/jbc.M501843200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817485	hybrid			2022-12-27	WOS:000229557900077
J	Druzhyna, NM; Musiyenko, SI; Wilson, GL; LeDoux, SP				Druzhyna, NM; Musiyenko, SI; Wilson, GL; LeDoux, SP			Cytokines induce nitric oxide-mediated mtDNA damage and apoptosis in oligodendrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-DNA DAMAGE; MULTIPLE-SCLEROSIS; CELL-DEATH; OXIDATIVE STRESS; SYNTHASE; REPAIR; EXPRESSION; GAMMA; 8-OXOGUANINE; DYSFUNCTION	Nitric oxide (NO) that is produced by inducible NO synthase (iNOS) in glial cells is thought to contribute significantly to the pathogenesis of multiple sclerosis. Oligodendrocytes can be stimulated to express iNOS by inflammatory cytokines, which are known to accumulate in the multiple sclerotic brain. The potentially pathological levels of NO produced under these circumstances can target a wide spectrum of intracellular components. We hypothesized that one of the critical targets for damage that leads to disease is mtDNA. In this study, we found that cytokines, in particular a combination of tumor necrosis factor-alpha (50 ng/ml) and IFN gamma (25 ng/ml), cause elevated NO production in primary cultures of rat oligodendrocytes. Western blot analysis revealed a strong enhancement of iNOS expression 48 h after cytokine treatment. Within the same time period, NO-mediated mtDNA damage was shown by Southern blot analysis and by ligation-mediated PCR. Targeting the DNA repair enzyme human 8-oxoguanine DNA glycosylase (hOGG1) to the mitochondria of oligodendrocytes had a protective effect against this cytokine-mediated mtDNA damage. Moreover, it was shown that mitochondrial transport sequence hOGG1-transfected oligodendrocytes had fewer apoptotic cells compared with cells containing vector only following treatment with the cytokines. Subsequent experiments revealed that targeting hOGG1 to mitochondria reduces the activation of caspase-9, showing that this recombinant protein works to reduce apoptosis that is occurring through a mitochondria-based pathway.	Univ S Alabama, Dept Cell Biol & Neurosci, Coll Med, Mobile, AL 36688 USA	University of South Alabama	LeDoux, SP (corresponding author), Univ S Alabama, Dept Cell Biol & Neurosci, Coll Med, MSB 1200, Mobile, AL 36688 USA.	sledoux@usouthal.edu						Andrews T, 1998, J NEUROSCI RES, V54, P574, DOI 10.1002/(SICI)1097-4547(19981201)54:5<574::AID-JNR2>3.3.CO;2-S; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Begolka WS, 1998, J IMMUNOL, V161, P4437; Bhat NR, 1999, J NEUROCHEM, V72, P472, DOI 10.1046/j.1471-4159.1999.0720472.x; Blasi F, 1999, BIOL CHEM, V380, P259, DOI 10.1515/BC.1999.034; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; Boullerne AI, 1999, J NEUROCHEM, V72, P1050, DOI 10.1046/j.1471-4159.1999.0721050.x; Brosnan CF, 1997, BIOCHEM SOC T, V25, P679, DOI 10.1042/bst0250679; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; Dobson AW, 2002, AM J PHYSIOL-LUNG C, V283, pL205, DOI 10.1152/ajplung.00443.2001; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; Druzhyna NM, 2003, GLIA, V42, P370, DOI 10.1002/glia.10230; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Grishko VI, 1999, NUCLEIC ACIDS RES, V27, P4510, DOI 10.1093/nar/27.22.4510; Hewett JA, 1999, J NEUROSCI RES, V56, P189, DOI 10.1002/(SICI)1097-4547(19990415)56:2<189::AID-JNR8>3.3.CO;2-2; Horwitz MS, 1997, NAT MED, V3, P1037, DOI 10.1038/nm0997-1037; Jurewicz A, 2003, BRAIN, V126, P1358, DOI 10.1093/brain/awg146; Kennedy LJ, 1997, CHEM RES TOXICOL, V10, P386, DOI 10.1021/tx960102w; LeDoux SP, 1998, GLIA, V24, P304, DOI 10.1002/(SICI)1098-1136(199811)24:3<304::AID-GLIA4>3.3.CO;2-J; Lucchinetti CF, 1997, MAYO CLIN PROC, V72, P665; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Merrill JE, 1997, J NEUROSCI RES, V48, P372, DOI 10.1002/(SICI)1097-4547(19970515)48:4<372::AID-JNR9>3.0.CO;2-8; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MITROVIC B, 1995, J NEUROSCI, V61, P575; Molina-Holgado E, 2001, EUR J NEUROSCI, V13, P493, DOI 10.1046/j.0953-816x.2000.01412.x; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; PFEIFER GP, 1993, MUTAT RES, V288, P39, DOI 10.1016/0027-5107(93)90206-U; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; Phoa N, 2002, CARCINOGENESIS, V23, P469, DOI 10.1093/carcin/23.3.469; PIKO L, 1992, ANN NY ACAD SCI, V663, P450, DOI 10.1111/j.1749-6632.1992.tb38698.x; Popko B, 1997, MOL NEUROBIOL, V14, P19, DOI 10.1007/BF02740619; PROBERT L, 1995, P NATL ACAD SCI USA, V92, P11294, DOI 10.1073/pnas.92.24.11294; Rachek LI, 2002, J BIOL CHEM, V277, P44932, DOI 10.1074/jbc.M208770200; Rachek LI, 2004, NUCLEIC ACIDS RES, V32, P3240, DOI 10.1093/nar/gkh648; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; RAINE CS, 1994, ANN NEUROL, V36, pS61, DOI 10.1002/ana.410360716; RAINE CS, 1995, NAT MED, V1, P211, DOI 10.1038/nm0395-211; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Suematsu N, 2003, CIRCULATION, V107, P1418, DOI 10.1161/01.CIR.0000055318.09997.1F; Tamir S, 1996, CHEM RES TOXICOL, V9, P821, DOI 10.1021/tx9600311; Wilson GL, 1997, DIABETES, V46, P1291, DOI 10.2337/diabetes.46.8.1291; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Zhao WG, 1996, J NEUROIMMUNOL, V64, P123, DOI 10.1016/0165-5728(95)00158-1	51	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21673	21679		10.1074/jbc.m411531200	http://dx.doi.org/10.1074/jbc.m411531200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15811855	hybrid			2022-12-27	WOS:000229438800094
J	Mancl, ME; Hu, GD; Sangster-Guity, N; Olshalsky, SL; Hoops, K; Fitzgerald-Bocarsly, P; Pitha, PM; Pinder, K; Barnes, BJ				Mancl, ME; Hu, GD; Sangster-Guity, N; Olshalsky, SL; Hoops, K; Fitzgerald-Bocarsly, P; Pitha, PM; Pinder, K; Barnes, BJ			Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMACYTOID DENDRITIC CELLS; IFN-ALPHA PRODUCTION; FUNCTIONAL-ANALYSIS; VIRUS; IRF-5; GENE; TRANSCRIPTION; EXPRESSION; ACTIVATION; INDUCTION	Interferon regulatory factor-5 (IRF-5) is a mediator of virus-induced immune activation and type I interferon (IFN) gene regulation. In human primary plasmacytoid dendritic cells (PDC), IRF-5 is transcribed into four distinct alternatively spliced isoforms (V1, V2, V3, and V4), whereas in human primary peripheral blood mononuclear cells two additional new isoforms (V5 and V6) were identified. The IRF-5 V1, V2, and V3 transcripts have different noncoding first exons and distinct insertion/ deletion patterns in exon 6. Here we showed that V1 and V3 have distinct transcription start sites and are regulated by two discrete promoters. The V1 promoter (P- V1) is constitutively active, contains an IRF-E consensus-binding site, and is further stimulated in virus-infected cells by IRF family members. In contrast, endogenous V3 transcripts were up-regulated by type I IFNs, and the V3 promoter ( P- V3) contains an IFN-stimulated responsive element-binding site that confers responsiveness to IFN through binding of the ISGF3 complex. In addition to V5 and V6, we have identified three more alternatively spliced IRF-5 isoforms (V7, V8, and V9); V5 and V6 were expressed in peripheral blood mononuclear cells from healthy donors and in immortalized B and T cell malignancies, whereas expression of V7, V8, and V9 transcripts were detected only in human cancers. The results of this study demonstrated the existence of multiple IRF-5 spliced isoforms with distinct cell type-specific expression, cellular localization, differential regulation, and dissimilar functions in virus-mediated type I IFN gene induction.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Div Viral Oncol, Baltimore, MD 21231 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Univ Med & Dent New Jersey Grad Sch Biomed Sci, Newark, NJ 07103 USA	Johns Hopkins University; Johns Hopkins Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Barnes, BJ (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Div Viral Oncol, 1650 Orleans St, Baltimore, MD 21231 USA.	barnebe@jhmi.edu	hu, guodong/B-4794-2010	Pinder, Karen/0000-0003-4173-4759	NATIONAL CANCER INSTITUTE [P50CA096888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI019737, R01AI026806, R01AI019737] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA96888] Funding Source: Medline; NIAID NIH HHS [R01 AI26806, R01 AI19737-21] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AU WC, 1993, J BIOL CHEM, V268, P24032; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Barnes BJ, 2004, J BIOL CHEM, V279, P45194, DOI 10.1074/jbc.M400726200; Barnes BJ, 2003, CANCER RES, V63, P6424; Barnes BJ, 2003, J BIOL CHEM, V278, P16630, DOI 10.1074/jbc.M212609200; Barnes BJ, 2002, MOL CELL BIOL, V22, P5721, DOI 10.1128/MCB.22.16.5721-5740.2002; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; CHENG F, 2004, JOINT M ICS ISICR SA, P27; CHEUNG SC, 1991, J IMMUNOL, V146, P121; Coccia EM, 2004, EUR J IMMUNOL, V34, P796, DOI 10.1002/eji.200324610; Dai JH, 2004, J IMMUNOL, V173, P1535, DOI 10.4049/jimmunol.173.3.1535; Dent CL, 1996, J INTERF CYTOK RES, V16, P99, DOI 10.1089/jir.1996.16.99; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; INCE TA, 1995, GENE, V156, P287, DOI 10.1016/0378-1119(94)00907-A; Izaguirre A, 2003, J LEUKOCYTE BIOL, V74, P1125, DOI 10.1189/jlb.0603255; Karpova AY, 2001, MOL CELL BIOL, V21, P4169, DOI 10.1128/MCB.21.13.4169-4176.2001; Karpova AY, 2000, GENE DEV, V14, P2813, DOI 10.1101/gad.813800; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; Lin RT, 2005, J BIOL CHEM, V280, P3088, DOI 10.1074/jbc.M408452200; Lowther WJ, 1999, DNA CELL BIOL, V18, P685, DOI 10.1089/104454999314962; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Megjugorac NJ, 2004, J LEUKOCYTE BIOL, V75, P504, DOI 10.1189/jlb.0603291; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Rothenfusser S, 2002, HUM IMMUNOL, V63, P1111, DOI 10.1016/S0198-8859(02)00749-8; Scherer SW, 2003, SCIENCE, V300, P767, DOI 10.1126/science.1083423; Schoenemeyer A, 2005, J BIOL CHEM, V280, P17005, DOI 10.1074/jbc.M412584200; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Takauji R, 2002, J LEUKOCYTE BIOL, V72, P1011; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Tanaka N, 2000, SEMIN CANCER BIOL, V10, P73, DOI 10.1006/scbi.2000.0310; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748; Zhang LW, 2001, SEMIN CANCER BIOL, V11, P445, DOI 10.1006/scbi.2001.0411	45	127	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21078	21090		10.1074/jbc.M500543200	http://dx.doi.org/10.1074/jbc.M500543200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15805103	hybrid			2022-12-27	WOS:000229438800023
J	Uchida, T; Sato, E; Sato, A; Sagami, I; Shimizu, T; Kitagawa, T				Uchida, T; Sato, E; Sato, A; Sagami, I; Shimizu, T; Kitagawa, T			CO-dependent activity-controlling mechanism of heme-containing CO-sensor protein, neuronal PAS domain protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; SOLUBLE GUANYLATE-CYCLASE; TRANSCRIPTIONAL ACTIVATOR COOA; DIRECT OXYGEN SENSOR; CIRCADIAN CLOCK GENE; ESCHERICHIA-COLI; NITRIC-OXIDE; CARBON-MONOXIDE; RHODOSPIRILLUM-RUBRUM; SIGNAL-TRANSDUCTION	Neuronal PAS domain protein 2, which was recently established to be a heme protein, acts as a CO-dependent transcription factor. The protein consists of the basic helix-loop-helix domain and two heme- containing PAS domains (PAS-A and PAS-B). In this study, we prepared wild type and mutants of the isolated PAS-A domain and measured resonance Raman spectra of these proteins. Upon excitation of the Raman spectrum at 363.8 nm, a band assignable to Fe3+-S stretching was observed at 334 cm(-1) for the ferric wild type protein; in contrast, this band was drastically weaker in the spectrum of C170A, suggesting that Cys(170) is an axial ligand of the ferric heme. The Raman spectrum of the reduced form of wild type was mainly of six-coordinate low spin, and the v(11) band, which is sensitive to the donor strength of the axial ligand, was lower than that of reduced cytochrome c(3), suggesting coordination of a strong ligand and thus a deprotonated His. In the reduced forms of H119A and H171A, the five-coordinate species became more prevalent, whereas no such changes were observed for C170A, indicating that His(119) and His(171), but not Cys(170), are axial ligands in the ferrous heme. This means that ligand replacement from Cys to His occurs upon heme reduction. The v(Fe-CO) versus v(C-O) correlation indicates that a neutral His is a trans ligand of CO. Our results support a mechanism in which CO binding disrupts the hydrogen bonding of His(171) with surrounding amino acids, which induces conformational changes in the His(171)- Cys(170) moiety, leading to physiological signaling.	Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Tohoku University	Kitagawa, T (corresponding author), Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan.	teizo@ims.ac.jp	Uchida, Takeshi/A-6455-2017	Uchida, Takeshi/0000-0001-9270-8329				ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; ANDERSSON LA, 1992, NEW J CHEM, V16, P569; ANDERSSON LA, 1989, J BIOL CHEM, V264, P19099; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Aono S, 2002, J BIOL CHEM, V277, P13528, DOI 10.1074/jbc.M112256200; ASHER SA, 1979, BIOCHEMISTRY-US, V18, P5377, DOI 10.1021/bi00591a019; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Cerda-Colon JF, 1998, J AM CHEM SOC, V120, P9312, DOI 10.1021/ja972654m; CHAMPION PM, 1982, J AM CHEM SOC, V104, P5469, DOI 10.1021/ja00384a037; Chan MK, 2001, CURR OPIN CHEM BIOL, V5, P216, DOI 10.1016/S1367-5931(00)00193-9; Chang AL, 2001, BIOCHEMISTRY-US, V40, P3420, DOI 10.1021/bi0100236; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; DESBOIS A, 1979, BIOCHEMISTRY-US, V18, P1510, DOI 10.1021/bi00575a019; DESBOIS A, 1992, EUR BIOPHYS J BIOPHY, V20, P321, DOI 10.1007/BF00196591; Dioum EM, 2002, SCIENCE, V298, P2385, DOI 10.1126/science.1078456; Fan BC, 1998, BIOCHEMISTRY-US, V37, P1178, DOI 10.1021/bi971934b; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; Gao F, 1998, BIOCHEMISTRY-US, V37, P9751, DOI 10.1021/bi9800653; Gao F, 1999, BBA-PROTEIN STRUCT M, V1430, P203, DOI 10.1016/S0167-4838(98)00284-2; Garcia JA, 2000, SCIENCE, V288, P2226, DOI 10.1126/science.288.5474.2226; Gilles-Gonzalez MA, 2004, J APPL PHYSIOL, V96, P774, DOI 10.1152/japplphysiol.00941.2003; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Gong WM, 2000, BIOCHEMISTRY-US, V39, P3955, DOI 10.1021/bi992346w; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; HASHIMOTO S, 1986, J BIOL CHEM, V261, P1110; HOBBS JD, 1990, BIOCHEMISTRY-US, V29, P4166, DOI 10.1021/bi00469a020; Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570; HU SZ, 1993, J AM CHEM SOC, V115, P12446, DOI 10.1021/ja00079a028; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Igarashi J, 2004, J BIOL CHEM, V279, P15752, DOI 10.1074/jbc.M310273200; Kim Sunyoung, 1998, Biochimica et Biophysica Acta, V1366, P331, DOI 10.1016/S0005-2728(98)00133-9; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Kurokawa H, 2004, J BIOL CHEM, V279, P20186, DOI 10.1074/jbc.M314199200; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Liu Y, 1999, BIOCHEMISTRY-US, V38, P3733, DOI 10.1021/bi982707s; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Mukai M, 2000, BIOCHEMISTRY-US, V39, P13810, DOI 10.1021/bi001184x; Nakajima H, 2001, J BIOL CHEM, V276, P37895; Othman S, 1996, BIOCHEMISTRY-US, V35, P9224, DOI 10.1021/bi952818g; Pal B, 2005, J INORG BIOCHEM, V99, P267, DOI 10.1016/j.jinorgbio.2004.09.027; Park HJ, 2004, BIOCHEMISTRY-US, V43, P2738, DOI 10.1021/bi035980p; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P12301, DOI 10.1021/bi980752u; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Rodgers KR, 1996, BIOCHEMISTRY-US, V35, P9539, DOI 10.1021/bi9530853; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Sasakura Y, 2002, J BIOL CHEM, V277, P23821, DOI 10.1074/jbc.M202738200; Sato A, 2002, J BIOL CHEM, V277, P32650, DOI 10.1074/jbc.M204559200; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; SMULEVICH G, 1988, BIOCHEMISTRY-US, V27, P5477, DOI 10.1021/bi00415a014; SPIRO TG, 1979, J AM CHEM SOC, V101, P2648, DOI 10.1021/ja00504a027; SPIRO TG, 1990, BIOCHEMISTRY-US, V29, P4497, DOI 10.1021/bi00471a001; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; Tamura K, 1996, J AM CHEM SOC, V118, P9434, DOI 10.1021/ja9543457; Taylor BL, 1999, ANNU REV MICROBIOL, V53, P103, DOI 10.1146/annurev.micro.53.1.103; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; VERMA AL, 1988, J AM CHEM SOC, V110, P6617, DOI 10.1021/ja00228a004; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; WELLS AV, 1992, BIOCHEMISTRY-US, V31, P4384, DOI 10.1021/bi00133a002; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200; YU AE, 1994, J AM CHEM SOC, V116, P4117, DOI 10.1021/ja00088a073; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713	76	66	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21358	21368		10.1074/jbc.M412350200	http://dx.doi.org/10.1074/jbc.M412350200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797872	hybrid			2022-12-27	WOS:000229438800055
J	Verdier, L; Al-Sabi, A; Rivier, JEF; Olivera, BM; Terlau, H; Carlomagno, T				Verdier, L; Al-Sabi, A; Rivier, JEF; Olivera, BM; Terlau, H; Carlomagno, T			Identification of a novel pharmacophore for peptide toxins interacting with K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU-CONOTOXIN-GIIIA; AMINO-ACID SUBSTITUTIONS; POTASSIUM CHANNEL; MOLECULAR-BASIS; SCORPION TOXIN; MUTANT CYCLES; BLOCKER; CHARYBDOTOXIN; SELECTIVITY; SIMULATION	kappa M-conotoxin RIIIK blocks TSha1 K+ channels from trout with high affinity by interacting with the ion channel pore. As opposed to many other peptides targeting K+ channels, kappa M-RIIIK does not possess a functional dyad. In this study we combine thermodynamic mutant cycle analysis and docking calculations to derive the binding mode of kappa M-conotoxin RIIIK to the TSha1 channel. The final model reveals a novel pharmacophore, where no positively charged side chain occludes the channel pore. Instead the positive-charged residues of the toxin form a basic ring; kappa M-RIIIK is anchored to the K+ channel via electrostatic interactions of this basic ring with the loop and pore helix residues of the channel. The channel amino acid Glu-354 is likely to be a fundamental determinant of the selectivity of kappa M-RIIIK for the TSha1 channel. The C gamma-OH of Hyp-15 is in contact with the carbonyls of the selectivity filter, disturbing the charge distribution pattern necessary for the coordination of K+ ions. This novel, experimentally based pharmacophore model proves the existence of diverse binding modes of peptidic toxins to K+ channels and underlines the role of intermolecular electrostatic interactions involving channel loop side chains in determining the selectivity of toxins for specific K+ channel types.	Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, D-37077 Gottingen, Germany; Max Planck Inst Expt Med, Grp Mol & Cellular Neuropharmacol, D-37075 Gottingen, Germany; Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	Max Planck Society; Max Planck Society; Salk Institute; Utah System of Higher Education; University of Utah	Terlau, H (corresponding author), Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, Fassberg 11, D-37077 Gottingen, Germany.	hterlau@gwdg.de	Al-Sabi, Ahmed/H-3438-2015; Al-Sabi, AHMED/AAF-9211-2020	Al-Sabi, Ahmed/0000-0002-1957-7569; Carlomagno, Teresa/0000-0002-2437-2760				Al-Sabi A, 2004, BIOCHEMISTRY-US, V43, P8625, DOI 10.1021/bi0495681; BECKER S, 1992, BIOCHEMISTRY-US, V31, P8229, DOI 10.1021/bi00150a016; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; de la Vega RCR, 2003, TRENDS PHARMACOL SCI, V24, P222, DOI 10.1016/S0165-6147(02)00080-4; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Eriksson MAL, 2002, BIOPHYS J, V83, P2595, DOI 10.1016/S0006-3495(02)75270-3; Ferber M, 2004, TOXICON, V43, P915, DOI 10.1016/j.toxicon.2003.12.010; Ferber M, 2003, J BIOL CHEM, V278, P2177, DOI 10.1074/jbc.M205953200; Gao YD, 2003, PROTEINS, V52, P146, DOI 10.1002/prot.10341; Gilquin B, 2002, J BIOL CHEM, V277, P37406, DOI 10.1074/jbc.M206205200; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Hill JM, 1996, BIOCHEMISTRY-US, V35, P8824, DOI 10.1021/bi960073o; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Huys I, 2004, BIOCHEM J, V378, P745, DOI 10.1042/BJ20031324; Ishii TM, 1998, METHOD ENZYMOL, V293, P53; Jacobsen RB, 2000, J BIOL CHEM, V275, P24639, DOI 10.1074/jbc.C900990199; LANCELIN JM, 1991, BIOCHEMISTRY-US, V30, P6908, DOI 10.1021/bi00242a014; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Mouhat S, 2004, BIOCHEM J, V377, P25, DOI 10.1042/BJ20030115; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 2001, MOL CLONING LAB MANU; SATO K, 1991, J BIOL CHEM, V266, P16989; Savarin P, 1998, BIOCHEMISTRY-US, V37, P5407, DOI 10.1021/bi9730341; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Srinivasan KN, 2002, J BIOL CHEM, V277, P30040, DOI 10.1074/jbc.M111258200; Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P12577, DOI 10.1021/bi00165a006; Xu CQ, 2003, TRENDS PHARMACOL SCI, V24, P446, DOI 10.1016/S0165-6147(03)00223-2	33	27	31	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21246	21255		10.1074/jbc.M502376200	http://dx.doi.org/10.1074/jbc.M502376200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799976	hybrid			2022-12-27	WOS:000229438800043
J	Lei, M; Zaug, AJ; Podell, ER; Cech, TR				Lei, M; Zaug, AJ; Podell, ER; Cech, TR			Switching human telomerase on and off with hPOT1 protein in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POT1; LENGTH REGULATOR; BINDING PROTEIN; DNA; END; PROTECTION; YEAST; CDC13; STN1; TRF1	POT1 ( protection of telomeres 1) protein binds the G-rich single-stranded telomeric DNA at the ends of chromosomes. In human cells hPOT1 is involved in telomere length regulation, but the mechanism of this regulation remains unknown. Examination of the high-resolution crystal structure of the hPOT1-TTAGGGTTAG complex suggested that it would not be extended by telomerase, a hypothesis that we confirm by in vitro assays with recombinant telomerase. On the other hand, when hPOT1 is bound at a position one telomeric repeat before the 3'-end, leaving an 8-nucleotide 3'-tail, the complex is extended with improved activity and processivity. Thus, depending on its location relative to the DNA 3'-end, hPOT1 can either inhibit telomerase action or form a preferred substrate for telomerase. We propose that another factor catalyzes the interconversion of these states in vivo.	Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Cech, TR (corresponding author), Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA.	Thomas.Cech@colorado.edu						Armbruster BN, 2004, MOL CELL BIOL, V24, P3552, DOI 10.1128/MCB.24.8.3552-3561.2004; Baumann P, 2002, MOL CELL BIOL, V22, P8079, DOI 10.1128/MCB.22.22.8079-8087.2002; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bryan TM, 2000, J BIOL CHEM, V275, P24199, DOI 10.1074/jbc.M003246200; Chandra A, 2001, GENE DEV, V15, P404, DOI 10.1101/gad.861001; Chen JL, 2003, EMBO J, V22, P304, DOI 10.1093/emboj/cdg024; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; Evans SK, 2002, GENETICS, V162, P1101; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; Froelich-Ammon SJ, 1998, GENE DEV, V12, P1504, DOI 10.1101/gad.12.10.1504; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; Grandin N, 2000, MOL CELL BIOL, V20, P8397, DOI 10.1128/MCB.20.22.8397-8408.2000; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; Grandin N, 2001, EMBO J, V20, P1173, DOI 10.1093/emboj/20.5.1173; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Houghtaling BR, 2004, CURR BIOL, V14, P1621, DOI 10.1016/j.cub.2004.08.052; Kelleher C, 2005, MOL CELL BIOL, V25, P808, DOI 10.1128/MCB.25.2.808-818.2005; Kim S, 2004, J BIOL CHEM, V279, P43799, DOI 10.1074/jbc.M408650200; Lei M, 2004, NAT STRUCT MOL BIOL, V11, P1223, DOI 10.1038/nsmb867; Lei M, 2003, NATURE, V426, P198, DOI 10.1038/nature02092; Lei M, 2002, BIOCHEMISTRY-US, V41, P14560, DOI 10.1021/bi026674z; Liu D, 2004, J BIOL CHEM, V279, P51338, DOI 10.1074/jbc.M409293200; Liu D, 2004, NAT CELL BIOL, V6, P673, DOI 10.1038/ncb1142; Loayza D, 2004, J BIOL CHEM, V279, P13241, DOI 10.1074/jbc.M312309200; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Lundblad V, 2003, CURR BIOL, V13, pR439, DOI 10.1016/S0960-9822(03)00365-8; Maine IP, 1999, BIOCHEMISTRY-US, V38, P15325, DOI 10.1021/bi991596+; Mitton-Fry RM, 2002, SCIENCE, V296, P145, DOI 10.1126/science.1068799; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nikitina T, 2004, J CELL BIOL, V166, P161, DOI 10.1083/jcb.200403118; PRICE CM, 1990, MOL CELL BIOL, V10, P3421, DOI 10.1128/MCB.10.7.3421; Reichenbach P, 2003, CURR BIOL, V13, P568, DOI 10.1016/S0960-9822(03)00173-8; Rivera MA, 2004, J BIOL CHEM, V279, P53770, DOI 10.1074/jbc.M407768200; SHIPPEN DE, 1994, P NATL ACAD SCI USA, V91, P405, DOI 10.1073/pnas.91.1.405; Snow BE, 2003, CURR BIOL, V13, P698, DOI 10.1016/S0960-9822(03)00210-0; Sun D, 1999, BIOCHEMISTRY-US, V38, P4037, DOI 10.1021/bi982249n; Taggart AKP, 2002, SCIENCE, V297, P1023, DOI 10.1126/science.1074968; Wei C, 2004, MOL CELL BIOL, V24, P2091, DOI 10.1128/MCB.24.5.2091-2102.2004; Ye JZS, 2004, J BIOL CHEM, V279, P47264, DOI 10.1074/jbc.M409047200; Ye JZS, 2004, GENE DEV, V18, P1649, DOI 10.1101/gad.1215404	44	130	137	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20449	20456		10.1074/jbc.M502212200	http://dx.doi.org/10.1074/jbc.M502212200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15792951	hybrid			2022-12-27	WOS:000229242000037
J	Morosinotto, T; Mozzo, M; Bassi, R; Croce, R				Morosinotto, T; Mozzo, M; Bassi, R; Croce, R			Pigment-pigment interactions in Lhca4 antenna complex of higher plants photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; FLUORESCENCE EMISSION; CRYSTAL-STRUCTURE; MUTATION ANALYSIS; BINDING; PROTEINS; RECONSTITUTION; ORGANIZATION; FORMS	The red-most fluorescence emission of photosystem I (733 nm at 4 K) is associated with the Lhca4 subunit of the antenna complex. It has been proposed that this unique spectral feature originates from the low energy absorption band of an excitonic interaction involving chlorophyll A5 and a second chlorophyll a molecule, probably B5 (Morosinotto, T., Breton, J., Bassi, R., and Croce, R. (2003) J. Biol. Chem. 278, 49223-49229). Because of the short distances between chromophores in Lhc proteins, the possibility that other pigments are involved in the red-shifted spectral forms could not be ruled out. In this study, we have analyzed the pigment-pigment interactions between nearest neighboring chromophores in Lhca4. This was done by deleting individual chlorophyll binding sites by mutagenesis, and analyzing the changes in the spectroscopic properties of recombinant proteins refolded in vitro. The red-shifted ( 733 nm) fluorescence peak, the major target of this analysis, was lost upon mutations affecting sites A4, A5, and B5 and was modified by mutating site B6. In agreement with the shorter distance between chlorophylls A5 and B5 ( 7.9 A) versus A4 and A5 ( 12.2 A) in Lhca4 (Ben-Shem, A., Frolow, F., and Nelson, N. ( 2003) Nature 426, 630 - 635), we conclude that the low energy spectral form originates from an interaction involving pigments in sites A5 and B5. Mutation at site B6, although inducing a 15-nm blue-shift of the emission peak, maintains the red- shifted emission. This implies that chromophores responsible for the interaction are conserved and suggests a modification in the pigment organization. Besides the A5 - B5 pair, evidence for additional pigment-pigment interactions between chlorophylls in sites B3-A3 and B6-A6 was obtained. However, these features do not affect the red- most spectral form responsible for the 733-nm fluorescence emission band.	ITC, CNR, Ist Biofis, I-38100 Trento, Italy; Univ Verona, Dipartimento Sci & Tecnol, I-37134 Verona, Italy; Univ Aix Marseille 2, Fac Sci Luminy, LGBP, Dept Biol, F-13288 Marseille, France	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); Istituto per le Tecnologie della Costruzione (ITC-CNR); University of Verona; UDICE-French Research Universities; Aix-Marseille Universite	Croce, R (corresponding author), ITC, CNR, Ist Biofis, Via Sommarive 18, I-38100 Trento, Italy.	croce@itc.it	Croce, Roberta/ABG-3595-2021; Croce, Roberta/F-1174-2014; Croce, Roberta/N-4067-2014; Croce, Roberta/HGU-9554-2022; Morosinotto, Tomas/AAC-3188-2019	Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; Morosinotto, Tomas/0000-0002-0803-7591; bassi, roberto/0000-0002-4140-8446				Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Castelletti S, 2003, BIOCHEMISTRY-US, V42, P4226, DOI 10.1021/bi027398r; Croce R, 1996, BIOCHEMISTRY-US, V35, P8572, DOI 10.1021/bi960214m; Croce R, 2004, J BIOL CHEM, V279, P48543, DOI 10.1074/jbc.M408908200; Croce R, 2002, BBA-BIOENERGETICS, V1556, P29, DOI 10.1016/S0005-2728(02)00304-3; Croce R, 2002, BIOCHEMISTRY-US, V41, P7334, DOI 10.1021/bi0257437; Formaggio E, 2001, J MOL BIOL, V314, P1157, DOI 10.1006/jmbi.2000.5179; GILMORE AM, 1991, PLANT PHYSIOL, V96, P635, DOI 10.1104/pp.96.2.635; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; Gobets B, 2001, BBA-BIOENERGETICS, V1507, P80, DOI 10.1016/S0005-2728(01)00203-1; HAWORTH P, 1983, BIOCHIM BIOPHYS ACTA, V724, P151, DOI 10.1016/0005-2728(83)90036-1; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; JENNINGS RC, 1992, RES PHOTOSYNTH, V1, P291; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Morosinotto T, 2003, J BIOL CHEM, V278, P49223, DOI 10.1074/jbc.M309203200; Morosinotto T, 2002, J BIOL CHEM, V277, P36253, DOI 10.1074/jbc.M205062200; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; Remelli R, 1999, J BIOL CHEM, V274, P33510, DOI 10.1074/jbc.274.47.33510; Rivadossi A, 1999, PHOTOSYNTH RES, V60, P209, DOI 10.1023/A:1006236829711; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; Schmid VHR, 2002, J BIOL CHEM, V277, P37307, DOI 10.1074/jbc.M205889200; VANAMERONGEN H, 2000, PHOTOSYNTHETIC EXCIT, P52	25	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20612	20619		10.1074/jbc.M500705200	http://dx.doi.org/10.1074/jbc.M500705200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788395	hybrid			2022-12-27	WOS:000229242000057
J	Akimoto, T; Pohnert, SC; Li, P; Zhang, M; Gumbs, C; Rosenberg, PB; Williams, RS; Yan, Z				Akimoto, T; Pohnert, SC; Li, P; Zhang, M; Gumbs, C; Rosenberg, PB; Williams, RS; Yan, Z			Exercise stimulates Pgc-1 alpha transcription in skeletal muscle through activation of the p38 MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA COACTIVATOR-1-ALPHA EXPRESSION; JUN NH2-TERMINAL KINASE; PROTEIN-KINASE; MITOCHONDRIAL BIOGENESIS; GENE-EXPRESSION; CONTRACTILE ACTIVITY; MEF2 FAMILY; AMP KINASE; FIBER-TYPE; CALCINEURIN	Peroxisome proliferator-activated receptor gamma co-activator 1 alpha (PGC-1 alpha) promotes mitochondrial biogenesis and slow fiber formation in skeletal muscle. We hypothesized that activation of the p38 mitogen-activated protein kinase ( MAPK) pathway in response to increased muscle activity stimulated Pgc-1 alpha gene transcription as part of the mechanisms for skeletal muscle adaptation. Here we report that a single bout of voluntary running induced a transient increase of Pgc-1 alpha mRNA expression in mouse plantaris muscle, concurrent with an activation of the p38 MAPK pathway. Activation of the p38 MAPK pathway in cultured C2C12 myocytes stimulated Pgc-1 alpha promoter activity, which could be blocked by the specific inhibitors of p38, SB203580 and SB202190, or a dominant negative p38. Furthermore, the p38-mediated increase in Pgc-1 alpha promoter activity was enhanced by increased expression of the downstream transcription factor ATF2 and completely blocked by ATF2 Delta N, a dominant negative ATF2. Skeletal muscle-specific expression of a constitutively active activator of p38, MKK6E, in transgenic mice resulted in enhanced Pgc-1 alpha and cytochrome oxidase IV protein expression in fast-twitch skeletal muscles. These findings suggest that contractile activity-induced activation of the p38 MAPK pathway promotes Pgc-1 alpha gene expression and skeletal muscle adaptation.	Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27704 USA	Duke University	Yan, Z (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Cardiol, 4321 Med Pk Dr,Suite 200, Durham, NC 27704 USA.	zhen.yan@duke.edu	Akimoto, Takayuki/H-6704-2012	Akimoto, Takayuki/0000-0002-8874-7779; Yan, Zhen/0000-0002-4826-9813; Rosenberg, Paul/0000-0002-5659-160X				ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; Akimoto T, 2004, AM J PHYSIOL-CELL PH, V287, pC1311, DOI 10.1152/ajpcell.00248.2004; Akimoto T, 2004, AM J PHYSIOL-CELL PH, V287, pC790, DOI 10.1152/ajpcell.00425.2003; Allen DL, 2001, J APPL PHYSIOL, V90, P1900, DOI 10.1152/jappl.2001.90.5.1900; Ambrosino C, 2003, MOL CELL BIOL, V23, P370, DOI 10.1128/MCB.23.1.370-381.2003; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; Booth FW, 2002, J APPL PHYSIOL, V93, P3, DOI 10.1152/japplphysiol.00073.2002; Boppart MD, 2001, AM J PHYSIOL-CELL PH, V280, pC352, DOI 10.1152/ajpcell.2001.280.2.C352; Boppart MD, 2000, J PHYSIOL-LONDON, V526, P663, DOI 10.1111/j.1469-7793.2000.00663.x; Cao WH, 2004, MOL CELL BIOL, V24, P3057, DOI 10.1128/MCB.24.7.3057-3067.2004; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100; Fan M, 2004, GENE DEV, V18, P278, DOI 10.1101/gad.1152204; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Holmes BF, 2004, AM J PHYSIOL-ENDOC M, V287, pE739, DOI 10.1152/ajpendo.00080.2004; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Irrcher I, 2003, AM J PHYSIOL-CELL PH, V284, pC1669, DOI 10.1152/ajpcell.00409.2002; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Li YQ, 2000, CELL SIGNAL, V12, P751, DOI 10.1016/S0898-6568(00)00120-0; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Nader GA, 2001, J APPL PHYSIOL, V90, P1936, DOI 10.1152/jappl.2001.90.5.1936; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Nielsen JN, 2003, BIOCHEM BIOPH RES CO, V312, P1147, DOI 10.1016/j.bbrc.2003.11.041; Niu WY, 2003, J BIOL CHEM, V278, P17953, DOI 10.1074/jbc.M211136200; Ojuka EO, 2003, FASEB J, V17, P675, DOI 10.1096/fj.02-0951com; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Steinmuller L, 2003, BIOL CHEM, V384, P667, DOI 10.1515/BC.2003.074; SUZUKI M, 1983, J NUTR SCI VITAMINOL, V29, P545, DOI 10.3177/jnsv.29.545; Terada S, 2004, AM J PHYSIOL-ENDOC M, V286, pE208, DOI 10.1152/ajpendo.00051.2003; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Waters RE, 2004, AM J PHYSIOL-CELL PH, V287, pC1342, DOI 10.1152/ajpcell.00247.2004; Widegren U, 1998, FASEB J, V12, P1379, DOI 10.1096/fasebj.12.13.1379; Williams RS, 1996, HDB PHYSL EXERCISE R, P1124; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yan Z, 2003, J BIOL CHEM, V278, P8826, DOI 10.1074/jbc.M209879200; Yan Z, 2001, J BIOL CHEM, V276, P17361, DOI 10.1074/jbc.M101251200; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599; [No title captured]	51	485	509	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19587	19593		10.1074/jbc.M408862200	http://dx.doi.org/10.1074/jbc.M408862200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15767263	hybrid			2022-12-27	WOS:000229113700021
J	Bautista, JA; Rappaport, F; Guergova-Kuras, M; Cohen, RO; Golbeck, JH; Wang, JY; Beal, D; Diner, BA				Bautista, JA; Rappaport, F; Guergova-Kuras, M; Cohen, RO; Golbeck, JH; Wang, JY; Beal, D; Diner, BA			Biochemical and biophysical characterization of photosystem I from phytoene desaturase and xi-carotene desaturase deletion mutants of Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIDIRECTIONAL ELECTRON-TRANSFER; PRIMARY CHARGE SEPARATION; IRON-SULFUR CENTERS; SYNECHOCOCCUS-SP; PHOTOCHEMICAL PROPERTIES; VIVO ANALYSIS; WILD-TYPE; A(1); PLASTOCYANIN; TEMPERATURE	In photosystem I, oxidation of reduced acceptor A(1) - through iron-sulfur cluster F-X is biphasic with half-times of similar to 5-30 ns ("fast" phase) and similar to 150-300 ns ("slow" phase). Whether these biphasic kinetics reflect unidirectional electron transfer, involving only the PsaA-side phylloquinone or bi-directional electron transfer, involving both the PsaA- and PsaB-side phylloquinones, has been the source of some controversy. Brettel ( Brettel, K. ( 1988) FEBS Lett. 239, 93 - 98) and Joliot and Joliot ( Joliot, P., and Joliot, A. ( 1999) Biochemistry 38, 11130 - 11136) have attributed to nearby carotenoids electrochromic band shifts, accompanying A(1) reduction, centered at similar to 450 and 500-510 nm. As a test of these assignments, we separately deleted in Synechocystis sp. PCC 6803 the genes that encode phytoene desaturase ( encoded by crtP (pds)) and zeta-carotene desaturase ( encoded by crtQ (zds)). The pds(-) and zds(-) strains synthesize phytoene and zeta-carotene, respectively, both of which absorb to shorter wavelength than zeta-carotene. Compared with wild type, the mutant A(1)(-)(FeS) similar to A(1)(FeS)(-) difference spectra, measured in cells and photosystem I complexes, retain the electrochromic band shift centered at 450 nm but show a complete loss of the electrochromic band shifts centered at 500 - 510 nm. Thus, the latter clearly arise from beta-carotene. In the wild type, the electrochromic band shift of the slow phase ( centered at 500 nm) is shifted by 6 nm to the blue compared with the fast phase ( centered at 506 nm). Thus, the carotenoid pigments acting as electrochromic markers during the fast and slow phases of A(1)(-) oxidation are different, indicating the involvement of both the PsaA- and the PsaB-side phylloquinones in photosystem I electron transport.	EI Du Pont Nemours & Co, Cent Res & Dev, Expt Stn, Wilmington, DE 19880 USA; Univ Paris 06, UMR 7141, CNRS, Inst Biol Phys Chim, F-75005 Paris, France; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Dept Chem, University Pk, PA 16802 USA	DuPont; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Diner, BA (corresponding author), EI Du Pont Nemours & Co, Cent Res & Dev, Expt Stn, Wilmington, DE 19880 USA.	bruce.a.diner@usa.dupont.com		Rappaport, Fabrice/0000-0001-9377-4934				Agalarov R, 2003, BBA-BIOENERGETICS, V1604, P7, DOI 10.1016/S0005-2728(03)00024-0; Bautista JA, 1998, PHOTOSYNTH RES, V55, P49, DOI 10.1023/A:1005955425420; Beal D, 1999, REV SCI INSTRUM, V70, P202, DOI 10.1063/1.1149566; BRETTEL K, 1988, FEBS LETT, V239, P93, DOI 10.1016/0014-5793(88)80552-0; BRETTEL K, 1986, FEBS LETT, V203, P220, DOI 10.1016/0014-5793(86)80746-3; Brettel K, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P611; BRITTON G, 1985, METHOD ENZYMOL, V111, P113, DOI 10.1016/S0076-6879(85)11007-4; Britton G., 1995, SPECTROSCOPY-US, V1B, P13; Britton G., 1995, CAROTENOIDS B; Cohen RO, 2004, BIOCHEMISTRY-US, V43, P4741, DOI 10.1021/bi035633f; COUFAL J, 1989, PHOTOSYNTHETICA, V23, P603; Diner BA, 1998, METHOD ENZYMOL, V297, P337; DOBEK K, 2004, P 13 INT C PHOT MONT, P91; Fairclough WV, 2003, BBA-BIOENERGETICS, V1606, P43, DOI 10.1016/S0005-2728(03)00083-5; FARAH J, 1995, EMBO J, V14, P4976, DOI 10.1002/j.1460-2075.1995.tb00180.x; Frank HA, 1996, PHOTOCHEM PHOTOBIOL, V63, P257, DOI 10.1111/j.1751-1097.1996.tb03022.x; Fromme P, 2001, BBA-BIOENERGETICS, V1507, P5, DOI 10.1016/S0005-2728(01)00195-5; Giorgi LB, 1996, J BIOL CHEM, V271, P2093, DOI 10.1074/jbc.271.4.2093; Guergova-Kuras M, 2001, P NATL ACAD SCI USA, V98, P4437, DOI 10.1073/pnas.081078898; HASHIMOTO H, 1988, J PHYS CHEM-US, V92, P2101, DOI 10.1021/j100319a004; Heathcote P, 1996, BIOCHEMISTRY-US, V35, P6644, DOI 10.1021/bi9526185; HECKS B, 1994, BIOCHEMISTRY-US, V33, P8619, DOI 10.1021/bi00195a001; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; Ishikita H, 2003, J BIOL CHEM, V278, P52002, DOI 10.1074/jbc.M306434200; Joliot P, 1999, BIOCHEMISTRY-US, V38, P11130, DOI 10.1021/bi990857c; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KOBAYASHI M, 1988, BIOCHIM BIOPHYS ACTA, V936, P81, DOI 10.1016/0005-2728(88)90254-X; LEIBL W, 1995, BIOCHEMISTRY-US, V34, P10237, DOI 10.1021/bi00032a018; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MacMillan F, 1997, BIOCHEMISTRY-US, V36, P9297, DOI 10.1021/bi971097d; Muhiuddin IP, 2001, FEBS LETT, V503, P56, DOI 10.1016/S0014-5793(01)02696-5; MULLER KH, 1991, EUR BIOPHYS J, V19, P231; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; Ramesh VM, 2004, BIOCHEMISTRY-US, V43, P1369, DOI 10.1021/bi0354177; RAPPAPORT F, 2005, IN PRESS PHOTOSYSTEM, V1; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; ROGNER M, 1990, J BIOL CHEM, V265, P6189; ROMIJN JC, 1977, BIOCHIM BIOPHYS ACTA, V461, P327, DOI 10.1016/0005-2728(77)90223-7; SETIF P, 1993, BIOCHEMISTRY-US, V32, P7846, DOI 10.1021/bi00082a002; Setif P, 2002, BBA-BIOENERGETICS, V1555, P204, DOI 10.1016/S0005-2728(02)00279-7; Shen GZ, 2002, J BIOL CHEM, V277, P20355, DOI 10.1074/jbc.M201104200; SIEFERMANNHARMS D, 1987, PHYSIOL PLANTARUM, V69, P561, DOI 10.1111/j.1399-3054.1987.tb09240.x; TAKAHASHI Y, 1985, PHOTOSYNTH RES, V6, P183, DOI 10.1007/BF00032792; TANG XS, 1994, BIOCHEMISTRY-US, V33, P4594, DOI 10.1021/bi00181a021; Trebst A, 1997, FEBS LETT, V400, P359, DOI 10.1016/S0014-5793(96)01419-6; van der Est A, 2004, BIOCHEMISTRY-US, V43, P1264, DOI 10.1021/bi035431j; vanderEst A, 1997, J PHYS CHEM B, V101, P1437, DOI 10.1021/jp9622086; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; Xu W, 2003, J BIOL CHEM, V278, P27876, DOI 10.1074/jbc.M302965200; Yang F, 1998, J PHYS CHEM B, V102, P8288, DOI 10.1021/jp981952i; ZECHMASTER L, 1962, CIS T ISOMERIC CAROT; Zybailov B, 2000, J BIOL CHEM, V275, P8531, DOI 10.1074/jbc.275.12.8531	53	65	68	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20030	20041		10.1074/jbc.M500809200	http://dx.doi.org/10.1074/jbc.M500809200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15760840	hybrid			2022-12-27	WOS:000229113700073
J	Guo, XM; Razandi, M; Pedram, A; Kassab, G; Levin, ER				Guo, XM; Razandi, M; Pedram, A; Kassab, G; Levin, ER			Estrogen induces vascular wall dilation - Mediation through kinase signaling to nitric oxide and estrogen receptors alpha and beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; POSTMENOPAUSAL WOMEN; MYOCARDIAL-ISCHEMIA; PLASMA-MEMBRANE; BINDING SITES; ER-BETA; PATHWAY; INJURY; GENE; 17-BETA-ESTRADIOL	Estrogen has been shown to affect vascular cell and arterial function in vitro and in vivo. Here we examined the ability of estradiol (E-2) to cause rapid arterial dilation of elastic and muscular arteries in vivo and the mechanisms involved. E-2 administration caused a rapid increase in the outer wall diameter of both types of arteries in ovariectomized female mice. This resulted from estrogen receptor (ER)- mediated stimulation of nitric oxide production, demonstrated by preinjecting the mice arteries with a soluble inhibitor of nitric oxide ( monomethyl L-arginine) and by showing the absence of E-2 action in eNOS-/- mice. Rapid activation of both ERK/MAP kinase and phosphatidylinositol 3-kinase activity was found in the E-2-exposed arteries, and inhibiting either kinase prevented the vasodilatory action of E-2. Kinase activation and vasodilator responses to E-2 were absent in either ER alpha or ER beta knock-out mice, implicating both receptor subtypes as mediating this E-2 action. These results indicate that E-2 modulation of arterial tonus through plasma membrane ER and rapid signaling could underlie many previously observed actions of estrogen reported to occur in women.	Calif State Univ Long Beach, Vet Affairs Med Ctr, Med Serv, Div Endocrinol, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Biomed Engn, Irvine, CA 92717 USA	California State University System; California State University Long Beach; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine	Levin, ER (corresponding author), Calif State Univ Long Beach, Vet Affairs Med Ctr, Med Serv, Div Endocrinol, 5901 E 7th St, Long Beach, CA 90822 USA.	ellis.levin@med.va.gov	Levin, Ellis/J-5402-2013		NHLBI NIH HHS [HL055554-06, HL59890] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055554, R29HL055554, R01HL059890] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Benten WPM, 2001, ENDOCRINOLOGY, V142, P1669, DOI 10.1210/en.142.4.1669; Chambliss KL, 2002, ENDOCR REV, V23, P665, DOI 10.1210/er.2001-0045; Chambliss KL, 2002, MOL ENDOCRINOL, V16, P938, DOI 10.1210/me.16.5.938; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Cho MM, 1999, AM J PHYSIOL-CELL PH, V276, pC337; COLBURN P, 1978, SCIENCE, V201, P817, DOI 10.1126/science.684408; COLLINS P, 1995, CIRCULATION, V92, P24, DOI 10.1161/01.CIR.92.1.24; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; HERRINGTON DM, 1994, AM J CARDIOL, V73, P951, DOI 10.1016/0002-9149(94)90136-8; KARRAS RH, 1994, CIRCULATION, V89, P1943; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Konidala S, 2004, PROG CARDIOVASC DIS, V46, P349, DOI 10.1016/j.pcad.2003.10.001; Levin ER, 2001, J APPL PHYSIOL, V91, P1860, DOI 10.1152/jappl.2001.91.4.1860; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; McCrohon JA, 1997, J AM COLL CARDIOL, V29, P1432, DOI 10.1016/S0735-1097(97)00063-6; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Node K, 1997, CIRCULATION, V96, P1953, DOI 10.1161/01.CIR.96.6.1953; PAPPAS TC, 1994, ENDOCRINE, V2, P813; Pare G, 2002, CIRC RES, V90, P1087, DOI 10.1161/01.RES.0000021114.92282.FA; Pedram A, 2002, J BIOL CHEM, V277, P50768, DOI 10.1074/jbc.M210106200; Pedram A, 2002, J BIOL CHEM, V277, P44385, DOI 10.1074/jbc.M202391200; Razandi M, 2000, J BIOL CHEM, V275, P38540, DOI 10.1074/jbc.M007555200; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Razandi M, 2004, MOL ENDOCRINOL, V18, P2854, DOI 10.1210/me.2004-0115; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; ROSANO GMC, 1993, LANCET, V342, P133, DOI 10.1016/0140-6736(93)91343-K; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rubanyi GM, 1997, J CLIN INVEST, V99, P2429, DOI 10.1172/JCI119426; Sanada M, 2003, J CLIN ENDOCR METAB, V88, P1303, DOI 10.1210/jc.2002-021147; Shlipak MG, 2001, CIRCULATION, V104, P2300, DOI 10.1161/hc4401.98414; Shughrue PJ, 2002, ENDOCRINOLOGY, V143, P1643, DOI 10.1210/en.143.5.1643; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Singer CA, 1999, J NEUROSCI, V19, P2455; TESARIK J, 1995, J CLIN ENDOCR METAB, V80, P1438, DOI 10.1210/jc.80.4.1438; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Wassmann S, 2001, CIRCULATION, V103, P435; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; Williams MRI, 2001, J CLIN ENDOCR METAB, V86, P5389, DOI 10.1210/jc.86.11.5389; Zhai PY, 2000, AM J PHYSIOL-HEART C, V278, pH1640, DOI 10.1152/ajpheart.2000.278.5.H1640; Zhu Y, 2002, SCIENCE, V295, P505, DOI 10.1126/science.1065250	43	134	139	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19704	19710		10.1074/jbc.M501244200	http://dx.doi.org/10.1074/jbc.M501244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15764600	hybrid			2022-12-27	WOS:000229113700036
J	Iancu, CV; Mukund, S; Fromm, HJ; Honzatko, RB				Iancu, CV; Mukund, S; Fromm, HJ; Honzatko, RB			R-state AMP complex reveals initial steps of the quaternary transition of fructose-1,6-bisphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-KIDNEY FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE; LIVER FRUCTOSE-1,6-BISPHOSPHATASE; ALLOSTERIC INHIBITION; CRYSTAL-STRUCTURE; MECHANISM; SITE; INTERFACE; 1,6-BISPHOSPHATASE; FLUORESCENCE	AMP transforms fructose-1,6-bisphosphatase from its active R-state to its inactive T-state; however, the mechanism of that transformation is poorly understood. The mutation of Ala(54) to leucine destabilizes the T-state of fructose-1,6-bisphosphatase. The mutant enzyme retains wild-type levels of activity, but the concentration of AMP that causes 50% inhibition increases 50-fold. In the absence of AMP, the Leu(54) enzyme adopts an R-state conformation nearly identical to that of the wild-type enzyme. The mutant enzyme, however, grows in two crystal forms in the presence of saturating AMP. In one form, the AMP-bound tetramer is in a T-like conformation, whereas in the other form, the AMP-bound tetramer is in a R-like conformation. The latter reveals conformational changes in two helices due to the binding of AMP. Helix H1 moves toward the center of the tetramer and displaces Ile(10) from a hydrophobic pocket. The displacement of Ile(10) exposes a hydrophobic surface critical to interactions that stabilize the T-state. Helix H2 moves away from the center of the tetramer, breaking hydrogen bonds with a buried loop ( residues 187 195) in an adjacent subunit. The same hydrogen bonds reform but only after the quaternary transition to the T-state. Proposed here is a model that accounts for the quaternary transition and cooperativity in the inhibition of catalysis by AMP.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	honzatko@iastate.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546, R01 NS010546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carcamo JG, 2000, EUR J BIOCHEM, V267, P2242, DOI 10.1046/j.1432-1327.2000.01227.x; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; Choe JY, 1998, BIOCHEMISTRY-US, V37, P11441, DOI 10.1021/bi981112u; Choe JY, 2003, J BIOL CHEM, V278, P51176, DOI 10.1074/jbc.M308396200; Choe JY, 2003, J BIOL CHEM, V278, P16008, DOI 10.1074/jbc.M212394200; Choe JY, 2003, J BIOL CHEM, V278, P16015, DOI 10.1074/jbc.M212395200; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; KE H, 1990, J MOL BIOL, V212, P513, DOI 10.1016/0022-2836(90)90329-K; KE HM, 1991, P NATL ACAD SCI USA, V88, P2989, DOI 10.1073/pnas.88.8.2989; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LIU F, 1988, J BIOL CHEM, V263, P9122; LIU F, 1991, J BIOL CHEM, V266, P11774; LIU F, 1990, J BIOL CHEM, V265, P7401; Lu GQ, 1996, PROTEIN SCI, V5, P2333, DOI 10.1002/pro.5560051120; Lu GQ, 1997, J BIOL CHEM, V272, P5076, DOI 10.1074/jbc.272.8.5076; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Nelson SW, 2002, J BIOL CHEM, V277, P15539, DOI 10.1074/jbc.M112304200; Nelson SW, 2001, J BIOL CHEM, V276, P6119, DOI 10.1074/jbc.M009485200; Nelson SW, 2001, FEBS LETT, V492, P254, DOI 10.1016/S0014-5793(01)02262-1; Nelson SW, 2000, BIOCHEMISTRY-US, V39, P11100, DOI 10.1021/bi000609c; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; Shyur LF, 1996, J BIOL CHEM, V271, P33301, DOI 10.1074/jbc.271.52.33301; Shyur LF, 1996, J BIOL CHEM, V271, P3005, DOI 10.1074/jbc.271.6.3005; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Van Schaftingen E., 1987, ADV ENZYMOL RELAT AR, V59, P45; Wen J, 2001, PHOTOCHEM PHOTOBIOL, V74, P679, DOI 10.1562/0031-8655(2001)074<0679:EOTIPF>2.0.CO;2; XUE YF, 1994, P NATL ACAD SCI USA, V91, P12482, DOI 10.1073/pnas.91.26.12482; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	38	21	22	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19737	19745		10.1074/jbc.M501011200	http://dx.doi.org/10.1074/jbc.M501011200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15767255	hybrid			2022-12-27	WOS:000229113700040
J	Petrakis, TG; Sogaard, TMM; Erdjument-Bromage, H; Tempst, P; Svejstrup, JQ				Petrakis, TG; Sogaard, TMM; Erdjument-Bromage, H; Tempst, P; Svejstrup, JQ			Physical and functional interaction between Elongator and the chromatin-associated Kti12 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; KLUYVEROMYCES-LACTIS ZYMOCIN; SACCHAROMYCES-CEREVISIAE ELONGATOR; HISTONE ACETYLTRANSFERASE; SUBUNIT; HOLOENZYME; COMPLEX; TOXIN; GENES	Cells lacking KTI12 or Elongator (ELP) genes are insensitive to the toxin zymocin and also share more general phenotypes. Moreover, data from low stringency immunoprecipitation experiments suggest that Elongator and Kti12 may interact. However, the precise relationship between these factors has not been determined. Here we use a variety of approaches to investigate the possibility that Elongator and Kti12 functionally overlap. Native Kti12 purified to virtual homogeneity under stringent conditions is a single polypeptide, but depletion of Kti12 from a yeast extract results in co-depletion of Elongator, indicating that these factors do interact. Indeed, biochemical evidence suggests that Elongator and Kti12 form a fragile complex under physiological salt conditions. Purified Kti12 does not affect Elongator histone acetyltransferase activity in vitro. However, a variety of genetic experiments comparing the effects of mutation in ELP3 and KTI12 alone and in combination with other transcription factor mutations clearly demonstrate a significant functional overlap between Elongator and Kti12 in vivo. Intriguingly, chromatin immunoprecipitation experiments show that Kti12 is associated with chromatin throughout the genome, even in non-transcribed regions and in the absence of Elongator. Conversely, RNA-immunoprecipitation experiments indicate that Kti12 only plays a minor role for Elongator association with active genes. Together, these experiments indicate a close physical and functional relationship between Elongator and the highly conserved Kti12 protein.	Imperial Canc Res Fund, Clare Hall Labs, Canc Res UK London Res Inst, S Mimms EN6 3LD, Herts, England; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Cancer Research UK; Memorial Sloan Kettering Cancer Center	Svejstrup, JQ (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, Canc Res UK London Res Inst, Blanche Lane, S Mimms EN6 3LD, Herts, England.	J.svejstrup@cancer.org.uk		Svejstrup, Jesper/0000-0003-4964-6147; Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Sogaard, Teit Max Moscote/0000-0001-6224-4818				BUTLER AR, 1991, YEAST, V7, P617, DOI 10.1002/yea.320070610; Fellows J, 2000, J BIOL CHEM, V275, P12896, DOI 10.1074/jbc.275.17.12896; Fichtner L, 2003, MOL MICROBIOL, V49, P1297, DOI 10.1046/j.1365-2958.2003.03632.x; Fichtner L, 2002, MOL MICROBIOL, V45, P817, DOI 10.1046/j.1365-2958.2002.03055.x; Fichtner L, 2002, MOL MICROBIOL, V43, P783, DOI 10.1046/j.1365-2958.2002.02794.x; Frohloff F, 2003, J BIOL CHEM, V278, P956, DOI 10.1074/jbc.M210060200; Frohloff F, 2001, EMBO J, V20, P1993, DOI 10.1093/emboj/20.8.1993; Gilbert C, 2004, MOL CELL, V14, P457, DOI 10.1016/S1097-2765(04)00239-4; Gilbert CS, 2003, EMBO REP, V4, P953, DOI 10.1038/sj.embor.embor935; Jablonowski D, 2002, J BIOL CHEM, V277, P26276, DOI 10.1074/jbc.M203354200; Jablonowski D, 2001, MOL MICROBIOL, V42, P1095, DOI 10.1046/j.1365-2958.2001.02705.x; Kishida M, 1996, BIOSCI BIOTECH BIOCH, V60, P798, DOI 10.1271/bbb.60.798; Kitamoto HK, 2002, MOL GENET GENOMICS, V268, P49, DOI 10.1007/s00438-002-0720-3; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kristjuhan A, 2002, MOL CELL, V10, P925, DOI 10.1016/S1097-2765(02)00647-0; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Petrakis TG, 2004, J BIOL CHEM, V279, P32087, DOI 10.1074/jbc.M403361200; STARK MJR, 1990, YEAST, V6, P1, DOI 10.1002/yea.320060102; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0; Winkler GS, 2001, J BIOL CHEM, V276, P32743, DOI 10.1074/jbc.M105303200; Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X	24	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19454	19460		10.1074/jbc.M413373200	http://dx.doi.org/10.1074/jbc.M413373200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772087	hybrid			2022-12-27	WOS:000229113700006
J	Price, MG; Davis, CF; Deng, F; Burgess, DL				Price, MG; Davis, CF; Deng, F; Burgess, DL			The alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate receptor trafficking regulator " stargazin" is related to the Claudin family of proteins by its ability to mediate cell-cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL MYELIN PROTEIN-22; CHANNEL GAMMA-SUBUNITS; CA2+ CHANNEL; TIGHT JUNCTIONS; AMPA RECEPTORS; BINDING-SITE; EXPRESSION; MUTANT; MOUSE; IDENTIFICATION	Mutations in the Cacng2 gene encoding the neuronal transmembrane protein stargazin result in recessively inherited epilepsy and ataxia in "stargazer" mice. Functional studies suggest a dual role for stargazin, both as a modulatory gamma subunit for voltage-dependent calcium channels and as a regulator of post- synaptic membrane targeting for alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate (AMPA)-type glutamate receptors. Co-immunoprecipitation experiments demonstrate that stargazin can bind proteins of either complex in vivo, but it remains unclear whether it can associate with both complexes simultaneously. Cacng2 is one of eight closely related genes (Cacng1-8) encoding proteins with four transmembrane segments, cytoplasmic termini, and molecular masses between 25 and 44 kDa. This group of Cacng genes constitutes only one branch of a larger monophyletic assembly dominated by over 20 genes encoding proteins known as claudins. Claudins regulate cell adhesion and paracellular permeability as fundamental components of non-neuronal tight junctions. Because stargazin is structurally similar to claudins, we hypothesized that it might also have retained claudin-like functions inherited from a common ancestor. Here, we report that expression of stargazin in mouse L-fibroblasts results in cell aggregation comparable with that produced by claudins, and present evidence that the interaction is heterotypic and calcium dependent. The data suggest that the cell adhesion function of stargazin preceded its current role in neurons as a regulator of either voltage-dependent calcium channels or AMPA receptors. We speculate these complexes may have co-opted the established presence of stargazin at sites of close cell-cell contact to facilitate their own evolving intercellular signaling functions.	Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA	Baylor College of Medicine	Burgess, DL (corresponding author), Baylor Coll Med, Dept Neurol, NB206,1 Baylor Plaza, Houston, TX 77030 USA.	dburgess@bcm.tmc.edu		Davis, Caleb/0000-0002-5125-0494	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042632] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS042632-01, NS042632, R01 NS042632-04, R01 NS042632, R01 NS042632-03, R01 NS042632-02] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adato A, 2002, EUR J HUM GENET, V10, P339, DOI 10.1038/sj.ejhg.5200831; Black JL, 2003, J BIOENERG BIOMEMBR, V35, P649, DOI 10.1023/B:JOBB.0000008029.22650.c5; Black JL, 1999, MAYO CLIN PROC, V74, P357, DOI 10.4065/74.4.357; Burgess DL, 2001, GENOMICS, V71, P339, DOI 10.1006/geno.2000.6440; Burgess DL, 1999, GENOME RES, V9, P1204, DOI 10.1101/gr.9.12.1204; CAMPBELL KP, 1989, ANN NY ACAD SCI, V560, P251, DOI 10.1111/j.1749-6632.1989.tb24102.x; Cereijido M, 2000, AM J PHYSIOL-GASTR L, V279, pG477, DOI 10.1152/ajpgi.2000.279.3.G477; Chen CL, 2004, J NEUROSCI, V24, P4030, DOI 10.1523/JNEUROSCI.4139-03.2004; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Chen T, 2002, MOL VIS, V8, P372; Chetkovich DM, 2002, J NEUROSCI, V22, P5791; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; Chu PJ, 2001, GENE, V280, P37, DOI 10.1016/S0378-1119(01)00738-7; Cuadra AE, 2004, J NEUROSCI, V24, P7491, DOI 10.1523/JNEUROSCI.1255-04.2004; Davis TH, 2004, J BIOL CHEM, V279, P51424, DOI 10.1074/jbc.M410830200; DOHERTY P, 1995, J NEUROBIOL, V26, P437, DOI 10.1002/neu.480260315; Duguay D, 2003, DEV BIOL, V253, P309, DOI 10.1016/S0012-1606(02)00016-7; Fields RD, 1996, TRENDS NEUROSCI, V19, P473, DOI 10.1016/S0166-2236(96)30013-1; Force A, 1999, GENETICS, V151, P1531; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; GLOSSMANN H, 1987, BIOMED BIOCHIM ACTA, V46, pS351; Green PJ, 2001, J PHYSIOL-LONDON, V533, P467, DOI 10.1111/j.1469-7793.2001.0467a.x; Grey AC, 2003, EXP EYE RES, V77, P567, DOI 10.1016/S0014-4835(03)00192-1; Hansen JP, 2004, J MOL CELL CARDIOL, V37, P1147, DOI 10.1016/j.yjmcc.2004.08.005; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Isom LL, 2002, FRONT BIOSCI, V7, P12; Kang MG, 2003, J BIOL CHEM, V278, P21315, DOI 10.1074/jbc.R300004200; Kang MG, 2001, J BIOL CHEM, V276, P32917, DOI 10.1074/jbc.M100787200; Kious BM, 2002, DEV BIOL, V243, P249, DOI 10.1006/dbio.2001.0570; Kleene R, 2004, NAT REV NEUROSCI, V5, P195, DOI 10.1038/nrn1349; Klugbauer N, 2000, FEBS LETT, V470, P189, DOI 10.1016/S0014-5793(00)01306-5; Kobayashi J, 2002, HISTOCHEM CELL BIOL, V117, P29, DOI 10.1007/s00418-001-0359-x; Kubota K, 1999, CURR BIOL, V9, P1035, DOI 10.1016/S0960-9822(99)80452-7; LacazVieira F, 1997, J GEN PHYSIOL, V110, P727, DOI 10.1085/jgp.110.6.727; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; Martin PT, 2003, J NEUROCYTOL, V32, P915, DOI 10.1023/B:NEUR.0000020632.41508.83; Mi RF, 2004, NEURON, V44, P335, DOI 10.1016/j.neuron.2004.09.029; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Moss FJ, 2002, EMBO J, V21, P1514, DOI 10.1093/emboj/21.7.1514; Nadeau JH, 1997, GENETICS, V147, P1259; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NOEBELS JL, 1990, EPILEPSY RES, V7, P129, DOI 10.1016/0920-1211(90)90098-G; Notterpek L, 2001, P NATL ACAD SCI USA, V98, P14404, DOI 10.1073/pnas.251548398; Ohno S., 1970, EVOLUTION GENE DUPLI; Prince VE, 2002, NAT REV GENET, V3, P827, DOI 10.1038/nrg928; Qiao XO, 1996, J NEUROSCI, V16, P640; Qiao XX, 1998, J NEUROSCI, V18, P6990; Richardson CA, 2005, J COMP NEUROL, V481, P145, DOI 10.1002/cne.20386; Richardson CA, 2002, J COMP NEUROL, V453, P85, DOI 10.1002/cne.10406; Rothen-Rutishauser B, 2002, J MEMBRANE BIOL, V188, P151, DOI 10.1007/s00232-001-0182-2; Rousset M, 2001, J PHYSIOL-LONDON, V532, P583, DOI 10.1111/j.1469-7793.2001.0583e.x; Sanders CR, 2001, BIOCHEMISTRY-US, V40, P9453, DOI 10.1021/bi010894f; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Sharp AH, 2001, NEUROSCIENCE, V105, P599, DOI 10.1016/S0306-4522(01)00220-2; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Spacek J, 1998, J COMP NEUROL, V393, P58, DOI 10.1002/(SICI)1096-9861(19980330)393:1<58::AID-CNE6>3.0.CO;2-P; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; Tomita S, 2003, J CELL BIOL, V161, P805, DOI 10.1083/jcb.200212116; Tomita S, 2004, SCIENCE, V303, P1508, DOI 10.1126/science.1090262; Tsukita S, 2000, ANN NY ACAD SCI, V915, P129, DOI 10.1111/j.1749-6632.2000.tb05235.x; Van Itallie CM, 2004, PHYSIOLOGY, V19, P331, DOI 10.1152/physiol.00027.2004; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; Yamada A, 2003, GENES CELLS, V8, P985, DOI 10.1046/j.1356-9597.2003.00690.x; Yamagata M, 2003, CURR OPIN CELL BIOL, V15, P621, DOI 10.1016/S0955-0674(03)00107-8; Yamazaki M, 2004, NEUROSCI RES, V50, P369, DOI 10.1016/j.neures.2004.10.002; Zahraoui A, 2000, J CELL BIOL, V151, pF31, DOI 10.1083/jcb.151.5.F31; Zhang JZ, 2000, J MOL EVOL, V50, P56, DOI 10.1007/s002399910007	71	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19711	19720		10.1074/jbc.M500623200	http://dx.doi.org/10.1074/jbc.M500623200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15760900	Green Accepted, hybrid			2022-12-27	WOS:000229113700037
J	Yanagi, K; Mizuno, T; Tsuyama, T; Tada, S; Iida, Y; Sugimoto, A; Eki, T; Enomoto, T; Hanaoka, F				Yanagi, K; Mizuno, T; Tsuyama, T; Tada, S; Iida, Y; Sugimoto, A; Eki, T; Enomoto, T; Hanaoka, F			Caenorhabditis elegans geminin homologue participates in cell cycle regulation and germ line development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LICENSING FACTOR CDT1; EUKARYOTIC DNA-REPLICATION; XENOPUS EGG EXTRACTS; DOWN-REGULATION; S-PHASE; INHIBITION; REREPLICATION; RNAI; PROTEOLYSIS; COMPLEX	Cdt1 is an essential component for the assembly of a pre-replicative complex. Cdt1 activity is inhibited by geminin, which also participates in neural development and embryonic differentiation in many eukaryotes. Although Cdt1 homologues have been identified in organisms ranging from yeast to human, geminin homologues had not been described for Caenorhabditis elegans and fungi. Here, we identify the C. elegans geminin, GMN-1. Biochemical analysis reveals that GMN-1 associates with C. elegans CDT-1, the Hox protein NOB-1, and the Six protein CEH-32. GMN-1 inhibits not only the interaction between mouse Cdt1 and Mcm6 but also licensing activity in Xenopus egg extracts. RNA interference-mediated reduction of GMN-1 is associated with enlarged germ nuclei with aberrant nucleolar morphology, severely impaired gametogenesis, and chromosome bridging in intestinal cells. We conclude that the Cdt1-geminin system is conserved throughout metazoans and that geminin has evolved in these taxa to regulate proliferation and differentiation by directly interacting with Cdt1 and homeobox proteins.	Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; RIKEN, Discovery Res Inst, Cellular Physiol Lab, Wako, Saitama 3510198, Japan; CREST, Japan Sci & Technol Corp, Wako, Saitama 3510198, Japan; Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi 9808578, Japan; RIKEN, Ctr Dev Biol, Lab Dev Genet, Kobe, Hyogo 6500047, Japan; Toyohashi Univ Technol, Dept Ecol Engn, Toyohashi, Aichi 4418580, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan	Osaka University; RIKEN; Japan Science & Technology Agency (JST); Tohoku University; RIKEN; Toyohashi University of Technology; Osaka University	Hanaoka, F (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, 1-3 Yamada Oka, Suita, Osaka 5650871, Japan.	fhanaoka@fbs.osaka-u.ac.jp	Sugimoto, Asako/U-3707-2019; Sugimoto, Asako/I-7239-2015	Sugimoto, Asako/0000-0001-6001-4293; Sugimoto, Asako/0000-0001-6001-4293				Aboobaker A, 2003, CURR OPIN GENET DEV, V13, P593, DOI 10.1016/j.gde.2003.10.009; Arias EE, 2005, GENE DEV, V19, P114, DOI 10.1101/gad.1255805; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Del Bene F, 2004, NATURE, V427, P745, DOI 10.1038/nature02292; Devault A, 2002, CURR BIOL, V12, P689, DOI 10.1016/S0960-9822(02)00768-6; Dozier C, 2001, DEV BIOL, V236, P289, DOI 10.1006/dbio.2001.0325; Ferenbach A, 2005, NUCLEIC ACIDS RES, V33, P316, DOI 10.1093/nar/gki176; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; HEDGECOCK EM, 1985, DEV BIOL, V107, P128, DOI 10.1016/0012-1606(85)90381-1; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; Kroll KL, 1998, DEVELOPMENT, V125, P3247; Lee C, 2004, NATURE, V430, P913, DOI 10.1038/nature02813; Li A, 2005, EMBO J, V24, P395, DOI 10.1038/sj.emboj.7600520; Luo LF, 2004, NATURE, V427, P749, DOI 10.1038/nature02305; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; Maiorano D, 2005, CURR BIOL, V15, P146, DOI 10.1016/j.cub.2004.12.002; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 2002, MOL BIOL CELL, V13, P3662, DOI 10.1091/mbc.E02-04-0199; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Melixetian M, 2004, J CELL BIOL, V165, P473, DOI 10.1083/jcb.200403106; Mendez J, 2003, BIOESSAYS, V25, P1158, DOI 10.1002/bies.10370; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Mizuno T, 1998, MOL CELL BIOL, V18, P3552, DOI 10.1128/MCB.18.6.3552; Nishitani H, 2004, J BIOL CHEM, V279, P30807, DOI 10.1074/jbc.M312644200; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Saxena S, 2004, MOL CELL, V15, P245, DOI 10.1016/j.molcel.2004.06.045; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Whittaker AJ, 2000, GENE DEV, V14, P1765; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Yoshida K, 2005, GENES CELLS, V10, P63, DOI 10.1111/j.1365-2443.2005.00815.x; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004	40	31	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19689	19694		10.1074/jbc.C500070200	http://dx.doi.org/10.1074/jbc.C500070200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15811859	hybrid			2022-12-27	WOS:000229113700034
J	Rahuel-Clermont, S; Arutyunov, D; Marchal, S; Orlov, V; Muronetz, V; Branlant, G				Rahuel-Clermont, S; Arutyunov, D; Marchal, S; Orlov, V; Muronetz, V; Branlant, G			Thermal destabilization of non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase from Streptococcus mutans upon phosphate binding in the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; DEPENDENT ALDEHYDE DEHYDROGENASE; D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; CATALYTIC MECHANISM; DENATURATION; SPECIFICITY; PROTEIN	Catalysis by the NADP-dependent non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPN) from Streptococcus mutans, a member of the aldehyde dehydrogenase (ALDH) family, relies on a local conformational reorganization of the active site. This rearrangement is promoted by the binding of NADP and is strongly kinetically favored by the formation of the ternary complex enzyme.NADP.substrate. Adiabatic differential scanning calorimetry was used to investigate the effect of ligands on the irreversible thermal denaturation of GAPN. We showed that phosphate binds to GAPN, resulting in the formation of a GAPN.phosphate binary complex characterized by a strongly decreased thermal stability, with a difference of at least 15 degrees C between the maximum temperatures of the thermal transition peaks. The kinetics of phosphate association and dissociation are slow, allowing both free and GAPN.phosphate complexes to be observed by differential scanning calorimetry and to be separated by native polyacrylamide electrophoresis run in phosphate buffer. Analysis of a set of mutants of GAPN strongly suggests that phosphate is bound to the substrate C-3 subsite. In addition, the substrate analog glycerol-3-phosphate has similar effects as does phosphate on the thermal behavior of GAPN. Based on the current knowledge on the catalytic mechanism of GAPN and other ALDHs, we propose that ligand-induced thermal destabilization is a mechanism that provides to ALDHs the required flexibility for an efficient catalysis.	Univ Nancy 1, Fac Sci, CNRS, UMR 7567, F-54506 Vandoeuvre Les Nancy, France; Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Moscow 119992, Russia	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Lomonosov Moscow State University	Branlant, G (corresponding author), Univ Nancy 1, Fac Sci, CNRS, UMR 7567, BP 239, F-54506 Vandoeuvre Les Nancy, France.	guy.branlant@maem.uhp-nancy.fr	Орлов, Виктор/AAH-3795-2019; Muronetz, Vladimir/C-8337-2012; MARCHAL, stéphane/M-4324-2017; Rahuel-Clermont, Sophie/AAB-3451-2020	Орлов, Виктор/0000-0001-5641-864X; MARCHAL, stéphane/0000-0002-1101-7890; Rahuel-Clermont, Sophie/0000-0001-5143-0105; Muronetz, Vladimir/0000-0001-7838-3089				BOYD DA, 1995, J BACTERIOL, V177, P2622, DOI 10.1128/jb.177.10.2622-2627.1995; Cobessi D, 1999, J MOL BIOL, V290, P161, DOI 10.1006/jmbi.1999.2853; Cobessi D, 2000, J MOL BIOL, V300, P141, DOI 10.1006/jmbi.2000.3824; Cogan EB, 1999, ANAL BIOCHEM, V271, P29, DOI 10.1006/abio.1999.4100; Habenicht A, 1997, BIOL CHEM, V378, P1413; Hammen PK, 2002, BIOCHEMISTRY-US, V41, P7156, DOI 10.1021/bi012197t; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Kurganov BI, 1997, BIOPHYS CHEM, V69, P125, DOI 10.1016/S0301-4622(97)80552-2; Levashov P, 1999, BBA-PROTEIN STRUCT M, V1433, P294, DOI 10.1016/S0167-4838(99)00132-6; Marchal S, 2002, J BIOL CHEM, V277, P39235, DOI 10.1074/jbc.M205633200; Marchal S, 2000, BIOCHEMISTRY-US, V39, P3327, DOI 10.1021/bi9914208; Marchal S, 1999, BIOCHEMISTRY-US, V38, P12950, DOI 10.1021/bi990453k; MARCHAL S, 2001, FS UFR SCI TECHNIQUE, P200; Perez-Miller SJ, 2003, BIOCHEMISTRY-US, V42, P7100, DOI 10.1021/bi034182w; Roitel O, 2002, BIOCHEMISTRY-US, V41, P7556, DOI 10.1021/bi012084+; SANCHEZRUIZ JM, 1992, BIOPHYS J, V61, P921, DOI 10.1016/S0006-3495(92)81899-4; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; Zhang L, 1999, BIOCHEMISTRY-US, V38, P11440, DOI 10.1021/bi991101g	20	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18590	18597		10.1074/jbc.M414110200	http://dx.doi.org/10.1074/jbc.M414110200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757901	hybrid, Green Published			2022-12-27	WOS:000228932300007
J	Shim, M; Eling, TE				Shim, M; Eling, TE			Protein kinase C-dependent regulation of NAG-1/placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA SUPERFAMILY; NF-KAPPA-B; MACROPHAGE INHIBITORY CYTOKINE; ACTIVATED GENE NAG-1; GROWTH-FACTOR-BETA; CANCER CELLS; 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED APOPTOSIS; T-LYMPHOCYTES; FAS-LIGAND; MEMBER	NAG-1 (nonsteroidal anti-inflammatory drug-activated gene), a member of the transforming growth factor beta superfamily, is involved in cellular processes such as inflammation, apoptosis/survival, and tumorigenesis and is regulated by p53, Sp1, and Egr-1. In the current study, the regulation of NAG-1 expression in LNCaP human prostate carcinoma cells by 12-O-tetradecanoyl-phorbol-13-acetate (TPA) was examined. TPA treatment increased NAG-1 protein and mRNA levels in a time- and concentration-dependent manner as well as NF-kappa B binding/transcriptional activity in LNCaP cells. Pretreatment with protein kinase C (PKC) inhibitor blocked the TPA-induced increase in NAG-1 protein levels and NF-kappa B binding/transcriptional activity, whereas an inhibition of p38, JNK, MEK activity had no effect on TPA-induced NAG-1 levels and NF-kappa B transcriptional activity. Expression of constitutively active PKCs induced an increase in NF-kappa B transcriptional activity and NAG-1 protein levels in LNCaP cells. The expression of NF-kappa B p65 induced NAG-1 promoter activity, and chromatin immunoprecipitation assay for p65 showed that NF-kappa B binds the NAG-1 promoter in LNCaP cells. Inhibition of TPA-induced NAG-1 expression by NAG-1 short interfering RNA blocked TPA-induced apoptosis in LNCaP cells, suggesting induction of NAG-1 negatively affects LNCaP cell survival. These results demonstrate that NAG-1 expression is up-regulated by TPA in LNCaP cells through a PKC-dependent pathway involving the activation of NF-kappa B.	NIEHS, Eicosanoids Biochem Sect, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Eling, TE (corresponding author), NIEHS, Eicosanoids Biochem Sect, Mol Carcinogenesis Lab, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	eling@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010016, ZIAES010016] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baek SJ, 2004, J BIOL CHEM, V279, P6883, DOI 10.1074/jbc.M305295200; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Bauskin AR, 2000, EMBO J, V19, P2212, DOI 10.1093/emboj/19.10.2212; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Engedal N, 2002, ONCOGENE, V21, P1017, DOI 10.1038/sj.onc.1205167; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Fujioka S, 2004, J BIOL CHEM, V279, P27549, DOI 10.1074/jbc.M313435200; Garcia-Bermejo ML, 2002, J BIOL CHEM, V277, P645, DOI 10.1074/jbc.M107639200; Garzotto M, 1998, CANCER RES, V58, P2260; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kimura K, 2002, CELL DEATH DIFFER, V9, P972, DOI 10.1038/sj.cdd.4401049; Lawton LN, 1997, GENE, V203, P17, DOI 10.1016/S0378-1119(97)00485-X; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Liu T, 2003, CANCER RES, V63, P5034; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Rameshwar P, 2000, J IMMUNOL, V165, P2271, DOI 10.4049/jimmunol.165.4.2271; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Soh JW, 2003, J BIOL CHEM, V278, P34709, DOI 10.1074/jbc.M302016200; Spitaler M, 2004, NAT IMMUNOL, V5, P785, DOI 10.1038/ni1097; Strelau J, 2000, ADV RES NEURODEGENER, V8, P273; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Yamaguchi K, 2004, J BIOL CHEM, V279, P49617, DOI 10.1074/jbc.M408796200; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	40	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18636	18642		10.1074/jbc.M414613200	http://dx.doi.org/10.1074/jbc.M414613200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757899	hybrid			2022-12-27	WOS:000228932300013
J	Dodge, JE; Okano, M; Dick, F; Tsujimoto, N; Chen, TP; Wang, SM; Ueda, Y; Dyson, N; Li, E				Dodge, JE; Okano, M; Dick, F; Tsujimoto, N; Chen, TP; Wang, SM; Ueda, Y; Dyson, N; Li, E			Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CANCER-CELLS; DE-NOVO METHYLATION; CPG METHYLATION; TUMOR-FORMATION; STEM-CELLS; LSH; METHYLTRANSFERASES; HETEROCHROMATIN; PROLIFERATION; PATTERNS	DNA hypomethylation is a hallmark of many types of solid tumors. However, it remains elusive how DNA hypomethylation may contribute to tumorigenesis. In this study, we have investigated how targeted disruption of the DNA methyltransferases Dnmt3a and Dnmt3b affects the growth of mouse embryonic fibroblasts (MEFs). Our studies led to the following observations. 1) Constitutive or conditional deletion of Dnmt3b, but not Dnmt3a, resulted in partial loss of DNA methylation throughout the genome, suggesting that Dnmt3b, in addition to the major maintenance methyltransferase Dnmt1, is required for maintaining DNA methylation in MEF cells. 2) Dnmt3b-deficient MEF cells showed aneuploidy and polyploidy, chromosomal breaks, and fusions. 3) Inactivation of Dnmt3b resulted in either premature senescence or spontaneous immortalization of MEF cells. 4) The G(1) to S-phase checkpoint was intact in primary and spontaneously immortalized Dnmt3b-deficient MEFs because the p53 protein was inducible by DNA damage. Interestingly, protein levels of the cyclin-dependent kinase inhibitor p21 were increased in immortalized Dnmt3b-deficient MEFs even in the absence of p53 induction. These results suggest that DNA hypomethylation may induce genomic instability, which in turn leads to spontaneous immortalization or premature senescence of Dnmt3b-deficient MEFs via a p53-independent mechanism.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Canc Res Ctr, Charlestown, MA 02129 USA; RIKEN, Ctr Dev Biol, Kobe, Hyogo 6500047, Japan	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; RIKEN	Li, E (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Charlestown, MA 02129 USA.	en.li@pharma.novartis.com	Ueda, Yoshihide/S-7620-2016	Ueda, Yoshihide/0000-0003-3196-3494	NCI NIH HHS [CA82389] Funding Source: Medline; NIGMS NIH HHS [GM52106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Chen TP, 2004, CURR TOP DEV BIOL, V60, P55; Chen TP, 2004, MOL CELL BIOL, V24, P9048, DOI 10.1128/MCB.24.20.9048-9058.2004; Chen TP, 2002, J BIOL CHEM, V277, P38746, DOI 10.1074/jbc.M205312200; Dennis K, 2001, GENE DEV, V15, P2940, DOI 10.1101/gad.929101; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dodge JE, 1998, INT J CANCER, V78, P561, DOI 10.1002/(SICI)1097-0215(19981123)78:5<561::AID-IJC6>3.0.CO;2-R; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Fan T, 2003, CANCER RES, V63, P4677; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Hernandez L, 2003, P NATL ACAD SCI USA, V100, P13344, DOI 10.1073/pnas.2234026100; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633; Lei H, 1996, DEVELOPMENT, V122, P3195; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Yan QS, 2003, MOL CELL BIOL, V23, P8416, DOI 10.1128/MCB.23.23.8416-8428.2003	26	192	202	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17986	17991		10.1074/jbc.M413246200	http://dx.doi.org/10.1074/jbc.M413246200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15757890	hybrid			2022-12-27	WOS:000228807200053
J	Fukuen, S; Iwaki, M; Yasui, A; Makishima, M; Matsuda, M; Shimomura, I				Fukuen, S; Iwaki, M; Yasui, A; Makishima, M; Matsuda, M; Shimomura, I			Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITS ADIPOCYTE DIFFERENTIATION; TYPE-2 DIABETIC SUBJECTS; PPAR-GAMMA; 3T3-L1 ADIPOCYTES; NUCLEAR RECEPTORS; GENE-EXPRESSION; INSULIN-RESISTANCE; X-RECEPTOR; LIGAND; IDENTIFICATION	Sulfonylurea (SU) agents, including glimepiride and glibenclamide, are the most widely used oral hypoglycemic drugs, which stimulate insulin secretion primarily by binding to the SU receptor on the plasma membrane of pancreatic beta-cells. Thiazolidinediones, such as pioglitazone and rosiglitazone, are other hypoglycemic agents that effectively improve peripheral insulin resistance through activation of peroxisome proliferator-activated receptor gamma( PPAR gamma). In the present study, we found that glimepiride specifically induced the transcriptional activity of PPAR gamma in luciferase reporter assays. Glimepiride enhanced the recruitment of coactivator DRIP205 and dissociation of corepressors such as nuclear receptor corepressor and silencing mediator for retinoid and thyroid hormone receptors. In addition, glimepride directly bound to PPAR delta in a manner competitive to rosiglitazone, which is a proven ligand for PPAR delta. Furthermore, in 3T3-L1 adipocytes, glimepiride stimulated the transcriptional activity of the gene promoter containing PPAR gamma responsive element and altered mRNA levels of PPAR gamma target genes including aP2, leptin, and adiponectin. Finally, glimepiride induced adipose differentiation in 3T3- F442A cells, which was known to differentiate into adipocytes in a PPAR gamma-dependent manner. Most effects observed with glimepiride were also seen with glibenclamide. These data strongly suggest that glimepiride and glibenclamide, both of which belong to SU agents, should have PPAR gamma agonist activity, whose potencies were 16-25% of the maximum level achieved by pioglitazone. Our observation that glimepiride and glibenclamide could act not only on SU receptor but also on PPAR gamma may give an important clue to the development of novel antidiabetic drugs, which can enhance both insulin secretion from pancreatic beta-cells and peripheral insulin sensitivity.	Osaka Univ, Grad Sch Forntier Biosci, Dept Med & Pathophysiol, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Mol sci, Suita, Osaka 5650871, Japan; Japan Sci & Technol agcy, PREST, Kawaguchi, Saitama 3320012, Japan; Japan Soc Promot Sci, Century COE Program 21, Tokyo, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST); Japan Society for the Promotion of Science	Matsuda, M (corresponding author), Osaka Univ, Grad Sch Forntier Biosci, Dept Med & Pathophysiol, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	mmatsuda@fbs.osaka-u.ac.jp		Yasui, Atsutaka/0000-0003-4903-7210				Adachi R, 2004, MOL ENDOCRINOL, V18, P43, DOI 10.1210/me.2003-0244; Benson SC, 2004, HYPERTENSION, V43, P993, DOI 10.1161/01.HYP.0000123072.34629.57; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Glass CK, 2000, GENE DEV, V14, P121; Gribble FM, 2000, METABOLISM, V49, P3, DOI 10.1053/meta.2000.17822; Hsu MH, 2001, J BIOL CHEM, V276, P27950, DOI 10.1074/jbc.M100258200; Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655; JACOBS DB, 1985, J BIOL CHEM, V260, P2593; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Kaneko E, 2003, J BIOL CHEM, V278, P36091, DOI 10.1074/jbc.M304153200; Kishida K, 2001, J BIOL CHEM, V276, P48572, DOI 10.1074/jbc.M108213200; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Lee G, 2002, J BIOL CHEM, V277, P19649, DOI 10.1074/jbc.M200743200; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Malerczyk V., 1994, Drug Metabolism and Drug Interactions, V11, P341; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; MILLER RE, 1986, BIOCHEM INT, V13, P313; MULLER G, 1995, DIABETES RES CLIN S, V28, P115; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nishizawa H, 2002, J BIOL CHEM, V277, P1586, DOI 10.1074/jbc.M104301200; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Perrey S, 2001, METABOLISM, V50, P36, DOI 10.1053/meta.2001.19505; Rangwala SM, 2004, TRENDS PHARMACOL SCI, V25, P331, DOI 10.1016/j.tips.2004.03.012; Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Tamori Y, 2002, DIABETES, V51, P2045, DOI 10.2337/diabetes.51.7.2045; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tsunekawa T, 2003, DIABETES CARE, V26, P285, DOI 10.2337/diacare.26.2.285; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; Yang W, 2000, MOL CELL BIOL, V20, P8008, DOI 10.1128/MCB.20.21.8008-8017.2000; Yu JG, 2002, DIABETES, V51, P2968, DOI 10.2337/diabetes.51.10.2968; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	43	90	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23653	23659		10.1074/jbc.M412113200	http://dx.doi.org/10.1074/jbc.M412113200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15764598	hybrid			2022-12-27	WOS:000229880000032
J	Jaskolski, F; Normand, E; Mulle, C; Coussen, F				Jaskolski, F; Normand, E; Mulle, C; Coussen, F			Differential trafficking of GluR7 kainate receptor subunit splice variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; ER RETENTION SIGNAL; ENDOPLASMIC-RETICULUM; GLUTAMATE-RECEPTOR; AMPA RECEPTOR; HIPPOCAMPAL INTERNEURONS; SYNAPTIC-TRANSMISSION; EXCITATORY SYNAPSES; LOCALIZATION; DOMAIN	Kainate receptors (KARs) are heteromeric ionotropic glutamate receptors that play a variety of roles in the regulation of synaptic network activity. The function of glutamate receptors (GluRs) is highly dependent on their surface density in specific neuronal domains. Alternative splicing is known to regulate surface expression of GluR5 and GluR6 subunits. The KAR subunit GluR7 exists under different splice variant isoforms in the C-terminal domain (GluR7a and GluR7b). Here we have studied the trafficking of GluR7 splice variants in cultured hippocampal neurons from wild-type and KAR mutant mice. We have found that alternative splicing regulates surface expression of GluR7-containing KARs. GluR7a and GluR7b differentially traffic from the ER to the plasma membrane. GluR7a is highly expressed at the plasma membrane, and its trafficking is dependent on a stretch of positively charged amino acids also found in GluR6a. In contrast, GluR7b is detected at the plasma membrane at a low level and retained mostly in the endoplasmic reticulum (ER). The RXR motif of GluR7b does not act as an ER retention motif, at variance with other receptors and ion channels, but might be involved during the assembly process. Like GluR6a, GluR7a promotes surface expression of ER-retained subunit splice variants when assembled in heteromeric KARs. However, our results also suggest that this positive regulation of KAR trafficking is limited by the ability of different combinations of subunits to form heteromeric receptor assemblies. These data further define the complex rules that govern membrane delivery and subcellular distribution of KARs.	Univ Bordeaux 2, UMR 5091, Lab Phys Cellulaire Synapse, CNRS,Inst Magendie, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Mulle, C (corresponding author), Univ Bordeaux 2, UMR 5091, Lab Phys Cellulaire Synapse, CNRS,Inst Magendie, Rue C St Saens, F-33077 Bordeaux, France.	mulle@u-bordeaux2.fr		Mulle, Christophe/0000-0003-2709-6615				Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; Barlowe C, 2003, TRENDS CELL BIOL, V13, P295, DOI 10.1016/S0962-8924(03)00082-5; Barry MF, 2002, CURR OPIN NEUROBIOL, V12, P279, DOI 10.1016/S0959-4388(02)00329-X; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; BETTLER B, 1992, NEURON, V8, P257, DOI 10.1016/0896-6273(92)90292-L; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Bureau I, 2000, P NATL ACAD SCI USA, V97, P6838, DOI 10.1073/pnas.97.12.6838; Bureau I, 1999, J NEUROSCI, V19, P653; Carroll RC, 2002, TRENDS NEUROSCI, V25, P571, DOI 10.1016/S0166-2236(02)02272-5; Chen GQ, 1999, NATURE, V402, P817, DOI 10.1038/45568; Chittajallu R, 1999, TRENDS PHARMACOL SCI, V20, P26, DOI 10.1016/S0165-6147(98)01286-3; Christensen JK, 2004, J NEUROSCI, V24, P8986, DOI 10.1523/JNEUROSCI.2156-04.2004; Coleman SK, 2003, J NEUROSCI, V23, P798; Coussen F, 2002, J NEUROSCI, V22, P6426, DOI 10.1523/jneurosci.22-15-06426.2002; Cui CH, 1999, J NEUROSCI, V19, P8281; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Gallyas F, 2003, J NEUROCHEM, V86, P1414, DOI 10.1046/j.1471-4159.2003.01945.x; Herzog E, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-22-j0001.2001; Huettner JE, 2003, PROG NEUROBIOL, V70, P387, DOI 10.1016/S0301-0082(03)00122-9; Janssens N, 2001, J NEUROCHEM, V77, P1457, DOI 10.1046/j.1471-4159.2001.00369.x; Jaskolski F, 2005, TRENDS PHARMACOL SCI, V26, P20, DOI 10.1016/j.tips.2004.11.008; Jaskolski F, 2004, J NEUROSCI, V24, P2506, DOI 10.1523/JNEUROSCI.5116-03.2004; JASKOLSKI F, 2005, IN PRESS J NEUROSCI; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; Lerma J, 2001, PHYSIOL REV, V81, P971, DOI 10.1152/physrev.2001.81.3.971; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Mulle C, 2000, NEURON, V28, P475, DOI 10.1016/S0896-6273(00)00126-4; Pagano A, 2001, J NEUROSCI, V21, P1189; Pickering DS, 1995, P NATL ACAD SCI USA, V92, P12090, DOI 10.1073/pnas.92.26.12090; Ren Z, 2003, J BIOL CHEM, V278, P52700, DOI 10.1074/jbc.M309585200; Ren Z, 2003, J NEUROSCI, V23, P6608; RUANO D, 1995, NEURON, V14, P1009, DOI 10.1016/0896-6273(95)90339-9; Schiffer HH, 1997, NEURON, V19, P1141, DOI 10.1016/S0896-6273(00)80404-3; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Shen L, 2000, J NEUROSCI, V20, P7932; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Strutz N, 2001, J NEUROSCI, V21, P401, DOI 10.1523/JNEUROSCI.21-02-00401.2001; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; WISDEN W, 1993, J NEUROSCI, V13, P3582; Xia HH, 2002, J BIOL CHEM, V277, P47765, DOI 10.1074/jbc.M207122200; Yan S, 2004, J NEUROSCI, V24, P679, DOI 10.1523/JNEUROSCI.4985-03.2004; Yuan HB, 2003, CURR BIOL, V13, P638, DOI 10.1016/S0960-9822(03)00208-2; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zerangue N, 2001, P NATL ACAD SCI USA, V98, P2431, DOI 10.1073/pnas.051630198	45	33	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22968	22976		10.1074/jbc.M413166200	http://dx.doi.org/10.1074/jbc.M413166200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15805114	hybrid			2022-12-27	WOS:000229741800051
J	Chao, W; Shen, Y; Zhu, XS; Zhao, HL; Novikov, M; Schmidt, U; Rosenzweig, A				Chao, W; Shen, Y; Zhu, XS; Zhao, HL; Novikov, M; Schmidt, U; Rosenzweig, A			Lipopolysaccharide improves cardiomyocyte survival and function after serum deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ISCHEMIA-REPERFUSION INJURY; RECEPTOR-ASSOCIATED KINASE; NF-KAPPA-B; APOPTOTIC CELL-DEATH; HEAT-SHOCK PROTEINS; BACTERIAL LIPOPOLYSACCHARIDE; INFARCT SIZE; NITRIC-OXIDE; CARDIAC MYOCYTES	Toll-like receptor-4 ( TLR4) and its signaling molecule interleukin-1 receptor-associated kinase (IRAK-1) play an important role in host defense and tissue inflammation. Intriguingly, systemic administration of lipopolysaccharide (LPS), the agonist for TLR4, confers a cardio-protective effect against ischemic injury. However, the mechanisms leading to the cardiac protection remain largely unknown. The present study was designed to investigate the role of TLR4 activation by LPS in protecting cardiomyocytes (CM) against apoptosis in an in vitro model of ischemia and to explore the downstream mechanisms leading to the protective effect. Incubation with LPS led to activation of IRAK-1 and protected CMs against serum deprivation (SD)induced apoptosis as demonstrated by DNA laddering, histone-DNA fragment enzyme-linked immunosorbent assay, and activation of caspase-3. Phosphatidylinositol 3-kinase/Akt, extracellular signal-regulated kinase 1/2, and I kappa B kinase beta appear to contribute to the antiapoptotic effect of LPS since the specific inhibitors, wortmannin, PD98059, and dominant negative IKK beta transgene expression reversed the LPS effect. To assess whether LPS improves CM function, we examined intracellular Ca2+ transients and cell shortening in single adult rat CMs. SD for 6 h dramatically inhibited Ca2+ transients and CM contractility. LPS at 500 ng/ml significantly improved the [Ca2+](i) transients and enhanced contractility in control CMs as well as in CMs subjected to SD. Importantly, transient ischemia led to rapid activation of IRAK-1 in cultured CMs and in adult rat myocardium. Adenovirus-mediated transgene expression of IRAK-1 but not its kinase-deficient mutant IRAK-1( K239S) protected CMs against SD-induced apoptosis. Taken together, these data suggest an important role of TLR4 signaling via IRAK-1 in protecting against SD-induced apoptosis.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Program Cardiovasc Gene Therapy, Charlestown, MA 02139 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Chao, W (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Jackson 4,Rm 462,55 Fruit St, Boston, MA 02114 USA.	wchao@partners.org		Chao, Wei/0000-0002-2505-1360	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004336, R01HL061557] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 04336, HL 61557] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Bannerman DD, 2002, J BIOL CHEM, V277, P8048, DOI 10.1074/jbc.M111249200; Bannerman DD, 2001, J BIOL CHEM, V276, P14924, DOI 10.1074/jbc.M100819200; Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371; Baumgarten G, 2001, J INFECT DIS, V183, P1617, DOI 10.1086/320712; Belosjorow S, 1999, AM J PHYSIOL-HEART C, V277, pH2470, DOI 10.1152/ajpheart.1999.277.6.H2470; BROWN JM, 1989, P NATL ACAD SCI USA, V86, P2516, DOI 10.1073/pnas.86.7.2516; Cain BS, 1999, CRIT CARE MED, V27, P1309, DOI 10.1097/00003246-199907000-00018; Chao W, 2003, J GENE MED, V5, P277, DOI 10.1002/jgm.347; Chao W, 2002, J BIOL CHEM, V277, P31639, DOI 10.1074/jbc.M204104200; Cowan DB, 2000, AM J PHYSIOL-HEART C, V279, pH619, DOI 10.1152/ajpheart.2000.279.2.H619; Demidov ON, 1999, EUR J CARDIO-THORAC, V16, P444, DOI 10.1016/S1010-7940(99)00291-2; Dybdahl B, 2002, CIRCULATION, V105, P685, DOI 10.1161/hc0602.103617; Eising GP, 1996, CARDIOVASC RES, V31, P73, DOI 10.1016/0008-6363(95)00173-5; Frantz S, 1999, J CLIN INVEST, V104, P271, DOI 10.1172/JCI6709; Frantz S, 2001, J BIOL CHEM, V276, P5197, DOI 10.1074/jbc.M009160200; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEARD SO, 1992, CRIT CARE MED, V20, P523, DOI 10.1097/00003246-199204000-00015; Hotchkiss RS, 2000, CRIT CARE MED, V28, P3207, DOI 10.1097/00003246-200009000-00016; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Hotchkiss RS, 1997, CRIT CARE MED, V25, P1298, DOI 10.1097/00003246-199708000-00015; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Hull C, 2002, J IMMUNOL, V169, P2611, DOI 10.4049/jimmunol.169.5.2611; ITOH G, 1995, AM J PATHOL, V146, P1325; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Kajstura J, 1996, LAB INVEST, V74, P86; KAPADIA S, 1995, J CLIN INVEST, V96, P1042, DOI 10.1172/JCI118090; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Knuefermann P, 2002, CIRCULATION, V106, P2608, DOI 10.1161/01.CIR.0000038110.69369.4C; Kumar A, 1996, J EXP MED, V183, P949, DOI 10.1084/jem.183.3.949; Li HL, 2002, AM J PHYSIOL-HEART C, V283, pH461, DOI 10.1152/ajpheart.00701.2001; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Martinez-Cordova L. R., 1998, Journal of Applied Aquaculture, V8, P17, DOI 10.1300/J028v08n03_02; Matsui T, 2001, CIRCULATION, V104, P330; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Meiler SE, 2002, J MOL CELL CARDIOL, V34, P349, DOI 10.1006/jmcc.2001.1519; Meng XZ, 1997, AM J PHYSIOL-HEART C, V273, pH1894, DOI 10.1152/ajpheart.1997.273.4.H1894; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Olivetti G, 1996, J MOL CELL CARDIOL, V28, P2005, DOI 10.1006/jmcc.1996.0193; Oyama J, 2004, CIRCULATION, V109, P784, DOI 10.1161/01.CIR.0000112575.66565.84; Ozes ON, 1999, NATURE, V401, P82; PAGANI FD, 1992, SURGERY, V111, P683; Sam F, 2000, AM J PHYSIOL-HEART C, V279, pH422, DOI 10.1152/ajpheart.2000.279.1.H422; Saraste A, 1997, CIRCULATION, V95, P320; Song W, 1996, BRIT J PHARMACOL, V118, P2157, DOI 10.1111/j.1476-5381.1996.tb15657.x; Song W, 1998, EUR J PHARMACOL, V345, P285, DOI 10.1016/S0014-2999(98)00126-5; Stein B, 1996, J MOL CELL CARDIOL, V28, P1631, DOI 10.1006/jmcc.1996.0153; Tavener SA, 2004, CIRC RES, V95, P700, DOI 10.1161/01.RES.0000144175.70140.8c; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Valen G, 2000, CARDIOVASC RES, V47, P49, DOI 10.1016/S0008-6363(00)00071-7; Venkataraman C, 1999, IMMUNOL LETT, V69, P233, DOI 10.1016/S0165-2478(99)00068-1; Vivarelli MS, 2004, J EXP MED, V200, P399, DOI 10.1084/jem.20040446; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Watters JJ, 2002, J BIOL CHEM, V277, P9077, DOI 10.1074/jbc.M104385200; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664; Wong F, 2004, BLOOD, V103, P4520, DOI 10.1182/blood-2003-06-2118; Yamashita N, 1999, BRIT J PHARMACOL, V128, P412, DOI 10.1038/sj.bjp.0702809; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Yasuda S, 1997, CIRC RES, V81, P1011; Yue TL, 2000, CIRC RES, V86, P692, DOI 10.1161/01.RES.86.6.692	68	52	53	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21997	22005		10.1074/jbc.M413676200	http://dx.doi.org/10.1074/jbc.M413676200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15793310	hybrid			2022-12-27	WOS:000229557900042
J	Estall, JL; Koehler, JA; Yusta, B; Drucker, DJ				Estall, JL; Koehler, JA; Yusta, B; Drucker, DJ			The glucagon-like peptide-2 receptor C terminus modulates beta-arrestin-2 association but is dispensable for ligand-induced desensitization, endocytosis, and G-protein-dependent effector activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE-1; BETA-ARRESTIN; COUPLED RECEPTOR; HORMONE RECEPTOR; PHOSPHORYLATION; INTERNALIZATION; EXPRESSION; DOMAIN; PROLIFERATION; TRAFFICKING	Classic models of receptor desensitization and internalization have been largely based on the behavior of Family A G-protein-coupled receptors (GPCRs). The glucagon-like peptide-2 receptor (GLP-2R) is a member of the Family B glucagon-secretin GPCR family, which exhibit significant sequence and structural differences from the Family A receptors in their intracellular and extracellular domains. To identify structural motifs that regulate GLP-2R signaling and cell surface receptor expression, we analyzed the functional properties of a series of mutant GLP-2Rs. The majority of the C-terminal receptor tail was dispensable for GLP-2-induced cAMP accumulation, ERK1/2 activation, and endocytosis in transfected cells. However, progressive truncation of the C terminus reduced cell surface receptor expression, altered agonist-induced GLP-2R trafficking, and abrogated protein kinase A-mediated heterologous receptor desensitization. Elimination of the distal 21 amino acids of the receptor was sufficient to promote constitutive receptor internalization and prevent agonist-induced recruitment of beta-arrestin-2. Site-directed mutagenesis identified specific amino acid residues within the distal GLP-2R C terminus that mediate the stable association with beta-arrestin-2. Surprisingly, although the truncated mutant receptors failed to interact with beta-arrestin-2, they underwent homologous desensitization and subsequent resensitization with kinetics similar to that observed with the wild-type GLP-2R. Our data suggest that, although the GLP-2R C terminus is not required for coupling to cellular machinery regulating signaling or desensitization, it may serve as a sorting signal for intracellular trafficking. Taken together with the previously demonstrated clathrin and dynamin-independent, lipid-raft-dependent pathways for internalization, our data suggest that GLP-2 receptor signaling has evolved unique structural and functional mechanisms for control of receptor trafficking, desensitization, and resensitization.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2C4, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Toronto, ON M5G 2C4, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Drucker, DJ (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, 100 Coll St, Toronto, ON M5G 2C4, Canada.	d.drucker@utoronto.ca	Drucker, Daniel J/A-4092-2010	Estall, Jennifer/0000-0002-9838-1440				Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; Bjerknes M, 2001, P NATL ACAD SCI USA, V98, P12497, DOI 10.1073/pnas.211278098; Blomenrohr M, 1999, MOL PHARMACOL, V56, P1229, DOI 10.1124/mol.56.6.1229; Buggy JJ, 1997, DIABETES, V46, P1400, DOI 10.2337/diabetes.46.9.1400; Chauvin S, 2002, MOL ENDOCRINOL, V16, P2720, DOI 10.1210/me.2002-0049; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dhami GK, 2004, J BIOL CHEM, V279, P16614, DOI 10.1074/jbc.M314090200; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; Drucker DJ, 2001, ENDOCRINOLOGY, V142, P521, DOI 10.1210/en.142.2.521; Drucker DJ, 1996, P NATL ACAD SCI USA, V93, P7911, DOI 10.1073/pnas.93.15.7911; Estall JL, 2004, MOL BIOL CELL, V15, P3673, DOI 10.1091/mbc.E03-11-0825; Estall JL, 2003, J NUTR, V133, P3708, DOI 10.1093/jn/133.11.3708; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; Koehler JA, 2005, MOL ENDOCRINOL, V19, P459, DOI 10.1210/me.2004-0196; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lin XW, 1998, MOL ENDOCRINOL, V12, P161, DOI 10.1210/me.12.2.161; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mayo KE, 2003, PHARMACOL REV, V55, P167, DOI 10.1124/pr.55.1.6; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Munroe DG, 1999, P NATL ACAD SCI USA, V96, P1569, DOI 10.1073/pnas.96.4.1569; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Orskov C, 2005, REGUL PEPTIDES, V124, P105, DOI 10.1016/j.regpep.2004.07.009; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qian HW, 2001, MOL ENDOCRINOL, V15, P1706, DOI 10.1210/me.15.10.1706; Rasmussen TN, 2004, EUR J BIOCHEM, V271, P4366, DOI 10.1111/j.1432-1033.2004.04371.x; Schwartkop CP, 1999, J NEUROCHEM, V72, P1275, DOI 10.1046/j.1471-4159.1999.0721275.x; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Tsai CH, 1997, AM J PHYSIOL-ENDOC M, V273, pE77, DOI 10.1152/ajpendo.1997.273.1.E77; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Wei HJ, 2004, J BIOL CHEM, V279, P48255, DOI 10.1074/jbc.M406205200; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Wheeler MB, 1999, J BIOL CHEM, V274, P24593, DOI 10.1074/jbc.274.35.24593; Yusta B, 2000, J BIOL CHEM, V275, P35345, DOI 10.1074/jbc.M005510200; Yusta B, 1999, J BIOL CHEM, V274, P30459, DOI 10.1074/jbc.274.43.30459; Yusta B, 2002, J BIOL CHEM, V277, P24896, DOI 10.1074/jbc.M201358200; Yusta B, 2000, GASTROENTEROLOGY, V119, P744, DOI 10.1053/gast.2000.16489; Zhong HL, 2001, J PHARMACOL EXP THER, V297, P837	48	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22124	22134		10.1074/jbc.M500078200	http://dx.doi.org/10.1074/jbc.M500078200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817468	hybrid			2022-12-27	WOS:000229557900057
J	Kumar, MS; Kapoor, M; Sinha, S; Reddy, GB				Kumar, MS; Kapoor, M; Sinha, S; Reddy, GB			Insights into hydrophobicity and the chaperone-like function of alpha A- and alpha B-crystallins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS EPITHELIAL-CELLS; 1,1'-BI(4-ANILINO)NAPHTHALENE-5,5'-DISULFONIC ACID; KNOCKOUT MICE; TEMPERATURE; BINDING; HYPERPROLIFERATION; AGGREGATION; PROTEINS/; STABILITY; CATARACT	Crystallin, composed of two subunits, alpha A and alpha B, has been shown to function as a molecular chaperone that prevents aggregation of other proteins under stress conditions. The exposed hydrophobic surfaces of alpha-crystallins have been implicated in this process, but their exact role has not been elucidated. In this study, we quantify the hydrophobic surfaces of alpha A- and alpha B-crystallins by isothermal titration calorimetry using 8-anilino-1-napthalenesulfonic acid (ANS) as a hydrophobic probe and analyze its correlation to the chaperone potential of alpha A- and alpha B-crystallins under various conditions. Two ANS binding sites, one with low and another with high affinity, were clearly detected, with alpha B showing a higher number of sites than alpha A at 30 degrees C. In agreement with the higher number of hydrophobic sites, alpha B-crystallin demonstrated higher chaperone activity than alpha A at this temperature. Thermodynamic analysis of ANS binding to alpha A- and alpha B-crystallins indicates that high affinity binding is driven by both enthalpy and entropy changes, with entropy dominating the low affinity binding. Interestingly, although the number of ANS binding sites was similar for alpha A and alpha B at 15 degrees C, alpha A was more potent than alpha B in preventing aggregation of the insulin B-chain. Although there was no change in the number of high affinity binding sites of alpha A and alpha B for ANS upon preheating, there was an increase in the number of low affinity sites of alpha A and alpha B. Preheated alpha A, in contrast to alpha B, exhibited remarkably enhanced chaperone activity. Our results indicate that although hydrophobicity appears to be a factor in determining the chaperone-like activity of alpha-crystallins, it does not quantitatively correlate with the chaperone function of alpha-crystallins.	Natl Inst Nutr, Div Biochem, Hyderabad 500007, Andhra Pradesh, India; Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Nutrition (NIN); Indian Institute of Science (IISC) - Bangalore	Reddy, GB (corresponding author), Natl Inst Nutr, Div Biochem, Hyderabad 500007, Andhra Pradesh, India.	geereddy@yahoo.com	Reddy, G Bhanuprakash/AAJ-3494-2020	Reddy, G Bhanuprakash/0000-0003-4787-3944; Sinha, Sharmistha/0000-0003-2459-650X				Andley UP, 2001, FASEB J, V15, P221, DOI 10.1096/fj.00-0296com; Andley UP, 2000, J BIOL CHEM, V275, P36823, DOI 10.1074/jbc.M004233200; Bai F, 2003, J BIOL CHEM, V278, P36876, DOI 10.1074/jbc.M304010200; Bhat SP, 2003, PROG DRUG RES, V60, P205; Bhattacharyya J, 2002, J PROTEIN CHEM, V21, P65, DOI 10.1023/A:1014187300930; Bloemendal H, 2004, PROG BIOPHYS MOL BIO, V86, P407, DOI 10.1016/j.pbiomolbio.2003.11.012; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Burgio MR, 2000, BIOCHEM BIOPH RES CO, V268, P426, DOI 10.1006/bbrc.1999.2036; Burgio MR, 2001, MOL VIS, V7, P228; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Datta SA, 1999, J BIOL CHEM, V274, P34773, DOI 10.1074/jbc.274.49.34773; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Fujita Y, 2004, J CELL SCI, V117, P1719, DOI 10.1242/jcs.01021; Ganea E, 2001, CURR PROTEIN PEPT SC, V2, P205, DOI 10.2174/1389203013381107; Gomez-Puertas P, 2004, J MOL RECOGNIT, V17, P85, DOI 10.1002/jmr.654; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; Kumar LVS, 2000, J BIOL CHEM, V275, P22009, DOI 10.1074/jbc.M003307200; Kumar MS, 2004, BIOCHEM J, V379, P273, DOI 10.1042/BJ20031633; LIANG JN, 1991, EXP EYE RES, V53, P61, DOI 10.1016/0014-4835(91)90145-5; Liao JH, 2002, BIOCHEM BIOPH RES CO, V295, P854, DOI 10.1016/S0006-291X(02)00784-2; Mao Q, 2001, BIOCHEMISTRY-MOSCOW+, V66, P904, DOI 10.1023/A:1011960904542; Mchaourab HS, 2002, J BIOL CHEM, V277, P40557, DOI 10.1074/jbc.M206250200; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; Reddy GB, 2000, J BIOL CHEM, V275, P4565, DOI 10.1074/jbc.275.7.4565; Santhoshkumar P, 2001, J BIOL CHEM, V276, P47094, DOI 10.1074/jbc.M107737200; Sharma KK, 1998, J BIOL CHEM, V273, P15474, DOI 10.1074/jbc.273.25.15474; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; Smulders RHPH, 1997, FEBS LETT, V409, P101, DOI 10.1016/S0014-5793(97)00498-5; Stevens A, 1997, EUR J BIOCHEM, V243, P792, DOI 10.1111/j.1432-1033.1997.00792.x; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; van Boekel MAM, 1999, BBA-PROTEIN STRUCT M, V1434, P114, DOI 10.1016/S0167-4838(99)00178-8; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	35	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21726	21730		10.1074/jbc.M500405200	http://dx.doi.org/10.1074/jbc.M500405200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817465	hybrid			2022-12-27	WOS:000229557900008
J	Moren, A; Imamura, T; Miyazono, K; Heldin, CH; Moustakas, A				Moren, A; Imamura, T; Miyazono, K; Heldin, CH; Moustakas, A			Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; BONE MORPHOGENETIC PROTEIN; TGF-BETA; TRANSCRIPTIONAL ACTIVITY; FUNCTIONAL CONSEQUENCES; DEPENDENT DEGRADATION; SUMO-1 MODIFICATION; MISSENSE MUTATIONS; STRUCTURAL BASIS; I RECEPTOR	Smad4 mediates signaling by the transforming growth factor-beta (TGF-beta) superfamily of cytokines. Smad signaling is negatively regulated by inhibitory (I) Smads and ubiquitin-mediated processes. Known mechanisms of proteasomal degradation of Smads depend on the direct interaction of specific E3 ligases with Smads. Alternatively, I-Smads elicit degradation of the TGF-beta receptor by recruiting the WW and HECT domain E3 ligases, Smurfs, WWP1, or NEDD4-2. We describe an equivalent mechanism of degradation of Smad4 by the above E3 ligases, via formation of ternary complexes between Smad4 and Smurfs, mediated by R-Smads (Smad2) or I-Smads (Smad6/7), acting as adaptors. Smurfs, which otherwise cannot directly bind to Smad4, mediated polyubiquitination of Smad4 in the presence of Smad6 or Smad7. Smad4 co-localized with Smad7 and Smurf1 primarily in the cytoplasm and in peripheral cell protrusions. Smad2 or Smad7 mutants defective in Smad4 interaction failed to induce Smurf1-mediated down-regulation of Smad4. A Smad4 mutant defective in Smad2 or Smad7 interaction could not be effectively down-regulated by Smurf1. We propose that Smad4 is targeted for degradation by multiple ubiquitin ligases that can simultaneously act on R-Smads and signaling receptors. Such mechanisms of down-regulation of TGF-beta signaling may be critical for proper physiological response to this pathway.	Uppsala Univ, Biomed Ctr, Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Univ Tokyo, Grad Sch Med, Dept Med Pathol, Bunkyo Ku, Tokyo 1130033, Japan	Ludwig Institute for Cancer Research; Uppsala University; Japanese Foundation for Cancer Research; University of Tokyo	Moustakas, A (corresponding author), Uppsala Univ, Biomed Ctr, Ludwig Inst Canc Res, Box 595, SE-75124 Uppsala, Sweden.	aris.moustakas@licr.uu.se						Bai YL, 2004, MOL CELL, V15, P825, DOI 10.1016/j.molcel.2004.07.021; Brodin G, 1999, CANCER RES, V59, P2731; Chacko BM, 2004, MOL CELL, V15, P813, DOI 10.1016/j.molcel.2004.07.016; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; De Bosscher K, 2004, BIOCHEM J, V379, P209, DOI 10.1042/BJ20031886; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim BC, 2004, MOL CELL BIOL, V24, P2251, DOI 10.1128/MCB.24.6.2251-2262.2004; Koinuma D, 2003, EMBO J, V22, P6458, DOI 10.1093/emboj/cdg632; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Kuratomi G, 2005, BIOCHEM J, V386, P461, DOI 10.1042/BJ20040738; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Li LY, 2004, MOL CELL BIOL, V24, P856, DOI 10.1128/MCB.24.2.856-864.2004; Liang M, 2004, MOL CELL BIOL, V24, P7524, DOI 10.1128/MCB.24.17.7524-7537.2004; Liang M, 2004, J BIOL CHEM, V279, P22857, DOI 10.1074/jbc.M401554200; Liang YY, 2003, J BIOL CHEM, V278, P26307, DOI 10.1074/jbc.C300028200; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Long JY, 2004, BIOCHEM J, V379, P23, DOI 10.1042/BJ20031867; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; McCabe BD, 2004, NEURON, V41, P891, DOI 10.1016/S0896-6273(04)00073-X; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Moren A, 2000, ONCOGENE, V19, P4396, DOI 10.1038/sj.onc.1203798; Moren A, 2003, J BIOL CHEM, V278, P33571, DOI 10.1074/jbc.M300159200; Moustakas A, 2001, J CELL SCI, V114, P4359; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ohshima T, 2003, J BIOL CHEM, V278, P50833, DOI 10.1074/jbc.M307533200; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Podos SD, 2001, DEV CELL, V1, P567, DOI 10.1016/S1534-5807(01)00057-0; Reguly T, 2003, TRENDS CELL BIOL, V13, P216, DOI 10.1016/S0962-8924(03)00075-8; Seo SR, 2004, EMBO J, V23, P3780, DOI 10.1038/sj.emboj.7600398; Shi W, 2004, AM J PHYSIOL-LUNG C, V286, pL293, DOI 10.1152/ajplung.00228.2003; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Wan M, 2004, J BIOL CHEM, V279, P14484, DOI 10.1074/jbc.C400005200; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Ying SX, 2003, J BIOL CHEM, V278, P39029, DOI 10.1074/jbc.M301193200; Zhang LX, 2004, SCIENCE, V306, P114, DOI 10.1126/science.1100569; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	58	148	165	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22115	22123		10.1074/jbc.M414027200	http://dx.doi.org/10.1074/jbc.M414027200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817471	hybrid			2022-12-27	WOS:000229557900056
J	Szczepanowski, RH; Filipek, R; Bochtler, M				Szczepanowski, RH; Filipek, R; Bochtler, M			Crystal structure of a fragment of mouse ubiquitin-activating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME PATHWAY; PROTEIN-ACTIVATION; E1; SYSTEM; RECRUITMENT; CONJUGATION; MECHANISM; INSIGHTS; COMPLEX; NEDD8	Protein ubiquitination requires the sequential activity of three enzymes: a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2), and a ubiquitinligase (E3). The ubiquitin-transfer machinery is hierarchically organized; for every ubiquitin-activating enzyme, there are several ubiquitin-conjugating enzymes, and most ubiquitin-conjugating enzymes can in turn interact with multiple ubiquitin ligases. Despite the central role of ubiquitin-activating enzyme in this cascade, a crystal structure of a ubiquitin-activating enzyme is not available. The enzyme is thought to consist of an adenylation domain, a catalytic cysteine domain, a four-helix bundle, and possibly, a ubiquitin-like domain. Its adenylation domain can be modeled because it is clearly homologous to the structurally known adenylation domains of the activating enzymes for the small ubiquitinlike modifier ( SUMO) and for the protein encoded by the neuronal precursor cell-expressed, developmentally down-regulated gene 8 (NEDD8). Low sequence similarity and vastly different domain lengths make modeling difficult for the catalytic cysteine domain that results from the juxtaposition of two catalytic cysteine halfdomains. Here, we present a biochemical and crystallographic characterization of the two half-domains and the crystal structure of the larger, second catalytic cysteine half-domain of mouse ubiquitin-activating enzyme. We show that the domain is organized around a conserved folding motif that is also present in the NEDD8- and SUMO-activating enzymes, and we propose a tentative model for full-length ubiquitin-activating enzyme.	Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland; Max Planck Inst Mol Cell Biol & Genet, D-01309 Dresden, Germany	Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Max Planck Society	Bochtler, M (corresponding author), Int Inst Mol & Cell Biol, Ul Trojdena 4, PL-02109 Warsaw, Poland.	MBochtler@iimcb.gov.pl	Bochtler, Matthias/A-4514-2010	Bochtler, Matthias/0000-0001-7884-4463				ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; HAAS AL, 1982, J BIOL CHEM, V257, P2543; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Holm L, 2000, BIOINFORMATICS, V16, P566, DOI 10.1093/bioinformatics/16.6.566; Huang DT, 2005, MOL CELL, V17, P341, DOI 10.1016/j.molcel.2004.12.020; Huang DT, 2004, ONCOGENE, V23, P1958, DOI 10.1038/sj.onc.1207393; Huang DT, 2004, NAT STRUCT MOL BIOL, V11, P927, DOI 10.1038/nsmb826; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Liu YC, 2004, ANNU REV IMMUNOL, V22, P81, DOI 10.1146/annurev.immunol.22.012703.104813; Lois LM, 2005, EMBO J, V24, P439, DOI 10.1038/sj.emboj.7600552; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; VanDemark AP, 2003, NAT STRUCT BIOL, V10, P244, DOI 10.1038/nsb0403-244; Walden H, 2003, MOL CELL, V12, P1427, DOI 10.1016/S1097-2765(03)00452-0; Walden H, 2003, NATURE, V422, P330, DOI 10.1038/nature01456	23	39	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22006	22011		10.1074/jbc.M502583200	http://dx.doi.org/10.1074/jbc.M502583200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15774460	hybrid			2022-12-27	WOS:000229557900043
J	Yu, XS; Yin, XY; Lafer, EM; Jiang, JX				Yu, XS; Yin, XY; Lafer, EM; Jiang, JX			Development regulation of the direct interaction between the intracellular loop of connexin 45.6 and the C terminus of major intrinsic protein (aquaporin-0)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC CHICK LENS; PLASMON RESONANCE; GAP-JUNCTIONS; DYE TRANSFER; EXPRESSION; MEMBRANE; WATER; MIP; COMMUNICATION; PERMEABILITY	The eye lens is dependent upon a network of gap junction-mediated intercellular communication to facilitate its homeostasis and development. Three gap junction-forming proteins are expressed in the lens of which two are in lens fibers, namely connexin (Cx) 45.6 and 56. Major intrinsic protein (MIP), also known as aquaporin-0 (AQP0), is the most abundant membrane protein in lens fibers. However, its role in the lens is not clear. Our previous studies show that MIP( AQP0) associates with gap junction plaques formed by Cx45.6 and Cx56 during the early stages of embryonic chick lens development but not in late embryonic and adult lenses. We report here that MIP( AQP0) directly interacts with Cx45.6 but not with Cx56. We further identified the intracellular loop of Cx45.6 as the interacting domain for the MIP(AQP0) C terminus. Surface plasmon resonance experiments indicated that the C-terminal domain of MIP(AQP0) interacts with two binding sites within the intracellular loop region of Cx45.6 with a K-D(app) of 7.5 and 10.3 mu M, respectively. The K-D(app) for the full-length loop region is 7.7 mu M. The cleavage at the intracellular loop of Cx45.6 was observed during lens development, and the C terminus of MIP( AQP0) did not interact with the loop-cleaved form of Cx45.6. Thus, the dissociation between these two proteins that occurs in the mature fibers of late lens development is likely caused by this cleavage. Finally this interaction had no impact on Cx45.6-mediated intercellular communication, suggesting that the Cx45.6-MIP(AQP0) interaction plays a novel unidentified role in lens fibers.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Jiang, JX (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, MSC 7760,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	jiangj@uthscsa.edu		Lafer, Eileen/0000-0002-0493-6522; Jiang, Jean/0000-0002-2185-5716	NATIONAL CANCER INSTITUTE [P30CA054174] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012085, R29EY012085] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA054174] Funding Source: Medline; NEI NIH HHS [EY 12085] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Al-Ghoul KJ, 2003, ANAT REC PART A, V273A, P714, DOI 10.1002/ar.a.10080; BEEBE DC, 1981, DEV BIOL, V84, P96, DOI 10.1016/0012-1606(81)90374-2; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; DONALDSON PJ, 1995, AM J PHYSIOL-CELL PH, V269, pC590, DOI 10.1152/ajpcell.1995.269.3.C590; Duchesne L, 2002, J BIOL CHEM, V277, P20598, DOI 10.1074/jbc.M201179200; Dunia I, 1998, J CELL SCI, V111, P2109; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; FISCHBARG J, 1995, INVEST OPHTH VIS SCI, V36, P758; GEORGE AJT, 1995, J IMMUNOL METHODS, V183, P51, DOI 10.1016/0022-1759(95)00031-5; Gong XH, 1997, CELL, V91, P833, DOI 10.1016/S0092-8674(00)80471-7; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; HARLOW E, 1999, USING ANTIBODIES LAB, P245; Jiang JX, 1998, INVEST OPHTH VIS SCI, V39, P537; JIANG JX, 1994, MOL BIOL CELL, V5, P363, DOI 10.1091/mbc.5.3.363; Jiang JX, 2001, METH MOL B, V154, P159; Jiang JX, 1996, P NATL ACAD SCI USA, V93, P1287, DOI 10.1073/pnas.93.3.1287; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KUSHMERICK C, 1995, EXP EYE RES, V61, P351, DOI 10.1016/S0014-4835(05)80129-0; McDonnell JM, 2001, CURR OPIN CHEM BIOL, V5, P572, DOI 10.1016/S1367-5931(00)00251-9; MILLER AG, 1992, J MEMBRANE BIOL, V128, P91; MILLER TM, 1986, J CELL BIOL, V102, P194, DOI 10.1083/jcb.102.1.194; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nemeth-Cahalan KL, 2000, J BIOL CHEM, V275, P6777, DOI 10.1074/jbc.275.10.6777; Nielsen PA, 2003, MOL BIOL CELL, V14, P2470, DOI 10.1091/mbc.E02-10-0637; OSTRER H, 1981, DEV BIOL, V86, P403, DOI 10.1016/0012-1606(81)90198-6; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; Salamon Z, 1999, TRENDS BIOCHEM SCI, V24, P213, DOI 10.1016/S0968-0004(99)01394-8; SAS DF, 1985, CURR EYE RES, V4, P1171, DOI 10.3109/02713688509003363; SCHUETZE SM, 1982, J CELL BIOL, V92, P694, DOI 10.1083/jcb.92.3.694; Tan FG, 2004, INVEST OPHTH VIS SCI, V45, P863, DOI 10.1167/iovs.03-0708; TANAKA M, 1980, INVEST OPHTH VIS SCI, V19, P619; Thomas MA, 2002, BIOL CELL, V94, P445, DOI 10.1016/S0248-4900(02)00015-1; Virkki LV, 2001, AM J PHYSIOL-REG I, V281, pR1994, DOI 10.1152/ajpregu.2001.281.6.R1994; White TW, 1998, J CELL BIOL, V143, P815, DOI 10.1083/jcb.143.3.815; WHITE TW, 1992, MOL BIOL CELL, V3, P711, DOI 10.1091/mbc.3.7.711; YANCEY SB, 1988, J CELL BIOL, V106, P705, DOI 10.1083/jcb.106.3.705; Yin XY, 2001, J BIOL CHEM, V276, P34567, DOI 10.1074/jbc.M106073200; Yu XS, 2004, J CELL SCI, V117, P871, DOI 10.1242/jcs.00945	40	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22081	22090		10.1074/jbc.M414377200	http://dx.doi.org/10.1074/jbc.M414377200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15802270	hybrid			2022-12-27	WOS:000229557900052
J	Dudas, KC; Kreuzer, KN				Dudas, KC; Kreuzer, KN			Bacteriophage T4 helicase loader protein gp59 functions as gatekeeper in origin-dependent replication in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; DNA-BINDING-PROTEIN; GENE 59; LEADING-STRAND; MINICIRCLE SUBSTRATE; LOADING PROTEIN; R-LOOPS; RECOMBINATION; MUTATIONS; PLASMIDS	Bacteriophage T4 initiates origin-dependent replication via an R-loop mechanism in vivo. During in vitro reactions, the phage-encoded gp59 stimulates loading of the replicative helicase, gp41, onto branched intermediates, including origin R-loops. However, although gp59 is essential for recombination-dependent replication from D-loops, it does not appear to be required for origin-dependent replication in vivo. In this study, we have analyzed the origin-replicative intermediates formed during infections that are deficient in gp59 and other phage replication proteins. During infections lacking gp59, the initial replication forks from two different T4 origins actively replicated both leading- and lagging-strands. However, the retrograde replication forks from both origins were abnormal in the gp59-deficient infections. The lagging-strand from the initial fork was elongated as a new leading- strand in the retrograde direction without lagging-strand synthesis, whereas in the wild-type, leading- and lagging-strand synthesis appeared to be coupled. These results imply that gp59 inhibits the polymerase holoenzyme in vivo until the helicase-primase (gp41-gp61) complex is loaded, and we thereby refer to gp59 as a gatekeeper. We also found that all origin-replicative intermediates were absent in infections deficient in the helicase gp41 or the single-strand-binding protein gp32, regardless of whether gp59 was present or absent. These results argue that replication from the origin in vivo is dependent on both the helicase and single-strand-binding protein and demonstrate that the strong replication defect of gene 41 and 32 single mutants is not caused by gp59 inhibition of the polymerase.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Kreuzer, KN (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	kenneth.kreuzer@duke.edu			NIGMS NIH HHS [GM34622, R01 GM034622, R37 GM034622] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034622, R01GM034622] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRY J, 1994, J BIOL CHEM, V269, P33049; Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; Belanger KG, 1996, NUCLEIC ACIDS RES, V24, P2166, DOI 10.1093/nar/24.11.2166; Belanger KG, 1998, MOL CELL, V2, P693, DOI 10.1016/S1097-2765(00)80167-7; BENSON KH, 1992, J VIROL, V66, P6960, DOI 10.1128/JVI.66.12.6960-6968.1992; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; CarlesKinch K, 1997, J MOL BIOL, V266, P915, DOI 10.1006/jmbi.1996.0844; Chastain PD, 2003, J BIOL CHEM, V278, P21276, DOI 10.1074/jbc.M301573200; CUNNINGHAM RP, 1977, VIROLOGY, V80, P67, DOI 10.1016/0042-6822(77)90381-6; Doan PL, 2001, GENETICS, V157, P1077; Dudas KC, 2001, MOL CELL BIOL, V21, P2706, DOI 10.1128/MCB.21.8.2706-2715.2001; EDGAR RS, 1964, GENETICS, V49, P635; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; GAUSS P, 1994, J BACTERIOL, V176, P1667, DOI 10.1128/jb.176.6.1667-1672.1994; George JW, 1996, GENETICS, V143, P1507; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; Ishmael FT, 2003, J BIOL CHEM, V278, P3145, DOI 10.1074/jbc.M209858200; Ishmael FT, 2002, J BIOL CHEM, V277, P20555, DOI 10.1074/jbc.M111951200; Jones CE, 2004, J BIOL CHEM, V279, P25721, DOI 10.1074/jbc.M402128200; Jones CE, 2000, J BIOL CHEM, V275, P27145; KABACK DB, 1979, NUCLEIC ACIDS RES, V6, P2499, DOI 10.1093/nar/6.7.2499; Kadyrov FA, 2001, J BIOL CHEM, V276, P29559, DOI 10.1074/jbc.M101310200; KARAM JD, 1973, J VIROL, V11, P933, DOI 10.1128/JVI.11.6.933-945.1973; Kornberg A., 1992, DNA REPLICATION; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; KREUZER KN, 1995, J BACTERIOL, V177, P6844, DOI 10.1128/jb.177.23.6844-6853.1995; KREUZER KN, 1988, J BIOL CHEM, V263, P11366; KREUZER KN, 1986, J MOL BIOL, V188, P185, DOI 10.1016/0022-2836(86)90303-7; KREUZER KN, 1988, J BIOL CHEM, V263, P11348; KREUZER KN, 1994, MOL BIOL BACTERIOP T, V4, P452; KUES U, 1989, MICROBIOL REV, V53, P491; LANDGRAF R, 1995, NUCLEIC ACIDS RES, V23, P3516, DOI 10.1093/nar/23.17.3516; Lee DY, 1996, J BIOL CHEM, V271, P24262, DOI 10.1074/jbc.271.39.24262; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; LUDER A, 1982, P NATL ACAD SCI-BIOL, V79, P1101, DOI 10.1073/pnas.79.4.1101; Ma YJ, 2004, J BIOL CHEM, V279, P19035, DOI 10.1074/jbc.M311738200; MENKENS AE, 1988, J BIOL CHEM, V263, P11358; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; MOSIG G, 1995, FEMS MICROBIOL REV, V17, P83, DOI 10.1111/j.1574-6976.1995.tb00190.x; Mueser TC, 2000, J MOL BIOL, V296, P597, DOI 10.1006/jmbi.1999.3438; Nossal NG, 2001, MOL CELL, V7, P31, DOI 10.1016/S1097-2765(01)00152-6; Raney KD, 1996, J BIOL CHEM, V271, P14074, DOI 10.1074/jbc.271.24.14074; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; SELICK HE, 1988, J BIOL CHEM, V263, P11336; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; Tomso DJ, 2000, GENETICS, V155, P1493; Trakselis MA, 2003, J BIOL CHEM, V278, P49839, DOI 10.1074/jbc.M307405200; Trakselis MA, 2001, TRENDS BIOCHEM SCI, V26, P566, DOI 10.1016/S0968-0004(01)01929-6; WU JR, 1978, J VIROL, V27, P103, DOI 10.1128/JVI.27.1.103-117.1978; WU R, 1972, VIROLOGY, V47, P147, DOI 10.1016/0042-6822(72)90248-6; WU R, 1974, VIROLOGY, V59, P108, DOI 10.1016/0042-6822(74)90209-8; Xi J, 2005, BIOCHEMISTRY-US, V44, P2305, DOI 10.1021/bi0479508; Xu H, 2001, BIOCHEMISTRY-US, V40, P7651, DOI 10.1021/bi010116n; Yang JS, 2003, J BIOL CHEM, V278, P49828, DOI 10.1074/jbc.M307406200; YONESAKI T, 1994, J BIOL CHEM, V269, P1284	56	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21561	21569		10.1074/jbc.m502351200	http://dx.doi.org/10.1074/jbc.m502351200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15781450	hybrid, Green Accepted			2022-12-27	WOS:000229438800079
J	Godley, BF; Shamsi, FA; Liang, FQ; Jarrett, SG; Davies, S; Boulton, M				Godley, BF; Shamsi, FA; Liang, FQ; Jarrett, SG; Davies, S; Boulton, M			Blue light induces mitochondrial DNA damage and free radical production in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; BLOOD-RETINAL BARRIER; BASE EXCISION-REPAIR; OXIDATIVE STRESS; PIGMENT-EPITHELIUM; AGE PIGMENT; NUCLEAR-DNA; IN-VITRO; OXYGEN; ULTRAVIOLET	Exposure of biological chromophores to ultraviolet radiation can lead to photochemical damage. However, the role of visible light, particularly in the blue region of the spectrum, has been largely ignored. To test the hypothesis that blue light is toxic to non-pigmented epithelial cells, confluent cultures of human primary retinal epithelial cells were exposed to visible light (390 - 550 nm at 2.8 milliwatts/cm(2)) for up to 6 h. A small loss of mitochondrial respiratory activity was observed at 6 h compared with dark-maintained cells, and this loss became greater with increasing time. To investigate the mechanism of cell loss, the damage to mitochondrial and nuclear genes was assessed using the quantitative PCR. Light exposure significantly damaged mitochondrial DNA at 3 h (0.7 lesion/10 kb DNA) compared with dark-maintained controls. However, by 6 h of light exposure, the number of lesions was decreased in the surviving cells, indicating DNA repair. Isolated mitochondria exposed to light generated singlet oxygen, superoxide anion, and the hydroxyl radical. Antioxidants confirmed the superoxide anion to be the primary species responsible for the mitochondrial DNA lesions. The effect of lipofuscin, a photoinducible intracellular generator of reactive oxygen intermediates, was investigated for comparison. Exposure of lipofuscin-containing cells to visible light caused an increase in both mitochondrial and nuclear DNA lesions compared with non-pigmented cells. We conclude that visible light can cause cell dysfunction through the action of reactive oxygen species on DNA and that this may contribute to cellular aging, age-related pathologies, and tumorigenesis.	Retina Fdn SW, Dallas, TX 75231 USA; Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF10 3NB, Wales; King Khalid Eye Specialist Hosp, Dept Res, Riyadh 11462, Saudi Arabia	Retina Foundation of the Southwest; Cardiff University; King Khaled Eye Specialist Hospital	Godley, BF (corresponding author), Retina Fdn SW, 9900 N Cent Expressway,Suite 400, Dallas, TX 75231 USA.	bgodley@retinafoundation.org			NATIONAL EYE INSTITUTE [R01EY012850] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY12850] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661; BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Bunik VI, 2002, EUR J BIOCHEM, V269, P5004, DOI 10.1046/j.1432-1033.2002.03204.x; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; CHEN EP, 1992, CURR EYE RES, V11, P825, DOI 10.3109/02713689209033480; CRAWFORD DR, 1994, ENVIRON HEALTH PERSP, V102, P25, DOI 10.2307/3432208; Croteau DL, 1999, MUTAT RES-DNA REPAIR, V434, P137, DOI 10.1016/S0921-8777(99)00025-7; CUNNINGHAM M L, 1985, Journal of Free Radicals in Biology and Medicine, V1, P381, DOI 10.1016/0748-5514(85)90150-3; Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2; Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285; Genova ML, 2004, ANN NY ACAD SCI, V1011, P86, DOI 10.1196/annals.1293.010; Goyns MH, 2002, MECH AGEING DEV, V123, P791, DOI 10.1016/S0047-6374(01)00424-9; HENDERSON LM, 1993, EUR J BIOCHEM, V217, P973, DOI 10.1111/j.1432-1033.1993.tb18328.x; Hockberger PE, 1999, P NATL ACAD SCI USA, V96, P6255, DOI 10.1073/pnas.96.11.6255; Hoffmann S, 2004, FREE RADICAL BIO MED, V36, P765, DOI 10.1016/j.freeradbiomed.2003.12.019; JARRETT SG, 2005, IN PRESS FREE RADIC; Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517; JONES CA, 1987, RADIAT RES, V110, P244, DOI 10.2307/3576902; Jou MJ, 2004, J PINEAL RES, V37, P55, DOI 10.1111/j.1600-079X.2004.00140.x; Jou MJ, 2002, J BIOMED SCI, V9, P507; Kagan VE, 2002, ANN NY ACAD SCI, V959, P188, DOI 10.1111/j.1749-6632.2002.tb02093.x; Kang D, 2003, CLIN CHEM LAB MED, V41, P1281, DOI 10.1515/CCLM.2003.195; King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1; KRALJIC I, 1978, PHOTOCHEM PHOTOBIOL, V28, P577, DOI 10.1111/j.1751-1097.1978.tb06972.x; Kravchenko LV, 2003, B EXP BIOL MED+, V136, P572, DOI 10.1023/B:BEBM.0000020207.67705.59; LeDoux SP, 2001, PROG NUCLEIC ACID RE, V68, P273; Lee HC, 2001, BIOGERONTOLOGY, V2, P231, DOI 10.1023/A:1013270512172; LUBART R, 1992, J PHOTOCH PHOTOBIO B, V12, P305, DOI 10.1016/1011-1344(92)85032-P; Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8; MASSEY V, 1994, J BIOL CHEM, V269, P22459; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; Pang JJ, 1998, GRAEF ARCH CLIN EXP, V236, P696, DOI 10.1007/s004170050143; Pang JJ, 1999, JPN J OPHTHALMOL, V43, P103, DOI 10.1016/S0021-5155(98)00073-2; PEAK JG, 1985, PHOTOCHEM PHOTOBIOL, V41, P295, DOI 10.1111/j.1751-1097.1985.tb03488.x; PEAK JG, 1995, PHOTOCHEM PHOTOBIOL, V61, P484, DOI 10.1111/j.1751-1097.1995.tb02349.x; PEAK MJ, 1990, PHOTOCHEM PHOTOBIOL, V51, P649, DOI 10.1111/php.1990.51.6.649; PEAK MJ, 1989, PHOTODERMATOLOGY, V6, P1; Peng TI, 2004, ANN NY ACAD SCI, V1011, P112, DOI 10.1196/annals.1293.012; Pflaum M, 1998, MUTAT RES-DNA REPAIR, V408, P137, DOI 10.1016/S0921-8777(98)00029-9; PUTTING BJ, 1993, GRAEF ARCH CLIN EXP, V231, P600, DOI 10.1007/BF00936526; PUTTING BJ, 1994, EXP EYE RES, V58, P31, DOI 10.1006/exer.1994.1192; Rabilloud T, 2001, PROTEOMICS, V1, P1105, DOI 10.1002/1615-9861(200109)1:9<1105::AID-PROT1105>3.0.CO;2-M; RICHMOND R, 1981, ANAL BIOCHEM, V118, P328, DOI 10.1016/0003-2697(81)90590-X; ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825; RYAN TC, 1990, J IMMUNOL METHODS, V130, P223, DOI 10.1016/0022-1759(90)90052-W; Sasaki N, 2003, CHEM-BIOL INTERACT, V145, P101, DOI 10.1016/S0009-2797(02)00248-X; Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303; SETLOW RB, 1994, MUTAT RES, V307, P365, DOI 10.1016/0027-5107(94)90310-7; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041; Suematsu N, 2003, CIRCULATION, V107, P1418, DOI 10.1161/01.CIR.0000055318.09997.1F; Takahashi A, 2004, BRAIN RES BULL, V62, P497, DOI 10.1016/j.brainresbull.2003.07.009; TYRRELL RM, 1984, PHOTOCHEM PHOTOBIOL, V39, P183, DOI 10.1111/j.1751-1097.1984.tb03426.x; Vamecq J, 1989, Essays Biochem, V24, P115; Van Remmen H, 2001, EXP GERONTOL, V36, P957; Wei YH, 2002, EXP BIOL MED, V227, P671, DOI 10.1177/153537020222700901; Wihlmark U, 1997, FREE RADICAL BIO MED, V22, P1229, DOI 10.1016/S0891-5849(96)00555-2; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972	60	288	299	2	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21061	21066		10.1074/jbc.M502194200	http://dx.doi.org/10.1074/jbc.M502194200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797866	hybrid			2022-12-27	WOS:000229438800021
J	Thomas, JL; Boswell, EL; Scaccia, LA; Pletnev, V; Umland, TC				Thomas, JL; Boswell, EL; Scaccia, LA; Pletnev, V; Umland, TC			Identification of key amino acids responsible for the substantially higher affinities of human type 1 3 beta-hydroxysteroid dehydrogenase/isomerase (3 beta-HSD1) for substrates, coenzymes, and inhibitors relative to human 3 beta-HSD2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL 3-BETA-HYDROXY-5-ENE-STEROID DEHYDROGENASE; STEROID 5->4-ENE-ISOMERASE; EPITHELIAL-CELLS; BREAST-CANCER; PURIFICATION; EXPRESSION; INTERLEUKIN-4; INDUCTION; THERAPY	The human type 1 ( placenta, breast tumors, and prostate tumors) and type 2 ( adrenals and gonads) isoforms of 3 beta-hydroxysteroid dehydrogenase/ isomerase (3 beta-HSD1 and 3 beta-HSD2) are encoded by two distinct genes that are expressed in a tissue-specific pattern. Our recent studies have shown that His(156) contributes to the 14-fold higher affinity that 3 beta-HSD1 exhibits for substrate and inhibitor steroids compared with human 3 beta-HSD2 containing Tyr(156) in the otherwise identical catalytic domain. Our structural model of human 3 beta-HSD localizes His(156) or Tyr(156) in the subunit interface of the enzyme homodimer. The model predicts that Gln(105) on one enzyme subunit has a higher probability of interacting with His(156) on the other subunit in 3 beta-HSD1 than with Tyr(156) in 3 beta-HSD2. The Q105M mutant of 3 beta-HSD1 (Q105M1) shifts the Michaelis-Menten constant (K-m) for 3 beta-HSD substrate and inhibition constants (K-i) for epostane and trilostane to the much lower affinity profiles measured for wild-type 3 beta-HSD2 and H156Y1. However, the Q105M2 mutant retains substrate and inhibitor kinetic profiles similar to those of 3 beta-HSD2. Our model also predicts that Gln(240) in 3 beta-HSD1 and Arg(240) in 3 beta-HSD2 may be responsible for the 3-fold higher affinity of the type 1 isomerase activity for substrate steroid and cofactors. The Q240R1 mutation increases the isomerase substrate K-m by 2.2- fold to a value similar to that of 3 beta-HSD2 isomerase and abolishes the allosteric activation of isomerase by NADH. The R240Q2 mutation converts the isomerase substrate, cofactor, and inhibitor kinetic profiles to the 4-14-fold higher affinity profiles of 3 beta-HSD1. Thus, key structural reasons for the substantially higher affinities of 3 beta-HSD1 for substrates, coenzymes, and inhibitors have been identified. These structure and function relationships can be used in future docking studies to design better inhibitors of the 3 beta-HSD1 that may be useful in the treatment of hormone-sensitive cancers and preterm labor.	Mercer Univ, Sch Med, Div Basic Med Sci, Macon, GA 31207 USA; Mercer Univ, Sch Med, Dept Obstet Gynecol, Macon, GA 31207 USA; Hauptman Woodward Med Res Inst, Buffalo, NY 14203 USA; Russian Acad Sci, Inst Bioorgan Chem, Moscow 142290, Russia; SUNY Buffalo, Dept Biol Struct, Buffalo, NY 14203 USA	Mercer University; Mercer University; Hauptman Woodward Medical Research Institute; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Thomas, JL (corresponding author), Mercer Univ, Sch Med, Div Basic Med Sci, 1550 Coll St, Macon, GA 31207 USA.	Thomas_J@Mercer.edu	Pletnev, Vladimir/Q-6151-2016	Umland, Timothy/0000-0002-0772-9510	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020055] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA114717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026546, R37DK026546] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA114717, CA114717] Funding Source: Medline; NICHD NIH HHS [HD20055, R01 HD020055] Funding Source: Medline; NIDDK NIH HHS [R01 DK026546, DK26546, R37 DK026546] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Dowsett M, 2003, SEMIN ONCOL, V30, P58, DOI 10.1016/S0093-7754(03)00300-2; GELDOF AA, 1995, ANTICANCER RES, V15, P1349; Ghosh D, 2001, J BIOL CHEM, V276, P18457, DOI 10.1074/jbc.M100538200; Gingras S, 1999, MOL ENDOCRINOL, V13, P66, DOI 10.1210/me.13.1.66; Gingras S, 1999, ENDOCRINOLOGY, V140, P4573, DOI 10.1210/en.140.10.4573; KACSOH B, 2000, ENDOCRINE PHYSL, P566; Kasperk CH, 1997, J BONE MINER RES, V12, P464, DOI 10.1359/jbmr.1997.12.3.464; McLeod DG, 2003, UROLOGY, V61, P3, DOI 10.1016/S0090-4295(02)02393-2; NAWATA H, 1995, J STEROID BIOCHEM, V53, P165, DOI 10.1016/0960-0760(95)00031-T; Pasqualini JR, 2004, BBA-REV CANCER, V1654, P123, DOI 10.1016/j.bbcan.2004.03.001; Penning TM, 2004, MOL CELL ENDOCRINOL, V215, P63, DOI 10.1016/j.mce.2003.11.006; Rainey WE, 2002, TRENDS ENDOCRIN MET, V13, P234, DOI 10.1016/S1043-2760(02)00609-4; Reddy G Kesava, 2004, Clin Prostate Cancer, V2, P206; RHEAUME E, 1991, MOL ENDOCRINOL, V5, P1147, DOI 10.1210/mend-5-8-1147; Richter ON, 2004, MOL HUM REPROD, V10, P339, DOI 10.1093/molehr/gah039; SEGEL IH, 1975, ENZYME KINETICS, P109; Simpson ER, 2002, FERTIL STERIL, V77, pS6; SINGH J, 1992, ATLAS PROTEIN SIDE C, V1, P244; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; Thomas JL, 2004, ENDOCR RES, V30, P935, DOI 10.1081/ERC-200044164; THOMAS JL, 1988, J STEROID BIOCHEM, V31, P785, DOI 10.1016/0022-4731(88)90287-7; Thomas JL, 1998, J STEROID BIOCHEM, V66, P327, DOI 10.1016/S0960-0760(98)00058-2; Thomas JL, 2003, J BIOL CHEM, V278, P35483, DOI 10.1074/jbc.M304752200; THOMAS JL, 1989, J STEROID BIOCHEM, V33, P209, DOI 10.1016/0022-4731(89)90296-3; Thomas JL, 2002, J BIOL CHEM, V277, P42795, DOI 10.1074/jbc.M208537200; THOMAS JL, 1995, J BIOL CHEM, V270, P21003, DOI 10.1074/jbc.270.36.21003; Thomas JL, 2001, J MOL ENDOCRINOL, V27, P77, DOI 10.1677/jme.0.0270077; Xu D, 1997, PROTEIN ENG, V10, P999, DOI 10.1093/protein/10.9.999	32	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21321	21328		10.1074/jbc.M501269200	http://dx.doi.org/10.1074/jbc.M501269200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797861	Green Accepted, hybrid			2022-12-27	WOS:000229438800050
J	van Meeteren, LA; Ruurs, P; Christodoulou, E; Goding, JW; Takakusa, H; Kikuchi, K; Perrakis, A; Nagano, T; Moolenaar, WH				van Meeteren, LA; Ruurs, P; Christodoulou, E; Goding, JW; Takakusa, H; Kikuchi, K; Perrakis, A; Nagano, T; Moolenaar, WH			Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTILITY-STIMULATING PROTEIN; LYSOPHOSPHOLIPASE-D; NUCLEOTIDE PYROPHOSPHATASES/PHOSPHODIESTERASES; CATALYTIC SITE; PHOSPHODIESTERASE; PLASMA; SPHINGOSINE-1-PHOSPHATE; HYDROLYSIS; RECEPTORS; BLOOD	Autotaxin (ATX) or nucleotide pyrophosphatase/ phosphodiesterase 2 (NPP2) is an NPP family member that promotes tumor cell motility, experimental metastasis, and angiogenesis. ATX primarily functions as a lysophospholipase D, generating the lipid mediator lysophosphatidic acid (LPA) from lysophosphatidylcholine. ATX uses a single catalytic site for the hydrolysis of both lipid and non-lipid phosphodiesters, but its regulation is not well understood. Using a new fluorescence resonance energy transfer-based phosphodiesterase sensor that reports ATX activity with high sensitivity, we show here that ATX is potently and specifically inhibited by LPA and sphingosine 1-phosphate (S1P) in a mixed-type manner (K-i similar to 10(-7) M). The homologous ecto-phosphodiesterase NPP1, which lacks lysophospholipase D activity, is insensitive to LPA and S1P. Our results suggest that, by repressing ATX activity, LPA can regulate its own biosynthesis in the extracellular environment, and they reveal a novel role for S1P as an inhibitor of ATX, in addition to its well established role as a receptor ligand.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Monash Univ, Sch Med, Dept Pathol & Immunol, Melbourne, Vic 3181, Australia; Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo 1130033, Japan	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Monash University; University of Tokyo	Moolenaar, WH (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	moolenaar@nki.nl	van Meeteren, Laurens/A-9890-2008; Perrakis, Anastassis/E-8704-2013; Kikuchi, Kazuya/D-2370-2009; Van Meeteren, Laurens A./AGQ-6139-2022	van Meeteren, Laurens/0000-0001-9885-0668; Perrakis, Anastassis/0000-0002-1151-6227; Christodoulou, Evangelos/0000-0001-8464-1558				Bachner D, 1999, MECH DEVELOP, V84, P121, DOI 10.1016/S0925-4773(99)00048-9; Baker DL, 2002, JAMA-J AM MED ASSOC, V287, P3081, DOI 10.1001/jama.287.23.3081; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Clair T, 2003, CANCER RES, V63, P5446; Clair T, 1997, BIOCHEM BIOPH RES CO, V236, P449, DOI 10.1006/bbrc.1997.6982; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; Croset M, 2000, BIOCHEM J, V345, P61, DOI 10.1042/0264-6021:3450061; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Fuss B, 1997, J NEUROSCI, V17, P9095; Gijsbers R, 2003, FEBS LETT, V538, P60, DOI 10.1016/S0014-5793(03)00133-9; Goding JW, 2003, BBA-MOL BASIS DIS, V1638, P1, DOI 10.1016/S0925-4439(03)00058-9; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; KELLY SJ, 1975, BIOCHEMISTRY-US, V14, P4983, DOI 10.1021/bi00693a030; Koh E, 2003, CANCER RES, V63, P2042; Lee HY, 1996, J BIOL CHEM, V271, P24408, DOI 10.1074/jbc.271.40.24408; Liliom K, 2001, BIOCHEM J, V355, P189, DOI 10.1042/0264-6021:3550189; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; MURATA J, 1994, J BIOL CHEM, V269, P30479; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; Nam SW, 2001, CANCER RES, V61, P6938; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; Rudolph AE, 1999, J BIOL CHEM, V274, P11824, DOI 10.1074/jbc.274.17.11824; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Stracke ML, 1997, ADV ENZYME REGUL, V37, P135, DOI 10.1016/S0065-2571(96)00017-9; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Takakusa H, 2002, J AM CHEM SOC, V124, P1653, DOI 10.1021/ja011251q; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Meeteren LA, 2004, J BIOL CHEM, V279, P10833, DOI 10.1074/jbc.C300563200; Vollmayer P, 2003, EUR J BIOCHEM, V270, P2971, DOI 10.1046/j.1432-1033.2003.03674.x; Yang LB, 1999, BRIT J HAEMATOL, V107, P282, DOI 10.1046/j.1365-2141.1999.01697.x; Zambonelli C, 2003, J BIOL CHEM, V278, P52282, DOI 10.1074/jbc.M310252200	35	166	184	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21155	21161		10.1074/jbc.M413183200	http://dx.doi.org/10.1074/jbc.M413183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15769751	hybrid			2022-12-27	WOS:000229438800032
J	Cho, J; Melnick, M; Solidakis, GP; Tsichlis, PN				Cho, J; Melnick, M; Solidakis, GP; Tsichlis, PN			Tpl2 (tumor progression locus 2) phosphorylation at Thr(290) is induced by lipopolysaccharide via an I kappa-B kinase-beta-dependent pathway and is required for Tpl2 activation by external signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LINES; PROTEIN-KINASE; NF-KAPPA-B1 P105; COT KINASE; INDUCTION; ONCOPROTEIN; PROTEOLYSIS; EXPRESSION; STABILITY; DISEASE	The serine-threonine protein kinase encoded by the tumor progression locus 2 ( Tpl2) proto-oncogene transduces Toll-like receptor and death receptor signals in a variety of cell types. Here we show that Tpl2 undergoes phosphorylation at Thr(290) both in cells overexpressing Tpl2 and in cells stimulated with lipopolysaccharide (LPS) or tumor necrosis factor-alpha and that phosphorylation on this site parallels Tpl2 activation. Reconstitution of Tpl2(-/-) macrophages with wild type Tpl2 or Tpl2 T290D restored ERK activation by LPS, whereas reconstitution of the same cells with Tpl2 T290A did not, suggesting that phosphorylation at Thr290 is required for the physiological activation of Tpl2 by external signals. Both the wild type Tpl2 and the kinase-inactive mutant Tpl2 K167M undergo Thr290 phosphorylation, suggesting that Thr290 may be a site of trans-phosphorylation rather than auto-phosphorylation. Pretreatment of 293 cells and primary macrophages with the I kappa-B kinase-beta (IKK beta) inhibitor PS-1145 blocked Tpl2 phosphorylation at Thr290, suggesting that phosphorylation depends on IKK beta, an obligatory positive regulator of Tpl2. We conclude that Tpl2 phosphorylation at Thr290 is induced by LPS, depends on IKK beta, and is required for the physiological activation of Tpl2 by external signals.	Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; Tufts Canc Ctr, Boston, MA 02111 USA; Cell Signaling Technol Inc, Beverly, MA 01915 USA	Tufts Medical Center; Tufts University	Tsichlis, PN (corresponding author), Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, 750 Washington St,Box 5609, Boston, MA 02111 USA.	ptsichlis@tufts-nemc.org			NATIONAL CANCER INSTITUTE [R01CA038047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NCI NIH HHS [CA R01 38047] Funding Source: Medline; NIDDK NIH HHS [P30DK34928] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Cho JH, 2005, P NATL ACAD SCI USA, V102, P2350, DOI 10.1073/pnas.0409856102; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Eliopoulos AG, 2003, EMBO J, V22, P3855, DOI 10.1093/emboj/cdg386; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; Erny KM, 1996, ONCOGENE, V13, P2015; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; Gandara ML, 2003, MOL CELL BIOL, V23, P7377, DOI 10.1128/MCB.23.20.7377-7390.2003; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Kontoyiannis D, 2002, J EXP MED, V196, P1563, DOI 10.1084/jem.20020281; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Luciano BS, 2004, J BIOL CHEM, V279, P52117, DOI 10.1074/jbc.M403716200; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; Velasco-Sampayo A, 2001, J IMMUNOL, V166, P6084, DOI 10.4049/jimmunol.166.10.6084; Waterfield M, 2004, MOL CELL BIOL, V24, P6040, DOI 10.1128/MCB.24.13.6040-6048.2004; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4	28	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20442	20448		10.1074/jbc.M413554200	http://dx.doi.org/10.1074/jbc.M413554200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15778223	hybrid			2022-12-27	WOS:000229242000036
J	Kneuper, H; Janausch, IG; Vijayan, V; Zweckstetter, M; Bock, V; Griesinger, C; Unden, G				Kneuper, H; Janausch, IG; Vijayan, V; Zweckstetter, M; Bock, V; Griesinger, C; Unden, G			The nature of the stimulus and of the fumarate binding site of the fumarate sensor DcuS of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; KINASE; DOMAIN; PROTEIN; C-4-DICARBOXYLATES; IDENTIFICATION; TRANSFORMATION; ENERGETICS; TRANSPORT; REVEALS	DcuS is a membrane-associated sensory histidine kinase of Escherichia coli specific for C-4-dicarboxylates. The nature of the stimulus and its structural prerequisites were determined by measuring the induction of DcuS-dependent dcuB'-'lacZ gene expression. C4-dicarboxylates without or with substitutions at C-2/C-3 by hydrophilic (hydroxy, amino, or thiolate) groups stimulated gene expression in a similar way. When one carboxylate was replaced by sulfonate, methoxy, or nitro groups, only the latter (3-nitropropionate) was active. Thus, the ligand of DcuS has to carry two carboxylate or carboxylate/nitro groups 3.1-3.8 A apart from each other. The effector concentrations for half-maximal induction of dcuB'-'lacZ expression were 2-3 mM for the C-4-dicarboxylates and 0.5 mM for 3-nitropropionate or D-tartrate. The periplasmic domain of DcuS contains a conserved cluster of positively charged or polar amino acid residues (Arg(107)-X-2-His(110)-X-9-Phe(120)-X-26-Arg(147)-X-Phe(149)) that were essential for fumarate-dependent transcriptional regulation. The presence of fumarate or D-tartrate caused sharpening of peaks or chemical shift changes in HSQC NMR spectra of the isolated C-4-dicarboylate binding domain. The amino acid residues responding to fumarate or D-tartrate were in the region comprising residues 89-150 and including the supposed binding site. DcuS( R147A) mutant with an inactivated binding site was isolated and reconstituted in liposomes. The protein showed the same (activation-independent) kinase activity as DcuS, but autophosphorylation of DcuS was no longer stimulated by C-4-dicarboxylates. Therefore, the R147A mutation affected signal perception and transfer to the kinase but not the kinase activity per se.	Johannes Gutenberg Univ Mainz, Inst Mikrobiol & Weinforsch, D-55099 Mainz, Germany; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany	Johannes Gutenberg University of Mainz; Max Planck Society	Unden, G (corresponding author), Johannes Gutenberg Univ Mainz, Inst Mikrobiol & Weinforsch, Becherweg 15, D-55099 Mainz, Germany.	unden@uni-mainz.de		Zweckstetter, Markus/0000-0002-2536-6581; vijayan, vinesh/0000-0001-5483-1860				Abo-Amer AE, 2004, J BACTERIOL, V186, P1879, DOI 10.1128/JB.186.6.1879-1889.2004; Aizawa S, 2000, J BACTERIOL, V182, P1459, DOI 10.1128/JB.182.6.1459-1471.2000; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; BOTT M, 1995, MOL MICROBIOL, V18, P533, DOI 10.1111/j.1365-2958.1995.mmi_18030533.x; CHEN WP, 1993, NUCLEIC ACIDS RES, V21, P2260, DOI 10.1093/nar/21.9.2260; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; ENGEL P, 1994, EUR J BIOCHEM, V222, P605, DOI 10.1111/j.1432-1033.1994.tb18903.x; Gerharz T, 2003, BIOCHEMISTRY-US, V42, P5917, DOI 10.1021/bi0340595; Golby P, 1999, J BACTERIOL, V181, P1238, DOI 10.1128/JB.181.4.1238-1248.1999; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Janausch IG, 2004, MICROBIOL-SGM, V150, P877, DOI 10.1099/mic.0.26900-0; Janausch IG, 2002, J BIOL CHEM, V277, P39809, DOI 10.1074/jbc.M204482200; Janausch IG, 2002, BBA-BIOENERGETICS, V1553, P39, DOI 10.1016/S0005-2728(01)00233-X; Kaspar S, 1999, MOL MICROBIOL, V33, P858, DOI 10.1046/j.1365-2958.1999.01536.x; Kaspar S, 2002, ARCH MICROBIOL, V177, P313, DOI 10.1007/s00203-001-0393-z; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lancaster CRD, 2001, EUR J BIOCHEM, V268, P1820, DOI 10.1046/j.1432-1327.2001.02053.x; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Mizuno T, 1997, DNA Res, V4, P161, DOI 10.1093/dnares/4.2.161; Pappalardo L, 2003, J BIOL CHEM, V278, P39185, DOI 10.1074/jbc.C300344200; Parac TN, 2001, J BIOMOL NMR, V19, P91, DOI 10.1023/A:1008301425100; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Reinelt S, 2003, J BIOL CHEM, V278, P39189, DOI 10.1074/jbc.M305864200; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIX S, 1994, J BACTERIOL, V176, P6470, DOI 10.1128/JB.176.21.6470-6478.1994; Tran QH, 1998, EUR J BIOCHEM, V251, P538, DOI 10.1046/j.1432-1327.1998.2510538.x; Zientz E, 1998, J BACTERIOL, V180, P5421, DOI 10.1128/JB.180.20.5421-5425.1998	31	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20596	20603		10.1074/jbc.M502015200	http://dx.doi.org/10.1074/jbc.M502015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781452	hybrid, Green Published			2022-12-27	WOS:000229242000055
J	Shang, F; Deng, GJ; Liu, Q; Guo, WM; Haas, AL; Crosas, B; Finley, D; Taylor, A				Shang, F; Deng, GJ; Liu, Q; Guo, WM; Haas, AL; Crosas, B; Finley, D; Taylor, A			Lys(6)-modified ubiquitin inhibits ubiquitin-dependent protein degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS EPITHELIAL-CELLS; MULTIUBIQUITIN CHAIN; ACTIVATING ENZYME; OXIDATIVE STRESS; POLYUBIQUITIN CHAINS; CALORIE RESTRICTION; RETICULOCYTE LYSATE; 20S PROTEASOME; KAPPA-B; PROTEOLYSIS	Ubiquitin plays essential roles in various cellular processes; therefore, it is of keen interest to study the structure-function relationship of ubiquitin itself. We investigated the modification of Lys(6) of ubiquitin and its physiological consequences. Mass spectrometry-based peptide mapping and N-terminal sequencing demonstrated that, of the 7 Lys residues in ubiquitin, Lys6 was the most readily labeled with sulfosuccinimidobiotin. Lys(6)-biotinylated ubiquitin was incorporated into high molecular mass ubiquitin conjugates as efficiently as unmodified ubiquitin. However, Lys(6)-biotinylated ubiquitin inhibited ubiquitin-dependent proteolysis, as conjugates formed with Lys(6)-biotinylated ubiquitin were resistant to proteasomal degradation. Ubiquitins with a mutation of Lys(6) had similar phenotypes as Lys(6)-biotinylated ubiquitin. Lys(6) mutant ubiquitins (K6A, K6R, and K6W) also inhibited ATP-dependent proteolysis and caused accumulation of ubiquitin conjugates. Conjugates formed with K6W mutant ubiquitin were also resistant to proteasomal degradation. The dominant-negative effect of Lys(6)-modified ubiquitin was further demonstrated in intact cells. Overexpression of K6W mutant ubiquitin resulted in accumulation of intracellular ubiquitin conjugates, stabilization of typical substrates for ubiquitin-dependent proteolysis, and enhanced susceptibility to oxidative stress. Taken together, these results show that Lys(6)-modified ubiquitin is a potent and specific inhibitor of ubiquitin-mediated protein degradation.	Tufts Univ, Jean Mayer USDA, HNRCA, Lab Nutr & Vis Res, Boston, MA 02111 USA; Louisiana State Univ, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Harvard Univ, Sch Med, Dept Cell Biol, Cambridge, MA 02138 USA	Tufts University; United States Department of Agriculture (USDA); Louisiana State University System; Harvard University	Shang, F (corresponding author), Tufts Univ, Jean Mayer USDA, HNRCA, Lab Nutr & Vis Res, 711 Washington St, Boston, MA 02111 USA.	fu.shang@tufts.edu	Guo, Weimin/B-3155-2009	Guo, Weimin/0000-0003-4318-7154	NATIONAL EYE INSTITUTE [R01EY011717, R29EY011717, R01EY013250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER; NEI NIH HHS [EY13250, R01 EY011717-07, R29 EY011717, EY11717, R01 EY013250, R01 EY011717, R01 EY011717-06A1] Funding Source: Medline; NIGMS NIH HHS [GM34009, R01 GM034009] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; Ciechanover A, 2000, J CELL BIOCHEM, P40; CORSI D, 1995, J BIOL CHEM, V270, P8928, DOI 10.1074/jbc.270.15.8928; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Dudek EJ, 2001, FREE RADICAL BIO MED, V31, P651, DOI 10.1016/S0891-5849(01)00634-7; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Elsasser S, 2004, J BIOL CHEM, V279, P26817, DOI 10.1074/jbc.M404020200; FINCH JS, 1990, NUCLEIC ACIDS RES, V18, P1907, DOI 10.1093/nar/18.7.1907; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Gaczynska M, 1996, J BIOL CHEM, V271, P17275, DOI 10.1074/jbc.271.29.17275; GREGORI L, 1990, J BIOL CHEM, V265, P8354; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; HAAS A, 1990, J BIOL CHEM, V265, P21664; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; HUANG LL, 1993, BIOCHIM BIOPHYS ACTA, V1175, P181, DOI 10.1016/0167-4889(93)90021-G; IVY GO, 1989, BRAIN RES, V498, P360, DOI 10.1016/0006-8993(89)91117-7; JABUSCH JR, 1985, ARCH BIOCHEM BIOPHYS, V238, P170, DOI 10.1016/0003-9861(85)90153-5; JAHNGEN JH, 1990, ARCH BIOCHEM BIOPHYS, V276, P32, DOI 10.1016/0003-9861(90)90006-K; JAHNGENHODGE J, 1992, EXP EYE RES, V55, P897, DOI 10.1016/0014-4835(92)90016-L; KUDO T, 1994, BRAIN RES, V639, P1, DOI 10.1016/0006-8993(94)91757-4; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lam YA, 1997, J BIOL CHEM, V272, P28438, DOI 10.1074/jbc.272.45.28438; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Layfield R, 2001, PROTEOMICS, V1, P773, DOI 10.1002/1615-9861(200106)1:6<773::AID-PROT773>3.0.CO;2-0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Macdonald JM, 1999, BIOCHEM PHARMACOL, V57, P1233, DOI 10.1016/S0006-2952(99)00039-8; Macdonald JM, 2000, J BIOL CHEM, V275, P31908, DOI 10.1074/jbc.M000684200; Morris JR, 2004, HUM MOL GENET, V13, P807, DOI 10.1093/hmg/ddh095; OBIN M, 1995, CURR EYE RES, V14, P751, DOI 10.3109/02713689508995796; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Scrofano MM, 1998, MECH AGEING DEV, V105, P273, DOI 10.1016/S0047-6374(98)00097-9; Scrofano MM, 1998, MECH AGEING DEV, V101, P277, DOI 10.1016/S0047-6374(97)00178-4; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 1997, EXP EYE RES, V64, P21, DOI 10.1006/exer.1996.0176; Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; SHANG F, 1994, CURR EYE RES, V13, P423, DOI 10.3109/02713689408999870; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; VIJAYKUMAR S, 1987, J BIOL CHEM, V262, P6396; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wee KE, 2000, J PROTEIN CHEM, V19, P489, DOI 10.1023/A:1026501515450; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071	60	67	71	5	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20365	20374		10.1074/jbc.M414356200	http://dx.doi.org/10.1074/jbc.M414356200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15790562	Green Accepted, hybrid			2022-12-27	WOS:000229242000027
J	Bao, JJ; Jana, SS; Adelstein, RS				Bao, JJ; Jana, SS; Adelstein, RS			Vertebrate nonmuscle myosin II Isoforms rescue small interfering RNA-induced defects in COS-7 cell cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN ISOFORMS; CONTRACTILE RING; CULTURED-CELLS; GENE; LOCALIZATION; EXPRESSION; MECHANISM; ABLATION; IDENTIFICATION; DICTYOSTELIUM	RNA interference (RNAi) treatment of monkey COS-7 cells, a cell line that lacks nonmuscle myosin heavy chain II-A (NMHC II-A) but contains NMHC II-B and II-C, was used to investigate the participation of NMHC isoforms in cytokinesis. We specifically suppressed the expression of NMHC II-B or II-C using 21 nucleotide small interfering RNA (siRNA) duplexes. Down-regulation of NMHC II-B protein expression to 10.2 +/- 0.7% inhibited COS-7 cell proliferation by 50% in the RNAi-treated cells compared with control cells. Moreover, whereas 8.7 +/- 1.0% of control cells were multinucleated, 62.4 +/- 8.8% of the NMHC II-B RNAi-treated cells were multinucleated 72 h after transfection. The RNAi-treated cells had increased surface areas and, unlike control cells, lacked actin stress fibers. Treatment of the COS-7 cells with NMHC II-C siRNA decreased NMHC II-C expression to 5.2 +/- 0.1% compared with the endogenous content of II-C; however, down-regulation of NMHC II-C did not cause increased multinucleation. Immunoblot analysis using a pan-myosin antibody showed that the content of NMHC II-C was less than one-twentieth the amount of NMHC II-B, thereby explaining the lack of response to II-C siRNA. Introducing green fluorescent protein (GFP)-tagged NMHC II isoforms into II-B siRNA-treated cells resulted in reduction of multinucleation from 62.4 +/- 8.8% to 17.8 +/- 2.2% using GFP-NMHC II-B, to 29.8 +/- 7.4% using GFP-NMHC II-A, and to 34.1 +/- 8.6% using NMHC II-C- GFP. These studies have shown that expression of endogenous NMHC II-C in COS-7 cells is insufficient for normal cytokinesis and that exogenous NMHC II-A and NMHC II-C can, at least partially, rescue the defect in cytokinesis due to the loss of NMHC II-B.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Adelstein, RS (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N202,10 Ctr Dr,MSC 1762, Bethesda, MD 20892 USA.	AdelsteR@NHLBI.NationalInstitutesofHealth.GOV		Adelstein, Robert/0000-0002-8683-2144	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004216, ZIAHL004216] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Buxton DB, 2003, J BIOL CHEM, V278, P15449, DOI 10.1074/jbc.M210145200; Conti MA, 2004, J BIOL CHEM, V279, P41263, DOI 10.1074/jbc.C400352200; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; FUJIWARA K, 1978, J CELL BIOL, V79, P268, DOI 10.1083/jcb.79.1.268; FUKUI Y, 1991, CELL MOTIL CYTOSKEL, V18, P41, DOI 10.1002/cm.970180105; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; KIM K, 2005, J BIOL CHEM; Kolega J, 1998, J CELL SCI, V111, P2085; Kolega J, 2003, MOL BIOL CELL, V14, P4745, DOI 10.1091/mbc.E03-04-0205; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Leal A, 2003, GENE, V312, P165, DOI 10.1016/S0378-1119(03)00613-9; Lippincott J, 1998, J CELL BIOL, V140, P355, DOI 10.1083/jcb.140.2.355; Lo CM, 2004, MOL BIOL CELL, V15, P982, DOI 10.1091/mbc.E03-06-0359; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; MAUPIN P, 1994, J CELL SCI, V107, P3077; Meshel AS, 2005, NAT CELL BIOL, V7, P157, DOI 10.1038/ncb1216; MURAKAMI N, 1993, DEV BIOL, V157, P19, DOI 10.1006/dbio.1993.1108; SCHROEDER TE, 1973, P NATL ACAD SCI USA, V70, P1688, DOI 10.1073/pnas.70.6.1688; Sellers J. R., 1999, MYOSINS; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; Straight AF, 2005, MOL BIOL CELL, V16, P193, DOI 10.1091/mbc.E04-08-0758; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; Takeda K, 2003, CIRC RES, V93, P330, DOI 10.1161/01.RES.0000089256.00309.CB; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; Tullio AN, 2001, J COMP NEUROL, V433, P62, DOI 10.1002/cne.1125; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wang YL, 2001, CELL STRUCT FUNCT, V26, P633, DOI 10.1247/csf.26.633; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29	34	92	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19594	19599		10.1074/jbc.M501573200	http://dx.doi.org/10.1074/jbc.M501573200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774463	hybrid			2022-12-27	WOS:000229113700022
J	Legiewicz, M; Yarus, M				Legiewicz, M; Yarus, M			A more complex isoleucine aptamer with a cognate triplet	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA APTAMERS; IN-VITRO; STRUCTURAL BASIS; GENETIC-CODE; AMINO-ACIDS; SELECTION; BINDING; ARGININE; RECOGNITION; EVOLUTION	The simplest RNA that can meet a column affinity selection for isoleucine was previously defined using selection amplification with decreasing numbers of randomized nucleotides. This simplest UAUU motif was a small asymmetric internal loop. Conserved positions of the loop include isoleucine codon and anticodon triplets (Lozupone C., Changayil, S., Majerfeld, I., and Yarus, M. (2003) RNA (N.Y.) 9, 1315-1322). Using new primer sequences, we now select a somewhat more complex isoleucine binding RNA, requiring 4.7 more bits of information to describe. The newly selected structure is a terminal or hairpin loop of 20 nucleotides, 15 being invariant. An information profile shows that the new binding site contains five short functional loop regions joined by less significant single nucleotide positions. Among the important nucleotides is a conserved isoleucine anticodon, supporting the escaped triplet theory, which posits a stereochemical genetic code originating in RNA amino acid binding sites.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Yarus, M (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.	yarus@colorado.edu	Yarus, Michael/Q-9813-2019		NIGMS NIH HHS [GM 48080] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048080] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burgstaller P, 1995, NUCLEIC ACIDS RES, V23, P4769, DOI 10.1093/nar/23.23.4769; Carothers JM, 2004, J AM CHEM SOC, V126, P5130, DOI 10.1021/ja031504a; Ciesiolka J, 1996, METHOD ENZYMOL, V267, P315; Ciesiolka J, 1996, RNA, V2, P785; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; CONNELL GJ, 1994, SCIENCE, V264, P1137, DOI 10.1126/science.7513905; de Zwart I, 2005, HANDBOOK OF RNA BIOCHEMISTRY, P783, DOI 10.1002/9783527619504.ch47; Doudna JA, 2002, NATURE, V418, P222, DOI 10.1038/418222a; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; Geiger A, 1996, NUCLEIC ACIDS RES, V24, P1029, DOI 10.1093/nar/24.6.1029; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; Gorodkin J, 1997, COMPUT APPL BIOSCI, V13, P583; Illangasekare M, 2002, J MOL EVOL, V54, P298, DOI 10.1007/s00239-001-0045-6; Knight R, 2004, RNA, V10, P1323, DOI 10.1261/rna.5168504; Knight R, 2003, RNA, V9, P218, DOI 10.1261/rna.2138803; KNIGHT RD, 2000, NUCLEIC ACIDS RES, V31, pE30; KROL A, 1989, METHOD ENZYMOL, V180, P212; Lozupone C, 2003, RNA, V9, P1315, DOI 10.1261/rna.5114503; MAJERFELD I, 1994, NAT STRUCT BIOL, V1, P287, DOI 10.1038/nsb0594-287; Majerfeld I, 1998, RNA, V4, P471; Mandal M, 2004, NAT REV MOL CELL BIO, V5, P451, DOI 10.1038/nrm1403; Mannironi C, 2000, RNA, V6, P520, DOI 10.1017/S1355838200991763; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SCHNEIDER TD, 1986, J MOL BIOL, V188, P415, DOI 10.1016/0022-2836(86)90165-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WALTER AE, 1994, P NATL ACAD SCI USA, V91, P9218, DOI 10.1073/pnas.91.20.9218; Winkler WC, 2003, CHEMBIOCHEM, V4, P1024, DOI 10.1002/cbic.200300685; Yang YS, 1996, SCIENCE, V272, P1343, DOI 10.1126/science.272.5266.1343; Yarus M, 2005, ANNU REV BIOCHEM, V74, P179, DOI 10.1146/annurev.biochem.74.082803.133119; Yarus M, 1998, J MOL EVOL, V47, P109, DOI 10.1007/PL00006357; Yarus M, 2000, RNA, V6, P475, DOI 10.1017/S1355838200002569; Yarus M, 2004, MOL B INT U, P75	35	32	38	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19815	19822		10.1074/jbc.M502329200	http://dx.doi.org/10.1074/jbc.M502329200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772067	hybrid			2022-12-27	WOS:000229113700048
J	Zhang, Y; Lyver, ER; Knight, SAB; Lesuisse, E; Dancis, A				Zhang, Y; Lyver, ER; Knight, SAB; Lesuisse, E; Dancis, A			Frataxin and mitochondrial carrier proteins, Mrs3p and Mrs4p, cooperate in providing iron for heme synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; SULFUR CLUSTER BIOSYNTHESIS; FRIEDREICHS-ATAXIA; CRYSTAL-STRUCTURE; PRECURSOR FORM; HOMOLOG; FERROCHELATASE; ACCUMULATION; PURIFICATION; DEFICIENCY	Frataxin is a conserved mitochondrial protein implicated in cellular iron metabolism. Deletion of the yeast frataxin homolog (YFH1) was combined with deletions of MRS3 and MRS4, mitochondrial carrier proteins implicated in iron homeostasis. As previously reported, the Delta yfh1 mutant accumulated iron in mitochondria, whereas the triple mutant (Delta Delta Delta) did not. When wildtype, Delta mrs3/4, Delta yfh1, and Delta Delta Delta strains were incubated anaerobically, all strains were devoid of heme and protected from iron and oxygen toxicity. The cultures were then shifted to air for a short time (4-5 h) or a longer time ( 15 h), and the evolving mutant phenotypes were analyzed (heme-dependent growth, total heme, cytochromes, heme proteins, and iron levels). A picture emerges from these data of defective heme formation in the mutants, with a markedly more severe defect in the Delta Delta Delta than in the individual Delta mrs3/4 or Delta yfh1 mutants (a "synthetic" defect in the genetic sense). The defect(s) in heme formation could be traced to lack of iron. Using a real time assay of heme biosynthesis, porphyrin precursor and iron were presented to permeabilized cells, and the appearance and disappearance of fluorescent porphyrins were followed. The Mrs3/4p carriers were required for rapid iron transport into mitochondria for heme synthesis, whereas there was also evidence for an alternative slower system. A different role for Yfh1p was observed under conditions of low mitochondrial iron and aerobic growth (revealed in the Delta Delta Delta), acting to protect bioavailable iron within mitochondria and to facilitate its use for heme synthesis.	Univ Penn, Dept Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA; Univ Paris 06, Inst Jacques Monod, Dept Biol Genomes, Lab Ingn Prot & Controle Metab,UMR 7592,CNRS, F-75251 Paris, France; Univ Paris 07, Inst Jacques Monod, Dept Biol Genomes, Lab Ingn Prot & Controle Metab,UMR 7592,CNRS, F-75251 Paris, France	University of Pennsylvania; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Dancis, A (corresponding author), Univ Penn, Dept Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA.	adancis@mail.med.upenn.edu	Zhang, Yan/K-1638-2015	Zhang, Yan/0000-0003-2031-0631; Knight, Simon/0000-0001-7407-3390	NIDDK NIH HHS [DK53953] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK053953, R01DK053953] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHLEITNER G, 1995, J BIOL CHEM, V270, P29836; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Aloria K, 2004, EMBO REP, V5, P1096, DOI 10.1038/sj.embor.7400272; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Branda SS, 1999, HUM MOL GENET, V8, P1099, DOI 10.1093/hmg/8.6.1099; Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; CAMADRO JM, 1994, J BIOL CHEM, V269, P32085; CAMADRO JM, 1986, EUR J BIOCHEM, V156, P579, DOI 10.1111/j.1432-1033.1986.tb09617.x; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Chen XJ, 2005, SCIENCE, V307, P714, DOI 10.1126/science.1106391; Cho SJ, 2000, P NATL ACAD SCI USA, V97, P8932, DOI 10.1073/pnas.160270897; Dhe-Paganon S, 2000, J BIOL CHEM, V275, P30753, DOI 10.1074/jbc.C000407200; Farrelly E, 2001, ANAL BIOCHEM, V293, P269, DOI 10.1006/abio.2001.5139; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; Gakh O, 2002, BIOCHEMISTRY-US, V41, P6798, DOI 10.1021/bi025566+; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Gordon DM, 2001, HUM MOL GENET, V10, P259, DOI 10.1093/hmg/10.3.259; HE YA, 2004, BIOCHEMISTRY-US, V51, P16254; Horng YC, 2004, J BIOL CHEM, V279, P35334, DOI 10.1074/jbc.M404747200; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; Karthikeyan G, 2003, HUM MOL GENET, V12, P3331, DOI 10.1093/hmg/ddg349; Kastaniotis AJ, 2000, ADV EXP MED BIOL, V475, P185; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Labbe P, 1969, Bull Soc Chim Biol (Paris), V51, P1642; Labbe-Bois Rosine, 1994, V11, P413; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; Lesuisse E, 2005, GENETICS, V169, P107, DOI 10.1534/genetics.104.035873; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Lesuisse Emmanuel, 1994, V11, P149; Li LT, 2004, J BIOL CHEM, V279, P33653, DOI 10.1074/jbc.M403146200; Luk E, 2003, J BIOL INORG CHEM, V8, P803, DOI 10.1007/s00775-003-0482-3; Miranda CJ, 2004, FEBS LETT, V572, P281, DOI 10.1016/j.febslet.2004.07.022; Muhlenhoff U, 2003, J BIOL CHEM, V278, P40612, DOI 10.1074/jbc.M307847200; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Park S, 2003, J BIOL CHEM, V278, P31340, DOI 10.1074/jbc.M303158200; Petracek ME, 2002, METHOD ENZYMOL, V350, P445, DOI 10.1016/S0076-6879(02)50978-2; PON L, MOL CELLULAR BIOL YE, P333; PORRA RJ, 1963, BIOCHEM J, V87, P181, DOI 10.1042/bj0870181; Puccio H, 2002, CURR OPIN GENET DEV, V12, P272, DOI 10.1016/S0959-437X(02)00298-8; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Puig S, 2005, CELL, V120, P99, DOI 10.1016/j.cell.2004.11.032; Ramazzotti A, 2004, FEBS LETT, V557, P215, DOI 10.1016/S0014-5793(03)01498-4; ROGGENKAMP R, 1974, FEBS LETT, V41, P283, DOI 10.1016/0014-5793(74)81230-5; Rotig A, 2002, TRENDS MOL MED, V8, P221, DOI 10.1016/S1471-4914(02)02330-4; Santos R, 2004, MOL MICROBIOL, V54, P507, DOI 10.1111/j.1365-2958.2004.04281.x; Shi Z, 2003, ANAL BIOCHEM, V318, P18, DOI 10.1016/S0003-2697(03)00175-1; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352; Yoon T, 2004, J BIOL CHEM, V279, P25943, DOI 10.1074/jbc.C400107200; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i; Zeth K, 2004, P NATL ACAD SCI USA, V101, P13780, DOI 10.1073/pnas.0401821101	57	98	98	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19794	19807		10.1074/jbc.M500397200	http://dx.doi.org/10.1074/jbc.M500397200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15767258	hybrid			2022-12-27	WOS:000229113700046
J	Byrd, MP; Zamora, M; Lloyd, RE				Byrd, MP; Zamora, M; Lloyd, RE			Translation of eukaryotic translation initiation factor 4GI (eIF4GI) proceeds from multiple mRNAs containing a novel cap-dependent internal ribosome entry site (IRES) that is active during poliovirus infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; POLY(A)-BINDING PROTEIN; BINDING-PROTEIN; C-MYC; PROTEOLYTIC CLEAVAGE; GENE-EXPRESSION; VIRUS; INHIBITION; ADENOVIRUS; APOPTOSIS	Eukaryotic translation initiation factor 4GI (eIF4GI) is an essential scaffolding protein required to recruit the 43 S complex to the 5'-end of mRNA during translation initiation. We have previously demonstrated that eIF4GI protein expression is translationally regulated. This regulation is mediated by cis-acting RNA elements, including an upstream open reading frame and an IRES that directs synthesis of five eIF4GI protein isoforms via alternative AUG initiation codon selection. Here, we further characterize eIF4GI IRES function and show that eIF4GI is expressed from several distinct mRNAs that vary via alternate promoter use and alternate splicing. Several mRNA variants contain the IRES element. We found that IRES activity mapped to multiple regions within the eIF4GI RNA sequence, but not within the 5'-UTR per se. However, the 5'-UTR enhanced IRES activity in vivo and played a role in initiation codon selection. The eIF4GI IRES was active when transfected into cells in an RNA form, and thus, does not require nuclear processing events for its function. However, IRES activity was found to be dependent upon the presence, in cis, of a 5' m(7)guanosine-cap. Despite this requirement, the eIF4GI IRES was activated by 2A protease cleavage of eIF4GI, in vitro, and retained the ability to promote translation during poliovirus-mediated inhibition of cap-dependent translation. These data indicate that intact eIF4GI protein is not required for the de novo synthesis of eIF4GI, suggesting its expression can continue under stress or infection conditions where eIF4GI is cleaved.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine	Lloyd, RE (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Rm 860E,1 Baylor Plaza, Houston, TX 77030 USA.	rlloyd@bcm.tmc.edu			NIAID NIH HHS [AI 50237, T32 AI07471] Funding Source: Medline; NIGMS NIH HHS [GM 59803] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI050237, R01AI050237, T32AI007471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059803] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali IK, 2001, J VIROL, V75, P7854, DOI 10.1128/JVI.75.17.7854-7863.2001; ALI N, 1995, J VIROL, V69, P6367, DOI 10.1128/JVI.69.10.6367-6375.1995; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; Bushell M, 2000, CELL DEATH DIFFER, V7, P628, DOI 10.1038/sj.cdd.4400699; Byrd MP, 2002, MOL CELL BIOL, V22, P4499, DOI 10.1128/MCB.22.13.4499-4511.2002; CASTRILLO JL, 1987, J BIOL CHEM, V262, P7328; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; De Gregorio E, 1999, EMBO J, V18, P4865, DOI 10.1093/emboj/18.17.4865; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; Dominguez DI, 1998, J BIOL CHEM, V273, P3669, DOI 10.1074/jbc.273.6.3669; ETCHISON D, 1985, J VIROL, V54, P634, DOI 10.1128/JVI.54.2.634-638.1985; Eu JY, 2001, LUMINESCENCE, V16, P57, DOI 10.1002/bio.612; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; Han BG, 2002, MOL CELL BIOL, V22, P7372, DOI 10.1128/MCB.22.21.7372-7384.2002; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Honda M, 2000, GASTROENTEROLOGY, V118, P152, DOI 10.1016/S0016-5085(00)70424-0; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Joachims M, 1999, J VIROL, V73, P718, DOI 10.1128/JVI.73.1.718-727.1999; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kean KM, 2003, BIOL CELL, V95, P129, DOI 10.1016/S0248-4900(03)00030-3; Kozak M, 2003, GENE, V318, P1, DOI 10.1016/S0378-1119(03)00774-1; Kozak M, 2001, MOL CELL BIOL, V21, P1899, DOI 10.1128/MCB.21.6.1899-1907.2001; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kuyumcu-Martinez NM, 2004, MOL CELL BIOL, V24, P1779, DOI 10.1128/MCB.24.4.1779-1790.2004; Kuyumcu-Martinez NM, 2002, J VIROL, V76, P2062, DOI 10.1128/JVI.76.5.2062-2074.2002; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; MADER S, 1995, BIOCHIMIE, V77, P40, DOI 10.1016/0300-9084(96)88102-8; Marcotrigiano J, 2001, MOL CELL, V7, P193, DOI 10.1016/S1097-2765(01)00167-8; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Michel YM, 2000, J BIOL CHEM, V275, P32268, DOI 10.1074/jbc.M004304200; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Prevot D, 2003, BIOL CELL, V95, P141, DOI 10.1016/S0248-4900(03)00031-5; Pudi R, 2003, J BIOL CHEM, V278, P12231, DOI 10.1074/jbc.M210287200; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; ROSE JK, 1978, P NATL ACAD SCI USA, V75, P2732, DOI 10.1073/pnas.75.6.2732; Schneider RJ, 2000, COLD SPRING HARBOR M, V39, P901; Sherrill KW, 2004, J BIOL CHEM, V279, P29066, DOI 10.1074/jbc.M402727200; SOMMERGRUBER W, 1994, VIROLOGY, V198, P741, DOI 10.1006/viro.1994.1089; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Van Eden ME, 2004, RNA, V10, P720, DOI 10.1261/rna.5225204; Van Eden ME, 2004, RNA, V10, P469, DOI 10.1261/rna.5156804; Ventoso I, 2001, P NATL ACAD SCI USA, V98, P12966, DOI 10.1073/pnas.231343498; YAN RQ, 1992, J BIOL CHEM, V267, P23226; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; Yueh A, 2000, GENE DEV, V14, P414; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557; Zamora M, 2002, J VIROL, V76, P165, DOI 10.1128/JVI.76.1.165-177.2002	58	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18610	18622		10.1074/jbc.M414014200	http://dx.doi.org/10.1074/jbc.M414014200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755734	hybrid			2022-12-27	WOS:000228932300010
J	Fernandez, E; Torrents, D; Zorzano, A; Palacin, M; Chillaron, J				Fernandez, E; Torrents, D; Zorzano, A; Palacin, M; Chillaron, J			Identification and functional characterization of a novel low affinity aromatic-preferring amino acid transporter (arpAT) - One of the few proteins silenced during primate evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTINE/GLUTAMATE EXCHANGE TRANSPORTER; 4F2 HEAVY-CHAIN; MULTIPLE SEQUENCE ALIGNMENT; HUMAN JEJUNAL ENTEROCYTES; STRUCTURAL SIMILARITY; MEMBRANE-PROTEIN; SYSTEM X(C)(-); MESSENGER-RNA; LIGHT SUBUNIT; MOUSE-BRAIN	We have identified in silico arpAT, a gene encoding a new member of the LSHAT family, and cloned it from kidney. Co-expression of arpAT with the heavy subunits rBAT or 4F2hc elicited a sodium-independent alanine transport activity in HeLa cells. L-Tyrosine, L-3,4-dihydroxyphenylalanine (L-DOPA), L-glutamine, L-serine, L-cystine, and L-arginine were also transported. Kinetic and cis-inhibition studies showed a K-m = 1.59 +/- 0.24 mM for L-alanine or IC50 in the millimolar range for most amino acids, except L-proline, glycine, anionic and D-amino acids, which were not inhibitory. L-DOPA and L-tyrosine were the most effective competitive inhibitors of L-alanine transport, with IC50 values of 272.2 +/- 57.1 and 716.3 +/- 112.4 mu M, respectively. In the small intestine, arpAT mRNA was located at the enterocytes, in a decreasing gradient from the crypts to the tip of the villi. It was also expressed in neurons from different brain areas. Finally, we show that while the arpAT gene is conserved in rat, dog, and chicken, it has become silenced in humans and chimpanzee. Actually, it has been recently reported that it is one of the 33 recently inactivated genes in the human lineage. The evolutionary implications of the silencing process and the roles of arpAT in transport of L-DOPA in the brain and in aromatic amino acid absorption are discussed.	Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Univ Barcelona, Barcelona Sci Pk, E-08028 Barcelona, Spain; European Mol Biol Lab, D-69117 Heidelberg, Germany	University of Barcelona; University of Barcelona; European Molecular Biology Laboratory (EMBL)	Chillaron, J (corresponding author), Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, New Bldg,Av Diagonal 645, E-08028 Barcelona, Spain.	chillaro@worldonline.es	Zorzano, Antonio/R-5479-2018; Palacín, Manuel/G-9786-2015; Chillaron, Josep/ABF-7663-2021; Torrents, David/G-5785-2015	Chillaron, Josep/0000-0003-3068-7598; Palacin, Manuel/0000-0002-8670-293X; Torrents, David/0000-0002-6086-9037				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bauch C, 2003, J BIOL CHEM, V278, P1316, DOI 10.1074/jbc.M210449200; BAUMAN A, 1974, BRAIN RES, V66, P253, DOI 10.1016/0006-8993(74)90144-9; Birney E, 2004, GENOME RES, V14, P988, DOI 10.1101/gr.1865504; Boado RJ, 1999, P NATL ACAD SCI USA, V96, P12079, DOI 10.1073/pnas.96.21.12079; Borsani G, 1999, NAT GENET, V21, P297, DOI 10.1038/6815; Broer A, 2004, J BIOL CHEM, V279, P24467, DOI 10.1074/jbc.M400904200; Broer A, 2000, BIOCHEM J, V349, P787, DOI 10.1042/bj3490787; Campbell WA, 2000, J BIOL CHEM, V275, P5347, DOI 10.1074/jbc.275.8.5347; Chairoungdua A, 2001, J BIOL CHEM, V276, P49390, DOI 10.1074/jbc.M107517200; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Dave MH, 2004, J PHYSIOL-LONDON, V558, P597, DOI 10.1113/jphysiol.2004.065037; Duelli R, 2000, J CEREBR BLOOD F MET, V20, P1557, DOI 10.1097/00004647-200011000-00005; Fernandez E, 2003, J AM SOC NEPHROL, V14, P837, DOI 10.1097/01.ASN.0000057852.35075.AC; Fernandez E, 2002, AM J PHYSIOL-RENAL, V283, pF540, DOI 10.1152/ajprenal.00071.2002; Font M, 2001, HUM MOL GENET, V10, P305, DOI 10.1093/hmg/10.4.305; Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690; GARCIASANCHO FJ, 1975, BIOCHIM BIOPHYS ACTA, V406, P538, DOI 10.1016/0005-2736(75)90031-0; Gasol E, 2004, J BIOL CHEM, V279, P31228, DOI 10.1074/jbc.M402428200; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; Helboe L, 2003, EUR J NEUROSCI, V18, P2227, DOI 10.1046/j.1460-9568.2003.02966.x; Hisano S, 1996, BRAIN RES, V710, P299, DOI 10.1016/0006-8993(95)01442-X; Kageyama T, 2000, NEUROREPORT, V11, P3663, DOI 10.1097/00001756-200011270-00015; Kim DK, 2002, GENOMICS, V79, P95, DOI 10.1006/geno.2001.6678; Kim DK, 2001, J BIOL CHEM, V276, P17221, DOI 10.1074/jbc.M009462200; Kleta R, 2004, NAT GENET, V36, P999, DOI 10.1038/ng1405; Li W, 2000, J HISTOCHEM CYTOCHEM, V48, P89, DOI 10.1177/002215540004800109; Li W, 1998, GASTROENTEROLOGY, V115, P86, DOI 10.1016/S0016-5085(98)70368-3; LI WH, 1981, NATURE, V292, P237, DOI 10.1038/292237a0; Liu XM, 2004, FASEB J, V18, P768, DOI 10.1096/fj.03-0886fje; Matsuo H, 2002, J BIOL CHEM, V277, P21017, DOI 10.1074/jbc.M200019200; Meier C, 2002, EMBO J, V21, P580, DOI 10.1093/emboj/21.4.580; Misu Y, 2003, PHARMACOL THERAPEUT, V97, P117, DOI 10.1016/S0163-7258(02)00325-X; NIRENBERG MJ, 1995, J COMP NEUROL, V356, P505, DOI 10.1002/cne.903560403; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Palacin M, 2004, PFLUG ARCH EUR J PHY, V447, P490, DOI 10.1007/s00424-003-1062-7; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; Pineda M, 2004, KIDNEY INT, V66, P1453, DOI 10.1111/j.1523-1755.2004.00908.x; Pineda M, 2004, BIOCHEM J, V377, P665, DOI 10.1042/BJ20030956; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Rajan DP, 2000, J BIOL CHEM, V275, P14331, DOI 10.1074/jbc.275.19.14331; Reig N, 2002, EMBO J, V21, P4906, DOI 10.1093/emboj/cdf500; Rome S, 2002, J NUTR, V132, P1009, DOI 10.1093/jn/132.5.1009; Sasaki H, 2002, J BIOL CHEM, V277, P44765, DOI 10.1074/jbc.M208704200; Sato H, 2002, J NEUROSCI, V22, P8028; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Seow HF, 2004, NAT GENET, V36, P1003, DOI 10.1038/ng1406; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tome D, 2004, BRIT J NUTR, V92, pS27, DOI 10.1079/BJN20041138; Torrents D, 2003, GENOME RES, V13, P2559, DOI 10.1101/gr.1455503; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; Uchino H, 2002, MOL PHARMACOL, V61, P729, DOI 10.1124/mol.61.4.729; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; Vieira-Coelho MA, 1998, LIFE SCI, V64, P69, DOI 10.1016/S0024-3205(98)00535-9; VieiraCoelho MA, 1997, CLIN EXP HYPERTENS, V19, P43, DOI 10.3109/10641969709080803; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; YAN N, 1992, P NATL ACAD SCI USA, V89, P9982, DOI 10.1073/pnas.89.21.9982; Yanagida O, 2001, BBA-BIOMEMBRANES, V1514, P291, DOI 10.1016/S0005-2736(01)00384-4; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555	64	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19364	19372		10.1074/jbc.M412516200	http://dx.doi.org/10.1074/jbc.M412516200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757906	hybrid			2022-12-27	WOS:000228932300094
J	Harikumar, KG; Miller, LJ				Harikumar, KG; Miller, LJ			Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2) ADRENERGIC-RECEPTOR; PROTEIN-COUPLED RECEPTOR; PEPTIDE AGONIST; CONFORMATIONAL-CHANGES; REFINEMENT; SITE	Changes in receptor conformation are believed to be key for ligand-induced regulation of cellular signaling cascades. However, little information exists about specific conformations of a receptor. We recently applied fluorescence resonance energy transfer to determine distances from distinct points distributed over the surface and within the helical bundle of the cholecystokinin receptor to the amino terminus of a full agonist CCK analogue (Harikumar, K. G., Pinon, D. I., Wessels, W. S., Dawson, E. S., Lybrand, T. P., Prendergast, F. G., and Miller, L. J. ( 2004) Mol. Pharmacol. 65, 28-35). Here, we apply the same experimental strategy to determine distances from the same receptor positions to an analogous point at the amino terminus of structurally related partial agonist (Alexa(488)-Gly-[(Nle(28,31))CCK-26-32]phenethyl ester) and antagonist (Alexa(488)-Gly-[(D-Trp(31), Nle(28,31)) CCK-26-32]phenethyl ester) ligands. A high degree of spectral overlap and fluorescence transfer was observed for ligand-occupied fluorescent-tagged receptors with no transfer observed for the ligand-occupied pseudo-wild type null cysteine-reactive mutant receptor (C94S). For the partial agonist, calculated distances to receptor positions 94, 102, 204, and 341, representing sites within the helical confluence, and the first, second, and third loops, were 21 +/- 0.4, 18 +/- 0.4, 25 +/- 1, and 17 +/- 1 angstrom, not different from those measured previously for the analogous full agonist. For the antagonist, the analogous distances were 21 +/- 2, 28 +/- 2, 15 +/- 1 and 21 +/- 1 angstrom. Distances to the first and third loops were longer and the distance to the second loop was shorter for the antagonist relative to both the full and partial agonist probes, whereas all three probes demonstrated similar distances to the intrahelical reference point. This supports the possibilities of changes in the conformation of the probe and/or the receptor induced by structurally similar ligands having distinct intrinsic biological activities.	Mayo Clin Scottsdale, Ctr Canc, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Miller, LJ (corresponding author), Mayo Clin Scottsdale, Ctr Canc, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	miller@mayo.edu			NIDDK NIH HHS [DK32878] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032878, R01DK032878] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arlander SJH, 2004, MOL PHARMACOL, V66, P545, DOI 10.1124/mol.104.001396; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Ding XQ, 2003, RECEPTOR CHANNEL, V9, P83, DOI 10.1080/10606820308249; Ding XQ, 2002, MOL PHARMACOL, V61, P1041, DOI 10.1124/mol.61.5.1041; Ding XQ, 2001, J BIOL CHEM, V276, P4236, DOI 10.1074/jbc.M003798200; Dong MQ, 1999, J BIOL CHEM, V274, P4778, DOI 10.1074/jbc.274.8.4778; Donnelly D, 1997, FEBS LETT, V409, P431, DOI 10.1016/S0014-5793(97)00546-2; GETHER U, 1995, J BIOL CHEM, V270, P28268; Hadac EM, 1999, J MED CHEM, V42, P2105, DOI 10.1021/jm980732q; Harikumar KG, 2004, MOL PHARMACOL, V65, P28, DOI 10.1124/mol.65.1.28; Harikumar KG, 2002, J BIOL CHEM, V277, P18552, DOI 10.1074/jbc.M201164200; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; LAKOWICZ JR, 1980, J BIOCHEM BIOPH METH, V2, P91, DOI 10.1016/0165-022X(80)90077-9; Lin SS, 1996, BIOCHEMISTRY-US, V35, P14445, DOI 10.1021/bi961619+; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719	17	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18631	18635		10.1074/jbc.M410834200	http://dx.doi.org/10.1074/jbc.M410834200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757907	hybrid			2022-12-27	WOS:000228932300012
J	Lussier, MP; Cayouette, S; Lepage, PK; Bernier, CL; Francoeur, N; St Hilaire, M; Pinard, M; Boulay, G				Lussier, MP; Cayouette, S; Lepage, PK; Bernier, CL; Francoeur, N; St Hilaire, M; Pinard, M; Boulay, G			MxA, a member of the dynamin superfamily, interacts with the ankyrin-like repeat domain of TRPC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; VIRUS NUCLEOCAPSID PROTEIN; PLASMA-MEMBRANE; CA2+ ENTRY; CALMODULIN-BINDING; POTENTIAL TRP; IP3 RECEPTOR; SH3 DOMAINS; GTPASE; FAMILY	Mammalian transient receptor potential canonical channels have been proposed as the molecular entities associated with calcium entry activity in nonexcitable cells. Amino acid sequence analyses of TRPCs revealed the presence of ankyrin-like repeat domains, one of the most common protein-protein interaction motifs. Using a yeast two-hybrid interaction assay, we found that the second ankyrin-like repeat domain of TRPC6 interacted with MxA, a member of the dynamin superfamily. Using a GST pull-down and co-immunoprecipitation assay, we showed that MxA interacted with TRPC1, -3, -4, -5, -6, and -7. Overexpression of MxA in HEK293T cells slightly increased endogenous calcium entry subsequent to stimulation of G(q) protein-coupled receptors or store depletion by thapsigargin. Co-expression of MxA with TRPC6 enhanced agonist-induced or OAG-induced calcium entry activity. GTP binding-defective MxA mutants had only a minor potentiating effect on OAG-induced TRPC6 activity. However, a MxA mutant that could bind GTP but that lacked GTPase activity produced the same effect as MxA on OAG-induced TRPC6 activity. These results indicated that MxA interacted specifically with the second ankyrin-like repeat domain of TRPCs and suggested that monomeric MxA regulated the activity of TRPC6 by a mechanism requiring GTP binding. Additional results showed that an increase in the endogenous expression of MxA, induced by a treatment with interferon alpha, regulated the activity of TRPC6. The study clearly identified MxA as a new regulatory protein involved in Ca2+ signaling.	Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Boulay, G (corresponding author), Univ Sherbrooke, Fac Med, Dept Pharmacol, 3001 12th Ave N, Sherbrooke, PQ J1H 5N4, Canada.	Guylain.Boulay@USherbrooke.ca	Boulay, Guylain/D-9773-2010	Lussier, Marc/0000-0001-5568-0072				Accola MA, 2002, J BIOL CHEM, V277, P21829, DOI 10.1074/jbc.M201641200; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson I, 2004, J VIROL, V78, P4323, DOI 10.1128/JVI.78.8.4323-4329.2004; AUSUBEL FM, 2002, CURRENT PROTOCOLS MO; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Boulay G, 2002, CELL CALCIUM, V32, P201, DOI 10.1016/S0143416002001550; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Burysek L, 2001, J VIROL, V75, P2345, DOI 10.1128/JVI.75.5.2345-2352.2001; Cayouette S, 2004, J BIOL CHEM, V279, P7241, DOI 10.1074/jbc.M312042200; Di Paolo C, 1999, J BIOL CHEM, V274, P32071, DOI 10.1074/jbc.274.45.32071; Engelhardt OG, 2001, EXP CELL RES, V271, P286, DOI 10.1006/excr.2001.5380; Estacion M, 2004, J BIOL CHEM, V279, P22047, DOI 10.1074/jbc.M402320200; Foord R, 1999, NAT STRUCT BIOL, V6, P157; FRESE M, 1995, J VIROL, V69, P3904, DOI 10.1128/JVI.69.6.3904-3909.1995; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Greka A, 2003, NAT NEUROSCI, V6, P837, DOI 10.1038/nn1092; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haller O, 2002, TRAFFIC, V3, P710, DOI 10.1034/j.1600-0854.2002.31003.x; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; HORISBERGER MA, 1992, J VIROL, V66, P4705, DOI 10.1128/JVI.66.8.4705-4709.1992; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Janzen C, 2000, J VIROL, V74, P8202, DOI 10.1128/JVI.74.17.8202-8206.2000; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kochs G, 2002, J BIOL CHEM, V277, P14172, DOI 10.1074/jbc.M200244200; Kochs G, 2002, P NATL ACAD SCI USA, V99, P3153, DOI 10.1073/pnas.052430399; Lai MM, 2000, J BIOL CHEM, V275, P34017, DOI 10.1074/jbc.C000429200; Ma R, 2003, J BIOL CHEM, V278, P52763, DOI 10.1074/jbc.M309610200; Main ERG, 2003, CURR OPIN STRUC BIOL, V13, P482, DOI 10.1016/S0959-440X(03)00105-2; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; MELEN K, 1992, J BIOL CHEM, V267, P25898; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; Ponten A, 1997, J VIROL, V71, P2591, DOI 10.1128/JVI.71.4.2591-2599.1997; Reichelt M, 2004, TRAFFIC, V5, P772, DOI 10.1111/j.1600-0854.2004.00219.x; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Sambrook J., 2001, MOL CLONING LAB MANU; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Trost C, 2001, BIOCHEM J, V355, P663, DOI 10.1042/bj3550663; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Vennekens R, 2002, CELL CALCIUM, V31, P253, DOI 10.1016/S0143-4160(02)00055-6; Wedel BJ, 2003, J BIOL CHEM, V278, P25758, DOI 10.1074/jbc.M303890200; Yildirim E, 2003, P NATL ACAD SCI USA, V100, P2220, DOI 10.1073/pnas.0438036100; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; ZURCHER T, 1992, J VIROL, V66, P5059	71	51	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					19393	19400		10.1074/jbc.M500391200	http://dx.doi.org/10.1074/jbc.M500391200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757897	hybrid			2022-12-27	WOS:000228932300097
J	Pastan, I				Pastan, I			An NIH career: from bedside to basic research and back	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT IMMUNOTOXIN; ESCHERICHIA-COLI; PSEUDOMONAS EXOTOXIN; ANTIBODY; HORMONE; CELLS; FIBROBLASTS; SEQUENCE; DOMAINS; BINDING		NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pastan, I (corresponding author), NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	pastani@mail.nih.gov	pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270	NATIONAL CANCER INSTITUTE [Z01BC008753, ZIABC008753] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BRINKMANN U, 1993, P NATL ACAD SCI USA, V90, P7538, DOI 10.1073/pnas.90.16.7538; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; DECROMBRUGGHE B, 1971, J BIOL CHEM, V246, P7343; FAGAN JB, 1980, NUCLEIC ACIDS RES, V8, P3055, DOI 10.1093/nar/8.13.3055; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kreitman RJ, 2001, NEW ENGL J MED, V345, P241, DOI 10.1056/NEJM200107263450402; LEFKOWITZ RJ, 1970, SCIENCE, V170, P633, DOI 10.1126/science.170.3958.633; LEFKOWITZ RJ, 1970, P NATL ACAD SCI USA, V65, P745, DOI 10.1073/pnas.65.3.745; PASTAN I, 1970, SCIENCE, V169, P339, DOI 10.1126/science.169.3943.339; PASTAN I, 1966, P NATL ACAD SCI USA, V56, P1802, DOI 10.1073/pnas.56.6.1802; SCHLESSINGER J, 1978, P NATL ACAD SCI USA, V75, P5353, DOI 10.1073/pnas.75.11.5353; SOBEL ME, 1978, P NATL ACAD SCI USA, V75, P5846, DOI 10.1073/pnas.75.12.5846; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; VARMUS HE, 1970, J BIOL CHEM, V245, P6366; WILLINGHAM MC, 1978, CELL, V13, P501, DOI 10.1016/0092-8674(78)90323-9; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217	18	1	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18553	18557		10.1074/jbc.X500002200	http://dx.doi.org/10.1074/jbc.X500002200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15797860	hybrid			2022-12-27	WOS:000228932300001
J	Morand, JPF; Macri, J; Adeli, K				Morand, JPF; Macri, J; Adeli, K			Proteomic profiling of hepatic endoplasmic reticulum-associated proteins in an animal model of insulin resistance and metabolic dyslipidemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE TRANSFER PROTEIN; RETINOL-BINDING-PROTEIN; MOUSE-LIVER PROTEINS; KINASE-C; APOLIPOPROTEIN-B; 2-DIMENSIONAL DATABASE; GEL-ELECTROPHORESIS; RAT HEPATOCYTES; ER-60 PROTEASE	Hepatic insulin resistance and lipoprotein overproduction are common features of the metabolic syndrome and insulin-resistant states. A fructose-fed, insulin-resistant hamster model was recently developed to investigate mechanisms linking the development of hepatic insulin resistance and overproduction of atherogenic lipoproteins. Here we report a systematic analysis of protein expression profiles in the endoplasmic reticulum (ER) fractions isolated from livers of fructose-fed hamsters with the intention of identifying new candidate proteins involved in hepatic complications of insulin resistance and lipoprotein dysregulation. We have profiled hepatic ER-associated proteins from chow-fed (control) and fructose-fed (insulin-resistant) hamsters using two-dimensional gel electrophoresis and mass spectrometry. A total of 26 large scale two-dimensional gels of hepatic ER were used to identify 34 differentially expressed hepatic ER protein spots observed to be at least 2-fold differentially expressed with fructose feeding and the onset of insulin resistance. Differentially expressed proteins were identified by matrix-assisted laser desorption ionization-quadrupole time of flight (MALDI-Q-TOF), MALDI-TOF-postsource decay, and database mining using ProteinProspector MS-fit and MS-tag or the PROWL ProFound search engine using a focused rodent or mammalian search. Hepatic ER proteins ER60, ERp46, ERp29, glutamate dehydrogenase, and TAP1 were shown to be more than 2-fold downregulated, whereas alpha-glucosidase, P-glycoprotein, fibrinogen, protein disulfide isomerase, GRP94, and apolipoprotein E were all found to be up-regulated in the hepatic ER of the fructose-fed hamster. Seven isoforms of ER60 in the hepatic ER were all shown to be downregulated at least 2-fold in hepatocytes from fructose-fed/insulin-resistant hamsters. Implications of the differential expression of positively identified protein factors in the development of hepatic insulin resistance and lipoprotein abnormalities are discussed.	Univ Toronto, Hosp Sick Children, Div Clin Biochem, DPLM,Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Div Struct Biol & Biochem, DPLM,Res Inst, Toronto, ON M5G 1X8, Canada; Hamilton Reg Lab Med Program, Dept Lab Med, Hamilton, ON L8L 2X2, Canada; McMaster Univ, Hamilton, ON L8L 2X2, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McMaster University	Adeli, K (corresponding author), Univ Toronto, Hosp Sick Children, Div Clin Biochem, DPLM,Res Inst, Toronto, ON M5G 1X8, Canada.	k.adeli@utoronto.ca		Adeli, Khosrow/0000-0002-5839-5709				Adeli K, 1997, J BIOL CHEM, V272, P22489, DOI 10.1074/jbc.272.36.22489; Andersson C, 1994, Adv Pharmacol, V27, P19, DOI 10.1016/S1054-3589(08)61028-5; Avramoglu RK, 2003, FRONT BIOSCI, V8, pD464, DOI 10.2741/1022; Bagshaw RD, 2000, ANAL BIOCHEM, V284, P432, DOI 10.1006/abio.2000.4718; Boedeker JC, 1999, J LIPID RES, V40, P1627; BOSCA L, 1989, BIOCHEM BIOPH RES CO, V160, P1243, DOI 10.1016/S0006-291X(89)80137-8; Carpentier A, 2002, J BIOL CHEM, V277, P28795, DOI 10.1074/jbc.M204568200; Chiarpotto E, 1999, HEPATOLOGY, V29, P1565, DOI 10.1002/hep.510290510; Croquet F, 1996, BBA-MOL BASIS DIS, V1315, P163, DOI 10.1016/0925-4439(95)00124-7; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Edvardsson U, 2003, PROTEOMICS, V3, P468, DOI 10.1002/pmic.200390061; Efferth T, 2003, AGEING RES REV, V2, P11, DOI 10.1016/S1568-1637(02)00046-6; FERNANDEZALVAREZ J, 1994, DIABETOLOGIA, V37, P177, DOI 10.1007/s001250050090; FOEMMEL RS, 1975, J BIOL CHEM, V250, P1892; Fossey SC, 2000, MAMM GENOME, V11, P919, DOI 10.1007/s003350010174; Fountoulakis M, 2000, ELECTROPHORESIS, V21, P2148, DOI 10.1002/1522-2683(20000601)21:11<2148::AID-ELPS2148>3.0.CO;2-X; Fountoulakis M, 2001, ELECTROPHORESIS, V22, P1747, DOI 10.1002/1522-2683(200105)22:9<1747::AID-ELPS1747>3.0.CO;2-H; Frickel EM, 2004, J BIOL CHEM, V279, P18277, DOI 10.1074/jbc.M314089200; Gaetani S, 2002, CLIN CHEM LAB MED, V40, P1211, DOI 10.1515/CCLM.2002.211; Garcia-Rodriguez S, 2003, FREE RADICAL BIO MED, V35, P428, DOI 10.1016/S0891-5849(03)00321-6; Gregory RB, 1999, BIOCHEM J, V341, P401, DOI 10.1042/0264-6021:3410401; Grundy SM, 1998, AM J CARDIOL, V81, p18B, DOI 10.1016/S0002-9149(98)00033-2; Higashi Y, 2002, BBA-MOL CELL BIOL L, V1581, P127, DOI 10.1016/S1388-1981(02)00157-9; Ishii T, 1999, J IMMUNOL, V162, P1303; Janson IM, 1997, J BIOCHEM-TOKYO, V121, P112; Kang YH, 2002, TISSUE ENG, V8, P681, DOI 10.1089/107632702760240599; Kim J, 2002, ELECTROPHORESIS, V23, P4142, DOI 10.1002/elps.200290032; Knoblach B, 2003, MOL CELL PROTEOMICS, V2, P1104, DOI 10.1074/mcp.M300053-MCP200; KOSMOPOULOU I, 1994, INT J BIOCHEM, V26, P403, DOI 10.1016/0020-711X(94)90061-2; KRAUSFRIEDMANN N, 1995, BRAZ J MED BIOL RES, V28, P275; Kumar Y, 2003, PROTEOMICS, V3, P513, DOI 10.1002/pmic.200390065; Lan H, 2004, DIABETES, V53, P240, DOI 10.2337/diabetes.53.1.240; Ledoux S, 2003, CANCER RES, V63, P7284; Lee KH, 2003, BIOPOLYMERS, V69, P260, DOI 10.1002/bip.10360; Lee WK, 2000, J CELL BIOCHEM, V76, P244; LEWIS MJ, 1986, ARCH BIOCHEM BIOPHYS, V245, P389, DOI 10.1016/0003-9861(86)90230-4; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; LUTSCH G, 1990, EUR J CELL BIOL, V51, P140; Marusina K, 1997, BIOCHEMISTRY-US, V36, P856, DOI 10.1021/bi9619738; NIETO A, 1990, BIOCHEM J, V267, P317, DOI 10.1042/bj2670317; Pagetta A, 2003, DIABETOLOGIA, V46, P996, DOI 10.1007/s00125-003-1133-5; Penfornis A, 2003, HUM IMMUNOL, V64, P156, DOI 10.1016/S0198-8859(02)00687-0; Qiu W, 2004, DIABETES, V53, P3057, DOI 10.2337/diabetes.53.12.3057; Qiu W, 2004, BIOCHEMISTRY-US, V43, P4819, DOI 10.1021/bi034862z; Rashid KA, 2002, J BIOL CHEM, V277, P22010, DOI 10.1074/jbc.M112448200; RASSCHAERT J, 1994, MOL CELL BIOCHEM, V135, P137, DOI 10.1007/BF00926516; Sargsyan E, 2002, J BIOL CHEM, V277, P17009, DOI 10.1074/jbc.M200539200; Sawamoto K, 1995, INT J TISSUE REACT, V17, P205; Seow TK, 2000, ELECTROPHORESIS, V21, P1787, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1787::AID-ELPS1787>3.3.CO;2-1; SHARMA RN, 1978, J BIOL CHEM, V253, P2033; Sidhu JS, 2003, J AM COLL CARDIOL, V42, P1757, DOI 10.1016/j.jacc.2003.04.001; Smith JE, 1998, BBA-GEN SUBJECTS, V1380, P10, DOI 10.1016/S0304-4165(97)00122-0; Suzuki K, 2002, CLIN EXP IMMUNOL, V127, P234, DOI 10.1046/j.1365-2249.2002.01767.x; Taghibiglou C, 2000, J BIOL CHEM, V275, P8416, DOI 10.1074/jbc.275.12.8416; Taghibiglou C, 2000, J LIPID RES, V41, P499; Taghibiglou C, 2002, J BIOL CHEM, V277, P793, DOI 10.1074/jbc.M106737200; TANG EY, 1993, FEBS LETT, V326, P117, DOI 10.1016/0014-5793(93)81774-T; Tanizawa Y, 2002, DIABETES, V51, P712, DOI 10.2337/diabetes.51.3.712; Tatidis L, 2002, BIOCHEM PHARMACOL, V63, P2169, DOI 10.1016/S0006-2952(02)01018-3; Timar O, 2000, CAN J CARDIOL, V16, P779; URADE R, 1992, FEBS LETT, V312, P83, DOI 10.1016/0014-5793(92)81415-I; van der Vlies D, 2002, BIOCHEM J, V366, P825, DOI 10.1042/BJ20020618; WITZMANN FA, 1994, FUND APPL TOXICOL, V23, P1, DOI 10.1006/faat.1994.1072; Witzmann FA, 1996, ELECTROPHORESIS, V17, P198, DOI 10.1002/elps.1150170132; Yan G, 1997, TISSUE ANTIGENS, V50, P576, DOI 10.1111/j.1399-0039.1997.tb02915.x; Yudkin JS, 2003, INT J OBESITY, V27, pS25, DOI 10.1038/sj.ijo.0802496; Zhang JY, 2003, J BIOL CHEM, V278, P7459, DOI 10.1074/jbc.M207976200; Zhang LY, 2003, J BIOL CHEM, V278, P29344, DOI 10.1074/jbc.M300455200; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	69	58	67	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17626	17633		10.1074/jbc.M413343200	http://dx.doi.org/10.1074/jbc.M413343200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15760893	hybrid			2022-12-27	WOS:000228807200009
J	Rangel, R; McKeller, MR; Sims-Mourtada, JC; Kashi, C; Cain, K; Wieder, ED; Molldrem, JJ; Pham, LV; Ford, RJ; Yotnda, P; Guret, C; Frances, V; Martinez-Valdez, H				Rangel, R; McKeller, MR; Sims-Mourtada, JC; Kashi, C; Cain, K; Wieder, ED; Molldrem, JJ; Pham, LV; Ford, RJ; Yotnda, P; Guret, C; Frances, V; Martinez-Valdez, H			Assembly of the kappa PreB receptor requires a V kappa-like protein encoded by a germline transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL DEVELOPMENT; ACUTE LYMPHOBLASTIC-LEUKEMIA; LIGHT-CHAIN EXPRESSION; MU-HEAVY-CHAIN; ACCESSIBILITY CONTROL; V(D)J RECOMBINATION; GENE-TRANSCRIPTION; ALLELIC EXCLUSION; VDJ RECOMBINATION; DEFICIENT MICE	By confining germline transcription as a byproduct of the mechanisms inherent to genetic rearrangements, the translation of respective mRNAs and their biological relevance might have been overlooked. Here we report the identification, cloning, and biochemical characterization of a human V kappa-like protein that is encoded by a germline transcript. This surrogate protein assembles with the immunoglobulin mu heavy chain at the surface of B cell progenitors and precursors to form a kappa-like antigen receptor. These findings support the notion that germline transcription is not futile and stress the flexibility in eukaryotic gene usage and expression. In addition, the present study confirms the co-existence of surrogate lambda and kappa receptors that are proposed to work in concert to promote B lymphocyte maturation.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77054 USA; Univ Texas, MD Anderson Canc Ctr, Sect Transplant Immunol, Dept Blood & Bone Marrow Transplantat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Schering Plough Corp, Lab Immunol Res, F-69571 Dardilly, France	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Merck & Company; Schering Plough Corporation	Martinez-Valdez, H (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Unit 902, 1515 Holcombe Blvd, Houston, TX 77030 USA.	hmartine@mail.mdanderson.org	Rangel, Roberto/AHE-6583-2022	Rangel, Roberto/0000-0002-9088-7957	NATIONAL CANCER INSTITUTE [T32CA009598] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009598-15] Funding Source: Medline; NIAID NIH HHS [AI 05625-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; Bachl J, 1996, EUR J IMMUNOL, V26, P870, DOI 10.1002/eji.1830260422; BOSSY D, 1993, INT IMMUNOL, V5, P467, DOI 10.1093/intimm/5.5.467; BROUNS GS, 1993, EUR J IMMUNOL, V23, P1088, DOI 10.1002/eji.1830230517; Burrows PD, 2002, SEMIN IMMUNOL, V14, P343, DOI 10.1016/S1044-5323(02)00067-2; CHANG H, 1986, J EXP MED, V163, P425, DOI 10.1084/jem.163.2.425; CHEN JZ, 1993, CURR OPIN IMMUNOL, V5, P194, DOI 10.1016/0952-7915(93)90004-C; Cocea L, 1999, J EXP MED, V189, P1443, DOI 10.1084/jem.189.9.1443; Erdmann VA, 2000, NUCLEIC ACIDS RES, V28, P197, DOI 10.1093/nar/28.1.197; FINDLEY HW, 1982, BLOOD, V60, P1305; FRANCES V, 1994, EMBO J, V13, P5937, DOI 10.1002/j.1460-2075.1994.tb06939.x; Gellert M, 1996, GENES CELLS, V1, P269, DOI 10.1046/j.1365-2443.1996.22023.x; Jolly CJ, 1997, IMMUNOL CELL BIOL, V75, P13, DOI 10.1038/icb.1997.3; KABAT EA, 1987, SEQUENCE PROTEINS IM; Kaplan D, 2000, CYTOMETRY, V40, P81, DOI 10.1002/(SICI)1097-0320(20000501)40:1<81::AID-CYTO11>3.0.CO;2-K; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KLOBECK HG, 1985, NUCLEIC ACIDS RES, V13, P6515, DOI 10.1093/nar/13.18.6515; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJUNGBERG UK, 1993, MOL IMMUNOL, V30, P1279, DOI 10.1016/0161-5890(93)90044-C; Martensson A, 1999, INT IMMUNOL, V11, P453, DOI 10.1093/intimm/11.3.453; MARTIN D, 1991, J EXP MED, V173, P639, DOI 10.1084/jem.173.3.639; Meffre E, 1998, J EXP MED, V188, P765, DOI 10.1084/jem.188.4.765; Minegishi Y, 1998, J EXP MED, V187, P71, DOI 10.1084/jem.187.1.71; MISENER V, 1991, INT IMMUNOL, V3, P1129, DOI 10.1093/intimm/3.11.1129; Mundt C, 2001, J EXP MED, V193, P435, DOI 10.1084/jem.193.4.435; Oltz EM, 2001, IMMUNOL RES, V23, P121, DOI 10.1385/IR:23:2-3:121; PANDRAU D, 1993, LEUKEMIA, V7, P635; Pelanda R, 2002, J IMMUNOL, V169, P865, DOI 10.4049/jimmunol.169.2.865; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; Scherer DC, 1996, IMMUNITY, V5, P563, DOI 10.1016/S1074-7613(00)80271-X; Schlissel M S, 1997, Semin Immunol, V9, P161, DOI 10.1006/smim.1997.0066; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; Shimizu T, 2002, J IMMUNOL, V168, P6286, DOI 10.4049/jimmunol.168.12.6286; Sleckman BP, 1998, IMMUNOL REV, V165, P121, DOI 10.1111/j.1600-065X.1998.tb01235.x; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; TAKEMORI T, 1990, EMBO J, V9, P2493, DOI 10.1002/j.1460-2075.1990.tb07428.x; Thompson A, 1998, IMMUNOGENETICS, V48, P305, DOI 10.1007/s002510050437; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Wang YH, 1998, J IMMUNOL, V161, P1132; Wang YH, 2002, BLOOD, V99, P2459, DOI 10.1182/blood.V99.7.2459; Weng WK, 1997, J IMMUNOL, V159, P5502; Yang XXO, 2003, BLOOD, V101, P4492, DOI 10.1182/blood-2002-08-2579	46	10	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17807	17814		10.1074/jbc.M409479200	http://dx.doi.org/10.1074/jbc.M409479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15757909	hybrid			2022-12-27	WOS:000228807200032
J	Caldinelli, L; Iametti, S; Barbiroli, A; Bonomi, F; Fessas, D; Molla, G; Pilone, MS; Pollegioni, L				Caldinelli, L; Iametti, S; Barbiroli, A; Bonomi, F; Fessas, D; Molla, G; Pilone, MS; Pollegioni, L			Dissecting the structural determinants of the stability of cholesterol oxidase containing covalently bound flavin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-HYGROSCOPICUS; BREVIBACTERIUM-STEROLICUM; FAD; FLAVINYLATION; DENATURATION; BINDING; STATE	Cholesterol oxidase from Brevibacterium sterolicum is a monomeric flavoenzyme catalyzing the oxidation and isomerization of cholesterol to cholest-4-en-3-one. This protein is a class II cholesterol oxidases, with the FAD cofactor covalently linked to the enzyme through the His(69) residue. In this work, unfolding of wild-type cholesterol oxidase was compared with that of a H69A mutant, which does not covalently bind the flavin cofactor. The two protein forms do not show significant differences in their overall topology, but the urea-induced unfolding of the H69A mutant occurred at significant lower urea concentrations than wild-type (similar to 3 versus similar to 5 M, respectively), and the mutant protein had a melting temperature similar to 10 - 15 degrees C lower than wild-type in thermal denaturation experiments. The different sensitivity of the various spectroscopic features used to monitor protein unfolding indicated that in both proteins a two-step (three-state) process occurs. The presence of an intermediate was more evident for the H69A mutant at 2 M urea, where catalytic activity and tertiary structure were lost, and new hydrophobic patches were exposed on the protein surface, resulting in protein aggregation. Comparative analysis of the changes occurring upon urea and thermal treatment of the wild-type and H69A protein showed a good correlation between protein instability and the elimination of the covalent link between the flavin and the protein. This covalent bond represents a structural device to modify the flavin redox potentials and stabilize the tertiary structure of cholesterol oxidase, thus pointing to a specific meaning of the flavin binding mode in enzymes that carry out the same reaction in pathogenic versus non-pathogenic bacteria.	Univ Insubria, Dept Biotechnol & Mol Sci, I-21100 Varese, Italy; Univ Milan, DISMA, I-20133 Milan, Italy; Univ Milan, DISTAM, I-20133 Milan, Italy	University of Insubria; University of Milan; University of Milan	Pollegioni, L (corresponding author), Univ Insubria, Dept Biotechnol & Mol Sci, Via JH Dunant 3, I-21100 Varese, Italy.	loredano.pollegioni@uninsubria.it	Iametti, Stefania/AGY-9694-2022	Bonomi, Francesco/0000-0003-4556-2640; Iametti, Stefania/0000-0002-4159-3768; POLLEGIONI, LOREDANO/0000-0003-1733-7243; Molla, Gianluca/0000-0003-3688-3397; BARBIROLI, ALBERTO GIUSEPPE/0000-0003-1678-5431				BARONE G, 1992, J THERM ANAL, V38, P2779, DOI 10.1007/BF01979752; BARONE G, 1994, CHEM PROPERTIES BIOM, P67; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CAIROLI S, 1994, J PROTEIN CHEM, V13, P347, DOI 10.1007/BF01901568; Caldinelli L, 2004, J BIOL CHEM, V279, P28426, DOI 10.1074/jbc.M403489200; Corbin DR, 2001, PLANT PHYSIOL, V126, P1116, DOI 10.1104/pp.126.3.1116; Coulombe R, 2001, J BIOL CHEM, V276, P30435, DOI 10.1074/jbc.M104103200; DAuria S, 1997, BIOCHEM J, V323, P833, DOI 10.1042/bj3230833; DEFRANCESCO R, 1988, ARCH BIOCHEM BIOPHYS, V264, P281, DOI 10.1016/0003-9861(88)90595-4; Edmondson DE, 2001, ANTIOXID REDOX SIGN, V3, P789, DOI 10.1089/15230860152664984; Fessas D, 2001, EUR J BIOCHEM, V268, P5439, DOI 10.1046/j.0014-2956.2001.02484.x; Fraaije MW, 1998, TRENDS BIOCHEM SCI, V23, P206, DOI 10.1016/S0968-0004(98)01210-9; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; Gadda G, 1997, EUR J BIOCHEM, V250, P369, DOI 10.1111/j.1432-1033.1997.0369a.x; Iametti S, 1998, J AGR FOOD CHEM, V46, P2159, DOI 10.1021/jf980004b; Iametti S, 1996, EUR J BIOCHEM, V237, P106, DOI 10.1111/j.1432-1033.1996.0106n.x; KEARNEY EB, 1960, J BIOL CHEM, V235, P865; MacLachlan J, 2000, J STEROID BIOCHEM, V72, P169, DOI 10.1016/S0960-0760(00)00044-3; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; Motteran L, 2001, J BIOL CHEM, V276, P18024, DOI 10.1074/jbc.M010953200; Nandigama RK, 2000, J BIOL CHEM, V275, P20527, DOI 10.1074/jbc.M002132200; Navas J, 2001, J BACTERIOL, V183, P4796, DOI 10.1128/JB.183.16.4796-4805.2001; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; Pollegioni L, 2003, PROTEIN SCI, V12, P1018, DOI 10.1110/ps.0234603; Pollegioni L, 1999, EUR J BIOCHEM, V264, P140, DOI 10.1046/j.1432-1327.1999.00586.x; Prakash K, 2002, PROTEIN SCI, V11, P46, DOI 10.1110/ps.ps.20102; PRESS WH, 1989, NUMERICAL RECIPLES; PTISTYN OB, 1992, PROTEIN FOLDING, P243; Sampson NS, 2003, ACCOUNTS CHEM RES, V36, P713, DOI 10.1021/ar9800587; TANFORD C, 1968, ADV PROTEIN CHEM, V23, P69; VRIELINK A, 1991, J MOL BIOL, V219, P533, DOI 10.1016/0022-2836(91)90192-9; Yue QK, 1999, BIOCHEMISTRY-US, V38, P4277, DOI 10.1021/bi982497j	32	55	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22572	22581		10.1074/jbc.M500549200	http://dx.doi.org/10.1074/jbc.M500549200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15817448	hybrid			2022-12-27	WOS:000229741800005
J	Thompson, ME; Robinson-Benion, CL; Holt, JT				Thompson, ME; Robinson-Benion, CL; Holt, JT			An amino-terminal motif functions as a second nuclear export sequence in BRCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN-CANCER; DNA-REPAIR; PROTEIN; SIGNAL; LOCALIZATION; BREAST; TRANSCRIPTION; ASSOCIATION; EXPRESSION; RECEPTOR	Mutations in the breast cancer susceptibility gene 1 (BRCA1) account for a substantial percentage of familial breast and ovarian cancers. Although BRCA1 is thought to function within the nucleus, it has also been located in the cytoplasm. In addition, BRCA1 accumulates in the nucleus of cells treated with leptomycin B, an inhibitor of chromosome region maintenance 1-mediated nuclear export, indicative of its active nuclear export via this pathway. The nuclear export signal in BRCA1 has been described as consisting of amino acid residues 81-99. However, a number of other tumor suppressors have multiple nuclear export sequences, and we sought to determine whether BRCA1 did also. Here, we report that BRCA1 contains a second nuclear export sequence that comprises amino acid residues 22-30. By use of the human immunodeficiency virus-1 Rev complementation assay, this sequence was shown to confer export capability to an export-defective Rev fusion protein. The level of export activity was comparable with that of residues 81-99 comprising the previously reported nuclear export sequence in BRCA1. Mutation of leucine 28 to an alanine reduced nuclear export by similar to 75%. In MCF-7 cells stably transfected with a BRCA1 cDNA containing mutations in this novel sequence or the previously reported export sequence, BRCA1 accumulated in the nucleus. These data imply that BRCA1 contains at least two leucine-dependent nuclear export sequences.	Meharry Med Coll, Dept Biochem, Nashville, TN 37208 USA; Vanderbilt Univ, Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA	Meharry Medical College; Vanderbilt University; Vanderbilt University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Thompson, ME (corresponding author), Meharry Med Coll, Dept Biochem, 1005 DB Todd Blvd, Nashville, TN 37208 USA.	methompson@mmc.edu			NATIONAL CANCER INSTITUTE [P30CA068485, R01CA085269, K01CA089494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK058404] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 85269, K01 CA 89494, CA 68485] Funding Source: Medline; NCRR NIH HHS [2G12 RR 03032] Funding Source: Medline; NIDDK NIH HHS [DK 58404, DK 20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; BEGERD HP, 1996, MOL CELL BIOL, V16, P4207; Bienstock RJ, 1996, CANCER RES, V56, P2539; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; EASTON DF, 1993, AM J HUM GENET, V52, P678; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; KAMATA N, 1991, MOL CELL BIOL, V11, P765, DOI 10.1128/MCB.11.2.765; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Ossareh-Nazari B, 2001, TRAFFIC, V2, P684, DOI 10.1034/j.1600-0854.2001.21002.x; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tickenbrock L, 2002, J BIOL CHEM, V277, P32332, DOI 10.1074/jbc.M203990200; Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	28	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21854	21857		10.1074/jbc.M502676200	http://dx.doi.org/10.1074/jbc.M502676200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15811849	hybrid			2022-12-27	WOS:000229557900025
J	Dhanalakshmi, S; Agarwal, C; Singh, RP; Agarwal, R				Dhanalakshmi, S; Agarwal, C; Singh, RP; Agarwal, R			Silibinin up-regulates DNA-protein kinase-dependent p53 activation to enhance UVB-induced apoptosis in mouse epithelial JB6 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVONOID ANTIOXIDANT SILYMARIN; ULTRAVIOLET-B RADIATION; NEOPLASTIC TRANSFORMATION; P53-DEPENDENT APOPTOSIS; CANCER CHEMOPREVENTION; SIGNAL-TRANSDUCTION; CATALYTIC SUBUNIT; LATENT POPULATION; REPAIR PATHWAYS; TUMOR PROMOTION	In the present study, we employed a well established JB6 mouse epithelial cell model to define the molecular mechanism of efficacy of a naturally occurring flavonoid silibinin against ultraviolet B (UVB)-induced skin tumorigenesis. UVB exposure of cells caused a moderate phosphorylation of ERK1/2 and Akt and a stronger phosphorylation of p53 at Ser(15), which was enhanced markedly by silibinin pretreatment. Kinase activity of ERK1/2 for Elk-1 and Akt for glycogen synthase kinase-3 beta was also potently enhanced by silibinin pretreatment. Furthermore, silibinin increased the UVB-induced level of cleaved caspase 3 as well as apoptotic cells. Based on these observations, next we investigated the role of upstream kinases, ATM/ATR and DNA-PK, which act as sensors for UVB-induced DNA damage and transduce signals leading to DNA repair or apoptosis. Whereas UVB strongly activated ATM as observed by Ser(1981) phosphorylation, it was not affected by silibinin pretreatment. However, pretreatment of cells with the DNA-protein kinase (PK) inhibitor LY294002 strongly reversed silibinin-enhanced Akt-Ser(473) and p53-Ser(15) as well as ERK1/2 phosphorylation together with a dose-dependent decrease in cleaved caspase 3 and apoptosis (p < 0.05). In addition, silibinin pretreatment strongly enhanced H2A.X-Ser(139) phosphorylation and DNA-PK-associated kinase activity as well as the physical interaction of p53 with DNA-PK; pretreatment of cells with LY294002 but not caffeine abolished the silibinin-caused increase in both DNA-PK activation and p53-Ser(15) phosphorylations. Together, these findings suggest that silibinin preferentially activates the DNA-PK-p53 pathway for apoptosis in response to UVB-induced DNA damage, and that this could be a predominant mechanism of silibinin efficacy against UVB-induced skin cancer.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th Ave,Box C238, Denver, CO 80262 USA.	Rajesh.Agarwal@UCHSC.edu		Singh, Rana Pratap/0000-0003-4261-7044	NATIONAL CANCER INSTITUTE [R29CA064514, R01CA064514] Funding Source: NIH RePORTER; NCI NIH HHS [CA64514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Achanta G, 2001, CANCER RES, V61, P8723; Bachelor MA, 2004, SEMIN CANCER BIOL, V14, P131, DOI 10.1016/j.semcancer.2003.09.017; Bai L, 2004, CELL DEATH DIFFER, V11, P663, DOI 10.1038/sj.cdd.4401393; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Brash DE, 1996, J INVEST DERMATOL S, V1, P136; Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021; Chang KL, 2004, BIOCHEM PHARMACOL, V67, P717, DOI 10.1016/j.bcp.2003.10.003; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Dhanalakshmi S, 2004, CARCINOGENESIS, V25, P99, DOI 10.1093/carcin/bgg188; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gines S, 2003, J BIOL CHEM, V278, P50514, DOI 10.1074/jbc.M309348200; He ZW, 2003, CANCER RES, V63, P4396; Heck DE, 2004, TOXICOL APPL PHARM, V195, P288, DOI 10.1016/j.taap.2003.09.028; Hofmann CS, 2003, FASEB J, V17, P702, DOI 10.1096/fj.02-0665fje; Holmes WF, 2004, J CELL PHYSIOL, V199, P317, DOI 10.1002/jcp.10338; Huang CS, 2002, CANCER RES, V62, P6857; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1; Jack MT, 2004, J BIOL CHEM, V279, P15269, DOI 10.1074/jbc.M309917200; Kaji A, 2003, MOL CARCINOGEN, V37, P138, DOI 10.1002/mc.10130; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; Kim KY, 2004, J BIOL CHEM, V279, P29478, DOI 10.1074/jbc.M313947200; Kulms D, 2000, PHOTODERMATOL PHOTO, V16, P195, DOI 10.1034/j.1600-0781.2000.160501.x; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee JK, 2003, J DERMATOL SCI, V32, P171, DOI 10.1016/S0923-1811(03)00094-X; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; Li JJ, 1997, CANCER RES, V57, P3569; Ma CL, 2003, J BIOL CHEM, V278, P44265, DOI 10.1074/jbc.M309023200; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P1302, DOI 10.1210/en.2003-0709; Mallikarjuna G, 2004, CANCER RES, V64, P6349, DOI 10.1158/0008-5472.CAN-04-1632; Manson MM, 2000, TOXICOL LETT, V112, P499, DOI 10.1016/S0378-4274(99)00211-8; Mohan S, 2004, BIOCHEM BIOPH RES CO, V320, P183, DOI 10.1016/j.bbrc.2004.05.153; Qin JZ, 2002, ONCOGENE, V21, P2991, DOI 10.1038/sj.onc.1205404; Rul W, 2002, ANN NY ACAD SCI, V973, P145, DOI 10.1111/j.1749-6632.2002.tb04624.x; Sarkaria JN, 1999, CANCER RES, V59, P4375; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; She QB, 2001, CANCER RES, V61, P1604; Singh RP, 2002, CARCINOGENESIS, V23, P499, DOI 10.1093/carcin/23.3.499; Singh RP, 2002, ANTIOXID REDOX SIGN, V4, P655, DOI 10.1089/15230860260220166; Sinha R, 2004, CURR CANCER DRUG TAR, V4, P13, DOI 10.2174/1568009043481614; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sodhi A, 2003, IMMUNOL LETT, V90, P123, DOI 10.1016/j.imlet.2003.08.008; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Suzukawa K, 2002, ENVIRON HEALTH PERSP, V110, P865, DOI 10.1289/ehp.02110865; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Whittaker S, 1996, BRIT J HOSP MED, V56, P515; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Xiao D, 2002, CANCER RES, V62, P3615; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Zhang Z, 2002, CHEM RES TOXICOL, V15, P950, DOI 10.1021/tx0255018; Zhao JF, 1999, MOL CARCINOGEN, V26, P321, DOI 10.1002/(SICI)1098-2744(199912)26:4<321::AID-MC11>3.3.CO;2-0; Zhao JF, 1999, CARCINOGENESIS, V20, P2101, DOI 10.1093/carcin/20.11.2101	57	59	60	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20375	20383		10.1074/jbc.M414640200	http://dx.doi.org/10.1074/jbc.M414640200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15792956	hybrid			2022-12-27	WOS:000229242000028
J	Mishra, V; Bilgrami, S; Sharma, RS; Kaur, P; Yadav, S; Krauspenhaar, R; Betzel, C; Voelter, W; Babu, CR; Singh, TP				Mishra, V; Bilgrami, S; Sharma, RS; Kaur, P; Yadav, S; Krauspenhaar, R; Betzel, C; Voelter, W; Babu, CR; Singh, TP			Crystal structure of Himalayan mistletoe ribosome-inactivating protein reveals the presence of a natural inhibitor and a new functionally active sugar-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN A-CHAIN; POKEWEED ANTIVIRAL PROTEIN; RNA N-GLYCOSIDASE; VISCUM-ALBUM; B-CHAIN; SUBSTRATE-ANALOGS; GALACTOSE-BINDING; LECTIN-I; MECHANISM; IDENTIFICATION	Ribosome-inactivating proteins (RIPs) are toxins involved in plant defense. How the plant prevents autotoxicity is not yet fully understood. The present study is the first structural evidence of a naturally inhibited form of RIP from a plant. Himalayan mistletoe RIP (HmRIP) was purified from Viscum album leaves and crystallized with lactose. The structure was determined by the molecular replacement method and refined at 2.8-angstrom resolution. The crystal structure revealed the presence of high quality non-protein electron density at the active site, into which a pteridine derivative (2-amino 4-isopropyl 6-carboxyl pteridine) was modeled. The carboxyl group of the ligand binds strongly with the key active site residue Arg(162), nullifies the positive charge required for catalysis, and thereby acts as a natural inhibitor. Lectin subunits of RIPs have two active sugar-binding sites present in 1 alpha- and 2 gamma-subdomains. A third functionally active site has been identified in the 1 beta-subdomain of HmRIP. The 1 beta-site is active despite the absence of conserved polar sugar-binding residues. Loss of these residues is compensated by the following: (i) the presence of an extended site where the penultimate sugar also interacts with the protein; (ii) the interactions of galactose with the protein main chain carbonyl and amide nitrogen atoms; (iii) the presence of a well defined pocket encircled by four walls; and (iv) a favorable stacking of the galactose ring with Tyr(66) besides the conserved Phe(75). The mode of sugar binding is also distinct at the 1 alpha and 2 gamma sugar-binding sites.	All India Inst Med Sci, Dept Biophys, New Delhi 110029, India; Univ Delhi, Dept Bot, Delhi 100007, India; Univ Delhi, Ctr Environm Management Degraded Ecosyst, Sch Environm Sci, Delhi 100007, India; Inst Med Biochem & Mol Biol, D-22603 Hamburg, Germany; Univ Tubingen, Inst Physiol Chem, D-72076 Tubingen, Germany	All India Institute of Medical Sciences (AIIMS) New Delhi; University of Delhi; University of Delhi; Eberhard Karls University of Tubingen	Singh, TP (corresponding author), All India Inst Med Sci, Dept Biophys, New Delhi 110029, India.	tps@aiims.aiims.ac.in	Betzel, Christian/G-8105-2018	Betzel, Christian/0000-0002-3879-5019				Bagga S, 2003, J BIOL CHEM, V278, P4813, DOI 10.1074/jbc.M207389200; Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518; Bolognesi A, 2004, MINI-REV MED CHEM, V4, P563, DOI 10.2174/1389557043403864; Bussing A., 2000, MISTLETOE GENUS VISC; Day PJ, 1996, BIOCHEMISTRY-US, V35, P11098, DOI 10.1021/bi960880n; Desvoyes B, 1997, FEBS LETT, V410, P303, DOI 10.1016/S0014-5793(97)00648-0; Elhaggar S, 1993, Arch AIDS Res, V7, P120; ELPIDINA EN, 1991, PLANTA, V185, P46, DOI 10.1007/BF00194513; ENDO Y, 1988, J BIOL CHEM, V263, P8735; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Frankel A, 1996, PROTEIN ENG, V9, P371, DOI 10.1093/protein/9.4.371; Frigerio L, 1998, J EXP BOT, V49, P1473, DOI 10.1093/jexbot/49.326.1473; Gabius H.-J., 1991, LECTINS CANC; Gu YJ, 2000, PROTEINS, V39, P37, DOI 10.1002/(SICI)1097-0134(20000401)39:1<37::AID-PROT4>3.3.CO;2-7; HAJTO T, 1989, CANCER RES, V49, P4803; HARLEY SM, 1982, P NATL ACAD SCI-BIOL, V79, P5935, DOI 10.1073/pnas.79.19.5935; HARTLEY MR, 1996, TRENDS PLANT SCI, V1, P260; Heiny BM, 1998, ANTICANCER RES, V18, P583; HOUSTON LL, 1982, J BIOL CHEM, V257, P4147; HUANG QC, 1995, BIOCHEM J, V309, P285, DOI 10.1042/bj3090285; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kovacs E, 2000, BIOMED PHARMACOTHER, V54, P305, DOI 10.1016/S0753-3322(00)80052-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krauspenhaar R, 1999, BIOCHEM BIOPH RES CO, V257, P418, DOI 10.1006/bbrc.1999.0470; Kurinov IV, 1999, PROTEIN SCI, V8, P1765, DOI 10.1110/ps.8.9.1765; Lam SK, 2001, ARCH BIOCHEM BIOPHYS, V393, P271, DOI 10.1006/abbi.2001.2506; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE RT, 1994, CARBOHYD RES, V254, P269, DOI 10.1016/0008-6215(94)84259-0; LEE RT, 1992, J BIOL CHEM, V267, P23722; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mishra V, 2005, PLANT SCI, V168, P615, DOI 10.1016/j.plantsci.2004.09.024; Mishra V, 2004, ACTA CRYSTALLOGR D, V60, P2295, DOI 10.1107/S0907444904023534; Mishra V, 2004, ARCH BIOCHEM BIOPHYS, V423, P288, DOI 10.1016/j.abb.2003.12.033; MISHRA V, 1908, THESIS U DELHI DELHI; MONZINGO AF, 1992, J MOL BIOL, V227, P1136, DOI 10.1016/0022-2836(92)90526-P; Motto M, 2004, MINI-REV MED CHEM, V4, P493, DOI 10.2174/1389557043403873; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nielsen K, 2001, ANNU REV PLANT PHYS, V52, P785, DOI 10.1146/annurev.arplant.52.1.785; Niwa H, 2003, EUR J BIOCHEM, V270, P2739, DOI 10.1046/j.1432-1033.2003.03646.x; Oettl K, 1999, BBA-PROTEIN STRUCT M, V1430, P387, DOI 10.1016/S0167-4838(99)00023-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parikh BA, 2004, MINI-REV MED CHEM, V4, P523, DOI 10.2174/1389557043403800; Park SW, 2002, PLANTA, V216, P227, DOI 10.1007/s00425-002-0851-0; Park SW, 2004, PLANTA, V219, P1093, DOI 10.1007/s00425-004-1357-8; Pascal JM, 2001, PROTEINS, V43, P319, DOI 10.1002/prot.1043; Peumans WJ, 2001, FASEB J, V15, P1493, DOI 10.1096/fj.00-0751rev; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; READY MP, 1991, PROTEINS, V10, P270, DOI 10.1002/prot.340100311; REINBOTHE S, 1994, P NATL ACAD SCI USA, V91, P7012, DOI 10.1073/pnas.91.15.7012; REN JS, 1994, STRUCTURE, V2, P7, DOI 10.1016/S0969-2126(00)00004-6; Robertus JD, 1996, TOXICON, V34, P1325, DOI 10.1016/S0041-0101(96)00103-1; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; RUTENBER E, 1991, PROTEINS, V10, P241; Schlick JL, 1999, PLANT SCI, V140, P1, DOI 10.1016/S0168-9452(98)00208-8; Steeves RM, 1999, BIOCHEMISTRY-US, V38, P11677, DOI 10.1021/bi990493o; TAHIROV TH, 1995, J MOL BIOL, V250, P354, DOI 10.1006/jmbi.1995.0382; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Yan XJ, 1998, PROTEINS, V31, P33, DOI 10.1002/(SICI)1097-0134(19980401)31:1<33::AID-PROT4>3.0.CO;2-I; Yan XJ, 1997, J MOL BIOL, V266, P1043, DOI 10.1006/jmbi.1996.0865; YOULE RJ, 1981, CELL, V23, P551, DOI 10.1016/0092-8674(81)90151-3; ZISKA P, 1993, LECTINS BIOL BIOCH C, V8, P10	64	27	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20712	20721		10.1074/jbc.M500735200	http://dx.doi.org/10.1074/jbc.M500735200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15774467	hybrid			2022-12-27	WOS:000229242000069
J	Timchenko, NA; Wang, GL; Timchenko, LT				Timchenko, NA; Wang, GL; Timchenko, LT			RNA CUG-binding protein 1 increases translation of 20-kDa isoform of CCAAT/enhancer-binding protein beta by interacting with the alpha and beta subunits of eukaryotic initiation translation factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL INHIBITORY PROTEIN; C/EBP-ALPHA; MESSENGER-RNA; CALRETICULIN; LIVER; ACTIVATION; EXPRESSION; PROLIFERATION; REGION; MICE	Expression of a dominant negative 20-kDa isoform of CCAAT/enhancer-binding protein (C/EBP beta), LIP, is increased in proliferating livers and in tumor cells. Two RNA-binding proteins, CUGBP1 and calreticulin, have been implicated in the translational regulation of C/EBP beta. In this paper, we present evidence showing several critical steps by which liver increases translation of LIP after partial hepatectomy. At early stages after partial hepatectomy, liver activates CUGBP1 by a hyperphosphorylation. The activated CUGBP1 binds to the 5' region of C/EBP beta mRNA and replaces calreticulin, which partially represses translation of C/EBP beta in quiescent livers. The hyperphosphorylated CUGBP1 also interacts with the alpha and beta subunits of initiation factor eIF2. Our data demonstrate that the interaction of CUGBP1 with the eIF2 alpha enhances the association of CUGBP1 with ribosomes and correlates with increased translation of LIP in the liver after partial hepatectomy. Our data support the hypothesis that CUGBP1 increases translation of LIP by the interaction with the eIF2 alpha subunit. This facilitates subsequent recruitment of larger numbers of ribosomes to initiate translation of LIP.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Huffington Ctr Aging, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Huffington Ctr Aging, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Timchenko, LT (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.	lubovt@bcm.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA100070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049222, R01AR044387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG020752] Funding Source: NIH RePORTER; NCI NIH HHS [CA100070, R01 CA100070] Funding Source: Medline; NIAMS NIH HHS [AR49222, AR44387] Funding Source: Medline; NIA NIH HHS [AG20752] Funding Source: Medline; NIGMS NIH HHS [GM55188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An MR, 1996, MOL CELL BIOL, V16, P2295; ATREYA CD, 1995, J VIROL, V69, P3848, DOI 10.1128/JVI.69.6.3848-3851.1995; CALKHOVEN CF, 1994, NUCLEIC ACIDS RES, V22, P5540, DOI 10.1093/nar/22.25.5540; Calkhoven CF, 2000, GENE DEV, V14, P1920; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; Helbling D, 2004, P NATL ACAD SCI USA, V101, P13312, DOI 10.1073/pnas.0404731101; Iakova P, 2004, EMBO J, V23, P406, DOI 10.1038/sj.emboj.7600052; Iakova P, 2003, CELL, V113, P495, DOI 10.1016/S0092-8674(03)00318-0; Kimball SR, 1999, INT J BIOCHEM CELL B, V31, P25, DOI 10.1016/S1357-2725(98)00128-9; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Luedde T, 2004, HEPATOLOGY, V40, P356, DOI 10.1002/hep.20333; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Pugachev KV, 1998, J VIROL, V72, P641, DOI 10.1128/JVI.72.1.641-650.1998; Raught B, 1996, CANCER RES, V56, P4382; Shi YG, 2003, ENDOCR REV, V24, P91, DOI 10.1210/er.2002-0018; Shim M, 2003, J BIOL CHEM, V278, P19674, DOI 10.1074/jbc.M301356200; SINGH NK, 1994, P NATL ACAD SCI USA, V91, P12770, DOI 10.1073/pnas.91.26.12770; Timchenko LT, 2002, MOL CELL BIOL, V22, P7242, DOI 10.1128/MCB.22.20.7242-7257.2002; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Timchenko NA, 2004, J BIOL CHEM, V279, P13129, DOI 10.1074/jbc.M312923200; Timchenko NA, 2001, J BIOL CHEM, V276, P7820, DOI 10.1074/jbc.M005960200; Timchenko NA, 2001, MOL CELL BIOL, V21, P6927, DOI 10.1128/MCB.21.20.6927-6938.2001; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; Welm AL, 1999, MOL CELL BIOL, V19, P1695; Welm AL, 2000, J BIOL CHEM, V275, P27406; Zahnow CA, 2001, CANCER RES, V61, P261	35	69	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20549	20557		10.1074/jbc.M409563200	http://dx.doi.org/10.1074/jbc.M409563200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788409	hybrid			2022-12-27	WOS:000229242000049
J	Kumar, S; Chen, CS; Waxman, DJ; Halpert, JR				Kumar, S; Chen, CS; Waxman, DJ; Halpert, JR			Directed evolution of mammalian cytochrome P4502B1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; LABORATORY EVOLUTION; ENZYMES; MUTAGENESIS; ACTIVATION; RESIDUES; MUTANTS; CYCLOPHOSPHAMIDE; IDENTIFICATION; AGGREGATION	Cytochrome P450 2B1 has been subjected to directed evolution to investigate the role of amino acid residues outside of the active site and to engineer novel, more active P450 catalysts. A high throughput screening system was developed to measure H2O2-supported oxidation of the marker fluorogenic substrate 7-ethoxy-4-trifluoromethylcoumarin (7-EFC). Random mutagenesis by error-prone polymerase chain reaction and activity screening were optimized using the L209A mutant of P450 2B1 in an N-terminally modified construct with a C-terminal His tag (P450 2B1dH). Two rounds of mutagenesis and screening and one subcloning step yielded the P450 2B1 quadruple mutant V183L/F202L/L209A/S334P, which demonstrated a 6-fold higher k(cat) than L209A. Further random or site-directed mutagenesis did not improve the activity. When assayed in an NADPH-supported reconstituted system, V183L/L209A demonstrated lower 7-EFC oxidation than L209A. Therefore, F202L/L209A/S334P was generated, which showed a 2.5-fold higher k(cat)/K-m for NADPH-dependent 7-EFC oxidation than L209A. F202L/L209A/S334P also showed enhanced catalytic efficiency with 7-benzyloxyresorufin, benzphetamine, and testosterone, and a 10-fold increase in stereoselectivity for testosterone 16 alpha- versus 16 beta-hydroxylation compared with 2B1dH. Enhanced catalytic efficiency of F202L/L209A/S334P was also retained in the full-length P450 2B1 background with 7-EFC and testosterone as substrates. Finally, the individual mutants were tested for metabolism of the anti-cancer prodrugs cyclophosphamide and ifosfamide. Several of the mutants showed increased metabolism via the therapeutically beneficial 4-hydroxylation pathway, with L209A/S334P showing 2.8-fold enhancement of k(cat)/K-m with cyclophosphamide and V183L/L209A showing 3.5-fold enhancement with ifosfamide. Directed evolution can thus be used to enhance P450 2B1 catalytic efficiency across a panel of substrates and to identify functionally important residues distant from the active site.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Boston Univ, Dept Biol, Boston, MA 02215 USA	University of Texas System; University of Texas Medical Branch Galveston; Boston University	Kumar, S (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, 301 Univ Blvd, Galveston, TX 77555 USA.	sakumar@utmb.edu		Waxman, David/0000-0001-7982-9206	NATIONAL CANCER INSTITUTE [R01CA049248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, P42ES007381, R01ES003619] Funding Source: NIH RePORTER; NCI NIH HHS [CA49248] Funding Source: Medline; NIEHS NIH HHS [ES03619, ES06676, 5 P42 ES07381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CHANG TKH, 1993, CANCER RES, V53, P5629; Chen CS, 2004, MOL PHARMACOL, V65, P1278, DOI 10.1124/mol.65.5.1278; Chen L, 2002, CURR PHARM DESIGN, V8, P1405, DOI 10.2174/1381612023394566; Cherry JR, 2003, CURR OPIN BIOTECH, V14, P438, DOI 10.1016/S0958-1669(03)00099-5; Cirino Patrick C, 2003, Methods Mol Biol, V231, P3; Cosme J, 2000, J BIOL CHEM, V275, P2545, DOI 10.1074/jbc.275.4.2545; Domanski TL, 2001, CURR DRUG METAB, V2, P117, DOI 10.2174/1389200013338612; Farinas ET, 2001, ADV SYNTH CATAL, V343, P601, DOI 10.1002/1615-4169(200108)343:6/7<601::AID-ADSC601>3.0.CO;2-9; Glieder A, 2002, NAT BIOTECHNOL, V20, P1135, DOI 10.1038/nbt744; Harlow GR, 1997, BBA-PROTEIN STRUCT M, V1338, P259, DOI 10.1016/S0167-4838(96)00209-9; He YQ, 1996, ARCH BIOCHEM BIOPHYS, V335, P152, DOI 10.1006/abbi.1996.0493; Hilser V J, 2001, Methods Mol Biol, V168, P93; Hilser VJ, 1998, P NATL ACAD SCI USA, V95, P9903, DOI 10.1073/pnas.95.17.9903; Hult K, 2003, CURR OPIN BIOTECH, V14, P395, DOI 10.1016/S0958-1669(03)00095-8; Joo H, 1999, NATURE, V399, P670, DOI 10.1038/21395; Jounaidi Y, 2004, CANCER RES, V64, P292, DOI 10.1158/0008-5472.CAN-03-1798; Khan KK, 2002, CHEM RES TOXICOL, V15, P806, DOI 10.1021/tx0200010; Kim D, 2004, BIOCHEMISTRY-US, V43, P981, DOI 10.1021/bi035593f; Kim D, 2004, ARCH BIOCHEM BIOPHYS, V432, P102, DOI 10.1016/j.abb.2004.09.001; Kirk O, 2002, CURR OPIN BIOTECH, V13, P345, DOI 10.1016/S0958-1669(02)00328-2; Kumar S, 2003, J BIOL CHEM, V278, P17178, DOI 10.1074/jbc.M212515200; Salazar Oriana, 2003, V230, P85; Schmid A, 2001, NATURE, V409, P258, DOI 10.1038/35051736; Schoemaker HE, 2003, SCIENCE, V299, P1694, DOI 10.1126/science.1079237; Scott EE, 2004, ARCH BIOCHEM BIOPHYS, V423, P266, DOI 10.1016/j.abb.2003.12.035; Scott EE, 2001, ARCH BIOCHEM BIOPHYS, V395, P57, DOI 10.1006/abbi.2001.2574; Scott EE, 2002, CHEM RES TOXICOL, V15, P1407, DOI 10.1021/tx020057u; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; Scott EE, 2004, J BIOL CHEM, V279, P27294, DOI 10.1074/jbc.M403349200; Spatzenegger M, 2001, MOL PHARMACOL, V59, P475, DOI 10.1124/mol.59.3.475; Strobel SM, 1997, BIOCHEMISTRY-US, V36, P11697, DOI 10.1021/bi9710176; Tobias Alexander V, 2003, Methods Mol Biol, V231, P11; Turner NJ, 2003, TRENDS BIOTECHNOL, V21, P474, DOI 10.1016/j.tibtech.2003.09.001; Waller SC, 1999, CHEM RES TOXICOL, V12, P690, DOI 10.1021/tx990030j; Williams D, 2000, PERFORM RES, V5, P131; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200	37	78	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19569	19575		10.1074/jbc.M500158200	http://dx.doi.org/10.1074/jbc.M500158200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774478	hybrid			2022-12-27	WOS:000229113700019
J	Lu, D; Zhang, HF; Koo, H; Tonra, J; Balderes, P; Prewett, M; Corcoran, E; Mangalampalli, V; Bassi, R; Anselma, D; Patel, D; Kang, XQ; Ludwig, DL; Hicklin, DJ; Bohlen, P; Witte, L; Zhu, ZP				Lu, D; Zhang, HF; Koo, H; Tonra, J; Balderes, P; Prewett, M; Corcoran, E; Mangalampalli, V; Bassi, R; Anselma, D; Patel, D; Kang, XQ; Ludwig, DL; Hicklin, DJ; Bohlen, P; Witte, L; Zhu, ZP			A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; BREAST-CANCER CELLS; MONOCLONAL-ANTIBODY; SIGNALING PATHWAYS; COLORECTAL-CANCER; EGF RECEPTOR; COLON-CANCER; THERAPY; DESIGN; CHEMOTHERAPY	Both the epidermal growth factor receptor ( EGFR) and the insulin-like growth factor receptor (IGFR) have been implicated in the tumorigenesis of a variety of cancers. Here we propose that simultaneous targeting of both receptors with a bispecific antibody would lead to enhanced antitumor activity. To this end, we produced a recombinant human IgG-like bispecific antibody, a Di-diabody, using the variable regions from two antagonistic antibodies: IMC-11F8 to EGFR and IMC-A12 to IGFR. The Di-diabody binds to both EGFR and IGFR and effectively blocked both EGF- and IGF-stimulated receptor activation and tumor cell proliferation. The Di-diabody also inherited the biological properties from both of its parent antibodies; it triggers rapid and significant IGFR internalization and degradation and mediates effective antibody-dependent cellular cytotoxicity in a variety of tumor cells. Finally, the Di-diabody strongly inhibited the growth of two different human tumor xenografts in vivo. Our results underscore the benefits of simultaneous targeting of two tumor targets with bispecific antibodies.	ImClone Syst Inc, Dept Antibody Technol, New York, NY 10014 USA; ImClone Syst Inc, Dept Mol & Cell Biol, New York, NY 10014 USA; ImClone Syst Inc, Dept Expt Therapeut, New York, NY 10014 USA; ImClone Syst Inc, Dept Prot Sci, New York, NY 10014 USA; ImClone Syst Inc, Res Dept, New York, NY 10014 USA	Eli Lilly; Eli Lilly; Eli Lilly; Eli Lilly; Eli Lilly	Zhu, ZP (corresponding author), ImClone Syst Inc, Dept Antibody Technol, 180 Varick St, New York, NY 10014 USA.	Zhenping@imclone.com						Alt M, 1999, FEBS LETT, V454, P90, DOI 10.1016/S0014-5793(99)00782-6; Arteaga C, 2003, SEMIN ONCOL, V30, P3, DOI 10.1016/S0093-7754(03)00185-4; Arteaga CL, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.35642; Baselga J, 2001, ONCOLOGY-BASEL, V61, P14, DOI 10.1159/000055397; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Benini S, 2001, CLIN CANCER RES, V7, P1790; Bonner JA, 2004, J CLIN ONCOL, V22, p489S; Boylan M, 1998, ANN ONCOL, V9, P205, DOI 10.1023/A:1008241804078; Burtrum D, 2003, CANCER RES, V63, P8912; Cao Y, 2003, ADV DRUG DELIVER REV, V55, P171, DOI 10.1016/S0169-409X(02)00178-3; Carter P, 1995, J Hematother, V4, P463, DOI 10.1089/scd.1.1995.4.463; Carter P, 2001, J IMMUNOL METHODS, V248, P7, DOI 10.1016/S0022-1759(00)00339-2; Chakravarti A, 2002, CANCER RES, V62, P200; Clark AS, 2002, MOL CANCER THER, V1, P707; Coloma MJ, 1997, NAT BIOTECHNOL, V15, P159, DOI 10.1038/nbt0297-159; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Khalil Mazen Y, 2003, Expert Rev Anticancer Ther, V3, P367, DOI 10.1586/14737140.3.3.367; Kufer P, 2004, TRENDS BIOTECHNOL, V22, P238, DOI 10.1016/j.tibtech.2004.03.006; Lee CT, 1996, CANCER RES, V56, P3038; Lenz HJ, 2004, J CLIN ONCOL, V22, p247S; Lu D, 2004, J BIOL CHEM, V279, P2856, DOI 10.1074/jbc.M310132200; Lu D, 2004, BIOCHEM BIOPH RES CO, V318, P507, DOI 10.1016/j.bbrc.2004.04.060; Lu D, 2003, J BIOL CHEM, V278, P43496, DOI 10.1074/jbc.M307742200; Lu D, 2003, J IMMUNOL METHODS, V279, P219, DOI 10.1016/S0022-1759(03)00251-5; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Mendelsohn J, 2003, CANCER IMMUNOL IMMUN, V52, P342, DOI 10.1007/s00262-002-0354-7; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Merchant AM, 1998, NAT BIOTECHNOL, V16, P677, DOI 10.1038/nbt0798-677; Perer ES, 2000, J SURG RES, V94, P1, DOI 10.1006/jsre.2000.5923; Pluckthun A, 1997, IMMUNOTECHNOLOGY, V3, P83, DOI 10.1016/S1380-2933(97)00067-5; Prewett M, 2004, P AM ASS CANC RES, V45; Reinmuth N, 2002, CLIN CANCER RES, V8, P3259; Ross JS, 2003, AM J CLIN PATHOL, V119, P472, DOI 10.1309/Y6LPC0LR726L9DX9; RUBIN R, 1995, LAB INVEST, V73, P311; Sachdev D, 2003, CANCER RES, V63, P627; Todorovska A, 2001, J IMMUNOL METHODS, V248, P47, DOI 10.1016/S0022-1759(00)00342-2; Turner BC, 1997, CANCER RES, V57, P3079; van Spriel AB, 2000, IMMUNOL TODAY, V21, P391, DOI 10.1016/S0167-5699(00)01659-5; vandenBerg HW, 1996, BRIT J CANCER, V73, P477, DOI 10.1038/bjc.1996.84; Waksal HW, 1999, CANCER METAST REV, V18, P427, DOI 10.1023/A:1006302101468; Wang YL, 2002, CURR CANCER DRUG TAR, V2, P191, DOI 10.2174/1568009023333863; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; Yarden Y, 2001, EUR J CANCER, V37, pS3; ZHU ZP, 1995, INT J CANCER, V62, P319, DOI 10.1002/ijc.2910620315; Zhu ZP, 1997, PROTEIN SCI, V6, P781; ZHUANG Z, 2000, PROTEIN ENG, V13, P361; Zia F, 1996, J CELL BIOCHEM, P269	51	153	284	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19665	19672		10.1074/jbc.M500815200	http://dx.doi.org/10.1074/jbc.M500815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15757893	hybrid			2022-12-27	WOS:000229113700031
J	Riewald, M; Ruf, W				Riewald, M; Ruf, W			Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BRAIN ENDOTHELIUM; FACTOR XA; APOPTOSIS; P53; COAGULATION; PAR2; IDENTIFICATION; ANGIOGENESIS; INFLAMMATION; MECHANISMS	Activated protein C (APC) has anti-inflammatory and vascular protective effects independent of anticoagulation. We previously identified the prototypical thrombin receptor, protease-activated receptor-1 (PAR1), as part of a novel APC-endothelial cell protein C receptor ( EPCR) signaling pathway in endothelial cells. Experiments in wild-type and PAR1(-/-) mice demonstrated that intravenous injection of APC leads to PAR1-dependent gene induction in the lung. The vascular endothelium undergoes profound changes in severe sepsis, the approved therapeutic indication for APC. Similar to PAR1, APC activated PAR2 through canonical cleavage. Although PAR2 was up-regulated in cytokine-stimulated endothelial cells, APC signaling remained PAR1-dependent. Large scale gene expression profiling documented marked differences in both up- and down-regulated genes between APC and thrombin signaling in cytokine-stimulated cells. APC down-regulated transcripts for proapoptotic proteins including p53 and thrombospondin-1, but p53 was unchanged, and thrombospondin was even upregulated by thrombin. Concordant PAR1-dependent effects on protein levels were found. Thus, by signaling through the same receptor PAR1, APC, and thrombin can exert distinct biological effects in perturbed endothelium. These data may explain how APC can be therapeutically protective through the EPCR-PAR1 signaling despite ongoing thrombin generation due to disseminated intravascular coagulopathy.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Riewald, M (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd,VB-4, La Jolla, CA 92037 USA.	riewald@scripps.edu			NHLBI NIH HHS [HL 48752, HL 78614] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048752, R01HL078614] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bono F, 2000, ARTERIOSCL THROM VAS, V20, pE107, DOI 10.1161/01.ATV.20.11.e107; Camerer E, 2002, J BIOL CHEM, V277, P16081, DOI 10.1074/jbc.M108555200; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Cohen DM, 1996, J BIOL CHEM, V271, P12903, DOI 10.1074/jbc.271.22.12903; Compton SJ, 2001, BRIT J PHARMACOL, V134, P705, DOI 10.1038/sj.bjp.0704303; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Cunningham MA, 2000, J EXP MED, V191, P455, DOI 10.1084/jem.191.3.455; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; Darrow AL, 1996, THROMB HAEMOSTASIS, V76, P860; Domotor E, 2003, BLOOD, V101, P4797, DOI 10.1182/blood-2002-12-3680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Esmon CT, 1999, THROMB HAEMOSTASIS, V82, P251; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Esmon CT, 2001, THROMB HAEMOSTASIS, V86, P51; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; Fernandez JA, 2003, BLOOD CELL MOL DIS, V30, P271, DOI 10.1016/S1079-9796(03)00034-2; Franscini N, 2004, CIRCULATION, V110, P2903, DOI 10.1161/01.CIR.0000146344.49689.BB; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; Hotchkiss RS, 2002, CRIT CARE MED, V30, pS225, DOI 10.1097/00003246-200205001-00009; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Kataoka H, 2003, BLOOD, V102, P3224, DOI 10.1182/blood-2003-04-1130; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; Liaw PCY, 2001, J BIOL CHEM, V276, P8364, DOI 10.1074/jbc.M010572200; Mosnier LO, 2004, BLOOD, V104, P1740, DOI 10.1182/blood-2004-01-0110; Mosnier LO, 2003, BIOCHEM J, V373, P65, DOI 10.1042/BJ20030341; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pawlinski R, 2004, BLOOD, V103, P1342, DOI 10.1182/blood-2003-09-3051; Perez-Casal M, 2005, BLOOD, V105, P1515, DOI 10.1182/blood-2004-05-1896; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698; Riewald M, 2001, BLOOD, V97, P3109, DOI 10.1182/blood.V97.10.3109; Shi XL, 2004, MOL CANCER RES, V2, P395; Uchiba M, 2004, CIRC RES, V95, P34, DOI 10.1161/01.RES.0000133680.87668.FA; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; Xu J, 1999, THROMB HAEMOSTASIS, P695; Ye XF, 1999, BIOCHEM BIOPH RES CO, V259, P671, DOI 10.1006/bbrc.1999.0846; Yoon H, 2002, P NATL ACAD SCI USA, V99, P15632, DOI 10.1073/pnas.242597299; Zhang HC, 2001, J MED CHEM, V44, P1021, DOI 10.1021/jm000506s	46	171	184	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19808	19814		10.1074/jbc.M500747200	http://dx.doi.org/10.1074/jbc.M500747200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769747	hybrid			2022-12-27	WOS:000229113700047
J	Salaun, C; Gould, GW; Chamberlain, LH				Salaun, C; Gould, GW; Chamberlain, LH			Lipid raft association of SNARE proteins regulates exocytosis in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM NEUROTOXIN E; MEMBRANE-FUSION; PLASMA-MEMBRANE; GLUT4 TRANSLOCATION; SNAP-25; VESICLE; PALMITOYLATION	SNAP25 and SNAP23 are plasma membrane SNARE proteins essential for regulated exocytosis in diverse cell types. Several recent studies have shown that these proteins are partly localized in lipid rafts, domains of the plasma membrane enriched in sphingolipids, and cholesterol. Here, we have employed cysteine mutants of SNAP25/SNAP23, which have modified affinities for raft domains, to examine whether raft association of these proteins is important for the regulation of exocytosis. PC12 cells were engineered that express the light chain of botulinum neurotoxin; in these cells all of the SNAP25 was cleaved to a lower molecular weight form, and regulated exocytosis was essentially absent. Exocytosis was rescued by expressing toxin-resistant SNAP25 or wildtype SNAP23, which is naturally toxin-resistant. Remarkably, a mutant SNAP25 protein with an increased affinity for rafts displayed a reduced ability to support exocytosis, whereas SNAP23 mutants with a decreased affinity for rafts displayed an enhancement of exocytosis when compared with wild-type SNAP23. The effects of the mutant proteins on exocytosis were dependent upon the integrity of the plasma membrane and lipid rafts. These results provide the first direct evidence that rafts regulate SNARE function and exocytosis and identify the central cysteine-rich region of SNAP25/23 as an important regulatory domain.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Henry Wellcome Lab Cell Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Chamberlain, LH (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Henry Wellcome Lab Cell Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	l.chamberlain@bio.gla.ac.uk	Taylor, Graham/A-4027-2012; Gould, Gwyn/AAF-6721-2019	Gould, Gwyn/0000-0001-6571-2875; Salaun, Christine/0000-0003-3002-6810	Biotechnology and Biological Sciences Research Council [C16435] Funding Source: Medline; Wellcome Trust [070835] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Bark C, 2004, J NEUROSCI, V24, P8796, DOI 10.1523/JNEUROSCI.1940-04.2004; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Chamberlain LH, 2004, FEBS LETT, V559, P1, DOI 10.1016/S0014-5793(04)00050-X; Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; Gonzalo S, 1999, J BIOL CHEM, V274, P21313, DOI 10.1074/jbc.274.30.21313; Graham ME, 2000, BIOCHIMIE, V82, P469, DOI 10.1016/S0300-9084(00)00196-6; Graham ME, 2002, ANN NY ACAD SCI, V971, P210, DOI 10.1111/j.1749-6632.2002.tb04465.x; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Koticha DK, 2002, J CELL SCI, V115, P3341; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Liu P, 2004, AM J PHYSIOL-CELL PH, V286, pC317, DOI 10.1152/ajpcell.00073.2003; Macaulay SL, 1997, BIOCHEM BIOPH RES CO, V237, P388, DOI 10.1006/bbrc.1997.7143; Pombo I, 2003, FEBS LETT, V550, P144, DOI 10.1016/S0014-5793(03)00864-0; Sadoul K, 1997, J BIOL CHEM, V272, P33023, DOI 10.1074/jbc.272.52.33023; Salaun C, 2004, TRAFFIC, V5, P255, DOI 10.1111/j.1600-0854.2004.0162.x; Salaun C, 2005, J BIOL CHEM, V280, P1236, DOI 10.1074/jbc.M410674200; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sorensen JB, 2003, CELL, V114, P75, DOI 10.1016/S0092-8674(03)00477-X; Taverna E, 2004, J BIOL CHEM, V279, P5127, DOI 10.1074/jbc.M308798200; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; Washbourne P, 1999, J NEUROCHEM, V73, P2424, DOI 10.1046/j.1471-4159.1999.0732424.x; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xia FZ, 2004, J BIOL CHEM, V279, P24685, DOI 10.1074/jbc.M314314200	32	106	108	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19449	19453		10.1074/jbc.M501923200	http://dx.doi.org/10.1074/jbc.M501923200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769746	Green Accepted, hybrid			2022-12-27	WOS:000229113700005
J	Gioia, U; Laneve, P; Dlakic, M; Arceci, M; Bozzoni, I; Caffarelli, E				Gioia, U; Laneve, P; Dlakic, M; Arceci, M; Bozzoni, I; Caffarelli, E			Functional characterization of XendoU, the endoribonuclease involved in small nucleolar RNA biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRON-ENCODED U16; XENOPUS-LAEVIS; DNA-REPAIR; SNORNA; RECOGNITION; CLEAVAGE; CLONING; MARKER; ENZYME	XendoU is the endoribonuclease involved in the biosynthesis of a specific subclass of Xenopus laevis intron-encoded small nucleolar RNAs. XendoU has no homology to any known cellular RNase, although it has sequence similarity with proteins tentatively annotated as serine proteases. It has been recently shown that XendoU represents the cellular counterpart of a nidovirus replicative endoribonuclease (NendoU), which plays a critical role in viral replication and transcription. In this paper, we combined prediction and experimental data to define the amino acid residues directly involved in XendoU catalysis. Specifically, we find that XendoU residues Glu-161, Glu-167, His-162, His-178, and Lys-224 are essential for RNA cleavage, which occurs in the presence of manganese ions. Furthermore, we identified the RNA sequence required for XendoU binding and showed that the formation of XendoU-RNA complex is Mn2+-independent.	Univ Roma La Sapienza, Dept Genet & Mol Biol, Fdn Cenci Bolognetti, Inst Pasteur, I-00185 Rome, Italy; CNR, Inst Mol Biol & Pathol, I-00185 Rome, Italy; Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA	Fondazione Cenci Bolognetti; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Montana State University System; Montana State University Bozeman	Caffarelli, E (corresponding author), Univ Roma La Sapienza, Dept Genet & Mol Biol, Inst Mol Biol & Pathol, Ple A Moro 5, I-00185 Rome, Italy.	elisa.caffarelli@uniroma1.it	Gioia, Ubaldo/O-1660-2014; Dlakic, Mensur/S-2702-2019; Gioia, Ubaldo/GZL-7436-2022; laneve, pietro/ABD-1633-2020; laneve, pietro/M-3386-2014	Gioia, Ubaldo/0000-0002-4993-5283; Dlakic, Mensur/0000-0003-4315-1514; Gioia, Ubaldo/0000-0002-4993-5283; bozzoni, irene/0000-0002-3485-8537; laneve, pietro/0000-0002-8865-4038	NCRR NIH HHS [P20 RR16455] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016455] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Caffarelli E, 1996, EMBO J, V15, P1121, DOI 10.1002/j.1460-2075.1996.tb00450.x; CAFFARELLI E, 1994, MOL CELL BIOL, V14, P2966, DOI 10.1128/MCB.14.5.2966; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; Dlakic M, 2000, TRENDS BIOCHEM SCI, V25, P272, DOI 10.1016/S0968-0004(00)01582-6; Edgar RC, 2004, BIOINFORMATICS, V20, P1309, DOI 10.1093/bioinformatics/bth091; Fatica A, 2004, RNA, V10, P1698, DOI 10.1261/rna.7123504; Filipowicz W, 2002, CURR OPIN CELL BIOL, V14, P319, DOI 10.1016/S0955-0674(02)00334-4; FRAGAPANE P, 1993, EMBO J, V12, P2921, DOI 10.1002/j.1460-2075.1993.tb05954.x; Giorgi C, 2001, EMBO J, V20, P6856, DOI 10.1093/emboj/20.23.6856; Goodstadt L, 2001, BIOINFORMATICS, V17, P845, DOI 10.1093/bioinformatics/17.9.845; GRUNDMANN U, 1990, DNA CELL BIOL, V9, P243, DOI 10.1089/dna.1990.9.243; Irie M, 1997, J BIOCHEM-TOKYO, V121, P849; Ivanov KA, 2004, P NATL ACAD SCI USA, V101, P12694, DOI 10.1073/pnas.0403127101; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Laneve P, 2003, J BIOL CHEM, V278, P13026, DOI 10.1074/jbc.M211937200; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Mol CD, 1999, ANNU REV BIOPH BIOM, V28, P101, DOI 10.1146/annurev.biophys.28.1.101; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; NISHIKAWA S, 1987, BIOCHEMISTRY-US, V26, P8620, DOI 10.1021/bi00400a019; PRISLEI S, 1995, GENE, V163, P221, DOI 10.1016/0378-1119(95)00344-6; Saida F, 2003, NUCLEIC ACIDS RES, V31, P2751, DOI 10.1093/nar/gkg377; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; STEYAERT J, 1990, BIOCHEMISTRY-US, V29, P9064, DOI 10.1021/bi00490a025; Suck D, 1997, BIOPOLYMERS, V44, P405, DOI 10.1002/(SICI)1097-0282(1997)44:4<405::AID-BIP5>3.0.CO;2-L; THOMPSON JE, 1994, BIOCHEMISTRY-US, V33, P7408, DOI 10.1021/bi00189a047; Tsujishita Y, 2001, CELL, V105, P379, DOI 10.1016/S0092-8674(01)00326-9	30	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18996	19002		10.1074/jbc.M501160200	http://dx.doi.org/10.1074/jbc.M501160200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755742	hybrid			2022-12-27	WOS:000228932300054
J	Roux, J; Kawakatsu, H; Gartland, B; Pespeni, M; Sheppard, D; Matthay, MA; Canessa, CM; Pittet, JF				Roux, J; Kawakatsu, H; Gartland, B; Pespeni, M; Sheppard, D; Matthay, MA; Canessa, CM; Pittet, JF			Interleukin-1 beta decreases expression of the epithelial sodium channel alpha-subunit in alveolar epithelial cells via a p38 MAPK-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS-SYNDROME; ACTIVATED PROTEIN-KINASE; SENSITIVE NA+ CHANNEL; LUNG LIQUID CLEARANCE; COLLECTING DUCT CELLS; NECROSIS-FACTOR-ALPHA; FLUID TRANSPORT; II CELLS; MESSENGER-RNA; IN-VITRO	Acute lung injury (ALI) is a devastating syndrome characterized by diffuse alveolar damage, elevated airspace levels of pro-inflammatory cytokines, and flooding of the alveolar spaces with protein-rich edema fluid. Interleukin-1 beta (IL-1 beta) is one of the most biologically active cytokines in the distal airspaces of patients with ALI. IL-1 beta has been shown to increase lung epithelial and endothelial permeability. In this study, we hypothesized that IL-1 beta would decrease vectorial ion and water transport across the distal lung epithelium. Therefore, we measured the effects of IL-1 beta on transepithelial current, resistance, and sodium transport in primary cultures of alveolar epithelial type II (ATII) cells. IL-1 beta significantly reduced the amiloride-sensitive fraction of the transepithelial current and sodium transport across rat ATII cell monolayers. Moreover, IL-1 beta decreased basal and dexamethasone-induced epithelial sodium channel alpha-subunit (alpha ENaC) mRNA levels and total and cell-surface protein expression. The inhibitory effect of IL-1 beta on alpha ENaC expression was mediated by the activation of p38 MAPK in both rat and human ATII cells and was independent of the activation of alpha v beta 6 integrin and transforming growth factor-beta. These results indicate that IL-1 beta may contribute to alveolar edema in ALI by reducing distal lung epithelial sodium absorption. This reduction in ion and water transport across the lung epithelium is in large part due to a decrease in alpha ENaC expression through p38 MAPK-dependent inhibition of alpha ENaC promoter activity and to an alteration in ENaC trafficking to the apical membrane of ATII cells.	Univ Calif San Francisco, Surg Res Lab, San Francisco, CA 94110 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94110 USA; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Yale University	Pittet, JF (corresponding author), San Francisco Gen Hosp, Dept Anesthesia, Rm 3C-38,1001 Potrero Ave, San Francisco, CA 94110 USA.	pittetj@anesthesia.ucsf.edu	Roux, Jeremie/A-9746-2013	Roux, Jeremie/0000-0001-5712-8660	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051854, P50HL074005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062188] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51854, P50HL074005] Funding Source: Medline; NIGMS NIH HHS [R01GM62188] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adir Y, 2003, AM J RESP CRIT CARE, V168, P1445, DOI 10.1164/rccm.200207-702OC; Baines DL, 2000, J PHYSIOL-LONDON, V522, P147, DOI 10.1111/j.1469-7793.2000.t01-2-00147.xm; Barker PM, 1998, J CLIN INVEST, V102, P1634, DOI 10.1172/JCI3971; Barmeyer C, 2004, BIOCHEM BIOPH RES CO, V317, P500, DOI 10.1016/j.bbrc.2004.03.072; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; Benito E, 1998, MOL CELL BIOCHEM, V189, P169, DOI 10.1023/A:1006997731607; Blazer-Yost BL, 1998, AM J PHYSIOL-CELL PH, V274, pC1373, DOI 10.1152/ajpcell.1998.274.5.C1373; BREUSS JM, 1995, J CELL SCI, V108, P2241; BREUSS JM, 1993, J HISTOCHEM CYTOCHEM, V41, P1521, DOI 10.1177/41.10.8245410; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Chen XJ, 2002, AM J PHYSIOL-LUNG C, V282, pL609, DOI 10.1152/ajplung.00356.2001; Cui CH, 2002, AM J RESP CELL MOL, V27, P329, DOI 10.1165/rcmb.4762; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Dagenais A, 2001, AM J PHYSIOL-LUNG C, V281, pL217, DOI 10.1152/ajplung.2001.281.1.L217; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; DOBBS LG, 1990, AM J PHYSIOL, V258, pL134, DOI 10.1152/ajplung.1990.258.4.L134; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; Fang XH, 2004, AM J PHYSIOL-LUNG C, V287, pL104, DOI 10.1152/ajplung.00176.2003; Frank J, 2003, J BIOL CHEM, V278, P43939, DOI 10.1074/jbc.M304882200; Furuichi S, 2002, RESPIROLOGY, V7, P193, DOI 10.1046/j.1440-1843.2002.00401.x; Galietta LJV, 2002, J IMMUNOL, V168, P839, DOI 10.4049/jimmunol.168.2.839; Geiser T, 2000, AM J PHYSIOL-LUNG C, V279, pL1184, DOI 10.1152/ajplung.2000.279.6.L1184; Gray T, 2004, AM J PHYSIOL-LUNG C, V286, pL320, DOI 10.1152/ajplung.00440.2002; Hashimoto S, 1999, AM J RESP CRIT CARE, V159, P634, DOI 10.1164/ajrccm.159.2.9712090; Huang XZ, 1998, J CELL SCI, V111, P2189; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Hybertson BM, 2000, INFLAMMATION, V24, P289, DOI 10.1023/A:1007092529261; Itani OA, 2003, AM J PHYSIOL-RENAL, V284, pF778, DOI 10.1152/ajprenal.00088.2002; Jain L, 2001, AM J PHYSIOL-LUNG C, V280, pL646, DOI 10.1152/ajplung.2001.280.4.L646; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Laffon M, 1999, AM J PHYSIOL-LUNG C, V277, pL760, DOI 10.1152/ajplung.1999.277.4.L760; Lee YM, 2000, AM J PHYSIOL-LUNG C, V279, pL75, DOI 10.1152/ajplung.2000.279.1.L75; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; Mairbaurl H, 1997, AM J PHYSIOL-LUNG C, V273, pL797, DOI 10.1152/ajplung.1997.273.4.L797; MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250; McDonald FJ, 1999, P NATL ACAD SCI USA, V96, P1727, DOI 10.1073/pnas.96.4.1727; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Norlin A, 1999, J PHYSIOL-LONDON, V519, P261, DOI 10.1111/j.1469-7793.1999.0261o.x; Olman MA, 2004, J IMMUNOL, V172, P2668, DOI 10.4049/jimmunol.172.4.2668; Otulakowski G, 1999, AM J RESP CELL MOL, V20, P1028, DOI 10.1165/ajrcmb.20.5.3382; Pittet JF, 2001, J CLIN INVEST, V107, P1537, DOI 10.1172/JCI11963; Pittet JF, 2001, J IMMUNOL, V166, P6301, DOI 10.4049/jimmunol.166.10.6301; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Pugin J, 1996, AM J RESP CRIT CARE, V153, P1850, DOI 10.1164/ajrccm.153.6.8665045; Pugin J, 1999, CRIT CARE MED, V27, P304, DOI 10.1097/00003246-199902000-00036; RENARD S, 1995, PFLUG ARCH EUR J PHY, V430, P299, DOI 10.1007/BF00373903; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; Stokes JB, 1998, AM J PHYSIOL-CELL PH, V274, pC1699, DOI 10.1152/ajpcell.1998.274.6.C1699; SUZUKI S, 1995, AM J PHYSIOL-LUNG C, V268, pL983, DOI 10.1152/ajplung.1995.268.6.L983; TCHEPICHEV S, 1995, AM J PHYSIOL, V269, P805; TIBALLI RN, 1995, J CLIN MICROBIOL, V33, P915, DOI 10.1128/JCM.33.4.915-917.1995; Towne JE, 2004, J BIOL CHEM, V279, P13677, DOI 10.1074/jbc.M400117200; Wang X, 2004, MOL PSYCHIATR, V9, P65, DOI 10.1038/sj.mp.4001339; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Ware LB, 2002, LANCET, V360, P619, DOI 10.1016/S0140-6736(02)09774-X; Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035; Webster JC, 2001, P NATL ACAD SCI USA, V98, P6865, DOI 10.1073/pnas.121455098; WEINACKER A, 1995, AM J RESP CELL MOL, V12, P547, DOI 10.1165/ajrcmb.12.5.7537970; ZEIDEL ML, 1991, AM J PHYSIOL, V261, pF1013, DOI 10.1152/ajprenal.1991.261.6.F1013	61	141	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18579	18589		10.1074/jbc.M410561200	http://dx.doi.org/10.1074/jbc.M410561200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15755725	hybrid			2022-12-27	WOS:000228932300006
J	Kristiansen, PE; Fimland, G; Mantzilas, D; Nissen-Meyer, J				Kristiansen, PE; Fimland, G; Mantzilas, D; Nissen-Meyer, J			Structure and mode of action of the membrane-permeabilizing antimicrobial peptide pheromone plantaricin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM SPECTRA; TORSION ANGLE DYNAMICS; LACTOBACILLUS-PLANTARUM; 3-DIMENSIONAL STRUCTURE; PROTEIN; BACTERIOCIN; MICELLES; SEQUENCE; C-11; SPECTROSCOPY	The three-dimensional structure in dodecyl phosphocholine micelles of the 26-mer membrane-permeabilizing bacteriocin-like pheromone plantaricin A (PlnA) has been determined by use of nuclear magnetic resonance spectroscopy. The peptide was unstructured in water but became partly structured upon exposure to micelles. An amphiphilic alpha-helix stretching from residue 12 to 21 (possibly also including residues 22 and 23) was then formed in the C-terminal part of the peptide, whereas the N-terminal part remained largely unstructured. PlnA exerted its membrane-permeabilizing antimicrobial activity through a nonchiral interaction with the target cell membrane because the D-enantiomeric form had the same activity as the natural L-form. This nonchiral interaction involved the amphiphilic alpha-helical region in the C-terminal half of PlnA because a 17-mer fragment that contains the amphiphilic alpha-helical part of the peptide had antimicrobial potency that was similar to that of the L- and D-enantiomeric forms of PlnA. Also the pheromone activity of PlnA depended on this nonchiral interaction because both the L- and D-enantiomeric forms of the 17-mer fragment inhibited the pheromone activity. The pheromone activity also involved, however, a chiral interaction between the N-terminal part of PlnA and its receptor because high concentrations of the L-form (but not the D-form) of a 5-mer fragment derived from the N-terminal part of PlnA had pheromone activity. The results thus reveal a novel mechanism whereby peptide pheromones such as PlnA may function. An initial nonchiral interaction with membrane lipids induces alpha-helical structuring in a segment of the peptide pheromone. The peptide becomes thereby sufficiently structured and properly positioned in the membrane interface, thus enabling it to engage in a chiral interaction with its receptor in or near the membrane water interface. This membrane-interacting mode of action explains why some peptide pheromones/hormones such as PlnA sometimes display antimicrobial activity in addition to their pheromone activity.	Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway	University of Oslo	Kristiansen, PE (corresponding author), Univ Oslo, Dept Mol Biosci, POB 1041, N-0316 Oslo, Norway.	eugen@kjemi.uio.no	Nissen-Meyer, Jon/Y-8727-2019; Kristiansen, Per Eugen/L-5798-2019; Nissen-Meyer, Jon/A-5581-2008					Anderssen EL, 1998, APPL ENVIRON MICROB, V64, P2269; BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DIEP DB, 1994, APPL ENVIRON MICROB, V60, P160, DOI 10.1128/AEM.60.1.160-166.1994; Diep DB, 1995, MOL MICROBIOL, V18, P631, DOI 10.1111/j.1365-2958.1995.mmi_18040631.x; Gallagher NLF, 1997, BIOCHEMISTRY-US, V36, P15062, DOI 10.1021/bi971263h; Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hauge HH, 1998, BIOCHEMISTRY-US, V37, P16026, DOI 10.1021/bi981532j; HAVARSTEIN LS, 2002, HISTIDINE KINASES SI, P341; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Johnsborg O, 2004, ARCH MICROBIOL, V182, P450, DOI 10.1007/s00203-004-0728-7; Johnsborg O, 2003, J BACTERIOL, V185, P6913, DOI 10.1128/JB.185.23.6913-6920.2003; Kleerebezem M, 2001, PEPTIDES, V22, P1579, DOI 10.1016/S0196-9781(01)00493-4; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nes IF, 1999, CELL-CELL SIGNALING IN BACTERIA, P175; NissenMeyer J, 1997, ARCH MICROBIOL, V167, P67, DOI 10.1007/s002030050418; Risoen PA, 2001, MOL GENET GENOMICS, V265, P198, DOI 10.1007/s004380000397; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; Shenkarev ZO, 2002, BIOPHYS J, V82, P762, DOI 10.1016/S0006-3495(02)75438-6; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SLETTEN K, 1974, EUR J BIOCHEM, V41, P117, DOI 10.1111/j.1432-1033.1974.tb03251.x; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sreerama N, 2004, PROTEIN SCI, V13, P100, DOI 10.1110/ps.03258404; Uteng M, 2003, BIOCHEMISTRY-US, V42, P11417, DOI 10.1021/bi034572i; Wuthrich K, 1986, NMR PROTEINS NUCL AC	31	63	69	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22945	22950		10.1074/jbc.M501620200	http://dx.doi.org/10.1074/jbc.M501620200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15805109	hybrid			2022-12-27	WOS:000229741800048
J	Wong, HK; Sakurai, T; Oyama, F; Kaneko, K; Wada, K; Miyazaki, H; Kurosawa, M; De Strooper, B; Saftig, P; Nukina, N				Wong, HK; Sakurai, T; Oyama, F; Kaneko, K; Wada, K; Miyazaki, H; Kurosawa, M; De Strooper, B; Saftig, P; Nukina, N			beta subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; ASPARTYL PROTEASE; KNOCKOUT MICE; STEM-CELLS; CLEAVAGE; PRESENILIN; MEMBRANE; FAMILY; ALPHA-2,6-SIALYLTRANSFERASE; IDENTIFICATION	Sequential processing of amyloid precursor protein (APP) by membrane-bound proteases, BACE1 and gamma-secretase, plays a crucial role in the pathogenesis of Alzheimer disease. Much has been discovered on the properties of these proteases; however, regulatory mechanisms of enzyme-substrate interaction in neurons and their involvement in pathological changes are still not fully understood. It is mainly because of the membrane-associated cleavage of these proteases and the lack of information on new substrates processed in a similar way to APP. Here, using RNA interference-mediated BACE1 knockdown, mouse embryonic fibroblasts that are deficient in either BACE1 or presenilins, and BACE1-deficient mouse brain, we show clear evidence that beta subunits of voltage-gated sodium channels are sequentially processed by BACE1 and gamma-secretase. These results may provide new insights into the underlying pathology of Alzheimer disease.	RIKEN, Brain Sci Inst, Lab Struct Neuropathol, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Lab Neurodegenerat Signal, Wako, Saitama 3510198, Japan; Katholieke Univ Leuven, CME, Neuronal Cell Biol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium; Univ Kiel, Inst Biochem, D-24018 Kiel, Germany	RIKEN; RIKEN; KU Leuven; University of Kiel	Nukina, N (corresponding author), RIKEN, Brain Sci Inst, Lab Struct Neuropathol, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	nukina@brain.riken.jp	Nukina, Nobuyuki/GPP-6265-2022; Wong, Hon-Kit/G-3944-2014; Oyama, Fumitaka/P-6186-2016	Wong, Hon-Kit/0000-0003-0049-8454; Oyama, Fumitaka/0000-0002-1095-8306				De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Eggert S, 2004, J BIOL CHEM, V279, P18146, DOI 10.1074/jbc.M311601200; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Feng RB, 2004, P NATL ACAD SCI USA, V101, P8162, DOI 10.1073/pnas.0402733101; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Hanlon MR, 2002, BIOCHEMISTRY-US, V41, P2886, DOI 10.1021/bi0119565; Harrison SM, 2003, MOL CELL NEUROSCI, V24, P646, DOI 10.1016/S1044-7431(03)00227-6; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; KIKUCHI H, 1995, BBA-MOL CELL RES, V1269, P253, DOI 10.1016/0167-4889(95)00127-3; Kitazume S, 2005, J BIOL CHEM, V280, P8589, DOI 10.1074/jbc.M409417200; Kitazume S, 2003, J BIOL CHEM, V278, P14865, DOI 10.1074/jbc.M206262200; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walsh DM, 2003, BIOCHEMISTRY-US, V42, P6664, DOI 10.1021/bi027375c; Wolfe MS, 2003, CURR TOP DEV BIOL, V54, P233, DOI 10.1016/S0070-2153(03)54011-X; Xia WM, 2003, J CELL SCI, V116, P2839, DOI 10.1242/jcs.00651; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207; Yu FH, 2003, J NEUROSCI, V23, P7577	35	250	253	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23009	23017		10.1074/jbc.M414648200	http://dx.doi.org/10.1074/jbc.M414648200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15824102	hybrid			2022-12-27	WOS:000229741800056
J	Briknarova, K; Nasertorabi, F; Havert, ML; Eggleston, E; Hoyt, DW; Li, CL; Olson, AJ; Vuori, K; Ely, KR				Briknarova, K; Nasertorabi, F; Havert, ML; Eggleston, E; Hoyt, DW; Li, CL; Olson, AJ; Vuori, K; Ely, KR			The serine-rich domain from Crk-associated substrate (p130(cas)) is a four-helix bundle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN SECONDARY STRUCTURE; CHEMICAL-SHIFT INDEX; BREAST-CANCER CELLS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; ADAPTER PROTEIN; VINCULIN ACTIVATION; TARGETING DOMAIN; DOCKING PROTEIN	p130(cas) (Crk-associated substrate) is a docking protein that is involved in assembly of focal adhesions and concomitant cellular signaling. It plays a role in physiological regulation of cell adhesion, migration, survival, and proliferation, as well as in oncogenic transformation. The molecule consists of multiple protein-protein interaction motifs, including a serine-rich region that is positioned between Crk and Src-binding sites. This study reports the first structure of a functional domain of Cas. The solution structure of the serine-rich region has been determined by NMR spectroscopy, demonstrating that this is a stable domain that folds as a four-helix bundle, a protein-interaction motif. The serine-rich region bears strong structural similarity to four-helix bundles found in other adhesion components like focal adhesion kinase, alpha-catenin, or vinculin. Potential sites for phosphorylation and interaction with the 14-3-3 family of cellular regulators are identified in the domain and characterized by site-directed mutagenesis and binding assays. Mapping the degree of amino acid conservation onto the molecular surface reveals a patch of invariant residues near the C terminus of the bundle, which may represent a previously unidentified site for protein interaction.	Burnham Inst, La Jolla, CA 92037 USA; Pacific NW Natl Lab, Environm Mol Sci Lab, Richland, WA 99352 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; United States Department of Energy (DOE); Pacific Northwest National Laboratory; Scripps Research Institute	Ely, KR (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ely@burnham.org	Hoyt, David/H-6295-2013; Li, Chenglong/E-7182-2010	Hoyt, David/0000-0002-2857-719X; Li, Chenglong/0000-0003-3174-8719	NATIONAL CANCER INSTITUTE [R01CA071560] Funding Source: NIH RePORTER; NCI NIH HHS [CA 71560] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Arold ST, 2002, STRUCTURE, V10, P319, DOI 10.1016/S0969-2126(02)00717-7; Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; Bakolitsa C, 2004, NATURE, V430, P583, DOI 10.1038/nature02610; Borgon RA, 2004, STRUCTURE, V12, P1189, DOI 10.1016/j.str.2004.05.009; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Bridges D, 2004, SCI STKE, pre10; Brinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Burnham MR, 1996, ONCOGENE, V12, P2467; Cai DP, 1999, J IMMUNOL, V163, P2104; Clore GM, 2002, J AM CHEM SOC, V124, P2866, DOI 10.1021/ja017712p; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; GRZESIEK S, 1995, J AM CHEM SOC, V117, P9594, DOI 10.1021/ja00142a040; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hayashi I, 2002, NAT STRUCT BIOL, V9, P101, DOI 10.1038/nsb755; Hoellerer MK, 2003, STRUCTURE, V11, P1207, DOI 10.1016/j.str.2003.08.010; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ishino M, 1995, ONCOGENE, V11, P2331; Izard T, 2004, J BIOL CHEM, V279, P27667, DOI 10.1074/jbc.M403076200; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuszewski J, 1997, J MAGN RESON, V125, P171, DOI 10.1006/jmre.1997.1116; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; Kuszewski J, 1996, PROTEIN SCI, V5, P1067; Kuszewski J, 1999, J AM CHEM SOC, V121, P2337, DOI 10.1021/ja9843730; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Law SF, 1996, MOL CELL BIOL, V16, P3327; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Lu YM, 1999, J BIOL CHEM, V274, P10047, DOI 10.1074/jbc.274.15.10047; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nasertorabi F, 2004, BIOCHEM BIOPH RES CO, V324, P993, DOI 10.1016/j.bbrc.2004.09.148; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Papagrigoriou E, 2004, EMBO J, V23, P2942, DOI 10.1038/sj.emboj.7600285; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Prutzman KC, 2004, STRUCTURE, V12, P881, DOI 10.1016/S0969-2126(04)00097-8; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sakakibara A, 2000, J BIOL CHEM, V275, P6404, DOI 10.1074/jbc.275.9.6404; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tjandra N, 1996, J AM CHEM SOC, V118, P6264, DOI 10.1021/ja960106n; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; VUISTER GW, 1993, J MAGN RESON SER B, V101, P210, DOI 10.1006/jmrb.1993.1035; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wurtele M, 2003, EMBO J, V22, P987, DOI 10.1093/emboj/cdg104; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang J, 2001, EMBO J, V20, P3645, DOI 10.1093/emboj/20.14.3645; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	71	20	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21908	21914		10.1074/jbc.M501258200	http://dx.doi.org/10.1074/jbc.M501258200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15795225	hybrid			2022-12-27	WOS:000229557900031
J	Litjens, SHM; Wilhelmsen, K; de Pereda, JM; Perrakis, A; Sonnenberg, A				Litjens, SHM; Wilhelmsen, K; de Pereda, JM; Perrakis, A; Sonnenberg, A			Modeling and experimental validation of the binary complex of the plectin actin-binding domain and the first pair of fibronectin type III (FNIII) domains of the beta 4 integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; INTEGRIN BETA-4 SUBUNIT; PYLORIC ATRESIA; MUSCULAR-DYSTROPHY; CRYSTAL-STRUCTURE; ALPHA-6-BETA-4 INTEGRIN; CSF-1 RECEPTOR; F-ACTIN; HEMIDESMOSOMES; PROTEIN	The binding of plectin to the beta 4 subunit of the alpha 6 beta 4 integrin is a critical step in the formation of hemidesmosomes. An important interaction between these two proteins occurs between the actin-binding domain (ABD) of plectin and the first pair of fibronectin type III (FNIII) domains and a small part of the connecting segment of beta 4. Previously, a few amino acids, critical for this interaction, were identified in both plectin and beta 4 and mapped on the crystal structures of the ABD of plectin and the first pair of FNIII domains of beta 4. In the present study, we used this biochemical information and protein-protein docking calculations to construct a model of the binary complex between these two protein domains. The top scoring computational model predicts that the calponin-homology 1 (CH1) domain of the ABD associates with the first and the second FNIII domains of beta 4. Our mutational analysis of the residues at the proposed interface of both the FNIII and the CH1 domains is in agreement with the suggested interaction model. Computational simulations to predict protein motions suggest that the exact model of FNIII and plectin CH1 interaction might well differ in detail from the suggested model due to the conformational plasticity of the FNIII domains, which might lead to a closely related but different mode of interaction with the plectin-ABD. Furthermore, we show that Ser-1325 in the connecting segment of beta 4 appears to be essential for the recruitment of plectin into hemidesmosomes in vivo. This is consistent with the proposed model and previously published mutational data. In conclusion, our data support a model in which the CH1 domain of the plectin-ABD associates with the groove between the two FNIII domains of beta 4.	Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Univ Salamanca, CSIC, Ctr Invest Canc, E-37007 Salamanca, Spain	Netherlands Cancer Institute; Netherlands Cancer Institute; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Sonnenberg, A (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.sonnenberg@nki.nl	Perrakis, Anastassis/E-8704-2013; de Pereda, Jose M/AAE-5226-2022; de Pereda, Jose M/F-1733-2010	Perrakis, Anastassis/0000-0002-1151-6227; de Pereda, Jose M/0000-0002-8912-6739; de Pereda, Jose M/0000-0002-8912-6739				Altroff H, 2004, J BIOL CHEM, V279, P55995, DOI 10.1074/jbc.M406976200; Andra K, 2003, J INVEST DERMATOL, V120, P189, DOI 10.1046/j.1523-1747.2003.12027.x; Andra K, 1997, GENE DEV, V11, P3143, DOI 10.1101/gad.11.23.3143; Barrett CP, 2004, ACTA CRYSTALLOGR D, V60, P2280, DOI 10.1107/S0907444904019171; de Pereda JM, 1999, EMBO J, V18, P4087, DOI 10.1093/emboj/18.15.4087; deGroot BL, 1997, PROTEINS, V29, P240, DOI 10.1002/(SICI)1097-0134(199710)29:2<240::AID-PROT11>3.0.CO;2-O; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Fontao L, 2001, J CELL SCI, V114, P2065; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Gache Y, 1996, J CLIN INVEST, V97, P2289, DOI 10.1172/JCI118671; Garcia-Alvarez B, 2003, STRUCTURE, V11, P615, DOI 10.1016/S0969-2126(03)00090-X; Geerts D, 1999, J CELL BIOL, V147, P417, DOI 10.1083/jcb.147.2.417; Geuijen CAW, 2002, MOL BIOL CELL, V13, P3845, DOI 10.1091/mbc.02-01-0601; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; HIEDA Y, 1992, J CELL BIOL, V116, P1497, DOI 10.1083/jcb.116.6.1497; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; James P, 1996, GENETICS, V144, P1425; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; Koster J, 2004, HANDB EXP PHARM, V165, P243, DOI 10.1007/978-3-540-68170-0_9; Koster J, 2004, MOL BIOL CELL, V15, P1211, DOI 10.1091/mbc.E03-09-0697; Koster J, 2003, J CELL SCI, V116, P387, DOI 10.1242/jcs.00241; Koster J, 2001, J INVEST DERMATOL, V117, P1405, DOI 10.1046/j.0022-202x.2001.01567.x; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Litjens SHM, 2003, MOL BIOL CELL, V14, P4039, DOI 10.1091/mbc.E03-05-0268; McLean WHI, 1996, GENE DEV, V10, P1724, DOI 10.1101/gad.10.14.1724; Nakano A, 2001, PEDIATR RES, V49, P618, DOI 10.1203/00006450-200105000-00003; Nievers MG, 1998, J CELL SCI, V111, P1659; Pulkkinen L, 1998, AM J HUM GENET, V63, P1376, DOI 10.1086/302116; Resjo S, 1999, BIOCHEM J, V341, P839, DOI 10.1042/0264-6021:3410839; Ruzzi L, 1997, J CLIN INVEST, V99, P2826, DOI 10.1172/JCI119474; Schaapveld RQJ, 1998, J CELL BIOL, V142, P271, DOI 10.1083/jcb.142.1.271; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Sevcik J, 2004, EUR J BIOCHEM, V271, P1873, DOI 10.1111/j.1432-1033.2004.04095.x; SKALLI O, 1994, J CELL BIOL, V125, P159, DOI 10.1083/jcb.125.1.159; Smith FJD, 1996, NAT GENET, V13, P450, DOI 10.1038/ng0896-450; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; Sterk LMT, 2000, J CELL BIOL, V149, P969, DOI 10.1083/jcb.149.4.969; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; Wilhelmsen K, 2002, ONCOGENE, V21, P1079, DOI 10.1038/sj.onc.1205166	42	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22270	22277		10.1074/jbc.M411818200	http://dx.doi.org/10.1074/jbc.M411818200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817481	hybrid			2022-12-27	WOS:000229557900072
J	Polykratis, A; Katsoris, P; Courty, J; Papadimitriou, E				Polykratis, A; Katsoris, P; Courty, J; Papadimitriou, E			Characterization of heparin affin regulatory peptide signaling in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; FOCAL ADHESION KINASE; MOLECULE HB-GAM; ACTIVATION LOOP PHOSPHORYLATION; ANAPLASTIC LYMPHOMA KINASE; GROWTH-FACTOR PLEIOTROPHIN; ZETA/RPTP-BETA; N-SYNDECAN; IN-VITRO; RECEPTOR	Heparin affin regulatory peptide (HARP) is an 18-kDa secreted growth factor that has a high affinity for heparin and a potent role on tumor growth and angiogenesis. We have previously reported that HARP is mitogenic for different types of endothelial cells and also affects cell migration and differentiation (12). In this study we examined the signaling pathways involved in the migration and tube formation on matrigel of human umbilical vein endothelial cells (HUVEC) induced by HARP. We report for the first time that receptor-type protein- tyrosine phosphatase beta/zeta (RPTP beta/zeta), which is a receptor for HARP in neuronal cell types, is also expressed in HUVEC. We also document that HARP signaling through RPTP beta/zeta leads to activation of Src kinase, focal adhesion kinase, phosphatidylinositol 3-kinase, and Erk1/2. Sodium orthovanadate, chondroitin sulfate-C, PP1, wortmannin, LY294002, and U0126 inhibit HARP-mediated signaling and HUVEC migration and tube formation. In addition, RPTP beta/zeta suppression using small interfering RNA technology interrupts intracellular signals and HUVEC migration and tube formation induced by HARP. These results establish the role of RPTP beta/zeta as a receptor of HARP in HUVEC and elucidate the HARP signaling pathway in endothelial cells.	Univ Patras, Dept Pharm, Mol Pharmacol Lab, Patras 26504, Greece; Univ Patras, Dept Biol, Div Genet, Patras 26504, Greece; Univ Paris 12, CNRS, UMR 7149, Lab Rech Croissance Cellulaire, F-94010 Creteil, France	University of Patras; University of Patras; Centre National de la Recherche Scientifique (CNRS); Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Papadimitriou, E (corresponding author), Univ Patras, Dept Pharm, Mol Pharmacol Lab, Patras 26504, Greece.	epapad@upatras.gr	Papadimitriou, Evangelia/ABG-1356-2020; Papadimitriou, Evangelia/F-3396-2010; Courty, Jose/Q-3702-2018	Papadimitriou, Evangelia/0000-0001-6429-4325; Polykratis, Apostolos/0000-0001-6720-3302				Chattopadhyay N, 2003, J CELL BIOL, V163, P1351, DOI 10.1083/jcb.200306067; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Ensslen-Craig SE, 2004, DEV BIOL, V275, P12, DOI 10.1016/j.ydbio.2004.08.009; FANG WJ, 1992, J BIOL CHEM, V267, P25889; GIEFFERS C, 1993, EUR J CELL BIOL, V62, P352; GRUMET M, 1994, J BIOL CHEM, V269, P12142; KATCHALSKI HT, 1999, ONCOGENE, V18, P5024; Kinnunen A, 1998, EUR J NEUROSCI, V10, P635, DOI 10.1046/j.1460-9568.1998.00082.x; Kronenwett R, 2002, CANCER GENE THER, V9, P587, DOI 10.1038/sj.cgt.7700474; Lin MT, 2003, MOL PHARMACOL, V64, P1029, DOI 10.1124/mol.64.5.1029; Maa MC, 1998, BIOCHEM BIOPH RES CO, V251, P344, DOI 10.1006/bbrc.1998.9464; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; Muller S, 2003, ONCOGENE, V22, P6661, DOI 10.1038/sj.onc.1206763; Muramatsu H, 2004, J CELL SCI, V117, P5405, DOI 10.1242/jcs.01423; NEAME PJ, 1993, J ORTHOP RES, V11, P479, DOI 10.1002/jor.1100110403; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Papadimitriou E, 2004, CURR CANCER DRUG TAR, V4, P471, DOI 10.2174/1568009043332835; Papadimitriou E, 2000, BIOCHEM BIOPH RES CO, V274, P242, DOI 10.1006/bbrc.2000.3126; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Petrone A, 2000, J CELL SCI, V113, P2345; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; Sakurai T, 1996, J NEUROSCI RES, V43, P694, DOI 10.1002/(SICI)1097-4547(19960315)43:6<694::AID-JNR6>3.3.CO;2-9; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; Souttou B, 2001, J CELL PHYSIOL, V187, P59, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1051>3.0.CO;2-F; Souttou B, 1998, J NATL CANCER I, V90, P1468, DOI 10.1093/jnci/90.19.1468; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Zhang N, 1997, J BIOL CHEM, V272, P16733, DOI 10.1074/jbc.272.27.16733; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964	41	73	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22454	22461		10.1074/jbc.M414407200	http://dx.doi.org/10.1074/jbc.M414407200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15797857	hybrid			2022-12-27	WOS:000229557900091
J	Huang, SX; Gilfillan, S; Cella, M; Miley, MJ; Lantz, O; Lybarger, L; Fremont, DH; Hansen, TH				Huang, SX; Gilfillan, S; Cella, M; Miley, MJ; Lantz, O; Lybarger, L; Fremont, DH; Hansen, TH			Evidence for MR1 antigen presentation to mucosal-associated invariant T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDE-LOADING COMPLEX; CRYSTAL-STRUCTURE; NKT CELLS; STRUCTURAL BASIS; ALPHA-BETA; RECEPTOR RECOGNITION; POLYMORPHIC RESIDUE; SURFACE EXPRESSION	The novel class Ib molecule MR1 is highly conserved in mammals, particularly in its alpha 1/alpha 2 domains. Recent studies demonstrated that MR1 expression is required for development and expansion of a small population of T cells expressing an invariant T cell receptor (TCR) alpha chain called mucosal-associated invariant T (MAIT) cells. Despite these intriguing properties it has been difficult to determine whether MR1 expression and MAIT cell recognition is ligand-dependent. To address these outstanding questions, monoclonal antibodies were produced in MR1 knock-out mice immunized with recombinant MR1 protein, and a series of MR1 mutations were generated at sites previously shown to disrupt the ability of class Ia molecules to bind peptide or TCR. Here we show that 1) MR1 molecules are detected by monoclonal antibodies in either an open or folded conformation that correlates precisely with peptide-induced conformational changes in class Ia molecules, 2) only the folded MR1 conformer activated 2/2 MAIT hybridoma cells tested, 3) the pattern of MAIT cell activation by the MR1 mutants implies the MR1/TCR orientation is strikingly similar to published major histocompatibility complex/alpha beta TCR engagements, 4) all the MR1 mutations tested and found to severely reduce surface expression of folded molecules were located in the putative ligand binding groove, and 5) certain groove mutants of MR1 that are highly expressed on the cell surface disrupt MAIT cell activation. These combined data strongly support the conclusion that MR1 has an antigen presentation function.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; XCInst Curie, Immunol Lab, Paris, France; XCInst Curie, INSERM, U520, Paris, France; Univ Arizona, Arizona Hlth Sci Ctr, Dept Cell Biol & Anat, Tucson, AZ 85724 USA	Washington University (WUSTL); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Arizona; University of Arizona Health Sciences	Hansen, TH (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 4566 Scott Ave, St Louis, MO 63110 USA.	hansen@pathology.wustl.edu	Cella, Marina/ABA-8564-2020; Lantz, Olivier J/J-4960-2012	Lantz, Olivier J/0000-0003-3161-7719; Cella, Marina/0000-0003-1230-1313; Huang, Shouxiong/0000-0001-7797-3626; Fremont, Daved/0000-0002-8544-2689	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019687, R01AI046553] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19687, AI46553] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABASTADO JP, 1993, J IMMUNOL, V151, P3569; Allison TJ, 2002, MOL IMMUNOL, V38, P1051, DOI 10.1016/S0161-5890(02)00034-2; Bai A, 2000, J IMMUNOL, V165, P7025, DOI 10.4049/jimmunol.165.12.7025; Bai A, 1998, IMMUNITY, V9, P413, DOI 10.1016/S1074-7613(00)80624-X; Bendelac A, 2001, NAT REV IMMUNOL, V1, P177, DOI 10.1038/35105052; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; Bennett MJ, 2000, NATURE, V403, P46, DOI 10.1038/47417; BLUESTONE JA, 1992, J EXP MED, V176, P1757, DOI 10.1084/jem.176.6.1757; Braud VM, 1999, CURR OPIN IMMUNOL, V11, P100, DOI 10.1016/S0952-7915(99)80018-1; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; Buslepp J, 2003, IMMUNITY, V19, P595, DOI 10.1016/S1074-7613(03)00269-3; Carayannopoulos LN, 2002, EUR J IMMUNOL, V32, P597, DOI 10.1002/1521-4141(200203)32:3<597::AID-IMMU597>3.3.CO;2-5; CARRENO BM, 1993, INT IMMUNOL, V5, P353, DOI 10.1093/intimm/5.4.353; CATIPOVIC B, 1992, J EXP MED, V176, P1611, DOI 10.1084/jem.176.6.1611; Chiu NM, 1999, J EXP MED, V190, P423, DOI 10.1084/jem.190.3.423; Crowley MP, 1997, J EXP MED, V185, P1223, DOI 10.1084/jem.185.7.1223; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; Gao XJ, 2001, NEW ENGL J MED, V344, P1668, DOI 10.1056/NEJM200105313442203; Garboczi DN, 1999, IMMUNITY, V10, P1, DOI 10.1016/S1074-7613(00)80001-1; Garboczi DN, 1996, J IMMUNOL, V157, P5403; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; GIGLIA JS, 1985, CANCER RES, V45, P5027; Hansen T, 2000, IMMUNOL TODAY, V21, P83, DOI 10.1016/S0167-5699(98)01426-1; HASHIMOTO K, 1995, SCIENCE, V269, P693, DOI 10.1126/science.7624800; He XL, 2001, STRUCTURE, V9, P1213, DOI 10.1016/S0969-2126(01)00689-X; HEMMI S, 1988, J EXP MED, V168, P2319, DOI 10.1084/jem.168.6.2319; Hennecke J, 2001, CELL, V104, P1, DOI 10.1016/S0092-8674(01)00185-4; Hornell TMC, 1999, J IMMUNOL, V163, P3217; Kjer-Nielsen L, 2003, IMMUNITY, V18, P53, DOI 10.1016/S1074-7613(02)00513-7; Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854; Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742; Lee N, 1998, J IMMUNOL, V160, P4951; Li PW, 2002, IMMUNITY, V16, P77, DOI 10.1016/S1074-7613(02)00258-3; Lybarger L, 2003, IMMUNITY, V18, P121, DOI 10.1016/S1074-7613(02)00509-5; Lybarger L, 2001, J IMMUNOL, V167, P2097, DOI 10.4049/jimmunol.167.4.2097; Marguet D, 1999, IMMUNITY, V11, P231, DOI 10.1016/S1074-7613(00)80098-9; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; Miley MJ, 2003, J IMMUNOL, V170, P6090, DOI 10.4049/jimmunol.170.12.6090; MORIWAKI S, 1993, P NATL ACAD SCI USA, V90, P11396, DOI 10.1073/pnas.90.23.11396; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; Myers NB, 2000, J IMMUNOL, V165, P5656, DOI 10.4049/jimmunol.165.10.5656; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Park B, 2003, J IMMUNOL, V170, P961, DOI 10.4049/jimmunol.170.2.961; Park SH, 2000, EUR J IMMUNOL, V30, P620, DOI 10.1002/1521-4141(200002)30:2<620::AID-IMMU620>3.0.CO;2-4; PRETELL J, 1979, VIROLOGY, V97, P32, DOI 10.1016/0042-6822(79)90370-2; PULLEN JK, 1991, J IMMUNOL, V146, P2145; Reinherz EL, 1999, SCIENCE, V286, P1913, DOI 10.1126/science.286.5446.1913; Reiser JB, 2000, NAT IMMUNOL, V1, P291, DOI 10.1038/79728; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; RIBAUDO RK, 1995, J IMMUNOL, V155, P3481; Riegert P, 1998, J IMMUNOL, V161, P4066; Sanchez LM, 1999, SCIENCE, V283, P1914, DOI 10.1126/science.283.5409.1914; SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.immunol.11.1.385; SMITH JD, 1993, J EXP MED, V178, P2035, DOI 10.1084/jem.178.6.2035; SMITH JD, 1992, J EXP MED, V175, P191, DOI 10.1084/jem.175.1.191; Smith KD, 1996, IMMUNOGENETICS, V43, P27; Smith RA, 2002, J IMMUNOL, V169, P3105, DOI 10.4049/jimmunol.169.6.3105; Smyth MJ, 2002, CURR OPIN IMMUNOL, V14, P165, DOI 10.1016/S0952-7915(02)00316-3; SOLHEIM JC, 1993, J IMMUNOL, V151, P5387; Stanic AK, 2003, P NATL ACAD SCI USA, V100, P1849, DOI 10.1073/pnas.0430327100; Stein-Streilein J, 2003, J EXP MED, V198, P1779, DOI 10.1084/jem.20031946; Steinle A, 2001, IMMUNOGENETICS, V53, P279, DOI 10.1007/s002510100325; Stewart-Jones GBE, 2003, NAT IMMUNOL, V4, P657, DOI 10.1038/ni942; TALKEN BL, 1994, MOL IMMUNOL, V31, P1169, DOI 10.1016/0161-5890(94)90031-0; Taniguchi M, 2003, ANNU REV IMMUNOL, V21, P483, DOI 10.1146/annurev.immunol.21.120601.141057; Teng MK, 1998, CURR BIOL, V8, P409, DOI 10.1016/S0960-9822(98)70160-5; Tilloy F, 1999, J EXP MED, V189, P1907, DOI 10.1084/jem.189.12.1907; Treiner E, 2003, NATURE, V422, P164, DOI 10.1038/nature01433; TREINER E, 2005, IN PRESS MICROBES IN; Wang CR, 1996, RES IMMUNOL, V147, P313, DOI 10.1016/0923-2494(96)89644-1; Wang XL, 2004, J VIROL, V78, P8673, DOI 10.1128/JVI.78.16.8673-8686.2004; Wingren C, 2000, SCIENCE, V287, P310, DOI 10.1126/science.287.5451.310; Yamaguchi H, 1997, BIOCHEM BIOPH RES CO, V238, P697, DOI 10.1006/bbrc.1997.7379; Yu YYL, 1999, INT IMMUNOL, V11, P1897, DOI 10.1093/intimm/11.12.1897; Yu YYL, 2002, J VIROL, V76, P2796, DOI 10.1128/JVI.76.6.2796-2803.2002; Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science.1103440	81	118	121	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21183	21193		10.1074/jbc.M501087200	http://dx.doi.org/10.1074/jbc.M501087200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802267	hybrid			2022-12-27	WOS:000229438800036
J	Morel, C; Ibarz, G; Oiry, C; Carnazzi, E; Berge, G; Gagne, D; Galleyrand, JC; Martinez, J				Morel, C; Ibarz, G; Oiry, C; Carnazzi, E; Berge, G; Gagne, D; Galleyrand, JC; Martinez, J			Cross-interactions of two p38 mitogen-activated protein (MAP) kinase inhibitors and two cholecystokinin (CCK) receptor antagonists with the CCK1 receptor and p38 MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PANCREATIC ACINI; NUCLEOSIDE TRANSPORT; SB 203580; IN-VITRO; PATHWAYS; POTENT; CELLS; IDENTIFICATION; DETERMINANTS; ISOFORMS	Although SB202190 and SB203580 are described as specific p38 MAP kinase inhibitors, several reports have indicated that other enzymes are also sensitive to SB203580. Using a pharmacological approach, we report for the first time that compounds SB202190 and SB203580 were able to directly and selectively interact with a G-protein-coupled receptor, namely the cholecystokinin receptor subtype CCK1, but not with the CCK2 receptor. We demonstrated that these compounds were non-competitive antagonists of the CCK1 receptor at concentrations typically used to inhibit protein kinases. By chimeric construction of the CCK2 receptor, we determined the involvement of two CCK1 receptor intracellular loops in the binding of SB202190 and SB203580. We also showed that two CCK antagonists, L364,718 and L365,260, were able to regulate p38 mitogen-activated protein ( MAP) kinase activity. Using a reporter gene strategy and immunoblotting experiments, we demonstrated that both CCK antagonists inhibited selectively the enzymatic activity of p38 MAP kinase. Kinase assays suggested that this inhibition resulted from a direct interaction with both CCK antagonists. Molecular modeling simulations suggested that this interaction occurs in the ATP binding pocket of p38 MAP kinase. These results suggest that SB202190 and SB203580 bind to the CCK1 receptor and, as such, these compounds should be used with caution in models that express this receptor. We also found that L364,718 and L365,260, two CCK receptor antagonists, directly interacted with p38 MAP kinase and inhibited its activity. These findings suggest that the CCK1 receptor shares structural analogies with the p38 MAP kinase ATP binding site. They open the way to potential design of either a new family of MAP kinase inhibitors from CCK1 receptor ligand structures or new CCK1 receptor ligands based on p38 MAP kinase inhibitor structures.	CNRS, Lab Aminoacides Peptides & Prot, UMI & UMII, UFR Pharm,UMR 5810, F-34093 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Galleyrand, JC (corresponding author), CNRS, Lab Aminoacides Peptides & Prot, UMI & UMII, UFR Pharm,UMR 5810, 15 Ave Charles Flahault, F-34093 Montpellier, France.	jean-claude.galleyrand@univ-montp1.fr	Martinez, Jean/R-9421-2019	Martinez, Jean/0000-0002-9267-4621				BATTEY J, 1991, TRENDS NEUROSCI, V14, P524, DOI 10.1016/0166-2236(91)90005-F; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; CHANG RSL, 1986, P NATL ACAD SCI USA, V83, P4923, DOI 10.1073/pnas.83.13.4923; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CRAWLEY JN, 1994, PEPTIDES, V15, P731, DOI 10.1016/0196-9781(94)90104-X; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dabrowski A, 1996, J BIOL CHEM, V271, P5686, DOI 10.1074/jbc.271.10.5686; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUAN RD, 1995, AM J PHYSIOL-GASTR L, V268, pG1060, DOI 10.1152/ajpgi.1995.268.6.G1060; DUAN RD, 1994, AM J PHYSIOL, V267, pG401, DOI 10.1152/ajpgi.1994.267.3.G401; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; EVANS BE, 1986, P NATL ACAD SCI USA, V83, P4918, DOI 10.1073/pnas.83.13.4918; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603; Han JH, 1997, FEBS LETT, V403, P19, DOI 10.1016/S0014-5793(97)00021-5; Huang M, 2003, J PHARMACOL EXP THER, V304, P753, DOI 10.1124/jpet.102.044214; Huang M, 2002, J BIOL CHEM, V277, P28364, DOI 10.1074/jbc.C200321200; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; Kalmes A, 1999, FEBS LETT, V444, P71, DOI 10.1016/S0014-5793(99)00034-4; Kennedy K, 1997, J BIOL CHEM, V272, P2920, DOI 10.1074/jbc.272.5.2920; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LOTTI VJ, 1989, EUR J PHARMACOL, V162, P273, DOI 10.1016/0014-2999(89)90290-2; Mas JS, 2002, EUR J BIOCHEM, V269, P6133, DOI 10.1046/j.1432-1033.2002.03329.x; Noble F, 1999, PHARMACOL REV, V51, P745; Oiry C, 1997, MOL PHARMACOL, V52, P292, DOI 10.1124/mol.52.2.292; Oiry C, 1995, EUR J PHARMACOL, V294, P511, DOI 10.1016/0014-2999(95)00574-9; Piiper A, 1997, AM J PHYSIOL-GASTR L, V272, pG135, DOI 10.1152/ajpgi.1997.272.1.G135; PONTKINGDON G, 1994, BIOTECHNIQUES, V16, P1010; POOTSI R, 2000, MOL PHARMACOL, V58, P1381; QIAN JM, 1993, AM J PHYSIOL, V264, P718; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sambrook J., 2002, MOL CLONING LAB MANU; SANKARAN H, 1979, J BIOL CHEM, V254, P9349; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Silvente-Poirot S, 1998, MOL PHARMACOL, V54, P364, DOI 10.1124/mol.54.2.364; Szewczyk JR, 2003, CURR TOP MED CHEM, V3, P837, DOI 10.2174/1568026033452258; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Williams John A., 1993, P167	45	16	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21384	21393		10.1074/jbc.M408851200	http://dx.doi.org/10.1074/jbc.M408851200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15772081	hybrid, Green Published			2022-12-27	WOS:000229438800058
J	Morita, YS; Velasquez, R; Taig, E; Waller, RF; Patterson, JH; Tull, D; Williams, SJ; Billman-Jacobe, H; McConville, MJ				Morita, YS; Velasquez, R; Taig, E; Waller, RF; Patterson, JH; Tull, D; Williams, SJ; Billman-Jacobe, H; McConville, MJ			Compartmentalization of lipid biosynthesis in mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; CELL-WALL; IN-VITRO; PHOSPHATIDYLINOSITOL; LIPOARABINOMANNAN; TUBERCULOSIS; IDENTIFICATION; BIOGENESIS; METABOLISM; SYNTHASE	The plasma membrane of Mycobacterium sp. is the site of synthesis of several distinct classes of lipids that are either retained in the membrane or exported to the overlying cell envelope. Here, we provide evidence that enzymes involved in the biosynthesis of two major lipid classes, the phosphatidylinositol mannosides (PIMs) and aminophospholipids, are compartmentalized within the plasma membrane. Enzymes involved in the synthesis of early PIM intermediates were localized to a membrane subdomain termed PMf, that was clearly resolved from the cell wall by isopyknic density centrifugation and amplified in rapidly dividing Mycobacterium smegmatis. In contrast, the major pool of apolar PIMs and enzymes involved in polar PIM biosynthesis were localized to a denser fraction that contained both plasma membrane and cell wall markers (PM-CW). Based on the resistance of the PIMs to solvent extraction in live but not lysed cells, we propose that polar PIM biosynthesis occurs in the plasma membrane rather than the cell wall component of the PM-CW. Enzymes involved in phosphatidylethanolamine biosynthesis also displayed a highly polarized distribution between the PMf and PM-CW fractions. The PMf was greatly reduced in non-dividing cells, concomitant with a reduction in the synthesis and steady-state levels of PIMs and amino-phospholipids and the redistribution of PMf marker enzymes to non-PM-CW fractions. The formation of the PMf and recruitment of enzymes to this domain may thus play a role in regulating growth-specific changes in the biosynthesis of membrane and cell wall lipids.	Univ Melbourne, Mol Sci & Biotechnol Inst B1021, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia; Univ Melbourne, Mol Sci & Biotechnol Inst B1021, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia; Univ Melbourne, Mol Sci & Biotechnol Inst B1021, Sch Chem, Parkville, Vic 3010, Australia	University of Melbourne; University of Melbourne; University of Melbourne	McConville, MJ (corresponding author), Univ Melbourne, Mol Sci & Biotechnol Inst B1021, Dept Biochem & Mol Biol, 30 Flemington Rd, Parkville, Vic 3010, Australia.	malcolmm@unimelb.edu.au	Waller, Ross F/D-5761-2016; Williams, Spencer/C-3545-2009	Waller, Ross F/0000-0001-6961-9344; Williams, Spencer/0000-0001-6341-4364; Billman-Jacobe, Helen/0000-0001-5713-4657; Morita, Yasu/0000-0002-4514-9242; Tull, Dedreia/0000-0003-2546-6707				Baulard AR, 2003, J BIOL CHEM, V278, P2242, DOI 10.1074/jbc.M207922200; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BRENNAN P, 1967, J BIOL CHEM, V242, P3046; Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6; Briken V, 2004, MOL MICROBIOL, V53, P391, DOI 10.1111/j.1365-2958.2004.04183.x; Brown JR, 2001, BIOORGAN MED CHEM, V9, P815, DOI 10.1016/S0968-0896(00)00300-X; Campo N, 2004, MOL MICROBIOL, V53, P1583, DOI 10.1111/j.1365-2958.2004.04278.x; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; Christensen H, 1999, MOL MICROBIOL, V31, P1561, DOI 10.1046/j.1365-2958.1999.01304.x; Crick DC, 2001, GLYCOBIOLOGY, V11, p107R, DOI 10.1093/glycob/11.9.107R; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; DAVIS WB, 1975, J BIOL CHEM, V250, P1648; Garton NJ, 2002, MICROBIOL-SGM, V148, P2951, DOI 10.1099/00221287-148-10-2951; Gurcha SS, 2002, BIOCHEM J, V365, P441, DOI 10.1042/BJ20020107; Haites RE, 2005, J BIOL CHEM, V280, P10981, DOI 10.1074/jbc.M413443200; Jackson M, 2000, J BIOL CHEM, V275, P30092, DOI 10.1074/jbc.M004658200; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; Kawai F, 2004, J BACTERIOL, V186, P1475, DOI 10.1128/JB.186.5.1475-1483.2004; Koppelman CM, 2001, J BACTERIOL, V183, P6144, DOI 10.1128/JB.183.20.6144-6147.2001; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; Mawuenyega KG, 2005, MOL BIOL CELL, V16, P396, DOI 10.1091/mbc.e04-04-0329; Mileykovskaya E, 2003, J BIOL CHEM, V278, P22193, DOI 10.1074/jbc.M302603200; Morita YS, 2004, BIOCHEM J, V378, P589, DOI 10.1042/BJ20031372; Mullin KA, 2001, MOL BIOL CELL, V12, P2364, DOI 10.1091/mbc.12.8.2364; Onyebujoh P, 2004, NAT REV MICROBIOL, V2, P930, DOI 10.1038/nrmicro1050; OrtaloMagne A, 1996, J BACTERIOL, V178, P456, DOI 10.1128/jb.178.2.456-461.1996; Patterson JH, 2000, J BIOL CHEM, V275, P24900, DOI 10.1074/jbc.M000147200; Patterson JH, 2003, BIOCHEM J, V372, P77, DOI 10.1042/BJ20021700; Pinho MG, 2003, MOL MICROBIOL, V50, P871, DOI 10.1046/j.1365-2958.2003.03719.x; Pugsley AP, 2004, MOL MICROBIOL, V53, P1559, DOI 10.1111/j.1365-2958.2004.04273.x; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAMAKRISHNAN T, 1972, BACTERIOL REV, V36, P65, DOI 10.1128/MMBR.36.1.65-108.1972; Rosch J, 2004, SCIENCE, V304, P1513, DOI 10.1126/science.1097404; Russell DG, 2002, J CELL BIOL, V158, P421, DOI 10.1083/jcb.200205034; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Triccas JA, 1998, FEMS MICROBIOL LETT, V167, P151, DOI 10.1111/j.1574-6968.1998.tb13221.x; Vidugiriene J, 1999, J BIOL CHEM, V274, P15203, DOI 10.1074/jbc.274.21.15203; Voelker DR, 2003, J LIPID RES, V44, P441, DOI 10.1194/jlr.R200020-JLR200	39	59	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21645	21652		10.1074/jbc.m414181200	http://dx.doi.org/10.1074/jbc.m414181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15805104	hybrid			2022-12-27	WOS:000229438800090
J	Davidson, D; Blanc, A; Filion, D; Wang, HF; Plut, P; Pfeffer, G; Buschmann, MD; Henderson, JE				Davidson, D; Blanc, A; Filion, D; Wang, HF; Plut, P; Pfeffer, G; Buschmann, MD; Henderson, JE			Fibroblast growth factor (FGF) 18 signals through FGF receptor 3 to promote chondrogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL PROGENITOR DIFFERENTIATION; CARTILAGE REPAIR; IN-VITRO; CHONDROCYTES; LIMB; PROLIFERATION; MOUSE; INTEGRIN; CELLS; MICE	Signaling by fibroblast growth factor (FGF) 18 and FGF receptor 3 (FGFR3) have been shown to regulate proliferation, differentiation, and matrix production of articular and growth plate chondrocytes in vivo and in vitro. Notably, the congenital absence of either FGF18 or FGFR3 resulted in similar expansion of the growth plates of fetal mice and the addition of FGF18 to human articular chondrocytes in culture enhanced proliferation and matrix production. Based on these and other experiments it has been proposed that FGF18 signals through FGFR3 to promote cartilage production by chondrocytes. Its role in chondrogenesis remains to be defined. In the current work we used the limb buds of FGFR3(+/+) and FGFR3(-/-) embryonic mice as a source of mesenchymal cells to determine how FGF18 signaling affects chondrogenesis. Confocal laser-scanning microscopy demonstrated impaired cartilage nodule formation in the FGFR3(-/-) cultures. Potential contributing factors to the phenotype were identified as impaired mitogenic response to FGF18, decreased production of type II collagen and proteoglycan in response to FGF18 stimulation, impaired interactions with the extracellular matrix resulting from altered integrin receptor expression, and altered expression of FGFR1 and FGFR2. The data identified FGF18 as a selective ligand for FGFR3 in limb bud mesenchymal cells, which suppressed proliferation and promoted their differentiation and production of cartilage matrix. This work, thus, identifies FGF18 and FGFR3 as potential molecular targets for intervention in tissue engineering aimed at cartilage repair and regeneration of damaged cartilage.	McGill Univ, Ctr Bone & Periodontal Res, Dept Med, Montreal, PQ H3A 1A4, Canada; Ecole Polytech, Dept Chem Engn, Montreal, PQ H3C 3A7, Canada	McGill University; Universite de Montreal; Polytechnique Montreal	Henderson, JE (corresponding author), McGill Univ, Ctr Bone & Periodontal Res, Dept Med, 740 Ave Dr Penfield Rm 2203, Montreal, PQ H3A 1A4, Canada.	janet.henderson@mcgill.ca		Pfeffer, Gerald/0000-0002-7657-7098; Blanc, Antoine/0000-0002-8305-2513; Buschmann, Michael/0000-0002-2242-6198				Aarts MM, 2001, J BIOL CHEM, V276, P37934; Amizuka N, 2004, BONE, V34, P13, DOI 10.1016/j.bone.2003.08.009; Baird Andrew, 2000, P167; Barbero A, 2004, OSTEOARTHR CARTILAGE, V12, P476, DOI 10.1016/j.joca.2004.02.010; Barbieri O, 2003, AM J PHYSIOL-CELL PH, V285, pC1504, DOI 10.1152/ajpcell.00579.2002; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; CUEVAS P, 1988, BIOCHEM BIOPH RES CO, V156, P611, DOI 10.1016/S0006-291X(88)80887-8; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Dowthwaite GP, 2004, J CELL SCI, V117, P889, DOI 10.1242/jcs.00912; Ekholm E, 2002, AM J PATHOL, V160, P1779, DOI 10.1016/S0002-9440(10)61124-8; Ellsworth JL, 2002, OSTEOARTHR CARTILAGE, V10, P308, DOI 10.1053/joca.2002.0514; EnomotoIwamoto M, 1997, J BONE MINER RES, V12, P1124, DOI 10.1359/jbmr.1997.12.7.1124; Henderson JE, 2000, J BONE MINER RES, V15, P155, DOI 10.1359/jbmr.2000.15.1.155; Hickey Derrick G, 2003, Am J Orthop (Belle Mead NJ), V32, P70; Hunziker EB, 2002, OSTEOARTHR CARTILAGE, V10, P432, DOI 10.1053/joca.2002.0801; JONES KL, 1975, ENDOCRINOLOGY, V97, P359, DOI 10.1210/endo-97-2-359; KAPLOWITZ PB, 1982, J CELL PHYSIOL, V112, P353, DOI 10.1002/jcp.1041120307; Knezevic V, 1997, DEVELOPMENT, V124, P4523; Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361; Laplantine E, 2002, J CELL BIOL, V158, P741, DOI 10.1083/jcb.200205025; Legeai-Mallet L, 2004, BONE, V34, P26, DOI 10.1016/j.bone.2003.09.002; Liu ZH, 2002, GENE DEV, V16, P859, DOI 10.1101/gad.965602; Loeser RF, 2000, OSTEOARTHR CARTILAGE, V8, P96, DOI 10.1053/joca.1999.0277; Miao DS, 2004, EXP CELL RES, V294, P210, DOI 10.1016/j.yexcr.2003.10.021; Minina E, 2002, DEV CELL, V3, P439, DOI 10.1016/S1534-5807(02)00261-7; Murakami S, 2004, GENE DEV, V18, P290, DOI 10.1101/gad.1179104; Naski MC, 1998, DEVELOPMENT, V125, P4977; Neubert R, 1995, LIFE SCI, V58, P295, DOI 10.1016/0024-3205(95)02290-2; O'Connor WJ, 2000, ORTHOP CLIN N AM, V31, P399, DOI 10.1016/S0030-5898(05)70159-0; O'Driscoll SW, 2001, CLIN ORTHOP S, V391, P190; Ochi M, 2004, ARTIF ORGANS, V28, P28, DOI 10.1111/j.1525-1594.2004.07317.x; Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PETERS KG, 1992, DEVELOPMENT, V114, P233; Pizette S, 2000, DEV BIOL, V219, P237, DOI 10.1006/dbio.2000.9610; Sass JO, 1997, ARCH TOXICOL, V71, P142, DOI 10.1007/s002040050368; Shakibaei M, 1998, EXP CELL RES, V240, P95, DOI 10.1006/excr.1998.3933; Solchaga LA, 2001, CLIN ORTHOP RELAT R, pS161; Valverde-Franco G, 2004, HUM MOL GENET, V13, P271, DOI 10.1093/hmg/ddh034; van den Berg WB, 2001, CLIN ORTHOP RELAT R, pS244; van der Kraan PM, 2002, OSTEOARTHR CARTILAGE, V10, P631, DOI 10.1053/joca.2002.0806; Wang DS, 2001, J BIOL CHEM, V276, P33995, DOI 10.1074/jbc.M007757200; Wang O, 2001, DEVELOPMENT, V128, P3867; Weston AD, 2000, J CELL BIOL, V148, P679, DOI 10.1083/jcb.148.4.679; Weston AD, 2002, J CELL BIOL, V158, P39, DOI 10.1083/jcb.200112029; Yasoda A, 2004, NAT MED, V10, P80, DOI 10.1038/nm971; ZANETTI NC, 1984, J CELL BIOL, V99, P115, DOI 10.1083/jcb.99.1.115	50	188	209	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20509	20515		10.1074/jbc.M410148200	http://dx.doi.org/10.1074/jbc.M410148200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781473	hybrid			2022-12-27	WOS:000229242000044
J	Deponte, M; Urig, S; Arscott, LD; Wolf, KF; Reau, R; Herold-Mende, C; Koncarevic, S; Meyer, M; Davioud-Charvet, E; Ballou, DP; Williams, CH; Becker, K				Deponte, M; Urig, S; Arscott, LD; Wolf, KF; Reau, R; Herold-Mende, C; Koncarevic, S; Meyer, M; Davioud-Charvet, E; Ballou, DP; Williams, CH; Becker, K			Mechanistic studies on a novel, highly potent gold-phosphole inhibitor of human glutathione reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITE PLASMODIUM-FALCIPARUM; THIOREDOXIN REDUCTASE; CRYSTAL-STRUCTURE; CATALYSIS; ENZYME; 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA; SUBSTRATE; BINDING; SYSTEMS; DRUGS	The homodimeric flavoprotein glutathione reductase (GR) is a central player of cellular redox metabolism, connecting NADPH to the large pool of redox-active thiols. In this work, the inhibition of human GR by a novel gold-phosphole inhibitor (GoPI) has been studied in vitro. Two modes of inhibition are observed, reversible inhibition that is competitive with GSSG followed by irreversible inhibition. When similar to 1 nM GoPI is incubated with NADPH-reduced GR (1.4 nM) the enzyme becomes 50% inhibited. This appears to be the most potent stable inhibitor of human GR to date. Analyzing the monophasic oxidative half-reaction of reduced GR with GSSG at pH 6.9 revealed a K-d( app) for GSSG of 63 mu M, and a k((obs)max) of 106 s(-1) at 4 degrees C. The reversible inhibition by the gold-phosphole complex [{1-phenyl-2,5-di(2pyridyl) phosphole} AuCI] involves formation of a complex at the GSSG-binding site of GR ( K-d = 0.46 mu M) followed by nucleophilic attack of an active site cysteine residue that leads to covalent modification and complete inactivation of the enzyme. Data from titration spectra, molecular modeling, stopped-flow, and steady-state kinetics support this theory. In addition, covalent binding of the inhibitor to human GR was demonstrated by mass spectrometry. The extraordinary properties of the compound and its derivatives might be exploited for cell biological studies or medical applications, e. g. as an anti-tumor or antiparasitic drug. Preliminary experiments with glioblastoma cells cultured in vitro indicate an anti-proliferative effect of the inhibitor in the lower micromolar range.	Univ Giessen, Interdisciplinary Res Ctr, D-35392 Giessen, Germany; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Max Planck Inst Med Res, Dept Biophys, D-69120 Heidelberg, Germany; Univ Rennes 1, CNRS, UMR 6509, Inst Chim, F-35042 Rennes, France; Univ Heidelberg, Zentrum Biochem, Dept Head & Neck Surg, D-69120 Heidelberg, Germany; Ciphergen Biosyst GmbH, D-37085 Gottingen, Germany	Justus Liebig University Giessen; University of Michigan System; University of Michigan; Max Planck Society; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; Ruprecht Karls University Heidelberg	Becker, K (corresponding author), Univ Giessen, Interdisciplinary Res Ctr, Heinrich Buff Ring 26-32, D-35392 Giessen, Germany.	becker.katja@gmx.de	dballou@umich.edu, David P/A-1298-2007; Davioud-Charvet, Elisabeth/I-3805-2013	Davioud-Charvet, Elisabeth/0000-0001-7026-4034; Deponte, Marcel/0000-0003-2141-917X	NIGMS NIH HHS [GM11106] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS MJ, 1993, SCIENCE, V261, P725, DOI 10.1126/science.8102010; BECKER K, 1995, EUR J BIOCHEM, V234, P472, DOI 10.1111/j.1432-1033.1995.472_b.x; BECKER K, 1995, METHOD ENZYMOL, V251, P173, DOI 10.1016/0076-6879(95)51120-2; Becker K, 2003, BIOL CHEM, V384, P551, DOI 10.1515/BC.2003.063; Becker K, 2001, J MED CHEM, V44, P2784, DOI 10.1021/jm001014i; Bisswanger H, 2000, ENZYMKINETIK; Bohme CC, 2000, J BIOL CHEM, V275, P37317, DOI 10.1074/jbc.M007695200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Davioud-Charvet E, 2003, BIOCHEMISTRY-US, V42, P13319, DOI 10.1021/bi0353629; Davioud-Charvet E, 2001, J MED CHEM, V44, P4268, DOI 10.1021/jm010268g; DAVIS RE, 1960, J AM CHEM SOC, V82, P5949, DOI 10.1021/ja01507a039; Fave C, 2004, J AM CHEM SOC, V126, P6058, DOI 10.1021/ja0317067; Fave C, 2003, J AM CHEM SOC, V125, P9254, DOI 10.1021/ja035155w; Hay C, 2001, CHEM-EUR J, V7, P4222, DOI 10.1002/1521-3765(20011001)7:19<4222::AID-CHEM4222>3.0.CO;2-3; Hay C, 1999, CHEM COMMUN, P345, DOI 10.1039/a808408d; Herold-Mende C, 1999, LAB INVEST, V79, P1573; Irmler A, 2002, FLAVINS FLAVOPROTEIN, P803; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KARPLUS PA, 1988, EUR J BIOCHEM, V171, P193, DOI 10.1111/j.1432-1033.1988.tb13775.x; KITZ R, 1962, J BIOL CHEM, V237, P3245; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krauth-Siegel RL, 1998, BIOCHEMISTRY-US, V37, P13968, DOI 10.1021/bi980637j; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NORDHOFF A, 1993, BIOCHEMISTRY-US, V32, P4060, DOI 10.1021/bi00066a029; PAI EF, 1983, J BIOL CHEM, V258, P1752; RIETVELD P, 1994, BIOCHEMISTRY-US, V33, P13888, DOI 10.1021/bi00250a043; Sarma GN, 2003, J MOL BIOL, V328, P893, DOI 10.1016/S0022-2836(03)00347-4; Shaw CF, 1999, CHEM REV, V99, P2589, DOI 10.1021/cr980431o; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; Zou J, 2000, ANGEW CHEM INT EDIT, V39, P2931, DOI 10.1002/1521-3773(20000818)39:16<2931::AID-ANIE2931>3.0.CO;2-W	31	73	76	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20628	20637		10.1074/jbc.M412519200	http://dx.doi.org/10.1074/jbc.M412519200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15792952	hybrid			2022-12-27	WOS:000229242000059
J	Essex-Fraser, PA; Steele, SL; Bernier, NJ; Murray, BW; Stevens, ED; Wright, PA				Essex-Fraser, PA; Steele, SL; Bernier, NJ; Murray, BW; Stevens, ED; Wright, PA			Expression of four glutamine synthetase genes in the early stages of development of rainbow trout (Oncorhynchus mykiss) in relationship to nitrogen excretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UREA CYCLE ENZYMES; EARLY-LIFE STAGES; RESPIRATORY GAS-EXCHANGE; GULF TOADFISH; MOLECULAR CHARACTERIZATION; POTENTIAL IMPORTANCE; BRANCHIAL SURFACES; AMMONIA; TELEOST; LIVER	The incorporation of ammonia into glutamine, catalyzed by glutamine synthetase, is thought to be important in the detoxification of ammonia in animals. During early fish development, ammonia is continuously formed as yolk proteins and amino acids are catabolized. We followed the changes in ammonia and ureanitrogen content, ammonia and urea-nitrogen excretion, glutamine synthetase activity, and mRNA expression of four genes coding for glutamine synthetase (Onmy-GS01-GS04) over 3-80 days post fertilization and in adult liver and skeletal muscle of the rainbow trout ( Oncorhynchus mykiss). Both ammonia and urea-nitrogen accumulate before hatching, although the rate of ammonia excretion is considerably higher relative to urea-nitrogen excretion. All four genes were expressed during early development, but only Onmy-GS01 and -GS02 were expressed at appreciable levels in adult liver, and expression was very low in muscle tissue. The high level of expression of Onmy-GS01 and -GS03 prior to hatching corresponded to a linear increase in glutamine synthetase activity. We propose that the induction of glutamine synthetase genes early in development and the subsequent formation of the active protein are preparatory for the increased capacity of the embryo to convert the toxic nitrogen end product, ammonia, into glutamine, which may then be utilized in the ornithineurea cycle or other pathways.	Univ Guelph, Dept Zool, Guelph, ON N1G 2W1, Canada	University of Guelph	Wright, PA (corresponding author), Univ Guelph, Dept Zool, 50 Stone Rd, Guelph, ON N1G 2W1, Canada.	patwrigh@uoguelph.ca	Murray, Brent/F-5031-2012; stevens, don/AAI-6983-2021; Stevens, Ernest/G-9569-2014	Stevens, Ernest/0000-0002-3113-1543				Allendorf F.W., 1984, P1; ANDERSON PM, 1984, J BIOL CHEM, V259, P456; BALLARD WW, 1973, J EXP ZOOL, V184, P7, DOI 10.1002/jez.1401840103; Barimo JF, 2004, J EXP BIOL, V207, P2011, DOI 10.1242/jeb.00956; Billiau AD, 2001, TRANSPLANTATION, V71, P292, DOI 10.1097/00007890-200101270-00022; CAGGESE C, 1994, GENETICA, V94, P275, DOI 10.1007/BF01443441; Chadwick TD, 1999, J EXP BIOL, V202, P2653; COOPER AJL, 1987, PHYSIOL REV, V67, P440, DOI 10.1152/physrev.1987.67.2.440; DEPECHE J, 1979, COMP BIOCHEM PHYS A, V63, P51, DOI 10.1016/0300-9629(79)90626-1; FUCCI L, 1995, GENE, V152, P205, DOI 10.1016/0378-1119(94)00719-9; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; GRIFFITH RW, 1991, ENVIRON BIOL FISH, V32, P199, DOI 10.1007/BF00007454; Ip Y.K., 2001, Fish Physiology, V20, P109; Kelly SP, 2001, J EXP BIOL, V204, P4115; Korsgaard B., 1995, NITROGEN METABOLISM, P259; Korte JJ, 1997, J BIOL CHEM, V272, P6270, DOI 10.1074/jbc.272.10.6270; LAUD PR, 1994, J MOL EVOL, V39, P93; MEAROW KM, 1989, MOL BRAIN RES, V6, P223, DOI 10.1016/0169-328X(89)90068-5; Mistry AC, 2001, AM J PHYSIOL-REG I, V281, pR1594, DOI 10.1152/ajpregu.2001.281.5.R1594; Mommsen TP, 2003, J COMP PHYSIOL B, V173, P419, DOI 10.1007/s00360-003-0350-z; Murray BW, 2003, J EXP BIOL, V206, P1511, DOI 10.1242/jeb.00283; Nagler JJ, 2000, FISH PHYSIOL BIOCHEM, V22, P61, DOI 10.1023/A:1007825013917; Part P, 1998, COMP BIOCHEM PHYS A, V119, P117, DOI 10.1016/S1095-6433(97)00400-5; Pilley CM, 2000, J EXP BIOL, V203, P3199; RahamanNoronha E, 1996, J EXP BIOL, V199, P2713; RAHMATULLAH M, 1980, CLIN CHIM ACTA, V107, P3, DOI 10.1016/0009-8981(80)90407-6; Randall D. J., 2002, Marine Pollution Bulletin, V45, P17, DOI 10.1016/S0025-326X(02)00227-8; Rice S.D., 1974, P325; ROMBOUGH PJ, 1990, J EXP BIOL, V154, P1; Rombough PJ, 1997, J EXP BIOL, V200, P2459; Sakamoto T, 2000, GENETICS, V155, P1331; SHANKAR RA, 1985, ARCH BIOCHEM BIOPHYS, V239, P248, DOI 10.1016/0003-9861(85)90833-1; Smirnov AV, 2000, CLIN CHIM ACTA, V292, P1, DOI 10.1016/S0009-8981(99)00180-1; SMITH S, 1957, METABOLISM, P323; Steele SL, 2001, J EXP BIOL, V204, P2145; Terjesen BF, 1997, FISH PHYSIOL BIOCHEM, V16, P311, DOI 10.1023/A:1007719618473; Terjesen BF, 2001, J EXP BIOL, V204, P2155; Terjesen BF, 2000, COMP BIOCHEM PHYS B, V126, P521, DOI 10.1016/S0305-0491(00)00221-2; Todgham AE, 2001, COMP BIOCHEM PHYS A, V129, P527, DOI 10.1016/S1095-6433(01)00290-2; VERDOUW H, 1978, WATER RES, V12, P399, DOI 10.1016/0043-1354(78)90107-0; Walsh PJ, 2000, J EXP BIOL, V203, P2357; Walsh PJ, 1999, COMP BIOCHEM PHYS B, V124, P251, DOI 10.1016/S0305-0491(99)00105-4; Walsh PJ, 2001, J EXP BIOL, V204, P509; Walsh PJ, 2003, J EXP BIOL, V206, P1523, DOI 10.1242/jeb.00251; Wood Chris M., 1993, P379; Wright P.A., 2001, Fish Physiology, V20, P149; WRIGHT PA, 1995, J EXP BIOL, V198, P127	47	64	66	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20268	20273		10.1074/jbc.M412338200	http://dx.doi.org/10.1074/jbc.M412338200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781468	hybrid			2022-12-27	WOS:000229242000015
J	Martens, GA; Cai, Y; Hinke, S; Stange, G; Van de Casteele, M; Pipeleers, D				Martens, GA; Cai, Y; Hinke, S; Stange, G; Van de Casteele, M; Pipeleers, D			Glucose suppresses superoxide generation in metabolically responsive pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; B-CELLS; MITOCHONDRIAL SUPEROXIDE; UNCOUPLING PROTEINS; INSULIN-SECRETION; ISLET CELLS; TOXICITY; ACTIVATION; EXPRESSION; OXYGEN	High rates of glucose metabolism and mitochondrial electron transport have been associated with increased mitochondrial production of reactive oxygen species (ROS). This mechanism was also proposed as a possible cause for dysfunction and death of pancreatic beta cells exposed to high glucose levels. We examined whether high rates of glucose metabolism increase ROS production in purified rat beta cells. Glucose up to 20 mM did not stimulate H2O2 or superoxide production, whereas it dose-dependently increased cellular NAD(P)H and FADH(2) levels with an EC50 around 8 mM. On the contrary, glucose concentration-dependently suppressed H2O2 and superoxide formation, with a major effect between 0 and 5 mM, parallel to an increase in cellular NAD(P)H levels. This suppressive effect was more marked in beta cells with higher NAD(P)H responsiveness to glucose; it was not observed in glucagon-containing alpha cells, which lacked a glucose-induced increase in NAD(P)H. Suppression was also induced by the mitochondrial substrates leucine and succinate. Experiments with electron transport chain inhibitors indicate a role of respiratory complex I in ROS production at low mitochondrial activity and low NADH levels. Superoxide production at low glucose is potentially cytotoxic, because scavenging by the superoxide dismutase mimetic agent manganese(III)tetrakis(4-benzoic acid) porphyrin was found to reduce the rate of beta cell apoptosis. Analysis of islets cultured at 20 mM glucose confirmed that this condition does not induce ROS production in beta cells as a result of their increased rates of glucose metabolism. Our study indicates the need of beta cells for basal nutrients maintaining mitochondrial NADH production at levels that suppress ROS accumulation from an inadequate respiratory complex I activity and thus inhibit a potential apoptotic pathway.	Free Univ Brussels, VUB, Diabet Res Ctr, B-1090 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Pipeleers, D (corresponding author), Free Univ Brussels, VUB, Diabet Res Ctr, Laarbeeklaan 103, B-1090 Brussels, Belgium.	Daniel.Pipeleers@vub.ac.be	stange, geert m/C-1092-2009; Hinke, Simon/R-7120-2019; Martens, Geert/ABA-6297-2020; Martens, Geert A./F-6920-2015	stange, geert m/0000-0003-3148-1372; Martens, Geert/0000-0003-1208-6289; Martens, Geert A./0000-0003-1208-6289; Van De Casteele, mark/0000-0002-8594-9260; Pipeleers, Daniel/0000-0002-6440-2485				Bennett BD, 1996, J BIOL CHEM, V271, P3647; Bindokas VP, 2003, J BIOL CHEM, V278, P9796, DOI 10.1074/jbc.M206913200; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; CHANCE B, 1967, P NATL ACAD SCI USA, V57, P1498, DOI 10.1073/pnas.57.5.1498; Du YP, 2003, FREE RADICAL BIO MED, V35, P1491, DOI 10.1016/j.freeradbiomed.2003.08.018; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; Fahien LA, 2002, DIABETES, V51, P2669, DOI 10.2337/diabetes.51.9.2669; Fridlyand LE, 2004, DIABETES, V53, P1942, DOI 10.2337/diabetes.53.8.1942; GRANKVIST K, 1981, BIOCHEM J, V199, P393, DOI 10.1042/bj1990393; HATEFI Y, 1968, P NATL ACAD SCI USA, V60, P733, DOI 10.1073/pnas.60.2.733; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; IMLAY JA, 1995, J BIOL CHEM, V270, P19767; Jonas JC, 2003, DIABETOLOGIA, V46, P1234, DOI 10.1007/s00125-003-1174-9; Kaneto H, 1999, DIABETES, V48, P2398, DOI 10.2337/diabetes.48.12.2398; KIEKENS R, 1992, J CLIN INVEST, V89, P117, DOI 10.1172/JCI115551; Kilpatrick ED, 1998, DIABETES, V47, P606, DOI 10.2337/diabetes.47.4.606; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Krauss S, 2003, J CLIN INVEST, V112, P1831, DOI 10.1172/JCI200319774; Kubisch HM, 1997, DIABETES, V46, P1563, DOI 10.2337/diabetes.46.10.1563; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Laybutt DR, 2002, DIABETES, V51, P413, DOI 10.2337/diabetes.51.2.413; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Ling ZD, 1996, DIABETES, V45, P1774, DOI 10.2337/diabetes.45.12.1774; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; MASSEY V, 1994, J BIOL CHEM, V269, P22459; Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; PIPELEERS D, 1986, P NATL ACAD SCI USA, V83, P5267, DOI 10.1073/pnas.83.14.5267; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; Robertson RP, 2004, DIABETES, V53, pS119, DOI 10.2337/diabetes.53.2007.S119; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; Schuit F, 1999, J BIOL CHEM, V274, P32803, DOI 10.1074/jbc.274.46.32803; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; Van de Casteele M, 2002, ENDOCRINOLOGY, V143, P320, DOI 10.1210/en.143.1.320; VANDEWINKEL M, 1983, BIOCHEM BIOPH RES CO, V114, P835, DOI 10.1016/0006-291X(83)90857-4; VANDEWINKEL M, 1982, BIOCHEM BIOPH RES CO, V107, P525, DOI 10.1016/0006-291X(82)91523-6; Vincent AM, 2004, DIABETES, V53, P726, DOI 10.2337/diabetes.53.3.726; Wang HY, 1997, J BIOL CHEM, V272, P25731, DOI 10.1074/jbc.272.41.25731; Wu L, 2004, J BIOL CHEM, V279, P12126, DOI 10.1074/jbc.M307097200; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4	47	100	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20389	20396		10.1074/jbc.M411869200	http://dx.doi.org/10.1074/jbc.M411869200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15774474	hybrid			2022-12-27	WOS:000229242000030
J	Ren, SY; Nguyen, L; Wu, SX; Encinas, C; Adams, JS; Hewison, M				Ren, SY; Nguyen, L; Wu, SX; Encinas, C; Adams, JS; Hewison, M			Alternative splicing of vitamin D-24-hydroxylase - A novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D METABOLISM; CULTURED ALVEOLAR MACROPHAGES; D-RESPONSIVE ELEMENTS; 25-HYDROXYVITAMIN D-3-1-ALPHA-HYDROXYLASE; ELEVATED 1,25-DIHYDROXYVITAMIN-D; 24-HYDROXYLASE CYP24; PROSTATE-CANCER; CALCITROIC ACID; CELL-LINE; D-3	Synthesis of the active form of vitamin D, 1,25-dihydroxyvitamin D ( 1,25-(OH)(2)D), by renal epithelial cells is tightly controlled during normal calcium homeostasis. By contrast, macrophage production of 1,25-( OH) 2D is often dysregulated with potential hypercalcemic complications. We have postulated that this is due to abnormal catabolism of 1,25-(OH) 2D by the feedback control enzyme, vitamin D-24-hydroxylase (CYP24). Using chick HD-11 and human THP-1 myelomonocytic cell lines, we have shown that macrophage-like cells express a splice variant of the CYP24 gene (CYP24-SV), which encodes a truncated protein. Compared with the holo-CYP24 gene product in chick and human cells (508 and 513 amino acids, respectively), the truncated CYP24-SV versions consisted of 351 and 372 amino acids. These CYP24-SV proteins retained intact substrate- binding domains but lacked mitochondrial targeting sequences and were therefore catalytically inactive. In common with CYP24, expression of the CYP24 variants was induced by 1,25( OH) 2D but without a concomitant rise in 24-hydroxylase activity. However, overexpression of CYP24-SV in HD-11 and THP-1 cells reduced synthesis of 1,25-(OH) 2D (40-50%), whereas antisense CYP24-SV expression increased 1,25-(OH) 2D production by 2-7-fold. These data suggest that alternative splicing of CYP24 leads to the generation of a dominant negative-acting protein that is catalytically dysfunctional. We theorize that expression of the CYP24-SV may contribute to the extracellular accumulation of 1,25(OH) 2D in human health and disease.	Univ Birmingham, Biomed Res Inst, Div Med Sci, Birmingham B15 2TT, W Midlands, England; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Div Endocrinol, Dept Med, Los Angeles, CA 90048 USA	University of Birmingham; Cedars Sinai Medical Center	Hewison, M (corresponding author), Univ Birmingham, Biomed Res Inst, Div Med Sci, Birmingham B15 2TT, W Midlands, England.	M.Hewison@bham.ac.uk	Adams, John S/I-3365-2013	Adams, John S/0000-0001-9607-5020	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050626] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00425] Funding Source: Medline; NIAID NIH HHS [AI40403] Funding Source: Medline; NIAMS NIH HHS [AR50626] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abreu MT, 2004, GUT, V53, P1129, DOI 10.1136/gut.2003.036657; ADAMS JS, 1985, J EXP MED, V161, P755, DOI 10.1084/jem.161.4.755; ADAMS JS, 1983, J CLIN INVEST, V72, P1856, DOI 10.1172/JCI111147; ADAMS JS, 1994, ENDOCRINOLOGY, V134, P2567, DOI 10.1210/en.134.6.2567; Akker SA, 2001, J MOL ENDOCRINOL, V27, P123, DOI 10.1677/jme.0.0270123; Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Armbrecht HJ, 1998, ENDOCRINOLOGY, V139, P3375, DOI 10.1210/en.139.8.3375; Bland R, 1999, ENDOCRINOLOGY, V140, P2027, DOI 10.1210/en.140.5.2027; Bland R, 2000, CURR OPIN NEPHROL HY, V9, P17, DOI 10.1097/00041552-200001000-00004; Chen TC, 2003, J CELL BIOCHEM, V88, P315, DOI 10.1002/jcb.10342; Christakos S, 2003, J CELL BIOCHEM, V88, P695, DOI 10.1002/jcb.10423; Christmas P, 1999, J BIOL CHEM, V274, P21191, DOI 10.1074/jbc.274.30.21191; Christmas P, 2001, J BIOL CHEM, V276, P38166; DING SH, 1995, BIOCHEM J, V306, P161, DOI 10.1042/bj3060161; Dusso AS, 1997, J CLIN ENDOCR METAB, V82, P2222, DOI 10.1210/jc.82.7.2222; Fu GK, 1997, MOL ENDOCRINOL, V11, P1961, DOI 10.1210/me.11.13.1961; Henry HL, 2001, STEROIDS, V66, P391, DOI 10.1016/S0039-128X(00)00158-6; Hewison M, 2003, J IMMUNOL, V170, P5382, DOI 10.4049/jimmunol.170.11.5382; Hewison M, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P1379; Huang ZQ, 1997, ARCH BIOCHEM BIOPHYS, V343, P101, DOI 10.1006/abbi.1997.0153; Kerry DM, 1996, J BIOL CHEM, V271, P29715, DOI 10.1074/jbc.271.47.29715; Kong XF, 1999, P NATL ACAD SCI USA, V96, P6988, DOI 10.1073/pnas.96.12.6988; KUMAMOTO T, 1989, J BIOCHEM-TOKYO, V105, P72, DOI 10.1093/oxfordjournals.jbchem.a122622; Lou YR, 2003, FASEB J, V17, P332, DOI 10.1096/fj.03-0140fje; Ly LH, 1999, ENDOCRINOLOGY, V140, P2071, DOI 10.1210/en.140.5.2071; Maas RM, 2001, CLIN CANCER RES, V7, P868; MAKIN G, 1989, BIOCHEM J, V262, P173, DOI 10.1042/bj2620173; Masuda S, 2005, ENDOCRINOLOGY, V146, P825, DOI 10.1210/en.2004-1116; Miller WL, 2000, TRENDS ENDOCRIN MET, V11, P315, DOI 10.1016/S1043-2760(00)00287-3; Monkawa T, 2000, KIDNEY INT, V58, P559, DOI 10.1046/j.1523-1755.2000.00202.x; Neve EPA, 2001, J BIOL CHEM, V276, P11317, DOI 10.1074/jbc.M008640200; Ohyama Y, 1996, J BIOL CHEM, V271, P30381, DOI 10.1074/jbc.271.48.30381; Ohyama Y, 2004, FRONT BIOSCI-LANDMRK, V9, P3007, DOI 10.2741/1455; Omdahl JL, 2002, ANNU REV NUTR, V22, P139, DOI 10.1146/annurev.nutr.22.120501.150216; OMURA T, 1991, METHOD ENZYMOL, V206, P75; OU W, 1986, J BIOCHEM-TOKYO, V100, P1287, DOI 10.1093/oxfordjournals.jbchem.a121835; OU WJ, 1994, J BIOL CHEM, V269, P24673; Panda DK, 2001, P NATL ACAD SCI USA, V98, P7498, DOI 10.1073/pnas.131029498; Pfanner N, 2000, CURR BIOL, V10, pR412, DOI 10.1016/S0960-9822(00)00507-8; REDDY GS, 1989, BIOCHEMISTRY-US, V28, P1763, DOI 10.1021/bi00430a051; REICHEL H, 1987, J CLIN ENDOCR METAB, V65, P1201, DOI 10.1210/jcem-65-6-1201; SHANY S, 1993, J BONE MINER RES, V8, P269; Smith SJ, 1999, J BONE MINER RES, V14, P730, DOI 10.1359/jbmr.1999.14.5.730; St-Arnaud R, 2000, ENDOCRINOLOGY, V141, P2658, DOI 10.1210/en.141.7.2658; Xie ZJ, 2002, J BIOL CHEM, V277, P36987, DOI 10.1074/jbc.M201404200; Zehnder D, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133621; Zehnder D, 2002, AM J PATHOL, V161, P105, DOI 10.1016/S0002-9440(10)64162-4; Zehnder D, 1999, MOL CELL ENDOCRINOL, V151, P213, DOI 10.1016/S0303-7207(99)00039-8; Zehnder D, 2001, J CLIN ENDOCR METAB, V86, P888, DOI 10.1210/jc.86.2.888	49	88	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20604	20611		10.1074/jbc.M414522200	http://dx.doi.org/10.1074/jbc.M414522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15788398	hybrid			2022-12-27	WOS:000229242000056
J	Shi, WW; Mersfelder, J; Hille, R				Shi, WW; Mersfelder, J; Hille, R			The interaction of trimethylamine dehydrogenase and electron-transferring flavoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND COENZYME; AMINO-ACID OXIDASE; METHYLOPHILUS-METHYLOTROPHUS; BACTERIUM W3A1; 3-DIMENSIONAL STRUCTURE; OXIDATION-REDUCTION; TRANSFER COMPLEX; IDENTIFICATION; SULFUR; IRON	The interaction between the physiological electron transfer partners trimethylamine dehydrogenase (TMADH) and electron-transferring flavoprotein (ETF) from Methylophilus methylotrophus has been examined with particular regard to the proposal that the former protein "imprints" a conformational change on the latter. The results indicate that the absorbance change previously attributed to changes in the environment of the FAD of ETF upon binding to TMADH is instead caused by electron transfer from partially reduced, as-isolated TMADH to ETF. Prior treatment of the as-isolated enzyme with the oxidant ferricenium essentially abolishes the observed spectral change. Further, when the semiquinone form of ETF is used instead of the oxidized form, the mirror image of the spectral change seen with as-isolated TMADH and oxidized ETF is observed. This is attributable to a small amount of electron transfer in the reverse of the physiological direction. Kinetic determination of the dissociation constant and limiting rate constant for electron transfer within the complex of (reduced) TMADH with (oxidized) ETF is reconfirmed and discussed in the context of a recently proposed model for the interaction between the two proteins that involves "structural imprinting" of ETF.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	Ohio State University	Hille, R (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	hille.1@osu.edu			NIGMS NIH HHS [GM 52322] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052322] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5327; Basran J, 2000, BIOCHEMISTRY-US, V39, P9188, DOI 10.1021/bi0006868; Basran J, 2001, J BIOL CHEM, V276, P42887, DOI 10.1074/jbc.M108296200; Beinert H, 1978, Methods Enzymol, V54, P111; BEVINGTON RR, 1996, DATA REDUCTION ERROR, P235; DAVIDSON VL, 1986, J BACTERIOL, V166, P812, DOI 10.1128/jb.166.3.812-817.1986; DUPLESSIS ER, 1994, BIOCHEM MOL BIOL INT, V32, P195; FOUST GP, 1969, ANAL BIOCHEM, V27, P530, DOI 10.1016/0003-2697(69)90066-9; GHISLA S, 1979, J BIOL CHEM, V254, P662; HILL CL, 1977, P NATL ACAD SCI USA, V74, P547, DOI 10.1073/pnas.74.2.547; HILLE R, 1984, J BIOL CHEM, V259, P1570; HUSAIN M, 1990, METHOD ENZYMOL, V188, P309; Jang MH, 2000, J BIOL CHEM, V275, P12546, DOI 10.1074/jbc.275.17.12546; Jones M, 2000, J BIOL CHEM, V275, P21349, DOI 10.1074/jbc.M001564200; Jones M, 2002, J BIOL CHEM, V277, P8457, DOI 10.1074/jbc.M111105200; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; LEHMAN TC, 1990, BIOCHEMISTRY-US, V29, P10594, DOI 10.1021/bi00499a004; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; Leys D, 2003, NAT STRUCT BIOL, V10, P219, DOI 10.1038/nsb894; LIM LW, 1988, J BIOL CHEM, V263, P3075; LIM LW, 1986, J BIOL CHEM, V261, P5140; MASSEY V, 1965, BIOCHEMISTRY-US, V4, P1161, DOI 10.1021/bi00882a027; MCINTIRE WS, 1990, METHOD ENZYMOL, V188, P250; NAGY J, 1979, J BIOL CHEM, V254, P2684; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; QUAY S, 1977, BIOCHEMISTRY-US, V16, P3348, DOI 10.1021/bi00634a010; Roberts DL, 1996, P NATL ACAD SCI USA, V93, P14355, DOI 10.1073/pnas.93.25.14355; ROHLFS RJ, 1995, J BIOL CHEM, V270, P22196, DOI 10.1074/jbc.270.38.22196; STEENKAMP DJ, 1976, BIOCHEM BIOPH RES CO, V71, P1289, DOI 10.1016/0006-291X(76)90794-4; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2812; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; Wills PR, 1996, BIOPOLYMERS, V38, P119, DOI 10.1002/(SICI)1097-0282(199601)38:1<119::AID-BIP10>3.0.CO;2-C; Wilson EK, 1997, EUR J BIOCHEM, V243, P393, DOI 10.1111/j.1432-1033.1997.0393a.x; Wilson EK, 1997, BIOCHEMISTRY-US, V36, P41, DOI 10.1021/bi961224q	37	5	6	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20239	20246		10.1074/jbc.M500582200	http://dx.doi.org/10.1074/jbc.M500582200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15760891	hybrid			2022-12-27	WOS:000229242000011
J	Mulrooney, EF; Poon, KKH; McNally, DJ; Brisson, JR; Lam, JS				Mulrooney, EF; Poon, KKH; McNally, DJ; Brisson, JR; Lam, JS			Biosynthesis of UDP-N-acetyl-L-fucosamine, a precursor to the biosynthesis of lipopolysaccharide in Pseudomonas aeruginosa serotype O11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR SOMATIC ANTIGENS; ACETYLGLUCOSAMINE 2-EPIMERASE; O-ANTIGEN; STAPHYLOCOCCUS-AUREUS; CAPSULAR POLYSACCHARIDE; ENZYMATIC-SYNTHESIS; ESCHERICHIA-COLI; D-GLUCOSAMINE; MECHANISM; BACTERIA	UDP-N-acetyl-L-fucosamine is a precursor to L-fucosamine in the lipopolysaccharide of Pseudomonas aeruginosa serotype O11 and the capsule of Staphylococcus aureus type 5. We have demonstrated previously the involvement of three enzymes, WbjB, WbjC, and WbjD, in the biosynthesis of UDP-2-acetamido-2,6-dideoxy-L-galactose or UDP-N-acetyl-L-fucosamine (UDP-L-FucNAc). An intermediate compound from the coupled-reaction of WbjB-WbjC with the initial substrate UDP-2-acetamido-2deoxy-beta-D-glucose or UDP-N-acetyl-D-glucosamine (UDPGlcNAc) was purified, and the structure was determined by NMR spectroscopy to be UDP-2-acetamido-2,6-dideoxy-L-talose (UDP-L-PneNAc). WbjD could then convert this intermediate into a new product with the same mass, consistent with a C-2 epimerization reaction. Those results led us to propose a pathway for the biosynthesis of UDP-L-FucNAc; however, the exact enzymatic activity of each of these proteins has not been defined. Here, we describe a fast protein liquid chromatography (FPLC)-based anion-exchange procedure, which allowed the separation and purification of the products of C-2 epimerization due to WbjD. Also, the application of a cryogenically cooled probe in NMR spectrometry offers the greatest sensitivity for determining the structures of minute quantities of materials, allowing the identification of the final product of the pathway. Our results showed that WbjB is bifunctional, catalyzing firstly C-4, C-6 dehydration and secondly C-5 epimerization in the reaction with the substrate UDP-D-GlcNAc, producing two intermediates. WbjC is also bifunctional, catalyzing C-3 epimerization of the second intermediate followed by reduction at C-4. The FPLC-based procedure provided good resolution of the final product of WbjD reaction from its epimer/substrate UDP-L-PneNAc, and the use of the cryogenically cooled probe in NMR revealed unequivocally that the final product is UDP-L-FucNAc.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Lam, JS (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.	jlam@uoguelph.ca						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISSON JR, 2002, NMR SPECTROSCOPY GLY, P59; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P14993, DOI 10.1021/bi001627x; Chen HW, 2000, P NATL ACAD SCI USA, V97, P11942, DOI 10.1073/pnas.210395097; Chou WK, 2003, J AM CHEM SOC, V125, P2455, DOI 10.1021/ja021309g; Creuzenet C, 2002, J BIOL CHEM, V277, P26769, DOI 10.1074/jbc.M202882200; CRYZ SJ, 1984, INFECT IMMUN, V44, P508, DOI 10.1128/IAI.44.2.508-513.1984; DASGUPTA T, 1994, INFECT IMMUN, V62, P809, DOI 10.1128/IAI.62.3.809-817.1994; Dong CJ, 2003, STRUCTURE, V11, P715, DOI 10.1016/S0969-2126(03)00098-4; ENGELS W, 1985, INFECT IMMUN, V49, P182, DOI 10.1128/IAI.49.1.182-189.1985; Field RA, 2003, BIOCHEMISTRY-US, V42, P7637, DOI 10.1021/bi0345079; FOURNIER JM, 1984, INFECT IMMUN, V45, P87, DOI 10.1128/IAI.45.1.87-93.1984; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; JONES C, 1991, CARBOHYD RES, V221, P95, DOI 10.1016/0008-6215(91)80051-N; Jornvall H, 1999, FEBS LETT, V445, P261, DOI 10.1016/S0014-5793(99)00130-1; KAWAMURA T, 1979, J BIOL CHEM, V254, P8457; Kirkpatrick PN, 2000, CHEM COMMUN, P1565, DOI 10.1039/b004463f; Kneidinger B, 2003, BIOCHEM J, V371, P989, DOI 10.1042/BJ20030099; Kneidinger B, 2003, J BIOL CHEM, V278, P3615, DOI 10.1074/jbc.M203867200; KNIREL YA, 1994, BIOCHEMISTRY-MOSCOW+, V59, P1325; Koplin R, 1997, J BIOL CHEM, V272, P4121, DOI 10.1074/jbc.272.7.4121; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU PHV, 1990, J CLIN MICROBIOL, V28, P922, DOI 10.1128/JCM.28.5.922-925.1990; LIU PV, 1983, INT J SYST BACTERIOL, V33, P256, DOI 10.1099/00207713-33-2-256; Manca MC, 1996, CARBOHYD RES, V281, P155, DOI 10.1016/0008-6215(95)00333-9; Merkel AB, 2004, J BIOL CHEM, V279, P32684, DOI 10.1074/jbc.M404091200; Miller WL, 2004, J BIOL CHEM, V279, P37551, DOI 10.1074/jbc.M404749200; MOREAU M, 1990, CARBOHYD RES, V201, P285, DOI 10.1016/0008-6215(90)84244-O; Morgan PM, 1997, J AM CHEM SOC, V119, P10269, DOI 10.1021/ja971718q; Murkin AS, 2004, BIOCHEMISTRY-US, V43, P14290, DOI 10.1021/bi048606d; PITT TL, 1988, EUR J CLIN MICROBIOL, V7, P238, DOI 10.1007/BF01963095; PRIHAR HS, 1980, BIOCHEMISTRY-US, V19, P495, DOI 10.1021/bi00544a016; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Rocchetta HL, 1999, MICROBIOL MOL BIOL R, V63, P523, DOI 10.1128/MMBR.63.3.523-553.1999; Sala RF, 1996, J AM CHEM SOC, V118, P3033, DOI 10.1021/ja960266z; SALO WL, 1976, BIOCHIM BIOPHYS ACTA, V452, P625, DOI 10.1016/0005-2744(76)90216-3; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SOMPOLINSKY D, 1985, J CLIN MICROBIOL, V22, P828, DOI 10.1128/JCM.22.5.828-834.1985	39	30	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19535	19542		10.1074/jbc.M500612200	http://dx.doi.org/10.1074/jbc.M500612200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15778500	hybrid			2022-12-27	WOS:000229113700015
J	Picard, D; Kao, CC; Hudak, KA				Picard, D; Kao, CC; Hudak, KA			Pokeweed antiviral protein inhibits brome mosaic virus replication in plant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; RIBOSOME-INACTIVATING PROTEINS; TERMINAL DELETION MUTANT; N-GLYCOSIDASE ACTIVITY; EUKARYOTIC RIBOSOMES; SARCIN/RICIN LOOP; MESSENGER-RNA; IN-VIVO; INFECTION; INITIATION	Pokeweed antiviral protein ( PAP) is a ribosome-inactivating protein isolated from the pokeweed plant ( Phytolacca americana) that inhibits the proliferation of several plant and animal viruses. We have shown previously that PAP and nontoxic mutants of PAP can directly depurinate brome mosaic virus (BMV) RNA in vitro, resulting in reduced viral protein translation. Here we expand on these initial studies and, using a barley protoplast system, demonstrate that recombinant PAP and nontoxic mutants isolated from E. coli are able to reduce the accumulation of BMV RNAs in vivo. Pretreatment of only BMV RNA3 with PAP prior to transfection of barley protoplasts reduced the accumulation of all BMV RNAs, with a more severe effect on subgenomic RNA4 levels. Using in vitro RNA synthesis assays, we show that a depurinated template causes the BMV replicase to stall at the template nucleotide adjacent to the missing base. These results provide new insight into the antiviral mechanism of PAP, namely that PAP depurination of BMV RNA impedes both RNA replication and subgenomic RNA transcription. These novel activities are distinct from the PAP-induced reduction of viral RNA translation and represent new targets for the inhibition of viral infection.	York Univ, Dept Biol, Toronto, ON M3J 1P3, Canada; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	York University - Canada; Texas A&M University System; Texas A&M University College Station	Hudak, KA (corresponding author), York Univ, Dept Biol, 4700 Keele St, Toronto, ON M3J 1P3, Canada.	hudak@yorku.ca						Adkins S, 1998, RNA, V4, P455; Ahlquist P, 1992, CURR OPIN GENET DEV, V2, P71, DOI 10.1016/S0959-437X(05)80325-9; Ahola T, 2000, J VIROL, V74, P8803, DOI 10.1128/JVI.74.19.8803-8811.2000; ALLISON R, 1990, P NATL ACAD SCI USA, V87, P1820, DOI 10.1073/pnas.87.5.1820; ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; Bhardwaj K, 2004, J VIROL, V78, P12218, DOI 10.1128/JVI.78.22.12218-12224.2004; Bolognesi A, 2002, J BIOL CHEM, V277, P13709, DOI 10.1074/jbc.M111514200; CHAUDHRY B, 1994, PLANT J, V6, P815, DOI 10.1046/j.1365-313X.1994.6060815.x; DUGGAR B. M., 1925, Ann. Mo. Bot. Gdn., V12, P359, DOI 10.2307/2394061; EADY MP, 1986, P NATL ACAD SCI USA, V84, P5053; ENDO Y, 1988, BIOCHEM BIOPH RES CO, V150, P1032, DOI 10.1016/0006-291X(88)90733-4; ENDO Y, 1987, J BIOL CHEM, V262, P8128; FRENCH R, 1986, SCIENCE, V231, P1294, DOI 10.1126/science.231.4743.1294; FRENCH R, 1987, J VIROL, V61, P1457, DOI 10.1128/JVI.61.5.1457-1465.1987; Hema M, 2004, J VIROL, V78, P1169, DOI 10.1128/JVI.78.3.1169-1180.2004; Hogg M, 2004, EMBO J, V23, P1483, DOI 10.1038/sj.emboj.7600150; Honjo E, 1999, BIOSCI BIOTECH BIOCH, V63, P1291, DOI 10.1271/bbb.63.1291; Hudak KA, 2000, RNA, V6, P369, DOI 10.1017/S1355838200991337; Hudak KA, 2001, VIROLOGY, V279, P292, DOI 10.1006/viro.2000.0647; HUR Y, 1995, P NATL ACAD SCI USA, V92, P8448, DOI 10.1073/pnas.92.18.8448; Kao CC, 2000, MOL PLANT PATHOL, V1, P91, DOI 10.1046/j.1364-3703.2000.00017.x; Kim CH, 2000, NAT STRUCT BIOL, V7, P415, DOI 10.1038/75202; Kong F, 1999, VIROLOGY, V259, P200, DOI 10.1006/viro.1999.9763; KRONER P, 1989, J VIROL, V63, P5302, DOI 10.1128/JVI.63.12.5302-5309.1989; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MARSH LE, 1991, VIROLOGY, V182, P76, DOI 10.1016/0042-6822(91)90650-Z; MILLER WA, 1985, NATURE, V313, P68, DOI 10.1038/313068a0; Nicolas E, 1998, J BIOL CHEM, V273, P17216, DOI 10.1074/jbc.273.27.17216; Parikh BA, 2002, J BIOL CHEM, V277, P41428, DOI 10.1074/jbc.M205463200; Rajamohan F, 1999, PROTEIN EXPRES PURIF, V16, P359, DOI 10.1006/prep.1999.1084; Rajamohan F, 1999, BIOCHEM BIOPH RES CO, V260, P453, DOI 10.1006/bbrc.1999.0922; Schmitz I, 1996, VIROLOGY, V226, P281, DOI 10.1006/viro.1996.0656; Sivakumaran K, 2004, J VIROL, V78, P6091, DOI 10.1128/JVI.78.12.6091-6101.2004; SMIRNYAGINA E, 1994, VIROLOGY, V198, P427, DOI 10.1006/viro.1994.1054; STIRPE F, 1988, NUCLEIC ACIDS RES, V16, P405; Sun JH, 1997, VIROLOGY, V236, P348, DOI 10.1006/viro.1997.8742; Sun JH, 1997, VIROLOGY, V233, P63, DOI 10.1006/viro.1997.8583; Sun JH, 1996, VIROLOGY, V226, P1, DOI 10.1006/viro.1996.0622; TAYLOR S, 1994, PLANT J, V5, P827, DOI 10.1046/j.1365-313X.1994.5060827.x; TOMLINSON JA, 1974, J GEN VIROL, V22, P225, DOI 10.1099/0022-1317-22-2-225; Toulme F, 2000, EMBO J, V19, P6853, DOI 10.1093/emboj/19.24.6853; Tumer NE, 1999, CURR TOP MICROBIOL, V240, P139; Tumer NE, 1997, P NATL ACAD SCI USA, V94, P3866, DOI 10.1073/pnas.94.8.3866; USSERY MA, 1977, ANN NY ACAD SCI, V284, P431, DOI 10.1111/j.1749-6632.1977.tb21979.x; Wang ML, 2003, GENET ENG P, V25, P143; Wang P, 1999, NUCLEIC ACIDS RES, V27, P1900, DOI 10.1093/nar/27.8.1900; Watanabe K, 1997, BIOSCI BIOTECH BIOCH, V61, P994, DOI 10.1271/bbb.61.994; ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0; Zoubenko O, 2000, PLANT MOL BIOL, V44, P219, DOI 10.1023/A:1006443626864	49	37	44	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20069	20075		10.1074/jbc.M413452200	http://dx.doi.org/10.1074/jbc.M413452200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15764597	hybrid			2022-12-27	WOS:000229113700077
J	Linke, T; Dawson, H; Harrison, EH				Linke, T; Dawson, H; Harrison, EH			Isolation and characterization of a microsomal acid retinyl ester hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CARBOXYLESTERASES; BILE-SALT; ENDOPLASMIC-RETICULUM; BINDING-PROTEIN; STELLATE CELLS; HEPATIC-UPTAKE; HYDROLYSIS; METABOLISM; PURIFICATION; EXPRESSION	Previous work demonstrated both acid and neutral, bile salt-independent retinyl ester hydrolase activities in rat liver homogenates. Here we present the purification, identification, and characterization of an acid retinyl ester hydrolase activity from solubilized rat liver microsomes. Purification to homogeneity was achieved by sequential chromatography using SP-Sepharose cation exchange, phenyl-Sepharose hydrophobic interaction, concanavalin A- Sepharose affinity and Superose 12 gel filtration chromatography. The isolated protein had a monomer molecular mass of similar to 62 kDa, as measured by mass spectrometry. Gel filtration chromatography of the purified protein revealed a native molecular mass of similar to 176 kDa, indicating that the protein exists as a homotrimeric complex in solution. The purified protein was identified as carboxylesterase ES-10 (EC 3.1.1.1) by N-terminal Edman sequencing and extensive LC-MS/MS sequence analysis and cross-reaction with an anti-ES-10 antibody. Glycosylation analysis revealed that only one of two potential N-linked glycosylation sites is occupied by a high mannose-type carbohydrate structure. Using retinyl palmitate in a micellar assay system the enzyme was active over a broad pH range and displayed Michaelis-Menten kinetics with a K-m of 86 mu M. Substrate specificity studies showed that ES-10 is also able to catalyze hydrolysis of triolein. Cholesteryl oleate was not a substrate for ES-10 under these assay conditions. Real time reverse transcriptase-PCR and Western blot analysis revealed that ES-10 is highly expressed in liver and lung. Lower levels of ES-10 mRNA were also found in kidney, testis, and heart. A comparison of mRNA expression levels in liver demonstrated that ES-10, ES-4,and ES-3 were expressed at significantly higher levels than ES-2, an enzyme previously thought to play a major role in retinyl ester metabolism in liver. Taken together these data indicate that carboxylesterase ES-10 plays a major role in the hydrolysis of newly-endocytosed, chylomicron retinyl esters in both neutral and acidic membrane compartments of liver cells.	USDA ARS, Lab Phytonutrients, Beltsville, MD 20705 USA; USDA ARS, Lab Nutrients Requirements & Funct, Beltsville, MD 20705 USA	United States Department of Agriculture (USDA); United States Department of Agriculture (USDA)	Harrison, EH (corresponding author), USDA ARS, Lab Phytonutrients, BARC E,Bldg 307C, Beltsville, MD 20705 USA.	harrisoe@ba.ars.usda.gov	Harrison, Earl H/AAN-5378-2021; Dawson, Harry/ABG-2734-2021; Dawson, Harry/H-8242-2013	Dawson, Harry/0000-0002-7648-9952; 	NIDDK NIH HHS [DK044498, R01 DK044498] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044498] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AzaisBraesco V, 1995, BBA-LIPID LIPID MET, V1259, P271, DOI 10.1016/0005-2760(95)00173-5; BLANER WS, 1994, RETINOIDS BIOL CHEM, P299; BLOMHOFF R, 1985, J BIOL CHEM, V260, P3566; BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; Cooper AD, 1997, J LIPID RES, V38, P2173; DIFALUSY MA, 1999, BIOCHIM BIOPHYS ACTA, V1439, P40; Fazio S, 2000, TRENDS CARDIOVAS MED, V10, P23, DOI 10.1016/S1050-1738(00)00033-5; GAD MZ, 1991, J LIPID RES, V32, P685; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; GOLDSTEIN JL, 1975, J BIOL CHEM, V250, P8487; Hagen E, 1999, J LIPID RES, V40, P309; Harrison EH, 1998, ANNU REV NUTR, V18, P259, DOI 10.1146/annurev.nutr.18.1.259; HARRISON EH, 1995, J LIPID RES, V36, P1498; HARRISON EH, 1990, METHOD ENZYMOL, V189, P459; Harrison EH, 1997, BBA-LIPID LIPID MET, V1347, P177, DOI 10.1016/S0005-2760(97)00052-0; HARRISON EH, 1989, J BIOL CHEM, V264, P17142; Hosokawa M, 2001, ARCH BIOCHEM BIOPHYS, V389, P245, DOI 10.1006/abbi.2001.2346; Kristensen DB, 2000, HEPATOLOGY, V32, P268; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MEDDA S, 1992, EUR J BIOCHEM, V206, P801, DOI 10.1111/j.1432-1033.1992.tb16987.x; MENTLEIN R, 1987, BIOCHIM BIOPHYS ACTA, V913, P27, DOI 10.1016/0167-4838(87)90228-7; MENTLEIN R, 1987, BIOCHEM J, V245, P863, DOI 10.1042/bj2450863; MERCIER M, 1994, BBA-LIPID LIPID MET, V1212, P176, DOI 10.1016/0005-2760(94)90251-8; Molotkov A, 2004, BIOCHEM J, V383, P295, DOI 10.1042/BJ20040621; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; NAPOLI JL, 1989, ARCH BIOCHEM BIOPHYS, V274, P192, DOI 10.1016/0003-9861(89)90430-X; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RIGTRUP KM, 1994, AM J CLIN NUTR, V60, P111, DOI 10.1093/ajcn/60.1.111; RIGTRUP KM, 1992, BIOCHEMISTRY-US, V31, P2920, DOI 10.1021/bi00126a011; Sanghani SP, 2002, EUR J BIOCHEM, V269, P4387, DOI 10.1046/j.1432-1033.2002.03121.x; Satoh T, 1998, ANNU REV PHARMACOL, V38, P257, DOI 10.1146/annurev.pharmtox.38.1.257; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schindler R, 1998, EUR J BIOCHEM, V251, P863, DOI 10.1046/j.1432-1327.1998.2510863.x; Silveira ER, 1998, J NUTR BIOCHEM, V9, P446, DOI 10.1016/S0955-2863(98)00040-0; Sun GS, 1997, J BIOL CHEM, V272, P24488, DOI 10.1074/jbc.272.39.24488; van Bennekum AM, 2000, BIOCHEMISTRY-US, V39, P4900, DOI 10.1021/bi9927235; YAN BF, 1995, J BIOL CHEM, V270, P19128, DOI 10.1074/jbc.270.32.19128	40	22	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23287	23294		10.1074/jbc.M413585200	http://dx.doi.org/10.1074/jbc.M413585200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15767260	hybrid			2022-12-27	WOS:000229741800087
J	Benetti, R; Copetti, T; Dell'Orso, S; Melloni, E; Brancolini, C; Monte, M; Schneider, C				Benetti, R; Copetti, T; Dell'Orso, S; Melloni, E; Brancolini, C; Monte, M; Schneider, C			The calpain system is involved in the constitutive regulation of beta-catenin signaling functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; E-CADHERIN; TRANSCRIPTIONAL ACTIVATION; TUMOR PROGRESSION; EPITHELIAL-CELLS; PROTEIN; DROSOPHILA; GROWTH; DEGRADATION; PROSTATE	beta-Catenin is a multifunctional protein serving both as a structural element in cell adhesion and as a signaling component in the Wnt pathway, regulating embryogenesis and tumorigenesis. The signaling fraction of beta-catenin is tightly controlled by the adenomatous polyposis coli-axin-glycogen synthase kinase 3 beta complex, which targets it for proteasomal degradation. It has been recently shown that Ca2(+) release from internal stores results in nuclear export and calpain-mediated degradation of beta-catenin in the cytoplasm. Here we have highlighted the critical relevance of constitutive calpain pathway in the control of beta-catenin levels and functions, showing that small interference RNA knock down of endogenous calpain per se (i.e. in the absence of external stimuli) induces an increase in the free transcriptional competent pool of endogenous beta-catenin. We further characterized the role of the known calpain inhibitors, Gas2 and Calpastatin, demonstrating that they can also control levels, function, and localization of beta-catenin through endogenous calpain regulation. Finally we present Gas2 dominant negative (Gas2DN) as a new tool for regulating calpain activity, providing evidence that it counteracts the described effects of both Gas2 and Calpastatin on beta-catenin and that it works via calpain independently of the classical glycogen synthase kinase 3 beta and proteasome pathway. Moreover, we provide in vitro biochemical evidence showing that Gas2DN can increase the activity of calpain and that in vivo it can induce degradation of stabilized/mutated beta-catenin. In fact, in a context where the classical proteasome pathway is impaired, as in colon cancer cells, Gas2DN biological effects accounted for a significant reduction in proliferation and anchorage-independent growth of colon cancer.	Lab Nazl Consorzio Interuniv Biotecnol, I-34012 Trieste, Italy; Univ Genoa, Dept Expt Med, Biochem Sect, I-16132 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	University of Genoa; University of Genoa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Schneider, C (corresponding author), Lab Nazl Consorzio Interuniv Biotecnol, Area Sci Pk,Padriciano 99, I-34012 Trieste, Italy.	schneide@lncib.it		Monte, Martin/0000-0002-5068-563X; Dell'Orso, Stefania/0000-0002-1634-5631; BRANCOLINI, Claudio/0000-0002-6597-5373; BENETTI, Roberta/0000-0001-8863-0821				Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Ali A, 2001, CHEM REV, V101, P2527, DOI 10.1021/cr000110o; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; BRANCOLINI C, 1992, J CELL BIOL, V117, P1251, DOI 10.1083/jcb.117.6.1251; Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228; Franco S, 2004, EXP CELL RES, V299, P179, DOI 10.1016/j.yexcr.2004.05.021; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gonzalez-Reyes A, 2003, J CELL SCI, V116, P949, DOI 10.1242/jcs.00310; Goriounov D, 2003, J CELL SCI, V116, P1045, DOI 10.1242/jcs.00272; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hegde P, 2001, CANCER RES, V61, P7792; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li G, 2002, P NATL ACAD SCI USA, V99, P13254, DOI 10.1073/pnas.202355799; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Melloni E, 2000, J BIOL CHEM, V275, P82, DOI 10.1074/jbc.275.1.82; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Oving IM, 2002, EUR J CLIN INVEST, V32, P448, DOI 10.1046/j.1365-2362.2002.01004.x; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Polakis P, 2000, GENE DEV, V14, P1837; Rios-Doria J, 2005, PROSTATE, V63, P259, DOI 10.1002/pros.20179; Rios-Doria J, 2004, CANCER RES, V64, P7237, DOI 10.1158/0008-5472.CAN-04-1048; Rios-Doria J, 2003, J BIOL CHEM, V278, P1372, DOI 10.1074/jbc.M208772200; Santella L, 1998, CELL CALCIUM, V23, P123, DOI 10.1016/S0143-4160(98)90110-5; TAKANO E, 1995, FEBS LETT, V362, P93, DOI 10.1016/0014-5793(95)00219-Y; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tompa P, 2001, BIOCHEM BIOPH RES CO, V280, P1333, DOI 10.1006/bbrc.2001.4279; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	42	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22070	22080		10.1074/jbc.M501810200	http://dx.doi.org/10.1074/jbc.M501810200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817486	hybrid			2022-12-27	WOS:000229557900051
J	Felice, MR; De Domenico, I; Li, LT; Ward, DM; Bartok, B; Musci, G; Kaplan, J				Felice, MR; De Domenico, I; Li, LT; Ward, DM; Bartok, B; Musci, G; Kaplan, J			Post-transcriptional regulation of the yeast high affinity iron transport system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICOPPER OXIDASE FET3P; FLUID-PHASE ENDOCYTOSIS; ZRT1 ZINC TRANSPORTER; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; GENE ENCODES; PERMEASE; UBIQUITIN; PROTEIN; EXPRESSION	Saccharomyces cerevisiae transcriptionally regulates the expression of the plasma membrane high affinity iron transport system in response to iron need. This transport system is comprised of the products of the FET3 and FTR1 genes. We show that Fet3p and Ftr1p are post-translationally regulated by iron. Incubation of cells in high iron leads to the internalization and degradation of both Fet3p and Ftr1p. Yeast strains defective in endocytosis (Delta end4) show a reduced iron-induced loss of Fet3p-Ftr1p. In cells with a deletion in the vacuolar protease PEP4, high iron medium leads to the accumulation of Fet3p and Ftr1p in the vacuole. Iron-induced degradation of Fet3p-Ftr1p is significantly reduced in strains containing a deletion of a gene, VTA1, which is involved in multivesicular body ( MVB) sorting in yeast. Sorting through the MVB can involve ubiquitination. We demonstrate that Ftr1p is ubiquitinated, whereas Fet3p is not ubiquitinated. Iron-induced internalization and degradation of Fet3p-Ftr1p occurs in a mutant strain of the E3 ubiquitin ligase RSP5 (rsp5-1), suggesting that Rsp5p is not required. Internalization of Fet3p-Ftr1p is specific for iron and requires both an active Fet3p and Ftr1p, indicating that it is the transport of iron through the iron permease Ftr1p that is responsible for the internalization and degradation of the Fet3p-Ftr1p complex.	Univ Utah, Sch Med, Dept Pathol, Div Immunol & Cell Biol, Salt Lake City, UT 84132 USA; Univ Messina, Dipartimento Sci Microbiol Genet & Mol, I-98166 Messina, Italy	Utah System of Higher Education; University of Utah; University of Messina	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, Div Immunol & Cell Biol, 50 N Med Dr, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu	Musci, Giovanni/H-2862-2012	Musci, Giovanni/0000-0002-5196-709X; felice, maria rosa/0000-0002-4224-2345	NCI NIH HHS [CA 43014] Funding Source: Medline; NIDDK NIH HHS [DK 30534] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030534, R01DK030534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; Askwith CC, 1998, J BIOL CHEM, V273, P22415, DOI 10.1074/jbc.273.35.22415; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; Chen OS, 2002, P NATL ACAD SCI USA, V99, P16922, DOI 10.1073/pnas.232392299; Davis-Kaplan SR, 2004, J BIOL CHEM, V279, P4322, DOI 10.1074/jbc.M310680200; Davis-Kaplan SR, 1998, P NATL ACAD SCI USA, V95, P13641, DOI 10.1073/pnas.95.23.13641; Dunn R, 2001, MOL BIOL CELL, V12, P421, DOI 10.1091/mbc.12.2.421; EIDE D, 1992, J BIOL CHEM, V267, P20774; Gaxiola RA, 1998, P NATL ACAD SCI USA, V95, P4046, DOI 10.1073/pnas.95.7.4046; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Gitan RS, 2000, BIOCHEM J, V346, P329, DOI 10.1042/0264-6021:3460329; Harris ZL, 2004, BLOOD, V103, P4672, DOI 10.1182/blood-2003-11-4060; Hassett RF, 1998, J BIOL CHEM, V273, P23274, DOI 10.1074/jbc.273.36.23274; Hettema EH, 2004, EMBO J, V23, P1279, DOI 10.1038/sj.emboj.7600137; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kosman DJ, 2003, MOL MICROBIOL, V47, P1185, DOI 10.1046/j.1365-2958.2003.03368.x; LESUISSE E, 1991, BIOCHEM J, V280, P545, DOI 10.1042/bj2800545; Lesuisse E, 1998, MICROBIOL-UK, V144, P3455, DOI 10.1099/00221287-144-12-3455; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Li LT, 2001, J BIOL CHEM, V276, P29515, DOI 10.1074/jbc.M103944200; Liu XF, 1999, J BIOL CHEM, V274, P4863, DOI 10.1074/jbc.274.8.4863; Mason PB, 2003, MOL CELL BIOL, V23, P8323, DOI 10.1128/MCB.23.22.8323-8333.2003; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Rutherford JC, 2003, J BIOL CHEM, V278, P27636, DOI 10.1074/jbc.M300076200; Severance S, 2004, BIOCHEM J, V380, P487, DOI 10.1042/BJ20031921; Shiflett SL, 2004, J BIOL CHEM, V279, P10982, DOI 10.1074/jbc.M312669200; Soetens O, 2001, J BIOL CHEM, V276, P43949, DOI 10.1074/jbc.M102945200; Spizzo T, 1997, MOL GEN GENET, V256, P547; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yeo SCL, 2003, J CELL SCI, V116, P3957, DOI 10.1242/jcs.00751; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709	38	84	85	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22181	22190		10.1074/jbc.M414663200	http://dx.doi.org/10.1074/jbc.M414663200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817488	hybrid			2022-12-27	WOS:000229557900063
J	Kim, SJ; Winter, K; Nian, C; Tsuneoka, M; Koda, Y; McIntosh, CHS				Kim, SJ; Winter, K; Nian, C; Tsuneoka, M; Koda, Y; McIntosh, CHS			Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; APOPTOSIS; PHOSPHORYLATION; ACTIVATION; MECHANISMS; CASPASE-9; AKTION; FAMILY; GROWTH	The hormone glucose-dependent insulinotropic polypeptide ( GIP) potently stimulates insulin secretion and promotes beta-cell proliferation and cell survival. In the present study we identified Forkhead (Foxo1)-mediated suppression of the bax gene as a critical component of the effects of GIP on cell survival. Treatment of INS-1( 832/13) beta-cells with GIP resulted in concentration-dependent activation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB)/Foxo1 signaling module. In parallel studies, GIP decreased bax promoter activity. Serial deletion analysis of the bax promoter demonstrated that the region -682 to -320, containing FHRE-II (5AAAACAAACA), was responsible for GIP-mediated effects. Foxo1 bound to FHRE-II in gel mobility shift assays, and Foxo1-FHRE-II interactions conferred GIP responsiveness to the bax promoter. INS-1 cells incubated under proapoptotic and glucolipotoxic conditions demonstrated increased nuclear localization of Foxo1 and bax promoter activity and decreased cytoplasmic phospho-PKB/Foxo1. GIP partially restored expression PKB/Foxo1 and bax promoter activity. Similar protective effects were found with dispersed islet cells from C57BL/6 mice, but not with those from GIP receptor knock-out (GIPR(-/-)) mice. GIP treatment reduced glucolipotoxicity-induced cell death in C57 BL/6 and Bax(-/-) islets, but not GIPR(-/-) mouse islets. Chronic treatment of Vancouver diabetic fatty Zucker rats with GIP resulted in down-regulation of Bax and up-regulation of Bcl-2 in pancreatic beta-cells. The results show that PI3K/PKB/Foxo1 signaling mediates GIP suppression of bax gene expression and that this module is a key pathway by which GIP regulates beta-cell apoptosis in vivo.	Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z3, Canada; Kurume Univ, Sch Med, Dept Forens Med, Div Human Genet, Kurume, Fukuoka 8300011, Japan	University of British Columbia; Kurume University	McIntosh, CHS (corresponding author), Univ British Columbia, Dept Cellular & Physiol Sci, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mcintoch@interchange.ubc.ca	Koda, Yoshiro/AAY-6902-2020	Koda, Yoshiro/0000-0003-1368-0116				Accili D, 2004, DIABETES, V53, P1633, DOI 10.2337/diabetes.53.7.1633; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Arden KC, 2002, ARCH BIOCHEM BIOPHYS, V403, P292, DOI 10.1016/S0003-9861(02)00207-2; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheung PY, 2004, J BIOL CHEM, V279, P45308, DOI 10.1074/jbc.C400333200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dockray JH., 1994, GUT PEPTIDES BIOCH P, P217; Drucker DJ, 2003, MOL ENDOCRINOL, V17, P161, DOI 10.1210/me.2002-0306; Ehses JA, 2003, ENDOCRINOLOGY, V144, P4433, DOI 10.1210/en.2002-0068; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; Farilla L, 2002, ENDOCRINOLOGY, V143, P4397, DOI 10.1210/en.2002-220405; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Hui HX, 2004, J CELL PHYSIOL, V200, P177, DOI 10.1002/jcp.20021; Kaestner KH, 2000, GENE DEV, V14, P142; Kharroubi I, 2004, ENDOCRINOLOGY, V145, P5087, DOI 10.1210/en.2004-0478; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; Kilic M, 2002, CELL DEATH DIFFER, V9, P125, DOI 10.1038/sj/cdd/4400968; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; MacDonald PE, 2001, MOL ENDOCRINOL, V15, P1423, DOI 10.1210/me.15.8.1423; Maestre I, 2003, ENDOCRINOLOGY, V144, P335, DOI 10.1210/en.2001-211282; Miyawaki K, 1999, P NATL ACAD SCI USA, V96, P14843, DOI 10.1073/pnas.96.26.14843; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Prentki M, 2002, DIABETES, V51, pS405, DOI 10.2337/diabetes.51.2007.S405; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Schamberger CJ, 2005, EXP CELL RES, V302, P115, DOI 10.1016/j.yexcr.2004.08.026; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Trumper A, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740233; Trumper A, 2001, MOL ENDOCRINOL, V15, P1559, DOI 10.1210/me.15.9.1559; Uhlik MT, 2003, NAT CELL BIOL, V5, P1104, DOI 10.1038/ncb1071; Unger RH, 2001, DIABETES, V50, pS118, DOI 10.2337/diabetes.50.2007.S118; Webster KA, 2004, CIRC RES, V94, P856, DOI 10.1161/01.RES.0000126699.49835.5D; Winter KD, 2004, DIABETES, V53, pA447; Yamauchi J, 2001, J BIOL CHEM, V276, P23362, DOI 10.1074/jbc.M011752200	41	188	201	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22297	22307		10.1074/jbc.M500540200	http://dx.doi.org/10.1074/jbc.M500540200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817464	hybrid			2022-12-27	WOS:000229557900075
J	Langer, I; Tikhonova, IG; Travers, MA; Archer-Lahlou, E; Escrieut, C; Maigret, B; Fourmy, D				Langer, I; Tikhonova, IG; Travers, MA; Archer-Lahlou, E; Escrieut, C; Maigret, B; Fourmy, D			Evidence that interspecies polymorphism in the human and rat cholecystokinin receptor-2 affects structure of the binding site for the endogenous agonist cholecystokinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B GASTRIN RECEPTOR; PENULTIMATE ASPARTIC-ACID; SINGLE AMINO-ACID; C-TERMINAL AMIDE; A RECEPTOR; DIRECTED MUTAGENESIS; FUNCTIONAL EXPRESSION; TRANSMEMBRANE DOMAINS; NONPEPTIDE AGONISTS; EXTRACELLULAR LOOP	The cholecystokinin (CCK) receptor-2 exerts very important central and peripheral functions by binding the neuropeptides cholecystokinin or gastrin. Because this receptor is a potential therapeutic target, great interest has been devoted to the identification of efficient antagonists. However, interspecies genetic polymorphism that does not alter cholecystokinin-induced signaling was shown to markedly affect activity of synthetic ligands. In this context, precise structural study of the agonist binding site on the human cholecystokinin receptor-2 is a prerequisite to elucidating the molecular basis for its activation and to optimizing properties of synthetic ligands. In this study, using site-directed mutagenesis and molecular modeling, we delineated the binding site for CCK on the human cholecystokinin receptor-2 by mutating amino acids corresponding to that of the rat homolog. By doing so, we demonstrated that, although resembling that of rat homolog, the human cholecystokinin receptor-2 binding site also displays important distinct structural features that were demonstrated by susceptibility to several point mutations (F120A, Y189A, H207A). Furthermore, docking of CCK in the human and rat cholecystokinin receptor-2, followed by dynamic simulations, allowed us to propose a plausible structural explanation of the experimentally observed difference between rat and human cholecystokinin-2 receptors.	CHU Rangueil, Inst Louis Bugnard, INSERM, F-31432 Toulouse, France; Univ Nancy, Chim Theor Lab, F-54506 Vandoeuvre Les Nancy, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine	Fourmy, D (corresponding author), Univ Libre Bruxelles, Fac Med, Chim Biol Lab, 808 Route Lennik, F-31432 Toulouse, France.	fourmyd@toulouse.inserm.fr	Fourmy, Daniel/AAE-3703-2019	Fourmy, Daniel/0000-0001-9910-4827; Travers, Marie-Agnes/0000-0001-5340-7435				Anders J, 1999, BIOCHEMISTRY-US, V38, P6043, DOI 10.1021/bi990269z; Archer-Lahlou E, 2005, J BIOL CHEM, V280, P10664, DOI 10.1074/jbc.M409451200; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; Blaker M, 1998, MOL PHARMACOL, V54, P857, DOI 10.1124/mol.54.5.857; CASCIERI MA, 1992, MOL PHARMACOL, V41, P1096; DEWEERTH A, 1993, BIOCHEM BIOPH RES CO, V194, P811, DOI 10.1006/bbrc.1993.1894; Escrieut C, 2002, J BIOL CHEM, V277, P7546, DOI 10.1074/jbc.M108563200; FONG TM, 1992, J BIOL CHEM, V267, P25668; FOURMY D, 1989, EUR J BIOCHEM, V185, P397, DOI 10.1111/j.1432-1033.1989.tb15128.x; Gales C, 2003, MOL PHARMACOL, V63, P973, DOI 10.1124/mol.63.5.973; Gigoux V, 1999, PROTEIN SCI, V8, P2347; Gigoux V, 1998, J BIOL CHEM, V273, P14380, DOI 10.1074/jbc.273.23.14380; Gigoux V, 1999, J BIOL CHEM, V274, P20457, DOI 10.1074/jbc.274.29.20457; Giragossian C, 2002, BIOCHEMISTRY-US, V41, P4560, DOI 10.1021/bi0160009; Herranz R, 2003, MED RES REV, V23, P559, DOI 10.1002/med.10042; Jagerschmidt A, 1996, EUR J PHARMACOL, V296, P97, DOI 10.1016/0014-2999(95)00676-1; Jagerschmidt A, 1998, MOL PHARMACOL, V53, P878; Kopin AS, 2000, TRENDS PHARMACOL SCI, V21, P346, DOI 10.1016/S0165-6147(00)01526-1; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; Kopin AS, 2003, P NATL ACAD SCI USA, V100, P5525, DOI 10.1073/pnas.0831223100; Kopin AS, 1997, P NATL ACAD SCI USA, V94, P11043, DOI 10.1073/pnas.94.20.11043; LEE YM, 1993, J BIOL CHEM, V268, P8164; MORODER L, 1981, H-S Z PHYSIOL CHEM, V362, P929, DOI 10.1515/bchm2.1981.362.2.929; Noble F, 1999, PHARMACOL REV, V51, P745; OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0; Pommier B, 2003, J NEUROCHEM, V85, P454, DOI 10.1046/j.1471-4159.2003.01690.x; Silvente-Poirot S, 1999, J BIOL CHEM, V274, P23191, DOI 10.1074/jbc.274.33.23191; Silvente-Poirot S, 1998, MOL PHARMACOL, V54, P364, DOI 10.1124/mol.54.2.364; SILVENTE-POIROT S, 1993, EUR J BIOCHEM, V215, P513, DOI 10.1111/j.1432-1033.1993.tb18061.x; VIGUERA AR, 1995, BIOCHEMISTRY-US, V34, P8771, DOI 10.1021/bi00027a028; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691	31	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22198	22204		10.1074/jbc.M501786200	http://dx.doi.org/10.1074/jbc.M501786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817487	Green Published, hybrid			2022-12-27	WOS:000229557900065
J	Chen, LN; Cagniard, B; Mathews, T; Jones, S; Koh, HC; Ding, YM; Carvey, PM; Ling, ZD; Kang, UJ; Zhuang, XX				Chen, LN; Cagniard, B; Mathews, T; Jones, S; Koh, HC; Ding, YM; Carvey, PM; Ling, ZD; Kang, UJ; Zhuang, XX			Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL PARKINSONS-DISEASE; CRYSTAL-STRUCTURE; ANTIOXIDATIVE STRESS; ANDROGEN RECEPTOR; ALPHA-SYNUCLEIN; PROTEIN; ONSET; MUTATIONS; TRANSPORTER; EXPRESSION	Mutations in the DJ-1 gene were recently identified in an autosomal recessive form of early-onset familial Parkinson disease. Structural biology, biochemistry, and cell biology studies have suggested potential functions of DJ-1 in oxidative stress, protein folding, and degradation pathways. However, animal models are needed to determine whether and how loss of DJ-1 function leads to Parkinson disease. We have generated DJ-1 null mice with a mutation that resembles the large deletion mutation reported in patients. Our behavioral analyses indicated that DJ-1 deficiency led to age-dependent and task-dependent motoric behavioral deficits that are detectable by 5 months of age. Unbiased stereological studies did not find obvious dopamine neuron loss in 6-month-and 11-month-old mice. Neurochemical examination revealed significant changes in striatal dopaminergic function consisting of increased dopamine reuptake rates and elevated tissue dopamine content. These data represent the in vivo evidence that loss of DJ-1 function alters nigrostriatal dopaminergic function and produces motor deficits.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA; Univ Chicago, Dept Neurol, Chicago, IL 60637 USA; Rush Univ, Ctr Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Chicago; Wake Forest University; University of Chicago; Rush University	Zhuang, XX (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 924 E 57th St, Chicago, IL 60637 USA.	xzhuang@bsd.uchicago.edu	Jones, Sara R/K-4816-2014; Kang, Un/AAV-2858-2020	Jones, Sara R/0000-0002-3424-7576; Kang, Un/0000-0002-5970-6839; Chen, Lie/0000-0001-9764-4299; Macdonald, Stephen/0000-0001-6306-8035	NIAAA NIH HHS [AA014091] Funding Source: Medline; NINDS NIH HHS [NS32080] Funding Source: Medline; PHS HHS [MS43286] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032080, R01NS032080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [U01AA014091] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abou-Sleiman PM, 2003, ANN NEUROL, V54, P283, DOI 10.1002/ana.10675; Bandopadhyay R, 2004, BRAIN, V127, P420, DOI 10.1093/brain/awh054; BARNEOUD P, 1995, NEUROSCIENCE, V67, P837, DOI 10.1016/0306-4522(95)00112-V; Barzilai A, 2000, ADV RES NEURODEGENER, V8, P59; Ben-Shachar D, 2004, BIOCHEM PHARMACOL, V67, P1965, DOI 10.1016/j.bcp.2004.02.015; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Braak H, 2000, J NEUROL, V247, P3; Budygin EA, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0002.2002; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Carneiro AM, 2002, J NEUROSCI, V22, P7045; Carter RJ, 1999, J NEUROSCI, V19, P3248; Chang JW, 1999, NEUROSCIENCE, V88, P617, DOI 10.1016/S0306-4522(98)00217-6; Dekker MCJ, 2004, J NEURAL TRANSM, V111, P1575, DOI 10.1007/s00702-004-0165-4; Fleming SM, 2004, J NEUROSCI, V24, P9434, DOI 10.1523/JNEUROSCI.3080-04.2004; Gainetdinov RR, 1997, J NEUROCHEM, V69, P1322; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Gorner K, 2004, J BIOL CHEM, V279, P6943, DOI 10.1074/jbc.M309204200; Hague S, 2003, ANN NEUROL, V54, P271, DOI 10.1002/ana.10663; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; Hedrich K, 2004, NEUROLOGY, V62, P389, DOI 10.1212/01.WNL.0000113022.51739.88; Hering R, 2004, HUM MUTAT, V24, P321, DOI 10.1002/humu.20089; Hod Y, 1999, J CELL BIOCHEM, V72, P435, DOI 10.1002/(SICI)1097-4644(19990301)72:3<435::AID-JCB12>3.3.CO;2-8; Honbou K, 2003, J BIOL CHEM, V278, P31380, DOI 10.1074/jbc.M305878200; Huai Q, 2003, FEBS LETT, V549, P171, DOI 10.1016/S0014-5793(03)00764-6; Jankovic J, 2000, ARCH NEUROL-CHICAGO, V57, P369, DOI 10.1001/archneur.57.3.369; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; Lee SJ, 2003, J BIOL CHEM, V278, P44552, DOI 10.1074/jbc.M304517200; Lotharius J, 2000, J BIOL CHEM, V275, P38581, DOI 10.1074/jbc.M005385200; LOWE J, 1988, J PATHOL, V155, P9, DOI 10.1002/path.1711550105; Macedo MG, 2003, HUM MOL GENET, V12, P2807, DOI 10.1093/hmg/ddg304; MANETTO V, 1988, P NATL ACAD SCI USA, V85, P4501, DOI 10.1073/pnas.85.12.4501; Martinat C, 2004, PLOS BIOL, V2, P1754, DOI 10.1371/journal.pbio.0020327; Mazzola JL, 2002, NEUROTOXICOLOGY, V23, P603, DOI 10.1016/S0161-813X(02)00062-1; McLaughlin BA, 1998, J NEUROCHEM, V70, P2406; Miller DW, 2003, J BIOL CHEM, V278, P36588, DOI 10.1074/jbc.M304272200; Mitsumoto A, 2001, FREE RADICAL RES, V35, P885, DOI 10.1080/10715760100301381; Mitsumoto A, 2001, FREE RADICAL RES, V35, P301, DOI 10.1080/10715760100300831; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; Moore DJ, 2003, J NEUROCHEM, V87, P1558, DOI 10.1111/j.1471-4159.2003.02265.x; Mouton P.R., 2001, PRINCIPLES PRACTICES; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Niki T, 2003, MOL CANCER RES, V1, P247; Nolan MF, 2003, CELL, V115, P551, DOI 10.1016/S0092-8674(03)00884-5; Okada M, 2002, BIOL PHARM BULL, V25, P853, DOI 10.1248/bpb.25.853; Olzmann JA, 2004, J BIOL CHEM, V279, P8506, DOI 10.1074/jbc.M311017200; Phillips PEM, 2003, BRAIN RES, V961, P63, DOI 10.1016/S0006-8993(02)03840-4; Sasaki S, 2004, NEUROLOGY, V63, P678, DOI 10.1212/01.WNL.0000134657.25904.0B; Shang H, 2004, NEUROSCI LETT, V367, P273, DOI 10.1016/j.neulet.2004.06.002; Shendelman S, 2004, PLOS BIOL, V2, P1764, DOI 10.1371/journal.pbio.0020362; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; Stokes AH, 2000, BRAIN RES, V858, P1, DOI 10.1016/S0006-8993(99)02329-X; Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Takahashi-Niki K, 2004, BIOCHEM BIOPH RES CO, V320, P389, DOI 10.1016/j.bbrc.2004.05.187; Tao X, 2003, J BIOL CHEM, V278, P31372, DOI 10.1074/jbc.M304221200; Tatton NA, 2000, EXP NEUROL, V166, P29, DOI 10.1006/exnr.2000.7489; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aje/kwg068; Wagenfeld A, 2000, J ANDROL, V21, P954; Weydt P, 2003, NEUROREPORT, V14, P1051, DOI 10.1097/01.wnr.0000073685.00308.89; Whishaw IQ, 2002, BEHAV BRAIN RES, V133, P165, DOI 10.1016/S0166-4328(01)00479-X; Wilson MA, 2003, P NATL ACAD SCI USA, V100, P9256, DOI 10.1073/pnas.1133288100; Zhuang XX, 2001, P NATL ACAD SCI USA, V98, P1982, DOI 10.1073/pnas.98.4.1982	66	285	294	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21418	21426		10.1074/jbc.M413955200	http://dx.doi.org/10.1074/jbc.M413955200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799973	hybrid			2022-12-27	WOS:000229438800062
J	Nemeria, N; Tittmann, K; Joseph, E; Zhou, L; Vazquez-Coll, MB; Arjunan, P; Hubner, G; Furey, W; Jordan, F				Nemeria, N; Tittmann, K; Joseph, E; Zhou, L; Vazquez-Coll, MB; Arjunan, P; Hubner, G; Furey, W; Jordan, F			Glutamate 636 of the Escherichia coli pyruvate dehydrogenase-E1 participates in active center communication and behaves as an engineered acetolactate synthase with unusual stereoselectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX E1 SUBUNIT; REDUCTIVE ACETYLATION; MULTIENZYME COMPLEX; BENZOYLFORMATE DECARBOXYLASE; ACETOHYDROXYACID SYNTHASE; ANGSTROM RESOLUTION; ACID-BASE; DIPHOSPHATE; ENZYMES; BINDING	The residue Glu(636) is located near the thiamine diphosphate ( ThDP) binding site of the Escherichia coli pyruvate dehydrogenase complex E1 subunit (PDHc-E1), and to probe its function two variants, E636A and E636Q were created with specific activities of 2.5 and 26% compared with parental PDHc-E1. According to both fluorescence binding and kinetic assays, the E636A variant behaved according to half-of-the-sites mechanism with respect to ThDP. In contrast, with the E636Q variant a K-d,K-ThDP = 4.34 mu M and K-m,K- ThDP = 11 mu M were obtained with behavior more reminiscent of the parental enzyme. The CD spectra of both variants gave evidence for formation of the 1', 4'- iminopyrimidine tautomer on binding of phosphonolactylthiamine diphosphate, a stable analog of the substrate-ThDP covalent complex. Rapid formation of optically active (R)- acetolactate by both variants, but not by the parental enzyme, was observed by CD and NMR spectroscopy. The acetolactate configuration produced by the Glu636 variants is opposite that produced by the enzyme acetolactate synthase and the Asp(28)-substituted variants of yeast pyruvate decarboxylase, suggesting that the active centers of the two sets of enzymes exhibit different facial selectivity ( re or si) vis a vis pyruvate. The tryptic peptide map ( mass spectral analysis) revealed that the Glu636 substitution changed the mobility of a loop comprising amino acid residues from the ThDP binding fold. Apparently, the residue Glu636 has important functions both in active center communication and in protecting the active center from undesirable "carboligase" side reactions.	Rutgers State Univ, Dept Chem, Newark, NJ 07102 USA; Univ Halle Wittenberg, D-06099 Halle An Der Saale, Germany; Univ Puerto Rico, Mayaguez, PR 00681 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Vet Affairs Med Ctr, Pittsburgh, PA 15240 USA	Rutgers State University Newark; Rutgers State University New Brunswick; Martin Luther University Halle Wittenberg; University of Puerto Rico; University of Puerto Rico Mayaguez; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Nemeria, N (corresponding author), Rutgers State Univ, Dept Chem, 73 Warren St, Newark, NJ 07102 USA.	nemeria@andromeda.rutgers.edu; frjordan@newark.rutgers.edu			NIGMS NIH HHS [GM-61791, GM-62330] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061791, R01GM062330] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI ST, 1990, BIOCHEM J, V271, P39; Arjunan P, 2002, BIOCHEMISTRY-US, V41, P5213, DOI 10.1021/bi0118557; Arjunan P, 2004, BIOCHEMISTRY-US, V43, P2405, DOI 10.1021/bi030200y; BAGGETTO LG, 1987, J BIOL CHEM, V262, P9535; BERNASCONI CF, 1976, RELAXATION KINETICS, P24; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chipman D, 1998, BBA-PROTEIN STRUCT M, V1385, P401, DOI 10.1016/S0167-4838(98)00083-1; Engel S, 2004, J BIOL CHEM, V279, P24803, DOI 10.1074/jbc.M401667200; Frank RAW, 2004, SCIENCE, V306, P872, DOI 10.1126/science.1101030; Hasson MS, 1998, BIOCHEMISTRY-US, V37, P9918, DOI 10.1021/bi973047e; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; Jordan F, 2003, J AM CHEM SOC, V125, P12732, DOI 10.1021/ja0346126; JORDAN F, 2004, PERSPECT SCI, V306, P818; JUNI E, 1956, J BIOL CHEM, V218, P365; KHAILOVA LS, 1983, BIOCHEM INT, V7, P423; KOIKE M, 1960, J BIOL CHEM, V235, P1924; Nakai T, 2004, J MOL BIOL, V337, P1011, DOI 10.1016/j.jmb.2004.02.011; NEET KE, 1983, CONT ENZYME KINETICS, P267; Nemeria N, 2004, BIOCHEMISTRY-US, V43, P6565, DOI 10.1021/bi049549r; Nemeria N, 2002, BIOCHEMISTRY-US, V41, P15459, DOI 10.1021/bi0205909; Nemeria N, 1998, BIOCHEMISTRY-US, V37, P911, DOI 10.1021/bi9722251; Nemeria N, 2001, J BIOL CHEM, V276, P45969, DOI 10.1074/jbc.M104116200; Park YH, 2004, BIOCHEMISTRY-US, V43, P14037, DOI 10.1021/bi049027b; Polovnikova ES, 2003, BIOCHEMISTRY-US, V42, P1820, DOI 10.1021/bi026490k; Sergienko EA, 2001, BIOCHEMISTRY-US, V40, P7369, DOI 10.1021/bi002856m; SUNDSTROM M, 1992, FEBS LETT, V313, P229, DOI 10.1016/0014-5793(92)81197-T; Tittmann K, 2005, P NATL ACAD SCI USA, V102, P553, DOI 10.1073/pnas.0408210101; Tittmann K, 2003, BIOCHEMISTRY-US, V42, P7885, DOI 10.1021/bi034465o; Tittmann K, 2004, BIOCHEMISTRY-US, V43, P8652, DOI 10.1021/bi049897t; Wei W, 2003, PROTEIN EXPRES PURIF, V28, P140, DOI 10.1016/S1046-5928(02)00674-5; Wu YG, 2000, EUR J BIOCHEM, V267, P6493, DOI 10.1046/j.1432-1327.2000.01744.x; Yi JZ, 1996, J BIOL CHEM, V271, P33192, DOI 10.1074/jbc.271.52.33192	32	29	31	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21473	21482		10.1074/jbc.M502691200	http://dx.doi.org/10.1074/jbc.M502691200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802265	hybrid			2022-12-27	WOS:000229438800068
J	Rose, C; Kresse, W; Kettenmann, H				Rose, C; Kresse, W; Kettenmann, H			Acute insult of ammonia leads to calcium-dependent glutamate release from cultured astrocytes, an effect of pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LIVER-FAILURE; EXTRACELLULAR BRAIN GLUTAMATE; RAT CORTICAL ASTROCYTES; NEUROACTIVE AMINO-ACIDS; INTRACELLULAR PH; SENSORY NEURONS; FRONTAL-CORTEX; GLIAL-CELLS; MICRODIALYSIS; EXOCYTOSIS	Hyperammonemia is a key factor in the pathogenesis of hepatic encephalopathy (HE) as well as other metabolic encephalopathies, such as those associated with inherited disorders of urea cycle enzymes and in Reye's syndrome. Acute HE results in increased brain ammonia (up to 5 mM), astrocytic swelling, and altered glutamatergic function. In the present study, using fluorescence imaging techniques, acute exposure (10 min) of ammonia (NH4+/NH3) to cultured astrocytes resulted in a concentration-dependent, transient increase in [Ca2+](i). This calcium transient was due to release from intracellular calcium stores, since the response was thapsigargin-sensitive and was still observed in calcium-free buffer. Using an enzyme-linked fluorescence assay, glutamate release was measured indirectly via the production of NADH ( a naturally fluorescent product when excited with UV light). NH4+/NH3 (5 mM) stimulated a calcium- dependent glutamate release from cultured astrocytes, which was inhibited after preincubation with 1,2-bis(2-aminophenoxy) ethane- N, N, N', N'-tetraacetic acid acetoxymethyl ester but unaffected after preincubation with glutamate transport inhibitors dihydrokainate and DL-threo-beta-benzyloxyaspartate. NH4+/NH3 (5 mM) also induced a transient intracellular alkaline shift. To investigate whether the effects of NH4+/ NH3 were mediated by an increase in pH(i), we applied trimethylamine (TMA(+)/TMA) as another weak base. TMA(+)/TMA ( 5 mM) induced a similar transient increase in both pHi and [Ca2+](i) ( mobilization from intracellular calcium stores) and resulted in calcium-dependent release of glutamate. These results indicate that an acute exposure to ammonia, resulting in cytosolic alkalinization, leads to calcium- dependent glutamate release from astrocytes. A deregulation of glutamate release from astrocytes by ammonia could contribute to glutamate dysfunction consistently observed in acute HE.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kettenmann, H (corresponding author), Max Delbruck Ctr Mol Med, 10 Robert Rossle Str, D-13092 Berlin, Germany.	kettenmann@mdc-berlin.de	Rose, Christopher F/F-1105-2010; Kettenmann, Helmut/AAJ-5142-2021	Rose, Christopher F/0000-0001-9854-6834; Kettenmann, Helmut/0000-0001-8208-0291				ALBRECHT J, 1994, BRAIN RES, V660, P228; Allert N, 1998, BRAIN RES, V782, P261, DOI 10.1016/S0006-8993(97)01288-2; Anderson CM, 2001, J NEUROCHEM, V79, P1207; Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; AYOUB GS, 1991, J NEUROSCI METH, V37, P7, DOI 10.1016/0165-0270(91)90016-S; Bezzi P, 2004, NAT NEUROSCI, V7, P613, DOI 10.1038/nn1246; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; BOSMAN DK, 1992, J NEUROCHEM, V59, P591, DOI 10.1111/j.1471-4159.1992.tb09410.x; BOYARSKY G, 1993, GLIA, V8, P241, DOI 10.1002/glia.440080404; Chan H, 2000, NEUROCHEM INT, V37, P243, DOI 10.1016/S0197-0186(00)00026-7; DANTHULURI NR, 1990, J BIOL CHEM, V265, P19071; DEKNEGT RJ, 1994, J HEPATOL, V20, P19, DOI 10.1016/S0168-8278(05)80462-3; FAFFMICHALAK L, 1994, GLIA, V10, P114, DOI 10.1002/glia.440100205; Felipo V, 2002, PROG NEUROBIOL, V67, P259, DOI 10.1016/S0301-0082(02)00019-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hermenegildo C, 2000, HEPATOLOGY, V31, P709, DOI 10.1002/hep.510310322; Hilgier W, 1999, J NEUROSCI RES, V56, P76, DOI 10.1002/(SICI)1097-4547(19990401)56:1<76::AID-JNR10>3.0.CO;2-Y; Innocenti B, 2000, J NEUROSCI, V20, P1800; Jeremic A, 2001, J NEUROCHEM, V77, P664, DOI 10.1046/j.1471-4159.2001.00272.x; Kaila K., 1998, PH BRAIN FUNCTION; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Knecht K, 1997, NEUROSCI LETT, V229, P201, DOI 10.1016/S0304-3940(97)00444-8; Kreft M, 2004, GLIA, V46, P437, DOI 10.1002/glia.20018; Longuemare MC, 1999, NEUROSCIENCE, V93, P285, DOI 10.1016/S0306-4522(99)00152-9; Lyons SA, 1998, J CEREBR BLOOD F MET, V18, P521, DOI 10.1097/00004647-199805000-00007; Marcaggi P, 2001, PROG NEUROBIOL, V64, P157, DOI 10.1016/S0301-0082(00)00043-5; Michalak A, 1996, HEPATOLOGY, V24, P908, DOI 10.1002/hep.510240425; Minelli A, 2000, PFLUG ARCH EUR J PHY, V439, P370, DOI 10.1007/s004240050952; MIRONOV SL, 1993, NEUROREPORT, V4, P1055, DOI 10.1097/00001756-199308000-00016; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; Nicholson C, 1998, TRENDS NEUROSCI, V21, P207, DOI 10.1016/S0166-2236(98)01261-2; Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pasti L, 2001, J NEUROSCI, V21, P477, DOI 10.1523/JNEUROSCI.21-02-00477.2001; Rose C, 2000, HEPATOLOGY, V31, P872, DOI 10.1053/he.2000.5923; Rose C, 2002, METAB BRAIN DIS, V17, P251, DOI 10.1023/A:1021945515514; Rose Christine R., 1998, P253; SALTER MW, 1994, J NEUROSCI, V14, P1563, DOI 10.1523/JNEUROSCI.14-03-01563.1994; SHORTE SL, 1991, CELL CALCIUM, V12, P301, DOI 10.1016/0143-4160(91)90004-X; Speake T, 1998, J PHYSIOL-LONDON, V506, P415, DOI 10.1111/j.1469-7793.1998.415bw.x; SWAIN M, 1992, HEPATOLOGY, V15, P449, DOI 10.1002/hep.1840150316; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; USACHEV Y, 1993, NEUROSCIENCE, V57, P845, DOI 10.1016/0306-4522(93)90029-F; Zhang Q, 2004, J BIOL CHEM, V279, P12724, DOI 10.1074/jbc.M312845200; Zwingmann C, 2003, HEPATOLOGY, V37, P420, DOI 10.1053/jhep.2003.50052	45	87	90	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20937	20944		10.1074/jbc.M412448200	http://dx.doi.org/10.1074/jbc.M412448200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802262	Green Submitted, hybrid			2022-12-27	WOS:000229438800006
J	Seidle, HF; Bieganowski, P; Brenner, C				Seidle, HF; Bieganowski, P; Brenner, C			Disease-associated mutations inactivate AMP-lysine hydrolase activity of aprataxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCULAR MOTOR APRAXIA; EARLY-ONSET ATAXIA; GENE-MUTATIONS; CEREBELLAR-ATAXIA; HISTIDINE TRIAD; HINT; FHIT; SPECIFICITY; PROTEIN; HYPOALBUMINEMIA	Ataxia-oculomotor apraxia syndrome 1 is an early onset cerebellar ataxia that results from loss of function mutations in the APTX gene, encoding Aprataxin, which contains three conserved domains. The forkhead-associated domain of Aprataxin mediates protein-protein interactions with molecules that respond to DNA damage, but the cellular phenotype of the disease does not appear to be consistent with a major loss in DNA damage responses. Disease-associated mutations in Aprataxin target a histidine triad domain that is similar to Hint, a universally conserved AMP-lysine hydrolase, or truncate the protein NH2-terminal to a zinc finger. With novel fluorigenic substrates, we demonstrate that Aprataxin possesses an active-site-dependent AMP-lysine and GMP-lysine hydrolase activity that depends additionally on the zinc finger for protein stability and on the forkhead associated domain for enzymatic activity. Alleles carrying any of eight recessive mutations associated with ataxia and oculomotor apraxia encode proteins with huge losses in protein stability and enzymatic activity, consistent with a null phenotype. The mild presentation allele, APTX-K197Q, associated with ataxia but not oculomotor apraxia, encodes a protein with a mild defect in stability and activity, while enzyme encoded by the atypical presentation allele, APTX-R199H, retained substantial function, consistent with altered and not loss of activity. The data suggest that the essential function of Aprataxin is reversal of nucleoti-dylylated protein modifications, that all three domains contribute to formation of a stable enzyme, and that the in vitro behavior of cloned APTX alleles can score disease-associated mutations.	Dartmouth Coll Sch Med, Sch Med, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Sch Med, Dept Genet, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Sch Med, Dept Biochem, Lebanon, NH 03756 USA	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Dartmouth College	Brenner, C (corresponding author), Dartmouth Coll Sch Med, Sch Med, Norris Cotton Canc Ctr, Rubin 733-HB7937, Lebanon, NH 03756 USA.	charles.brenner@dartmouth.edu	Bieganowski, Pawel/ABC-8554-2021; Brenner, Charles/D-6339-2014	Bieganowski, Pawel/0000-0002-1169-4517; Brenner, Charles/0000-0002-4955-3226	NCI NIH HHS [R01 CA075954-08, CA75954, R01 CA075954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AICARDI J, 1988, ANN NEUROL, V24, P497, DOI 10.1002/ana.410240404; Amouri R, 2004, NEUROLOGY, V63, P928, DOI 10.1212/01.WNL.0000137044.06573.46; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Chen YZ, 2004, AM J HUM GENET, V74, P1128, DOI 10.1086/421054; Chou TF, 2005, J BIOL CHEM, V280, P15356, DOI 10.1074/jbc.M500434200; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Clements PM, 2004, DNA REPAIR, V3, P1493, DOI 10.1016/j.dnarep.2004.06.017; Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Draganescu A, 2000, J BIOL CHEM, V275, P4555, DOI 10.1074/jbc.275.7.4555; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Gueven N, 2004, HUM MOL GENET, V13, P1081, DOI 10.1093/hmg/ddh122; Habeck M, 2004, J NEUROL, V251, P591, DOI 10.1007/s00415-004-0374-7; Hirano M, 2004, BIOCHEM BIOPH RES CO, V322, P380, DOI 10.1016/j.bbrc.2004.07.135; Huang K, 2004, BIOCHEMISTRY-US, V43, P7637, DOI 10.1021/bi049762n; Kaytor MD, 2002, CURR OPIN NEUROBIOL, V12, P275, DOI 10.1016/S0959-4388(02)00320-3; Krakowiak A, 2004, J BIOL CHEM, V279, P18711, DOI 10.1074/jbc.M314271200; Kwasnicka DA, 2003, J BIOL CHEM, V278, P39051, DOI 10.1074/jbc.M306355200; Le Ber I, 2003, BRAIN, V126, P2761, DOI 10.1093/brain/awg283; Luo H, 2004, MOL CELL BIOL, V24, P8356, DOI 10.1128/MCB.24.19.8356-8365.2004; Moreira MC, 2004, NAT GENET, V36, P225, DOI 10.1038/ng1303; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; Pace HC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r18; Parks KP, 2004, PHYSIOL GENOMICS, V20, P12, DOI 10.1152/physiolgenomics.00204.2004; Quinzii CM, 2005, NEUROLOGY, V64, P539, DOI 10.1212/01.WNL.0000150588.75281.58; Sano Y, 2004, ANN NEUROL, V55, P241, DOI 10.1002/ana.10808; Shimazaki H, 2002, NEUROLOGY, V59, P590, DOI 10.1212/WNL.59.4.590; Shults CW, 2003, CURR MED CHEM, V10, P1917, DOI 10.2174/0929867033456882; Tranchant C, 2003, NEUROLOGY, V60, P868, DOI 10.1212/01.WNL.0000048562.88536.A4	31	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20927	20931		10.1074/jbc.M502889200	http://dx.doi.org/10.1074/jbc.M502889200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15790557	hybrid, Green Accepted			2022-12-27	WOS:000229438800004
J	Wei, AD; Butler, A; Salkoff, L				Wei, AD; Butler, A; Salkoff, L			KCNQ-like potassium channels in Caenorhabditis elegans - Conserved properties and modulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; FUNCTIONAL EXPRESSION; SIGNALING COMPLEX; C-ELEGANS; INHIBITION; GENE; MUTATION; SUBUNIT; PIP2; MECHANISM	The human KCNQ gene family encodes potassium channels linked to several genetic syndromes including neonatal epilepsy, cardiac arrhythmia, and progressive deafness. KCNQ channels form M-type potassium channels, which are critical regulators of neuronal excitability that mediate autonomic responses, pain, and higher brain function. Fundamental mechanisms of the normal and abnormal cellular roles for these channels may be gained from their study in simple model organisms. Here we report that a multigene family of KCNQ-like channels is present in the nematode, Caenorhabditis elegans. We show that many aspects of the functional properties, tissue expression pattern, and modulation of these C. elegans channels are conserved, including suppression by the M1 muscarinic receptor. We also describe a conserved mechanism of modulation by diacylglycerol for a subset of C. elegans and vertebrate KCNQ/ KQT channels, which is dependent upon the carboxyl-terminal domains of channel subunits and activated protein kinase C.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Salkoff, L (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	salkoffl@wustl.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR017342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067154] Funding Source: NIH RePORTER; NCRR NIH HHS [R24RR017342-02] Funding Source: Medline; NIGMS NIH HHS [R01GM067154-02] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVERY L, 1997, C ELEGANS, V2, P679, DOI [10.1101/087969532.33.679, DOI 10.1101/087969532.33.679]; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bianchi L, 2003, J BIOL CHEM, V278, P12415, DOI 10.1074/jbc.M212788200; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; BROWN DA, 1989, J PHYSIOL-LONDON, V413, P469, DOI 10.1113/jphysiol.1989.sp017664; CAULFIELD MP, 1994, J PHYSIOL-LONDON, V477, P415, DOI 10.1113/jphysiol.1994.sp020203; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; Crary JI, 2000, J GEN PHYSIOL, V116, P769, DOI 10.1085/jgp.116.6.769; Crary JI, 2000, J GEN PHYSIOL, V116, P755, DOI 10.1085/jgp.116.6.755; Gamper N, 2003, J GEN PHYSIOL, V122, P17, DOI 10.1085/jgp.200208783; Gamper N, 2003, J NEUROSCI, V23, P84; GORDON SE, 1995, BIOPHYS J, V69, P409, DOI 10.1016/S0006-3495(95)79913-1; Hadley JK, 2003, J NEUROSCI, V23, P5012; Haley JE, 2000, J NEUROSCI, V20, P3973; Hardie RC, 2003, ANNU REV PHYSIOL, V65, P735, DOI 10.1146/annurev.physiol.65.092101.142505; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HIGASHIDA H, 1995, J PHYSIOL-LONDON, V482, P317, DOI 10.1113/jphysiol.1995.sp020520; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hoshi N, 2003, NAT NEUROSCI, V6, P564, DOI 10.1038/nn1062; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; Jentsch TJ, 2000, NAT REV NEUROSCI, V1, P21, DOI 10.1038/35036198; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Lerche C, 2000, J BIOL CHEM, V275, P22395, DOI 10.1074/jbc.M002378200; Loussouarn G, 2003, EMBO J, V22, P5412, DOI 10.1093/emboj/cdg526; Maljevic S, 2003, J PHYSIOL-LONDON, V548, P353, DOI 10.1113/jphysiol.2003.040980; Marrion NV, 1996, NEURON, V16, P163, DOI 10.1016/S0896-6273(00)80033-1; Marx SO, 2002, SCIENCE, V295, P496, DOI 10.1126/science.1066843; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Montell C, 2005, SCI STKE; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Santi CM, 2003, P NATL ACAD SCI USA, V100, P14391, DOI 10.1073/pnas.1935976100; Schroeder BC, 2000, J BIOL CHEM, V275, P24089, DOI 10.1074/jbc.M003245200; Schroeder BC, 1998, NATURE, V396, P687, DOI 10.1038/25367; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Schwake M, 2003, EMBO REP, V4, P76, DOI 10.1038/sj.embor.embor715; Selyanko AA, 2000, J PHYSIOL-LONDON, V522, P349, DOI 10.1111/j.1469-7793.2000.t01-2-00349.x; Selyanko AA, 1996, NEURON, V16, P151, DOI 10.1016/S0896-6273(00)80032-X; SIMS SM, 1988, SCIENCE, V239, P190, DOI 10.1126/science.2827305; Singh NA, 2003, BRAIN, V126, P2726, DOI 10.1093/brain/awg286; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Stemkowski PL, 2002, J NEUROPHYSIOL, V88, P277, DOI 10.1152/jn.2002.88.1.277; Suh BC, 2002, NEURON, V35, P507, DOI 10.1016/S0896-6273(02)00790-0; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; Wei AG, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf109; Yang WP, 1998, J BIOL CHEM, V273, P19419, DOI 10.1074/jbc.273.31.19419; Yuan A, 2000, NAT NEUROSCI, V3, P771, DOI 10.1038/77670; Zhang HL, 2003, NEURON, V37, P963, DOI 10.1016/S0896-6273(03)00125-9	56	30	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21337	21345		10.1074/jbc.M502734200	http://dx.doi.org/10.1074/jbc.M502734200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15797864	hybrid			2022-12-27	WOS:000229438800052
J	Marbois, B; Gin, P; Faull, KF; Poon, WW; Lee, PT; Strahan, J; Shepherd, JN; Clarke, CF				Marbois, B; Gin, P; Faull, KF; Poon, WW; Lee, PT; Strahan, J; Shepherd, JN; Clarke, CF			Coq3 and Coq4 define a polypeptide complex in yeast mitochondria for the biosynthesis of coenzyme Q	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-METHYLTRANSFERASE STEPS; SACCHAROMYCES-CEREVISIAE; UBIQUINONE BIOSYNTHESIS; QH2-CYTOCHROME-C REDUCTASE; CAENORHABDITIS-ELEGANS; CYTOCHROME-OXIDASE; MEMBRANE SYSTEM; STRUCTURAL GENE; LIFE-SPAN; PROTEIN	Coenzyme Q (Q) is a redox active lipid essential for aerobic respiration in eukaryotes. In Saccharomyces cerevisiae at least eight mitochondrial polypeptides, designated Coq1-Coq8, are required for Q biosynthesis. Here we present physical evidence for a coenzyme Q-biosynthetic polypeptide complex in isolated mitochondria. Separation of digitonin-solubilized mitochondrial extracts in one- and two-dimensional Blue Native PAGE analyses shows that Coq3 and Coq4 polypeptides co-migrate as high molecular mass complexes. Similarly, gel filtration chromatography shows that Coq1p, Coq3p, Coq4p, Coq5p, and Coq6p elute in fractions higher than expected for their respective subunit molecular masses. Coq3p, Coq4p, and Coq6p coelute with an apparent molecular mass exceeding 700 kDa. Coq3 O-methyltransferase activity, a surrogate for Q biosynthesis and complex activity, also elutes at this high molecular mass. We have determined the quinone content in lipid extracts of gel filtration fractions by liquid chromatography-tandem mass spectrometry and find that demethoxy-Q(6) is enriched in fractions with Coq3p. Co-precipitation of biotinylated-Coq3 and Coq4 polypeptide from digitonin-solubilized mitochondrial extracts shows their physical association. This study identifies Coq3p and Coq4p as defining members of a Q-biosynthetic Coq polypeptide complex.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Pasarow Mass Spectrometry Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; Gonzaga Univ, Dept Chem, Spokane, WA 99258 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Gonzaga University	Clarke, CF (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E,Box 951569, Los Angeles, CA 90095 USA.	cathy@chem.ucla.edu		Poon, Wayne/0000-0003-0625-3968	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45952] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY MN, 1992, J BIOL CHEM, V267, P4128; Baba SW, 2004, J BIOL CHEM, V279, P10052, DOI 10.1074/jbc.M313712200; Baker W, 1941, J CHEM SOC, P670, DOI 10.1039/jr9410000670; Beal F, 2004, METHOD ENZYMOL, V382, P473; BECKMANN JD, 1987, J BIOL CHEM, V262, P8901; Belogrudov GI, 2001, ARCH BIOCHEM BIOPHYS, V392, P48, DOI 10.1006/abbi.2001.2448; Burke D., 2000, METHODS YEAST GENETI, P171; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; CRANE FL, 1965, BIOCH QUINONES, V1, P183; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; Dutton P.L., 2001, COENZYME Q OXIDATION, P65; Geromel V, 2002, MOL GENET METAB, V77, P21, DOI 10.1016/S1096-7192(02)00145-2; GIBSON F, 1973, Biochemical Society Transactions, V1, P317; Gille L, 2000, ARCH BIOCHEM BIOPHYS, V375, P347, DOI 10.1006/abbi.1999.1649; Gin P, 2003, J BIOL CHEM, V278, P25308, DOI 10.1074/jbc.M303234200; GIN P, 1980, J BIOL CHEM, P2676; Glerum DM, 1998, ANAL BIOCHEM, V260, P38, DOI 10.1006/abio.1998.2683; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Hsieh EJ, 2004, BIOCHEM BIOPH RES CO, V317, P648, DOI 10.1016/j.bbrc.2004.03.096; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Ishii N, 2004, MECH AGEING DEV, V125, P41, DOI 10.1016/j.mad.2003.10.002; Jonassen T, 2002, J BIOL CHEM, V277, P45020, DOI 10.1074/jbc.M204758200; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; JONASSEN T, 2001, EOENZYME Q MOL MECH, P185; KAGAN VE, 1996, HDB ANTIOXIDANTS, P157; Kainou T, 2001, J BIOL CHEM, V276, P7876, DOI 10.1074/jbc.M007472200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; Lass A, 1997, J BIOL CHEM, V272, P19199, DOI 10.1074/jbc.272.31.19199; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; MATARASSOTCHIROUKHINE E, 1976, J ORGANOMET CHEM, V121, P155, DOI 10.1016/S0022-328X(00)80763-9; McAlisterHenn L, 1997, PROG NUCLEIC ACID RE, V57, P317, DOI 10.1016/S0079-6603(08)60285-8; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; Meganathan R, 2001, FEMS MICROBIOL LETT, V203, P131, DOI 10.1016/S0378-1097(01)00330-5; MURACA RF, 1967, J AM CHEM SOC, V89, P1505, DOI 10.1021/ja00982a038; Nakai D, 2004, AGING CELL, V3, P273, DOI 10.1111/j.1474-9728.2004.00116.x; NARUTA Y, 1980, J ORG CHEM, V45, P4097, DOI 10.1021/jo01309a006; Padilla S, 2004, J BIOL CHEM, V279, P25995, DOI 10.1074/jbc.M400001200; Poon WW, 1999, J BIOL CHEM, V274, P21665, DOI 10.1074/jbc.274.31.21665; POON WW, 1995, ARCH BIOCHEM BIOPHYS, V320, P305, DOI 10.1016/0003-9861(95)90014-4; POON WW, 1997, MOL ASPECTS MED, V18, P121; Radin N S, 1981, Methods Enzymol, V72, P5; Saiki R, 2003, EUR J BIOCHEM, V270, P4113, DOI 10.1046/j.1432-1033.2003.03804.x; Santos-Ocana C, 1998, J BIOL CHEM, V273, P8099, DOI 10.1074/jbc.273.14.8099; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Shepherd JA, 1996, TETRAHEDRON LETT, V37, P2395, DOI 10.1016/0040-4039(96)00324-3; Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541; SIKORSKI RS, 1989, GENETICS, V122, P19; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; Turunen M, 2004, BBA-BIOMEMBRANES, V1660, P171, DOI 10.1016/j.bbamem.2003.11.012; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1986, J BIOL CHEM, V261, P7163; WAITE JH, 1990, COMP BIOCHEM PHYS B, V97, P19, DOI 10.1016/0305-0491(90)90172-P	59	69	73	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20231	20238		10.1074/jbc.M501315200	http://dx.doi.org/10.1074/jbc.M501315200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15792955	hybrid			2022-12-27	WOS:000229242000010
J	Wang, W; Jia, LY; Wang, TK; Sun, WT; Wu, S; Wang, X				Wang, W; Jia, LY; Wang, TK; Sun, WT; Wu, S; Wang, X			Endogenous calcitonin gene-related peptide protects human alveolar epithelial cells through protein kinase C epsilon and heat shock protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; REPERFUSION; MODULATION; INJURY; PKC; ACTIVATION; PHYSIOLOGY; RECEPTORS; CHANNELS	The intracellular mechanisms of ischemic preconditioning (PC) in preventing lung dysfunction following transplantation, shock, and trauma remain poorly understood. Previously, we have shown that alveolar epithelial cells secrete calcitonin gene-related peptide (CGRP) under inflammatory stress. Using a hypoxia/reoxygenation (H/R) and PC model, we found that CGRP was also secreted from human type II alveolar epithelial cells (A549) after PC. The locally released CGRP interacted with its receptor on the membrane of A549 cells and elicited downstream signals mediating the PC effect, because hCGRP(8-37), a specific CGRP receptor antagonist, attenuated the protective effect of PC. Preinhibition of CGRP protein synthesis by small interfering RNA exacerbated (but overexpression of the CGRP gene ameliorated) H/R-induced cell death, which supports the autocrine effect of CGRP on A549 cells. Exogenous bioactive CGRP mimicked the beneficial effect of PC and up-regulated the expression of heat shock protein 70 (HSP70), which might act as the end effector to maintain cell viability. These effects were sensitive to hCGRP(8-37), calphostin C (a protein kinase C (PKC) inhibitor), and 5-hydroxydecanoic acid ( a mitochondrial K-ATP(+) channel blocker) but were insensitive to protein kinase A blockers. Moreover, CGRP induced the membrane translocation of PKC is an element of. PKCV1-2 (a cell-permeable inhibitory peptide of PKC is an element of) effectively abolished CGRP-induced HSP70 expression and cell protection. Therefore, PC induces CGRP secretion from human alveolar epithelial cells, and the locally released CGRP acts back on these cells, protecting them from H/R injury. The post-receptor signaling of CGRP is through PKC is an element of-dependent expression of HSP70.	Peking Univ, Hosp 3, Inst Vasc Med, Beijing 100083, Peoples R China; Peking Univ, Dept Physiol, Key Lab Mol Cardiovasc Sci, Minist Educ,Hlth Sci Ctr, Beijing 100083, Peoples R China	Peking University; Peking University	Wang, X (corresponding author), Peking Univ, Hosp 3, Inst Vasc Med, 38,Xue Yuan Rd, Beijing 100083, Peoples R China.	xwang@bjmu.edu.cn	wang, wang/GWQ-7272-2022	Wang, Wang/0000-0001-9093-412X				Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025; Bell D, 1996, PHARMACOL REV, V48, P253; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; Dakhama A, 2004, CURR OPIN PHARMACOL, V4, P215, DOI 10.1016/j.coph.2004.01.006; de Perrot M, 2003, AM J RESP CRIT CARE, V167, P490, DOI 10.1164/rccm.200207-670SO; Ding XZ, 1997, J CLIN INVEST, V99, P136, DOI 10.1172/JCI119124; Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345; Drissi H, 1998, J BIOL CHEM, V273, P20168, DOI 10.1074/jbc.273.32.20168; Drissi H, 1999, CYTOKINE, V11, P200, DOI 10.1006/cyto.1998.0415; Fehrenbach H, 2001, RESP RES, V2, P33, DOI 10.1186/rr36; Ferdinandy P, 2003, BRIT J PHARMACOL, V138, P532, DOI 10.1038/sj.bjp.0705080; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Gross GJ, 2003, AM J PHYSIOL-HEART C, V285, pH921, DOI 10.1152/ajpheart.00421.2003; Inagaki K, 2003, CIRCULATION, V108, P869, DOI 10.1161/01.CIR.0000081943.93653.73; Kallner G, 1998, J CARDIOVASC PHARM, V32, P500, DOI 10.1097/00005344-199809000-00023; Latchman DS, 2001, CARDIOVASC RES, V51, P637, DOI 10.1016/S0008-6363(01)00354-6; LECHLEITNER P, 1992, AM HEART J, V124, P1433, DOI 10.1016/0002-8703(92)90054-Y; Li WJ, 2004, FASEB J, V18, P1603, DOI 10.1096/fj.04-1737fje; Li Y, 1997, NEUROPEPTIDES, V31, P503, DOI 10.1016/S0143-4179(97)90046-9; Mubagwa K, 2001, CARDIOVASC RES, V52, P25, DOI 10.1016/S0008-6363(01)00358-3; Napoli C, 2000, PHARMACOL THERAPEUT, V88, P311, DOI 10.1016/S0163-7258(00)00093-0; Ohnuma Y, 2002, AM J PHYSIOL-HEART C, V283, pH440, DOI 10.1152/ajpheart.00434.2001; Ping PP, 1997, CIRC RES, V81, P404, DOI 10.1161/01.RES.81.3.404; Sato T, 1998, CIRC RES, V83, P110, DOI 10.1161/01.RES.83.1.110; Schulz R, 2001, CARDIOVASC RES, V52, P181, DOI 10.1016/S0008-6363(01)00384-4; Schulz R, 2004, CARDIOVASC RES, V61, P402, DOI 10.1016/j.cardiores.2003.09.019; Simkhovich BZ, 1998, CARDIOVASC RES, V40, P9, DOI 10.1016/S0008-6363(98)00142-4; Sun W, 2003, EUR J IMMUNOL, V33, P233, DOI 10.1002/immu.200390026; Villa I, 2003, AM J PHYSIOL-ENDOC M, V284, pE627, DOI 10.1152/ajpendo.00307.2002; Wang W, 2004, AM J PHYSIOL-HEART C, V287, pH1582, DOI 10.1152/ajpheart.00168.2004; WANG X, 1991, CIRC SHOCK, V34, P217; Wang YG, 1999, CIRC RES, V84, P1156, DOI 10.1161/01.RES.84.10.1156; Wimalawansa SJ, 1996, ENDOCR REV, V17, P533, DOI 10.1210/er.17.5.533; Wong HR, 1998, AM J PHYSIOL-LUNG C, V275, pL836, DOI 10.1152/ajplung.1998.275.4.L836; Xiao L, 2001, EUR J PHARMACOL, V427, P131, DOI 10.1016/S0014-2999(01)01231-6; Yellon DM, 2003, PHYSIOL REV, V83, P1113, DOI 10.1152/physrev.00009.2003	38	29	38	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20325	20330		10.1074/jbc.M413864200	http://dx.doi.org/10.1074/jbc.M413864200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15784626	hybrid			2022-12-27	WOS:000229242000022
J	Ferdinandusse, S; Denis, S; Overmars, H; Van Eeckhoudt, L; Van Veldhoven, PP; Duran, M; Wanders, RJA; Baes, M				Ferdinandusse, S; Denis, S; Overmars, H; Van Eeckhoudt, L; Van Veldhoven, PP; Duran, M; Wanders, RJA; Baes, M			Developmental changes of bile acid composition and conjugation in L- and D-bifunctional protein single and double knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL BETA-OXIDATION; CHROMATOGRAPHY-MASS SPECTROMETRY; FARNESOID-X RECEPTOR; ACYL-COA OXIDASE; ZELLWEGER-SYNDROME; N-ACYLTRANSFERASE; RAT-LIVER; 25-HYDROXYLATION PATHWAY; ONTOGENIC REGULATION; BINDING-PROTEIN	Peroxisomal beta-oxidation is an essential step in bile acid synthesis, since it is required for shortening of C27-bile acid intermediates to produce mature C24-bile acids. D-Bifunctional protein (DBP) is responsible for the second and third step of this beta-oxidation process. However, both patients and mice with a DBP deficiency still produce C24-bile acids, although C27-intermediates accumulate. An alternative pathway for bile acid biosynthesis involving the peroxisomal L-bifunctional protein (LBP) has been proposed. We investigated the role of LBP and DBP in bile acid synthesis by analyzing bile acids in bile, liver, and plasma from LBP, DBP, and LBP: DBP double knock-out mice. Bile acid biosynthesis, estimated by the ratio of C27/C24-bile acids, was more severely affected in double knock-out mice as compared with DBP-/- mice but was normal in LBP-/- mice. Unexpectedly, trihydroxycholestanoyl-CoA oxidase was inactive in double knock-out mice due to a peroxisomal import defect, preventing us from drawing any firm conclusion about the potential role of LBP in an alternative bile acid biosynthesis pathway. Interestingly, the immature C27-bile acids in DBP and double knock-out mice remained unconjugated in juvenile mice, whereas they occurred as taurine conjugates after weaning, probably contributing to the minimal weight gain of the mice during the lactation period. This correlated with a marked induction of bile acyl-CoA:amino acid N-acyltransferase expression and enzyme activity between postnatal days 10 and 21, whereas the bile acyl-CoA synthetases increased gradually with age. The nuclear receptors hepatocyte nuclear factor-4 alpha, farnesoid X receptor, and peroxisome proliferator receptor alpha did not appear to be involved in the up-regulation of the transferase.	Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands; Katholieke Univ Leuven, Clin Chem Lab, B-3000 Louvain, Belgium; Dept Pharmacol, B-3000 Louvain, Belgium	University of Amsterdam; Academic Medical Center Amsterdam; KU Leuven	Ferdinandusse, S (corresponding author), Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, F0-224,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	S.Ferdinandusse@amc.uva.nl	, Van Veldhoven Paul/U-6359-2019	, Van Veldhoven Paul/0000-0002-4478-2564; Baes, Myriam/0000-0002-2525-2269; Ferdinandusse, Sacha/0000-0002-7738-5709				Baes M, 2000, J BIOL CHEM, V275, P16329, DOI 10.1074/jbc.M001994200; Baes M, 2002, J NEUROPATH EXP NEUR, V61, P368, DOI 10.1093/jnen/61.4.368; Balasubramaniyan N, 2005, AM J PHYSIOL-GASTR L, V288, pG251, DOI 10.1152/ajpgi.00351.2004; Baumgart E, 1996, P NATL ACAD SCI USA, V93, P13748, DOI 10.1073/pnas.93.24.13748; Bjorkhem I, 2001, J BIOL CHEM, V276, P37004, DOI 10.1074/jbc.M103828200; Bootsma AH, 1999, J INHERIT METAB DIS, V22, P307, DOI 10.1023/A:1005543802724; Bove KE, 2000, PEDIATR DEVEL PATHOL, V3, P1, DOI 10.1007/s100240050001; CLAYTON PT, 1988, J INHERIT METAB DIS, V11, P165, DOI 10.1007/BF01804226; Cuebas DA, 2002, BIOCHEM J, V363, P801, DOI 10.1042/0264-6021:3630801; CZUBA B, 1982, J BIOL CHEM, V257, P8761; DUANE WC, 1988, J CLIN INVEST, V82, P82, DOI 10.1172/JCI113605; DUANE WC, 1988, HEPATOLOGY, V8, P613, DOI 10.1002/hep.1840080329; Falany CN, 1997, J LIPID RES, V38, P1139; Ferdinandusse S, 2003, MOL GENET METAB, V79, P281, DOI 10.1016/S1096-7192(03)00108-2; Gao B, 2004, J HEPATOL, V41, P201, DOI 10.1016/j.jhep.2004.04.029; Honda A, 2000, J LIPID RES, V41, P442; Huyghe S, 2001, BIOCHEM J, V353, P673, DOI 10.1042/0264-6021:3530673; Hwang ST, 2001, EXP BIOL MED, V226, P674, DOI 10.1177/153537020222600713; Hwang ST, 2002, GASTROENTEROLOGY, V122, P1483, DOI 10.1053/gast.2002.32982; Inoue Y, 2004, J BIOL CHEM, V279, P2480, DOI 10.1074/jbc.M311015200; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; Jia YZ, 2003, J BIOL CHEM, V278, P47232, DOI 10.1074/jbc.M306363200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mihalik SJ, 2002, J BIOL CHEM, V277, P24771, DOI 10.1074/jbc.M203295200; O'Byrne J, 2003, J BIOL CHEM, V278, P34237, DOI 10.1074/jbc.M300987200; Pircher PC, 2003, J BIOL CHEM, V278, P27703, DOI 10.1074/jbc.M302128200; Qi C, 1999, J BIOL CHEM, V274, P15775, DOI 10.1074/jbc.274.22.15775; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Solaas K, 2004, J LIPID RES, V45, P1051, DOI 10.1194/jlr.M300291-JLR200; SUCHY FJ, 1985, PEDIATR RES, V19, P97, DOI 10.1203/00006450-198501000-00026; Une M, 1997, J BIOCHEM-TOKYO, V122, P655; VANVELDHOVEN PP, 1987, J BIOL CHEM, V262, P4310; Vreken P, 1998, J LIPID RES, V39, P2452; Wanders R.J., 2001, METABOLIC MOL BASES, P3219; WANDERS RJA, 1993, J BIOCHEM-TOKYO, V113, P577; Wanders RJA, 2001, BIOCHEM SOC T, V29, P250, DOI 10.1042/0300-5127:0290250; Xu RF, 1996, BIOCHEM BIOPH RES CO, V221, P271, DOI 10.1006/bbrc.1996.0585	38	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18658	18666		10.1074/jbc.M414311200	http://dx.doi.org/10.1074/jbc.M414311200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15769750	hybrid			2022-12-27	WOS:000228932300016
J	Mukherjee, S; Conrad, SE				Mukherjee, S; Conrad, SE			c-Myc suppresses p21(WAF1/CIP1) expression during estrogen signaling and antiestrogen resistance in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN E-CDK2 ACTIVATION; RETINOBLASTOMA PROTEIN; ONCOGENE EXPRESSION; ACQUIRED-RESISTANCE; FUNCTIONAL-ANALYSIS; GENE-TRANSCRIPTION; PHASE PROGRESSION; S-PHASE; KINASE; GROWTH	Estrogen rapidly induces expression of the proto-oncogene c-myc. c-Myc is required for estrogen-stimulated proliferation of breast cancer cells, and deregulated c-Myc expression has been implicated in antiestrogen resistance. In this report, we investigate the mechanism(s) by which c-Myc mediates estrogen-stimulated proliferation and contributes to cell cycle progression in the presence of antiestrogen. The MCF-7 cell line is a model of estrogen-dependent, antiestrogen-sensitive human breast cancer. Using stable MCF-7 derivatives with inducible c-Myc expression, we demonstrated that in antiestrogen-treated cells, the elevated mRNA and protein levels of p21(WAF1/CIP1), a cell cycle inhibitor, decreased upon either c-Myc induction or estrogen treatment. Expression of p21 blocked c-Myc-mediated cell cycle progression in the presence of antiestrogen, suggesting that the decrease in p21 is necessary for this process. Using RNA interference to suppress c-Myc expression, we further established that c-Myc is required for estrogen-mediated decreases in p21(WAF1/CIP1). Finally, we observed that neither c-Myc nor p21(WAF1/CIP1) is regulated by estrogen or antiestrogen in an antiestrogen-resistant MCF-7 derivative. The p21 levels in the antiestrogen-resistant cells increased when c-Myc expression was suppressed, suggesting that loss of p21 regulation was a consequence of constitutive c-Myc expression. Together, these studies implicate p21(WAF1/CIP1) as an important target of c-Myc in breast cancer cells and provide a link between estrogen, c-Myc, and the cell cycle machinery. They further suggest that aberrant c-Myc expression, which is frequently observed in human breast cancers, can contribute to antiestrogen resistance by altering p21(WAF1/CIP1) regulation.	Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA	Michigan State University	Conrad, SE (corresponding author), Michigan State Univ, Dept Microbiol & Mol Genet, 2209 BPS, E Lansing, MI 48824 USA.	conrad@msu.edu			NCI NIH HHS [CA76647] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076647] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Altucci L, 1996, ONCOGENE, V12, P2315; Amara JF, 1997, P NATL ACAD SCI USA, V94, P10618, DOI 10.1073/pnas.94.20.10618; [Anonymous], 1992, Lancet, V339, P1; Bindels EMJ, 2002, ONCOGENE, V21, P8158, DOI 10.1038/sj.onc.1206012; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; Blancato J, 2004, BRIT J CANCER, V90, P1612, DOI 10.1038/sj.bjc.6601703; Brunner N, 1997, CANCER RES, V57, P3486; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Carroll JS, 2002, CANCER RES, V62, P3126; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Clarke M, 1998, LANCET, V351, P1451; COEZY E, 1982, CANCER RES, V42, P317; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Deming SL, 2000, BRIT J CANCER, V83, P1688, DOI 10.1054/bjoc.2000.1522; Dhillon NK, 2002, ONCOGENE, V21, P4626, DOI 10.1038/sj.onc.1205576; Donovan JCH, 2001, J BIOL CHEM, V276, P40888, DOI 10.1074/jbc.M106448200; DUBIK D, 1987, CANCER RES, V47, P6517; DUBIK D, 1992, ONCOGENE, V7, P1587; DUBIK D, 1988, J BIOL CHEM, V263, P12705; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; Gu ZP, 2002, CANCER RES, V62, P3428; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; KATO J, 1993, GENE DEV, V7, P331; Knight-Krajewski S, 2004, ONCOGENE, V23, P5513, DOI 10.1038/sj.onc.1207708; LA RF, 1994, MOL CELL BIOL, V14, P1039; LEUNG BS, 1987, J CELL BIOCHEM, V34, P213, DOI 10.1002/jcb.240340307; LIPPMAN M, 1976, CANCER RES, V36, P4595; MAI S, 1994, GENE, V148, P253, DOI 10.1016/0378-1119(94)90696-3; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nasi S, 2001, FEBS LETT, V490, P153, DOI 10.1016/S0014-5793(01)02118-4; Olson LK, 1998, MOL ENDOCRINOL, V12, P207, DOI 10.1210/me.12.2.207; OSBORNE CK, 1984, CANCER RES, V44, P1433; OSBORNE CK, 1983, CANCER RES, V43, P3583; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Prall OWJ, 2001, J BIOL CHEM, V276, P45433, DOI 10.1074/jbc.M104752200; RUTQVIST LE, 1987, BREAST CANCER RES TR, V10, P255, DOI 10.1007/BF01805762; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; SHAFIE SM, 1981, J NATL CANCER I, V67, P51; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Skildum AJ, 2002, J BIOL CHEM, V277, P5145, DOI 10.1074/jbc.M109179200; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; TSAI LH, 1993, ONCOGENE, V8, P1593; Varma H, 2000, ONCOGENE, V19, P4746, DOI 10.1038/sj.onc.1203827; Venditti M, 2002, INT J CANCER, V99, P35, DOI 10.1002/ijc.10269; WATSON PH, 1991, CANCER RES, V51, P3996; WOLF DM, 1993, BREAST CANCER RES TR, V27, P27, DOI 10.1007/BF00683191; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zeller KI, 2001, J BIOL CHEM, V276, P48285, DOI 10.1074/jbc.M108506200; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	68	87	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	2005	280	18					17617	17625		10.1074/jbc.M502278200	http://dx.doi.org/10.1074/jbc.M502278200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	922AH	15757889	hybrid			2022-12-27	WOS:000228807200008
J	Hsu, MF; Kuo, CJ; Chang, KT; Chang, HC; Chou, CC; Ko, TP; Shr, HL; Chang, GG; Wang, AHJ; Liang, PH				Hsu, MF; Kuo, CJ; Chang, KT; Chang, HC; Chou, CC; Ko, TP; Shr, HL; Chang, GG; Wang, AHJ; Liang, PH			Mechanism of the maturation process of SARS-CoV 3CL protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAIN PROTEASE; GENOME SEQUENCE; CORONAVIRUS; INHIBITORS; DESIGN; IDENTIFICATION; REVEALS	Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by a novel human coronavirus. Viral maturation requires a main protease (3CL(pro)) to cleave the virus-encoded polyproteins. We report here that the 3CLpro containing additional N- and/or C-terminal segments of the polyprotein sequences undergoes autoprocessing and yields the mature protease in vitro. The dimeric three-dimensional structure of the C145A mutant protease shows that the active site of one protomer binds with the C-terminal six amino acids of the protomer from another asymmetric unit, mimicking the product-bound form and suggesting a possible mechanism for maturation. The P1 pocket of the active site binds the Gln side chain specifically, and the P2 and P4 sites are clustered together to accommodate large hydrophobic side chains. The tagged C145A mutant protein served as a substrate for the wild-type protease, and the N terminus was first digested (55-fold faster) at the Gln(-1)-Ser(1) site followed by the C-terminal cleavage at the Gln(306)-Gly(307) site. Analytical ultracentrifuge of the quaternary structures of the tagged and mature proteases reveals the remarkably tighter dimer formation for the mature enzyme (K-d = 0.35 nM) than for the mutant (C145A) containing 10 extra N- terminal (K-d = 17.2 nM) or C-terminal amino acids (K-d = 5.6 nM). The data indicate that immature 3CLpro can form dimer enabling it to undergo autoprocessing to yield the mature enzyme, which further serves as a seed for facilitated maturation. Taken together, this study provides insights into the maturation process of the SARS 3CLpro from the polyprotein and design of new structure-based inhibitors.	Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan; Acad Sinica, Core Facil Prot Xray Crystallog, Taipei 115, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Yang Ming Univ, Fac Life Sci, Taipei 112, Taiwan	National Taiwan University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Wang, AHJ (corresponding author), Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan.	ahjwang@gate.sinica.edu.tw; phliang@gate.sinica.edu.tw	Liang, Po-Huang/H-6610-2015	Liang, Po-Huang/0000-0003-1207-5256; Kuo, Chih-Jung/0000-0002-4988-5124				Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327; Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang HC, 2003, J BIOL CHEM, V278, P23996, DOI 10.1074/jbc.M213242200; Chou CY, 2004, BIOCHEMISTRY-US, V43, P14958, DOI 10.1021/bi0490237; De Clercq E, 2002, NAT REV DRUG DISCOV, V1, P13, DOI 10.1038/nrd703; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595; Hsu JTA, 2004, FEBS LETT, V574, P116, DOI 10.1016/j.febslet.2004.08.015; Jain RP, 2004, J MED CHEM, V47, P6113, DOI 10.1021/jm0494873; Kao RY, 2004, CHEM BIOL, V11, P1293, DOI 10.1016/j.chembiol.2004.07.013; Kuo CJ, 2004, BIOCHEM BIOPH RES CO, V318, P862, DOI 10.1016/j.bbrc.2004.04.098; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Matthews DA, 1999, P NATL ACAD SCI USA, V96, P11000, DOI 10.1073/pnas.96.20.11000; McQueney MS, 1997, J BIOL CHEM, V272, P13955, DOI 10.1074/jbc.272.21.13955; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9; Shi JH, 2004, J BIOL CHEM, V279, P24765, DOI 10.1074/jbc.M311744200; Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101; Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100	31	169	177	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					31257	31266		10.1074/jbc.M502577200	http://dx.doi.org/10.1074/jbc.M502577200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15788388	Green Published, hybrid			2022-12-27	WOS:000231487800073
J	Urbaniak, MD; Crossman, A; Chang, TH; Smith, TK; van Aalten, DMF; Ferguson, MAJ				Urbaniak, MD; Crossman, A; Chang, TH; Smith, TK; van Aalten, DMF; Ferguson, MAJ			The N-acetyl-d-glucosaminylphosphatidylinositol De-N-acetylase of glycosylphosphatidylinositol biosynthesis is a zinc metalloenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ANCHOR BIOSYNTHESIS; GPI BIOSYNTHESIS; MEMBRANE ANCHOR; MYCOBACTERIUM-TUBERCULOSIS; SUBSTRATE-SPECIFICITY; AFRICAN TRYPANOSOMES; INOSITOL-ACYLATION; PATHWAY; ENZYMES	The de-N-acetylation of N-acetyl-D-glucosaminylphosphatidylinositol (GlcNAc-PI) is the second step of mammalian and trypanosomal glycosylphosphatidylinositol biosynthesis. Glycosylphosphatidylinositol biosynthesis is essential for Trypanosoma brucei, the causative agent of African sleeping sickness, and GlcNAc-PI de-N-acetylase has previously been validated as a drug target. Inhibition of the trypanosome cell-free system and recombinant rat GlcNAc-PI de-N-acetylase by divalent metal cation chelators demonstrates that a tightly bound divalent metal cation is essential for activity. Reconstitution of metal-free GlcNAc-PI de-N-acetylase with divalent metal cations restores activity in the order Zn2+ > Cu2+ > Ni2+ > Co2+ > Mg2+. Site-directed mutagenesis and homology modeling were used to identify active site residues and postulate a mechanism of action. The characterization of GlcNAc-PI de-N-acetylase as a zinc metalloenzyme will facilitate the rational design of anti-protozoan parasite drugs.	Univ Dundee, Div Biol Chem & Mol Microbiol, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland	University of Dundee	Ferguson, MAJ (corresponding author), Univ Dundee, Div Biol Chem & Mol Microbiol, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.	m.a.j.ferguson@dundee.ac.uk	Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714; van Aalten, Daan/0000-0002-1499-6908; Urbaniak, Michael/0000-0003-2745-9420	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AULD DS, 1995, METHOD ENZYMOL, V248, P228; Chang TH, 2002, J BIOL CHEM, V277, P50176, DOI 10.1074/jbc.M208374200; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; Crossman A, 2002, CARBOHYD RES, V337, P2049, DOI 10.1016/S0008-6215(02)00187-8; DeLano W.L, PYMOL MOL GRAPHICS S; DOERING TL, 1989, J BIOL CHEM, V264, P11168; Eisenhaber B, 2003, BIOESSAYS, V25, P367, DOI 10.1002/bies.10254; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; FERGUSON MAJ, 1994, GLYCOBIOLOGY PRACTIC, P349; GUTHER MLS, 1994, J BIOL CHEM, V269, P18694; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; Handa N, 2003, PROTEIN SCI, V12, P1621, DOI 10.1110/gad.03104003; Jackman JE, 1999, BIOCHEMISTRY-US, V38, P1902, DOI 10.1021/bi982339s; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; LARSEN KS, 1989, BIOCHEMISTRY-US, V28, P9620, DOI 10.1021/bi00451a012; Lillico S, 2003, MOL BIOL CELL, V14, P1182, DOI 10.1091/mbc.E02-03-0167; MACEDO CSD, 2003, BIOCHIMIE, V85, P465; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; Maynes JT, 2003, J BIOL CHEM, V278, P47166, DOI 10.1074/jbc.M308914200; McCarthy AA, 2004, J MOL BIOL, V335, P1131, DOI 10.1016/j.jmb.2003.11.034; Mehlert A, 1998, MOL BIOCHEM PARASIT, V91, P145, DOI 10.1016/S0166-6851(97)00187-4; MILNE KG, 1994, J BIOL CHEM, V269, P16403; Morita Y. S., 2000, OLIGOSACCHARIDES CHE, P417; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Nakamura N, 1997, J BIOL CHEM, V272, P15834, DOI 10.1074/jbc.272.25.15834; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Sharma DK, 1999, GLYCOBIOLOGY, V9, P415, DOI 10.1093/glycob/9.4.415; Sharma DK, 1997, BIOCHEM J, V328, P171; Smith TK, 2000, BIOCHEMISTRY-US, V39, P11801, DOI 10.1021/bi000854w; Smith TK, 2004, EMBO J, V23, P4701, DOI 10.1038/sj.emboj.7600456; Smith TK, 1996, J BIOL CHEM, V271, P6476, DOI 10.1074/jbc.271.11.6476; Smith TK, 2002, J BIOL CHEM, V277, P37147, DOI 10.1074/jbc.M203371200; Smith TK, 2001, EMBO J, V20, P3322, DOI 10.1093/emboj/20.13.3322; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Watanabe R, 1999, BIOCHEM J, V339, P185, DOI 10.1042/0264-6021:3390185; White RJ, 2003, CURR OPIN PHARMACOL, V3, P502, DOI 10.1016/S1471-4892(03)00115-2; Whittington DA, 2003, P NATL ACAD SCI USA, V100, P8146, DOI 10.1073/pnas.1432990100	40	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22831	22838		10.1074/jbc.M502402200	http://dx.doi.org/10.1074/jbc.M502402200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15817455	hybrid			2022-12-27	WOS:000229741800035
J	Argmann, CA; Edwards, JY; Sawyez, CG; O'Neil, CH; Hegele, RA; Pickering, JG; Huff, MW				Argmann, CA; Edwards, JY; Sawyez, CG; O'Neil, CH; Hegele, RA; Pickering, JG; Huff, MW			Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; HIGH-DENSITY-LIPOPROTEINS; CASSETTE TRANSPORTER A1; PPAR-GAMMA; X-RECEPTOR; HYPERTRIGLYCERIDEMIC VLDL; CARDIOVASCULAR-DISEASE; ESTER ACCUMULATION; SCAVENGER RECEPTOR; FOAM CELL	The cholesterol biosynthetic pathway produces numerous signaling molecules. Oxysterols through liver X receptor (LXR) activation regulate cholesterol efflux, whereas the non-sterol mevalonate metabolite, geranylgeranyl pyrophosphate (GGPP), was recently demonstrated to inhibit ABCA1 expression directly, through antagonism of LXR and indirectly through enhanced RhoA geranylgeranylation. We used HMG-CoA reductase inhibitors (statins) to test the hypothesis that reduced synthesis of mevalonate metabolites would enhance cholesterol efflux and attenuate foam cell formation. Preincubation of THP-1 macrophages with atorvastatin, dose dependently (1-10 mu M) stimulated cholesterol efflux to apolipoprotein AI (apoAI, 10-60%, p < 0.05) and high density lipoprotein (HDL3) (2-50%, p < 0.05), despite a significant decrease in cholesterol synthesis (2-90%). Atorvastatin also increased ABCA1 and ABCG1 mRNA abundance ( 30 and 35%, p < 0.05). Addition of mevalonate, GGPP or farnesyl pyrophosphate completely blocked the statin-induced increase in ABCA1 expression and apoAI-mediated cholesterol efflux. A role for RhoA was established, because two inhibitors of Rho protein activity, a geranylgeranyl transferase inhibitor and C3 exoenzyme, increased cholesterol efflux to apoAI (20-35%, p < 0.05), and macrophage expression of dominant-negative RhoA enhanced cholesterol efflux to apoAI (20%, p < 0.05). In addition, atorvastatin increased the RhoA levels in the cytosol fraction and decreased the membrane localization of RhoA. Atorvastatin treatment activated peroxisome proliferator activated receptor gamma and increased LXR-mediated gene expression suggesting that atorvastatin induces cholesterol efflux through a molecular cascade involving inhibition of RhoA signaling, leading to increased peroxisome proliferator activated receptor gamma activity, enhanced LXR activation, increased ABCA1 expression, and cholesterol efflux. Finally, statin treatment inhibited cholesteryl ester accumulation in macrophages challenged with atherogenic hypertriglyceridemic very low density lipoproteins indicating that statins can regulate foam cell formation.	Univ Western Ontario, Vasc Biol Grp, Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Med, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5K8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Huff, MW (corresponding author), Univ Western Ontario, Vasc Biol Grp, Robarts Res Inst, Rm 4-16,100 Perth Dr, London, ON N6A 5K8, Canada.	mhuff@uwo.ca	Huff, Murray/G-3307-2011; Hegele, Robert/AAF-6482-2020; Hegele, Robert/G-3301-2011; Pickering, J. Geoffrey/G-3341-2011	Hegele, Robert/0000-0003-2861-5325; Pickering, J. Geoffrey/0000-0001-6474-3274				Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Argmann CA, 2001, ARTERIOSCL THROM VAS, V21, P2011, DOI 10.1161/hq1201.099426; Argmann CA, 2003, ARTERIOSCL THROM VAS, V23, P475, DOI 10.1161/01.ATV.0000058860.62870.6E; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bocher V, 2002, ANN NY ACAD SCI, V967, P7; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1980, J LIPID RES, V21, P505; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Costet P, 2000, J BIOL CHEM, V275, P28240; Dussault I, 2000, PROSTAG OTH LIPID M, V62, P1, DOI 10.1016/S0090-6980(00)00071-X; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; EVANS AJ, 1993, J LIPID RES, V34, P703; EVANS AJ, 1992, J BIOL CHEM, V267, P10743; Fitzgerald ML, 2002, J MOL MED, V80, P271, DOI 10.1007/s00109-001-0318-y; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Grip O, 2002, INFLAMM RES, V51, P58, DOI 10.1007/BF02684000; Han JH, 2004, CIRCULATION, V110, P3472, DOI 10.1161/01.CIR.0000148368.79202.F1; Han JH, 2000, J BIOL CHEM, V275, P1241, DOI 10.1074/jbc.275.2.1241; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hillyard DZ, 2004, ATHEROSCLEROSIS, V175, P305, DOI 10.1016/j.atherosclerosis.2004.03.018; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Inoue I, 2002, BIOCHEM BIOPH RES CO, V290, P131, DOI 10.1006/bbrc.2001.6141; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344; Keller RK, 1996, ARCH BIOCHEM BIOPHYS, V328, P324, DOI 10.1006/abbi.1996.0180; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Laufs U, 2000, CIRC RES, V87, P526, DOI 10.1161/01.RES.87.7.526; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; Li AC, 2002, NAT MED, V8, P1235, DOI 10.1038/nm1102-1235; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Maejima T, 2004, BIOCHEM BIOPH RES CO, V324, P835, DOI 10.1016/j.bbrc.2004.09.122; Martin G, 2001, J CLIN INVEST, V107, P1423, DOI 10.1172/JCI10852; Meigs TE, 1996, J BIOL CHEM, V271, P7916, DOI 10.1074/jbc.271.14.7916; Meiner V, 1997, J LIPID RES, V38, P1928; Oram JF, 2002, CURR OPIN LIPIDOL, V13, P373, DOI 10.1097/00041433-200208000-00004; Ory DS, 2004, CIRC RES, V95, P660, DOI 10.1161/01.RES.0000143422.83209.be; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rowe AH, 2003, CIRC RES, V93, P717, DOI 10.1161/01.RES.0000097606.43659.F4; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Shimokawa H, 2002, J CARDIOVASC PHARM, V39, P319, DOI 10.1097/00005344-200203000-00001; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1529, P203, DOI 10.1016/S1388-1981(00)00149-9; Sone H, 2004, BIOCHEM BIOPH RES CO, V316, P790, DOI 10.1016/j.bbrc.2004.02.121; Song C, 2001, STEROIDS, V66, P473, DOI 10.1016/S0039-128X(00)00239-7; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Tall AR, 2002, J CLIN INVEST, V110, P899, DOI 10.1172/JCI200216391; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; Whitman SC, 1997, ARTERIOSCL THROM VAS, V17, P1707, DOI 10.1161/01.ATV.17.9.1707; Whitman SC, 1998, J LIPID RES, V39, P1008; Wilcox LJ, 2001, J LIPID RES, V42, P725; Wilcox LJ, 1999, CARDIOVASC DRUG REV, V17, P160, DOI 10.1111/j.1527-3466.1999.tb00011.x; Wong J, 2004, ARTERIOSCL THROM VAS, V24, P2365, DOI 10.1161/01.ATV.0000148707.93054.7d; Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873	57	112	122	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22212	22221		10.1074/jbc.M502761200	http://dx.doi.org/10.1074/jbc.M502761200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817453	hybrid			2022-12-27	WOS:000229557900067
J	Arnold, NB; Korc, M				Arnold, NB; Korc, M			Smad7 abrogates transforming growth factor-beta 1-mediated growth inhibition in COLO-357 cells through functional inactivation of the retinoblastoma protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA-RECEPTOR; PANCREATIC-CANCER CELLS; TUMOR-SUPPRESSOR GENE; CYCLIN D1 EXPRESSION; MESENCHYMAL TRANSDIFFERENTIATION; NEGATIVE REGULATION; UP-REGULATION; KINASE; ROLES; APOPTOSIS	Smad7 is overexpressed in 50% of human pancreatic cancers. COLO-357 pancreatic cancer cells engineered to overexpress Smad7 are resistant to the actions of transforming growth factor-beta 1 (TGF-beta 1) with respect to growth inhibition and cisplatin-induced apoptosis but not with respect to modulation of gene expression. To delineate the mechanisms underlying these divergent consequences of Smad7 overexpression, we studied the effects of Smad7 on TGF-beta 1-dependent signaling pathways and cell cycle regulating proteins. TGF-beta 1 induced the phosphorylation of MAPK, p38 MAPK, and AKT2 irrespective of the levels of Smad7, and inhibitors of these pathways did not alter TGF-beta 1 actions on cell growth. By contrast, Smad7 overexpression interfered with TGF-beta 1-mediated attenuation of cyclin A and B levels, inhibition of cdc2 dephosphorylation and CDK2 inactivation, up-regulation of p27, and the maintenance of the retinoblastoma protein (RB) in a hypophosphorylated state. Smad7 also suppressed TGF-beta 1-mediated inhibition of E2F activity but did not alter TGF-beta 1-mediated phosphorylation of Smad2, the nuclear translocation of Smad2/3/4, or DNA binding of the Smad2/3/4 complex. Although Smad7 did not associate with the type I TGF-beta receptor (T beta RI), SB-431542, an inhibitor of the kinase activity of this receptor, blocked TGF-beta 1-mediated effects on Smad-2 phosphorylation. These findings point toward a novel paradigm whereby Smad7 acts to functionally inactivate RB and de-repress E2F without blocking the activation of T beta RI and the nuclear translocation of Smad2/3, thereby allowing for TGF-beta 1 to exert effects in a cancer cell that is resistant to TGF-beta 1-mediated growth inhibition.	Dartmouth Coll, Hitchcock Med Ctr, Dept Med, Lebanon, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dept Pharmacol & Toxicol, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Lebanon, NH 03756 USA	Dartmouth College; Dartmouth College; Dartmouth College	Korc, M (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Dept Med, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	Murray.Korc@Dartmouth.edu			NCI NIH HHS [CA 75059] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA075059, R01CA075059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnold NB, 2004, CANCER RES, V64, P3599, DOI 10.1158/0008-5472.CAN-03-2999; Asano Y, 2004, J CLIN INVEST, V113, P253, DOI 10.1172/JCI200416269; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2002, J CELL SCI, V115, P3193; BARTON CM, 1995, MOL CARCINOGEN, V13, P61, DOI 10.1002/mc.2940130202; Berg DT, 2005, J BIOL CHEM, V280, P14943, DOI 10.1074/jbc.C400579200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chung DC, 1997, CLIN ENDOCRINOL, V47, P523, DOI 10.1046/j.1365-2265.1997.2861110.x; Claudio P, 2002, GENOME BIOL, V3; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Cowgill SM, 2003, AM J SURG, V186, P279, DOI 10.1016/S0002-9610(03)00226-5; Dahler AL, 2001, J INVEST DERMATOL, V116, P266, DOI 10.1046/j.1523-1747.2001.01243.x; Davoodpour P, 2005, J BIOL CHEM, V280, P14773, DOI 10.1074/jbc.M414470200; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ellenrieder V, 2001, CANCER RES, V61, P4222; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Ferrigno O, 2002, ONCOGENE, V21, P4879, DOI 10.1038/sj.onc.1205623; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FRIESS H, 1993, CANCER RES, V53, P2704; Goggins M, 1998, AM J PATHOL, V152, P1501; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Ishisaki A, 1998, J BIOL CHEM, V273, P24293, DOI 10.1074/jbc.273.38.24293; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; JEOUNG DI, 1995, BIOCHEM BIOPH RES CO, V216, P964, DOI 10.1006/bbrc.1995.2714; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kleeff J, 1998, J BIOL CHEM, V273, P7495, DOI 10.1074/jbc.273.13.7495; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; KO TC, 1995, ONCOGENE, V10, P177; KORC M, 2003, GASTROINTESTINAL CAN, V1, P519; Kornmann M, 1997, ONCOGENE, V15, P1417, DOI 10.1038/sj.onc.1201307; Kornmann M, 1999, INT J CANCER, V83, P247, DOI 10.1002/(SICI)1097-0215(19991008)83:2<247::AID-IJC17>3.0.CO;2-0; MANAGHIJAULIN J, 1998, NATURE, V391, P601; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Munger K, 2002, FRONT BIOSCI-LANDMRK, V7, pD641, DOI 10.2741/munger; Nagahara H, 1999, P NATL ACAD SCI USA, V96, P14961, DOI 10.1073/pnas.96.26.14961; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Pulaski L, 2001, J BIOL CHEM, V276, P14344, DOI 10.1074/jbc.M011019200; RAITANO AB, 1990, J BIOL CHEM, V265, P10466; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; Roberts AB, 2002, CYTOKINE GROWTH F R, V13, P3, DOI 10.1016/S1359-6101(01)00027-2; ROBERTS AB, 1983, FED PROC, V42, P2621; ROBERTS AB, 1988, BRIT J CANCER, V57, P594, DOI 10.1038/bjc.1988.135; Robson CN, 1999, J ENDOCRINOL, V160, P257, DOI 10.1677/joe.0.1600257; Shi WB, 2004, J CELL BIOL, V164, P291, DOI 10.1083/jcb.200307151; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Wong C, 1999, MOL CELL BIOL, V19, P1821; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Zhu HJ, 1999, J BIOL CHEM, V274, P32258, DOI 10.1074/jbc.274.45.32258	66	27	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21858	21866		10.1074/jbc.M500583200	http://dx.doi.org/10.1074/jbc.M500583200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15811853	hybrid			2022-12-27	WOS:000229557900026
J	Bartlett, PJ; Young, KW; Nahorski, SR; Challiss, RAJ				Bartlett, PJ; Young, KW; Nahorski, SR; Challiss, RAJ			Single cell analysis and temporal profiling of agonist-mediated inositol 1,4,5-trisphosphate, Ca2+, diacylglycerol, and protein kinase C signaling using fluorescent biosensors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D; RECEPTOR; CALCIUM; PHOSPHORYLATION; ACTIVATION; OSCILLATIONS; DYNAMICS; PHOSPHATIDATE; VISUALIZATION; TRANSLOCATION	The magnitude and temporal nature of intracellular signaling cascades can now be visualized directly in single cells by the use of protein domains tagged with enhanced green fluorescent protein (eGFP). In this study, signaling downstream of G protein-coupled receptor-mediated phospholipase C (PLC) activation has been investigated in a cell line coexpressing recombinant M-3 muscarinic acetylcholine and alpha(1B)-adrenergic receptors. Confocal measurements of changes in inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3), using the pleckstrin homology domain of PLC delta 1 tagged to eGFP (eGFP-PHPLC delta), and 1,2-diacylglycerol (DAG), using the C1 domain of protein kinase C gamma (PKC gamma) (eGFP-C1(2)-PKC gamma), demonstrated clear translocation responses to methacholine and noradrenaline. Single cell EC50 values calculated for each agonist indicated that responses to downstream signaling targets (Ca2+ mobilization and PKC activation) were approximately 10-fold lower compared with respective Ins(1,4,5)P-3 and DAG EC50 values. Examining the temporal profile of second messenger responses to sub-EC50 concentrations of noradrenaline revealed oscillatory Ins(1,4,5)P-3, DAG, and Ca2+ responses. Oscillatory recruitments of conventional (PKC beta II) and novel (PKC epsilon) PKC isoenzymes were also observed which were synchronous with the Ca2+ response measured simultaneously in the same cell. However, oscillatory PKC activity (as determined by translocation of eGFP-tagged myristoylated alanine-rich C kinase substrate protein) required oscillatory DAG production. We suggest a model that uses regenerative Ca2+ release via Ins(1,4,5)P-3 receptors to initiate oscillatory second messenger production through a positive feedback effect on PLC. By acting on various components of the PLC signaling pathway the frequency-encoded Ca2+ response is able to maintain signal specificity at a level downstream of PKC activation.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Bartlett, PJ (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Maurice Shock Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.	pb70@le.ac.uk	Challiss, R.A. John/A-9412-2008	Challiss, John/0000-0001-5506-2848	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; Babwah AV, 2003, J BIOL CHEM, V278, P5419, DOI 10.1074/jbc.M211053200; BATTY IH, 1997, NEUROCHEMISTRY PRACT, P229; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHALLISS RAJ, 1988, BIOCHEM BIOPH RES CO, V157, P684, DOI 10.1016/S0006-291X(88)80304-8; Codazzi F, 2001, CURR BIOL, V11, P1089, DOI 10.1016/S0960-9822(01)00326-8; Dale LB, 2001, J BIOL CHEM, V276, P35900, DOI 10.1074/jbc.M103847200; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; Kiselyov K, 2003, CELL SIGNAL, V15, P243, DOI 10.1016/S0898-6568(02)00074-8; Lee TW, 1997, BIOCHEM J, V325, P733, DOI 10.1042/bj3250733; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; Meyer T, 2003, TRENDS CELL BIOL, V13, P101, DOI 10.1016/S0962-8924(02)00040-5; Miyawaki A, 2003, CURR OPIN NEUROBIOL, V13, P591, DOI 10.1016/j.conb.2003.09.005; Mogami H, 2003, J BIOL CHEM, V278, P9896, DOI 10.1074/jbc.M210653200; Nahorski SR, 2003, TRENDS NEUROSCI, V26, P444, DOI 10.1016/S0166-2236(03)00178-4; Nash MS, 2002, J BIOL CHEM, V277, P35947, DOI 10.1074/jbc.M205622200; Nash MS, 2001, BIOCHEM J, V356, P137, DOI 10.1042/0264-6021:3560137; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ohmori S, 2000, J BIOL CHEM, V275, P26449, DOI 10.1074/jbc.M003588200; Okubo Y, 2001, NEURON, V32, P113, DOI 10.1016/S0896-6273(01)00464-0; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; PURKISS JR, 1992, BIOCHEM J, V287, P31, DOI 10.1042/bj2870031; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; SCHMIDT M, 1995, J BIOL CHEM, V270, P19949, DOI 10.1074/jbc.270.34.19949; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TOBIN AB, 1995, BRIT J PHARMACOL, V116, P1723, DOI 10.1111/j.1476-5381.1995.tb16654.x; Uchino M, 2004, J BIOL CHEM, V279, P2254, DOI 10.1074/jbc.M309894200; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; WILLARS GB, 1995, BRIT J PHARMACOL, V114, P1133, DOI 10.1111/j.1476-5381.1995.tb13325.x; Xu C, 2003, J CELL BIOL, V161, P779, DOI 10.1083/jcb.200301070; Young KW, 2003, J BIOL CHEM, V278, P20753, DOI 10.1074/jbc.M211555200; Young KW, 2004, J NEUROCHEM, V89, P1537, DOI 10.1111/j.1471-4159.2004.02458.x	40	46	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					21837	21846		10.1074/jbc.M411843200	http://dx.doi.org/10.1074/jbc.M411843200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15788407	hybrid			2022-12-27	WOS:000229557900023
J	Humphrey, D; Rajfur, Z; Vazquez, ME; Scheswohl, D; Schaller, MD; Jacobson, K; Imperiali, B				Humphrey, D; Rajfur, Z; Vazquez, ME; Scheswohl, D; Schaller, MD; Jacobson, K; Imperiali, B			In Situ photoactivation of a caged phosphotyrosine peptide derived from focal adhesion kinase temporarily halts lamellar extension of single migrating tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC SH2 DOMAIN; TYROSINE PHOSPHORYLATION; C-SRC; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; NULL CELLS; INTEGRIN; BINDING; ASSOCIATION	Focal adhesion kinase (FAK), a non-receptor tyrosine kinase, mediates integrin-based cell signaling by transferring signals regulating cell migration, adhesion, and survival from the extracellular matrix to the cytoplasm. Following autophosphorylation at tyrosine 397, FAK binds the Src homology 2 domains of Src and phosphoinositide 3-kinase, among several other possible binding partners. To further investigate the role of phosphorylated FAK in cell migration in situ, peptides comprising residues 391-406 of human FAK with caged phosphotyrosine 397 were synthesized. Although the caged phosphopeptides were stable to phosphatase activity, the free phosphopeptides showed a half-life of beta 10-15 min in cell lysates. Migrating NBT-II cells (a rat bladder tumor cell line) were microinjected with the caged FAK peptide and locally photoactivated using a focused laser beam. The photoactivation of caged FAK peptide in 8-mu m diameter spots over the cell body led to the temporary arrest of the leading edge migration within similar to 1 min of irradiation. In contrast, cell body migration was not inhibited. Microinjection of a noncaged phosphorylated tyrosine 397 FAK peptide into migrating NBT-II cells also led to lamellar arrest; however, this approach lacks the temporal control afforded by the caged phosphopeptides. Photoactivation of related phosphotyrosine peptides with altered sequences did not result in transient lamellar arrest. We hypothesize that the phosphorylated FAK peptide competes with the endogenous FAK for binding to FAK effectors including, but not limited to, Src and phosphoinositide 3-kinase, causing spatiotemporal misregulation and subsequent lamellar arrest.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Jacobson, K (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.	frap@med.unc.edu	Jacobson, Kenneth Alan/A-1530-2009; Rajfur, Zenon/H-2506-2013; Vazquez, M. Eugenio/D-4083-2012	Jacobson, Kenneth Alan/0000-0001-8104-1493; Vazquez, M. Eugenio/0000-0001-7500-985X; Imperiali, Barbara/0000-0002-5749-7869; Rajfur, Zenon/0000-0003-1265-6480	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM064346] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 64346] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; Chen BH, 2002, J BIOL CHEM, V277, P33857, DOI 10.1074/jbc.M204429200; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Corrie J. E. T., 1993, BIOORGANIC PHOTOCHEM, P243; de Beus E, 1998, CELL MOTIL CYTOSKEL, V41, P126, DOI 10.1002/(SICI)1097-0169(1998)41:2<126::AID-CM4>3.0.CO;2-C; Ghosh M, 2004, SCIENCE, V304, P743, DOI 10.1126/science.1094561; Ghosh M, 2002, J AM CHEM SOC, V124, P2440, DOI 10.1021/ja017592l; GILMER T, 1994, J BIOL CHEM, V269, P31711; Goicoechea SM, 2002, INT J BIOCHEM CELL B, V34, P791, DOI 10.1016/S1357-2725(02)00002-X; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; HANCOCK WS, 1976, ANAL BIOCHEM, V71, P260, DOI 10.1016/0003-2697(76)90034-8; HUMPHREY D, 2005, LIVE CELL IMAGING LA, P159; ILLC D, 1995, NATURE, V377, P539; KAPLAN JH, 1978, BIOCHEMISTRY-US, V17, P1929, DOI 10.1021/bi00603a020; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU XQ, 1993, ONCOGENE, V8, P1119; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Park CH, 1997, J AM CHEM SOC, V119, P2453, DOI 10.1021/ja9635589; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Ren XD, 2000, J CELL SCI, V113, P3673; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rothman DM, 2005, J AM CHEM SOC, V127, P846, DOI 10.1021/ja043875c; Rothman DM, 2003, J ORG CHEM, V68, P6795, DOI 10.1021/jo0344891; Rothman DM, 2002, ORG LETT, V4, P2865, DOI 10.1021/ol0262587; Roy P, 2001, J CELL BIOL, V153, P1035, DOI 10.1083/jcb.153.5.1035; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Shen TL, 2002, J BIOL CHEM, V277, P29069, DOI 10.1074/jbc.M203085200; Sieg DJ, 1999, J CELL SCI, V112, P2677; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Walker JW, 1998, P NATL ACAD SCI USA, V95, P1568, DOI 10.1073/pnas.95.4.1568; Wells A, 1999, CELL MOTIL CYTOSKEL, V44, P227, DOI 10.1002/(SICI)1097-0169(199912)44:4<227::AID-CM1>3.0.CO;2-B; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yeh RH, 2002, J BIOL CHEM, V277, P11527, DOI 10.1074/jbc.M111300200; Zamir E, 2001, J CELL SCI, V114, P3583; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	26	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22091	22101		10.1074/jbc.M502726200	http://dx.doi.org/10.1074/jbc.M502726200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817454	hybrid, Green Published			2022-12-27	WOS:000229557900053
J	Choi, CY; Kim, YH; Kim, YO; Park, SJ; Kim, EA; Riemenschneider, W; Gajewski, K; Schulz, RA; Kim, Y				Choi, CY; Kim, YH; Kim, YO; Park, SJ; Kim, EA; Riemenschneider, W; Gajewski, K; Schulz, RA; Kim, Y			Phosphorylation by the DHIPK2 protein kinase modulates the corepressor activity of groucho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TCF; EYE-SPECIFIC ENHANCER; EYELESS GENE; VISCERAL MESODERM; DROSOPHILA EMBRYO; CO-REPRESSORS; EXPRESSION; INTERACTS; HIPK2; DIFFERENTIATION	Groucho function is essential for Drosophila development, acting as a corepressor for specific transcription factors that are downstream targets of various signaling pathways. Here we provide evidence that Groucho is phosphorylated by the DHIPK2 protein kinase. Phosphorylation modulates Groucho corepressor activity by attenuating its protein-protein interaction with a DNA-bound transcription factor. During eye development, DHIPK2 modifies Groucho activity, and eye phenotypes generated by overexpression of Groucho differ depending on its phosphorylation state. Moreover, analysis of nuclear extracts fractionated by column chromatography further shows that phospho- Groucho associates poorly with the corepressor complex, whereas the unphosphorylated form binds tightly. We propose that Groucho phosphorylation by DHIPK2 and its subsequent dissociation from the corepressor complex play a key role in relieving the transcriptional repression of target genes regulated by Groucho, thereby controlling cell fate determination during development.	NHLBI, Lab Res Program, NIH, Bethesda, MD 20892 USA; Sungkyunkwan Univ, Dept Sci Biol, Suwon 440746, South Korea; Digital Biotech, Ansan 425839, South Korea; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Sungkyunkwan University (SKKU); University of Texas System; UTMD Anderson Cancer Center	Choi, CY (corresponding author), NHLBI, Lab Res Program, NIH, Bldg 10, Bethesda, MD 20892 USA.	choicy@skku.ac.kr; yongsok@helix.nih.gov			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Barolo S, 1997, EMBO J, V16, P2883, DOI 10.1093/emboj/16.10.2883; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Chen GQ, 1998, MOL CELL BIOL, V18, P7259, DOI 10.1128/MCB.18.12.7259; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Choi CY, 1999, J BIOL CHEM, V274, P31543, DOI 10.1074/jbc.274.44.31543; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Courey AJ, 2001, GENE DEV, V15, P2786; Czerny T, 1999, MOL CELL, V3, P297, DOI 10.1016/S1097-2765(00)80457-8; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Flores GV, 2000, CELL, V103, P75, DOI 10.1016/S0092-8674(00)00106-9; Gajewski K, 2001, DEV BIOL, V233, P425, DOI 10.1006/dbio.2001.0220; Goldstein RE, 1999, DEVELOPMENT, V126, P3747; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Hasson P, 2005, NAT GENET, V37, P101, DOI 10.1038/ng1486; Hasson P, 2001, EMBO J, V20, P5725, DOI 10.1093/emboj/20.20.5725; Hauck B, 1999, P NATL ACAD SCI USA, V96, P564, DOI 10.1073/pnas.96.2.564; Husain J, 1996, BIOCHEM J, V317, P523, DOI 10.1042/bj3170523; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; Jimenez G, 2000, GENE DEV, V14, P224; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Kanei-Ishii C, 2004, GENE DEV, V18, P816, DOI 10.1101/gad.1170604; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kim YO, 2004, P NATL ACAD SCI USA, V101, P159, DOI 10.1073/pnas.0307205101; Kosman D, 1998, DEV GENES EVOL, V208, P290, DOI 10.1007/s004270050184; Kurata S, 2000, P NATL ACAD SCI USA, V97, P2117, DOI 10.1073/pnas.040556497; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lawrence N, 2001, CURR BIOL, V11, P375, DOI 10.1016/S0960-9822(01)00120-8; Lee YM, 1997, J BIOL CHEM, V272, P17531, DOI 10.1074/jbc.272.28.17531; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; MARDON G, 1994, DEVELOPMENT, V120, P3473; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Niimi T, 1999, DEVELOPMENT, V126, P2253; Nuthall HN, 2004, MOL CELL BIOL, V24, P8395, DOI 10.1128/MCB.24.19.8395-8407.2004; Paroush Z, 1997, DEVELOPMENT, V124, P3827; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Song HY, 2004, MOL CELL BIOL, V24, P4341, DOI 10.1128/MCB.24.10.4341-4350.2004; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; Valentine SA, 1998, MOL CELL BIOL, V18, P6584, DOI 10.1128/MCB.18.11.6584; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wiggins AK, 2004, J CELL BIOL, V167, P257, DOI 10.1083/jcb.200406131; WOLFF T, 2000, DROSOPHILA PROTOCOLS, P201; Zhang HL, 2001, GENE DEV, V15, P261, DOI 10.1101/gad.861201; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	62	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21427	21436		10.1074/jbc.M500496200	http://dx.doi.org/10.1074/jbc.M500496200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15802274	hybrid			2022-12-27	WOS:000229438800063
J	Pamplona, R; Dalfo, E; Ayala, VR; Bellmunt, MJ; Prat, J; Ferrer, I; Portero-Otin, M				Pamplona, R; Dalfo, E; Ayala, VR; Bellmunt, MJ; Prat, J; Ferrer, I; Portero-Otin, M			Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation - Effects of Alzheimer disease and identification of lipoxidation targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; LIPID-PEROXIDATION; GLUTAMINE-SYNTHETASE; CREATINE-KINASE; ALPHA-CHAIN; RAT-BRAIN; RECEPTOR; BETA; ASTROCYTES; EXPRESSION	Diverse oxidative pathways, such as direct oxidation of amino acids, glycoxidation, and lipoxidation could contribute to Alzheimer disease pathogenesis. A global survey for the amount of structurally characterized probes for these reactions is lacking and could overcome the lack of specificity derived from measurement of 2,4-dinitrophenylhydrazine reactive carbonyls. Consequently we analyzed (i) the presence and concentrations of glutamic and aminoadipic semialdehydes, N-is an element of(carboxymethyl)-lysine, N-is an element of-(carboxyethyl)-lysine, and N-is an element of-(malondialdehyde)-lysine by means of gas chromatography/mass spectrometry, (ii) the biological response through expression of the receptor for advanced glycation end products, (iii) the fatty acid composition in brain samples from Alzheimer disease patients and age-matched controls, and (iv) the targets of N-is an element of-(malondialdehyde)lysine formation in brain cortex by proteomic techniques. Alzheimer disease was associated with significant, although heterogeneous, increases in the concentrations of all evaluated markers. Alzheimer disease samples presented increases in expression of the receptor for advanced glycation end products with high molecular heterogeneity. Samples from Alzheimer disease patients also showed content of docosahexaenoic acid, which increased lipid peroxidizability. In accordance, N-is an element of-(malondialdehyde)-lysine formation targeted important proteins for both glial and neuronal homeostasis such as neurofilament L, alpha-tubulin, glial fibrillary acidic protein, ubiquinol-cytochrome c reductase complex protein I, and the beta chain of ATP synthase. These data support an important role for lipid peroxidation-derived protein modifications in Alzheimer disease pathogenesis.	Univ Lleida, Fac Med & Ciencies Salut, Dept Ciencies Med Basiques, Metab Pathophysiol Res Grp, E-25008 Lleida, Spain; Univ Barcelona, Bellvitge Hosp, Hosp Llobregat, Inst Neuropatol,Serv Anat Patol, E-08907 Barcelona, Spain; Univ Barcelona, Hosp Llobregat, Fac Med, Dept Biol Cellular & Anat Patol, E-08907 Barcelona, Spain	Universitat de Lleida; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; University of Barcelona	Portero-Otin, M (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, C Montserrat Roig 2, E-25008 Lleida, Spain.	manuel.portero@cmb.udl.es	Dalfo, Esther/AAW-5581-2020; Pamplona, Reinald/A-7359-2010; Prat Sala, Joan/HCI-3331-2022; Portero-Otin, Manuel/B-7122-2009; Ayala, Maria Victoria/A-7391-2010; Curcó, Maria Josep Bellmunt/C-3784-2011	Dalfo, Esther/0000-0003-4677-8515; Pamplona, Reinald/0000-0003-4337-6107; Portero-Otin, Manuel/0000-0002-1823-0299; Ayala, Maria Victoria/0000-0002-1496-966X; Curcó, Maria Josep Bellmunt/0000-0002-3187-1576				Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Aksenov MY, 2001, NEUROSCIENCE, V103, P373, DOI 10.1016/S0306-4522(00)00580-7; AMICI A, 1988, J BIOL CHEM, V365, P3341; Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; Balcz B, 2001, J NEURAL TRANSM-SUPP, P193; Barcelo-Coblijn G, 2003, P NATL ACAD SCI USA, V100, P11321, DOI 10.1073/pnas.1734008100; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bogdanovic N, 2001, DEMENT GERIATR COGN, V12, P364, DOI 10.1159/000051282; BRAAK H, 1999, CEREBRAL CORTEX NEUR, V14; BRETT J, 1993, AM J PATHOL, V143, P1699; Butterfield DA, 2002, NEUROBIOL AGING, V23, P655; CAO GH, 1995, ARCH BIOCHEM BIOPHYS, V320, P106, DOI 10.1006/abbi.1995.1347; Castegna A, 2002, J NEUROCHEM, V82, P1524, DOI 10.1046/j.1471-4159.2002.01103.x; Chen F, 2004, P NATL ACAD SCI USA, V101, P7687, DOI 10.1073/pnas.0402338101; COSGROVE JP, 1987, LIPIDS, V22, P299, DOI 10.1007/BF02533996; David S, 1998, MOL BRAIN RES, V54, P276, DOI 10.1016/S0169-328X(97)00343-4; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Forne I, 2003, J BIOL CHEM, V278, P50641, DOI 10.1074/jbc.M308531200; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; HAGA S, 1993, BRAIN RES, V601, P88, DOI 10.1016/0006-8993(93)91698-R; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; Kikuchi S, 2003, BRAIN RES REV, V41, P306, DOI 10.1016/S0165-0173(02)00273-4; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Lyras L, 1997, J NEUROCHEM, V68, P2061; Mark RJ, 1997, J NEUROSCI, V17, P1046; Montine TJ, 1999, AM J PATHOL, V155, P863, DOI 10.1016/S0002-9440(10)65185-1; Munch G, 2002, NEUROREPORT, V13, P601; Oyama R, 2000, BBA-PROTEIN STRUCT M, V1479, P91, DOI 10.1016/S0167-4838(00)00057-1; Palmer AM, 1999, J NEURAL TRANSM, V106, P317, DOI 10.1007/s007020050161; Pamplona R, 2002, MECH AGEING DEV, V123, P1437, DOI 10.1016/S0047-6374(02)00076-3; Park IH, 2004, MOL IMMUNOL, V40, P1203, DOI 10.1016/j.molimm.2003.11.027; Poon HF, 2004, NEUROSCIENCE, V126, P915, DOI 10.1016/j.neuroscience.2004.04.046; Porchet R, 2003, PROTEOMICS, V3, P1476, DOI 10.1002/pmic.200300456; Portero-Otin M, 1999, DIABETES, V48, P2215, DOI 10.2337/diabetes.48.11.2215; Rapoport SI, 2001, J LIPID RES, V42, P678; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; Requena JR, 2001, P NATL ACAD SCI USA, V98, P69, DOI 10.1073/pnas.011526698; Robinson SR, 2000, NEUROCHEM INT, V36, P471, DOI 10.1016/S0197-0186(99)00150-3; Sasaki N, 2001, BRAIN RES, V888, P256, DOI 10.1016/S0006-8993(00)03075-4; Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2; Schmidt AM, 1999, CIRC RES, V84, P489, DOI 10.1161/01.RES.84.5.489; Sergeant N, 2003, NEUROSCIENCE, V117, P293, DOI 10.1016/S0306-4522(02)00747-9; Shoffner JM, 1997, NEUROGENETICS, V1, P13, DOI 10.1007/s100480050002; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Sorensen BK, 2002, ANAL BIOCHEM, V304, P33, DOI 10.1006/abio.2001.5604; Thornalley PJ, 1999, BIOCHEM J, V344, P109, DOI 10.1042/0264-6021:3440109; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yatin SM, 1999, NEUROCHEM RES, V24, P427, DOI 10.1023/A:1020997903147; Yonekura H, 2003, BIOCHEM J, V370, P1097, DOI 10.1042/BJ20021371	50	221	226	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21522	21530		10.1074/jbc.M502255200	http://dx.doi.org/10.1074/jbc.M502255200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15799962	Green Published, hybrid			2022-12-27	WOS:000229438800074
J	Ali, SM; Sabatini, DM				Ali, SM; Sabatini, DM			Structure of S6 kinase 1 determines whether raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPAMYCIN-INDUCED INHIBITION; MAMMALIAN TARGET; BINDING PARTNER; TOR; ACTIVATION; CYTOSKELETON; PATHWAY; COMPLEX; 4E-BP1; CELLS	The mTOR protein kinase is the target of the immunosuppressive and anti-cancer drug rapamycin and is increasingly recognized as a key regulator of cell growth in mammals. S6 kinase 1 (S6K1) is the best characterized effector of mTOR, and its regulation serves as a model for mTOR signaling. Nutrients and growth factors activate S6K1 by inducing the phosphorylation of threonine 389 in the hydrophobic motif of S6K1. As phosphorylation of Thr(389) is rapamycin sensitive and mTOR can phosphorylate the same site in vitro, it has been suggested that mTOR is the physiological Thr389 kinase. This proposal is not supported, however, by the existence of mutants of S6K1 that are phosphorylated in vivo on Thr389 in a rapamycin-resistant fashion. Here, we demonstrate that the raptor-mTOR complex phosphorylates the rapamycin-sensitive forms of S6K1, while the distinct rictor-mTOR complex phosphorylates the rapamycin-resistant mutants of S6K1. Phosphorylation of Thr389 by rictor-mTOR is independent of the TOR signaling motif and depends on removal of the carboxyl terminal domain of S6K1. Because many members of the AGC family of kinases lack an analogous domain, rictor-mTOR may phosphorylate the hydrophobic motifs of other kinases.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Sabatini, DM (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	sabatini@wi.mit.edu	Ali, Siraj/AAE-2958-2019	/0000-0002-1446-7256	NATIONAL CANCER INSTITUTE [R01CA103866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI047389, R01AI047389] Funding Source: NIH RePORTER; NCI NIH HHS [CA103866] Funding Source: Medline; NIAID NIH HHS [AI47389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; GREZ M, 1990, P NATL ACAD SCI USA, V87, P9202, DOI 10.1073/pnas.87.23.9202; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Oshiro N, 2004, GENES CELLS, V9, P359, DOI 10.1111/j.1356-9597.2004.00727.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; WENG QP, 1995, MOL CELL BIOL, V15, P2333	21	115	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19445	19448		10.1074/jbc.C500125200	http://dx.doi.org/10.1074/jbc.C500125200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15809305	hybrid			2022-12-27	WOS:000229113700004
J	Carriere, V; Le Gall, M; Saumande, FG; Schmoll, D; Brot-Laroche, E; Chauffeton, V; Chambaz, J; Rousset, M				Carriere, V; Le Gall, M; Saumande, FG; Schmoll, D; Brot-Laroche, E; Chauffeton, V; Chambaz, J; Rousset, M			Intestinal glucose-dependent expression of glucose-6-phosphatase - Involvement of the aryl receptor nuclear translocator transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; BINDING PROTEIN CHREBP; RAT SMALL-INTESTINE; CELL-LINE CACO-2; GENE-EXPRESSION; RESPONSE ELEMENT; DIFFERENTIAL EXPRESSION; SUCRASE-ISOMALTASE; CATALYTIC SUBUNIT; DIABETIC-RATS	Glucose-6-phosphatase (G6Pase) catalyzes the release of glucose from glucose 6-phosphate. This enzyme was mainly studied in the liver, but while detected in the small intestine little is known about the regulation of its intestinal expression. This study describes the mechanisms of the glucose-dependent regulation of G6Pase expression in intestinal cells. Results obtained in vivo and in Caco-2/TC7 enterocytes showed that glucose increases the G6Pase mRNA level. In Caco-2/TC7 cells, glucose stabilized G6Pase mRNA and activated the transcription of the gene, meaning that glucose-dependent G6Pase expression involved both transcriptional and post-transcriptional mechanisms. Reporter-gene studies showed that, although the -299/+57 region of the human G6Pase promoter was sufficient to trigger the glucose response in the hepatoma cell line HepG2, the -1157/+1133 fragment was required for maximal activation of glucose-6-phosphatase gene transcription in Caco-2/TC7 cells. This fragment binds the aryl receptor nuclear translocator ( ARNT), cAMP-responsive element-binding protein, and upstream stimulatory factor transcription factors. The DNA binding activity of these transcription factors was increased in nuclear extracts of differentiated cells from the intestinal villus of mice fed sugar-rich diets as compared with mice fed a no-sugar diet. A direct implication of ARNT in the activation of G6Pase gene transcription by glucose has been observed in Caco-2/TC7 cells using RNA interference experiments. These results support a physiological role for G6Pase in the control of nutrient absorption in the small intestine.	Univ Paris 06, INSERM, UMR 505, F-75006 Paris, France; Sanofi Aventis Pharma, DG Metab Dis, D-65926 Frankfurt, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Sanofi-Aventis	Carriere, V (corresponding author), Ctr Rech Biomed Cordeliers, UMR 505, 15 Rue Ecole Med, F-75006 Paris, France.	veronique.carriere-u505@bhdc.jussieu.fr	Carrière, Véronique/AAQ-5027-2021; Le Gall, Maude/W-2593-2019; Le Gall, Maude/C-3917-2017	Carrière, Véronique/0000-0002-6263-0847; Le Gall, Maude/0000-0002-5372-4585; Le Gall, Maude/0000-0002-5372-4585; Schmoll, Dieter/0000-0003-2578-3366				Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; Bandsma RHJ, 2002, EUR J PEDIATR, V161, pS65, DOI 10.1007/s00431-002-1007-8; Bandsma RHJ, 2001, DIABETES, V50, P2591, DOI 10.2337/diabetes.50.11.2591; Bissonnette P, 1996, AM J PHYSIOL-GASTR L, V270, pG153, DOI 10.1152/ajpgi.1996.270.1.G153; Bizeau ME, 2001, J APPL PHYSIOL, V91, P2041, DOI 10.1152/jappl.2001.91.5.2041; Brahimi-Horn C, 2001, TRENDS CELL BIOL, V11, pS32, DOI 10.1016/S0962-8924(01)02126-2; Carriere V, 1998, AM J PHYSIOL-GASTR L, V274, pG1101, DOI 10.1152/ajpgi.1998.274.6.G1101; CHANTRET I, 1994, J CELL SCI, V107, P213; Chatelain F, 1998, DIABETES, V47, P882, DOI 10.2337/diabetes.47.6.882; Chou Janice Yang, 2002, Current Molecular Medicine (Hilversum), V2, P121, DOI 10.2174/1566524024605798; Collier JJ, 2003, J BIOL CHEM, V278, P6588, DOI 10.1074/jbc.M208011200; Croset M, 2001, DIABETES, V50, P740, DOI 10.2337/diabetes.50.4.740; Delie F, 1997, CRIT REV THER DRUG, V14, P221; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Gouyon F, 2003, J PHYSIOL-LONDON, V552, P823, DOI 10.1113/jphysiol.2003.049247; HORD NG, 1994, MOL PHARMACOL, V46, P618; HUGON JS, 1973, J HISTOCHEM CYTOCHEM, V21, P426, DOI 10.1177/21.5.426; Iizuka K, 2004, P NATL ACAD SCI USA, V101, P7281, DOI 10.1073/pnas.0401516101; Kellett GL, 2001, J PHYSIOL-LONDON, V531, P585, DOI 10.1111/j.1469-7793.2001.0585h.x; KORIEH A, 1991, ARCH INT PHYSIOL BIO, V99, P455; Krones A, 2001, ENDOCRINOLOGY, V142, P2707, DOI 10.1210/en.142.6.2707; Li YZ, 1999, J BIOL CHEM, V274, P33866, DOI 10.1074/jbc.274.48.33866; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Massillon D, 2003, J BIOL CHEM, V278, P40694, DOI 10.1074/jbc.M303182200; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; Massillon D, 2001, J BIOL CHEM, V276, P4055, DOI 10.1074/jbc.M007939200; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mithieux G, 2004, AM J PHYSIOL-ENDOC M, V286, pE370, DOI 10.1152/ajpendo.00299.2003; OCKERMAN PA, 1965, BIOCHIM BIOPHYS ACTA, V105, P22; PINTO M, 1983, BIOL CELL, V47, P323; Rajas F, 1999, GASTROENTEROLOGY, V117, P132, DOI 10.1016/S0016-5085(99)70559-7; Rajas F, 2002, J BIOL CHEM, V277, P15736, DOI 10.1074/jbc.M200971200; Rodolosse A, 1998, BIOCHEM J, V336, P115, DOI 10.1042/bj3360115; Santer R, 2003, GASTROENTEROLOGY, V124, P34, DOI 10.1053/gast.2003.50009; Sauvaget D, 2002, J BIOL CHEM, V277, P34540, DOI 10.1074/jbc.M206074200; Schmoll D, 1999, BIOCHEM J, V338, P457, DOI 10.1042/0264-6021:3380457; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Stumpel F, 2001, P NATL ACAD SCI USA, V98, P11330, DOI 10.1073/pnas.211357698; Swanson HI, 2002, CHEM-BIOL INTERACT, V141, P63, DOI 10.1016/S0009-2797(02)00066-2; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; Uyeda K, 2002, BIOCHEM PHARMACOL, V63, P2075, DOI 10.1016/S0006-2952(02)01012-2; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	46	13	14	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20094	20101		10.1074/jbc.M502192200	http://dx.doi.org/10.1074/jbc.M502192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15767253	hybrid			2022-12-27	WOS:000229113700080
J	Kambacheld, M; Augustin, S; Tatsuta, T; Muller, S; Langer, T				Kambacheld, M; Augustin, S; Tatsuta, T; Muller, S; Langer, T			Role of the novel metallopeptidase MoP112 and saccharolysin for the complete degradation of proteins residing in different subcompartments of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-AAA PROTEASE; YEAST SACCHAROMYCES-CEREVISIAE; CHAPERONE-LIKE ACTIVITY; INNER MEMBRANE; THIMET OLIGOPEPTIDASE; OXIDATIVE STRESS; ATP; YME1; PROHIBITINS; PEPTIDES	Mitochondria harbor a conserved proteolytic system that mediates the complete degradation of organellar proteins. ATP-dependent proteases, like a Lon protease in the matrix space and m- and i-AAA proteases in the inner membrane, degrade malfolded proteins within mitochondria and thereby protect the cell against mitochondrial damage. Proteolytic breakdown products include peptides and free amino acids, which are constantly released from mitochondria. It remained unclear, however, whether the turnover of malfolded proteins involves only ATP-dependent proteases or also oligopeptidases within mitochondria. Here we describe the identification of Mop112, a novel metallopeptidase of the pitrilysin family M16 localized in the intermembrane space of yeast mitochondria. This peptidase exerts important functions for the maintenance of the respiratory competence of the cells that overlap with the i-AAA protease. Deletion of MOP112 did not affect the stability of misfolded proteins in mitochondria, but resulted in an increased release from the organelle of peptides, generated upon proteolysis of mitochondrial proteins. We find that the previously described metallopeptidase saccharolysin ( or Prd1) exerts a similar function in the intermembrane space. The identification of peptides released from peptidase-deficient mitochondria by mass spectrometry indicates a dual function of Mop112 and saccharolysin: they degrade peptides generated upon proteolysis of proteins both in the intermembrane and matrix space and presequence peptides cleaved off by specific processing peptidases in both compartments. These results suggest that the turnover of mitochondrial proteins is mediated by the sequential action of ATP-dependent proteases and oligopeptidases, some of them localized in the intermembrane space.	Univ Cologne, Inst Genet, D-50674 Cologne, Germany; Univ Cologne, ZMMK, D-50674 Cologne, Germany	University of Cologne; University of Cologne	Langer, T (corresponding author), Univ Cologne, Inst Genet, Zulpicher Str 47, D-50674 Cologne, Germany.	Thomas.Langer@uni-koeln.de		Langer, Thomas/0000-0003-1250-1462				Arlt H, 1998, EMBO J, V17, P4837, DOI 10.1093/emboj/17.16.4837; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; Atorino L, 2003, J CELL BIOL, V163, P777, DOI 10.1083/jcb.200304112; Augustin S, 2005, J BIOL CHEM, V280, P2691, DOI 10.1074/jbc.M410609200; BARRETT AJ, 2004, HDB PROTEOLYTIC ENZY, V1, P1112; Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836; Bota DA, 2001, MITOCHONDRION, V1, P33, DOI 10.1016/S1567-7249(01)00005-8; BUCHLER M, 1994, EUR J BIOCHEM, V219, P627, DOI 10.1111/j.1432-1033.1994.tb19978.x; DENFERT C, 2004, HDB PROTEOLYTIC ENZY, V1, P1115; DESAUTELS M, 1982, P NATL ACAD SCI-BIOL, V79, P1869, DOI 10.1073/pnas.79.6.1869; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; Ferreirinha F, 2004, J CLIN INVEST, V113, P231, DOI 10.1172/JCI200420138; Gakh E, 2002, BBA-MOL CELL RES, V1592, P63, DOI 10.1016/S0167-4889(02)00265-3; GARCIAALVAREZ N, 1987, EUR J BIOCHEM, V163, P339, DOI 10.1111/j.1432-1033.1987.tb10805.x; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Kaser M, 2003, J BIOL CHEM, V278, P46414, DOI 10.1074/jbc.M305584200; Koehler CM, 2004, ANNU REV CELL DEV BI, V20, P309, DOI 10.1146/annurev.cellbio.20.010403.105057; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Langer T, 1995, METHOD ENZYMOL, V260, P495, DOI 10.1016/0076-6879(95)60161-9; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; Leonhard K, 2000, MOL CELL, V5, P629, DOI 10.1016/S1097-2765(00)80242-7; Leonhard K, 1999, NATURE, V398, P348, DOI 10.1038/18704; LIPSKY NG, 1981, J BIOL CHEM, V256, P8652; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Meisinger C, 2000, ANAL BIOCHEM, V287, P339, DOI 10.1006/abio.2000.4868; Moberg P, 2003, PLANT J, V36, P616, DOI 10.1046/j.1365-313X.2003.01904.x; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Oliveira V, 2002, EUR J BIOCHEM, V269, P4326, DOI 10.1046/j.1432-1033.2002.03129.x; Shah ZH, 2000, FEBS LETT, V478, P267, DOI 10.1016/S0014-5793(00)01859-7; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Steglich G, 1999, MOL CELL BIOL, V19, P3435; Tatsuta T, 2005, MOL BIOL CELL, V16, P248, DOI 10.1091/mbc.e04-09-0807; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; Van Dyck L, 1999, CELL MOL LIFE SCI, V56, P825, DOI 10.1007/s000180050029; WALKER JH, 1978, BIOCHEM J, V176, P927, DOI 10.1042/bj1760927; Weber ER, 1996, MOL BIOL CELL, V7, P307, DOI 10.1091/mbc.7.2.307; Young L, 2001, SCIENCE, V291, P2135, DOI 10.1126/science.1056957	38	69	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20132	20139		10.1074/jbc.M500398200	http://dx.doi.org/10.1074/jbc.M500398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772085	hybrid			2022-12-27	WOS:000229113700085
J	Li, S; Whorton, AR				Li, S; Whorton, AR			Identification of stereoselective transporters for s-nitroso-L-cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; NITRIC-OXIDE; HEAVY-CHAIN; SYSTEM L; PROTEIN; SUBSTRATE; CELLS; NITROSOCYSTEINE; MECHANISM; RAT	Many of the biological effects of nitric oxide are mediated by S-nitrosothiols. However, the mechanisms by which S-nitrosothiols transduce their activity across cell membranes are unclear. We show that the pathway responsible for the cellular effects of S-nitrosothiols is specific for S-nitrosocysteine (CSNO), is stereoselective, and requires direct uptake of intact L-CSNO. Transport is independent of extracellular sodium, competitively inhibited by leucine, and blocked by 2-aminobicyclo[2.2.1] heptane-2-carboxylic acid, a specific inhibitor of the system L amino acid transporter family. Other nitrosothiols such as S-nitrosoglutathione are not substrates for transport and require reaction with L-cysteine for activity. To show that system L family members mediate uptake, we expressed two members, LAT1 and LAT2, in Xenopus oocytes. Both LAT1 and LAT2, when co-expressed with 4F2 heavy chain, were found to efficiently transport L-CSNO. Mammalian cells were shown to express LAT1 and LAT2. A431 cells express both proteins, whereas T24 cells express only LAT1. Overexpression of LAT1 in T24 cells using recombinant adenoviruses led to increased uptake of L-CSNO, whereas knockdown using a specific small interfering RNA led to decreased uptake. These data definitively identify LAT1 and LAT2 as members of system L that mediate transmembrane movement of L-CSNO and suggest that system L family members are involved in the cellular activity of small molecular weight nitrosothiols.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Whorton, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, C138B LSRC,Box 3813, Durham, NC 27710 USA.	awho@duke.edu						Davisson RL, 1996, CIRC RES, V79, P256, DOI 10.1161/01.RES.79.2.256; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Fraga S, 2002, J NUTR, V132, P733, DOI 10.1093/jn/132.4.733; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gow AJ, 2004, AM J PHYSIOL-LUNG C, V287, pL262, DOI 10.1152/ajplung.00295.2003; Grossi L, 2002, J ORG CHEM, V67, P8625, DOI 10.1021/jo026154+; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Hogg N, 1997, BIOCHEM J, V323, P477, DOI 10.1042/bj3230477; Hogg N, 2002, ANNU REV PHARMACOL, V42, P585, DOI 10.1146/annurev.pharmtox.42.092501.104328; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Josch C, 2003, BIOL CHEM, V384, P213, DOI 10.1515/BC.2003.023; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kim D, 2002, BBA-BIOMEMBRANES, V1565, P112, DOI 10.1016/S0005-2736(02)00516-3; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; Li S, 2003, ARCH BIOCHEM BIOPHYS, V410, P269, DOI 10.1016/S0003-9861(02)00696-3; Lipton AJ, 2001, NATURE, V413, P171, DOI 10.1038/35093117; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Mallis RJ, 2000, ARCH BIOCHEM BIOPHYS, V383, P60, DOI 10.1006/abbi.2000.2048; MATHEWS WR, 1993, J PHARMACOL EXP THER, V267, P1529; McMahon TJ, 2003, BLOOD, V102, P410, DOI 10.1182/blood-2003-04-1058; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; Nemoto T, 2003, EUR J PHARMACOL, V458, P17, DOI 10.1016/S0014-2999(02)02699-7; Padgett C. M., 1995, AM J PHYSIOL, V269, pC739; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Ramachandran N, 2001, P NATL ACAD SCI USA, V98, P9539, DOI 10.1073/pnas.171180998; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; Satoh S, 1997, J NEUROCHEM, V69, P2197; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Simmons-Willis TA, 2002, BIOCHEM J, V367, P239, DOI 10.1042/BJ20020841; Stamler JS, 2002, CURR OPIN CHEM BIOL, V6, P779, DOI 10.1016/S1367-5931(02)00383-6; Travis MD, 1997, AM J PHYSIOL-HEART C, V273, pH1493, DOI 10.1152/ajpheart.1997.273.3.H1493; Tsikas D, 1999, ANAL BIOCHEM, V270, P231, DOI 10.1006/abio.1999.4084; Uchino H, 2002, MOL PHARMACOL, V61, P729, DOI 10.1124/mol.61.4.729; Verrey F, 2003, PFLUG ARCH EUR J PHY, V445, P529, DOI 10.1007/S00424-002-0973-Z; Yanagida O, 2001, BBA-BIOMEMBRANES, V1514, P291, DOI 10.1016/S0005-2736(01)00384-4; Zai A, 1999, J CLIN INVEST, V103, P393, DOI 10.1172/JCI4890; Zhang YH, 2004, P NATL ACAD SCI USA, V101, P7891, DOI 10.1073/pnas.0401167101	38	66	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					20102	20110		10.1074/jbc.M413164200	http://dx.doi.org/10.1074/jbc.M413164200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15769744	hybrid			2022-12-27	WOS:000229113700081
J	Tonazzi, A; Giangregorio, N; Indiveri, C; Palmieri, F				Tonazzi, A; Giangregorio, N; Indiveri, C; Palmieri, F			Identification by site-directed mutagenesis and chemical modification of three vicinal cysteine residues in rat mitochondrial carnitine/acylcarnitine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECONSTITUTED CARNITINE CARRIER; LIVER MITOCHONDRIA; ESCHERICHIA-COLI; SWISS-MODEL; ARSA ATPASE; PROTEIN; PURIFICATION; METALLOACTIVATION; COMPLEX; GENE	The proximity of the Cys residues present in the mitochondrial rat carnitine/acylcarnitine carrier (CAC) primary structure was studied by using site-directed mutagenesis in combination with chemical modification. CAC mutants, in which one or more Cys residues had been replaced with Ser, were overexpressed in Escherichia coli and reconstituted into liposomes. The effect of SH oxidizing, cross-linking, and coordinating reagents was evaluated on the carnitine/carnitine exchange catalyzed by the recombinant reconstituted CAC proteins. All the tested reagents efficiently inhibited the wild-type CAC. The inhibitory effect of diamide, Cu2+-phenanthroline, or phenylarsine oxide was largely reduced or abolished by the double substitutions C136S/C155S, C58S/C136S, and C58S/C155S. The decrease in sensitivity to these reagents was much lower in double mutants in which Cys(23) was substituted with Cys(136) or Cys(155). No decrease in inhibition was found when Cys(89) and/or Cys(283) were replaced with Ser. Sb3+, which coordinates three cysteines, inhibited only the Cys replacement mutants containing cysteines 58, 136, and 155 of the six native cysteines. In addition, the mutant C23S/C89S/C155S/C283S, in which double tandem fXa recognition sites were inserted in positions 65-72, i.e. between Cys(58) and Cys(136), was not cleaved into two fragments by fXa protease after treatment with diamide. These results are interpreted in light of the homology model of CAC based on the available x-ray structure of the ADP/ATP carrier. They indicate that Cys(58), Cys(136), and Cys(155) become close in the tertiary structure of the CAC during its catalytic cycle.	Univ Bari, Dipartimento Farmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy; CNR, Inst Biomembranes & Bioenerget, I-70125 Bari, Italy; Univ Calabria, Dept Cellular Biol, I-87030 Cosenza, Italy	Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR); University of Calabria	Palmieri, F (corresponding author), Univ Bari, Dipartimento Farmacobiol, Biochem & Mol Biol Lab, Via E Orabona 4, I-70125 Bari, Italy.	fpalm@farmbiol.uniba.it	tonazzi, annamaria/G-9799-2012	Indiveri, Cesare/0000-0001-9818-6621				Bhattacharjee H, 1996, J BIOL CHEM, V271, P24465, DOI 10.1074/jbc.271.40.24465; BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; De Lucas JR, 1999, ARCH MICROBIOL, V171, P386, DOI 10.1007/s002030050725; Fiermonte G, 1998, J BIOL CHEM, V273, P22782, DOI 10.1074/jbc.273.35.22782; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iacobazzi V, 1998, BIOCHEM BIOPH RES CO, V252, P770, DOI 10.1006/bbrc.1998.9738; IDELLWENGER JA, 1981, J BIOL CHEM, V256, P5579; Indiveri C, 1998, BIOCHEM BIOPH RES CO, V249, P589, DOI 10.1006/bbrc.1998.9197; INDIVERI C, 1990, BIOCHIM BIOPHYS ACTA, V1020, P81, DOI 10.1016/0005-2728(90)90096-M; Indiveri C, 2002, BIOCHEMISTRY-US, V41, P8649, DOI 10.1021/bi012183n; Indiveri C, 1997, BIOCHEM J, V321, P713, DOI 10.1042/bj3210713; INDIVERI C, 1995, EUR J BIOCHEM, V228, P271; INDIVERI C, 1994, BBA-BIOMEMBRANES, V1189, P65, DOI 10.1016/0005-2736(94)90281-X; KALEF E, 1994, METHOD ENZYMOL, V233, P395; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Krumer R., 1992, MOL MECHANISMS BIOEN, P359, DOI DOI 10.1016/50167-7306(08)60184-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Nagano N, 1999, FEBS LETT, V458, P69, DOI 10.1016/S0014-5793(99)01122-9; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; Palmieri F, 2004, ENCY BIOL CHEM, V2, P725; Palmieri L, 1999, FEBS LETT, V462, P472, DOI 10.1016/S0014-5793(99)01555-0; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Phelps A, 1996, BIOCHEMISTRY-US, V35, P10757, DOI 10.1021/bi961052x; Raso SW, 2001, J MOL BIOL, V307, P899, DOI 10.1006/jmbi.2001.4476; SAHINTOTH M, 1995, BIOCHEMISTRY-US, V34, P1107, DOI 10.1021/bi00004a001; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520	30	40	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19607	19612		10.1074/jbc.M411181200	http://dx.doi.org/10.1074/jbc.M411181200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15757911	hybrid			2022-12-27	WOS:000229113700024
J	Tsui, C; Raguraj, A; Pickart, CM				Tsui, C; Raguraj, A; Pickart, CM			Ubiquitin binding site of the ubiquitin E2 variant (UEV) protein Mms2 is required for DNA damage tolerance in the yeast RAD6 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATING ENZYME COMPLEX; POSTREPLICATION REPAIR; POLYUBIQUITIN CHAINS; CRYSTAL-STRUCTURE; LYSINE; PCNA; RECOGNITION; DOMAINS; DEGRADATION; SPECIFICITY	Different ubiquitin modifications to proliferating cell nuclear antigen ( PCNA) signal distinct modes of lesion bypass in the RAD6 pathway of DNA damage tolerance. The modification of PCNA with monoubiquitin signals an error-prone bypass, whereas the extension of this modification into a Lys-63-linked polyubiquitin chain promotes error-free bypass. Chain formation is catalyzed by the Mms2/Ubc13 conjugating enzyme variant/conjugating enzyme (UEV center dot E2) complex together with the Rad5 ubiquitin ligase. In vitro studies of this UEV center dot E2 complex have identified a ubiquitin binding site that is mainly localized on Mms2. However, the role of this site in DNA damage tolerance and the molecular features of the ubiquitin/Mms2 interaction are poorly understood. Here we identify two molecular determinants, the side chains of Mms2-Ile-57 and ubiquitin-Ile-44, that are required for chain assembly in vitro and error-free lesion bypass in vivo. Mutating either of these side chains to alanine elicits a severe 10-20-fold inhibition of chain synthesis that is caused by compromised binding of the acceptor ubiquitin to Mms2. These results suggest that the ubiquitin binding site of Mms2 is necessary for error-free lesion bypass in the RAD6 pathway and provide new insights into ubiquitin recognition by UEV proteins.	Johns Hopkins Univ, Dept Biochem & Mol Biol, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Pickart, CM (corresponding author), Johns Hopkins Univ, Dept Biochem & Mol Biol, Bloomberg Sch Publ Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.	cpickart@jhmi.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060372] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60372] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam SL, 2004, EMBO J, V23, P1411, DOI 10.1038/sj.emboj.7600114; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; Bernstein CN, 2002, INFLAMM BOWEL DIS, V8, P356, DOI 10.1097/00054725-200209000-00007; Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; Broomfield S, 2001, MUTAT RES-DNA REPAIR, V486, P167, DOI 10.1016/S0921-8777(01)00091-X; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; HAAS AL, 1982, J BIOL CHEM, V257, P329; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; HALDEMAN MT, 1981, BIOCHEMISTRY-US, V266, P9235; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Haracska L, 2004, MOL CELL BIOL, V24, P4267, DOI 10.1128/MCB.24.10.4267-4274.2004; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Mastrandrea LD, 1999, J BIOL CHEM, V274, P27299, DOI 10.1074/jbc.274.38.27299; McKenna S, 2003, BIOCHEMISTRY-US, V42, P7922, DOI 10.1021/bi034480t; McKenna S, 2003, J BIOL CHEM, V278, P13151, DOI 10.1074/jbc.M212353200; McKenna S, 2001, J BIOL CHEM, V276, P40120, DOI 10.1074/jbc.M102858200; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; Mueller TD, 2004, J BIOL CHEM, V279, P11926, DOI 10.1074/jbc.M312865200; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Ryu KS, 2003, J BIOL CHEM, V278, P36621, DOI 10.1074/jbc.M304628200; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Sun LJ, 2004, CURR OPIN CELL BIOL, V16, P119, DOI 10.1016/j.ceb.2004.02.005; Sundquist WI, 2004, MOL CELL, V13, P783, DOI 10.1016/S1097-2765(04)00129-7; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Torres-Ramos CA, 2002, MOL CELL BIOL, V22, P2419, DOI 10.1128/MCB.22.7.2419-2426.2002; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Ulrich HD, 2003, J BIOL CHEM, V278, P7051, DOI 10.1074/jbc.M212195200; Ulrich HD, 2002, EUKARYOT CELL, V1, P1, DOI 10.1128/EC.1.1.1-10.2002; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Varadan R, 2004, J BIOL CHEM, V279, P7055, DOI 10.1074/jbc.M309184200; Verma R, 2004, SCIENCE, V306, P117, DOI 10.1126/science.1100946; Wang QH, 2003, BIOCHEMISTRY-US, V42, P13529, DOI 10.1021/bi035391j; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; WILKINSON KD, 1981, J BIOL CHEM, V256, P9235; Xiao W, 2000, GENETICS, V155, P1633; You JX, 1999, BIOTECHNIQUES, V27, P950, DOI 10.2144/99275st01	66	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19829	19835		10.1074/jbc.M414060200	http://dx.doi.org/10.1074/jbc.M414060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772086	hybrid			2022-12-27	WOS:000229113700050
J	Ariyoshi, W; Takahashi, T; Kanno, T; Ichimiya, H; Takano, H; Koseki, T; Nishihara, T				Ariyoshi, W; Takahashi, T; Kanno, T; Ichimiya, H; Takano, H; Koseki, T; Nishihara, T			Mechanisms involved in enhancement of osteoclast formation and function by low molecular weight hyaluronic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EXPRESS HIGH-LEVELS; NF-KAPPA-B; RHEUMATOID-ARTHRITIS; RECEPTOR ACTIVATOR; SIGNALING PATHWAY; BONE-RESORPTION; SYNOVIAL-FLUID; MAP KINASE; PC12 CELLS	Hyaluronic acid ( HA) is a component of the extracellular matrix that has been shown to play an important role in bone formation, resorption, and mineralization both in vivo and in vitro. We examined the effects of HA at several molecular weights on osteoclast formation and function induced by RANKL ( receptor activator of NF-kappa B ligand) in a mouse monocyte cell line (RAW 264.7). HA atM(r) < 8,000 (low molecular weight HA (LMW-HA)) enhanced tartrate-resistant acid phosphatase-positive multinucleated cell formation and tartrate-resistant acid phosphatase activity induced by RANKL in a dose-dependent manner, whereas HA at M-r > 900,000 ( high molecular weight HA (HMW-HA)) showed no effect on osteoclast differentiation. LMW-HA enhanced pit formation induced by RAW 264.7 cells, whereas HMW-HA did not, and LMW-HA stimulated the expression of RANK (receptor activator of NF-kappa B) protein in RAW 264.7 cells. In addition, we found that LMW-HA enhanced the levels of c-Src protein and phosphorylation of ERKs and p38 MAPK in RAW 264.7 cells stimulated with RANKL, whereas the p38 MAPK inhibitor SB203580 inhibited RANKL-induced osteoclast differentiation. This enhancement of c-Src and RANK proteins induced by LMW-HA was inhibited by CD44 function-blocking monoclonal antibody. These results indicate that LMW-HA plays an important role in osteoclast differentiation and function through the interaction of RANKL and RANK.	Kyushu Dent Coll, Sch Dent, Dept Oral Microbiol, Kitakyushu, Fukuoka 8038580, Japan; Kyushu Dent Coll, Sch Dent, Dept Oral & Maxillofacial Surg 2, Kitakyushu, Fukuoka 8038580, Japan; Tohoku Univ, Grad Sch Dent, Dept Lifelong Oral Hlth Sci, Div Prevent Dent, Sendai, Miyagi 9808575, Japan	Kyushu Dental University; Kyushu Dental University; Tohoku University	Nishihara, T (corresponding author), Kyushu Dent Coll, Sch Dent, Dept Oral Microbiol, Kitakyushu, Fukuoka 8038580, Japan.	tatsujin@kyu-dent.ac.jp		Nishihara, Tatsuji/0000-0001-7075-9678				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Brun P, 1999, J BIOMED MATER RES, V46, P337, DOI 10.1002/(SICI)1097-4636(19990905)46:3<337::AID-JBM5>3.0.CO;2-Q; Cao JJ, 2005, J BONE MINER RES, V20, P30, DOI 10.1359/JBMR.041014; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CULTY M, 1994, J LEUKOCYTE BIOL, V56, P605, DOI 10.1002/jlb.56.5.605; DAHL LB, 1985, ANN RHEUM DIS, V44, P817, DOI 10.1136/ard.44.12.817; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Fukuda K, 1996, J PHARMACOL EXP THER, V277, P1672; FULLER K, 1994, J BONE MINER RES, V9, P17; Homandberg GA, 1997, OSTEOARTHR CARTILAGE, V5, P309, DOI 10.1016/S1063-4584(97)80035-0; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Iwasaki S, 1996, J BIOL CHEM, V271, P17360, DOI 10.1074/jbc.271.29.17360; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Kawasaki K, 1999, J CELL PHYSIOL, V179, P142, DOI 10.1002/(SICI)1097-4652(199905)179:2<142::AID-JCP4>3.0.CO;2-Q; KIND PRN, 1954, J CLIN PATHOL, V7, P322, DOI 10.1136/jcp.7.4.322; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; Knudson W, 1996, EXP CELL RES, V228, P216, DOI 10.1006/excr.1996.0320; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Kumar S, 2001, J CELL PHYSIOL, V187, P294, DOI 10.1002/jcp.1082; LARSEN NE, 1992, J ORTHOPAED RES, V10, P23, DOI 10.1002/jor.1100100104; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Okahashi N, 1997, J BONE MINER RES, V12, P1116, DOI 10.1359/jbmr.1997.12.7.1116; Prince CW, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471-2474-5-12; SAKAMOTO T, 1984, ORTHOPEDIC RES SCI, V11, P264; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; SHIMAZU A, 1993, ARTHRITIS RHEUM, V36, P247, DOI 10.1002/art.1780360217; SMITH MM, 1987, RHEUMATOL INT, V7, P113, DOI 10.1007/BF00270463; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Suzuki K, 2002, J BONE MINER RES, V17, P1486, DOI 10.1359/jbmr.2002.17.8.1486; Takahashi T, 2004, J ORAL PATHOL MED, V33, P224, DOI 10.1111/j.0904-2512.2004.00024.x; TANAKA S, 1992, FEBS LETT, V313, P85, DOI 10.1016/0014-5793(92)81190-W; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; UNDERHILL C, 1992, J CELL SCI, V103, P293; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; YASUI T, 1992, BIOMED RES-TOKYO, V13, P343, DOI 10.2220/biomedres.13.343	44	56	58	1	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18967	18972		10.1074/jbc.M412740200	http://dx.doi.org/10.1074/jbc.M412740200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15757905	hybrid			2022-12-27	WOS:000228932300050
J	Imagawa, T; Yamamoto, T; Kaya, S; Sakaguchi, K; Taniguchi, K				Imagawa, T; Yamamoto, T; Kaya, S; Sakaguchi, K; Taniguchi, K			Thr-774 (transmembrane segment M5), Val-920 (M8), and Glu-954 (M9) are involved in Na+ transport, and Gln-923 (m8) is essential for Na,K-ATPaseActivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY NA+,K+-ATPASE; SITE-DIRECTED MUTAGENESIS; INDUCED CONFORMATIONAL-CHANGES; AMINO-ACID SUBSTITUTIONS; CATION-BINDING POCKET; SHEEP ALPHA-1 ISOFORM; SARCOPLASMIC-RETICULUM; FUNCTIONAL CONSEQUENCES; RENAL NA,K-ATPASE; ACTIVE-TRANSPORT	The highly conserved amino acids of rat Na,K-ATPase, Thr-774 in the transmembrane helices M5, Val-920 and Gln-923 in M8, and Glu-953 and Glu-954 in M9, the side chains of which appear to be in close proximity, were mutated, and the resulting proteins, T774A, E953A/K, and E954A/K, V920E and Q923N/E/D/L, were expressed in HeLa cells. Ouabain-resistant cell lines were obtained from T774A, V920E, E953A, and E954A, whereas Q923N/E/D/L, E953K, and E954K could only be transiently expressed as fusion proteins with an enhanced green fluorescent protein. The apparent K-0.5 values for Na+, as estimated by the Na+-dependent phosphoenzyme formation (K-0.5(Na,EP)) or Na, K-ATPase activity (K-0.5(Na,ATPase)), were increased by around 2 similar to 8- fold in the case of T774A, V920E, and E954A. The apparent K-0.5 values for K+, as estimated by the Na,K-ATPase (K-0.5(K,ATPase)) or p-nitrophenylphosphatase activity (K-0.5(K,pNPPase)), were affected only slightly by the 3 mutations, except that V920E showed a 1.7-fold increase in the K-0.5(K,ATPase). The apparent K-0.5 values for ATP (K-0.5(EP)), as estimated by phosphorylation ( a high affinity ATP effect), were increased by 1.6 similar to 2.6-fold in the case of T774A, V920E, and E954A. Those estimated by Na, K-ATPase activity (K-0.5(ATPase)) and ATP-induced inhibition (K-i,0.5(pNPPase)) of K-pNPPase activity (low affinity ATP effects) were, respectively, increased by 1.8-fold and unchanged in the case of T774A but decreased by 2- and 4.8-fold in the case of V920E and were slightly changed and increased by 1.7-fold in the case of E954A. The E953A showed little significant change in the apparent affinities. These results suggest that Gln-923 in M8 is crucial for the active transport of Na+ and/or K+ across membranes and that the side chain oxygen atom of Thr-774 in M5, the methyl group(s) of Val-920 in M8, and the carboxyl oxygen(s) of Glu-954 in M9 mainly play some role in the transport of Na+ and also in the high and low affinity ATP effects rather than the transport of K+.	Hokkaido Univ, Grad Sch Sci, Div Chem, Kita Ku, Sapporo, Hokkaido 0600810, Japan	Hokkaido University	Imagawa, T (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Chem, Kita Ku, Kita 10 Nishi 8, Sapporo, Hokkaido 0600810, Japan.	toshi@sci.hokudai.ac.jp	Imagawa, Toshiaki/A-4255-2012					ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; Arguello JM, 1999, ARCH BIOCHEM BIOPHYS, V367, P341, DOI 10.1006/abbi.1999.1278; Arguello JM, 1999, ARCH BIOCHEM BIOPHYS, V364, P254, DOI 10.1006/abbi.1999.1124; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Arguello JM, 1996, J BIOL CHEM, V271, P24610, DOI 10.1074/jbc.271.40.24610; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; Blostein R, 1999, BIOCHEM CELL BIOL, V77, P1, DOI 10.1139/bcb-77-1-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; Domaszewicz W, 1999, FEBS LETT, V458, P241, DOI 10.1016/S0014-5793(99)01162-X; FENG JN, 1995, CELL MOL BIOL RES, V41, P29; Gatto C, 1998, J BIOL CHEM, V273, P10578, DOI 10.1074/jbc.273.17.10578; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; Hilge M, 2003, NAT STRUCT BIOL, V10, P468, DOI 10.1038/nsb924; Imagawa T, 2003, J BIOL CHEM, V278, P50283, DOI 10.1074/jbc.M309833200; Imagawa T, 1998, JPN J PHARMACOL, V76, P415, DOI 10.1254/jjp.76.415; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JOHNSON CL, 1995, BIOCHEM J, V309, P187, DOI 10.1042/bj3090187; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; Jorgensen PL, 1998, ACTA PHYSIOL SCAND, V163, P79; Jorgensen PL, 1998, BBA-BIOENERGETICS, V1365, P65, DOI 10.1016/S0005-2728(98)00043-7; Jorgensen PL, 2001, BBA-BIOENERGETICS, V1505, P57, DOI 10.1016/S0005-2728(00)00277-2; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Koenderink JB, 2000, BIOCHEMISTRY-US, V39, P9959, DOI 10.1021/bi0001168; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P2993, DOI 10.1074/jbc.270.7.2993; Lingrel JB, 1998, ACTA PHYSIOL SCAND, V163, P69; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MAEDA M, 1988, BIOCHEM BIOPH RES CO, V157, P203, DOI 10.1016/S0006-291X(88)80033-0; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; Mense M, 2000, J BIOL CHEM, V275, P1749, DOI 10.1074/jbc.275.3.1749; MOLLER M, 1986, ADV PINEAL RES, V1, P51; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; POST RL, 1972, J BIOL CHEM, V247, P6530; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Segall L, 2002, J BIOL CHEM, V277, P35202, DOI 10.1074/jbc.M206115200; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Taniguchi K, 2001, J BIOCHEM, V129, P335, DOI 10.1093/oxfordjournals.jbchem.a002862; Tao Bernard Y., 1994, P69; Tepperman K, 1997, AM J PHYSIOL-CELL PH, V273, pC2065, DOI 10.1152/ajpcell.1997.273.6.C2065; Teramachi S, 2002, J BIOL CHEM, V277, P37394, DOI 10.1074/jbc.M204772200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VANHUYSSE JW, 1993, BIOCHEMISTRY-US, V32, P819, DOI 10.1021/bi00054a012; VANHUYSSE JW, 1993, CELL MOL BIOL RES, V39, P497; VanHuysse JW, 1996, FEBS LETT, V389, P179, DOI 10.1016/0014-5793(96)00578-9; Vasilets LA, 1998, BBA-BIOMEMBRANES, V1368, P137, DOI 10.1016/S0005-2736(97)00195-8; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; VILSEN B, 1995, FEBS LETT, V363, P179, DOI 10.1016/0014-5793(95)00313-X; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; VILSEN B, 1993, FEBS LETT, V333, P44, DOI 10.1016/0014-5793(93)80372-2; WEBER K, 1969, J BIOL CHEM, V244, P4406	65	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2005	280	19					18736	18744		10.1074/jbc.M500137200	http://dx.doi.org/10.1074/jbc.M500137200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	923TN	15764602	hybrid			2022-12-27	WOS:000228932300025
J	Vetting, MW; de Carvalho, LPS; Roderick, SL; Blanchard, JS				Vetting, MW; de Carvalho, LPS; Roderick, SL; Blanchard, JS			A novel dimeric structure of the RimL N-alpha-acetyltransferase from Salmonella typhimurium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN MODIFICATION; 1.8 ANGSTROM RESOLUTION; ESCHERICHIA-COLI; TERMINAL ACETYLATION; CRYSTAL-STRUCTURE; HISTONE ACETYLTRANSFERASE; GNAT SUPERFAMILY; MUTANT LACKING; L12; ENZYME	RimL is responsible for converting the prokaryotic ribosomal protein from L12 to L7 by acetylation of its N-terminal amino group. We demonstrate that purified RimL is capable of posttranslationally acetylating L12, exhibiting a V-max of 21 min(-1). We have also determined the apostructure of RimL from Salmonella typhimurium and its complex with coenzyme A, revealing a homodimeric oligomer with structural similarity to other Gcn5-related N-acetyltransferase superfamily members. A large central trough located at the dimer interface provides sufficient room to bind both L12 N-terminal helices. Structural and biochemical analysis indicates that RimL proceeds by single-step transfer rather than a covalent-enzyme intermediate. This is the first structure of a Gen5-related N-acetyltransferase family member with demonstrated activity toward a protein N(alpha)amino group and is a first step toward understanding the molecular basis for N(alpha)acetylation and its function in cellular regulation.	Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Blanchard, JS (corresponding author), Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	blanchar@aecom.yu.edu		Sorio de Carvalho, Luiz Pedro/0000-0003-2875-4552	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060899, R01AI033696] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 33696, AI 60899] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABSHIRE KZ, 1993, J BACTERIOL, V175, P3744, DOI 10.1128/JB.175.12.3744-3748.1993; Angus-Hill ML, 1999, J MOL BIOL, V294, P1311, DOI 10.1006/jmbi.1999.3338; Bhatnagar RS, 1998, NAT STRUCT BIOL, V5, P1091, DOI 10.1038/4202; Bocharov EV, 2004, J BIOL CHEM, V279, P17697, DOI 10.1074/jbc.M313384200; BROT N, 1973, J BIOL CHEM, V248, P6952; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brunzelle JS, 2004, PROTEINS, V57, P850, DOI 10.1002/prot.10601; Burk DL, 2003, PROTEIN SCI, V12, P426, DOI 10.1110/ps.0233503; CUMBERLIDGE AG, 1979, J MOL BIOL, V131, P169, DOI 10.1016/0022-2836(79)90072-X; Griaznova O, 2000, BIOCHEMISTRY-US, V39, P4075, DOI 10.1021/bi992621e; GUDKOV AT, 1989, BIOCHIMIE, V71, P779, DOI 10.1016/0300-9084(89)90040-0; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; ISONO K, 1980, MOL GEN GENET, V177, P645; ISONO S, 1981, MOL GEN GENET, V183, P473, DOI 10.1007/BF00268767; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kalpaxis DL, 1995, BIOCHIMIE, V77, P963, DOI 10.1016/0300-9084(95)80009-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; KUNG HF, 1973, J BIOL CHEM, V248, P5012; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; LILJAS A, 1982, PROG BIOPHYS MOL BIO, V40, P161, DOI 10.1016/0079-6107(82)90013-X; LOCKWOOD AH, 1974, J BIOL CHEM, V249, P1213; Mohr D, 2002, BIOCHEMISTRY-US, V41, P12520, DOI 10.1021/bi026301y; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Okkels LM, 2004, PROTEOMICS, V4, P2954, DOI 10.1002/pmic.200400906; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PETTERSSON I, 1976, FEBS LETT, V64, P135, DOI 10.1016/0014-5793(76)80267-0; PETTERSSON I, 1980, P NATL ACAD SCI-BIOL, V77, P4007, DOI 10.1073/pnas.77.7.4007; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; RAMAGOPA.S, 1974, P NATL ACAD SCI USA, V71, P2136, DOI 10.1073/pnas.71.5.2136; SUBRAMANIAN AR, 1975, J MOL BIOL, V95, P1, DOI 10.1016/0022-2836(75)90330-7; Sun PD, 2002, ACTA CRYSTALLOGR D, V58, P1092, DOI 10.1107/S0907444902006510; TANAKA S, 1989, MOL GEN GENET, V217, P289, DOI 10.1007/BF02464895; TERHORST C, 1972, EUR J BIOCHEM, V25, P13, DOI 10.1111/j.1432-1033.1972.tb01661.x; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Vetting MW, 2005, ARCH BIOCHEM BIOPHYS, V433, P212, DOI 10.1016/j.abb.2004.09.003; Vetting MW, 2004, CHEM BIOL, V11, P565, DOI 10.1016/j.chembiol.2004.03.017; Wahl MC, 2000, EMBO J, V19, P174, DOI 10.1093/emboj/19.2.174; Wybenga-Groot LE, 1999, STRUCTURE, V7, P497, DOI 10.1016/S0969-2126(99)80066-5; Yan Y, 2002, NAT STRUCT BIOL, V9, P862, DOI 10.1038/nsb849; YOSHIKAWA A, 1987, MOL GEN GENET, V209, P481, DOI 10.1007/BF00331153	41	49	50	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22108	22114		10.1074/jbc.M502401200	http://dx.doi.org/10.1074/jbc.M502401200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817456	hybrid			2022-12-27	WOS:000229557900055
J	Brunati, AM; Deana, R; Folda, A; Massimino, ML; Marin, O; Ledro, S; Pinna, LA; Donella-Deana, AD				Brunati, AM; Deana, R; Folda, A; Massimino, ML; Marin, O; Ledro, S; Pinna, LA; Donella-Deana, AD			Thrombin-induced tyrosine phosphorylation of HS1 in human platelets is sequentially catalyzed by Syk and Lyn tyrosine kinases and associated with the cellular migration of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-FAMILY; HEMATOPOIETIC LINEAGE; SIGNAL-TRANSDUCTION; INTEGRIN ALPHA(IIB)BETA(3); MEDIATED APOPTOSIS; BINDING-PROTEIN; SH3 DOMAINS; C-SRC; ACTIVATION; CELLS	Thrombin stimulation of platelets triggers Tyr phosphorylation of several signaling proteins, most of which remain unidentified. In this study, we demonstrate for the first time that hematopoietic lineage cell-specific protein 1 (HS1) undergoes a transient Tyr phosphorylation in human platelets stimulated with thrombin. The protein is synergistically phosphorylated by Syk and Lyn tyrosine kinases according to a sequential phosphorylation mechanism. By means of specific inhibitors (PP2, SU6656, and piceatannol) and phosphopeptide-specific antibodies, as well as by coimmunoprecipitation and binding competition experiments, we show that Syk acts as the primary kinase that phosphorylates HS1 at Tyr(397) and that Syk phosphorylation is required for HS1 interaction with the Lyn SH2 domain. Upon docking to Syk-phosphorylated HS1, Lyn catalyzes the secondary phosphorylation of the protein at Tyr(222). Once the secondary Tyr phosphorylation of HS1 is accomplished the protein dissociates from Lyn and undergoes a dephosphorylation process. HS1 Tyr phosphorylation does not occur when thrombin-induced actin assembly is inhibited by cytochalasin D even under conditions in which Syk and Lyn are still active. Immunofluorescence microscopic analysis shows that the agonist promotes HS1 migration to the plasma membrane and that the inhibition of Lyn-mediated secondary phosphorylation of HS1 abrogates the subcellular translocation of the protein. All together these results indicate that HS1 Tyr phosphorylation catalyzed by Syk and Lyn plays a crucial role in the translocation of the protein to the membrane and is involved in the cytoskeleton rearrangement triggered by thrombin in human platelets.	Univ Padua, Dept Biochem, I-35121 Padua, Italy	University of Padua	Donella-Deana, AD (corresponding author), Univ Padua, Dipartimento Chim Biol, Viale G Colombo 3, I-35121 Padua, Italy.	arianna.donella@unipd.it	Brunati, Anna Maria/I-8136-2018; Massimino, Maria Lina/AAX-8773-2020	Brunati, Anna Maria/0000-0002-3481-9503; massimino, maria lina/0000-0002-1839-1404				Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bauer M, 2001, THROMB HAEMOSTASIS, V85, P331, DOI 10.1055/s-0037-1615689; Bertagnolli ME, 1999, BIOCHEM BIOPH RES CO, V260, P790, DOI 10.1006/bbrc.1999.0985; Brunati AM, 2000, BLOOD, V96, P1550, DOI 10.1182/blood.V96.4.1550.h8001550_1550_1557; Brunati AM, 1999, J BIOL CHEM, V274, P7557, DOI 10.1074/jbc.274.11.7557; Brunati AM, 1996, EUR J BIOCHEM, V240, P400, DOI 10.1111/j.1432-1033.1996.0400h.x; BRUNATI AM, 1995, FEBS LETT, V367, P149, DOI 10.1016/0014-5793(95)00555-N; BRUNATI AM, 1993, EUR J BIOCHEM, V216, P323, DOI 10.1111/j.1432-1033.1993.tb18149.x; Chen YR, 2001, BIOCHEM BIOPH RES CO, V288, P981, DOI 10.1006/bbrc.2001.5862; Cho MJ, 2002, BLOOD, V99, P2442, DOI 10.1182/blood.V99.7.2442; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1994, J BIOL CHEM, V269, P28859; Deana R, 2003, THROMB HAEMOSTASIS, V89, P866, DOI 10.1055/s-0037-1613474; Donella-Deana A, 1998, BIOCHEMISTRY-US, V37, P1438, DOI 10.1021/bi971332s; FUKUDA T, 1995, P NATL ACAD SCI USA, V92, P7302, DOI 10.1073/pnas.92.16.7302; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hao JJ, 2004, J BIOL CHEM, V279, P33413, DOI 10.1074/jbc.M313564200; HATA D, 1993, IMMUNOL LETT, V40, P65; He H, 1998, MOL CELL BIOL, V18, P3829, DOI 10.1128/MCB.18.7.3829; Hutchcroft JE, 1998, J IMMUNOL, V161, P4506; Ingley E, 2000, J BIOL CHEM, V275, P7887, DOI 10.1074/jbc.275.11.7887; Jackson SP, 1996, THROMB HAEMOSTASIS, V76, P640; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; Kurosaki T, 1998, INT J MOL MED, V1, P515; LevyToledano S, 1997, THROMB HAEMOSTASIS, V78, P226; Maguire PB, 2002, PROTEOMICS, V2, P642, DOI 10.1002/1615-9861(200206)2:6<642::AID-PROT642>3.0.CO;2-I; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Rosado JA, 2000, BIOCHEM J, V351, P429, DOI 10.1042/0264-6021:3510429; Ruzzene M, 1996, BIOCHEMISTRY-US, V35, P5327, DOI 10.1021/bi9528614; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Suzuki H, 1997, J IMMUNOL, V159, P5881; Takemoto Y, 1996, INT IMMUNOL, V8, P1699, DOI 10.1093/intimm/8.11.1699; TANIUCHI I, 1995, EMBO J, V14, P3664, DOI 10.1002/j.1460-2075.1995.tb00036.x; TOHYAMA Y, 1994, J BIOL CHEM, V269, P32796; Uruno T, 2003, BIOCHEM J, V371, P485, DOI 10.1042/BJ20021791; WONG S, 1992, ONCOGENE, V7, P2407; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; Yamanashi Y, 1997, J EXP MED, V185, P1387, DOI 10.1084/jem.185.7.1387	46	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21029	21035		10.1074/jbc.M412634200	http://dx.doi.org/10.1074/jbc.M412634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15795233	hybrid			2022-12-27	WOS:000229438800017
J	Oh, JE; Kook, JK; Min, BM				Oh, JE; Kook, JK; Min, BM			beta ig-h3 induces keratinocyte differentiation via modulation of involucrin and transglutaminase expression through the integrin alpha 3 beta 1 and the phosphatidylinositol 3-kinase/Akt signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HUMAN ORAL KERATINOCYTES; MATRIX PROTEIN BETA-IG-H3; TERMINAL DIFFERENTIATION; REPLICATIVE SENESCENCE; EXTRACELLULAR-MATRIX; CELL-ADHESION; IN-VITRO; TGF-BETA; GENE	beta ig-h3 is an extracellular matrix protein whose expression is highly induced by transforming growth factor (TGF)-beta 1. Whereas beta ig-h3 is known to mediate keratinocyte adhesion and migration, its effects on keratinocyte differentiation remain unclear. In the present study, it was demonstrated that expression of both beta ig-h3 and TGF-beta 1 was enhanced during keratinocyte differentiation and that expression of the former was strongly induced by that of the latter. This study also asked whether changes in beta ig-h3 expression would affect keratinocyte differentiation. Indeed, down-regulation of beta ig-h3 by transfection with antisense beta ig-h3 cDNA constructs effectively inhibited keratinocyte differentiation by decreasing the promoter activities and thus expression of involucrin and transglutaminase. The result was a similar to 2-fold increase in mitotic capacity of the cells. Conversely, overexpression of beta ig-h3, either by transfection with beta ig-h3 expression plasmids or by exposure to recombinant beta ig-h3, enhanced keratinocyte differentiation by inhibiting cell proliferation and concomitantly increasing involucrin and transglutaminase expression. Recombinant beta ig-h3 also promoted keratinocyte adhesion through interaction with integrin alpha 3 beta 1. Changes in beta ig-h3 expression did not affect intracellular calcium levels. Subsequent analysis revealed not only induction of Akt phosphorylation by recombinant beta ig-h3 but also blockage of Akt phosphorylation by LY294002, an inhibitor of phosphatidylinositol 3-kinase. Taken together, these findings indicate that enhanced beta ig-h3, induced by enhanced TGF-beta during keratinocyte differentiation, provoked cell differentiation by enhancing involucrin and transglutaminase expression through the integrin alpha 3 beta 1 and phosphatidylinositol 3-kinase/Akt signaling pathway. Lastly, it was observed that beta ig-h3-mediated keratinocyte differentiation was caused by promotion of cell adhesion and not by calcium regulation.	Seoul Natl Univ, Coll Dent, Dept Oral Biochem & Craniomaxillofacial Reconstru, Dent Res Inst, Seoul 110749, South Korea; Seoul Natl Univ, Coll Dent, BK21 HLS, Seoul 110749, South Korea; Chosun Univ, Coll Dent, Dept Oral Biochem, Kwangju 501759, South Korea	Seoul National University (SNU); Seoul National University (SNU); Chosun University	Min, BM (corresponding author), Seoul Natl Univ, Coll Dent, Dept Oral Biochem & Craniomaxillofacial Reconstru, Dent Res Inst, 28 Yeonkun Dong, Seoul 110749, South Korea.	bmmin@snu.ac.kr	Min, Byung-Moo/F-2854-2012	Kook, Joong-Ki/0000-0003-2628-2870				Bae JS, 2002, BIOCHEM BIOPH RES CO, V294, P940, DOI 10.1016/S0006-291X(02)00576-4; Billings PC, 2002, J BIOL CHEM, V277, P28003, DOI 10.1074/jbc.M106837200; Billings PC, 2000, J CELL BIOCHEM, V79, P261, DOI 10.1002/1097-4644(20001101)79:2<261::AID-JCB90>3.0.CO;2-#; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dieudonne SC, 2000, J CELL BIOCHEM, V76, P231, DOI 10.1002/(SICI)1097-4644(20000201)76:2<231::AID-JCB7>3.0.CO;2-X; Fuchs E, 1990, CURR OPIN CELL BIOL, V2, P1028, DOI 10.1016/0955-0674(90)90152-5; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gibson MA, 1997, J HISTOCHEM CYTOCHEM, V45, P1683, DOI 10.1177/002215549704501212; Gilbert RE, 1998, KIDNEY INT, V54, P1052, DOI 10.1046/j.1523-1755.1998.00081.x; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; HENNINGS H, 1989, CARCINOGENESIS, V10, P777, DOI 10.1093/carcin/10.4.777; Jeong HW, 2004, J CELL BIOCHEM, V92, P770, DOI 10.1002/jcb.20110; JIANG CK, 1991, J INVEST DERMATOL, V97, P969, DOI 10.1111/1523-1747.ep12491889; KANE CJM, 1991, J CELL PHYSIOL, V148, P157, DOI 10.1002/jcp.1041480119; Kang MK, 1998, CELL GROWTH DIFFER, V9, P85; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200; Kim JE, 2002, J BIOL CHEM, V277, P46159, DOI 10.1074/jbc.M207055200; Kim JE, 2002, INVEST OPHTH VIS SCI, V43, P656; Kook JK, 1998, INT J ONCOL, V13, P765; LARJAVA H, 1991, AM J MED SCI, V301, P63, DOI 10.1097/00000441-199101000-00012; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; Lee G, 2000, ARCH ORAL BIOL, V45, P809, DOI 10.1016/S0003-9969(00)00061-3; LEVINE JH, 1993, AM J PATHOL, V143, P368; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; Maruoka Y, 1997, BIOCHEM BIOPH RES CO, V238, P886, DOI 10.1006/bbrc.1997.7405; Min BM, 1999, EXP CELL RES, V249, P377, DOI 10.1006/excr.1999.4489; Nam JO, 2003, J BIOL CHEM, V278, P25902, DOI 10.1074/jbc.M300358200; OBrien ER, 1996, ARTERIOSCL THROM VAS, V16, P576, DOI 10.1161/01.ATV.16.4.576; Oh JE, 2003, INT J MOL MED, V11, P491; Ohno S, 1999, BBA-MOL CELL RES, V1451, P196, DOI 10.1016/S0167-4889(99)00093-2; Ohno S, 2002, J DENT RES, V81, P822, DOI 10.1177/154405910208101205; Okazaki I, 2002, J BIOL CHEM, V277, P37070, DOI 10.1074/jbc.M201672200; Rawe IM, 1997, INVEST OPHTH VIS SCI, V38, P893; Rodeck U, 1997, J CELL SCI, V110, P113; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858	38	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21629	21637		10.1074/jbc.m412293200	http://dx.doi.org/10.1074/jbc.m412293200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15805105	hybrid			2022-12-27	WOS:000229438800088
J	Venkataraman, P; Lamb, RA; Pinto, LH				Venkataraman, P; Lamb, RA; Pinto, LH			Chemical rescue of histidine selectivity filter mutants of the M2 ion channel of influenza A virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC-ANHYDRASE-II; BACTERIAL REACTION CENTERS; INTEGRAL MEMBRANE-PROTEIN; PLANAR LIPID-BILAYERS; SITE-SPECIFIC MUTANT; M-2 PROTON CHANNEL; TRANSMEMBRANE DOMAIN; CATALYTIC BASE; M(2) PROTEIN; ACTIVATION	The influenza virus M2 proton- selective ion channel activity facilitates virus uncoating, a process that occurs in the acidic environment of the endosome. The M2 channel causes acidification of the interior of the virus particle, which results in viral protein-protein dissociation. The M2 protein is a homotetramer that contains in its aqueous pore a histidine residue (His-37) that acts as a selectivity filter and a tryptophan residue (Trp-41) that acts as a channel gate. Substitution of His-37 modifies M2 ion channel properties drastically. However, the results of such experiments are difficult to interpret because substitution of His-37 could cause gross structural changes to the channel pore. We described here experiments in which partial or, in some cases, full rescue of specific M2 ion channel properties of His-37 substitution mutants was achieved by addition of imidazole to the bathing medium. Chemical rescue was demonstrated for three histidine substitution mutant ion channels (M2-H37G, M2-H37S, and M2-H37T) and for two double mutants in which the Trp-41 channel gate was also mutated (H37G/W41Y and H37G/W41A). Currents of the M2-H37G mutant ion channel were inhibited by Cu(II), which has been shown to coordinate with His- 37 in the wild- type channel. Chemical rescue was very specific for imidazole. Buffer molecules that were neutral when protonated (4-morpholineethanesulfonic acid and 3- morpholino-2- hydroxypropanesulfonic acid) did not rescue ion channel activity of the M2-H37G mutant ion channel, but 1-methylimidazole did provide partial rescue of function. These results were consistent with a model for proton transport through the pore of the wildtype channel in which the imidazole side chain of His-37 acted as an intermediate proton acceptor/ donor group.	Northwestern Univ, Howard Hughes Med Inst, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Northwestern Univ, Howard Hughes Med Inst, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Howard Hughes Medical Institute; Northwestern University; Howard Hughes Medical Institute; Northwestern University	Pinto, LH (corresponding author), Northwestern Univ, Howard Hughes Med Inst, Dept Neurobiol & Physiol, Hogan Hall,2205 Tech Dr, Evanston, IL 60208 USA.	larry-pinto@northwestern.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020201, R01AI031882] Funding Source: NIH RePORTER; NIAID NIH HHS [R37AI-20201, R01AI-31882] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adelroth P, 2001, BIOCHEMISTRY-US, V40, P14538, DOI 10.1021/bi011585s; Admiraal SJ, 1999, BIOCHEMISTRY-US, V38, P4701, DOI 10.1021/bi9827565; An HQ, 2002, BIOCHEMISTRY-US, V41, P3235, DOI 10.1021/bi0120695; Chizhmakov IV, 1996, J PHYSIOL-LONDON, V494, P329, DOI 10.1113/jphysiol.1996.sp021495; Duda D, 2001, BIOCHEMISTRY-US, V40, P1741, DOI 10.1021/bi002295z; Duda D, 2003, ACTA CRYSTALLOGR D, V59, P93, DOI 10.1107/S0907444902019455; DUFF KC, 1992, VIROLOGY, V190, P485, DOI 10.1016/0042-6822(92)91239-Q; Gandhi CS, 1999, J BIOL CHEM, V274, P5474, DOI 10.1074/jbc.274.9.5474; Hay A.J., 1992, SEMIN VIROL, V3, P21, DOI DOI 10.1016/J.BMC.2015.06.030; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; Hopkins CE, 2002, PROTEIN SCI, V11, P1591, DOI 10.1110/ps.3900102; Huang SQ, 1997, BIOCHEMISTRY-US, V36, P14609, DOI 10.1021/bi9722554; KURTZ S, 1995, ANTIMICROB AGENTS CH, V39, P2204, DOI 10.1128/AAC.39.10.2204; Lamb R. A., 1994, RECEPTOR MEDIATED VI, P303; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LAMB RA, 2005, IN PRESS CONT TOPICS; Lehoux IE, 1999, BIOCHEMISTRY-US, V38, P9948, DOI 10.1021/bi9907532; Lin TI, 2001, J VIROL, V75, P3647, DOI 10.1128/JVI.75.8.3647-3656.2001; Matsunami H, 2004, BIOCHEMISTRY-US, V43, P2178, DOI 10.1021/bi0361923; Mould JA, 2000, J BIOL CHEM, V275, P31038, DOI 10.1074/jbc.M003663200; Mould JA, 2000, J BIOL CHEM, V275, P8592, DOI 10.1074/jbc.275.12.8592; Okada A, 2001, BIOCHEMISTRY-US, V40, P6053, DOI 10.1021/bi0028441; Paddock ML, 2002, BIOCHEMISTRY-US, V41, P14716, DOI 10.1021/bi020419x; PANAYOTOV PP, 1992, VIROLOGY, V186, P352, DOI 10.1016/0042-6822(92)90096-8; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Sakaguchi T, 1997, P NATL ACAD SCI USA, V94, P5000, DOI 10.1073/pnas.94.10.5000; SHIMBO K, 1996, BIOPHYS J, V70, P1336; Shuck K, 2000, J VIROL, V74, P7755, DOI 10.1128/JVI.74.17.7755-7761.2000; Smondyrev AM, 2002, BIOPHYS J, V83, P1987, DOI 10.1016/S0006-3495(02)73960-X; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; Tang YJ, 2002, J BIOL CHEM, V277, P39880, DOI 10.1074/jbc.M206582200; TOSTESON MT, 1994, J MEMBRANE BIOL, V142, P117; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; Tu CK, 2002, BIOCHEMISTRY-US, V41, P15429, DOI 10.1021/bi026831u; Tu Q, 1996, J VIROL, V70, P4246, DOI 10.1128/JVI.70.7.4246-4252.1996; Vijayvergiya V, 2004, BIOPHYS J, V87, P1697, DOI 10.1529/biophysj.104.043018; WANG C, 1995, BIOPHYS J, V69, P1363, DOI 10.1016/S0006-3495(95)80003-2; WANG C, 1993, J VIROL, V67, P5585, DOI 10.1128/JVI.67.9.5585-5594.1993; WANG C, 1994, VIROLOGY, V205, P133, DOI 10.1006/viro.1994.1628; ZEBEDEE SL, 1988, J VIROL, V62, P2762, DOI 10.1128/JVI.62.8.2762-2772.1988	42	85	93	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21463	21472		10.1074/jbc.M412406200	http://dx.doi.org/10.1074/jbc.M412406200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15784624	hybrid			2022-12-27	WOS:000229438800067
J	Naumann, B; Stauber, EJ; Busch, A; Sommer, F; Hippler, M				Naumann, B; Stauber, EJ; Busch, A; Sommer, F; Hippler, M			N-terminal processing of Lhca3 is a key step in remodeling of the photosystem I-light-harvesting complex under iron deficiency in Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-PROTEIN COMPLEX; PHOTO-CHEMICAL CAPACITY; LIMITING FACTORS; PSI-LHCI; PROTEOMICS; STRESS; PHOTOSYNTHESIS; CYANOBACTERIA/; EXPRESSION; SELECTION	Iron deficiency induces a remodeling of the photosynthetic apparatus in Chlamydomonas reinhardtii. In this study we showed that a key mechanistic event in the remodeling process of photosystem I (PSI) and its associated light-harvesting proteins (LHCI) is the N-terminal processing of Lhca3. N-terminal processing of Lhca3 is documented independently by two-dimensional gel electrophoresis and tandem mass spectrometric (MS/MS) analysis as well as by quantitative comparative MS/MS peptide profiling using isotopic labeling of proteins. Dynamic remodeling of the LHCI complex under iron deficiency is further exemplified by depletion of Lhca5 and up-regulation of Lhca4 and Lhca9 polypeptides in respect to photosystem I. Most importantly, the induction of N-terminal processing of Lhca3 by progression of iron deficiency correlates with the functional drop in excitation energy transfer efficiency between LHCI and PSI as assessed by low temperature fluorescence emission spectroscopy. Using an RNA interference (RNAi) strategy, we showed that the truncated form of Lhca3 is essential for the structural stability of LHCI. Depletion of Lhca3 by RNAi strongly impacted the efficiency of excitation energy transfer between PSI and LHCI, as is the case for iron deficiency. However, in contrast to iron deficiency, comparative MS/MS peptide profiling using isotopic labeling of proteins demonstrated that RNAi depletion of Lhca3 caused strong reduction of almost all Lhca proteins in isolated PSI particles.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA; Univ Jena, Lehrstuhl Pflanzenphysiol, D-07743 Jena, Germany	University of Pennsylvania; Friedrich Schiller University of Jena	Hippler, M (corresponding author), Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA.	mhippler@sas.upenn.edu						Asamizu E, 1999, DNA Res, V6, P369, DOI 10.1093/dnares/6.6.369; BASSI R, 1992, J BIOL CHEM, V267, P25714; Behrenfeld MJ, 1999, SCIENCE, V283, P840, DOI 10.1126/science.283.5403.840; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Bibby TS, 2001, NATURE, V412, P743, DOI 10.1038/35089098; Boekema EJ, 2001, NATURE, V412, P745, DOI 10.1038/35089104; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNAP RL, 1993, PLANT PHYSIOL, V103, P893, DOI 10.1104/pp.103.3.893; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; Croce R, 1998, BIOCHEMISTRY-US, V37, P17355, DOI 10.1021/bi9813227; Ganeteg U, 2004, PLANT MOL BIOL, V54, P641, DOI 10.1023/B:PLAN.0000040813.05224.94; Ganeteg U, 2001, PLANT PHYSIOL, V127, P150, DOI 10.1104/pp.127.1.150; GUIKEMA JA, 1984, PLANT PHYSIOL, V74, P90, DOI 10.1104/pp.74.1.90; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Harris EH, 2001, ANNU REV PLANT PHYS, V52, P363, DOI 10.1146/annurev.arplant.52.1.363; Hippler M, 1997, BIOCHEMISTRY-US, V36, P6343, DOI 10.1021/bi970082c; Hippler M, 2002, PROTIST, V153, P197, DOI 10.1078/1434-4610-00098; Hippler M, 2001, PLANT J, V28, P595, DOI 10.1046/j.1365-313X.2001.01175.x; Jennings RC, 2003, BBA-BIOENERGETICS, V1557, P91, DOI 10.1016/S0005-2728(02)00399-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDENBACH DE, 1988, J BACTERIOL, V170, P5018, DOI 10.1128/jb.170.11.5018-5026.1988; Morosinotto T, 2003, J BIOL CHEM, V278, P49223, DOI 10.1074/jbc.M309203200; Moseley JL, 2002, EMBO J, V21, P6709, DOI 10.1093/emboj/cdf666; Nield J, 2004, EUKARYOT CELL, V3, P1370, DOI 10.1128/EC.3.6.1370-1380.2004; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Ranish JA, 2003, NAT GENET, V33, P349, DOI 10.1038/ng1101; Regnier FE, 2002, J MASS SPECTROM, V37, P133, DOI 10.1002/jms.290; Rochaix JD, 2002, FEBS LETT, V529, P34, DOI 10.1016/S0014-5793(02)03181-2; Rohr J, 2004, PLANT J, V40, P611, DOI 10.1111/j.1365-313X.2004.02227.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmid VHR, 2002, J BIOL CHEM, V277, P37307, DOI 10.1074/jbc.M205889200; Shrager J, 2003, PLANT PHYSIOL, V131, P401, DOI 10.1104/pp.016899; SPILLER S, 1980, PLANT PHYSIOL, V65, P121, DOI 10.1104/pp.65.1.121; Stauber EJ, 2004, PLANT PHYSIOL BIOCH, V42, P989, DOI 10.1016/j.plaphy.2004.09.008; Stauber EJ, 2003, EUKARYOT CELL, V2, P978, DOI 10.1128/EC.2.5.978-994.2003; Steen H, 2002, TRENDS BIOTECHNOL, V20, P361, DOI 10.1016/S0167-7799(02)02009-7; STRAUS NA, 1994, MOL BIOL CYANOBACTER; Takahashi Y, 2004, BIOCHEMISTRY-US, V43, P7816, DOI 10.1021/bi035988z; TERRY N, 1980, PLANT PHYSIOL, V65, P114, DOI 10.1104/pp.65.1.114; Wehner A, 2004, J BIOL CHEM, V279, P26823, DOI 10.1074/jbc.M402399200; WOLLMAN FA, 1982, BIOCHIM BIOPHYS ACTA, V680, P352, DOI 10.1016/0005-2728(82)90149-9; Yamaguchi K, 2002, PLANT CELL, V14, P2957, DOI 10.1105/tpc.004341	43	109	111	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20431	20441		10.1074/jbc.M414486200	http://dx.doi.org/10.1074/jbc.M414486200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15774469	hybrid			2022-12-27	WOS:000229242000035
J	Ahlers, BA; Zhang, XQ; Moorman, JR; Rothblum, LI; Carl, LL; Song, JL; Wang, JF; Geddis, LM; Tucker, AL; Mounsey, JP; Cheung, JY				Ahlers, BA; Zhang, XQ; Moorman, JR; Rothblum, LI; Carl, LL; Song, JL; Wang, JF; Geddis, LM; Tucker, AL; Mounsey, JP; Cheung, JY			Identification of an endogenous inhibitor of the cardiac Na+/Ca2+ exchanger, phospholemman	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ALTERS CONTRACTILITY; DEPENDENT REGULATION; SARCOLEMMAL PROTEIN; NA+-CA2+ EXCHANGE; DOWN-REGULATION; PHOSPHORYLATION; TRANSIENTS; CHANNELS; RELEASE	Rapid and precise control of Na+/Ca2+ exchanger (NCX1) activity is essential in the maintenance of beat-to-beat Ca2+ homeostasis in cardiac myocytes. Here, we show that phospholemman (PLM), a 15-kDa integral sarcolemmal phosphoprotein, is a novel endogenous protein inhibitor of cardiac NCX1. Using a heterologous expression system that is devoid of both endogenous PLM and NCX1, we first demonstrated by confocal immunofluorescence studies that both exogenous PLM and NCX1 co-localized at the plasma membrane. Reciprocal co-immunoprecipitation studies revealed specific protein-protein interaction between PLM and NCX1. The functional consequences of direct association of PLM with NCX1 was the inhibition of NCX1 activity, as demonstrated by whole-cell patch clamp studies to measure NCX1 current density and radiotracer flux assays to assess Na+-dependent Ca-45(2+) uptake. Inhibition of NCX1 by PLM was specific, because a single mutation of serine 68 to alanine in PLM resulted in a complete loss of inhibition of NCX1 current, although association of the PLM mutant with NCX1 was unaltered. In native adult cardiac myocytes, PLM co-immunoprecipitated with NCX1. We conclude that PLM, a member of the FXYD family of small ion transport regulators known to modulate Na+-K+-ATPase, also regulates Na+/Ca2+ exchange in the heart.	Penn State Univ, Milton S Hershey Med Ctr, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr, Dept Med, Hershey, PA 17033 USA; Geisinger Med Ctr, Weis Ctr Res, Danville, PA 17822 USA; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Cardiovasc, Charlottesville, VA 22908 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Geisinger Medical Center; University of Virginia	Cheung, JY (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Dept Cellular & Mol Physiol, MC-H166, Hershey, PA 17033 USA.	jyc1@psu.edu	Moorman, J Randall/ABG-9946-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058672, R01HL070548, R01HL069074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064640] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-58672, HL-69074, HL-70548] Funding Source: Medline; NIDDK NIH HHS [DK-46678] Funding Source: Medline; NIGMS NIH HHS [GM-64640] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; CRAMBERT G, 2003, SCI STKE 2003 RE1; Davis CE, 2004, NEUROCHEM RES, V29, P177, DOI 10.1023/B:NERE.0000010447.24128.ac; DIXON IMC, 1992, AM J PHYSIOL, V262, pH1387, DOI 10.1152/ajpheart.1992.262.5.H1387; Dong H, 2002, BIOPHYS J, V82, P1943, DOI 10.1016/S0006-3495(02)75543-4; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hilgemann DW, 2004, AM J PHYSIOL-CELL PH, V287, pC1167, DOI 10.1152/ajpcell.00288.2004; Hinata M, 2002, J PHYSIOL-LONDON, V545, P453, DOI 10.1113/jphysiol.2002.025866; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; Kang TM, 2004, NATURE, V427, P544, DOI 10.1038/nature02271; Kowdley GC, 1997, BIOPHYS J, V72, P141, DOI 10.1016/S0006-3495(97)78653-3; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LINDEMANN JP, 1986, J BIOL CHEM, V261, P4860; Mirza MA, 2004, AM J PHYSIOL-HEART C, V286, pH1322, DOI 10.1152/ajpheart.00997.2003; MOORMAN JR, 1995, NATURE, V377, P737, DOI 10.1038/377737a0; NUSS HB, 1992, AM J PHYSIOL, V263, pH1161, DOI 10.1152/ajpheart.1992.263.4.H1161; Ottolia M, 2004, BIOPHYS J, V87, P899, DOI 10.1529/biophysj.104.043471; Pan Y, 2000, AM J PHYSIOL-CELL PH, V279, pC393, DOI 10.1152/ajpcell.2000.279.2.C393; PRESTI CF, 1985, J BIOL CHEM, V260, P3879; PRESTI CF, 1985, J BIOL CHEM, V260, P3860; Scriven DRL, 2000, BIOPHYS J, V79, P2682, DOI 10.1016/S0006-3495(00)76506-4; Sehl PD, 2000, CIRCULATION, V101, P1990, DOI 10.1161/01.CIR.101.16.1990; Shigekawa M, 2001, CIRC RES, V88, P864, DOI 10.1161/hh0901.090298; Shimbo K, 1995, BIOPHYS J, V69, P1819, DOI 10.1016/S0006-3495(95)80052-4; Sogaard R, 2001, AM J PHYSIOL-CELL PH, V280, pC859; Song JL, 2002, AM J PHYSIOL-HEART C, V283, pH576, DOI 10.1152/ajpheart.00197.2002; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Tadros GM, 2002, AM J PHYSIOL-HEART C, V283, pH1616, DOI 10.1152/ajpheart.00186.2002; Tong JF, 1999, J BIOL CHEM, V274, P693, DOI 10.1074/jbc.274.2.693; VORNANEN M, 1994, AM J PHYSIOL, V267, pC623, DOI 10.1152/ajpcell.1994.267.2.C623; WALAAS SI, 1994, BIOCHEM J, V304, P635, DOI 10.1042/bj3040635; Zhang XQ, 2003, AM J PHYSIOL-HEART C, V284, pH225, DOI 10.1152/ajpheart.00698.2002; Zhang XQ, 2001, J APPL PHYSIOL, V90, P1720, DOI 10.1152/jappl.2001.90.5.1720; Zhang XQ, 2001, AM J PHYSIOL-HEART C, V281, pH2079, DOI 10.1152/ajpheart.2001.281.5.H2079	36	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19875	19882		10.1074/jbc.M414703200	http://dx.doi.org/10.1074/jbc.M414703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15774479	hybrid			2022-12-27	WOS:000229113700056
J	Hurbin, A; Coll, JL; Dubrez-Daloz, L; Mari, B; Auberger, P; Brambilla, C; Favrot, MC				Hurbin, A; Coll, JL; Dubrez-Daloz, L; Mari, B; Auberger, P; Brambilla, C; Favrot, MC			Cooperation of amphiregulin and insulin-like growth factor-1 inhibits bax- and bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGE; SIGNALING PATHWAYS; FACTOR RECEPTOR; PKC-ZETA; SURVIVAL; PHOSPHORYLATION; DELTA; DEATH; ACTIVATION; AKT	Amphiregulin (AR) and insulin-like growth factor-1 (IGF1) are growth factors known to promote non-small cell lung cancer (NSCLC) survival. We have previously published that 1) AR and IGF1, secreted by H358 NSCLC cells, cooperate to protect those cells and H322 NSCLC cells from serum-starved apoptosis; 2) H358 cells resist Bax-induced apoptosis through an inhibition of Bax conformational change. We show here that the antiapoptotic activity of the AR/IGF1 combination is specifically abolished by the PKC inhibitors calphostin C and staurosporine, but not by the MAPK and phosphatidylinositol 3-kinase inhibitors PD98059 and wortmannin, suggesting the involvement of a PKC-dependent and MAPK- and phosphatidylinositol 3-kinase-independent survival pathway. The PKC delta inhibitor rottlerin restores apoptosis induced by serum deprivation. In addition, phosphorylation of PKC delta and PKC zeta/lambda, but not of PKC alpha/beta(II), increases in serum-starved H358 cells and in H322 cells treated with an AR/IGF1 combination and is blocked by calphostin C. The combination of AR and IGF1 increases p90(rsk) and Bad phosphorylation as well as inhibiting the conformational change of Bax by a PKC-dependent mechanism. Finally, PKC delta, PKC zeta, or p90(rsk) small interfering RNAs block the antiapoptotic activity of AR/IGF1 combination but have no effect on partial apoptosis inhibition observed with each factor used alone. Constitutively active PKC expression inhibits serum deprivation-induced apoptosis, whereas a catalytically inactive form of p90(rsk) restores it. Thus, AR and IGF1 cooperate to prevent apoptosis by activating a specific PKC-p90(rsk)-dependent pathway, which leads to Bad and Bax inactivation. This signaling pathway is different to that used by single factor.	INSERM, Inst Albert Bonniot, U578, Grp Rech Canc Poumon, F-38706 La Tronche, France; INSERM, U517, Fac Med Pharm, F-21033 Dijon, France; INSERM, Fac Med Pasteur, U526, F-06107 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Favrot, MC (corresponding author), INSERM, Inst Albert Bonniot, U578, Grp Rech Canc Poumon, F-38706 La Tronche, France.	MCFavrot@chu-grenoble.fr	Coll, Jean-Luc/G-2520-2013; Dubrez, Laurence/I-4971-2016; AUBERGER, Patrick/G-1491-2013; Mari, Bernard P/GVS-3100-2022; Mari, Bernard P/F-8960-2013; Mari, Bernard/Q-5832-2019; Laurence, Dubrez/P-9472-2019; Mari, Bernard P/D-7445-2015; Hurbin, Amandine/M-2693-2013	Coll, Jean-Luc/0000-0002-2453-3552; Dubrez, Laurence/0000-0002-7030-2181; AUBERGER, Patrick/0000-0002-2481-8275; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Laurence, Dubrez/0000-0002-7030-2181; Mari, Bernard P/0000-0002-0422-9182; Hurbin, Amandine/0000-0003-0535-1945				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Andre F, 1999, GASTROENTEROLOGY, V116, P64, DOI 10.1016/S0016-5085(99)70230-1; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Barr LF, 1997, CELL GROWTH DIFFER, V8, P381; Basu A, 2003, J CELL MOL MED, V7, P341, DOI 10.1111/j.1582-4934.2003.tb00237.x; Basu A, 1999, BIOCHEMISTRY-US, V38, P4245, DOI 10.1021/bi982854q; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brognard J, 2002, CELL DEATH DIFFER, V9, P893, DOI 10.1038/sj.cdd.4401054; Brognard J, 2001, CANCER RES, V61, P3986; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; Cheng HL, 2000, MOL CELL ENDOCRINOL, V170, P211, DOI 10.1016/S0303-7207(00)00324-5; Clark AS, 2003, CANCER RES, V63, P780; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dubrez L, 2001, J BIOL CHEM, V276, P38980, DOI 10.1074/jbc.M102683200; Fernandes AM, 1999, CANCER LETT, V142, P55, DOI 10.1016/S0304-3835(99)00166-4; Fontanini G, 1998, CLIN CANCER RES, V4, P241; Gagnon A, 2001, ENDOCRINOLOGY, V142, P205, DOI 10.1210/en.142.1.205; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hennige AM, 2002, BIOCHEM BIOPH RES CO, V290, P85, DOI 10.1006/bbrc.2001.6144; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; Hofmann J, 2001, REV PHYSIOL BIOCH P, V142, P1, DOI 10.1007/BFb0117491; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hurbin A, 2002, J BIOL CHEM, V277, P49127, DOI 10.1074/jbc.M207584200; Ikeo S, 2001, AM J PHYSIOL-CELL PH, V280, pC1255, DOI 10.1152/ajpcell.2001.280.5.C1255; Irie N, 2002, BIOCHEM BIOPH RES CO, V298, P738, DOI 10.1016/S0006-291X(02)02531-7; Iwabu A, 2004, J BIOL CHEM, V279, P14551, DOI 10.1074/jbc.M311981200; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; McJilton MA, 2003, ONCOGENE, V22, P7958, DOI 10.1038/sj.onc.1206795; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rozengurt Enrique, 1999, Current Opinion in Oncology, V11, P116; RUSCH V, 1995, CANCER RES, V55, P1365; Rusch V, 1997, CLIN CANCER RES, V3, P515; Shen L, 1999, MOL PHARMACOL, V55, P396, DOI 10.1124/mol.55.2.396; Shen S, 2001, DIABETES, V50, P255, DOI 10.2337/diabetes.50.2.255; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; TATEISHI M, 1990, CANCER RES, V50, P7077; Valverde AM, 1996, ENDOCRINOLOGY, V137, P3832, DOI 10.1210/en.137.9.3832; WELSH JB, 1991, J CELL BIOL, V114, P533, DOI 10.1083/jcb.114.3.533; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yano KJ, 1999, ENDOCRINOLOGY, V140, P4622, DOI 10.1210/en.140.10.4622; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	57	34	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19757	19767		10.1074/jbc.M413516200	http://dx.doi.org/10.1074/jbc.M413516200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15767261	Green Accepted, Green Submitted, hybrid			2022-12-27	WOS:000229113700042
J	Wing, LYC; Chen, HM; Chuang, PC; Wu, MH; Tsai, SJ				Wing, LYC; Chen, HM; Chuang, PC; Wu, MH; Tsai, SJ			The mammalian target of rapamycin-p70 ribosomal S6 kinase but not phosphatidylinositol 3-kinase-Akt signaling is responsible for fibroblast growth factor-9-induced cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR-1; PHOSPHOINOSITIDE 3-KINASE; AMINO-ACIDS; MAP KINASE; FACTOR FGF; PROTEIN; ACTIVATION; EXPRESSION; MTOR; PHOSPHORYLATION	Fibroblast growth factor-9 (FGF9) is a potent mitogen that stimulates normal and cancer cell proliferation though the signaling mechanism is not fully understood. In this study, we aimed to unravel the signaling cascades mediate FGF9 actions in human uterine endometrial stromal cell. Our results demonstrate that the mitogenic effect of FGF9 is transduced via two parallel but additive signaling pathways involving mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase. Activation of mTOR by FGF9 induces p70 ribosomal S6 kinase (S6K1) phosphorylation, cyclin expression, and cell proliferation, which are independent of phosphatidylinositol 3-kinase and Akt. Coimmuno-precipitation analysis demonstrates that mTOR physically associates with S6K1 upon FGF9 treatment, whereas ablation of mTOR activity using RNA interference or pharmacological inhibitor blocks S6K1 phosphorylation and cell proliferation induced by FGF9. Further study demonstrates that activation of mTOR is regulated by a phospholipase C gamma-controlled calcium signaling pathway. These studies provide evidence to demonstrate, for the first time, that a novel signaling cascade involving phospholipase C gamma, calcium, mTOR, and S6K1 is activated by FGF9 in a receptor-specific manner.	Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Obstet & Gynecol, Tainan 70101, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University	Wing, LYC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 70101, Taiwan.	wing@mail.ncku.edu.tw; seantsai@mail.ncku.edu.tw	Tsai, Shaw-Jenq/AAG-6569-2019	TSAI, SHAW-JENQ/0000-0002-3569-5813				AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; Ballou LM, 2003, FEBS LETT, V550, P51, DOI 10.1016/S0014-5793(03)00816-0; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Cailliau K, 2001, BBA-MOL CELL RES, V1538, P228, DOI 10.1016/S0167-4889(01)00074-X; Carballada R, 2001, DEVELOPMENT, V128, P35; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; Chen Y, 2000, ONCOGENE, V19, P3750, DOI 10.1038/sj.onc.1203726; Cohen RI, 2000, J NEUROSCI RES, V61, P273, DOI 10.1002/1097-4547(20000801)61:3<273::AID-JNR5>3.0.CO;2-I; Colvin JS, 2001, DEVELOPMENT, V128, P2095; Debiais F, 2004, EXP CELL RES, V297, P235, DOI 10.1016/j.yexcr.2004.03.032; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garces A, 2000, J NEUROSCI RES, V60, P1, DOI 10.1002/(SICI)1097-4547(20000401)60:1<1::AID-JNR1>3.0.CO;2-P; Giri D, 1999, J CELL PHYSIOL, V180, P53, DOI 10.1002/(SICI)1097-4652(199907)180:1<53::AID-JCP6>3.0.CO;2-P; Goncharova EA, 2002, AM J PHYSIOL-LUNG C, V283, pL354, DOI 10.1152/ajplung.00010.2002; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hinault C, 2004, FASEB J, V18, P1894, DOI 10.1096/fj.03-1409fje; Hinsby AM, 2003, MOL CELL PROTEOMICS, V2, P29, DOI 10.1074/mcp.M200075-MCP200; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Kam Y, 2004, FASEB J, V18, P311, DOI 10.1096/fj.03-0731com; Kanda T, 2000, BRAIN RES, V876, P22, DOI 10.1016/S0006-8993(00)02563-4; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Larsson H, 1999, J BIOL CHEM, V274, P25726, DOI 10.1074/jbc.274.36.25726; Lovicu FJ, 1998, DEVELOPMENT, V125, P3365; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mochizuki Y, 2002, ONCOGENE, V21, P7027, DOI 10.1038/sj.onc.1205736; Mothe-Satney I, 2004, J BIOL CHEM, V279, P42628, DOI 10.1074/jbc.M405173200; Nauc V, 2004, J ANDROL, V25, P573; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; Ozeki M, 2004, MOL CELL BIOCHEM, V259, P169, DOI 10.1023/B:MCBI.0000021369.17958.f4; Pham PTT, 2000, J CELL BIOCHEM, V79, P427, DOI 10.1002/1097-4644(20001201)79:3<427::AID-JCB80>3.0.CO;2-0; Pirvola U, 2004, DEV BIOL, V273, P350, DOI 10.1016/j.ydbio.2004.06.010; Portnoy J, 2004, AM J RESP CELL MOL, V30, P901, DOI 10.1165/rcmb.2003-0406OC; Reuss B, 2000, GLIA, V30, P231, DOI 10.1002/(SICI)1098-1136(200005)30:3<231::AID-GLIA3>3.3.CO;2-T; Saitoh M, 2002, J BIOL CHEM, V277, P20104, DOI 10.1074/jbc.M201745200; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekulic A, 2000, CANCER RES, V60, P3504; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Todo T, 1998, NEUROSURGERY, V43, P337, DOI 10.1097/00006123-199808000-00098; Tsai SJ, 2002, ENDOCRINOLOGY, V143, P2715, DOI 10.1210/en.143.7.2715; Tsai SJ, 2001, J CLIN ENDOCR METAB, V86, P5765, DOI 10.1210/jc.86.12.5765; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; Wing LYC, 2003, J CLIN ENDOCR METAB, V88, P5547, DOI 10.1210/jc.2003-030597; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899; Wu MH, 2002, MOL HUM REPROD, V8, P456, DOI 10.1093/molehr/8.5.456; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200	66	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19937	19947		10.1074/jbc.M411865200	http://dx.doi.org/10.1074/jbc.M411865200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15760907	hybrid			2022-12-27	WOS:000229113700063
J	Macauley, MS; Whitworth, GE; Debowski, AW; Chin, D; Vocadlo, DJ				Macauley, MS; Whitworth, GE; Debowski, AW; Chin, D; Vocadlo, DJ			O-GlcNAcase uses substrate-assisted catalysis - Kinetic analysis and development of highly selective mechanism-inspired inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; BETA-D-GLUCOSAMINIDASE; TAY-SACHS-DISEASE; INSULIN-RESISTANCE; CRYSTAL-STRUCTURE; NUCLEOCYTOPLASMIC PROTEINS; GLYCOSYL HYDROLASES; DIABETOGENIC ACTION; ALZHEIMERS-DISEASE; CYTOSOLIC PROTEINS	The post-translational modification of serine and threonine residues of nucleocytoplasmic proteins with 2-acetamido-2-deoxy-D-glucopyranose ( GlcNAc) is a reversible process implicated in multiple cellular processes. The enzyme O-GlcNAcase catalyzes the cleavage of beta-O-linked GlcNAc (O-GlcNAc) from modified proteins and is a member of the family 84 glycoside hydrolases. The family 20 beta-hexosaminidases bear no apparent sequence similarity yet are functionally related to O-GlcNAcase because both enzymes cleave terminal GlcNAc residues from glycoconjugates. Lysosomal beta-hexosaminidase is known to use substrate-assisted catalysis involving the 2-acetamido group of the substrate; however, the catalytic mechanism of human O-GlcNAcase is unknown. By using a series of 4-methylumbelliferyl 2-deoxy-2-N-fluoroacetyl-beta-D-glucopyranoside substrates, Taft-like linear free energy analyses of these enzymes indicates that O-GlcNAcase uses a catalytic mechanism involving anchimeric assistance. Consistent with this proposal, 1,2-dideoxy-2'-methyl-alpha-D-glucopyranoso-[2,1-d]-Delta 2'-thiazoline, an inhibitor that mimics the oxazoline intermediate proposed in the catalytic mechanism of family 20 glycoside hydrolases, is shown to act as a potent competitive inhibitor of both O-GlcNAcase (K-I = 0.070 mu M) and beta-hexosaminidase (KI = 0.070 mu M). A series of 1,2-dideoxy-2'-methyl-alpha-D-glucopyranoso[2,1-d]-Delta 2'-thiazoline analogues were prepared, and one inhibitor demonstrated a remarkable 1500-fold selectivity for O-GlcNAcase (K-I = 0.230 mu M) over beta-hexosaminidase (K-I = 340 mu M). These inhibitors are cell permeable and modulate the activity of O-GlcNAcase in tissue culture. Because both enzymes have vital roles in organismal health, these potent and selective inhibitors of O-GlcNAcase should prove useful in studying the role of this enzyme at the organismal level without generating a complex chemical phenotype stemming from concomitant inhibition of beta-hexosaminidase.	Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada	Simon Fraser University	Vocadlo, DJ (corresponding author), Simon Fraser Univ, Dept Chem, 8888 Univ Blvd, Burnaby, BC V5A 1S6, Canada.	dvocadlo@sfu.ca	Vocadlo, David J/E-5508-2014	Vocadlo, David J/0000-0001-6897-5558; Macauley, Matthew/0000-0003-4579-1048				Arias EB, 2004, DIABETES, V53, P921, DOI 10.2337/diabetes.53.4.921; BENNETT RA, 1981, CANCER RES, V41, P2786; Bergmann M, 1931, BER DTSCH CHEM GES, V64, P975, DOI 10.1002/cber.19310640506; BRAIDMAN I, 1974, BIOCHEM J, V143, P295, DOI 10.1042/bj1430295; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Chou TY, 2001, ADV EXP MED BIOL, V491, P413; Cole RN, 1999, J NEUROCHEM, V73, P418, DOI 10.1046/j.1471-4159.1999.0730418.x; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Gao Y, 2000, ARCH BIOCHEM BIOPHYS, V383, P296, DOI 10.1006/abbi.2000.2094; GRIFFITH LS, 1995, BIOCHEM BIOPH RES CO, V213, P424, DOI 10.1006/bbrc.1995.2149; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Hanover JA, 1999, ARCH BIOCHEM BIOPHYS, V362, P38, DOI 10.1006/abbi.1998.1016; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; Hansch C, 1979, SUBSTITUENT CONSTANT, P1; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HORSCH M, 1991, EUR J BIOCHEM, V197, P815, DOI 10.1111/j.1432-1033.1991.tb15976.x; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JONES CS, 1980, J BIOL CHEM, V255, P1861; JUNOD A, 1967, P SOC EXP BIOL MED, V126, P201; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Knapp S, 1996, J AM CHEM SOC, V118, P6804, DOI 10.1021/ja960826u; Konrad RJ, 2001, BIOCHEM J, V356, P31, DOI 10.1042/0264-6021:3560031; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P179, DOI 10.1515/bchm3.1995.376.3.179; Kuroki R, 1999, P NATL ACAD SCI USA, V96, P8949, DOI 10.1073/pnas.96.16.8949; Lamarre-Vincent N, 2003, J AM CHEM SOC, V125, P6612, DOI 10.1021/ja028200t; LEGLER G, 1991, BIOCHIM BIOPHYS ACTA, V1080, P89, DOI 10.1016/0167-4838(91)90133-K; Lillelund VH, 2002, CHEM REV, V102, P515, DOI 10.1021/cr000433k; Liu F, 2004, P NATL ACAD SCI USA, V101, P10804, DOI 10.1073/pnas.0400348101; Liu JJ, 2001, CHEM BIOL, V8, P701, DOI 10.1016/S1074-5521(01)00045-X; Liu K, 2004, J NEUROCHEM, V89, P1044, DOI 10.1111/j.1471-4159.2004.02389.x; Liu K, 2002, MOL CELL ENDOCRINOL, V194, P135, DOI 10.1016/S0303-7207(02)00155-7; LUBAS WA, 1995, BIOCHEMISTRY-US, V34, P1686, DOI 10.1021/bi00005a025; Maier T, 2003, J MOL BIOL, V328, P669, DOI 10.1016/S0022-2836(03)00311-5; Mark BL, 2003, J MOL BIOL, V327, P1093, DOI 10.1016/S0022-2836(03)00216-X; Mark BL, 2002, CAN J CHEM, V80, P1064, DOI 10.1139/V02-130; Mark BL, 2001, J BIOL CHEM, V276, P10330, DOI 10.1074/jbc.M011067200; Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; MILLER DJ, 1993, DEVELOPMENT, V118, P1279; Okuyama R, 2001, BIOCHEM BIOPH RES CO, V287, P366, DOI 10.1006/bbrc.2001.5607; Parker G, 2004, J BIOL CHEM, V279, P20636, DOI 10.1074/jbc.M312139200; ROESER KR, 1981, BIOCHIM BIOPHYS ACTA, V657, P321, DOI 10.1016/0005-2744(81)90318-1; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Roos MD, 1998, P ASSOC AM PHYSICIAN, V110, P422; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; Toleman C, 2004, J BIOL CHEM, V279, P53665, DOI 10.1074/jbc.M410406200; TORRES CR, 1984, J BIOL CHEM, V259, P3308; Triggs-Raine B, 2001, ADV GENET, V44, P199; Tropak MB, 2004, J BIOL CHEM, V279, P13478, DOI 10.1074/jbc.M308523200; UENO R, 1991, BIOCHIM BIOPHYS ACTA, V1074, P79, DOI 10.1016/0304-4165(91)90043-G; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; Vocadlo DJ, 2000, BIOCHEMISTRY-US, V39, P117, DOI 10.1021/bi991958d; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Wells L, 2002, J BIOL CHEM, V277, P1755, DOI 10.1074/jbc.M109656200; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; YAMADA K, 1982, DIABETES, V31, P749, DOI 10.2337/diabetes.31.9.749; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0; Yao PJ, 1998, J NEUROSCI, V18, P2399; Zachara NE, 2004, J BIOL CHEM, V279, P30133, DOI 10.1074/jbc.M403773200; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science.1103440	66	304	326	2	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25313	25322		10.1074/jbc.M413819200	http://dx.doi.org/10.1074/jbc.M413819200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15795231	hybrid			2022-12-27	WOS:000230207900003
J	Fragnet, L; Kut, E; Rasschaert, D				Fragnet, L; Kut, E; Rasschaert, D			Comparative functional study of the viral telomerase RNA based on natural mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE; IDENTIFICATION; ACTIVATION; DOMAINS; CELLS; DETERMINANTS; PROCESSIVITY; EXPRESSION; PROTEIN	Telomerase activity is present in most malignant tumors and provides a mechanism for the unlimited potential for division of neoplastic cells. We previously characterized the first identified viral telomerase RNA (vTR) encoded by the Marek's disease virus (MDV) (Fragnet, L., Blasco, M. A., Klapper, W., and Rasschaert, D. ( 2003) J. Virol. 77, 5985-5996). This avian herpesvirus induces T-lymphomas. We demonstrated that the vTR subunit of the oncogenic MDV-RB1B strain is functional and would be more efficient than its chicken counterpart, cTR, which is 88% homologous. We take advantage of the functionality of those natural mutant TRs to investigate the involvement of the mutations of vTR on its efficiency in a heterologous murine cell system and in a homologous in vitro system using the recombinant chicken telomerase reverse transcriptase. The P2 helix of the pseudoknot seems to be more stable in vTR than in cTR, and this may account for the higher activity of vTR than cTR. Moreover, the five adenines just upstream from the P3 helix of vTR may also play an important role in its efficiency. We also established that the substitution of a single nucleotide at the 3'-extremity of the H-box of the vaccine MDV-Rispens strain vTR resulted in a lack of its accumulation within the cell, especially in the nucleus, correlated with a decrease in telomerase activity.	INRA, Lab Telomerase Lymphome Viroinduit, Ctr Rech INRA Tours, F-37380 Nouzilly, France	INRAE	Rasschaert, D (corresponding author), INRA, Lab Telomerase Lymphome Viroinduit, Ctr Rech INRA Tours, UR BASE 086, F-37380 Nouzilly, France.	rasschae@tours.inra.fr						Autexier C, 1998, NUCLEIC ACIDS RES, V26, P787, DOI 10.1093/nar/26.3.787; Bachand F, 2001, MOL CELL BIOL, V21, P1888, DOI 10.1128/MCB.21.5.1888-1897.2001; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Chen JL, 2003, EMBO J, V22, P304, DOI 10.1093/emboj/cdg024; Chen ZP, 2001, EXP BIOL MED, V226, P753, DOI 10.1177/153537020222600807; Delany ME, 2004, GENE, V339, P61, DOI 10.1016/j.gene.2004.05.024; Fragnet L, 2003, J VIROL, V77, P5985, DOI 10.1128/JVI.77.10.5985-5996.2003; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Joubert P, 2000, J GEN VIROL, V81, P481, DOI 10.1099/0022-1317-81-2-481; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lukowiak AA, 2001, RNA, V7, P1833; Ly H, 2003, MOL CELL BIOL, V23, P6849, DOI 10.1128/MCB.23.19.6849-6856.2003; Marrone A, 2003, CELL MOL LIFE SCI, V60, P507, DOI 10.1007/s000180300042; Martin-Rivera L, 2001, J BIOL CHEM, V276, P5856, DOI 10.1074/jbc.M008419200; Mason PJ, 2003, BIOESSAYS, V25, P126, DOI 10.1002/bies.10229; Mitchell JR, 2000, MOL CELL, V6, P361, DOI 10.1016/S1097-2765(00)00036-8; Moriarty TJ, 2004, MOL CELL BIOL, V24, P3720, DOI 10.1128/MCB.24.9.3720-3733.2004; Moriarty TJ, 2002, MOL CELL BIOL, V22, P1253, DOI 10.1128/MCB.22.4.1253-1265.2002; Narayanan A, 1999, EMBO J, V18, P5120, DOI 10.1093/emboj/18.18.5120; Oh ST, 2001, J VIROL, V75, P5559, DOI 10.1128/JVI.75.12.5559-5566.2001; Okubo M, 2001, CANCER GENET CYTOGEN, V129, P30, DOI 10.1016/S0165-4608(01)00420-4; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Ware TL, 2000, EMBO J, V19, P3119, DOI 10.1093/emboj/19.12.3119; Wright WE, 1996, DEV GENET, V18, P173; Xia JQ, 2000, MOL CELL BIOL, V20, P5196, DOI 10.1128/MCB.20.14.5196-5207.2000; Yeo M, 2005, FEBS LETT, V579, P127, DOI 10.1016/j.febslet.2004.11.058; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	32	37	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23502	23515		10.1074/jbc.M501163200	http://dx.doi.org/10.1074/jbc.M501163200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15811851	Green Published, hybrid			2022-12-27	WOS:000229880000014
J	Okhrimenko, H; Lu, W; Xiang, CL; Ju, DH; Blumberg, PM; Gomel, R; Kazimirsky, G; Brodie, C				Okhrimenko, H; Lu, W; Xiang, CL; Ju, DH; Blumberg, PM; Gomel, R; Kazimirsky, G; Brodie, C			Roles of tyrosine phosphorylation and cleavage of protein kinase C delta in its protective effect against tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; RADIATION-INDUCED APOPTOSIS; DAMAGE-INDUCED APOPTOSIS; PROSTATE-CANCER CELLS; PROTEOLYTIC ACTIVATION; HUMAN KERATINOCYTES; GROWTH-FACTOR; DNA-DAMAGE; PKC-DELTA; ENDOPLASMIC-RETICULUM	Protein kinase C delta (PKC delta) regulates cell apoptosis in a cell- and stimulus-specific manner. Here, we studied the role of PKC delta in the apoptotic effect of TRAIL in glioma cells. We found that transfection of the cells with a PKC delta kinase-dead mutant (K376R) or with a small interfering RNA targeting the PKC delta mRNA increased the apoptotic effect of tumor necrosis factor-related apoptosis inducing ligand ( TRAIL), whereas overexpression of PKC delta decreased it. PKC delta acted downstream of caspase 8 and upstream of cytochrome c release from the mitochondria. TRAIL induced cleavage of PKC delta within 2-3 h of treatment, which was abolished by caspase 3, 8, and 9 inhibitors. The cleavage of PKC delta was essential for its protective effect because overexpression of a caspase-resistant mutant (PKC delta D327A) did not protect glioma cells from TRAIL-induced apoptosis but rather increased it. TRAIL induced translocation of PKC delta to the perinuclear region and the endoplasmic reticulum and phosphorylation of PKC delta on tyrosine 155. Using a PKC delta Y155F mutant, we found that the phosphorylation of PKC delta on tyrosine 155 was essential for the cleavage of PKC delta in response to TRAIL and for its translocation to the endoplasmic reticulum. In addition, phosphorylation of PKC delta on tyrosine 155 was necessary for the activation of AKT in response to TRAIL. Our results indicate that PKC delta protects glioma cells from the apoptosis induced by TRAIL and implicate the phosphorylation of PKC delta on tyrosine 155 and its cleavage as essential factors in the anti-apoptotic effect of PKC delta.	Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, Detroit, MI 48202 USA; NCI, Lab Cellular Carcinogenesis & Tumor Promot, NIH, Bethesda, MD 20892 USA; Bar Ilan Univ, Fac Life Sci, Gonda Goldschmied Med Diagnosis Res Ctr, IL-52900 Ramat Gan, Israel	Henry Ford Health System; Henry Ford Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Bar Ilan University	Brodie, C (corresponding author), Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, Detroit, MI 48202 USA.	chaya@mail.biu.ac.il			NATIONAL CANCER INSTITUTE [ZIABC005270, Z01BC005270] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Basu A, 2003, J CELL MOL MED, V7, P341, DOI 10.1111/j.1582-4934.2003.tb00237.x; Basu A, 2002, J BIOL CHEM, V277, P41850, DOI 10.1074/jbc.M205997200; Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Brodie C, 1998, J BIOL CHEM, V273, P30713, DOI 10.1074/jbc.273.46.30713; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Chawla-Sarkar M, 2003, J BIOL CHEM, V278, P39461, DOI 10.1074/jbc.M306111200; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Chen YR, 2000, INT J ONCOL, V16, P651; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Deutsch E, 2004, J VIROL, V78, P10187, DOI 10.1128/JVI.78.18.10187-10192.2004; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Goerke A, 2002, J BIOL CHEM, V277, P32054, DOI 10.1074/jbc.M203734200; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Harper N, 2003, J BIOL CHEM, V278, P44338, DOI 10.1074/jbc.M307376200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jun CD, 1999, J IMMUNOL, V162, P3395; Kajimoto T, 2004, J BIOL CHEM, V279, P12668, DOI 10.1074/jbc.M312350200; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kim KM, 2005, ONCOGENE, V24, P355, DOI 10.1038/sj.onc.1208213; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Larribere L, 2004, CELL DEATH DIFFER, V11, P1084, DOI 10.1038/sj.cdd.4401475; Leverrier S, 2002, BIOCHEM J, V368, P905, DOI 10.1042/BJ20021253; Li LW, 1999, MOL CELL BIOL, V19, P8547; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Lynch K, 2000, ENDOCRINOLOGY, V141, P4209, DOI 10.1210/en.141.11.4209; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Milani D, 2003, J NEUROCHEM, V86, P126, DOI 10.1046/j.1471-4159.2003.01805.x; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schultz A, 2003, CELL DEATH DIFFER, V10, P662, DOI 10.1038/sj.cdd.4401235; Sitailo LA, 2004, J INVEST DERMATOL, V123, P434, DOI 10.1111/j.0022-202X.2004.23403.x; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; Song JH, 2003, BRAIN PATHOL, V13, P539; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wert MM, 2000, BIOCHEM J, V352, P175, DOI 10.1042/0264-6021:3520175; White WO, 2002, J CELL BIOCHEM, V85, P42, DOI 10.1002/jcb.10101; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zrachia A, 2002, J BIOL CHEM, V277, P23693, DOI 10.1074/jbc.M111658200	71	52	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23643	23652		10.1074/jbc.M501374200	http://dx.doi.org/10.1074/jbc.M501374200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15774464	hybrid			2022-12-27	WOS:000229880000031
J	Drosopoulos, KG; Roberts, ML; Cermak, L; Sasazuki, T; Shirasawa, S; Andera, L; Pintzas, A				Drosopoulos, KG; Roberts, ML; Cermak, L; Sasazuki, T; Shirasawa, S; Andera, L; Pintzas, A			Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LIGAND-INDUCED APOPTOSIS; TUMORICIDAL ACTIVITY; CARCINOMA-CELLS; CANCER-CELLS; ACTIVATION; ERK; CASPASE-8; FADD; TNF	RAS oncogenes play a major role in cancer development by activating an array of signaling pathways, most notably mitogen-activated protein kinases, resulting in aberrant proliferation and inhibition of apoptotic signaling cascades, rendering transformed cells resistant to extrinsic death stimuli. However, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is able to kill specific tumor cells through the engagement of its receptors, death receptor 4 (DR4) and death receptor 5 (DR5), and the activation of apoptotic pathways, providing promising targets for anticancer therapies. In this study, we show that TRAIL induces cell death in human colon adenocarcinoma cells in a MEK-dependent manner. We also report a prolonged MEK-dependent activation of ERK1/2 and increased c-FOS expression induced by TRAIL in this system. Our study reveals that transformation of the colon cell line Caco-2 by Ki- and mainly by Ha-ras oncogenes sensitizes these cells to TRAIL-induced apoptosis by causing specific MEK-dependent up-regulation of DR4 and DR5. These observations taken together reveal that RAS-MEK-ERK1/2 signaling pathway can sensitize cells to TRAIL-induced apoptosis by up-regulating DR4 and DR5 and overall imply that TRAIL-based therapeutic strategies using TRAIL agonists could be used in cases of human colon cancers bearing RAS mutations.	Natl Hellen Res Fdn, Lab Signal Mediated Gene Express, Inst Biol Res & Biotechnol, Athens 11635, Greece; Acad Sci Czech Republ, Inst Mol Genet, Lab Cell Signaling Apoptosis, CZ-14220 Prague, Czech Republic; Int Med Ctr Japan, Dept Pathol, Shinjuku Ku, Tokyo 1628655, Japan; Univ Patras, Dept Pharm, Rion 26500, Greece	National Hellenic Research Foundation; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; National Center for Global Health & Medicine - Japan; University of Patras	Pintzas, A (corresponding author), Natl Hellen Res Fdn, Lab Signal Mediated Gene Express, Inst Biol Res & Biotechnol, 48 Vasileos Konstantinou Ave, Athens 11635, Greece.	apint@eie.gr	Andera, Ladislav/ABA-3403-2020; Cermak, Lukas/N-2254-2016; Andera, Ladislav/A-4536-2011	Cermak, Lukas/0000-0002-8777-3692; Roberts, Michael/0000-0001-7387-1155				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BOS JL, 1989, CANCER RES, V49, P4682; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Guan BX, 2002, ONCOGENE, V21, P3121, DOI 10.1038/sj.onc.1205430; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Koornstra JJ, 2003, J PATHOL, V200, P327, DOI 10.1002/path.1364; LE LH, 2004, J CLIN ONCOL S, V22; Li WQ, 2004, J BIOL CHEM, V279, P37398, DOI 10.1074/jbc.M405730200; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Mizutani Y, 2002, EUR J CANCER, V38, P167, DOI 10.1016/S0959-8049(01)00339-2; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Nesterov A, 2004, CANCER RES, V64, P3922, DOI 10.1158/0008-5472.CAN-03-2219; Nimmanapalli R, 2001, CANCER RES, V61, P759; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Plattner R, 1999, ONCOGENE, V18, P1807, DOI 10.1038/sj.onc.1202482; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Secchiero P, 2003, CIRCULATION, V107, P2250, DOI 10.1161/01.CIR.0000062702.60708.C4; Shetty S, 2002, APOPTOSIS, V7, P413, DOI 10.1023/A:1020031023947; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Siegmund D, 2001, J BIOL CHEM, V276, P32585, DOI 10.1074/jbc.M100444200; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; TOLCHER AW, 2004, J CLIN ONCOL S, V22; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WORKMAN P, 2002, TRENDS MOL MED, V8, P1	43	74	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22856	22867		10.1074/jbc.M412483200	http://dx.doi.org/10.1074/jbc.M412483200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15757891	hybrid			2022-12-27	WOS:000229741800038
J	Petropoulou, V; Garrigue-Antar, L; Kadler, KE				Petropoulou, V; Garrigue-Antar, L; Kadler, KE			Identification of the minimal domain structure of bone morphogenetic protein-1 (BMP-1) for chordinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN C-PROTEINASE; EPIDERMAL-GROWTH-FACTOR; MAMMALIAN TOLLOID-LIKE; POSTTRANSLATIONAL MODIFICATION; DROSOPHILA EMBRYO; LYSYL OXIDASE; COLLAGEN; METALLOPROTEINASES; ENHANCER; GENE	Bone morphogenetic protein 1 (BMP-1), which is a tolloid member of the astacin-like family of zinc metalloproteinases, is a highly effective procollagen C-proteinase (PCP) and chordinase. On the other hand, mammalian tolloid like-2 (mTLL-2) does not cleave chordin or procollagen; procollagen is cleaved by mTLL-2 in the presence of high levels of procollagen C-proteinase enhancer-1 (PCPE-1), for reasons that are unknown. We used these differences in activity between BMP-1 and mTLL-2 to narrow in on the domains in BMP-1 that specify PCP and chordinase activity. Using a domain swap approach, we showed that: 1) the metalloproteinase and CUB2 domains of BMP-1 are absolutely required for PCP activity; swaps with either of the corresponding domains in BMP-1 and mTLL-2 did not result in procollagen cleavage and 2) the proteinase domain of mTLL-2 can cleave chordin if coupled to the CUB1 domain of BMP-1. Therefore, the minimal structure for chordinase activity comprises a metalloproteinase domain (either from BMP-1 or from mTLL-2) and the CUB1 domain of BMP-1 (the CUB1 domain of mTLL-2 cannot substitute for the CUB1 domain of BMP-1). We showed that the minimal procollagen C-proteinase (BMP-1 lacking the EGF and CUB3 domain) was enhanced by PCPE-1 but not as well as BMP-1 retaining the CUB3 domain. Further studies showed that PCPE-1 had no effect on the ability of BMP-1 to cleave chordin. The data support a previously suggested mechanism of PCPE-1 whereby PCPE-1 interacts with procollagen, but in addition, the CUB3 domain of BMP-1 appears to augment the interaction.	Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Kadler, KE (corresponding author), Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	karl.kadler@manchester.ac.uk	KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683; Garrigue-Antar, Laure/0000-0001-6331-8882	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAR R, 1986, COLLAGEN REL RES, V6, P267; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; Garrigue-Antar L, 2004, J BIOL CHEM, V279, P49835, DOI 10.1074/jbc.M408134200; Garrigue-Antar L, 2002, J BIOL CHEM, V277, P43327, DOI 10.1074/jbc.M207342200; Garrigue-Antar L, 2001, J BIOL CHEM, V276, P26237, DOI 10.1074/jbc.M010814200; Ge GX, 2004, J BIOL CHEM, V279, P41626, DOI 10.1074/jbc.M406630200; Gopalakrishnan B, 2004, J BIOL CHEM, V279, P30904, DOI 10.1074/jbc.M402252200; Hartigan N, 2003, J BIOL CHEM, V278, P18045, DOI 10.1074/jbc.M211448200; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; HULMES D, 2004, ABSTR AM SOC MATRIX; Hulmes DJS, 1997, MATRIX BIOL, V16, P41, DOI 10.1016/S0945-053X(97)90115-3; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; Larrain J, 2000, DEVELOPMENT, V127, P821; Leighton M, 2003, J BIOL CHEM, V278, P18478, DOI 10.1074/jbc.M213021200; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Medeck RJ, 2003, BIOCHEM J, V376, P361, DOI 10.1042/BJ20030894; Millet C, 2001, MECH DEVELOP, V106, P85, DOI 10.1016/S0925-4773(01)00423-3; Moschcovich L, 2001, EUR J BIOCHEM, V268, P2991, DOI 10.1046/j.1432-1327.2001.02189.x; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Pappano WN, 2003, MOL CELL BIOL, V23, P4428, DOI 10.1128/MCB.23.13.4428-4438.2003; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; Ricard-Blum S, 2002, J BIOL CHEM, V277, P33864, DOI 10.1074/jbc.M205018200; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Steiglitz BM, 2004, J BIOL CHEM, V279, P980, DOI 10.1074/jbc.M310179200; Steiglitz BM, 2002, J BIOL CHEM, V277, P49820, DOI 10.1074/jbc.M209891200; Suzuki N, 1996, DEVELOPMENT, V122, P3587; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Van de Putte K A, 1965, Clin Orthop Relat Res, V43, P257; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; Wolfman NM, 2003, P NATL ACAD SCI USA, V100, P15842, DOI 10.1073/pnas.2534946100; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	48	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22616	22623		10.1074/jbc.M413468200	http://dx.doi.org/10.1074/jbc.M413468200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15817489	hybrid			2022-12-27	WOS:000229741800010
J	Lupu, C; Hu, XH; Lupu, F				Lupu, C; Hu, XH; Lupu, F			Caveolin-1 enhances tissue factor pathway inhibitor exposure and function on the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; COAGULATION INHIBITOR; LIPID RAFTS; FACTOR VIIA; IN-VITRO; EXPRESSION; RELEASE; COMPLEX; LOCALIZATION; LYMPHOCYTES	Tissue factor pathway inhibitor ( TFPI) blocks tissue factor-factor VIIa (TF-FVIIa) activation of factors X and IX through the formation of the TF-FVIIa-FXa-TFPI complex. Most TFPI in vivo associates with caveolae in endothelial cells (EC). The mechanism of this association and the anticoagulant role of caveolar TFPI are not yet known. Here we show that expression of caveolin-1 (Cav-1) in 293 cells keeps TFPI exposed on the plasmalemma surface, decreases the membrane lateral mobility of TFPI, and increases the TFPI-dependent inhibition of TF-FVIIa. Caveolae-associated TFPI supports the co-localization of the quaternary complex with caveolae. To investigate the significance of these observations for EC we used RNA interference to deplete the cells of Cav-1. Functional assays and fluorescence microscopy revealed that the inhibitory properties of TFPI were diminished in EC lacking Cav-1, apparently through deficient assembly of the quaternary complex. These findings demonstrate that caveolae regulate the inhibition by cell-bound TFPI of the active protease production by the extrinsic pathway of coagulation.	Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	Lupu, C (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	cristina-lupu@omrf.ouhsc.edu	Lupu, Florea/AAV-3257-2021; Lupu, Florea/C-3162-2009	Lupu, Florea/0000-0003-1249-9278; Lupu, Florea/0000-0003-1249-9278	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018758] Funding Source: NIH RePORTER; NCRR NIH HHS [5P20 RR 018758-02] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAJAJ MS, 1990, P NATL ACAD SCI USA, V87, P8869, DOI 10.1073/pnas.87.22.8869; BROZE GJ, 1988, BLOOD, V71, P335; Caplice NM, 1998, CIRC RES, V83, P1264, DOI 10.1161/01.RES.83.12.1264; CONTRINO J, 1994, AM J PATHOL, V145, P1315; Crawley J, 2000, ARTERIOSCL THROM VAS, V20, P1362, DOI 10.1161/01.ATV.20.5.1362; Dietzen DJ, 2003, THROMB HAEMOSTASIS, V89, P65; DRAKE TA, 1993, AM J PATHOL, V142, P1458; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Feng X, 2001, J BIOL CHEM, V276, P8341, DOI 10.1074/jbc.M007116200; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1994, J BIOL CHEM, V269, P30745; Hansen JB, 2000, THROMB RES, V100, P413, DOI 10.1016/S0049-3848(00)00351-0; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Krajewska WM, 2004, CELL MOL BIOL LETT, V9, P195; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Lupu C, 1997, ARTERIOSCL THROM VAS, V17, P2964, DOI 10.1161/01.ATV.17.11.2964; Lupu C, 1999, ARTERIOSCL THROM VAS, V19, P2251, DOI 10.1161/01.ATV.19.9.2251; Lupu C, 1999, THROMB HAEMOSTASIS, V82, P1652; Mast AE, 2002, ARTERIOSCL THROM VAS, V22, P2099, DOI 10.1161/01.ATV.0000042456.84190.F0; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; NORDFANG O, 1991, BIOCHEMISTRY-US, V30, P10371, DOI 10.1021/bi00107a002; Ott I, 2000, ARTERIOSCL THROM VAS, V20, P874, DOI 10.1161/01.ATV.20.3.874; Ott I, 2001, BLOOD, V97, P3721, DOI 10.1182/blood.V97.12.3721; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Roque M, 2000, J AM COLL CARDIOL, V36, P2303, DOI 10.1016/S0735-1097(00)01018-4; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; Ruf W, 1996, Curr Opin Hematol, V3, P379; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; SIMIONESCU N, 1983, J CELL BIOL, V97, P1592, DOI 10.1083/jcb.97.5.1592; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; van Deurs B, 2003, TRENDS CELL BIOL, V13, P92, DOI 10.1016/S0962-8924(02)00039-9; Vogel U, 1998, J CELL SCI, V111, P825; Westmuckett AD, 2000, ARTERIOSCL THROM VAS, V20, P2474, DOI 10.1161/01.ATV.20.11.2474; Westmuckett AD, 2001, THROMB HAEMOSTASIS, V86, P1547, DOI 10.1055/s-0037-1616761; Xu J, 2000, J BIOL CHEM, V275, P6038, DOI 10.1074/jbc.275.8.6038; Zhang J, 2003, CIRCULATION, V108, P623, DOI 10.1161/01.CIR.0000078642.45127.7B	37	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22308	22317		10.1074/jbc.M503333200	http://dx.doi.org/10.1074/jbc.M503333200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15817451	hybrid			2022-12-27	WOS:000229557900076
J	Weber, CC; Cai, H; Ehrbar, M; Kubota, H; Martiny-Baron, G; Weber, W; Djonov, V; Weber, E; Mallik, AS; Fussenegger, M; Frei, K; Hubbell, JA; Zisch, AH				Weber, CC; Cai, H; Ehrbar, M; Kubota, H; Martiny-Baron, G; Weber, W; Djonov, V; Weber, E; Mallik, AS; Fussenegger, M; Frei, K; Hubbell, JA; Zisch, AH			Effects of protein and gene transfer of the angiopoietin-1 fibrinogen-like receptor-binding domain on endothelial and vessel organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; IN-VITRO; OVEREXPRESSING ANGIOPOIETIN-1; TYROSINE KINASES; BLOOD-VESSELS; CELLS; ANGIOGENESIS; EXPRESSION; VEGF; PERMEABILITY	The vessel-stabilizing effect of angiopoietin-1 (Ang1)/ Tie2 receptor signaling is a potential target for pro-angiogenic therapies as well as anti-angiogenic inhibition of tumor growth. We explored the endothelial and vascular specific activities of the Ang1 monomer, i.e. dissociated from its state as an oligomer. A truncated monomeric Ang1 variant (i.e. Delta Ang1) containing the isolated fibrinogen-like receptor-binding domain of Ang1 was created and recombinantly produced in insect cells. Delta Ang1 ligated the Tie2 receptor without triggering its phosphorylation. Moreover, monomeric Delta Ang1 was observed to bind alpha(5)beta(1) integrin with similar affinity compared with Tie2. Unexpectedly, in vitro treatment of endothelial cells with Delta Ang1 showed some of the known effects of full-length Ang1, including inhibition of basal endothelial cell permeability and stimulation of cell adhesion as well as activation of MAPKs. Local treatment of the microvasculature of the developing chicken chorioallantoic membrane with the Delta Ang1 protein led to profound reduction of the mean vascular length density, thinning of vessels, and reduction of the number of vessel branching points. Similar effects were observed in side-by-side experiments with the recombinant full-length Ang1 protein. These effects of simplification of the vessel branching pattern were confirmed through local gene transfer with lentiviral particles encoding Delta Ang1 or full- length Ang1. Together, our findings suggest a potential use for exogenous Ang1 in reducing rather than increasing vascular density. Furthermore, we show that the isolated receptor-binding domain of Ang1 is capable of mediating some effects of full- length Ang1 independently of Tie2 phosphorylation, possibly through integrin ligation.	Univ Zurich Hosp, Dept Obstet, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland; Swiss Fed Inst Technol, Dept Mat Sci, CH-8044 Zurich, Switzerland; Swiss Fed Inst Technol, Inst Biomed Engn, CH-8044 Zurich, Switzerland; Univ Zurich, CH-8044 Zurich, Switzerland; Novartis Pharma AG, CH-4002 Basel, Switzerland; Swiss Fed Inst Technol, Inst Biotechnol, CH-8093 Zurich, Switzerland; Univ Bern, Inst Anat, CH-3000 Bern, Switzerland; German Canc Res Ctr, Dept Biostat, D-69210 Heidelberg, Germany	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; Novartis; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Bern; Helmholtz Association; German Cancer Research Center (DKFZ)	Zisch, AH (corresponding author), Univ Zurich Hosp, Dept Obstet, Frauenklinstr 10, CH-8091 Zurich, Switzerland.	andreas.zisch@usz.ch	Ehrbar, Martin/F-4578-2012; Hubbell, Jeffrey A/A-9266-2008; Weber, Wilfried/B-4732-2012	Ehrbar, Martin/0000-0003-2707-4870; Hubbell, Jeffrey A/0000-0003-0276-5456; Weber, Wilfried/0000-0003-4340-4446; Djonov, Valentin/0000-0002-5062-1169				ABT K, 1987, METHOD INFORM MED, V26, P77; AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Arsic N, 2003, MOL THER, V7, P450, DOI 10.1016/S1525-0016(03)00034-0; AUERBACH R, 1974, DEV BIOL, V41, P391, DOI 10.1016/0012-1606(74)90316-9; AUSUBEL FM, 1995, SHORT PROTOCOLS MOL, P11; BATSCHELET E, 1980, EINFUHRUNG MATH BIOL; Birgbauer E, 2000, DEVELOPMENT, V127, P1231; Carlson TR, 2001, J BIOL CHEM, V276, P26516, DOI 10.1074/jbc.M100282200; Cho CH, 2004, P NATL ACAD SCI USA, V101, P5547, DOI 10.1073/pnas.0307574101; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Davis S, 2003, NAT STRUCT BIOL, V10, P38, DOI 10.1038/nsb880; Djonov V, 2000, CIRC RES, V86, P286, DOI 10.1161/01.RES.86.3.286; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Ehrbar M, 2005, J CONTROL RELEASE, V101, P93, DOI 10.1016/j.jconrel.2004.07.018; Ehrbar M, 2004, CIRC RES, V94, P1124, DOI 10.1161/01.RES.0000126411.29641.08; Ellis LM, 2002, ONCOLOGY-NY, V16, P31; Fiedler U, 2003, J BIOL CHEM, V278, P1721, DOI 10.1074/jbc.M208550200; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Gloor SM, 1997, BIOCHEM BIOPH RES CO, V239, P804, DOI 10.1006/bbrc.1997.7557; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Harfouche R, 2002, MICROVASC RES, V64, P135, DOI 10.1006/mvre.2002.2421; Hayes AJ, 2000, BRIT J CANCER, V83, P1154, DOI 10.1054/bjoc.2000.1437; Hori S, 2004, J NEUROCHEM, V89, P503, DOI 10.1111/j.1471-4159.2004.02343.x; Joussen AM, 2002, AM J PATHOL, V160, P1683, DOI 10.1016/S0002-9440(10)61115-7; Jung SM, 1998, J BIOL CHEM, V273, P14827, DOI 10.1074/jbc.273.24.14827; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim I, 2001, CIRC RES, V89, P477, DOI 10.1161/hh1801.097034; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mitta B, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf112; Pizurki L, 2003, BRIT J PHARMACOL, V139, P329, DOI 10.1038/sj.bjp.0705259; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029; Sakiyama-Elbert SE, 2001, FASEB J, V15, P1300, DOI 10.1096/fj.00-0564fje; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schense JC, 1999, BIOCONJUGATE CHEM, V10, P75, DOI 10.1021/bc9800769; Schmoekel HG, 2005, BIOTECHNOL BIOENG, V89, P253, DOI 10.1002/bit.20168; Shyu KG, 2003, LIFE SCI, V73, P563, DOI 10.1016/S0024-3205(03)00318-7; Stoeltzing O, 2003, CANCER RES, V63, P3370; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 2003, CELL TISSUE RES, V314, P61, DOI 10.1007/s00441-003-0749-6; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Uemura A, 2002, J CLIN INVEST, V110, P1619, DOI 10.1172/JCI200215621; Ward NL, 2002, SEMIN CELL DEV BIOL, V13, P19, DOI 10.1006/scdb.2001.0288; WEBER E, 1985, STAT AUSWERTUNG BIOM; Weber W, 2002, CYTOTECHNOLOGY, V38, P77, DOI 10.1023/A:1021102015070; Weibel E.R., 1967, QUANTITATIVE METHODS, P89, DOI 10.1007/978-3-642-50130-2_7; Xu Y, 2001, J BIOL CHEM, V276, P34990, DOI 10.1074/jbc.M103661200; Yamauchi A, 2003, J GENE MED, V5, P994, DOI 10.1002/jgm.439; Zhou DP, 2000, ARCH BIOCHEM BIOPHYS, V374, P3, DOI 10.1006/abbi.1999.1622	53	30	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22445	22453		10.1074/jbc.M410367200	http://dx.doi.org/10.1074/jbc.M410367200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15781448	hybrid			2022-12-27	WOS:000229557900090
J	Dammermann, W; Guse, AH				Dammermann, W; Guse, AH			Functional ryanodine receptor expression is required for NAADP-mediated local Ca2+ signaling in T-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; ADENINE-DINUCLEOTIDE PHOSPHATE; PANCREATIC ACINAR-CELLS; INOSITOL TRISPHOSPHATE; CALCIUM-RELEASE; MOBILIZES CA2+; ENTRY; PROPAGATION; STORE	Nicotinic acid adenine dinucleotide phosphate (NAADP) is a potent Ca2+-mobilizing nucleotide involved in T cell Ca2+ signaling ( Berg, I., Potter, B. V. L., Mayr, G. W., and Guse, A. H. (2000) J. Cell Biol. 150, 581-588). The objective of this study was to analyze whether the first subcellular Ca2+ signals obtained upon NAADP stimulation of T-lymphocytes depend on the functional expression of ryanodine receptors. Using combined microinjection and high resolution confocal calcium imaging, we demonstrate here that subcellular Ca2+ signals, characterized by amplitudes between similar to 30 and 100 nM and diameters of similar to 0.5 mu m, preceded global Ca2+ signals. Co-injection of the ryanodine receptor antagonists ruthenium red and ryanodine together with NAADP abolished the effects of NAADP, whereas the D-myo-inositol 1,4,5- trisphosphate antagonist heparin and the Ca2+ entry blocker SKF& 96365 were without effect. This pharmacological approach was confirmed by a molecular knock-down approach. Jurkat T cell clones with largely reduced expression of ryanodine receptors did not respond to microinjections of NAADP. Taken together, our data suggest that the Ca2+ release channel sensitive to NAADP in T- lymphocytes is the ryanodine receptor.	Univ Hamburg, Hosp Eppendorf, Ctr Med Expt, Inst Biochem & Mol Biol Cellular Signal Transduct, D-20246 Hamburg, Germany	University of Hamburg	Guse, AH (corresponding author), Univ Hamburg, Hosp Eppendorf, Ctr Med Expt, Inst Biochem & Mol Biol Cellular Signal Transduct, Martinistr 52, D-20246 Hamburg, Germany.	guse@uke.uni-hamburg.de	Dammermann, Werner/G-5811-2016; Dammermann, Werner/GZN-1268-2022	Dammermann, Werner/0000-0001-6847-3769; 				Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; BEZPROZVANNY IB, 1993, MOL BIOL CELL, V4, P347, DOI 10.1091/mbc.4.3.347; Brailoiu E, 2005, J BIOL CHEM, V280, P5646, DOI 10.1074/jbc.M408746200; Bruzzone S, 2003, J CELL BIOL, V163, P837, DOI 10.1083/jcb.200307016; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Gerasimenko JV, 2003, J CELL BIOL, V163, P271, DOI 10.1083/jcb.200306134; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; Guse AH, 1997, J BIOL CHEM, V272, P8546, DOI 10.1074/jbc.272.13.8546; Hohenegger M, 2002, BIOCHEM J, V367, P423, DOI 10.1042/BJ20020584; Kunerth S, 2004, J CELL SCI, V117, P2141, DOI 10.1242/jcs.01063; Kunerth S, 2003, CELL SIGNAL, V15, P783, DOI 10.1016/S0898-6568(03)00015-9; Langhorst MF, 2004, CELL SIGNAL, V16, P1283, DOI 10.1016/j.cellsig.2004.03.013; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 2000, J CELL SCI, V113, P4413; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lipp P, 1996, J PHYSIOL-LONDON, V492, P31, DOI 10.1113/jphysiol.1996.sp021286; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Mojzisova A, 2001, PFLUG ARCH EUR J PHY, V441, P674, DOI 10.1007/s004240000465; Schwarzmann N, 2002, J BIOL CHEM, V277, P50636, DOI 10.1074/jbc.M209061200; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; Yamasaki M, 2004, J BIOL CHEM, V279, P7234, DOI 10.1074/jbc.M311088200	24	92	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21394	21399		10.1074/jbc.M413085200	http://dx.doi.org/10.1074/jbc.M413085200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15774471	hybrid			2022-12-27	WOS:000229438800059
J	Kopp, J; Preis, E; Said, H; Hafemann, B; Wickert, L; Gressner, AM; Pallua, N; Dooley, S				Kopp, J; Preis, E; Said, H; Hafemann, B; Wickert, L; Gressner, AM; Pallua, N; Dooley, S			Abrogation of transforming growth factor-beta signaling by SMAD7 inhibits collagen gel contraction of human dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; TGF-BETA; GENE-TRANSFER; IN-VIVO; FIBROSIS; RECEPTOR; ANTAGONIST; ACTIVATION; EXPRESSION; TRANSDIFFERENTIATION	Human fibroproliferative disorders like hypertrophic scarring of the skin are characterized by increased contractility and excess extracellular matrix synthesis. A beneficial role of transforming growth factor (TGF)-beta in wound healing was proposed; however, chronic stimulation by this cytokine leads to fibrosis. In the present report, the intracellular TGF-beta signaling in fibroblasts derived from hypertrophic scars and normal skin was examined. In an attempt to intervene in profibrogenic TGF-beta functions, ectopic expression of Smad7 or dominant negative Smads3/4 completely inhibited contractility of scar-derived and normal fibroblasts after suspension in collagen gels. Both cell types displayed constitutive Smad2/3 phosphorylation and (CAGA)(9)MLP-Luc activity with expression and phosphorylation of Smad3 being predominant in hypertrophic scar-derived fibroblasts. Down-regulation of intrinsic signaling with various TGF-beta antagonists, e. g. soluble TGF-beta receptor, latency-associated peptide, and anti-TGF-beta(1) antibodies, confirms autocrine TGF-beta stimulation of both cell populations. Further, Smad7 expression inhibited alpha 1 (I) collagen and alpha-smooth muscle actin expression. In summary, our data indicate that autocrine TGF-beta/Smad signaling is involved in contractility and matrix gene expression of fibroblasts from normal and hypertrophic scars. Smad7 inhibits these processes and may exert beneficial effects on excessive scar formation.	Univ Erlangen Nurnberg, Chirurg Klin, D-91054 Erlangen, Germany; Rhein Westfal TH Aachen, Univ Klinikum, Klin Plast Chirurg, D-52074 Aachen, Germany; Rhein Westfal TH Aachen, Univ Klinikum, Inst Clin Chem & Pathobiochem, D-52074 Aachen, Germany; Heidelberg Univ, Univ Klinikum Mannheim, Med Klin 2, D-68167 Mannheim, Germany	University of Erlangen Nuremberg; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Dooley, S (corresponding author), Heidelberg Univ, Univ Hosp Mannheim, Med Clin, Bergheimer Str 58, Heidelberg, Germany.	dooley@med.ma.uni-heidelberg.de	Said, Harun Muayad/AAZ-7299-2021; Dooley, Steven/T-6491-2018	Dooley, Steven/0000-0002-4840-6240; Said, Harun M./0000-0002-7032-2668				Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Ashcroft GS, 2000, CYTOKINE GROWTH F R, V11, P125, DOI 10.1016/S1359-6101(99)00036-2; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; BERG F, 2002, SIGNAL TRANSDUCT, V2, P11; Berry DP, 1998, PLAST RECONSTR SURG, V102, P124, DOI 10.1097/00006534-199807000-00019; Brissett A E, 2001, Facial Plast Surg, V17, P263, DOI 10.1055/s-2001-18827; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CLARK RAF, 1993, AM J MED SCI, V306, P42, DOI 10.1097/00000441-199307000-00011; Cowin AJ, 2001, EUR J DERMATOL, V11, P424; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dooley S, 2000, HEPATOLOGY, V31, P1094, DOI 10.1053/he.2000.6126; Dooley S, 2003, GASTROENTEROLOGY, V125, P178, DOI 10.1016/S0016-5085(03)00666-8; Dooley S, 2001, FEBS LETT, V502, P4, DOI 10.1016/S0014-5793(01)02656-4; ENGEL K, 1993, FEBS LETT, V336, P143, DOI 10.1016/0014-5793(93)81628-D; Flanders KC, 2003, AM J PATHOL, V163, P2247, DOI 10.1016/S0002-9440(10)63582-1; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; George J, 1999, P NATL ACAD SCI USA, V96, P12719, DOI 10.1073/pnas.96.22.12719; Gressner AM, 2003, J HEPATOL, V39, P856, DOI 10.1016/S0168-8278(03)00432-X; Hasegawa T, 2003, J DERMATOL SCI, V32, P19, DOI 10.1016/S0923-1811(03)00044-6; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Herrmann J, 2004, ARCH VIROL, V149, P1611, DOI 10.1007/s00705-004-0300-4; Huang JS, 2002, FASEB J, V16, P1269, DOI 10.1096/fj.02-0103fje; Isaka Y, 1999, KIDNEY INT, V55, P465, DOI 10.1046/j.1523-1755.1999.00275.x; Lan HY, 2003, J AM SOC NEPHROL, V14, P1535, DOI 10.1097/01.ASN.0000067632.04658.B8; Liu XD, 2003, CELL MOTIL CYTOSKEL, V54, P248, DOI 10.1002/cm.10098; MARTIN P, 1992, Progress in Growth Factor Research, V4, P25, DOI 10.1016/0955-2235(92)90003-Z; Moustakas A, 2001, J CELL SCI, V114, P4359; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Schmid P, 1998, AM J PATHOL, V152, P485; Schnabl B, 2001, HEPATOLOGY, V34, P89, DOI 10.1053/jhep.2001.25349; SHAH M, 1995, J CELL SCI, V108, P985; SHAH M, 1994, J CELL SCI, V107, P1137; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; TERADA Y, 2002, KIDNEY INT S1, V61, P94, DOI DOI 10.1046/J.1523-1755.2002.0610S1094.X; Tredget EE, 1998, PLAST RECONSTR SURG, V102, P1317, DOI 10.1097/00006534-199810000-00001; Ueno H, 2000, HUM GENE THER, V11, P33, DOI 10.1089/10430340050016139; WEBER L, 1986, J INVEST DERMATOL, V87, P217, DOI 10.1111/1523-1747.ep12696545; Zhang Y, 2003, J INVEST DERMATOL, V121, P713, DOI 10.1046/j.1523-1747.2003.12517.x; Zhao JS, 2002, AM J PHYSIOL-LUNG C, V282, pL585, DOI 10.1152/ajplung.00151.2001	44	77	110	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21570	21576		10.1074/jbc.m502071200	http://dx.doi.org/10.1074/jbc.m502071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15788410	hybrid			2022-12-27	WOS:000229438800080
J	Reynolds, CM; Kalb, SR; Cotter, RJ; Raetz, CRH				Reynolds, CM; Kalb, SR; Cotter, RJ; Raetz, CRH			A phosphoethanolamine transferase specific for the outer 3-deoxy-D-manno-octulosonic acid residue of Escherichia coli lipopolysaccharide - Identification of the EptB gene and Ca2+ hypersensitivity of an EptB deletion mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-A; SALMONELLA-TYPHIMURIUM; RESISTANT MUTANTS; MEMBRANE-LIPIDS; INNER MEMBRANE; ACYL CHAINS; BIOSYNTHESIS; 4-AMINO-4-DEOXY-L-ARABINOSE; PURIFICATION; LACKING	Addition of a phosphoethanolamine (pEtN) moiety to the outer 3-deoxy-D-manno-octulosonic acid (Kdo) residue of lipopolysaccharide (LPS) in WBB06, a heptose-deficient Escherichia coli mutant, occurs when cells are grown in 5-50 mM CaCl2 (Kanipes, M. I., Lin, S., Cotter, R. J., and Raetz, C. R. H. ( 2001) J. Biol. Chem. 276, 1156-1163). A Ca2+-induced, membrane-bound enzyme was responsible for the transfer of the pEtN unit to the Kdo domain. We now report the identification of the gene encoding the pEtN transferase. E. coli yhjW was cloned and overexpressed, because it is homologous to a putative pEtN transferase implicated in the modification of the beta-chain heptose residue of Neisseria meningitidis lipo-oligosaccharide (Mackinnon, F. G., Cox, A. D., Plested, J. S., Tang, C. M., Makepeace, K., Coull, P. A., Wright, J. C., Chalmers, R., Hood, D. W., Richards, J. C., and Moxon, E. R. (2002) Mol. Microbiol. 43, 931-943). In vitro assays with Kdo(2)-4'-[P-32] lipid A as the acceptor showed that YhjW ( renamed EptB) utilizes phosphatidylethanolamine in the presence of Ca2+ to transfer the pEtN group. Stoichiometric amounts of diacylglycerol were generated during the EptB-catalyzed transfer of pEtN to Kdo(2)-lipid A. EptB is an inner membrane protein of 574 amino acid residues with five predicted trans-membrane segments within its N-terminal region. An in-frame replacement of eptB with a kanamycin resistance cassette rendered E. coli WBB06 ( but not wild-type WBB06) hypersensitive to CaCl2 at 5mM or higher. Ca2+ hypersensitivity was suppressed by excess Mg2+ in the medium or by restoring the LPS core of WBB06. The latter was achieved by reintroducing the waaC and waaF genes, which encode LPS heptosyl transferases I and II, respectively. Our data demonstrate that pEtN modification of the outer Kdo protected cells containing heptose-deficient LPS from damage by high concentrations of Ca2+. Based on its sequence similarity to EptA(PmrC), we propose that the active site of EptB faces the periplasmic surface of the inner membrane.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectrometry Lab, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu		Kalb, Suzanne/0000-0002-8067-136X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310, R01GM064402] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-64402, GM-51310] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; Brade H, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P927; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; COSTELLO CE, 1990, METHOD ENZYMOL, V193, P738, DOI 10.1016/0076-6879(90)93448-T; CRONAN JE, 1975, BACTERIOL REV, V39, P232, DOI 10.1128/MMBR.39.3.232-256.1975; Cronan JE, 2003, ANNU REV MICROBIOL, V57, P203, DOI 10.1146/annurev.micro.57.030502.090851; CRONAN JE, 1987, ESCHERICHIA COLI SAL, V1; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Doerrler WT, 2004, J BIOL CHEM, V279, P45102, DOI 10.1074/jbc.M408106200; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Fahy E, 2005, J LIPID RES, V46, P839, DOI 10.1194/jlr.E400004-JLR200; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; GANGOLA P, 1987, J BIOL CHEM, V262, P12570; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; GOLDMAN RC, 1985, J BACTERIOL, V163, P256, DOI 10.1128/JB.163.1.256-261.1985; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Kadrmas JL, 1998, J BIOL CHEM, V273, P2799, DOI 10.1074/jbc.273.5.2799; Kanipes MI, 2001, J BIOL CHEM, V276, P1156, DOI 10.1074/jbc.M009019200; KENNEDY EP, 1987, ESCHERICHIA COLI SAL, V1, P672; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lazar K, 2002, CURR OPIN CHEM BIOL, V6, P786, DOI 10.1016/S1367-5931(02)00355-1; Lee H, 2004, J BACTERIOL, V186, P4124, DOI 10.1128/JB.186.13.4124-4133.2004; Mackinnon FG, 2002, MOL MICROBIOL, V43, P931, DOI 10.1046/j.1365-2958.2002.02754.x; MILLER KJ, 1987, J BACTERIOL, V169, P682, DOI 10.1128/jb.169.2.682-686.1987; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Osborn M J, 1974, Methods Enzymol, V31, P642; RADIKA K, 1988, J BIOL CHEM, V263, P14859; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P498; RAY BL, 1984, J BIOL CHEM, V259, P4852; ROTERING H, 1983, J BIOL CHEM, V258, P8068; Sambrook J., 2001, MOL CLONING LAB MANU; SIRISENA DM, 1992, J BIOL CHEM, V267, P18874; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snijder HJ, 1999, NATURE, V401, P717, DOI 10.1038/44890; Tran AX, 2004, J BIOL CHEM, V279, P55780, DOI 10.1074/jbc.M406480200; Trent M. Stephen, 2002, Journal of Endotoxin Research, V8, P158; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14194, DOI 10.1074/jbc.M200409200; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14186, DOI 10.1074/jbc.M200408200; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466; Zwaal R F, 1974, Methods Enzymol, V32, P154	57	113	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					21202	21211		10.1074/jbc.M500964200	http://dx.doi.org/10.1074/jbc.M500964200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15795227	hybrid			2022-12-27	WOS:000229438800038
J	Wu, PP; Ma, DD; Pierzchala, M; Wu, J; Yang, LC; Mai, XP; Chang, XY; Schmidt-Glenewinkel, TS				Wu, PP; Ma, DD; Pierzchala, M; Wu, J; Yang, LC; Mai, XP; Chang, XY; Schmidt-Glenewinkel, TS			The Drosophila acetylcholine receptor subunit D alpha 5 is part of an alpha-bungarotoxin binding acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL NERVOUS-SYSTEM; CHOLINERGIC RECEPTOR; NICOTINIC RECEPTOR; DETERGENT BINDING; CROSS-LINKING; CO-ASSEMBLE; PROTEIN; MELANOGASTER; COMPLEX; EXPRESSION	The central nervous system of Drosophila melanogaster contains an alpha-bungarotoxin-binding protein with the properties expected of a nicotinic acetylcholine receptor. This protein was purified 5800-fold from membranes prepared from Drosophila heads. The protein was solubilized with 1 % Triton X-100 and 0.5 M sodium chloride and then purified using an alpha-cobratoxin column followed by a lentil lectin affinity column. The purified protein had a specific activity of 3.9 mu mol of I-125- bungarotoxin binding sites/g of protein. The subunit composition of the purified receptor was determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis. This subunit profile was identical with that revealed by in situ labeling of the membrane-bound protein using the photolyzable methyl-4-azidobenzoimidate derivative of I-125-alpha-bungarotoxin. The purified receptor reveals two different protein bands with molecular masses of 42 and 57 kDa. From sedimentation analysis of the purified protein complex in H2O and D2O and gel filtration, a mass of 270 kDa was calculated. The receptor has a s(20),omega of 9.4 and a Stoke's radius of 7.4 nm. The frictional coefficient was calculated to be 1.7 indicating a highly asymmetric protein complex compatible with a transmembrane protein forming an ion channel. The sequence of a peptide obtained after tryptic digestion of the 42-kDa protein allowed the specific identification of the Drosophila D alpha 5 subunit by sequence comparison. A peptide-specific antibody raised against the D alpha 5 subunit provides further evidence that this subunit is a component of an alpha-bungarotoxin binding nicotinic acetylcholine receptor from the central nervous system of Drosophila.	CUNY Hunter Coll, Ctr Study Gene Struct & Funct, Dept Sci Biol, New York, NY 10021 USA; CUNY Hunter Coll, Grad Ctr, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY)	Schmidt-Glenewinkel, TS (corresponding author), CUNY Hunter Coll, Ctr Study Gene Struct & Funct, Dept Sci Biol, 695 Pk Ave, New York, NY 10021 USA.	thomas@genectr.hunter.cuny.edu	Pierzchala, Mariusz/G-1052-2013; Ma, Diane/AAR-6749-2021	Pierzchala, Mariusz/0000-0001-7001-1336; Ma, Diane/0000-0001-7125-9587	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [SC3GM086323, S06GM060654] Funding Source: NIH RePORTER; NCRR NIH HHS [G12 RR003037, RR-03037] Funding Source: Medline; NIGMS NIH HHS [SC3 GM086323, 1SO6 GM 60654, S06 GM060654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BLANCHARD SG, 1979, BIOCHEMISTRY-US, V18, P1875, DOI 10.1021/bi00577a005; BOSSY B, 1988, EMBO J, V7, P611, DOI 10.1002/j.1460-2075.1988.tb02854.x; Chamaon K, 2000, FEBS LETT, V482, P189, DOI 10.1016/S0014-5793(00)02057-3; Chamaon K, 2002, J NEUROCHEM, V80, P149, DOI 10.1046/j.0022-3042.2001.00685.x; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Changeux JP, 2001, CURR OPIN NEUROBIOL, V11, P369, DOI 10.1016/S0959-4388(00)00221-X; CLARKE S, 1975, J BIOL CHEM, V250, P5459; CONTITRONCONI BM, 1982, ANNU REV BIOCHEM, V51, P491, DOI 10.1146/annurev.bi.51.070182.002423; COOPER D, 1972, J BIOL CHEM, V247, P3008; DUDAI Y, 1978, BIOCHIM BIOPHYS ACTA, V539, P505, DOI 10.1016/0304-4165(78)90084-3; Grauso M, 2002, GENETICS, V160, P1519; HAYMAN MJ, 1972, BIOCHEM BIOPH RES CO, V47, P923, DOI 10.1016/0006-291X(72)90581-5; HERMANSBORGMEYER I, 1986, EMBO J, V5, P1503, DOI 10.1002/j.1460-2075.1986.tb04389.x; JI I, 1985, ANAL BIOCHEM, V151, P348, DOI 10.1016/0003-2697(85)90186-1; JI TH, 1977, J BIOL CHEM, V252, P1566; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lansdell SJ, 2004, J NEUROCHEM, V90, P479, DOI 10.1111/j.1471-4159.2004.02499.x; Lansdell SJ, 1997, J NEUROCHEM, V68, P1812; Lansdell SJ, 2002, J NEUROCHEM, V80, P1009, DOI 10.1046/j.0022-3042.2002.00789.x; Leech C.A., 1993, Experientia Supplementum (Basel), V63, P81; Lewis E.B., 1960, DROS INFORM SERV, V34, P117, DOI DOI 10.1101/PDB.REC081414; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; MA D, 2001, 31 ANN M SOC NEUR SA; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MEUNIER JC, 1972, FEBS LETT, V24, P63, DOI 10.1016/0014-5793(72)80827-5; NATHANSON NM, 1980, J BIOL CHEM, V255, P1698; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PINNOCK RD, 1988, BRAIN RES, V458, P45, DOI 10.1016/0006-8993(88)90494-5; REYNOLDS JA, 1976, P NATL ACAD SCI USA, V73, P4467, DOI 10.1073/pnas.73.12.4467; Role L W, 1992, Curr Opin Neurobiol, V2, P254, DOI 10.1016/0959-4388(92)90112-X; RUDLOFF E, 1978, EXP CELL RES, V111, P185, DOI 10.1016/0014-4827(78)90248-3; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SAWRUK E, 1990, EMBO J, V9, P2671, DOI 10.1002/j.1460-2075.1990.tb07452.x; SAWRUK E, 1990, FEBS LETT, V273, P177, DOI 10.1016/0014-5793(90)81078-3; SCHLOSS P, 1988, EMBO J, V7, P2889, DOI 10.1002/j.1460-2075.1988.tb03146.x; SCHLOSS P, 1992, NEUROSCI LETT, V145, P63, DOI 10.1016/0304-3940(92)90204-K; SCHMIDTNIELSEN BK, 1977, J NEUROCHEM, V29, P1013, DOI 10.1111/j.1471-4159.1977.tb06505.x; Schulz R, 2000, J NEUROCHEM, V74, P2537, DOI 10.1046/j.1471-4159.2000.0742537.x; Schulz R, 1998, J NEUROCHEM, V71, P853; SIEGEL LM, 1965, BIOCHEM BIOPH RES CO, V19, P494, DOI 10.1016/0006-291X(65)90152-X; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; Tomizawa M, 1997, NEUROSCI LETT, V237, P61, DOI 10.1016/S0304-3940(97)00811-2; Tomizawa M, 1996, J NEUROCHEM, V67, P1669; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	49	12	15	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2005	280	22					20987	20994		10.1074/jbc.M409639200	http://dx.doi.org/10.1074/jbc.M409639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	930TA	15781463	Green Accepted, hybrid			2022-12-27	WOS:000229438800012
J	Kurata, A; Kurihara, T; Kamachi, H; Esaki, N				Kurata, A; Kurihara, T; Kamachi, H; Esaki, N			2-Haloacrylate reductase, a novel enzyme of the medium chain dehydrogenase/reductase superfamily that catalyzes the reduction of a carbon-carbon double bond of unsaturated organohalogen compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINONE OXIDOREDUCTASE; L-2-HALOACID DEHALOGENASE; REACTION-MECHANISM; ACID DEHALOGENASE; ZETA-CRYSTALLIN; IDENTIFICATION; DEGRADATION; DIVERSITY; EVOLUTION; INSIGHT	A soil bacterium, Burkholderia sp. WS, grows on 2-chloroacrylate as the sole carbon source. To identify the enzymes metabolizing 2-chloroacrylate, we carried out comparative two-dimensional gel electrophoresis of the proteins from 2-chloroacrylate- and lactate-grown bacterial cells. As a result, we found that a protein named CAA43 was inducibly synthesized when the cells were grown on 2-chloroacrylate. The CAA43 gene was cloned and shown to encode a protein of 333 amino acid residues (M-r 35,788) that shared a significant sequence similarity with NADPH-dependent quinone oxidoreductase from Escherichia coli (38.2% identity). CAA43 was overproduced in E. coli and purified to homogeneity. The purified protein catalyzed the NADPH-dependent reduction of the carbon-carbon double bond of 2-chloroacrylate to produce (S)-2-chloropropionate, which is probably further metabolized to (R)-lactate by (S)-2-haloacid dehalogenase in Burkholderia sp. WS. NADH did not serve as a reductant. Despite the sequence similarity to quinone oxidoreductases, CAA43 did not act on 1,4-benzoquinone and 1,4-naphthoquinone. 2-Chloroacrylate analogs, such as acrylate and methacrylate, were also inert as the substrates. In contrast, 2-bromoacrylate served as the substrate. Thus, we named this novel enzyme 2-haloacrylate reductase. This study revealed a new pathway for the degradation of unsaturated organohalogen compounds. It is also notable that the enzyme is useful for the production of (S)-2-chloropropionate, which is used for the industrial production of aryloxyphenoxypropionic acid herbicides.	Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan; Showa Denko Co Ltd, Corp R&D Ctr, Chiba 2670056, Japan	Kyoto University; Showa Denko K.K.	Kurihara, T (corresponding author), Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan.	kurihara@mbc.kuicr.kyoto-u.ac.jp; esaki@scl.kyoto-u.ac.jp						Banerjee R, 2003, ANNU REV BIOCHEM, V72, P209, DOI 10.1146/annurev.biochem.72.121801.161828; Bossi RT, 2002, BIOCHEMISTRY-US, V41, P3018, DOI 10.1021/bi015939r; Breuer M, 2004, ANGEW CHEM INT EDIT, V43, P788, DOI 10.1002/anie.200300599; Copley SD, 1998, CURR OPIN CHEM BIOL, V2, P613, DOI 10.1016/S1367-5931(98)80092-6; de Jong RM, 2003, EMBO J, V22, P4933, DOI 10.1093/emboj/cdg479; de Jong RM, 2004, J BIOL CHEM, V279, P11546, DOI 10.1074/jbc.M311966200; de Jong RM, 2003, CURR OPIN STRUC BIOL, V13, P722, DOI 10.1016/j.sbi.2003.10.009; Edwards KJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P173, DOI 10.1006/abbi.1996.0158; Furukawa K, 2000, J GEN APPL MICROBIOL, V46, P283, DOI 10.2323/jgam.46.283; Gribble GW, 2003, CHEMOSPHERE, V52, P289, DOI 10.1016/S0045-6535(03)00207-8; Haga T, 1998, W S AGROCHEM PLANT, P175; HASAN AKMQ, 1994, BIOSCI BIOTECH BIOCH, V58, P1599, DOI 10.1271/bbb.58.1599; Janssen DB, 2004, CURR OPIN CHEM BIOL, V8, P150, DOI 10.1016/j.cbpa.2004.02.012; Janssen DB, 2001, CURR OPIN BIOTECH, V12, P254, DOI 10.1016/S0958-1669(00)00208-1; Kurata A, 2004, TETRAHEDRON-ASYMMETR, V15, P2837, DOI 10.1016/j.tetasy.2004.06.035; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; LeBrun LA, 2004, BIOCHEMISTRY-US, V43, P3014, DOI 10.1021/bi036103m; Li YF, 1998, J BIOL CHEM, V273, P15035, DOI 10.1074/jbc.273.24.15035; LIU JQ, 1995, J BIOL CHEM, V270, P18309, DOI 10.1074/jbc.270.31.18309; LIU JQ, 1994, APPL ENVIRON MICROB, V60, P2389, DOI 10.1128/AEM.60.7.2389-2393.1994; Liu JQ, 1998, J BIOL CHEM, V273, P30897, DOI 10.1074/jbc.273.47.30897; MARSDEN PJ, 1982, J AGR FOOD CHEM, V30, P627, DOI 10.1021/jf00112a002; Nardi-Dei V, 1999, J BIOL CHEM, V274, P20977, DOI 10.1074/jbc.274.30.20977; Poelarends GJ, 2004, BIOORG CHEM, V32, P376, DOI 10.1016/j.bioorg.2004.05.006; Poelarends GJ, 2004, BIOCHEMISTRY-US, V43, P759, DOI 10.1021/bi0355948; RAO PV, 1992, J BIOL CHEM, V267, P96; Riveros-Rosas H, 2003, EUR J BIOCHEM, V270, P3309, DOI 10.1046/j.1432-1033.2003.03704.x; Shimomura Y, 2002, ACTA CRYSTALLOGR D, V58, P1365, DOI 10.1107/S090744490201003X; Swanson PE, 1999, CURR OPIN BIOTECH, V10, P365, DOI 10.1016/S0958-1669(99)80066-4; THORN JM, 1995, J MOL BIOL, V249, P785, DOI 10.1006/jmbi.1995.0337; VANDERWAARDE JJ, 1993, APPL ENVIRON MICROB, V59, P528, DOI 10.1128/AEM.59.2.528-535.1993; WOODLARD FX, 1979, PHYTOCHEMISTRY, V18, P617; Xu DG, 2004, J AM CHEM SOC, V126, P13649, DOI 10.1021/ja0460211	33	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	2005	280	21					20286	20291		10.1074/jbc.M414605200	http://dx.doi.org/10.1074/jbc.M414605200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	927ZX	15781461	hybrid			2022-12-27	WOS:000229242000017
J	Patton, JR; Bykhovskaya, Y; Mengesha, E; Bertolotto, C; Fischel-Ghodsian, N				Patton, JR; Bykhovskaya, Y; Mengesha, E; Bertolotto, C; Fischel-Ghodsian, N			Mitochondrial myopathy and sideroblastic anemia (MLASA) - Missense mutation in the pseudouridine synthase 1 (PUS1) gene is associated with the loss of tRNA pseudouridylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							U2 SNRNA; DYSKERATOSIS-CONGENITA; RIBOSOMAL-RNA; IN-VIVO; CONSERVED PSEUDOURIDINE; ANTICODON LOOP; CHAIN-REACTION; DNA INVITRO; BIOGENESIS; STABILIZATION	A missense mutation in the PUS1 gene affecting a highly conserved amino acid has been associated with mitochondrial myopathy and sideroblastic anemia (MLASA), a rare autosomal recessive oxidative phosphorylation disorder. The PUS1 gene encodes the enzyme pseudouridine synthase 1 (Pus1p) that is known to pseudouridylate tRNAs in other species. Total RNA was isolated from lymphoblastoid cell lines established from patients, parents, unaffected siblings, and unrelated controls, and the tRNAs were assayed for the presence of pseudouridine (Psi) at the expected positions. Mitochondrial and cytoplasmic tRNAs from MLASA patients are lacking modification at sites normally modified by Pus1p, whereas tRNAs from controls, unaffected siblings, or parents all have Psi at these positions. In addition, there was no Pus1p activity in an extract made from a cell line derived from a patient with MLASA. Immunohistochemical staining of Pus1p in cell lines showed nuclear, cytoplasmic, and mitochondrial distribution of the protein, and there is no difference in staining between patients and unaffected family members. MLASA is thus associated with absent or greatly reduced tRNA pseudouridylation at specific sites, implicating this pathway in its molecular pathogenesis.	Univ S Carolina, Sch Med, Dept Pathol & Microbiol, Columbia, SC 29209 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Inst Med Genet,David Geffen Sch Med, Ahmanson Dept Pediat,Steven Spielberg Pediat Res, Los Angeles, CA 90048 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Fischel-Ghodsian, N (corresponding author), Cedars Sinai Med Ctr, Dept Pediat, 8700 Beverly Blvd,Ste 1165 WT, Los Angeles, CA 90048 USA.	nathan.fischel@cshs.org	Alu, Andrea/A-1328-2007; Chen, Pai-Yen/AAR-3291-2020	Alu, Andrea/0000-0002-4297-5274; Chen, Pai-Yen/0000-0002-8112-8457; Mengesha, Emebet/0000-0001-7830-1557	NIDCD NIH HHS [R01DC01402] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001402] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Ansmant I, 2000, NUCLEIC ACIDS RES, V28, P1941, DOI 10.1093/nar/28.9.1941; Auffinger P, 1998, Modification and Editing of RNA, P103, DOI [10.1128/9781555818296.ch6, DOI 10.1128/9781555818296.CH6]; Auffinger P, 1998, MODIFICATION EDITING, P569; Bakin AV, 1998, METH MOL B, V77, P297; Baumstark T, 2001, RNA, V7, P1652; Becker HF, 1997, NUCLEIC ACIDS RES, V25, P4493, DOI 10.1093/nar/25.22.4493; Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530; Casas KA, 2004, AM J MED GENET A, V125A, P201, DOI 10.1002/ajmg.a.20368; Chen JG, 2000, BIOCHEMISTRY-US, V39, P12723, DOI 10.1021/bi001109m; Chen JG, 1999, RNA, V5, P409, DOI 10.1017/S1355838299981591; Davis DR, 1995, NUCLEIC ACIDS RES, V23, P5020, DOI 10.1093/nar/23.24.5020; Davis DR, 1998, J BIOMOL STRUCT DYN, V15, P1121, DOI 10.1080/07391102.1998.10509006; DAVIS DR, 1991, BIOCHEMISTRY-US, V30, P4223, DOI 10.1021/bi00231a017; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Donmez G, 2004, RNA, V10, P1925, DOI 10.1261/rna.7186504; GRIFFEY RH, 1985, J BIOL CHEM, V260, P9734; Grosshans H, 2001, J BIOL CHEM, V276, P46333, DOI 10.1074/jbc.M107141200; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Hellmuth K, 2000, NUCLEIC ACIDS RES, V28, P4604, DOI 10.1093/nar/28.23.4604; Helm M, 2004, J MOL BIOL, V337, P545, DOI 10.1016/j.jmb.2004.01.036; Huang LX, 1998, BIOCHEMISTRY-US, V37, P344, DOI 10.1021/bi971874+; Lecointe F, 1998, J BIOL CHEM, V273, P1316, DOI 10.1074/jbc.273.3.1316; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Motorin Y, 1998, RNA, V4, P856, DOI 10.1017/S1355838298980396; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; Newby MI, 2002, NAT STRUCT BIOL, V9, P958, DOI 10.1038/nsb873; Newby MI, 2001, RNA, V7, P833, DOI 10.1017/S1355838201002308; Nishimura S, 1972, Prog Nucleic Acid Res Mol Biol, V12, P49; Patton JR, 2003, BIOCHEM J, V372, P595, DOI 10.1042/BJ20021938; Ramamurthy V, 1999, J BIOL CHEM, V274, P22225, DOI 10.1074/jbc.274.32.22225; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; SAMBROOK J, 2001, MOL CLONING LAB MANU, P776; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656; WU XQ, 1993, NUCLEIC ACIDS RES, V21, P5589, DOI 10.1093/nar/21.24.5589; Yu YT, 1998, EMBO J, V17, P5783, DOI 10.1093/emboj/17.19.5783; Zebarjadian Y, 1999, MOL CELL BIOL, V19, P7461; Zhao XL, 2004, RNA, V10, P681, DOI 10.1261/rna.5159504; Zhao XS, 2004, MOL CELL, V15, P549, DOI 10.1016/j.molcel.2004.06.044	43	95	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	2005	280	20					19823	19828		10.1074/jbc.M500216200	http://dx.doi.org/10.1074/jbc.M500216200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HH	15772074	hybrid			2022-12-27	WOS:000229113700049
